<SEC-DOCUMENT>0000939767-19-000190.txt : 20191030
<SEC-HEADER>0000939767-19-000190.hdr.sgml : 20191030
<ACCEPTANCE-DATETIME>20191030161422
ACCESSION NUMBER:		0000939767-19-000190
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		106
CONFORMED PERIOD OF REPORT:	20190927
FILED AS OF DATE:		20191030
DATE AS OF CHANGE:		20191030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0103

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		191180242

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel2019093010-q.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:4c9c79b3b42e4e3ab60af831198c33c2,x:fba4f13efd3847c8874930ed99158007-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2019 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:exel="http://www.exelixis.com/20190927" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:AmendmentFlag" id="Fact-90130B52240754BFBD4ACE2FBAD7E75C-wk-Fact-90130B52240754BFBD4ACE2FBAD7E75C" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-3366777BF46E510C98916E6DBFF07E96-wk-Fact-3366777BF46E510C98916E6DBFF07E96">--01-03</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-05083A5D1DD353D0AA93885FBC19CF82-wk-Fact-05083A5D1DD353D0AA93885FBC19CF82">Q3</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:DocumentFiscalYearFocus" id="Fact-B75A1E0C17D05C4AACEB9F0B2F6CC94E-wk-Fact-B75A1E0C17D05C4AACEB9F0B2F6CC94E">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="dei:EntityCentralIndexKey" id="Fact-053840D9B6F751719E957327AFBEC5B4-wk-Fact-053840D9B6F751719E957327AFBEC5B4">0000939767</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-1FDCD14F45CC5DDBB2A28AED832BD909-wk-Fact-1FDCD14F45CC5DDBB2A28AED832BD909">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q3" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-B710FC8934175587AF2B96D5BC1010C9-wk-Fact-B710FC8934175587AF2B96D5BC1010C9">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6-wk-Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6">400000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:CommonStockSharesAuthorized" id="Fact-1922FCA641AF522EB2B857F94C40B32B-wk-Fact-1922FCA641AF522EB2B857F94C40B32B">400000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-3A3CB57BA0E558FB978C7EE61115D8C2-wk-Fact-3A3CB57BA0E558FB978C7EE61115D8C2">299876080</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:CommonStockSharesIssued" id="Fact-31CB9B5A4D885F20BD244C1134369DE0-wk-Fact-31CB9B5A4D885F20BD244C1134369DE0">303776032</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesOutstanding" id="Fact-96FAB434AD8F5D11AC63A2E44BFB4D84-wk-Fact-96FAB434AD8F5D11AC63A2E44BFB4D84">299876080</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:CommonStockSharesOutstanding" id="Fact-00D22AC9AE5755A3AEDC259B91811B94-wk-Fact-00D22AC9AE5755A3AEDC259B91811B94">303776032</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:ContractWithCustomerAssetNetCurrent" id="Fact-2B848B92F5E56EF406510331C239084F-wk-Fact-2B848B92F5E56EF406510331C239084F">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="D2018Q3QTD1" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-89333FE7A1C25B4F812199DA398B6464-wk-Fact-89333FE7A1C25B4F812199DA398B6464">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="D2018Q3YTD1" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-DDB856B579565390995F04925F386F17-wk-Fact-DDB856B579565390995F04925F386F17">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q3QTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-6D709DEE66015CAEA33BF3270CDBFA98-wk-Fact-6D709DEE66015CAEA33BF3270CDBFA98">0</ix:nonFraction><ix:nonFraction decimals="-5" unitRef="usd" contextRef="FD2019Q3YTD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" id="Fact-89E76D54C2C55D51A3BEFF93D9C10C7F-wk-Fact-89E76D54C2C55D51A3BEFF93D9C10C7F">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2018Q3QTD" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact-4F55382AC8DA2ED35112D0C88F397AE3-wk-Fact-4F55382AC8DA2ED35112D0C88F397AE3">0.21</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2018Q3YTD" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact-869F531062DD2F3E86E5D0C88EADE9E1-wk-Fact-869F531062DD2F3E86E5D0C88EADE9E1">0.21</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2019Q3QTD" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" id="Fact-AD89F39D7093AD7E455AD0C88E8956DE-wk-Fact-AD89F39D7093AD7E455AD0C88E8956DE">0.21</ix:nonFraction><ix:nonNumeric contextRef="FI2019Q3_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-0B86817CA6062DE64B51CA96F70810DE-wk-Fact-0B86817CA6062DE64B51CA96F70810DE">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="I2019Q4Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Fact-62A9290A95E8C913316D0FCB77CCEF6E-wk-Fact-62A9290A95E8C913316D0FCB77CCEF6E">P5Y</ix:nonNumeric><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q3QTD1" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact-3EDD54626C9C5D5BA8022B8844B1CC2C-wk-Fact-3EDD54626C9C5D5BA8022B8844B1CC2C">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q3YTD1" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact-26C5E255184058CC8EDA74308334DDD5-wk-Fact-26C5E255184058CC8EDA74308334DDD5">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q3QTD" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact-4D436781DBF75309969FF24DBE49959D-wk-Fact-4D436781DBF75309969FF24DBE49959D">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q3YTD" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" id="Fact-031FC6C6A04E50B183ED2F8F2DF8E98E-wk-Fact-031FC6C6A04E50B183ED2F8F2DF8E98E">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q3QTD1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-7C09168D16E6596E8CC06D0F4194272F-wk-Fact-7C09168D16E6596E8CC06D0F4194272F">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q3YTD1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-C13A23C74E0D50B8899D4B80905C37A9-wk-Fact-C13A23C74E0D50B8899D4B80905C37A9">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q3QTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-8BFBAF39D5A55A316236CE66326C799D-wk-Fact-8BFBAF39D5A55A316236CE66326C799D">129000</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q3YTD" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" id="Fact-CD99ECE0ABB48F441D26D07CA252D54D-wk-Fact-CD99ECE0ABB48F441D26D07CA252D54D">936000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="D2018Q3QTD1" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" id="Fact-F10A5A5724F95A6E88E9152B5142BF9D-wk-Fact-F10A5A5724F95A6E88E9152B5142BF9D">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FD2019Q3QTD" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" id="Fact-945E5B89E1005230B183EE73474C6481-wk-Fact-945E5B89E1005230B183EE73474C6481">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-907BC12DCE8D570AA65EDF690CD8E735-wk-Fact-907BC12DCE8D570AA65EDF690CD8E735">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q3" name="us-gaap:PreferredStockParOrStatedValuePerShare" id="Fact-0ADDFDCFD15F55CA8AE32B7B19DDA8C1-wk-Fact-0ADDFDCFD15F55CA8AE32B7B19DDA8C1">0.001</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-CB6AD27B04B2595487B5177029EF3D5F-wk-Fact-CB6AD27B04B2595487B5177029EF3D5F">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-04B8693E63295C078A1B5748BC974E54-wk-Fact-04B8693E63295C078A1B5748BC974E54">10000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-07C6863E94BD55FABFECD845862794AE-wk-Fact-07C6863E94BD55FABFECD845862794AE">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q3" name="us-gaap:PreferredStockSharesIssued" id="Fact-F2662FA093745F70ACC49E2965E5C26B-wk-Fact-F2662FA093745F70ACC49E2965E5C26B">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact-EB65A169AB0056192321F054FD5A5BDA-wk-Fact-EB65A169AB0056192321F054FD5A5BDA">0</ix:nonFraction><ix:nonFraction decimals="-3" unitRef="usd" contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" id="Fact-CAD46E175A261649DB4EF054FAC96D9C-wk-Fact-CAD46E175A261649DB4EF054FAC96D9C">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="exel-20190927.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Oct21">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-10-21</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Sept28">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Dec29">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_ASDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_ASDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CabometyxMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_ProductGrossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_ASDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_IpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_ASDMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_StatementGeographicalAxis_country_JP">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3June_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-29</xbrli:startDate>
			<xbrli:endDate>2019-04-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul01-Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-29</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2April28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-28</xbrli:startDate>
			<xbrli:endDate>2019-04-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-05-01</xbrli:startDate>
			<xbrli:endDate>2019-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul01-Jul31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-12-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesSecondProductApprovalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312020Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3QTD1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-06-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3YTD1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-30</xbrli:startDate>
			<xbrli:endDate>2018-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q2Apr30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May01-May31_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-01</xbrli:startDate>
			<xbrli:endDate>2017-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3YTD_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-29</xbrli:startDate>
			<xbrli:endDate>2019-09-27</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q3_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-27</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Aug30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-08-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-25</xbrli:startDate>
			<xbrli:endDate>2019-10-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-10-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-10-25</xbrli:startDate>
			<xbrli:endDate>2019-10-25</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="segment">
		<xbrli:measure>exel:segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="investment">
		<xbrli:measure>exel:investment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="program">
		<xbrli:measure>exel:program</xbrli:measure>
	</xbrli:unit><xbrli:unit id="product">
		<xbrli:measure>exel:product</xbrli:measure>
	</xbrli:unit><xbrli:unit id="renewal_option">
		<xbrli:measure>exel:renewal_option</xbrli:measure>
	</xbrli:unit><xbrli:unit id="sqft">
		<xbrli:measure>utreg:sqft</xbrli:measure>
	</xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-07C6863E94BD55FABFECD845862794AE-wk-Fact-07C6863E94BD55FABFECD845862794AE" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143642947e840-wk-Fact-14E885DDB89252BF889F99D9D6F1341F" toRefs="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e631-wk-Fact-1B51FFE1147D5FE58E267C0E99DF0679" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e748-wk-Fact-1CAD89A8AC4D5908802B975A1F373BBD" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-1FDCD14F45CC5DDBB2A28AED832BD909-wk-Fact-1FDCD14F45CC5DDBB2A28AED832BD909" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143642947e820-wk-Fact-22BD4054D3175141A024292FEF769ABE" toRefs="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1612-wk-Fact-2B3D678BFB975C4D9FE3267DC25A4C4F" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1888-wk-Fact-3312CFD2A55C599E9B2030A1E7EF75BC" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e597-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7 d143671945e577-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-3A3CB57BA0E558FB978C7EE61115D8C2-wk-Fact-3A3CB57BA0E558FB978C7EE61115D8C2" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1100-wk-Fact-3AF94EE58E535745846C93F98A4BA069" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1534-wk-Fact-3B8C779DD1845402B360FDB026EE42CF" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e670-wk-Fact-3E92163B9BE350AFB9540EBCDF6E7BE5" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e905-wk-Fact-3F4129D37BE15987B315F13735F8FDBE d143671945e728-wk-Fact-3F4129D37BE15987B315F13735F8FDBE" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e787-wk-Fact-4755812CBC2651E2944688760840B953" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143647870e2390-wk-Fact-4780137C336F5EF1BD4398EF0E381194" toRefs="TextSelection-DBCE478F5687586C8FE8858A03A0EF92-0-wk-Footnote-DBCE478F5687586C8FE8858A03A0EF92_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1810-wk-Fact-4B15B67A4563571C963E04A7E55BE47A" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1299-wk-Fact-4E0A79CE4D22556C8CD82B6BFF283BEC" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1061-wk-Fact-4FA0D3DD22145129854A4C161726D0EC" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1495-wk-Fact-54D1CCCBA98756C59B50269447F29C65" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1690-wk-Fact-6239E69403E55431B38A5B9E7597A2AE" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e709-wk-Fact-669EC1AB746A532489CA1474200178BF" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1339-wk-Fact-6C00EBF1ABD15088AAA6675B42373AEB" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e865-wk-Fact-70884DAF9D095D6F8EC7BDABD302EE15" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1929-wk-Fact-73F0483E60EE53B29E4058F0AF045381" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1456-wk-Fact-7F0E267AC54F587AA0AFE7D5EBC39566" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e983-wk-Fact-85CE777F29DC5425AE5D2A1350EB3BAA" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-907BC12DCE8D570AA65EDF690CD8E735-wk-Fact-907BC12DCE8D570AA65EDF690CD8E735" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1651-wk-Fact-96ECA7A9CBA75A7ABDD94D5CA8925270" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-96FAB434AD8F5D11AC63A2E44BFB4D84-wk-Fact-96FAB434AD8F5D11AC63A2E44BFB4D84" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1417-wk-Fact-9E5F11DE05B3550581DF7177D9B31246" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1573-wk-Fact-A224167B234059F188989D11E3324BC2" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e2013-wk-Fact-B0DA545136C555089C9EDE3307AB7DE0" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e826-wk-Fact-C2EB0F1D2C255F8E9B07698707668AA7" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6-wk-Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e944-wk-Fact-C991BEDAA3F551B189FD2DED431834BC d143660005e795-wk-Fact-C991BEDAA3F551B189FD2DED431834BC" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-CB6AD27B04B2595487B5177029EF3D5F-wk-Fact-CB6AD27B04B2595487B5177029EF3D5F" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143671945e650-wk-Fact-D04C68F48EE857BBAB9EB561BCBE190C" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1144-wk-Fact-D20CC27ECE3A55B7A4EF8855DB4C6203" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143642947e782-wk-Fact-D2CF652C6C6D541A8E57A47FBBD0AC49" toRefs="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1378-wk-Fact-DE1420696CD35A0DAC8D9C5F03CA227C" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143647870e2371-wk-Fact-DF694A70CE785E2FBC25B383B4F0BF21" toRefs="TextSelection-DBCE478F5687586C8FE8858A03A0EF92-0-wk-Footnote-DBCE478F5687586C8FE8858A03A0EF92_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1771-wk-Fact-E48A728D16DA58FC9EC32263F9980934" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1022-wk-Fact-E9FEA5177DA65B4C95480E3130D8839E" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1969-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC d143661439e3055-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143642947e801-wk-Fact-F2E10EF5A2AA516EA18DC933946B00C4" toRefs="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1849-wk-Fact-F6C33F96BF935687A3F2657317EA8820" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d143645401e1265-wk-Fact-FC51C4202CA358D68E09A0F06F4AFD5E" toRefs="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"></ix:relationship></ix:resources></ix:header></div><div><a id="s809BA9F997765CE188AB6592EC55F291"></a></div><div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:20px;text-align:left;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">UNITED STATES</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:12pt;"><span style="font-family:Calibri,sans-serif;font-size:12pt;font-weight:bold;">Washington, D.C. 20549</span></div><div style="line-height:120%;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:298px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:149px;"></td><td style="width:149px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:right;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;">FORM </span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:2px;text-align:left;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;"><span><ix:nonNumeric id="d143643716e440-wk-Fact-0947692385925B2DAD330D67576A8B6B" name="dei:DocumentType" contextRef="FD2019Q3YTD">10-Q</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:8px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:2%;"></td><td style="width:98%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d143643716e455-wk-Fact-648A81E047945122AFBDD0940B304D32" name="dei:DocumentQuarterlyReport" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:24px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">For the quarterly period ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d143643716e466-wk-Fact-4AA11BE69C615394BC8BEC576A9D1C88" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q3YTD" format="ixt:datemonthdayyearen">September 27, 2019</ix:nonNumeric></span></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> </span></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">or</span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:2%;"></td><td style="width:98%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d143643716e486-wk-Fact-A5FFAB5F4E655408BFD88CDED46FDE00" name="dei:DocumentTransitionReport" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;padding-left:48px;text-indent:-48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Commission File Number: </span><span><ix:nonNumeric id="d143643716e496-wk-Fact-4F10F9B88F845547B803E2D15061B0F4" name="dei:EntityFileNumber" contextRef="FD2019Q3YTD"><span style="font-family:Calibri,sans-serif;">000-30235</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:16pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:300px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:300px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;"><img src="exellogo19q3.jpg" alt="exellogo19q3.jpg" style="height:64px;width:188px;"></img></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:center;font-size:16pt;"><span style="font-family:Calibri,sans-serif;font-size:16pt;font-weight:bold;"><span><ix:nonNumeric id="d143643716e518-wk-Fact-9E49C76B87615DE5AB10DCDD38DF8350" name="dei:EntityRegistrantName" contextRef="FD2019Q3YTD">EXELIXIS, INC.</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Exact name of registrant as specified in its charter)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d143643716e539-wk-Fact-7E66EEF6246359F19FEE3E38C626299C" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q3YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d143643716e544-wk-Fact-FB594FE10E6F5FB2BAC07CDEC387B865" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q3YTD">04-3257395</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(I.R.S. Employer Identification Number)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:10pt;"><span><ix:nonNumeric id="d143643716e559-wk-Fact-613513231A605E758D52D2C87371D223" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q3YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">1851 Harbor Bay Parkway</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><span><ix:nonNumeric id="d143643716e565-wk-Fact-DB3EDB6DE6D3571BA680690FD90F3B0F" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q3YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">Alameda,</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d143643716e570-wk-Fact-D5E816E5648352B1AD99C65627F8D63A" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q3YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">CA</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span><span><ix:nonNumeric id="d143643716e575-wk-Fact-457A7E5EE0C958A58B6D609F030946F2" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q3YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">94502</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(</span><span><ix:nonNumeric id="d143643716e583-wk-Fact-64DEE6063C1E5631A737EB2BCA7EB2F4" name="dei:CityAreaCode" contextRef="FD2019Q3YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">650</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">) </span><span><ix:nonNumeric id="d143643716e588-wk-Fact-CDEDB53CCB5F51FC98BDFF92DBA8575A" name="dei:LocalPhoneNumber" contextRef="FD2019Q3YTD"><span style="font-family:Calibri,sans-serif;font-weight:bold;">837-7000</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:center;text-indent:0px;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:96.62698412698413%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:39%;"></td><td style="width:21%;"></td><td style="width:40%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Name of each exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d143643716e629-wk-Fact-9E44922ABA7B55CBBBBCBBB2865A8D00" name="dei:Security12bTitle" contextRef="FD2019Q3YTD">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d143643716e634-wk-Fact-9FEC905BCB8C5069A98350CB6B087349" name="dei:TradingSymbol" contextRef="FD2019Q3YTD">EXEL</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;"><span><ix:nonNumeric id="d143643716e639-wk-Fact-5D77922F9575547DBC612413AEECDAF3" name="dei:SecurityExchangeName" contextRef="FD2019Q3YTD" format="ixt-sec:exchnameen">The Nasdaq Stock Market LLC</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d143643716e644-wk-Fact-80711FE3D50C56AFA2A28ED97311F4F4" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q3YTD"><span style="font-family:Calibri,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#253; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d143643716e658-wk-Fact-848F3D5780D6538AA5062FD31B926B61" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q3YTD"><span style="font-family:Calibri,sans-serif;">Yes</span></ix:nonNumeric></span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#253; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:26%;"></td><td style="width:4%;"></td><td style="width:20%;"></td><td style="width:27%;"></td><td style="width:3%;"></td><td style="width:20%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143643716e689-wk-Fact-5072A390211254CC89E7758685961739" name="dei:EntityFilerCategory" contextRef="FD2019Q3YTD" format="ixt-sec:entityfilercategoryen">Large accelerated filer</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9746;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accelerated&#160;filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Non-accelerated filer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;">&#9744;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Smaller&#160;reporting&#160;company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d143643716e740-wk-Fact-0F4FC365BC8356E08E79997FD59E82E1" name="dei:EntitySmallBusiness" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Emerging growth company</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Arial Unicode MS;font-size:10pt;"><span><ix:nonNumeric id="d143643716e756-wk-Fact-B2F201B0B60F547594695F36EC4DD997" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="font-family:Wingdings;font-size:10pt;">&#168;</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d143643716e787-wk-Fact-C32EC84BEA8C5E65B63BB67382F191C8" name="dei:EntityShellCompany" contextRef="FD2019Q3YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial Unicode MS;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Wingdings;font-size:10pt;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">No&#160;</span><span style="font-family:Wingdings;font-size:10pt;">&#253;</span></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">October&#160;21, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">, there were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143643716e803-wk-Fact-9A3A41EE03765EE9BD8FE68B8ABB4E8C" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2019Q4Oct21" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">303,846,306</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;"> shares of the registrant&#8217;s common stock outstanding. </span></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s5FFC97A89F7456FA99870DF1EB2511D4"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">INDEX</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:10%;"></td><td style="width:80%;"></td><td style="width:10%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Page</span></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s4D20A2966E5455ACAA6942891F1B9D33"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART I - FINANCIAL INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD3A941979F795D589B4D18717DB57AAD"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD3A941979F795D589B4D18717DB57AAD">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s48FE097CD7345887BDCC472109206FDB"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Balance Sheets</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s48FE097CD7345887BDCC472109206FDB">3</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s78CE85265BA75254AB11E10E544F9285"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s78CE85265BA75254AB11E10E544F9285">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3657C07C740E5DFB91AA19ABBFDDE854"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Comprehensive Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s3657C07C740E5DFB91AA19ABBFDDE854">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s250B5BBAB38F589C88E4EDBA12FF42FB"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Stockholders&#8217; Equity</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s250B5BBAB38F589C88E4EDBA12FF42FB">5</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sCF812675C98C528BAB1527B3966E9588"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Condensed Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sCF812675C98C528BAB1527B3966E9588">7</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5E1D0C9A14BF565ABD0242AAC7F5EA08"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Notes to Condensed Consolidated Financial Statements</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5E1D0C9A14BF565ABD0242AAC7F5EA08">9</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5892EFCBE0B451CD8E8D1AE7930ED818"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s5892EFCBE0B451CD8E8D1AE7930ED818">26</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s093265DF965755CE8A36764F34BC6D4E"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Quantitative and Qualitative Disclosures About Market Risk</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s093265DF965755CE8A36764F34BC6D4E">38</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s07603B58A06A5C89B73532DD521F5BA6"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Controls and Procedures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s07603B58A06A5C89B73532DD521F5BA6">38</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#sF64E98704A2759F59FC63940E2A6B4C5"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PART II - OTHER INFORMATION</span></a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE468DF99D2735E7290E8EA12FD8D1D0A"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Legal Proceedings</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE468DF99D2735E7290E8EA12FD8D1D0A">39</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s65E5951E9AAE54EDA46618F1C82D3D11"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk Factors</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s65E5951E9AAE54EDA46618F1C82D3D11">39</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s1EFEDFDCDB0457848B97E455D925AA98"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s1EFEDFDCDB0457848B97E455D925AA98">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s28D8227C66AF59A88E06A6329DB606D6"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Defaults Upon Senior Securities</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#s28D8227C66AF59A88E06A6329DB606D6">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE85B4FBC2598528DBAB8400EC8C5276F"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Mine Safety Disclosures</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sE85B4FBC2598528DBAB8400EC8C5276F">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item 5.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sEDB35078A2AD51C587990ED7F15F624A"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sEDB35078A2AD51C587990ED7F15F624A">62</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Item&#160;6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD003A006BF6E5F7E9A2B1DF3FA74D123"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibits</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;" href="#sD003A006BF6E5F7E9A2B1DF3FA74D123">63</a></div></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;" href="#s0ED39B5FB7C559B0A46C8A0E58E4C56C"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SIGNATURES</span></a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2</span></div></div><hr style="page-break-after:always"></hr><div><a id="s4D20A2966E5455ACAA6942891F1B9D33"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART I - FINANCIAL INFORMATION</span></div><div><a id="sD3A941979F795D589B4D18717DB57AAD"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"> Item 1. Financial Statements</span></div><div><a id="s48FE097CD7345887BDCC472109206FDB"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share and per share amounts)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2018*</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ASSETS</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current assets:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e578-wk-Fact-A2EF7BBAD72B5637A44FD42AF030F687" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">242,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e597-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">314,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Short-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e612-wk-Fact-DE84CF33BB8D5292B41A416DCC90F33B" name="us-gaap:ShortTermInvestments" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">518,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e631-wk-Fact-1B51FFE1147D5FE58E267C0E99DF0679" name="us-gaap:ShortTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">378,559</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Trade receivables, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e651-wk-Fact-83BBDD0E14E05765B6C5DE136BF6A307" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">169,788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e670-wk-Fact-3E92163B9BE350AFB9540EBCDF6E7BE5" name="us-gaap:ReceivablesNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,771</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e690-wk-Fact-2E9292B583955A37BC811559AF1B0691" name="us-gaap:OtherReceivablesNetCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e709-wk-Fact-669EC1AB746A532489CA1474200178BF" name="us-gaap:OtherReceivablesNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,056</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e729-wk-Fact-D00F652C36A35B91801D7220E8E4CDBA" name="us-gaap:InventoryNet" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e748-wk-Fact-1CAD89A8AC4D5908802B975A1F373BBD" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e768-wk-Fact-1E3B4536FB115AAFA275875AF72AB3A4" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e787-wk-Fact-4755812CBC2651E2944688760840B953" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e807-wk-Fact-568AE2AA79865175913CD8D815AFACC4" name="us-gaap:AssetsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">972,112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e826-wk-Fact-C2EB0F1D2C255F8E9B07698707668AA7" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">897,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e846-wk-Fact-0C4D822199D15923A75EABD87BF6CEA1" name="us-gaap:LongTermInvestments" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">486,763</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e865-wk-Fact-70884DAF9D095D6F8EC7BDABD302EE15" name="us-gaap:LongTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">157,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e886-wk-Fact-B89A41F9770A5B909B2A62EEA3EE1ACC" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e905-wk-Fact-3F4129D37BE15987B315F13735F8FDBE" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e925-wk-Fact-FFFCB7E5E0345888A600381F271F9035" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e944-wk-Fact-C991BEDAA3F551B189FD2DED431834BC" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e964-wk-Fact-11CD05BE41DC52F5A55F2028C864E6CD" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,735</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e983-wk-Fact-85CE777F29DC5425AE5D2A1350EB3BAA" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred tax assets, net</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1003-wk-Fact-53B988AA586F51348268E4E070AD000E" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1022-wk-Fact-E9FEA5177DA65B4C95480E3130D8839E" name="us-gaap:DeferredIncomeTaxAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">244,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Goodwill</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1042-wk-Fact-3CBF36F5437E5E64BFA89138571F020C" name="us-gaap:Goodwill" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1061-wk-Fact-4FA0D3DD22145129854A4C161726D0EC" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">63,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1081-wk-Fact-6CB28A01D6A9552C850A0AFD5FCD1B6A" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1100-wk-Fact-3AF94EE58E535745846C93F98A4BA069" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1125-wk-Fact-624AE281FEA75EEDB44208DD232226D5" name="us-gaap:Assets" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,784,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1144-wk-Fact-D20CC27ECE3A55B7A4EF8855DB4C6203" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,422,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1246-wk-Fact-BAF5EB4FC9485D2981589A0B8D8381F1" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,352</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1265-wk-Fact-FC51C4202CA358D68E09A0F06F4AFD5E" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1280-wk-Fact-6C8244381F905DE29971505CD97B7428" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,713</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1299-wk-Fact-4E0A79CE4D22556C8CD82B6BFF283BEC" name="us-gaap:AccruedEmployeeBenefitsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1320-wk-Fact-54F45C96743C5B8788A863C0311CA4E2" name="exel:AccruedClinicalLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1339-wk-Fact-6C00EBF1ABD15088AAA6675B42373AEB" name="exel:AccruedClinicalLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Rebates and fees due to customers</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1359-wk-Fact-69FF45101EA655E5A48BA56AE8B9206D" name="us-gaap:CustomerRefundLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1378-wk-Fact-DE1420696CD35A0DAC8D9C5F03CA227C" name="us-gaap:CustomerRefundLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1398-wk-Fact-E59061B9E9405DEEA4FA05B5F49C32F7" name="exel:AccruedCollaborationLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,973</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1417-wk-Fact-9E5F11DE05B3550581DF7177D9B31246" name="exel:AccruedCollaborationLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1437-wk-Fact-E31153978311579A82147506D2EE97E4" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">45,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1456-wk-Fact-7F0E267AC54F587AA0AFE7D5EBC39566" name="us-gaap:OtherAccruedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">21,825</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1476-wk-Fact-A869D86B20D3598D9A4EA8A309A82937" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">141,069</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1495-wk-Fact-54D1CCCBA98756C59B50269447F29C65" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1515-wk-Fact-4315B0293B5E519E9FEF2A0ED4B9280B" name="exel:OperatingAndFinanceLeasesLiabilityLongTerm" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1534-wk-Fact-3B8C779DD1845402B360FDB026EE42CF" name="exel:OperatingAndFinanceLeasesLiabilityLongTerm" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1554-wk-Fact-33F7C8BE5DCD53C38384E77B5BDF1564" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,399</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1573-wk-Fact-A224167B234059F188989D11E3324BC2" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1593-wk-Fact-834F5FF4D4A1571494944FFC2649A5B4" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1612-wk-Fact-2B3D678BFB975C4D9FE3267DC25A4C4F" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1632-wk-Fact-1A4DA437F0AE51969B9EB6139327951D" name="us-gaap:Liabilities" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">181,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1651-wk-Fact-96ECA7A9CBA75A7ABDD94D5CA8925270" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">134,833</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commitments</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1671-wk-Fact-81AFE926392A55F799DF22FB90346128" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q3" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1690-wk-Fact-6239E69403E55431B38A5B9E7597A2AE" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="3" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stockholders&#8217; equity:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1752-wk-Fact-377CC9EDE0095E5FA6E0AE25E341FB29" name="us-gaap:PreferredStockValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1771-wk-Fact-E48A728D16DA58FC9EC32263F9980934" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 303,776,032 and 299,876,080 at September 30, 2019 and December 31, 2018, respectively</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1791-wk-Fact-DCF649A807B7563191A726C436C2D529" name="us-gaap:CommonStockValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1810-wk-Fact-4B15B67A4563571C963E04A7E55BE47A" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Additional paid-in capital</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1830-wk-Fact-99D5EE0577DD50D3A476BCE9F5225236" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,228,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1849-wk-Fact-F6C33F96BF935687A3F2657317EA8820" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,168,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1869-wk-Fact-8CAAA9D2E560596B96A1F1120873A265" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143645401e1888-wk-Fact-3312CFD2A55C599E9B2030A1E7EF75BC" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accumulated deficit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143645401e1909-wk-Fact-EB3BCB4D59F8580E9662F587003C8484" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">628,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143645401e1929-wk-Fact-73F0483E60EE53B29E4058F0AF045381" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">880,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stockholders&#8217; equity</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1950-wk-Fact-291D88D306F657CDA774FA58C8EF7E56" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,603,717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1969-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,287,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:44px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total liabilities and stockholders&#8217; equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e1994-wk-Fact-EDBBA10C3DB15245A79DF77EFA3B737F" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,784,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143645401e2013-wk-Fact-B0DA545136C555089C9EDE3307AB7DE0" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,422,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">*</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3</span></div></div><hr style="page-break-after:always"></hr><div><a id="s78CE85265BA75254AB11E10E544F9285"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except per share amounts)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e707-wk-Fact-13C7A41F37725EB8B706C7A807584BBF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">191,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e726-wk-Fact-A3A260830AF7574094095B1E462A1635" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e745-wk-Fact-F0EFE7C281A95AD9B2D218FBA067F5D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">565,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e765-wk-Fact-2BCECF9B512F5FD6A12DE4E58A50DD70" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">443,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenue</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e780-wk-Fact-43C7D839ACFA5CC29516954B25CA6CBF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e799-wk-Fact-E4ED43C9E7AC58B1A6BE7BF6E14F1B33" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e818-wk-Fact-95EF234B5DB954128FB68B0CD9D59DE3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e838-wk-Fact-FE403DC09F4A52B38F68D10219F89E45" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e858-wk-Fact-0FD3BD1F4272593786021250887B7DCA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e877-wk-Fact-E6B3BE7A5FD954AE933CF2B974B2DDA6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e896-wk-Fact-7654B036962C5DE7B24FDFD8B0563694" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">727,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e916-wk-Fact-2CB1AC25C2D25B03AD4E742BBB6610B2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">625,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1018-wk-Fact-1040DACBC5725452A3C835D49E28C7C9" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,537</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1037-wk-Fact-A6C99693899052FDA3B647CBE6E6CC75" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1056-wk-Fact-27C0B897CDF551DA8F025B5960727005" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">22,577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1076-wk-Fact-EA40B67CC7F8502EBDA0F7E754048B4E" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">18,996</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1096-wk-Fact-501D21B52F4156ACA18A28167EA19345" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1115-wk-Fact-54D4F40502885CB2B29829CB3C9E20F3" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1134-wk-Fact-0CC5349F94BF59F79C800F76C9B4997B" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">242,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1154-wk-Fact-B47DDBAE42C35E7DBF42355EFEAA0A94" name="us-gaap:ResearchAndDevelopmentExpense" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">124,986</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1174-wk-Fact-F16D75F287165F17AFA8B08BF64BD572" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1193-wk-Fact-186335E0A0DA5725BAF0FAF7A9816159" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1212-wk-Fact-1641454E46BF5E7FBAA5A5C7040FD34A" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">170,218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1232-wk-Fact-F71A419FE7245EF798793D32DEFAF9B0" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">153,989</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating expenses</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1252-wk-Fact-7C248C1DBA7957F8BB746B76ABD22308" name="us-gaap:OperatingExpenses" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">156,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1271-wk-Fact-7D9A48DFF66957B895FBB046FB88B08B" name="us-gaap:OperatingExpenses" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">100,221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1290-wk-Fact-2B6A170BD4EE59558CB444786FE6F299" name="us-gaap:OperatingExpenses" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">435,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1310-wk-Fact-ECA5FBBE64E058DE931990EC3350C8AF" name="us-gaap:OperatingExpenses" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">297,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income from operations</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1331-wk-Fact-B5FCD4A5AE635DDB878619B8322C4073" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">115,606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1350-wk-Fact-21E5C4CA204357FDAB0DDE12D68649AC" name="us-gaap:OperatingIncomeLoss" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">125,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1369-wk-Fact-62A6CEE6EA2852AA9D1F3BEEC6B0FFFE" name="us-gaap:OperatingIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">292,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1389-wk-Fact-7D3EC453912D5473AC5486F8533DAC1A" name="us-gaap:OperatingIncomeLoss" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">327,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other income (expense), net:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1491-wk-Fact-CC812B7FA6CD58CAB275DE294D6E6443" name="us-gaap:InterestIncomeOther" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1510-wk-Fact-977DE8F1A4B457EE8F4651EC066072FC" name="us-gaap:InterestIncomeOther" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,507</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1529-wk-Fact-8D3C455B40825FFD9EF34AFA95720BE1" name="us-gaap:InterestIncomeOther" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1549-wk-Fact-6EB78E55B2BB55B3B07C6D495ED7101B" name="us-gaap:InterestIncomeOther" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655124e1569-wk-Fact-99B049136B755D258ABEA56A97B528AA" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1589-wk-Fact-6F969AA8BB7F5796AC737B0AF3155742" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1608-wk-Fact-FD6AB4A4D20E54D1ACCCCE70D92F8F62" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1628-wk-Fact-EC5DFF30A0C95BB5A356815B80814FA9" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">368</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net:</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1648-wk-Fact-F4596684920F5D09AE1591417E204F35" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1667-wk-Fact-1F8CD777EDA75CF985EF902AD9D43634" name="us-gaap:NonoperatingIncomeExpense" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,778</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1686-wk-Fact-71ED33DE8D025B79A4D19BE192C9C489" name="us-gaap:NonoperatingIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1706-wk-Fact-D5E2DF139D95506A96E80E6A2FE283F5" name="us-gaap:NonoperatingIncomeExpense" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Income before income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1726-wk-Fact-C7FEB46C50EF5D3488F91BC91A00C656" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">122,657</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1745-wk-Fact-B28446BB5A775A578C14872234E8C7C3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1764-wk-Fact-07565F9CFD945B28B54122733E720D63" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">313,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1784-wk-Fact-66E55983DD10518C96D2A3FA0EEAEB4D" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">335,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655124e1804-wk-Fact-D0F0357F5C845FC9A880552A5A9AFF5C" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655124e1824-wk-Fact-0B63F71E65D956AAAA459E920911C33E" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,324</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655124e1844-wk-Fact-03AEC7D5BAE05D13AC03CF5AD71E0ABE" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">60,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655124e1865-wk-Fact-C64E4939D7A055968A6A9FC2E64E3597" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,739</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1891-wk-Fact-33514420391A5101991C7BB7C90293A3" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1910-wk-Fact-8C3C2FC35F795107AAE02B8C4A08884B" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1929-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">252,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1949-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1969-wk-Fact-46B6F1340B325926B636C2196DE13C68" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e1988-wk-Fact-8CA9C79F88205827970EA61D11A2992D" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q3QTD1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2007-wk-Fact-B75F2EEA889D5D88A99E107841855D59" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2027-wk-Fact-19D1A4B42FA550EDB8287A92F1203E8E" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q3YTD1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2047-wk-Fact-85C96FDDE2775831935EC174B4BAB3AC" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2066-wk-Fact-9472515601E8583EB376A8ADDF708C8C" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q3QTD1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2085-wk-Fact-9C881D80109855308725A2DA072883D8" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2105-wk-Fact-68993515AEDD56A8994B919BD2AB4430" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q3YTD1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.05</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income per share, basic </span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2120-wk-Fact-B2460438003B573BB27D88592E43DFF0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">303,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2139-wk-Fact-904A3CF19F5155C896687A434A608ABA" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q3QTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">298,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2158-wk-Fact-F68635B2F0675E93843E7DCBDB37B465" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">301,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2178-wk-Fact-40A13BFAEDB552D8A32F7A6DB7E3A3FB" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q3YTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">297,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Shares used in computing net income per share, diluted</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2199-wk-Fact-EEF4AE03E94B5C6E8E384202B0413F9A" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">315,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2218-wk-Fact-A9F1D9BC443D55E599B95686A10E4AEC" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q3QTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">312,346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2237-wk-Fact-B53428C464DB589AB5C824036B2F50A4" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">315,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655124e2257-wk-Fact-6BD2776EB4935083A5A3E0C2DAA2ADAD" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q3YTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">313,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">      </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><a id="s3657C07C740E5DFB91AA19ABBFDDE854"></a></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e625-wk-Fact-33514420391A5101991C7BB7C90293A3" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e644-wk-Fact-8C3C2FC35F795107AAE02B8C4A08884B" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e663-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">252,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e683-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income (loss):</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net unrealized gains or losses on available-for-sale securities, net of tax impact of $129, $0, $936 and $0, respectively</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e782-wk-Fact-D2CF652C6C6D541A8E57A47FBBD0AC49" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e801-wk-Fact-F2E10EF5A2AA516EA18DC933946B00C4" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e820-wk-Fact-22BD4054D3175141A024292FEF769ABE" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143642947e840-wk-Fact-14E885DDB89252BF889F99D9D6F1341F" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total other comprehensive income (loss)</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e861-wk-Fact-42C46533EF0F5580AF0F69FA40565357" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e880-wk-Fact-A0EF5891DC8151329B09346C90B42E7C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e899-wk-Fact-BDB33C7513E253C2BE77D94960FA67B6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143642947e919-wk-Fact-55B07392D26E5C4BAC3CB1A720BF2D7D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e945-wk-Fact-229A18181488526EB628D9D23E03C30B" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e964-wk-Fact-F0D3EEB92CBE5732BD1182D396BAA157" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e983-wk-Fact-D2B8CF4E77B557A88052BA91F1A3E685" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">255,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143642947e1003-wk-Fact-7D509D8DF6295AF2AB5343AA48390628" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329,815</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Reclassification adjustments to net income resulting from realized gains or losses on the sale of securities and the related tax impact were nominal or zero during the periods presented.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4</span></div></div><hr style="page-break-after:always"></hr><div><a id="s250B5BBAB38F589C88E4EDBA12FF42FB"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share data)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e818-wk-Fact-4619E8D81EDA54B7BEC12DDE76FCB237" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">302,784,854</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e837-wk-Fact-01180DF9A0285919B8025863814D970F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e856-wk-Fact-649912CA37405B528593B8694925B0E4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,211,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e876-wk-Fact-11A14997562C5F0AA1C4F7571A5B71CA" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e895-wk-Fact-AED4EF1FF22D57E59BA14DCB146C83B7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">725,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e915-wk-Fact-F1096C017F4F5B3E8319B344E8C92CE4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,488,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1003-wk-Fact-5855043CE04C520DB2B19C0C582C8A3A" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1022-wk-Fact-33514420391A5101991C7BB7C90293A3" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1096-wk-Fact-8B737285773A59A79849185C62CE926A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1134-wk-Fact-42C46533EF0F5580AF0F69FA40565357" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1155-wk-Fact-5269AD6ECE1955B1805BE730A0D38AF9" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">991,178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1169-wk-Fact-2662AF1346F5595EA81EE5913B2FD410" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1188-wk-Fact-956BA4354A4355AFA54644096B4894CE" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1246-wk-Fact-6230E729206F5DC0BA7EEEAB22A9CEBC" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,033</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1300-wk-Fact-891410A9CB9651F2B4D8C1FFB83D926F" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1358-wk-Fact-617542DC16245F4CA4242DE5C3D79100" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1379-wk-Fact-7EC834A569625A1B81609C657AFF887E" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">303,776,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1398-wk-Fact-364A7A384A1E5756BA4390788275FFCE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1417-wk-Fact-796CD10F471E510CA705967C74048E7E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,228,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1437-wk-Fact-1ACA01126D17538F984029B56B84C7D3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e1456-wk-Fact-132D1A65F37557259B9A139D2EE245D7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">628,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1476-wk-Fact-291D88D306F657CDA774FA58C8EF7E56" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,603,717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at June 30, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1878-wk-Fact-5FADB7CC78C55B289AC3F82B5860C4B7" name="us-gaap:CommonStockSharesOutstanding" contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">297,892,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1897-wk-Fact-1290069A15DC55669A72898D0DB710B3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1916-wk-Fact-6570CACADE1E532385475A9E5006FC87" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,142,717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e1936-wk-Fact-6BB849B56179540B8B9B0E7F861A876D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e1956-wk-Fact-FB45F43B11AF553893F216D03A878985" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,367,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e1976-wk-Fact-077DC83554FF5ED18CDE9430B51FCA08" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q2Q2" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">775,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2064-wk-Fact-A07B8E7BCF5250099339ADE1C0893643" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2083-wk-Fact-8C3C2FC35F795107AAE02B8C4A08884B" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2157-wk-Fact-E76966D4F0D65E8492CC3DC02FB32121" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2195-wk-Fact-A0EF5891DC8151329B09346C90B42E7C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">218</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2216-wk-Fact-91435A8C81B151E3A9EAAB10802180D2" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">989,704</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2230-wk-Fact-6350E2F90ED3574198A9D84019D808A6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2249-wk-Fact-C8635E38EAB2540FAF3232CCE0592844" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2307-wk-Fact-AF67670B54FF517F8353D911F4F044DB" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2361-wk-Fact-656BD245D14558019945D130F7655FEF" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2419-wk-Fact-E255EF32B7595B29BB086179A59EF398" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2440-wk-Fact-44B1C45FFE7F5AF8B1E901BCA36F197B" name="us-gaap:CommonStockSharesOutstanding" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">298,881,884</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2459-wk-Fact-35413FCEA78C59EFB742CEC6F16EEC2D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2478-wk-Fact-C105955B95FB5EF484C9CBB20DEABF16" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,156,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e2498-wk-Fact-D6A2AD306E0352249DE89DBFDE5CB6CF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">513</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e2518-wk-Fact-55D098EC8F4655E9828CA9E80730E462" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,240,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2538-wk-Fact-CA55498B92C8585699BDCD209B6F0E65" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">915,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Continued on next page</span></div><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands, except share data)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2957-wk-Fact-625BFFA518245725A183C6FE9C3EFE6F" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">299,876,080</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2976-wk-Fact-3C0B3749D8055ED2BA0DE9DD87136772" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e2995-wk-Fact-25B89238DEC55D12B0248BCB672178DD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,168,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e3015-wk-Fact-CCC753FF6F6853E6AF5C00D10B13ECEE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e3035-wk-Fact-A8D214661D475B3EA384D32B751DA4FE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">880,363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3055-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,287,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3143-wk-Fact-73F2E1010E9E5B65BC56E3AE0F7EECDB" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">252,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3162-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">252,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive income</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3236-wk-Fact-B339D38806D15E84B4E13455D106521F" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3274-wk-Fact-BDB33C7513E253C2BE77D94960FA67B6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3295-wk-Fact-C0954B46F062518FA4AF10D6E8D6AC7B" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,899,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3309-wk-Fact-AB512F97D4D75C5FA3F84216159110B0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3328-wk-Fact-1849FCB53FD35C9DB363B0C0B26A9868" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3386-wk-Fact-781A819FB85454869F7F0D40145E664C" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3440-wk-Fact-7E61155DC064575C96F5E3CBD8E292AA" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,747</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3498-wk-Fact-8C90F5C2E32752AF80256DE9C422D45C" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,747</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3519-wk-Fact-7EC834A569625A1B81609C657AFF887E" name="us-gaap:CommonStockSharesOutstanding" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">303,776,032</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3538-wk-Fact-364A7A384A1E5756BA4390788275FFCE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3557-wk-Fact-796CD10F471E510CA705967C74048E7E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,228,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3577-wk-Fact-1ACA01126D17538F984029B56B84C7D3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e3596-wk-Fact-132D1A65F37557259B9A139D2EE245D7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">628,094</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e3616-wk-Fact-291D88D306F657CDA774FA58C8EF7E56" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,603,717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="23"></td></tr><tr><td style="width:40%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="22" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Additional<br/>Paid-in<br/>Capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Other<br/>Comprehensive<br/>Loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Accumulated<br/>Deficit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total<br/>Stockholders&#8217;<br/>Equity</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4018-wk-Fact-7D9E00B98E4D5A68B824D5FF2D29BF2D" name="us-gaap:CommonStockSharesOutstanding" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">296,209,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4037-wk-Fact-AD851AF0FB82520BAB83C473AF7F98C8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4056-wk-Fact-01C3DE3AAEFE5ABF8D547DE618D1E60A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,114,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e4076-wk-Fact-C0E7B2AC014A5AEEA51163D5956C8922" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e4096-wk-Fact-B3BF93EF26A65E91B9DB33297F326F3F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,829,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4116-wk-Fact-ED274640F9F05D9687CA48894B15D11E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">284,961</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of Accounting Standards Update (ASU) No. 2014-09, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Revenue from Contracts with Customers (Topic 606)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4206-wk-Fact-759CBD1B3CDD5D4AAE5CBFD654C59CCF" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4225-wk-Fact-604D4D268A705CCF94A8B9A68FAACA41" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">258,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adoption of ASU No.&#160;2016-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Leases (Topic 842)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4320-wk-Fact-2B2F0C25548C5C7B9D7CF3804B4C9F10" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4339-wk-Fact-A5D08D038E455D10A6DC6ABA1BE4F375" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">234</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4432-wk-Fact-178E54675B945C1FA2CDC23FC869B647" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4451-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other comprehensive loss</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e4525-wk-Fact-B6A273DD059158BF839EBF5994DC9CC1" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e4564-wk-Fact-55B07392D26E5C4BAC3CB1A720BF2D7D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Issuance of common stock under equity incentive and stock purchase plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4586-wk-Fact-A0294D8CD23B51EBB25B3E729417E583" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,672,458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4600-wk-Fact-8117B4420F9E5556A35F6DE3764FF2F6" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4619-wk-Fact-296B001AED85573AA8CD6952BE3B0C85" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4677-wk-Fact-6829711E71975372B8CB130B68009480" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4731-wk-Fact-93E8EB80662A5508AAB75C178F78488D" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4789-wk-Fact-870BA21CAABF574FA5AB8F544790AC7D" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at September 30, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4810-wk-Fact-44B1C45FFE7F5AF8B1E901BCA36F197B" name="us-gaap:CommonStockSharesOutstanding" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">298,881,884</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4829-wk-Fact-35413FCEA78C59EFB742CEC6F16EEC2D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4848-wk-Fact-C105955B95FB5EF484C9CBB20DEABF16" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,156,632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e4868-wk-Fact-D6A2AD306E0352249DE89DBFDE5CB6CF" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">513</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143661439e4888-wk-Fact-55D098EC8F4655E9828CA9E80730E462" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,240,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143661439e4908-wk-Fact-CA55498B92C8585699BDCD209B6F0E65" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="I2018Q3Sept28" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">915,966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">6</span></div></div><hr style="page-break-after:always"></hr><div><a id="sCF812675C98C528BAB1527B3966E9588"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e536-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">252,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e555-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Adjustments to reconcile net income to net cash provided by operating activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e611-wk-Fact-FADF3F9D623359CC8E397C4AEE68F0BB" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e630-wk-Fact-687DC0EC7A055328985CC13FAEAC3F60" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock-based compensation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e650-wk-Fact-379233D815EA540D9711C40F0F0DEBDD" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,747</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e669-wk-Fact-14830A2EDC8D59AAA0490B01504C27C9" name="us-gaap:ShareBasedCompensation" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">401(k) matching contributions made in common stock</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e689-wk-Fact-64FEA128A25F5444ACD024AF5243408D" name="us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e708-wk-Fact-3C49F038EE165E97B146594DD3A7BA9F" name="us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amortization and other changes in right-of-use assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e728-wk-Fact-9FA4A7DE7DBF535DB3030DA3BA26EF91" name="exel:RightOfUseAssetAmortization" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">6,367</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e748-wk-Fact-5299E0C1830A5170B5131B1AD682F7B4" name="exel:RightOfUseAssetAmortization" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,732</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Deferred income taxes</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e768-wk-Fact-CD9DE337EEF75CBCB09DBBFED845442E" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">56,339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e787-wk-Fact-7A4B1D314A285D8D84C7423CD3599D48" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gain on other equity investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e807-wk-Fact-6951FB4A20855EA99C8AF906A0170940" name="us-gaap:GainLossOnSaleOfOtherInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e827-wk-Fact-3377730FF9845C118231F3EE8DD9B633" name="us-gaap:GainLossOnSaleOfOtherInvestments" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accretion of investments, net and other</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e848-wk-Fact-1F45C8C47625558DA9020C7FF80A4A7A" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e868-wk-Fact-7F3913B80239564AAB60364709A9C57F" name="us-gaap:OtherNoncashIncomeExpense" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Changes in operating assets and liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Trade receivables, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e931-wk-Fact-7C53B864A84B5879AE8207014B7AC8A5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e951-wk-Fact-A764C342344B53AE9C67DAAAA4CE4D3A" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,707</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other receivables</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e972-wk-Fact-FD57AA20FD515BDB9DAD2F462EFC3AA2" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e991-wk-Fact-88FE7D9BAF395E4B9E1D9D652DF1A6BB" name="us-gaap:IncreaseDecreaseInOtherReceivables" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inventory, net</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1012-wk-Fact-78F9A0CC46D6567B82ACF82965A4A7F3" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,528</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1032-wk-Fact-F3B9832BA9F75123A438E3DFA9CA1762" name="us-gaap:IncreaseDecreaseInInventories" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,776</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion of unbilled collaboration revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1053-wk-Fact-340E90A3B7575A6FA37415E046ED8CF5" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1073-wk-Fact-04D6F38C6CEF5E5BA56FDC600F48AEEA" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">32,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1094-wk-Fact-A80BA1227D775499A2EA658BEF840459" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">527</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1113-wk-Fact-EB06CC05C0DD58179535618B944040BB" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1134-wk-Fact-A24622652B1956268043A377171FF81A" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1154-wk-Fact-0964257EE6B55166A59B1075345CAC6B" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">542</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accounts payable</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1175-wk-Fact-4189DB5D4EB35220AEFE8B058D0A54AA" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1195-wk-Fact-FA6EC6EB7F8A5B188FDB8B2BE982390F" name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued compensation and benefits</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1216-wk-Fact-9A0B8D238D2F5A13812B918B91D2719A" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">429</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1236-wk-Fact-AB80DB28465E5CC4AFCB552987EB9151" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,210</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued clinical trial liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1256-wk-Fact-AAAE082B4F855D2F9DE30F81EAB7ED75" name="exel:IncreaseDecreaseInAccruedClinicalLiabilities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1275-wk-Fact-9776E47C89425E1BB16947E3662AAEA7" name="exel:IncreaseDecreaseInAccruedClinicalLiabilities" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">891</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Rebates and fees due customers</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1296-wk-Fact-F947884CFE4D5D9583AA624A8B256AAE" name="exel:IncreaseDecreaseInRebatesAndFeesPayable" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,828</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1315-wk-Fact-1D1F49397861587F81F238FE304F4243" name="exel:IncreaseDecreaseInRebatesAndFeesPayable" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Accrued collaboration liability</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1336-wk-Fact-A0EE0207750954918D7DC725F9AEF3F5" name="exel:IncreaseDecreaseInAccruedCollaborationLiability" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1355-wk-Fact-0D3934FCDF6759C6A95892E6D5E70E98" name="exel:IncreaseDecreaseInAccruedCollaborationLiability" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">577</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current and long-term deferred revenue</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1376-wk-Fact-9F79453FFFB85DE7AC5026AC0658A996" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1395-wk-Fact-04B02366E9CC521280D54397E95569EC" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1416-wk-Fact-CCD2B9142326567087C49D3D1766A2E4" name="exel:IncreaseDecreaseInLeaseLiabilityNoncurrent" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,087</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1435-wk-Fact-609F9524627C51DCBC53C5202148F305" name="exel:IncreaseDecreaseInLeaseLiabilityNoncurrent" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">974</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other current and long-term liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1456-wk-Fact-2CF7C89F1CC15B3B8D80F11E0C596558" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1475-wk-Fact-458019B1323453C8B0297DD2DD9961F3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">3,321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1496-wk-Fact-2D4339A1FF885165ADDC15E950B8F27D" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">368,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1515-wk-Fact-405EF42481985A92AF1F1042295D9518" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">311,129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from investing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1576-wk-Fact-E9FB5D606882500EA5CFCC573D8368DA" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1596-wk-Fact-C1EFAE091B685E8097EDCFC55787CA74" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from sale of property and equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1617-wk-Fact-6558493D57835C588730E811895421F6" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1636-wk-Fact-CF9FF455C3D15DC2AFC9BE26D9776A77" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Purchases of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1656-wk-Fact-4B3358B1699E5AEBAA95EE8E442E645C" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">887,698</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1676-wk-Fact-87C1FEC62BE45D959721880837F7DA26" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">368,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from maturities of investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1697-wk-Fact-7D487A67969A5B2C8ABD232E8FD9FB32" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">422,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1716-wk-Fact-6AF37F1DC7C75C5DB95024B7E7FF5FE9" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">231,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from sale of investments</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1736-wk-Fact-CE3A8DB792A85EE6A69A2D06A86BA2A1" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,078</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1755-wk-Fact-BA54CA04D42455BAA9FD8C00ADF5DFB7" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from other equity investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1776-wk-Fact-73332485A6C15A30BE088E4DD16B6464" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1795-wk-Fact-2AE8F06EAA7A52648115C8268E4AF64A" name="us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash used in investing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1815-wk-Fact-F0CD44721B96595B838BB44319F3A92A" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">457,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1835-wk-Fact-4ABA710C285D56909232E99B0478594F" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">155,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash flows from financing activities:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from exercise of stock options</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1897-wk-Fact-1646697EC55A5FA8A877904A8250741A" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1916-wk-Fact-25AB369FF65855C680BE21A08094E84A" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Proceeds from employee stock purchase plan</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1936-wk-Fact-7C4C4432E89054EEABF764C8BC9E3CF4" name="us-gaap:ProceedsFromStockPlans" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e1955-wk-Fact-A83A01062C115771B1504CE3D4A8B6AE" name="us-gaap:ProceedsFromStockPlans" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Taxes paid related to net share settlement of equity awards</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1975-wk-Fact-1350882C91CD5DBEA3C89E145A217080" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e1995-wk-Fact-C387ACBE24B755D5A5D5F1DCC72BA077" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Principal payments on financing lease obligation</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e2016-wk-Fact-F26403CCAE055D999B4D6E426F025D5A" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e2036-wk-Fact-027B13F1EDFF5C1DBF0488752BC73D0B" name="us-gaap:RepaymentsOfLongTermCapitalLeaseObligations" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by financing activities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e2056-wk-Fact-CF70CD229A6E511D88471E2AB1F2B0DC" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,553</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e2075-wk-Fact-C60DC77D3BF954AAB7F8AAD6FAE4D597" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net (decrease) increase in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span>(<ix:nonFraction id="d143647870e2095-wk-Fact-D8AE7123A1F051BDBEADA5336283FDA3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">72,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e2115-wk-Fact-B802A525113659C987170ABFF8090950" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at beginning of period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e2135-wk-Fact-811D8D4A22775A0FBC1C6BB6FF2394BA" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">315,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e2154-wk-Fact-01657473A2A055D8A1ABA999157FCC91" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,314</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents and restricted cash at end of period</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e2179-wk-Fact-2F215124757457DC87AE35B7D9CCCBC3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">243,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9.5pt;"><span style="font-family:Calibri,sans-serif;font-size:9.5pt;"><span><ix:nonFraction id="d143647870e2198-wk-Fact-CB6AEE8FC12F5B38A6B288EB0E1CCDB3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2018Q3Sept28" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">355,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Continued on next page</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">7</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - continued</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(in thousands)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Supplemental cash flow disclosure:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Right-of-use assets obtained in exchange for lease obligations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143647870e2371-wk-Fact-DF694A70CE785E2FBC25B383B4F0BF21" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143647870e2390-wk-Fact-4780137C336F5EF1BD4398EF0E381194" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unpaid liabilities incurred to acquire Property and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143647870e2410-wk-Fact-EF45BDBF588757A08420A1F54359C888" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">159</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143647870e2429-wk-Fact-1343A9E7B4D8550E9AA846F6BAEA34C8" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Unpaid liabilities incurred to acquire investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143647870e2449-wk-Fact-7B47872985DF34A362F303214B4522AB" name="exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,961</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143647870e2468-wk-Fact-011F21154366628AAA9603214B6967D3" name="exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-DBCE478F5687586C8FE8858A03A0EF92-0-wk-Footnote-DBCE478F5687586C8FE8858A03A0EF92_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Amounts for the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include receipt of a tenant incentive payment and an amendment to our existing lease for office and research space. Amounts for the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include the transition adjustment for the adoption of Topic 842.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5E1D0C9A14BF565ABD0242AAC7F5EA08"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXELIXIS, INC.</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(unaudited)</span></div><div><a id="s82B21B85FA65534896CAFEB2EF779EDE"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 1. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="TextSelection-1BE73F03E25352E1A73A1318780A90C9-0-wk-Fact-A14B3FCB6C165869946D51559933BBE5" continuedAt="TextSelection-1BE73F03E25352E1A73A1318780A90C9-1" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1BE73F03E25352E1A73A1318780A90C9-1" continuedAt="TextSelection-1BE73F03E25352E1A73A1318780A90C9-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143648547e459-wk-Fact-D547572BD1F158FF84FC753E0FA1ED2F" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2019Q3YTD" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and have launched commercially. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143648547e463-wk-Fact-27D733CB59695F2FB2C75795035D4D33" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">Two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143648547e467-wk-Fact-FC1F63C24DF45C49AD0ECCFD5F0891D4" name="exel:NumberofProductsinCommercialMarket" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember" unitRef="product" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat a specific form of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-909B3D41BF255495870E1DA0CAD7DF4D-0-wk-Fact-4AAB8E449F1B5D36B0B7E46340DB6A49" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-4A8F6278D4585F0992A067C48A7641A6-0-wk-Fact-4D6BFB10E55B56279D36BB62BC8D01D7" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:FiscalPeriod" id="TextSelection-F6A5206224E15CC5BE042868E411309C-0-wk-Fact-F7BAF78AFB165082BC6FCD91ACEBC700" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended September 27, 2019, June 28, 2019, September 28, 2018 and June 29, 2018, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended September 30, 2019, June 30, 2019, September 30, 2018 and June 30, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019 and the first day of the fiscal quarter ended September 27, 2019 are indicated as being as of July 1, 2019.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating results for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="TextSelection-E3916892B95E5393A9D719A1AAFEFE59-0-wk-Fact-9117D5C8393A59C9A1FF4934F5B3BFF2" continuedAt="TextSelection-E3916892B95E5393A9D719A1AAFEFE59-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143648547e561-wk-Fact-31186DDE8BB95C58940C6E4C3302005D" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q3YTD" unitRef="segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines for difficult-to-treat cancers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">9</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-1BE73F03E25352E1A73A1318780A90C9-2" continuedAt="TextSelection-1BE73F03E25352E1A73A1318780A90C9-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-E3916892B95E5393A9D719A1AAFEFE59-1">All of our long-lived assets are located in the U.S.</ix:continuation> See &#8220;Note 2. Revenues&#8221; for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:UseOfEstimates" id="TextSelection-646BBCFCBD3652DEBEE7E293B5AB01BE-0-wk-Fact-898AFF10392750D9B5262BBEEB034B7F" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-F7BE0A3612185221910CED788945DB3C-0-wk-Fact-8365F67F7DE85347827D02D731464B66" continuedAt="TextSelection-F7BE0A3612185221910CED788945DB3C-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On July 1, 2019, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU No.&#160;2018-15,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense and requires us to expense the capitalized implementation costs over the term of the hosting arrangement, which includes reasonably certain renewals.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2018-15 was adopted using the prospective transition method in the accompanying Condensed Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we adopted ASU </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income (Topic 220) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the individual unit of account approach for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">releasing income tax effects from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accumulated other comprehensive income (loss)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we also adopted ASU 2017-08</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2017-08). ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">shortens the amortization period for certain callable debt securities held at a premium. Specifically, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">requires the premium to be amortized to the earliest call date. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The financial impact from the adoption of ASU 2017-08 was nominal.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the Financial Accounting Standards Board (FASB) issued ASU No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-F7BE0A3612185221910CED788945DB3C-1"><ix:continuation id="TextSelection-1BE73F03E25352E1A73A1318780A90C9-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.</span></div></ix:continuation></ix:continuation><div><a id="s3C9B2132BFB6594CA37667690F225497"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 2. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="TextSelection-F05A88C7B2645309825CAF7C9E0776B6-0-wk-Fact-1A8CB2465E755F5AB9C79604AE5CD653" continuedAt="TextSelection-F05A88C7B2645309825CAF7C9E0776B6-1" escape="true">REVENUES</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="TextSelection-462A8F1555CA5612B255AAB6DF3DD392-0-wk-Fact-4CD78E78DAD556F496135EF75F05AE64" continuedAt="TextSelection-462A8F1555CA5612B255AAB6DF3DD392-1" escape="true"><ix:continuation id="TextSelection-F05A88C7B2645309825CAF7C9E0776B6-1" continuedAt="TextSelection-F05A88C7B2645309825CAF7C9E0776B6-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e710-wk-Fact-A05500D9E52C5EA0A5B40759B1EB4B39" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">239,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e729-wk-Fact-71DB3522A75D5CC9B2CC69B7E837CCE3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">193,356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e748-wk-Fact-CD8E5D97B7785FB1ACE0BAF87932D61C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">704,084</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e768-wk-Fact-9E6DDA6F634E55C5AFFD0458481823CB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_ProductGrossMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">525,438</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e783-wk-Fact-E408B0284FED5977BD7C8C9BA423967E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,148</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e803-wk-Fact-952BD629E2AE5AB09A2DA3CF8C5C82F2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,410</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e823-wk-Fact-C59EB092C7995F87BFC7654F9D382FA1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">139,060</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e844-wk-Fact-7F4BDAC181335D88BF51584A99DAB484" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">82,384</ix:nonFraction></span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e865-wk-Fact-13C7A41F37725EB8B706C7A807584BBF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">191,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e884-wk-Fact-A3A260830AF7574094095B1E462A1635" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e903-wk-Fact-F0EFE7C281A95AD9B2D218FBA067F5D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">565,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e923-wk-Fact-2BCECF9B512F5FD6A12DE4E58A50DD70" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">443,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1027-wk-Fact-F8548ACE1FDF525DB4873DD5A1EE7F2D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,035</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1046-wk-Fact-EEB94F9C761052A6AFE208ED24F18CC6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">51,323</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1065-wk-Fact-2952866758B95F14A852A785A6D7F24F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128,937</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1085-wk-Fact-B2A0CA8381D65BE9827BD7CC4BA18A51" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_LicenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1107-wk-Fact-4F5E62DD18E2505783226D86D484E151" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1126-wk-Fact-57EB6D8A5D74565999FBF4E1DC86F010" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">10,560</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1145-wk-Fact-7B6A7B64A8FD5460AB2294EF6A484111" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1165-wk-Fact-653096BDB80B5D648A13DA2A59B769B1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e1187-wk-Fact-02EE4B446411586CA6647A8B7DB1FECF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">1,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1207-wk-Fact-EA7955AB20CB5750B6F677B598441905" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e1226-wk-Fact-E508656BD0085748AF8C587334B10DB7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">2,310</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1247-wk-Fact-4BD41FD23C7153E7B36D613A07FA9178" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_OtherCollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,445</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1267-wk-Fact-43C7D839ACFA5CC29516954B25CA6CBF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1286-wk-Fact-E4ED43C9E7AC58B1A6BE7BF6E14F1B33" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">62,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1305-wk-Fact-95EF234B5DB954128FB68B0CD9D59DE3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1325-wk-Fact-FE403DC09F4A52B38F68D10219F89E45" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CollaborationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1351-wk-Fact-0FD3BD1F4272593786021250887B7DCA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1370-wk-Fact-E6B3BE7A5FD954AE933CF2B974B2DDA6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1389-wk-Fact-7654B036962C5DE7B24FDFD8B0563694" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">727,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1409-wk-Fact-2CB1AC25C2D25B03AD4E742BBB6610B2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">625,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were offset by the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span><ix:nonFraction id="d143655126e1439-wk-Fact-5AE28279074556DFB8A3C8C48DA57017" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.</span></div></td></tr></table><ix:continuation id="TextSelection-A7E2264852A45192AE12EED9C8A56FFB-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, License revenues and Research and development services revenues were recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 for all periods presented. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other collaboration revenues, which included the p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for all periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></ix:continuation></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">11</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-F05A88C7B2645309825CAF7C9E0776B6-2" continuedAt="TextSelection-F05A88C7B2645309825CAF7C9E0776B6-3"><ix:continuation id="TextSelection-462A8F1555CA5612B255AAB6DF3DD392-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1675-wk-Fact-7B83B21719855D99816A17AEA5F0EA78" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">187,410</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1694-wk-Fact-808D21C66880500D8E9DE5E5443D48AC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">158,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1713-wk-Fact-B23FAFFE8E725087A0B851D4A023A7E4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">552,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1733-wk-Fact-14A4C33445E25E1A986B51C11B9EFBB6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CabometyxMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">428,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1748-wk-Fact-390E7726E03D5B56833995CB61817D40" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1767-wk-Fact-63ADB9EFE55E503DBE613FB0FF6456EC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1786-wk-Fact-2A973B372ED953D997D4D566D1390BB7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1806-wk-Fact-0785016859F85242870A1D64A4C4BBA7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CometriqMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,737</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1831-wk-Fact-13C7A41F37725EB8B706C7A807584BBF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">191,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1850-wk-Fact-A3A260830AF7574094095B1E462A1635" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">162,946</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1869-wk-Fact-F0EFE7C281A95AD9B2D218FBA067F5D0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">565,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e1889-wk-Fact-2BCECF9B512F5FD6A12DE4E58A50DD70" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">443,054</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2152-wk-Fact-9B7D081826035C019236728F0BE4BA88" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_IpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2166-wk-Fact-FFC3A404A5ED5C568336E13BB256CDBA" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2186-wk-Fact-7ABC7DC3501B5BAFB407A66B1D79D272" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_IpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2201-wk-Fact-D7CB49840D4956CFB3583CF2C6A9CA64" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2217-wk-Fact-99028D1B39425DC8A1F03355A62CCBEC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2236-wk-Fact-94A64B1CA0B85F4B908858DB9B1ED0AD" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2251-wk-Fact-F9C5FE3A68565A32940CF5C277DE3BB7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">30,707</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2271-wk-Fact-D382940789CD55BB87F82D42AD854C34" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2287-wk-Fact-4B2F682AE9315C50BA5618C5422683AB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">31,901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2306-wk-Fact-9364A2797B3A5DFC9CD03B6A91C584E0" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2321-wk-Fact-51E94386F12750C6863E0A80A30DAC5A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2341-wk-Fact-22E1F711BFEE5CD7B9144E200D8F19BB" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2357-wk-Fact-D62CB7DB0D125DC0BBAE8053CC584888" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_ASDMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25,235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2376-wk-Fact-1B5DD8743F315769BF22B3C95CAD5F1B" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2391-wk-Fact-CC0B308C26235629B3577FAA9E625700" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_ASDMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2411-wk-Fact-C8166CFD30155F83BC68E2A6701B4A2C" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2427-wk-Fact-75A975CED3EB59119894C9176CAC424B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">102,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2446-wk-Fact-791B996DC4C95B9C91CF51EB02BC595B" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2461-wk-Fact-1C0250E0BBA75623B0ADCBBC553AE7EA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">93,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2480-wk-Fact-2C73EA1E8AD75290B38814564DE8D277" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2501-wk-Fact-0FD3BD1F4272593786021250887B7DCA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2515-wk-Fact-99B589D163B759C896DABC294B2E4AFD" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2535-wk-Fact-E6B3BE7A5FD954AE933CF2B974B2DDA6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2550-wk-Fact-2E7B13068C7D5AE1987436FC0388AE05" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3QTD1_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2808-wk-Fact-C3021ACC073751E08B7720AA2C9EA882" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_IpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2822-wk-Fact-D1BBF961050758E1AE78495573E2F240" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2842-wk-Fact-493F645032D3586A98C31438842E5688" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_IpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2857-wk-Fact-BBA8FC109E8256F1A56E9D1E10FCA2D0" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2873-wk-Fact-1E70263BBA195B0CAF4055F6FCCEACFC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">105,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2892-wk-Fact-41FCFD6864D7507E91673B4F517D3CA0" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2907-wk-Fact-78C492C22B765C0D81E4FAE01386B10A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">83,516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2927-wk-Fact-7A1B335AEE2F5EBAA228E57ECA54A12E" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2943-wk-Fact-4EF63E3BA3025DA78468FBC1C80376F4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">88,496</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2962-wk-Fact-0C27373C856F5993A4B30A7AB05A8D50" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2977-wk-Fact-369E78893BBF53BC818ED353EB78B837" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">71,249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e2997-wk-Fact-BEFB9C0DCDD05BA0B79D461DB3ACDD2D" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3013-wk-Fact-870B81D620D7504D8874C98751431145" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_ASDMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">70,503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3032-wk-Fact-13072B89EC9E5E8C9A69BD1A790D469E" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3047-wk-Fact-23025FE225515010AFF69C52446DB8D8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_ASDMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,995</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3067-wk-Fact-94F71A0157B859EA894220D2AD383784" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3083-wk-Fact-EE6DF48638A25AD1A45D01E93FC8C7AE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">342,695</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3101-wk-Fact-6C2BF7CCB1C858FF84690DD29FCDCB8D" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3115-wk-Fact-1DE4EF391E0251139CE42B68B4CF878A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">275,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3134-wk-Fact-16E7995F3E73549696E9B5AEE8096F16" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3155-wk-Fact-7654B036962C5DE7B24FDFD8B0563694" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">727,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3169-wk-Fact-291A4FE8928E58FD9368AA48584057E6" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3189-wk-Fact-2CB1AC25C2D25B03AD4E742BBB6610B2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">625,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3204-wk-Fact-8FDDC0831FD85A2888C1C9FF62731342" name="us-gaap:ConcentrationRiskPercentage1" contextRef="D2018Q3YTD1_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3417-wk-Fact-C92B044177655B4A98DAF1C6F10BA320" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">194,484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3436-wk-Fact-C2FEE3005C9E54CB8D16FA8EE5EFE51F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">166,270</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3455-wk-Fact-A49F0584D1655F47AF176354EF630932" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">572,957</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3475-wk-Fact-5E04756B8D9C5771A359B45445A28CAD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">453,342</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3490-wk-Fact-1FF85895C6095AB8A2E234D2B5D9DD25" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3509-wk-Fact-3F084D8012745835B21A5F5FA0B38366" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3528-wk-Fact-C051CB103B8B579CB3A2D13C4484B78F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120,134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3548-wk-Fact-27AA792A73175E82AED66272E228541B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_StatementGeographicalAxis_srt_EuropeMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3568-wk-Fact-742D1A387BB85C62AC146934A87D55C8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3587-wk-Fact-A3BBB8E6D3345D0489849AA9070B52E3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3606-wk-Fact-0F4E7B80F74D5F0D89E2FF9703427F1D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">34,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3626-wk-Fact-8AA2B5DD5CAA594497F8C21F2C99919D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_srt_StatementGeographicalAxis_country_JP" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,844</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3651-wk-Fact-0FD3BD1F4272593786021250887B7DCA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3670-wk-Fact-E6B3BE7A5FD954AE933CF2B974B2DDA6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">225,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3689-wk-Fact-7654B036962C5DE7B24FDFD8B0563694" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">727,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3709-wk-Fact-2CB1AC25C2D25B03AD4E742BBB6610B2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">625,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><ix:continuation id="TextSelection-DD139D44A1905B1FA89EC803E3C2D00A-0" continuedAt="TextSelection-A7E2264852A45192AE12EED9C8A56FFB-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-F05A88C7B2645309825CAF7C9E0776B6-3"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="TextSelection-8415C991A2475EFFBA35B375D59BA03C-0-wk-Fact-3E9CAFA6B7C25A599A9CF3CE07146059" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3861-wk-Fact-25BFD09C54F9559387E2824FEBCE19EE" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3880-wk-Fact-D5094717E0B25C74AB93ACD83C090EEE" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3899-wk-Fact-90617D66BA345C7EA9440879264380DA" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,916</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e3919-wk-Fact-211D85F132F050978B0CB8128A3473A1" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e4016-wk-Fact-35C3D83D62EA59C7BBBE645A87F573FE" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,769</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e4035-wk-Fact-02958B032F595E79B01F28396D4A8C62" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e4054-wk-Fact-7DBCDEB3B8FE5A91B4FD84CC863D3AED" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">35,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e4074-wk-Fact-30F9A7E5D79553C29A2D977752DAACC3" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">139,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e4094-wk-Fact-964128BA8E4F55C19C2B3A97C2A26A12" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e4114-wk-Fact-48511F0384C255E2B26118D6CA51A780" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e4134-wk-Fact-511474CFE8F758929081E08B18E45E36" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e4155-wk-Fact-129FAD03E82E510294A289B33AC67EFB" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" sign="-" format="ixt:numdotdecimal">321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e4176-wk-Fact-9E386B4730725BA38EC14162DB36D4C2" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">92,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e4196-wk-Fact-0674BF3DE80051A380E3CA416C65EC3D" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,466</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e4216-wk-Fact-F1B04CCC7E83568E888F387DBB2E6DCB" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143655126e4237-wk-Fact-FE3CCB57BD2959C59065FB0934877BD9" name="us-gaap:ValuationAllowancesAndReservesDeductions" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">136,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e4263-wk-Fact-374815A8F1BC5C89994C738D8F4833CA" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e4282-wk-Fact-30FA4A3D136D5EBA9475C567845C4455" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e4301-wk-Fact-DC3685B8063559919114CBFD5510CCEA" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143655126e4321-wk-Fact-A23F1320DA6A51A3AF5A36930B462814" name="us-gaap:ValuationAllowancesAndReservesBalance" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-7455B4ACE00F51B2B5996B22F3F191A7-0-wk-Fact-45EE4EE2A42D521C92D400583329C8A7" continuedAt="TextSelection-7455B4ACE00F51B2B5996B22F3F191A7-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-7455B4ACE00F51B2B5996B22F3F191A7-1" continuedAt="TextSelection-7455B4ACE00F51B2B5996B22F3F191A7-2"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Unbilled collaboration revenue was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143655126e4345-wk-Fact-91CFF63C0F1CFEF4EEFF03297D9FB3C9" name="us-gaap:ContractWithCustomerAssetNetCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of both </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-7455B4ACE00F51B2B5996B22F3F191A7-2" continuedAt="TextSelection-DD139D44A1905B1FA89EC803E3C2D00A-0">. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. </ix:continuation>Deferred revenue was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143655126e4361-wk-Fact-834316E65C1611A2263A0F987DCEFBCD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143655126e4365-wk-Fact-2AFBD85DCDBD4976AA1A0F984B8AC9BB" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">15.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The amount of revenues recognized during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> that were included in the beginning deferred revenue balance as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and December 31, 2017 was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143655126e4395-wk-Fact-C2CDC2D901AF7F6FC1BCFA3F958B63CE" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143655126e4399-wk-Fact-51CDBD3DC2D1AA23FF31FA3F95C06564" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143655126e4427-wk-Fact-8771FEF48A3A529A9452D26F3536E628" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">67.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143655126e4431-wk-Fact-CC5314AD523B58289355CBE3EF1AC2BB" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">129.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues under Topic 606 for performance obligations satisfied in previous periods as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143655126e4435-wk-Fact-21808AF773FA5350AB1EE96D4B6CBE41" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">48.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143655126e4440-wk-Fact-0DD0A3FF21E857A2A3FC8BCBDF12E158" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">151.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the same periods in 2018. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen, Takeda and Daiichi Sankyo.</span></div></ix:continuation><div><a id="sF1561075F4E951C19129119CE8B3A60C"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 3. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-0-wk-Fact-04AC739539F259BFBDCB2EC6DBCB21BD" continuedAt="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-1" escape="true">COLLABORATION AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-1" continuedAt="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and Bristol-Myers Squibb Company for other compounds and programs in our portfolio. See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for a description of each of our collaboration agreements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit-sharing payments. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for information on collaboration revenues recognized during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Commercial Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">13</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-2" continuedAt="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-3"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. <ix:continuation id="TextSelection-F5ADEE77164D5A40982A7852E4C3A708-0" continuedAt="TextSelection-F5ADEE77164D5A40982A7852E4C3A708-1">Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</ix:continuation></span></div><ix:continuation id="TextSelection-F5ADEE77164D5A40982A7852E4C3A708-1" continuedAt="TextSelection-E04C0D62582959358D894DCDDDE7F2ED-0"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e667-wk-Fact-EBC42824D29658AA92FBAF6D3814B71F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">76,016</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e686-wk-Fact-0F024F41042F52C9B1212CF5D589FD52" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">57,186</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e705-wk-Fact-F4DA74CE4A5658CE9C7EA9BAD2B77C6D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">120,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e725-wk-Fact-14718243279852439359F4D23AD983FE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">145,038</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e742-wk-Fact-0F9A815B5D045806B8820CED56EE33DC" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">47.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Ipsen was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e751-wk-Fact-64F1910F27415835A4AE5118A203F7BB" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The collaboration agreement was subsequently amended in March 2018 and April 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The second amendment to the collaboration agreement with Takeda, which was executed on April 29, 2019 and became effective on May 7, 2019 (the Amendment), among other things, reduced the amount of reimbursements we will receive from Takeda for costs associated with our required global pharmacovigilance activities and limits those reimbursements to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e770-wk-Fact-71A6D930FB0C5B9090B1F186ACC1C789" name="exel:CollaborativeArrangementAnnualReimbursementLimit" contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per year. It also increased the total potential development, regulatory and first-sale milestone payments to be paid to us by Takeda for second-line </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">RCC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, first-line RCC and second-line HCC by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e778-wk-Fact-4B7FB4BA35C353A7AC61709E1724F381" name="exel:IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e782-wk-Fact-FBD88E9C370152AB8C6128813764712A" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">102.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including an increase from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e786-wk-Fact-B3AE80B6206D5A06943006337558E689" name="exel:CollaborationAgreementMilestonePaymentsEarned" contextRef="D2019Q2April28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e791-wk-Fact-346788C394195CA08319C6DC63BDEE74" name="exel:CollaborationAgreementMilestonePaymentsEarned" contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">16.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the milestone we received for the April 2019 submission of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese Ministry of Health, Labour and Welfare</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (MHLW)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We continue to be eligible to receive additional development, regulatory and first-sale milestone payments for other potential future indications. The Amendment also increased the amount of Takeda&#8217;s total potential commercial milestones by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e799-wk-Fact-E22C4499D73A5F74B953E8FE6CA4850A" name="exel:IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e803-wk-Fact-EB17F8D082155896A03405DF8EDDA676" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">89.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We continue to be eligible to receive royalties on net sales of cabozantinib in Japan.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-D2F2CC9C7DFD515F84009ADF831F770C-0-wk-Fact-EA641A6B751F57C985C807742D965B1F" continuedAt="TextSelection-F5ADEE77164D5A40982A7852E4C3A708-0" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1013-wk-Fact-245F5EE0656B52F5B574102C36CDBF7B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1032-wk-Fact-BEA97BEA980E5F9995EC3490B787D152" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,940</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1051-wk-Fact-0B71BBC1020E53A1A31621A7A7C32F4B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,245</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1071-wk-Fact-AD3148F1BFB95E619857A9B5B011D16B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1088-wk-Fact-AE6470107FD85C3C9F63624C8D717461" name="us-gaap:RevenueRemainingPerformanceObligation" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">18.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Takeda was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1102-wk-Fact-262DDB35A41C55259BE3B60EBCB36067" name="us-gaap:ContractWithCustomerLiability" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and the subsequent clinical development. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">14</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-3" continuedAt="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-4"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in the European Union and multiple additional countries for use in the same indication. <ix:continuation id="TextSelection-E04C0D62582959358D894DCDDDE7F2ED-0" continuedAt="TextSelection-E04C0D62582959358D894DCDDDE7F2ED-1">Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):</ix:continuation></span></div><ix:continuation id="TextSelection-E04C0D62582959358D894DCDDDE7F2ED-1" continuedAt="TextSelection-34F10D2DA17C56D8B742D4814BB588B0-0"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1324-wk-Fact-C7B8D124F9B85EE3BC114EC4BD082EE6" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1343-wk-Fact-4E9CD515F479554CA31F80CF37A111C7" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,935</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1362-wk-Fact-9CC7BB8C2F5354AF900F11278E577348" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,507</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1382-wk-Fact-8B027B196F8F552E98F3CBA5200B9FC1" name="exel:CollaborativeArrangementIncomeLossFromAgreement" contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,004</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1402-wk-Fact-B17D01D8A5A55FB69FDCD715A6D67E32" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1421-wk-Fact-758D86C9D4155012944A95B0172A217B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1440-wk-Fact-D0C735EBB208534DB2CE99C3C1FD784D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1460-wk-Fact-EF223054A1115468A7DFE1E2B0178C01" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Daiichi Sankyo</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo was responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;January 2019, the Japanese MHLW approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019, Daiichi Sankyo had its first commercial sale of MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the launch,&#160;we&#160;received a&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1487-wk-Fact-72BC68C00AE75A78A80C4E4249BB52F9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2019Q3June_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;milestone payment from Daiichi Sankyo in June 2019. We are </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">eligible for low double-digit royalties on sales of MINNEBRO. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143663103e1493-wk-Fact-1DC405181E477D3870A0B447FFB9871F" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Ligand on net sales of MINNEBRO.</span></div><ix:continuation id="TextSelection-34F10D2DA17C56D8B742D4814BB588B0-0" continuedAt="TextSelection-17A38A3B173B5E28ABEB19BD5CD56946-0"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Daiichi Sankyo collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1612-wk-Fact-72E9B2B9D18B5744BACB7F29F0D964CF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,130</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1631-wk-Fact-2FAEBCB33C065D66A0CDD57DB4884481" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Such collaboration revenues were nominal or zero for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Iconic Therapeutics, Inc. (Iconic) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">entered into an exclusive option and license agreement with Iconic. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#8217;s lead oncology </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">antibody-drug conjugate</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> program, in exchange for an upfront payment to Iconic of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1662-wk-Fact-A3E07891857A58C58BE8BB1FE4DB579B" name="exel:CollaborationAgreementsUpfrontPayments" contextRef="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and a commitment for preclinical development funding. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we accrued </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1670-wk-Fact-22144DC4186F5BBD96B1B1BAD87E6880" name="exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the preclinical development funding commitment. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Both the upfront payment and the accrual for the preclinical development funding commitment were included in Research and development expenses in the accompanying Condensed Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we exercise the option, we</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> would be required to make an option exercise fee payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1681-wk-Fact-9F8E204184835D219A340378FDBEB104" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">20.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Iconic, we would assume responsibilities for all subsequent clinical development and commercialization activities, and Iconic would become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1685-wk-Fact-BAFE238F798A51348AA11224B1EDFF36" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">190.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential development, regulatory and first-sale milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1689-wk-Fact-013EE803F11E5FCD92AB59CD7DE13140" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">262.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aurigene Discovery Technologies Limited (Aurigene) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">entered into</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> an exclusive collaboration, option and license agreement with Aurigene, and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> India-based biotechnology company focused on oncology and inflammatory disorders, to in-license as many as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143663103e1705-wk-Fact-56CFDD5FCDBB53FE81B75348020E2BBE" name="exel:CollaborationAgreementNumberOfPrograms" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> programs. Under the terms of the agreement, we made an upfront payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1709-wk-Fact-E541BDBD60585330A243C8D93A0D26A6" name="exel:CollaborationAgreementsUpfrontPayments" contextRef="D2019Q3Jul01-Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for exclusive options to license </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143663103e1713-wk-Fact-D44D73DBD29F5B9AF947B476BA31BD88" name="exel:CollaborationAgreementNumberOfPreexistingPrograms" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> preexisting programs. In addition, we and Aurigene selected </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143663103e1717-wk-Fact-5C2E773D137C996F25ABB47AB0AB9BAE" name="exel:CollaborationAgreementNumberOfDrugDiscoveryPrograms" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="program" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional Aurigene-led drug discovery programs on mutually agreed upon targets, in exchange for additional option payments totaling </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1722-wk-Fact-D0D37010AB0434A0CD31F05803A758C1" name="exel:CollaborationAgreementAdditionalOptionPayments" contextRef="D2019Q3Jul01-Jul31" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">7.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We are also responsible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1726-wk-Fact-A76A63EB248E5113AA20F91C04D86586" name="exel:CollaborationAgreementResearchAndDevelopmentObligation" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">32.6</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in research funding for the discovery and preclinical development work on these programs. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we accrued </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1736-wk-Fact-09C29C41B8F9ABCA4637F06720FA2076" name="exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued" contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.3</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the discovery and preclinical development funding commitment. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For each option we decide to exercise, we would be required to pay an exercise fee of either </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1743-wk-Fact-3EA62E15CBE056B38053E85CC0083F37" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">10.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1747-wk-Fact-131604BD33DE5B2A9F833A0535B1C99F" name="exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">12.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, depending on the program, and would assume responsibilities for all subsequent clinical development, </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">15</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-4"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization and global manufacturing of that program. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Aurigene would then become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1756-wk-Fact-9EA58BD0E85E58D785CF57E115ED5C50" name="exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">148.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential development and regulatory milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143663103e1760-wk-Fact-1151E56DB7ED52B88D5EE3051FF8E4EF" name="exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">280.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential commercial milestone payments, as well as royalties on potential sales. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">GSK</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated in December 2014, we continue to be required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143663103e1773-wk-Fact-5AE28279074556DFB8A3C8C48DA57017" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties accruing to GSK in connection with the sales of cabozantinib are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen. <ix:continuation id="TextSelection-17A38A3B173B5E28ABEB19BD5CD56946-0" continuedAt="TextSelection-17A38A3B173B5E28ABEB19BD5CD56946-1">Such royalties accruing to GSK were as follows (in thousands):</ix:continuation></span></div><ix:continuation id="TextSelection-17A38A3B173B5E28ABEB19BD5CD56946-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1980-wk-Fact-9BCFC6093928514DA0E11771E52C44BA" name="us-gaap:RoyaltyExpense" contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e1999-wk-Fact-9428C6B8D4185E73875FAA3AF619813B" name="us-gaap:RoyaltyExpense" contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e2018-wk-Fact-C1FCF709D1D1553FA971C1788C0027F3" name="us-gaap:RoyaltyExpense" contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,079</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143663103e2038-wk-Fact-12DA99DA6E7852618D1FE63B87EC2885" name="us-gaap:RoyaltyExpense" contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="sD3482C38255058E7B23507A567909FC7"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 4. <ix:nonNumeric contextRef="FD2019Q3YTD" name="exel:CashCashEquivalentsAndInvestmentsTextBlock" id="TextSelection-C4B8357B2A3551509C17F4016BA28FDC-0-wk-Fact-6928CB05B8C1538F973C722A60FBE312" continuedAt="TextSelection-C4B8357B2A3551509C17F4016BA28FDC-1" escape="true">CASH AND INVESTMENTS </ix:nonNumeric></span></div><ix:continuation id="TextSelection-C4B8357B2A3551509C17F4016BA28FDC-1" continuedAt="TextSelection-C4B8357B2A3551509C17F4016BA28FDC-2"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="TextSelection-63C82923299E58B4A0D0288A3CA4CAF0-0-wk-Fact-54038BC2FA5453888AA5965A8294FA9C" escape="true"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="TextSelection-C35F7BAB66415625A631FA4193CB766C-0-wk-Fact-F6EEBCDC5F5A5AE9AAE738E4FD84FE3C" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e558-wk-Fact-A2EF7BBAD72B5637A44FD42AF030F687" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">242,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e577-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">314,775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e596-wk-Fact-9A4B2A109056533283BC18C08A46E7C3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="I2018Q3Sept28" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">353,623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e616-wk-Fact-ACAFF014B6F357E6BAEC1C510EC5B7DA" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">183,164</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e631-wk-Fact-02571D7B7E7F5AF49B05E69736731F3B" name="us-gaap:RestrictedCashCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e650-wk-Fact-D04C68F48EE857BBAB9EB561BCBE190C" name="us-gaap:RestrictedCashCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e669-wk-Fact-59DF140D0E5C5F86B2234C21D421CCCB" name="us-gaap:RestrictedCashCurrent" contextRef="I2018Q3Sept28" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e689-wk-Fact-00137C9ABCFC5CAAB0F59D00A6FEE760" name="us-gaap:RestrictedCashCurrent" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e709-wk-Fact-B89A41F9770A5B909B2A62EEA3EE1ACC" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e728-wk-Fact-3F4129D37BE15987B315F13735F8FDBE" name="us-gaap:RestrictedCashNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e747-wk-Fact-0AC9E33ADF7F545AAF228A016AC20E7F" name="us-gaap:RestrictedCashNoncurrent" contextRef="I2018Q3Sept28" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e767-wk-Fact-EDB4EAD74619585CB3B95E0AEE698322" name="us-gaap:RestrictedCashNoncurrent" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,646</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e792-wk-Fact-2F215124757457DC87AE35B7D9CCCBC3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">243,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e811-wk-Fact-811D8D4A22775A0FBC1C6BB6FF2394BA" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">315,875</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e830-wk-Fact-CB6AEE8FC12F5B38A6B288EB0E1CCDB3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2018Q3Sept28" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">355,227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e850-wk-Fact-01657473A2A055D8A1ABA999157FCC91" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="I2017Q4Dec29" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">188,314</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">16</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-C4B8357B2A3551509C17F4016BA28FDC-2" continuedAt="TextSelection-C4B8357B2A3551509C17F4016BA28FDC-3"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="TextSelection-4ED0E32BB7495E65861A93FF307AFB54-0-wk-Fact-BB7407C47FD15358BCC5BFF8EDFD0437" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments by security type were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1175-wk-Fact-337A61FADBA85DD2BA0BCE8820A0815F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1194-wk-Fact-B57C6114AD4450969AA6A25471F45D37" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1213-wk-Fact-3AD4B2EADBE95BB187E3E28021147F04" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1233-wk-Fact-44580F5B60555029B82B538AE6E68C36" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1248-wk-Fact-9AF943076B2E5270BD071DF85247BFE5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1267-wk-Fact-A272ABCA01EB5054AC9A39B1ADC4F43B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1286-wk-Fact-7DA2A061CFA05911992ACA5D92FF83B2" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1306-wk-Fact-967198C6C8CD53C28A2621913C442033" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1326-wk-Fact-D5F348F2D5995AB580E0BA86CFB2FDD0" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">703,325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1345-wk-Fact-BF5F6FB2E3975842BCD29FB733E0CF07" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,549</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e1364-wk-Fact-4C938D4A10A35D3E9FAE4E5CAE8EC87A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1385-wk-Fact-72B1FD27DEB5568D9CC7819DE5F31132" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">706,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1405-wk-Fact-11F5239A25595248916D0CEC518C107E" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1424-wk-Fact-EC8CFF49953B55AD9130C13390EF3E20" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e1443-wk-Fact-FD5B9BB95419505783D3B77039507365" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1464-wk-Fact-57C7F017A9465FD185D052B1CC801043" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1484-wk-Fact-77FE5F447BD95D8EB47808E698D94B0C" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,214,736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1503-wk-Fact-0E994E623A3C50FF9A1B2D4393EE0AEA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,692</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e1522-wk-Fact-61FA6FE58E935F84B7EBC1C54114513F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1543-wk-Fact-E91A118BF7525CB2975AC30E5897A32B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,218,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1563-wk-Fact-C63413E8BCF150D69AED84E98FF6FFF6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1582-wk-Fact-6331428E98FC5E53B9C781F486E06AD2" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1601-wk-Fact-93831773EB6454C8A74A4103558D224F" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1621-wk-Fact-8B07DC6CBFA556B29F11CCD545042B25" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">901</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1641-wk-Fact-B9E9652CADE85206AFBE25497CCBAAF3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1660-wk-Fact-847CDF1CC49C558D9A2335CD19783178" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1679-wk-Fact-9FD3DB6D12735EA6840BCF9BB7EBE19C" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1699-wk-Fact-BA972B93B77956109CACAFF79563D500" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1724-wk-Fact-A88C2584601D5095A87EB6167D48C3AE" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,244,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1743-wk-Fact-E346D3A5D53E50B1A9336544350FA0D8" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,695</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e1762-wk-Fact-C9747740D6635CA7A90217CD91755BC5" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e1783-wk-Fact-BACEC49ED2CB5A4FAE3CE403AB8BF865" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,248,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2089-wk-Fact-83FD683CE5A95741AE6F735F27ED50E8" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2108-wk-Fact-56F22C4802B25E3499EFCF77A3EE7F04" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2127-wk-Fact-36C927A1BBEC52DEB7445661ECDD8627" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2147-wk-Fact-18005F6D372156A985DDD4232885BE31" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2162-wk-Fact-716904550C0E51FFAABB9FFD662EAFC1" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2181-wk-Fact-66ACBB81F5DB5CAFA94DFEEF66A9150A" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e2200-wk-Fact-1801E8AB406A5CEE883E2266084AAD18" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2221-wk-Fact-FB53A528BD1051AF8441F4229C83D9DF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2241-wk-Fact-2BF966242943571DB60C36593A2511F2" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2260-wk-Fact-2F3B72FD629452FBA1EA6453878E2A15" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e2279-wk-Fact-DA19868D011753F1B4AFC96E61F2BF0B" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2300-wk-Fact-476C2DD2FD4B5AC794C15B90F408463A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2320-wk-Fact-E4C1AD9AAF345FE5AC2A1AACC4564F59" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2339-wk-Fact-B334E6C73BC75C73A9B616A41C2E7410" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e2358-wk-Fact-5EB25CB135BA5119B567076D530119F4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2379-wk-Fact-0FE0E6CB84E25BD3A23E44D6F827809A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2399-wk-Fact-788246C0DC815E939BB0CEE689E3A4B5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2418-wk-Fact-2E752FFE534E5696994306A28DA515DE" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e2437-wk-Fact-2FD6E16E5D9957A78FC462637DB276CF" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2458-wk-Fact-49FC0313E7EF513E8D58AB82AFF52A84" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2478-wk-Fact-DBBD08CB6AF45D6EB156FB3ED487E8DF" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2497-wk-Fact-798BB587C1A6503B83124495F8E07655" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2516-wk-Fact-616ABFAC518D57C8BFEFC2A221F486C0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2536-wk-Fact-01729804E0C354F29F1903B6A5D50CB8" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2556-wk-Fact-ACA1FB55281355998E6CB5712632B238" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2575-wk-Fact-E69866A06E1654CE8B697DB59E7817E8" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2594-wk-Fact-01EB61A5F8AB597EAE1177AFE172A6EC" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2614-wk-Fact-A9528E77A54B5BADA8568A9BBE7327C8" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2639-wk-Fact-5777066680C35A50827677DE686C9CA5" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">852,322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2658-wk-Fact-A7F844565EA750F581DFBB22392831EB" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e2677-wk-Fact-BA7BE1D9B9E2598D91F2ECE2D1CA7708" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e2698-wk-Fact-2EA494E595F5583091C1D748AD1961EF" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">851,621</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nominal</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="TextSelection-F5EB6F008AF45E3EB1FE7354BA2E2350-0-wk-Fact-21422133549159CE81A2B2EC6EA83EE1" continuedAt="TextSelection-F5EB6F008AF45E3EB1FE7354BA2E2350-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3148-wk-Fact-CFAAE8E4AC7654DD9704D25AD31FB2CA" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">73,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3167-wk-Fact-8120CBF24D5D5496AB97BC4511A91B47" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3187-wk-Fact-AE49D6BBB9A25542B2D1E7F004CF8F8F" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3207-wk-Fact-43DDBB014D215152B0A44A5CA8ABFBA9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3227-wk-Fact-504B5EFCED5E5562A3B6909CE7B1ED24" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">77,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3247-wk-Fact-BEBB0389CE46552A985F9F530ABC363E" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3263-wk-Fact-EA39A5DEFA9C58BC9AE3D6868BECC033" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3282-wk-Fact-F9D198314EE65B038AA1F360F9F18232" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3302-wk-Fact-049D1EC2CD2855DCBB27EB50B8F7ACDB" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3322-wk-Fact-16A9BB4B63EF5F7EB6F45D9393027530" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3341-wk-Fact-CC8A62AD9F9755F89A015CC6C866540D" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">46,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3360-wk-Fact-E245764C81B3592E973759AE060AC8CE" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3387-wk-Fact-A31AB5A465B455008D698E03DB5D20E5" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">119,808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3406-wk-Fact-7EA86A7C6C0053228910240280CD8C35" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3426-wk-Fact-B3D9151747FC5A5BB4C127293EDA5298" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3446-wk-Fact-2D915A5E86855F3BB494C9AF0627F201" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3466-wk-Fact-3829F0E9F0E75322ABFC8F13025C79F0" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">124,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3486-wk-Fact-A00EC9C8D39554EFBA52CA998AF4C936" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">17</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-C4B8357B2A3551509C17F4016BA28FDC-3"><ix:continuation id="TextSelection-F5EB6F008AF45E3EB1FE7354BA2E2350-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3907-wk-Fact-AF3FC49B17C657C9A9AD9BE9B8578089" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">236,162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3926-wk-Fact-07482191F7245442A44858F9784E6D49" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3946-wk-Fact-5C68B722921D5037992C07476F133306" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">39,627</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e3966-wk-Fact-FDAA055594D4500CB11E10E4BAEC5CD9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e3986-wk-Fact-4A0F6E0262465DB5AF54FEC602E6327C" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">275,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e4006-wk-Fact-423E2EFEEE585CE69D5B28BDCEC928D3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">857</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4022-wk-Fact-22E351281A7B5989A036AD7513FEEB78" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e4041-wk-Fact-D85D6E65A1E65D0485F7686D327FBA92" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4061-wk-Fact-D9FB17BCEF0556389E5EB822144D10F9" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e4081-wk-Fact-989941EF5D4D5288ACA7DD17BADB4975" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4101-wk-Fact-0F40D14108C95881B18733EFAB26A002" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">37,287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e4120-wk-Fact-D9A32A9CC2075EE5A9AEACA925881DBF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4142-wk-Fact-DC15A9B211C45B71A428A03713FC9847" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e4161-wk-Fact-E6B5EB9E5449534987D467B3FDC53E7E" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4181-wk-Fact-2453EA623EB1592E9B0B46E46C08305F" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4201-wk-Fact-2428B557AABC5B2C8831318D2422FDCF" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4220-wk-Fact-B8D31D23BFE35DC0B406F495C7D35289" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e4239-wk-Fact-EB4E55C4AD8F5E80AC0BE55F0217AC6B" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4266-wk-Fact-D0B8639509985886B8B5B308813BAE53" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">271,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e4285-wk-Fact-1A6527AD5F78575C9E07BC0F5FB8AA79" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4305-wk-Fact-D593E064BEA75D64B44600EB4C395546" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">48,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e4325-wk-Fact-F045672B07E559F9B9661B75EFDBE4FC" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4345-wk-Fact-920BAFF7821957BB84F7E09E73E319BA" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">320,167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143671945e4365-wk-Fact-18CDC15B051A5AC8A196DED3CB775E8A" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">883</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143671945e4380-wk-Fact-D76360FDF39E5DF495927D6693530966" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="FI2019Q3" unitRef="investment" decimals="INF" scale="0" format="ixt:numdotdecimal">43</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143671945e4384-wk-Fact-2B3B3A947F785757BCCDAD67C03ACD04" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" contextRef="FI2018Q4" unitRef="investment" decimals="INF" scale="0" format="ixt:numdotdecimal">199</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investments in an unrealized loss position as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143671945e4409-wk-Fact-3C36AE4E3A495EE18974951EA7C432D8" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" contextRef="FD2019Q3YTD" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">no</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-15E4062619C95B35B2CE6529208723ED-0-wk-Fact-2F459344FE7756C39BF466BD2DCA2E02" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4523-wk-Fact-21780DCB01985417BEDBE2743BE6C52F" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">743,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4542-wk-Fact-77D67A9592F856CBA07C91D661774764" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">674,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4557-wk-Fact-2EA321E64A35505793021CFB866EDE42" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">474,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4576-wk-Fact-2172B57EADFF50EBA3CDB98722D0BDFC" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">153,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4601-wk-Fact-E91A118BF7525CB2975AC30E5897A32B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,218,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143671945e4620-wk-Fact-49FC0313E7EF513E8D58AB82AFF52A84" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Related Party Transactions</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;BlackRock,&#160;Inc. (BlackRock), a global provider of investment, advisory and risk management solutions, reported that as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the most recent date for which they reported ownership data, their beneficial ownership was more than </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143671945e4640-wk-Fact-5E75EC7332A85270B217018FB60833C8" name="exel:OwnershipInterestByMinorityShareholder" contextRef="FI2018Q4" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our outstanding common stock. BlackRock manages a portion of our cash and investments portfolio. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, the fair value of cash and investments managed by BlackRock was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143671945e4654-wk-Fact-B475DFF648E053CD91BA04CF5D42CF18" name="exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">470.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143671945e4659-wk-Fact-BAF5556FC5AE5113BBB19BAE06D04436" name="exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">298.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143671945e4663-wk-Fact-C4F6D4D1D4405108AD478E2D28F724DC" name="exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143671945e4667-wk-Fact-2DDA9FD7738D59998881FB7AD31EFEE6" name="exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" contextRef="FI2018Q4" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> invested in the BlackRock Liquidity Money Market Fund. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we also had a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143671945e4675-wk-Fact-6C562E809D33CD53CCD8003E9DF8DA66" name="us-gaap:DueToRelatedPartiesCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">9.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> payable to BlackRock for unsettled trades that was included in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> We incurred </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143671945e4684-wk-Fact-9C21F5556764526EAF68FAECF645EDCA" name="exel:RelatedPartyTransactionsAdvisoryFeesIncurred" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in fees for BlackRock advisory services performed during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></ix:continuation><div><a id="sEFA135BA6776585F9E55130693EFD958"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 5. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-6995F3DB6AE75E758EE6188561F3684E-0-wk-Fact-71C27A01E46152AFBF2B8872D07D039B" continuedAt="TextSelection-6995F3DB6AE75E758EE6188561F3684E-1" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-112526C7CCBE562A8F19F1AA5DC284C9-0-wk-Fact-704AA602CEFD50D5B50427C75E1F15A0" escape="true"><ix:continuation id="TextSelection-6995F3DB6AE75E758EE6188561F3684E-1" continuedAt="TextSelection-6995F3DB6AE75E758EE6188561F3684E-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e514-wk-Fact-ECE0497F7C3B51FA8C555B05ABC338F4" name="us-gaap:InventoryRawMaterials" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,906</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e533-wk-Fact-511D99820A4B5F9F80B3885182B49CDC" name="us-gaap:InventoryRawMaterials" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e548-wk-Fact-A27757F1D40F5181AC8FF3FC9BF4B7C2" name="us-gaap:InventoryWorkInProcess" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,035</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e567-wk-Fact-E9CB03A31A9C5297835A04F7E94EADE3" name="us-gaap:InventoryWorkInProcess" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e587-wk-Fact-FFCCB9C06B7C5BF5AAE4C03AE71536D9" name="us-gaap:InventoryFinishedGoods" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">7,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e606-wk-Fact-085E320AED60516BBDE74DF418458A5B" name="us-gaap:InventoryFinishedGoods" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,836</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e631-wk-Fact-C05DECB69BF15ECBBCB11B1B2155E936" name="us-gaap:InventoryGross" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e650-wk-Fact-6C65BEC07798519AA7754C3436057C22" name="us-gaap:InventoryGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e752-wk-Fact-944E4D5054F75A1384514F3D3FABA1EE" name="us-gaap:InventoryGross" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e771-wk-Fact-70F8572A0D315F7386646E0B51872C20" name="us-gaap:InventoryGross" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e786-wk-Fact-160D7639DFC0553D9C0797B8D703595D" name="us-gaap:InventoryGross" contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,886</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e805-wk-Fact-4AAB4C196BF158B7B3690C9E8D821B96" name="us-gaap:InventoryGross" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,090</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e830-wk-Fact-C05DECB69BF15ECBBCB11B1B2155E936" name="us-gaap:InventoryGross" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">20,252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143657110e849-wk-Fact-6C65BEC07798519AA7754C3436057C22" name="us-gaap:InventoryGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">11,928</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">18</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-6995F3DB6AE75E758EE6188561F3684E-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory are charged to Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143657110e863-wk-Fact-ECE9900BAD12568B89D9DC1AA8AC9CF2" name="us-gaap:InventoryWriteDown" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143657110e867-wk-Fact-6D22965D90685A3086091F6BFD17D839" name="us-gaap:InventoryWriteDown" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.8</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory not expected to be used in production or sold in the next 12 months is classified as Other long-term assets in the accompanying Condensed Consolidated Balance Sheets. As of both </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the long-term portion of inventory consisted of portions of our raw materials and finished goods, and as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, also a portion of our work in process.</span></div></ix:continuation><div><a id="s499EF255F0E25596B21BD740A9CCCE28"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 6. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-D807BB3E6F5B5D068CD5B838B42DE491-0-wk-Fact-572FE19D83F05A0EB91EEB144DB2BECE" continuedAt="TextSelection-D807BB3E6F5B5D068CD5B838B42DE491-1" escape="true">PROPERTY AND EQUIPMENT </ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-6F7214D306D85950B9AEDAAF5ED079B8-0-wk-Fact-4965F52DD1FA55418F7734C8FE2647BA" escape="true"><ix:continuation id="TextSelection-D807BB3E6F5B5D068CD5B838B42DE491-1" continuedAt="TextSelection-D807BB3E6F5B5D068CD5B838B42DE491-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e501-wk-Fact-4DCB05F2FA2557FCAFF7BD7ECED43A2E" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,769</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e520-wk-Fact-402BF78B61605C9AA70D86C7924DCAD1" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,941</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e535-wk-Fact-706B01DE05B155368D16A61AF221F143" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,017</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e554-wk-Fact-79B6C4AC254D5BE19857115BC5DEF965" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">15,022</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e574-wk-Fact-65577948D0415DC6BF420D73CF8E5B5F" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,053</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e593-wk-Fact-E20D57F00E7251F69E228B23F1636FED" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e613-wk-Fact-F3CBEA8C8FBF52019B8AEA63E45EC373" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,408</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e632-wk-Fact-B8C396A8E49658CDB462786A6EBE691D" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e652-wk-Fact-57901F8602EA520E9D294C213D9705E5" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e671-wk-Fact-CA2AFB0FA14A54DCBF8EF340ACDFF9FE" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">866</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e691-wk-Fact-0A9414B32014507B82A0C9C6FAC9C443" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">72,864</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e710-wk-Fact-AF5E9D08B25353B4AA4EDC8EC67048D9" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">68,206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143660005e730-wk-Fact-3C718879C78B59549736A659DB48ABA8" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143660005e750-wk-Fact-9682A3F265A55C0887F6AE30FDF54EA9" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,309</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e776-wk-Fact-FFFCB7E5E0345888A600381F271F9035" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49,467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143660005e795-wk-Fact-C991BEDAA3F551B189FD2DED431834BC" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50,897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-D807BB3E6F5B5D068CD5B838B42DE491-2" continuedAt="TextSelection-D807BB3E6F5B5D068CD5B838B42DE491-3"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143660005e810-wk-Fact-ACCA02623D5E0973B412F05905880943" name="us-gaap:Depreciation" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143660005e814-wk-Fact-555A49264CDD56E38A2B6434E71CF7E3" name="us-gaap:Depreciation" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">6.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143660005e826-wk-Fact-1DC4C34AFAA2F866EFE8B4A53C3FD65C" name="us-gaap:Depreciation" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143660005e831-wk-Fact-1B1B0564332C54BB94D407397D4D1E9D" name="us-gaap:Depreciation" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-D807BB3E6F5B5D068CD5B838B42DE491-3">.</ix:continuation> </span></div><div><a id="sE5ECD39054FB50F59C6BC94057AF00F8"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 7. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-901C6A70EBAD51CBBD5167883D0CC259-0-wk-Fact-57207428418E58DF872D369099D97D0D" continuedAt="TextSelection-901C6A70EBAD51CBBD5167883D0CC259-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="TextSelection-901C6A70EBAD51CBBD5167883D0CC259-1" continuedAt="TextSelection-901C6A70EBAD51CBBD5167883D0CC259-2"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-CA0545C00FED5C2D81FCA2BDE7354588-0-wk-Fact-36FD582755F5514F90A881B5D0DAF4F8" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e639-wk-Fact-C62701B908255334B4CB57D8FA8608C6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e658-wk-Fact-EB1314AE60955CD088C8FD1DFB294E1F" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q3QTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,169</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e677-wk-Fact-16807CD9F7F0519B8A7532B741C6C87E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,745</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e697-wk-Fact-647291F1FC1D5DDE9BC6A7F87801D0F6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q3YTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e712-wk-Fact-99484990538359E1801AFC3B1F708836" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">8,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e731-wk-Fact-F7882D71944052A785D043299B32A643" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q3QTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">6,573</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e750-wk-Fact-A8B2D3FD779F59EEA9948C66EF69175D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">27,002</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e770-wk-Fact-6DB2B76C7B5A56C488C38D689E74C5E0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q3YTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">19,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e795-wk-Fact-F717B99DCA7F58808ABA00BCB3FF9AB7" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">13,139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e814-wk-Fact-E0789D6740D25554B7EC3B0B3604A2D8" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">9,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e833-wk-Fact-498D1EB89533578CB672D3FB7970E3D6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">40,747</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e853-wk-Fact-7767985AB1CB511B94D3B4DD1F0F68B6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">28,330</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we have granted stock options and restricted stock units (RSUs) to employees and directors. At </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143674968e878-wk-Fact-F0B0A82238505028984DD8A6C52C43D1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">6,024,995</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under our equity incentive plans.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" id="TextSelection-5FD1B6EE3B6A5E5281B9B9541BD5F448-0-wk-Fact-D2C2DE752A985CFF8D3EAA20EF072417" continuedAt="TextSelection-5FD1B6EE3B6A5E5281B9B9541BD5F448-1" escape="true">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</ix:nonNumeric></span></div><ix:continuation id="TextSelection-5FD1B6EE3B6A5E5281B9B9541BD5F448-1"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1093-wk-Fact-BB0741BC6FC7582AB6625933CADCBC0A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1112-wk-Fact-B1457153AD1E5B85854E32DFB0D1D3D1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1131-wk-Fact-9F3A3CADB8375024989209566088AE4A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1151-wk-Fact-4BF439A8DE385045B64845C474DC6235" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1171-wk-Fact-223AAD6C12585F268E2A3B16155E3A6E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1190-wk-Fact-798DA50E194F501884F1E8B79ECE31E7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1209-wk-Fact-815DC44774395812A319465BBF389B5D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1229-wk-Fact-4232E61BBED4501E801D9F0ED694639A" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-901C6A70EBAD51CBBD5167883D0CC259-2" continuedAt="TextSelection-901C6A70EBAD51CBBD5167883D0CC259-3"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-7A05F98B42575D129F061BCE6A4DD637-0-wk-Fact-01641E1E41A050DABDAF1F2A698C0AD6" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:44%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1467-wk-Fact-5A070C540F10598D9285FA315431F529" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1482-wk-Fact-7CE8795E7F12571CAD9B27384DE9D549" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1497-wk-Fact-1D234BD904AE5CA1948D4DE3DBF033D6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1512-wk-Fact-6348CD79F9B25E4D869D8CCB54EEF21F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1529-wk-Fact-353F876E0D8B58FBA957E65452BF8F72" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1544-wk-Fact-39EF00A402C45480BBC7A5B316FE6AEE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1559-wk-Fact-E02E64A472575D4D886391531806933C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1574-wk-Fact-BD386A0E39A353179899351C95A640B8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1591-wk-Fact-272CE0DFE0FA59918CA712E4A84F6D9C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1606-wk-Fact-04F0B1D7E92E5970B4965896A59EA3AC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1621-wk-Fact-4289D643EFE455C3A5EAB5C4821A4A27" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1636-wk-Fact-6D88B87E32E5549A81F3B76F937AC7B1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e1653-wk-Fact-22FC4A45F0935B43AB55DF874365EEE8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.0</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e1667-wk-Fact-FB9186E5457955D69015CC412AFAF3F8" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.4</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e1681-wk-Fact-607841F135F5501CA043E8279C47578D" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.4</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e1695-wk-Fact-892763382AD35727A5EBE579ED9B6942" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">4.4</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1773-wk-Fact-533C42963F6C570B99FDC79203D179BB" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.09</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1788-wk-Fact-01F286598A6A5880BB60EB7A7A0340BF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1803-wk-Fact-79FCD18DC0BD542E9014A388D2111253" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1818-wk-Fact-00F2E7EE8C8B5887AD5363D49B04016D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1835-wk-Fact-0BAE95D5170B52E3AA31AB764A2AF462" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1850-wk-Fact-B64A85C597EF578BBC1DDDF1D96B5E64" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1865-wk-Fact-AE7CB2CF49B854A890E85C5ED5832194" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1880-wk-Fact-BB01805194585D42BC1BC49F628C8EE2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1897-wk-Fact-B2DD9A2CC05D589B9638FF6687D06861" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1912-wk-Fact-E250BB8FC4C65023BA790476DD0889BD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1927-wk-Fact-F9AB99C99817516287CE7B92B195BCF3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e1942-wk-Fact-AE72B75F26EA586C9ED81092F5B83CF6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e1960-wk-Fact-41F28C3F86E6560A9165BE80CB2A69EA" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e1974-wk-Fact-A447D81345CA510BA0289F6EB27A1BE0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e1988-wk-Fact-0BC4603A5EEA5EB68B7D92CB9AAF188B" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e2002-wk-Fact-F8AFC08B7BA85B63877C8D03E4B68B9C" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember" format="ixt-sec:durmonth">6</ix:nonNumeric> months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. </span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-34DEFEA1649651CBA4B65C0C00888C51-0-wk-Fact-DB04720DEC9C5A6F96781CDA3E47EF69" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:46%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2170-wk-Fact-6B64D35BF76A538BAAC77DB319B276D7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">22,674,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2189-wk-Fact-BB985348AE2C54E0938FB50EE6042FB4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2235-wk-Fact-239843759B2A54FD856FD78177234CF2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q3YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,042,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2254-wk-Fact-B5F29355D2FF599B8230B9A1896740CF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">20.81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143674968e2300-wk-Fact-34FACB7DF8595CD8AB9B38051F3BCE58" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q3YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">3,042,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2320-wk-Fact-A44B26FA1A6C54699D16E3959E99B8D0" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143674968e2366-wk-Fact-435B1FA3A7455176AA72D836D9C3B6C1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q3YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">160,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2386-wk-Fact-F7DB2F5786545435A61BA49836591F0C" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">16.76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143674968e2432-wk-Fact-69D74B8552B05C37B3361208A2B3C22C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="FD2019Q3YTD" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">35,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2452-wk-Fact-7CDD322371595D578425599B76100E36" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">23.41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2498-wk-Fact-A3B9FD49714559CF9362EF3510579F48" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">20,478,861</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2517-wk-Fact-3991AB6E3F065BE38D0F1049FDFE1415" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q3" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">9.80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e2531-wk-Fact-F11FE3C0BD45524ABF9EBECBD4EEF916" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q3YTD" format="ixt-sec:duryear">3.4</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2547-wk-Fact-CC60CACB9F9C5A4E8B2BE3BA1A9D8527" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">186,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2562-wk-Fact-FE67A4B1751B5AAC90B00EFFD1A3EFA9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="FI2019Q3" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">15,860,131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2581-wk-Fact-20E7C3561B6F5017B2207E8C61C2BF32" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="FI2019Q3" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.02</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e2595-wk-Fact-31D4C8490CB7576BA034131C4E7DB789" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q3YTD" format="ixt-sec:duryear">2.8</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2611-wk-Fact-12D23F71CDF151C79D0C9870600D487D" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">181,542</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d143674968e2636-wk-Fact-BE9636119A235B8D8A561156B1CE1B7B" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">38.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span><ix:nonNumeric id="d143674968e2640-wk-Fact-EFF9E6B88A9D5045BEA5D8E95DCE1114" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">2.3</ix:nonNumeric> years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-901C6A70EBAD51CBBD5167883D0CC259-3"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-8BCD520A6EC459FBBDC80A21558D6705-0-wk-Fact-2FA2C8BF21FD58EAABF75A0D2742B6AF" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for RSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:46%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2793-wk-Fact-A71E1C1511C25EBEB0A0865EC47924EF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">4,857,334</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2812-wk-Fact-609F3C1A506F5887AA552DB30ED33F19" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2858-wk-Fact-15FEE31749CC57518B64075964FA72D3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,635,362</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2877-wk-Fact-56F6AB6BA39257BDBFF55D282180E468" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143674968e2923-wk-Fact-E1BEE2B3B23A591FA5D58D942153A5DB" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">484,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e2943-wk-Fact-679BADBD1A005665947765552FC5F2CA" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">12.33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143674968e2989-wk-Fact-4342E17DBBAA5E63ADC8EF298947100E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">258,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e3009-wk-Fact-B773D76588F7531095C23D3A7C21B102" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">18.47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e3055-wk-Fact-D03D21B3748759C78DD612D1EC0E3D25" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">9,749,823</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e3074-wk-Fact-62EFD57E2BA75AC789F5B6403C222A9E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">19.37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonNumeric id="d143674968e3088-wk-Fact-422446928FB1556DB02EB522B35E50AC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">2.2</ix:nonNumeric> years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143674968e3104-wk-Fact-D5DB4F92AFAC53ABACFD132F0CF48BD2" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">175,448</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143674968e3127-wk-Fact-C7567192148E5985A2CEBF396C91C579" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">166.0</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested RSUs, including those RSUs granted in September 2018 and September 2019 that will vest upon the achievement of specific performance targets (PSUs) described below. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d143674968e3131-wk-Fact-E88B5B4A9E2958E988D9AFF45A12F7A3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">2.8</ix:nonNumeric> years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2019, in connection with our long-term incentive compensation program, we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143674968e3138-wk-Fact-B2DFCA7301D040D8B2A9B4AFAFCB5C7D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,926,605</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(the target amount) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that will vest upon the achievement of a performance target related to a product approval by the FDA (the 2019 PSUs); employees may earn </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143674968e3146-wk-Fact-7D2499B902C18379CF0D03A54F6BAA00" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">150</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the target amount</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143674968e3152-wk-Fact-E1D756560B8DCC4AFF0E03A7F4FAAC1D" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">963,136</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares relative to the target amount, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">if the performance target is achieved before December 31, 2020 and may earn the full </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143674968e3159-wk-Fact-4F89A92DC28A14952C1003A5B2E95EF6" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">200</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the target amount, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">or up to an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143674968e3165-wk-Fact-5FEE1391A41D2302C7D903A7F4FEDA5B" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,926,605</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares relative to the target amount, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">if we receive a second product approval. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2018 we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143674968e3173-wk-Fact-2D5D3F2F6FBA56EDA026C82EE25919A3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">693,131</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (the 2018 PSUs). The 2018 PSUs and 2019 PSUs were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Expense recognition for PSUs commences when it is determined that attainment of the performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is probable. During the quarter ended June </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we achieved one of the two </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product revenue related </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">targets</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143674968e3196-wk-Fact-9CA243739686566CBEFF8E14D139A89B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">114,843</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the 2018 PSUs and determined that it was probable that we would achieve the second </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product revenue related </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143674968e3209-wk-Fact-2230C8136FE95CFABACD4134E165762B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">172,272</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional 2018 PSUs. D</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">uring the quarter ended September 30, 2019, the second product revenue related performance target </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of the 2018 PSUs </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was achieved</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Those 2018 PSUs will vest over various dates through February 2021. We recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143674968e3221-wk-Fact-AEA461C020C9A58C7E18B4AF77F8BAC5" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">0.9</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143674968e3226-wk-Fact-7F0A28D63D5A53ADAD0CDFC84FB1B94E" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">3.5</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in compensation expense related to those 2018 PSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively; the remaining unrecognized compensation expense for those 2018 PSUs was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143674968e3238-wk-Fact-64A6E3348EDA5F9EBFD37B1BFFF884D4" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q3_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total unrecognized compensation expense for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">both the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019 PSUs and the remaining 2018 PSUs for which we have not yet determined that attainment of the performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is probable was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143674968e3255-wk-Fact-E93D9E84221659DFAC6425787B148091" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q3_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">82.4</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></ix:continuation><div><a id="s3F3A6D46F4A257CC9837484C96D96D14"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 8. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-D8E336F84EB15A119F445D0EB22BEEF8-0-wk-Fact-F265E97DFDB75C8E87D3556C1594AD9C" continuedAt="TextSelection-D8E336F84EB15A119F445D0EB22BEEF8-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="TextSelection-D8E336F84EB15A119F445D0EB22BEEF8-1" continuedAt="TextSelection-D8E336F84EB15A119F445D0EB22BEEF8-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our effective income tax rate was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143667629e431-wk-Fact-738EF8E4B1A457F184297C63551BA2F3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q3QTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">20.5</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143667629e435-wk-Fact-BAAD485ABBBE57ADBF1B4EF3E417CCAB" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q3YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">19.4</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143667629e449-wk-Fact-1B42BDC211F45D36B71B654C154FDC35" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="D2018Q3QTD1" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.8</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143667629e454-wk-Fact-567CA0013E885E109CD4781A8921B4EF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="D2018Q3YTD1" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">relating to our pre-tax income </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was largely offset by a valuation allowance against our net operating loss carryforwards and other deferred tax assets. At December 31, 2018, we released substantially all of our valuation allowance against our deferred tax assets, after we determined that it was more likely than not that these deferred tax assets would be realized.</span></div></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-D8E336F84EB15A119F445D0EB22BEEF8-2" continuedAt="TextSelection-D8E336F84EB15A119F445D0EB22BEEF8-3"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The effective tax rate for the&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> differed from the U.S. federal statutory rate of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143667629e494-wk-Fact-76B5A5EAC767B4AB8BD9D0CA74D2FA93" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q3YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21</ix:nonFraction>%</span></span></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-D8E336F84EB15A119F445D0EB22BEEF8-3">&#160;primarily due to excess tax benefits related to the exercise of certain stock options during those periods.</ix:continuation> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">21</span></div></div><hr style="page-break-after:always"></hr><div><a id="s8CA661CB71005E06BC59998B07F83D43"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 9. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-1CA8933A9964558C902EB15BD7C2EABF-0-wk-Fact-D50DEFEC6318520A86E3EA270A96859A" continuedAt="TextSelection-1CA8933A9964558C902EB15BD7C2EABF-1" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="TextSelection-1CA8933A9964558C902EB15BD7C2EABF-1"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-D6688AE1DC515E9A8952676AEBF23204-0-wk-Fact-DA30B75D3BF95359AA3381FEEB36F69E" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e720-wk-Fact-33514420391A5101991C7BB7C90293A3" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">97,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e739-wk-Fact-8C3C2FC35F795107AAE02B8C4A08884B" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">126,630</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e758-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">252,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e778-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3" name="us-gaap:NetIncomeLoss" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">329,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e875-wk-Fact-B2460438003B573BB27D88592E43DFF0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">303,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e894-wk-Fact-904A3CF19F5155C896687A434A608ABA" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q3QTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">298,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e913-wk-Fact-F68635B2F0675E93843E7DCBDB37B465" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">301,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e933-wk-Fact-40A13BFAEDB552D8A32F7A6DB7E3A3FB" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="D2018Q3YTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">297,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e953-wk-Fact-3769215076BB57A0A3B9877CEA07DBCE" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">12,185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e972-wk-Fact-E5BB75B624015322B41F960DA950A2EC" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D2018Q3QTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">13,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e991-wk-Fact-A787E60DD6A05F97B400FF1B9AADE45C" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">13,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1011-wk-Fact-5ED4FD084F285F4791DA8BA229BEE364" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="D2018Q3YTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1031-wk-Fact-EEF4AE03E94B5C6E8E384202B0413F9A" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3QTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">315,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1050-wk-Fact-A9F1D9BC443D55E599B95686A10E4AEC" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q3QTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">312,346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1069-wk-Fact-B53428C464DB589AB5C824036B2F50A4" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q3YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">315,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1089-wk-Fact-6BD2776EB4935083A5A3E0C2DAA2ADAD" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="D2018Q3YTD1" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">313,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1196-wk-Fact-46B6F1340B325926B636C2196DE13C68" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1215-wk-Fact-8CA9C79F88205827970EA61D11A2992D" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q3QTD1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1234-wk-Fact-B75F2EEA889D5D88A99E107841855D59" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1254-wk-Fact-19D1A4B42FA550EDB8287A92F1203E8E" name="us-gaap:EarningsPerShareBasic" contextRef="D2018Q3YTD1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1274-wk-Fact-85C96FDDE2775831935EC174B4BAB3AC" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3QTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1293-wk-Fact-9472515601E8583EB376A8ADDF708C8C" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q3QTD1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1312-wk-Fact-9C881D80109855308725A2DA072883D8" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q3YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">0.80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1332-wk-Fact-68993515AEDD56A8994B919BD2AB4430" name="us-gaap:EarningsPerShareDiluted" contextRef="D2018Q3YTD1" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.05</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Dilutive securities include outstanding stock options, unvested RSUs and ESPP contributions. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="TextSelection-1B397273EFB9527BA2A322652F56D347-0-wk-Fact-D5D15E63D5765B40AA554E76AD56970A" continuedAt="TextSelection-1B397273EFB9527BA2A322652F56D347-1" escape="true">Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="TextSelection-1B397273EFB9527BA2A322652F56D347-1" continuedAt="TextSelection-1B397273EFB9527BA2A322652F56D347-2"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></ix:continuation></div><ix:continuation id="TextSelection-1B397273EFB9527BA2A322652F56D347-2"><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:44%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Potentially dilutive securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1515-wk-Fact-2170CAEE363251A2B5F741D45DEE80CF" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">6,153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1529-wk-Fact-4EA3D9CFA8B053078A00BB3C260EB3F1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="D2018Q3QTD1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1543-wk-Fact-397100959AF6595A89FA5A5A6CC6129D" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143664420e1557-wk-Fact-5FE36E95409E522E8CBCD5D66B6BC2B5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="D2018Q3YTD1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">2,938</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="s253611353D265D1484CC735527BEE3A2"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 10. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:FairValueDisclosuresTextBlock" id="TextSelection-97735B41758A58058A1E5255193A307F-0-wk-Fact-B8D4B1E1C44D549BA8BBE42F5197E471" continuedAt="TextSelection-97735B41758A58058A1E5255193A307F-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="TextSelection-4CA41CEF47535BE6A71C7DB25F503E38-0-wk-Fact-A49D75EC355950A299B77D16687D5726" continuedAt="TextSelection-4CA41CEF47535BE6A71C7DB25F503E38-1" escape="true"><ix:continuation id="TextSelection-97735B41758A58058A1E5255193A307F-1" continuedAt="TextSelection-97735B41758A58058A1E5255193A307F-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e589-wk-Fact-5E944502D05E5B639F826A5D3C6A2185" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e608-wk-Fact-F6D6D631DDBE579D86980F9A455EFFCA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e627-wk-Fact-907E98BB300A5F628BADAE4A09ED77F5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e643-wk-Fact-805B49093CBC503692ED72AA471F0470" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e662-wk-Fact-4CA5942CAE115017B1AC56F3D70C28B6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e681-wk-Fact-2FA5F044FC445065938D03DC98FAA3A8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">332,239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e702-wk-Fact-5C338E39D6125169AF1201A0653A3711" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e721-wk-Fact-9FF81BB40BDE5170ACFB9476F028BCFD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">706,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e740-wk-Fact-1B6EC08818665CBBB98E7121C0EF7CD0" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">706,807</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e761-wk-Fact-8649669847B855BB95A673E148603501" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e780-wk-Fact-CE98B93F9850555BAC72FDA0F1C76411" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e799-wk-Fact-B8A692BA52E05758B864609DD26C0EAB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">152,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e820-wk-Fact-C45F0725EB575FADA2334C69C91A71EE" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e839-wk-Fact-EC0AFEE2201259E984C1498D3BE5D0E3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,191,696</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e858-wk-Fact-7EFE5CC2CACB588E9A2D0D7BDE55B5A1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,218,337</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e879-wk-Fact-DAD9B67489675230BBABE24F17692345" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e898-wk-Fact-A0AA4DD1EF765388B31D4F35976911E4" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e917-wk-Fact-87A82FC157A057C4AF4743C1CE21B732" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">29,192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e943-wk-Fact-7A2FEF06CCDE5483A292A2AD9CA1720C" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e962-wk-Fact-E5C97B29F7ED519CBE92543DEA87514D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,220,888</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e981-wk-Fact-7A1FBEA4679B582CAB8255CE3728890D" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,247,529</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1145-wk-Fact-3954DC7118BE522B9DD6DDDAFB1BD18A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1164-wk-Fact-CCE6079BB812545CB252CD97DD38623A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1183-wk-Fact-124E5DA8D46358E08279D27F09170B16" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1199-wk-Fact-18F9FC603BBD5EEA90F5EB3C6B5B3EDF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1218-wk-Fact-146023E096EA5E399651720A1C17F687" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1237-wk-Fact-00E39D1BB25D56CB92ED15FD33074A9B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">381,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1258-wk-Fact-D83521A0D25050219C5DC15762AB040F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1277-wk-Fact-4959B09F66815E41AAD52F545830698E" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1296-wk-Fact-3F9D16759B3253D8B9B1630170963386" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">344,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1317-wk-Fact-50AD1B97330F51E2BAAEB299C34D8B17" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1336-wk-Fact-ABC67A5FD2D451A1BA692B1D5E4FD46A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1355-wk-Fact-7593CBBD03B35C078B56EBEA4C652EBF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">55,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1376-wk-Fact-4F77915F61055B5A86056ABF2DD97F36" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1395-wk-Fact-664218DA3284530CBB9B8E2785B309E4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">780,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1414-wk-Fact-5CCB09C813745A228066D4B223793599" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">828,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1435-wk-Fact-1E2CBC7FE3E45346A4EB9E3C3E92C6CF" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1454-wk-Fact-E19A6075A4D55C73B66C640970AD65AA" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1473-wk-Fact-E0E3AF894E915D8AA7EED84DFAC6F03D" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">16,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1499-wk-Fact-3F3672B587045025B42FDDFE25FD379A" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">47,744</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1518-wk-Fact-2249445266015242A615BEF15BFD34DA" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">796,994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143665822e1537-wk-Fact-992D38885D8D5148A2F463F4E52781BB" name="us-gaap:AssetsFairValueDisclosure" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">844,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-97735B41758A58058A1E5255193A307F-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-4CA41CEF47535BE6A71C7DB25F503E38-1"></ix:continuation>We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 11. Leases&#8221; for a description of the determination of the amount of operating lease liabilities. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities and Rebates and fees due to customers. Those financial assets and liabilities are carried at cost, which approximates their fair values.</span></div></ix:continuation><div><a id="s7057DD31D8375E918E956B7100A486DD"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 11. <ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LesseeFinanceLeasesTextBlock" id="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-0-wk-Fact-D55B96AF23D15896A7FC2C6955D94ED1" continuedAt="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-1" escape="true"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LesseeOperatingLeasesTextBlock" id="TextSelection-163174E70F8955A499118BE05BA795B4-0-wk-Fact-29B6146B1FF9527386750E5DB0C360D1" continuedAt="TextSelection-163174E70F8955A499118BE05BA795B4-1" escape="true">LEASES</ix:nonNumeric></ix:nonNumeric></span></div><ix:continuation id="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-1" continuedAt="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-2"><ix:continuation id="TextSelection-163174E70F8955A499118BE05BA795B4-1" continuedAt="TextSelection-163174E70F8955A499118BE05BA795B4-2"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143670801e424-wk-Fact-1E9A5513AD445625AB3CB4DF9B760982" name="us-gaap:AreaOfRealEstateProperty" contextRef="FI2019Q3_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">169,606</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet (the Current Premises) as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We have made certain tenant improvements to the space leased on the Initial Premises, for which we received </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143670801e432-wk-Fact-FF3D326C8CFA5927876ACA1327AB6CD9" name="exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" contextRef="I2019Q1_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">8.2</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in reimbursements in January 2019. The Lease&#8217;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143670801e436-wk-Fact-FCE670852B3B372607AFCA97D9302A56" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="renewal_option" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d143670801e440-wk-Fact-991E7FB9B6D779CBDC260FE320954FBC" name="exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod" contextRef="D2017Q2May01-May31_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" format="ixt-sec:duryear">8</ix:nonNumeric></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year of the initial term (the Early Termination Right); none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The April 2019 amendment to the Lease (the Third Lease Amendment) provides, among other things, for the (i) expansion of the Initial Premises by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143670801e453-wk-Fact-F61F288917055701A54B690E6DAA603F" name="exel:OperatingLeaseAdditionalAreaOfRealEstateProperty" contextRef="I2019Q2Apr30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">37,544</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143670801e457-wk-Fact-0D32F2D499295CC3B715C2D1ED7595A7" name="exel:OperatingLeaseSurrenderedAreaOfRealEstateProperty" contextRef="I2019Q2Apr30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">2,703</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143670801e461-wk-Fact-9DC20545C22451A79E3C14ED9B644690" name="exel:TenantLeaseImprovementsAllowance" contextRef="I2019Q2Apr30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">1.7</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for tenant improvements to the 1601 Expansion Space. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have surrendered the 1751 Space and we have taken possession of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for the Third Lease Amendment.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" id="TextSelection-1EAEF0C8ED9B567A81849DC40062A287-0-wk-Fact-E2EB34205879518193DF84F373BE176F" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e586-wk-Fact-58878CD749C55E9FAF6BB8DE5360E150" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,695</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e605-wk-Fact-51A717694F0A5265AFF1A577BAB8A4F8" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e620-wk-Fact-1690CE2B290A5E6AAC589FBB36970521" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">23,661</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e639-wk-Fact-07568CEE8CD8552C827CB11F03AA763F" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">12,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e659-wk-Fact-49E54CFCE6F05ACF9DE33946C151018E" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e678-wk-Fact-193212A5733E5CDC9DBB4B2A24528628" name="us-gaap:OperatingLeaseLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,837</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e739-wk-Fact-8F62FEE0596356A1A0540C3CC361BA4A" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e758-wk-Fact-FAFA0B271B7A53DA99C1B99DF42170C2" name="us-gaap:FinanceLeaseLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e778-wk-Fact-A36D0507F78A57A4A5897D79CD703429" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e797-wk-Fact-3C9E2889C598597887C86F97D814B38D" name="us-gaap:FinanceLeaseLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e817-wk-Fact-F08B55C6593D5E90A2C49C2A13550B1A" name="us-gaap:FinanceLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e836-wk-Fact-4DEC2E9632165F739FA846F5CA79F8C2" name="us-gaap:FinanceLeaseLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e861-wk-Fact-7119BC44EE5150479574F177510CFED0" name="exel:OperatingAndFinanceLeasesLiabilityTotal" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e880-wk-Fact-070A9FB005CD50DB9D803A0938D5824F" name="exel:OperatingAndFinanceLeasesLiabilityTotal" contextRef="FI2018Q4" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">14,965</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">23</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-2" continuedAt="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-3"><ix:continuation id="TextSelection-163174E70F8955A499118BE05BA795B4-2" continuedAt="TextSelection-163174E70F8955A499118BE05BA795B4-3"><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-4260E94805715DE0B9F4D3A21001EE00-0-wk-Fact-F80F2B9C3A8D5BC3A7F18F89D15D611F" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs for operating leases, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1097-wk-Fact-328FC93EC67E5E2DBA8A3F676A2AFC46" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">692</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1116-wk-Fact-B10AADDEBAE85A13A874AEC301304592" name="us-gaap:OperatingLeaseCost" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1135-wk-Fact-0C249F6F98B7562983513ADD589F96B8" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,768</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1155-wk-Fact-0C58184363F252A289F684C21B253115" name="us-gaap:OperatingLeaseCost" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,587</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1170-wk-Fact-8749271C523452F787865EAE2F2D8658" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1189-wk-Fact-137720D0471A54E0B93E0CBDACFCA8B4" name="us-gaap:VariableLeaseCost" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1208-wk-Fact-144B8463FFBE56EBBDB673665C3E2CAF" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1228-wk-Fact-F774A225473354EEA7B338407088C27E" name="us-gaap:VariableLeaseCost" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1253-wk-Fact-BF77F3F4305558AA8B5DAEA04BEB3EA3" name="us-gaap:LeaseCost" contextRef="FD2019Q3QTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1272-wk-Fact-8EE1724AC89555248604A02807F20EDB" name="us-gaap:LeaseCost" contextRef="D2018Q3QTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1291-wk-Fact-D693863BAC5A5E0DB413D47DAF4D9FB8" name="us-gaap:LeaseCost" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">2,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1311-wk-Fact-49E93B6919665C9D9DA8846DDFFD3A50" name="us-gaap:LeaseCost" contextRef="D2018Q3YTD1" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">4,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143670801e1332-wk-Fact-E7C4122A516658E79E628348C5C8D785" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q3YTD" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">2.1</ix:nonFraction> million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.</span></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-29F67A61DE815D16BBFBADFC5D20D8A1-0-wk-Fact-7E52B614E63555CCA41AEA92E5A53CA8" continuedAt="TextSelection-29F67A61DE815D16BBFBADFC5D20D8A1-1" escape="true"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1371-wk-Fact-A51E7FB0C028530498F8851E54EFB6F4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">745</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1407-wk-Fact-8BE4A1D8031454A2B9C3D5097D2FE1D6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1427-wk-Fact-B5640C40C0775411927288034EDEC2D4" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,731</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1447-wk-Fact-EB3E61D712CB5DF391EFAED36CF9D458" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1467-wk-Fact-63A6FEF6685C5F7BAB719EE740D990E6" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">3,959</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1487-wk-Fact-25419927EF765F09B6C366224B46A0C1" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">17,444</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1507-wk-Fact-571DB291A3C85BBEB86F4CCB5CB7747A" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">33,356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143670801e1548-wk-Fact-2D93B9F978DE5A529D82CA25536CB83B" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">5,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(<ix:nonFraction id="d143670801e1571-wk-Fact-CF3FC5A4D6A35F1DB0F06AF54BDAF52D" name="exel:TenantLeaseImprovementsAllowance" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">1,742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span><ix:nonFraction id="d143670801e1598-wk-Fact-49E54CFCE6F05ACF9DE33946C151018E" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q3" unitRef="usd" decimals="-3" scale="3" format="ixt:numdotdecimal">26,356</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-29F67A61DE815D16BBFBADFC5D20D8A1-1" continuedAt="TextSelection-29F67A61DE815D16BBFBADFC5D20D8A1-2"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-29F67A61DE815D16BBFBADFC5D20D8A1-2"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space.</span></div></ix:continuation></td></tr></table></ix:continuation></ix:continuation><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><ix:continuation id="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-3" continuedAt="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-4"><ix:continuation id="TextSelection-163174E70F8955A499118BE05BA795B4-3" continuedAt="TextSelection-163174E70F8955A499118BE05BA795B4-4"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143670801e1622-wk-Fact-0F2A1E3A20BE5D09B0575E4235D32049" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q3" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">4.20</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average remaining lease term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d143670801e1630-wk-Fact-BDC0E8A196AE53C0874F75B8EEEC3946" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q3" format="ixt-sec:duryear">8.3</ix:nonNumeric> years</span></span></ix:continuation></ix:continuation><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><ix:continuation id="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-4"><ix:continuation id="TextSelection-163174E70F8955A499118BE05BA795B4-4">.</ix:continuation></ix:continuation> </span></div><div><a id="s9fd30a42f54b42ebbf1abd2c806d78cf"></a></div><ix:nonNumeric contextRef="FD2019Q3YTD" name="us-gaap:SubsequentEventsTextBlock" id="TextSelection-79571114B1D9385A2EB00F81A189ABB6-0-wk-Fact-891A664A1F067727FC240F83F72DADB8" continuedAt="TextSelection-79571114B1D9385A2EB00F81A189ABB6-1" escape="true"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12. SUBSEQUENT EVENTS</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Build to Suit Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On </span><span style="color:#000000;font-family:Calibri,sans-serif;font-size:10pt;">October 25, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) with Ernst Development Partners, Inc. (Ernst), for approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143675358e428-wk-Fact-6834FC4F972510C083EE012249CF8C03" name="us-gaap:AreaOfRealEstateProperty" contextRef="I2019Q4Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="sqft" decimals="-3" scale="0" format="ixt:numdotdecimal">220,000</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises. The term of the Build-to-Suit Lease is for a period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d143675358e432-wk-Fact-71AB05984899C41494810137DB2FA292" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="I2019Q4Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" format="ixt-sec:durmonth">242</ix:nonNumeric></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> months (the Term), which will begin on the completion of the building and tenant improvements by Ernst. The Term is currently anticipated to begin on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">October 25, 2021</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The monthly base rent under the Build-to-Suit Lease will equal to a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by Ernst and any development costs we pay) and is currently estimated to be about </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$<ix:nonFraction id="d143675358e440-wk-Fact-BC101FFF2C8C22E9261A016537B255D9" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" contextRef="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="usd" decimals="-3" scale="0" format="ixt:numdotdecimal">726,000</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, subject to an annual increase of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143675358e445-wk-Fact-29B7486EF6CCF3082F7B03BF51293920" name="exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" contextRef="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the Term. The monthly base rent will begin sixty days following commencement of the Term. We will also be responsible for paying operating expenses related to the New Premises. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Build-to-Suit Lease includes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143675358e452-wk-Fact-F7F5A65F69878B2F87250124CCE236FF" name="exel:LesseeOperatingLeaseNumberOfRenewalOptions" contextRef="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="renewal_option" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonNumeric id="d143675358e456-wk-Fact-E203FBD076C46F4328020FD4B1E1CAD3" name="exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod" contextRef="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" format="ixt-sec:durmonth">180</ix:nonNumeric></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. </span></div></ix:nonNumeric><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">24</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><ix:continuation id="TextSelection-79571114B1D9385A2EB00F81A189ABB6-1"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See Part II, Item 5 of this Quarterly Report on Form 10-Q for more information about the Build to Suit Lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fourth Amendment to the Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the fourth quarter of 2019, Hillwood Enterprises, L.P. (Hillwood) is expected to purchase the project known as 1750 North Loop Road and 1601, 1701, 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California from Ascentris 105, LLC (the Purchase), which project includes the Current Premises. Effective upon the Purchase, Hillwood will become the landlord pursuant to the Lease.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On August 30, 2019, we entered into an amendment to the Lease with Hillwood (the Fourth Lease Amendment), pursuant to which each of our rights and obligations are contingent upon the Purchase. Effective upon the Purchase, the Fourth Lease Amendment will provide for, among other things, the (i) expansion of the Current Premises by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span><ix:nonFraction id="d143675358e474-wk-Fact-D128E4A7BC7FF63E1CC5F05F04E8A666" name="exel:OperatingLeaseAdditionalAreaOfRealEstateProperty" contextRef="I2019Q3Aug30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember" unitRef="sqft" decimals="0" scale="0" format="ixt:numdotdecimal">59,335</ix:nonFraction></span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of laboratory facilities located at 1701 Harbor Bay Parkway, Alameda, California, (ii) extension of the Lease term through October 31, 2031 and (iii) elimination of the Early Termination Right. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of September 30, 2019, we have not yet recorded a right-of-use asset or lease liability for the Fourth Lease Amendment, and the remainder of the disclosures in this note do not reflect the impact of this amendment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See Part II, Item 5 of this Quarterly Report on Form 10-Q for more information about the Fourth Lease Amendment.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">25</span></div></div><hr style="page-break-after:always"></hr><div><a id="s5892EFCBE0B451CD8E8D1AE7930ED818"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> filed with the Securities and Exchange Commission (SEC) on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">February&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Overview</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and have launched commercially. Two are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat a specific form of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX was first approved by the U.S. Food and Drug Administration (FDA) for previously treated patients with advanced RCC in April 2016, and then in December 2017, the FDA expanded CABOMETYX&#8217;s approval to include previously untreated patients with advanced RCC. Additionally, in January 2019, the FDA approved CABOMETYX as a treatment for patients with HCC who have been previously treated with sorafenib. This approval was based on results from CELESTIAL, our phase 3 pivotal trial evaluating cabozantinib in patients with previously treated HCC, which demonstrated a statistically significant and clinically meaningful improvement in overall survival versus placebo.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Ltd. (Takeda). Ipsen has been granted rights to cabozantinib outside of the U.S. and Japan, and Takeda has been granted rights to cabozantinib in Japan. Both partners also contribute financially and operationally to the further global development and commercialization of cabozantinib in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the United States, including in the European Union (EU), as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib, and in Canada where CABOMETYX has recently been approved for previously untreated advanced RCC in addition to the earlier approval for advanced RCC who have received prior VEGF-targeting therapy. Takeda has also made significant progress on bridging studies in both RCC and HCC and achieved an important regulatory milestone in April 2019 with its application to the Japanese Ministry of Health, Labour and Welfare (MHLW) for approval to manufacture and sell CABOMETYX as a treatment for unresectable and metastatic RCC in Japan</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our partners for rest of world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could benefit from this medicine.&#160;We are evaluating cabozantinib, both as a single agent and in combination with other therapies, in a broad development program comprising&#160;over </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">80</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ongoing or planned clinical trials across multiple indications. We, along with our clinical and commercial </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator sponsored trial program. Informed by the available data from these clinical trials, we continue to advance cabozantinib&#8217;s late-stage development program. One pivotal trial that has resulted from this effort is COSMIC-311, our ongoing phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with radioactive iodine-refractory differentiated thyroid cancer who have progressed after up to two VEGF receptor-targeted therapies. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are particularly interested in examining cabozantinib&#8217;s potential in combination with immune checkpoint inhibitors (ICIs) to determine if such combinations further improve outcomes for patients. Building on preclinical and clinical observations that cabozantinib may promote a more immune-permissive tumor environment potentially resulting in cooperative activity of cabozantinib in combination with these products, we are evaluating cabozantinib in combination with a variety of ICIs. The most advanced of these combination studies include CheckMate 9ER, a phase 3 pivotal trial evaluating cabozantinib in combination with nivolumab in previously untreated advanced or metastatic RCC, for which our collaboration partner Bristol-Myers Squibb Company (BMS) has announced top line results are expected in early 2020, and CheckMate 040, a phase 1/2 trial evaluating cabozantinib in combination with nivolumab and in combination with both nivolumab and ipilimumab in patients with previously treated or previously untreated advanced HCC, also in collaboration with BMS. Additionally in May 2019, as part of our clinical collaboration with BMS, we initiated COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC, and plan to further evaluate the combination of cabozantinib and nivolumab, with or without ipilimumab, in various other tumor types. In an effort to diversify our exploration of combinations with ICIs, we also initiated COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with the Roche Group&#8217;s (Roche&#8217;s) ICI, atezolizumab, versus sorafenib in previously untreated advanced HCC, and COSMIC-021, a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors. COSMIC-021 is divided into two parts: a dose-escalation phase, which was completed in 2018; and an expansion phase, which is ongoing. Findings from the dose-escalation stage of COSMIC-021 demonstrated that the combination was well-tolerated and showed encouraging anti-tumor activity in patients with advanced RCC. The expansion phase of COSMIC-021 comprises 24 total cohorts, with 20 cohorts evaluating the combination of cabozantinib and atezolizumab and four cohorts evaluating cabozantinib or atezolizumab as single-agent therapies. Based on initial encouraging results from the ongoing expansion cohorts in patients with castration-resistant prostate cancer (CRPC) and in ICI-pretreated non-small cell lung cancer (NSCLC), in July 2019, we expanded the original 30-patient cohorts for each of these disease states to allow enrollment of an additional 50 patients for a total of 80 patients each. Additionally, four new cohorts, consisting of two expansion and two exploratory cohorts, were added to COSMIC-021 in July 2019: two new expansion cohorts evaluating the combination of cabozantinib and atezolizumab in patients with metastatic CRPC who have received prior enzalutamide or abiraterone therapy, with or without prior docetaxel therapy; and two new exploratory cohorts evaluating single-agent cabozantinib and single-agent atezolizumab in patients with metastatic CRPC, with the purpose of determining the individual contribution of each therapy. Depending on the results from COSMIC-021, we may evaluate the combination of cabozantinib and atezolizumab in various late-stage clinical trials, including in NSCLC and CRPC.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As we continue to work to maximize the clinical and commercial potential of cabozantinib, we also remain committed to building our product pipeline by discovering and developing new cancer therapies for patients. In this regard, we reinitiated internal drug discovery efforts in 2017 with the goal of identifying new product candidates to advance into clinical trials. Notably, these efforts are led by some of the same experienced scientists responsible for the discovery of cabozantinib, cobimetinib and esaxerenone, which have been approved for commercialization by regulatory authorities. Using our expertise in medicinal chemistry, tumor biology and pharmacology, we are advancing drug candidates toward and through preclinical development. Furthest along in these internal drug discovery efforts is XL092, a next-generation oral tyrosine kinase inhibitor that is currently in a phase 1 clinical trial in patients with advanced solid malignancies.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We augment these internal drug discovery activities with business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure. In furtherance of this strategy, we have entered into multiple collaboration and license agreements, including with:&#160;StemSynergy Therapeutics, Inc., which is focused on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the discovery and development of novel oncology compounds aimed to inhibit tumor growth by targeting Casein Kinase 1&#945;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; Invenra, Inc. (Invenra), which is focused on the discovery and development of multispecific antibodies for the treatment of cancer; Iconic Therapeutics, Inc. (Iconic), which is focused on the advancement of a next-generation antibody-drug conjugate program targeting tissue factor in solid tumors; and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Aurigene Discovery Technologies Limited (Aurigene), which is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the discovery and development of novel small molecules as therapies for cancer</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. To further enhance our early-stage pipeline, we expect to enter into </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">27</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">additional, external collaborative relationships around assets and technologies that complement our internal drug discovery and development efforts.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Third Quarter 2019 Business Updates and Financial Highlights</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During the third quarter of 2019, we continued to execute on our business objectives, generating significant revenue from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Business Updates</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we announced an amendment to the protocol for COSMIC-021, the phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic solid tumors, to expand patient enrollment in certain existing CRPC and NSCLC cohorts and to add new expansion and exploratory cohorts in CRPC (</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">an aggregate of 24 total cohorts, with 20 expansion cohorts evaluating the combination of cabozantinib and atezolizumab </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and four exploratory cohorts </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">evaluating cabozantinib or atezolizumab as single-agent therapies</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we announced an exclusive collaboration, option and license agreement with Aurigene, and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> India-based biotechnology company </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">focused on oncology</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and inflammatory disorders</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, to in-license as many as six programs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, Ipsen received regulatory approval from Health Canada for CABOMETYX for the first-line treatment of adults with advanced RCC.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, we expanded our collaboration with Invenra focused on the discovery and development of multispecific antibodies for the treatment of cancer to include the development of novel binders against six additional targets which we can use to generate multispecific antibodies based on Invenra&#8217;s B-Body&#8482; technology platform, or with other platforms and formats at our option.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, we filed a patent infringement lawsuit against MSN Pharmaceuticals, Inc. (MSN), following receipt of a Paragraph IV certification notice letter from MSN that it had filed an Abbreviated New Drug Application (ANDA) with the FDA requesting approval to market a generic version of CABOMETYX tablets, following expiration of the CABOMETYX composition of matter patent, U.S. Patent No. 7,579,473, which expires on August 14, 2026. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of U.S. Patent No. 8,877,776 on October 8, 2030 and equitable relief enjoining MSN from infringing this patent. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Financial Highlights</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues for the third quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$191.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$162.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the third quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues for the third quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$271.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$225.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the third quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses for the third quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$97.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$44.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the third quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses for the third quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$51.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$48.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the third quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provision for income taxes for the third quarter of 2019 increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$25.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$2.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the third quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net income for the third quarter of 2019 was </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$97.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.32</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, basic and </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, diluted, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$126.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.42</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share, basic and </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$0.41</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per share diluted, for the third quarter of 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments increased to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$1.2 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">$851.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> at </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#8220;Results of Operations&#8221;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">28</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Challenges and Risks</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We will continue to face challenges and risks that may impact our ability to execute on our remaining 2019 business objectives. In particular, for the foreseeable future, we expect our ability to maintain or increase unrestricted cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX as a treatment for advanced RCC and previously treated HCC, and potentially for other indications for which cabozantinib is in late-stage clinical trials, if warranted by the data generated from such trials. The commercial success of CABOMETYX in its approved indications is subject to a variety of factors, most importantly, the drug&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other competitive treatments available or in development for these conditions. CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at limiting access to, and restricting the prices of, pharmaceuticals. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Achievement of our remaining 2019 business objectives and the continued success of CABOMETYX will also depend on the success of our development and commercialization strategies to navigate increased competition, including that from, but not limited to, ICIs, as well as the use of combination therapy to treat cancer. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic version of CABOMETYX tablets that is the subject of the ANDA submitted to the FDA by MSN, which if approved following the expiration of our composition of matter patent in 2026, could result in significant decreases in the revenue derived from sales of CABOMETYX and thereby materially harm our business and financial condition. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with internal drug discovery operations. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Some of these challenges and risks are specific to our business, and others are common to companies in the pharmaceutical industry with development and commercial operations. For a more detailed discussion of challenges and risks we face, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fiscal Year Convention</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended September 27, 2019 and September 28, 2018, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018, are indicated as being as of and for the periods ended September 30, 2019 and September 30, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018, respectively. </span></div><div><a id="sD05899692A3E512C84DE42450FB380BA"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Results of Operations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by category were as follows (dollars in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q3 2019 v. Q3 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">191,768</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">162,946</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">18</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">565,024</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">443,054</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">79,935</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">62,451</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">162,441</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">182,170</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(11</span></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">271,703</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">225,397</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">21</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">727,465</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">625,224</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">16</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">29</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Net Product Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gross product revenues, Discounts and allowances, and Net product revenues were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q3 2019 v. Q3 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">239,916</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">193,356</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">24</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">704,084</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">525,438</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">34</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(48,148</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(30,410</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">58</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(139,060</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(82,384</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">69</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">191,768</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">162,946</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">565,024</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">443,054</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q3 2019 v. Q3 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">187,410</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">158,262</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">552,315</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">428,317</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">29</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,358</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,684</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,709</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">14,737</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(14</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">191,768</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">162,946</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">18</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">565,024</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">443,054</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in product revenues for CABOMETYX for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily due to a 12% and 21% increase, respectively, in the number of units of CABOMETYX sold </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increases in the average selling price of the product. The increases in CABOMETYX sales volumes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">reflects the continued growth of CABOMETYX in advanced RCC </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">following FDA approvals in April 2016 of CABOMETYX for the treatment of patients with advanced RCC who have received prior anti-angiogenic therapy and in December 2017 for previously untreated patients with advanced RCC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as well as the U.S. launch of CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib, following FDA approval in January 2019. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The decreases in product revenues for COMETRIQ for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily due to a 8% and 18% decline, respectively, the number of units of COMETRIQ sold. COMETRIQ sales volumes have continued to decrease since the launch of CABOMETYX in April 2016.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increases in discounts and allowances for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily the result of the overall increases in product sales volume and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increases in Public Health Service hospital utilization and the dollar amount of the related chargebacks</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and, to a lesser extent, increases to the dollar amount of chargebacks associated with Veterans Affairs hospitals, as well as increases to other government and commercial rebates.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> We expect our discounts and allowances as a percentage of gross product revenues to increase during the remainder of 2019 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as compared to 2018 as the number of patients participating in government programs increases, and as the discounts and rebates paid to government payers increase</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Collaboration Revenues</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q3 2019 v. Q3 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">68,035</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">51,323</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">33</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">128,937</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">152,261</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(15</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,988</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,560</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">23</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">35,814</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">27,464</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">30</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(1,088</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">568</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(2,310</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2,445</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">79,935</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">62,451</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">28</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">162,441</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">182,170</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(11</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen, Genentech and Daiichi Sankyo. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda, which were offset by the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues were $50.6 million and $81.1 million, respectively, for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to $42.6 million and $134.8 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Milestone revenues by period included the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included recognition of a $50.0 million commercial milestone from Ipsen that we earned </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">in the third quarter of 2019 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">upon Ipsen&#8217;s achievement of $250.0 million in net sales of cabozantinib in its territories over four consecutive quarters. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> also included recognition of a $20.0 million milestone from Daiichi Sankyo for the launch of MINNEBRO tablets as a treatment for patients with hypertension in Japan and $9.7 million in revenues recognized in connection with a $16.0 million milestone from Takeda for the submission in April 2019 of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese MHLW. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> included $36.9 million in revenue related to a $40.0 million milestone from Ipsen for the approval by the European Commission (EC) of cabozantinib for previously-treated HCC and $5.0 million in revenue for a milestone from Ipsen on the approval by Health Canada of cabozantinib for the treatment of adults with advanced RCC. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Milestone revenues for the </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri;font-size:10pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> also included: i) recognition of $46.2 million in revenue of a $50.0 million milestone from Ipsen for the approval of cabozantinib for the first-line treatment of adults with intermediate- or poor-risk advanced RCC by the EC, of which $0.2 million was recognized in the third quarter of 2018; ii) recognition of a $25.0 million commercial milestone from Ipsen that we earned in the second quarter of 2018 upon Ipsen&#8217;s achievement of $100.0 million in net sales </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of cabozantinib in its territories </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">over four consecutive quarters; and iii) recognition of a $20.0 million milestone upon Daiichi Sankyo&#8217;s submission to the Japanese MHLW of a regulatory application for esaxerenone as a treatment for patients with hypertension. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and such milestones can vary significantly from period to period.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">R</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">oyalties on net sales of cabozantinib by Ipsen outside of the U.S. and Japan were $16.4 million and $45.3 million </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $10.3 million and $20.0 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increased demand of CABOMETYX</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which, as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, is approved and commercially available in 48 and 33 countries </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">outside of the U.S.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We were entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">12%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on the initial $</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">150.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of net sales; this amount was reached in the second quarter of 2018. As of June 30, 2018 and going forward, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales (with separate tiers for Canada); these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers reset each calendar year. In Canada, we are entitled to receive a tiered royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the first CAD$30.0 million of annual net sales and a tiered royalty thereafter </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">to</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> on annual net sales; these </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">22%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">26%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty tiers for Canada will also reset each calendar year. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">we also began to earn low double-digit royalties on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sale of MINNEBRO by Daiichi Sankyo in Japan.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Development cost reimbursements in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">connection with our collaboration arrangements with Ipsen and Takeda were $12.0 million and $32.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $6.9 million and $17.7 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The increases were primarily the result of reimbursements from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Ipsen and Takeda for their share of the increase in spending on the CheckMate 9ER</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> study.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Profits on the U.S. commercialization of COTELLIC and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">r</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">oyalties on ex-U.S. net sales of COTELLIC under our collaboration agreement with Genentech were $2.7</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> million and $7.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to $3.3 million and $10.3 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Sales of COTELLIC in the U.S. have declined following </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Genentech&#8217;s decision to scale back the personal promotion of COTELLIC commencing in January 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">collaboration revenues were reduced by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$8.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$23.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty we are required to pay GSK</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on the net sales by Ipsen of any product incorporating cabozantinib, as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">compared to $6.3 million and $17.0 million for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As royalty generating sales of cabozantinib by Ipsen have increased as described above, our royalty payments to GSK have also increased. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of 0.5% to Ligand on net sales of MINNEBRO. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Cost of Goods Sold</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q3 2019 v. Q3 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cost of goods sold</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,537</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,360</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">22,577</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">18,996</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">19</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross margin</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">95</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">96</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cost of goods sold is related to our product revenues and consists primarily of a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty payable to GSK on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring and excess inventory, and other third-party logistics costs. The increases in Cost of goods sold for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily the result of the increases in product sales volume described above. We do not expect our gross margin to change significantly during the remainder of 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Research and Development Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q3 2019 v. Q3 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">97,295</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">44,741</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">117</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">242,516</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">124,986</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">94</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Research and development expenses consist primarily of clinical trial costs, personnel expenses, license </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and other collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs, consulting and outside services, stock-based compensation and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the allocation of general corporate costs</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Research and development expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to increases in clinical trial costs, license </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and other collaboration </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs, personnel expenses, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the allocation of general corporate costs and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">stock-based compensation</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Clinical trial costs, which includes services performed by third-party contract research organizations and other vendors who support our clinical trials, and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">comparator drug purchases</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$54.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in clinical trial costs were primarily due to costs associated with the expanding clinical trial program for cabozantinib that now includes four phase 3 pivotal studies (CheckMate 9ER, COSMIC-311, COSMIC-312 and COSMIC-313), as well as the multi-cohort phase 1b study (COSMIC-021). License and other collaboration costs </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$20.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$30.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily as a result of the collaboration agreements we entered into with&#160;Aurigene in July 2019 and Iconic in May 2019. Personnel expenses increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the allocation of general corporate costs increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.5 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">support our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">expanded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery and development efforts</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Stock-based compensation increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$4.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to the increases in headcount, as well as the expense recognition for restricted stock units that were granted in September 2018 that either have vested or will vest upon the achievement of specific performance targets (the 2018 PSUs).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not track fully-burdened Research and development expenses on a project-by-project basis.&#160;We group our Research and development expenses into three categories: Development, Drug discovery and Other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development. Research and development expenses by category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development expenses:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Development:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Clinical trial costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">38,055</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">17,242</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">94,612</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">40,482</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Personnel expenses</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">14,964</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">12,316</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">44,077</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">34,182</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Consulting and outside services</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,084</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">1,943</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,884</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,969</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other development costs</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,754</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2,925</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11,824</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,257</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total development</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">60,857</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">34,426</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">161,397</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">91,890</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Drug discovery:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License and other collaboration costs</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">20,910</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">367</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">38,390</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,708</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other drug discovery</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,896</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,706</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">17,870</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">9,646</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total drug discovery</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">27,806</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">4,073</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">56,260</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">17,354</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,632</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">6,242</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">24,859</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">15,742</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total research and development expenses</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">97,295</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">44,741</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">242,516</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">124,986</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Includes stock-based compensation and the allocation of general corporate costs to research and development.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition to reviewing the three categories of Research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. Such factors include enrollment in clinical trials for our drug candidates, preliminary data from and final results of clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are focusing our development efforts primarily on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we expect our near-term research and development expenses to primarily </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">33</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">relate to the clinical development of cabozantinib. We expect to continue to incur significant development costs for cabozantinib in future periods as we evaluate its potential in a broad development program comprising over </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">80</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ongoing or planned clinical trials across multiple indications. Notable studies of this program include: CheckMate 9ER and CheckMate&#160;040, each in collaboration with BMS; company-sponsored COSMIC-021 and COSMIC-312, for which Roche is providing atezolizumab free of charge; company-sponsored COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge; and company-sponsored COSMIC-311. In addition, post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC dictate that we conduct an additional study in that indication.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are also committed to building our product pipeline by discovering and developing new cancer therapies for patients. In this regard, we are conducting internal drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. We augment these internal drug discovery activities with business development initiatives aimed at identifying and in-licensing promising, early-stage oncology assets and then further develop them utilizing our established clinical development infrastructure.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our Research and development expenses to continue to increase as we expand the cabozantinib development program and our product pipeline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The length of time required for clinical development of a particular product candidate and our&#160;development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate&#160;for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet&#160;know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of or complete costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In any event, our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities, including completing the development of our product candidates, and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Selling, General and Administrative Expenses</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses were as follows (dollars in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q3 2019 v. Q3 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">51,265</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">48,120</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">170,218</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">153,989</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">11</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Selling, general and administrative expenses consist primarily of personnel expenses, consulting and outside services, stock-based compensation and marketing costs. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Selling, general and administrative expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were primarily related to increases in stock-based compensation, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">34</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">personnel expenses and consulting and outside services, and were partially offset by a decrease in corporate giving. Stock-based compensation increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in administrative headcount to support the company&#8217;s commercial and research and development organizations as well as the expense recognition for the 2018 PSUs. Personnel expenses increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$2.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$7.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to increases in headcount. Consulting and outside services increased </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$0.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, primarily due to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">increases in marketing activities in support of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the CABOMETYX </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">launch in HCC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and continued support of the product in an increasingly competitive RCC market</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Corporate giving, consisting predominantly of donations to independent patient support foundations, decreased $2.1 million and $6.9 million for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect our Selling, general and administrative expenses to increase modestly to support our overall organizational growth.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Other Income (Expense), Net</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other income (expense), net, was as follows (dollars in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q3 2019 v. Q3 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Interest income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,191</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,507</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">105</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">20,253</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,099</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">150</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other, net</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(140</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">271</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">n/m</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">688</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">368</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">87</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total other income (expense), net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">7,051</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3,778</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">87</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">20,941</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8,467</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">147</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The increases in Interest income for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, were the result of both an increase in our investment balances and an increase in the yield earned on those investments.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Provision for Income Taxes</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes was as follows (dollars in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="22"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percentage Change - <br/>Q3 2019 v. Q3 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;Percentage Change - Year to Date 2019 v. 2018</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision for income taxes</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">25,205</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2,324</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">985</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">60,826</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5,739</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">960</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our effective income tax rates were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">20.5%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">19.4%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1.8%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">1.7%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> relating to our pre-tax income </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was largely offset by a valuation allowance against our net operating loss carryforwards and other deferred tax assets. At December 31, 2018, we released substantially all of the remaining valuation allowance against our deferred tax assets, after we determined that it was more likely than not that these deferred tax assets would be realized.</span></div><div><a id="s08A8080BA7225FBAA946CFD5BBB41930"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Liquidity and Capital Resources</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1.2 billion</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in cash and investments. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report. The sufficiency of our cash resources depends on numerous assumptions, including assumptions related to product sales and operating expenses, as well as the other factors set forth in &#8220;Risk Factors&#8221; under the headings &#8220;Risks Related to our Capital Requirements, Accounting and Financial Results,&#8221; in Part&#160;II, Item&#160;1A of this Quarterly Report on Form&#160;10-Q.&#160;Our </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">35</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">assumptions may prove to be wrong or other factors may adversely affect our sources of cash and, as a result, we may not have the cash resources to fund our operations as currently planned, which would have a material adverse effect on our business. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We expect to continue to spend significant amounts to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of strategic transactions that align with our oncology drug expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Furthermore, even if we believe we have sufficient funds for our current and future operating plans</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Sources and Uses of Cash</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The following table summarizes our cash flow activities (in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">368,935</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">311,129</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash used in investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(457,046</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">(155,051</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net cash provided by financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">15,553</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10,835</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Operating Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our operating activities provided cash of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$368.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$311.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of for the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as deferred income taxes, share-based compensation charges, depreciation and amortization, and 401(k) matching contributions made in common stock; and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The most significant factors that contributed to the increase in cash provided by operating activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, was $96.0 million in milestone payments received from Ipsen, Takeda and Daiichi Sankyo, including $60.0 million in payments for milestones that had previously been recognized and were included in Trade receivables, net as of December 31, 2018, and an increase in cash received on sales of our products. Those increases were partially offset by an increase in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">cash paid for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">operating expenses for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Investing Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our investing activities used cash of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$457.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$155.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in investing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily due to investment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$887.7 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and Property and equipment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$5.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash provided by the maturity and sale of investments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$422.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$13.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash used in investing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was primarily due to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">investment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$368.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and Property and equipment purchases of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$30.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, less cash provided by the maturity and sale of investments of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$231.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$11.9 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:96px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:normal;text-decoration:none;">Financing Activities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$15.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$10.8 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the comparable period in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">36</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily a result of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$19.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in proceeds from the issuance of common stock under our equity incentive plans, partially offset by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of taxes paid related to net share settlements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash provided by financing activities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was primarily a result of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$14.0 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in proceeds from the issuance of common stock under our equity incentive plans, partially offset by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$3.2 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of taxes paid related to net share settlements.</span></div><div><a id="sF8E64EC5D10F518CB18E872C4D3675EB"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual Obligations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Except as follows, there were no material changes outside of the ordinary course of business in our contractual obligations as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> from those as of December 31, 2018.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In April 2019, we entered into an amendment to the existing Lease Agreement</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> dated May 2, 2017, as amended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(the Lease) relating to our corporate headquarters located in Alameda, California, and in August 2019 we entered into an agreement that will further amend the Lease upon consummation of a third-party transaction. See &#8220;Note 11. Leases&#8221; in our &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q for more information about these amendments to the Lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div><a id="sBB6C20A59CE85088BAEE76EB72BE8B3C"></a></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Critical Accounting Estimates </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock option valuation and income taxes reflect the more significant estimates and assumptions used in the preparation of our Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There have been no significant changes in our critical accounting policies and estimates during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">37</span></div></div><hr style="page-break-after:always"></hr><div><a id="s093265DF965755CE8A36764F34BC6D4E"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our market risks at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> have not changed significantly from those described in Item&#160;7A of our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div><a id="s07603B58A06A5C89B73532DD521F5BA6"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Controls and Procedures.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Evaluation of disclosure controls and procedures.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Limitations on the effectiveness of controls.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Changes in internal control over financial reporting. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">38</span></div></div><hr style="page-break-after:always"></hr><div><a id="sF64E98704A2759F59FC63940E2A6B4C5"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">PART II. OTHER INFORMATION</span></div><div><a id="sE468DF99D2735E7290E8EA12FD8D1D0A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1. Legal Proceedings</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets.&#160;The notice letter included a Paragraph IV certification with respect to our&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;listed in the FDA publication&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">also referred to as the&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">MSN&#8217;s notice&#160;letter does not&#160;provide a Paragraph IV certification&#160;against the CABOMETYX composition of matter patent, U.S. Patent No. 7,579,473, which expires on August 14, 2026, and therefore this patent is not presently at issue. On </span><span style="color:#000000;font-family:Calibri,sans-serif;font-size:10pt;">October 29, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we filed a complaint for patent infringement against MSN asserting U.S. Patent No. 8,877,776 in the United States District Court for the District of Delaware (the Delaware District Federal Court) arising from MSN&#8217;s ANDA filing with the FDA. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Based on the information we have received to date, our complaint does not allege infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of U.S. Patent No. 8,877,776 on October 8, 2030 and equitable relief enjoining MSN from infringing this patent.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160; </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div><a id="s65E5951E9AAE54EDA46618F1C82D3D11"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 1A. Risk Factors</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">In addition to the factors discussed elsewhere in this report and our other reports filed with the SEC, the following are important factors that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business could be harmed.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Business and Industry</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of cabozantinib in additional indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our mission is to maximize the clinical and commercial potential of cabozantinib, and to position us for future growth through our discovery efforts and expansion of our development pipeline. We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase unrestricted cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX as a treatment for advanced RCC and previously treated HCC, and potentially for other indications for which cabozantinib is in late-stage clinical trials, if warranted by the data generated from such trials. The commercial success of CABOMETYX in its approved indications is subject to a variety of factors, most importantly, the drug&#8217;s perceived benefit/risk profile as compared to the benefit/risk profiles of other treatments available or in development for these conditions.&#160;If revenue from CABOMETYX decreases or remains flat, or if we fail to achieve anticipated product royalties and collaboration milestones, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations. Furthermore, as a consequence of our collaboration agreements with Ipsen and Takeda, we rely heavily upon their regulatory, commercial, medical affairs, market access and other expertise and resources for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaborators dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaborators depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, foreign sales of CABOMETYX by our collaborators could be adversely affected by the imposition of governmental controls, political and economic instability, trade restrictions or barriers and changes in tariffs, including as a result of the pending withdrawal of the United Kingdom (UK) from the EU (commonly referred to as &#8220;Brexit&#8221;) and the uncertainty surrounding the date and the terms of the withdrawal, escalating global trade and political tensions, or otherwise. If our collaborators are unable to, or do not invest the resources necessary to successfully commercialize CABOMETYX in the EU </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">39</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX has been approved for the treatment of advanced RCC and previously treated HCC in the U.S., the EU and other territories. With these approvals, our ability to grow our company remains contingent upon, among other things, further success in the clinical development, regulatory approval and market acceptance of cabozantinib, the active pharmaceutical ingredient in CABOMETYX, in potential additional indications. We cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval. Even if we and our partners receive the required regulatory approvals to market cabozantinib for any additional indications or in additional territories, we and our partners may not be able to effectively commercialize CABOMETYX in these additional indications or territories. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to grow revenues from sales of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, health care payers, and the medical community.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to increase revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government health care payers such as Medicare and Medicaid, commercial health care plans and the medical community. If CABOMETYX does not continue to be prescribed broadly for the treatment of its approved RCC and HCC indications, we may not be able to grow product revenues. The degree of market acceptance of CABOMETYX will depend upon a number of factors, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the effectiveness, or perceived effectiveness, of CABOMETYX in comparison to competing products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the safety of CABOMETYX, including the existence of serious side effects of CABOMETYX and their severity in comparison to those of competing products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">CABOMETYX&#8217;s relative convenience and ease of administration;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">potential unexpected results connected with analysis of data from future or ongoing clinical trials of cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of CABOMETYX label expansions for additional indications, if any, relative to competitive treatments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the price of CABOMETYX relative to competitive therapies;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">price increases taken by us and the impact on the net sales price of CABOMETYX as a result of any new laws, regulations or other government initiatives affecting pharmaceutical pricing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the strength of CABOMETYX sales efforts, marketing, market access and product distribution support;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to obtain and maintain coverage and reimbursement for CABOMETYX from commercial and government payers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to enforce our intellectual property rights with respect to CABOMETYX</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including against potential generic competition</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Further, in the event that any of these or other factors cause market acceptance of CABOMETYX to decrease, this could negatively impact our revenues, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our competitors may develop products and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The pharmaceutical, biopharmaceutical and biotechnology industries are competitive, highly diversified and are characterized by rapid technological change, particularly in the area of novel oncology therapies. Many of the organizations competing with us have greater capital resources, larger research and development staff and facilities, more experience in obtaining regulatory approvals and more extensive product manufacturing and commercial capabilities than we do, which may allow them to have a competitive advantage. Further, our competitors may be more effective at using their technologies to develop commercial products. As a result, our competitors may be able to more easily develop products that would render our products, and those of our collaborators, obsolete and noncompetitive. There may also be drug candidates that we are not aware of at an earlier stage of development that may compete with our marketed products and product candidates. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">40</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">agencies that are pursuing research activities similar to ours. Delays in the development of cabozantinib for the treatment of additional tumor types, for example, could allow our competitors to bring products to market before us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Furthermore, the specific indications for which CABOMETYX is approved are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. We believe our future success will depend upon our ability to maintain a competitive position with respect to technological advances and the shifting landscape of therapeutic strategy following the advent of ICIs. While we have adapted our cabozantinib development strategy to address the fact that the approach to treating cancer with ICIs in combination with other therapeutic agents has become highly prevalent in indications for which our products are approved, we cannot ensure that our clinical trials will show efficacy in comparison to competing products or product combinations. Moreover, the complexities of such a development strategy have required and may continue to require collaboration with some of our competitors. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We also may face competition from manufacturers of generic versions of our marketed products, and both Congress and the FDA are seeking to promote generic competition, including through proposals focused on drug patenting, importation and provision of drug to generic applicants for testing. Such generic competition often results in very significant decreases in the overall sales or prices at which branded products can be sold. Please also see the risk factor entitled, &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">If competitors use litigation and regulatory means to obtain approval for generic versions of our marketed products, our business will suffer.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to maintain or scale adequate sales, marketing, market access and product distribution capabilities for our products or enter into or maintain agreements with third parties to do so, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with managing such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and pre-commercial-stage oncology-focused biotechnology companies seeking to build out their commercial organizations, as well as other large pharmaceutical organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. If we cannot maintain effective sales, marketing, market access and product distribution capabilities, we may be unable to maximize the commercial potential of CABOMETYX and COMETRIQ in their approved indications. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly judge the requisite size and experience of our current commercialization teams or the level of distribution necessary to market and sell CABOMETYX successfully in multiple indications. If we are unable to maintain or scale our organization appropriately, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to successfully commercialize our products will depend, in part, on the extent to which we are able to adequately distribute the products to eligible patients. We currently rely on third-party providers for storage and distribution of our commercial supplies of both CABOMETYX and COMETRIQ in the U.S. Furthermore, we rely on our collaboration partners for ongoing and further commercialization and distribution of CABOMETYX and COMETRIQ in their respective territories outside of the U.S., as well as for access and distribution activities for the approved products under named patient use programs (or similar programs) with the effect of introducing earlier patient access to CABOMETYX and COMETRIQ.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our current and anticipated future dependence upon the activities, support, and legal and regulatory compliance of third parties may adversely affect our ability to supply CABOMETYX and COMETRIQ to the marketplace on a timely and competitive basis. These third parties may not provide services in the time required to meet our commercial timelines and objectives or to meet regulatory requirements. We may not be able to maintain or renew our arrangements with third parties, or enter into new arrangements, on acceptable terms, or at all. Third parties could terminate or decline to renew our arrangements based on their own business priorities. If we are unable to contract for these third-party services related to the distribution of CABOMETYX and COMETRIQ on acceptable terms, our commercialization efforts and those of our collaboration partners may be delayed or otherwise adversely affected, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">41</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and press manufacturers for discounts and rebates. Payers may also limit reimbursement for newly approved products and indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to certain healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to certain healthcare laws and regulations and enforcement by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper conduct or inaccurate reporting, the laws that may affect our ability to operate include, without limitation:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the federal Anti-Kickback Statute (AKS), which governs our business activities, including our marketing practices, medical educational programs, pricing policies, and relationships with healthcare providers or other entities. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The AKS has been broadly interpreted to apply to manufacturer arrangements with prescribers, purchasers and formulary managers, among others. Among other things, this statute prohibits persons and entities </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">from knowingly and willfully soliciting, receiving, offering or paying remuneration, directly or indirectly, in exchange for or to induce either the referral of an individual for, or the purchase, order or recommendation of, any good or service for which payment may be made under federal healthcare programs such as the Medicare and Medicaid programs. Remuneration is not defined in the AKS and has been broadly interpreted to include anything of value, including for example, gifts, discounts, coupons, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payments, ownership interests, value-added services to customers, and providing anything at less than its fair market value;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Federal Food, Drug, and Cosmetic Act (FDCA) and its implementing regulations, which prohibit, among other things, the introduction or delivery for introduction into interstate commerce of any drug that is adulterated or misbranded;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal civil and criminal false claims laws, including the civil False Claims Act, and civil monetary penalty laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payers that are false or fraudulent, or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, which impose certain requirements relating to the privacy, security and transmission of individually identifiable health information on covered entities and business associates that access such information on behalf of a covered entity; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Open Payments program of the Patient Protection and Affordable Care Act, as amended by the Healthcare and Education Reconciliation Act (PPACA), which was created under the Physician Payments Sunshine Act and its implementing regulations and requires certain manufacturers </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of drugs, devices, biologics and medical supplies that are reimbursable under Medicare, Medicaid, or the Children&#8217;s Health Insurance Program, with specific exceptions, to report annually to the government information related to certain payments and other </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">42</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-left:72px;padding-bottom:0px;padding-top:4px;text-align:left;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities, as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">well as state and local laws requiring the registration of pharmaceutical sales representatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, certain medical professionals) and its foreign equivalents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">state pharmaceutical price and price reporting laws and regulations that require us to provide notice of price increases and/or file complex ancillary reports concerning prices and pricing and discount practices. Laws and regulations in this area, and associated compliance obligations, may increase general and administrative costs, cause volatility in our revenues due to speculative buying practices by purchasers, or diminish our revenues as a result of the imposition of caps on pricing and price increases</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These federal and state healthcare fraud and abuse laws, FDA rules and regulations, as well as false claims laws, including the civil False Claims Act, govern certain marketing practices, including off-label promotion. If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we, or our officers or employees, may be subject to penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, reputational harm, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Of particular concern are suits filed under the civil False Claims Act, known as &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; actions, which can be brought by any individual on behalf of the government. These individuals, commonly known as relators or &#8220;whistleblowers,&#8221; may potentially then share in amounts paid by the entity to the government in fines or settlement. The filing of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">qui tam</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;actions has caused a number of pharmaceutical, medical device and other healthcare companies to have to defend civil False Claims Act actions. When an entity is determined to have violated the civil False Claims Act, it may be required to pay up to three times the actual damages sustained by the government, plus civil penalties for each separate false claim. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Current healthcare laws and regulations and future legislative or regulatory reforms to the healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The U.S. and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Among policy makers and payers in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specifically, we may face uncertainties as a result of executive, legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. On December 14, 2018, a Texas U.S. District Court Judge ruled that the PPACA is unconstitutional in its entirety because the penalty enforcing the &#8220;individual mandate&#8221; was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. The decision has been appealed to the U.S. Court of Appeals for the Fifth Circuit, and the Trump administration filed its brief in support of the decision of the Texas District Court judge on May 1, 2019. While the Texas District Court Judge, as well as the Trump Administration and the Centers for Medicare and Medicaid Services, have stated that the ruling will have no immediate effect pending the appeal, it is unclear how this decision, subsequent appeals and other efforts to repeal and replace the PPACA will impact the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not have a material adverse impact on our business financial condition and results of operations, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business. The Trump Administration has also indicated an intention to regulate prescription drug pricing, and recent Congressional hearings and proposed legislation have brought increased public attention to the costs of prescription drugs. These actions and the uncertainty about the future of the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">43</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">PPACA, healthcare laws or future legislation on drug pricing at the federal level may put downward pressure on pharmaceutical pricing and increase our regulatory burdens and operating costs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There are pending federal and state Congressional proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited buy-in options that would be available to individuals above a certain age. Federal legislation has also been proposed that would authorize states to permit individuals to &#8220;buy in&#8221; to their state Medicaid programs. Several states are also considering or have already enacted legislation that would allow individuals to &#8220;buy in&#8221; to the state&#8217;s Medicaid program or that would otherwise establish a &#8220;public health option,&#8221; which could have a significant impact on the healthcare industry. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At this stage, we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business. However, such proposals could have the potential to impact access to and sales of our products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In August 2017, President Trump signed the FDA Reauthorization Act of 2017, which reauthorized the FDA user fee programs for prescription drugs, generic drugs, medical devices, and biosimilars, under which applicants for such products partially pay for the FDA&#8217;s pre-market review of their product candidates and pay other specified fees, including yearly program fees in the case of most New Drug Application (NDA)-approved prescription drugs. The legislation includes, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter alia,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; health care costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting, importation, and provision of drug to generic applicants for testing. While we cannot currently predict the specific outcome or impact on our business of such regulatory actions or legislation, they do have the potential to facilitate the development and future approval of generic versions of our products, or otherwise limit or reduce the term for our market exclusivity, which could result in significant decreases in the revenue derived from sales of our marketed products and thereby materially harm our business and financial condition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the overall trend towards managed healthcare in the U.S., third-party payers are increasingly attempting to contain healthcare costs by limiting both coverage and the level of reimbursement of new drugs. Insurers also continue to pursue means of contracting for pharmaceutical &#8220;value&#8221; or &#8220;outcomes.&#8221; These entities could refuse or limit coverage for CABOMETYX and COMETRIQ, such as by using tiered reimbursement or pressing for new forms of value-based contracting, which would adversely affect demand for CABOMETYX and COMETRIQ. They may also refuse to provide coverage for uses of CABOMETYX and COMETRIQ for medical indications other than those for which the FDA has granted market approval. As a result, significant uncertainty exists as to whether and how much third-party payers will cover newly approved drugs, which in turn will put pressure on the pricing of drugs. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, third-party payer or policy actions, which may include cost containment and healthcare reform measures. These policy actions could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Pricing for, and patient access to, pharmaceutical products has come under increasing attention and scrutiny by governments, legislative bodies and enforcement agencies. These activities may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There have been several recent U.S. Congressional inquiries, hearings and proposed and enacted federal legislation designed to, among other things: reduce or limit the prices of drugs and make them more accessible and affordable for patients; reform the structure and financing of public health insurance pharmaceutical benefits, most importantly, Medicare and Medicaid, including through increasing manufacturer contributions to offset Medicare beneficiary costs; facilitate value-based arrangements between manufacturers and payers; bring more transparency to drug pricing rationale and methodologies; and expedite the development and approval of generic drugs and biosimilars. It is entirely unclear what, if any, legislative, regulatory and/or administrative measures that impact the biopharmaceutical industry will eventually be implemented; however, both Congress, and the Trump Administration have indicated that they will continue to seek reforms in this area. While we cannot know the final form of any such reforms, some of the pending legislative proposals, such as those incorporating International Pricing Index models, if enacted, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">44</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with its evaluation of proposals concerning the pricing of, and access to, pharmaceutical products, many companies in our industry have received governmental requests for documents and information relating to drug pricing and patient support programs. Requests take various forms, including through a Congressional inquiry (e.g., from the U.S. Senate Finance Committee) or a subpoena from the U.S. Department of Justice. We could receive a similar request, which would require us to incur significant expense and result in distraction for our management team. Additionally, to the extent there are findings, or even allegations, of improper conduct on the part of the company, these findings could further harm our business, reputation and/or prospects. It is possible that these inquiries could result in: negative publicity or other negative actions that could harm our reputation; changes in our product pricing and distribution strategies; reduced demand for our approved products; and/or reduced reimbursement of our approved products, including by federal health care programs such as Medicare and Medicaid as well as state health care programs.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, to encourage importation from other countries and bulk purchasing, including the National Medicaid Pooling Initiative. With respect to drug pricing transparency, for example, in October 2017, Jerry Brown, the Governor of California at the time, signed SB-17, which requires, among other provisions, pharmaceutical manufacturers to provide notice of price increases above a defined threshold to certain purchasers and related reports to the government. SB-17 is currently subject to challenge, but in the meantime, manufacturers must comply with its requirements. It is possible that laws such as SB-17 will encourage federal and state healthcare programs to reduce the amount of reimbursements they provide for prescription drugs, and any reduction in reimbursement from these government healthcare programs may result in a similar reduction in payments from private payers. We also believe that pricing transparency requirements, such as the requirement for us, in certain circumstances, to provide lengthy notices of price increases to purchasers, may influence customer ordering patterns for CABOMETYX and COMETRIQ, and that this, in turn, may increase the volatility of our revenues as a reflection of changes in inventory volumes. Therefore, the implementation of these cost</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">containment measures or other healthcare reforms may result in fluctuations in our results of operations and limit our ability to generate product revenue or commercialize our current products and/or those for which we may receive regulatory approval in the future.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Further, in some foreign countries, particularly in the EU, the pricing and reimbursement of prescription pharmaceuticals is subject to governmental control under the respective national health system. In these EU countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partner, Ipsen, may be required to conduct a study that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives, increasingly based on affordability, could decrease the price we and our collaboration partner, Ipsen, might establish for CABOMETYX, which would result in lower license revenues to us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer donations to patient assistance programs offered by charitable foundations may require us to modify our programs and could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of scrutiny. In recent years, some pharmaceutical manufacturers were named in class action lawsuits challenging the legality of their patient assistance programs and support of independent charitable patient support foundations under a variety of federal and state laws. Notably, certain of these manufacturers have entered into significant monetary or other settlements with the federal government, including entering into Corporate Integrity Agreements, to resolve allegations that they paid kickbacks through independent charitable foundations. Our patient assistance program and support of independent charitable foundations could become the target of similar litigation. Though not affecting CABOMETYX, at least one insurer also has directed its network pharmacies to no longer accept manufacturer co-payment coupons for certain specialty drugs the insurer identified. In addition, certain state and federal enforcement authorities and members of Congress have initiated inquiries about co-pay assistance programs. Some state legislatures have also been considering proposals that would restrict or ban co-pay coupons.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">45</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, there has been regulatory review, Congressional interest and enhanced government scrutiny of donations by pharmaceutical companies to patient assistance programs operated by charitable foundations. The U.S. Department of Health and Human Services Office of Inspector General has established specific guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients, provided that such organizations are bona fide charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria, and do not link aid to use of a donor&#8217;s product. If we are deemed not to have complied with laws or regulations in the operation of these programs, we could be subject to damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. Further, numerous organizations, including pharmaceutical manufacturers, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support, and, as noted above, certain of these organizations have entered into, or have otherwise agreed to, significant civil settlements with applicable enforcement authorities. Additionally, in March 2019, the Senate Finance Committee launched an inquiry into alleged ties between pharmaceutical manufacturers and patient assistance charitable foundations. It is possible that future legislation may propose establishing requirements that affect pharmaceutical manufacturers and such charitable organizations. We cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, business partners or vendors that may violate the laws or regulations of the jurisdictions in which we operate. Regardless of whether we have complied with the law, a government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are subject to laws and government regulations relating to privacy and data protection that have required us to modify certain of our policies and procedures with respect to the collection and processing of personal data, and future laws and regulations may cause us to incur additional expenses or otherwise limit our ability to collect and process personal data. Failure to maintain compliance with these regulations could jeopardize certain business transactions and create additional liabilities for us.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The legislative and regulatory landscape for privacy and data protection in the U.S. continues to evolve, and there has been an increasing focus on privacy and data protection, including state security breach notification laws, state health information privacy laws and federal and state consumer protection laws governing the collection, use and disclosure of personal information. For example, in June 2018, Jerry Brown, the Governor of California at the time, signed into law the California Consumer Privacy Act of 2018 (CCPA),&#160;which was subsequently amended, and which goes into operation on January 1, 2020 and will give California residents expanded privacy rights and protections and will provide for civil penalties for violations and statutory damages under a private right of action for data breaches. There are similar legislative proposals being advanced in other states, and Congress is also considering federal privacy legislation. In addition, most healthcare providers who are expected to prescribe our products, and from whom we obtain patient health information, are subject to privacy and security requirements under HIPAA. Although we are not directly subject to HIPAA, we could be subject to criminal penalties if we knowingly encourage a HIPAA-covered entity (or its business associate) to use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU General Data Protection Regulation 2016/679 (GDPR), which became enforceable on May 25, 2018, regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also restricts transfers of such data to countries outside of the EU, including the United States. Switzerland is updating the Swiss Data Protection Act, and updates to data protection laws in other countries may occur in due course. In connection with these new laws, in particular the CCPA and GDPR, we have modified or are reviewing certain of our policies and procedures with respect to the collection and processing of personal data. We will continue to review all future privacy and other regulations implemented pursuant to the CCPA, GDPR and other applicable laws to assess whether additional procedural safeguards are warranted, which may cause us to incur additional expenses or otherwise limit our ability to collect and process personal data. Failure to provide adequate privacy or data security protections or maintain compliance with these laws and regulations could jeopardize certain domestic and cross-border business transactions and create additional liabilities for us, including the imposition of sanctions or other penalties, litigation or an increase in our cost of doing business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If competitors use litigation and regulatory means to obtain approval for generic versions of our marketed products, our business will suffer.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the FDCA, the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve an NDA under section 505(b)(2) of the FDCA that relies in whole or in part on the agency&#8217;s findings of safety and/or </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">46</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">effectiveness for a previously approved drug. Both the ANDA and 505(b)(2) processes are discussed in more detail under &#8220;Item 1. Business-Government Regulation-The Hatch-Waxman Act&#8221; in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the SEC on February 22, 2019. In either case, if an ANDA or 505(b)(2) applicant submits an application referencing one of our marketed products prior to the expiry of one or more our </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">-listed patents for the applicable product, we may engage in litigation with the potential generic competitor to protect our patent rights, which will require us to incur significant expense and result in distraction for our management team, and could also have an adverse impact on our stock price.  If one or more companies receive FDA approval of an ANDA or 505(b)(2) NDA, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable. In particular, we expect generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Regardless of the regulatory approach, whether through the ANDA or 505(b)(2) pathways or otherwise, the introduction of a generic version of any of our marketed products could result in significant decreases in the revenue derived from sales of our marketed products and thereby materially harm our business and financial condition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets.&#160;The notice letter included a Paragraph IV certification with respect to our&#160;U.S. Patent Nos.&#160;8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are&#160;listed in the&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Orange Book.&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> MSN&#8217;s notice letter does not provide a Paragraph IV certification against the CABOMETYX composition of matter patent, U.S. Patent No. 7,579,473, which expires on August 16, 2026. On October 29, 2019, we filed a complaint for patent infringement against MSN asserting U.S. Patent No. 8,877,776 in the Delaware District Federal Court arising from MSN&#8217;s ANDA filing with the FDA. Based on the information we have received to date, our complaint does not allege infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. We are seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of U.S. Patent No. 8,877,776 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">on October 8, 2030 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and equitable relief enjoining MSN from infringing this patent</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We cannot assure you that the lawsuit will prevent the introduction of a generic version of CABOMETYX for any particular length of time, or at all. If MSN&#8217;s ANDA is approved, and a generic version of CABOMETYX is introduced following the expiration of our composition of matter patent in 2026, our sales of CABOMETYX would be adversely affected. In addition, we cannot predict what additional ANDAs could be filed by MSN or other potential generic competitors requesting approval to market generic forms of cabozantinib, including against the cabozantinib composition of matter patent that MSN has not challenged, which would require us to incur significant additional expense and result in distraction for our management team, and if approved, result in significant decreases in the revenue derived from sales of our marketed products and thereby materially harm our business and financial condition.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Clinical testing of cabozantinib for new indications, or of new potential product candidates, is a lengthy, costly, complex and uncertain process and may fail to demonstrate safety and efficacy.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new potential product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval in a particular indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and later stage clinical trials may fail to confirm the results observed in earlier stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may experience numerous unforeseen events, during or as a result of clinical testing, that could delay or prevent commercialization of cabozantinib in new indications</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or of our other product candidates, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lack of efficacy or a tolerable safety profile;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects that we had expected to be promising;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to identify and maintain a sufficient number of trial sites, many of which may already be engaged in other clinical trial programs; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">lower-than-anticipated patient registration or enrollment in our clinical testing, resulting in the delay or cancellation of clinical testing; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure by our collaborators to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">47</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials of cabozantinib or another product candidate, or delays, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we were to have significant delays in or termination of the clinical testing of cabozantinib or our other product candidates as a result of any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our clinical and commercial collaboration partners to fund a significant portion of the clinical development of cabozantinib and our product candidates. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for the financial obligations associated with the further development of cabozantinib or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may not be able to rapidly or effectively continue the further development of cabozantinib or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions, including those identified based on our discussions with the FDA or such other regulatory authorities. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">characteristics of the product candidate under investigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of patients who ultimately participate in the clinical trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the duration of patient follow-up that is appropriate in view of the results or required by regulatory authorities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number of clinical sites included in the trials; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the length of time required to enroll suitable patient subjects.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain, and may not result in regulatory approvals for cabozantinib or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities associated with the research, development and commercialization of cabozantinib and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S. and by comparable authorities in other countries. The process of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive, and often takes many years, if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or supplemental New Drug Application (sNDA) can be submitted to the FDA, or a marketing authorization application to the European Medicines Agency or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. For example, the FDA could determine that the design of a clinical trial is inadequate to produce reliable results. The regulatory process also requires preclinical testing, and data obtained from preclinical and clinical activities are susceptible to varying interpretations. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA and decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. For </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">48</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">example, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent regulatory approval of cabozantinib for any individual, additional indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, delays or rejections may be encountered based upon changes in regulatory policy for product approval during the period of product development and regulatory agency review, which may cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more indications beyond advanced RCC, previously treated HCC and MTC, or approves one of our other product candidates, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, advertising, promotion, marketing and/or production of the product and could impose ongoing requirements for post-approval studies, including additional research and development and clinical trials. For example, in connection with the FDA&#8217;s approval of COMETRIQ for the treatment of progressive, metastatic MTC in November 2012, we are subject to a post-marketing requirement to conduct a clinical study comparing a lower dose of cabozantinib to the approved dose of 140 mg daily cabozantinib in progressive, metastatic MTC. Failure to complete any post-marketing requirements in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or eliminate the commercialization of cabozantinib. Further, these agencies may also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we are pursuing internal drug discovery efforts with the goal of identifying new product candidates to advance into clinical trials. Internal discovery efforts to identify new product candidates require substantial technical, financial and human resources. These internal discovery efforts may initially show promise in identifying potential product candidates, yet ultimately fail to yield product candidates for clinical development for a number of reasons. For example, potential product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Apart from our internal discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates.&#160;However, the in-licensing and acquisition of product candidates is a highly competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive. In particular, larger companies with more well-established and diverse revenue streams may have a competitive advantage over us due to their size, financial resources and more extensive clinical development and commercialization capabilities.&#160;Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us.&#160; We may also be unable to in-license or acquire additional relevant product candidates on acceptable terms that would allow us to realize an appropriate return on our investment. If we are unable to develop suitable product candidates through internal discovery efforts or if we are unable to successfully obtain rights to suitable product candidates, our business and prospects for growth could suffer. Even if we succeed in our efforts to obtain rights to suitable product candidates, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target, or retain key personnel of an acquired business. Furthermore, we could assume unknown or contingent liabilities or incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our operating results.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Increasing use of social media could give rise to liability and result in harm to our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We and our employees are increasingly utilizing social media tools and our website as a means of communication. For example, we use Facebook and Twitter to communicate with the medical community and the investing public, although we do not intend to disclose material, nonpublic information through these means. Despite our efforts to monitor evolving </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">49</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">social media communication guidelines and comply with applicable laws and regulations, there is risk that the unauthorized use of social media by us or our employees to communicate about our products or business, or any inadvertent disclosure of material, nonpublic information through these means, may cause us to be found in violation of applicable laws and regulations, which may give rise to liability and result in harm to our business. In addition, there is also risk of inappropriate disclosure of sensitive information, which could result in significant legal and financial exposure and reputational damages that could potentially have a material adverse impact on our business, financial condition and results of operations. Furthermore, negative posts or comments about us or our products on social media could seriously damage our reputation, brand image and goodwill.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Capital Requirements, Accounting and Financial Results</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be unable to maintain or increase profitability.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Although we reported net income of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$252.3 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$690.1 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and the year ended December 31, 2018, respectively, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of long-range future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements with Ipsen and Takeda; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements with Ipsen and Takeda; other collaboration revenues; and the level of our expenses, including development and commercialization activities for cabozantinib and any pipeline expansion efforts. We expect to continue to spend significant additional amounts to fund the continued development of cabozantinib for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our product pipeline through our internal drug discovery efforts and the execution of strategic transactions that align with our oncology drug development expertise, which efforts could involve substantial costs. To offset these costs, we will need to generate substantial revenues. If these costs exceed our expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we had </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$1,248.4 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in cash and investments as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$851.6 million</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of December 31, 2018. Our business operations grew substantially during 2018 and the first nine months of 2019. In order to maintain business growth, we plan to continue to execute on our U.S. commercialization plans for CABOMETYX, while reinvesting in our product pipeline through the continued development of cabozantinib and our other product candidates, internal discovery activities and the execution of strategic transactions. Our ability to achieve these business objectives will depend on many factors including but not limited to: </span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our expanded sales, marketing, market access, medical affairs and product distribution capabilities for CABOMETYX and COMETRIQ;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones and royalties paid under our collaboration agreements with Ipsen and Takeda; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of and revenues generated by products marketed under our collaboration and license agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the level of our investments in the expansion of our pipeline through internal drug discovery and business development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our ability to control costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the number and size of clinical trials we conduct and the cost of drug supply for such clinical trials evaluating our products with other therapeutic agents;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">trends and developments in the pricing of oncologic therapeutics in the U.S. and abroad, especially in the EU;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">scientific developments in the market for oncologic therapeutics and the timing of regulatory approvals for competing oncologic therapies; and</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">50</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the filing, maintenance, prosecution, defense and enforcement of patent claims and other intellectual property rights.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of cabozantinib and increasing internal drug discovery activities, as well as through the execution of strategic transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing&#160;economic conditions&#160;and financial, business and other factors beyond our control. Disruptions in the U.S. and&#160;global&#160;financial markets, including any disruptions resulting from government shutdowns, the uncertainty surrounding the date and the terms of the pending Brexit, rising interest rate environments, increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise money in the capital markets.&#160;Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business.&#160; Accordingly, we do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our financial results are impacted by management&#8217;s selection of accounting methods, certain assumptions and estimates and future changes in accounting standards.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our accounting policies and methods are fundamental to how we record and report our financial condition and results of operations. Our management must exercise judgment in selecting and applying many of these accounting policies and methods so they comply with generally accepted accounting principles and reflect management&#8217;s judgment of the most appropriate manner to report our financial condition and results of operations. In some cases, management must select the accounting policy or method to apply from two or more alternatives, any of which may be reasonable under the circumstances, yet may result in our reporting materially different results than would have been reported under a different alternative.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certain accounting policies are critical to the presentation of our financial condition and results of operations. The preparation of our financial statements requires us to make significant estimates, assumptions and judgments that affect the amounts of assets, liabilities, revenues and expenses and related disclosures. We believe our critical accounting policies relating to revenue recognition, clinical trial accruals, inventory and stock-based compensation reflect the more significant estimates and judgments used in the preparation of our Condensed Consolidated Financial Statements. Although we base our estimates and judgments on historical experience, our interpretation of existing accounting literature and on various other assumptions that we believe to be reasonable under the circumstances, if our assumptions prove to be materially incorrect, actual results may differ materially from these estimates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our financial position or results of operations. New pronouncements from the Financial Accounting Standards Board (FASB) and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again in the future and, as a result, we may be required to make changes in our accounting policies. Those changes could adversely affect our reported revenues and expenses, our other results of operations or our current financial position. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The 2017 comprehensive tax reform bill could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Tax Cuts and Jobs Act could be amended or subject to technical correction, which could change the financial impacts that were recorded at December 31, 2018 and September 30, 2019, or are expected to be recorded in future periods. Additionally, further guidance may be forthcoming from the FASB and SEC, as well as regulations, interpretations and rulings from federal and state tax agencies, which could result in additional impacts, possibly with retroactive effect. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are subject to income tax in the U.S. as well as numerous U.S. states and territories, municipalities, and other local jurisdictions. As a result, our effective tax rate is derived from various factors including the mix of earnings and applicable tax rates in the various places that we operate, the accounting for stock options and share based awards, and research and development spending. In preparing our financial statements, we estimate the amount of tax that will become </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">51</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">payable in each jurisdiction. Our effective tax rate, however, may be different than experienced in the past due to numerous factors, including changes in tax laws such as the passage of the Tax Cuts and Jobs Act, changes in the mix of our earnings from state to state, the results of examinations and audits of our tax filings, or our inability to secure or sustain acceptable agreements with tax authorities. Any of these factors could cause our effective tax rate to fluctuate. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our ability to use net operating losses and tax credits to offset future taxable income may be subject to limitations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of December&#160;31, 2018, we had federal and state net operating loss carryforwards of approximately $1.1&#160;billion. The federal and state net operating loss carryforwards will begin to expire, if not utilized, beginning in 2031 for federal income tax purposes and 2028 for California state income tax purposes. These net operating loss carryforwards could expire unused and be unavailable to offset future income tax liabilities. Under the Internal Revenue Code (the Code) and similar state provisions, certain substantial changes in our ownership could result in an annual limitation on the amount of net operating loss carryforwards that can be utilized in future years to offset future taxable income. The annual limitation may result in the expiration of net operating losses and credit carryforwards before utilization. Based on our review and analysis, we concluded, as of December 31, 2018, that an ownership change, as defined under Section 382, had not occurred. However, if there is an ownership change under Section 382 of the Code in the future, we may not be able to utilize a material portion of our net operating losses. Furthermore, our ability to utilize our net operating losses is conditioned upon our maintaining profitability and generating U.S. federal taxable income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The transition away from the London Interbank Offered Rate (LIBOR) could affect the value of certain short-term investments, as well as our ability to seek additional debt financing.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Actions by governmental entities may impact certain financial instruments in which we have invested or may invest in the future. For example, some of these financial instruments may rely in some fashion upon LIBOR, which is an average interest rate, determined by the ICE Benchmark Administration, that banks charge one another for the use of short-term money. The UK's Financial Conduct Authority, which regulates LIBOR, has announced plans to phase out the use of LIBOR by the end of 2021. While only a small percentage of our short-term investments include financial instruments subject to LIBOR, and while we do not currently have any outstanding debt that is subject to LIBOR, there remains uncertainty regarding the future utilization of LIBOR and the nature of any replacement rate, and any potential effects of the transition away from LIBOR on certain instruments in to which we may enter in the future are not known. The transition process may involve, among other things, increased volatility or illiquidity in markets for instruments that currently rely on LIBOR. The transition may also result in reductions in the value of certain instruments or the effectiveness of related transactions such as hedges, increased borrowing costs, uncertainty under applicable documentation, or difficult and costly consent processes.&#160; Any such effects of the transition away from LIBOR, as well as other unforeseen effects, result in expenses, difficulties, complications or delays in connection with future financing efforts, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The UK&#8217;s pending withdrawal from the EU&#160;may have a negative effect on global economic conditions, financial markets and our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Brexit has created significant uncertainty concerning the terms of the UK withdrawal from the EU and the future relationship between the UK and the EU. On April 11, 2019, the European Council agreed at its Special Meeting to extend the UK&#8217;s departure date to October 31, 2019, and then on October 28, 2019, the European Council informally agreed to further extend the departure date to January 31, 2020, though this latest extension allows the UK to withdraw from the EU prior to January 31, 2020 if a transition agreement is ratified by both the UK Parliament and the European Parliament. However, despite numerous proposals to provide for a more fair and reasonable exit, both the EU and the UK are preparing for a &#8220;no deal&#8221; scenario in which the UK will leave the EU as a &#8220;third country&#8221; without the benefit of any transition arrangements. In addition, the resignation of Theresa May and election of Boris Johnson as UK Prime Minister has further increased this uncertainty, since the UK&#8217;s future position on Brexit will depend significantly upon the policies and political decisions of the new administration under the premiership of Prime Minister Johnson.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The &#8220;no deal&#8221; scenario has been recognized by the policy makers in the UK and the EU as likely to cause significant market and economic disruption. The effects of Brexit will depend on whether the UK retains access to EU markets either during a transitional period or more permanently. Brexit could disrupt the single internal market principle, which ensures the free movement of goods, services and people between the UK and the EU, undermine bilateral cooperation in key policy areas and significantly disturb trade relationships between the UK and the EU. In addition, Brexit&#160;could lead to legal </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">52</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">uncertainty and potentially divergent national laws and regulations as the UK determines which EU laws to replace, amend or adopt.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Given the lack of comparable precedent, it is unclear what financial, trade, regulatory and legal implications the withdrawal of the UK from the EU would have, and how such withdrawal would affect us. For example, we rely on third-party contract manufacturing organization facilities located in the UK, responsible for packaging, labeling, storing and subsequently distributing supplies of our product to the EU. Any tariffs, differing regulatory requirements and other restrictions on the free movement of goods between the UK and the EU that result from Brexit may have an adverse impact on this part of our supply chain. Trade restrictions, changes to the regulatory approval or drug cost reimbursement systems, and additional administrative costs may impede the ability of our collaborator Ipsen to market our products in Europe. Furthermore, the announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations, and the pending withdrawal of the UK from the EU may also adversely affect European and global economic and market conditions, which may cause third-party payers, including governmental organizations, to closely monitor their costs and reduce their spending budgets, and which could contribute to instability in the global financial and foreign exchange markets. Any of these effects of Brexit could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Relationships with Third Parties</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We are dependent upon our collaborations with major companies, which subject us to a number of risks.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established collaborations with leading pharmaceutical and biotechnology companies, including, Ipsen, Takeda, Genentech, Daiichi Sankyo and BMS for the development and ultimate commercialization of certain compounds generated from our research and development efforts. Our dependence on our relationships with collaborators for the development and commercialization of compounds subjects us to, a number of risks, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to control the amount and timing of resources that our collaborators or potential future collaborators will devote to the development or commercialization of drug candidates or to their marketing and distribution;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that collaborators may delay clinical trials, fail to supply us on a timely basis with the product required for a combination trial, deliver product that fails to meet appropriate quality and regulatory standards and results in a market recall or withdrawal, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a drug candidate, repeat or conduct new clinical trials or require a new formulation of a drug candidate for clinical testing;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes that may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration that diverts management&#8217;s attention and resources;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to control the U.S. commercial resourcing decisions made and resulting costs incurred by Genentech for COTELLIC, which costs we are obligated to share, in part, under our collaboration agreement with Genentech;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our collaborators may experience financial difficulties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; lack of success in their efforts to obtain regulatory approvals in a timely manner, or at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; failure to comply with the terms of our collaboration agreements and related ancillary agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our collaborators&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">related to Good Manufacturing Practice, Good Clinical Practice, Good Distribution Practice and Good Pharmacovigilance Practice;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that our collaborators could independently move forward with competing drug candidates, developed either independently or in collaboration with others, including our competitors;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">53</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our inability to enter into additional collaboration arrangements with third parties in an area or field of exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that future collaborators may require us to relinquish some important rights, such as marketing and distribution rights; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the possibility that collaborations may be terminated or allowed to expire, which would delay, and may increase the cost of, development of our drug candidates.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations and our product development efforts could be delayed, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new potential product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, including our post-marketing commitments in connection with the approval of COMETRIQ in progressive, metastatic MTC, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to further our internal drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We lack internal manufacturing capabilities necessary for us to produce our products for clinical development or for commercial sale and rely on third parties to do so, which subjects us to various risks.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We do not own or operate manufacturing facilities, distribution facilities or resources for clinical or commercial production and distribution of our products. Instead, we have multiple contractual agreements in place with third-party contract manufacturing organizations that, on our behalf, manufacture&#160;clinical and commercial supplies of CABOMETYX and COMETRIQ. As our operations continue to expand through our clinical development and commercial progress, we are appropriately expanding our supply chain by entering into new agreements with additional third-party contract manufacturers and suppliers. This will continue for the foreseeable future for all of our product candidates, as well as our current and future commercial products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to ensure compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our development and commercial needs and applicable regulatory requirements. If our third-party contract manufacturers and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our supply and manufacturing arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude our ability to meet our commercial supply requirements, or our supply needs for clinical trials, including those being conducted in collaboration with our partners, which could delay our product development efforts and have a material adverse impact on our business, financial condition and results of operations. Through our third-party contract manufacturers and data service providers, we have implemented product serialization designed to comply with the Drug Supply Chain Security Act (DSCSA), pursuant to which, subject to limited exemptions, all prescription pharmaceutical products manufactured and distributed in the U.S. were required to be serialized as of November 27, 2018. If our third-party </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">54</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As part of our collaboration agreements with Ipsen and Takeda, we are responsible for the supply of CABOMETYX and COMETRIQ for global development and commercial purposes. Failure to meet our supply obligations under these collaboration agreements could impair our collaborators&#8217; ability to successfully develop and commercialize CABOMETYX and COMETRIQ and generate revenues to which we are entitled under the collaborations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our collaborations with outside scientific advisors and collaborators may be subject to restriction and change.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We work with scientific and clinical advisors and collaborators at academic and other institutions that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These advisors and collaborators are not our employees and may have other commitments or pursue other opportunities that limit their availability to us. Although these advisors and collaborators generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as advisors and collaborators or otherwise limit our access to these experts, or that the advisors themselves may now be more reluctant to work with industry partners. In any of these circumstances, we may lose work performed by these advisors and collaborators or be unable to engage them in the first place, and our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected. In addition, although our advisors and collaborators sign agreements not to disclose our confidential information, it is possible that valuable proprietary knowledge may become publicly known through them.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Information Technology, Data Privacy and Intellectual Property</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Data breaches, cyber-attacks and other failures in our information technology infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the ordinary course of our business, we collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our business partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cyber-security efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt key business operations and divert attention of management and key information technology resources.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Numerous companies have been subject to a wide variety of security incidents, cyber-attacks (including through use of ransomware) and other attempts to gain unauthorized access or otherwise compromise information technology systems. In fact, although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we have frequently been the target of threats of this nature and expect them to continue. These threats can come from a variety of sources, ranging in sophistication from an individual hacker to a state-sponsored attack, and such threats can also vary in motive (including corporate espionage). Cyber threats may be generic, or they may be custom-crafted against our information systems. Cyber-attacks continue to become more prevalent and much harder to detect and defend against. Our network and storage applications and those of our contract manufacturing organizations, contract research organizations or vendors may be subject to unauthorized access by hackers or breached due to operator error, malfeasance or other system disruptions. It is often difficult to anticipate or immediately detect such incidents and the damage caused by such incidents. These data breaches and any unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information (or sensitive business information of our collaboration partners, which may lead to significant liability for us). A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others. Any such event </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">55</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that leads to unauthorized access, use or disclosure of personal information, including personal information regarding our patients or employees, could harm our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents (including the GDPR), subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cyber-security systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our vendors may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">inter partes</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, in October 2019, we received a notice letter from MSN that it has filed an ANDA with the FDA for a generic version of CABOMETYX tablets, and we subsequently filed a patent infringement lawsuit against MSN on </span><span style="color:#000000;font-family:Calibri,sans-serif;font-size:10pt;">October 29, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Should MSN or any other third parties receive FDA approval of an ANDA for a generic version of cabozantinib or a 505(b)(2) NDA with respect to cabozantinib</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, and if our patents covering cabozantinib were held to be invalid (or if such competing generic versions of cabozantinib were found to not infringe our patents), then they could introduce generic versions of cabozantinib or other such 505(b)(2) products before our patents expire, and the resulting generic competition would negatively affect our business, financial condition and results of operations. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Please also see the risk factor entitled, &#8220;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">If competitors use litigation and regulatory means to obtain approval for generic versions of our marketed products, our business will suffer.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8221; </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">56</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, collaborators and consultants, we cannot assure you that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs, including the diversion of management and technical personnel, in defending ourselves against any such claims or enforcing our own patents. In the event that a successful claim of infringement is brought against us, we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that we, our employees or independent contractors have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Many of our employees and independent contractors were previously employed at universities or other biotechnology, biopharmaceutical or pharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that we or these employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or used or sought to use patent inventions belonging to their former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and divert management&#8217;s attention. If we fail in defending such claims, in addition to paying damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel and/or their work product could hamper or prevent our ability to develop or commercialize certain product candidates, which could severely harm our business.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Employees and Location</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations. This growth places significant demands on our management, operational and financial resources, and our current and planned personnel, facilities, systems, procedures and controls may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We expect that we may need to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, or are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">57</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial and scientific personnel will be critical to support activities related to advancing the development program for cabozantinib and our other compounds, successfully executing upon our commercialization plan for cabozantinib and our internal proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Additionally, in the second quarter of 2018, we moved our corporate headquarters from South San Francisco, California to Alameda, California. This relocation may make it more difficult to retain certain employees, and any resulting loss of talent and need to recruit and train new employees could be disruptive to our business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;"> Our operations might be interrupted by the occurrence of a natural disaster or other catastrophic event.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our headquarters in Alameda, California is located in the San Francisco Bay Area, and therefore our facilities are vulnerable to damage from earthquakes. We have limited earthquake insurance, which may not cover all of the damage we may suffer in the event of an earthquake. We are also vulnerable to damage from other types of disasters, including fires and floods, which have become a significant danger in California during recent years, as well as power loss, communications failures, terrorism and similar events, and any insurance we may maintain may be inadequate to cover our losses. If any disaster were to occur, our ability to operate our business at our facilities could be seriously, or potentially completely, impaired. In addition, a disaster could cause significant delays in our programs and make it difficult for us to recover due to the unique nature of our research activities. Accordingly, an earthquake or other disaster could materially and adversely harm our ability to conduct business.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Facility security breaches may disrupt our operations, subject us to liability and harm our operating results.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Any break-in or trespass at our facilities that results in the misappropriation, theft, sabotage or any other type of security breach with respect to our proprietary and confidential information, including research or clinical data, or that results in damage to our research and development equipment and assets, or that results in physical or psychological harm to any of our employees, could subject us to liability or otherwise have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Environmental and Product Liability</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials. Federal, state and local laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may face liability for any injury or contamination that results from our use or the use by third parties of these materials, and such liability may exceed our insurance coverage and our total assets. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, our collaborators may use hazardous materials in connection with our collaborative efforts. In the event of a lawsuit or investigation, we could be held responsible for any injury caused to persons or property by exposure to, or release of, any hazardous materials used by these parties. Further, we may be required to indemnify our collaborators against all damages and other liabilities arising out of our development activities or products produced in connection with these collaborations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We may be held liable if any product we or our collaborators develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">58</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. These claims might be made directly by consumers, health care providers, pharmaceutical companies or others selling or testing our products. We have obtained limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib in the amount of $20.0 million per occurrence and $20.0 million in the aggregate. However, our insurance may not reimburse us or may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability. On occasion, juries have awarded large judgments in class action lawsuits for claims based on drugs that had unanticipated side effects. In addition, the pharmaceutical, biopharmaceutical and biotechnology industries, in general, have been subject to significant medical malpractice litigation. A successful product liability claim or series of claims brought against us could harm our reputation and business and would decrease our cash reserves.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Risks Related to Our Common Stock</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">We expect that our quarterly results of operations will fluctuate, and this fluctuation could cause our stock price to decline, causing investor losses.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our quarterly operating results have fluctuated in the past and are likely to fluctuate in the future. A number of factors, many of which we cannot control, could subject our operating results to volatility, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">customer ordering patterns for CABOMETYX and COMETRIQ, which may vary significantly from period to period</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as a result of multiple factors, including pricing information required to be disclosed by us pursuant to drug pricing transparency laws</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the overall level of demand for CABOMETYX and COMETRIQ, including the impact of any competitive products and the duration of therapy for patients receiving CABOMETYX or COMETRIQ;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the achievement of stated regulatory and commercial milestones and royalties paid under our collaboration agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of and revenues generated by products marketed under our collaboration and license agreements, including COTELLIC and MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in the amount of deductions from gross sales, including changes to the discount percentage of rebates and chargebacks mandated by the government programs in which we participate, including increases in the government discount percentage resulting from price increases we have taken or may take in the future, or due to different levels of utilization by entities entitled to government rebates and chargebacks and changes in patient demographics;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">costs associated with maintaining our sales, marketing, market access, medical affairs and product distribution capabilities for CABOMETYX and COMETRIQ;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the progress and scope of other development and commercialization activities for cabozantinib and our other compounds;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">future clinical trial results;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">our future investments in the expansion of our pipeline through internal drug discovery and business development activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability to obtain adequate product supply for any approved drug product or inability to do so at acceptable prices;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recognition of upfront licensing or other fees or revenues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">payments of non-refundable upfront or licensing fees, or payment for cost-sharing expenses, to third parties;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the introduction of new technologies or products by our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and willingness of collaborators to further develop or, if approved, commercialize our product candidates out-licensed to them;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the termination or non-renewal of existing collaborations or third-party vendor relationships;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">regulatory actions with respect to our product candidates and any approved products or our competitors&#8217; products;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">59</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including with respect our current and potential future patent litigations against MSN and potential future generic applicants</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adjustments to expenses accrued in prior periods based on management&#8217;s estimates after the actual level of activity relating to such expenses becomes more certain;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the impairment of acquired goodwill and other assets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">significant fluctuations in interest rates or foreign currency exchange rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general and industry-specific economic conditions that may affect our or our collaborators&#8217; research and development expenditures; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">other factors described in this &#8220;Risk Factors&#8221; section.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In addition, in the fourth quarter of 2018, we determined, based on our facts and circumstances, that it was more likely than not that a substantial portion of our deferred tax assets would be realized and, as a result, substantially all of our valuation allowance against deferred tax assets was released. Therefore, beginning in 2019, we record income tax expense at </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">an estimated tax rate that will likely approximate statutory tax rates, adjusted for discrete tax items, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">which has resulted in a significant reduction in our net income and net income per share. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Due to the possibility of such fluctuations in our revenues and expenses, we believe that quarter-over-quarter comparisons of our operating results are not a good indication of our future performance. As a result, in some future quarters, our operating results may not meet the expectations of securities analysts and investors, which could result in a decline in the price of our common stock.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Our stock price has been and may in the future be highly volatile.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The trading price of our common stock has been highly volatile, and we believe the trading price of our common stock will remain highly volatile and may fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">adverse or inconclusive results or announcements related to our or our collaborators&#8217; clinical trials or delays in those clinical trials;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of FDA approval or non-approval, or delays in the FDA review process with respect to cabozantinib, our collaborators&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the commercial success of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the timing of achievement of our clinical, regulatory, partnering and other milestones, such as the commencement of clinical development, the completion of a clinical trial, the filing for regulatory approval or the establishment of collaborative arrangements for cabozantinib or any of our other programs or compounds;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of new products or clinical trial data by our competitors;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of regulatory applications</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, such as MSN&#8217;s ANDA, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">seeking approval of generic versions of our marketed products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">quarterly variations in our or our competitors&#8217; results of operations;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in our relationships with our collaborators, including the termination or modification of our agreements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the announcement of an in-licensed product candidate or strategic acquisition;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">conflicts or litigation with our collaborators;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">60</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">changes in earnings estimates or recommendations by securities analysts </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and any failure to achieve the operating results projected by securities analysts</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the entry into new financing arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">additions and departures of key personnel or board members;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the extent to which coverage and reimbursement is available for both CABOMETYX and COMETRIQ from government and health administration authorities, private health insurers, managed care programs and other third-party payers;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">disposition of any of our technologies or compounds; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">These factors, as well as general economic, political and market conditions, may materially adversely affect the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. For example, negative publicity regarding drug pricing and price increases by pharmaceutical companies has negatively impacted, and may continue to negatively impact, the markets for biotechnology and pharmaceutical stocks. Likewise, as a result of the uncertainty of the date and the terms of the pending Brexit and/or significant changes in U.S. social, political, regulatory and economic conditions or in laws and policies governing foreign trade and health care spending and delivery, including possible repeal and/or replacement of or adverse judicial rulings against all or portions of PPACA or increases or changes in tariffs and other trade restrictions stemming from Trump administration and foreign government policies, or future U.S. federal government shutdowns, the financial markets could experience significant volatility that could also negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected, and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert management&#8217;s attention and resources, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:12px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">a prohibition on actions by our stockholders by written consent;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the inability of our stockholders to call special meetings of stockholders;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:48px;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">advance notice requirements for director nominations and stockholder proposals.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">61</span></div></div><hr style="page-break-after:always"></hr><div><a id="s1EFEDFDCDB0457848B97E455D925AA98"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="s28D8227C66AF59A88E06A6329DB606D6"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 3. Defaults Upon Senior Securities</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="sE85B4FBC2598528DBAB8400EC8C5276F"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 4. Mine Safety Disclosures</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Not applicable.</span></div><div><a id="sEDB35078A2AD51C587990ED7F15F624A"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 5. Other Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Build to Suit Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On </span><span style="color:#000000;font-family:Calibri,sans-serif;font-size:10pt;">October 25, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) with Ernst Development Partners, Inc. (Ernst), for approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">220,000</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office space located in Alameda, California (the New Premises), adjacent to our current corporate headquarters (the Current Premises).</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The term of the Build-to-Suit Lease is for a period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">242</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> months (the Term), which will begin on the completion of the building and tenant improvements by Ernst. The Term is currently anticipated to begin on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">October 25, 2021</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The monthly base rent under the Build-to-Suit Lease will equal to a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by Ernst and any development costs we pay) and is currently estimated to be about </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">$726,000</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, subject to an annual increase of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3%</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the Term. The monthly base rent will begin sixty days following commencement of the Term. We will also be responsible for paying operating expenses related to the New Premises. We have been provided an allowance of $75 per square foot of the New Premises (approximately $16.5 million) for tenant improvements to the New Premises. To the extent that the total development costs of the New Premises exceeds $525 per square foot, we will also pay 50% of such excess costs prior to the commencement of the Term, and may be required to secure such amount and the cost of the tenant improvements in excess of the allowance by providing a letter of credit or depositing such amounts in an account with Ernst&#8217;s lender prior to the start of construction.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Build-to-Suit Lease includes two five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the 180</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. In addition, we have a right of first offer to purchase the New Premises, subject to certain procedures and exclusions set forth in the Build-to-Suit Lease. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In connection with the Build-to-Suit Lease, we will deliver to Ernst an irrevocable standby letter of credit for $726,000, which amount will be adjusted to reflect the initial monthly base rent once it is determined, as security for our performance of our obligations under the Build-to-Suit Lease.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Ernst does not yet own the land upon which the New Premises will be built, and the Build-to-Suit Lease is subject to termination if Ernst does not acquire such land. The Build-to-Suit Lease contains customary events of default, representations, warranties and covenants.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;The foregoing summary of the Build-to-Suit Lease does not purport to be complete and is qualified in its entirety by the full text of the Build-to-Suit Lease, which is filed as Exhibit 10.2 to this Quarterly Report on Form 10-Q and incorporated herein by reference.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Fourth Amendment to the Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the fourth quarter of 2019, Hillwood Enterprises, L.P. (Hillwood) is expected to purchase the project known as 1750 North Loop Road and 1601, 1701, 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California from Ascentris 105, LLC (the Purchase), which project includes the Current Premises. Effective upon the Purchase, Hillwood will become the landlord pursuant to that certain Lease Agreement dated May 2, 2017, as amended (the Lease).</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">62</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On August 30, 2019, we entered into an amendment to the Lease with Hillwood (the Fourth Lease Amendment), pursuant to which each of our rights and obligations are contingent upon the Purchase. Effective upon the Purchase, the Fourth Lease Amendment will provide for, among other things, the (i) expansion of the Current Premises by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">59,335</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of laboratory facilities located at 1701 Harbor Bay Parkway, Alameda, California (the 1701 Expansion Space), (ii) extension of the Lease term through October 31, 2031 (the New Term) and (iii) elimination of our early termination right. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Assuming the Purchase occurs, we expect to take possession of the 1701 Expansion Space on or prior to April 30, 2020 and will begin to pay rent on or within fifteen days following delivery of each respective portion of the 1701 Expansion Space. Following receipt of the entire 1701 Expansion Space, and assuming such receipt occurs on April 30, 2020 (the 1701 Expansion Space Commencement Date), the total monthly base rent under the Lease for the entire premises, consisting of the Current Premises and the 1701 Expansion Space (the Entire Premises) will be $391,580 per month, increasing throughout the remainder of the New Term to $574,975 at the end of the New Term. The aggregate contractual base rent for the entire </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">228,941</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of the Entire Premises from the 1701 Expansion Space Commencement Date through the remainder of the New Term of Lease will be approximately $67.0 million. If any portion of the 1701 Expansion Space is delivered prior to the 1701 Expansion Space Commencement Date, our base rent obligations will increase in accordance with the terms of the Lease. In addition, we will pay the New Landlord specified percentages of certain operating expenses and taxes related to the leased facilities incurred by the New Landlord.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The foregoing summary of the Fourth Lease Amendment does not purport to be complete and is qualified in its entirety by reference to the Fourth Lease Amendment, which is filed as Exhibit 10.3 to this Quarterly Report on Form 10-Q and incorporated herein by reference.</span></div><div><a id="sD003A006BF6E5F7E9A2B1DF3FA74D123"></a></div><div style="line-height:120%;padding-bottom:0px;padding-top:20px;text-align:left;padding-left:0px;text-indent:0px;-sec-extract:summary;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Item 6. Exhibits</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3/10/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312510052759/dex32.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">10-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3/10/2010</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000119312512249218/d357973dex31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5/25/2012</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit31.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Change of Registered Agent and/or Registered Office of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976714000039/exel20141009exhibit32.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Ownership and Merger Merging X-Ceptor Therapeutics, Inc. with and into Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10/15/2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit31certificateofamen.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">3.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">5/23/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000093976719000125/exhibit32amendedandrestate.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Amended and Restated Bylaws of Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">8-K</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">000-30235</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">3.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">5/23/2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/939767/000101287000001947/0001012870-00-001947.txt"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Specimen Common Stock Certificate</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">S-1,</span></div><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">as amended</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">333-96335</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">4/7/2000</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.1*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190930exhibit101.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Amendment No. 2 dated August 15, 2019 to the Clinical Trial Collaboration Agreement dated February 24, 2017, by and between Exelixis, Inc. and Bristol-Myers Squibb Company</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">63</span></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Number</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit Description</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Incorporation by Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filed</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Herewith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Form</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">File Number</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exhibit/</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Appendix</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Reference</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Filing Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190930exhibit102.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Lease Agreement dated October 25, 2019, between Ernst Development Partners, Inc. and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">10.3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190930exhibit103.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Fourth Amendment dated August 30, 2019, to Lease Agreement dated May 2, 2017, between Hillwood Enterprises, L.P. (as successor in interest to Ascentris 105, LLC) and Exelixis, Inc.</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190930exhibit311.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">31.2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190930exhibit312.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">32.1&#8225;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="exel20190930exhibit321.htm"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Instance Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Schema Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Inline </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">X</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cover Page Interactive Data File</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="9" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Formatted as Inline XBRL and contained in Exhibit 101.</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Portions of this exhibit have been omitted as being immaterial and would be competitively harmful if publicly disclosed.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#8225;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. </span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">64</span></div></div><hr style="page-break-after:always"></hr><div><a id="s0ED39B5FB7C559B0A46C8A0E58E4C56C"></a></div><div><div style="line-height:120%;padding-top:20px;text-align:left;text-indent:0px;font-size:8pt;"><a style="font-family:Calibri,sans-serif;font-size:8pt;" href="#s5FFC97A89F7456FA99870DF1EB2511D4"><span style="font-family:Calibri,sans-serif;font-size:8pt;">Table of Contents</span></a></div></div><div><br/></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">SIGNATURES</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-top:12px;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:71.42857142857143%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="4"></td></tr><tr><td style="width:28%;"></td><td style="width:8%;"></td><td style="width:8%;"></td><td style="width:56%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">E</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">XELIXIS, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;">I</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">NC.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">October&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">By:</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</span><span style="font-family:Calibri,sans-serif;font-size:9pt;">HRISTOPHER</span><span style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</span><span style="font-family:Calibri,sans-serif;font-size:9pt;">ENNER</span><span style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief&#160;Financial&#160;Officer </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;padding-top:12px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">65</span></div></div>	</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>exel20190930exhibit101.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s361754F34922AB88F2D413AEA17F5B18"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.</font></div></div><div><br></div><div style="line-height:120%;text-align:left;text-indent:576px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.1</font></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT  No. 2</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Amendment No. 2 (this </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">&#8220;Amendment No. 2&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) is effective as of the date signed by the last party to sign below  (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Amendment No. 2 Effective Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) and is made and entered into by and among Exelixis, Inc., a Delaware corporation, located at 1851 Harbor Bay Parkway, Alameda, California 94502 (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Exelixis</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) and Bristol-Myers Squibb Company, a Delaware corporation, with a place of business at Route 206 &amp; Province Line Road, Princeton, New Jersey 08543-4000, New York, New York 10154 (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">BMS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis and BMS entered into that certain Clinical Trial Collaboration Agreement dated February 24, 2017, as amended (the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Agreement&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">).</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, BMS desires to conduct separate Stage 1 Studies with Exelixis and two Third Parties and, dependent on the results of such Stage 1 Studies, potentially conduct a Stage 2 Study with Exelixis. </font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">WHEREAS</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Exelixis and BMS want to amend the Agreement to (a) include the Stage 1 Study and Stage 2 Study, (b) memorialize their understanding regarding the conduct of the Stage 1 Study and Stage 2 Study and (c) agree to certain matters relating to the rights, obligations and liabilities of the Parties relating to such Stage 1 Study and Stage 2 Study.</font></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#160;&#160;&#160;&#160;NOW, THEREFORE</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, in consideration of the foregoing premises and the mutual promises and covenants contained herein, Exelixis and BMS agree as follows: </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;The terms in this Amendment No. 2 with initial letters capitalized, whether used in the singular or the plural, shall have the meaning set forth herein, or if not defined herein, as set forth in the Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Definitions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The following definitions are hereby added to the Agreement:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stage 1 Study</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;&#160;shall mean [ * ]. </font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">Stage 2 Study</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">shall mean [ * ]. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Publication and Disclosure</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 9.7 of the Agreement is hereby amended to include the following after the last sentence:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;Notwithstanding the above, the Parties agree that BMS has the unilateral right to publish or disclose Stage 1 Study Data and Stage 2 Study Data to the extent that such Study also evaluates a Third Party compound.  Any presentation, publication or other disclosure (each a &#8220;Disclosure&#8221;), whether electronic, written or oral to any person or party not subject to an obligation of confidentiality pursuant to the Agreement, concerning or relating to the Stage 1 Study or the Stage 2 Study (solely to the extent that the Stage 2 Study includes the Exelixis Compound)shall first be provided by BMS to Exelixis for review and comment at least [ * ] prior to submission for publication or other disclosure. Where Exelixis determines that such proposed presentation, publication or other disclosure contains or may contain confidential or proprietary information or patentable subject matter, it shall so notify BMS within [ * ] of receipt thereof, and BMS shall remove such confidential or proprietary information, or in the case of patentable subject matter, delay such presentation, publication or other disclosure for an additional [ * ] to allow sufficient time for the drafting and filing of a patent application directed to such subject matter.&#8221;</font></div><div style="line-height:120%;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Study Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis hereby agrees that BMS has the right to fully exploit, without accounting to Exelixis, the Stage 1 Combined Therapy Study Data solely for the limited purpose of enabling BMS to determine whether to conduct, and to conduct, a Stage 2 Study and whether to use the Exelixis Compound and/or a Compound of a Third Party, provided that BMS may not disclose the Stage 1 Combined Therapy Study Data to a Third Party, except to the extent reasonably required to obtain Regulatory Approval of a combination therapy involving the BMS Compound and a Third Party Compound.  For clarity, Exelixis&#8217; rights to </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:Calibri,sans-serif;font-size:11pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Study Data related to the Exelixis Compound, including but not limited to Study Data arising from the Stage 1 Study and the Stage 2 Study (if applicable), are unchanged under the Agreement.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Combined Therapy Inventions and Patent Rights</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis hereby agrees that BMS has the right to exploit Stage 1 Combined Therapy Inventions and Combined Therapy Patent Rights (if any) solely as needed to (A) conduct a Stage 2 Study with a Third Party and (B) obtain Regulatory Approval of a combination therapy involving the BMS Compound and a Third Party Compound.  For clarity, to the extent that such Combined Therapy Inventions or Combined Therapy Patent Rights disclose or claim the Exelixis Compound, BMS shall notify Exelixis as provided in the Agreement and the terms of the Agreement shall apply.  Exelixis shall grant, and hereby does grant, to BMS a non-exclusive, sublicensable license to such Combined Therapy Inventions and Combined Therapy Patent Rights to conduct such Stage 2 Study and obtain Regulatory Approval only.  For clarity, such license does not extend to commercial uses or sales for BMS or such Third Party.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Combined Therapy Regulatory Documentation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis hereby agrees that BMS has the right to exploit Combined Therapy Regulatory Documentation related to combinations with Third Parties only, without accounting to Exelixis, solely for the limited purpose of (A) conducting a Stage 2 Study with a Third Party and (B) obtaining Regulatory Approval of a combination therapy involving the BMS Compound and a Third Party Compound.  For clarity, Exelixis&#8217; rights to Combined Therapy Regulatory Documentation related to the Exelixis Compound, including but not limited to Study Data arising from the Stage 1 Study and the Stage 2 Study (if applicable), are unchanged under the Agreement.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Other Agreements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  BMS represents and warrants that its agreements with Third Parties related to the Stage 1 Studies and the Stage 2 Study grant Exelixis rights commensurate to the rights granted to BMS and such Third Parties under this Amendment No. 2, and that pursuant to any such agreements with Third Parties, Exelixis has the right to exploit Study Data, Combination Therapy Inventions and Combination Therapy Patent Rights, and Combined Therapy Regulatory Documentation related to such Stage 1 Studies and Stage 2 Study as otherwise permitted under the Agreement. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.&#160;&#160;&#160;&#160;Exhibit A-1 of the Agreement is hereby amended to include the Stage 1 Study and the Stage 2 Study.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.&#160;&#160;&#160;&#160;The JDC has agreed that there are no Shared Costs for the Stage 1 Study or the Stage 2 Study (each, for clarity, a Combined Therapy Trial under the Agreement to the extent each includes an Exelixis Compound) identified in Exhibt A-1. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Stage 2 Selection Criteria</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis hereby acknowledges that the Stage 1 Protocol will provide BMS with the selection criteria it needs to select either Exelixis&#8217; Compound and/or a Compound of a Third Party to conduct the Stage 2 Study, and that BMS will make such selection in its sole discretion.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">.&#160;&#160;&#160;&#160;No Assurances</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis hereby acknowledges that it has received no assurances that the Exelixis Compound will be selected by BMS to conduct a Stage 2 Study and fully understands that BMS may select a Compound of a Third Party to conduct a Stage 2 Study. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Commitment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Exelixis hereby acknowledges that it commits to supply the Exelixis Compound to conduct the Stage 2 Study, if BMS selects the Exelixis Compound for the Stage 2 Study, which Stage 2 Study will be deemed to be a Combined Therapy Trial under the Agreement to the extent such Stage 2 Study relates to the combination of the Exelixis Compound and the BMS Compound, </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Stage 2 Study with the BMS Compound, Exelixis Compound and a Third Party Compound</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the event that a Stage 2 Study involves an Exelixis Compound, a BMS Compound and a Third Party Compound, Exelixis hereby grants to BMS and such Third Party the right to use and disclose Stage 1 and Stage 2 Study Data, Stage 1 and Stage 2 Combined Therapy Inventions, Stage 1 and Stage 2 Combined Patent Rights and Stage 1 and Stage 2 Combined Therapy Regulatory Documentation to the extent needed to seek Regulatory Approval of a combined therapy involving the BMS Compound and a Third Party Compound.  BMS hereby grants to Exelixis the right to use and disclose such Stage Stage 1 and Stage 2 Study Data, Stage 1 and Stage 2 Combined Therapy Inventions, Stage 1 and Stage 2 Combined Patent Rights and Stage 1 and Stage 2 Combined Therapy Regulatory Documentation to the extent needed to seek Regulatory Approval of a combined therapy involving the Exelixis Compound and the BMS Compound.  Exelixis shall grant to BMS and such Third Party, and hereby does grant to BMS and such Third Party, a non-exclusive, sublicensable license to such Stage 1 and Stage 2 Study Data, Stage 1 and Stage 2 Combined Therapy Inventions, Stage 1 and Stage 2 Combined Patent Rights and Stage 1 and Stage 2 Combined Therapy Regulatory </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Documentation to the extent needed to seek Regulatory Approval.  For clarity, such license does not extend to commercial uses or sales for BMS or such Third Party.  BMS and such Third Party shall grant to Exelixis, and hereby do grant to Exelixis, a non-exclusive, sublicensable license to such Stage 1 and Stage 2 Study Data, Stage 1 and Stage 2 Combined Therapy Inventions, Stage 1 and Stage 2 Combined Patent Rights and Stage 1 and Stage 2 Combined Therapy Regulatory Documentation to the extent needed to seek Regulatory Approval.  For clarity, such license does not extend to commercial uses or sales for Exelixis.  To the extent that an additional agreement is required to give full effect to this Paragraph 13 and/or to protect the Parties&#8217; rights with respect to confidentiality and the use of information, Exelixis agrees to enter into negotiations for such an agreement with such Third Party on reasonable commercial terms.   </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.&#160;&#160;&#160;&#160;Except as expressly set forth herein, all provisions of the Agreement shall remain unchanged and in full force and effect.  </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.&#160;&#160;&#160;&#160;This Amendment No. 2 shall be governed and construed in accordance with the internal laws of the State of New York, USA, excluding any choice of law rules that may direct the application of the laws.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16.&#160;&#160;&#160;&#160;This Amendment No. 2 may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one (1) and the same instrument.  This Amendment No. 2 may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each party hereto as if they were original signatures. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signature page follows]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;IN WITNESS WHEREOF, Exelixis and BMS, intending to be legally bound hereby, have caused this Amendment No. 2 to be executed by their duly authorized representatives as of the date(s) below.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:87.6984126984127%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exelixis, Inc.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Bristol-Myers Squibb Company</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: /s/ Gisela Schwab         </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By: /s/ Nancy P. Forrest         </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:    Gisela Schwab      </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Name:    Nancy P. Forrest      </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: President, Product Development and Med Affairs &amp; CMO</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date:   8/15/2019 </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;padding-left:40px;text-indent:-40px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Title: Vice President, Global Allicance Management</font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Date: Aug 12, 2019    </font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signature Page to Amendment No. 2]</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">EXHIBIT A-1</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">New Combined Therapy Trials Expected to be Conducted</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[ * ]</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>exel20190930exhibit102.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE19F9926FB75C7F3AA9821652DD5C6EE"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 10.2</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">FOURTH AMENDMENT TO LEASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">THIS FOURTH AMENDMENT TO LEASE AGREEMENT (this &#8220;Fourth Amendment&#8221;) is made and entered into on August 30, 2019 (the "Execution Date") by and between HILLWOOD ENTERPRISES, L.P., a Texas limited partnership ("Hillwood Enterprises"), and EXELIXIS, INC., a Delaware corporation (&#8220;Tenant&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">RECITALS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A.&#160;&#160;&#160;&#160;Ascentris 105, LLC (&#8220;Existing Landlord&#8221;) and Tenant are parties to (i)&#160;that certain Lease Agreement dated May&#160;2, 2017 (the &#8220;Original Lease&#8221;) for premises consisting of approximately 110,783 square feet of Rentable Area (the &#8220;Original Premises&#8221;) in the multiple building project known as 1750 North Loop Road and 1601, 1701, 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California (as further defined in the Original Lease, the &#8220;Project&#8221;), and (ii)&#160;that certain Agreement for Conditional Option to Amend Lease dated as of May&#160;2, 2017 (the &#8220;Additional 1801 Space Option Agreement&#8221;), pursuant to which Tenant had the right to add Suite&#160;125 consisting of approximately 17,075 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached to the First Amendment (as defined below) (the &#8220;Additional 1801 Space&#8221;) on the first floor of the 1801 Building (as defined in the Original Lease) to the Premises, by amending the Original Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B.&#160;&#160;&#160;&#160;Existing Landlord and Tenant are parties to that certain First Amendment to Lease Agreement dated October&#160;16, 2017 (the &#8220;First Amendment&#8221;), pursuant to which the Original Premises was expanded to include the Additional 1801 Space and the premises known as Suite&#160;115 consisting of 2,703 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A&#8209;2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached to the First Amendment (the &#8220;Additional 1751 Space&#8221;) on the first floor of the 1751 Building (as defined in the Original Lease).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">C.&#160;&#160;&#160;&#160;Existing Landlord and Tenant are parties to the certain Second Amendment to Lease Agreement dated June&#160;13, 2018 (the &#8220;Second Amendment&#8221;), pursuant to which, among other things, the Premises under the Lease was further expanded to include the premises known as Suite&#160;150 consisting of 4,204 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A&#8209;3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached to the Second Amendment (the &#8220;Second Amendment Expansion 1751 Space&#8221;) on the first floor of the 1751 Building.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">D.&#160;&#160;&#160;&#160;Existing Landlord and Tenant are parties to the certain Third Amendment to Lease Agreement dated April 1, 2019 (the &#8220;Third Amendment&#8221;), pursuant to which, among other things, the Tenant agreed to surrender the Additional 1751 Space and to expand the Premises under the Lease to include the premises known as Suites 100, 120, and 150 and common areas of the building located at 1601 Harbor Bay Parkway, Alameda, California (the &#8220;1601 Building&#8221;), consisting of 37,544 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A&#8209;3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached to the Third Amendment (the &#8220;1601 Space&#8221;). The 1601 Space comprises the entirety of the 1601 Building. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">E.&#160;&#160;&#160;&#160;The Original Premises, as expanded by the Additional 1801 Space, the Second Amendment Expansion 1751 Space, and the 1601 Space, is hereinafter referred to as the &#8220;Existing Premises.&#8221;  The Original Lease, as amended by the First Amendment, the Second Amendment, and the Third Amendment, is hereinafter referred to as the &#8220;Lease.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">F.&#160;&#160;&#160;&#160;Existing Landlord, as seller, and Hillwood Enterprises, as purchaser, have entered into a purchase and sale agreement for the Project (as the same may be amended from time to time, the "Contract").  The closing of the acquisition of the Project pursuant to the terms of the Contract is anticipated to occur on or about September 27, 2019, subject to extensions as set forth in the Contract (as such date may be extended, &#8220;Closing&#8221;).  As used herein, (i) the term "Landlord" shall mean either Hillwood Enterprises or the successor-in-interest to the rights and obligations of Hillwood Enterprises under the Contract acquiring fee title to the Project at Closing and (ii) the term &#8220;Fourth Amendment Effective Date&#8221; shall mean the date of the Closing.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">G.&#160;&#160;&#160;&#160;Hillwood Enterprises&#8217; election to acquire the Project under the Contract is contingent on Tenant&#8217;s agreeing to amend the terms of the Lease as described in clauses (i), (ii) and (iii) immediately below, and, prior to </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Closing, Hillwood Enterprises and Tenant desire to enter into this Fourth Amendment to agree on the terms and conditions upon which the parties will, conditioned on occurrence of the Closing, (i)&#160;extend the Term to expire on October 31, 2031 (as provided below in Section 3 below), (ii) expand the Existing Premises to include the premises known as Suites 100, 125, 150, 115, and 200 and common areas of the building located at 1701 Harbor Bay Parkway, Alameda, California (the &#8220;1701 Building&#8221;), consisting of 59,335 square feet of Rentable Area and depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit A-4</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached hereto (the &#8220;1701 Space&#8221;), and (iii) terminate Tenant&#8217;s early termination right pursuant to Section 29 of the Lease. The 1701 Space comprises the entirety of the 1701 Building. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AMENDMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">NOW THEREFORE, in consideration of good and valuable consideration and the mutual agreements herein contained, and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties do hereby agree as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.&#160;&#160;&#160;&#160;Defined Terms</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All capitalized terms used but not defined in this Fourth Amendment will have the meanings set forth for such terms in the Lease.  All terms that are defined in this Fourth Amendment and used in any provisions that are added to the Lease pursuant to this Fourth Amendment will have the meanings in the Lease set forth for such terms in this Fourth Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.&#160;&#160;&#160;&#160;Delivery and Demise of the 1701 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Lease of 1701 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the terms, covenants, conditions and provisions of the Lease, as amended by this Fourth Amendment, Landlord leases to Tenant and Tenant leases from Landlord the 1701 Space for the remainder of the Term (as such term is amended in Section 3 below).  On the applicable &#8220;Start Dates&#8221; (as defined in Section 2(c) below) for the 1701 Space, Landlord shall Deliver to Tenant, and Tenant shall accept possession of, the applicable portions of the 1701 Space in the following condition notwithstanding anything in Section 2.2 of the Lease to the contrary: in its as-is, where-as condition, provided that the 1701 Space shall be vacant and broom clean and fully decommissioned with respect to any Hazardous Materials used therein.  Landlord represents that, to Landlord&#8217;s knowledge, (a)&#160;Suite&#160;100 of the 1701 Space is currently occupied by a tenant pursuant to a lease (the &#8220;Current Suite&#160;100 Lease&#8221;), which is set to expire on November 30, 2023; (b)&#160;Suite&#160;125 of the 1701 Space is currently occupied by a tenant pursuant to a lease (the &#8220;Current Suite&#160;125 Lease&#8221;), which is set to expire on May 31, 2021; (c)&#160;Suite 150 of the 1701 Space is currently used for the property management office; and (d) the Closing is conditioned on the seller under the Contract delivering Suites 115 and 200 of the 1701 Space vacant and unleased at Closing. Landlord will use commercially reasonable efforts to Deliver (i)&#160;Suite&#160;100 of the 1701 Space to Tenant within 15&#160;days following the date that the tenant under the Current Suite&#160;100 Lease vacates Suite&#160;100 of the 1701 Space, (ii) Suite&#160;125 of the 1701 Space to Tenant within 15&#160;days following the date that the tenant under the Current Suite&#160;125 Lease vacates Suite&#160;125 of the 1701 Space, (iii)&#160;Suites&#160;115 and 200 of the 1701 Space to Tenant within 15 days after the Closing, and (iv)&#160;Suite&#160;150 of the 1701 Space within 15 days following the date that the property management office is relocated to an alternative location at the Project. Landlord shall use commercially reasonable efforts to relocate the property manager currently occupying Suite 150 of the 1701 Space as soon as reasonably practical after the Closing. Landlord shall use commercially reasonable efforts to relocate the tenants currently occupying Suites 100 and 125 of the 1701 Space as soon as reasonably practical after the Closing.  Tenant shall use reasonable efforts to cooperate with Landlord to relocate such tenants, which efforts shall include, without limitation, negotiating in good faith with Landlord to vacate a portion of the Premises located in the 1751 Building to make space available to such tenants.  Notwithstanding anything to the contrary herein, until all of the 1701 Space has been Delivered to Tenant, the 1701 Building shall be considered a Multi User Building and Tenant shall have the non-exclusive right to use the interior Common Areas within the 1701 Building.  Upon the Delivery of the final portion of the 1701 Space, the 1701 Building will be considered a Single User Building fully leased by Tenant and there shall be no interior Common Areas therein.  As used herein, &#8220;Landlord&#8217;s knowledge&#8221; shall mean the current, actual knowledge of Joseph Ernst without a duty to investigate or inquire.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1701 Space Rent Commencement Dates</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Suite 100</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Commencing on the date that is 15 days after Landlord Delivers Suite 100 of the 1701 Space in accordance with Section 2(a), Tenant shall pay Landlord Base Rent for such space according to Section 8(b) and shall pay Additional Rent for such space according to Section&#160;3.2 of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Suite 125</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Commencing on the date that is 15 days after Landlord Delivers Suite 125 of the 1701 Space in accordance with Section 2(a), Tenant shall pay Landlord Base Rent for such space according to Section 8(b) and shall pay Additional Rent for such space according to Section&#160;3.2 of the Lease. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Suite 150</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Commencing on the later of December 1, 2019 and the date Landlord Delivers Suite 150 of the 1701 Space in accordance with Section 2(a), Tenant shall pay Landlord Base Rent for such space according to Section 8(b) and shall pay Additional Rent for such space according to Section&#160;3.2 of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Suites 115 and 200</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Commencing on the later of December 1, 2019 and the date that Landlord Delivers Suites 115 and 200 of the 1701 Space in accordance with Section 2(a), Tenant shall pay Landlord Base Rent for such space according to Section 8(b) and shall pay Additional Rent for such space according to Section&#160;3.2 of the Lease.&#160; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Start Dates</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  &#8220;Start Date&#8221; with respect to each portion of the 1701 Space means the date that Landlord Delivers such portion to Tenant. The targeted Start Dates with respect to the 1701 Space are as follows:</font></div><div style="line-height:120%;padding-left:102px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:78.84615384615384%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:39%;"></td><td style="width:61%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Portion of 1701 Space</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Targeted Start Date</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suites 115 and 200</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15 days after the Closing</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite&#160;100</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Within 6 months after the Closing</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite&#160;125</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Within 6 months after the Closing</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Suite&#160;150</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #00000a;border-right:1px solid #00000a;border-top:1px solid #00000a;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Within 6 months after the Closing</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Landlord shall have no liability to Tenant for its failure to deliver any portion of the 1701 Space to Tenant on the applicable targeted Start Date if a delay in Delivery is caused by a tenant&#8217;s holding over in a portion of the 1701 Space or refusal to relocate from its portion of the 1701 Space, so long as Landlord is using commercially reasonable efforts to cause such tenant to vacate or relocate from the applicable portion of the 1701 Space, which commercially reasonable efforts shall include filing an unlawful detainer action if a tenant is holding over and such holdover continues for a period in excess of 30 days.  </font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">If the Start Date for a specified portion of the 1701 Space has not occurred within 120&#160;days after the targeted Start Date specified in this Section 1(c), then Tenant will have the right to terminate the Lease with respect to such undelivered portion of the 1701 Space (the &#8220;Terminated Space&#8221;) by delivering written notice of termination to Landlord not more than 30&#160;days after the end of such 120&#8209;day period.  Upon such termination, Tenant will, upon Landlord&#8217;s request, execute and deliver an agreement in recordable form containing a release and surrender of all right, title and interest in and to the Terminated Space except as otherwise provided in this paragraph; neither Landlord nor Tenant will have any further obligations to each other with respect to the Terminated Space under this Amendment, including, without limitation, any obligations to pay for work previously performed in the Terminated Space; all improvements to the Terminated Space will become and remain the property of Landlord; Landlord will refund to Tenant any sums paid to Landlord by Tenant for the Terminated Space in connection with the Lease.  Such termination and refund rights will be Tenant&#8217;s sole and exclusive remedies for Landlord&#8217;s failure to deliver any portion of the 1701 Space by the targeted Start Dates described above other than the right to seek specific performance to enforce Landlord&#8217;s obligations to use commercially reasonable efforts to relocate the tenants in Suites 100, 125 and 150 of the </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1701 Space and thereafter deliver such space to Tenant, and Tenant expressly waives any other rights, claims or remedies that Tenant might otherwise have against Landlord by reason of Landlord&#8217;s failure to deliver any portion of the 1701 Space.</font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.&#160;&#160;&#160;&#160;Term</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 1.1(h) of the Lease is hereby replaced in its entirety with the following as of the Fourth Amendment Effective Date: </font></div><div style="line-height:120%;text-align:justify;padding-left:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;(h)&#160;&#160;&#160;&#160;&#8220;Term&#8221; means the duration of this Lease, beginning on February 1, 2018 (the &#8220;Commencement Date&#8221;) and ending on the &#8220;Expiration Date&#8221; (as defined below), unless terminated earlier or extended further as provided in this Lease.  The &#8220;Expiration Date&#8221; means October 31, 2031.&#8221;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.&#160;&#160;&#160;&#160;Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1701 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Fourth Amendment Effective Date (as defined in Section 26 below), Section&#160;1.1(d) of the Original Lease is hereby amended by the addition of the following as Section&#160;1.1(d)(v):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;(v)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;font-weight:bold;">1701 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Premises known as Suites&#160;100, 125, 150, 115 and 200 and common areas located at the 1701 Building identified on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;1701 Space&#8221;), which constitute the entire 1701 Building and contain approximately 59,335 square feet of the Rentable Area, which shall not be subject to re&#8209;measurement except as set forth in Section 2.6 below.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Rentable Area of the Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Fourth Amendment Effective Date, the last paragraph of Section&#160;1.1(d) of the Original Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;The Premises contains total square feet of Rentable Area equal to the total square feet of Rentable Area of the Premises that has been Delivered to Tenant (see Exhibit A of the Original Lease for the Rentable Area table). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;The Rentable Area table set forth in Exhibit&#160;A of the Original Lease, as previously replaced, is hereby replaced with the Rentable Area table attached hereto as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;A-4</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;of this Fourth Amendment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.&#160;&#160;&#160;&#160;1701 Building</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Fourth Amendment Effective Date, Section&#160;1.1(e) of the Original Lease is hereby amended by the addition of the following as Section&#160;1.1(e)(v):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;(v)&#160;&#160;&#160;&#160;1701 Harbor Bay Parkway, Alameda, California, in which the 1701 Space is located (the &#8220;1701 Building&#8221;), which Building contains approximately 59,335 square feet of Rentable Area and is a Single User Building.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.&#160;&#160;&#160;&#160;Project</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Fourth Amendment Effective Date, Section&#160;1.1(f) of the Original Lease is hereby amended by replacing &#8220;386,283&#8221; with &#8220;385,967&#8221;.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">7.&#160;&#160;&#160;&#160;Exhibits</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Fourth Amendment Effective Date, Exhibit&#160;A to the Lease, entitled &#8220;Plan Delineating the Premises and Tenant Maintained Outdoor Areas&#8221; is hereby replaced by the updated Exhibit&#160;A-4 attached hereto. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">8.&#160;&#160;&#160;&#160;Base Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section&#160;1.1(i) of the Original Lease, as previously amended, is hereby further amended as of the Fourth Amendment Effective Date as follows:  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;The Base Rent schedule for the Existing Premises for the remainder of the Term shall be paid in accordance with the schedules for the Existing Premises shown on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Commencing on the dates stated in Section 2(b) above, Base Rent for the 1701 Space, or applicable portion thereof, shall be paid in accordance with the schedule for the 1701 Space shown on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. If the commencement of Base Rent for a portion of the 1701 Space does not occur on the first day of the month, then the Base Rent paid during such partial month shall be prorated based on the number of days in such partial month from and after such Base Rent commencement date through the end of the month.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">9.&#160;&#160;&#160;&#160;Building Shares; Project Shares</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1801 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Fourth Amendment Effective Date, Section&#160;1.1(k)(ii) of the Original Lease is hereby further amended so that the 1801 Project Share is 15.14%, subject to adjustment pursuant to Section&#160;2.6 of the Original Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1851 Project Share.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Effective as of the Fourth Amendment Effective Date, Section&#160;1.1(k)(iii) of the Original Lease is hereby further amended so that the 1851 Project Share is 14.89%, subject to adjustment pursuant to Section&#160;2.6 of the Original Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1751 Building Share; 1751 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Fourth Amendment Effective Date, (i) Section 1.1(e)(i) of the Original Lease is hereby amended to delete the phrase &#8220;74,390 square feet of Rentable Area&#8221; and replace such phrase with &#8220;73,854 square feet of Rentable Area&#8221;, (ii) Section 1.1(j)(i) of the Original Lease is amended so that the 1751 Building Share is 21.89%, subject to adjustment pursuant to Section 2.6 of the Original Lease, and (iii) Section&#160;1.1(k)(i) of the Original Lease is hereby amended so that the 1751 Project Share is 4.19%, subject to adjustment pursuant to Section&#160;2.6 of the Original Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1601 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Fourth Amendment Effective Date, Section&#160;1.1(k)(iv) of the Original Lease is hereby amended so that the 1601 Project Share is 9.73%, subject to adjustment pursuant to Section&#160;2.6 of the Original Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1701 Building Share; 1701 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the Fourth Amendment Effective Date, the Lease is hereby amended as follows:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1701 Building Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section&#160;1.1(j) of the Original Lease is hereby further amended by adding the following as Section&#160;1.1(j)(v):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;(v)&#160;&#160;&#160;&#160;With respect to the 1701 Building, percentage obtained by dividing the Rentable Area of the 1701 Space which has been Delivered by Landlord by the total Rentable Area of the 1701 Building and multiplying the resulting quotient by 100 and rounding to the second decimal place (the &#8220;1701 Building Share&#8221;).  The 1701 Building Share will be 100%, subject to adjustment pursuant to Section&#160;2.6 below.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">1701 Project Share</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section&#160;1.1(k) of the Original Lease is hereby further amended by adding the following as Section&#160;1.1(k)(v):</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:144px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;(v)&#160;&#160;&#160;&#160;With respect to the 1701 Building, percentage obtained by dividing the Rentable Area of the 1701 Space which has been Delivered by Landlord by the total rentable square footage of the Project and multiplying the resulting quotient by 100 and rounding to the second decimal place (the &#8220;1701 Project Share&#8221;).  The 1701 Project Share will be 15.37%, subject to adjustment pursuant to Section&#160;2.6 below.&#8221;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:96px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;Notwithstanding the foregoing, prior to the last Start Date of the 1701 Space, the 1701 Building Share and the 1701 Project Share will be adjusted proportionately to apply only to the portion of the 1701 Space that has been Delivered to Tenant.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">10.&#160;&#160;&#160;&#160;Parking; Signage</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective as of the &#8220;Start Date&#8221; for Suite 100 of the 1701 Space, Section&#160;19 of the Lease is hereby amended so that Tenant may utilize up to 14 additional unassigned parking spaces within the Project at no charge. Effective as of the &#8220;Start Date&#8221; for Suite 125 of the 1701 Space, Section&#160;19 of the Lease is hereby amended so that Tenant may utilize up to 8 additional unassigned parking spaces within the Project at no charge. Effective as of the &#8220;Start Date&#8221; for Suite 150 of the 1701 Space, Section&#160;19 of the Lease is hereby amended so that Tenant may utilize up to 3 additional unassigned parking spaces within the Project at no charge. Effective as of the &#8220;Start Date&#8221; for Suites 115 and 200 of the 1701 Space, Section&#160;19 of the Lease is hereby amended so that Tenant may utilize up to 182 additional unassigned parking spaces within the Project at no charge. Accordingly, following the &#8220;Start Dates&#8221; for all 1701 Space and 1601 Space, Tenant may utilize up to 800 unassigned parking spaces within the Project at no charge. Notwithstanding anything in the Lease to the contrary, including but not limited to Section 1.3(g) of the Lease, Landlord may enter parking agreements with an affiliate of Hillwood Enterprises that owns property adjacent to the east of the Project (the &#8220;BTS Site&#8221;) to permit a parking allocation for the buildings at the Project (other than the building located at 1750 North Loop Road) and the BTS Site of three (3) spaces per 1,000 square feet of building area.  Section&#160;21.3 of the Lease is hereby amended so that Tenant may install exterior signs on the 1601 Building and, effective as of the first &#8220;Start Date&#8221; for the 1701 Space, the 1701 Building in accordance with the terms of Section 21.3 of the Lease. Such signage shall be substantially similar to the signage at the 1801 Building and the 1851 Building.    </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">11.&#160;&#160;&#160;&#160;Single User Buildings; Excluded and Common Areas</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding Section 11 of the Third Amendment or any other provision in the Lease to the contrary, the 1601 Building and any other Single User Building shall be considered a Single User Building for the purposes of Article 5 of the Lease (Services and Utilities; Repair and Maintenance Obligations). Notwithstanding anything in this Amendment or the Lease (including without limitation Section 1.3(e) of the Lease) to the contrary, the areas of the 1701 Space shown as &#8220;Restricted Common Area&#8221; on Exhibit A-4 (the &#8220;Restricted Common Areas&#8221;) shall be deemed to be Common Areas under the Lease except that Tenant shall have no right to access or use the Restricted Common Areas; provided, that, upon not less than 24 hours&#8217; prior actual notice to Landlord (except in the event of an emergency, in which case no notice shall be required), Tenant shall have the right to access the Restricted Common Areas to the extent necessary to access, repair, maintain, and modify the panels that control the fire and life safety systems serving the Premises. The Restricted Common Areas shall be accessible to Landlord in accordance with Section 2.5 of the Lease in the same manner in which the Landlord may access the roof and other structural elements of a Single User Building. Landlord may lease space in the Restricted Common Areas for the storage and installation of telecommunications equipment, and Tenant shall permit reasonable access to the Restricted Common Areas to such tenants and shall not interfere with any such tenant&#8217;s operations of its telecommunications equipment or diminish any such tenant&#8217;s signal quality. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">12.&#160;&#160;&#160;&#160;Tenant Alterations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant may construct any Tenant Alterations in the 1701 Space in accordance with the Lease, including but not limited to Section 7 of the Original Lease.  Landlord hereby consents to Tenant&#8217;s use of DGA as the architect and the provisions of (a)&#160;the tenth sentence of Section&#160;8 and (b)&#160;Section 19 of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;of the Original Lease shall apply as to the 1701 Space.  Landlord shall not be obligated to make or pay for any alterations or improvements to the 1701 Space whatsoever or to the Premises other than in connection with Landlord&#8217;s maintenance and repair obligations expressly stated in the Lease. The parties agree that any Tenant Alterations constructed in the 1701 Space in accordance with the Lease shall become the Landlord&#8217;s property upon installation and will remain Landlord&#8217;s property at the expiration or earlier termination of the Term.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">13.&#160;&#160;&#160;&#160;Occupancy Estoppel Certificate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant will deliver an Occupancy Estoppel Certificate in substantially the form attached as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibit&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to the Original Lease, as previously amended, for the Start Dates, move-in dates and Base Rent commencement dates for the 1701 Space.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">14.&#160;&#160;&#160;&#160;1750 Right of First Offer; 1701 Space Right of First Offer Terminated</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Effective on the Fourth Amendment Effective Date, the right of first offer in Section&#160;30 of the Original Lease shall also apply as to the building located at 1750 North Loop Road. Tenant&#8217;s rights pursuant to Section 30 of the Original Lease are terminated with respect to the 1701 Space and shall no longer have any force or effect with respect the 1701 Space.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">15.&#160;&#160;&#160;&#160;Tenant&#8217;s Waiver of Termination Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant&#8217;s right to terminate the Lease pursuant to Section 29 of the Original Lease is hereby terminated, and Section 29 of the Original Lease shall have no further force or effect.  </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">16.&#160;&#160;&#160;&#160;Use</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Section 1.1(g) of the Lease is hereby revised to permit vivariums and manufacturing in all of the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">17.&#160;&#160;&#160;&#160;Brokers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant represent and warrant that no broker or agent negotiated or was instrumental in negotiating or consummating this Fourth Amendment.  Neither party knows of any real estate broker or agent who is or might be entitled to a commission or compensation in connection with this Fourth Amendment other than other than Greg Domanico of Kidder Mathews (&#8220;Broker&#8221;).  Tenant and Landlord will indemnify and hold each other harmless from all damages paid or incurred by the other resulting from any claims asserted against either party by brokers or agents claiming through the other party, except Tenant shall not indemnify Landlord from claims by Broker.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18.&#160;&#160;&#160;&#160;Whole Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Fourth Amendment sets forth the entire agreement between the parties with respect to the matters set forth herein.  There have been no additional oral or written representations or agreements.  Except as amended herein, or in a future writing signed by both parties, there shall be no other changes or modifications to the Lease between the parties and the Lease and the terms and provision contained therein shall remain in full force and effect. The terms of this Amendment will control over any conflicts between it and the terms of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">19.&#160;&#160;&#160;&#160;Successors and Assigns</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Fourth Amendment shall be binding upon the parties hereto, their heirs, successors and assigns.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">20.&#160;&#160;&#160;&#160;Ratification</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except as amended by this Fourth Amendment, the Lease has not been amended, and the parties ratify and confirm the Lease, as amended by the Fourth Amendment, as being in full force and effect.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">21.&#160;&#160;&#160;&#160;Counterparts; Execution by Telecopy</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Fourth Amendment may be executed in counterparts, each of which will constitute an original, but all of which, when taken together, will constitute but one agreement.  Executed copies hereof may be delivered by telecopier or other electronic means, and upon receipt will be deemed originals and binding upon the parties hereto, regardless of whether originals are delivered thereafter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">22.&#160;&#160;&#160;&#160;Representations; Occupancy Certificate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Tenant certifies, represents and warrants to Landlord that, except as to the Overpayment Amount (defined below): (i) a true, correct, and complete copy of the Lease has been provided to Hillwood Enterprises; (ii) the Lease is in full force and effect and has not been modified or amended, except as otherwise set forth herein; (iii) to Tenant&#8217;s actual knowledge, without inquiry, neither Existing Landlord nor Tenant is in default under the Lease and there does not exist any facts or circumstances which, with the giving of notice, the passage of time or both, would constitute a default by either Existing Landlord or Tenant; (iv) to Tenant&#8217;s actual knowledge, without inquiry, all conditions of the Lease to be performed by the Existing Landlord and necessary to the enforceability of the Lease have been satisfied; (v) to Tenant&#8217;s actual knowledge, without inquiry, all improvements or work required under the Lease to be made by the Existing Landlord to date, if any, have been completed to the satisfaction of the Tenant; (vi) except with respect to those under the Third Amendment, allowances or other amounts payable by Existing Landlord to Tenant have been paid in full; (vii) to Tenant&#8217;s actual knowledge, without inquiry, charges for all labor and materials used or furnished in connection with improvements and/or alterations made for the account of the Tenant at the Premises and common areas have been paid in full; (viii)&#160;to Tenant&#8217;s actual knowledge, without inquiry, on the Execution Date there are no existing defenses, offsets, or claims that the Tenant has against the enforcement of the Lease by the Existing Landlord; (ix) Tenant has no option or preferential right to purchase all or any part of the Project, or the land of which the Project are a part; (x) Tenant has no rights or interest with respect to the Premises other than as a tenant under the Lease; (xi) Tenant has not assigned or sublet its interest in the Premises; and (xii) as of the Execution Date, there are no actions, whether voluntary or otherwise, pending against the Tenant under the bankruptcy or insolvency laws of the United States or any state thereof.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Prior to the Closing, upon ten (10) business days&#8217; request by Existing Landlord, Tenant shall deliver to Existing Landlord (for the benefit of Existing Landlord and Landlord) an Occupancy Certificate in accordance with  Section 16 of the Lease. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">23.&#160;&#160;&#160;&#160;Disclosures</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Pursuant to California Civil Code Section 1938, Landlord hereby notifies Tenant that neither the Buildings nor the Premises have been inspected by a Certified Access Specialist. A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">24.&#160;&#160;&#160;&#160;Intentionally deleted.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">25.&#160;&#160;&#160;&#160;No Restoration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall not be required to remove any alterations or improvements located in the Premises as of the Execution Date upon the surrender of the Premises pursuant to Section 15.1 of the Lease. The foregoing shall not be interpreted to limit Tenant&#8217;s obligation to repair damage to the Premises caused by its removal of any alterations or improvements that it is permitted to remove under the Lease. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">26.&#160;&#160;&#160;&#160;Closing; Termination of this Fourth Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant agree that this Fourth Amendment and the obligations of Landlord and Tenant hereunder are contingent on the Closing, and, if the Contract is terminated, then this Fourth Amendment shall terminate, and neither party shall have any obligation to the other hereunder; provided, however, Landlord shall promptly notify Tenant of the termination of the Contract. For the sake of clarity, the parties acknowledge that this Fourth Amendment is a binding agreement between Hillwood Enterprises and its successor-in-interest to the rights and obligations of Hillwood Enterprises under the Contract acquiring fee title to the Project at Closing (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;the Landlord) and Tenant, with all obligations contingent upon the Closing (i.e. prior to the Fourth Amendment Effective Date, neither party shall have a right to terminate this Fourth Amendment except for a failure of the Closing to timely occur as expressly provided below). Upon the Closing, no further documentation shall be required to evidence the effectiveness of this Fourth Amendment; provided, however, at the request of either party, both parties will execute a document confirming the occurrence of the Fourth Amendment Effective Date.  Tenant acknowledges and agrees that, in connection with the Closing, Hillwood Enterprises will assign its rights under the Contract to an entity affiliated with Hillwood Enterprises that will be formed to acquire the Project.  Accordingly, Hillwood Enterprises shall assign its right and obligations under this Fourth Amendment to the successor-in-interest to the rights and obligations of Hillwood Enterprises under the Contract acquiring fee title to the Project at Closing (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;the Landlord); provided, however, prior to the Closing this Fourth Amendment may not be assigned by Hillwood Enterprises to any other parties.  If the Closing has not occurred on or before March 31, 2020, then either Landlord or Tenant may terminate this Fourth Amendment, prior to the Closing, by prior written notice to the other party. Tenant acknowledges that (i) prior to the Closing, Landlord has no right, title, or interest in the Buildings and (ii) Landlord has no right to bind or act on behalf of the Existing Landlord. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">27.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional 1751 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord acknowledges that, for a period beginning on the Third Amendment Vacation Date and continuing through August 31, 2019, Existing Landlord incorrectly charged Tenant rent for the Additional 1751 Space, resulting in an overpayment by Tenant in the amount of $20,677.95 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Overpayment Amount</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Tenant acknowledges that Landlord shall not be liable for the Overpayment Amount in the event that Existing Landlord has not reimbursed Tenant for the Overpayment Amount by the Fourth Amendment Effective Date, provided that the foregoing shall not limit Tenant&#8217;s recourse against Existing Landlord with respect to the Overpayment Amount. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">[Signatures appear on next page]</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:288px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sB3F440D2CF1A378D64EF21652E091AF0"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amendment as of the Execution Date.</font></div><div style="line-height:120%;padding-left:126px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:80.76923076923077%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:32%;"></td><td style="width:68%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">LANDLORD:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">HILLWOOD ENTERPRISES, L.P., <br>a Texas limited partnership</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: AHB, LLC, a Texas limited liability company</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">its general partner</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:   </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Larry Blair</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Larry Blair</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:   </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Senior Vice President</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">TENANT:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">EXELIXIS, INC.,</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">a Delaware corporation</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="padding-bottom:16px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By:   </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Michael M. Morrissey</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name:  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Michael M. Morrissey</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">&#160;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title:   </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">President &amp; Chief Executive Officer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;&#160;&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">[Signature Page &#8211; Fourth Amendment]</font></div></div><hr style="page-break-after:always"><div><a name="sB3C7FE4BB1E524DD2D9721652E295221"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT A-4</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PLAN DELINEATING THE PREMISES AND </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TENANT MAINTAINED OUTDOOR AREAS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(See attached.)</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image1601.jpg" alt="exhibit102image1601.jpg" style="height:540px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image1751a.jpg" alt="exhibit102image1751a.jpg" style="height:544px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image1751b.jpg" alt="exhibit102image1751b.jpg" style="height:450px;width:624px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image1801a.jpg" alt="exhibit102image1801a.jpg" style="height:382px;width:493px;"><img src="exhibit102image1801b.jpg" alt="exhibit102image1801b.jpg" style="height:382px;width:509px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image1851a.jpg" alt="exhibit102image1851a.jpg" style="height:413px;width:546px;"><img src="exhibit102image1851b.jpg" alt="exhibit102image1851b.jpg" style="height:417px;width:554px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image1701a.jpg" alt="exhibit102image1701a.jpg" style="height:864px;width:541px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102image1701b.jpg" alt="exhibit102image1701b.jpg" style="height:864px;width:542px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TENANT MAINTAINED OUTDOOR AREAS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;"><img src="exhibit102imagetma.jpg" alt="exhibit102imagetma.jpg" style="height:398px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1601.jpg" alt="exhibit102imagerent1601.jpg" style="height:864px;width:449px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1701.jpg" alt="exhibit102imagerent1701.jpg" style="height:864px;width:588px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1751.jpg" alt="exhibit102imagerent1751.jpg" style="height:279px;width:623px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1801.jpg" alt="exhibit102imagerent1801.jpg" style="height:288px;width:623px;"></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1851.jpg" alt="exhibit102imagerent1851.jpg" style="height:258px;width:624px;"></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:100%;text-align:left;font-size:6pt;"><font style="font-family:inherit;font-size:6pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s36CB8F20DD79EDC944ED21652E5CE9CB"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXHIBIT B</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">BASE RENT SCHEDULES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(See attached.)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1601.jpg" alt="exhibit102imagerent1601.jpg" style="font-family:Calibri,sans-serif;font-style:italic;font-weight:bold;height:864px;width:449px;"></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1701.jpg" alt="exhibit102imagerent1701.jpg" style="font-family:Calibri,sans-serif;font-style:italic;font-weight:bold;height:864px;width:588px;"></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1751.jpg" alt="exhibit102imagerent1751.jpg" style="font-family:Calibri,sans-serif;font-style:italic;font-weight:bold;height:279px;width:623px;"></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1801.jpg" alt="exhibit102imagerent1801.jpg" style="font-family:Calibri,sans-serif;font-style:italic;font-weight:bold;height:288px;width:623px;"></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;"><img src="exhibit102imagerent1851.jpg" alt="exhibit102imagerent1851.jpg" style="font-family:Calibri,sans-serif;font-style:italic;font-weight:bold;height:258px;width:624px;"></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>exel20190930exhibit103.htm
<DESCRIPTION>EXHIBIT 10.3
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8AC6EC224FF54646B45B13FD3EE00853"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit 10.3</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">LEASE AGREEMENT </font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(COMMERCIAL SINGLE-TENANT NET LEASE)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">EXELIXIS, INC.,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A DELAWARE CORPORATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sAC488836E053AAA3AEF713FD3F122310"></a></div><div></div><div><br></div><div style="line-height:120%;text-align:center;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">LEASE AGREEMENT</font></div><div style="line-height:120%;text-align:center;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(COMMERCIAL SINGLE-TENANT NET LEASE)</font></div><div style="line-height:120%;text-align:center;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;padding-left:1px;text-indent:0px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">BASIC LEASE INFORMATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.52991452991454%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:40%;"></td><td style="width:60%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Defined Term or Terminology</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Definition or Description</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Execution Date:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">October 25, 2019</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Landlord:     </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Ernst Development Partners, Inc., a California corporation</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant:   </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exelixis, Inc., a Delaware corporation</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;padding-left:96px;text-indent:-96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Premises:   </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Building and the Tenant Exclusive Outdoor Areas. The Premises are generally depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  At the request of either party, Landlord and Tenant shall execute an amendment to this Lease to modify </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;to be consistent with the Construction Document Packages</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;padding-left:102px;text-indent:-103px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Building:   </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The building to be constructed on the Land in accordance with the Work Letter (as defined in Section 1(b))</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;padding-left:102px;text-indent:-103px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Land:   </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Portions of APNs 74-1359-15-2, 74-1359-9, and 74-1359-18-1 (commonly referred to as 1951 and 2001 Harbor Bay Parkway) in Alameda, California, to be acquired by Landlord pursuant to that certain Purchase and Sale Agreement dated June 12, 2019 between Peet&#8217;s Coffee Inc. and Landlord, as amended from time to time (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Land Purchase Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). The Land is approximately 5.13 acres. The Land is depicted on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;attached hereto. </font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant Exclusive Outdoor Areas:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Certain exterior areas located outside of the Building as generally depicted in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, as may be adjusted by Landlord and Tenant, from time to time; provided, however, upon the approval of the Construction Document Packages, the Tenant Exclusive Outdoor Areas shown on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit A</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;will be automatically amended to reflect the Tenant Exclusive Outdoor Areas identified in the Construction Document Packages.  </font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Project:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The Premises and Land collectively</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rentable Area of Building:   </font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Approximately 220,000 square feet. The parties shall determine the Rentable Area of the Building (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, the rentable square footage) calculated pursuant to the BOMA Standard set forth in Section 4.1(a) of the Work Letter. </font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term Commencement:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The date of Substantial Completion of the Improvements and delivery of the Premises to Tenant in the required condition, which date shall be automatically adjusted for Tenant Delay as provided in the Work Letter (&#8220;Substantial Completion,&#8221; &#8220;Improvements&#8221; and &#8220;Tenant Delay&#8221; are each defined in the Work Letter).</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- i -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.52991452991454%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:40%;"></td><td style="width:60%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Estimated Date of Substantial Completion:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">October 25, 2021, which date is shown as the &#8220;Estimated Date of Substantial Completion&#8221; in the Progress Schedule (as defined in the Work Letter), and which date shall be automatically extended for Excusable Delays as permitted in the Work Letter and for other adjustments to the Progress Schedule permitted in Section 1.4 of the Work Letter.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:180px;text-indent:-180px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Base Rent Commencement:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Sixty (60) days after Term Commencement</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:120px;text-indent:-120px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term Expiration:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">242 months after the Term Commencement, provided that if such date is not the last day of a calendar month, then the Term Expiration shall be the last day of the calendar month in which such date occurs.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:72px;text-indent:-72px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Base Rent:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #00000a;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Initial Base Rent (per month), as defined in and calculated in accordance with Section 3(a)(ii), provided that Base Rent shall increase by 3% each year on each anniversary of the Term Commencement. </font></div><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">A proforma (preliminary) Base Rent schedule is attached as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;solely for the purpose of demonstrating how the actual, final Base Rent will be determined in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;and </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:36px;text-indent:-36px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Use:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #00000a;"><div style="padding-bottom:8px;padding-top:8px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Office, research and development, manufacturing, and other legally permitted uses, subject to the limitations in this Lease; provided, however, with respect to the Tenant Exclusive Outdoor Areas, the Tenant's use shall be restricted to (i) uses that are ancillary to general office use (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">e.g.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, outdoor meeting space and break areas) and (ii) the installation, operation and maintenance of the Building Equipment as provided in Section 9.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:8px;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Security Deposit amount or</font></div><div style="padding-bottom:8px;padding-left:48px;text-indent:-48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Letter of Credit amount: </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">An amount equal to Initial Base Rent, as defined in and calculated in accordance with Section&#160;3(a)(ii); provided, until the amount of the Initial Base Rent is established, it shall be $726,000.00.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant&#8217;s Address for Notices:</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-indent:1px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1851 Harbor Bay Parkway</font></div><div style="text-indent:1px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Alameda, CA 94502</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Attn:  General Counsel</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- ii -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:89.52991452991454%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:40%;"></td><td style="width:60%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Landlord&#8217;s Address for Notices and Payment of Rent:</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c/o srmErnst Development Partners</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2220 Livingston Street, Suite 208 <br>Oakland, CA 94606 <br>Attn: Joseph Ernst</font></div><div style="padding-left:42px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">With a copy to:</font><font style="font-family:inherit;font-size:10pt;">&#160;<br> <br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">c/o Hillwood</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3000 Turtle Creek Boulevard</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dallas, Texas 75219</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Attn: Chris Brown, Senior Vice President</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">With a copy to:</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Waterfront &amp; BTS Harbor Bay Project, LLC</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c/o Hillwood</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3000 Turtle Creek Boulevard </font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dallas, Texas 75219</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Attn:&#160; Thomas D. Williams</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phone: XXX-XXX-XXXX</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Email: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">XXX@XXX</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">With a copy to:</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">FISHMAN I JACKSON I RONQUILLO</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13155 Noel Road, Suite 700, L.B. 13</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Dallas, Texas 75240</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Attn: Clay B. Pulliam</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Phone: XXX-XXX-XXXX</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Email: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">XXX@XXX</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;padding-left:72px;text-indent:-72px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Broker(s):</font></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:8px;padding-bottom:8px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:8px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">None</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In the event of any conflict between any Basic Lease Information and the Lease, the Basic Lease Information shall control.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- iii -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s14DBBF45C3E344AF9EE013FD3F35D9F0"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">TABLE OF CONTENTS</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s3EF6650411F1DC3F0C6313FD3F86756E"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">1.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Premises.&#160;&#160;&#160;&#160;1</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#sF1A76F52811F4E45F77D13FD3FC18647"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Term.&#160;&#160;&#160;&#160;1</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s82550B397E5131724CB613FD3FE91FA7"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">3.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rent.&#160;&#160;&#160;&#160;4</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s2FC3A264F1D73EA0CABC13FD400BA41E"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">4.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Operating Expenses.&#160;&#160;&#160;&#160;6</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s6DECC2AC3DDD9B34F82513FD402DB6B5"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">5.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Other Taxes&#160;&#160;&#160;&#160;12</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s38143E5604559020E18813FD405E9BFB"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">6.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Use.&#160;&#160;&#160;&#160;12</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#sD5C85D6D78D274A3EBCC13FD4081EFD3"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">7.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Services and Utilities.&#160;&#160;&#160;&#160;15</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s447C20C19F77292A66E713FD40B232BA"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">8.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Maintenance, Repairs and Alterations.&#160;&#160;&#160;&#160;16</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#sCA47885C4A84C427FBF713FD413FC575"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">9.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant&#8217;s Alterations&#160;&#160;&#160;&#160;17</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s795A99948074795C153D13FD415171F5"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">10.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Insurance and Indemnity. &#160;&#160;&#160;&#160;19</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s93C0512662C54C0B832E13FD41656352"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">11.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Damage or Destruction.&#160;&#160;&#160;&#160;21</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s7EF04186816FC3B4D80113FD4177A6A2"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">12.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Eminent Domain&#160;&#160;&#160;&#160;22</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s833A2B61C6DE4D6FDC9813FD41892C72"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">13.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Assignment and Subletting.&#160;&#160;&#160;&#160;22</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s8CF953468D4525B6B67313FD41AC9A0F"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">14.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Default by Tenant.&#160;&#160;&#160;&#160;25</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s541AAB4418B94E675DE413FD41CDE74C"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">15.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Landlord&#8217;s Right to Cure Events of Default&#160;&#160;&#160;&#160;27</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s98275F60C4B0709ABC1913FD41FF82E5"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">16.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Default by Landlord&#160;&#160;&#160;&#160;28</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#sF609DB5A681A49640BEB13FD422019C7"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">17.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Intentionally Omitted.&#160;&#160;&#160;&#160;30</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s7753DD0660D973BDAC7213FD42524C45"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">18.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Estoppel Certificate and Financial Statements.&#160;&#160;&#160;&#160;30</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s56663887287B6F51A7F613FD4274DFBA"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">19.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Subordination; Amendment for Lender.&#160;&#160;&#160;&#160;30</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s880A3E14D62156A27B0713FD42AA4A68"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">20.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Attorneys&#8217; Fees&#160;&#160;&#160;&#160;31</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s932CD04C4E709A74A3DA13FD42CAF511"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">21.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notices&#160;&#160;&#160;&#160;31</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#sF65E4D8BD5CDED0C947413FD42FCE756"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">22.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Signage&#160;&#160;&#160;&#160;31</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s00D57B71F61042A3C63313FD431EAE71"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">23.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Security Deposit&#160;&#160;&#160;&#160;32</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s8F4FF3ED17AA1400431313FD434DE9AA"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">24.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Letter of Credit&#160;&#160;&#160;&#160;32</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#s6F6D1B20B395A1A5F42C13FD436EF716"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">25.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">Right of First Offer.&#160;&#160;&#160;&#160;34</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:left;padding-left:48px;text-indent:96px;font-size:10pt;"><a style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;" href="#sAC1F8468EF9FC78C4A0913FD43A16C95"><font style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">26.</font></a><font style="font-family:Calibri,sans-serif;font-size:10pt;">General Provisions.&#160;&#160;&#160;&#160;35</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit A &#8211; Diagram of Premises <br>Exhibit B &#8211; Initial Improvements Work Letter  <br>Exhibit C &#8211; Verification Memorandum <br>Exhibit D-1 &#8211; Base Rent Determination </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit D-2 &#8211; Proforma Base Rent Schedule</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit E-1 &#8211; Title Report</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit E-2 &#8211; Specific Permitted Exceptions</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit E-3 &#8211; Form of Restrictive Covenant</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit F &#8211; Rules and Regulations</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit G &#8211; Form of Environmental Questionnaire</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit H &#8211; List of Environmental Documents</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit I &#8211;  Tenant&#8217;s Property</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Exhibit J &#8211; Amortization Schedule&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- iv -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sDFF62E7BD843A94F5A7B13FD3F668B0A"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">LEASE AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(COMMERCIAL SINGLE-TENANT NET LEASE)</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">THIS LEASE AGREEMENT is made and entered into as of the Execution Date by and between ERNST DEVELOPMENT PARTNERS, INC., a California corporation (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Landlord</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and EXELIXIS, INC., a Delaware corporation (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">WITNESSETH</font></div><div><a name="s3EF6650411F1DC3F0C6313FD3F86756E"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the terms and conditions of this Lease, Landlord leases to Tenant, and Tenant leases from Landlord for the term of this Lease and at the rental and upon the conditions set forth below, the Premises, as described in the Basic Lease Information. Subject to the terms and conditions of this Lease and to the Title Exceptions, Tenant shall have the non-exclusive right to use the Land.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">&#8220;As-Is&#8221; Condition</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to Substantial Completion of the Improvements and delivery of the Premises to Tenant in the required condition in accordance with the Initial Improvements Work Letter attached hereto as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Work Letter</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and subject to the express covenants, representations and warranties of Landlord contained herein, Tenant shall accept the Premises and the balance of the Project in its &#8220;as is&#8221; condition as of the date of delivery by Landlord. Notwithstanding the foregoing, Tenant&#8217;s acceptance of the Premises and the balance of the Project shall not be deemed a waiver of Landlord's obligations with respect to the repairs of such defects, as expressly set forth herein.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Surrender Condition</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  At the expiration or earlier termination of the Lease, Tenant shall surrender possession of the Premises in the same condition and repair existing on Term Commencement (but including the completion of any punchlist items with respect to the Improvements in accordance with the Work Letter), only excepting ordinary wear and tear, damage by casualty (except for any damage the repairs for which Tenant is responsible under this Lease) and condemnation, Hazardous Materials (other than those used, generated, stored, released or emitted by Tenant&#8217;s Parties or their contractors, invitees, or other guests), and repairs that Tenant is not responsible for under this Lease, and with all Alterations (as defined below), except as set forth in the immediately succeeding sentence.  Notwithstanding the preceding sentence, except Alterations that constitute Tenant Improvements (other than laboratory improvements) and Alterations that constitute general office improvements, Tenant shall be obligated to remove upon the surrender of the Premises: (i) all Permitted Alterations and all other Alterations made without Landlord&#8217;s consent, (ii) Tenant Improvements (that are laboratory improvements) that Landlord has required Tenant to remove as a condition to Landlord&#8217;s granting consent or approval to such Alterations, and (iii) Alterations (including Tenant's Work) that Landlord has required Tenant to remove as a condition to Landlord&#8217;s granting consent or approval to such Alterations.  Upon surrender of the Premises, Tenant shall have obtained from all appropriate regulatory authorities (including any applicable fire department or regional water quality control board) all permits, approvals and clearances required by Law (as defined below) for the decommissioning or other closure of the Premises for Tenant&#8217;s uses.  If any Hazardous Materials (as defined below) have been used, generated, stored, released, or emitted at the Project in violation of applicable Laws by Tenant&#8217;s Parties, Tenant shall have obtained a &#8220;no further action letter&#8221; or the equivalent from applicable regulatory authorities having jurisdiction over the Premises. </font></div><div><a name="sF1A76F52811F4E45F77D13FD3FC18647"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Term</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Initial Term</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The term of this Lease (sometimes referred to herein as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Term</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) shall commence on the Term Commencement as specified in the Basic Lease Information and, unless sooner terminated as hereinafter provided, shall end on the Term Expiration as specified in the Basic Lease Information.  If Landlord permits Tenant to occupy the Premises prior to the date of Term Commencement, such occupancy shall be subject to all the terms of this Lease other than the obligation to pay Rent.  If Term Commencement has not occurred on or prior to the Estimated Date of Substantial Completion as set forth in the Basic Lease Information, this Lease shall not be void or voidable, nor shall Landlord be liable to Tenant for any loss or damage resulting therefrom, except as </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 1 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">expressly provided in this Section 2(a). If Term Commencement has not occurred within forty-five (45) days after the Estimated Date of Substantial Completion (as the same may be extended as set forth in the Basic Lease Information), then Landlord shall credit against the first amounts of Base Rent otherwise becoming due an amount equal to one (1) day of Base Rent for each day that Term Commencement is delayed beyond such 45</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;day after the Estimated Date of Substantial Completion (as the same may be extended as set forth herein). If Term Commencement has not occurred by the date that is one year after the Estimated Date of Substantial Completion (as the same may be extended as set forth in the Basic Lease Information) (such date, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Outside Completion Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), Tenant, at its option, may either (i) terminate this Lease by written notice to Landlord given before Term Commencement or (ii) waive its right to terminate this Lease and pursue specific performance. Landlord and Tenant agree that the rent credit, the termination right and the right to seek specific performance provided in this Section 2(a) are Tenant&#8217;s sole remedies for late delivery, and the rent credit is intended to compensate Tenant based on Landlord and Tenant's best estimate of the damages, including any lost business opportunity that Tenant will incur as a result of Landlord's failure to deliver the Premises timely, and such amount is not to be deemed a penalty.  The dates of the Term Commencement and Term Expiration shall be confirmed in a Verification Memorandum (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Verification Memorandum</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) in the form of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit C</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;executed by Landlord and Tenant promptly following delivery of possession. Notwithstanding anything in this Lease to the contrary, if a Tenant Delay (as defined in the Work Letter) occurs, then Term Commencement shall be deemed to be the date that Substantial Completion of the Improvements (as defined in the Work Letter) would have occurred and the Premises would have been delivered to Tenant in the required condition but for the Tenant Delay.  Such date will be reasonably determined by Landlord in consultation with the Architect and the General Contractor.  For the sake of clarity, the parties acknowledge that the Estimated Date of Substantial Completion, as referenced in this Section, shall be adjusted for certain Excusable Delays in accordance with the Basic Lease Information.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Early Termination Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Provided that Exelixis, Inc. has not assigned this Lease other than to a Permitted Transferee (it being intended that all rights pursuant to this provision are and shall be personal to the original Tenant under this Lease and shall not be transferable or exercisable for the benefit of any Transferee other than a Permitted Transferee), and provided that an Event of Default hereunder is not continuing at the time of exercise, Tenant shall have the one-time right to elect to have the Term expire on a date stated in Tenant&#8217;s written notice to Landlord as provided below (but in no event prior to the end of the one hundred eightieth (180</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) month after the Term Commencement) (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Termination Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) instead of the Term Expiration specified in the Basic Lease Information, by giving written notice to Landlord of the exercise of such termination option at least twelve (12) months prior to the end of the one hundred eightieth (180</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) month after the Term Commencement and paying to Landlord, not later than six (6) months prior to the Termination Date, the amount of the unamortized portion (as of the Termination Date) of the Allowance and, if applicable, the Landlord&#8217;s Excess Development Costs (such amortization to be calculated as a monthly amortization at 8% per annum in accordance with the amortization schedule attached hereto as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;J</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) as consideration for the early termination of the Lease. Tenant shall have such option to terminate only if such option is exercised precisely in the manner provided herein (the "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Termination Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">").  Upon timely and proper exercise of such option and the timely payment of the Termination Payment, the Term shall expire on the Termination Date, with the same force and effect as if the Lease were amended to provide for the Term to expire on the Termination Date instead of the Term Expiration specified on the Basic Lease Information.  If Tenant has not delivered written notice to Landlord of the exercise of such termination option at least twelve (12) months prior to the end of the one hundred eightieth (180</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) month after the Term Commencement or timely delivered the Termination Payment to Landlord, then the right to terminate this Lease pursuant to this Section&#160;2(b) shall be null and void.  Notwithstanding any of the foregoing, if an Event of Default exists on the Termination Date, then, at Landlord&#8217;s sole option, the Lease will not terminate but will remain in full force and effect until such Event of Default is cured, subject to Landlord&#8217;s rights and remedies with respect to such (and any other) Event of Default.  Promptly upon the request of either party, the other party will confirm that the Event of Default has been cured and the Lease has been terminated. If an Event of Default exists on the Termination Date and Landlord does not elect to terminate this Lease pursuant to Section 14(b), Tenant shall retain its rights and obligations under this lease, including the payment of Rent, provided that the Termination Payment shall be applied against the components of the Base Rent consisting of the unamortized portion of the Allowance and Landlord&#8217;s Excess Development Costs that are included in monthly Base Rent after the scheduled Termination Date and until this Lease is terminated pursuant to the terms set forth above following Tenant's cure of the Event of Default.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 2 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Option to Extend</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Tenant shall have two options (each an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Option</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to extend the Term of the Lease for consecutive and successive periods of five (5) years (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Option Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) each, subject to the following conditions: (i) at the time an Option is exercised and as of the commencement of an Option Period, this Lease shall be in full force and effect and no Event of Default then exists; (ii) an Option must be exercised by notice given to Landlord not later than nine (9) months prior to the then-scheduled expiration of the Term, which notice shall be irrevocable regardless of the fact that Base Rent for the Option Period has not yet been finally determined; and (iii) Tenant shall not have assigned the Lease or sublet substantially all of the Premises for substantially the remainder of the Term other than in a transaction that does not require Landlord&#8217;s consent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;In the event an Option is timely and effectively exercised, the Term shall be extended for the Option Period upon all of the terms and conditions of the Lease; provided, however, that (1) the Base Rent during the first year of the Option Period shall be the then fair market rental value of the Premises and Base Rent during the Option Period shall increase by three percent (3%) as of each anniversary of the commencement of the Option Period; (2) upon the exercise by Tenant of the first Option, if at all, Tenant will have only one (1) remaining Option, and upon Tenant&#8217;s exercise of the second Option, if at all, Tenant will have no further remaining rights or options to extend the Term; (3) the Work Letter attached hereto and any allowances and other or inducements provided by Landlord in connection with the original Term (or any previous Option Period), will not apply with respect to the subject Option Period; and (4) Operating Expenses shall not include the amortization of any capital expenditures incurred by Landlord prior to the commencement of each Option Period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;For the purposes hereof, the fair market rental value of the Premises for the applicable Option Period shall be the monthly rental rate per square foot of rentable area then prevailing for comparable space in the Oakland Metropolitan area (excluding downtown Oakland), multiplied by the Rentable Area of the Premises.  Not later than eight (8) months prior to the commencement of the Option Period, Landlord shall give Tenant Landlord&#8217;s determination of fair market rental value that takes into account all of the factors required to be considered in the determination of fair market rental value in subsection (iv) below (the "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">FMRV Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">").  Tenant may dispute Landlord&#8217;s determination of fair rental value by notice to Landlord given within fifteen (15) days following the giving of Landlord&#8217;s determination, in which event the parties shall negotiate in good faith to resolve the dispute.  If such dispute is not resolved by negotiation between the parties within thirty (30) days following delivery of Tenant&#8217;s notice of dispute of Landlord&#8217;s determination of fair market rental value, then fair market rental value shall be determined by appraisal under subsection (iv) below and from the commencement of the Option Period, Tenant shall pay Base Rent when due based upon the Base Rent in effect at the end of the initial Term, subject to retroactive adjustment between the parties if the determination by appraisal is different from the Base Rent in effect at the end of the initial Term.  If Tenant does not timely dispute Landlord&#8217;s determination of the fair market rental, then Tenant will be deemed to have accepted the fair market rental value as set forth in the FMRV Notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;When fair market rental value is to be determined by appraisal, within fifteen (15) days after the expiration of the 30-day negotiation period, Landlord and Tenant shall each appoint as an appraiser, a real estate appraiser with at least fifteen (15) years of experience in appraising real property in the Alameda and Oakland area, and give written notice of such appointment to the other.  If either Landlord or Tenant shall fail to appoint an appraiser within such 15-day period, then the single appraiser appointed shall be the sole appraiser and shall determine the fair market rental value of the Premises.  In the event each party appoints an appraiser, such appraisers shall, within thirty (30) days after the appointment of the last of them to be appointed, complete their independent determinations of fair market rental value and furnish the same to Landlord and Tenant.  In making the determination of fair market rental value of the Premises, such appraisers shall base such appraisal on the fair market base rent then being charged to non-renewing, non-equity tenants in comparable buildings in the Oakland Metropolitan area of comparable age, construction, capital improvements, size, location and quality for leases with terms equal to the Option Period and shall take into consideration the creditworthiness and financial strength of the tenant, any &#8220;base year&#8221; or &#8220;expense stop&#8221; provisions applicable to such value, and the value of market concessions.  The determination of fair market rental value will account for the lack of concessions under this Lease as to the Option Period. The concessions to be considered in adjusting fair market rental value shall include (a) rental abatement concessions, if any, being granted such tenants in connection with such comparable space, (b) tenant improvements </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 3 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">or allowances provided or to be provided for such comparable space, taking into account the value, if any, of the existing improvements in the subject space, such value to be based on the age, condition, design, quality of finishes and layout of the improvements, and (c) other reasonable monetary concessions being granted such tenants in connection with such comparable space.  If any concessions are paid in cash, such as moving allowances or tenant improvement reimbursements, Tenant shall have the option of receiving the payment or concession in cash or receiving the benefit of the relevant concession through an adjustment to the net effective Base Rent that shall reflect the reasonable present value of the relevant concession.  Notwithstanding the foregoing, the determination of fair market rental value of the Premises shall exclude the value of the Improvements (as defined in the Work Letter) and any Alterations to the extent paid for by Tenant.  If the aggregate Base Rent over the Option Period under the lower appraisal varies from the higher appraisal by five percent (5%) or less of the total Base Rent payable over the Option Period under the lower appraisal, the fair market rental value shall be the average of the two valuations.  The appraisal shall not provide for any interim increases in Base Rent during the Option Period.  If the total Base Rent during the Option Period under the lower appraisal varies from the higher appraisal by more than five percent (5%), the two appraisers shall, within thirty (30) days after submission of the last appraisal report, appoint an independent third appraiser who shall be similarly qualified and such appraiser (i.e. the individual, in contrast to his or her employer) shall not have been previously employed by Landlord or Tenant.  If the two appraisers shall be unable to agree on the selection of a third appraiser in a timely manner then either Landlord or Tenant may request such appointment by the presiding judge of the Superior Court of Alameda County.  The third appraiser shall, within forty-five (45) days after appointment, select which of the two appraisals most closely represents the third appraiser&#8217;s determination of fair market rental value and submit that determination to Landlord and Tenant which shall be deemed the fair market rental value of the Premises.  All fees and costs incurred in connection with the determination of fair market rental value by the third appraiser, if any, shall be paid one-half by Landlord and one-half by Tenant.  Following the determination of the Base Rent during the Option Period, either by the process outlined above or by agreement, and prior to the commencement of the Option Period, Tenant and Landlord shall execute an amendment to this Lease extending the Term by the Option Period and establishing the Base Rent during the Option Period.</font></div><div><a name="s82550B397E5131724CB613FD3FE91FA7"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Base Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Base Rent Generally</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Commencing on the Base Rent Commencement, Tenant shall pay to Landlord as rental the amount specified in the Basic Lease Information as the Base Rent.  Base Rent shall be payable in advance on or before the first day of each successive calendar month during the term in which Base Rent is payable. Base Rent for any partial month hereunder will be prorated based on the actual number of days in the relevant period.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Calculation of Initial Base Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. As soon as practical after Landlord enters into all Contracts and procures all applicable permits for the construction of the Improvements, Landlord shall deliver notice to Tenant of Landlord&#8217;s calculation of Base Rent for the first month of the Term for which Base Rent is due in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached hereto (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Initial Base Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), together with reasonably-detailed documentation supporting such calculation. If Tenant disagrees with Landlord&#8217;s calculation, then, within ten (10) business days after delivery of Landlord&#8217;s notice, Tenant shall notify Landlord of its objections in reasonable detail and, thereafter, the parties shall use reasonable efforts to agree on the Initial Base Rent calculated in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. If Tenant fails to notify Landlord of any objections within such 10-business day period, then Tenant shall be deemed to have approved Landlord&#8217;s calculation. As soon as practicable after the calculation of Initial Base Rent, the parties shall amend this Lease to insert a Base Rent schedule in the Base Lease Information; provided, however, Landlord&#8217;s failure to prepare or Tenant&#8217;s failure to execute such amendment shall not affect the validity of the determination of the Initial Base Rent or alter Tenant&#8217;s obligations with respect thereto. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Adjustments to Base Rent due to Changes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Following agreement (or deemed agreement) by the parties with respect to the calculation of the Initial Base Rent pursuant to Section 3(a)(ii), Initial Base Rent shall not be adjusted (except as provided in subparagraph (iv) below) unless:  (A) Total Development Costs (as defined in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) increase or decrease as a result of Changes in the amount set </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 4 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">forth in approved Changed Orders (as defined in the Work Letter) after the date that Initial Base Rent is determined in accordance with Section 3(a)(ii), (B) Total Development Costs increase as a result of Tenant Delays (as defined in the Work Letter) after the date that Initial Base Rent is determined in accordance with Section 3(a)(ii), or (C) as of the Base Rent Commencement, there is an actual, documented reduction in Total Development Costs resulting from cost savings in the construction of the Improvements.  In such events, Landlord shall re-calculate Initial Base Rent in accordance with </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, provided that Initial Base Rent shall be adjusted only to the extent necessary to account for the changes to Total Development Costs due to circumstances described in clauses (A), (B), and (C) immediately above. Any change to Initial Base Rent pursuant to this subsection shall be documented by notice from Landlord to Tenant, together with reasonable documentation supporting such change, and shall be subject to the same review and objection process set forth in subsection (ii) above. For the sake of clarity, the parties agree that any reduction in Total Development Costs as described in clause (C) immediately above shall exclude reductions that have been reflected in an adjustment to the Initial Base Rent pursuant to clause (A) immediately above. Any adjustments to Base Rent pursuant to this subsection shall be reflected in the Base Rent schedule in the Verification Memorandum. As soon as practicable after the mutual execution and delivery of the Verification Memorandum, the parties shall amend this Lease to insert the revised Base Rent schedule in the Base Lease Information; provided, however, that Landlord&#8217;s failure to prepare or Tenant&#8217;s failure to execute such amendment shall not affect the validity of the subject adjustments or alter Tenant&#8217;s obligations with respect thereto.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Other Equitable Adjustments</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The parties acknowledge that Tenant may be obligated to make a payment of Base Rent prior to final adjustments to Initial Base Rent in accordance with Section 3(a)(iii).  Tenant shall make any such payment in accordance with the Base Rent then-calculated by the parties, and any shortfall due to Landlord as a result of adjustments pursuant to Section 3(a)(iii) shall be paid to Landlord within thirty (30) days, and any refund due to Tenant as a result of adjustments pursuant to Section 3(a)(iii) shall be deducted by Tenant from Tenant&#8217;s next payment of Rent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Additional Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall pay, as additional rent, all amounts of money required to be paid to Landlord by Tenant under this Lease (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) in addition to Base Rent, whether or not the same is designated &#8220;additional rent.&#8221;  Base Rent and Additional Rent are sometimes collectively referred to in this Lease as &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.&#8221;  Additional Rent shall be payable on or before the first day of each month during the Term contemporaneously with Tenant's payment of Base Rent or, if such amount is not a periodic payment, then within thirty (30) days after Landlord's request or as otherwise required in this Lease.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Late Charge</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant hereby acknowledges that late payment by Tenant to Landlord of Base Rent and other amounts due under this Lease will cause Landlord to incur costs not contemplated by this Lease, the exact amount of which will be extremely difficult to ascertain.  Such costs include, but are not limited to, processing, accounting and late charges which may be imposed on Landlord by the terms of any loan secured by the Building.  Accordingly, if any Rent shall not be received by Landlord within five (5) days of the date due, Tenant shall pay to Landlord a late charge equal to five percent (5%) of such overdue amount.  The parties hereby agree that such late charge represents a fair and reasonable estimate of the costs Landlord will incur by reason of late payment by Tenant and shall not be construed as a penalty.  Acceptance of such late charge by Landlord shall in no event constitute a waiver of Tenant&#8217;s default with respect to such overdue amount, nor prevent Landlord from exercising any of the other rights and remedies granted under this Lease.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Default Rate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any amount payable by Tenant to Landlord, if not paid by the fifth (5</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) day after such amount was due, shall bear interest from the sixth (6</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) day after such amount was due until paid at the &#8220;prime&#8221; rate as announced from time to time in the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Wall Street Journal</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;for short term commercial loans, plus three percent (3%) per annum or such lower rate as is the maximum rate permitted by law (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Default Rate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), provided that interest shall not be payable on late charges incurred by Tenant nor on any amounts upon which late charges are paid by Tenant to the extent such interest would cause the total interest to be in excess of that legally permitted.  Payment of interest shall not excuse or cure any default or Event of Default under this Lease by Tenant. Notwithstanding the foregoing, before assessing a late charge or interest for the first time in any twelve (12) month period (but not if a late charge or interest has been assessed more than two (2) times during the immediately preceding three years), Landlord </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 5 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">shall provide Tenant written notice of the delinquency, and shall waive such late charge and interest if Tenant pays such delinquency within five (5) days thereafter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Payment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All payments due from Tenant to Landlord under this Lease shall be made to Landlord without deduction or offset in lawful money of the United States of America by a check for currency or wire transfer at the address for payment set forth in the Basic Lease Information, or to such other person or at such other place as Landlord may from time to time designate by notice to Tenant.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">f.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Independent Covenants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Lease shall be construed as though the covenants herein between Landlord and Tenant are independent, and not dependent. Except as otherwise set forth herein, Tenant shall not be entitled to any setoff of the Rent owing hereunder against Landlord if Landlord fails to perform its obligations set forth herein.</font></div><div><a name="s2FC3A264F1D73EA0CABC13FD400BA41E"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Operating Expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Obligation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Commencing on Term Commencement, in addition to its obligations under Section 5 below, Tenant shall pay all of the Operating Expenses in accordance with this Section 4.    </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Operating Expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Operating Expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall mean all actual, reasonable, third party (except as expressly provided below with respect to Landlord's employees) expenses, costs and amounts of every kind and nature which Landlord pays or accrues after the Term Commencement because of or in connection with the ownership, management, maintenance, security, repair, replacement, restoration or operation of the Project, or any portion thereof.  Without limiting the generality of the foregoing, Operating Expenses shall specifically include any and all of the following:  (i)&#160;the cost of supplying all utilities, the cost of operating, repairing, maintaining, and renovating the utility, telephone, mechanical, sanitary, storm drainage, and elevator systems, and the cost of maintenance and service contracts in connection therewith; (ii)&#160;the cost of licenses, certificates, permits and inspections and the cost of contesting any governmental enactments which may increase Operating Expenses, and the costs incurred in connection with a governmentally mandated transportation system management program or similar program; (iii)&#160;the cost of all insurance carried by Landlord in connection with the Project as reasonably determined by Landlord, including insurance deductibles not to exceed commercially reasonable deductibles carried by owners of buildings in the Oakland Metropolitan Area that are comparable to the Building, subject to the terms of Section 4(c); (iv)&#160;the cost of landscaping, relamping, and all supplies, tools, equipment and materials used in the operation, repair and maintenance of the Project, or any portion thereof; (v)&#160;the cost of parking area operation, repair, restoration, and maintenance; (vi)&#160;fees and other costs, including management and/or incentive fees, consulting fees, legal fees and accounting fees, of all contractors and consultants in connection with the management, operation, maintenance and repair of the Project; (vii)&#160;payments under any equipment rental agreements; (viii)&#160;wages, salaries and other compensation and benefits, including taxes levied thereon, of all persons to the extent engaged in the operation, maintenance and security of the Project; (ix)&#160;costs under any instrument pertaining to the sharing of costs by the Project, including as relating to any business improvement district; (x)&#160;non-capital costs incurred in connection with the operation, repair, maintenance and replacement of all systems and equipment and components thereof of the Project; (xi)&#160;the cost of janitorial, alarm, security and other services, replacement of wall and floor coverings, ceiling tiles and fixtures in common areas, maintenance and replacement of curbs and walkways, repair to roofs and non-capital re-roofing; (xii)&#160;amortization (including interest on the unamortized cost at a commercially reasonable annual interest rate determined by Landlord, not to exceed the prime rate plus 250 basis points), over the useful life of the item in question as Landlord shall reasonably determine in accordance with generally accepted accounting principles, of the cost of acquiring or the rental expense of personal property used in the maintenance, operation and repair of the Project, or any portion thereof; (xiii)&#160;the cost of capital improvements or other capital costs incurred in connection with the Project (A)&#160;which are intended to effect economies in the operation or maintenance of the Project, or any portion thereof, or to cause a net reduction in current or future Operating Expenses (collectively, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cost-Saving Capital Items</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which Cost-Saving Capital Items will </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 6 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">be included in Operating Expenses only to the extent of the anticipated savings resulting therefrom, or to enhance the safety or security of the Project or its occupants, (B)&#160;that are required to comply with conservation programs first enacted or imposed upon the Project after the Term Commencement, (C)&#160;that are required under any governmental law or regulation, except for expenditures to remedy a condition existing prior to the Term Commencement that was not in compliance with then-current applicable laws, statutes, ordinances or governmental rules or regulations or any orders pursuant thereto (collectively &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Laws</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) in their form existing as of the Term Commencement, or (D) which are replacements, maintenance, or modifications, except to the extent such work is to correct or remedy any construction defects in the Improvements discovered not later than the second anniversary of the Term Commencement (the costs described in clauses&#160;(A), (B), (C), and (D) being referred to collectively as &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Permitted Capital Expenditures</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;); provided, however, that any Permitted Capital Expenditure shall be amortized (including interest at the rate set forth in subpart (xii) above on the amortized cost) over the useful life of the item in question, as reasonably determined by Landlord, in accordance with generally accepted accounting principles; (xiv)&#160;costs, fees, charges or assessments imposed by, or resulting from any mandate imposed on Landlord by, any federal, state or local government for fire and police protection, trash removal, community services, or other services, (xv)&#160;intentionally omitted, (xvi) Property Taxes (as defined below in this subsection), (xvii)&#160;wages and salaries of all employees of Landlord or its Affiliates, if any, to the extent engaged in the operation, repair, replacement, maintenance and security of the Project, including taxes, insurance and benefits relating thereto (except to the extent that the cost thereof exceeds the amount that Landlord would pay to a third party in an arms length transaction for similar services) and (xviii) payments under any easement, license, operating agreement, declaration, restrictive covenant, or instrument pertaining to the sharing of costs by the Building or the Project the terms of which must be complied with by Tenant pursuant to Section 6, and reciprocal easement agreements affecting the property, any parking licenses, parking easements, and other parking agreements relating to use of parking off-site, and any agreements with transit agencies affecting the Project, in each case the terms of which Tenant must comply with pursuant to Section&#160;6.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Property Taxes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall mean all federal, state, county, or local governmental or municipal taxes, fees, charges or other impositions of every kind and nature, whether general, special, ordinary or extraordinary, (including, without limitation, real estate taxes, general and special assessments, transit taxes, leasehold taxes or taxes based upon the receipt of rent, including gross receipts or sales taxes applicable to the receipt of rent, unless required to be paid directly by Tenant, personal property taxes imposed upon the fixtures, machinery, equipment, apparatus, systems and equipment, appurtenances, furniture and other personal property used in connection with the Project, or any portion thereof, and including estimated amounts based on pending but uncompleted reassessments of the Project, as reasonably determined by Landlord), which shall be paid or accrued because of or in connection with the ownership, leasing and operation of the Project, or any portion thereof. Property Taxes shall include, without limitation:  (i)&#160;any tax on the rent, right to rent or other income from the Project, or any portion thereof, or as against the business of leasing the Project, or any portion thereof; (ii)&#160;any assessment, tax, fee, levy or charge in addition to, or in substitution, partially or totally, of any assessment, tax, fee, levy or charge previously included within the definition of real property tax, it being acknowledged by Tenant and Landlord that Proposition 13 was adopted by the voters of the State of California in the June 1978 election (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Proposition 13</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and that assessments, taxes, fees, levies and charges may be imposed by governmental agencies for such services as fire protection, street, sidewalk and road maintenance, refuse removal and for other governmental services formerly provided without charge to property owners or occupants, and, in further recognition of the decrease in the level and quality of governmental services and amenities as a result of Proposition 13, Property Taxes shall also include any governmental or private assessments or the Project contribution towards a governmental or private cost-sharing agreement for the purpose of augmenting or improving the quality of services and amenities normally provided by governmental agencies; (iii)&#160;any assessment, tax, fee, levy, or charge allocable to or measured by the area of the Project or the Rent payable hereunder, including, without limitation, any business or gross income tax or excise tax with respect to the receipt of such rent, or upon or with respect to the possession, leasing, operating, management, maintenance, alteration, repair, use or occupancy by Tenant of the Project, or any portion thereof; and (iv)&#160;any assessment, tax, fee, levy or charge, upon this transaction or any document to which Tenant is a party, creating or transferring an interest or an estate in the Project. Any costs and expenses (including, without limitation, reasonable attorneys&#8217; and consultants&#8217; </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 7 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">fees) incurred in attempting to protest, reduce or minimize Property Taxes shall be included in Property Taxes.  If Property Taxes for any period during the Term or any extension thereof are increased after payment thereof for any reason, including, without limitation, error or reassessment by applicable governmental or municipal authorities, Tenant shall pay such increase to Landlord within thirty&#160;(30) days following Landlord&#8217;s request accompanied by reasonably detailed back-up documentation.  Notwithstanding anything to the contrary contained in this Section, Property Taxes shall exclude (such exclusions, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Excluded Taxes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) (A)&#160;all franchise taxes, gift taxes, transfer taxes (as distinct from reassessments of the Project resulting from any transfers), capital stock taxes, inheritance and succession taxes, estate taxes, occupational taxes, local, federal and state income taxes, and other taxes to the extent applicable to Landlord&#8217;s general or net income (as opposed to rents, receipts or income attributable to operations at the Project), (B)&#160;all penalties and interest on any Property Taxes as a result of Landlord&#8217;s failure to pay the same as and when payable (except to the extent caused by Tenant) and (C) all assessments in excess of the amount that would be payable if such assessments were paid over the longest permitted term.  Notwithstanding the immediately preceding subparagraph (C), if (1) Landlord elects to pay any assessments that would constitute Excluded Taxes by virtue of Landlord's election to make such payment within a shorter period of time, Landlord shall have the right to include in future Taxes the amounts so paid as and when such payments could have been made over the longest permitted term and (2) the total amount of any payment of an assessment would be lower if paid in a shorter period of time and Landlord elects to make such payment within such shorter period of time, such payment shall not constitute an Excluded Tax.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exclusions from Operating Expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary contained in this Lease, Operating Expenses, however characterized, shall not include and Tenant shall in no event have any obligation to perform or to pay directly, or to reimburse Landlord for, all or any portion of:  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;costs incurred in connection with the original construction, development or leasing of the Project, including legal fees, space planners&#8217; fees, advertising and promotional expenses (except as otherwise set forth above), and brokerage fees, and the costs to correct or remedy any construction defects in the Improvements discovered not later than the second anniversary of Term Commencement; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;except as set forth in items&#160;(xii) and (xiii) in Section 4(b)(i) above, depreciation, interest and principal payments on mortgages and other debt costs, if any, penalties and interest, costs of capital repairs and alterations, and costs of capital improvements and equipment, and any other costs which would be properly capitalized pursuant to generally accepted accounting principles, other than Permitted Capital Expenditures;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;costs for which the Landlord is actually reimbursed by insurance by its carrier or any tenant&#8217;s carrier or by another third party (provided Landlord shall use commercially reasonable efforts to obtain such reimbursement from any such third party with an obligation to provide such reimbursement);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;costs of all items and services for which Tenant reimburses Landlord (other than as reimbursements of Operating Expenses) or is required to and does pay to third parties pursuant to the terms of this Lease, including electric power and other utility costs for which Tenant directly contracts with a local utilities company;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(v)&#160;&#160;&#160;&#160;charitable and political contributions or reserves of any kind;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(vi)&#160;&#160;&#160;&#160;Landlord&#8217;s and Landlord&#8217;s managing agent&#8217;s general corporate or partnership overhead and general administrative expenses, and all costs associated with the operation of the business of the ownership or entity which constitutes &#8220;Landlord,&#8221; as distinguished from the costs of Building operations, management, maintenance or repair;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(vii)&#160;&#160;&#160;&#160;payments to subsidiaries or affiliates of Landlord, for management (but not including the management fee) or other services in or to the Project, or for supplies or other materials to the extent that the costs of such services, supplies, or materials exceed the costs that would have been paid </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 8 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">had the services, supplies or materials been provided by parties unaffiliated with the Landlord on a competitive basis;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(viii)&#160;&#160;&#160;&#160;marketing, advertising and promotional costs and cost of signs in or on the Project identifying the owner of the Project;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ix)&#160;&#160;&#160;&#160;leasing commissions, attorneys&#8217; fees, costs and disbursements and other expenses incurred in connection with negotiations or disputes with other tenants or other occupants or prospective tenants or other occupants, or associated with the enforcement of any leases or the defense of Landlord&#8217;s title to or interest in the Project;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(x)&#160;&#160;&#160;&#160;legal, auditing, consulting and professional fees and other costs paid or incurred in connection with financings, refinancings or sales of any interest in Landlord or of Landlord&#8217;s interest in the Project or in connection with any ground lease (including, without limitation, recording costs, mortgage recording taxes, title insurance premiums and other similar costs, but excluding those legal, auditing, consulting and professional fees and other costs incurred in connection with the normal and routine maintenance and operation of the Project);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xi)&#160;&#160;&#160;&#160;legal fees, space planner&#8217;s fees, architect&#8217;s fees, leasing and brokerage commissions, advertising and promotional expenditures and any other marketing expense incurred in connection with the leasing of space in the Building (including new leases, lease amendments, lease terminations and lease renewals);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xii)&#160;&#160;&#160;&#160;the cost of any items to the extent such cost is covered by a warranty to the extent of reimbursement for such coverage (provided Landlord shall use commercially reasonable efforts to obtain such reimbursements from any third parties with an obligation to deliver such reimbursements, except that Landlord&#8217;s obligations with respect to the Warranties shall be governed by Section 8(b) of this Lease and Section 3.4 of the Work Letter);</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xiii)&#160;&#160;&#160;&#160;the cost of acquiring sculptures, paintings or other objects of fine art in the Building;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xiv)&#160;&#160;&#160;&#160;any bad debt loss, rent loss, or reserves for bad debts or rent loss;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xv)&#160;&#160;&#160;&#160;costs due to the violation of this Lease or the gross negligence or willful misconduct of Landlord&#8217;s Parties;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xvi)&#160;&#160;&#160;&#160;interest, fines or penalties for late payment or violations of Laws by Landlord&#8217;s Parties, except to the extent incurring such expense is caused by a corresponding late payment or violation of a Law by Tenant, in which event Tenant shall be responsible for the amount of such expense to the extent caused by Tenant&#8217;s late payment or violation;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xvii)&#160;&#160;&#160;&#160;the wages and benefits of any employee who does not devote substantially all of his or her employed time to the Project unless such wages and benefits are prorated to reflect time spent on operating and managing the Project vis-a-vis time spent on matters unrelated to operating and managing the Project; provided, that in no event shall Operating Expenses for purposes of this Lease include wages and/or benefits attributable to personnel above the level of property manager;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xviii)&#160;&#160;&#160;&#160;reserves of any kind, including for expenses for future improvements, repairs, additions, etc.;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xix)&#160;&#160;&#160;&#160;salaries and all other compensation (including fringe benefits) of partners, officers and executives at and above the grade of senior property manager;</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 9 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xx)&#160;&#160;&#160;&#160;amounts paid as ground rental for the Project by the Landlord;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxi)&#160;&#160;&#160;&#160;any compensation paid to clerks, attendants or other persons in commercial concessions operated by the Landlord;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxii)&#160;&#160;&#160;&#160; any costs expressly excluded from Operating Expenses elsewhere in this Lease;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxiii)&#160;&#160;&#160;&#160;rent for any office space occupied by property management personnel to the extent (A) not providing service to the Premises, (B) Landlord is reimbursed such costs from other tenants and (C) the size or rental rate of such office space exceeds the size or fair market rental value of office space occupied by management personnel of the comparable buildings in the vicinity of the Building, with adjustment where appropriate for the size of the applicable project;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxiv)&#160;&#160;&#160;&#160;except with respect to Tenant&#8217;s obligations with regard to Hazardous Materials (as defined in Section 6(c)) under this Lease), any liabilities, costs or expenses associated with or incurred in connection with the presence of Hazardous Materials and the cost of defending against claims in regard to the existence or release of Hazardous Materials at the Project; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxv)&#160;&#160;&#160;&#160;fees payable or retained by Landlord or its Affiliates for management of the Project in excess of two percent (2%) of gross rental revenues received by Landlord under this Lease, including base rent, pass-throughs, for any calendar year or portion thereof; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxvi)&#160;&#160;&#160;&#160; the costs of Landlord&#8217;s Structural Repair Obligations (as defined in Section 8(a)); </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxvii)&#160;&#160;&#160;&#160;costs incurred by Landlord with respect to casualties or condemnations, except insurance deductibles as provided in Section 4(b)(i)(iii); provided, however, that the amount of any deductible under any earthquake insurance shall be amortized (including interest on the unamortized cost at a commercially reasonable annual interest rate determined by Landlord, not to exceed the prime rate plus 250 basis points) over the estimated useful life of the improvements constructed or restored with the deductible as Landlord shall reasonably determine in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxviii)&#160;&#160;&#160;&#160; costs to comply with any Laws applicable to the Project on Term Commencement;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxix)&#160;&#160;&#160;&#160;costs relating to the acquisition of the Project; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(xxx)&#160;&#160;&#160;&#160;any other expenses that under standard real estate accounting principles consistently applied would not be considered normal maintenance, repair, management or operation expenses (provided that the parties agree that the expenses expressly and specifically enumerated as items (i) through (xviii) in Section 4(b)(i) above that are not expressly excluded under clauses (i) through (xxix) in this Section 4(c) are deemed normal maintenance, repair, management or operation expenses). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding anything in this Section 4 to the contrary, this Section 4 shall not preclude Landlord&#8217;s recovery of its costs incurred to comply with Laws to the extent that such compliance is necessary due to Tenant&#8217;s particular use of the Premises or of its costs incurred to repair damage to the Project caused by Tenant&#8217;s Parties or their contractors, invitees, or other guests.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Determination of Operating Expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The inclusion of the improvements, facilities and services set forth in this Section 4 </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;">(e.g.,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;text-decoration:underline;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">items (iv), (v), (x) and (xi) in Section 4(b)(i))</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">shall not be deemed to impose an obligation upon Landlord to either have said improvements or facilities or to provide those services unless the Landlord is required in this Lease to provide the same or some of them.  Landlord may determine some items of Operating Expenses on a cash basis and other items on an accrual basis, so long as such determination is consistently applied to the same item during all accounting periods, and is otherwise consistent with generally accepted accounting principles.  </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 10 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Payment; Audit Rights</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall pay to Landlord each month at the same time and in the same manner as monthly Base Rent one-twelfth (1/12</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) of Landlord&#8217;s estimate of Tenant&#8217;s share of Operating Expenses for the then current calendar year.  Landlord shall deliver its estimate of Operating Expenses within ninety (90) days after the commencement of any calendar year (provided that, with respect to the calendar year in which the Term Commencement occurs, Landlord shall use reasonable efforts to deliver such estimate at least 30 days prior to Term Commencement).  Following delivery of Landlord&#8217;s statement of estimated Operating Expenses, Landlord will adjust Tenant&#8217;s monthly payment of Operating Expenses by providing not less than thirty (30) days&#8217; written notice to Tenant so that by the end of the calendar year, Tenant shall have paid Operating Expenses for the current calendar year in accordance with Landlord&#8217;s estimate. Operating Expense payments shall continue at the rate specified for the prior year until Landlord&#8217;s statement of estimated Operating Expenses for the current calendar year is delivered, provided any over or under payment will be reconciled through Landlord&#8217;s adjustment of monthly payments per the preceding sentence. Notwithstanding anything to the contrary herein, Tenant shall not be required to pay any Operating Expenses otherwise due hereunder if Landlord first notifies Tenant of such Operating Expenses in a statement received by Tenant more than eighteen (18) months after such Operating Expenses are incurred; provided, however, Landlord shall have the right to amend any Annual Statement (as defined below) after Landlord&#8217;s delivery thereof, regardless of such eighteen (18) month period, if Landlord receives additional bills or invoices relating to such calendar year after Landlord&#8217;s delivery of the Annual Statement, provided Landlord amends the Annual Statement within three (3) months after Landlord&#8217;s receipt of the additional bill or invoice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Within ninety (90) days after the close of each calendar year Landlord shall deliver to Tenant a statement of actual Operating Expenses for such calendar year (an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Annual Statement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), along with supportive documentation as may be reasonably requested by Tenant, including invoices and receipts.  If on the basis of such statement and supportive documentation Tenant owes an amount that is less than the estimated payments for such calendar year previously made by Tenant, Landlord shall credit such excess against the Operating Expenses, as applicable, subsequently payable by Tenant or, if the Lease has expired or terminated (unless such termination arose from Event of Default by Tenant), refund such amounts to Tenant within thirty (30) days after Landlord's delivery of the Annual Statement.  If on the basis of such statement Tenant owes an amount that is more than the estimated payments for such calendar year previously made by Tenant, Tenant shall pay the deficiency to Landlord within thirty (30) days after delivery of the statement.  The obligations of Landlord and Tenant under this Section with respect to the reconciliation between estimated payments and actual Operating Expenses for the last year of the term shall survive the expiration or termination of this Lease.  The amount payable by Tenant as its share of Operating Expenses for any portion of the term which is not an entire calendar year shall be prorated based upon the ratio that the number of days of the term in such calendar year bears to three hundred sixty-five (365).  Landlord shall keep records showing all expenditures incurred as Operating Expenses for each calendar year for a period of three (3) years following each year, and such records shall be made available at Landlord&#8217;s corporate offices during normal business hours and upon reasonable advance notice for inspection and photocopying (at Tenant&#8217;s sole cost and expense) by Tenant and/or its agents.  Within one hundred eighty (180) days after receipt of an Annual Statement by Tenant (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Audit Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and provided that no Event of Default then exists, if Tenant disputes the amount of the expenses set forth in the Annual Statement, an independent certified public accountant (which accountant (A)&#160;is a member of a nationally or regionally recognized certified public accounting firm which has previous experience in auditing financial operating records of landlords of industrial buildings, and (B) is not working on a contingency fee basis) designated and paid for by Tenant, may, after reasonable advanced written notice to Landlord and during reasonable business hours, audit Landlord&#8217;s records with respect to the expenses set forth in the Annual Statement at Landlord&#8217;s corporate offices.  Any audit report prepared by Tenant&#8217;s certified public accounting firm shall be delivered concurrently to Landlord and Tenant, and shall be completed within sixty (60) days after Tenant&#8217;s accountant is provide access to the books and records of Landlord.  If such audit proves that the expenses in the subject Annual Statement were overstated by more than five percent (5%), then Landlord will pay the actual out of pocket cost of the audit.  Tenant and Landlord shall work together in good faith to resolve any issues raised in the audit.  If Tenant and Landlord determine that Operating Expenses set forth in the Annual Statement for the calendar year are less than reported, Landlord shall provide Tenant with a credit against the next installment of Additional Rent in the amount of the overpayment by Tenant or, if the Lease has expired or terminated, refund such amounts to Tenant within thirty (30) days within 30 days after Landlord's delivery of the Annual Statement.  Likewise, if Landlord and Tenant determine that Operating Expenses for the calendar year are greater than reported, Tenant shall pay Landlord the amount of any underpayment within thirty (30) days after such determination. The records obtained by Tenant shall be treated as confidential; provided, that, Tenant shall be </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 11 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">permitted to disclose such records to its employees, accountants, attorneys, agents, and consultants to the extent required to complete its audit or as required by law or in litigation with Landlord in which in the amount of or substance of the Operating Expenses are at issue.  If the parties cannot agree then at any time after the audit is delivered to Landlord, either party may refer the matter to arbitration, by a single arbitrator in accordance with the AAA Streamlined Rules and such arbitration will be completed within forty-five (45) days after the matter is referred to the arbitrator. </font></div><div><a name="s6DECC2AC3DDD9B34F82513FD402DB6B5"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Other Taxes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except to the extent already reimbursed by Tenant as Property Taxes and except for Excluded Taxes, Tenant shall pay or reimburse Landlord within thirty (30) days following its demand for any taxes, assessments, excises, levies, license, permit, inspection, service payments in lieu of taxes and any other fees or charges of any kind, which are levied, assessed, confirmed or imposed by any public authority:  (a) upon, measured by or reasonably attributable to the cost or value of Tenant&#8217;s equipment, furniture, fixtures and other personal property located in the Premises or leasehold improvements made in or to the Premises at Tenant&#8217;s expense; (b) upon or by reason of the development, possession, use or occupancy of the Premises or other areas of the Project used by Tenant in connection with the Premises; (c) imposed with respect to the Rent paid under this Lease, such as gross receipts tax; or (d) upon this transaction or any document to which Tenant is a party in connection with this Lease.  </font></div><div><a name="s38143E5604559020E18813FD405E9BFB"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Use</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Use Restrictions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Subject to the other restrictions and requirements of this Lease, the Premises shall be used and occupied by Tenant only for the uses specified in the Basic Lease Information and for no other purpose without Landlord&#8217;s consent, which Landlord may withhold in its sole and absolute discretion.  Landlord makes no representation to the effect that the Premises can be, under applicable Laws, used for any specific uses desired by Tenant.   Subject to Landlord&#8217;s obligations under the Work Letter, Tenant is solely responsible for obtaining all necessary permits and approvals required under applicable Laws for its desired uses of the Premises.  Tenant shall, at Tenant&#8217;s expense, comply promptly with all applicable Laws in effect during the term regulating the use by Tenant of the Premises and the balance of the Project.  Tenant shall not use or permit the use of the Project by any Tenant Parties, their guests or invitees in any manner that would constitute waste or a nuisance, nor shall Tenant, its employees, agents or invitees damage the Building or any other portion of the Project, nor place or maintain any signs on or visible from the exterior of the Premises except as permitted under this Lease, or use any corridors, sidewalks or other areas outside of the Premises not specifically designated for Tenant&#8217;s use for storage or for any purpose other than access to the Premises and, in locations designated by Landlord in its reasonable discretion, the storage of bicycles.  Tenant shall not do or permit any of Tenant&#8217;s Parties (as defined below) or Tenant&#8217;s contractors or guests to do anything in and about the Premises, either in connection with activities under this Lease expressly permitted or otherwise, which would cause an increase in premiums payable under, or a cancellation of, any policy of insurance maintained by Landlord in connection with the Building or the balance of the Project (unless, in the case of increased premiums, Tenant reimburses Landlord for any such increases as set forth below) or which would violate the terms of any covenants, conditions, restrictions or other matters of record affecting the Project shown in the Preliminary Report &#8211; Update &#8220;A&#8221; dated September 4, 2019 prepared by Chicago Title Company under Order No. 58211261-582-HA-DP attached hereto as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit E-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(as such covenants, conditions, and restrictions may be modified) or that hereinafter affect the Project, provided that such new or modified covenants, conditions, restrictions and other matters of record either are consented to by Tenant (which consent shall not be unreasonably withheld, conditioned or delayed and which shall be deemed given if Tenant has failed to respond to Landlord&#8217;s request for approval within five (5) business days after such request has been made) or do not unreasonably interfere with Tenant&#8217;s use of the Premises, materially increase the obligations of Tenant hereunder, or materially decrease the rights of Tenant hereunder (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Title Exceptions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Notwithstanding the foregoing, Tenant hereby consents to the agreements and other documents described on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit E-2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;that Landlord intends to record in connection with the acquisition and development of the Land.  If any activity of Tenant shall increase any insurance premiums, Landlord shall provide Tenant with a notice that shall identify the relevant activity and the increase in the premium and Tenant may elect by written notice within ten (10) days after Landlord&#8217;s notice, either to discontinue the activity or pay the additional premium as Additional Rent hereunder. Subject to Tenant&#8217;s obligation to pay Operating Expenses in accordance with Section 4, notwithstanding anything to the contrary herein, Tenant shall not be required to comply with or cause the Project to comply with any Laws, rules, regulations or insurance requirements requiring the construction of capital alterations unless such compliance is necessitated solely due to Tenant&#8217;s Alterations, Tenant&#8217;s particular use of the Premises or the balance of the Project, or damage caused by Tenant&#8217;s Parties or their contractors, invitees or other guests. Tenant acknowledges </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 12 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">and agrees that (i) the Land will, at the closing under the Land Purchase Agreement, be subject to that certain Declaration of Restrictive Covenants attached as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;E-3</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Restrictive Covenant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">") by and between Landlord (or Landlord's successor-in-interest acquiring title to the Land at the time of such closing), as "Declarant" and Peet&#8217;s Coffee, Inc. ("</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Peet's</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">") and (ii) that the real property adjacent to the Project currently owned by Peet's is and will be used for coffee roasting activity, including, without limitation, manufacturing and distribution related to coffee products.  Accordingly, Tenant hereby waives, for itself and its successors and assigns, any rights and claims against Peet&#8217;s, and its successors and assigns, to the same extent that the Declarant (as defined in the Restrictive Covenant) waives such rights and claims pursuant to the terms of the Restrictive Covenant.  WITH RESPECT TO THE FOREGOING WAIVER, TENANT SPECIFICALLY WAIVES WITH RESPECT TO ALL SUCH MATTERS THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, AND ANY COMPARABLE LAW IN THE STATE OF CALIFORNIA, REGARDING THE MATTERS COVERED BY A GENERAL RELEASE, WHICH PROVIDES AS FOLLOWS:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR THE RELEASED PARTY.&#8221;      </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Landlord shall provide a recorded copy of the Restrictive Covenant upon Tenant's request following the recordation of the Restrictive Covenant in the Official Records of Alameda County, California. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Rules and Regulations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall faithfully observe and comply with the Rules and Regulations attached to this Lease as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit F</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, and, after notice thereof, all reasonable modifications thereof and additions thereto from time to time promulgated in writing by Landlord (as so amended, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Rules and Regulations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;); provided that, such modifications thereof and additions thereto do not unreasonably interfere with Tenant&#8217;s use of the Project or Tenant&#8217;s parking rights and do not materially increase the obligations or decrease the rights of Tenant under this Lease. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Hazardous Materials &#8211; Tenant&#8217;s Covenants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Tenant shall give prompt written notice to Landlord when Tenant becomes aware of:  (a) any proceeding by any governmental authority with respect to the presence of any Hazardous Materials on the Project or the Building (or off-site of the Project that might affect the Project) or related to any loss or injury that might result from any Hazardous Materials; (b) all claims made or threatened by any third party against Tenant or the Project or the Building relating to any loss or injury resulting from any Hazardous Materials; and (c) any occurrence or condition on the Project, or the Building (or off-site of the Project that is likely to affect the Project) that could cause the Project, or any part of either, to be subject to any restriction on occupancy or use of the Project under any applicable Law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:144px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;Tenant shall comply with all Laws and precautions now or hereafter mandated by any federal, state, local or other governmental agency with respect to the use, generation, storage, or disposal of hazardous, toxic, flammable, or radioactive materials introduced into the Project by Tenant&#8217;s Parties (collectively, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Hazardous Materials</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  As herein used, Hazardous Materials shall include, but not be limited to, (i) asbestos and any asbestos containing material and any substance that is then defined or listed in, or otherwise classified pursuant to, any present and future Laws, orders, permits, licenses, approvals, authorizations and other requirements of any kind applicable to Hazardous Materials as a &#8220;hazardous substance,&#8221; &#8220;hazardous material,&#8221; &#8220;hazardous waste,&#8221; &#8220;infectious waste,&#8221; &#8220;toxic substance,&#8221; &#8220;toxic pollutant&#8221; or any other formulation intended to define, list, or classify substances by reason of deleterious properties such as ignitability, corrosivity, reactivity, carcinogenicity, toxicity, reproductive toxicity, or Toxicity Characteristic Leaching Procedure (TCLP) toxicity, (ii) any petroleum and drilling fluids, produced waters, and other wastes associated with the exploration, development or production of crude oil, natural gas, or geothermal resources, (iii) toxic mold, mildew or any substance that reasonably can be expected to give rise to toxic mold or mildew, or (iv) any petroleum product, polychlorinated biphenyls, urea formaldehyde, radon gas, radioactive material (including any source, special nuclear, or by product material), medical waste, chlorofluorocarbon, lead or lead based product, and any other substance whose presence is likely to be hazardous to health or the environment.  Tenant shall not cause, or allow anyone in the reasonable control of Tenant to cause, any Hazardous Materials to be used, generated, stored, or disposed of, on or about the Project or the Building other than Hazardous </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 13 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Materials necessary or desirable in connection with Tenant&#8217;s use of the Premises for the permitted use, provided that such materials are stored and used in compliance with all applicable Laws, and are disclosed to Landlord in writing to the extent required by law or following Landlord&#8217;s request.  Upon Landlord&#8217;s request, Tenant shall promptly provide to Landlord copies of any safety data sheets, permits and approvals, compliance certificates, management plans, or other reports required by applicable Laws with respect to Tenant&#8217;s use of Hazardous Materials, including but not limited to Tenant&#8217;s removal of any Hazardous Materials upon the expiration or termination of this Lease.  Tenant shall defend, indemnify and hold Landlord&#8217;s Parties, any entity having a security interest in the Project or the Building and its and their employees and agents (collectively, </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;Indemnitees&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">) harmless from and against all liabilities, claims, costs, damages and depreciation of property value, including all foreseeable and unforeseeable consequential damages, arising out of the use, generation, storage, release or emission of Hazardous Materials by Tenant or any person under the reasonable control of Tenant, including, without limitation, the cost of any required or necessary investigation, monitoring, repair, cleanup, or detoxification and the preparation of any closure or other required plans, required by Law or in good faith required by Landlord whether such action is required or necessary prior to or following the termination of this Lease, as well as reasonable attorneys&#8217; fees, penalties, fines and claims for contribution to the full extent that such action is attributable to the use, generation, storage, release or emission of Hazardous Materials by Tenant or any person under the reasonable control of Tenant; provided that, Tenant&#8217;s foregoing obligation shall not apply to the extent that such liabilities, claims, costs, damages and depreciation arise from the negligence or willful misconduct of Indemnitees.  Neither the consent by Landlord to the use, generation, storage, or disposal of Hazardous Materials nor the strict compliance by Tenant with all Laws and precautions pertaining to Hazardous Materials shall excuse Tenant from Tenant&#8217;s obligation of indemnification set forth above.  Tenant&#8217;s obligations under this Section 6(c) shall survive the expiration or termination of this Lease. Within ten (10) business days following Landlord&#8217;s request from time to time but not more than once each calendar year, Tenant shall deliver to Landlord a completed Environmental Questionnaire in the form of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit G</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord will, subject to applicable laws and disclosure requirements, keep confidential any information contained in the Environmental Questionnaire or in the other documentation delivered to Landlord pursuant to this Section, provided that Landlord may disclose such information on a confidential basis to its directors, officers, managers, employees, agents, advisers, consultants, investors and prospective investors, prospective purchasers, lenders and prospective lenders to the extent required or permitted to exercise its rights or perform its obligations under this Lease or applicable Law.  If Landlord violates the foregoing obligation of confidentiality, Tenant's sole and exclusive remedy shall be to seek injunctive relief or pursue Landlord for Tenant's actual damages resulting from such violation, and in no event shall a violation by Landlord of the foregoing confidentiality provision give rise to a right for Tenant to terminate this Lease. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Hazardous Materials &#8211; Landlord&#8217;s Covenants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Tenant acknowledges receipt of those documents listed in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;H</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;attached hereto. Tenant may order at its expense a new or updated Phase I environmental site assessment of the Project, a copy of which shall be provided to Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;Landlord shall give prompt written notice to Tenant when Landlord becomes aware of:  (a) any proceeding by any governmental authority with respect to the presence of any Hazardous Materials on the Project or the Building (or off-site of the Project that might affect the Project) or related to any loss or injury that might result from any Hazardous Materials; (b) all claims made or threatened by any third party against Landlord or the Project or the Building relating to any loss or injury resulting from any Hazardous Materials; and (c) any occurrence or condition on the Project, or the Building (or off-site of the Project that is likely to affect the Project) that could cause the Project, or any part of either, to be subject to any restriction on occupancy or use of the Premises or the balance of the Project under any applicable Law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;In the event there shall now or in the future exist any Hazardous Materials in, on, under, or about the Project or the Building that (A) are caused by Landlord&#8217;s Parties (as defined below) or (B) were preexisting prior to the date of this Lease, and, in either case, the presence of which materially and adversely affect Tenant's use of or operations from the Premises or access to the Premises, Tenant's construction of its improvements, or that shall make Tenant a responsible party liable to remediate any such condition (collectively, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Interference</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;); then Landlord shall defend, indemnify and hold Tenant&#8217;s Parties harmless from and against all liabilities, claims, costs, and damages arising out of the Interference, including, </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 14 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">without limitation, the cost of any required or necessary investigation, monitoring, repair, cleanup, or detoxification and the preparation of any closure or other required plans, whether such action is required or necessary prior to or following the termination of this Lease, including reasonable attorneys&#8217; fees, penalties, fines and claims for contribution to the full extent that such action is attributable to the Interference; provided that, Landlord&#8217;s foregoing obligation shall not apply to extent that such liabilities, claims, costs, damages and depreciation arise from the use, generation, storage, release, or emission of Hazardous Materials by Tenant&#8217;s Parties or their contractors, invitees, or other guests.  Landlord&#8217;s obligations under this Section 6(d)(iii) shall survive the expiration or termination of this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;To Landlord&#8217;s actual knowledge, except as disclosed in those documents listed in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit H</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, there are no Hazardous Materials present at the Project, including in the soil or groundwater at the Project. &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Landlord&#8217;s actual knowledge</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the present, actual knowledge of Joseph Ernst, without any duty of inquiry or investigation. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Floor Load</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall design the installation of its trade fixtures and equipment, including racking and equipment platforms, and operate its equipment so as not to overload and damage the floor of the Premises, ordinary wear and tear excepted.</font></div><div><a name="sD5C85D6D78D274A3EBCC13FD4081EFD3"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Services and Utilities</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Services</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  There shall be available to the Premises gas, electricity, water and related sewer capacity as described in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Schedule 1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;as being part of Landlord&#8217;s Work.  Tenant shall be responsible for establishing accounts to obtain service (other than any initial hookups required by Landlord pursuant to the previous sentence) and paying for all utilities and services to the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">No Landlord Liability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord will use due diligence to resume any service that Landlord is obligated to provide pursuant to Section 7(a) if such service is curtailed or interrupted, provided that, except as expressly provided in Section 16 and this Section 7(b), Landlord shall not be liable to Tenant or those claiming under it for damages, nor shall there be any abatement of Base Rent or other amounts payable by Tenant under this Lease, arising out of any curtailment or interruption whatsoever in utility services, and no such interruption or cessation of service shall be deemed an eviction or disturbance of Tenant's use and possession of the Premises or any part thereof, or render Landlord liable to Tenant for damages, or relieve Tenant from performance of Tenant's obligations under this Lease including the obligation to pay Rent. Notwithstanding the foregoing, (i) if any interruption or cessation of any Essential Utilities continue for five (5) consecutive business days after Landlord receives written notice from Tenant of the interruption or cessation; (ii) such interruption or cessation actually renders any portion of the Premises unusable for the normal conduct of Tenant's business and Tenant, in fact, ceases to use and occupy such portion of the Premises for the normal conduct of its business; and (iii) such interruption or cessation is either due to Landlord&#8217;s negligence or due to causes within Landlord&#8217;s control and the repair of such interruption or cessation is within Landlord&#8217;s control, then all Base Rent and Operating Expenses payable hereunder with respect to such portion of the Premises rendered unusable for the normal conduct of Tenant's business and in which Tenant, in fact, ceases to use and occupy, shall be abated beginning with the sixth (6th) business day after the date on which Landlord received Tenant&#8217;s notice of the interruption, and such abatement shall continue until such time that the subject Essential Utilities is/are restored.  As used herein, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Essential Utilities</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means only electricity, water, sewer and natural gas service.  The foregoing right to seek specific performance and abatement of Base Rent shall be Tenant&#8217;s sole and exclusive remedies, at law or in equity, for any interruption of utilities service to the Premises, subject to the terms of Section 11 below, which will supersede this Section 7(b) with respect to any interruption caused by a casualty event, and subject to the terms of Section 16, which governs with respect to Landlord&#8217;s defaults under this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Energy Consumption Data</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  To the extent Landlord is required by any present or future law, ordinance, rule, regulation or order of any governmental authority having jurisdiction over the Premises to disclose or cause the applicable utility and energy providers to disclose the energy consumption data relating to the Premises, Tenant shall cooperate with Landlord in disclosing the energy consumption data relating to the Premises, including authorizing the applicable utility and energy providers to upload energy consumption data related to the Premises; provided, that, (i) Landlord shall only disclose such information to the extent required by such law, ordinance, rule, </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 15 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">regulation or order of any governmental authority and shall otherwise keep such information strictly confidential and (ii) Landlord may disclose such information on a confidential basis to its directors, officers, managers, employees, agents, advisers, consultants, investors and prospective investors, prospective purchasers, lenders and prospective lenders.  If Landlord violates the foregoing obligation of confidentiality, Tenant's sole and exclusive remedy shall be to seek injunctive relief or pursue Landlord for Tenant's actual damages resulting from such violation, and in no event shall a violation by Landlord of the foregoing confidentiality provision give rise to a right for Tenant to terminate this Lease.</font></div><div><a name="s447C20C19F77292A66E713FD40B232BA"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Maintenance, Repairs and Alterations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Obligations/Tenant&#8217;s Waiver</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the provisions of Section 10 below, and except for damages caused by Tenant&#8217;s Parties or their contractors, invitees or other guests, Landlord shall keep in good condition and repair only (1) the foundation, floor slabs (excluding non-structural portion of the floor slabs), exterior structural walls, structural columns, structural support beams, girders, load-bearing walls of the Building and structural elements of the roof (Landlord&#8217;s obligations with respect to such structural elements, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Landlord&#8217;s Structural Repair Obligations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and (2) underground utilities serving the Project.  Pursuant to Section 4, Landlord&#8217;s Structural Repair Obligations are expressly excluded from Operating Expenses.  The term &#8220;walls&#8221; as used herein shall not include windows, glass or plate glass, doors, special store fronts or office entries; (ii) the term &#8220;roof&#8221; does not include gutters or downspouts, and (iii) the term &#8220;foundation&#8221; does not include any wearing surface of the floor slab or any floor coverings.  Landlord&#8217;s Structural Repair Obligations shall not include the repair of any structural elements of the Building constructed by or on behalf of Tenant from and after the Term Commencement.  Notwithstanding the above, if the necessity for any replacement or repairs are due to Tenant's or its employees, contractors, agents or vendors own misconduct or negligence or caused by Tenant&#8217;s violation of the terms of this Lease, then Landlord shall perform such repairs or replacements at Tenant's expense and Tenant shall reimburse Landlord for the cost, plus an administrative fee in the amount of 5% of the actual costs of performing such work within thirty (30) days after receipt of invoice as Additional Rent.  Notwithstanding anything herein to the contrary, Tenant expressly waives the benefits of any statute now or hereafter in effect which would otherwise afford Tenant the right to make repairs at Landlord&#8217;s expense or to terminate this Lease because of Landlord&#8217;s failure to keep the Project or the Building in good order, condition and repair. Landlord shall make all repairs under this Section within a reasonable time after Landlord learns of the need for such repairs but in any event within thirty (30) days after Tenant notifies Landlord of the need for such repairs.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Obligations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall, at Tenant&#8217;s expense and in accordance with the Rules and Regulations, keep the Premises and the Land in a clean, safe and orderly condition and maintain in good condition and repair the entirety of the Premises and the Land (other than the portions required to be maintained by Landlord pursuant to Section 8(a) above), including, but not limited to, the roof membrane, the Building&#8217;s HVAC, electrical, mechanical and plumbing systems, and fire sprinkler and other life safety systems (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Building Systems</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), exterior glass, floors and floor coverings, ceiling (ceiling tiles and grid), landscaping, parking areas (including security lighting around the parking areas), security fencing and other fencing on the Premises and the Land, Tenant Improvements, Alterations, fire extinguishers, outlets and fixtures, and any appliances (including dishwashers, hot water heaters and garbage disposers) in the Premises and repairs and repairs and replacements of other components of the Building that would ordinarily be treated as a &#8220;capital expenditure&#8221; under generally accepted accounting principles, subject to Section 8(c).  Notwithstanding anything to the contrary herein, Landlord shall perform and construct, and Tenant shall have no responsibility to perform or construct any repair, maintenance or improvements that are required due to construction defects discovered in the first two (2) years of the Term.  To the extent that any Warranty (as defined in Section 3.4 of the Work Letter) covers an item that Tenant is responsible for maintaining or repairing pursuant to the Lease, Tenant will be solely responsible for enforcing such Warranty.  In such event, such assignment shall remain in effect until the expiration or earlier termination of this Lease, whereupon each such assigned Warranty shall automatically revert to Landlord.  In confirmation of such reversion Tenant shall execute and deliver promptly any assignment or certificate or other document reasonably required by Landlord.  As provided above in this Section&#160;8(b) and in the Work Letter, Tenant shall have the benefit of any Warranties obtained by Landlord in connection with the original construction of the Project, and Landlord will provide to Tenant copies of any such Warranties to Tenant upon request and, notwithstanding the foregoing, will reasonably cooperate with Tenant to enforce any such Warranties, at Tenant's sole cost and expense.  If Tenant fails to perform any maintenance required </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 16 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">hereunder within thirty (30) days after Landlord&#8217;s written notice (except when the repairs require more than thirty (30) days for performance and Tenant commences the repair within thirty (30) days and continues to diligently pursue the repair to completion), Landlord may, but shall not be required to, enter the Premises and perform such maintenance; provided that (1) no such written notice shall be required in the event of an emergency and (2) the 30-day cure period permitted in this sentence shall run concurrently with any grace or cure periods permitted under Section 14.  Landlord&#8217;s reasonable out-of-pocket costs thereof as set forth in Landlord&#8217;s demand and supportive documentation to Tenant, plus an administrative fee in the amount of 5% of such costs shall automatically become due and payable as Additional Rent. If Landlord is obligated to make alterations to the Building that are required under applicable Laws as a result of Tenant&#8217;s particular use of the Premises or Alterations made by Tenant or by Landlord at the request of Tenant, then Tenant shall reimburse Landlord within thirty (30) days following its demand for all costs incurred by Landlord, plus an administrative fee of 5% of such costs, in making such alterations. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Major Replacements; Reimbursement of Major Replacement Expenditures</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall be responsible for making repairs and replacements of the Building Systems (as defined below) and other components of the Building that would ordinarily be treated as a &#8220;capital expenditure&#8221; under generally accepted accounting principles (each, a "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Capital Replacement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">"), except for Landlord's Structural Repair Obligations and Major Replacements.  To the extent that any single Capital Replacement exceeds (i) $75,000.000 or (ii) in the last two years of the Term, $50,000 (each a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Major Replacement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; and the costs incurred by Landlord in connection with a Major Replacement being a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Major Replacement Expenditure</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), Landlord shall be responsible for making such Major Replacement and for the cost of the Major Replacement Expenditure; provided, however, Landlord will be permitted to include in the Operating Expenses annual installments for the amortization of each Major Replacement Expenditure over the useful life of the applicable Major Replacement.  Tenant will provide notice to Landlord if Tenant determines, in its reasonable business judgement, that a Major Replacement is required, and Landlord will have the right to review and inspect the equipment or the portion of the Building requiring the Major Replacement and to approve the Major Replacement, which approval will not be unreasonably withheld, conditioned, or delayed.  If Landlord does not, in the exercise of its reasonable business judgment, determine that a Major Replacement is required, then Tenant shall proceed with a repair (as required herein), unless such repair also constitutes a Major Replacement.  Upon Landlord's approval of a Major Replacement, Landlord will cause such Major Replacement to be performed.  If Landlord and Tenant cannot agree on whether a required Capital Replacement is a Major Replacement, Landlord shall obtain a bid from a contractor reasonably acceptable to Landlord and Tenant for the performance of such work, and the bid from such contractor (i.e., the cost of the proposed Capital Replacement) shall be determinative as to whether or not such Capital Replacement constitutes a Major Replacement.</font></div><div><a name="sCA47885C4A84C427FBF713FD413FC575"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Alterations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except for the Improvements (as defined in the Work Letter), the construction of which is governed by the Work Letter, Tenant shall not, without Landlord&#8217;s prior consent, make any alterations, improvements or additions in or about the Premises (collectively, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Alterations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), provided that Landlord agrees not to unreasonably withhold, condition or delay its consent to Alterations. As a condition to giving such consent to any Alterations (to the extent expressly provided in Section&#160;1(c)), Landlord may require that Tenant remove (or leave in place and convey to Landlord)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">any such Alterations at the end of the term and restore the portions of the Premises affected by such removal to their condition existing prior to installation of the relevant Alterations, reasonable wear and damage by casualty excepted.  Before commencing any work relating to Alterations (other than Decorative Changes), Tenant shall notify Landlord of the expected date of commencement thereof and of the anticipated cost thereof.  Tenant shall furnish complete drawings and specifications (which shall be in electronic form, if required by Landlord) describing such Alterations (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Plans</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) (other than Decorative Changes, and other Permitted Alterations costing less than $25,000 and not requiring a building permit (collectively, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Minor Alterations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)), and all building permits for such Alterations (if such permits are required for such Alterations pursuant to applicable Laws).  Tenant shall not commence any such Alterations until Landlord has reviewed and consented to the work as described in such Plans.  Approval by Landlord of any of Tenant's Plans prepared in connection with any Alterations shall not constitute a representation or warranty of Landlord as to the adequacy or sufficiency of such Plans or the improvements to which they relate, for any use, purpose, or condition, but such approval shall merely be the consent of Landlord as required hereunder.  Tenant shall reimburse Landlord within thirty (30) days following its demand for any reasonable, third-party, out-of-pocket costs incurred by Landlord in having such Plans reviewed by its consultants, to the extent such costs do not exceed $7,500 per project.  Tenant shall give Landlord at least five (5) business days&#8217; notice prior to commencing any Alterations (other than Decorative Changes) and Landlord shall then have the right at any time and </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 17 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">from time to time to post and maintain on the Premises such notices of non-responsibility as Landlord reasonably deems necessary to protect the Project, the Building and Landlord from mechanics&#8217; liens or any other liens.  In any event, Tenant shall pay when due all claims for labor or materials furnished to or for Tenant at or for use in the Project.  Tenant shall not permit any mechanics&#8217; liens to be levied against the Project for any labor or materials furnished to Tenant or claimed to have been furnished to Tenant or to Tenant&#8217;s agents or contractors in connection with work performed or claimed to have been performed on the Project by or at the direction of Tenant.  All Alterations performed by or on behalf of Tenant shall be done by contractors reasonably approved by Landlord, in a first&#8209;class, workmanlike manner in compliance with all applicable Laws as well as the requirements of insurers of the Project and the Building that are communicated to Tenant in writing.  Prior to commencing any Alterations, if required by Landlord, Tenant shall maintain builder&#8217;s risk insurance in an amount no less than the value of the completed work of alteration, addition or improvement on an all&#8209;risk basis, covering all perils then customarily covered by such insurance.  All contractors performing Alterations other than Minor Alterations to the portions of the Project that Landlord is required to maintain pursuant to Section 8(a) above are subject to Landlord&#8217;s reasonable prior approval.  Further, all of Tenant's contractors performing Alterations other than Decorative Changes, regardless of whether such contractors require Landlord's approval must provide evidence that they have the insurance required under Section 6.3 of the Work Letter, or other insurance reasonably acceptable to Landlord, prior to entering the Premises to perform any work.  Notwithstanding anything in this Section 9 to the contrary, upon Landlord&#8217;s request, Tenant shall promptly remove, or cause to be removed, any contractor, subcontractor or material supplier from the Project and the Building if the work or presence of such person or entity results in material damage to the Project or the Building.  Tenant shall indemnify, hold harmless and defend Landlord from any liens and encumbrances arising out of any work performed or materials furnished by or at the direction of Tenant.  In the event that Tenant shall not, within thirty (30) days following Tenant&#8217;s actual notice of the imposition of any lien or stop notice, cause such lien or stop notice to be released of record by payment or posting of a proper bond, Landlord shall have, in addition to all other remedies provided herein or by law, the right, but not the obligation, to cause the same to be released by such means as it may deem proper, including payment of the claim giving rise to such lien, after providing five (5) days&#8217; prior written notice to Tenant of Landlord&#8217;s intent to do so.  All such sums paid by Landlord and expenses reasonably incurred in connection therewith, including attorneys&#8217; fees and costs, shall be payable to Landlord by Tenant on demand.   Upon completion of any work performed for Tenant costing in excess of $100,000, Tenant shall deliver to Landlord evidence of full payment for the Alterations and full and unconditional waivers and releases of liens for all labor, services and/or materials used, copies of any building permits that were required for such work pursuant to applicable Laws, and, if the work involves any significant physical alteration of the Premises, at least three (3) sets of &#8220;as built&#8221; drawings and specifications (as well as a set in PDF or CAD format, if requested by Landlord).  Unless Landlord requires their removal, as set forth above, all Alterations shall become the property of Landlord and remain upon and be surrendered with the Premises at the termination or expiration of the term; provided that Tenant&#8217;s machinery, equipment and trade fixtures and other personal property, other than any which may be permanently affixed to the Premises so that they cannot be removed without material damage to the Premises, shall remain the property of Tenant and shall be removed by Tenant on or before such time. For the avoidance of doubt, the items set forth in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit I</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;shall be considered Tenant&#8217;s personal property and shall not become the property of Landlord.  Notwithstanding the foregoing, after completion of the Improvements, Tenant shall not be required to obtain the consent or approval of Landlord in connection with the construction or installation of any of the following Alterations:  (a) decorations, painting, plastering, carpeting or other floor coverings, or window coverings, within the Building that will not require Landlord to modify its then-current insurance coverage for Alterations and do not require a building permit (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Decorative Changes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;); and (b) alterations or improvements wholly within the Building that do not affect in any material way the Building Systems or the structural components of the Building and which cost less than One Hundred Thousand Dollars ($100,000.00) in one single instance or series of related alterations performed within a calendar year period (provided that Tenant shall not perform any improvements, alterations or additions to the Premises in stages as a means to subvert this provision) (collectively the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Permitted Alterations</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Tenant shall provide Landlord prior notice of any Permitted Alterations (other than Decorative Changes) and copies of Plans (if any), all building permits for such Permitted Alterations (if such permits are required for such Permitted Alterations pursuant to applicable Laws) and the contracts for any Permitted Alterations other than Decorative Changes prior to the commencement of such work. Following completion of any Permitted Alterations, Tenant shall deliver to Landlord copies of any building permits that were required for such work pursuant to applicable Laws. Landlord shall respond to any request for consent to an Alteration by Tenant under this Section 9 no later than five (5) business days after Landlord receives such request.  Landlord&#8217;s failure to respond to Tenant&#8217;s request for consent during such period shall be deemed Landlord&#8217;s consent to such request. Any rejection by Landlord of Plans </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 18 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">submitted by Tenant shall include a description of Landlord&#8217;s specific objections and the parties shall thereafter work together in good faith to arrive at a mutually agreeable set of Plans.  Notwithstanding anything to the contrary contained herein, Tenant shall not penetrate the roof of the Building in any manner, nor install or construct any Alterations, additions or improvements thereon, nor otherwise use or occupy the roof at any time during the Term hereof, to the extent any of the foregoing would violate, void or reduce the roof warranty unless, in each instance, given prior written approval from Landlord, which approval shall not be unreasonably withheld, conditioned or delayed. Notwithstanding the foregoing, Landlord hereby consents to Tenant&#8217;s installation of (i) a backup generator and (ii) other building equipment that (A) is required for the Permitted Use, (B) serves the Premises and (C) is approved by Landlord pursuant to the terms of Section 9 ((i) and (ii) collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Building Equipment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), either as a part of the Tenant's Work or a subsequent Alteration in a location approved by Landlord, in its reasonable discretion, within the Tenant Exclusive Outdoor Areas provided that Tenant otherwise complies with this Section 9. </font></div><div><a name="s795A99948074795C153D13FD415171F5"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Insurance and Indemnity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Insurance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall obtain and maintain during the term of this Lease: (i) workers compensation insurance as required by Law; (ii) employers liability insurance with limits of at least: $1,000,000 each accident for bodily injury by accident, $1,000,000 policy limit for bodily injury by disease and $1,000,000 each employee for bodily injury by disease with a waiver of subrogation in favor of Landlord, Ernst Development Partners, Inc., and other entities having an equity interest in the Project designated by Landlord to be named as additional insureds (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Insureds</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;); (iii) automobile liability insurance providing coverage for all owned, hired and non-owned automobiles with limits of at least $1,000,000 combined single limit each accident for bodily injury and property damage; (iv) commercial general liability insurance with a combined single limit for personal injury and property damage of at least $5,000,000 each occurrence and $5,000,000 annual aggregate; (v) a Commercial Pollution Legal Liability Insurance with coverage limits of not less than $2,000,000 annual aggregate covering claims arising out of or related to Tenant&#8217;s acts or omissions with respect to Hazardous Materials during the term of the Lease, provided that if such coverage is no longer available at commercially reasonable rates, then Tenant shall be required to carry such coverage only if Tenant intends to use (or is using) any portion of the Project for the use, generation, storage, or disposal of Hazardous Materials (other than in de minimis quantities common in a normal office use [e.g., cleaning supplies]); and (vi) Umbrella or Excess liability over general liability, automobile liability and employers&#8217; liability in an amount not less than $5,000,000 per occurrence and $5,000,000 aggregate.  Tenant&#8217;s commercial general liability insurance policy shall&#160;include coverage for premises and operations liability, products and completed operations liability, broad form property damage, blanket contractual liability and personal and advertising liability.  All of Tenant&#8217;s liability insurance shall provide that (A) the insurer has the duty to defend all insureds, (B) defense costs do not deplete policy limits; (C) the Additional Insureds are named as additional insureds on the liability policies pursuant to an endorsement or policy provision at least as broad as the Insurance Service Organization's "Additional Insured-Managers or Lessors of Premises" endorsement form; (D) the insurer acknowledges acceptance of the mutual waiver of claims by Landlord and Tenant pursuant to Section 10(b)&#160;below or the subject policy expressly permits the insured to contractually waive the insurer&#8217;s rights of subrogation; and (E) such insurance is primary with respect to Landlord and that any other insurance maintained by Landlord is excess and noncontributing with such insurance. Tenant shall also obtain and maintain insurance (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Personal Property Insurance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) covering all Tenant&#8217;s personal property and fixtures from time to time in, on, or at the Premises, in an amount not less than one hundred percent (100%) of the full replacement cost, without deduction for depreciation, providing protection against events protected under &#8220;All Risk Coverage,&#8221; as well as against sprinkler damage, vandalism and malicious mischief.  Any proceeds from the Personal Property Insurance may be used for the repair or replacement of the personal property damaged or destroyed, unless this Lease is terminated under an applicable provision herein.  Tenant shall also maintain in full force and effect during the term business interruption insurance with a limit of liability in an amount of at least approximately twelve (12) months of Base Rent.  Prior to the commencement of the term, Tenant shall deliver to Landlord certificates of insurance with endorsements.  No later than five (5) days following the expiration of such policy or any renewal thereof, Tenant shall deliver to Landlord replacement or renewal binders, followed by certificates and endorsements within a reasonable time thereafter.  Tenant shall have the right to provide all insurance coverage required herein to be provided by Tenant pursuant to blanket policies so long as such coverage is expressly afforded by such policies for the location which is the Premises.  All insurance shall be written by carriers which are admitted in California and which have a rating by A.M. Best Insurance Service, or its successor, of at least &#8220;A-/VII&#8221; or equivalent. Tenant shall increase the amounts of insurance as required by any lender of Landlord if consistent with then customary </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 19 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">practice for comparable tenants operating for comparable purposes from comparable premises in the vicinity of the Premises (and Landlord shall deliver to Tenant documentation evidencing such customary practice). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Mutual Waiver</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything to the contrary herein, Landlord hereby waives and releases all claims against Tenant and Tenant&#8217;s members, managers, officers, directors, partners, employees, agents, contractors, subcontractors and representatives for loss or damage to the property of Landlord to the extent that such loss or damage arises from a risk that is insured against under any valid and collectable insurance policy insuring Landlord or required to be maintained by Landlord under this Lease, or would have been insured against but for any deductible amount under any such policy.  Tenant waives and releases all claims against Landlord, Landlord&#8217;s Affiliates, Landlord&#8217;s members and managers and agents, and its and their respective members, managers, officers, directors, partners, employees, contractors, agents and representatives (collectively with Landlord, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Landlord&#8217;s Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), for loss or damage to Tenant's property to the extent such loss or damage arises from a risk that is insured against under any valid and collectable insurance policy insuring Tenant or required to be maintained by Tenant under this Lease, or would have been insured against but for any deductible amount under any such policy.  The waivers contained in this paragraph shall apply without regard to the negligence of the entity so released. All of Landlord&#8217;s and Tenant&#8217;s repair and indemnity obligations under this Lease shall be subject to the waivers contained in this paragraph (for the sake of clarity, any indemnity obligations with respect to third-party claims are not affected by such waivers).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Waiver and Indemnity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord shall not be liable to Tenant for any loss, injury or other damage to Tenant or to Tenant&#8217;s property in or about the Project from any cause (including defects in the Project or in any equipment in the Project; fire, explosion or other casualty; bursting, rupture, leakage or overflow of any plumbing or other pipes or lines, sprinklers, tanks, drains, drinking fountains or washstands in, above, or about the Project; or acts of other occupants at the Project), except to the extent such loss, injury or other damage is caused by the violation of this Lease, negligence, or willful misconduct of Landlord&#8217;s Parties.  Notwithstanding any other provision of this Lease to the contrary, in no event shall Landlord be liable to Tenant for any punitive or consequential damages or damages for loss of business by Tenant.  Tenant hereby waives all claims against Landlord for any such loss, injury or damage and the cost and expense of defending against claims relating thereto, except to the extent caused by the violation of this Lease, willful misconduct or negligence of Landlord. Notwithstanding any other provision of this Lease to the contrary, in no event shall Landlord be liable to Tenant for any punitive or consequential damages or damages for loss of business by Tenant.  Tenant shall indemnify, hold Landlord&#8217;s Parties harmless from and defend Landlord&#8217;s Parties against all out-of-pocket claims, liabilities, losses, damages and expenses (including reasonable attorneys&#8217; fees and costs): (i) arising in the Premises or from the use of the Premises by Tenant, (ii) as a result of Tenant&#8217;s breach of this Lease, or (iii) arising from the negligence or willful misconduct of Tenant&#8217;s Parties and their contractors, invitees, and other guests in, upon or about the portions of the Project outside the Premises, except (in each instance under clauses (i), (ii) and (iii)) to the extent such claims, liabilities, losses, damages and expenses are caused by the violation of this Lease, negligence, or willful misconduct of Landlord&#8217;s Parties.  The foregoing indemnity obligation of Tenant shall include reasonable attorneys&#8217; fees, investigation costs and all other costs and expenses incurred by any of Landlord&#8217;s Parties from the first notice that any claim or demand is to be made or may be made.  The provisions of this Section 10(c) shall survive the expiration or termination of this Lease with respect to any damage, injury or death occurring prior to such time.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Indemnity</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord shall indemnify, protect, hold Tenant, Tenant&#8217;s Affiliates, Tenant&#8217;s members and manager and agents, and its and their respective members, managers, officers, directors, partners, employees, agents, and representatives (collectively with Tenant, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant&#8217;s Parties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) harmless from and defend Tenant and Tenant&#8217;s Parties against all out-of-pocket claims, liabilities, losses, damages and expenses (including reasonable attorneys&#8217; fees and costs) arising from the violation of this Lease, negligence or willful misconduct of Landlord&#8217;s Parties.  The foregoing indemnity obligation of Landlord shall include reasonable attorneys&#8217; fees, investigation costs and all other costs and expenses incurred by any of Tenant&#8217;s Parties from the first notice that any claim or demand is to be made or may be made.  The provisions of this Section 10(d) shall survive the expiration or termination of this Lease with respect to any damage, injury or death occurring prior to such time</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Insurance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord shall during the term hereof maintain &#8220;all-risk&#8221; property insurance covering 100% of the replacement value of the Building (including the Tenant Improvements and any Tenant&#8217;s </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 20 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Work and Alterations and any other leasehold improvements installed and paid for by Tenant), as well as such liability insurances and other coverages, including earthquake coverage, in Landlord&#8217;s discretion.      </font></div><div><a name="s93C0512662C54C0B832E13FD41656352"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">11.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Damage or Destruction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Insured Loss</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If during the Term the Building is totally destroyed, or partially destroyed, by fire or other casualty in such a way that Tenant&#8217;s use of the Premises is materially interfered with, from a risk which is wholly covered by insurance proceeds made available to Landlord for such purpose (provided a  risk will not be deemed to be not covered by insurance by virtue of the operation of any deductibles, failure of Landlord to maintain the insurance required hereunder or if the amount of the uninsured loss is less than ten percent (10%) of the replacement cost of the Building), Landlord shall proceed with reasonable diligence to repair the damage or destruction and this Lease shall not be terminated; provided that if in the reasonable opinion of Landlord&#8217;s architect or contractor the work of repair cannot reasonably be completed using appropriate diligence within twelve (12) months following the date of destruction or damage and Landlord does not actually intend to restore the damage, Landlord may at its election terminate this Lease by notice given to the Tenant within thirty (30) days following the event or such longer period as may reasonably be necessary to obtain information from its architect or contractor.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Uninsured Loss</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If during the Term the Building is totally destroyed, or partially destroyed in such a way that Tenant&#8217;s use of the Premises is materially interfered with, from a risk which is not wholly covered by insurance proceeds made available to Landlord for repair or reconstruction (as described in Section 11(a) above), Landlord may at its election by notice to Tenant given within thirty (30) days following the event or such longer period as may reasonably be necessary for Landlord to obtain information from its architect or contractor, either restore the Premises (which restoration shall not exceed twelve (12) months from the date of damage) or, unless Tenant agrees in a written agreement acceptable to Landlord&#8217;s lender and reasonably acceptable to Landlord and accompanied by evidence of sufficient available funds, to pay for such repairs or restoration and if Landlord does not actually intend to restore the damage, terminate this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Repair after Damage or Destruction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If the Lease is not terminated following a total or partial destruction of the Building, then Landlord shall, subject to the provisions of this Section, use commercially reasonable efforts to promptly commence and pursue to completion the repair of such damage so that the Building is restored to the condition existing prior to the casualty, including restoration of all items described in the Work Letter as Landlord&#8217;s Work and all Alterations and Tenant&#8217;s Work (which restoration shall not exceed twelve (12) months from the date of damage), subject to restrictions and modifications as may be required by applicable law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Abatement of Rent</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In case of destruction or damage which materially interferes with Tenant&#8217;s use of the Premises, Base Rent and Tenant&#8217;s share of Operating Expenses shall be abated from (i) the date of destruction to (ii) the earlier of the date of substantial completion of the restoration of the Premises or the termination of this Lease pursuant to this Section 11, in either case based upon the portion of the Premises that Tenant has reasonably ceased to use and occupy during the relevant period as a result of such damage.  Except for such abatement, Tenant shall have no claim against Landlord for any loss suffered by Tenant due to damage or destruction of the Premises or any work of repair undertaken as herein provided.  Tenant expressly waives the provisions of Section 1932 and Section 1933(4) of the California Civil Code and any other applicable Laws providing for termination of a hiring upon destruction of the thing hired, which are superseded by this Section&#160;11. If the damage to or destruction of the Premises is, in whole or in part, the result of the willful misconduct of Tenant&#8217;s Parties or their contractors performing construction, maintenance or repair work on the Building (except for those contractors approved by Landlord), Tenant shall be entitled to an abatement of Rent as provided in this Section 11(d), provided, however, the abatement of Rent shall be limited to the extent Landlord actually receives proceeds of insurance in connection with the interruption of Rent payable hereunder.  Landlord shall use reasonable efforts to obtain such proceeds of insurance.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e.&#160;&#160;&#160;&#160; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Termination Rights</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If destruction or damage to the Premises occurs, then Tenant may elect to terminate this Lease by giving Landlord notice of such election within thirty (30) days after Landlord&#8217;s period to terminate has expired (or after Landlord has delivered notice to Tenant of its intent to repair) if Landlord&#8217;s estimate of the time required to complete Landlord&#8217;s repair obligations under this Lease is greater than the Required Repair Period.  As used herein, the term "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Required Repair Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">" means twelve (12) months following the event of </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 21 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">destruction or damage unless such damage to or destruction of the Premises is, in whole or in part, the result of the negligent acts or omissions of Tenant&#8217;s Parties or their contractors performing construction, maintenance or repair work on the Building (except for those contractors approved by Landlord) in which event such period shall be four hundred and fifty (450) days from the event of such destruction or damage.  If Tenant fails to deliver timely notice to Landlord of its election to terminate this Lease pursuant to this Section 11(e), then Tenant&#8217;s rights to terminate this Lease as a result of such fire or other casualty shall be deemed to have been waived, other than Tenant&#8217;s right to terminate the Lease with respect to Landlord&#8217;s failure to complete the restoration by the Outside Restoration Date as provided below. If Landlord commences restoration of the Premises and fails to restore the Premises in accordance with Section 11(c) within the Required Repair Period, Landlord may, by notice to Tenant, extend its time to restore the Premises for an additional period equal to Landlord's initial estimate for such restoration, but in no event in excess of 120 days plus the number of days of extension due to Excusable Delay (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Outside Restoration Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  If Landlord has not completed its work in accordance with Section 11(c) on or before the Outside Restoration Date, then Tenant may, as its sole and exclusive remedy, elect in writing, within 30 days after the Outside Restoration Date but prior to completion of such work, to terminate this Lease effective as of a date which is 15 days after the date of Tenant&#8217;s termination notice provided such restoration is not completed within such 15 day period.  Notwithstanding the foregoing, Tenant shall not have the right to terminate this Lease pursuant to Section 11(e) if the damage to or destruction of the Premises is, in whole or in part, the result of the intentional or willful misconduct of Tenant&#8217;s Parties or their contractors performing construction, maintenance or repair work on the Building (except for those contractors approved by Landlord). </font></div><div><a name="s7EF04186816FC3B4D80113FD4177A6A2"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">12. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Eminent Domain</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If (a) all or substantially all of the Project should be taken as a result of the exercise of the power of eminent domain or sold by Landlord under threat thereof, or (b) if more than fifty percent (50%) of the Improvements are so taken, this Lease shall, at Tenant's option, terminate and the Rent shall be abated during the unexpired portion of this Lease, effective on the date physical or legal possession is taken by the condemning authority. Any election by Tenant to terminate this Lease in accordance with this Section 12 shall be evidenced by a written notice of termination delivered to Landlord within thirty (30) days after the date physical or legal possession of the Project is taken by the condemning authority.  At any time following Term Commencement, if Tenant either does not have the right or elects not to terminate this Lease as provided above, then following such partial taking, Landlord shall, subject to the terms of this Lease and availability of proceeds from compensation awarded for any such taking, make all necessary repairs or alterations to the remaining portions of the Project as may be required, as reasonably determined by Tenant, to make the remaining portions of the Project an architectural whole. In the event of any taking or such sale, Landlord shall be entitled to any and all compensation, damages, income, rent, awards, or any interest therein whatsoever which may be paid or made in connection therewith.  Tenant shall have no claim against Landlord.  Notwithstanding the foregoing, Tenant shall be entitled to receive, or to prosecute a separate claim for, an award for a temporary taking of the Premises or a portion thereof where this Lease is not terminated (to the extent such award relates to the unexpired term), an award or portion thereof separately designated for relocation expenses or the interruption of or damage to Tenant&#8217;s business or as compensation for Tenant&#8217;s personal property, trade fixtures or Alterations, to the extent such awards do not reduce an award paid to Landlord. In the event of a partial taking of the Project which does not result in a termination of this Lease, Base Rent and Tenant&#8217;s share of Operating Expenses payable by Tenant thereafter shall be equitably reduced on a pro rata basis based upon the relative area taken as compared to the total area of the Premises prior to the taking.  To the extent permitted by applicable Law, Tenant waives any benefit of California Code of Civil Procedure Sections 1265.130 and 1265.150, their successors and any other law that provides a tenant with any abatement or termination rights or the rights to receive any condemnation awards by virtue of the power of eminent domain, other than as described above.</font></div><div><a name="s833A2B61C6DE4D6FDC9813FD41892C72"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">13.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Assignment and Subletting</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">General Restriction</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall not assign this Lease or any interest herein or sublet the Premises or any part thereof, or permit the use of the Premises (by means other than assignment of this Lease or sublet of the Premises) by any party other than Tenant, either directly or by operation of law, without the prior consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed. Tenant shall not mortgage, pledge, hypothecate, or otherwise place a lien upon this Lease or any interest herein without the prior consent of Landlord, which consent may be withheld by Landlord in its absolute discretion.  Any of the foregoing acts without such consent shall be void and shall, at the option of Landlord, terminate this Lease after the expiration of applicable </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 22 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">notice and cure periods.  In connection with each consent requested by Tenant, Tenant shall submit to Landlord the terms of the proposed transaction, the identity of the parties to the transaction, the proposed documentation for the transaction, current financial statements of any proposed assignee or sublessee and all other information reasonably requested by Landlord within five (5) days of receipt of Tenant&#8217;s request concerning the proposed transaction and the parties involved therein, and Landlord shall reasonably approve or disapprove Tenant&#8217;s request within twenty (20) days.  As a further condition to any consent granted by Landlord, the proposed assignee shall agree in writing that upon succession to the interest of Tenant in the relevant portion of the Premises, such assignee shall perform for the benefit of Landlord all of Tenant&#8217;s obligations under this Lease.  Landlord and Tenant acknowledge that in exercising Landlord&#8217;s reasonable discretion to approve or disapprove of a proposed assignment or sublease hereunder, Landlord may consider any and all relevant information regarding such proposed assignment or sublease and any proposed assignee, or sublessee.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Definition of Assignment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  As used in this Section 13, the term &#8220;assign&#8221; or &#8220;assignment&#8221; shall include, without limitation, any sale, transfer or other disposition of all or any portion of Tenant&#8217;s estate under this Lease, whether voluntary or involuntary, and whether by operation of law or otherwise including any of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Subject to the last sentence of this Section 13(b), if Tenant is a corporation or a limited liability company: (1) a sale of all or substantially all of the assets of Tenant, (2) if Tenant is a corporation with fewer than two hundred fifty (250) shareholders or a limited liability company, sale or other transfer of a controlling percentage of the capital stock or the managing members&#8217; interest in Tenant, if Tenant is a corporation with two hundred fifty (250) or more shareholders, then a transfer of its stock shall not be deemed an assignment of the Lease), or (3) the transfer of a majority beneficial interest in Tenant.  The phrase &#8220;controlling percentage&#8221; means the ownership of, and the right to vote, stock possessing at least fifty percent (50%) of the total combined voting power of all classes of Tenant&#8217;s stock issued, outstanding and permitted to vote for the election of directors, or, in the case of a limited liability company, at least fifty percent (50%) of the voting right of the managing members&#8217; interest;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;If Tenant is a trust, the transfer of more than fifty percent (50%) of the beneficial interest of Tenant, or the dissolution of the trust;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;If Tenant is a partnership or joint venture, the withdrawal, or the transfer of the interest of any general partner or joint venturer or the dissolution of the partnership or joint venture; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;If Tenant is composed of tenants&#8209;in&#8209;common, the transfer of interest of any co&#8209;tenants, or the partition or dissolution of the co&#8209;tenancy.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, so long as the tenant under this Lease is a publicly traded company, then a transfer of stock shall not be deemed an assignment of the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Permitted Transfers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Notwithstanding anything in this Section 13 to the contrary, Tenant may, without the consent of Landlord and without being subject to Landlord&#8217;s profit sharing rights, undergo a deemed assignment as described in Section 13(b) above or assign this Lease or sublet the Premises to any Affiliate of Tenant, any entity that is a successor of Tenant by merger, consolidation, reorganization or similar change, or any entity that acquires all or substantially all of the assets or stock of Tenant (each a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Permitted Transferee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), provided that any such transfer to a Permitted Transferee shall be subject to the following conditions:  (a)&#160;at least five (5) days prior to the effective date of the assignment or sublease, Tenant shall deliver to Landlord written notice thereof and, no later than ten (10) days after such transfer, deliver to Landlord a copy of the relevant assignment or sublease instrument; (b)&#160;such assignment or sublease is not used as a subterfuge by Tenant to avoid its obligations under this Lease or the restrictions on transfers pursuant to this Section&#160;13; (c)&#160;any such assignment, sublease or transfer shall be subject to all of the other terms, covenants and conditions of the Lease (other than the contrary terms in this Section 13); (d)&#160;the Permitted </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 23 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Transferee, if an assignee of this Lease, shall expressly assume the obligations of Tenant under this Lease arising after the assignment; and (e) the net worth of the successor entity (other than an Affiliate) is at least equal to that of Tenant immediately prior to the transfer.  Notwithstanding an assignment to a Permitted Transferee, unless released by Landlord in writing, Tenant shall remain primarily liable for all obligations of &#8220;Tenant&#8221; under this Lease. &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Affiliate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means any entity that is Controlled by, under common Control with, or that Controls the subject entity.  &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Control</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;, as used in the previous sentence, mean the ownership, directly or indirectly, of more than fifty percent (50%) of the voting securities of an entity, possession of the right to vote more than fifty percent (50%) of the voting interests in the entity, and the power to control the direction, policies and management of such entity.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;Notwithstanding anything to the contrary in this Section 13, in addition to Tenant&#8217;s rights under Section 13(c)(i), Tenant may from time to time, without the prior consent of Landlord, sublease a portion of the Premises to an entity in which Tenant or its Affiliates have a material, direct investment or a collaboration agreement (such parties collectively being the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Additional Permitted Subtenants</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) subject to the following conditions: (i) each Additional Permitted Subtenant shall have executed a sublease in a form meeting the requirements below and satisfactory to Landlord in its reasonable discretion, (ii) each Additional Permitted Subtenant shall use the Premises in compliance with all applicable provisions of this Lease, (iii) the use of the space is not a use which materially increases Landlord&#8217;s obligations under this Lease, (iv) Tenant shall be fully responsible for the conduct of such Additional Permitted Subtenant within the Premises and the Project, and Tenant&#8217;s indemnification obligations set forth in Section 10 of this Lease shall apply with respect to the conduct of such Additional Permitted Subtenants, (v) in no event shall the space in the Premises occupied by Additional Permitted Subtenants exceed twenty percent (20%) of the area of the Premises, and (vi) in no event shall the space in the Premises occupied by any one Additional Permitted Subtenant exceed ten percent (10%) of the area of the Premises. The form sublease with respect to Additional Permitted Subtenants referenced in clause (i) above shall set forth, among other things: (A) that the Additional Permitted Subtenant&#8217;s occupancy is subject and subordinate to the terms and conditions of this Lease, (B) that upon a termination of the Lease, the Additional Permitted Subtenant shall vacate the Premises, (C) that Landlord and the Additional Permitted Subtenant have no direct relationship, (D) that the Additional Permitted Subtenant waives all claims against Landlord and Landlord&#8217;s authorized representatives for damage to person or property, including such subtenant&#8217;s personal property maintained at the Premises, and (E) that the Additional Permitted Subtenant indemnifies Landlord&#8217;s Parties to the same extent of Tenant's indemnification of the Landlord's Parties hereunder, including indemnification against all claims, loss, cost, liability, damage and expense, including, without limitation, reasonable attorneys&#8217; fees and costs, arising out of the negligence or willful misconduct of that Additional Permitted Subtenant. Tenant shall promptly deliver to Landlord each sublease executed by an Additional Permitted Subtenant. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;Any purported assignment or sublease to a Permitted Transferee or to an Additional Permitted Subtenant that does not satisfy the requirements of this Section 13(c) is voidable by Landlord and shall constitute a violation of this Lease, subject to Section 14(a)(iv) below.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Assignment or Subletting by Sublessee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any assignment or sublet by a sublessee of its sublease shall be subject to Landlord&#8217;s prior consent in the same manner as if Tenant were entering into a new sublease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Assignment Consideration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the case of an assignment other than to a Permitted Transferee, Tenant shall pay to Landlord one half of all sums or other economic consideration received by Tenant as compensation to Tenant for such assignment (excluding any amounts for equipment, services or other property provided by Tenant, except to the extent in excess of fair market value), after first deducting the actual, out-of-pocket cost of any real estate commissions, legal fees, tenant improvements, concessions, and other costs reasonably incurred to effect the assignment.  If such consideration is received by Tenant in installments, the portion of each installment to be paid to Landlord shall be determined by subtracting from the installment an amount equal to the total amount of the foregoing permitted deductions divided by the total number of installments.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">f. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Subletting Consideration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the case of a subletting other than to a Permitted Transferee, Tenant shall pay to Landlord one half of all sums or economic consideration received (excluding any amounts for </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 24 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">equipment, services or other property provided by Tenant, except to the extent in excess of fair market value therefor) in excess of the sum of (i) the then Rent due under this Lease for the relevant period, prorated to reflect only that portion allocable to the sublet portion of the Premises, and (ii) the actual, out-of-pocket costs of any real estate commissions legal fees, demising and improvement costs, concessions,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">and all other costs reasonably incurred to effect the subletting and are reasonably documented by Tenant, provided such amounts shall first be deducted from sublease rents before any excess rents are payable to Landlord.  For the purpose of determining the amount of excess rent under this Section 13(f), during the period between the Term Commencement and the Base Rent Commencement, Tenant shall be deemed to be paying Base Rent in the amount of the Initial Base Rent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">g. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Assignment of Consideration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant hereby irrevocably assigns to Landlord, as security for Tenant&#8217;s obligations under this Lease, all rent from any subletting of all or a part of the Premises, and Landlord as assignee and as attorney-in-fact for Tenant, or a receiver for Tenant appointed on Landlord&#8217;s applications, may collect such rent and apply it toward Tenant&#8217;s obligations under this Lease; except that during the existence of an Event of Default by Tenant, Tenant shall have the right to collect such rent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">i. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Effect of Assignment or Subletting</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Regardless of Landlord&#8217;s consent, no subletting or assignment shall release Tenant of Tenant&#8217;s obligations or alter the primary liability of Tenant to pay the rental and to perform all other obligations to be performed by Tenant under this Lease.  The acceptance of rental by Landlord from any other person shall not be deemed to be a waiver by Landlord of any provision hereof.  Consent to one assignment or subletting shall not be deemed consent to any subsequent assignment or subletting.  If there is an Event of Default by any assignee of Tenant or any successor of Tenant in the performance of any of the terms hereof, Landlord may proceed directly against Tenant without the necessity of exhausting remedies against such assignee or successor.  Landlord may consent to subsequent assignments or subletting of this Lease or amendments or modifications to this Lease with assignees of Tenant, with notification to Tenant, or any successor of Tenant, and without obtaining its or their consent thereto and such action shall not relieve Tenant of liability under this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">j. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If Tenant shall request the consent of Landlord to any assignment or subletting, then Tenant shall pay Landlord&#8217;s reasonable out-of-pocket costs, including attorneys&#8217; fees, incurred in connection therewith, as documented by Landlord, not to exceed (i) $7,500, in the aggregate, per request in the case of a sublease and (ii) $10,000, in the aggregate, per request in the case of an assignment.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">k.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">No Merger</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The voluntary or other surrender of this Lease by Tenant, the mutual cancellation thereof or the termination of this Lease by Landlord as a result of an Event of Default by Tenant shall, at the option of Landlord, terminate all or any existing subtenancies or may, at the option of Landlord, operate as an assignment to Landlord of any or all of such subtenancies.</font></div><div><a name="s8CF953468D4525B6B67313FD41AC9A0F"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Default by Tenant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Events of Default</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any of the following events shall constitute an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Event of Default</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; under this Lease and all references thereto shall mean the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Tenant&#8217;s failure to pay any Base Rent or other sum payable under this Lease (including without limitation a sum to restore the Deposit under Section 23) when due, where such failure shall continue for a period of five (5) days after notice from Landlord of such delinquency; provided, however, that once Landlord has delivered a second notice of such a failure during any calendar year, any subsequent failure to pay Base Rent or other sums when due shall constitute an Event of Default without the requirement of notice;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;The bankruptcy or insolvency of Tenant, any transfer by Tenant in fraud of creditors, assignment by Tenant for the benefit of creditors, or the commencement of any proceedings of any kind by or against Tenant under any provision of the Title 11 of the United States Code or its successor (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Bankruptcy Code</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;),  or under any other insolvency, bankruptcy or reorganization law, unless any such proceedings are dismissed within ninety (90) days thereafter; the appointment of a receiver for a substantial </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 25 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">part of the assets of Tenant unless dismissed within sixty (60) days; or the levy upon this Lease or any estate of Tenant under this Lease by any attachment or execution unless released within thirty (30) days; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;The abandonment of the Premises, together with Tenant&#8217;s failure to maintain the Premises in accordance with this Lease; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;Tenant&#8217;s failure to perform any of the other terms, covenants, agreements or conditions set forth in this Lease or act by Tenant in violation of this Lease (other than Tenant&#8217;s breach of Section 13(a) and (c), as to which a ten (10) day cure period shall apply, or the provisions of Section 18 regarding delivery of financial statements and estoppels, as to which a five (5) day cure period shall apply beyond the period provided in Section 18 to deliver the relevant statements) and, if the failure is curable, the continuation of such breach for a period of thirty (30) days after notice from Landlord or beyond the time reasonably necessary for cure if the failure is of the nature to require more than thirty (30) days to remedy, but in any event, within ninety (90) days following Landlord&#8217;s notice; provided that if Tenant has committed an Event of Default with respect to a violation of Law more than twice in any twelve-month period and written notice of Tenant's failure has been given by Landlord in such instance, then no cure period shall thereafter be applicable under this Lease; or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(v)&#160;&#160;&#160;&#160;Tenant&#8217;s failure to provide, renew, supplement, or replace the Letter of Credit or provide a cash equivalent when and as provided under Section 24 within five (5) days after the date when due.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Remedies</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Upon the occurrence of any Event of Default by Tenant under this Lease, Landlord may, at its option and without any further notice or demand, in addition to any other rights and remedies given under this Lease or by law, do any of the following:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Landlord shall have the right, so long as such Event of Default continues, to give written notice of termination to Tenant and on the date specified in such notice this Lease shall terminate;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;In the event of any such termination of this Lease, Landlord may then or at any time thereafter, reenter the Premises and remove therefrom all persons and property and again repossess and enjoy the Premises, without prejudice to any other remedies that Landlord may have by reason of Tenant&#8217;s Event of Default or of such termination;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;In the event of any such termination of this Lease, and in addition to any other rights and remedies Landlord may have, Landlord shall have all of the rights and remedies of a landlord provided by Section 1951.2 of the California Civil Code.  The amount of damages which Landlord may recover in event of such termination shall include, without limitation, (1) the worth at the time of award (computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent) of the amount by which the unpaid Base Rent for balance of the term after the time of award exceeds the amount of rental loss that Tenant proves could be reasonably avoided, (2) all legal expenses and other related costs reasonably incurred by Landlord following Tenant&#8217;s Event of Default, (3) all costs incurred by Landlord in restoring the Premises to good order and condition, or, to the extent allocable to the remainder of the Term, in remodeling, renovating or otherwise preparing the Premises for reletting, and (4) all costs (including, without limitation, any brokerage commissions) incurred by Landlord in reletting the Premises, to the extent allocable to the remainder of the Term.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;Landlord shall also have the remedy described in California Civil Code Section 1951.4 (lessor may continue the lease in effect after lessee&#8217;s breach and abandonment and recover Base Rent and additional rent as it becomes due, if lessee has right to sublet or assign, subject only to reasonable limitations);</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 26 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(v)&#160;&#160;&#160;&#160;For the purpose of determining the unpaid Base Rent in the event of a termination of this Lease, or the Base Rent due under this Lease in the event of a reletting of the Premises, the monthly Base Rent reserved in this Lease shall be deemed to be the Base Rent due under Section 3 above;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(vi)&#160;&#160;&#160;&#160;Landlord&#8217;s acceptance of payment from Tenant of less than the amount of Base Rent then due shall not constitute a waiver of any rights of Landlord or Tenant including, without limitation, any right of Landlord to recover possession of the Premises; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(vii)&#160;&#160;&#160;&#160;After terminating this Lease, Landlord may remove any and all personal property located in the Premises and place such property in a public or private warehouse or elsewhere at the sole cost and expense of Tenant, provided Landlord will provide written notice of such removal and storage to Tenant promptly after any such personal property is removed from the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Waiver of Reinstatement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. Tenant hereby waives all rights under California Code of Civil Procedure Section 1179 and California Civil Code Section 3275 providing for relief from forfeiture and any other right now or hereafter existing to redeem the Premises or reinstate this Lease after termination pursuant to this Section 14 or by order or judgment of any court or by any legal process.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Continuation of the Lease</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Even though an Event of Default by Tenant has occurred under this Lease, this Lease shall continue in effect for so long as Landlord does not terminate Tenant&#8217;s right to possession.  Landlord may enforce all its rights and remedies under this Lease, including the right to recover rental as it becomes due under this Lease.  Acts of maintenance or preservation, efforts to relet the Premises, or the appointment of a receiver upon initiative of Landlord to protect Landlord&#8217;s interest under this Lease, shall not constitute a termination of Tenant&#8217;s right to possession. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Waiver of Jury Trial</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If and to the extent permitted under applicable Law, Landlord and Tenant shall not seek jury trial, hereby waive trial by jury and any objection to venue in the county in which the Building is located and hereby consent to the personal jurisdiction of the courts of the state in which the Premises is located in any action, proceeding or counterclaim brought by either party against the other on any matters not relating to personal injury or property damage but otherwise arising out of or in any way connected with this Lease, the relationship of Landlord and Tenant, Tenant&#8217;s use or occupancy of the Premises, any claim or injury or damage or the enforcement of any remedy under any statute, whether any of the foregoing is based upon this Lease or law.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">f. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Non-Exclusive Remedies</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The remedies provided for in this Lease are in addition to any other remedies available to Landlord at law or in equity, by statute or otherwise.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">g. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Reimbursement of Landlord</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In addition to the foregoing remedies for Events of Default, subject to Section 20, Landlord is entitled to reimbursement of all of Landlord&#8217;s fees, expenses and damages, including, without limitation, reasonable attorneys&#8217; fees and paralegal and other professional fees and expenses, including expert witness or appraisal fees and expenses, that Landlord incurs in protecting its interests in any bankruptcy or insolvency proceeding involving Tenant (including, without limitation, any proceeding under the Bankruptcy Code) by, without limitation, (i) exercising and advocating rights under Section 365, or its successor, of the Bankruptcy Code, (ii) proposing a plan of reorganization and objecting to competing plans or (iii) filing motions for relief from stay.  Such fees and expenses are payable on demand or, in any event, upon assumption or rejection of this Lease in bankruptcy.</font></div><div><a name="s541AAB4418B94E675DE413FD41CDE74C"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Right to Cure Events of Default</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If Tenant shall fail to pay any sum of money, other than rental, required to be paid by it under this Lease or shall fail to perform any other act on its part to be performed under this Lease and such failure shall continue for thirty (30) days after notice thereof by Landlord, Landlord may, but shall not be obligated so to do, and without waiving or releasing Tenant from any obligations of Tenant, make any such payment or perform any such other act on Tenant&#8217;s part to be made or performed as in this Lease provided.  All sums so paid by Landlord and all necessary incidental costs shall be deemed additional rent under this Lease and shall be payable to Landlord on written demand.  Landlord shall have (in addition to any other right or remedy of Landlord) the same rights and remedies in the event of the nonpayment thereof by Tenant as in the case of an Event of Default by Tenant in the payment of rental.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 27 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s98275F60C4B0709ABC1913FD41FF82E5"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">16. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Default by Landlord</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Default and Remedies</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The occurrence of any one or more of the following events shall constitute a default under this Lease by Landlord:  Landlord's failure to do, observe, keep, and perform any of the terms, covenants, conditions, agreements, or provisions of this Lease required to be done, observed, kept, or performed by Landlord within thirty (30) days after written notice by Tenant to Landlord of said failure (except when the nature of Landlord's obligation is such that more than thirty (30) days are required for its performance, then Landlord shall not be deemed in default if it commences performance within the thirty (30)-day period and thereafter diligently pursues the cure to completion).  Notwithstanding the foregoing, in the event Tenant notifies Landlord that Landlord's breach creates an emergency situation or is of such a nature that impairs Tenant's ability to operate at the Premises (which shall include, by way of illustration and not limitation, obstructions or disruptions to parking, access to the Premises, visibility, utilities, roof leaks, health and safety, and quiet enjoyment), then Landlord shall be required to remedy such breach as soon as commercially reasonable and in any event without delay.  In the event of a default by Landlord, or failure to remedy a breach as set forth in the preceding sentence, Tenant may, as Tenant&#8217;s sole and exclusive remedies, (i) pursue specific performance, (ii) seek recovery of Tenant's actual money damages for loss arising from Landlord&#8217;s uncured breach under this Lease or (iii) cure any default of Landlord as and to the extent provided below in this Section 16. Notwithstanding anything in this Lease to the contrary, in no event shall this Lease be terminated.  In the event of any breach or default by Landlord of any term or provision of this Lease, Tenant must look solely to the amount of Landlord&#8217;s equity or interest then owned by Landlord in the Project and any proceeds therefrom; however, in no event, shall any deficiency judgment or any money judgment of any kind be sought or obtained against Landlord.  IN NO EVENT SHALL LANDLORD&#8217;S OR TENANT&#8217;S MEMBERS OR MANAGERS OR ITS OR THEIR DIRECT OR INDIRECT MANAGERS, MEMBERS, PARTNERS, SHAREHOLDERS OR AFFILIATES, ANY OFFICER, MANAGER, MEMBER, DIRECTOR, EMPLOYEE, OR AGENT OF THE FOREGOING, OR ANY AFFILIATE OR CONTROLLING PERSON THEREOF HAVE ANY PERSONAL LIABILITY FOR ANY CLAIM, CAUSE OF ACTION OR OTHER LIABILITY ARISING OUT OF OR RELATING TO THIS LEASE OR THE PREMISES, WHETHER BASED ON CONTRACT, COMMON LAW, STATUTE, EQUITY OR OTHERWISE.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Cure by Tenant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding any other provision of the Lease to the contrary (but subject to the provisions of Section 11 and Section 12), if, after Term Commencement, Landlord fails to perform Essential Repairs, Tenant may deliver a notice describing with reasonable specificity Landlord's failure to perform Essential Repairs (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cure Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  If Landlord fails to cure such failure within thirty (30) days after Landlord&#8217;s receipt of the Cure Notice (unless the failure is due to Excusable Delay or is of a nature that cannot reasonably be cured within thirty (30) days, in which event Landlord shall be allowed an additional reasonable period of time to diligently pursue cure of such failure), Tenant may deliver an additional notice to Landlord (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Second Cure Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) stating (A) that Landlord has failed to cure the failure to perform Essential Repairs within the cure period set in the third sentence of this Section 16(b), (B) the action that Tenant maintains is necessary to cure such failure and (C) the action that Tenant proposes to take to cure such failure of Landlord (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Cure Action</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  If within three (3) additional business days after Landlord&#8217;s receipt of the Second Cure Notice, Landlord fails to cure such failure (unless such failure is of a nature that cannot reasonably be cured within such three (3) business days, in which event Landlord shall be allowed an additional reasonable period of time to diligently pursue cure of such failure), then Tenant may proceed to undertake the Cure Action, subject to the provisions in Section 16(c) below.  Provided however, in the event any such failure of Landlord creates a Repair Emergency the required notice to Landlord may be given verbally to the property manager, as hereafter may be changed from time to time by Landlord or its property manager by written notice to Tenant.  Tenant shall confirm any verbal notice by written notice to Landlord given on the same day (or if the Repair Emergency occurs outside of normal business hours, then by written notice given the next business day).  In the event of a Repair Emergency, (1) if Landlord has not commenced to perform such Essential Repairs within two (2) business days following Landlord's receipt of the Cure Notice, then Tenant may deliver a Second Cure Notice (without regard for the time periods for cure set forth above) and (2) if Landlord has not commenced to perform such Essential Repairs within one (1) business day following Landlord's receipt of the Second Cure Notice then Tenant may proceed to undertake the Cure Action, without regard for the time periods for cure set forth above and subject to the provisions in Section 16(c) below.  As used herein, the term &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Essential Repair</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means a maintenance or repair obligation under Sections 8(a) or a failure to restore Essential Utilities (but only to the extent that Tenant would otherwise be entitled to an abatement of Rent pursuant to Section 7(b) as a result of such failure).  As used herein, the term &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Repair Emergency</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 28 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">failure of Landlord as described in the first sentence of this Section 16(b) that creates an imminent and unreasonable risk of serious bodily injury or material property damage.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Requirements of Tenant's Cure Right</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If Tenant takes any Cure Action permitted by Section 16(b) above with respect to any failure of Landlord to perform any Essential Repairs, Tenant shall comply with and observe the requirements set forth below.  Prior to commencement of any repair by Tenant, Tenant shall submit for Landlord&#8217;s approval, which shall not be unreasonably withheld, conditioned or delayed, plans and specifications for such repair work (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Repair Plans</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), and such of the following as requested by Landlord:  opinions from engineers reasonably acceptable to Landlord stating that such work will not in any way adversely affect the Building Systems, including, without limitation, the mechanical, heating, plumbing, security, ventilating, air conditioning, electrical, and the fire and life safety systems in the Building, necessary permits and licenses, certificates of insurance, and such other documents in such form reasonably requested by Landlord.  If, within two (2) business days following Landlord's receipt of the Repair Plans, Landlord has not either approved the Repair Plans or reasonably disapproved the Repair Plans (providing with reasonable specificity the reasons for such disapproval), Landlord will be deemed to have approved the Repair Plans.  Tenant shall use only the services of any qualified contractor which regularly performs similar work in comparable buildings in Oakland Metropolitan Area.  For all such work, Tenant shall use only materials and parts of kind and quality at least equal to the original and consistent with the Construction Document Packages.  Notwithstanding the foregoing, Tenant shall use only such contractor, materials, parts and techniques required under any warranty then in effect and of which Tenant is notified (in writing or verbally in event of a Repair Emergency).  Tenant shall furnish names and addresses of all contractors and subcontractors and copies of all contracts.  Upon completion of such repair, Tenant shall deliver to Landlord an as-built set of plans and specifications (digitized if available), if any, for such repair or maintenance.  Tenant shall not conduct any such repair in a manner that will draw picketers or demonstrators without the prior consent of Landlord.  Tenant shall comply with and observe the same requirements under Section 9 (except to the extent expressly set forth in, or inconsistent with, this Section 16) that would apply if Tenant seeks to perform Alterations and with other applicable provisions of the Lease.  In addition, any Cure Action shall be (i) subject to Tenant&#8217;s indemnification obligations set forth in Section 9 of this Lease, (ii) subject to Tenant's other obligations under this Lease, including without limitation, Tenant's obligations with respect to Alterations and liens, and (iii) such action shall be diligently prosecuted to completion and shall be undertaken in a good and workmanlike manner and in compliance with all Laws.  If any Cure Action to be undertaken by Tenant in accordance with the foregoing affects elements of the structural frame of the Building or the Building Systems, Tenant shall engage Landlord's contractors to effectuate such action.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Payment by Landlord and Offset</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Promptly following completion of any work by Tenant pursuant to Section 16(b), Tenant shall deliver to Landlord Tenant&#8217;s request for reimbursement of the actual, costs reasonably incurred by Tenant for the work permitted pursuant to Section 16(b), which request shall include the contractors and materials used, copy of all required permits and governmental approvals, copy of receipt(s) showing Tenant&#8217;s payment to those providing services or materials, and valid, final, unconditional mechanics&#8217; lien releases and waivers from all contractors, subcontractors and suppliers providing services or materials.  Within thirty (30) days after receipt of such invoice and documentation, Landlord shall reimburse Tenant the amount, if any, not reasonably disputed by Landlord, as more particularly set forth below (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Undisputed Amount</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Provided however, alternatively, within thirty (30) days after receipt of such invoice Landlord may give Tenant written notice of Landlord&#8217;s reasonable objection to the payment of such invoice, setting forth with reasonable specificity Landlord&#8217;s reasons for its claim that such action was not required to be taken by Landlord pursuant to the terms of the Lease, or that the work by Tenant was defective (or otherwise did not correctly repair the problem), or that the charges were not reasonably incurred (in which case Landlord shall pay the amount it contends was reasonably incurred for the repair required under the Lease) (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Dispute Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  If Landlord does not deliver Tenant a Dispute Notice within the time period set forth above, Landlord will be deemed to have approved such invoice and documentation.  In the event Tenant disputes Landlord&#8217;s timely delivered Dispute Notice, Tenant may, as its sole and exclusive remedy, bring a claim against Landlord for payment of the amount due in accordance with the foregoing.  If Landlord fails to pay Tenant any Undisputed Amount within ten (10) days after Landlord's approval (or deemed approval) of such invoice or documentation, then, notwithstanding any other provision of this Lease that prohibits any such withholding, deduction or offset of Rent, in lieu of its receipt of such unpaid amounts, Tenant may, as its sole and exclusive remedy for such failure, offset against Rent the Undisputed Amount, plus interest at the Default Rate on the Undisputed Amount until the full amount of the unpaid amounts, together with all interest thereon, has been recouped by Tenant. Tenant </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 29 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">acknowledges and agrees that Landlord's acceptance of such offset shall not in and of itself be an admission by Landlord that it is responsible for such expense, and Landlord reserves the right to contest the amount of such expense and/or Landlord's liability therefor.  Notwithstanding the foregoing, the maximum amount of Rent which Tenant shall be entitled to offset in any calendar year shall be 20% of the Base Rent for such period, and shall be limited to a maximum of 30% of each installment of the payment of Base Rent (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Maximum Annual Rent Abatement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;); provided, however, Tenant&#8217;s offset rights with respect to amounts owed to Tenant pursuant to a final, non-appealable judgment in court or an award shall not be subject to any limitation, including, without limitation, the Maximum Annual Rent Abatement.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Cure Rights Personal to Tenant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The right of cure and offset set forth in this Section 16 is personal to the original Tenant and may not be exercised by any other party, provided however, in the event this Lease is assigned to a Permitted Transferee that satisfies the provisions of Section 13(c), the right to cure and offset set forth in this Section 16 may be exercised by Tenant or by such Permitted Transferee, and such Permitted Transferee may exercise the right without Tenant joining in or consenting to such exercise, and notwithstanding any provision of the Lease to the contrary, Tenant shall remain liable for all obligations under the Lease, including those resulting from any such exercise, with the same force and effect as if Tenant had joined in the exercise of the right to cure.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">f.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Effect of Cure on Operating Expenses</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding the undertaking of a Cure Action by Tenant pursuant to this Section 16, the cost of such Cure Action, whether paid by Landlord to Tenant or offset from Tenant's Rent obligations as provided herein, shall be an Operating Expense to the extent the cost of such Cure Action would have constituted an Operating Expense if performed by Landlord; provided however, any interest payable to Tenant pursuant to the terms of this Section 16 shall not be an Operating Expense and shall be the sole cost of Landlord.</font></div><div><a name="sF609DB5A681A49640BEB13FD422019C7"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">17.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Intentionally Omitted</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div><a name="s7753DD0660D973BDAC7213FD42524C45"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">18.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Estoppel Certificate and Financial Statements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Tenant&#8217;s Estoppel Certificate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall at any time within ten (10) business days following written request from Landlord execute, acknowledge and deliver to Landlord a statement certifying: (i) that this Lease is unmodified and in full force and effect (or, if modified, stating the nature of such modification and certifying that this Lease, as so modified, is in full force and effect); (ii) the date to which the Base Rent and other sums payable under this Lease have been paid; (iii) the amount of the Letter of Credit or Deposit, as applicable; (iv) acknowledging that there are not, to Tenant&#8217;s actual knowledge, any uncured defaults on the part of Landlord under this Lease, or specifying such defaults, if any, which are claimed; and (v) such other factual matters as may reasonably be requested by Landlord.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Reliance and Failure to Deliver</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any such statement may be conclusively relied upon by any prospective purchaser or encumbrancer of the Building.  Tenant&#8217;s failure to deliver such statement within such time shall be deemed Tenant&#8217;s confirmation that: (i) this Lease is in full force and effect, without modification except as may be represented by Landlord; (ii) there are no uncured defaults in Landlord&#8217;s performance; and (iii) not more than one month&#8217;s Base Rent has been paid in advance.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Financial Statements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall deliver to Landlord within thirty (30) days following Landlord&#8217;s request, the most recent complete and accurate financial statements of Tenant.  Such statements shall be prepared in accordance with generally accepted accounting principles, to the extent applicable to Tenant&#8217;s business, consistently applied, and shall be certified as accurate and complete by an independent certified public accountant.  All such financial statements shall be received by Landlord in confidence and may only be disclosed by Landlord to its current and/or prospective lenders and/or purchasers who shall also be instructed to maintain such information in confidence pursuant to Section 26(m) of this Lease. Notwithstanding the foregoing, so long as Tenant is a publicly traded company, Tenant shall have no obligations under this Section 18(c).  </font></div><div><a name="s56663887287B6F51A7F613FD4274DFBA"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">19.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Subordination; Amendment for Lender</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Lease shall be subordinate to any mortgage, deed of trust, ground lease, underlying lease or any other hypothecation for security (each an &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Encumbrance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) hereafter placed upon the Project and to any </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 30 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">and all advances made on the security thereof and to all renewals, modifications, consolidations, replacements and extensions thereof; provided, however, that such subordination shall only be effective as to such future Encumbrances on the Project if the applicable holder of the Encumbrance executes a commercially reasonable subordination, non-disturbance and attornment agreement (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SNDA</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which shall, among other provisions, provide that notwithstanding any subordination in such SNDA, Tenant&#8217;s right to quiet possession of the Premises shall not be disturbed if there is not an Event of Default by Tenant unless this Lease is otherwise terminated pursuant to its terms.  If any holder of an Encumbrance on the Project shall elect to have this Lease prior to the lien of its Encumbrance, and shall give notice thereof to Tenant, this Lease shall be deemed prior to such Encumbrance, whether this Lease is dated prior to or subsequent to the date of said Encumbrance or the date of recording thereof.  If any mortgage or deed of trust to which this Lease is subordinate is foreclosed or a deed in lieu of foreclosure is given to the mortgagee or beneficiary, Tenant shall attorn to the purchaser at the foreclosure sale or to the grantee under the deed in lieu of foreclosure; if any master lease to which this Lease is subordinate is terminated, Tenant shall attorn to the master lessor, provided that for any of the foregoing events, Tenant has received an executed, commercially reasonable SNDA. Promptly following the request of any such purchaser, grantee, or master lessor, Tenant shall execute and deliver a new lease, in the form of this Lease, with such requesting party as Landlord.  Within ten (10) business days following Landlord&#8217;s request or the request of any such mortgagee, beneficiary or master lessor, Tenant shall execute an SNDA or any other documents reasonably required to effectuate such subordination or to make this Lease prior to the lien of any mortgage, deed of trust or master lease, as the case may be, or to evidence such attornment. Landlord represents that, as of the Execution Date, Landlord has not obtained financing from any lender with an Encumbrance on the Premises or any part or interest therein. Tenant acknowledges that, prior to the Execution Date, Tenant has received a copy of the preliminary title report with respect to the Land, which is attached hereto as part of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit &#160;E-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, which report does not include an exception to title with respect to an Encumbrance.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Modification for Lender</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Within ten (10) business days of Landlord&#8217;s request therefor, Tenant shall execute and deliver such amendments to this Lease as shall have been reasonably required by Landlord&#8217;s lender in connection with the making of a loan to be secured by the Project, provided that such amendment does not increase the obligations of Tenant under this Lease or materially and adversely affect Tenant&#8217;s leasehold interest or its other rights under this Lease.  Any costs incurred by Tenant to enter into any such amendment shall be borne by Landlord.</font></div><div><a name="s880A3E14D62156A27B0713FD42AA4A68"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">20.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Attorneys&#8217; Fees</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If either party commences an action or proceeding against the other party arising out of or in connection with this Lease, or institutes any proceeding in a bankruptcy or similar court which has jurisdiction over the other party or any or all of its property or assets, the prevailing party in such action or proceeding and in any appeal in connection therewith shall be entitled to have and recover from the unsuccessful party reasonable attorneys&#8217; fees, court costs, expenses and other costs of investigation and preparation.  If such prevailing party recovers a judgment in any such action, proceeding, or appeal, such attorneys&#8217; fees, court costs and expenses shall be included in and as a part of such judgment.  </font></div><div><a name="s932CD04C4E709A74A3DA13FD42CAF511"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">21.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Notices</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All notices, consents, demands and other communications from one party to the other given pursuant to the terms of this Lease shall be in writing and shall be provided (i) if to Tenant, by personal delivery at the address specified in the Basic Lease Information or to such other place and with such other copies as Tenant may from time to time designate in a notice to Landlord, (ii) by deposit in the United States mail, certified or registered, postage prepaid, or (iii) by delivery by a generally recognized overnight courier service, charges prepaid and addressed as follows: (a) if to Tenant, at the address specified in the Basic Lease Information or to such other place and with such other copies as Tenant may from time to time designate in a notice to Landlord or (b) if to Landlord, at the address specified in the Basic Lease Information, or to such other place and with such other copies as Landlord may from time to time designate in a notice to Tenant.  Notices, demands or declarations given under this Lease will be deemed to have been given when received or when receipt is refused.</font></div><div><a name="sF65E4D8BD5CDED0C947413FD42FCE756"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">22.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Signage</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  At Tenant&#8217;s cost, Tenant may erect, install and maintain signage of a kind and size and in a location (including monument signage and signage on the Building eyebrow) that is permitted by local regulatory codes and other applicable Laws, provided that Tenant shall obtain Landlord&#8217;s prior written consent, which shall not be unreasonably withheld, conditioned or delayed, with respect to the method of attachment of such signage to the Building.  Tenant shall maintain such signage in accordance with applicable Laws. </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 31 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s00D57B71F61042A3C63313FD431EAE71"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">23.&#160;&#160;&#160;&#160; </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Security Deposit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Upon execution of this Lease Tenant shall deliver to Landlord a security deposit in the amount specified in the Basic Lease Information (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Deposit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  The Deposit shall be held by Landlord as security for the performance by Tenant of all of the provisions of this Lease.  Following an Event of Default by Tenant under this Lease, Landlord may use, apply or retain all or any portion of the Deposit for the payment of any rent or other charge in default, or the payment of any other sum to which Landlord may become obligated by Tenant&#8217;s default, or to compensate Landlord for any expense, loss or damage which Landlord may suffer thereby.  If Landlord so uses or applies all or any portion of the Deposit, then within ten (10) days after demand therefor Tenant shall deposit cash with Landlord in an amount sufficient to restore the Deposit to the full amount thereof, and Tenant&#8217;s failure to do so prior to the expiration of all applicable notice and cure periods shall be an uncurable Event of Default under this Lease.  Landlord shall not be required to keep the Deposit separate from its general accounts.  The Deposit, or so much thereof as has not theretofore been applied by Landlord, shall be returned, without payment of interest for its use, to Tenant (or, at Landlord&#8217;s option, to the last assignee, if any, of Tenant&#8217;s interest under this Lease) not later than 30 days after the later of the date of termination or expiration of the Lease or the date that Tenant delivers possession of the Premises to Landlord, unless a longer time is reasonably required to ascertain damages payable from the Deposit (not to exceed sixty (60) days).  No trust relationship is created herein between Landlord and Tenant with respect to the Deposit.  Tenant waives the provisions of California Civil Code Section&#160;1950.7, and all other present and future laws to the extent the same restrict the amount or types of claim that a landlord may make upon a security deposit or, to the extent in conflict with the express terms of this Lease, imposes upon a landlord or a successor any obligation with respect to the handling or return of security deposits. Upon final determination of the Initial Base Rent pursuant to Section 3(a), if the Deposit then held by Landlord is greater than the Initial Base Rent, Landlord shall promptly refund such excess to Tenant, and if the Deposit held by Landlord is less than the Initial Base Rent, then Tenant shall deposit such shortfall amount with Landlord within ten (10) days after notice from Landlord.  </font></div><div><a name="s8F4FF3ED17AA1400431313FD434DE9AA"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">24. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Letter of Credit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">. At Tenant&#8217;s election, in lieu of the Deposit provided in Section 23, Tenant shall, within two business days of the mutual execution and delivery of this Lease, deliver to Landlord an irrevocable, unconditional and transferable (without cost to beneficiary) standby Letter of Credit (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Letter of Credit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), in a form reasonably approved by Landlord and meeting the requirements of this Section 24, in the amount stated in the Basic Lease Information.  The following provisions shall apply to the Letter of Credit:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a.&#160;&#160;&#160;&#160;The Letter of Credit shall be governed by ISP98, as revised from time to time, issued by a commercial bank (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Issuer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) reasonably satisfactory to Landlord with offices for banking purposes in the San Francisco Bay Area, and drawable by sight draft presented by Landlord from time to time.  Landlord hereby approves the following banks as an Issuer: Wells Fargo Bank. The Letter of Credit shall name Landlord as beneficiary, permit multiple drawings, be fully transferable by Landlord, and otherwise be in form and substance reasonably satisfactory to Landlord.  The Letter of Credit shall also provide that it shall be deemed automatically renewed, without amendment, for consecutive periods of one (1) year each during the Term plus sixty (60) days after the Term Expiration (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LC Term Expiration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), unless the Issuer delivers written notice (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Issuer Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to Landlord (with a simultaneous copy to Tenant) by any method specified for giving of notices under this Lease, as amended, not less than forty-five (45) days preceding the then-Term Expiration of a Letter of Credit that it elects not to have that Letter of Credit renewed.  If Landlord receives an Issuer Notice and, not later than fifteen (15) business days preceding the Term Expiration of the expiring Letter of Credit, Tenant fails to furnish Landlord with a replacement of the expiring Letter of Credit pursuant to and meeting the conditions of this Section 24, then Landlord shall have the right to draw the full amount of that Letter of Credit by delivering to the Issuer a statement that Tenant has failed timely to deliver to Landlord a replacement Letter of Credit pursuant to and meeting the conditions of this Section, in which event the Issuer shall disburse the full amount of the expiring Letter of Credit to Landlord and Landlord shall hold such amount pursuant to Section 24(f), below. Tenant shall, at any time after Landlord draws the Letter of Credit, be entitled to provide Landlord with a replacement Letter of Credit that satisfies the requirements hereunder, at which time Landlord shall return the cash proceeds of the original Letter of Credit drawn by Landlord to the extent Landlord has not applied such funds in curing an Event of Default by Tenant hereunder.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b.&#160;&#160;&#160;&#160;The Letter of Credit shall be held by Landlord for the faithful performance of all terms, covenants and conditions of this Lease.  The Letter of Credit shall be returned to Tenant within sixty (60) days after the later of the date of termination or expiration of the Lease or the date Tenant delivers possession of the Premises to Landlord, unless a longer time is reasonably required to ascertain damages payable from the Letter of Credit (not </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 32 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">to exceed an additional 30 days).  Tenant agrees that Landlord may, without waiving any of Landlord&#8217;s other rights and remedies under this Lease, draw upon the Letter of Credit and apply the proceeds of the Letter of Credit (i) in whole or in part to remedy, or compensate Landlord for any damages arising from any Event of Default by Tenant; (ii) in whole if a petition is filed by or against Tenant or, if Tenant is not the &#8220;Applicant&#8221; under the Letter of Credit, then by or against the Applicant, under Title 11 of the United States Code, or a proceeding has been commenced by or against Tenant or, if Tenant is not the Applicant under the Letter of Credit, then by or against the Applicant, under any other state or federal insolvency laws or under the insolvency laws of another country (any such proceeding defined herein as a &#8220;Bankruptcy Case&#8221;); or (iii) in whole if a renewal/extension of, amendment to or replacement or evidence of the restoration of the Letter of Credit as required under Section 24(a) is not timely received by Landlord in form and substance reasonably acceptable to Landlord.  If Landlord draws on the Letter of Credit, Tenant shall within five (5) business days restore the amount of the Letter of Credit to the full amount of the Letter of Credit as required to be maintained under this Section 24 pursuant to a replacement thereof or an amendment thereto in form and substance reasonably satisfactory to Landlord, or shall provide cash in lieu thereof, failing which Landlord may, without waiving its other remedies hereunder, draw down any sums then remaining unpaid under the Letter of Credit. If Landlord draws upon the Letter of Credit pursuant to subpart&#160;(i) above, Landlord shall only draw upon the Letter of Credit to the extent needed to cure such Event of Default.  In the event Landlord improperly draws upon the Letter of Credit or misapplies the Letter of Credit proceeds, Tenant shall have the right to offset such amounts against Rent and Tenant shall have no right or claim (and Landlord shall have no liability to Tenant) with respect to the funds so improperly drawn or misapplied.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c.&#160;&#160;&#160;&#160;If Landlord&#8217;s interest in the Premises is sold or otherwise assigned or transferred, then Tenant shall, upon ten (10) days prior notice from Landlord, at Tenant&#8217;s sole cost and expense, cause Issuer to amend the Letter of Credit, in form and substance reasonably satisfactory to Landlord, to transfer them to the new Landlord designated by Landlord in its notice, effective on the date designated by Landlord in its notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d.&#160;&#160;&#160;&#160;Any draw under the Letter of Credit shall be subscribed by a representative of Landlord.  The Issuer shall have no obligation to verify any matter or statement made in connection with any draw under the Letter of Credit and no good faith error in connection with any such matter or statement shall affect the validity of any draw by Landlord.  No draw under the Letter of Credit or failure or delay of Landlord to draw any portion of the Letter of Credit shall constitute a waiver of Landlord&#8217;s right to do so at any time thereafter, a waiver of Landlord&#8217;s other rights and remedies under this Lease, or a waiver of any default with respect to this Lease.  Tenant agrees that Tenant shall have no right to apply any portion of the cash security or proceeds of the Letter of Credit against any of Tenant&#8217;s obligations to pay rent or perform obligations under the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e.&#160;&#160;&#160;&#160;Landlord and Tenant acknowledge and agree that in no event or circumstance shall the Letter of Credit or any renewal thereof or any proceeds thereof be (i)&#160;deemed to be or treated as a &#8220;security deposit&#8221; within the meaning of California Civil Code Section&#160;1950.7, (ii)&#160;subject to the terms of such Section&#160;1950.7, or (iii)&#160;intended to serve as a &#8220;security deposit&#8221; within the meaning of such Section&#160;1950.7.  The parties hereto (A)&#160;recite that the Letter of Credit are not intended to serve as a security deposit and such Section&#160;1950.7 and any and all other Laws applicable to security deposits in the commercial context (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Security Deposit Laws</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) shall have no applicability or relevancy thereto and (B)&#160;waive any and all rights, duties and obligations either party may now or, in the future, will have relating to or arising from the Security Deposit Laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">f.&#160;&#160;&#160;&#160;In the event Landlord draws down on the Letter of Credit, the proceeds of the Letter of Credit may be held by Landlord and applied by Landlord against any Base Rent or Additional Rent payable by Tenant under this Lease that is not paid when due and/or to pay for all losses and damages that Landlord has suffered or that Landlord reasonably estimates that it will suffer as a result of any Event of Default by Tenant under this Lease.  Any unused proceeds of the Letter of Credit shall constitute the property of Landlord and need not be segregated from Landlord&#8217;s other assets.  Tenant hereby (i) agrees that (A) Tenant has no property interest whatsoever in the proceeds from any such draws, and (B) such proceeds shall not be deemed to be or treated as a &#8220;security deposit&#8221; under the Security Deposit Laws, and (ii) waives all rights, duties and obligations either party may now or, in the future, will have relating to or arising from the Security Deposit Laws.  Landlord agrees that the amount of any proceeds of the Letter of Credit received by Landlord, and not used to pay for any losses and/or damages suffered by Landlord (or reasonably estimated by Landlord that it will suffer) as provided for in this Section 24(f) (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Unused Letter of Credit Proceeds</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 33 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">shall be paid by Landlord to Tenant (x) upon receipt by Landlord of a replacement of the Letter of Credit in the full amount of the Letter of Credit, which replacement Letter of Credit shall comply in all respects with the requirements of this Section 24, or (y) within sixty (60) days after the later of the date of termination or expiration of the Lease or the date Tenant delivers possession of the Premises to Landlord, unless a longer time is reasonably required to ascertain damages payable from the Unused Letter of Credit Proceeds (not to exceed an additional 30 days), and except as provided otherwise herein; provided, however, that if prior to the LC Term Expiration a voluntary petition is filed by Tenant, or an involuntary petition is filed against Tenant by any of Tenant&#8217;s creditors, under the U.&#160;S.&#160;Bankruptcy Code or any state bankruptcy code, then Landlord shall not be obligated to make such payment in the amount of the Unused Letter of Credit Proceeds until either all preference issues relating to payments under this Lease have been resolved in such bankruptcy or reorganization case or such bankruptcy or reorganization case has been dismissed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">g.&#160;&#160;&#160;&#160;Upon final determination of the Initial Base Rent pursuant to Section 3(a), if the amount of the Letter of Credit then held by Landlord is not equal to the Initial Base Rent, then Tenant shall promptly obtain a revised Letter of Credit in an amount equal to the Initial Base Rent.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">h.&#160;&#160;&#160;&#160;If Tenant delivers a replacement or amended Letter of Credit to Landlord when and as required under this Section 24 in the form required herein, Landlord shall exchange the Letter of Credit then held by Landlord for the replacement or amended Letter of Credit delivered by Tenant. Tenant may at any time substitute a cash Deposit for the Letter of Credit, and upon such substitution, Landlord shall return the Letter of Credit to Tenant. </font></div><div><a name="s6F6D1B20B395A1A5F42C13FD436EF716"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">25.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Right of First Offer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Offer Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord shall not sell or otherwise convey Landlord&#8217;s fee title in the Project (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Fee Interest</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to any unaffiliated third party, unless Landlord shall have first given Tenant the one-time opportunity (subject to the terms of this Section 25) to buy the Fee Interest in accordance with this Section&#160;25 (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Right of First Offer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  In the event that Landlord desires to transfer the Fee Interest to an unaffiliated third party after the date of this Lease, Landlord shall first deliver to Tenant a written notice (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Offer Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which shall include, in good faith, the following terms: (i)&#160;the purchase price, (ii)&#160;the amount of any earnest money deposit, (iii)&#160;the length of any due diligence period, and (iv)&#160;the date of closing ("</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Offer Terms</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">").  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Acceptance; Counteroffer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Upon receipt of an Offer Notice, Tenant shall have the right to either (i) purchase the Fee Interest on the terms and conditions provided in the Offer Notice provided that Tenant exercises its right to purchase in strict accordance with this Section 25(b), (ii) reject the Offer Notice by delivering a notice to Landlord or failing to respond within the time period set forth below or (iii) reject the Offer Notice by delivering a notice to Landlord setting forth the terms upon which Tenant desires to purchase the Fee Interest, which notice shall include Tenant's Offer Terms (such notice under this clause (ii), a "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Counteroffer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">"). If Tenant desires to exercise such right to purchase the Fee Interest pursuant to the Offer Notice, Tenant must deliver to Landlord written notice of its exercise of such right (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Election Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) within the ten (10) business days after Tenant&#8217;s receipt of the Offer Notice, and if Tenant desires to deliver a Counteroffer to Landlord, Tenant must deliver such Counteroffer to Landlord within the same ten (10) business day period.  If Tenant delivers a Counteroffer, Landlord shall, within five (5) business days of Landlord's receipt thereof, notify Tenant of its acceptance or rejection of such Counteroffer, and any failure of Landlord to respond within such period shall be deemed to be Landlord's rejection of the Counteroffer.  If Tenant elects to purchase the Fee Interest pursuant to the Offer Notice (as set forth in clause (i) above) or if Tenant delivers a Counteroffer that Landlord accepts, Landlord and Tenant shall proceed to use commercially reasonable, good faith efforts to negotiate a purchase and sale agreement (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Purchase Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which Purchase Agreement shall include the terms set forth in the Offer Notice or the Counteroffer and such other terms otherwise agreed upon by Landlord and Tenant, for a period of not more than 30 days.  Notwithstanding the foregoing, if at the time Tenant delivers the Election Notice or Counteroffer or during the negotiation of the Purchase Agreement an Event of Default under this Lease has occurred and is continuing, the Election Notice (or the Counteroffer, as applicable) shall be ineffective (or </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">void ab initio</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">).  Upon the full execution and delivery of a Purchase Agreement this Section 25 will immediately be null and void and of no further force or effect and whether or not a closing occurs thereunder or the Purchase Agreement is terminated for any reason.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 34 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Rejection</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If (i) Tenant rejects the Offer Notice without delivering a Counteroffer, (ii) Tenant fails to respond to the Offer Notice within said ten (10) business day period, (iii) Landlord rejects Tenant's Counteroffer, (iv) Tenant fails to negotiate the Purchase Agreement in good faith (e.g. attempting to renegotiate terms in the Offer Notice), (v) the Purchase Agreement is not mutually executed or delivered within the 30-day period provided in Section 25(b) despite the parties&#8217; commercially reasonable, good faith efforts, or (vi) the Purchase Agreement is mutually executed and delivered but then Tenant elects not to close or fails to close under the terms of the Purchase Agreement, then Landlord shall have the right to sell the Fee Interest to a third party any terms and conditions Landlord so desires.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Second Offer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding the foregoing, if Tenant has delivered a Counteroffer to Landlord that Landlord has rejected and Landlord thereafter desires to sell the Fee Interest to a third party on terms and conditions materially more favorable to a third-party purchaser than the Offer Terms set forth in the Counteroffer, Landlord shall, prior to entering into a binding agreement to sell the Fee Interest to such third party, offer to sell the Fee Interest to Tenant on the terms and conditions proposed (or to be proposed) to such third-party purchaser (a "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Second Offer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">").  Landlord's good faith and reasonable judgment regarding the favorability of the Offer Terms offered to a third party versus the Offer Terms contained in any Counteroffer shall be determinative (i.e., whether or not such terms are more or less favorable than those set forth in the Counteroffer).  If Landlord is required to deliver a Second Offer to Tenant, then Landlord shall send a notice to Tenant setting forth the Offer Terms (the "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Second Offer Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">") and Tenant shall, by written notice to Landlord either accept or reject such Second Offer within five (5) business days of Tenant's receipt thereof.  Tenant's failure to timely accept the Second Offer shall be deemed to be a rejection of the Second Offer.  Upon Tenant's rejection (or deemed rejection) of any Offer Notice (without an accompanying Counteroffer) or, if applicable, Tenant's rejection of any Second Offer Notice, this Section 25 will immediately be null and void and of no further force or effect and whether or not a closing with a third party occurs thereafter for any reason.  For avoidance of doubt, the obligations of Landlord and the rights of Tenant set forth in this Section 25 are personal to the original Landlord (and its transferee pursuant to Section 26(u)) and the original Tenant named herein and Affiliate or Permitted Transferee of such Landlord and Tenant, and shall not be applicable to any successor-in-interest to Landlord or Tenant (other than an Affiliate or Permitted Transferee of such party succeeding directly to such party's interest herein).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Sales of Majority Interests in Landlord</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Any transfer of a majority or more of the Interests in Landlord (as defined below) to a third party that is not currently (i) a direct or indirect owner of Landlord or an Affiliate of such owner or (ii) an Affiliate of Landlord, shall constitute a sale of the Fee Interest for the purposes of this Section 25. Landlord shall not consummate such transfer unless the Fee Interest is offered to Tenant in accordance with Section 25(a). Such offer shall be set forth in an Offer Notice, which shall include, in good faith, the following terms: (i)&#160;the purchase price, (ii)&#160;the amount of any earnest money deposit, (iii)&#160;the length of any due diligence period, and (iv)&#160;the date of closing.  An &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Interest in Landlord</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall mean a direct partnership, membership or shareholder interest, as applicable, in Landlord or in any entity that owns, directly or indirectly, all or substantially all of the interests in Landlord and that does not own any other material assets other than income derived from the ownership of Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">f.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exclusions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Section 25 shall not apply to any (a) transfers of interests in connection with any mortgage financing transactions, (b) transfers </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">by devise or descent or by operation of law upon the death of an owner of Landlord, (c) transfers by an owner who has become incapacitated, (d) </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">if Landlord is a publicly traded entity, any transfers of interests in Landlord, (e) transfers of interests in connection with a foreclosure or a transfer in lieu of foreclosure, (f) any transfers by any lender that has taken ownership of the Fee Interest, whether directly or through an affiliated entity, (g) transfer of interests by Landlord at or prior to Closing, (h) grants of easements, covenants, restrictions and licenses with respect to the Premises or (i)  sale of a portfolio of real properties that includes property in addition to the Premises.   </font></div><div><a name="sAC1F8468EF9FC78C4A0913FD43A16C95"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">General Provisions</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Governing Law</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Lease shall be governed by and construed in accordance with the laws of the State of California.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">b. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Severability</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The invalidity of any provision of this Lease, as determined by a court of competent jurisdiction, shall in no way affect the validity of any other provision under this Lease. </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 35 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">c. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Prior Agreements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Lease contains all agreements of the parties with respect to any matter mentioned herein, supersedes any verbal and any prior written understanding, conditions, representations, agreements or covenants and may be modified in writing only, signed by the parties.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">d. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">No Waiver</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  No waiver by Landlord or Tenant of any provision under this Lease shall be deemed a waiver of any other provision or of any subsequent breach by Landlord or Tenant of the same or any other provision.  Landlord&#8217;s or Tenant&#8217;s consent to or approval of any act shall not be deemed to render unnecessary the obtaining of Landlord&#8217;s or Tenant&#8217;s consent to or approval of any subsequent act by Tenant or Landlord.  The acceptance of Base Rent, additional rent or any partial payment under this Lease by Landlord shall not be a waiver of any preceding breach by Tenant of any provision under this Lease, other than the failure of Tenant to pay the particular Base Rent or additional rent accepted, regardless of Landlord&#8217;s knowledge of such preceding breach at the time of acceptance of such payment.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">e. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Holding Over</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If Tenant remains in possession of the Premises or any part thereof after the expiration of the Term, such occupancy shall be a tenancy at sufferance at a rental in the amount of: 1) if, not later than 90 days prior to the expiration of the Term, Tenant delivers written notice to Landlord of Tenant&#8217;s intent to hold over, then (a) during the first 60 days of the hold over, one hundred twenty-five percent (125%) of the last month&#8217;s Base Rent plus all other charges payable under this Lease and upon all of the other terms of this Lease and (b) thereafter, one hundred fifty percent (150%) of the last month&#8217;s Base Rent plus all other charges payable under this Lease and upon all of the other terms of this Lease, and (2) if Tenant fails to deliver written notice to Landlord of Tenant&#8217;s intent to hold over not later than 90 days prior to the expiration of the Term, then one hundred fifty percent (150%) of the last month&#8217;s Base Rent plus all other charges payable under this Lease and upon all of the other terms of this Lease.  However, if Landlord has executed a lease with another tenant for all or a portion of the Premises and any unauthorized holding over will delay or prevent Landlord from delivering possession of all or a part of the Premises to another tenant or from commencing work to make all or part of the Premises available to another tenant, and Landlord has delivered written notice to Tenant specifying the same, then from the date of Landlord's delivery of such notice the rental rate applicable to such tenancy at sufferance shall be one hundred fifty percent (150%) of the last month&#8217;s Base Rent (notwithstanding any previous notice from Tenant as set forth above) plus all other charges payable under this Lease and upon all of the other terms of this Lease.  Notwithstanding the foregoing, Landlord's acceptance of Rent from Tenant during any period of tenancy at sufferance shall not be deemed to be the consent of Landlord to Tenant's continued occupancy of the Premises, and if Tenant remains in possession of the Premises or any part thereof after the expiration of the Term without Landlord&#8217;s consent, Landlord shall have all remedies at law or in equity.  In addition, if Tenant remains in possession of the Premises or any part thereof for more than sixty (60) days following the expiration of the Term with or without Landlord's consent, then, in addition to Landlord's remedies as set forth above, Tenant shall defend and indemnify Landlord from all loss, liabilities, damages and costs, including consequential damages and attorneys&#8217; fees, incurred by Landlord and resulting from Tenant&#8217;s failure to surrender possession of the Premises to Landlord when and as required under this Lease. The provisions of this Section shall survive the expiration or earlier termination of this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">f. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Successors and Assigns</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the provisions of this Lease restricting assignment or subletting by Tenant, this Lease shall bind the parties, their personal representatives, successors and assigns.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">g. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Landlord&#8217;s Entry</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and its agents shall have the right to enter the Premises, upon at least one (1) business day&#8217;s notice, at reasonable times during normal business hours (except in the event of emergencies, in which event no such entry limitations shall apply) for the purpose of inspecting the same, showing the same to prospective purchasers or lenders and making such alterations, repairs, improvements or additions to the Premises or to the Building as Landlord is required or permitted to make pursuant to the terms of this Lease.  Landlord and its agents, employees or contractors shall use commercially reasonable efforts to minimize interference with Tenant&#8217;s use, operations and access to and from the Premises and shall comply with Tenant&#8217;s reasonable security measures, including Tenant's restriction of access to secure areas reasonably designated by Tenant.  In addition, Landlord shall take reasonable measures to secure access to any keys to the Premises that are in Landlord's possession.  Landlord may at any time during the last sixty (60) days of the term place on or about the Project any ordinary &#8220;For Lease&#8221; sign.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 36 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">h. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Authority</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  If Landlord or Tenant is a corporation, limited liability company or other entity, Landlord and Tenant represent and warrant to the other party that each individual executing this Lease on behalf of such party is duly authorized to execute and deliver this Lease on its behalf and that this Lease is binding upon the entity in accordance with its terms.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">i. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Landlord Defined</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The term </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;Landlord&#8221;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;as used in this Lease means the then owner of the Building and in the event of a sale of the Building the selling owner shall be automatically relieved of all obligations of Landlord under this Lease, except for acts or omissions of Landlord occurring prior to such sale, provided that Landlord&#8217;s purchaser or assignee expressly assumes Landlord&#8217;s duties and covenants under this Lease first accruing on and after the date of such sale.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">j. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Brokers</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant and Landlord each warrant that it has had no dealings with any real estate broker or agent in connection with the Premises or this Lease.  Tenant shall indemnify, defend, reimburse and hold Landlord&#8217;s Parties harmless from and against any and all claims, demands, costs, charges, losses and liabilities (including, without limitation, reasonable attorneys&#8217; fees and costs) incurred by Landlord&#8217;s Parties asserted by any broker, agent, finder or other party for a fee or commission based upon dealings of that party with Tenant in connection with the Premises or this Lease.  Landlord shall indemnify, defend and reimburse Tenant&#8217;s Parties harmless from and against any and all claims, demands, costs, charges, losses and liabilities (including, without limitation, reasonable attorneys&#8217; fees and costs) incurred by Tenant&#8217;s Parties asserted by any broker, agent, finder or other party for a fee or commission based upon the dealings of that party with Landlord in connection with the Premises or the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">k. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Intentionally Deleted</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">l. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">OFAC Certification</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant represents, warrants and covenants that Tenant is not acting, and will not act, directly or indirectly, for or on behalf of any person, group, entity, or nation named by any Executive Order or the United States Treasury Department as a terrorist, &#8220;Specially Designated and Blocked Person&#8221; or other banned or blocked person, entity, nation, or transaction pursuant to any law, order, rule or regulation that is enforced or administered by the Office of Foreign Assets Control.  Landlord represents, warrants and covenants that Landlord is not acting, and will not act, directly or indirectly, for or on behalf of any person, group, entity, or nation named by any Executive Order or the United States Treasury Department as a terrorist, &#8220;Specially Designated and Blocked Person&#8221; or other banned or blocked person, entity, nation, or transaction pursuant to any law, order, rule or regulation that is enforced or administered by the Office of Foreign Assets Control.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">m. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Confidentiality</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The parties agree that the terms of this Lease shall not be confidential.  Subject to obligations, if any, under applicable Laws to disclose information to third parties, any confidential or financial nonpublic information that is disclosed or discovered in connection with the negotiation and performance of this Lease shall be confidential and constitute proprietary information.  Neither party, nor its respective owners, members, managers, shareholders, partners, officers, directors, employees, agents or attorneys, shall disclose such information to any other person without the prior written consent of the other party hereto, except that either party may disclose such information to its attorneys and accountants, and to any governmental entity, agency or person to whom disclosure is required by applicable Laws or ordered by a court of competent jurisdiction, and in connection with any action brought to enforce the terms of this Lease.  Any party disclosing any material information about this Lease shall require the recipient of the information to keep it confidential.  Either party may restrain or enjoin any breach or threatened breach of the provisions of this Section 26(m) and in the event of an actual breach of such provisions, the aggrieved party may seek to recover actual damages.  The foregoing remedies shall be the sole and exclusive remedies of the parties for a breach by the other party of the provisions of this Section 26(m) and in no event shall a breach of the provisions of this Section&#160;26(m) give rise to a right on the part of either party to terminate this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">n. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Dates and Time</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  As used herein, the term &#8220;business day&#8221; shall mean all days, excluding Saturdays, Sundays and all days observed by either the State of California or the United States government as legal holidays.  All references to &#8220;days&#8221; that do not specifically refer to &#8220;business days&#8221; will refer to calendar days.  Time is of the essence for the performance of each term, condition and covenant of this Lease and the exercise by Tenant of every right or option contained in this Lease and for the giving of any notice in each case for which deadlines for the performance, exercise or giving of such notice, as applicable, are expressly set forth herein. The foregoing shall not </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 37 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">operate, however, to reduce the time period allocated for the performance of any obligation or the curing of any default if a time period is specified in the Lease for the performance of such obligation.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">o. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Disclosures</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord hereby makes the following disclosures which Tenant acknowledges having received and reviewed before its execution and delivery of this Lease:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Pursuant to California Civil Code Section 1938, Landlord hereby notifies Tenant that neither the Building nor the Premises have been inspected by a Certified Access Specialist. A Certified Access Specialist (CASp) can inspect the subject premises and determine whether the subject premises comply with all of the applicable construction-related accessibility standards under state law. Although state law does not require a CASp inspection of the subject premises, the commercial property owner or lessor may not prohibit the lessee or tenant from obtaining a CASp inspection of the subject premises for the occupancy or potential occupancy of the lessee or tenant, if requested by the lessee or tenant. The parties shall mutually agree on the arrangements for the time and manner of the CASp inspection, the payment of the fee for the CASp inspection, and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;Pursuant to Health &amp; Safety Code &#167;25359.7, landlords are required to give notice to prospective tenants of the actual or possible presence of hazardous substances on or beneath their property.  Landlord&#8217;s knowledge regarding the possible presence of hazardous materials and substances, if any, is limited to any that may be described in any environmental site assessment or other report listed in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit H</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">,  copies of which shall be provided to Tenant by Landlord prior to Tenant&#8217;s execution of this Lease. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">p.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Excusable Delays</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the terms of the Work Letter and except as otherwise set forth herein (including Section 2(a)), all dates and time periods set forth in this Lease&#160;with respect to performance by a party shall be subject to extension for the period of Excusable Delay in the performance of the affected party&#8217;s obligations (other than its obligations to pay or deposit money), provided that the party whose performance is affected by the Excusable Delay provide written notice to the other party of such Excusable Delay within five (5) business days after the occurrence of the condition or event giving rise to the Excusable Delay; provided, however, Excusable Delay shall not delay Tenant&#8217;s Rent abatement or termination rights in Section&#160;2(a) except as may be expressly set forth in Section&#160;2(a) or in the Work Letter.  An &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Excusable Delay</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; shall be one that results from (i) events of force majeure, such as casualty, strike, labor action, act of war, or unusually severe weather, that prevent performance, (ii) unusual delay in the issuance of permits or governmental inspections, (iii) from the wrongful act or omission of the other party, (iv) the value engineering of the Landlord's Work and Tenant Improvements, as described in Section 4.1(f) or (v) another cause beyond the reasonable control of the party claiming the Excusable Delay.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">q. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Recordation</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall not have the right to record the Lease. Tenant shall have the right to record a memorandum of this Lease, in a form approved by Landlord in its reasonable discretion, setting forth the following terms only: (i) the term of the Lease, including the Term Commencement, Term Expiration, and Option Periods, and (ii) the existence of the Right of First Offer. Not later than thirty (30) days after Landlord&#8217;s request following (A) the expiration or termination of this Lease and (B) the termination of the Right of First Offer, Tenant shall execute, acknowledge, and deliver to Landlord a termination or quitclaim of such memorandum (which shall be limited to the Right of First Offer if this Lease has not terminated) in a form reasonably requested by Landlord (together with such other documentation reasonably required by a title company or required by a governmental authority in connection with such termination or quitclaim) to be recorded in the real property records upon the earlier to occur of: (1) Term Expiration and (2) the termination, expiration, or other lapse of the Right of First Offer.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">r. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Parking</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant shall have the right to use, on an unreserved basis, not less than the Tenant Allocable Share of Parking Spaces, on the Land and Adjacent Project.  In addition, Tenant may designate parking spaces on the Project that are immediately adjacent to the Building as being reserved for specific uses (e.g., visitor parking).  As used herein, the term "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Adjacent Project</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">" means the project adjacent to the Premises, being located at 1601, 1701, 1751, 1801 and 1851 Harbor Parkway and 1750 North Loop Road in Alameda, California.  As used herein, the term "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant Allocable Share of Parking Spaces</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">" means the number of parking spaces calculated as follows: (i) a fraction, (A) the numerator of which is rentable square footage of the Building and (B) the denominator of which is the total </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 38 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">rentable square footage of the Building and the Adjacent Project (excluding the 1750 Space), multiplied by (ii) the aggregate number of actual parking spaces on the Land and the Adjacent Property (excluding parking spaces designated, as of the Effective Date, for the exclusive use of the portion of the Adjacent Property known as 1750 North Loop Road, Alameda, California (the "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1750 Space</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">").  Upon the request of Landlord, Tenant shall enter into an amendment to its lease covering a portion of the Adjacent Property with the owner thereof (which is an Affiliate of Landlord) providing that Tenant will have the right to use a proportionate amount of parking spaces, calculated in the same manner as the Tenant Allocable Share of Parking Spaces (i</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">.e.,</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;replacing clause (A) above in such calculation with the square footage occupied by Tenant in the Adjacent Property). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">s. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Exhibits</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  The exhibits and any addendum specified in the Basic Lease Information are attached to this Lease and by this reference made a part of this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">t. &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Counterparts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  This Lease may be executed in counterparts and all of such counterparts, taken together, shall constitute one and the same instrument. Signatures to this Lease may be delivered electronically in portable document format (.pdf) or by facsimile, and such electronic signatures are deemed original signatures to this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">u.&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Land Purchase Agreement; Closing</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant acknowledge that (i) the closing of the acquisition of the Land pursuant to the Land Purchase Agreement (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Closing</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) is currently anticipated to occur on or about February 7, 2020 (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Existing Closing Date</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), (ii) Landlord is negotiating an amendment to the Land Purchase Agreement to extend either or both the diligence period or Existing Closing Date to accommodate obtaining entitlements for the construction of the Improvements prior to Closing (such amendment, the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;PSA Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), (iii) Peet&#8217;s Coffee Inc. may require an increase in the purchase price for the Land pursuant to the Land Purchase Agreement as consideration for the extension of the diligence period or closing date in the PSA Amendment, (iv) prior to the Closing, Landlord has no right, title, or interest in the Land except for the rights of Landlord to acquire fee ownership interest of the Land pursuant to the referenced Land Purchase Agreement, and (v) Landlord has no right to bind or act on behalf of the existing owner of the Fee Interest. Landlord shall use commercially reasonable efforts (e.g. by pursuing entitlements) to cause the Closing to occur on or before the Existing Closing Date (as such date may be extended by the PSA Amendment). Landlord and Tenant agree that if the Land Purchase Agreement is terminated, then this Lease shall terminate, and neither party shall have any obligation to the other hereunder accruing thereafter; provided, however, Landlord shall promptly notify Tenant of the termination of the Land Purchase Agreement and any monies previously paid by Tenant to Landlord for Landlord's account and not as a reimbursement to Landlord for a cost incurred by Landlord on Tenant's behalf (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">., monies paid to Landlord to pay the invoices of the Architect, mechanical, plumbing and electrical engineers and other design professionals for the design, permitting, and other pre-construction costs for the Tenant Improvements pursuant to the pre-lease services side letter between Landlord and Tenant) shall be reimbursed to Tenant.  Any monies paid to Landlord with respect to a cost incurred by Landlord on Tenant's behalf pursuant to such side letter are not reimbursable to Tenant upon a termination of the Land Purchase Agreement and resulting termination of this Lease.  Notwithstanding the above, Landlord and Tenant agree that this Lease is an effective and binding contract between them as of the Execution Date.  Upon the Closing, no further documentation shall be required to evidence the continued effectiveness of this Lease; provided, however, at the request of either party, both parties will execute a document confirming the occurrence of the Closing.  Tenant acknowledges and agrees that, in connection with the Closing, Landlord will assign its rights under the Land Purchase Agreement to an entity affiliated with Landlord or its principals that will be formed to acquire the Land.  Accordingly, Landlord will assign its right and obligations under this Lease to the successor-in-interest to the rights and obligations of Landlord under the Land Purchase Agreement acquiring the fee interest to the Land.  If the Closing has not occurred by the earlier of (A) the Existing Closing Date (as such date may be extended by the Land Purchase Agreement, the PSA Amendment or any subsequent amendment to the Land Purchase Agreement) or (B) June 30, 2020, then either Landlord (only if the Land Purchase Agreement has terminated and Landlord and its affiliates have determined in good faith and in the exercise of commercially reasonable business judgment not to purchase the Land) or Tenant, may terminate this Lease by prior written notice to the other party. For the purposes of clarification, until July 1, 2020, neither party may terminate this Lease if the Land Purchase Agreement is still in effect and the date for the scheduled Closing thereunder (as the same may have been extended) has not occurred. Promptly following the Closing, Landlord shall cause the Land to be consolidated into a single parcel if such consolidation has not occurred prior to the Closing. Except as provided in this sentence, Landlord shall not amend the Land Purchase Agreement in a manner that increases </font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 39 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">the purchase price for the Land above $9,779,859.70 without Tenant&#8217;s prior written approval; provided, however if (1) Landlord desires amend the Land Purchase Agreement in a manner that increases the purchase price for the Land above $9,779,859.70, (2) Landlord requests Tenant's consent to such amendment and (3) Tenant rejects Landlord's request within three business days, then Landlord may, nevertheless amend the purchase price for the Land; provided, however in no event will an increase in the purchase price for the Land of more than $9,779,859.70 be included in Total Development Costs, subject to the terms of Section&#160;4.1 of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  For purposes of clarification, any portion of an increase in the purchase price for the Land results in a total land purchase price of $9,779,859.70 or less will be included in the Total Development Costs, subject to the terms of Section 4.1 of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, and any portion of an increase in the purchase price for the Land above $9,779,859.70 that Tenant approves in writing will also be included in the Total Development Costs, subject to the terms of Section 4.1(f) of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">v.&#160;&#160;&#160;&#160;Landlord and Tenant acknowledge that the parties and their counsel have reviewed, fairly negotiated and revised this Lease and that the normal rule of construction to the effect that any ambiguities in a document are to be resolved against the original drafter of this Lease shall not be employed in the interpretation of this Lease. The use of captions, headings, boldface, italics or underlining is for convenience only, and will not affect the interpretation of this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">w.&#160;&#160;&#160;&#160;All obligations of Landlord and Tenant hereunder not fully performed as of the expiration or earlier termination of the Term of this Lease shall survive the expiration or earlier termination of the Term hereof, including without limitation, all payment obligations with respect to taxes and insurance and all obligations concerning the condition and repair of the Premises.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">x.&#160;&#160;&#160;&#160;Whenever this Lease requires an approval, consent, determination or judgment by either Landlord or Tenant, unless another standard is expressly set forth, such approval, consent, determination or judgment and any conditions imposed thereby shall be reasonable and shall not be unreasonably withheld or delayed.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">y.&#160;&#160;&#160;&#160;Any expenditure by a party permitted or required under this Lease, for which such party demands reimbursement from the other party, shall be reasonably incurred, and shall be substantiated by documentary evidence available for inspection and review by the other party. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">[Signature page follows.]</font></div><div><a name="s3800E97BEDA355D4AB4213FD43C17D58"></a></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">IN WITNESS WHEREOF, the parties have executed this Lease as of the Execution Date.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">LANDLORD:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">ERNST DEVELOPMENT PARTNERS, INC. <br>a California corporation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Joe Ernst</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">________________</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Joe Ernst</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">_________________</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Title: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">President</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">__________________</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">TENANT:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">EXELIXIS, INC.,</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a Delaware corporation</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Michael M. Morrissey, Ph.D.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Michael M. Morrissey, Ph.D.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;<br>Title: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">President &amp; CEO</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">___________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">By: &#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">/s/ Christopher J. Senner</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Name: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Christopher J. Senner</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;<br>Title: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">EVP &amp; CFO</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">_______________</font></div><div><br></div><div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">- 40 -</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sA4470D6B49EF449704EA13FD43F3C085"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">EXHIBIT B</font></div><div style="line-height:141%;padding-bottom:24px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">INITIAL IMPROVEMENTS WORK LETTER</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 1. <br>GENERAL</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Allocation of Responsibility</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">This Initial Improvements Works Letter exhibit (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Work Letter</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) describes the allocation of responsibility between Landlord and Tenant for the design and initial construction of improvements at the Project.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Landlord&#8217;s Work</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Landlord shall provide the base building and other improvements substantially as described in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Schedule 1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Landlord&#8217;s Work</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). Landlord shall complete Landlord&#8217;s Work at its sole cost and expense (subject to Section 2.7(c) below) in a good and workmanlike manner, free of defects and using new materials and equipment of good quality. Landlord's Work shall also include obtaining, at Landlord's sole cost, all permits and/or government approvals for the construction of Landlord&#8217;s Work.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Tenant Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Landlord shall also cause to be designed and permitted, and shall retain a contractor to cause to be performed, work of general construction consisting of improvements at the Project other than the Landlord&#8217;s Work (collectively, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; and together with Landlord&#8217;s Work the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), as described below, which Tenant Improvements shall be paid for in accordance with Article 4. Landlord shall complete the Tenant Improvements in a good and workmanlike manner, free of defects and using new materials and equipment of good quality. Notwithstanding anything in this Work Letter to the contrary, Landlord shall not be obligated to procure and install any furniture, fixtures and equipment for Tenant other than as documented in the TI Construction Documents (as defined below) approved by Landlord (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Excluded Work</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).      </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Progress Schedule</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;The initial progress schedule for the completion of the Improvements is attached hereto as </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Schedule 2</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Progress Schedule</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and represents Landlord&#8217;s good faith estimate of the timeline for the completion of the Improvements;  provided, however, that Tenant (a) acknowledges that such initial Progress Schedule (i) will be further revised in accordance with the terms of this Work Letter and (ii) takes into account the process for obtaining the bids described in Section 3.2 below and estimates for the time for the Substantial Completion of the Improvements, but may not reflect the actual time for performance set forth in the bids selected, as described in Section 3.2 and (b) agrees that Landlord shall revise the Progress Schedule to reflect the schedule approved by Landlord and Tenant (or deemed approved) in accordance with Section 3.2 below.  The Progress Schedule shall be adjusted from time to time to account for the actual progress of the work, provided Tenant will be provided with written notice of any material changes. Notwithstanding anything to the contrary herein, for the purpose of determining Tenant&#8217;s rights under Section 2(a) of the Lease, the Estimated Date of Substantial Completion shall not be adjusted except (A) in accordance with Section 3.2, (B) as expressly provided in this Work Letter for Excusable Delay, (C) pursuant to an executed Change Order requested by Tenant or (D) or as otherwise approved by Tenant. The parties acknowledge that because Tenant Delays (including pursuant to Change Orders) advance the date of the Term Commencement as provided in the Lease, Tenant Delays shall be included in the Estimated Date of Substantial Completion in the Progress Schedule for the sole purpose of informing the parties of and tracking the estimated date of Substantial Completion of the Improvements.  Except as expressly provided to the contrary, all time periods referred to in this Work Letter&#160;shall be computed on a calendar basis with no allowance for holidays or weekends.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.5&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Ownership of Tenant Improvements</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  All Tenant Improvements which may be installed or placed in or about the Project shall be and become the property of Landlord. Landlord and Tenant both understand, acknowledge and agree that Tenant&#8217;s machinery, equipment, trade fixtures, and other items of personal property that are not permanently attached to the Building or Land that may be purchased and installed during the construction of the Tenant Improvements (but that do not constitute Tenant Improvements or that are listed on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;I</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">), shall not be subject to this Section 1.5 and, instead, shall be considered owned solely by Tenant.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-1</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">1.6&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Condition of Premises</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  At the time of delivery of the Premises to Tenant, and Substantial Completion of the Improvements (but excluding any punchlist items and subject to any outstanding permit or other requirements resulting from any Tenant&#8217;s Work), the Improvements, Building and Land shall be (a) in compliance with all applicable Laws, including, without limitation, all handicapped accessibility standards, such as those promulgated under the Americans With Disabilities Act; and (b) vacant, broom-clean, in good condition, with all Building Systems in good operating condition. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 2. <br>DRAWINGS AND SPECIFICATIONS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Architect</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Landlord and Tenant have selected Brick Architecture (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Architect</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), as the architect for the Improvements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Selection of Other Design Professionals</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The mechanical, plumbing and electrical engineers and other design professionals engaged by Landlord (other than Architect) in connection with the Improvements shall be subject to Tenant&#8217;s prior approval, which shall not unreasonably be withheld.  Landlord&#8217;s request for Tenant&#8217;s approval shall include the engineer&#8217;s or design professional&#8217;s bid for the proposed work, together with the bids from two other engineers or design professionals if the scope of work for such bids pertains to a material trade; provided, however, Landlord shall have no obligation to select the lowest bid and may take into consideration the time and cost implications of performance by such professionals.  If Landlord does not receive Tenant&#8217;s response within five (5) business days of Landlord&#8217;s request for approval of a design professional, Landlord&#8217;s selection of such design professional shall be deemed approved.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Consultation; Information from Tenant</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Upon Landlord&#8217;s request, Tenant shall consult with Landlord and the Architect, and, within three (3) business days of Landlord&#8217;s request, shall use commercially reasonable efforts to furnish the Architect with all information reasonably requested by Landlord that may be necessary to finalize the TI Schematics (as defined below) within the time set forth in this Work Letter and in the Progress Schedule.  Provided that Landlord receives confirmation from Tenant that Tenant has received Landlord&#8217;s request for such additional information (e.g. an email read receipt from the construction representative designated by Tenant in Article 7 below), any delay in furnishing such information beyond such 3-business day period shall constitute a day-for-day Tenant Delay, subject to the terms of Section&#160;5.3.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Preconstruction Cost Estimate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  As soon as practicable (but in no event later than five (5) business days prior to the date for finalization of the Initial Pre-Construction Cost Estimate set forth in the Progress Schedule), Landlord shall prepare for Tenant&#8217;s review an initial estimate of the design, permitting, and other pre-construction costs for the Tenant Improvements (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Initial</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Pre-Construction Cost Estimate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). Tenant will have five (5) business days to approve or disapprove of the Initial Pre-Construction Cost Estimate, any disapproval to be made with reasonable specificity. If Tenant timely disapproves of the Initial Pre-Construction Cost Estimate in any respect, Landlord and Tenant shall use good faith efforts to agree on a revised Initial Pre-Construction Cost Estimate within five (5) business days after Landlord's receipt of Tenant's disapproval.  Such agreed upon (or, if applicable, deemed-approved) estimate shall be referred to as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Pre-Construction Cost Estimate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.  Landlord shall, not more frequently than monthly, submit a summary to Tenant by the 15</font><font style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;day of each month stating any pre-construction costs allocable to the Tenant Improvements, together with documentation describing in reasonable detail the work completed or to be completed in connection with such payment.  All pre-construction costs properly allocable to the Tenant Improvements shall be paid by Tenant in the manner set forth in Article 4, below.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.5&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Schematic Documents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Landlord shall cause the Architect to deliver to Tenant one (1) PDF copy and two (2) hardcopies of the drawings and specifications for Landlord&#8217;s Work based on </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Schedule 1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Base Building Schematics</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). Tenant shall review and approve the Base Building Schematics in accordance with Section 2.7. Landlord shall use commercially reasonable efforts to cause the Architect to deliver to Tenant the Base Building Schematics on or before the date set forth in the Progress Schedule for Landlord's delivery of the Base Building Schematics.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-2</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Landlord shall cause the Architect to deliver to Tenant a PDF copy and two (2) hardcopies of drawings and specifications showing the intended design character and finishes, including materials, of the major elements of the Tenant Improvements (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TI</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Schematics</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; and together with the Base Building Schematics, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Schematics</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), including the following documents: (a) scaled floor plan(s) showing all proposed partitions, doors and large fixtures; (b) reflected ceiling plan(s), including a lighting plan; and (c) architectural sections, and structural, plumbing and mechanical drawings showing any new or proposed additions to or modifications of structural, plumbing or mechanical systems in the Building. As a part of Landlord's submission of the TI Schematics to Tenant, a condition to giving such consent to any Alterations (except Alterations that constitute Tenant Improvements (other than laboratory improvements) and Alterations that constitute general office improvements), Landlord may require that Tenant remove (or leave in place and convey to Landlord) any such Alterations at the end of the term and restore the portions of the Project affected by such removal to their condition existing prior to installation of the relevant Alterations, reasonable wear and damage by casualty excepted Tenant shall review and approve the TI Schematics in accordance with Section 2.7. All TI Schematics, TI Construction Document Packages (as defined below), and TI Construction Documents (as defined below) shall be reimbursable from the Allowance (as defined below) after Closing; provided, however, that Landlord shall pay for revisions requested by Landlord.  As provided in Section 26(u) of the Lease, monies paid to Landlord with respect to a cost incurred by Landlord on Tenant's behalf pursuant to the side letter with respect to pre-lease services are not reimbursable to Tenant if the Closing does not occur and this Lease is terminated.  Landlord shall use commercially reasonable efforts to cause the Architect to deliver to Tenant the Tenant Schematics on or before the date set forth in the Progress Schedule for Landlord's delivery of the Tenant Schematics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.6&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Construction Drawings and Specifications</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Landlord shall cause the Architect to submit to Tenant after approval of the Base Building Schematics those sets of construction drawings for the Landlord&#8217;s Work referred to in the Progress Schedule, e.g. the design development package, permit submittal package, etc. (each a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Base Building Construction Document Package</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which shall include two (2) prints and electronic files of the relevant construction drawings for the Landlord&#8217;s Work.  Tenant shall review and approve each Base Building Construction Document Package in accordance with Section 2.7, and the Base Building Construction Document Package approved (or deemed approved) by Tenant shall be referred to collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Base Building Construction Documents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;.  Landlord shall use commercially reasonable efforts to cause the Architect to deliver to Tenant the Base Building Construction Document Package within the number of days set forth in the Progress Schedule between the deadline for Tenant's approval of the Base Building Schematics (regardless of whether Tenant has so approved the Base Building Schematics) and the deadline for the delivery of the subject Base Building Construction Document Packages.  Any delay by Landlord in causing the Architect to deliver the Base Building Construction Documents shall not constitute a Tenant Delay.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Landlord shall cause the Architect to submit to Tenant after approval of the TI Schematics those sets of construction drawings for the Tenant Improvements referred to in the Progress Schedule, e.g. the design development package, permit submittal package, etc. (each a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TI Construction Document Package</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; and collectively with the Base Building Construction Document Packages, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Construction Document Packages</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which shall include two (2) prints and electronic files of the relevant construction drawings for the Tenant Improvements.  Tenant shall review and approve each TI Construction Document Package in accordance with Section 2.7, and the TI Construction Document Packages approved (or deemed approved) by Tenant shall be referred to collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TI Construction Documents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; (and together with the Base Building Construction Documents, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Construction Documents</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;). Landlord shall cause the Architect to deliver to Tenant each of the TI Construction Document Package within the number of days set forth in the Progress Schedule between the deadline for Tenant's approval of the TI Schematics (regardless of whether Tenant has so approved the TI Schematics) and the deadline for the delivery of the subject TI Construction Document Package.  Any delay by Landlord in causing the Architect to deliver the TI Construction Documents shall not constitute a Tenant Delay.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">2.7&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Submission, Acceptance, and Change Procedures</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;The Schematics shall be subject to Landlord&#8217;s and Tenant&#8217;s review and consent, which shall not be unreasonably withheld.  Unless otherwise set forth herein, Tenant shall respond with any objections to the </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-3</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Schematics within five (5) business days after receipt by Tenant of such documents, specifying the reasons for any rejection or requested clarifications with sufficient detail that will enable Landlord to address Tenant's objections.  If Tenant has not delivered written notice of such an objection within such five (5) business day period, Tenant shall be deemed to have approved such Schematics. Landlord shall deliver Tenant&#8217;s timely objections to the relevant consultants and contractors for revisions, and shall use commercially reasonable efforts to cause the relevant consultants and contractors to deliver revised Schematics within ten (10) business days after receipt of Tenant&#8217;s objections.  Tenant will have five (5) business days to review the revised Schematics and to approve or disapprove of same; provided, however that Tenant's review of the revised Schematics shall be limited to the extent to which the revisions do not address Tenant's previous objections or basis for disapproval, provided that Tenant may request Changes (as defined below) other than those required to comply with the foregoing, in accordance with Section 2.7(c).  This process of review and resubmission shall continue as described above for as long as necessary until Tenant approves (or is deemed to have approved) the Schematics.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;The Construction Document Packages shall be subject to Landlord&#8217;s and Tenant&#8217;s review and consent, which shall not be unreasonably withheld.  Tenant may object to the Construction Document Packages only to the extent they are inconsistent with the final approved Schematics or previous Construction Document Packages or are not in compliance with applicable Laws, provided that Tenant may request Changes (as defined below) other than those required to comply with the foregoing, in accordance with Section 2.7(c).  Unless otherwise set forth herein, Tenant shall respond with any objections to each initial Base Building Construction Document Package and initial TI Construction Document Package within ten (10) business days after receipt by Tenant of such documents, specifying the reasons for any rejection or requested clarifications with sufficient detail that will enable Landlord to address Tenant's objections (for subsequent revisions Tenant&#8217;s response period shall be five (5) business days).  If Tenant has not delivered written notice of such an objection within such ten (10) or five (5) business day period, as applicable, Tenant shall be deemed to have approved that Construction Document Package. Landlord shall deliver Tenant&#8217;s timely objections to the relevant consultants and contractors for revisions, and shall use commercially reasonable efforts to cause the relevant consultants and contractors to deliver the relevant revised Construction Document Package within ten (10) business days after receipt of Tenant&#8217;s objections.  Tenant will have five (5) business days to review the revised Construction Document Package and to approve or disapprove of same; provided, however that Tenant's review of the revised Construction Document Package shall be limited to the extent to which the revisions do not address Tenant's previous objections or basis for disapproval, provided that Tenant may request Changes (as defined below) other than those required to comply with the foregoing, in accordance with Section 2.7(c).  This process of review and resubmission shall continue as described above for as long as necessary until Tenant approves (or is deemed to have approved) the relevant Construction Document Package. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;If Tenant requests in writing any change, addition or alteration in or to any Schematics, Construction Documents, or other Construction Document Package that previously had been approved by Tenant (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Changes</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), Landlord shall cause the Architect to prepare an estimate of the time and cost to revise the Schematics, Construction Documents, or Construction Document Package, as applicable, in accordance with the Changes. Landlord shall notify Tenant of the Architect&#8217;s estimated time for and cost of the Changes.  Within five (5) business days after delivery of such estimate to Tenant, Tenant shall notify Landlord in writing whether Tenant approves such estimate.  If Tenant approves such estimate, then Landlord shall cause the Architect to prepare revised Schematics, Construction Documents, or Construction Document Package, as applicable, implementing Tenant&#8217;s requested Changes, and any delay in completion of the Improvements resulting from the implementation of such Changes shall be a Tenant Delay in accordance with Section 5.3, to the extent set forth in an executed Change Order (as defined below).  Landlord shall deliver such revised or additional documentation to Tenant for its review promptly upon Landlord&#8217;s receipt of such documentation from the Architect.  Within five (5) business days after delivery of the revised or additional documentation to Tenant, Tenant shall notify Landlord in writing whether Tenant approves the Changes reflected in such documents. If Tenant approves the Changes, Landlord shall prepare a change order (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Change Order</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) addressing the approved Changes, the incremental increase in the Tenant Improvement Costs or costs of Landlord&#8217;s Work caused thereby, if any (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Change Order Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and the estimated number of Tenant Delay days that will result from the Changes.  If Tenant fails to execute and return the Change Order to Landlord within five (5) business days after submittal by Landlord, Tenant will be deemed to have elected to not proceed with the subject Changes and construction of the Improvements shall proceed as provided in accordance with the previously approved Schematics, Construction Documents, or other Construction Document Package. If Tenant timely executes and returns the Change Order, Tenant </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-4</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">must timely pay (subject to the Allowance balance) all associated Change Order Costs (to the extent set forth in the executed Change Order) in the manner set forth in Article 4, below. If Tenant does not timely pay all associated Change Order Costs (to the extent set forth in the executed Change Order) in the manner set forth in Article 4, below, then, at Landlord's election, either (i) the Change Order shall be null and void and Tenant will be deemed to have elected to not proceed with the subject Changes and construction of the Improvements shall proceed as provided in accordance with the previously approved Schematics, Construction Documents, or other Construction Document Package or (ii) Landlord may proceed with the subject Changes and Tenant's failure to timely pay shall be deemed to be a Contribution Failure.  Notwithstanding anything in this Section 2.7(c) to the contrary, Landlord shall cause the General Contractor to proceed with the Improvements based on the approved Construction Document Packages between the time a Tenant requests a Change and the time that Tenant has executed a Change Order and has paid the associated Change Order Cost.  Except with respect to errors made by the Architect or other design professionals, Tenant is assuming the risk that the General Contractor performs work that is inconsistent with the Change Order during such period of time or that will further increase the Change Order Cost. All Changes shall be subject to Landlord&#8217;s approval, which shall not be unreasonably withheld, conditioned or delayed. Whether or not Tenant executes a Change Order, the cost of preparing any additional or revised documentation pursuant to this subsection shall be a Tenant Improvement Cost, and, subject to the terms of Article 4 (including the application of the Allowance), Tenant shall be responsible for such costs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Notwithstanding anything in this Work Letter to the contrary, Landlord may disapprove of any proposed Tenant Improvements or any proposed Changes that, in Landlord&#8217;s reasonable judgment, (i) would not comply with applicable Laws, (ii) would affect the structural components of the Building in a manner that materially and adversely affects Landlord&#8217;s obligations under the Lease, (iii) would alter the exterior of the Building in a manner that materially and adversely affects Landlord&#8217;s obligations or costs under the Lease, (iv) increase the scope of Landlord&#8217;s Work beyond standard shell and core for the Building, unless such increased scope is paid for by Tenant, or involve the relocation or removal of material improvements comprising Landlord&#8217;s Work (e.g. removing or relocating staircases, restroom cores provided as part of Landlord Work or elevators) or (v) would likely delay the completion of the Improvements by more than two (2) months. Landlord&#8217;s review and acceptance or approval of any documents shall not be deemed to constitute any statement regarding the fitness or suitability of the design or construction of the Improvements for Tenant&#8217;s intended use nor an approval of the Improvements which does not meet legal requirements.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(e)&#160;&#160;&#160;&#160;Notwithstanding anything in this Work Letter to the contrary, if the City of Alameda or other governmental entity imposes conditions to the approval of the Final Development Plan, Major Design Review, Planned Development Amendment, or Parcel Map or Lot Line Adjustment Map with respect to the Project that would require completion of indirect offsite improvements (i.e., community benefits), and Tenant does not approve of any of the conditions imposed thereby, then within ten (10) business days after Tenant is notified in writing by Landlord of such conditions to approval, Tenant may elect to terminate this Lease by written notice to Landlord stating the fees or offsite improvements that are not approved, provided that (x) Tenant shall reimburse to Landlord Landlord&#8217;s documented third-party costs incurred in connection with the Lease, including Land purchase and planning related costs and any deposits made by Landlord, and (y) Tenant&#8217;s election shall be null and void if Landlord, within three (3) business days of receipt of Tenant&#8217;s notice, elects by notice to Tenant to pay the costs of the fees or offsite improvements disapproved by Tenant. Notwithstanding the foregoing, Tenant&#8217;s termination right pursuant to this subsection (e) shall terminate and have no further force or effect on and after the Closing.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(f)&#160;&#160;&#160;&#160;Except as otherwise expressly provided in this Work Letter, all consents and approvals that Landlord or Tenant may give pursuant hereto shall not be unreasonably withheld, conditioned or delayed. If Tenant reasonably withholds its approval to any request by Landlord under this Work Letter and Landlord submits a subsequent request for Tenant&#8217;s approval for the same matter (a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Subsequent Request</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then Tenant may only withhold its consent to such Subsequent Request if the Subsequent Request fails to address the grounds set forth in Tenant&#8217;s previous objection.  Unless a different time period is specified in this Work Letter, Tenant shall have five (5) business days to respond to each Subsequent Request.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(g)&#160;&#160;&#160;&#160;If Landlord requests Tenant&#8217;s approval for any matter specified in this Work Letter (including, without limitation, approval of: design professionals pursuant to Section 2.2; the Pre-Construction Cost </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-5</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Estimate pursuant to Section 2.4; the Schematics pursuant to Section 2.7(a); the Construction Document Packages pursuant to Sections 2.6(b) and 2.7(b); and the Contractors and the Cost Estimate pursuant to Section 3.2) and Tenant does not approve such matter or respond with a reasonable basis for disapproval within the applicable time period set forth in this Work Letter or if Tenant withholds its consent in a manner not permitted by this Work Letter (e.g., Tenant withholds its consent on grounds not set forth in Tenant&#8217;s previous objection in the case of a Subsequent Request for approval), then such failure (or withholding of consent, as the case may be) shall constitute a Tenant Delay, subject to the terms of Section&#160;5.3, and, if Landlord requests Tenant&#8217;s approval for any matter specified in this Work Letter and seven (7) days of Tenant Delay have accrued with respect to such request, then, at Landlord&#8217;s election, Tenant shall be deemed to have approved such matter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(h)&#160;&#160;&#160;&#160;If the Contract (as defined in the Fourth Amendment) terminates or Closing (as defined in the Fourth Amendment) otherwise fails to occur, then Landlord and Tenant shall cooperate to promptly revise any Schematics and Construction Document Packages to reflect a design for the Improvements that will meet City of Alameda applicable development standards despite the failure of the Closing (as defined in the Fourth Amendment) to occur. &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Fourth Amendment</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means that certain Fourth Amendment to Lease Agreement dated August 30, 2019 between Hillwood Enterprises, L.P. and Tenant.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 3. <br>CONSTRUCTION OF THE IMPROVEMENTS</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Management Fee</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In consideration for Landlord&#8217;s managing the design, permitting, and construction of the Improvements, the Total Development Costs (as defined in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to the Lease) shall include a management fee, subject to Section 4.1(f) below, as provided in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to the Lease.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Contractors and Contracts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord and Tenant have selected Pankow Builders (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">General Contractor</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) as the general contractor for the construction of the Improvements. Landlord shall enter into contracts for the construction of the Improvements with General Contractor, as provided below.  Landlord shall directly retain (or retain through the General Contractor) all contractors under guaranteed maximum price or lump sum contracts (collectively with the General Contractor, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Contractors</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Each of the Contractors in a material trade shall be subject to Tenant&#8217;s reasonable approval and be subject to bidding as set forth below. A &#8220;material trade&#8221; shall include, without limitation, site work, landscaping, roofing, drywall, concrete, steel, elevator, mechanical, electrical and plumbing. If Landlord does not receive Tenant&#8217;s response within five (5) business days of Landlord&#8217;s request for approval of a Contractor, Landlord&#8217;s selection of such Contractor shall be deemed approved.  Landlord shall cause the General Contractor to obtain at least three (3) competitive bids for each of the material trades for Landlord&#8217;s Work and the Tenant Improvements.  Landlord will deliver copies of all such bids to Tenant promptly following Landlord's receipt thereof, and such subcontractors shall be approved by each of Landlord and Tenant in its reasonable discretion. Such competitive bids shall include a schedule with a timeline to complete the work being bid.  Based on such subcontractor bids, Landlord shall obtain an estimate of the Tenant Improvement Costs (as defined below) and the cost of Landlord&#8217;s Work.  Unless required by law, this Lease shall not be subject to prevailing wage requirements nor require that any contractors hired in connection with this Lease be affiliated with any union or comply with any union requirements (except if affiliated with a union).  Landlord shall promptly revise (a) the schedule for the Landlord&#8217;s Work and the Tenant Improvements to reflect the differences between the times contained in the selected bids and the times contained in the initial Progress Schedule and (b) the cost estimate of Landlord&#8217;s Work and the Tenant Improvement Costs and submit the same to Tenant for review (the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#8220;Cost Estimate</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Within five (5) business days after Landlord&#8217;s submission of the schedule and cost estimates to Tenant, Tenant shall either (i)&#160;approve such schedule and cost estimate and, in the case of the Tenant Improvement Costs, be obligated to pay for all such costs exceeding the Allowance in accordance with the disbursement procedures set forth below, or (ii)&#160;disapprove such schedule and cost estimate, in which case Tenant shall provide Landlord with additional information adequate to permit the prompt revision of the Construction Documents and re-pricing of the Landlord&#8217;s Work or the Tenant Improvement Costs, as applicable.  Tenant&#8217;s failure to respond within such five (5) business-day period shall be deemed to be Tenant&#8217;s approval of such schedule and cost estimate.  Upon completion of the re-pricing of the Tenant Improvement Costs (or, if applicable, Landlord&#8217;s Work), Landlord shall deliver the revised schedule and estimate of the Tenant Improvement Costs (or, if applicable, Landlord&#8217;s Work) to Tenant for approval in the same manner as set forth above and once approved, such schedule and estimate shall be final and deemed approved by the parties, subject to Change Order </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-6</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Costs; provided if Tenant does not respond to the final estimate in the five (5) business day period, Tenant will be deemed to have approved such final schedule and estimate.  Upon approval (or deemed approval) of a Cost Estimate by Tenant and the Construction Documents, Landlord shall enter into a guaranteed maximum price contract for each of the Landlord&#8217;s Work and Tenant Improvements (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">GMP Contract</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) with General Contractor and any lump sum contracts with other Contractors (collectively with the GMP Contract, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Contracts</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) and give notice to Tenant of the total Tenant Improvement Costs (as defined below) and total costs for Landlord&#8217;s Work. Along with such notice, Landlord shall deliver to Tenant a budget showing the portion of the Tenant Improvement Costs that will be paid from the Allowance and that portion that will be paid by Tenant as Tenant&#8217;s Contribution (as defined below).  Notwithstanding the foregoing, Tenant shall be permitted to value engineer the Improvements to reduce costs; provided, however, except as provided in Section 4.1(f), (i) any cost associated with such value engineering by Tenant will be the responsibility of Tenant, subject to Landlord&#8217;s obligations with respect to the Allowance pursuant to Article&#160;4, (ii) any changes requested by Tenant as a part of the value engineering process shall be a Change subject to Section 2.7(c) and (iii) accordingly, any delays associated with the Tenant's efforts to value engineer the Improvements will constitute a Tenant Delay to the extent such value engineering (or delays associated therewith) causes actual delays in the completion of the Improvements beyond the Estimated Date of Substantial Completion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Construction Generally</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord shall cause the Improvements to be diligently constructed by the Contractors in conformance with the Construction Documents, as finally accepted or consented to by Landlord and Tenant pursuant to this Work Letter. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">3.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Warranties and Guaranties</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.   Landlord shall obtain from the General Contractor and each manufacturer of equipment installed in the Premises as part of the Improvements a standard construction or manufacturer&#8217;s warranty or guaranty, as applicable, in favor of Landlord and Tenant warranting that the Improvements, in the case of the General Contractor, or the equipment provided, in the case of the manufacturers, shall be free from any defects of workmanship and materials for a period of not less than one (1) year from the date of Substantial Completion (each a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Warranty</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 4. <br>COSTS AND ALLOWANCE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">4.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Allowance and Costs Generally</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Allowance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Landlord shall pay towards the costs of the Tenant Improvements, including all pre-construction costs, permit fees, project management, and costs of constructing the Tenant Improvements (collectively, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant Improvement Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), an amount equal to $75.00 per rentable square foot of the Building (as determined by Architect and reasonably approved by Tenant in the Construction Documents in accordance with ANSI/BOMA Z65.3-2018 Gross Area 1 (Leasing Method)</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">(the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">BOMA Standard</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;)) (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Allowance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), except that the Allowance shall not be used to pay for Tenant&#8217;s machinery, equipment and trade fixtures and other personal property (other than as documented in the approved TI Construction Documents), any Excluded Costs or any costs associated with construction management personnel engaged by Tenant in connection with this Lease.  For the avoidance of doubt, all Excluded Costs shall be payable solely by Landlord and shall not be included in the calculation of Tenant Improvement Costs for the purpose of determining Tenant&#8217;s Contribution.  Except as expressly set forth herein, Landlord&#8217;s payment of the Allowance or the Tenant Improvement Costs (if such amount is less than the Allowance), shall satisfy in full Landlord&#8217;s obligation to pay the Allowance hereunder, and Landlord shall not be obligated to make any payment for any subsequent alterations or improvements to the Project whether or not the entire Allowance was expended on the initial Tenant Improvements. Notwithstanding the foregoing, in the event the entire Allowance is not expended on the initial Tenant Improvements, any remaining amounts may be used for Tenant&#8217;s Work subject to a draw procedure agreed to by Landlord and Tenant in their reasonable discretion, including reasonable requirements regarding lien waivers delivered by Tenant. Furthermore, notwithstanding the foregoing, if an Event of Default is continuing at the time Landlord's payment of any portion of the Allowance is due under this Work Letter, then, in addition to any other remedies available to Landlord in this Work Letter or elsewhere in the Lease, Landlord may stop construction (including any pre-construction work) of the Improvements until such Event of Default is cured.  If Landlord stops construction due to an Event of Default, then any such delay shall be a Tenant Delay and Tenant shall be responsible for all costs in connection with remobilizing the Contractors and recommencing construction. </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-7</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Amount of Tenant&#8217;s Contribution</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Except with respect to Landlord&#8217;s Work, Excluded Costs, and as otherwise expressly stated herein, the Tenant Improvements and all work necessary to complete the Project for Tenant&#8217;s occupancy shall be completed at Tenant&#8217;s sole cost and expense, including without limitation architectural, engineering, permit and inspection fees, and all costs of construction and materials; provided that Landlord shall contribute the Allowance towards the Tenant Improvement Costs, which Allowance shall be disbursed on the terms and conditions set forth in this Article 4.  For the avoidance of doubt, Tenant shall bear and pay the Tenant Improvement Costs in excess of the Allowance other than Excluded Costs (as defined in </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit D-1</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;to the Lease) (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant&#8217;s Contribution</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), despite any increase in such costs.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Payment of Tenant&#8217;s Contribution</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  In the event that the estimated (as reasonably determined by the Landlord) or actual Tenant Improvement Costs are greater than the Allowance (i.e. Tenant is expected to pay Tenant&#8217;s Contribution), then within fifteen (15) business days after Tenant&#8217;s receipt of a monthly invoice from Landlord for the portion of Tenant&#8217;s Contribution due that month in accordance with this subsection, Tenant shall pay to Landlord such portion of Tenant&#8217;s Contribution.  The estimated Tenant Improvement Costs (as reasonably determined by Landlord) and the actual Tenant Improvement Costs (and, accordingly, Tenant&#8217;s Contribution) shall only be adjusted from time to time based on Changes approved by Landlord and Tenant.  Subject to the restriction that disbursements of the Allowance must be permissible under Section 4.1(a) and subject to the maximum Allowance under Section 4.1(a), Landlord&#8217;s monthly invoice to Tenant for the Tenant&#8217;s Contribution shall be for an amount equal to the product of (i) the Tenant Improvement Costs incurred that month and (ii) a fraction, the numerator of which is Tenant&#8217;s Contribution and the denominator of which is the Tenant Improvement Costs. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">TI Account; TI Deposit Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Notwithstanding anything in this Work Letter to the contrary, if Landlord&#8217;s construction lender for the Project (the "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Construction Lender</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">") requires that Tenant deposit Tenant&#8217;s Contribution and/or the Tenant's Excess Development Costs into a separate account with Landlord&#8217;s Construction Lender (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TI Account</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then Landlord and Tenant shall enter into an agreement with Landlord&#8217;s Construction Lender, in a form acceptable to each of Landlord and Tenant in its reasonable discretion, requiring the deposit of the Tenant&#8217;s Contribution and/or the Tenant's Excess Development Costs into the TI Account and governing the disbursements of such deposited funds (such agreement, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TI Deposit Agreement</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Landlord shall use commercially reasonable efforts to deliver a draft TI Deposit Agreement as soon as practical after identifying a Construction Lender.  If Tenant, Landlord and Landlord&#8217;s Construction Lender cannot agree on a form of TI Deposit Agreement, provided that Tenant has acted reasonably, Tenant shall not be obligated to enter into the TI Deposit Agreement or deposit Tenant&#8217;s Contribution and/or the Tenant's Excess Development Costs in a TI Account; provided, however, if required by Construction Lender, Tenant will be required to provide a Letter of Credit pursuant to Section 4.1(e) below.  Not later than two (2) business days after Landlord enters into the Contracts, Tenant shall deposit in the TI Account the amount of Tenant&#8217;s Contribution and/or the Tenant's Excess Development Costs (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant&#8217;s Deposit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  The funds in the TI Account with respect to both the Tenant Contribution and the Tenant's Excess Development Costs shall be accounted for separately and funds deposited with respect to Tenant's Contribution shall not be used to pay for Tenant's Excess Development Costs (and vice versa).  In the event there are approved Change Order Costs in connection with an executed Change Order, then, no later than five (5) business days after Landlord&#8217;s request (accompanied by contract documentation in reasonable detail supporting such request), Tenant shall deposit into the TI Account any amount by which Tenant&#8217;s Contribution exceeds Tenant's Deposit with respect to Tenant's Contribution. Furthermore, in the event there are approved changes in the Total Development Costs in connection with an executed Change Order, then, no later than five (5) business days after Landlord&#8217;s request (accompanied by contract documentation in reasonable detail supporting such request), Tenant shall deposit into the TI Account any amount by which Tenant's Excess Development Costs exceeds the portion of the Tenant's Deposit with respect to Tenant's Excess Development Costs.  The Tenant's Deposit shall be disbursed according to the procedures set forth in the TI Deposit Agreement.  Disbursements of the Allowance shall be made pari passu with disbursements of the Tenant's Deposit from the TI Account provided that such disbursements of the Allowance are otherwise permissible pursuant to this Work Letter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(e)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Letter of Credit; Tenant&#8217;s Contribution; Tenant's Excess Development Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  At Tenant&#8217;s election, in lieu of the Tenant&#8217;s Deposit provided in Section 4.1(d) if required by Landlord's Construction Lender, Tenant may provide an irrevocable, unconditional and transferable (without cost to beneficiary) standby Letter of Credit (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TI Letter of Credit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), in a form reasonably approved by Construction Lender and meeting the requirements of this Section </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-8</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.1(e), in the amount of the Tenant's Contribution and/or the Tenant's Excess Development Costs that would be required in a TI Account had Tenant elected to so deposit the Tenant's Contribution and/or the Tenant's Excess Development Costs in such TI Account, as the same may be increased or decreased from time to time.  Tenant shall fund Tenant's Contribution and/or Tenant's Excess Development costs according to the procedures set forth in Sections&#160;4.1(c) and (f) of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Exhibit&#160;B</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;of this Lease, and disbursements of the Allowance shall be made pari passu with Tenant's payments of installments of the Tenant's Contribution and/or Tenant's Excess Development Costs.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;The TI Letter of Credit shall be governed by ISP98, as revised from time to time, issued by Wells Fargo or another commercial bank ("</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TI LC Issuer</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">") reasonably satisfactory to the Construction Lender with offices for banking purposes in the San Francisco Bay Area, and drawable by sight draft presented by Construction Lender from time to time.  The TI Letter of Credit shall name Construction Lender as beneficiary, permit multiple drawings, be fully transferable by Construction Lender, and otherwise be in form and substance reasonably satisfactory to Construction Lender.  The TI Letter of Credit shall also provide that it shall be deemed automatically renewed, without amendment, for Substantial Completion plus sixty (60) days after Substantial Completion (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TI</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">LC Term Expiration</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), unless the TI LC Issuer delivers written notice (&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TI LC</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Issuer Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) to the Construction Lender (with a simultaneous copy to Tenant) by any method specified for giving of notices under this Lease, as amended, not less than forty-five (45) days preceding the then TI-LC Term Expiration of the TI Letter of Credit that it elects not to have that TI Letter of Credit renewed.  If the Construction Lender receives a TI LC Issuer Notice and, not later than fifteen (15) business days preceding the TI LC Term Expiration of the expiring TI Letter of Credit, Tenant fails to furnish the Construction Lender with a replacement of the expiring TI Letter of Credit pursuant to and meeting the conditions of this Section 4.1(e), then the Construction Lender shall have the right to draw the full amount of that TI Letter of Credit by delivering to the TI LC Issuer a statement that Tenant has failed timely to deliver to Construction Lender a replacement TI Letter of Credit pursuant to and meeting the conditions of this Section, in which event the TI LC Issuer shall disburse the full amount of the expiring TI Letter of Credit to Construction Lender and Construction Lender shall hold such amount pursuant to Section&#160;4.1(e)(vi), below. Tenant shall, at any time after Construction Lender draws the TI Letter of Credit, be entitled to provide Construction Lender with a replacement TI Letter of Credit that satisfies the requirements hereunder, at which time Construction Lender shall return the cash proceeds of the original TI Letter of Credit drawn by Construction Lender to the extent Construction Lender has not applied such funds as provided in Section&#160;4.1(e)(vi) below.  Tenant shall have the right to reduce the amount of the TI Letter of Credit no more often than monthly by the amount of the payments of Tenant&#8217;s Contribution and Tenant&#8217;s Excess Development Costs, and Tenant&#8217;s obligation to deliver the TI Letter of Credit is conditioned on the Construction Lender&#8217;s agreement to be bound by the terms of this Section&#160;4.1(e).  In addition, Tenant shall increase the amount of the TI Letter of Credit, no more often than monthly, by increases in the unpaid portions of Tenant&#8217;s Contribution and Tenant&#8217;s Excess Development Costs (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, due to Change Orders).  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;The TI Letter of Credit shall be held by Landlord and Construction Lender for the faithful performance of the obligations of Tenant under this Lease with respect to Tenant's Contribution and/or the Tenant's Excess Development Costs.  The TI Letter of Credit shall be returned to Tenant within a reasonable time after Construction Lender determines in its sole but reasonable discretion that substantial completion of the Improvements has occurred. Tenant agrees that (i) Construction Lender may, without waiving any of Landlord&#8217;s other rights and remedies under this Lease, draw upon the TI Letter of Credit and apply the proceeds of the TI Letter of Credit in whole or in part to remedy Tenant's failure to disburse the Tenant's Contribution or Tenant's Excess Development Costs within applicable notice and cure periods or (ii) Construction Lender may, without waiving any of Landlord&#8217;s other rights and remedies under this Lease, draw upon the TI Letter of Credit and hold the proceeds of the TI Letter of Credit pursuant to Section 4.1(e)(vi) in whole if a renewal/extension of, amendment to or replacement or evidence of the restoration of the TI Letter of Credit as required under Section 4.1(e)(i) is not timely received by Construction Lender in form and substance reasonably acceptable to Construction Lender.  If Construction Lender draws on the TI Letter of Credit, Tenant shall within five (5) business days restore the amount of the TI Letter of Credit to the full amount of the TI Letter of Credit as required to be maintained under this Section 4.1(e) pursuant to a replacement thereof or an amendment thereto in form and substance reasonably satisfactory to Landlord, or shall provide cash in lieu thereof, failing which Construction Lender may, without waiving its other remedies </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-9</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">hereunder, draw down any sums then remaining unpaid under the TI Letter of Credit. If Construction Lender draws upon the TI Letter of Credit pursuant to subpart&#160;(i) above in this Section 4.1(e)(ii), Construction Lender shall only draw upon the TI Letter of Credit to the extent needed to make the required payments of the Tenant's Contribution or Tenant's Excess Development Costs.  In the event Landlord or improperly draws upon the TI Letter of Credit or misapplies the TI Letter of Credit Construction Lender proceeds, Tenant shall have the right to offset such amounts against Rent and Tenant shall have no right or claim (and Landlord shall have no liability to Tenant) with respect to the funds so improperly drawn or misapplied.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;If Construction Lender&#8217;s interest in the Premises is sold or otherwise assigned or transferred, then Tenant shall, upon ten (10) days prior notice from Landlord, at Tenant&#8217;s sole cost and expense, cause TI LC Issuer to amend the TI Letter of Credit, in form and substance reasonably satisfactory to Construction Lender, to transfer them to the new Construction Lender designated by Landlord in its notice, effective on the date designated by Landlord in its notice.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;Any draw under the TI Letter of Credit shall be subscribed by a representative of Construction Lender, as the case may be.  The TI LC Issuer shall have no obligation to verify any matter or statement made in connection with any draw under the TI Letter of Credit and no good faith error in connection with any such matter or statement shall affect the validity of any draw by Landlord or Construction Lender.  No draw under the TI Letter of Credit or failure or delay of Construction Lender to draw any portion of the TI Letter of Credit shall constitute a waiver of Landlord&#8217;s Construction Lender's right to do so at any time thereafter, a waiver of Landlord&#8217;s other rights and remedies under this Lease, or a waiver of any default with respect to this Lease.  Tenant agrees that Tenant shall have no right to apply any portion of the cash security or proceeds of the TI Letter of Credit against any of Tenant&#8217;s obligations to pay rent or perform obligations under the Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(v)&#160;&#160;&#160;&#160;Landlord and Tenant acknowledge and agree that in no event or circumstance shall the TI Letter of Credit or any renewal thereof or any proceeds thereof be (i)&#160;deemed to be or treated as a &#8220;security deposit&#8221; within the meaning of California Civil Code Section&#160;1950.7, (ii)&#160;subject to the terms of such Section&#160;1950.7, or (iii)&#160;intended to serve as a &#8220;security deposit&#8221; within the meaning of such Section&#160;1950.7.  The parties hereto (A)&#160;recite that the TI Letter of Credit are not intended to serve as a security deposit and such Security Deposit Laws shall have no applicability or relevancy thereto and (B)&#160;waive any and all rights, duties and obligations either party may now or, in the future, will have relating to or arising from the Security Deposit Laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(vi)&#160;&#160;&#160;&#160;In the event Landlord or Construction Lender draws down on the TI Letter of Credit, the proceeds of the TI Letter of Credit may be held by Landlord or Construction Lender and applied by Construction Lender against any Tenant's Contribution or Tenant&#8217;s Excess Development Costs payable by Tenant under this Lease that is not paid when due.  The amount of any proceeds of the TI Letter of Credit received by Construction Lender, and not used to pay for any Tenant's Contribution or Tenant&#8217;s Excess Development Costs as provided for in this Section 4.1(e) (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Unused TI Letter of Credit Proceeds</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), shall be paid by Construction Lender to Tenant (x) upon receipt by Construction Lender of a replacement of the TI Letter of Credit in the full amount of the TI Letter of Credit, which replacement TI Letter of Credit shall comply in all respects with the requirements of this Section 4.1(e), or (y) within a reasonable time after Construction Lender determines in its sole but reasonable discretion that substantial completion of the Improvements has occurred.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(vii)&#160;&#160;&#160;&#160;If the amount of the TI Letter of Credit then held by Construction Lender is not equal to the estimate of the total Tenant's Contribution and Tenant&#8217;s Excess Development Costs, then Tenant shall (or may) promptly obtain a revised TI Letter of Credit in an amount equal to the total Tenant's Contribution and Tenant&#8217;s Excess Development Costs.  In the event there are approved Change Order Costs in connection with an executed Change Order, then, no later than five (5) business days after Landlord&#8217;s request (accompanied by contract documentation in reasonable detail supporting such request), Tenant promptly obtain a revised TI Letter of Credit in an amount equal to the total Tenant's Contribution and Tenant&#8217;s Excess </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-10</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Development Costs (if the TI Letter of Credit is in amount less than the Total Tenant's Contribution and Tenant&#8217;s Excess Development Costs).</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(viii)&#160;&#160;&#160;&#160;If Tenant delivers a replacement or amended TI Letter of Credit to Construction Lender when and as required under this Section 4(e) in the form required herein, Construction Lender shall exchange the TI Letter of Credit then held by Construction Lender for the replacement or amended TI Letter of Credit delivered by Tenant. Tenant may at any time substitute a cash Tenant's Deposit in a TI Deposit Account pursuant to a TI Deposit Agreement for the TI Letter of Credit, and upon such substitution, Construction Lender shall return the TI Letter of Credit to Tenant. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(f)&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Excess Development Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Subject to the terms of this Section 4.1(f), Landlord's obligation to solely fund Total Development Costs will not exceed $525 per rentable square foot in the Building (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Initial Cost Limit</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  If Total Development Costs exceed the Initial Cost Limit, then (i) Landlord shall be responsible for 50% of the Total Development Costs in excess of the Initial Cost Limit ("</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Landlord's Excess Development Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">") and (ii) Tenant shall be responsible for the remaining 50% of Total Development Costs in excess of the Initial Cost Limit (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant's</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Excess Development Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;, together with Landlord's Excess Development Costs, the "</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Excess Development Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">"), subject to the application of the Allowance as set forth in this Section 4.1(f). In the event that the estimated (as reasonably determined by the Landlord) or actual Total Development Costs are greater than the Initial Cost Limit (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, Landlord is expected to pay the Landlord's Excess Development Cost and Tenant is expected to pay Tenant's Excess Development Costs), then Landlord shall promptly notify Tenant (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Excess Development Cost Notice</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).  Thereafter, Landlord and Tenant shall work in good faith, for a period not to exceed thirty (30) days from the date that Landlord delivers the Excess Development Cost Notice to Tenant (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">VE Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), to value engineer the Improvements in an effort to decrease the Total Development Costs below the Initial Cost Limit.  Any cost associated with such value engineering design process will be the responsibility of Tenant, subject to Landlord&#8217;s obligations with respect to the Allowance pursuant to Article&#160;4, and any changes requested by Tenant as a part of the value engineering process shall be a Change subject to Section 2.7(c); provided, however, any delays associated with the Tenant's efforts to value engineer the Improvements will not constitute a Tenant Delay but will constitute an Excusable Delay as provided below, and the parties anticipate that any such Change shall result in a decrease in the Total Development Costs (</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">i.e.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, that there will be no additional Change Order Costs beyond the cost of value engineering).  If, within the VE Period, Landlord and Tenant are unable to value engineer the Landlord&#8217;s Work so that the Total Development Costs are below the Initial Cost Limit, then Landlord shall notify Tenant of the amount of Excess Development Cost (after taking into account the reduction, if any, in the Total Development Costs that result from Landlord's and Tenant's efforts to value engineer the Improvements) within five (5) business days after the expiration of the VE Period and shall commence (or recommence) the process for the approval of the Construction Document Packages or the construction of the Improvements, as applicable.  Thereafter, unless Section 4.1(d) governs (i.e. that Tenant is depositing Tenant&#8217;s Deposit into the TI Account), Landlord shall invoice Tenant on a monthly basis for the Tenant's Excess Development Costs (as provided in this Section 4.1(f) below), and the within 30 days following Tenant&#8217;s receipt of a monthly invoice from Landlord for the portion of the Tenant's Excess Development Costs due that month in accordance with this subsection, Tenant shall pay to Landlord such portion of the Tenant's Excess Development Costs.  The estimated Total Development Costs (as reasonably determined by Landlord) and the actual Total Development Costs (and, accordingly, the Excess Development Costs) shall only be adjusted from time to time based on Changes approved by Landlord and Tenant.  In lieu of the payment of any invoice for Tenant's Excess Development Costs, Tenant may notify Landlord of its election to apply the Allowance towards such Excess Development Costs.  Any application of the Allowance towards Tenant's Excess Development Costs shall be subject to the maximum Allowance under Section 4.1(a).  In addition, if Tenant fails to timely pay any invoice for Tenant's Excess Development Costs (or notify Landlord of its election to apply the Allowance towards any invoice for Tenant's Excess Development Costs), such failure shall be a Contribution Failure as set forth in Section 5.3 below.  Landlord&#8217;s monthly invoice to Tenant for Tenant's Excess Development Costs shall be for an amount equal to the product of (i) the Total Development Costs incurred that month (provided that Tenant&#8217;s Excess Development Costs will not be excluded from Total Development Costs for purposes of this calculation) and (ii) a fraction, the numerator of which is the Tenant's Excess Development Costs and the denominator of which is the Total Development Costs (provided that Tenant&#8217;s Excess Development Costs will not be excluded from Total Development Costs for purposes of this calculation).  The period of time between Landlord's delivery of the Excess Development Cost Notice and Landlord's commencement (or recommencement) of the process for the approval of the Construction Document Packages or the construction of the Improvements, as applicable, shall constitute </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-11</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Excusable Delay to the extent such value engineering (or delays associated therewith) causes actual delays in the completion of the Improvements beyond the Estimated Date of Substantial Completion.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 5. <br>TIME FOR PERFORMANCE; SUBSTANTIAL COMPLETION AND ACCEPTANCE</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Response Times</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Unless otherwise provided in this Work Letter, each party shall promptly respond to requests for information, review, approval and acceptance and in all events within three (3) business days following delivery of the request. If Tenant does not respond in writing to any request for approval submitted to Tenant under this Work Letter within any time period stated herein for Tenant to give or reject such approval, or within three (3) business days if no specific time period applies to such request, time being of the essence, then Tenant will be deemed to have given its approval.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Excusable Delay</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;Promptly after an Excusable Delay occurs, Landlord shall deliver to Tenant a revised Progress Schedule reflecting such Excusable Delay.  Notwithstanding anything in the Lease to the contrary, for the purposes of calculating the rent penalty date in Section 2(a) of the Lease, clause (v) of the definition of Excusable Delay in Section 26(p) of the Lease shall not include delays by caused by the general contractor or any subcontractors (or delays resulting from the failure of either to perform in accordance with the GMP Contract). Notwithstanding anything in the Lease to the contrary, for the purposes of calculating the Outside Completion Date, (a)&#160;clause&#160;(i) of the definition of Excusable Delay in Section 26(p) of the Lease is limited to only earthquakes that impact the Oakland/Alameda construction market generally and that cause actual delays in the completion of the Improvements beyond the Estimated Date of Substantial Completion; provided, however, in no event shall the Outside Completion Date be extended for more than 90 days as a result of earthquakes, (b)&#160;clause (ii) of the definition of Excusable Delay shall not apply for purposes of extending the Outside Completion Date, (c) there shall be no limitation on the extension of the Outside Completion Date pursuant to clauses (iii) and (iv) of the definition of Excusable Delay and (d)&#160;clause&#160;(v) of the definition of Excusable Delay is limited to only shortages in or the availability of materials or labor required for construction that impacts the Oakland/Alameda construction market generally and that cause actual delays in the completion of the Improvements beyond the Estimated Date of Substantial Completion not to exceed thirty (30) days.  For purposes of calculating the Outside Completion Date (and determining whether Tenant may exercise its termination right pursuant to Section 2(a) of the Lease), to the extent the Outside Completion Date is extended pursuant to clause (iii) of the definition of Excusable Delay, any day of Tenant Delay so extending the Outside Completion Date shall not also be counted to advance the date that Substantial Completion of the Improvements (for purposes of determining whether Tenant may exercise its termination right pursuant to Section 2(a) of the Lease).  If this Lease is not terminated pursuant to Section 2(a) hereof, then days of Tenant Delay will be used to determine the date that Substantial Completion of the Improvements would have occurred and the Premises would have been delivered to Tenant in the required condition but for the Tenant Delay for all other purposes under this Lease.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Tenant Delay</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;If Landlord is actually delayed in completing the Improvements as a result of </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Any Changes requested by Tenant (to the extent the delay is set forth in an executed Change Order), </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;Any Changes to the Landlord&#8217;s Work required by unusual specialized requirements in the TI Construction Documents, other than changes to the Landlord&#8217;s Work relating to compliance with applicable laws obligations that are solely Landlord&#8217;s responsibility, pursuant to the express terms of this Work Letter,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;A Tenant Delay as set forth in Section 2.7(g) of this Work Letter or Tenant's failure to otherwise comply with the time deadlines expressly set forth in this Work Letter, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Tenant&#8217;s failure to timely approve any matter requiring Tenant&#8217;s approval (provided, however, that Tenant&#8217;s failure to timely approve such matter will not be deemed a Tenant Delay if Tenant disapproved such matter because Tenant determined that the items submitted to Tenant were deficient [for example, if the proposed Construction Documents did not reflect a logical extension of the approved Schematics]),</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-12</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(e)&#160;&#160;&#160;&#160;Tenant&#8217;s rejections of Landlord&#8217;s submissions without reasonable basis or unreasonable requests by Tenant for clarifications or revisions in such submissions, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(f)&#160;&#160;&#160;&#160;hindrance or disruption of the Contractors&#8217; work resulting from the performance of the Tenant&#8217;s Work, if any, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(g)&#160;&#160;&#160;&#160;Any other acts or omissions of Tenant, or its agents, or employees which actually delays the Substantial Completion,</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(h)&#160;&#160;&#160;&#160;Landlord requests Tenant&#8217;s approval for any matter specified in this Work Letter (including, without limitation, approval of: design professionals pursuant to Section 2.2; the Pre-Construction Cost Estimate pursuant to Section 2.4; the Schematics pursuant to Section 2.7(a); the Construction Document Packages pursuant to Section 2.7(b); and the Contractors and the Cost Estimate pursuant to Section 3.2) and: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Tenant does approve such matter or respond with a reasonable basis for disapproval within the applicable time period set forth in this Work Letter or </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;if Tenant has timely responded to such request with a reasonable basis for disapproval, then, if Landlord submits a Subsequent Request that addresses Tenant&#8217;s original reasonable basis for disapproval, Tenant does not approve such Subsequent Request within five (5) business days after such Subsequent Request, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;delay or hindrance in obtaining any occupancy certificates or other permits for the Improvements as a result of Tenant&#8217;s Work, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(j)&#160;&#160;&#160;&#160;Tenant&#8217;s failure to timely make a deposit into the TI Account, failure to timely make a payment of Tenant&#8217;s Contribution, or other failure to pay when due all amounts payable by Tenant pursuant to this Work Letter, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(k)&#160;&#160;&#160;&#160;Tenant&#8217;s material breach of the Lease, including without limitation its obligations under this Work Letter, </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(l)&#160;&#160;&#160;&#160;Tenant&#8217;s requirement for materials, components, finishes or improvements which are not available in a commercially reasonable time given the anticipated date of Substantial Completion of the Tenant Improvements, as set forth in the Progress Schedule in the amount of time specified by Landlord at the time it approves the same, or</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(m)&#160;&#160;&#160;&#160;any other circumstance which is deemed or stated herein or in the Lease to constitute a Tenant Delay hereunder; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">then any such delay under the foregoing clauses shall be a &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant Delay</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; to the extent that Landlord is actually delayed in Substantial Completion beyond the Estimated Date of Substantial Completion as a result of such action of Tenant.  If a Tenant Delay occurs, then Term Commencement shall be deemed to be the date that Substantial Completion of the Improvements and delivery of the Premises to Tenant in the required condition would have occurred but for the Tenant Delay (such date will be reasonably determined by Landlord in consultation with the Architect and the General Contractor).  Notwithstanding the foregoing, except with respect to a Tenant Delay due to Tenant&#8217;s failure to comply with time deadlines expressly set forth in this Work Letter or a circumstance which is deemed to constitute a Tenant Delay hereunder, no Tenant Delay shall be deemed to have occurred unless and until Landlord has delivered notice of the event or circumstance that Landlord determines is a Tenant Delay and Tenant has failed to cure such event or circumstance within one (1) business day following the date of delivery of such notice; provided, however, Landlord shall have no obligation to give notice of a Tenant Delay as a condition to the occurrence thereof in the event such Tenant Delay arises from Tenant&#8217;s failure to take a specified action within a time period expressly required by the terms of this Work Letter. Promptly after a Tenant Delay in accordance with the foregoing occurs, Landlord shall deliver to Tenant a revised Progress Schedule reflecting the Tenant Delay and the new Estimated Date of Substantial </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-13</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Completion.  Furthermore, if Tenant fails to make any payment due in this Work Letter within the period required by this Work Letter (a "&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Contribution Failure</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), then (in addition to any other remedies available to Landlord in this Work Letter or elsewhere in the Lease) (x) Landlord may, after five (5) business days&#8217; prior written notice to Tenant, stop construction (including any pre-construction work) of the Improvements until such payment is made by Tenant or, if applicable, the TI Account is funded by Tenant in accordance with this Work Letter and any resulting stoppage shall be a Tenant Delay to the extent that Landlord is actually delayed in Substantial Completion beyond the Estimated Date of Substantial Completion as a result thereof, (y) Tenant's failure on the first or second occasion to timely make such payment where such failure shall continue for a period of five (5) days after notice from Landlord of such delinquency shall be an event of default under the Lease and (z) Tenant's failure on a third occasion to timely make such payment shall be an event of default under the Lease.  If Landlord stops construction due to a Contribution Failure, Tenant shall be responsible for all costs in connection with remobilizing the Contractors and recommencing construction.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">5.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Substantial Completion; Acceptance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;For the purposes of the Lease and this Work Letter, &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Substantial Completion</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; of the Improvements will have occurred upon the later to occur of Substantial Completion of each of the Landlord&#8217;s Work and the Tenant Improvements in accordance with the Construction Documents (as evidenced by certification by the Architect on form AIA G704, as described below), except to the extent that only minor punch list items remain to be performed so that Tenant can occupy or utilize the Premises for its intended use, and are otherwise in the condition required under Section 1.6 of this Work Letter.  With respect to Landlord&#8217;s Work, Substantial Completion shall be evidenced by a certificate of substantial completion (AIA G704) issued by the Architect and a copy of the permit job card confirming approval of final inspection, and, with respect to the Tenant Improvements, Substantial Completion shall be evidenced by (i) a certificate of substantial completion (AIA G704) issued by the Architect, (ii) a copy of the permit job card confirming approval of final inspection (iii) Architect's measurement and determination of the Rentable Area of the Premises, and (iv) the issuance of a temporary certificate of occupancy from the City of Alameda; provided, however, that if Landlord is unable to obtain a temporary certificate of occupancy because of Tenant&#8217;s ongoing performance of the Tenant&#8217;s Work, then Substantial Completion of the Tenant Improvements will have occurred on the date on which all of the events set forth in subclauses (i)-(iii) of the preceding sentence have occurred.  Landlord shall notify Tenant in writing at least ten (10) days prior to the date that Landlord anticipates that Substantial Completion of the Improvements will occur, and Tenant shall arrange promptly to inspect the Premises. Provided that Substantial Completion of the Improvements has occurred, Tenant shall&#160;accept delivery of the Premises on the date that Substantial Completion occurs, and Landlord shall complete any punch list items remaining to be performed within thirty (30)&#160;days after the date Tenant accepts the Premises or as soon thereafter as reasonably practicable.  Architect's measurement of the rentable square footage of the Building shall be calculated pursuant to the BOMA Standard</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">and will be subject to Tenant&#8217;s approval and will not be subject to remeasurement. The Verification Memorandum will include the square footage of the Building as measured by Architect.   </font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 6. <br>TENANT&#8217;S WORK</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.1&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">General Requirements for Tenant&#8217;s Work</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;If Tenant desires to have any contractors perform any work in the Project or on the Land prior to Substantial Completion of the Improvements (such work by Tenant or its contractors, the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Tenant&#8217;s Work</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), Tenant and the Tenant&#8217;s Parties shall have the right to enter the Project to perform such work and such work shall be subject to the safety, scheduling and coordination requirements of the General Contractor.  The provisions of the Lease that apply to the Alterations (e.g., the approval by Landlord and Tenant's construction thereof) shall apply to Tenant's Work.  Tenant shall deliver to Landlord at least five (5) business days prior to the commencement of any of Tenant&#8217;s Work, the following information and materials:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;The names and addresses of the subcontractors which will perform Tenant&#8217;s Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;A construction schedule for the significant tasks in Tenant&#8217;s Work which is in substantially the format of the schedule for construction of the Improvements maintained by the General Contractor and which is coordinated with construction of the Improvements.</font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-14</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;Evidence of Tenant&#8217;s compliance with the insurance requirements set forth in the Lease and in this Work Letter.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;An itemized budget for the costs of permits, architectural and engineering and permit fees and construction costs to be incurred, together with copies of executed agreements with all design professionals and Tenant&#8217;s contractor.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(v)&#160;&#160;&#160;&#160;Copies of all permits which may be required in connection with Tenant&#8217;s Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;The process of construction of Tenant&#8217;s Work shall comply in all respects with applicable Laws.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c)&#160;&#160;&#160;&#160;Tenant shall pay for all utility services furnished to the Project for Tenant&#8217;s Work in effect at the time of construction, including costs of temporary power, as well as all hoisting, debris removal and other costs incurred by the Contractors after its notice to Tenant and delivery of a cost estimate, together with its usual mark-up for overhead and profit, as a result of or in order to accommodate Tenant&#8217;s Work .</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d)&#160;&#160;&#160;&#160;Tenant&#8217;s Work shall be subject to the inspection of Landlord and its consultants at reasonable intervals and Tenant&#8217;s contractors shall make reasonable accommodations to facilitate such inspection.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(e)&#160;&#160;&#160;&#160;Tenant&#8217;s contractor shall present to Landlord and maintain on site at all times one (1) full set of the construction documents for Tenant&#8217;s Work which have been accepted by Landlord and evidence final approval by all other governmental agencies having jurisdiction over the construction and occupancy of the Project.  Such documents shall be carefully annotated during construction to reflect any material deviations in the Tenant&#8217;s Work &#8220;as-built&#8221; from that initially shown, and upon completion of Tenant&#8217;s Work, such drawings and electronic files or copies thereof shall be delivered to Landlord which describe accurately all of Tenant&#8217;s Work as built.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(f)&#160;&#160;&#160;&#160;Tenant shall perform or cause Tenant&#8217;s contractor to perform Tenant&#8217;s Work to avoid any labor dispute which causes or is likely to cause stoppage or impairment of construction of the Improvements or delivery service or any other services in the Building or to the Project.  In the event there shall be any such stoppage or impairment as the result of any such labor dispute or potential labor dispute, Tenant shall, after reasonable notice, promptly undertake such commercially reasonable actions as may be necessary to eliminate such dispute or potential dispute, to the extent permitted by law, including, but not limited to, (i) removing all disputants related to Tenant&#8217;s contractor or its subcontractors from the Building and the Project until such time as the labor dispute no longer exists, (ii) seeking an injunction in the event the dispute arises out of any alleged breach of contract between Tenant and Tenant&#8217;s contractor, and (iii) filing appropriate unfair labor practice charges in the event of a union jurisdictional dispute.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.2&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Temporary Facilities During Construction/Clean-Up Responsibilities</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant shall provide and pay for all temporary utility facilities used exclusively in connection with the construction of Tenant&#8217;s Work and shall pay for all utilities consumed in connection with Tenant&#8217;s Work and the removal of all debris, as necessary, created by the construction of Tenant&#8217;s Work.  Storage of Tenant&#8217;s contractors&#8217; construction material, tools, equipment and debris shall be confined to the Project or such other areas as shall be reasonably designated by Landlord.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant shall comply with all reasonable rules and regulations provided by Landlord in connection with Tenant&#8217;s construction, including, but not limited to access, truck traffic control, employee and contractor parking, loading, the use of elevators and hoists, all matters concerning fire safety, dust control and hours of construction.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant shall remove all debris resulting from Tenant&#8217;s Work on a daily basis, repair any damage caused to the Building, the Project, or the Improvements and use commercially reasonable efforts to keep the portions of the Project used by Tenant in a neat, orderly condition.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Landlord shall determine whether construction debris disposal related to Tenant&#8217;s Work shall be in separate containers contracted for by Tenant&#8217;s contractor or in containers arranged for by Landlord&#8217;s contractor.  Tenant shall pay for all related to disposal of debris from Tenant's Work and for costs for any separate containers contracted for by Tenant&#8217;s contractor </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.3&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Insurance</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">.  </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant shall</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">maintain, or cause its contractors to maintain during the period performance of Tenant's Work, in addition to the insurance required to be carried by Tenant pursuant to the Lease, all of the </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-15</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">insurance coverage in the minimum limits set forth below.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant shall not permit its contractors to commence any work until all required insurance has been obtained and certificates of such insurance have been delivered to Landlord.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a)&#160;&#160;&#160;&#160;Tenant&#8217;s General Contractor&#8217;s Required Minimum Coverage and Limits of Liability:</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(i)&#160;&#160;&#160;&#160;Worker&#8217;s Compensation, as required by law, and including Employer&#8217;s Liability Insurance with a limit of not less than $1,000,000.00, and any insurance required by the Employee Benefit Acts or other statutes applicable in the jurisdiction where the work is to be performed as will protect the contractor and sub-contractors from any and all liability under the aforementioned acts.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(ii)&#160;&#160;&#160;&#160;Commercial General Liability Insurance (including Contractor&#8217;s Protective Liability) in an amount not less than $2,000,000 for any one occurrence whether involving bodily injury liability (or death resulting therefrom) or property damage liability or a combination thereof with an aggregate limit of $2,000,000. </font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Such insurance shall provide for explosion, collapse and underground coverage.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Such insurance shall insure Landlord, Tenant and Tenant&#8217;s general contractor against any and all claims for bodily injury, including death resulting therefrom and damage to or destruction of property of any kind whatsoever and to whomsoever belonging and arising from operations under the contract or contracts for Tenant&#8217;s Work, whether such operations are performed by Tenant&#8217;s general contractor, sub-contractors, or any of their sub-contractors, or by anyone directly or indirectly employed by any of them.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iii)&#160;&#160;&#160;&#160;Umbrella/Excess Liability coverage in an amount not less than $5,000,000 in excess of Commercial General Liability Insurance, Comprehensive Automobile Liability Insurance, and Employers Liability Insurance. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(iv)&#160;&#160;&#160;&#160;Comprehensive Automobile Liability Insurance, including the ownership, maintenance, and operation of any automotive equipment, owned, hired, and non-owned, in an amount not less than $1,000,000 for any one occurrence whether involving bodily injury liability (or death resulting therefrom) or property damage liability or a combination thereof. Such insurance shall insure Tenant&#8217;s general contractor and subcontractors against any and all claims for bodily injury, including death resulting therefrom and damage to the property of others caused by accident and arising from operations under the contract or contracts for Tenant&#8217;s Work, whether such operations are performed by the general contractor, subcontractors, or by anyone directly or indirectly employed by any of them.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(v)&#160;&#160;&#160;&#160;Owner&#8217;s Protective Liability Insurance to insure Landlord and Tenant against any and all liability to third parties for damage due to bodily injury (or death resulting therefrom) and property damage of others or a combination thereof which may arise from work in connection with the Project, and any other liability for damages which Tenant&#8217;s general contractor and/or subcontractors are required to insure against under any provisions herein.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">Said insurance shall be provided in an amount not less than $3,000,000 for any one occurrence whether involving bodily injury liability (or death resulting therefrom) or property damage liability or a combination thereof; which limits may be provided by a combination of underlying and excess or umbrella coverage which follows the form of the underlying coverage.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(vi)&#160;&#160;&#160;&#160;&#8220;All Physical Loss&#8221; Builder&#8217;s Risk insurance covering Tenant&#8217;s Work.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The policy shall include as insureds Tenant, Landlord and its contractor and subcontractors, as their interests may appear.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">The amount of the insurance shall be one hundred percent (100%) of the replacement cost of Tenant&#8217;s Work.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(vii)&#160;&#160;&#160;&#160;With respect to Tenant's contractors whose scope of work includes or involves Hazardous Materials, Contractor&#8217;s Pollution Liability Insurance covering the General Contractor and all subcontractors in an amount of not less than Two Million Dollars ($2,000,000) with a maximum deductible of One Hundred Thousand Dollars ($100,000) with coverage continuing for ten years after completion of construction. Such insurance shall name Landlord as an additional insureds.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b)&#160;&#160;&#160;&#160;All insurance required under Section 6.3(a) other than Worker&#8217;s Compensation and Builder&#8217;s Risk insurance shall include as additional insureds Landlord, its property manager and any lender having a </font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-16</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">security interest in the Project.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">All insurance required under this Work Letter shall be endorsed to provide for at least thirty (30) days' prior written notice to Landlord for cancellation, nonrenewal or material reduction in coverage to the extent such endorsement is available from such contractor's insurer at a commercially reasonable rate.  The Worker&#8217;s Compensation Insurance shall contain an endorsement waiving all rights of subrogation against such persons and entities.</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">&#32;&#32;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">In addition to the evidence of insurance described above, Tenant shall deliver to Landlord upon request copies of policies of insurance or certificates thereof; and the policies of insurance required pursuant to this Work Letter shall in all other respects be kept and maintained, in accordance with the provisions of the Lease relating to insurance maintained by Tenant thereunder. </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">6.4&#160;&#160;&#160;&#160;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">LANDLORD MAKES NO REPRESENTATIONS REGARDING AND SHALL HAVE NO LIABILITY FOR ANY ABSENCE DURING ANY PERIOD OF EARLY ENTRY BY TENANT OR ITS CONTRACTORS INTO THE BUILDING OF (A) ELECTRICAL POWER OR (B) SECURITY FOR ANY OF TENANT&#8217;S PARTIES&#8217; PROPERTY LOCATED AT THE PROJECT.  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">DURING TENANT&#8217;S OR ANY TENANT PARTIES&#8217; OCCUPANCY OF THE PREMISES OR ACCESS TO THE PROJECT DURING ANY PERIOD OF EARLY ENTRY OF THE PROJECT, TENANT HEREBY ASSUMES ALL RISK OF DAMAGE TO AND THEFT OF TENANT&#8217;S PROPERTY AND INJURY TO PERSONS, IN, ON, OR ABOUT THE PROJECT AT TENANT&#8217;S REQUEST (EACH, A &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">TENANT RISK PARTY</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;) FROM ANY CAUSE WHATSOEVER AND AGREES THAT LANDLORD AND THE LANDORD PARTIES SHALL NOT BE LIABLE TO TENANT OR A TENANT PARTY FOR, AND ARE HEREBY RELEASED FROM ANY RESPONSIBILITY FOR, ANY DAMAGE TO OR THEFT OF PROPERTY OR INJURY TO PERSONS, WHICH DAMAGE, THEFT OR INJURY IS SUFFERED BY TENANT OR ANY TENANT PARTIES EXCEPT THAT ARISING OUT OF OR CAUSED BY THE NEGLIGENCE OR WILLFUL MISCONDUCT OF THE LANDLORD&#8217;S PARTIES.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">ARTICLE 7.</font><font style="font-family:inherit;font-size:10pt;">&#32;<br></font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CONSTRUCTION REPRESENTATIVES</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">Construction Representatives</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.  Tenant and Landlord shall each designate in writing one or more representatives to act on its behalf in dealing with the other party in matters relating to Improvements. Each of the representatives shall: (a) use commercially reasonable efforts to (and shall have the right to) attend or have its designee attend each project meeting as scheduled by Landlord and fully participate and cooperate with each other to ensure the orderly progression of the Improvements; and (b) be qualified to render decisions that are within their delegation of authority or, if outside their delegation of authority, to obtain such decisions in an expedited manner to ensure scope, cost and schedule are maintained. Each party shall be bound by any consents or approvals given by such designated representatives.  All consents and approvals or other notice or communications sent by email from one designated representative to the other will have the same binding force and effect as if sent in writing in accordance with the notice requirements of the Lease and will be deemed received on the business day sent if sent before 3:00 PM PST on such day.  Either party may, at any time, change its designated representative by giving a minimum of three (3) business days&#8217; notice of a change of designation, but such change will not affect or make void any previous rendered decisions, approvals or consents of such party&#8217;s previous designated representative. The designated representatives shall exert commercially reasonable efforts to render decisions and take actions in a timely manner so as to avoid unreasonable delay in the other party&#8217;s work and actions with respect to the construction of the Improvements. Tenant hereby designates Dana Aftab (email: XXX@XXX; telephone: XXX-XXX-XXXX) as its designated representative. Landlord hereby designates Laura Billings (email: XXX@XXX; telephone: XXX-XXX-XXXX), as its designated representative.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:96px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:312px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">B-17</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sA0259C5403DA864EDD4D13FD44143F33"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">EXHIBIT D-1</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">BASE RENT DETERMINATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Initial Base Rent shall be calculated using the following formula:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">(Total Development Costs (up to Initial Cost Limit) x .0775)/12 + (Landlord's Excess Development Costs x .10)/12</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Total Development Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221; means the sum of the following:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">acquisition costs for the Land, including, but not limited to, Landlord's due diligence costs, closing costs and the purchase price for the Land pursuant to the Land Purchase Agreement (approximately $36.17/sf, subject to further adjustment as described in the Land Purchase Agreement, and further subject to Section 26(u)); </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">the guaranteed maximum price or stipulated sum contract amounts for the Contracts (as defined in the Work Letter), including a general contractor fee not to exceed 4.00% and general conditions not to exceed 12%, for construction of site work, building shell and core per the Construction Documents approved by Tenant and Landlord;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">the Allowance (as defined in the Work Letter);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Contract fees and expenses for project architects, engineers and consultants for the Improvements, which fees shall be in conformance with market;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Fees and permit costs for the Improvements for the City of Alameda, including but not limited to fees to the health department and other agencies of the City of Alameda;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">utility company fees for the Improvements;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">construction financing costs, insurance costs, Landlord legal fees, and construction interest, at a rate not to exceed the maximum (non-default) interest rate set forth in the instrument evidencing such construction financing, actually incurred from the Execution Date to Base Rent Commencement (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Development Period</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), but excluding an interest reserve; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">estimated carry costs for the Project during the Development Period, excluding such carry costs that Tenant pays as Additional Rent between Term Commencement and Base Rent Commencement; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">9.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a project contingency amount with respect to the Improvements equal to ten (10%) percent of Total Development Costs only to the extent properly incurred for costs otherwise permitted hereunder during the Development Period, excluding land costs (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Project Contingency Amount</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;), which amount shall include the Contingency Excluded Costs (as provided below) and shall not include the Non-Contingency Excluded Costs (as provided below); and </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">10.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">a development and construction management fee equal to three percent (3%) of Total Development Costs (other than such fee).  </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, Total Development Costs shall exclude the amount of Tenant&#8217;s Contribution and the Tenant's Excess Development Costs, if any.   The Contingency Excluded Costs and the Non-Contingency Excluded Costs (each as defined below) are referred to herein collectively as the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Excluded Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following costs shall be excluded from Total Development Costs, except to the extent such costs are included in the Total Development Costs as a part of the Project Contingency Amount (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Contingency Excluded Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">costs for improvements which are not shown on or described in the Construction Documents approved by Tenant pursuant to the Work Letter; provided, however such costs shall only be included in the Project Contingency Amount to the extent Landlord verifies that such improvements are necessary for the construction of the Project;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">costs incurred as a consequence of unforeseen conditions affecting the Project; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">attorneys' fees and other costs in connection with disputes with third parties that did not arise through the acts or omissions of Tenant or its contractors, invitees or other guests; provided, however, such costs shall only be included in the Project Contingency Amount to the extent such disputes are not the result of </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">37199\12547593.38 &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">D-1-1</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;padding-left:48px;text-align:left;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">the negligent act or omission or willful misconduct of Landlord and to the extent such costs are not covered by Landlord's insurance; </font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">costs incurred as a consequence of delay in construction of the Improvements (unless the delay is a Tenant Delay);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">costs as a consequence of casualties; provided, however the costs that may be included in the Project Contingency Amount are limited to deductibles and non-insured losses; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">wages, labor and overhead for overtime and premium time; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">construction costs in excess of the Cost Estimate approved by Tenant, except for increases set forth in executed Change Orders requested by Tenant.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Notwithstanding the foregoing, the Contingency Excluded Costs numbered 3 through 7 immediately above shall be included in the Project Contingency Amount only to the extent approved by Tenant, which approval shall not be unreasonably withheld, conditioned or delayed; provided that it shall be unreasonable for Tenant to withhold its consent if Landlord delivers to Tenant reasonably sufficient evidence that such costs are incurred or to be incurred to maintain the critical path for the construction of the Improvements.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">The following costs shall be excluded from Total Development Costs and shall not be included in the Project Contingency Amount (the &#8220;</font><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Non-Contingency Excluded Costs</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#8221;):</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">costs for indirect offsite improvements (i.e. community benefits) that were not disclosed to Tenant at or prior to the approval of the development plan for the Project; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">costs incurred due to the presence of hazardous materials not caused by Tenant&#8217;s Parties or their contractors, invitees, or other guests; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">costs incurred as a consequence of construction defects;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">costs incurred as a consequence of a default by a Contractor (as defined in the Work Letter) under its Contract (as defined in the Work Letter);</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">costs recoverable by Landlord upon account of warranties and insurance; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">penalties and late charges attributable to Landlord&#8217;s failure to pay construction costs, unless such failure was caused by Tenant; </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">any leasing commissions with respect to the Lease; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">8.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">the costs of the Excluded Work (as defined in the Work Letter), unless and to the extent that Landlord and Tenant agree to include any Excluded Work in the scope of the Tenant Improvements.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">37199\12547593.38 &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">D-1-2</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sA4427F1A7685AE59427813FD44474840"></a></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;text-decoration:underline;">EXHIBIT D-2</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PROFORMA BASE RENT SCHEDULE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:62.82051282051282%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:14%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Initial Base</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Initial Base</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Month</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Month</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rent /Mo</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Rent /Yr</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Annual NNN</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Beg</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">End</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">PSF (1)</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">PSF</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;text-decoration:underline;">Rent $$</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$0.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$0.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$0</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">14</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$3.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$39.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$8,712,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">15</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$3.40</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$40.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$8,976,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">27</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">38</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$3.50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$42.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$9,240,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">39</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$3.61</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$43.32</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$9,530,400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">62</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$3.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$44.64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$9,820,800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">63</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$3.83</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$45.96</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,111,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">75</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">86</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$3.94</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$47.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,401,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">87</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">98</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$4.06</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$48.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$10,718,400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">99</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">110</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$4.18</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$50.16</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$11,035,200</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">111</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">122</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$4.31</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$51.72</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$11,378,400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">123</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">134</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$4.44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$53.28</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$11,721,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">135</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">146</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$4.57</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$54.84</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$12,064,800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">147</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">158</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$4.71</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$56.52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$12,434,400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">159</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">170</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$4.85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$58.20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$12,804,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">182</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$60.00</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$13,200,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">183</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">194</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5.15</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$61.80</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$13,596,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">195</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">206</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5.30</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$63.60</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$13,992,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">207</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">218</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5.46</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$65.52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$14,414,400</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">230</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5.62</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$67.44</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$14,836,800</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">231</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">242</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$5.79</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$69.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">$15,285,600</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">(1) Yr 1 = Total Development Costs x Rent Yield / 12, rounded</font></div></td></tr><tr><td colspan="12" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">to 2 decimal points; 3% escalation each year, thereafter,</font></div></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">rounded to 2 decimal points each year</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:8pt;">37199\12547593.38 &#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:10pt;">D-2-1</font></div><div style="line-height:100%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>exel20190930exhibit311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s7E457F73F278541384C72328B84B64C3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Michael M. Morrissey, Ph.D., certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/ M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">October&#160;30, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>exel20190930exhibit312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sE046D714A5D55FCD88C978D90B8D230B"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">I, Christopher J. Senner, certify that:</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">1. I have reviewed this Form 10-Q of Exelixis, Inc.;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:43.65079365079365%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;padding-top:12px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Date: </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">October&#160;30, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;</font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>exel20190930exhibit321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2019 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s3A0968AC26965365BB19095921AF9BD9"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">18 U.S.C. SECTION 1350,</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">AS ADOPTED PURSUANT TO</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;font-weight:bold;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge:</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;1. &#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">September&#160;27, 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended; and</font></div><div style="line-height:120%;padding-top:6px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;&#32;&#32;2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="line-height:120%;padding-top:12px;text-indent:48px;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">In Witness Whereof, the undersigned have set their hands hereto as of the </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">30th</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#32;day of </font><font style="font-family:Calibri,sans-serif;font-size:10pt;">October 2019</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">.</font></div><div style="line-height:120%;text-indent:48px;font-size:9pt;"><font style="font-family:Calibri,sans-serif;font-size:9pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:44%;"></td><td style="width:3%;"></td><td style="width:5%;"></td><td style="width:3%;"></td><td style="width:45%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ICHAEL</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;M. M</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ORRISSEY&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">/s/&#160;&#160;&#160;&#160;C</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">HRISTOPHER</font><font style="font-family:Calibri,sans-serif;font-size:10pt;">&#160;J. S</font><font style="font-family:Calibri,sans-serif;font-size:8pt;">ENNER&#160;&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Michael M. Morrissey, Ph.D.</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:Calibri,sans-serif;font-size:8pt;font-weight:bold;">Christopher J. Senner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">President and Chief Executive Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Executive Officer)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">Executive Vice President and Chief Financial Officer</font></div><div style="font-size:10pt;"><font style="font-family:Calibri,sans-serif;font-size:10pt;">(Principal Financial Officer)</font></div></td></tr></table></div></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>exel-20190927.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20190927" xmlns:exel="http://www.exelixis.com/20190927" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20190927_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20190927_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20190927_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20190927_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="CashAndInvestments" roleURI="http://www.exelixis.com/role/CashAndInvestments">
        <link:definition>2104100 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails">
        <link:definition>2404404 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails">
        <link:definition>2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsInvestmentsBySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails">
        <link:definition>2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails">
        <link:definition>2404405 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails">
        <link:definition>2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashAndInvestmentsTables" roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables">
        <link:definition>2304301 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreements" roleURI="http://www.exelixis.com/role/CollaborationAgreements">
        <link:definition>2103100 - Disclosure - Collaboration Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails">
        <link:definition>2403410 - Disclosure - Collaboration Agreements - Aurigene Discovery Technologies Limited (Aurigene) Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails">
        <link:definition>2403408 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails">
        <link:definition>2403402 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails">
        <link:definition>2403404 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsDaiichiSankyoDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails">
        <link:definition>2403407 - Disclosure - Collaboration Agreements - Daiichi Sankyo (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails">
        <link:definition>2403409 - Disclosure - Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsIpsenCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails">
        <link:definition>2403403 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails">
        <link:definition>2403406 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails">
        <link:definition>2403411 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables">
        <link:definition>2303301 - Disclosure - Collaboration Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsTakedaCollaborationDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails">
        <link:definition>2403405 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical">
        <link:definition>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2111100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2411402 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2311301 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.exelixis.com/role/IncomeTaxes">
        <link:definition>2108100 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDetails" roleURI="http://www.exelixis.com/role/IncomeTaxesDetails">
        <link:definition>2408401 - Disclosure - Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2105100 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2405402 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2305301 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.exelixis.com/role/Leases">
        <link:definition>2112100 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails">
        <link:definition>2412403 - Disclosure - Leases - Balance Sheet Classification of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsOfLeaseExpenseDetails" roleURI="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails">
        <link:definition>2412404 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>2412405 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2">
        <link:definition>2412405 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.exelixis.com/role/LeasesNarrativeDetails">
        <link:definition>2412402 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.exelixis.com/role/LeasesTables">
        <link:definition>2312301 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2110100 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails">
        <link:definition>2410402 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails">
        <link:definition>2410403 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2310301 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails">
        <link:definition>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.exelixis.com/role/PropertyAndEquipment">
        <link:definition>2106100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails">
        <link:definition>2406402 - Disclosure - Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentNarrativeDetails" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails">
        <link:definition>2406403 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables">
        <link:definition>2306301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2102100 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails">
        <link:definition>2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details">
        <link:definition>2402407 - Disclosure - Revenues - Contract Assets and Liabilities under Topic 606 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedByProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails">
        <link:definition>2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesByDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails">
        <link:definition>2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedByGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails">
        <link:definition>2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails">
        <link:definition>2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2302301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2107100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRsuActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails">
        <link:definition>2407407 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>2407406 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2307301 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails">
        <link:definition>2407405 - Disclosure - Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails">
        <link:definition>2407404 - Disclosure - Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.exelixis.com/role/SubsequentEvents">
        <link:definition>2113100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.exelixis.com/role/SubsequentEventsDetails">
        <link:definition>2413401 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="exel_ASDMember" name="ASDMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_AccruedClinicalLiabilitiesCurrent" name="AccruedClinicalLiabilitiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_AccruedCollaborationLiabilityCurrent" name="AccruedCollaborationLiabilityCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_AchievedMember" name="AchievedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AffiliatesofMcKessonCorporationMember" name="AffiliatesofMcKessonCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AlamedaCaliforniaMember" name="AlamedaCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_AllowanceForProductRebatesMember" name="AllowanceForProductRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_BuiltToSuitLeaseMember" name="BuiltToSuitLeaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CabometyxMember" name="CabometyxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CaremarkL.L.C.Member" name="CaremarkL.L.C.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CashAndRestrictedCashMember" name="CashAndRestrictedCashMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsAndInvestmentsTextBlock" name="CashCashEquivalentsAndInvestmentsTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_ChargebacksAndDiscountsForPromptPaymentMember" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementAdditionalOptionPayments" name="CollaborationAgreementAdditionalOptionPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementMilestonePaymentsEarned" name="CollaborationAgreementMilestonePaymentsEarned" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms" name="CollaborationAgreementNumberOfDrugDiscoveryPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementNumberOfPreexistingPrograms" name="CollaborationAgreementNumberOfPreexistingPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementNumberOfPrograms" name="CollaborationAgreementNumberOfPrograms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" name="CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" name="CollaborationAgreementResearchAndDevelopmentExpenseAccrued" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborationAgreementResearchAndDevelopmentObligation" name="CollaborationAgreementResearchAndDevelopmentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" name="CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" name="CollaborationAgreementWithIconicTherapeuticsInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborationAgreementsUpfrontPayments" name="CollaborationAgreementsUpfrontPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationAgreementwithDaiichiSankyoMember" name="CollaborationAgreementwithDaiichiSankyoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborationMember" name="CollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborativeArrangementAnnualReimbursementLimit" name="CollaborativeArrangementAnnualReimbursementLimit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" name="CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithGenentechMember" name="CollaborativeArrangementwithGenentechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithIpsenMember" name="CollaborativeArrangementwithIpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CollaborativeArrangementwithTakedaMember" name="CollaborativeArrangementwithTakedaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_CometriqMember" name="CometriqMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EarningsPerShareDenominatorAbstract" name="EarningsPerShareDenominatorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_EarningsPerShareNumeratorAbstract" name="EarningsPerShareNumeratorAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_FinancingLeaseLiabilitiesAbstract" name="FinancingLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_GlaxoSmithKlineMember" name="GlaxoSmithKlineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInAccruedClinicalLiabilities" name="IncreaseDecreaseInAccruedClinicalLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInAccruedCollaborationLiability" name="IncreaseDecreaseInAccruedCollaborationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" name="IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" name="IncreaseDecreaseInLeaseLiabilityNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" name="IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_IncreaseDecreaseInRebatesAndFeesPayable" name="IncreaseDecreaseInRebatesAndFeesPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_IpsenMember" name="IpsenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LeaseArrangementsAxis" name="LeaseArrangementsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LeaseArrangementsDomain" name="LeaseArrangementsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" name="LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" name="LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" name="LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseNumberOfRenewalOptions" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" name="LesseeOperatingLeaseOptionToTerminateAfterPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" name="LesseeOperatingLeaseReductionOfPaymentsDueAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" name="LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_NotProbableMember" name="NotProbableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_NumberofProductsinCommercialMarket" name="NumberofProductsinCommercialMarket" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OperatingAndFinanceLeasesLiabilityLongTerm" name="OperatingAndFinanceLeasesLiabilityLongTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_OperatingAndFinanceLeasesLiabilityTotal" name="OperatingAndFinanceLeasesLiabilityTotal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" name="OperatingLeaseAdditionalAreaOfRealEstateProperty" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_OperatingLeaseLiabilitiesAbstract" name="OperatingLeaseLiabilitiesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract" name="OperatingLeaseLiabilitiesDurationOfMaturityAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty" name="OperatingLeaseSurrenderedAreaOfRealEstateProperty" nillable="true" substitutionGroup="xbrli:item" type="num:areaItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherCollaborationMember" name="OtherCollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherCustomersMember" name="OtherCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_OtherLongtermAssetsMember" name="OtherLongtermAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_OwnershipInterestByMinorityShareholder" name="OwnershipInterestByMinorityShareholder" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_PerformanceSharesAchievedBeforeDecember312020Member" name="PerformanceSharesAchievedBeforeDecember312020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_PerformanceSharesSecondProductApprovalMember" name="PerformanceSharesSecondProductApprovalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProbableMember" name="ProbableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductGrossMember" name="ProductGrossMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ProductsDerivedFromCabozantinibMember" name="ProductsDerivedFromCabozantinibMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RelatedPartyTransactionsAdvisoryFeesIncurred" name="RelatedPartyTransactionsAdvisoryFeesIncurred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" name="RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" name="RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="exel_ResearchandDevelopmentMember" name="ResearchandDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ResultingFromDiscoveryEffortsMember" name="ResultingFromDiscoveryEffortsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_RightOfUseAssetAmortization" name="RightOfUseAssetAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" name="RightOfUseAssetObtainedInExchangeForLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SalesDiscountsAndAllowancesMember" name="SalesDiscountsAndAllowancesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StatusAxis" name="StatusAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_StatusDomain" name="StatusDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="exel_TenantLeaseImprovementsAllowance" name="TenantLeaseImprovementsAllowance" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>exel-20190927_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20190927.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20190927.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20190927.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20190927.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20190927.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20190927.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20190927.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20190927.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20190927.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20190927.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20190927.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20190927.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20190927.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20190927.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20190927.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Leases" xlink:href="exel-20190927.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20190927.xsd#LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="exel-20190927.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20190927.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:href="exel-20190927.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:href="exel-20190927.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesTables" xlink:href="exel-20190927.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20190927.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20190927.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20190927.xsd#NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20190927.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20190927.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20190927.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20190927.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20190927.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:href="exel-20190927.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20190927.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20190927.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20190927.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20190927.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20190927.xsd#RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20190927.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20190927.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20190927.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20190927.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20190927.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20190927.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20190927.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvents" xlink:href="exel-20190927.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:href="exel-20190927.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7d2f9305-3a51-279b-17e9-0a8bec7eba1b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_7d2f9305-3a51-279b-17e9-0a8bec7eba1b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fe6fe2fb-1c28-638d-7c2f-bc065610ad60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bd4abe0a-6fe6-2d88-cf98-52c493407bcd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_fe6fe2fb-1c28-638d-7c2f-bc065610ad60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_44b817b0-a9ec-08a0-e6d5-8738955fbd29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_447294e8-f4eb-2b40-51a5-60fa019f8c40" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_f50bd4fe-0acd-ab98-c92a-d313822079c5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DC8BC53B156A5651A31D579156BEC20B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_775FA78A24CA53A1AA463099B512DAD0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DC8BC53B156A5651A31D579156BEC20B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_775FA78A24CA53A1AA463099B512DAD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A0573586EB455BE4A8C1F282C08469F9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_DC8BC53B156A5651A31D579156BEC20B" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_A0573586EB455BE4A8C1F282C08469F9" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:type="locator" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_B1B5C59954ACD7227CEBD0F6D5060929" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_B1B5C59954ACD7227CEBD0F6D5060929" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_4E074AF6956734733DC5D0F957AA4316" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_4E074AF6956734733DC5D0F957AA4316" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_167ec6f2-cd00-1650-5a57-e231dd2cfd76" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_21c019f0-62e8-3b20-07d1-495695054dce" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_167ec6f2-cd00-1650-5a57-e231dd2cfd76" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:type="locator" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_384A7F6E47AF56369CF6D0E8B9A2494D" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_384A7F6E47AF56369CF6D0E8B9A2494D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A58B8844B69BDDC0A96D0EA2FC3037F" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_9A58B8844B69BDDC0A96D0EA2FC3037F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b9f01a60-37e3-9cac-628d-e231dc908029" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_335d8c05-95ed-2dfe-a9ca-e231dccdb6c2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_b9f01a60-37e3-9cac-628d-e231dc908029" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9655F218CB315EF9BF70FD0D0E33B8E7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84B51E41809F5BBABD4ADF36A2455E6B" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9655F218CB315EF9BF70FD0D0E33B8E7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_84B51E41809F5BBABD4ADF36A2455E6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_5A717DFBB799551092925090A7E1A4F2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9655F218CB315EF9BF70FD0D0E33B8E7" xlink:to="loc_us-gaap_RestrictedCashCurrent_5A717DFBB799551092925090A7E1A4F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_19C1991F0AB0557D89AB545BCC1702C8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9655F218CB315EF9BF70FD0D0E33B8E7" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_19C1991F0AB0557D89AB545BCC1702C8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ReceivablesNetCurrent_c4de65c9-dd27-7a0a-0b7a-4158d1967739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_6354506a-6731-cd90-1f5d-acac861303b2" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_6354506a-6731-cd90-1f5d-acac861303b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_5fd9c643-899e-95d7-aab9-c3a9d6240218" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_c8fd2d85-a7fd-d8bf-27f7-fb3ef5afcc7e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_dcf3df0d-2155-35f6-715d-83a9bc9cf3fb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_60654fa3-82c2-3e38-ce88-436acda713ac" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f46016be-a090-7f0b-44f7-8ddf156c8efc" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_f46016be-a090-7f0b-44f7-8ddf156c8efc" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_8181aa43-5e6e-efd7-8594-e231dc44bff4" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_8181aa43-5e6e-efd7-8594-e231dc44bff4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_ed5805c5-9fe5-ff84-0411-6c376b91c188" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_ed5805c5-9fe5-ff84-0411-6c376b91c188" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_070c23c0-5d18-82af-08b1-e231dbcc5321" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_070c23c0-5d18-82af-08b1-e231dbcc5321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fa7787c9-a33c-d084-bb97-5e2455f77a4c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_2bf7259d-4c54-f092-3b62-ad288c59c828" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingAndFinanceLeasesLiabilityLongTerm" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_46f34c13-26a5-ca6e-3613-e231dd1f2d6a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_46f34c13-26a5-ca6e-3613-e231dd1f2d6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_ebef248a-da21-637d-9d28-3d42ff90e8e2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_c52c87c0-47e1-9a76-3765-621be37e2286" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_c52c87c0-47e1-9a76-3765-621be37e2286" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_RightOfUseAssetAmortization" xlink:label="loc_exel_RightOfUseAssetAmortization_019ffeca-8dfc-b224-ad5b-e231dcac7db8" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_RightOfUseAssetAmortization_019ffeca-8dfc-b224-ad5b-e231dcac7db8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_bdb195e0-2bd9-1b65-83b4-44045e66ebea" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_bdb195e0-2bd9-1b65-83b4-44045e66ebea" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6990de1f-0b35-2b76-52bb-4b0ce17b5e4e" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_6990de1f-0b35-2b76-52bb-4b0ce17b5e4e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_dfcbd6f7-83fa-00c2-bd9e-6c5c1de7d890" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_596f4189-155d-4012-cbaf-764843162122" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_596f4189-155d-4012-cbaf-764843162122" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_792166b2-b561-55ef-12fd-ca8b50f64a38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_300c5b66-f508-fab7-3859-345853a2ad7c" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_300c5b66-f508-fab7-3859-345853a2ad7c" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_6b73ac58-d917-0794-67de-e231dcf86592" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_6b73ac58-d917-0794-67de-e231dcf86592" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInRebatesAndFeesPayable" xlink:label="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_697c6cb6-353c-94c4-b506-e231dd92e4bd" xlink:type="locator" />
    <link:calculationArc order="16" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_697c6cb6-353c-94c4-b506-e231dd92e4bd" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_ae174790-5ce3-87ae-3055-e231dd71f8f8" xlink:type="locator" />
    <link:calculationArc order="17" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_ae174790-5ce3-87ae-3055-e231dd71f8f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="locator" />
    <link:calculationArc order="18" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_8fa19589-0da6-036d-a79e-4bd2fa365a6d" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" xlink:label="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_f239b460-f317-6566-0193-e231dcdfbfbf" xlink:type="locator" />
    <link:calculationArc order="19" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_f239b460-f317-6566-0193-e231dcdfbfbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="locator" />
    <link:calculationArc order="20" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_591bbf45-d531-0671-adc1-cfca3447af6c" xlink:type="locator" />
    <link:calculationArc order="21" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_591bbf45-d531-0671-adc1-cfca3447af6c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0074e2ce-7b7b-56f1-34ed-f9d5bd5d1c3d" xlink:type="locator" />
    <link:calculationArc order="22" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_0074e2ce-7b7b-56f1-34ed-f9d5bd5d1c3d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_8b51ae5f-8f14-ae0e-00e7-8f4e716f2f96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e3f9215c-1f64-e636-ccb3-9c51d05b0a6d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_e3f9215c-1f64-e636-ccb3-9c51d05b0a6d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d1d20cfe-f038-824a-0236-247c2a122ebc" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_d1d20cfe-f038-824a-0236-247c2a122ebc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_25a8c943-d653-1f00-b8d3-0f47ff48fcf4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_25a8c943-d653-1f00-b8d3-0f47ff48fcf4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6d7a72cc-b15d-447c-3b26-c3564dc5b0b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_b130e83a-7e35-8950-f084-78ccb28f2eab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockPlans_b130e83a-7e35-8950-f084-78ccb28f2eab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_07e50027-f2db-6d1b-93ed-b22d6bd39351" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_b7e0679c-4684-33a3-1aa6-41b7f5823917" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_b7e0679c-4684-33a3-1aa6-41b7f5823917" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_B2EBE03410945FAA8AA0D42C7D4158B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_393F1C13A68D59E28EA7553E93C8CDC9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_B2EBE03410945FAA8AA0D42C7D4158B4" xlink:to="loc_us-gaap_NetIncomeLoss_393F1C13A68D59E28EA7553E93C8CDC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0F0EFF6839DD52C1990637D635DD3EF1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_B2EBE03410945FAA8AA0D42C7D4158B4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0F0EFF6839DD52C1990637D635DD3EF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6D97854351D75E69906557D59FCAC057" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0F0EFF6839DD52C1990637D635DD3EF1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_6D97854351D75E69906557D59FCAC057" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_393F1C13A68D59E28EA7553E93C8CDC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F4F9C70A8FC854D8956CD14F5C51C449" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_393F1C13A68D59E28EA7553E93C8CDC9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F4F9C70A8FC854D8956CD14F5C51C449" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_EF6EA68FB19956248E8235D16FE326A2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F4F9C70A8FC854D8956CD14F5C51C449" xlink:to="loc_us-gaap_OperatingIncomeLoss_EF6EA68FB19956248E8235D16FE326A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6D74F12B516852F88621B67F31FD86F3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_EF6EA68FB19956248E8235D16FE326A2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6D74F12B516852F88621B67F31FD86F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_3A6CCFDF24D955BD88AF3C569F18F0BA" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_EF6EA68FB19956248E8235D16FE326A2" xlink:to="loc_us-gaap_OperatingExpenses_3A6CCFDF24D955BD88AF3C569F18F0BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3C5A2F4F7F6F537F886662BDB0A6C497" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3A6CCFDF24D955BD88AF3C569F18F0BA" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_3C5A2F4F7F6F537F886662BDB0A6C497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_314E7AADD2CA5855ACD42A7EE35FC086" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3A6CCFDF24D955BD88AF3C569F18F0BA" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_314E7AADD2CA5855ACD42A7EE35FC086" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_FBD45FA013EC5B18AB71D3FB93B48968" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_3A6CCFDF24D955BD88AF3C569F18F0BA" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_FBD45FA013EC5B18AB71D3FB93B48968" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5C17C26DFE94552EBAA6A33C98658E30" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_F4F9C70A8FC854D8956CD14F5C51C449" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5C17C26DFE94552EBAA6A33C98658E30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_0ADF7C473D06589BA53498483B8A341C" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5C17C26DFE94552EBAA6A33C98658E30" xlink:to="loc_us-gaap_InterestIncomeOther_0ADF7C473D06589BA53498483B8A341C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_930CA51E443C59C98A6B49DD38E9FAAB" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_5C17C26DFE94552EBAA6A33C98658E30" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_930CA51E443C59C98A6B49DD38E9FAAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D6153862E3355445A0CEF90A57A20127" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_393F1C13A68D59E28EA7553E93C8CDC9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_D6153862E3355445A0CEF90A57A20127" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_416B7E30E6F1517CA5C34E0FB6FA4297" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_2EC885EDB51E5C90A16D8B98593069A7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_416B7E30E6F1517CA5C34E0FB6FA4297" xlink:to="loc_us-gaap_InventoryRawMaterials_2EC885EDB51E5C90A16D8B98593069A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_A36E11B5E1165FBC8A9608B7ECFEF114" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_416B7E30E6F1517CA5C34E0FB6FA4297" xlink:to="loc_us-gaap_InventoryWorkInProcess_A36E11B5E1165FBC8A9608B7ECFEF114" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_154413B1E1CF5236967DDD747241848D" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_416B7E30E6F1517CA5C34E0FB6FA4297" xlink:to="loc_us-gaap_InventoryFinishedGoods_154413B1E1CF5236967DDD747241848D" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Leases" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingAndFinanceLeasesLiabilityTotal" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_488A3760AA155DF0BCA5AF445A47CFEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_EE910A545607545DB07DD1DECDB187D3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_488A3760AA155DF0BCA5AF445A47CFEA" xlink:to="loc_us-gaap_OperatingLeaseLiability_EE910A545607545DB07DD1DECDB187D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_C6FB5EE1BE3157A6B9211E1C8FC4161C" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_EE910A545607545DB07DD1DECDB187D3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_C6FB5EE1BE3157A6B9211E1C8FC4161C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_50135B872BD456F689361FFAA862BA92" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_EE910A545607545DB07DD1DECDB187D3" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_50135B872BD456F689361FFAA862BA92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_2F654255FE565342A2BBF76AEAC17016" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_488A3760AA155DF0BCA5AF445A47CFEA" xlink:to="loc_us-gaap_FinanceLeaseLiability_2F654255FE565342A2BBF76AEAC17016" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_C814EECC699A5E10A9F7E3EC0D7B90B3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_2F654255FE565342A2BBF76AEAC17016" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_C814EECC699A5E10A9F7E3EC0D7B90B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7952B3D0A2CF55FFB49A5A1E76F5D7EB" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FinanceLeaseLiability_2F654255FE565342A2BBF76AEAC17016" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_7952B3D0A2CF55FFB49A5A1E76F5D7EB" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_340766EAAD3F5481AB4608FD52503C70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_76F27D353E565A989F0AAB2121FE3C4B" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_340766EAAD3F5481AB4608FD52503C70" xlink:to="loc_us-gaap_OperatingLeaseCost_76F27D353E565A989F0AAB2121FE3C4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_CE74820BE4AD5C4CAE5FA2D1567E00EF" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_340766EAAD3F5481AB4608FD52503C70" xlink:to="loc_us-gaap_VariableLeaseCost_CE74820BE4AD5C4CAE5FA2D1567E00EF" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_48abcf97-737b-2b2c-8a8c-c74539d0b215" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_9b040bc1-f43c-735d-05f7-679f319d2bb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2f0ec234-4f20-7099-efb3-3c0ab4d024dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1ed751b1-5f94-4f6f-41e9-ef873c9f2bab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_8a8de21f-aadc-3af7-8c96-d54cf42b401b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_b411eec9-2a0a-356b-e751-bd0680ab4d58" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_616A6F83DDC68B6E366C0F80C5031D9E_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_616A6F83DDC68B6E366C0F80C5031D9E_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_616A6F83DDC68B6E366C0F80C5031D9E_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_616A6F83DDC68B6E366C0F80C5031D9E_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_616A6F83DDC68B6E366C0F80C5031D9E_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_616A6F83DDC68B6E366C0F80C5031D9E_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_616A6F83DDC68B6E366C0F80C5031D9E_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_616A6F83DDC68B6E366C0F80C5031D9E_834dfbbf-9427-d763-5673-e231dcc3eb20" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_616A6F83DDC68B6E366C0F80C5031D9E_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_616A6F83DDC68B6E366C0F80C5031D9E_834dfbbf-9427-d763-5673-e231dcc3eb20" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/LeasesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4C0189A7FDD25D76A5F1E0B0F3F05968" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8D0C386BAAD750A6983B45FCA25EB11A" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4C0189A7FDD25D76A5F1E0B0F3F05968" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8D0C386BAAD750A6983B45FCA25EB11A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1A68CAF956F15276943E1A46A2225EB3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_4C0189A7FDD25D76A5F1E0B0F3F05968" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_1A68CAF956F15276943E1A46A2225EB3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6C33BF274306532A9826D225B7905F30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_7CA769891F635929826BA3BDD87C57A0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6C33BF274306532A9826D225B7905F30" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_7CA769891F635929826BA3BDD87C57A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2218E84E3E4056EABC2168E8F5F51E2E" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_6C33BF274306532A9826D225B7905F30" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2218E84E3E4056EABC2168E8F5F51E2E" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>exel-20190927_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20190927.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20190927.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20190927.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20190927.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20190927.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20190927.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20190927.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20190927.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20190927.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20190927.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20190927.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20190927.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20190927.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20190927.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20190927.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Leases" xlink:href="exel-20190927.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20190927.xsd#LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="exel-20190927.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20190927.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:href="exel-20190927.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesTables" xlink:href="exel-20190927.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20190927.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20190927.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20190927.xsd#NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20190927.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20190927.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20190927.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20190927.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20190927.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:href="exel-20190927.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20190927.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20190927.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20190927.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20190927.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20190927.xsd#RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20190927.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20190927.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20190927.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20190927.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20190927.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20190927.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20190927.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvents" xlink:href="exel-20190927.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:href="exel-20190927.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D8723BD9E5C9A0769544B97AF8181ED2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D8723BD9E5C9A0769544B97AF8181ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D8723BD9E5C9A0769544B97AF8181ED2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D8723BD9E5C9A0769544B97AF8181ED2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0881B987BDEF9F00ED72B97AF818A80F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0881B987BDEF9F00ED72B97AF818A80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0DCA26283D39A2A18101B97AF818779D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0DCA26283D39A2A18101B97AF818779D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DED3BDC7CC1EAB74B824B99E69FE38C4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:to="loc_us-gaap_CommercialPaperMember_DED3BDC7CC1EAB74B824B99E69FE38C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1AD5A1B9E05DEDD6B95F1A72633B33FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1AD5A1B9E05DEDD6B95F1A72633B33FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1AD5A1B9E05DEDD6B95F1A72633B33FE" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1AD5A1B9E05DEDD6B95F1A72633B33FE" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_FC3C19F95B92311DA2D21A72633CA236" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_MoneyMarketFundsMember_FC3C19F95B92311DA2D21A72633CA236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_AD150C4B3DB75421CE711A72633E2E0A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_CommercialPaperMember_AD150C4B3DB75421CE711A72633E2E0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_D9B8D9049D7CC77ECF111A72633EFD35" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_D9B8D9049D7CC77ECF111A72633EFD35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_193A59A7224BFAFC11EA1A72633EBDA2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_193A59A7224BFAFC11EA1A72633EBDA2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashAndRestrictedCashMember" xlink:label="loc_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_B7E2F1E31B97E6E6C1861A72633FA62B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_CertificatesOfDepositMember_B7E2F1E31B97E6E6C1861A72633FA62B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E22E0D448C9940B7A1651A72633F15C1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E22E0D448C9940B7A1651A72633F15C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_215BD65C5DD9BB2369E81A726340E5C7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_215BD65C5DD9BB2369E81A726340E5C7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27C2752B1FAF82B10BF4F047DEC2F8BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27C2752B1FAF82B10BF4F047DEC2F8BB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_57BD2EF25B284F3BF5D5F047DEC2C008" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27C2752B1FAF82B10BF4F047DEC2F8BB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_57BD2EF25B284F3BF5D5F047DEC2C008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BAEA0B6269F56CD64B7F047DEC38976_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_57BD2EF25B284F3BF5D5F047DEC2C008" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BAEA0B6269F56CD64B7F047DEC38976_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BAEA0B6269F56CD64B7F047DEC38976" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_57BD2EF25B284F3BF5D5F047DEC2C008" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BAEA0B6269F56CD64B7F047DEC38976" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BAEA0B6269F56CD64B7F047DEC38976" xlink:to="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27C2752B1FAF82B10BF4F047DEC2F8BB" xlink:to="loc_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:to="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:to="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:to="loc_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:to="loc_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementNumberOfPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_89259B571FB6586FD4BAF047DEC59DD5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_89259B571FB6586FD4BAF047DEC59DD5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementAdditionalOptionPayments" xlink:label="loc_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementResearchAndDevelopmentObligation" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_588E5274ECB4886DE74CF0679B1D9158" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_588E5274ECB4886DE74CF0679B1D9158" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_4BFDFC41073CC945F859F047DEC58BC2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_4BFDFC41073CC945F859F047DEC58BC2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_1E1D94CB1898592C99E1F047DEC589B9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_1E1D94CB1898592C99E1F047DEC589B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_3617FDF9ABBD5C964D71F047DEC6C04F" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_3617FDF9ABBD5C964D71F047DEC6C04F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A79520386792B15DB4CEF047DED00E83" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9435D3D9E152FEBA2149F047DECF3220" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A79520386792B15DB4CEF047DED00E83" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9435D3D9E152FEBA2149F047DECF3220" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_72B6F4460EFEB89EAE00F047DECF3EF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9435D3D9E152FEBA2149F047DECF3220" xlink:to="loc_us-gaap_TypeOfArrangementAxis_72B6F4460EFEB89EAE00F047DECF3EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8C38F8F4493ED05E6249F047DED0B35C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_72B6F4460EFEB89EAE00F047DECF3EF6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8C38F8F4493ED05E6249F047DED0B35C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8C38F8F4493ED05E6249F047DED0B35C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_72B6F4460EFEB89EAE00F047DECF3EF6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8C38F8F4493ED05E6249F047DED0B35C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_D39120226EE804EE54ABF047DED0A5E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8C38F8F4493ED05E6249F047DED0B35C" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_D39120226EE804EE54ABF047DED0A5E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C9D21FE30BC1D68B7D15F047DED0E67C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A79520386792B15DB4CEF047DED00E83" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C9D21FE30BC1D68B7D15F047DED0E67C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0B2A558EFB354A29DCB6F925C0A52CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10938FFB63675C1EB5B90275C35602A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0B2A558EFB354A29DCB6F925C0A52CD" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10938FFB63675C1EB5B90275C35602A1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_721C7C31254A52F2BDBE52742658DAF2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10938FFB63675C1EB5B90275C35602A1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_721C7C31254A52F2BDBE52742658DAF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_721C7C31254A52F2BDBE52742658DAF2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7452311D5DD1FE04F20AE23265D5D9E7_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_709BD66CC33D5BDDB19F544D527B795D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_721C7C31254A52F2BDBE52742658DAF2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_709BD66CC33D5BDDB19F544D527B795D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_576A3282DAD553EB9E0A25DB76655235" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_709BD66CC33D5BDDB19F544D527B795D" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_576A3282DAD553EB9E0A25DB76655235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CAD0BE9C4AF5E09A55B298E09F2AD9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0B2A558EFB354A29DCB6F925C0A52CD" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CAD0BE9C4AF5E09A55B298E09F2AD9B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6F982827751A5F0BA10D06474805B33E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F19ACBF9B25052D19D3AB45E01FD65A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6F982827751A5F0BA10D06474805B33E" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F19ACBF9B25052D19D3AB45E01FD65A4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7383D0504FC55487B58A12A524CE29E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F19ACBF9B25052D19D3AB45E01FD65A4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7383D0504FC55487B58A12A524CE29E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7383D0504FC55487B58A12A524CE29E7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_239EA94C6423FF6BFF39E2326563B742_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_23EED257CB87554A8ED138999BF4B5AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7383D0504FC55487B58A12A524CE29E7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_23EED257CB87554A8ED138999BF4B5AE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_23EED257CB87554A8ED138999BF4B5AE" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B18C6796A77755628371FD1FA816B246" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6F982827751A5F0BA10D06474805B33E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B18C6796A77755628371FD1FA816B246" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B6401B4D19A90B4A184FB3E451E5192B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_973319DD163192D5259DB3E451E32E43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B6401B4D19A90B4A184FB3E451E5192B" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_973319DD163192D5259DB3E451E32E43" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FF28B0DA84C5C37228A8B3E451E3EF75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_973319DD163192D5259DB3E451E32E43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FF28B0DA84C5C37228A8B3E451E3EF75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B57AF75733E7503C7E0FB3E451E386EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FF28B0DA84C5C37228A8B3E451E3EF75" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B57AF75733E7503C7E0FB3E451E386EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B57AF75733E7503C7E0FB3E451E386EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FF28B0DA84C5C37228A8B3E451E3EF75" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B57AF75733E7503C7E0FB3E451E386EF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B57AF75733E7503C7E0FB3E451E386EF" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_50E026369FB02182A29FB3E451E40690" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_973319DD163192D5259DB3E451E32E43" xlink:to="loc_srt_ProductOrServiceAxis_50E026369FB02182A29FB3E451E40690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_188AD269014C5BF4BA0AB3E451E453B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_50E026369FB02182A29FB3E451E40690" xlink:to="loc_srt_ProductsAndServicesDomain_188AD269014C5BF4BA0AB3E451E453B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_188AD269014C5BF4BA0AB3E451E453B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_50E026369FB02182A29FB3E451E40690" xlink:to="loc_srt_ProductsAndServicesDomain_188AD269014C5BF4BA0AB3E451E453B7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_C08ACD085607F5C64DF0B3E451E49EC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_188AD269014C5BF4BA0AB3E451E453B7" xlink:to="loc_exel_CollaborationMember_C08ACD085607F5C64DF0B3E451E49EC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8E5AFA143CABFF72A054B3E451E5256F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B6401B4D19A90B4A184FB3E451E5192B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8E5AFA143CABFF72A054B3E451E5256F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_886F782374058C7E0E6DB3E451E5CE72" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B6401B4D19A90B4A184FB3E451E5192B" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_886F782374058C7E0E6DB3E451E5CE72" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_68E90CD796F1BF0AA5EDFA3E4AF2A48C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_68E90CD796F1BF0AA5EDFA3E4AF2A48C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FB3175E19266B2056835FA3E4AF2FCD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_68E90CD796F1BF0AA5EDFA3E4AF2A48C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FB3175E19266B2056835FA3E4AF2FCD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80EB356F53262843D727FA3E4AF2A19E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FB3175E19266B2056835FA3E4AF2FCD9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80EB356F53262843D727FA3E4AF2A19E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80EB356F53262843D727FA3E4AF2A19E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FB3175E19266B2056835FA3E4AF2FCD9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80EB356F53262843D727FA3E4AF2A19E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80EB356F53262843D727FA3E4AF2A19E" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_028B3344DA095774D8A0F047DEEAC46A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_AD34C8EAA13C5748369CF047DEE91642" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_028B3344DA095774D8A0F047DEEAC46A" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_AD34C8EAA13C5748369CF047DEE91642" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EE098DC897FAA86D73A8F047DEE9B854" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_AD34C8EAA13C5748369CF047DEE91642" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EE098DC897FAA86D73A8F047DEE9B854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04583226057700FE90F9F047DEE9CAB3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EE098DC897FAA86D73A8F047DEE9B854" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04583226057700FE90F9F047DEE9CAB3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04583226057700FE90F9F047DEE9CAB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EE098DC897FAA86D73A8F047DEE9B854" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04583226057700FE90F9F047DEE9CAB3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_57DCB0F3455F5ED52E13F047DEEACDA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04583226057700FE90F9F047DEE9CAB3" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_57DCB0F3455F5ED52E13F047DEEACDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_028B3344DA095774D8A0F047DEEAC46A" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_872A3DA26E5E63786946F051A450C5D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_028B3344DA095774D8A0F047DEEAC46A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_872A3DA26E5E63786946F051A450C5D4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5275AACB7F8555928ABE3B4E2C13AC21" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CF9B067B6F1F5967B26039E64DE6F95C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5275AACB7F8555928ABE3B4E2C13AC21" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CF9B067B6F1F5967B26039E64DE6F95C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0457BE6BC5A5531EB8F318EFF5917D43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CF9B067B6F1F5967B26039E64DE6F95C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0457BE6BC5A5531EB8F318EFF5917D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0457BE6BC5A5531EB8F318EFF5917D43" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_851386B14D1ED10477E944A6D30DD0E7_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57C2469F36A354C1A3E5CB67BF72EEAC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0457BE6BC5A5531EB8F318EFF5917D43" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57C2469F36A354C1A3E5CB67BF72EEAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57C2469F36A354C1A3E5CB67BF72EEAC" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5275AACB7F8555928ABE3B4E2C13AC21" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8F4E097CB4CC59139845BF6DC074204E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5275AACB7F8555928ABE3B4E2C13AC21" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8F4E097CB4CC59139845BF6DC074204E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:to="loc_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:to="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:to="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:to="loc_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:to="loc_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:to="loc_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E91A75B1EAD112DDD3F417E2EDD678FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E91A75B1EAD112DDD3F417E2EDD678FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_CD0F035FE2E1F4D92AF617E2EDD7D3DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E91A75B1EAD112DDD3F417E2EDD678FF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_CD0F035FE2E1F4D92AF617E2EDD7D3DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_462DB8A8F276FA01F6A317E2EDD74663_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CD0F035FE2E1F4D92AF617E2EDD7D3DF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_462DB8A8F276FA01F6A317E2EDD74663_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_462DB8A8F276FA01F6A317E2EDD74663" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CD0F035FE2E1F4D92AF617E2EDD7D3DF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_462DB8A8F276FA01F6A317E2EDD74663" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_5DAED9E59D5D9BF8E60A17E2EDD769BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_462DB8A8F276FA01F6A317E2EDD74663" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_5DAED9E59D5D9BF8E60A17E2EDD769BE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementAnnualReimbursementLimit" xlink:label="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_401B8D8E41DE84D676D717E2EDD88ECB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_401B8D8E41DE84D676D717E2EDD88ECB" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementMilestonePaymentsEarned" xlink:label="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_EC8D541E38029E25CC0417E2EDD99DB9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_EC8D541E38029E25CC0417E2EDD99DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_C921E93FD8B8EA6F0EE917E2EDD9A4EE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_C921E93FD8B8EA6F0EE917E2EDD9A4EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0EE590C190555D48B475674DC1D96FD4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_StatementTable_0EE590C190555D48B475674DC1D96FD4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8BA26BAEAFF7599680F806FE7DA7C315" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_0EE590C190555D48B475674DC1D96FD4" xlink:to="loc_srt_ProductOrServiceAxis_8BA26BAEAFF7599680F806FE7DA7C315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8BA26BAEAFF7599680F806FE7DA7C315" xlink:to="loc_srt_ProductsAndServicesDomain_AA08CAF044F77A44249AE232661CD148_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7A570342F720581DBC1AFEFB29C1EC0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8BA26BAEAFF7599680F806FE7DA7C315" xlink:to="loc_srt_ProductsAndServicesDomain_7A570342F720581DBC1AFEFB29C1EC0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C145F313B55558C2A579396D2D94F166" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7A570342F720581DBC1AFEFB29C1EC0B" xlink:to="loc_us-gaap_ProductMember_C145F313B55558C2A579396D2D94F166" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7A570342F720581DBC1AFEFB29C1EC0B" xlink:to="loc_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0DFFFE4503B653A68593AE1CF4A43318" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0DFFFE4503B653A68593AE1CF4A43318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_F5614C6FEA5053C599C91A1EFD6AFD14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_F5614C6FEA5053C599C91A1EFD6AFD14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_F30BD9708FAC551F909A305D2E4FC24D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_F30BD9708FAC551F909A305D2E4FC24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D53D2C45253D5B3F9E0CD4C66085376B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D53D2C45253D5B3F9E0CD4C66085376B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8B1B82B93E8758BFB317EDC69A1AD070" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:to="loc_us-gaap_OperatingExpenses_8B1B82B93E8758BFB317EDC69A1AD070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_FB87D881E36E523EA3A33D58ED47F2A1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_OperatingIncomeLoss_FB87D881E36E523EA3A33D58ED47F2A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_094F72CAB6835E52BA4D26829AB7359A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:to="loc_us-gaap_InterestIncomeOther_094F72CAB6835E52BA4D26829AB7359A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_25C9575C14B25A8F9ED60D3B72C06AC7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_25C9575C14B25A8F9ED60D3B72C06AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_517FBB87479A569F82F4C63FBD90A1E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_517FBB87479A569F82F4C63FBD90A1E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9498C9781DA653FA8FBB4C439E9DF64F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9498C9781DA653FA8FBB4C439E9DF64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22B99C2A59415D6E999198DCDFCEBA18" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_22B99C2A59415D6E999198DCDFCEBA18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_207C0599653D549CB52001C5CCA70CCC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_NetIncomeLoss_207C0599653D549CB52001C5CCA70CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8CB7284A6BBA5BBFB900C02008A77EB6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_EarningsPerShareBasic_8CB7284A6BBA5BBFB900C02008A77EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_12A0394B75185897BE208F2CC6E9EC2C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_EarningsPerShareDiluted_12A0394B75185897BE208F2CC6E9EC2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20C9BF6963015616BDE14521997E2867" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20C9BF6963015616BDE14521997E2867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3102336355D955018A625AFA58971698" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3102336355D955018A625AFA58971698" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:to="loc_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:to="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E572807B86885864AFEAF34429C0D423" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:to="loc_us-gaap_CommonStockMember_E572807B86885864AFEAF34429C0D423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6C12A09216155809BB5AA9441CC610D0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6C12A09216155809BB5AA9441CC610D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34EF1A3742FB52E19A921971E66F2486" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34EF1A3742FB52E19A921971E66F2486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A9C2BB01D2DD5B59B605F9D4CD94EF10" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:to="loc_us-gaap_RetainedEarningsMember_A9C2BB01D2DD5B59B605F9D4CD94EF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:to="loc_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:to="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_17B80AD21F5058F091B8309975BD7F1F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_17B80AD21F5058F091B8309975BD7F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B26D1620F2725248B3AF4A99E988CB8D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B26D1620F2725248B3AF4A99E988CB8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_44AF6032CA7C5EEABF2C00D9442E067C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_44AF6032CA7C5EEABF2C00D9442E067C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40EF58C361BD55B893BC7742221EEFFF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40EF58C361BD55B893BC7742221EEFFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_56B7ECA2FEDF52709D291D21A039B8D4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_56B7ECA2FEDF52709D291D21A039B8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0CC7CB46CA8A5695988E97D0B83C6DB8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_NetIncomeLoss_0CC7CB46CA8A5695988E97D0B83C6DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12748503AD5A5FED9BF944F835C794DC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12748503AD5A5FED9BF944F835C794DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_366BC68F9CB553C086F6D199301D97E6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_366BC68F9CB553C086F6D199301D97E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_73A4AFCA1F785C789D84192851CFC48F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_73A4AFCA1F785C789D84192851CFC48F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5B0DD687B355550FB12035B2EA980EA1" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5B0DD687B355550FB12035B2EA980EA1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68296E3D267F697320D6B8C7A038385F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68296E3D267F697320D6B8C7A038385F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_E31F1D02E99B5F279E654FB968F68F51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:to="loc_us-gaap_InventoriesMember_E31F1D02E99B5F279E654FB968F68F51" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:to="loc_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_FF2ADDDC08DB517BA70A13BABDE1FBC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryRawMaterials_FF2ADDDC08DB517BA70A13BABDE1FBC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_1E4759A55FE451C292FE238E27772EDD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryWorkInProcess_1E4759A55FE451C292FE238E27772EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_00CF850B4C885E95B2CF31EBA80743AB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryFinishedGoods_00CF850B4C885E95B2CF31EBA80743AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_FA558EB5767A5577B10D77637A9D265E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryGross_FA558EB5767A5577B10D77637A9D265E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_22404E7B4C1C505EA5AF87DC873E671C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryWriteDown_22404E7B4C1C505EA5AF87DC873E671C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Leases" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_60B7A143F86B610A7E6E0F9CE28AC911" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:to="loc_srt_StatementGeographicalAxis_60B7A143F86B610A7E6E0F9CE28AC911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F48D83FD2B16D07A5B420F9CE28B8DAE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_60B7A143F86B610A7E6E0F9CE28AC911" xlink:to="loc_srt_SegmentGeographicalDomain_F48D83FD2B16D07A5B420F9CE28B8DAE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F48D83FD2B16D07A5B420F9CE28B8DAE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_60B7A143F86B610A7E6E0F9CE28AC911" xlink:to="loc_srt_SegmentGeographicalDomain_F48D83FD2B16D07A5B420F9CE28B8DAE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_9B6BB097CC56DBC01CAF0F9CE28B85BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_F48D83FD2B16D07A5B420F9CE28B8DAE" xlink:to="loc_exel_AlamedaCaliforniaMember_9B6BB097CC56DBC01CAF0F9CE28B85BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_869A58118CB420F51D490F9CE28BD682" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_869A58118CB420F51D490F9CE28BD682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_D7337E83BE05CD658EF70F9CE28C98EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_D7337E83BE05CD658EF70F9CE28C98EC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_157400389E6270DA4E860F9CE28C3881" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_157400389E6270DA4E860F9CE28C3881" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_58EC907D18B3594A17850F9CE28C1C5A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_58EC907D18B3594A17850F9CE28C1C5A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_840182D5B9E41A177D4B0F9CE28C07C4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_840182D5B9E41A177D4B0F9CE28C07C4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_A0397EEC0BBFC405951A0FE48C10F07E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_A0397EEC0BBFC405951A0FE48C10F07E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6511417704708081FCFB0F9CE28CC37C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6511417704708081FCFB0F9CE28CC37C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_31A0098696CBC54926B90F9CE28D732F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_31A0098696CBC54926B90F9CE28D732F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/LeasesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_0DF900E6C3E05B52B414EC9FE334880C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:to="loc_us-gaap_StockCompensationPlanMember_0DF900E6C3E05B52B414EC9FE334880C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19FC374A2ECB5065B5427938D2092576" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19FC374A2ECB5065B5427938D2092576" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="exel-20190927.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:type="locator" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_60873CF3C9406CFE40D8F047DF66E99D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:to="loc_srt_ProductOrServiceAxis_60873CF3C9406CFE40D8F047DF66E99D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_60873CF3C9406CFE40D8F047DF66E99D" xlink:to="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_60873CF3C9406CFE40D8F047DF66E99D" xlink:to="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:to="loc_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:to="loc_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_B7C8CA97568B5A2AA0485F5C989C460B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_B7C8CA97568B5A2AA0485F5C989C460B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_FA6D83194E17502998A59CE891201747" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_FA6D83194E17502998A59CE891201747" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_595960FA46955FFD9DA19F31C1BC41C1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_us-gaap_ConstructionInProgressMember_595960FA46955FFD9DA19F31C1BC41C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_57544161E0BB58CC97E5140A97003D1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_57544161E0BB58CC97E5140A97003D1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8E93F2D3893952A7A035AC78B1D7F650" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8E93F2D3893952A7A035AC78B1D7F650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C3B1A4AC0A3D5B128DD6549054A67D38" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_C3B1A4AC0A3D5B128DD6549054A67D38" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:to="loc_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_249B7CF35D4C5274AC283F6A1685D64E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_560F9DC2B79B5A11B04E9E30FC143BC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_249B7CF35D4C5274AC283F6A1685D64E" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_560F9DC2B79B5A11B04E9E30FC143BC6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_560F9DC2B79B5A11B04E9E30FC143BC6" xlink:to="loc_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:to="loc_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:to="loc_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:to="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:to="loc_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:to="loc_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7095DDFE493257BB90C00D27397D6C89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_249B7CF35D4C5274AC283F6A1685D64E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7095DDFE493257BB90C00D27397D6C89" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_22C8AE1BDF0C9126B9BEB3E452376F64" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22C8AE1BDF0C9126B9BEB3E452376F64" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2664187DF8E52F0D8B7EB3E452337322" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:to="loc_srt_ProductOrServiceAxis_2664187DF8E52F0D8B7EB3E452337322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2664187DF8E52F0D8B7EB3E452337322" xlink:to="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2664187DF8E52F0D8B7EB3E452337322" xlink:to="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E" xlink:to="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:to="loc_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_SalesDiscountsAndAllowancesMember" xlink:label="loc_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:to="loc_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E" xlink:to="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:to="loc_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ResearchandDevelopmentMember" xlink:label="loc_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:to="loc_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OtherCollaborationMember" xlink:label="loc_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:to="loc_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_E0F83B51F528E8E6DF0CB3E452356380" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:to="loc_srt_MajorCustomersAxis_E0F83B51F528E8E6DF0CB3E452356380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1A4F72B92C8B596AB1CCB3E45235314C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_E0F83B51F528E8E6DF0CB3E452356380" xlink:to="loc_srt_NameOfMajorCustomerDomain_1A4F72B92C8B596AB1CCB3E45235314C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1A4F72B92C8B596AB1CCB3E45235314C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_E0F83B51F528E8E6DF0CB3E452356380" xlink:to="loc_srt_NameOfMajorCustomerDomain_1A4F72B92C8B596AB1CCB3E45235314C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_CC5A586814234D4D1DE6B3E45236B02E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_1A4F72B92C8B596AB1CCB3E45235314C" xlink:to="loc_exel_GlaxoSmithKlineMember_CC5A586814234D4D1DE6B3E45236B02E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4D18C7DC3804FC8DA8C1B3E4523641CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4D18C7DC3804FC8DA8C1B3E4523641CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DFB85815D5E9088272DB3E452369CCE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4D18C7DC3804FC8DA8C1B3E4523641CA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DFB85815D5E9088272DB3E452369CCE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DFB85815D5E9088272DB3E452369CCE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4D18C7DC3804FC8DA8C1B3E4523641CA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DFB85815D5E9088272DB3E452369CCE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_22758885828F8E547F19B3E452365F4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DFB85815D5E9088272DB3E452369CCE" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_22758885828F8E547F19B3E452365F4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6DB574CFAE5D98F47EC5B3E452377804" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22C8AE1BDF0C9126B9BEB3E452376F64" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6DB574CFAE5D98F47EC5B3E452377804" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_B8F641AB694A93C1ABACB3E45237625E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22C8AE1BDF0C9126B9BEB3E452376F64" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_B8F641AB694A93C1ABACB3E45237625E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_42CB2B3299855694AC9B5C8AB20C8436" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:to="loc_srt_StatementGeographicalAxis_42CB2B3299855694AC9B5C8AB20C8436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_42CB2B3299855694AC9B5C8AB20C8436" xlink:to="loc_srt_SegmentGeographicalDomain_CF97174415722D938C5C27372F5946AD_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_42CB2B3299855694AC9B5C8AB20C8436" xlink:to="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_07AA191EA9615F098E24593D1C3AB8DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:to="loc_country_US_07AA191EA9615F098E24593D1C3AB8DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_4E9616F2DF1E5054AA66157C2ED97775" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:to="loc_srt_EuropeMember_4E9616F2DF1E5054AA66157C2ED97775" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_E6E81D1DE5B05ADBA6665FDF7EBD7119" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:to="loc_country_JP_E6E81D1DE5B05ADBA6665FDF7EBD7119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93E3C6C8BC8E55FC89C344C9B1C00F6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93E3C6C8BC8E55FC89C344C9B1C00F6E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3CE3178F66B5CC40074CF047DF4CB3EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:to="loc_srt_MajorCustomersAxis_3CE3178F66B5CC40074CF047DF4CB3EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_3CE3178F66B5CC40074CF047DF4CB3EE" xlink:to="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_3CE3178F66B5CC40074CF047DF4CB3EE" xlink:to="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ASDMember" xlink:label="loc_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84CF510273C66A81F7EFF047DF507C9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84CF510273C66A81F7EFF047DF507C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_939FA35144BD5AE1A079D97B825C984A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_939FA35144BD5AE1A079D97B825C984A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BC2796C31D7A56AAA48D85B1A6A51299" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BC2796C31D7A56AAA48D85B1A6A51299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D0E5E059660158A28B1964AE3BE0BB44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D0E5E059660158A28B1964AE3BE0BB44" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:to="loc_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_PerformanceSharesSecondProductApprovalMember" xlink:label="loc_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:to="loc_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:to="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:to="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:to="loc_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:to="loc_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_NotProbableMember" xlink:label="loc_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:to="loc_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_969AF404CB7FB05E5C8FB3E4516BCB4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_969AF404CB7FB05E5C8FB3E4516BCB4C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_47B4B5F59D4EDFD7108DB3E4516B109E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_969AF404CB7FB05E5C8FB3E4516BCB4C" xlink:to="loc_us-gaap_AwardTypeAxis_47B4B5F59D4EDFD7108DB3E4516B109E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9841BE6D3FB6498442DB3E4516C7EE8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_47B4B5F59D4EDFD7108DB3E4516B109E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9841BE6D3FB6498442DB3E4516C7EE8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9841BE6D3FB6498442DB3E4516C7EE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_47B4B5F59D4EDFD7108DB3E4516B109E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9841BE6D3FB6498442DB3E4516C7EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_67447978E2462F199903B3E4516C8EE8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9841BE6D3FB6498442DB3E4516C7EE8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_67447978E2462F199903B3E4516C8EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_455D17C804750BE791C0B3E4516D4E1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_455D17C804750BE791C0B3E4516D4E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5DF1F6F391EB23374E10B3E4516D8DB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5DF1F6F391EB23374E10B3E4516D8DB8" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6C6D0665960507C93DE10E092249340" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6C6D0665960507C93DE10E092249340" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_72684AA298045B2CA28D4E0D6AC48ECC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6C6D0665960507C93DE10E092249340" xlink:to="loc_us-gaap_AwardTypeAxis_72684AA298045B2CA28D4E0D6AC48ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_72684AA298045B2CA28D4E0D6AC48ECC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0F700B05A1F7B6A7E218E2326574BCD4_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3CE879DFA7735A3AAB3BB7330DE7EC47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_72684AA298045B2CA28D4E0D6AC48ECC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3CE879DFA7735A3AAB3BB7330DE7EC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_99E37DB45F645D98B833853F14AF5883" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3CE879DFA7735A3AAB3BB7330DE7EC47" xlink:to="loc_us-gaap_EmployeeStockOptionMember_99E37DB45F645D98B833853F14AF5883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_61D4FA5477005B77B77F0759FD6054CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3CE879DFA7735A3AAB3BB7330DE7EC47" xlink:to="loc_us-gaap_EmployeeStockMember_61D4FA5477005B77B77F0759FD6054CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E1D29ECD7780533D9398EB87484D523C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E1D29ECD7780533D9398EB87484D523C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E624A2FDC2845BA98A140BBCF67BED80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E624A2FDC2845BA98A140BBCF67BED80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03E958890B895C8EAED3AEE121823CCA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03E958890B895C8EAED3AEE121823CCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2165294CF2725B5BBEB46406B13895B3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2165294CF2725B5BBEB46406B13895B3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A6931B82AE5756A996736000CA8D69F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90AD70B222545824A2FA0E44491675E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A6931B82AE5756A996736000CA8D69F0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90AD70B222545824A2FA0E44491675E5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A0E25592FE865C71BB620C2C26C03823" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90AD70B222545824A2FA0E44491675E5" xlink:to="loc_us-gaap_AwardTypeAxis_A0E25592FE865C71BB620C2C26C03823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_A0E25592FE865C71BB620C2C26C03823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1B00460E916DAB41BC9AE232655ADE65_EC9C3A91FEE758C48CE3548A6C8DC14A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66B74CD9AA465AE5B419EF2D00B81512" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_A0E25592FE865C71BB620C2C26C03823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66B74CD9AA465AE5B419EF2D00B81512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1927665C74FC5836B4E644A933DE473D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66B74CD9AA465AE5B419EF2D00B81512" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1927665C74FC5836B4E644A933DE473D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_0055D20C1BB056B3AFED0A7BE85C9310" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66B74CD9AA465AE5B419EF2D00B81512" xlink:to="loc_us-gaap_EmployeeStockMember_0055D20C1BB056B3AFED0A7BE85C9310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5664F50C39CE5740A5AB286CC447A2A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A6931B82AE5756A996736000CA8D69F0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5664F50C39CE5740A5AB286CC447A2A3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:to="loc_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LeaseArrangementsAxis" xlink:label="loc_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:to="loc_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LeaseArrangementsDomain" xlink:label="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:to="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1_default" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LeaseArrangementsDomain" xlink:label="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:to="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_BuiltToSuitLeaseMember" xlink:label="loc_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:to="loc_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:to="loc_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:to="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:to="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:to="loc_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>exel-20190927_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_32AC46DC1152E599946FE23265ADE064_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2D668A08568E5675A28B2DF57291D1AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2D668A08568E5675A28B2DF57291D1AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2D668A08568E5675A28B2DF57291D1AF" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2D668A08568E5675A28B2DF57291D1AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_020D0BBC452A5464A041A771D1E218E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_988836B9D64DDA26590CE23265AD3F93_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_020D0BBC452A5464A041A771D1E218E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_020D0BBC452A5464A041A771D1E218E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_020D0BBC452A5464A041A771D1E218E6" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_020D0BBC452A5464A041A771D1E218E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9000CBDD58C35E25B056F8363EB95C30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_D7D46A2F53B020C1C401E23265AECE17_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9000CBDD58C35E25B056F8363EB95C30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9000CBDD58C35E25B056F8363EB95C30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9000CBDD58C35E25B056F8363EB95C30" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9000CBDD58C35E25B056F8363EB95C30" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82022B52F5F150B69D4C75DF91CFCF28" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3F15A4C2D6589A890A26E23265AE0C65_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82022B52F5F150B69D4C75DF91CFCF28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82022B52F5F150B69D4C75DF91CFCF28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82022B52F5F150B69D4C75DF91CFCF28" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82022B52F5F150B69D4C75DF91CFCF28" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_09A7E738C2652333EBABE23265CA2D73_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_4383E63833B754649C7BE4DF0A07507A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4383E63833B754649C7BE4DF0A07507A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4383E63833B754649C7BE4DF0A07507A" xlink:to="lab_us-gaap_EarningsPerShareAbstract_4383E63833B754649C7BE4DF0A07507A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2BFC0469EF5C56629641E7ED3199F370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computation of Basic and Diluted Net Income Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1AE609A7B4D599B11B04E23265CA4202_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2BFC0469EF5C56629641E7ED3199F370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2BFC0469EF5C56629641E7ED3199F370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2BFC0469EF5C56629641E7ED3199F370" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2BFC0469EF5C56629641E7ED3199F370" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B0F594E9CA5C5AB98A557CB83A9FA23E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B187B13008E3FD8C4B92E23265CA72AB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B0F594E9CA5C5AB98A557CB83A9FA23E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B0F594E9CA5C5AB98A557CB83A9FA23E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B0F594E9CA5C5AB98A557CB83A9FA23E" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B0F594E9CA5C5AB98A557CB83A9FA23E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_91BDE45DD2430310D5B20F9CE26D7B45_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_91BDE45DD2430310D5B20F9CE26D7B45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_91BDE45DD2430310D5B20F9CE26D7B45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_91BDE45DD2430310D5B20F9CE26D7B45" xlink:to="lab_us-gaap_SubsequentEventsAbstract_91BDE45DD2430310D5B20F9CE26D7B45" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:to="lab_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691" xlink:to="lab_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691" xlink:type="arc" />
    <link:label id="lab_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D_label_en-US" xlink:label="lab_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:label id="lab_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Axis]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LeaseArrangementsAxis" xlink:label="loc_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:to="lab_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:type="arc" />
    <link:label id="lab_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1_terseLabel_en-US" xlink:label="lab_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1_label_en-US" xlink:label="lab_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangements [Domain]</link:label>
    <link:label id="lab_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1_documentation_en-US" xlink:label="lab_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Lease Arrangements [Axis]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LeaseArrangementsDomain" xlink:label="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:to="lab_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:type="arc" />
    <link:label id="lab_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C_terseLabel_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Built-To-Suit Lease</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C_label_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:label id="lab_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C_documentation_en-US" xlink:label="lab_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Built-To-Suit Lease [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_BuiltToSuitLeaseMember" xlink:label="loc_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:to="lab_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:to="lab_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:to="lab_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:type="arc" />
    <link:label id="lab_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189_terseLabel_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alameda, California</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189_label_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:label id="lab_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189_documentation_en-US" xlink:label="lab_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alameda, California [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:to="lab_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="lab_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of lease property (in square feet)</link:label>
    <link:label id="lab_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573_label_en-US" xlink:label="lab_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573" xlink:to="lab_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated monthly base rent under Build-to-Suite Leases</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Monthly base rent, lease not yet commenced, annual percentage increase</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:to="lab_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of options to extend the Lease</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:to="lab_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease option to extend period</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option to terminate lease (after period)</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option To Terminate After Period</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:to="lab_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, expansion (in square feet)</link:label>
    <link:label id="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18_label_en-US" xlink:label="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Additional Area Of Real Estate Property</link:label>
    <link:label id="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18_documentation_en-US" xlink:label="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Additional Area Of Real Estate Property</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:to="lab_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_4D0B24537DD8F456ACEA12B8E4815D1A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_4D0B24537DD8F456ACEA12B8E4815D1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4D0B24537DD8F456ACEA12B8E4815D1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4D0B24537DD8F456ACEA12B8E4815D1A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_4D0B24537DD8F456ACEA12B8E4815D1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_Depreciation_C1D960ED24303E08E8C912B8E481578D_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation_C1D960ED24303E08E8C912B8E481578D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation expense</link:label>
    <link:label id="lab_us-gaap_Depreciation_C1D960ED24303E08E8C912B8E481578D_label_en-US" xlink:label="lab_us-gaap_Depreciation_C1D960ED24303E08E8C912B8E481578D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_C1D960ED24303E08E8C912B8E481578D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation_C1D960ED24303E08E8C912B8E481578D" xlink:to="lab_us-gaap_Depreciation_C1D960ED24303E08E8C912B8E481578D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_C896F222A6C050E34E3DE31EA0AD06D9_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_38AD0862840C5C3FBC23085A5D79775A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_38AD0862840C5C3FBC23085A5D79775A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_38AD0862840C5C3FBC23085A5D79775A" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_38AD0862840C5C3FBC23085A5D79775A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_BC95AF73ADB4B76A0E7BE31EA0AD73BE_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:to="lab_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_021E10D3DE46AB848EC4E31EA0ADB37E_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_75223321FA17AEA24E38E31EA0AD8D3D_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember_E31F1D02E99B5F279E654FB968F68F51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in Inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_403A904ABB913EE84C93E31EA0AE7D21_label_en-US" xlink:label="lab_us-gaap_InventoriesMember_E31F1D02E99B5F279E654FB968F68F51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_E31F1D02E99B5F279E654FB968F68F51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember_E31F1D02E99B5F279E654FB968F68F51" xlink:to="lab_us-gaap_InventoriesMember_E31F1D02E99B5F279E654FB968F68F51" xlink:type="arc" />
    <link:label id="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion included in Other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_4EA81FB03357B555A276E31EA0AEBADE_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:to="lab_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_805063A7B3FB11AE9A71E31EA0AE0495_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="lab_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_FF2ADDDC08DB517BA70A13BABDE1FBC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_EECB6DFE556F2F88DF80E31EA0AE85DE_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials_FF2ADDDC08DB517BA70A13BABDE1FBC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_FF2ADDDC08DB517BA70A13BABDE1FBC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials_FF2ADDDC08DB517BA70A13BABDE1FBC7" xlink:to="lab_us-gaap_InventoryRawMaterials_FF2ADDDC08DB517BA70A13BABDE1FBC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_1E4759A55FE451C292FE238E27772EDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_D6DEF1D584AFEDE28611E31EA0AFBB76_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess_1E4759A55FE451C292FE238E27772EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_1E4759A55FE451C292FE238E27772EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess_1E4759A55FE451C292FE238E27772EDD" xlink:to="lab_us-gaap_InventoryWorkInProcess_1E4759A55FE451C292FE238E27772EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_00CF850B4C885E95B2CF31EBA80743AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_E99D218346A6B5E73C69E31EA0B408E9_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods_00CF850B4C885E95B2CF31EBA80743AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_00CF850B4C885E95B2CF31EBA80743AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods_00CF850B4C885E95B2CF31EBA80743AB" xlink:to="lab_us-gaap_InventoryFinishedGoods_00CF850B4C885E95B2CF31EBA80743AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross_FA558EB5767A5577B10D77637A9D265E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_15CDE5C406D489BCFA04E31EA0B4348E_label_en-US" xlink:label="lab_us-gaap_InventoryGross_FA558EB5767A5577B10D77637A9D265E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_FA558EB5767A5577B10D77637A9D265E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross_FA558EB5767A5577B10D77637A9D265E" xlink:to="lab_us-gaap_InventoryGross_FA558EB5767A5577B10D77637A9D265E" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_22404E7B4C1C505EA5AF87DC873E671C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Write-downs on inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_59C2F60A3D16A5087B94E31EA0B47D25_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown_22404E7B4C1C505EA5AF87DC873E671C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_22404E7B4C1C505EA5AF87DC873E671C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown_22404E7B4C1C505EA5AF87DC873E671C" xlink:to="lab_us-gaap_InventoryWriteDown_22404E7B4C1C505EA5AF87DC873E671C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9D1C9C35C1E10D9AA9A203A4DA363E1B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9D1C9C35C1E10D9AA9A203A4DA363E1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9D1C9C35C1E10D9AA9A203A4DA363E1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9D1C9C35C1E10D9AA9A203A4DA363E1B" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9D1C9C35C1E10D9AA9A203A4DA363E1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:to="lab_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061" xlink:to="lab_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F" xlink:to="lab_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F" xlink:type="arc" />
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs, achieved before December 31, 2020</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68_label_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020 [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68_documentation_en-US" xlink:label="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Shares, Achieved Before December 31, 2020 [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:to="lab_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:type="arc" />
    <link:label id="lab_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40_terseLabel_en-US" xlink:label="lab_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PSUs, second product approval</link:label>
    <link:label id="lab_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40_label_en-US" xlink:label="lab_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares, Second Product Approval [Member]</link:label>
    <link:label id="lab_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40_documentation_en-US" xlink:label="lab_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Shares, Second Product Approval [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_PerformanceSharesSecondProductApprovalMember" xlink:label="loc_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:to="lab_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:type="arc" />
    <link:label id="lab_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9_terseLabel_en-US" xlink:label="lab_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9_label_en-US" xlink:label="lab_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:label id="lab_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9_documentation_en-US" xlink:label="lab_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Status [Axis]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:to="lab_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:type="arc" />
    <link:label id="lab_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383_terseLabel_en-US" xlink:label="lab_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383_label_en-US" xlink:label="lab_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Status [Domain]</link:label>
    <link:label id="lab_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383_documentation_en-US" xlink:label="lab_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Status [Axis]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:to="lab_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:type="arc" />
    <link:label id="lab_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789_terseLabel_en-US" xlink:label="lab_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Achieved</link:label>
    <link:label id="lab_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789_label_en-US" xlink:label="lab_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Achieved [Member]</link:label>
    <link:label id="lab_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789_documentation_en-US" xlink:label="lab_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Achieved [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:to="lab_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:type="arc" />
    <link:label id="lab_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E_terseLabel_en-US" xlink:label="lab_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probable</link:label>
    <link:label id="lab_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E_label_en-US" xlink:label="lab_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Probable [Member]</link:label>
    <link:label id="lab_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E_documentation_en-US" xlink:label="lab_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Probable [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:to="lab_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:type="arc" />
    <link:label id="lab_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF_terseLabel_en-US" xlink:label="lab_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Probable</link:label>
    <link:label id="lab_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF_label_en-US" xlink:label="lab_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:label id="lab_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF_documentation_en-US" xlink:label="lab_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Not Probable [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_NotProbableMember" xlink:label="loc_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:to="lab_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average cost recognition period</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs awarded (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential to vest, percentage</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential to vest (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue related performance targets, shares vested and released (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_40BDF72CD47C7FB564E5E2326612B40D_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_7E171786176D50F1AA56B9D1F22D6BE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7E171786176D50F1AA56B9D1F22D6BE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7E171786176D50F1AA56B9D1F22D6BE4" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_7E171786176D50F1AA56B9D1F22D6BE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9102EE91BAF6CA560C79E2326612F106_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B2AAB3AF47BA52338EE43E372B6A6754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9102EE91BAF6CA560C79E2326612F106_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B2AAB3AF47BA52338EE43E372B6A6754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B2AAB3AF47BA52338EE43E372B6A6754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B2AAB3AF47BA52338EE43E372B6A6754" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B2AAB3AF47BA52338EE43E372B6A6754" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_D87118028EB57F878DCDE23266128D58_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0E234CD9403F5BB787C5C6BE1414F9C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_D87118028EB57F878DCDE23266128D58_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_0E234CD9403F5BB787C5C6BE1414F9C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0E234CD9403F5BB787C5C6BE1414F9C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E234CD9403F5BB787C5C6BE1414F9C0" xlink:to="lab_us-gaap_StockholdersEquityAbstract_0E234CD9403F5BB787C5C6BE1414F9C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_0ED37BB16C4F19BC01A6E2326612C6E0_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C328381644CE538AA84E71E36B72ACF8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_0653A2C68F8DF65C213CE23266135B18_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C328381644CE538AA84E71E36B72ACF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C328381644CE538AA84E71E36B72ACF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C328381644CE538AA84E71E36B72ACF8" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C328381644CE538AA84E71E36B72ACF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_11F13744F1095CEAACFA13E1A8428CDB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_CDC0BA873ED8B616E5F2E232661300BB_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_11F13744F1095CEAACFA13E1A8428CDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_11F13744F1095CEAACFA13E1A8428CDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_11F13744F1095CEAACFA13E1A8428CDB" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_11F13744F1095CEAACFA13E1A8428CDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0DE59E2663C05F8292549333395B825F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_0331488FD8EC145C16B8E23266134F58_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_0DE59E2663C05F8292549333395B825F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0DE59E2663C05F8292549333395B825F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_0DE59E2663C05F8292549333395B825F" xlink:to="lab_us-gaap_PreferredStockSharesIssued_0DE59E2663C05F8292549333395B825F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_21C471FF768B4F381CD0E23266143536_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_A3FB92DD0DC358F98548AC897FC8FF87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_72FF99CD2E7F8B8EF35AE2326614AFC4_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_A3FB92DD0DC358F98548AC897FC8FF87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_A3FB92DD0DC358F98548AC897FC8FF87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_A3FB92DD0DC358F98548AC897FC8FF87" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_A3FB92DD0DC358F98548AC897FC8FF87" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A469C66C889253A8A00062DB0AC9FF04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_E93D1997DD83A614030CE23266140F24_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_A469C66C889253A8A00062DB0AC9FF04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A469C66C889253A8A00062DB0AC9FF04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_A469C66C889253A8A00062DB0AC9FF04" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_A469C66C889253A8A00062DB0AC9FF04" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_2C0F4FF75C7B54D6A120738CD1B32848" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_9880951E6B2C9EE343C5E23266146B1E_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_2C0F4FF75C7B54D6A120738CD1B32848" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2C0F4FF75C7B54D6A120738CD1B32848" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_2C0F4FF75C7B54D6A120738CD1B32848" xlink:to="lab_us-gaap_CommonStockSharesIssued_2C0F4FF75C7B54D6A120738CD1B32848" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A7D08F8F2E6140799CF1E23266147D0D_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B1D152A8EFCC55E6ACC1142C7670BB87" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A7D08F8F2E6140799CF1E23266147D0D_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B1D152A8EFCC55E6ACC1142C7670BB87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B1D152A8EFCC55E6ACC1142C7670BB87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_B1D152A8EFCC55E6ACC1142C7670BB87" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_B1D152A8EFCC55E6ACC1142C7670BB87" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_03421EAE34F1E318B6F8B8C7A0345C3C_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract_03421EAE34F1E318B6F8B8C7A0345C3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_03421EAE34F1E318B6F8B8C7A0345C3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_03421EAE34F1E318B6F8B8C7A0345C3C" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract_03421EAE34F1E318B6F8B8C7A0345C3C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:to="lab_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36" xlink:to="lab_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169" xlink:to="lab_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Treasury and government sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974" xlink:type="arc" />
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C" xlink:to="lab_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68296E3D267F697320D6B8C7A038385F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68296E3D267F697320D6B8C7A038385F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total investments available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68296E3D267F697320D6B8C7A038385F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68296E3D267F697320D6B8C7A038385F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68296E3D267F697320D6B8C7A038385F" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D" xlink:to="lab_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D" xlink:type="arc" />
    <link:label id="lab_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32_label_en-US" xlink:label="lab_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="lab_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_5DC8E02636B34F6735F2AF71E8806450_terseLabel_en-US" xlink:label="lab_dei_DocumentType_5DC8E02636B34F6735F2AF71E8806450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_5DC8E02636B34F6735F2AF71E8806450_label_en-US" xlink:label="lab_dei_DocumentType_5DC8E02636B34F6735F2AF71E8806450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5DC8E02636B34F6735F2AF71E8806450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_5DC8E02636B34F6735F2AF71E8806450" xlink:to="lab_dei_DocumentType_5DC8E02636B34F6735F2AF71E8806450" xlink:type="arc" />
    <link:label id="lab_dei_DocumentQuarterlyReport_FD4ED21992AB1D44FB6CAF71E8849672_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_FD4ED21992AB1D44FB6CAF71E8849672" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_FD4ED21992AB1D44FB6CAF71E8849672_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport_FD4ED21992AB1D44FB6CAF71E8849672" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_FD4ED21992AB1D44FB6CAF71E8849672" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport_FD4ED21992AB1D44FB6CAF71E8849672" xlink:to="lab_dei_DocumentQuarterlyReport_FD4ED21992AB1D44FB6CAF71E8849672" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_C29B7B76B518DCFA74C3AF71E880E707_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_C29B7B76B518DCFA74C3AF71E880E707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_C29B7B76B518DCFA74C3AF71E880E707_label_en-US" xlink:label="lab_dei_AmendmentFlag_C29B7B76B518DCFA74C3AF71E880E707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C29B7B76B518DCFA74C3AF71E880E707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_C29B7B76B518DCFA74C3AF71E880E707" xlink:to="lab_dei_AmendmentFlag_C29B7B76B518DCFA74C3AF71E880E707" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_EC5E4FDD4B3AAA31ACA7AF71E88101A3_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_EC5E4FDD4B3AAA31ACA7AF71E88101A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_EC5E4FDD4B3AAA31ACA7AF71E88101A3_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_EC5E4FDD4B3AAA31ACA7AF71E88101A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_EC5E4FDD4B3AAA31ACA7AF71E88101A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_EC5E4FDD4B3AAA31ACA7AF71E88101A3" xlink:to="lab_dei_DocumentPeriodEndDate_EC5E4FDD4B3AAA31ACA7AF71E88101A3" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_C15BC10A2C80A9A4C623AF71E881C5FC_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C15BC10A2C80A9A4C623AF71E881C5FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_C15BC10A2C80A9A4C623AF71E881C5FC_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_C15BC10A2C80A9A4C623AF71E881C5FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C15BC10A2C80A9A4C623AF71E881C5FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_C15BC10A2C80A9A4C623AF71E881C5FC" xlink:to="lab_dei_DocumentFiscalYearFocus_C15BC10A2C80A9A4C623AF71E881C5FC" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_FFE63DA37403154CC443AF71E881E54E_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_FFE63DA37403154CC443AF71E881E54E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_FFE63DA37403154CC443AF71E881E54E_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_FFE63DA37403154CC443AF71E881E54E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_FFE63DA37403154CC443AF71E881E54E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_FFE63DA37403154CC443AF71E881E54E" xlink:to="lab_dei_DocumentFiscalPeriodFocus_FFE63DA37403154CC443AF71E881E54E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_76AF309E213D36D61597AF71E8851594_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_76AF309E213D36D61597AF71E8851594" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_76AF309E213D36D61597AF71E8851594_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_76AF309E213D36D61597AF71E8851594" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_76AF309E213D36D61597AF71E8851594" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_76AF309E213D36D61597AF71E8851594" xlink:to="lab_dei_DocumentTransitionReport_76AF309E213D36D61597AF71E8851594" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_98081B18F47B63B924DDAF71E8839D3B_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_98081B18F47B63B924DDAF71E8839D3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_98081B18F47B63B924DDAF71E8839D3B_label_en-US" xlink:label="lab_dei_EntityFileNumber_98081B18F47B63B924DDAF71E8839D3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_98081B18F47B63B924DDAF71E8839D3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_98081B18F47B63B924DDAF71E8839D3B" xlink:to="lab_dei_EntityFileNumber_98081B18F47B63B924DDAF71E8839D3B" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_01A58FA5892AAF53B80EAF71E881FB96_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_01A58FA5892AAF53B80EAF71E881FB96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_01A58FA5892AAF53B80EAF71E881FB96_label_en-US" xlink:label="lab_dei_EntityRegistrantName_01A58FA5892AAF53B80EAF71E881FB96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_01A58FA5892AAF53B80EAF71E881FB96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_01A58FA5892AAF53B80EAF71E881FB96" xlink:to="lab_dei_EntityRegistrantName_01A58FA5892AAF53B80EAF71E881FB96" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_88306E8E0320E0A62CB5AF71E883F561_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_88306E8E0320E0A62CB5AF71E883F561" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_88306E8E0320E0A62CB5AF71E883F561_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_88306E8E0320E0A62CB5AF71E883F561" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_88306E8E0320E0A62CB5AF71E883F561" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_88306E8E0320E0A62CB5AF71E883F561" xlink:to="lab_dei_EntityIncorporationStateCountryCode_88306E8E0320E0A62CB5AF71E883F561" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_246AEC88269C44A29838AF71E883D2CA_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_246AEC88269C44A29838AF71E883D2CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_246AEC88269C44A29838AF71E883D2CA_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_246AEC88269C44A29838AF71E883D2CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_246AEC88269C44A29838AF71E883D2CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_246AEC88269C44A29838AF71E883D2CA" xlink:to="lab_dei_EntityTaxIdentificationNumber_246AEC88269C44A29838AF71E883D2CA" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_BBCA38BEA0624821461AAF71E8819E48_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_BBCA38BEA0624821461AAF71E8819E48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_BBCA38BEA0624821461AAF71E8819E48_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_BBCA38BEA0624821461AAF71E8819E48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_BBCA38BEA0624821461AAF71E8819E48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_BBCA38BEA0624821461AAF71E8819E48" xlink:to="lab_dei_EntityCentralIndexKey_BBCA38BEA0624821461AAF71E8819E48" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_68D42DFB188F4C6F011EAF71E882B071_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_68D42DFB188F4C6F011EAF71E882B071" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_68D42DFB188F4C6F011EAF71E882B071_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_68D42DFB188F4C6F011EAF71E882B071" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_68D42DFB188F4C6F011EAF71E882B071" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_68D42DFB188F4C6F011EAF71E882B071" xlink:to="lab_dei_CurrentFiscalYearEndDate_68D42DFB188F4C6F011EAF71E882B071" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_4F201816F4B5FA961842AF71E884EBF4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_4F201816F4B5FA961842AF71E884EBF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_4F201816F4B5FA961842AF71E884EBF4_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_4F201816F4B5FA961842AF71E884EBF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_4F201816F4B5FA961842AF71E884EBF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_4F201816F4B5FA961842AF71E884EBF4" xlink:to="lab_dei_EntityAddressAddressLine1_4F201816F4B5FA961842AF71E884EBF4" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_0ED609B852194FEB3CD3AF71E8841210_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_0ED609B852194FEB3CD3AF71E8841210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_0ED609B852194FEB3CD3AF71E8841210_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_0ED609B852194FEB3CD3AF71E8841210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_0ED609B852194FEB3CD3AF71E8841210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_0ED609B852194FEB3CD3AF71E8841210" xlink:to="lab_dei_EntityAddressCityOrTown_0ED609B852194FEB3CD3AF71E8841210" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_9CFC1542CAA8E2CEEF39AF71E884B572_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_9CFC1542CAA8E2CEEF39AF71E884B572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_9CFC1542CAA8E2CEEF39AF71E884B572_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_9CFC1542CAA8E2CEEF39AF71E884B572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_9CFC1542CAA8E2CEEF39AF71E884B572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_9CFC1542CAA8E2CEEF39AF71E884B572" xlink:to="lab_dei_EntityAddressStateOrProvince_9CFC1542CAA8E2CEEF39AF71E884B572" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_D4CB461466DF23248B59AF71E884A44A_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_D4CB461466DF23248B59AF71E884A44A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_D4CB461466DF23248B59AF71E884A44A_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_D4CB461466DF23248B59AF71E884A44A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_D4CB461466DF23248B59AF71E884A44A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_D4CB461466DF23248B59AF71E884A44A" xlink:to="lab_dei_EntityAddressPostalZipCode_D4CB461466DF23248B59AF71E884A44A" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_D8D74E6D8FB13B9DFE62AF71E884C4BE_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_D8D74E6D8FB13B9DFE62AF71E884C4BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_D8D74E6D8FB13B9DFE62AF71E884C4BE_label_en-US" xlink:label="lab_dei_CityAreaCode_D8D74E6D8FB13B9DFE62AF71E884C4BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_D8D74E6D8FB13B9DFE62AF71E884C4BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_D8D74E6D8FB13B9DFE62AF71E884C4BE" xlink:to="lab_dei_CityAreaCode_D8D74E6D8FB13B9DFE62AF71E884C4BE" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_B904C95A835D96399CE2AF71E8842F17_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_B904C95A835D96399CE2AF71E8842F17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_B904C95A835D96399CE2AF71E8842F17_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_B904C95A835D96399CE2AF71E8842F17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_B904C95A835D96399CE2AF71E8842F17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_B904C95A835D96399CE2AF71E8842F17" xlink:to="lab_dei_LocalPhoneNumber_B904C95A835D96399CE2AF71E8842F17" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_2D97B3B3B154CAC9B6D6AF71E883045D_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_2D97B3B3B154CAC9B6D6AF71E883045D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_2D97B3B3B154CAC9B6D6AF71E883045D_label_en-US" xlink:label="lab_dei_Security12bTitle_2D97B3B3B154CAC9B6D6AF71E883045D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_2D97B3B3B154CAC9B6D6AF71E883045D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_2D97B3B3B154CAC9B6D6AF71E883045D" xlink:to="lab_dei_Security12bTitle_2D97B3B3B154CAC9B6D6AF71E883045D" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_F7D2BDF008FBC80BB710AF71E8838E3C_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_F7D2BDF008FBC80BB710AF71E8838E3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_F7D2BDF008FBC80BB710AF71E8838E3C_label_en-US" xlink:label="lab_dei_TradingSymbol_F7D2BDF008FBC80BB710AF71E8838E3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_F7D2BDF008FBC80BB710AF71E8838E3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_F7D2BDF008FBC80BB710AF71E8838E3C" xlink:to="lab_dei_TradingSymbol_F7D2BDF008FBC80BB710AF71E8838E3C" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_C08A30CAD193F5BB1813AF71E8833973_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_C08A30CAD193F5BB1813AF71E8833973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_C08A30CAD193F5BB1813AF71E8833973_label_en-US" xlink:label="lab_dei_SecurityExchangeName_C08A30CAD193F5BB1813AF71E8833973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_C08A30CAD193F5BB1813AF71E8833973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_C08A30CAD193F5BB1813AF71E8833973" xlink:to="lab_dei_SecurityExchangeName_C08A30CAD193F5BB1813AF71E8833973" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_43828DBB35C3CB21EC7DAF71E8823154_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_43828DBB35C3CB21EC7DAF71E8823154" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_43828DBB35C3CB21EC7DAF71E8823154_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_43828DBB35C3CB21EC7DAF71E8823154" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_43828DBB35C3CB21EC7DAF71E8823154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_43828DBB35C3CB21EC7DAF71E8823154" xlink:to="lab_dei_EntityCurrentReportingStatus_43828DBB35C3CB21EC7DAF71E8823154" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6E0A0F1CB580271D6E71AF71E88234FA_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_6E0A0F1CB580271D6E71AF71E88234FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6E0A0F1CB580271D6E71AF71E88234FA_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_6E0A0F1CB580271D6E71AF71E88234FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_6E0A0F1CB580271D6E71AF71E88234FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_6E0A0F1CB580271D6E71AF71E88234FA" xlink:to="lab_dei_EntityInteractiveDataCurrent_6E0A0F1CB580271D6E71AF71E88234FA" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_101BB97BB2483123E1B4AF71E8828389_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_101BB97BB2483123E1B4AF71E8828389" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_101BB97BB2483123E1B4AF71E8828389_label_en-US" xlink:label="lab_dei_EntityFilerCategory_101BB97BB2483123E1B4AF71E8828389" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_101BB97BB2483123E1B4AF71E8828389" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_101BB97BB2483123E1B4AF71E8828389" xlink:to="lab_dei_EntityFilerCategory_101BB97BB2483123E1B4AF71E8828389" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_A9E9345B680097412163AF71E882E7DD_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_A9E9345B680097412163AF71E882E7DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_A9E9345B680097412163AF71E882E7DD_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_A9E9345B680097412163AF71E882E7DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_A9E9345B680097412163AF71E882E7DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_A9E9345B680097412163AF71E882E7DD" xlink:to="lab_dei_EntitySmallBusiness_A9E9345B680097412163AF71E882E7DD" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_A7EDC19775D811CAF478AF71E8838E68_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_A7EDC19775D811CAF478AF71E8838E68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_A7EDC19775D811CAF478AF71E8838E68_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_A7EDC19775D811CAF478AF71E8838E68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_A7EDC19775D811CAF478AF71E8838E68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_A7EDC19775D811CAF478AF71E8838E68" xlink:to="lab_dei_EntityEmergingGrowthCompany_A7EDC19775D811CAF478AF71E8838E68" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_DD13A94D71FC8127C241AF71E882CA53_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_DD13A94D71FC8127C241AF71E882CA53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_DD13A94D71FC8127C241AF71E882CA53_label_en-US" xlink:label="lab_dei_EntityShellCompany_DD13A94D71FC8127C241AF71E882CA53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_DD13A94D71FC8127C241AF71E882CA53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_DD13A94D71FC8127C241AF71E882CA53" xlink:to="lab_dei_EntityShellCompany_DD13A94D71FC8127C241AF71E882CA53" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_EF64A41DA0C5DA14B75CAF71E8823BE9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_EF64A41DA0C5DA14B75CAF71E8823BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_EF64A41DA0C5DA14B75CAF71E8823BE9_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_EF64A41DA0C5DA14B75CAF71E8823BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_EF64A41DA0C5DA14B75CAF71E8823BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_EF64A41DA0C5DA14B75CAF71E8823BE9" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_EF64A41DA0C5DA14B75CAF71E8823BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_133853DD30EC6115FC51B3E451D4402D_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_133853DD30EC6115FC51B3E451D4402D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_133853DD30EC6115FC51B3E451D4402D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_133853DD30EC6115FC51B3E451D4402D" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_133853DD30EC6115FC51B3E451D4402D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:to="lab_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:to="lab_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:type="arc" />
    <link:label id="lab_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:to="lab_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:to="lab_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties accruing to GSK</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423" xlink:to="lab_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9D0528BE81F354D0AE7378FF0F1C180C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_B6DC013CDC38075A043AE232660D12AC_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9D0528BE81F354D0AE7378FF0F1C180C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9D0528BE81F354D0AE7378FF0F1C180C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9D0528BE81F354D0AE7378FF0F1C180C" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9D0528BE81F354D0AE7378FF0F1C180C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_14D577AA99EB5FE89C805D02E6EFDB70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_56D746799A1D3ACB7624E2326598E5EB_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_14D577AA99EB5FE89C805D02E6EFDB70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_14D577AA99EB5FE89C805D02E6EFDB70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_14D577AA99EB5FE89C805D02E6EFDB70" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_14D577AA99EB5FE89C805D02E6EFDB70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_349365A1AB2154E5908173C42E0C22CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_EA598134735058648C89E23265BE792D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_349365A1AB2154E5908173C42E0C22CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_349365A1AB2154E5908173C42E0C22CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_349365A1AB2154E5908173C42E0C22CD" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_349365A1AB2154E5908173C42E0C22CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A05ED9FFCCF15C3D93F4C74608E860C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3B38191A486E8E190B52E23265BEEC7A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A05ED9FFCCF15C3D93F4C74608E860C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A05ED9FFCCF15C3D93F4C74608E860C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A05ED9FFCCF15C3D93F4C74608E860C6" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A05ED9FFCCF15C3D93F4C74608E860C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_51014443E6955E40B67E8CAA1EF17056" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_902FDFBFD0BC08E25BA1E23265BE8BF9_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_51014443E6955E40B67E8CAA1EF17056" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_51014443E6955E40B67E8CAA1EF17056" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_51014443E6955E40B67E8CAA1EF17056" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_51014443E6955E40B67E8CAA1EF17056" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_835B503545635ABA8FB49186F4AC2A07" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_90D9684C7DF3BBE2C786E23265BE66C6_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_835B503545635ABA8FB49186F4AC2A07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_835B503545635ABA8FB49186F4AC2A07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_835B503545635ABA8FB49186F4AC2A07" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_835B503545635ABA8FB49186F4AC2A07" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_E9B7E06249EF57F7A142D9DDC86AE85D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_470B2B4840920BA026D6E23265BFF505_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_E9B7E06249EF57F7A142D9DDC86AE85D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_E9B7E06249EF57F7A142D9DDC86AE85D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_E9B7E06249EF57F7A142D9DDC86AE85D" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_E9B7E06249EF57F7A142D9DDC86AE85D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_830D225E806E59D4B7A1DF311B9DAE8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PROPERTY AND EQUIPMENT</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_199C0B0B59FC432D83F8E232668F0D46_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_830D225E806E59D4B7A1DF311B9DAE8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_830D225E806E59D4B7A1DF311B9DAE8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_830D225E806E59D4B7A1DF311B9DAE8E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_830D225E806E59D4B7A1DF311B9DAE8E" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77_terseLabel_en-US" xlink:label="lab_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:label id="lab_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77_label_en-US" xlink:label="lab_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:to="lab_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:type="arc" />
    <link:label id="lab_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524_terseLabel_en-US" xlink:label="lab_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and restricted cash</link:label>
    <link:label id="lab_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524_label_en-US" xlink:label="lab_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash And Restricted Cash [Member]</link:label>
    <link:label id="lab_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524_documentation_en-US" xlink:label="lab_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash And Restricted Cash [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashAndRestrictedCashMember" xlink:label="loc_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:to="lab_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:type="arc" />
    <link:label id="lab_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE_terseLabel_en-US" xlink:label="lab_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:label id="lab_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE_label_en-US" xlink:label="lab_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="lab_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Investments, available-for-sale, Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments available-for-sale, Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Investments available-for-sale, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E22E0D448C9940B7A1651A72633F15C1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E22E0D448C9940B7A1651A72633F15C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments available-for-sale, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E22E0D448C9940B7A1651A72633F15C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E22E0D448C9940B7A1651A72633F15C1" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E22E0D448C9940B7A1651A72633F15C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2_negatedLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, and restricted cash, Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_215BD65C5DD9BB2369E81A726340E5C7_verboseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_215BD65C5DD9BB2369E81A726340E5C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash, restricted cash and certificates of deposit, Fair Value</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_215BD65C5DD9BB2369E81A726340E5C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_215BD65C5DD9BB2369E81A726340E5C7" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_215BD65C5DD9BB2369E81A726340E5C7" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cash and investments, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash and investments, Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4_negatedLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Total cash and investments, Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total cash and investments, Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_C5D1B910CF16CB640639E2326574AE5F_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_99E37DB45F645D98B833853F14AF5883" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_99E37DB45F645D98B833853F14AF5883" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_99E37DB45F645D98B833853F14AF5883" xlink:to="lab_us-gaap_EmployeeStockOptionMember_99E37DB45F645D98B833853F14AF5883" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_61D4FA5477005B77B77F0759FD6054CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_324F6E6B52069A838A2CE23265749F3D_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember_61D4FA5477005B77B77F0759FD6054CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_61D4FA5477005B77B77F0759FD6054CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember_61D4FA5477005B77B77F0759FD6054CC" xlink:to="lab_us-gaap_EmployeeStockMember_61D4FA5477005B77B77F0759FD6054CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E1D29ECD7780533D9398EB87484D523C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_54C619CB5F4E79EAC783E23265758049_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E1D29ECD7780533D9398EB87484D523C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E1D29ECD7780533D9398EB87484D523C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E1D29ECD7780533D9398EB87484D523C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E1D29ECD7780533D9398EB87484D523C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E624A2FDC2845BA98A140BBCF67BED80" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0CB7518E05B5F13F0CC9E2326575708E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E624A2FDC2845BA98A140BBCF67BED80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E624A2FDC2845BA98A140BBCF67BED80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E624A2FDC2845BA98A140BBCF67BED80" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E624A2FDC2845BA98A140BBCF67BED80" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03E958890B895C8EAED3AEE121823CCA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_76F1B8A0B13A26DA3A37E232657565E2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03E958890B895C8EAED3AEE121823CCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03E958890B895C8EAED3AEE121823CCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03E958890B895C8EAED3AEE121823CCA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03E958890B895C8EAED3AEE121823CCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2165294CF2725B5BBEB46406B13895B3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_612127326B4E47399EF5E23265753156_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2165294CF2725B5BBEB46406B13895B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2165294CF2725B5BBEB46406B13895B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2165294CF2725B5BBEB46406B13895B3" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2165294CF2725B5BBEB46406B13895B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_D5D480B136050EE5C729199E158056F2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D5D480B136050EE5C729199E158056F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_D5D480B136050EE5C729199E158056F2_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_D5D480B136050EE5C729199E158056F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D5D480B136050EE5C729199E158056F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_D5D480B136050EE5C729199E158056F2" xlink:to="lab_us-gaap_NetIncomeLoss_D5D480B136050EE5C729199E158056F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_E0E483C001504D060BC5199E1581A5DE_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_E0E483C001504D060BC5199E1581A5DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_E0E483C001504D060BC5199E1581A5DE_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_E0E483C001504D060BC5199E1581A5DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_E0E483C001504D060BC5199E1581A5DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_E0E483C001504D060BC5199E1581A5DE" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_E0E483C001504D060BC5199E1581A5DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_5DACA8C2F339291D0B89199E1581F956_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5DACA8C2F339291D0B89199E1581F956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_5DACA8C2F339291D0B89199E1581F956_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_5DACA8C2F339291D0B89199E1581F956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5DACA8C2F339291D0B89199E1581F956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_5DACA8C2F339291D0B89199E1581F956" xlink:to="lab_us-gaap_ShareBasedCompensation_5DACA8C2F339291D0B89199E1581F956" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2932D068622580DC3203199E15816F55_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2932D068622580DC3203199E15816F55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) matching contributions made in common stock</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2932D068622580DC3203199E15816F55_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2932D068622580DC3203199E15816F55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2932D068622580DC3203199E15816F55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2932D068622580DC3203199E15816F55" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2932D068622580DC3203199E15816F55" xlink:type="arc" />
    <link:label id="lab_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and other changes in right-of-use assets</link:label>
    <link:label id="lab_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0_label_en-US" xlink:label="lab_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset, Amortization</link:label>
    <link:label id="lab_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset, Amortization</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_RightOfUseAssetAmortization" xlink:label="loc_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0" xlink:to="lab_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ABA6EA6583608D45AECF199E15821127_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ABA6EA6583608D45AECF199E15821127" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ABA6EA6583608D45AECF199E15821127_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ABA6EA6583608D45AECF199E15821127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ABA6EA6583608D45AECF199E15821127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ABA6EA6583608D45AECF199E15821127" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ABA6EA6583608D45AECF199E15821127" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9660C587A5FEE65B298E199E1582A915_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9660C587A5FEE65B298E199E1582A915" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on other equity investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9660C587A5FEE65B298E199E1582A915_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9660C587A5FEE65B298E199E1582A915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Sale of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_9660C587A5FEE65B298E199E1582A915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfOtherInvestments_9660C587A5FEE65B298E199E1582A915" xlink:to="lab_us-gaap_GainLossOnSaleOfOtherInvestments_9660C587A5FEE65B298E199E1582A915" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_D43605A658FC4AC31A1F199E1582D30C_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_D43605A658FC4AC31A1F199E1582D30C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accretion of investments, net and other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_D43605A658FC4AC31A1F199E1582D30C_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_D43605A658FC4AC31A1F199E1582D30C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_D43605A658FC4AC31A1F199E1582D30C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_D43605A658FC4AC31A1F199E1582D30C" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_D43605A658FC4AC31A1F199E1582D30C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_33C93B111B97E3E42722199E1582481A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_33C93B111B97E3E42722199E1582481A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_33C93B111B97E3E42722199E1582481A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_33C93B111B97E3E42722199E1582481A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_33C93B111B97E3E42722199E1582481A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_33C93B111B97E3E42722199E1582481A" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_33C93B111B97E3E42722199E1582481A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_0CFA131CB22D20778923199E1583004C_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_0CFA131CB22D20778923199E1583004C" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_0CFA131CB22D20778923199E1583004C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables_0CFA131CB22D20778923199E1583004C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_0CFA131CB22D20778923199E1583004C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables_0CFA131CB22D20778923199E1583004C" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables_0CFA131CB22D20778923199E1583004C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_201B9CE7982C6B4060BD199E15836B85_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_201B9CE7982C6B4060BD199E15836B85" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_201B9CE7982C6B4060BD199E15836B85_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_201B9CE7982C6B4060BD199E15836B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_201B9CE7982C6B4060BD199E15836B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_201B9CE7982C6B4060BD199E15836B85" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_201B9CE7982C6B4060BD199E15836B85" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_EDE76C42E614106DDB73199E15837A40_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_EDE76C42E614106DDB73199E15837A40" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current portion of unbilled collaboration revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_EDE76C42E614106DDB73199E15837A40_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_EDE76C42E614106DDB73199E15837A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_EDE76C42E614106DDB73199E15837A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_EDE76C42E614106DDB73199E15837A40" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_EDE76C42E614106DDB73199E15837A40" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1719A8D0589DF0A9D75C199E158320D4_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1719A8D0589DF0A9D75C199E158320D4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1719A8D0589DF0A9D75C199E158320D4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1719A8D0589DF0A9D75C199E158320D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1719A8D0589DF0A9D75C199E158320D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1719A8D0589DF0A9D75C199E158320D4" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1719A8D0589DF0A9D75C199E158320D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8000F6E1F9691025AF8F199E15839F80_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8000F6E1F9691025AF8F199E15839F80" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8000F6E1F9691025AF8F199E15839F80_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8000F6E1F9691025AF8F199E15839F80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8000F6E1F9691025AF8F199E15839F80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8000F6E1F9691025AF8F199E15839F80" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8000F6E1F9691025AF8F199E15839F80" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_302E0A75F0F6CFD4B505199E1583457D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_302E0A75F0F6CFD4B505199E1583457D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_302E0A75F0F6CFD4B505199E1583457D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_302E0A75F0F6CFD4B505199E1583457D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_302E0A75F0F6CFD4B505199E1583457D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_302E0A75F0F6CFD4B505199E1583457D" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_302E0A75F0F6CFD4B505199E1583457D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_226E8BFFFF849A7BB9EE199E158406F5_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_226E8BFFFF849A7BB9EE199E158406F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_226E8BFFFF849A7BB9EE199E158406F5_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_226E8BFFFF849A7BB9EE199E158406F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_226E8BFFFF849A7BB9EE199E158406F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_226E8BFFFF849A7BB9EE199E158406F5" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_226E8BFFFF849A7BB9EE199E158406F5" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Clinical Liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (decrease) in accrued clinical liabilities</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513" xlink:to="lab_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due customers</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Rebates And Fees Payable</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Rebates And Fees Payable</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInRebatesAndFeesPayable" xlink:label="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E" xlink:to="lab_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liability</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Accrued Collaboration Liability</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Collaboration Liability</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F" xlink:to="lab_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_798939168D178572FDD0199E1584D208_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_798939168D178572FDD0199E1584D208" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current and long-term deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_798939168D178572FDD0199E1584D208_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_798939168D178572FDD0199E1584D208" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_798939168D178572FDD0199E1584D208" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_798939168D178572FDD0199E1584D208" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_798939168D178572FDD0199E1584D208" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815_terseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Lease Liability, Noncurrent</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Lease Liability, Noncurrent</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" xlink:label="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815" xlink:to="lab_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35828C7343ED34AB1FF1199E158485F3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35828C7343ED34AB1FF1199E158485F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current and long-term liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35828C7343ED34AB1FF1199E158485F3_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35828C7343ED34AB1FF1199E158485F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35828C7343ED34AB1FF1199E158485F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35828C7343ED34AB1FF1199E158485F3" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35828C7343ED34AB1FF1199E158485F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6C19D505A73C50FD3DBF199E15851384_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6C19D505A73C50FD3DBF199E15851384" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6C19D505A73C50FD3DBF199E15851384_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6C19D505A73C50FD3DBF199E15851384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6C19D505A73C50FD3DBF199E15851384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6C19D505A73C50FD3DBF199E15851384" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_6C19D505A73C50FD3DBF199E15851384" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11F2AC1FE3AEE27FF7FC199E158570DF_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11F2AC1FE3AEE27FF7FC199E158570DF" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11F2AC1FE3AEE27FF7FC199E158570DF_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11F2AC1FE3AEE27FF7FC199E158570DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11F2AC1FE3AEE27FF7FC199E158570DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11F2AC1FE3AEE27FF7FC199E158570DF" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11F2AC1FE3AEE27FF7FC199E158570DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94645B942AA9A3329BB9199E15851F75_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94645B942AA9A3329BB9199E15851F75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of property and equipment</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94645B942AA9A3329BB9199E15851F75_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94645B942AA9A3329BB9199E15851F75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94645B942AA9A3329BB9199E15851F75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94645B942AA9A3329BB9199E15851F75" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94645B942AA9A3329BB9199E15851F75" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2283158E97071C884A61199E1585A1FE_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2283158E97071C884A61199E1585A1FE" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2283158E97071C884A61199E1585A1FE_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2283158E97071C884A61199E1585A1FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2283158E97071C884A61199E1585A1FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2283158E97071C884A61199E1585A1FE" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2283158E97071C884A61199E1585A1FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_A21CC196E67CDABD2610199E1585435B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_A21CC196E67CDABD2610199E1585435B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_A21CC196E67CDABD2610199E1585435B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_A21CC196E67CDABD2610199E1585435B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_A21CC196E67CDABD2610199E1585435B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_A21CC196E67CDABD2610199E1585435B" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_A21CC196E67CDABD2610199E1585435B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6952A7B61F28DA6DB3DC199E1586A8AF_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6952A7B61F28DA6DB3DC199E1586A8AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6952A7B61F28DA6DB3DC199E1586A8AF_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6952A7B61F28DA6DB3DC199E1586A8AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6952A7B61F28DA6DB3DC199E1586A8AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6952A7B61F28DA6DB3DC199E1586A8AF" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6952A7B61F28DA6DB3DC199E1586A8AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_AF6B152E49B98E890DDC199E158609FC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_AF6B152E49B98E890DDC199E158609FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from other equity investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_AF6B152E49B98E890DDC199E158609FC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_AF6B152E49B98E890DDC199E158609FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale and Maturity of Other Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_AF6B152E49B98E890DDC199E158609FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_AF6B152E49B98E890DDC199E158609FC" xlink:to="lab_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_AF6B152E49B98E890DDC199E158609FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_76E52F8CC454D7C81D92199E1586708B_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_76E52F8CC454D7C81D92199E1586708B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_76E52F8CC454D7C81D92199E1586708B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_76E52F8CC454D7C81D92199E1586708B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76E52F8CC454D7C81D92199E1586708B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76E52F8CC454D7C81D92199E1586708B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_76E52F8CC454D7C81D92199E1586708B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_826BB352D74099556B53199E15867EE6_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_826BB352D74099556B53199E15867EE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_826BB352D74099556B53199E15867EE6_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_826BB352D74099556B53199E15867EE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_826BB352D74099556B53199E15867EE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_826BB352D74099556B53199E15867EE6" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_826BB352D74099556B53199E15867EE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_0B3EB01F125DDAC8B897199E1587B5CA_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_0B3EB01F125DDAC8B897199E1587B5CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockPlans_0B3EB01F125DDAC8B897199E1587B5CA_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockPlans_0B3EB01F125DDAC8B897199E1587B5CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_0B3EB01F125DDAC8B897199E1587B5CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockPlans_0B3EB01F125DDAC8B897199E1587B5CA" xlink:to="lab_us-gaap_ProceedsFromStockPlans_0B3EB01F125DDAC8B897199E1587B5CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4547EABC1A439419053A199E158766F4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4547EABC1A439419053A199E158766F4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4547EABC1A439419053A199E158766F4_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4547EABC1A439419053A199E158766F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4547EABC1A439419053A199E158766F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4547EABC1A439419053A199E158766F4" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4547EABC1A439419053A199E158766F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_337E8362566813E02761199E158746C2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_337E8362566813E02761199E158746C2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on financing lease obligation</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_337E8362566813E02761199E158746C2_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_337E8362566813E02761199E158746C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_337E8362566813E02761199E158746C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_337E8362566813E02761199E158746C2" xlink:to="lab_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_337E8362566813E02761199E158746C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D0B07C5657F7A02A7A10199E15873D32_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D0B07C5657F7A02A7A10199E15873D32" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D0B07C5657F7A02A7A10199E15873D32_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D0B07C5657F7A02A7A10199E15873D32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D0B07C5657F7A02A7A10199E15873D32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D0B07C5657F7A02A7A10199E15873D32" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_D0B07C5657F7A02A7A10199E15873D32" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1DF33012368A2FEB096F199E1587AAAD_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1DF33012368A2FEB096F199E1587AAAD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1DF33012368A2FEB096F199E1587AAAD_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1DF33012368A2FEB096F199E1587AAAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1DF33012368A2FEB096F199E1587AAAD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1DF33012368A2FEB096F199E1587AAAD" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1DF33012368A2FEB096F199E1587AAAD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90FC3930D98B022D37A3199E15872738_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90FC3930D98B022D37A3199E15872738" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90FC3930D98B022D37A3199E15872738" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90FC3930D98B022D37A3199E15872738" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90FC3930D98B022D37A3199E15872738" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B9E79AF4BD4A5B88DF5D199E1588FD82_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B9E79AF4BD4A5B88DF5D199E1588FD82" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B9E79AF4BD4A5B88DF5D199E1588FD82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B9E79AF4BD4A5B88DF5D199E1588FD82" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B9E79AF4BD4A5B88DF5D199E1588FD82" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental cash flow disclosure:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:type="arc" />
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23_label_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23" xlink:to="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23" xlink:type="arc" />
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_99E9E72A083BB5188936199E1588B71D_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_99E9E72A083BB5188936199E1588B71D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid liabilities incurred to acquire Property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_99E9E72A083BB5188936199E1588B71D_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_99E9E72A083BB5188936199E1588B71D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_99E9E72A083BB5188936199E1588B71D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_99E9E72A083BB5188936199E1588B71D" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_99E9E72A083BB5188936199E1588B71D" xlink:type="arc" />
    <link:label id="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984_terseLabel_en-US" xlink:label="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid liabilities incurred to acquire investments</link:label>
    <link:label id="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984_label_en-US" xlink:label="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions</link:label>
    <link:label id="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984_documentation_en-US" xlink:label="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" xlink:label="loc_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984" xlink:to="lab_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_4C0ED39D18D706663BD344A6D30E44E3_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profits and losses on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_D8DF2FBE2A774646212444A6D30EE410_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8F4E097CB4CC59139845BF6DC074204E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F4AB77D8408FEAB3F77244A6D313EF3B_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8F4E097CB4CC59139845BF6DC074204E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8F4E097CB4CC59139845BF6DC074204E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8F4E097CB4CC59139845BF6DC074204E" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8F4E097CB4CC59139845BF6DC074204E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_2A5E3EA2B5889D4C78D6E23266E7B322_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_4D3A0E2F8AA1173F1049E23266E79D96_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_47862172663205C91FB7E23266E860B6_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_939FA35144BD5AE1A079D97B825C984A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8E17B7326CBEAD8F1A5FE23266E886FA_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_939FA35144BD5AE1A079D97B825C984A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_939FA35144BD5AE1A079D97B825C984A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_939FA35144BD5AE1A079D97B825C984A" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_939FA35144BD5AE1A079D97B825C984A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BC2796C31D7A56AAA48D85B1A6A51299" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_1327A8F58D793BE508BCE23266E8CECC_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BC2796C31D7A56AAA48D85B1A6A51299" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BC2796C31D7A56AAA48D85B1A6A51299" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BC2796C31D7A56AAA48D85B1A6A51299" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BC2796C31D7A56AAA48D85B1A6A51299" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_10CDB158341AFC5708CEE23266E92B02_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_17D68360D8CAB8AB7AB7E23266E9E06E_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_D0E5E059660158A28B1964AE3BE0BB44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D0E5E059660158A28B1964AE3BE0BB44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_D0E5E059660158A28B1964AE3BE0BB44" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_D0E5E059660158A28B1964AE3BE0BB44" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeasesAbstract_9434618CBCD9F5E1328AE23265DF9334_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract_0AB59F28D6D15AB5B819079711C91CA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0AB59F28D6D15AB5B819079711C91CA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract_0AB59F28D6D15AB5B819079711C91CA4" xlink:to="lab_us-gaap_LeasesAbstract_0AB59F28D6D15AB5B819079711C91CA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_476D44B811AE5FF9A6EC6A1FF11CD223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_1C703F57BAE87997A593E23265DF01CE_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock_476D44B811AE5FF9A6EC6A1FF11CD223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_476D44B811AE5FF9A6EC6A1FF11CD223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock_476D44B811AE5FF9A6EC6A1FF11CD223" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock_476D44B811AE5FF9A6EC6A1FF11CD223" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_184AC2AEBC0257C38A16836CF744A9FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEASES</link:label>
    <link:label id="lab_us-gaap_LesseeFinanceLeasesTextBlock_65D8C3158A2A11D34478E23265DF721E_label_en-US" xlink:label="lab_us-gaap_LesseeFinanceLeasesTextBlock_184AC2AEBC0257C38A16836CF744A9FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Finance Leases [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_184AC2AEBC0257C38A16836CF744A9FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeFinanceLeasesTextBlock_184AC2AEBC0257C38A16836CF744A9FC" xlink:to="lab_us-gaap_LesseeFinanceLeasesTextBlock_184AC2AEBC0257C38A16836CF744A9FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_A047F1033F8C459643E6E2326580C9E0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_0EC4C524D4F35ED6B62DBD5C4F5F61A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0EC4C524D4F35ED6B62DBD5C4F5F61A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0EC4C524D4F35ED6B62DBD5C4F5F61A7" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_0EC4C524D4F35ED6B62DBD5C4F5F61A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F23C4DE95B645AD6BD3933A15D1618BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_247BD0F7234415D429FDE2326580293A_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_F23C4DE95B645AD6BD3933A15D1618BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F23C4DE95B645AD6BD3933A15D1618BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_F23C4DE95B645AD6BD3933A15D1618BE" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_F23C4DE95B645AD6BD3933A15D1618BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_C44B27C71577D3A9449DE23265D99A10_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8C84C970FEAB595398320BDC328361DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8C84C970FEAB595398320BDC328361DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8C84C970FEAB595398320BDC328361DE" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8C84C970FEAB595398320BDC328361DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_782806F435F55BF9A045BC1B02D7D785" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_26CC4F39F81632AD9B27E23265DA37ED_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_782806F435F55BF9A045BC1B02D7D785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_782806F435F55BF9A045BC1B02D7D785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_782806F435F55BF9A045BC1B02D7D785" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_782806F435F55BF9A045BC1B02D7D785" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CF80C448B593525DB3A4EA7AD6216ECC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gains or losses on available-for-sale securities, net of tax impact of $___, $0, $___ and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_5C331F7F2A23F6DEED32E23265DA7C20_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CF80C448B593525DB3A4EA7AD6216ECC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CF80C448B593525DB3A4EA7AD6216ECC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CF80C448B593525DB3A4EA7AD6216ECC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CF80C448B593525DB3A4EA7AD6216ECC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54E319ADEEB95DB8904EE99D7D23E217" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7F838F1010B09869714AE23265DA0903_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54E319ADEEB95DB8904EE99D7D23E217" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54E319ADEEB95DB8904EE99D7D23E217" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54E319ADEEB95DB8904EE99D7D23E217" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54E319ADEEB95DB8904EE99D7D23E217" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_6EFBE4F20AA25EE0A16614F9D31C6A5D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_B313E5018AF7B86C6FF0E23265DA1BF4_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_6EFBE4F20AA25EE0A16614F9D31C6A5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6EFBE4F20AA25EE0A16614F9D31C6A5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_6EFBE4F20AA25EE0A16614F9D31C6A5D" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_6EFBE4F20AA25EE0A16614F9D31C6A5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_85A65B43C47A873B8FF427372F58BB42_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract_B08643B244485F40937EF3BF46ECEA0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B08643B244485F40937EF3BF46ECEA0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B08643B244485F40937EF3BF46ECEA0B" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract_B08643B244485F40937EF3BF46ECEA0B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_CB9D54F4BAE64D10136E27372F58A2BF_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_CB9D54F4BAE64D10136E27372F58A2BF_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:type="arc" />
    <link:label id="lab_country_US_B8F416516D51CA82C83127372F59CD66_terseLabel_en-US" xlink:label="lab_country_US_07AA191EA9615F098E24593D1C3AB8DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_B8F416516D51CA82C83127372F59CD66_label_en-US" xlink:label="lab_country_US_07AA191EA9615F098E24593D1C3AB8DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_07AA191EA9615F098E24593D1C3AB8DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_07AA191EA9615F098E24593D1C3AB8DE" xlink:to="lab_country_US_07AA191EA9615F098E24593D1C3AB8DE" xlink:type="arc" />
    <link:label id="lab_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206_terseLabel_en-US" xlink:label="lab_srt_EuropeMember_4E9616F2DF1E5054AA66157C2ED97775" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_1AE74A089D9984E27F2F27372F596206_label_en-US" xlink:label="lab_srt_EuropeMember_4E9616F2DF1E5054AA66157C2ED97775" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_4E9616F2DF1E5054AA66157C2ED97775" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember_4E9616F2DF1E5054AA66157C2ED97775" xlink:to="lab_srt_EuropeMember_4E9616F2DF1E5054AA66157C2ED97775" xlink:type="arc" />
    <link:label id="lab_country_JP_A8815B663A9A8845A88527424DE16576_terseLabel_en-US" xlink:label="lab_country_JP_E6E81D1DE5B05ADBA6665FDF7EBD7119" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_A8815B663A9A8845A88527424DE16576_label_en-US" xlink:label="lab_country_JP_E6E81D1DE5B05ADBA6665FDF7EBD7119" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_E6E81D1DE5B05ADBA6665FDF7EBD7119" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_E6E81D1DE5B05ADBA6665FDF7EBD7119" xlink:to="lab_country_JP_E6E81D1DE5B05ADBA6665FDF7EBD7119" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_C0F6BCD44162D53BF10027372F5AFCD8_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_C0F6BCD44162D53BF10027372F5AFCD8_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0F73B190E07C218D92C827372F5A365C_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93E3C6C8BC8E55FC89C344C9B1C00F6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93E3C6C8BC8E55FC89C344C9B1C00F6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93E3C6C8BC8E55FC89C344C9B1C00F6E" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93E3C6C8BC8E55FC89C344C9B1C00F6E" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_BD69EBB28359F3454197E23264D21C2D_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_BD69EBB28359F3454197E23264D21C2D_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:to="lab_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_08B2F65B3CF6059DEFC5E23264D26F2B_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:to="lab_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_266843C342B8EDEC9FB9E23264D2DC6A_label_en-US" xlink:label="lab_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:to="lab_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:type="arc" />
    <link:label id="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246_label_en-US" xlink:label="lab_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_569622BA6BE99863562AE23264D3F246_documentation_en-US" xlink:label="lab_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:to="lab_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:type="arc" />
    <link:label id="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911_terseLabel_en-US" xlink:label="lab_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911_label_en-US" xlink:label="lab_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_68E5D03B53D2557899BFE23264D39911_documentation_en-US" xlink:label="lab_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:to="lab_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_FD4A4A47B862C2F1F1F3E23264D391F9_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7095DDFE493257BB90C00D27397D6C89" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7095DDFE493257BB90C00D27397D6C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7095DDFE493257BB90C00D27397D6C89" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7095DDFE493257BB90C00D27397D6C89" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5664F50C39CE5740A5AB286CC447A2A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7F8ECDFBDB120E3AA41CE232655BD26F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5664F50C39CE5740A5AB286CC447A2A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5664F50C39CE5740A5AB286CC447A2A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5664F50C39CE5740A5AB286CC447A2A3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5664F50C39CE5740A5AB286CC447A2A3" xlink:type="arc" />
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_5E49B6C9E49858E5A2A4EF7D7C1B4841" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93_label_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_5E49B6C9E49858E5A2A4EF7D7C1B4841" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareNumeratorAbstract_721E4EB25A4DE3313F45E2326684EB93_documentation_en-US" xlink:label="lab_exel_EarningsPerShareNumeratorAbstract_5E49B6C9E49858E5A2A4EF7D7C1B4841" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Numerator [Abstract]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_EarningsPerShareNumeratorAbstract" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract_5E49B6C9E49858E5A2A4EF7D7C1B4841" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_5E49B6C9E49858E5A2A4EF7D7C1B4841" xlink:to="lab_exel_EarningsPerShareNumeratorAbstract_5E49B6C9E49858E5A2A4EF7D7C1B4841" xlink:type="arc" />
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418_terseLabel_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418_label_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:label id="lab_exel_EarningsPerShareDenominatorAbstract_FEE846BE04CE873F3E3EE2326685E418_documentation_en-US" xlink:label="lab_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Denominator [Abstract]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_EarningsPerShareDenominatorAbstract" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:to="lab_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0402C55823C352678A3DECDCBDB920D9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding used in computing basic net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_E98C79714E4DC10EE9EEE23266853394_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0402C55823C352678A3DECDCBDB920D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0402C55823C352678A3DECDCBDB920D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0402C55823C352678A3DECDCBDB920D9" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0402C55823C352678A3DECDCBDB920D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_CCAA5D92FEE45063A970C9A9CFD35116" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7449420DC27BD18120A1E23266863B6A_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_CCAA5D92FEE45063A970C9A9CFD35116" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_CCAA5D92FEE45063A970C9A9CFD35116" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_CCAA5D92FEE45063A970C9A9CFD35116" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_CCAA5D92FEE45063A970C9A9CFD35116" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F93BCE2F834A5E21B13210CE78169C29" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7C041EA736463BEEA51AE23266869E31_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F93BCE2F834A5E21B13210CE78169C29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F93BCE2F834A5E21B13210CE78169C29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F93BCE2F834A5E21B13210CE78169C29" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F93BCE2F834A5E21B13210CE78169C29" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_093995D33ACD5E938EFABCD8BD9BCC4B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_0A092D145ECD460F2761E23266862C69_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_093995D33ACD5E938EFABCD8BD9BCC4B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_093995D33ACD5E938EFABCD8BD9BCC4B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_093995D33ACD5E938EFABCD8BD9BCC4B" xlink:to="lab_us-gaap_EarningsPerShareBasic_093995D33ACD5E938EFABCD8BD9BCC4B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_D54E72E9AEDE5456817A6F61ADC7B5A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_E709136D51FF4EA909C4E2326686F08D_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_D54E72E9AEDE5456817A6F61ADC7B5A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_D54E72E9AEDE5456817A6F61ADC7B5A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_D54E72E9AEDE5456817A6F61ADC7B5A4" xlink:to="lab_us-gaap_EarningsPerShareDiluted_D54E72E9AEDE5456817A6F61ADC7B5A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_C7941E937C12C8845F1044A6D4204EC7_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_5097D1C7717852CBA967971F7F633915" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5097D1C7717852CBA967971F7F633915" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5097D1C7717852CBA967971F7F633915" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_5097D1C7717852CBA967971F7F633915" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_E9B70F4BB92B74B4BD2344A6D4208371_label_en-US" xlink:label="lab_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:to="lab_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_3B3953254C9E3B8D5AFB44A6D4216B17_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_7894CB1ED1EE1405CFC744A6D4210CD4_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:to="lab_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_E572807B86885864AFEAF34429C0D423" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_709EB1346D50A8FA19E544A6D42103D4_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_E572807B86885864AFEAF34429C0D423" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E572807B86885864AFEAF34429C0D423" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_E572807B86885864AFEAF34429C0D423" xlink:to="lab_us-gaap_CommonStockMember_E572807B86885864AFEAF34429C0D423" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_6C12A09216155809BB5AA9441CC610D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_B097F449837C020DD54244A6D422BAC6_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_6C12A09216155809BB5AA9441CC610D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6C12A09216155809BB5AA9441CC610D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_6C12A09216155809BB5AA9441CC610D0" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_6C12A09216155809BB5AA9441CC610D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34EF1A3742FB52E19A921971E66F2486" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_B4D837B3D5E91DE987A144A6D42225F3_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34EF1A3742FB52E19A921971E66F2486" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34EF1A3742FB52E19A921971E66F2486" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34EF1A3742FB52E19A921971E66F2486" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34EF1A3742FB52E19A921971E66F2486" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_A9C2BB01D2DD5B59B605F9D4CD94EF10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_E427DF20921C7A4BE3B044A6D422F529_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_A9C2BB01D2DD5B59B605F9D4CD94EF10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A9C2BB01D2DD5B59B605F9D4CD94EF10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_A9C2BB01D2DD5B59B605F9D4CD94EF10" xlink:to="lab_us-gaap_RetainedEarningsMember_A9C2BB01D2DD5B59B605F9D4CD94EF10" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A170914563B02EB1134F44A6D423BAC9_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_D45C2EE5533FAE539D2844A6D4237C61_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:to="lab_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_17B80AD21F5058F091B8309975BD7F1F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASU No. 2014-09</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_61D3F0A21B891F69D82144A6D423348C_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_17B80AD21F5058F091B8309975BD7F1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_17B80AD21F5058F091B8309975BD7F1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_17B80AD21F5058F091B8309975BD7F1F" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_17B80AD21F5058F091B8309975BD7F1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B26D1620F2725248B3AF4A99E988CB8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASU No. 2016-02</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_A78D5B2F9DE3563749CE44A6D4233718_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_B26D1620F2725248B3AF4A99E988CB8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B26D1620F2725248B3AF4A99E988CB8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_B26D1620F2725248B3AF4A99E988CB8D" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_B26D1620F2725248B3AF4A99E988CB8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_CFEE3655AB2B0DBA9D7244A6D424D54C_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="lab_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_A7F3920FF1FBB62BD62344A6D424EA73_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_44AF6032CA7C5EEABF2C00D9442E067C" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_44AF6032CA7C5EEABF2C00D9442E067C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_44AF6032CA7C5EEABF2C00D9442E067C" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_44AF6032CA7C5EEABF2C00D9442E067C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40EF58C361BD55B893BC7742221EEFFF" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_87787E831DD7A1A9AB4E44A6D424440D_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40EF58C361BD55B893BC7742221EEFFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40EF58C361BD55B893BC7742221EEFFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40EF58C361BD55B893BC7742221EEFFF" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40EF58C361BD55B893BC7742221EEFFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_56B7ECA2FEDF52709D291D21A039B8D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of Accounting Standards Update No's. (2014-09 and 2016-02)</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_19DDE11F30E8E81D939344A6D425C556_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_56B7ECA2FEDF52709D291D21A039B8D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_56B7ECA2FEDF52709D291D21A039B8D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_56B7ECA2FEDF52709D291D21A039B8D4" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_56B7ECA2FEDF52709D291D21A039B8D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_04E25FDC128DD035B8F844A6D425040F_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12748503AD5A5FED9BF944F835C794DC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12748503AD5A5FED9BF944F835C794DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12748503AD5A5FED9BF944F835C794DC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12748503AD5A5FED9BF944F835C794DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_366BC68F9CB553C086F6D199301D97E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_70DAC2A91B2CF6BB24A544A6D425A96E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_366BC68F9CB553C086F6D199301D97E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_366BC68F9CB553C086F6D199301D97E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_366BC68F9CB553C086F6D199301D97E6" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_366BC68F9CB553C086F6D199301D97E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_73A4AFCA1F785C789D84192851CFC48F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_2F06B4CC73D855807A9444A6D426E3F8_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_73A4AFCA1F785C789D84192851CFC48F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_73A4AFCA1F785C789D84192851CFC48F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_73A4AFCA1F785C789D84192851CFC48F" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_73A4AFCA1F785C789D84192851CFC48F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5B0DD687B355550FB12035B2EA980EA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_96D35B507F86E413FA5844A6D426FBB0_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5B0DD687B355550FB12035B2EA980EA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5B0DD687B355550FB12035B2EA980EA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5B0DD687B355550FB12035B2EA980EA1" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5B0DD687B355550FB12035B2EA980EA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_CF8E2E4833546DDE550C44A6D426A8AF_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_AB596F9D2FBC52F884CC2FDF48479973" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_AB596F9D2FBC52F884CC2FDF48479973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_AB596F9D2FBC52F884CC2FDF48479973" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_AB596F9D2FBC52F884CC2FDF48479973" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_536EB3A154CBD00375F744A6D42642B3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4652A97AB605DEAA40E125E7E30167B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4652A97AB605DEAA40E125E7E30167B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4652A97AB605DEAA40E125E7E30167B" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4652A97AB605DEAA40E125E7E30167B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_F9103F06E7B3D5C160500F83F71D3CBD_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_F9103F06E7B3D5C160500F83F71D3CBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SUBSEQUENT EVENTS</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_F9103F06E7B3D5C160500F83F71D3CBD_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_F9103F06E7B3D5C160500F83F71D3CBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_F9103F06E7B3D5C160500F83F71D3CBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_F9103F06E7B3D5C160500F83F71D3CBD" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_F9103F06E7B3D5C160500F83F71D3CBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_7420357A3A1803B87C8A17E2EDECF62E_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_7420357A3A1803B87C8A17E2EDECF62E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unbilled collaboration revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_7420357A3A1803B87C8A17E2EDECF62E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent_7420357A3A1803B87C8A17E2EDECF62E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_7420357A3A1803B87C8A17E2EDECF62E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent_7420357A3A1803B87C8A17E2EDECF62E" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent_7420357A3A1803B87C8A17E2EDECF62E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7A0166B557659FA0398B17E2EDECCE10_netLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7A0166B557659FA0398B17E2EDECCE10" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7A0166B557659FA0398B17E2EDECCE10_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7A0166B557659FA0398B17E2EDECCE10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7A0166B557659FA0398B17E2EDECCE10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7A0166B557659FA0398B17E2EDECCE10" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_7A0166B557659FA0398B17E2EDECCE10" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9F6362D694CD78FAEF8317E2EDEC613E_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9F6362D694CD78FAEF8317E2EDEC613E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of revenues recognized included in the beginning contract liability balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9F6362D694CD78FAEF8317E2EDEC613E_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9F6362D694CD78FAEF8317E2EDEC613E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9F6362D694CD78FAEF8317E2EDEC613E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9F6362D694CD78FAEF8317E2EDEC613E" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9F6362D694CD78FAEF8317E2EDEC613E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_4CCA7E9DC2A9DBB42C2617E2EDEC007D_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_4CCA7E9DC2A9DBB42C2617E2EDEC007D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_4CCA7E9DC2A9DBB42C2617E2EDEC007D_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_4CCA7E9DC2A9DBB42C2617E2EDEC007D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_4CCA7E9DC2A9DBB42C2617E2EDEC007D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_4CCA7E9DC2A9DBB42C2617E2EDEC007D" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_4CCA7E9DC2A9DBB42C2617E2EDEC007D" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_73A114B709CA5A93A37F86512F635EB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_87485E3855F273E3EA04E2326553A022_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_73A114B709CA5A93A37F86512F635EB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_73A114B709CA5A93A37F86512F635EB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_73A114B709CA5A93A37F86512F635EB5" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_73A114B709CA5A93A37F86512F635EB5" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_79AF5D70CB2E556E9BCFF856A72B84F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Classification of Lease Liabilities</link:label>
    <link:label id="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5_label_en-US" xlink:label="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_79AF5D70CB2E556E9BCFF856A72B84F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Financing Lease Liabilities [Table Text Block]</link:label>
    <link:label id="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_EF8E125F121C102A9AE3E232668C16C5_documentation_en-US" xlink:label="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_79AF5D70CB2E556E9BCFF856A72B84F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating And Financing Lease Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" xlink:label="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_79AF5D70CB2E556E9BCFF856A72B84F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_79AF5D70CB2E556E9BCFF856A72B84F0" xlink:to="lab_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_79AF5D70CB2E556E9BCFF856A72B84F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_5B511FF73458588EAB02D1A8B4F7AEEA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_B9837EF100116B682FD3E232668C6DD0_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_5B511FF73458588EAB02D1A8B4F7AEEA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_5B511FF73458588EAB02D1A8B4F7AEEA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_5B511FF73458588EAB02D1A8B4F7AEEA" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_5B511FF73458588EAB02D1A8B4F7AEEA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_AD854F3B58CF5B3DA674FC5D73230EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_66FA81B3B741F39D726AE232668C5476_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_AD854F3B58CF5B3DA674FC5D73230EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_AD854F3B58CF5B3DA674FC5D73230EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_AD854F3B58CF5B3DA674FC5D73230EA4" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_AD854F3B58CF5B3DA674FC5D73230EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total, Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:type="arc" />
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chargebacks and Discounts for Prompt Payment</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:type="arc" />
    <link:label id="lab_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:to="lab_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:type="arc" />
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:type="arc" />
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at December 31, 2018</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:type="arc" />
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_8B80419E2A4404BD0F0DB3E452153D13_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance_8B80419E2A4404BD0F0DB3E452153D13" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at September 30, 2019</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8B80419E2A4404BD0F0DB3E452153D13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance_8B80419E2A4404BD0F0DB3E452153D13" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance_8B80419E2A4404BD0F0DB3E452153D13" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_C2AE219C5A795AD784677CE4BFB8C6E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">COLLABORATION AGREEMENTS</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_4E97527F5F994DD11426E2326689FD1E_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_C2AE219C5A795AD784677CE4BFB8C6E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_C2AE219C5A795AD784677CE4BFB8C6E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_C2AE219C5A795AD784677CE4BFB8C6E6" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_C2AE219C5A795AD784677CE4BFB8C6E6" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities:</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesAbstract_C279BAFA0D072160151244A6D0A828A3_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseLiabilitiesAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:to="lab_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_41352F160F5356E3A7BCA1655E30C052" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_81D379E3021F0744585544A6D0A98F26_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_41352F160F5356E3A7BCA1655E30C052" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_41352F160F5356E3A7BCA1655E30C052" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_41352F160F5356E3A7BCA1655E30C052" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_41352F160F5356E3A7BCA1655E30C052" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_207AE0D64029588CAA4CFA48CCC09589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_4E9AB6654218181106DC44A6D0A9E7F2_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_207AE0D64029588CAA4CFA48CCC09589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_207AE0D64029588CAA4CFA48CCC09589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_207AE0D64029588CAA4CFA48CCC09589" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_207AE0D64029588CAA4CFA48CCC09589" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7E4C6A54B4D9FBDED57644A6D0A99843_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_1E883B6455EC54AC82F8FDF882F3C694" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_7E4C6A54B4D9FBDED57644A6D0A99843_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_1E883B6455EC54AC82F8FDF882F3C694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1E883B6455EC54AC82F8FDF882F3C694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_1E883B6455EC54AC82F8FDF882F3C694" xlink:to="lab_us-gaap_OperatingLeaseLiability_1E883B6455EC54AC82F8FDF882F3C694" xlink:type="arc" />
    <link:label id="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3_terseLabel_en-US" xlink:label="lab_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing lease liabilities:</link:label>
    <link:label id="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3_label_en-US" xlink:label="lab_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_exel_FinancingLeaseLiabilitiesAbstract_50BB00002DD8D0F9D35E44A6D0AA54F3_documentation_en-US" xlink:label="lab_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financing Lease Liabilities [Abstract]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_FinancingLeaseLiabilitiesAbstract" xlink:label="loc_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:to="lab_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_5480A6F2B4115D8585FC28F74E177EEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion included in Other current liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_54A2D7942C6EB19875A044A6D0AA5543_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent_5480A6F2B4115D8585FC28F74E177EEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5480A6F2B4115D8585FC28F74E177EEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent_5480A6F2B4115D8585FC28F74E177EEC" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent_5480A6F2B4115D8585FC28F74E177EEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_F7A9C52A1F1B5C27B29F8C89950D95A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_9736C44CCBA5BF7CFDE944A6D0AA42BC_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_F7A9C52A1F1B5C27B29F8C89950D95A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_F7A9C52A1F1B5C27B29F8C89950D95A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_F7A9C52A1F1B5C27B29F8C89950D95A0" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_F7A9C52A1F1B5C27B29F8C89950D95A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983_totalLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_1149298E910F56FAA74BD21C3CB6A98B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Financing obligation for build-to-suit lease</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiability_85B1727D6CAAFED62D8D44A6D0AA5983_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiability_1149298E910F56FAA74BD21C3CB6A98B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finance Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1149298E910F56FAA74BD21C3CB6A98B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiability_1149298E910F56FAA74BD21C3CB6A98B" xlink:to="lab_us-gaap_FinanceLeaseLiability_1149298E910F56FAA74BD21C3CB6A98B" xlink:type="arc" />
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06_totalLabel_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_E064536FC06F549AAE59E289E9CF5364" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06_label_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_E064536FC06F549AAE59E289E9CF5364" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Total</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_0A1D03CADC0147EC320844A6D0AB8C06_documentation_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_E064536FC06F549AAE59E289E9CF5364" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Total</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingAndFinanceLeasesLiabilityTotal" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_E064536FC06F549AAE59E289E9CF5364" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_E064536FC06F549AAE59E289E9CF5364" xlink:to="lab_exel_OperatingAndFinanceLeasesLiabilityTotal_E064536FC06F549AAE59E289E9CF5364" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_05C0227D1F6E79ACAB1F0037B9D6B5B9_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_05C0227D1F6E79ACAB1F0037B9D6B5B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_05C0227D1F6E79ACAB1F0037B9D6B5B9_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_05C0227D1F6E79ACAB1F0037B9D6B5B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_05C0227D1F6E79ACAB1F0037B9D6B5B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_05C0227D1F6E79ACAB1F0037B9D6B5B9" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_05C0227D1F6E79ACAB1F0037B9D6B5B9" xlink:type="arc" />
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_F4CA045149D957EEBB7CDAC36C7C9553" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4755E8CBA05087CF7C95E23266A9BB8F_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_F4CA045149D957EEBB7CDAC36C7C9553" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_F4CA045149D957EEBB7CDAC36C7C9553" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_F4CA045149D957EEBB7CDAC36C7C9553" xlink:to="lab_us-gaap_OperatingLeaseCost_F4CA045149D957EEBB7CDAC36C7C9553" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_294B1A3866FB5B648E7CAD5EDD621519" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_31B5DAE11D56D174150DE23266AA1E45_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_294B1A3866FB5B648E7CAD5EDD621519" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_294B1A3866FB5B648E7CAD5EDD621519" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_294B1A3866FB5B648E7CAD5EDD621519" xlink:to="lab_us-gaap_VariableLeaseCost_294B1A3866FB5B648E7CAD5EDD621519" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_0EA017A7EE5F5B60A0A860EB3C563439" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease costs</link:label>
    <link:label id="lab_us-gaap_LeaseCost_6D9DDD46001A92BCACD9E23266AA130E_label_en-US" xlink:label="lab_us-gaap_LeaseCost_0EA017A7EE5F5B60A0A860EB3C563439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0EA017A7EE5F5B60A0A860EB3C563439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_0EA017A7EE5F5B60A0A860EB3C563439" xlink:to="lab_us-gaap_LeaseCost_0EA017A7EE5F5B60A0A860EB3C563439" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Iconic Therapeutics, Inc.</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Iconic Therapeutics, Inc. [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:to="lab_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D_label_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreements, Upfront Payments</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:to="lab_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preclinical development funding commitment accrued</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515_label_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Expense Accrued</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Expense Accrued</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:to="lab_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee payment, if exercised</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E_label_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:label id="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:to="lab_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D_netLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development, regulatory and first-sale milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D_label_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones</link:label>
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones under collaborations agreement.</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404_label_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:to="lab_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_B660C94BA873EB862B80E2326563009C_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_B660C94BA873EB862B80E2326563009C_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_B660C94BA873EB862B80E2326563009C_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_E093960FE7175CB2A35D4F88A4F00DE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_A193B3DEC4FC977227BAE232667FB762_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_E093960FE7175CB2A35D4F88A4F00DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_E093960FE7175CB2A35D4F88A4F00DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_E093960FE7175CB2A35D4F88A4F00DE3" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_E093960FE7175CB2A35D4F88A4F00DE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_05D4E0A50D625AD897C354ABDA9115D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E133B2446C881860A1ABE23266DC7FD5_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_05D4E0A50D625AD897C354ABDA9115D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_05D4E0A50D625AD897C354ABDA9115D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_05D4E0A50D625AD897C354ABDA9115D7" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_05D4E0A50D625AD897C354ABDA9115D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14F49506C88A89742E06D078F2597144_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14F49506C88A89742E06D078F2597144" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14F49506C88A89742E06D078F2597144_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14F49506C88A89742E06D078F2597144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14F49506C88A89742E06D078F2597144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14F49506C88A89742E06D078F2597144" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14F49506C88A89742E06D078F2597144" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C6EB95F75199DF63DF3DD0C88E7B9292_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C6EB95F75199DF63DF3DD0C88E7B9292" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. federal statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C6EB95F75199DF63DF3DD0C88E7B9292_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C6EB95F75199DF63DF3DD0C88E7B9292" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C6EB95F75199DF63DF3DD0C88E7B9292" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C6EB95F75199DF63DF3DD0C88E7B9292" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C6EB95F75199DF63DF3DD0C88E7B9292" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="lab_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:to="lab_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B2C0509DC60755571BFDF046BFE8BC12_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B2C0509DC60755571BFDF046BFE8BC12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B2C0509DC60755571BFDF046BFE8BC12_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B2C0509DC60755571BFDF046BFE8BC12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B2C0509DC60755571BFDF046BFE8BC12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B2C0509DC60755571BFDF046BFE8BC12" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_B2C0509DC60755571BFDF046BFE8BC12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_EFF330445412A306CF49F046BFE9C830_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_EFF330445412A306CF49F046BFE9C830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_EFF330445412A306CF49F046BFE9C830_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_EFF330445412A306CF49F046BFE9C830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_EFF330445412A306CF49F046BFE9C830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_EFF330445412A306CF49F046BFE9C830" xlink:to="lab_us-gaap_ShortTermInvestments_EFF330445412A306CF49F046BFE9C830" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_D046AC1AD5B631004A8FF046BFE9F85A_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_D046AC1AD5B631004A8FF046BFE9F85A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_D046AC1AD5B631004A8FF046BFE9F85A_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent_D046AC1AD5B631004A8FF046BFE9F85A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_D046AC1AD5B631004A8FF046BFE9F85A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent_D046AC1AD5B631004A8FF046BFE9F85A" xlink:to="lab_us-gaap_ReceivablesNetCurrent_D046AC1AD5B631004A8FF046BFE9F85A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_56F0C7BD3FF7CB2DA74FF046BFE9A5B2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_56F0C7BD3FF7CB2DA74FF046BFE9A5B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_56F0C7BD3FF7CB2DA74FF046BFE9A5B2_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent_56F0C7BD3FF7CB2DA74FF046BFE9A5B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_56F0C7BD3FF7CB2DA74FF046BFE9A5B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent_56F0C7BD3FF7CB2DA74FF046BFE9A5B2" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent_56F0C7BD3FF7CB2DA74FF046BFE9A5B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_2391734F822E1D43A013F046BFE97D6C_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_2391734F822E1D43A013F046BFE97D6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_2391734F822E1D43A013F046BFE97D6C_label_en-US" xlink:label="lab_us-gaap_InventoryNet_2391734F822E1D43A013F046BFE97D6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2391734F822E1D43A013F046BFE97D6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_2391734F822E1D43A013F046BFE97D6C" xlink:to="lab_us-gaap_InventoryNet_2391734F822E1D43A013F046BFE97D6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C0E3A546E62D84803AF6F046BFEA7305_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C0E3A546E62D84803AF6F046BFEA7305" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C0E3A546E62D84803AF6F046BFEA7305_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C0E3A546E62D84803AF6F046BFEA7305" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C0E3A546E62D84803AF6F046BFEA7305" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C0E3A546E62D84803AF6F046BFEA7305" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C0E3A546E62D84803AF6F046BFEA7305" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_1A5836BCC03B32C18C77F046BFEA2A2B_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1A5836BCC03B32C18C77F046BFEA2A2B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_1A5836BCC03B32C18C77F046BFEA2A2B_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_1A5836BCC03B32C18C77F046BFEA2A2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1A5836BCC03B32C18C77F046BFEA2A2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_1A5836BCC03B32C18C77F046BFEA2A2B" xlink:to="lab_us-gaap_AssetsCurrent_1A5836BCC03B32C18C77F046BFEA2A2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_EFF27BA6E8253ACEDA62F046BFEAB5AC_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_EFF27BA6E8253ACEDA62F046BFEAB5AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_EFF27BA6E8253ACEDA62F046BFEAB5AC_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_EFF27BA6E8253ACEDA62F046BFEAB5AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_EFF27BA6E8253ACEDA62F046BFEAB5AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_EFF27BA6E8253ACEDA62F046BFEAB5AC" xlink:to="lab_us-gaap_LongTermInvestments_EFF27BA6E8253ACEDA62F046BFEAB5AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_DFE7BE221925F9DD9F60F046BFEAA395_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_DFE7BE221925F9DD9F60F046BFEAA395" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_DFE7BE221925F9DD9F60F046BFEAA395_label_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_DFE7BE221925F9DD9F60F046BFEAA395" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_DFE7BE221925F9DD9F60F046BFEAA395" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_DFE7BE221925F9DD9F60F046BFEAA395" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_DFE7BE221925F9DD9F60F046BFEAA395" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8120C437505454D160CDF046BFEA934B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8120C437505454D160CDF046BFEA934B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_8120C437505454D160CDF046BFEA934B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_8120C437505454D160CDF046BFEA934B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8120C437505454D160CDF046BFEA934B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8120C437505454D160CDF046BFEA934B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_8120C437505454D160CDF046BFEA934B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_84BDBBAFA1F1D88401F2F046BFEA44B3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_84BDBBAFA1F1D88401F2F046BFEA44B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_84BDBBAFA1F1D88401F2F046BFEA44B3_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_84BDBBAFA1F1D88401F2F046BFEA44B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_84BDBBAFA1F1D88401F2F046BFEA44B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_84BDBBAFA1F1D88401F2F046BFEA44B3" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_84BDBBAFA1F1D88401F2F046BFEA44B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_DC5825D97F165E88D198F046BFEB6FCD_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_DC5825D97F165E88D198F046BFEB6FCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_DC5825D97F165E88D198F046BFEB6FCD_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet_DC5825D97F165E88D198F046BFEB6FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_DC5825D97F165E88D198F046BFEB6FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet_DC5825D97F165E88D198F046BFEB6FCD" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet_DC5825D97F165E88D198F046BFEB6FCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_3EBD4C579DB7E36E2462F046BFEB2370_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_3EBD4C579DB7E36E2462F046BFEB2370" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3EBD4C579DB7E36E2462F046BFEB2370_label_en-US" xlink:label="lab_us-gaap_Goodwill_3EBD4C579DB7E36E2462F046BFEB2370" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3EBD4C579DB7E36E2462F046BFEB2370" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_3EBD4C579DB7E36E2462F046BFEB2370" xlink:to="lab_us-gaap_Goodwill_3EBD4C579DB7E36E2462F046BFEB2370" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1642A7BEC7E82FAFE518F046BFEBA1BD_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_1642A7BEC7E82FAFE518F046BFEBA1BD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1642A7BEC7E82FAFE518F046BFEBA1BD_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_1642A7BEC7E82FAFE518F046BFEBA1BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1642A7BEC7E82FAFE518F046BFEBA1BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_1642A7BEC7E82FAFE518F046BFEBA1BD" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_1642A7BEC7E82FAFE518F046BFEBA1BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_FBB8CFBBFDD7E4ACDE0FF046BFEBF78F_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_FBB8CFBBFDD7E4ACDE0FF046BFEBF78F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_FBB8CFBBFDD7E4ACDE0FF046BFEBF78F_label_en-US" xlink:label="lab_us-gaap_Assets_FBB8CFBBFDD7E4ACDE0FF046BFEBF78F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_FBB8CFBBFDD7E4ACDE0FF046BFEBF78F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_FBB8CFBBFDD7E4ACDE0FF046BFEBF78F" xlink:to="lab_us-gaap_Assets_FBB8CFBBFDD7E4ACDE0FF046BFEBF78F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_811B63B5DE8884D5575CF046BFECE50E_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_811B63B5DE8884D5575CF046BFECE50E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_811B63B5DE8884D5575CF046BFECE50E_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_811B63B5DE8884D5575CF046BFECE50E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_811B63B5DE8884D5575CF046BFECE50E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_811B63B5DE8884D5575CF046BFECE50E" xlink:to="lab_us-gaap_AccountsPayableCurrent_811B63B5DE8884D5575CF046BFECE50E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_CCC34F3F5FD163817DD8F046BFEC35B4_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_CCC34F3F5FD163817DD8F046BFEC35B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_CCC34F3F5FD163817DD8F046BFEC35B4_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent_CCC34F3F5FD163817DD8F046BFEC35B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_CCC34F3F5FD163817DD8F046BFEC35B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent_CCC34F3F5FD163817DD8F046BFEC35B4" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent_CCC34F3F5FD163817DD8F046BFEC35B4" xlink:type="arc" />
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_21755B9FCFEBEF9BA7F3F046BFED42A1_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_21755B9FCFEBEF9BA7F3F046BFED42A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_21755B9FCFEBEF9BA7F3F046BFED42A1_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent_21755B9FCFEBEF9BA7F3F046BFED42A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_21755B9FCFEBEF9BA7F3F046BFED42A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent_21755B9FCFEBEF9BA7F3F046BFED42A1" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent_21755B9FCFEBEF9BA7F3F046BFED42A1" xlink:type="arc" />
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_408D86AEFC368696CC24F046BFED06FC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_408D86AEFC368696CC24F046BFED06FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_408D86AEFC368696CC24F046BFED06FC_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_408D86AEFC368696CC24F046BFED06FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_408D86AEFC368696CC24F046BFED06FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_408D86AEFC368696CC24F046BFED06FC" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_408D86AEFC368696CC24F046BFED06FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_C995E7C505A9A44FD2BAF046BFED50AE_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_C995E7C505A9A44FD2BAF046BFED50AE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_C995E7C505A9A44FD2BAF046BFED50AE_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_C995E7C505A9A44FD2BAF046BFED50AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_C995E7C505A9A44FD2BAF046BFED50AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_C995E7C505A9A44FD2BAF046BFED50AE" xlink:to="lab_us-gaap_LiabilitiesCurrent_C995E7C505A9A44FD2BAF046BFED50AE" xlink:type="arc" />
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F_terseLabel_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of lease liabilities</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F_label_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Long Term</link:label>
    <link:label id="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F_documentation_en-US" xlink:label="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating And Finance Leases, Liability - Long Term</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingAndFinanceLeasesLiabilityLongTerm" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F" xlink:to="lab_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_C890A33261262F6F1743F046BFEE04ED_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_C890A33261262F6F1743F046BFEE04ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term portion of deferred revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_C890A33261262F6F1743F046BFEE04ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_C890A33261262F6F1743F046BFEE04ED" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_C890A33261262F6F1743F046BFEE04ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_C1898EB6551FF1621A32F046BFEEB7AD_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_C1898EB6551FF1621A32F046BFEEB7AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_C1898EB6551FF1621A32F046BFEEB7AD_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_C1898EB6551FF1621A32F046BFEEB7AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C1898EB6551FF1621A32F046BFEEB7AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_C1898EB6551FF1621A32F046BFEEB7AD" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_C1898EB6551FF1621A32F046BFEEB7AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_ACF771910BA94F63D48FF046BFEE0EFA_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_ACF771910BA94F63D48FF046BFEE0EFA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_ACF771910BA94F63D48FF046BFEE0EFA_label_en-US" xlink:label="lab_us-gaap_Liabilities_ACF771910BA94F63D48FF046BFEE0EFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_ACF771910BA94F63D48FF046BFEE0EFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_ACF771910BA94F63D48FF046BFEE0EFA" xlink:to="lab_us-gaap_Liabilities_ACF771910BA94F63D48FF046BFEE0EFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_B0AD5ECD62C8317CF2B4F046BFEE08F6_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_B0AD5ECD62C8317CF2B4F046BFEE08F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_B0AD5ECD62C8317CF2B4F046BFEE08F6_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_B0AD5ECD62C8317CF2B4F046BFEE08F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_B0AD5ECD62C8317CF2B4F046BFEE08F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_B0AD5ECD62C8317CF2B4F046BFEE08F6" xlink:to="lab_us-gaap_CommitmentsAndContingencies_B0AD5ECD62C8317CF2B4F046BFEE08F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_CBAC3659BB18D0A92B8AF046BFEE5964_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_CBAC3659BB18D0A92B8AF046BFEE5964" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_CBAC3659BB18D0A92B8AF046BFEE5964_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_CBAC3659BB18D0A92B8AF046BFEE5964" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_CBAC3659BB18D0A92B8AF046BFEE5964" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_CBAC3659BB18D0A92B8AF046BFEE5964" xlink:to="lab_us-gaap_PreferredStockValue_CBAC3659BB18D0A92B8AF046BFEE5964" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_7C50E86D1E6F11A1CE94F046BFEF7018_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_7C50E86D1E6F11A1CE94F046BFEF7018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 303,776,032 and 299,876,080 at September 30, 2019 and December 31, 2018, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_7C50E86D1E6F11A1CE94F046BFEF7018_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_7C50E86D1E6F11A1CE94F046BFEF7018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_7C50E86D1E6F11A1CE94F046BFEF7018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_7C50E86D1E6F11A1CE94F046BFEF7018" xlink:to="lab_us-gaap_CommonStockValue_7C50E86D1E6F11A1CE94F046BFEF7018" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_075B1CBD296E0DC9EB01F046BFEF2760_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_075B1CBD296E0DC9EB01F046BFEF2760" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_075B1CBD296E0DC9EB01F046BFEF2760_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_075B1CBD296E0DC9EB01F046BFEF2760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_075B1CBD296E0DC9EB01F046BFEF2760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_075B1CBD296E0DC9EB01F046BFEF2760" xlink:to="lab_us-gaap_AdditionalPaidInCapital_075B1CBD296E0DC9EB01F046BFEF2760" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_413BC47BC9D46B02EE12F046BFEFC533_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_413BC47BC9D46B02EE12F046BFEFC533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_413BC47BC9D46B02EE12F046BFEFC533_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_413BC47BC9D46B02EE12F046BFEFC533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_413BC47BC9D46B02EE12F046BFEFC533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_413BC47BC9D46B02EE12F046BFEFC533" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_413BC47BC9D46B02EE12F046BFEFC533" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1F126A228A4910242E6F046BFEFA29F_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1F126A228A4910242E6F046BFEFA29F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1F126A228A4910242E6F046BFEFA29F_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1F126A228A4910242E6F046BFEFA29F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1F126A228A4910242E6F046BFEFA29F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1F126A228A4910242E6F046BFEFA29F" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_D1F126A228A4910242E6F046BFEFA29F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D13BE66E04EA3E57868BF046BFEFC21E_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D13BE66E04EA3E57868BF046BFEFC21E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D13BE66E04EA3E57868BF046BFEFC21E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D13BE66E04EA3E57868BF046BFEFC21E" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D13BE66E04EA3E57868BF046BFEFC21E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_BDF4E22C4E876B56CF77F046BFF0F5A6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_BDF4E22C4E876B56CF77F046BFF0F5A6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_BDF4E22C4E876B56CF77F046BFF0F5A6_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_BDF4E22C4E876B56CF77F046BFF0F5A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_BDF4E22C4E876B56CF77F046BFF0F5A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_BDF4E22C4E876B56CF77F046BFF0F5A6" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_BDF4E22C4E876B56CF77F046BFF0F5A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_FDF05CD8690E5896BDCB57EE1C658CBB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_2CDDF2DF0025679DDCBDE23265B8BBD0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_FDF05CD8690E5896BDCB57EE1C658CBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_FDF05CD8690E5896BDCB57EE1C658CBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_FDF05CD8690E5896BDCB57EE1C658CBB" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_FDF05CD8690E5896BDCB57EE1C658CBB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_E230C62F40535F77A65639D03DE1EFC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_A6480B2EC138C0FE5E41E23265B8C964_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_E230C62F40535F77A65639D03DE1EFC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_E230C62F40535F77A65639D03DE1EFC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_E230C62F40535F77A65639D03DE1EFC0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_E230C62F40535F77A65639D03DE1EFC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6CE420926E8A5E43AED026C321D79BF7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Valuation Assumptions Used to Estimate Grant-Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_01E57B45349864149CA9E23265B9FD47_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6CE420926E8A5E43AED026C321D79BF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6CE420926E8A5E43AED026C321D79BF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6CE420926E8A5E43AED026C321D79BF7" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6CE420926E8A5E43AED026C321D79BF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_642D5D1D6336528DA2D0348D55E185C1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D0B6807206449AEC4A1E23265B993A8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_642D5D1D6336528DA2D0348D55E185C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_642D5D1D6336528DA2D0348D55E185C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_642D5D1D6336528DA2D0348D55E185C1" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_642D5D1D6336528DA2D0348D55E185C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_17171091DC4354008F7990B08F279D01" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSU Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_742ADB7D7E0A22926844E23265B9794E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_17171091DC4354008F7990B08F279D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_17171091DC4354008F7990B08F279D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_17171091DC4354008F7990B08F279D01" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_17171091DC4354008F7990B08F279D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6776C4701C6A5933A45F94DB33660323" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1646C039156D6E13482BE23264DCE123_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6776C4701C6A5933A45F94DB33660323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6776C4701C6A5933A45F94DB33660323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6776C4701C6A5933A45F94DB33660323" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6776C4701C6A5933A45F94DB33660323" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B_label_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:to="lab_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98_label_en-US" xlink:label="lab_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:to="lab_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED_terseLabel_en-US" xlink:label="lab_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED_label_en-US" xlink:label="lab_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:to="lab_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B_label_en-US" xlink:label="lab_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B" xlink:to="lab_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5_label_en-US" xlink:label="lab_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5" xlink:to="lab_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, number of programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B_label_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Programs</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementNumberOfPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:to="lab_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, number of preexisting programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288_label_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Preexisting Programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Preexisting Programs</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:to="lab_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement, number of drug discovery programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F_label_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Drug Discovery Programs</link:label>
    <link:label id="lab_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Number Of Drug Discovery Programs</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:to="lab_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional option payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B_label_en-US" xlink:label="lab_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Option Payments</link:label>
    <link:label id="lab_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Additional Option Payments</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementAdditionalOptionPayments" xlink:label="loc_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:to="lab_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development obligation</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0_label_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Obligation</link:label>
    <link:label id="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Research And Development Obligation</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementResearchAndDevelopmentObligation" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:to="lab_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_1E1D94CB1898592C99E1F047DEC589B9_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_1E1D94CB1898592C99E1F047DEC589B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount eligible for development and regulatory milestones</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_1E1D94CB1898592C99E1F047DEC589B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_1E1D94CB1898592C99E1F047DEC589B9" xlink:to="lab_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_1E1D94CB1898592C99E1F047DEC589B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_10861936767453A3959A07B744B58898" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_7847A0CCC5369A4C7FA7E23264DA61D5_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_10861936767453A3959A07B744B58898" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_10861936767453A3959A07B744B58898" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_10861936767453A3959A07B744B58898" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_10861936767453A3959A07B744B58898" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_7097C73C70C45D66BD66F5B03E4F4033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_3CF447B1DC6019A49084E23264D7F2E8_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_7097C73C70C45D66BD66F5B03E4F4033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_7097C73C70C45D66BD66F5B03E4F4033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_7097C73C70C45D66BD66F5B03E4F4033" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_7097C73C70C45D66BD66F5B03E4F4033" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_519AB26A6A5E5E9BB8698C2D21BF3D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_1E41894A9920FCB54206E23264D71C59_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_519AB26A6A5E5E9BB8698C2D21BF3D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_519AB26A6A5E5E9BB8698C2D21BF3D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_519AB26A6A5E5E9BB8698C2D21BF3D52" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_519AB26A6A5E5E9BB8698C2D21BF3D52" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod_A30790E9AAAC54D6A7CDF7FF70DC09CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_8C8EEC530F0799EEF0B7E23264D7E4D0_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod_A30790E9AAAC54D6A7CDF7FF70DC09CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_A30790E9AAAC54D6A7CDF7FF70DC09CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod_A30790E9AAAC54D6A7CDF7FF70DC09CC" xlink:to="lab_us-gaap_FiscalPeriod_A30790E9AAAC54D6A7CDF7FF70DC09CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_D7A2F14902C25B6EA9AFD4C4AF65D94F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_97BB91A34366F3D6F79EE23264D8A95C_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_D7A2F14902C25B6EA9AFD4C4AF65D94F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_D7A2F14902C25B6EA9AFD4C4AF65D94F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_D7A2F14902C25B6EA9AFD4C4AF65D94F" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_D7A2F14902C25B6EA9AFD4C4AF65D94F" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_9A3C7306C9A25D50BE904A855A39E86D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_EBD3D201BAEED3CE7EFAE23264D8F2DD_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_9A3C7306C9A25D50BE904A855A39E86D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_9A3C7306C9A25D50BE904A855A39E86D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_9A3C7306C9A25D50BE904A855A39E86D" xlink:to="lab_us-gaap_UseOfEstimates_9A3C7306C9A25D50BE904A855A39E86D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4DDA9447149F5C35BE478670F3494751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0D5769538B157A8D3F47E23264D8B0B0_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4DDA9447149F5C35BE478670F3494751" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4DDA9447149F5C35BE478670F3494751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4DDA9447149F5C35BE478670F3494751" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4DDA9447149F5C35BE478670F3494751" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8FA144BC6B7455FB91534EA6B40C1747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_57F9C03B4CE9FCB656EAE23264D82886_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8FA144BC6B7455FB91534EA6B40C1747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8FA144BC6B7455FB91534EA6B40C1747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8FA144BC6B7455FB91534EA6B40C1747" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8FA144BC6B7455FB91534EA6B40C1747" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:type="arc" />
    <link:label id="lab_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C_terseLabel_en-US" xlink:label="lab_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ipsen</link:label>
    <link:label id="lab_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C_label_en-US" xlink:label="lab_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C_documentation_en-US" xlink:label="lab_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:to="lab_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:type="arc" />
    <link:label id="lab_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70_terseLabel_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caremark L.L.C.</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70_label_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:label id="lab_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70_documentation_en-US" xlink:label="lab_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caremark L.L.C. [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:to="lab_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:type="arc" />
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:type="arc" />
    <link:label id="lab_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41_terseLabel_en-US" xlink:label="lab_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41_label_en-US" xlink:label="lab_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ASD [Member]</link:label>
    <link:label id="lab_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41_documentation_en-US" xlink:label="lab_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ASD [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ASDMember" xlink:label="loc_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:to="lab_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:type="arc" />
    <link:label id="lab_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A_terseLabel_en-US" xlink:label="lab_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Others, individually less than 10% of Total revenues for all periods presented</link:label>
    <link:label id="lab_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A_label_en-US" xlink:label="lab_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Customers [Member]</link:label>
    <link:label id="lab_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A_documentation_en-US" xlink:label="lab_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Customers [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:to="lab_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_E200336CE3C864F6DFC8E232661C463A_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_A22103C0C0E4576B88FB0CDB3CE578D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_A22103C0C0E4576B88FB0CDB3CE578D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_A22103C0C0E4576B88FB0CDB3CE578D9" xlink:to="lab_us-gaap_IncomeStatementAbstract_A22103C0C0E4576B88FB0CDB3CE578D9" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_11D3ADC1962720366959E232661D4031_terseLabel_en-US" xlink:label="lab_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_exel_CollaborationMember_11D3ADC1962720366959E232661D4031_label_en-US" xlink:label="lab_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_11D3ADC1962720366959E232661D4031_documentation_en-US" xlink:label="lab_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:to="lab_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_90164142B7F4355EFD44E232661E3EAF_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:to="lab_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_F5614C6FEA5053C599C91A1EFD6AFD14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_6170CE73AE64008AD41AE232661E3AFF_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_F5614C6FEA5053C599C91A1EFD6AFD14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_F5614C6FEA5053C599C91A1EFD6AFD14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_F5614C6FEA5053C599C91A1EFD6AFD14" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_F5614C6FEA5053C599C91A1EFD6AFD14" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_F30BD9708FAC551F909A305D2E4FC24D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_03BEE1A8513C58F899CAE232661FAA74_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_F30BD9708FAC551F909A305D2E4FC24D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_F30BD9708FAC551F909A305D2E4FC24D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_F30BD9708FAC551F909A305D2E4FC24D" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_F30BD9708FAC551F909A305D2E4FC24D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_D53D2C45253D5B3F9E0CD4C66085376B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2CFC29A3CDD63C523D9CE232661FDA66_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_D53D2C45253D5B3F9E0CD4C66085376B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D53D2C45253D5B3F9E0CD4C66085376B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D53D2C45253D5B3F9E0CD4C66085376B" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_D53D2C45253D5B3F9E0CD4C66085376B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_8B1B82B93E8758BFB317EDC69A1AD070" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_7AF2E24C737E5270FCF6E232661F04E0_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_8B1B82B93E8758BFB317EDC69A1AD070" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8B1B82B93E8758BFB317EDC69A1AD070" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_8B1B82B93E8758BFB317EDC69A1AD070" xlink:to="lab_us-gaap_OperatingExpenses_8B1B82B93E8758BFB317EDC69A1AD070" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_FB87D881E36E523EA3A33D58ED47F2A1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_731DE428E0C94440030DE232661F2858_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_FB87D881E36E523EA3A33D58ED47F2A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_FB87D881E36E523EA3A33D58ED47F2A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_FB87D881E36E523EA3A33D58ED47F2A1" xlink:to="lab_us-gaap_OperatingIncomeLoss_FB87D881E36E523EA3A33D58ED47F2A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573_verboseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_33379476E6F3F4B03BA8E23266204573_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_094F72CAB6835E52BA4D26829AB7359A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_4AE89AD6679949C68DD3E2326620E49B_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther_094F72CAB6835E52BA4D26829AB7359A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_094F72CAB6835E52BA4D26829AB7359A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther_094F72CAB6835E52BA4D26829AB7359A" xlink:to="lab_us-gaap_InterestIncomeOther_094F72CAB6835E52BA4D26829AB7359A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_25C9575C14B25A8F9ED60D3B72C06AC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_E4BD253AE01903B34699E23266200695_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_25C9575C14B25A8F9ED60D3B72C06AC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_25C9575C14B25A8F9ED60D3B72C06AC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_25C9575C14B25A8F9ED60D3B72C06AC7" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_25C9575C14B25A8F9ED60D3B72C06AC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_517FBB87479A569F82F4C63FBD90A1E1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income (expense), net:</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_B0AACD03815BD6D74EE3E23266213FBF_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_517FBB87479A569F82F4C63FBD90A1E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_517FBB87479A569F82F4C63FBD90A1E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_517FBB87479A569F82F4C63FBD90A1E1" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_517FBB87479A569F82F4C63FBD90A1E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9498C9781DA653FA8FBB4C439E9DF64F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_E32A77CB1A707C5A14DAE2326621B82E_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9498C9781DA653FA8FBB4C439E9DF64F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9498C9781DA653FA8FBB4C439E9DF64F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9498C9781DA653FA8FBB4C439E9DF64F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9498C9781DA653FA8FBB4C439E9DF64F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_22B99C2A59415D6E999198DCDFCEBA18" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8082B178053E43992092E23266216B20_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_22B99C2A59415D6E999198DCDFCEBA18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22B99C2A59415D6E999198DCDFCEBA18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_22B99C2A59415D6E999198DCDFCEBA18" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_22B99C2A59415D6E999198DCDFCEBA18" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_289D323855382F6EAEA0E23266212075_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_207C0599653D549CB52001C5CCA70CCC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_207C0599653D549CB52001C5CCA70CCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_207C0599653D549CB52001C5CCA70CCC" xlink:to="lab_us-gaap_NetIncomeLoss_207C0599653D549CB52001C5CCA70CCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0CD17C26A440A996A45FE23266228B45_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20C9BF6963015616BDE14521997E2867" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income per share, basic (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20C9BF6963015616BDE14521997E2867" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20C9BF6963015616BDE14521997E2867" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20C9BF6963015616BDE14521997E2867" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_CF54F827406174BDE622E23266225339_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3102336355D955018A625AFA58971698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares used in computing net income per share, diluted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3102336355D955018A625AFA58971698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3102336355D955018A625AFA58971698" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3102336355D955018A625AFA58971698" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_872A3DA26E5E63786946F051A450C5D4_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_872A3DA26E5E63786946F051A450C5D4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net contract liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_872A3DA26E5E63786946F051A450C5D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_872A3DA26E5E63786946F051A450C5D4" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_872A3DA26E5E63786946F051A450C5D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_796AF7AA436E5BAB92AC57273C893BFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_EE099072EDF9C31C14DAE23265851E83_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock_796AF7AA436E5BAB92AC57273C893BFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_796AF7AA436E5BAB92AC57273C893BFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock_796AF7AA436E5BAB92AC57273C893BFA" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock_796AF7AA436E5BAB92AC57273C893BFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_5BD3D251791CA1A25A3DE2326589CB4F_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_F1B86C5016A6D2D6020EE232658981AE_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_55DFB2A36C9657AE89B292A7ABEDDE72" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55DFB2A36C9657AE89B292A7ABEDDE72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55DFB2A36C9657AE89B292A7ABEDDE72" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_55DFB2A36C9657AE89B292A7ABEDDE72" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_6E5BFE53462D55DCAA6BB2EDF92F8A67" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in short-term restricted cash and investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_ED9B10145D46195EB41EE2326589E684_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent_6E5BFE53462D55DCAA6BB2EDF92F8A67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_6E5BFE53462D55DCAA6BB2EDF92F8A67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent_6E5BFE53462D55DCAA6BB2EDF92F8A67" xlink:to="lab_us-gaap_RestrictedCashCurrent_6E5BFE53462D55DCAA6BB2EDF92F8A67" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedCashNoncurrent_05AE0E6DB7107746D941E2326589CAE5_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashNoncurrent_4787E0C5187056FE9FD2A51B41DF962D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash included in long-term restricted cash and investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4787E0C5187056FE9FD2A51B41DF962D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashNoncurrent_4787E0C5187056FE9FD2A51B41DF962D" xlink:to="lab_us-gaap_RestrictedCashNoncurrent_4787E0C5187056FE9FD2A51B41DF962D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_7C9C622DA7ED263A1539E23265D05CF0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5D77BA55771363C68C54E23265D0D650_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_AD481CB6CEA96EA8EE54E23265D191E7_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_0DF900E6C3E05B52B414EC9FE334880C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potentially dilutive securities</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_383A674EA70574C7564CE23265D1391B_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember_0DF900E6C3E05B52B414EC9FE334880C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_0DF900E6C3E05B52B414EC9FE334880C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember_0DF900E6C3E05B52B414EC9FE334880C" xlink:to="lab_us-gaap_StockCompensationPlanMember_0DF900E6C3E05B52B414EC9FE334880C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_C24E2ED1AD3AC70EE56CE23265D1A2A8_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19FC374A2ECB5065B5427938D2092576" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anti-dilutive shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_444C506AB2E5E09C88A8E23265D1E450_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19FC374A2ECB5065B5427938D2092576" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19FC374A2ECB5065B5427938D2092576" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19FC374A2ECB5065B5427938D2092576" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19FC374A2ECB5065B5427938D2092576" xlink:type="arc" />
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D843A2105DF6557B87A04496D66A4D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019_label_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D843A2105DF6557B87A04496D66A4D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:label id="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_AD589D8F44FFEE1F8F4CE232654FD019_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D843A2105DF6557B87A04496D66A4D26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Investments [Text Block]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_D843A2105DF6557B87A04496D66A4D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_D843A2105DF6557B87A04496D66A4D26" xlink:to="lab_exel_CashCashEquivalentsAndInvestmentsTextBlock_D843A2105DF6557B87A04496D66A4D26" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96A318CD7DE3E8AA8E61D078F46F88B2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96A318CD7DE3E8AA8E61D078F46F88B2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains or losses on available-for-sale securities, tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96A318CD7DE3E8AA8E61D078F46F88B2_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96A318CD7DE3E8AA8E61D078F46F88B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96A318CD7DE3E8AA8E61D078F46F88B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96A318CD7DE3E8AA8E61D078F46F88B2" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96A318CD7DE3E8AA8E61D078F46F88B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22FDC04A0E4DC7A4089BD078F4702203_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22FDC04A0E4DC7A4089BD078F4702203" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments to net income resulting from realized gains or losses on sale of securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22FDC04A0E4DC7A4089BD078F4702203_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22FDC04A0E4DC7A4089BD078F4702203" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22FDC04A0E4DC7A4089BD078F4702203" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22FDC04A0E4DC7A4089BD078F4702203" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22FDC04A0E4DC7A4089BD078F4702203" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_A2480D5639A95C75B82E648B633871DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_D552BECA74CF5CB09BBAE23265969770_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_A2480D5639A95C75B82E648B633871DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_A2480D5639A95C75B82E648B633871DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_A2480D5639A95C75B82E648B633871DC" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_A2480D5639A95C75B82E648B633871DC" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095_label_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:label id="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement with Daiichi Sankyo [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:to="lab_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_78A800B6275C3F50B05B003DF11C70EA_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_78A800B6275C3F50B05B003DF11C70EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sales of investments available-for-sale</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_78A800B6275C3F50B05B003DF11C70EA_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_78A800B6275C3F50B05B003DF11C70EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_78A800B6275C3F50B05B003DF11C70EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_78A800B6275C3F50B05B003DF11C70EA" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_78A800B6275C3F50B05B003DF11C70EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0AD0166FD94E0207E8D7003DF11C27FD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0AD0166FD94E0207E8D7003DF11C27FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0AD0166FD94E0207E8D7003DF11C27FD_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0AD0166FD94E0207E8D7003DF11C27FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0AD0166FD94E0207E8D7003DF11C27FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0AD0166FD94E0207E8D7003DF11C27FD" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0AD0166FD94E0207E8D7003DF11C27FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_731CF0E7B455F040ED86003DF11C486A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_731CF0E7B455F040ED86003DF11C486A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary impairment charges on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_731CF0E7B455F040ED86003DF11C486A_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_731CF0E7B455F040ED86003DF11C486A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_731CF0E7B455F040ED86003DF11C486A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_731CF0E7B455F040ED86003DF11C486A" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_731CF0E7B455F040ED86003DF11C486A" xlink:type="arc" />
    <link:label id="lab_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039_terseLabel_en-US" xlink:label="lab_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial ownership interest by BlackRock (more than)</link:label>
    <link:label id="lab_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039_label_en-US" xlink:label="lab_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership Interest By Minority Shareholder</link:label>
    <link:label id="lab_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039_documentation_en-US" xlink:label="lab_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Minority Ownership, Ownership Interest</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OwnershipInterestByMinorityShareholder" xlink:label="loc_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039" xlink:to="lab_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039" xlink:type="arc" />
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D_terseLabel_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of cash and investments managed by BlackRock</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D_label_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D_documentation_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D" xlink:to="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D" xlink:type="arc" />
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17_terseLabel_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of cash and investments managed by BlackRock in the BlackRock Liquidity Money Market Fund</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17_label_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17_documentation_en-US" xlink:label="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17" xlink:to="lab_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17" xlink:type="arc" />
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_EE79415CFD8EAD2EA1E9003E9DECC03D_terseLabel_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_EE79415CFD8EAD2EA1E9003E9DECC03D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payable to BlackRock</link:label>
    <link:label id="lab_us-gaap_DueToRelatedPartiesCurrent_EE79415CFD8EAD2EA1E9003E9DECC03D_label_en-US" xlink:label="lab_us-gaap_DueToRelatedPartiesCurrent_EE79415CFD8EAD2EA1E9003E9DECC03D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Due to Related Parties, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_EE79415CFD8EAD2EA1E9003E9DECC03D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DueToRelatedPartiesCurrent_EE79415CFD8EAD2EA1E9003E9DECC03D" xlink:to="lab_us-gaap_DueToRelatedPartiesCurrent_EE79415CFD8EAD2EA1E9003E9DECC03D" xlink:type="arc" />
    <link:label id="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52_terseLabel_en-US" xlink:label="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees for advisory services paid to BlackRock</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52_label_en-US" xlink:label="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Advisory Fees Incurred</link:label>
    <link:label id="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52_documentation_en-US" xlink:label="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related Party Transactions, Advisory Fees Incurred</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_RelatedPartyTransactionsAdvisoryFeesIncurred" xlink:label="loc_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52" xlink:to="lab_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_14281017C240C9BAC02FE23266A34DE4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_C4E64A0E27426939CEC5E23266A3E146_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_DF12596EF4BFE6F07BD0E23266A43DE0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_B7C8CA97568B5A2AA0485F5C989C460B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_073E1176E3F334B56D01E23266A43E29_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_B7C8CA97568B5A2AA0485F5C989C460B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_B7C8CA97568B5A2AA0485F5C989C460B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_B7C8CA97568B5A2AA0485F5C989C460B" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_B7C8CA97568B5A2AA0485F5C989C460B" xlink:type="arc" />
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30_terseLabel_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30_label_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member]</link:label>
    <link:label id="lab_exel_ComputerEquipmentAndSoftwareMember_FB1017B00A9D40D5B295E23266A41A30_documentation_en-US" xlink:label="lab_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Computer Equipment And Software [Member].</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:to="lab_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_FA6D83194E17502998A59CE891201747" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_885BF729AC91B3CC6035E23266A4D0D5_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_FA6D83194E17502998A59CE891201747" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_FA6D83194E17502998A59CE891201747" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_FA6D83194E17502998A59CE891201747" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_FA6D83194E17502998A59CE891201747" xlink:type="arc" />
    <link:label id="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0_terseLabel_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0_label_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_exel_LaboratoryEquipmentMember_E26806020AA1BB8014BFE23266A5EEC0_documentation_en-US" xlink:label="lab_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:to="lab_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_595960FA46955FFD9DA19F31C1BC41C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_4E2DC5D6998A291A04CDE23266A5E363_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_595960FA46955FFD9DA19F31C1BC41C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_595960FA46955FFD9DA19F31C1BC41C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_595960FA46955FFD9DA19F31C1BC41C1" xlink:to="lab_us-gaap_ConstructionInProgressMember_595960FA46955FFD9DA19F31C1BC41C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_06325C59D7D553503C7BE23266A5048C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_57544161E0BB58CC97E5140A97003D1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_6B965C8D8CC49C58D24FE23266A5A22E_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_57544161E0BB58CC97E5140A97003D1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_57544161E0BB58CC97E5140A97003D1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_57544161E0BB58CC97E5140A97003D1E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_57544161E0BB58CC97E5140A97003D1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8E93F2D3893952A7A035AC78B1D7F650" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_69D7530A8060BB16E9ACE23266A6C0E4_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8E93F2D3893952A7A035AC78B1D7F650" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8E93F2D3893952A7A035AC78B1D7F650" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8E93F2D3893952A7A035AC78B1D7F650" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8E93F2D3893952A7A035AC78B1D7F650" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_81D524CBAF849BC75E44E23266A6E5C9_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_C3B1A4AC0A3D5B128DD6549054A67D38" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C3B1A4AC0A3D5B128DD6549054A67D38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_C3B1A4AC0A3D5B128DD6549054A67D38" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_C3B1A4AC0A3D5B128DD6549054A67D38" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_DEC127E3012DBDD01C00E232662B53EA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_136142F19A6E5BA4B5092C01B7A7104F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_C924C7CA6CC551777904E232662BEB24_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_136142F19A6E5BA4B5092C01B7A7104F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_136142F19A6E5BA4B5092C01B7A7104F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_136142F19A6E5BA4B5092C01B7A7104F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_136142F19A6E5BA4B5092C01B7A7104F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36D54B8635C35155AE628C17C10B66D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_1C1AC675E5E342B62FC4E232662C1CFF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36D54B8635C35155AE628C17C10B66D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36D54B8635C35155AE628C17C10B66D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36D54B8635C35155AE628C17C10B66D1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36D54B8635C35155AE628C17C10B66D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6335DF02AE5E5F06A9E15E1A43202A15" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7744B9A4E8561DE705D4E232662CC224_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6335DF02AE5E5F06A9E15E1A43202A15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6335DF02AE5E5F06A9E15E1A43202A15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6335DF02AE5E5F06A9E15E1A43202A15" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6335DF02AE5E5F06A9E15E1A43202A15" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41260A25DEAD52E9B5ED8BD90C183E64" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_86CD02CE53BB9604EBC9E232662C04A4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41260A25DEAD52E9B5ED8BD90C183E64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41260A25DEAD52E9B5ED8BD90C183E64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41260A25DEAD52E9B5ED8BD90C183E64" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41260A25DEAD52E9B5ED8BD90C183E64" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_FB8611C130375A999639119B355CFF37" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_CC459C307A2D4A563A55E232662C5FBE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_FB8611C130375A999639119B355CFF37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_FB8611C130375A999639119B355CFF37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_FB8611C130375A999639119B355CFF37" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_FB8611C130375A999639119B355CFF37" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8C7FB73E25852E0BB776E232662CF343_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71F982EFAFF55837AD19FDB150B5434C" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71F982EFAFF55837AD19FDB150B5434C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71F982EFAFF55837AD19FDB150B5434C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71F982EFAFF55837AD19FDB150B5434C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23EFDA30030F5B9FBFA813661FF69133" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_BB137C67680E69E626AFE232662D0AB6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23EFDA30030F5B9FBFA813661FF69133" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23EFDA30030F5B9FBFA813661FF69133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23EFDA30030F5B9FBFA813661FF69133" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23EFDA30030F5B9FBFA813661FF69133" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_275814423A8A281E0C55E232662D0C31_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6D82C5A36745CA3A4FF56FFADD65F69" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0B69BB33C2868FA87534E232662D85FE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6D82C5A36745CA3A4FF56FFADD65F69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6D82C5A36745CA3A4FF56FFADD65F69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6D82C5A36745CA3A4FF56FFADD65F69" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6D82C5A36745CA3A4FF56FFADD65F69" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_366C7832C41F54C793C938201AAEE224" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_857352D0C583B45E61F3E232662D8854_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_366C7832C41F54C793C938201AAEE224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_366C7832C41F54C793C938201AAEE224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_366C7832C41F54C793C938201AAEE224" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_366C7832C41F54C793C938201AAEE224" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_98849AF6899E569EBFC33C6FCC07394A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_8EC754838023D30D1A3FE232662D34DC_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_98849AF6899E569EBFC33C6FCC07394A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_98849AF6899E569EBFC33C6FCC07394A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_98849AF6899E569EBFC33C6FCC07394A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_98849AF6899E569EBFC33C6FCC07394A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E74D68D1D78E5422BCF4BA58C0B6D98F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_10D5425F4D35430E67D4E232662D90E0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E74D68D1D78E5422BCF4BA58C0B6D98F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E74D68D1D78E5422BCF4BA58C0B6D98F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E74D68D1D78E5422BCF4BA58C0B6D98F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E74D68D1D78E5422BCF4BA58C0B6D98F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1220F50E2DFA5EF6A17B1538674B5638" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_74D22F1538C3C6E043B5E232662E84D4_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1220F50E2DFA5EF6A17B1538674B5638" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1220F50E2DFA5EF6A17B1538674B5638" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1220F50E2DFA5EF6A17B1538674B5638" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1220F50E2DFA5EF6A17B1538674B5638" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_D8282BFFCCC288BBCCBCE232662E742C_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6AD3BF27C3235CB0BCF83278EBCD32A9" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6AD3BF27C3235CB0BCF83278EBCD32A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6AD3BF27C3235CB0BCF83278EBCD32A9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6AD3BF27C3235CB0BCF83278EBCD32A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_345782D85B585D1C8FE933586AA73102" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_1FC9AF24D79D41D7166AE232662E052B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_345782D85B585D1C8FE933586AA73102" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_345782D85B585D1C8FE933586AA73102" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_345782D85B585D1C8FE933586AA73102" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_345782D85B585D1C8FE933586AA73102" xlink:type="arc" />
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_25C5CFF742CFFF461A85E232662E6F99_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:to="lab_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_92E8B59FB74356069D7C8EB93885ED15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_F067D81118ED684CFBC5E232662F2B84_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_92E8B59FB74356069D7C8EB93885ED15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_92E8B59FB74356069D7C8EB93885ED15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_92E8B59FB74356069D7C8EB93885ED15" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_92E8B59FB74356069D7C8EB93885ED15" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F43B10AA851A59DD91C0C5E3954B60C2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F57BF279D78C834D2ADFE232662FAC7D_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F43B10AA851A59DD91C0C5E3954B60C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F43B10AA851A59DD91C0C5E3954B60C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F43B10AA851A59DD91C0C5E3954B60C2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F43B10AA851A59DD91C0C5E3954B60C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_FAB9B122A781516A8CDF22426714039D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_B1C36BE241EECEE0EB9DE232662F8B54_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_FAB9B122A781516A8CDF22426714039D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_FAB9B122A781516A8CDF22426714039D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_FAB9B122A781516A8CDF22426714039D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_FAB9B122A781516A8CDF22426714039D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E7CF9D071AA054489D6C669376BC1783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_94A1663A7410B4A0F6E2E232662FA657_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E7CF9D071AA054489D6C669376BC1783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E7CF9D071AA054489D6C669376BC1783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E7CF9D071AA054489D6C669376BC1783" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E7CF9D071AA054489D6C669376BC1783" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6956E23C87B353F6B40270170E17C0B4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercisable at end of period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6C734778024ADA406B74E232663092C1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6956E23C87B353F6B40270170E17C0B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6956E23C87B353F6B40270170E17C0B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6956E23C87B353F6B40270170E17C0B4" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6956E23C87B353F6B40270170E17C0B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:to="lab_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, surrendered (in square feet)</link:label>
    <link:label id="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC_label_en-US" xlink:label="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Surrendered Area Of Real Estate Property</link:label>
    <link:label id="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC_documentation_en-US" xlink:label="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Surrendered Area Of Real Estate Property</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:to="lab_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:type="arc" />
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9_terseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9_label_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9_documentation_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tenant Lease Improvements, Allowance</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:to="lab_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629" xlink:to="lab_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average operating discount rate used to determine the operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average remaining lease term for operating lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:to="lab_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:type="arc" />
    <link:label id="lab_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752_label_en-US" xlink:label="lab_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752_documentation_en-US" xlink:label="lab_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:to="lab_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:type="arc" />
    <link:label id="lab_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8_terseLabel_en-US" xlink:label="lab_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8_label_en-US" xlink:label="lab_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8_documentation_en-US" xlink:label="lab_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_SalesDiscountsAndAllowancesMember" xlink:label="loc_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:to="lab_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:to="lab_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945_label_en-US" xlink:label="lab_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945" xlink:to="lab_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945" xlink:type="arc" />
    <link:label id="lab_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D_terseLabel_en-US" xlink:label="lab_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development services revenues</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D_label_en-US" xlink:label="lab_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:label id="lab_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D_documentation_en-US" xlink:label="lab_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ResearchandDevelopmentMember" xlink:label="loc_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:to="lab_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:type="arc" />
    <link:label id="lab_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D_terseLabel_en-US" xlink:label="lab_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other collaboration revenues</link:label>
    <link:label id="lab_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D_label_en-US" xlink:label="lab_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Collaboration [Member]</link:label>
    <link:label id="lab_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D_documentation_en-US" xlink:label="lab_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Collaboration [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OtherCollaborationMember" xlink:label="loc_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:to="lab_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_350A5742ABB7CF7C95FF0F844C3C3B80_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_350A5742ABB7CF7C95FF0F844C3C3B80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remainder of 2019</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_350A5742ABB7CF7C95FF0F844C3C3B80_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_350A5742ABB7CF7C95FF0F844C3C3B80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_350A5742ABB7CF7C95FF0F844C3C3B80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_350A5742ABB7CF7C95FF0F844C3C3B80" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_350A5742ABB7CF7C95FF0F844C3C3B80" xlink:type="arc" />
    <link:label id="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4_terseLabel_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Years ending December 31,</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4_label_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Duration Of Maturity [Abstract]</link:label>
    <link:label id="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4_documentation_en-US" xlink:label="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Liabilities, Duration Of Maturity [Abstract]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:to="lab_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88481A79624731142CBF0F844C3D2416_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88481A79624731142CBF0F844C3D2416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88481A79624731142CBF0F844C3D2416_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88481A79624731142CBF0F844C3D2416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88481A79624731142CBF0F844C3D2416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88481A79624731142CBF0F844C3D2416" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88481A79624731142CBF0F844C3D2416" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F40271ED025AE9FAC35A0F844C3EAF04_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F40271ED025AE9FAC35A0F844C3EAF04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F40271ED025AE9FAC35A0F844C3EAF04_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F40271ED025AE9FAC35A0F844C3EAF04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F40271ED025AE9FAC35A0F844C3EAF04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F40271ED025AE9FAC35A0F844C3EAF04" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F40271ED025AE9FAC35A0F844C3EAF04" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47A53C0562B19B830E830F844C3EAD7F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47A53C0562B19B830E830F844C3EAD7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47A53C0562B19B830E830F844C3EAD7F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47A53C0562B19B830E830F844C3EAD7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47A53C0562B19B830E830F844C3EAD7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47A53C0562B19B830E830F844C3EAD7F" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47A53C0562B19B830E830F844C3EAD7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9909FD86871D5BDEBF9C0F844C3E8A7B_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9909FD86871D5BDEBF9C0F844C3E8A7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9909FD86871D5BDEBF9C0F844C3E8A7B_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9909FD86871D5BDEBF9C0F844C3E8A7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9909FD86871D5BDEBF9C0F844C3E8A7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9909FD86871D5BDEBF9C0F844C3E8A7B" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9909FD86871D5BDEBF9C0F844C3E8A7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8430FB11B858A63A20010F844C3E1945_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8430FB11B858A63A20010F844C3E1945" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8430FB11B858A63A20010F844C3E1945_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8430FB11B858A63A20010F844C3E1945" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8430FB11B858A63A20010F844C3E1945" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8430FB11B858A63A20010F844C3E1945" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8430FB11B858A63A20010F844C3E1945" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A3C840609B1F780AA4940F844C3E3854_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A3C840609B1F780AA4940F844C3E3854" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A3C840609B1F780AA4940F844C3E3854_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A3C840609B1F780AA4940F844C3E3854" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A3C840609B1F780AA4940F844C3E3854" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A3C840609B1F780AA4940F844C3E3854" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A3C840609B1F780AA4940F844C3E3854" xlink:type="arc" />
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE_terseLabel_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE_label_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:label id="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE_documentation_en-US" xlink:label="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:to="lab_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6BAE89A850D4CB4F0D6E0F844C3FFC94_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6BAE89A850D4CB4F0D6E0F844C3FFC94" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Present value adjustment</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6BAE89A850D4CB4F0D6E0F844C3FFC94_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6BAE89A850D4CB4F0D6E0F844C3FFC94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6BAE89A850D4CB4F0D6E0F844C3FFC94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6BAE89A850D4CB4F0D6E0F844C3FFC94" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6BAE89A850D4CB4F0D6E0F844C3FFC94" xlink:type="arc" />
    <link:label id="lab_exel_TenantLeaseImprovementsAllowance_D5E8FEFB96AF2B7249AD0F844C3FEFB8_negatedTerseLabel_en-US" xlink:label="lab_exel_TenantLeaseImprovementsAllowance_D5E8FEFB96AF2B7249AD0F844C3FEFB8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tenant improvement reimbursements</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_D5E8FEFB96AF2B7249AD0F844C3FEFB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TenantLeaseImprovementsAllowance_D5E8FEFB96AF2B7249AD0F844C3FEFB8" xlink:to="lab_exel_TenantLeaseImprovementsAllowance_D5E8FEFB96AF2B7249AD0F844C3FEFB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_30493DFC71D602EB383C0F844C3F0410_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_30493DFC71D602EB383C0F844C3F0410" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_30493DFC71D602EB383C0F844C3F0410" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_30493DFC71D602EB383C0F844C3F0410" xlink:to="lab_us-gaap_OperatingLeaseLiability_30493DFC71D602EB383C0F844C3F0410" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:type="arc" />
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0_label_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Products Derived From Cabozantinib [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Products Derived from Cabozantinib [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:to="lab_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:type="arc" />
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Resulting from Discovery Efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:type="arc" />
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:type="arc" />
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:to="lab_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A" xlink:to="lab_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6BFFC701419650D2AE345266BD947660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_750E1C790D5FB569A4BEE232655E7E21_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6BFFC701419650D2AE345266BD947660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6BFFC701419650D2AE345266BD947660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6BFFC701419650D2AE345266BD947660" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6BFFC701419650D2AE345266BD947660" xlink:type="arc" />
    <link:label id="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA_verboseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit on reimbursement per year</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Annual Reimbursement Limit</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Annual Reimbursement Limit</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementAnnualReimbursementLimit" xlink:label="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:to="lab_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762_verboseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in maximum amount eligible for development and regulatory milestones</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:to="lab_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:type="arc" />
    <link:label id="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payments earned</link:label>
    <link:label id="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76_label_en-US" xlink:label="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Milestone Payments Earned</link:label>
    <link:label id="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement, Milestone Payments Earned</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementMilestonePaymentsEarned" xlink:label="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:to="lab_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:type="arc" />
    <link:label id="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC_verboseLabel_en-US" xlink:label="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Increase in maximum amount eligible for commercial milestones under collaborations agreement</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC_label_en-US" xlink:label="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:label id="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC_documentation_en-US" xlink:label="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase in Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:to="lab_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net contract liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5" xlink:to="lab_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_455D17C804750BE791C0B3E4516D4E1A_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_455D17C804750BE791C0B3E4516D4E1A" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at beginning of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_455D17C804750BE791C0B3E4516D4E1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_455D17C804750BE791C0B3E4516D4E1A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_455D17C804750BE791C0B3E4516D4E1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5DF1F6F391EB23374E10B3E4516D8DB8_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5DF1F6F391EB23374E10B3E4516D8DB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5DF1F6F391EB23374E10B3E4516D8DB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5DF1F6F391EB23374E10B3E4516D8DB8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5DF1F6F391EB23374E10B3E4516D8DB8" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E_negatedLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ACBEA33A45245ABCDC36B3E4516DCE30_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ACBEA33A45245ABCDC36B3E4516DCE30" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ACBEA33A45245ABCDC36B3E4516DCE30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ACBEA33A45245ABCDC36B3E4516DCE30" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ACBEA33A45245ABCDC36B3E4516DCE30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and released (in dollars per share)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C2521345A7166ADEB6DDB3E4516E7616_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C2521345A7166ADEB6DDB3E4516E7616" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C2521345A7166ADEB6DDB3E4516E7616" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C2521345A7166ADEB6DDB3E4516E7616" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C2521345A7166ADEB6DDB3E4516E7616" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:type="arc" />
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F_periodEndLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">RSUs outstanding at end of period</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</link:label>
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>exel-20190927_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestments" xlink:href="exel-20190927.xsd#CashAndInvestments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:href="exel-20190927.xsd#CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:href="exel-20190927.xsd#CashAndInvestmentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreements" xlink:href="exel-20190927.xsd#CollaborationAgreements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsDaiichiSankyoDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsIpsenCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:href="exel-20190927.xsd#CollaborationAgreementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:href="exel-20190927.xsd#CollaborationAgreementsTakedaCollaborationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:href="exel-20190927.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="exel-20190927.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:href="exel-20190927.xsd#CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:href="exel-20190927.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:href="exel-20190927.xsd#FairValueMeasurements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:href="exel-20190927.xsd#FairValueMeasurementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:href="exel-20190927.xsd#FairValueMeasurementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxes" xlink:href="exel-20190927.xsd#IncomeTaxes" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:href="exel-20190927.xsd#IncomeTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:href="exel-20190927.xsd#Inventory" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:href="exel-20190927.xsd#InventoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:href="exel-20190927.xsd#InventoryTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Leases" xlink:href="exel-20190927.xsd#Leases" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:href="exel-20190927.xsd#LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:href="exel-20190927.xsd#LeasesComponentsOfLeaseExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="exel-20190927.xsd#LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:href="exel-20190927.xsd#LeasesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/LeasesTables" xlink:href="exel-20190927.xsd#LeasesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:href="exel-20190927.xsd#NetIncomePerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:href="exel-20190927.xsd#NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:href="exel-20190927.xsd#NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:href="exel-20190927.xsd#NetIncomePerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="exel-20190927.xsd#OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:href="exel-20190927.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="exel-20190927.xsd#OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipment" xlink:href="exel-20190927.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:href="exel-20190927.xsd#PropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="exel-20190927.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:href="exel-20190927.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:href="exel-20190927.xsd#Revenues" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:href="exel-20190927.xsd#RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" xlink:href="exel-20190927.xsd#RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:href="exel-20190927.xsd#RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:href="exel-20190927.xsd#RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:href="exel-20190927.xsd#RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:href="exel-20190927.xsd#RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:href="exel-20190927.xsd#RevenuesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:href="exel-20190927.xsd#StockBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationRsuActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:href="exel-20190927.xsd#StockBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:href="exel-20190927.xsd#StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEvents" xlink:href="exel-20190927.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:href="exel-20190927.xsd#SubsequentEventsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C852EC23DB135865A8E0F05EB1E7BAF2" xlink:type="locator" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsAndInvestmentsTextBlock" xlink:label="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_D843A2105DF6557B87A04496D66A4D26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_C852EC23DB135865A8E0F05EB1E7BAF2" xlink:to="loc_exel_CashCashEquivalentsAndInvestmentsTextBlock_D843A2105DF6557B87A04496D66A4D26" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1C5FC90C3B38C089654CB97AF81888C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_1C5FC90C3B38C089654CB97AF81888C7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_D8723BD9E5C9A0769544B97AF8181ED2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:to="loc_us-gaap_FinancialInstrumentAxis_D8723BD9E5C9A0769544B97AF8181ED2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_D8723BD9E5C9A0769544B97AF8181ED2" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_0881B987BDEF9F00ED72B97AF818A80F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_0881B987BDEF9F00ED72B97AF818A80F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_0DCA26283D39A2A18101B97AF818779D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_0DCA26283D39A2A18101B97AF818779D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DED3BDC7CC1EAB74B824B99E69FE38C4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_74FBCD80AA2BD5F0B8B0B97AF818B035" xlink:to="loc_us-gaap_CommercialPaperMember_DED3BDC7CC1EAB74B824B99E69FE38C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_1A30F3486B83D43A1BE7B97AF8183C18" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_5B3B87BC193C99ACB632B97AF818CC0C" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months_BE89BCC7DC4B3FA8B582B97AF8183B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_708DF3FAA7F045BC3282B97AF8188C6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_6EC684A49040E083125FB97AF8187AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss_0B6F41E0F410E195E646B97AF8180301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_AA1772E4A5CA0C6AC416B97AF8183AE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_26BABB53300D0023B805B97AF8187118" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_C621254540B6F943995EB97AF818FDAA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2D668A08568E5675A28B2DF57291D1AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_020D0BBC452A5464A041A771D1E218E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2D668A08568E5675A28B2DF57291D1AF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_020D0BBC452A5464A041A771D1E218E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9000CBDD58C35E25B056F8363EB95C30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2D668A08568E5675A28B2DF57291D1AF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_9000CBDD58C35E25B056F8363EB95C30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82022B52F5F150B69D4C75DF91CFCF28" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_2D668A08568E5675A28B2DF57291D1AF" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_82022B52F5F150B69D4C75DF91CFCF28" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_F624640D0AB5ED12ABD71A7263383E72" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentTable" xlink:label="loc_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_F624640D0AB5ED12ABD71A7263383E72" xlink:to="loc_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_1AD5A1B9E05DEDD6B95F1A72633B33FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:to="loc_us-gaap_FinancialInstrumentAxis_1AD5A1B9E05DEDD6B95F1A72633B33FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_1AD5A1B9E05DEDD6B95F1A72633B33FE" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_FC3C19F95B92311DA2D21A72633CA236" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_MoneyMarketFundsMember_FC3C19F95B92311DA2D21A72633CA236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_AD150C4B3DB75421CE711A72633E2E0A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_CommercialPaperMember_AD150C4B3DB75421CE711A72633E2E0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_D9B8D9049D7CC77ECF111A72633EFD35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_D9B8D9049D7CC77ECF111A72633EFD35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_193A59A7224BFAFC11EA1A72633EBDA2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_193A59A7224BFAFC11EA1A72633EBDA2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashAndRestrictedCashMember" xlink:label="loc_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_exel_CashAndRestrictedCashMember_50AAB1B2B31BBD1D35441A72633E5524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_B7E2F1E31B97E6E6C1861A72633FA62B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3351E6BD5F96E23A90D21A72633B9025" xlink:to="loc_us-gaap_CertificatesOfDepositMember_B7E2F1E31B97E6E6C1861A72633FA62B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd#invest_InvestmentLineItems" xlink:label="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentTable_55F77F8C40C141C8E5021A72633ABA77" xlink:to="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_D08F3088384066A444DC1A72633F6FB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_4799D71C256D35226B2F1A72633F48F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_CACE7F8FF7630FA162731A72633F05CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E22E0D448C9940B7A1651A72633F15C1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_E22E0D448C9940B7A1651A72633F15C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_DC08A2B9A5E0A0746BDF1A726340D398" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_A67E206C03CF56B9045F1A7266166054" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_BAAFED90DA805D95533E1A730628C4E2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_215BD65C5DD9BB2369E81A726340E5C7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_215BD65C5DD9BB2369E81A726340E5C7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_86A8DF6A8CAFF6FBCC5B1A726340ABC0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_F205A022932EF7C99B911A726340C803" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_81D92738A3168AB700EC1A76530A4AA4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_invest_InvestmentLineItems_3DCA248595B3942978451A72633F26EE" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_04348E7732E19E5D9FF11A726340A94B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75BB612FB16099A02DE4003DF11B1D74" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_78A800B6275C3F50B05B003DF11C70EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75BB612FB16099A02DE4003DF11B1D74" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_78A800B6275C3F50B05B003DF11C70EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0AD0166FD94E0207E8D7003DF11C27FD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75BB612FB16099A02DE4003DF11B1D74" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_0AD0166FD94E0207E8D7003DF11C27FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_731CF0E7B455F040ED86003DF11C486A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75BB612FB16099A02DE4003DF11B1D74" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale_731CF0E7B455F040ED86003DF11C486A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OwnershipInterestByMinorityShareholder" xlink:label="loc_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75BB612FB16099A02DE4003DF11B1D74" xlink:to="loc_exel_OwnershipInterestByMinorityShareholder_0C88367D8CDA85CFBD78003DF11C1039" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75BB612FB16099A02DE4003DF11B1D74" xlink:to="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner_5810C39C265E89FCE969003DF11C172D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund" xlink:label="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75BB612FB16099A02DE4003DF11B1D74" xlink:to="loc_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund_44E7BB9AED52674109B0003DF11D3C17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DueToRelatedPartiesCurrent" xlink:label="loc_us-gaap_DueToRelatedPartiesCurrent_EE79415CFD8EAD2EA1E9003E9DECC03D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75BB612FB16099A02DE4003DF11B1D74" xlink:to="loc_us-gaap_DueToRelatedPartiesCurrent_EE79415CFD8EAD2EA1E9003E9DECC03D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_RelatedPartyTransactionsAdvisoryFeesIncurred" xlink:label="loc_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_75BB612FB16099A02DE4003DF11B1D74" xlink:to="loc_exel_RelatedPartyTransactionsAdvisoryFeesIncurred_8E144B0DDA1AF041E626003DF11D2C52" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9096BEDFBB635C3090817C3BEF69F9EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:type="locator" />
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_9096BEDFBB635C3090817C3BEF69F9EA" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55DFB2A36C9657AE89B292A7ABEDDE72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_55DFB2A36C9657AE89B292A7ABEDDE72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashCurrent" xlink:label="loc_us-gaap_RestrictedCashCurrent_6E5BFE53462D55DCAA6BB2EDF92F8A67" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:to="loc_us-gaap_RestrictedCashCurrent_6E5BFE53462D55DCAA6BB2EDF92F8A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_4787E0C5187056FE9FD2A51B41DF962D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_4787E0C5187056FE9FD2A51B41DF962D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8308AE3A4282557E869F1AD4F93176FA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_47F3460C9A5850878E97A22BA4C146EE" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8308AE3A4282557E869F1AD4F93176FA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashAndInvestmentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CC5CCA9965D55E2790A2B622CDE8EF5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_349365A1AB2154E5908173C42E0C22CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CC5CCA9965D55E2790A2B622CDE8EF5E" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_349365A1AB2154E5908173C42E0C22CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A05ED9FFCCF15C3D93F4C74608E860C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CC5CCA9965D55E2790A2B622CDE8EF5E" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_A05ED9FFCCF15C3D93F4C74608E860C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_51014443E6955E40B67E8CAA1EF17056" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CC5CCA9965D55E2790A2B622CDE8EF5E" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_51014443E6955E40B67E8CAA1EF17056" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_835B503545635ABA8FB49186F4AC2A07" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CC5CCA9965D55E2790A2B622CDE8EF5E" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_835B503545635ABA8FB49186F4AC2A07" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_E9B7E06249EF57F7A142D9DDC86AE85D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_CC5CCA9965D55E2790A2B622CDE8EF5E" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_E9B7E06249EF57F7A142D9DDC86AE85D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3521226B7C1456BF8572F0D0CECD9874" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_C2AE219C5A795AD784677CE4BFB8C6E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_3521226B7C1456BF8572F0D0CECD9874" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_C2AE219C5A795AD784677CE4BFB8C6E6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E2AD4AAF12F01C8E7299F047DEC2CD43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27C2752B1FAF82B10BF4F047DEC2F8BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E2AD4AAF12F01C8E7299F047DEC2CD43" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27C2752B1FAF82B10BF4F047DEC2F8BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_57BD2EF25B284F3BF5D5F047DEC2C008" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27C2752B1FAF82B10BF4F047DEC2F8BB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_57BD2EF25B284F3BF5D5F047DEC2C008" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BAEA0B6269F56CD64B7F047DEC38976" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_57BD2EF25B284F3BF5D5F047DEC2C008" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BAEA0B6269F56CD64B7F047DEC38976" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember" xlink:label="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3BAEA0B6269F56CD64B7F047DEC38976" xlink:to="loc_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember_938F3EC7E529D5E7E9F9F047DEC3904B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27C2752B1FAF82B10BF4F047DEC2F8BB" xlink:to="loc_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_B56CC7B298465C943977F047DEC32B98" xlink:to="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:to="loc_srt_MinimumMember_AAA951A40C7331B9A8B1F047DEC4DC3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_C5AA83F561D30F71A388F047DEC3B6ED" xlink:to="loc_srt_MaximumMember_7C7CA8BF8AD422EB50B1F047DEC44BC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_27C2752B1FAF82B10BF4F047DEC2F8BB" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementNumberOfPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementNumberOfPrograms_B4AD97015E3C0893EDB6F047DEC4908B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_89259B571FB6586FD4BAF047DEC59DD5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_89259B571FB6586FD4BAF047DEC59DD5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementNumberOfPreexistingPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementNumberOfPreexistingPrograms_8A340F957ADCAF6F3E7BF047DEC57288" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms" xlink:label="loc_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms_E1DB78AD10DCDE8DA64AF047DEC5956F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementAdditionalOptionPayments" xlink:label="loc_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementAdditionalOptionPayments_9DE04DDD7A8904CF4493F0691141248B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementResearchAndDevelopmentObligation" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentObligation_E7E0CD8817C41ABF59AEF047DEC547F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_588E5274ECB4886DE74CF0679B1D9158" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_588E5274ECB4886DE74CF0679B1D9158" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_4BFDFC41073CC945F859F047DEC58BC2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_4BFDFC41073CC945F859F047DEC58BC2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_1E1D94CB1898592C99E1F047DEC589B9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_1E1D94CB1898592C99E1F047DEC589B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_3617FDF9ABBD5C964D71F047DEC6C04F" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_99FA5670C3C49962BDF6F047DEC451A5" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_3617FDF9ABBD5C964D71F047DEC6C04F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_860EECB2E022251FBA1FF047DECF584F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9435D3D9E152FEBA2149F047DECF3220" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_860EECB2E022251FBA1FF047DECF584F" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9435D3D9E152FEBA2149F047DECF3220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_72B6F4460EFEB89EAE00F047DECF3EF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9435D3D9E152FEBA2149F047DECF3220" xlink:to="loc_us-gaap_TypeOfArrangementAxis_72B6F4460EFEB89EAE00F047DECF3EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8C38F8F4493ED05E6249F047DED0B35C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_72B6F4460EFEB89EAE00F047DECF3EF6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8C38F8F4493ED05E6249F047DED0B35C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_D39120226EE804EE54ABF047DED0A5E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8C38F8F4493ED05E6249F047DED0B35C" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_D39120226EE804EE54ABF047DED0A5E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A79520386792B15DB4CEF047DED00E83" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9435D3D9E152FEBA2149F047DECF3220" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A79520386792B15DB4CEF047DED00E83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C9D21FE30BC1D68B7D15F047DED0E67C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A79520386792B15DB4CEF047DED00E83" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_C9D21FE30BC1D68B7D15F047DED0E67C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_682846F9C35A54FA97C2525223ECE005" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10938FFB63675C1EB5B90275C35602A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_682846F9C35A54FA97C2525223ECE005" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10938FFB63675C1EB5B90275C35602A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_721C7C31254A52F2BDBE52742658DAF2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10938FFB63675C1EB5B90275C35602A1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_721C7C31254A52F2BDBE52742658DAF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_709BD66CC33D5BDDB19F544D527B795D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_721C7C31254A52F2BDBE52742658DAF2" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_709BD66CC33D5BDDB19F544D527B795D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_576A3282DAD553EB9E0A25DB76655235" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_709BD66CC33D5BDDB19F544D527B795D" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_576A3282DAD553EB9E0A25DB76655235" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0B2A558EFB354A29DCB6F925C0A52CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_10938FFB63675C1EB5B90275C35602A1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0B2A558EFB354A29DCB6F925C0A52CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CAD0BE9C4AF5E09A55B298E09F2AD9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E0B2A558EFB354A29DCB6F925C0A52CD" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3CAD0BE9C4AF5E09A55B298E09F2AD9B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E299607FA7E85EB8BF617ECE0FFE1CD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F19ACBF9B25052D19D3AB45E01FD65A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_E299607FA7E85EB8BF617ECE0FFE1CD6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F19ACBF9B25052D19D3AB45E01FD65A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_7383D0504FC55487B58A12A524CE29E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F19ACBF9B25052D19D3AB45E01FD65A4" xlink:to="loc_us-gaap_TypeOfArrangementAxis_7383D0504FC55487B58A12A524CE29E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_23EED257CB87554A8ED138999BF4B5AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_7383D0504FC55487B58A12A524CE29E7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_23EED257CB87554A8ED138999BF4B5AE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_23EED257CB87554A8ED138999BF4B5AE" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_939112AF3D265B0B8018D7052009811C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6F982827751A5F0BA10D06474805B33E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_F19ACBF9B25052D19D3AB45E01FD65A4" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6F982827751A5F0BA10D06474805B33E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B18C6796A77755628371FD1FA816B246" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6F982827751A5F0BA10D06474805B33E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_B18C6796A77755628371FD1FA816B246" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_832BEE27EF2942BC7B99B3E451E3F9ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_973319DD163192D5259DB3E451E32E43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_832BEE27EF2942BC7B99B3E451E3F9ED" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_973319DD163192D5259DB3E451E32E43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FF28B0DA84C5C37228A8B3E451E3EF75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_973319DD163192D5259DB3E451E32E43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FF28B0DA84C5C37228A8B3E451E3EF75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B57AF75733E7503C7E0FB3E451E386EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FF28B0DA84C5C37228A8B3E451E3EF75" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B57AF75733E7503C7E0FB3E451E386EF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementwithDaiichiSankyoMember" xlink:label="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_B57AF75733E7503C7E0FB3E451E386EF" xlink:to="loc_exel_CollaborationAgreementwithDaiichiSankyoMember_79BFC33BD543FC6986A2B3E451E4E095" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_50E026369FB02182A29FB3E451E40690" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_973319DD163192D5259DB3E451E32E43" xlink:to="loc_srt_ProductOrServiceAxis_50E026369FB02182A29FB3E451E40690" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_188AD269014C5BF4BA0AB3E451E453B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_50E026369FB02182A29FB3E451E40690" xlink:to="loc_srt_ProductsAndServicesDomain_188AD269014C5BF4BA0AB3E451E453B7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_C08ACD085607F5C64DF0B3E451E49EC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_188AD269014C5BF4BA0AB3E451E453B7" xlink:to="loc_exel_CollaborationMember_C08ACD085607F5C64DF0B3E451E49EC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B6401B4D19A90B4A184FB3E451E5192B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_973319DD163192D5259DB3E451E32E43" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B6401B4D19A90B4A184FB3E451E5192B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8E5AFA143CABFF72A054B3E451E5256F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B6401B4D19A90B4A184FB3E451E5192B" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8E5AFA143CABFF72A054B3E451E5256F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_886F782374058C7E0E6DB3E451E5CE72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_B6401B4D19A90B4A184FB3E451E5192B" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_886F782374058C7E0E6DB3E451E5CE72" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_667DB500F64CE1115079FA3E4AF25592" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_68E90CD796F1BF0AA5EDFA3E4AF2A48C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_667DB500F64CE1115079FA3E4AF25592" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_68E90CD796F1BF0AA5EDFA3E4AF2A48C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FB3175E19266B2056835FA3E4AF2FCD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_68E90CD796F1BF0AA5EDFA3E4AF2A48C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FB3175E19266B2056835FA3E4AF2FCD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80EB356F53262843D727FA3E4AF2A19E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FB3175E19266B2056835FA3E4AF2FCD9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80EB356F53262843D727FA3E4AF2A19E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementWithIconicTherapeuticsInc.Member" xlink:label="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_80EB356F53262843D727FA3E4AF2A19E" xlink:to="loc_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member_64EC91AA625AF6178E14FA3E4AF22EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_68E90CD796F1BF0AA5EDFA3E4AF2A48C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementsUpfrontPayments" xlink:label="loc_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborationAgreementsUpfrontPayments_1CDA867543598101437CFA3E4AF3B69D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued" xlink:label="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued_3A21EDB9BFB60F8A14D6FA3E4AF3C515" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption" xlink:label="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption_A1E48FD05318C5386C58FA3E4AF34F0E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_E103AD71D8726F89815CFA3E4AF4CA3D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_C6CA35EBE1ABA0A5575EFA3E4AF34247" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_84F038A0DBD8920E40D3FA3E4AF4B404" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CBB14499D74C132CB332F047DEE88DF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_AD34C8EAA13C5748369CF047DEE91642" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_CBB14499D74C132CB332F047DEE88DF5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_AD34C8EAA13C5748369CF047DEE91642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EE098DC897FAA86D73A8F047DEE9B854" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_AD34C8EAA13C5748369CF047DEE91642" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EE098DC897FAA86D73A8F047DEE9B854" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04583226057700FE90F9F047DEE9CAB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EE098DC897FAA86D73A8F047DEE9B854" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04583226057700FE90F9F047DEE9CAB3" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_57DCB0F3455F5ED52E13F047DEEACDA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04583226057700FE90F9F047DEE9CAB3" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_57DCB0F3455F5ED52E13F047DEEACDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_028B3344DA095774D8A0F047DEEAC46A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_AD34C8EAA13C5748369CF047DEE91642" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_028B3344DA095774D8A0F047DEEAC46A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_028B3344DA095774D8A0F047DEEAC46A" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_BBAE32ABA9D273AA8BBCF047DEEA51B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_872A3DA26E5E63786946F051A450C5D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_028B3344DA095774D8A0F047DEEAC46A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_872A3DA26E5E63786946F051A450C5D4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9E4F821FB8DC5DD4BF37681A0E932B66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CF9B067B6F1F5967B26039E64DE6F95C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9E4F821FB8DC5DD4BF37681A0E932B66" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CF9B067B6F1F5967B26039E64DE6F95C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_0457BE6BC5A5531EB8F318EFF5917D43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CF9B067B6F1F5967B26039E64DE6F95C" xlink:to="loc_us-gaap_TypeOfArrangementAxis_0457BE6BC5A5531EB8F318EFF5917D43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57C2469F36A354C1A3E5CB67BF72EEAC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_0457BE6BC5A5531EB8F318EFF5917D43" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57C2469F36A354C1A3E5CB67BF72EEAC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithGenentechMember" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_57C2469F36A354C1A3E5CB67BF72EEAC" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_C01B1E89105554328D4EABFA25CEF4A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5275AACB7F8555928ABE3B4E2C13AC21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_CF9B067B6F1F5967B26039E64DE6F95C" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5275AACB7F8555928ABE3B4E2C13AC21" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5275AACB7F8555928ABE3B4E2C13AC21" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_B92483EEC4C351C08C40E4DCD765FE52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8F4E097CB4CC59139845BF6DC074204E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5275AACB7F8555928ABE3B4E2C13AC21" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8F4E097CB4CC59139845BF6DC074204E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_133853DD30EC6115FC51B3E451D4402D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_133853DD30EC6115FC51B3E451D4402D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:to="loc_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_78D0BD709DE3FB19EE1CB3E451D58E40" xlink:to="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_EAAF7F47F795D7255C88B3E451D5496C" xlink:to="loc_exel_GlaxoSmithKlineMember_212243670A3567FF5AB5B3E451D521E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:to="loc_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_57EC4197E36FD849EEC7B3E451D5A6D7" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_C0E6AF374CD836E8A344B45DA6290B19" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_14FDA26EEC90523ADC21B3E451D6598E" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_63F71E4483A18EA36FE3B3E451D64BA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7D30BCCA40D5D3ACAC69B3E451D4B266" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_204631374041C734F92BB3E451D6AEDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3AD6074E3BA547C2B06EB3E451D68CF2" xlink:to="loc_us-gaap_RoyaltyExpense_484FA7F0FAF61C87EE2CB3E451D72423" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8552C95F6625AFFB79DC56484F19B0C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6BFFC701419650D2AE345266BD947660" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_F8552C95F6625AFFB79DC56484F19B0C" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_6BFFC701419650D2AE345266BD947660" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A7E720287E4C71945CFB17E2EDD65521" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E91A75B1EAD112DDD3F417E2EDD678FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_A7E720287E4C71945CFB17E2EDD65521" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E91A75B1EAD112DDD3F417E2EDD678FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_CD0F035FE2E1F4D92AF617E2EDD7D3DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E91A75B1EAD112DDD3F417E2EDD678FF" xlink:to="loc_us-gaap_TypeOfArrangementAxis_CD0F035FE2E1F4D92AF617E2EDD7D3DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_462DB8A8F276FA01F6A317E2EDD74663" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CD0F035FE2E1F4D92AF617E2EDD7D3DF" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_462DB8A8F276FA01F6A317E2EDD74663" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithTakedaMember" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_5DAED9E59D5D9BF8E60A17E2EDD769BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_462DB8A8F276FA01F6A317E2EDD74663" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_5DAED9E59D5D9BF8E60A17E2EDD769BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_E91A75B1EAD112DDD3F417E2EDD678FF" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementAnnualReimbursementLimit" xlink:label="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_CollaborativeArrangementAnnualReimbursementLimit_39F956CC35EA57BEF83617E2EDD8A0AA" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_98835A05C8D30783FFBB17E2EDD89762" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones" xlink:label="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_401B8D8E41DE84D676D717E2EDD88ECB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones_401B8D8E41DE84D676D717E2EDD88ECB" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementMilestonePaymentsEarned" xlink:label="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_CollaborationAgreementMilestonePaymentsEarned_D85D20BD617BFA7F554817E2EDD86E76" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_5E64B3B4469D367FCA8517E2EDD85DFC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement" xlink:label="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_EC8D541E38029E25CC0417E2EDD99DB9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement_EC8D541E38029E25CC0417E2EDD99DB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_C921E93FD8B8EA6F0EE917E2EDD9A4EE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_C921E93FD8B8EA6F0EE917E2EDD9A4EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="loc_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_AA0EB0EED33B74D9A40217E2EDD785FF" xlink:to="loc_us-gaap_ContractWithCustomerLiability_84AF4DA57537885CA30417E2EDD951F5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_9DCC981BE6B0452EA8ACF046BFE887B9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9DCC981BE6B0452EA8ACF046BFE887B9" xlink:to="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B2C0509DC60755571BFDF046BFE8BC12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_B2C0509DC60755571BFDF046BFE8BC12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_EFF330445412A306CF49F046BFE9C830" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:to="loc_us-gaap_ShortTermInvestments_EFF330445412A306CF49F046BFE9C830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="loc_us-gaap_ReceivablesNetCurrent_D046AC1AD5B631004A8FF046BFE9F85A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:to="loc_us-gaap_ReceivablesNetCurrent_D046AC1AD5B631004A8FF046BFE9F85A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherReceivablesNetCurrent" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_56F0C7BD3FF7CB2DA74FF046BFE9A5B2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_56F0C7BD3FF7CB2DA74FF046BFE9A5B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_2391734F822E1D43A013F046BFE97D6C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:to="loc_us-gaap_InventoryNet_2391734F822E1D43A013F046BFE97D6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C0E3A546E62D84803AF6F046BFEA7305" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_C0E3A546E62D84803AF6F046BFEA7305" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_1A5836BCC03B32C18C77F046BFEA2A2B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8D080EBFEB7E78F89E29F046BFE8A590" xlink:to="loc_us-gaap_AssetsCurrent_1A5836BCC03B32C18C77F046BFEA2A2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_EFF27BA6E8253ACEDA62F046BFEAB5AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="loc_us-gaap_LongTermInvestments_EFF27BA6E8253ACEDA62F046BFEAB5AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="loc_us-gaap_RestrictedCashNoncurrent_DFE7BE221925F9DD9F60F046BFEAA395" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="loc_us-gaap_RestrictedCashNoncurrent_DFE7BE221925F9DD9F60F046BFEAA395" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8120C437505454D160CDF046BFEA934B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8120C437505454D160CDF046BFEA934B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_84BDBBAFA1F1D88401F2F046BFEA44B3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_84BDBBAFA1F1D88401F2F046BFEA44B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_DC5825D97F165E88D198F046BFEB6FCD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_DC5825D97F165E88D198F046BFEB6FCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3EBD4C579DB7E36E2462F046BFEB2370" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="loc_us-gaap_Goodwill_3EBD4C579DB7E36E2462F046BFEB2370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_1642A7BEC7E82FAFE518F046BFEBA1BD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_1642A7BEC7E82FAFE518F046BFEBA1BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_FBB8CFBBFDD7E4ACDE0FF046BFEBF78F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_A6A40E76845FBD1D3748F046BFE8160C" xlink:to="loc_us-gaap_Assets_FBB8CFBBFDD7E4ACDE0FF046BFEBF78F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_9DCC981BE6B0452EA8ACF046BFE887B9" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_811B63B5DE8884D5575CF046BFECE50E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:to="loc_us-gaap_AccountsPayableCurrent_811B63B5DE8884D5575CF046BFECE50E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_CCC34F3F5FD163817DD8F046BFEC35B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_CCC34F3F5FD163817DD8F046BFEC35B4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AccruedClinicalLiabilitiesCurrent" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_8FBC2D501CE612F21A8BF046BFEC5996" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_21755B9FCFEBEF9BA7F3F046BFED42A1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_21755B9FCFEBEF9BA7F3F046BFED42A1" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AccruedCollaborationLiabilityCurrent" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_99D734BAE71B2E6FB56FF046BFED736C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_408D86AEFC368696CC24F046BFED06FC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_408D86AEFC368696CC24F046BFED06FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_C995E7C505A9A44FD2BAF046BFED50AE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_0F53F4E75725A7C9831CF046BFEB2B85" xlink:to="loc_us-gaap_LiabilitiesCurrent_C995E7C505A9A44FD2BAF046BFED50AE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingAndFinanceLeasesLiabilityLongTerm" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityLongTerm_A60748410791682C1C4AF046BFEDEF3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_C890A33261262F6F1743F046BFEE04ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_C890A33261262F6F1743F046BFEE04ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_C1898EB6551FF1621A32F046BFEEB7AD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_C1898EB6551FF1621A32F046BFEEB7AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_ACF771910BA94F63D48FF046BFEE0EFA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:to="loc_us-gaap_Liabilities_ACF771910BA94F63D48FF046BFEE0EFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_B0AD5ECD62C8317CF2B4F046BFEE08F6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:to="loc_us-gaap_CommitmentsAndContingencies_B0AD5ECD62C8317CF2B4F046BFEE08F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_C26E7B398279A5B3E78FF046BFEE15B6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:to="loc_us-gaap_StockholdersEquityAbstract_C26E7B398279A5B3E78FF046BFEE15B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_CBAC3659BB18D0A92B8AF046BFEE5964" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C26E7B398279A5B3E78FF046BFEE15B6" xlink:to="loc_us-gaap_PreferredStockValue_CBAC3659BB18D0A92B8AF046BFEE5964" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_7C50E86D1E6F11A1CE94F046BFEF7018" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C26E7B398279A5B3E78FF046BFEE15B6" xlink:to="loc_us-gaap_CommonStockValue_7C50E86D1E6F11A1CE94F046BFEF7018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_075B1CBD296E0DC9EB01F046BFEF2760" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C26E7B398279A5B3E78FF046BFEE15B6" xlink:to="loc_us-gaap_AdditionalPaidInCapital_075B1CBD296E0DC9EB01F046BFEF2760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_413BC47BC9D46B02EE12F046BFEFC533" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C26E7B398279A5B3E78FF046BFEE15B6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_413BC47BC9D46B02EE12F046BFEFC533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1F126A228A4910242E6F046BFEFA29F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C26E7B398279A5B3E78FF046BFEE15B6" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_D1F126A228A4910242E6F046BFEFA29F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D13BE66E04EA3E57868BF046BFEFC21E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_C26E7B398279A5B3E78FF046BFEE15B6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_D13BE66E04EA3E57868BF046BFEFC21E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_BDF4E22C4E876B56CF77F046BFF0F5A6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_D5E83FD5CC7D492D0D7FF046BFEB552A" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_BDF4E22C4E876B56CF77F046BFF0F5A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7E171786176D50F1AA56B9D1F22D6BE4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B2AAB3AF47BA52338EE43E372B6A6754" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7E171786176D50F1AA56B9D1F22D6BE4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B2AAB3AF47BA52338EE43E372B6A6754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_0E234CD9403F5BB787C5C6BE1414F9C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_B2AAB3AF47BA52338EE43E372B6A6754" xlink:to="loc_us-gaap_StockholdersEquityAbstract_0E234CD9403F5BB787C5C6BE1414F9C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E234CD9403F5BB787C5C6BE1414F9C0" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C328381644CE538AA84E71E36B72ACF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C328381644CE538AA84E71E36B72ACF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_11F13744F1095CEAACFA13E1A8428CDB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_11F13744F1095CEAACFA13E1A8428CDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_0DE59E2663C05F8292549333395B825F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_D56FF5E5AE015DA8AF8A1CA010BC9A3B" xlink:to="loc_us-gaap_PreferredStockSharesIssued_0DE59E2663C05F8292549333395B825F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_0E234CD9403F5BB787C5C6BE1414F9C0" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_A3FB92DD0DC358F98548AC897FC8FF87" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_A3FB92DD0DC358F98548AC897FC8FF87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_A469C66C889253A8A00062DB0AC9FF04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_A469C66C889253A8A00062DB0AC9FF04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_2C0F4FF75C7B54D6A120738CD1B32848" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:to="loc_us-gaap_CommonStockSharesIssued_2C0F4FF75C7B54D6A120738CD1B32848" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B1D152A8EFCC55E6ACC1142C7670BB87" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_45F12C3246695511B1BEF3CF977C3424" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B1D152A8EFCC55E6ACC1142C7670BB87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_D5D480B136050EE5C729199E158056F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="loc_us-gaap_NetIncomeLoss_D5D480B136050EE5C729199E158056F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_E0E483C001504D060BC5199E1581A5DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_E0E483C001504D060BC5199E1581A5DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_5DACA8C2F339291D0B89199E1581F956" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:to="loc_us-gaap_ShareBasedCompensation_5DACA8C2F339291D0B89199E1581F956" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2932D068622580DC3203199E15816F55" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash_2932D068622580DC3203199E15816F55" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_RightOfUseAssetAmortization" xlink:label="loc_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:to="loc_exel_RightOfUseAssetAmortization_D4B962B82DDF48A3A6A9199E1581F6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ABA6EA6583608D45AECF199E15821127" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_ABA6EA6583608D45AECF199E15821127" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfOtherInvestments" xlink:label="loc_us-gaap_GainLossOnSaleOfOtherInvestments_9660C587A5FEE65B298E199E1582A915" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:to="loc_us-gaap_GainLossOnSaleOfOtherInvestments_9660C587A5FEE65B298E199E1582A915" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_D43605A658FC4AC31A1F199E1582D30C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_D43605A658FC4AC31A1F199E1582D30C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4673C4BD3B97152A657B199E15815460" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_33C93B111B97E3E42722199E1582481A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_33C93B111B97E3E42722199E1582481A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherReceivables" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_0CFA131CB22D20778923199E1583004C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_0CFA131CB22D20778923199E1583004C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_201B9CE7982C6B4060BD199E15836B85" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_201B9CE7982C6B4060BD199E15836B85" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_EDE76C42E614106DDB73199E15837A40" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_EDE76C42E614106DDB73199E15837A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1719A8D0589DF0A9D75C199E158320D4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1719A8D0589DF0A9D75C199E158320D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8000F6E1F9691025AF8F199E15839F80" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_8000F6E1F9691025AF8F199E15839F80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_302E0A75F0F6CFD4B505199E1583457D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_302E0A75F0F6CFD4B505199E1583457D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_226E8BFFFF849A7BB9EE199E158406F5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_226E8BFFFF849A7BB9EE199E158406F5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInAccruedClinicalLiabilities" xlink:label="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_exel_IncreaseDecreaseInAccruedClinicalLiabilities_31F60ED1C757CE7A2D17199E15848513" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInRebatesAndFeesPayable" xlink:label="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_exel_IncreaseDecreaseInRebatesAndFeesPayable_93CC63D5B90017D7EFEA199E1584F51E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInAccruedCollaborationLiability" xlink:label="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_exel_IncreaseDecreaseInAccruedCollaborationLiability_D2C3781BEE878FC037C1199E1584951F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_798939168D178572FDD0199E1584D208" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_798939168D178572FDD0199E1584D208" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IncreaseDecreaseInLeaseLiabilityNoncurrent" xlink:label="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent_23EE4479CDB2455DF0E7199E1584C815" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35828C7343ED34AB1FF1199E158485F3" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_EFB84B4E6F6124B73CDA199E1582B661" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_35828C7343ED34AB1FF1199E158485F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6C19D505A73C50FD3DBF199E15851384" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_6C19D505A73C50FD3DBF199E15851384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11F2AC1FE3AEE27FF7FC199E158570DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_11F2AC1FE3AEE27FF7FC199E158570DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94645B942AA9A3329BB9199E15851F75" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_94645B942AA9A3329BB9199E15851F75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2283158E97071C884A61199E1585A1FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2283158E97071C884A61199E1585A1FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_A21CC196E67CDABD2610199E1585435B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities_A21CC196E67CDABD2610199E1585435B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6952A7B61F28DA6DB3DC199E1586A8AF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_6952A7B61F28DA6DB3DC199E1586A8AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_AF6B152E49B98E890DDC199E158609FC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:to="loc_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments_AF6B152E49B98E890DDC199E158609FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76E52F8CC454D7C81D92199E1586708B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_6AAE2A9E65BE76422A7E199E1585A3F6" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_76E52F8CC454D7C81D92199E1586708B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_826BB352D74099556B53199E15867EE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_826BB352D74099556B53199E15867EE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="loc_us-gaap_ProceedsFromStockPlans_0B3EB01F125DDAC8B897199E1587B5CA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:to="loc_us-gaap_ProceedsFromStockPlans_0B3EB01F125DDAC8B897199E1587B5CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4547EABC1A439419053A199E158766F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_4547EABC1A439419053A199E158766F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_337E8362566813E02761199E158746C2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:to="loc_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_337E8362566813E02761199E158746C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D0B07C5657F7A02A7A10199E15873D32" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_FB3B491F6EA7801319D4199E15869863" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_D0B07C5657F7A02A7A10199E15873D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1DF33012368A2FEB096F199E1587AAAD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1DF33012368A2FEB096F199E1587AAAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90FC3930D98B022D37A3199E15872738" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_90FC3930D98B022D37A3199E15872738" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B9E79AF4BD4A5B88DF5D199E1588FD82" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_B9E79AF4BD4A5B88DF5D199E1588FD82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0911D800D9B6A70989EF199E1580CD63" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:to="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_23F98D1866878BA43AED199E15886D23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_99E9E72A083BB5188936199E1588B71D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_99E9E72A083BB5188936199E1588B71D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions" xlink:label="loc_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_91AAAD11534D8BC78839199E15888DA8" xlink:to="loc_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions_2952F03F14259447278C199E15883984" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8C84C970FEAB595398320BDC328361DE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_BB8E97BF476E5B2DB5920E9EAAD2CA29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8C84C970FEAB595398320BDC328361DE" xlink:to="loc_us-gaap_NetIncomeLoss_BB8E97BF476E5B2DB5920E9EAAD2CA29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_782806F435F55BF9A045BC1B02D7D785" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8C84C970FEAB595398320BDC328361DE" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_782806F435F55BF9A045BC1B02D7D785" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CF80C448B593525DB3A4EA7AD6216ECC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_782806F435F55BF9A045BC1B02D7D785" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_CF80C448B593525DB3A4EA7AD6216ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54E319ADEEB95DB8904EE99D7D23E217" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_782806F435F55BF9A045BC1B02D7D785" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_54E319ADEEB95DB8904EE99D7D23E217" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_6EFBE4F20AA25EE0A16614F9D31C6A5D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_8C84C970FEAB595398320BDC328361DE" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_6EFBE4F20AA25EE0A16614F9D31C6A5D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A04EE53518B23F3BF6F3D078F46FAD66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_306FC93888D67C192C78D08B2E0F8E25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A04EE53518B23F3BF6F3D078F46FAD66" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_306FC93888D67C192C78D08B2E0F8E25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96A318CD7DE3E8AA8E61D078F46F88B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_306FC93888D67C192C78D08B2E0F8E25" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_96A318CD7DE3E8AA8E61D078F46F88B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22FDC04A0E4DC7A4089BD078F4702203" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A04EE53518B23F3BF6F3D078F46FAD66" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_22FDC04A0E4DC7A4089BD078F4702203" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_A22103C0C0E4576B88FB0CDB3CE578D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_0EE590C190555D48B475674DC1D96FD4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_A22103C0C0E4576B88FB0CDB3CE578D9" xlink:to="loc_us-gaap_StatementTable_0EE590C190555D48B475674DC1D96FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8BA26BAEAFF7599680F806FE7DA7C315" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0EE590C190555D48B475674DC1D96FD4" xlink:to="loc_srt_ProductOrServiceAxis_8BA26BAEAFF7599680F806FE7DA7C315" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7A570342F720581DBC1AFEFB29C1EC0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8BA26BAEAFF7599680F806FE7DA7C315" xlink:to="loc_srt_ProductsAndServicesDomain_7A570342F720581DBC1AFEFB29C1EC0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C145F313B55558C2A579396D2D94F166" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7A570342F720581DBC1AFEFB29C1EC0B" xlink:to="loc_us-gaap_ProductMember_C145F313B55558C2A579396D2D94F166" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7A570342F720581DBC1AFEFB29C1EC0B" xlink:to="loc_exel_CollaborationMember_7050FC40B5AF56449DD46B0197F50D72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_0EE590C190555D48B475674DC1D96FD4" xlink:to="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0DFFFE4503B653A68593AE1CF4A43318" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_0DFFFE4503B653A68593AE1CF4A43318" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_F5614C6FEA5053C599C91A1EFD6AFD14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_F5614C6FEA5053C599C91A1EFD6AFD14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_F30BD9708FAC551F909A305D2E4FC24D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_F30BD9708FAC551F909A305D2E4FC24D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D53D2C45253D5B3F9E0CD4C66085376B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D53D2C45253D5B3F9E0CD4C66085376B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_8B1B82B93E8758BFB317EDC69A1AD070" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_97732B3E1A0D5A8087BC3C03FA77D018" xlink:to="loc_us-gaap_OperatingExpenses_8B1B82B93E8758BFB317EDC69A1AD070" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_FB87D881E36E523EA3A33D58ED47F2A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_OperatingIncomeLoss_FB87D881E36E523EA3A33D58ED47F2A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestIncomeOther" xlink:label="loc_us-gaap_InterestIncomeOther_094F72CAB6835E52BA4D26829AB7359A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:to="loc_us-gaap_InterestIncomeOther_094F72CAB6835E52BA4D26829AB7359A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_25C9575C14B25A8F9ED60D3B72C06AC7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_25C9575C14B25A8F9ED60D3B72C06AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_517FBB87479A569F82F4C63FBD90A1E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_91FC2CA8B1F55A04B9BA80663C62B578" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_517FBB87479A569F82F4C63FBD90A1E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9498C9781DA653FA8FBB4C439E9DF64F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_9498C9781DA653FA8FBB4C439E9DF64F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_22B99C2A59415D6E999198DCDFCEBA18" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_22B99C2A59415D6E999198DCDFCEBA18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_207C0599653D549CB52001C5CCA70CCC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_NetIncomeLoss_207C0599653D549CB52001C5CCA70CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_8CB7284A6BBA5BBFB900C02008A77EB6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_EarningsPerShareBasic_8CB7284A6BBA5BBFB900C02008A77EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_12A0394B75185897BE208F2CC6E9EC2C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_EarningsPerShareDiluted_12A0394B75185897BE208F2CC6E9EC2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20C9BF6963015616BDE14521997E2867" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_20C9BF6963015616BDE14521997E2867" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3102336355D955018A625AFA58971698" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_06F4785CDA0C502CB68030B8F96DD7FF" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3102336355D955018A625AFA58971698" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5097D1C7717852CBA967971F7F633915" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5097D1C7717852CBA967971F7F633915" xlink:to="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_F35EB1EA370C58F2AEAD58078F4C032E" xlink:to="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_E572807B86885864AFEAF34429C0D423" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:to="loc_us-gaap_CommonStockMember_E572807B86885864AFEAF34429C0D423" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6C12A09216155809BB5AA9441CC610D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6C12A09216155809BB5AA9441CC610D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34EF1A3742FB52E19A921971E66F2486" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_34EF1A3742FB52E19A921971E66F2486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_A9C2BB01D2DD5B59B605F9D4CD94EF10" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_C863A0AAFA6B5C3CBECFC458E1D65EF6" xlink:to="loc_us-gaap_RetainedEarningsMember_A9C2BB01D2DD5B59B605F9D4CD94EF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A268B8C0739059B6A27ADF340E78C8CD" xlink:to="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_17B80AD21F5058F091B8309975BD7F1F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_17B80AD21F5058F091B8309975BD7F1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_B26D1620F2725248B3AF4A99E988CB8D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_27F17D526A74593480251154895D087F" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_B26D1620F2725248B3AF4A99E988CB8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_D61EBF748B62571BB1DD86B4784D937E" xlink:to="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_44AF6032CA7C5EEABF2C00D9442E067C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_44AF6032CA7C5EEABF2C00D9442E067C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40EF58C361BD55B893BC7742221EEFFF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_40EF58C361BD55B893BC7742221EEFFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_56B7ECA2FEDF52709D291D21A039B8D4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_56B7ECA2FEDF52709D291D21A039B8D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_0CC7CB46CA8A5695988E97D0B83C6DB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_NetIncomeLoss_0CC7CB46CA8A5695988E97D0B83C6DB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12748503AD5A5FED9BF944F835C794DC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_12748503AD5A5FED9BF944F835C794DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_366BC68F9CB553C086F6D199301D97E6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_366BC68F9CB553C086F6D199301D97E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_73A4AFCA1F785C789D84192851CFC48F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_73A4AFCA1F785C789D84192851CFC48F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5B0DD687B355550FB12035B2EA980EA1" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5B0DD687B355550FB12035B2EA980EA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_AB596F9D2FBC52F884CC2FDF48479973" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_AB596F9D2FBC52F884CC2FDF48479973" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4652A97AB605DEAA40E125E7E30167B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_E4A45FBA621859338910DAD99BA7A512" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4652A97AB605DEAA40E125E7E30167B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_5DC8E02636B34F6735F2AF71E8806450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_DocumentType_5DC8E02636B34F6735F2AF71E8806450" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_dei_DocumentQuarterlyReport_FD4ED21992AB1D44FB6CAF71E8849672" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_DocumentQuarterlyReport_FD4ED21992AB1D44FB6CAF71E8849672" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_C29B7B76B518DCFA74C3AF71E880E707" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_AmendmentFlag_C29B7B76B518DCFA74C3AF71E880E707" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_EC5E4FDD4B3AAA31ACA7AF71E88101A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_DocumentPeriodEndDate_EC5E4FDD4B3AAA31ACA7AF71E88101A3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_C15BC10A2C80A9A4C623AF71E881C5FC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_DocumentFiscalYearFocus_C15BC10A2C80A9A4C623AF71E881C5FC" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_FFE63DA37403154CC443AF71E881E54E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_DocumentFiscalPeriodFocus_FFE63DA37403154CC443AF71E881E54E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_76AF309E213D36D61597AF71E8851594" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_DocumentTransitionReport_76AF309E213D36D61597AF71E8851594" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_98081B18F47B63B924DDAF71E8839D3B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityFileNumber_98081B18F47B63B924DDAF71E8839D3B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_01A58FA5892AAF53B80EAF71E881FB96" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityRegistrantName_01A58FA5892AAF53B80EAF71E881FB96" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_88306E8E0320E0A62CB5AF71E883F561" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityIncorporationStateCountryCode_88306E8E0320E0A62CB5AF71E883F561" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_246AEC88269C44A29838AF71E883D2CA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityTaxIdentificationNumber_246AEC88269C44A29838AF71E883D2CA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_BBCA38BEA0624821461AAF71E8819E48" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityCentralIndexKey_BBCA38BEA0624821461AAF71E8819E48" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_68D42DFB188F4C6F011EAF71E882B071" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_CurrentFiscalYearEndDate_68D42DFB188F4C6F011EAF71E882B071" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_4F201816F4B5FA961842AF71E884EBF4" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityAddressAddressLine1_4F201816F4B5FA961842AF71E884EBF4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_0ED609B852194FEB3CD3AF71E8841210" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityAddressCityOrTown_0ED609B852194FEB3CD3AF71E8841210" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_9CFC1542CAA8E2CEEF39AF71E884B572" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityAddressStateOrProvince_9CFC1542CAA8E2CEEF39AF71E884B572" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_D4CB461466DF23248B59AF71E884A44A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityAddressPostalZipCode_D4CB461466DF23248B59AF71E884A44A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_D8D74E6D8FB13B9DFE62AF71E884C4BE" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_CityAreaCode_D8D74E6D8FB13B9DFE62AF71E884C4BE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_B904C95A835D96399CE2AF71E8842F17" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_LocalPhoneNumber_B904C95A835D96399CE2AF71E8842F17" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_2D97B3B3B154CAC9B6D6AF71E883045D" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_Security12bTitle_2D97B3B3B154CAC9B6D6AF71E883045D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_F7D2BDF008FBC80BB710AF71E8838E3C" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_TradingSymbol_F7D2BDF008FBC80BB710AF71E8838E3C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_C08A30CAD193F5BB1813AF71E8833973" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_SecurityExchangeName_C08A30CAD193F5BB1813AF71E8833973" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_43828DBB35C3CB21EC7DAF71E8823154" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityCurrentReportingStatus_43828DBB35C3CB21EC7DAF71E8823154" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_6E0A0F1CB580271D6E71AF71E88234FA" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityInteractiveDataCurrent_6E0A0F1CB580271D6E71AF71E88234FA" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_101BB97BB2483123E1B4AF71E8828389" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityFilerCategory_101BB97BB2483123E1B4AF71E8828389" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_A9E9345B680097412163AF71E882E7DD" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntitySmallBusiness_A9E9345B680097412163AF71E882E7DD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_A7EDC19775D811CAF478AF71E8838E68" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityEmergingGrowthCompany_A7EDC19775D811CAF478AF71E8838E68" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_DD13A94D71FC8127C241AF71E882CA53" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityShellCompany_DD13A94D71FC8127C241AF71E882CA53" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_EF64A41DA0C5DA14B75CAF71E8823BE9" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_F1F3E9550A95AF8B9285AF71E8801B32" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_EF64A41DA0C5DA14B75CAF71E8823BE9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_5192247722B55EF89DF821FB58A09CE1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_796AF7AA436E5BAB92AC57273C893BFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_5192247722B55EF89DF821FB58A09CE1" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_796AF7AA436E5BAB92AC57273C893BFA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_03421EAE34F1E318B6F8B8C7A0345C3C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_03421EAE34F1E318B6F8B8C7A0345C3C" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:to="loc_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_0D6306A94A8784BF1416B8C7A03544CF" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_MoneyMarketFundsMember_7B290A3FEE128EB77167B8C7A035FA36" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_CommercialPaperMember_C9C91667C72521D5C5C9B8C7A0360169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateBondSecuritiesMember" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_66EDA48B9BA18D6BFEEFB8C7A0363316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_6F92AF6B838A8CB42DF1B8C7A0361974" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CertificatesOfDepositMember" xlink:label="loc_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_366A4EFE39996F1DE9FFB8C7A035B174" xlink:to="loc_us-gaap_CertificatesOfDepositMember_46EF4D8179CEBC177F4DB8C7A0360E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_E104EC12FB3E2873AECCB8C7A0362CE3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4BA627A7930B5F7A779FB8C7A0372CC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8520F18B3E1937A26FC5B8C7A0367FD9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_002417A2737BAD31B2C1B8C7A03701BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_E7500B8520D680E9538CB8C7A0378983" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0F4D7265F00409EA6CC0B8C7A037086B" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_E2F047DC15C04FD54618B8C7A0385237" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_295A55FCA80AFBE4168DB8C7A0359C91" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68296E3D267F697320D6B8C7A038385F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_68296E3D267F697320D6B8C7A038385F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_D5001DB3A021100AAB0CB8C7A0380983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_F5DD24897824874CD81AB8C7A0382284" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_D50BB1C9C09CB06B6DABB8C7A0384F1D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_FB95F40B0FA85E01B5E7F41AA0259374" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_E093960FE7175CB2A35D4F88A4F00DE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_FB95F40B0FA85E01B5E7F41AA0259374" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_E093960FE7175CB2A35D4F88A4F00DE3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0EC4C524D4F35ED6B62DBD5C4F5F61A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_F23C4DE95B645AD6BD3933A15D1618BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0EC4C524D4F35ED6B62DBD5C4F5F61A7" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_F23C4DE95B645AD6BD3933A15D1618BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/IncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2369B4B90D88ACC84C20D078F258FCBB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14F49506C88A89742E06D078F2597144" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2369B4B90D88ACC84C20D078F258FCBB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_14F49506C88A89742E06D078F2597144" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C6EB95F75199DF63DF3DD0C88E7B9292" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2369B4B90D88ACC84C20D078F258FCBB" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_C6EB95F75199DF63DF3DD0C88E7B9292" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8623DF2A784B5ABF9893D3D12E150053" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_73A114B709CA5A93A37F86512F635EB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8623DF2A784B5ABF9893D3D12E150053" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_73A114B709CA5A93A37F86512F635EB5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_38AD0862840C5C3FBC23085A5D79775A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryCurrentTable" xlink:label="loc_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_38AD0862840C5C3FBC23085A5D79775A" xlink:to="loc_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BB36AF3C42915BA6B3D08778C14506B9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoriesMember" xlink:label="loc_us-gaap_InventoriesMember_E31F1D02E99B5F279E654FB968F68F51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:to="loc_us-gaap_InventoriesMember_E31F1D02E99B5F279E654FB968F68F51" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OtherLongtermAssetsMember" xlink:label="loc_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_5D22FEBE209A54558023752CEDF917C6" xlink:to="loc_exel_OtherLongtermAssetsMember_79412CF1235A5220BC3ED649E301738A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryLineItems" xlink:label="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_30013C2D7BCC56E5ABFA0139624BF509" xlink:to="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterials" xlink:label="loc_us-gaap_InventoryRawMaterials_FF2ADDDC08DB517BA70A13BABDE1FBC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryRawMaterials_FF2ADDDC08DB517BA70A13BABDE1FBC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcess" xlink:label="loc_us-gaap_InventoryWorkInProcess_1E4759A55FE451C292FE238E27772EDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryWorkInProcess_1E4759A55FE451C292FE238E27772EDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoods" xlink:label="loc_us-gaap_InventoryFinishedGoods_00CF850B4C885E95B2CF31EBA80743AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryFinishedGoods_00CF850B4C885E95B2CF31EBA80743AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryGross" xlink:label="loc_us-gaap_InventoryGross_FA558EB5767A5577B10D77637A9D265E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryGross_FA558EB5767A5577B10D77637A9D265E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="loc_us-gaap_InventoryWriteDown_22404E7B4C1C505EA5AF87DC873E671C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_FFA5F8E25FC357CCAF6D418F3478C95B" xlink:to="loc_us-gaap_InventoryWriteDown_22404E7B4C1C505EA5AF87DC873E671C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_2D05DDC39FAE504B856D9DBC3C97B74A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6776C4701C6A5933A45F94DB33660323" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_2D05DDC39FAE504B856D9DBC3C97B74A" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6776C4701C6A5933A45F94DB33660323" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Leases" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_0AB59F28D6D15AB5B819079711C91CA4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_476D44B811AE5FF9A6EC6A1FF11CD223" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0AB59F28D6D15AB5B819079711C91CA4" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_476D44B811AE5FF9A6EC6A1FF11CD223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeFinanceLeasesTextBlock" xlink:label="loc_us-gaap_LesseeFinanceLeasesTextBlock_184AC2AEBC0257C38A16836CF744A9FC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0AB59F28D6D15AB5B819079711C91CA4" xlink:to="loc_us-gaap_LesseeFinanceLeasesTextBlock_184AC2AEBC0257C38A16836CF744A9FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_57034DC3EF0858C787500EC6EB35F1B6" xlink:type="locator" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseLiabilitiesAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_57034DC3EF0858C787500EC6EB35F1B6" xlink:to="loc_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_41352F160F5356E3A7BCA1655E30C052" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_41352F160F5356E3A7BCA1655E30C052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_207AE0D64029588CAA4CFA48CCC09589" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_207AE0D64029588CAA4CFA48CCC09589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_1E883B6455EC54AC82F8FDF882F3C694" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesAbstract_0632926AD13459FB93A90CC7441B561C" xlink:to="loc_us-gaap_OperatingLeaseLiability_1E883B6455EC54AC82F8FDF882F3C694" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_FinancingLeaseLiabilitiesAbstract" xlink:label="loc_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_57034DC3EF0858C787500EC6EB35F1B6" xlink:to="loc_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityCurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_5480A6F2B4115D8585FC28F74E177EEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_5480A6F2B4115D8585FC28F74E177EEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_F7A9C52A1F1B5C27B29F8C89950D95A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_F7A9C52A1F1B5C27B29F8C89950D95A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="loc_us-gaap_FinanceLeaseLiability_1149298E910F56FAA74BD21C3CB6A98B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:to="loc_us-gaap_FinanceLeaseLiability_1149298E910F56FAA74BD21C3CB6A98B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingAndFinanceLeasesLiabilityTotal" xlink:label="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_E064536FC06F549AAE59E289E9CF5364" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_FinancingLeaseLiabilitiesAbstract_64F6C4C3CAB25145867F5935D42B2F0D" xlink:to="loc_exel_OperatingAndFinanceLeasesLiabilityTotal_E064536FC06F549AAE59E289E9CF5364" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_A8C13254BC895CB5998CCA85EFDEF6F5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_F4CA045149D957EEBB7CDAC36C7C9553" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_A8C13254BC895CB5998CCA85EFDEF6F5" xlink:to="loc_us-gaap_OperatingLeaseCost_F4CA045149D957EEBB7CDAC36C7C9553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_294B1A3866FB5B648E7CAD5EDD621519" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_A8C13254BC895CB5998CCA85EFDEF6F5" xlink:to="loc_us-gaap_VariableLeaseCost_294B1A3866FB5B648E7CAD5EDD621519" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0EA017A7EE5F5B60A0A860EB3C563439" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_A8C13254BC895CB5998CCA85EFDEF6F5" xlink:to="loc_us-gaap_LeaseCost_0EA017A7EE5F5B60A0A860EB3C563439" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_AB79D891930D205C7C7D0F844C3BED66" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_AB79D891930D205C7C7D0F844C3BED66" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_350A5742ABB7CF7C95FF0F844C3C3B80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_350A5742ABB7CF7C95FF0F844C3C3B80" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract" xlink:label="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:to="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88481A79624731142CBF0F844C3D2416" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_88481A79624731142CBF0F844C3D2416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F40271ED025AE9FAC35A0F844C3EAF04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_F40271ED025AE9FAC35A0F844C3EAF04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47A53C0562B19B830E830F844C3EAD7F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_47A53C0562B19B830E830F844C3EAD7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9909FD86871D5BDEBF9C0F844C3E8A7B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract_87CDD4D6BD02DED907D60F844C3DB3E4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_9909FD86871D5BDEBF9C0F844C3E8A7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8430FB11B858A63A20010F844C3E1945" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_8430FB11B858A63A20010F844C3E1945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A3C840609B1F780AA4940F844C3E3854" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_24169C126C7CBFB890300F844C3C0909" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_A3C840609B1F780AA4940F844C3E3854" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract" xlink:label="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_AB79D891930D205C7C7D0F844C3BED66" xlink:to="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6BAE89A850D4CB4F0D6E0F844C3FFC94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_6BAE89A850D4CB4F0D6E0F844C3FFC94" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_D5E8FEFB96AF2B7249AD0F844C3FEFB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_D5E8FEFB96AF2B7249AD0F844C3FEFB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_30493DFC71D602EB383C0F844C3F0410" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract_8D875303D9AC6F96A0D50F844C3F18EE" xlink:to="loc_us-gaap_OperatingLeaseLiability_30493DFC71D602EB383C0F844C3F0410" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_878BA57E881A2DD3E5C60F9CE28AB033" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_878BA57E881A2DD3E5C60F9CE28AB033" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_60B7A143F86B610A7E6E0F9CE28AC911" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:to="loc_srt_StatementGeographicalAxis_60B7A143F86B610A7E6E0F9CE28AC911" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F48D83FD2B16D07A5B420F9CE28B8DAE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_60B7A143F86B610A7E6E0F9CE28AC911" xlink:to="loc_srt_SegmentGeographicalDomain_F48D83FD2B16D07A5B420F9CE28B8DAE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_9B6BB097CC56DBC01CAF0F9CE28B85BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_F48D83FD2B16D07A5B420F9CE28B8DAE" xlink:to="loc_exel_AlamedaCaliforniaMember_9B6BB097CC56DBC01CAF0F9CE28B85BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_BA603E959831A3A8EB560F9CE28AB263" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_869A58118CB420F51D490F9CE28BD682" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_869A58118CB420F51D490F9CE28BD682" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_D7337E83BE05CD658EF70F9CE28C98EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_D7337E83BE05CD658EF70F9CE28C98EC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_157400389E6270DA4E860F9CE28C3881" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_157400389E6270DA4E860F9CE28C3881" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_58EC907D18B3594A17850F9CE28C1C5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_58EC907D18B3594A17850F9CE28C1C5A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements" xlink:label="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements_A9B94EE88334E9B3F10A0F9CE28C8D53" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_840182D5B9E41A177D4B0F9CE28C07C4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_840182D5B9E41A177D4B0F9CE28C07C4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_A0397EEC0BBFC405951A0FE48C10F07E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_A0397EEC0BBFC405951A0FE48C10F07E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6511417704708081FCFB0F9CE28CC37C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_6511417704708081FCFB0F9CE28CC37C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_31A0098696CBC54926B90F9CE28D732F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_31A0098696CBC54926B90F9CE28D732F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty_D874D8CE9A44B0BDD8820F9CE28D47DC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_TenantLeaseImprovementsAllowance" xlink:label="loc_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_exel_TenantLeaseImprovementsAllowance_B3B14444697CA42E142F0F9CE28DD6A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_OperatingLeasePayments_A15C3DCAF68AADF710570F9CE28DB629" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_0537168E188715E3C6A60F9CE28DE330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_DC11D22B00BFD4A08B0C0F9CE28BA02D" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_BA4D96227D88A0C4126D0F9CE28D1306" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeasesAbstract" xlink:label="loc_us-gaap_LeasesAbstract_AD95041D90DF5B539F8AB7077406B739" xlink:type="locator" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock" xlink:label="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_79AF5D70CB2E556E9BCFF856A72B84F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_AD95041D90DF5B539F8AB7077406B739" xlink:to="loc_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock_79AF5D70CB2E556E9BCFF856A72B84F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_5B511FF73458588EAB02D1A8B4F7AEEA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_AD95041D90DF5B539F8AB7077406B739" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_5B511FF73458588EAB02D1A8B4F7AEEA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_AD854F3B58CF5B3DA674FC5D73230EA4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_AD95041D90DF5B539F8AB7077406B739" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_AD854F3B58CF5B3DA674FC5D73230EA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4653360FD7CC55428F8BEAC9FC6BF333" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_05D4E0A50D625AD897C354ABDA9115D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4653360FD7CC55428F8BEAC9FC6BF333" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_05D4E0A50D625AD897C354ABDA9115D7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_B066B99C9AD15EEDAB9A5ED1A0D8AF29" xlink:type="locator" />
    <link:loc xlink:href="exel-20190927.xsd#exel_EarningsPerShareNumeratorAbstract" xlink:label="loc_exel_EarningsPerShareNumeratorAbstract_5E49B6C9E49858E5A2A4EF7D7C1B4841" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B066B99C9AD15EEDAB9A5ED1A0D8AF29" xlink:to="loc_exel_EarningsPerShareNumeratorAbstract_5E49B6C9E49858E5A2A4EF7D7C1B4841" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8CDC1B1790BB53889F0EA2963B169112" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareNumeratorAbstract_5E49B6C9E49858E5A2A4EF7D7C1B4841" xlink:to="loc_us-gaap_NetIncomeLoss_8CDC1B1790BB53889F0EA2963B169112" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_EarningsPerShareDenominatorAbstract" xlink:label="loc_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B066B99C9AD15EEDAB9A5ED1A0D8AF29" xlink:to="loc_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0402C55823C352678A3DECDCBDB920D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0402C55823C352678A3DECDCBDB920D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_CCAA5D92FEE45063A970C9A9CFD35116" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_CCAA5D92FEE45063A970C9A9CFD35116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F93BCE2F834A5E21B13210CE78169C29" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_EarningsPerShareDenominatorAbstract_2D8487A8CE885C209FF7BAAE230E0188" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_F93BCE2F834A5E21B13210CE78169C29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_093995D33ACD5E938EFABCD8BD9BCC4B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B066B99C9AD15EEDAB9A5ED1A0D8AF29" xlink:to="loc_us-gaap_EarningsPerShareBasic_093995D33ACD5E938EFABCD8BD9BCC4B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_D54E72E9AEDE5456817A6F61ADC7B5A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_B066B99C9AD15EEDAB9A5ED1A0D8AF29" xlink:to="loc_us-gaap_EarningsPerShareDiluted_D54E72E9AEDE5456817A6F61ADC7B5A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_745E27017859544FADA59E5CF89888BB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_745E27017859544FADA59E5CF89888BB" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_0860C6BDB02A5B27B0C213FF24E8E4A6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockCompensationPlanMember" xlink:label="loc_us-gaap_StockCompensationPlanMember_0DF900E6C3E05B52B414EC9FE334880C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_0B24FF8AEF0D54B0A60BCA59A22E13F3" xlink:to="loc_us-gaap_StockCompensationPlanMember_0DF900E6C3E05B52B414EC9FE334880C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_77E24F59904A555BBBEC45D60B9E4F46" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19FC374A2ECB5065B5427938D2092576" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_44A5D449CD9E52CA8EFDEDCA5AD027C8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_19FC374A2ECB5065B5427938D2092576" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_4383E63833B754649C7BE4DF0A07507A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2BFC0469EF5C56629641E7ED3199F370" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4383E63833B754649C7BE4DF0A07507A" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2BFC0469EF5C56629641E7ED3199F370" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B0F594E9CA5C5AB98A557CB83A9FA23E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_4383E63833B754649C7BE4DF0A07507A" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_B0F594E9CA5C5AB98A557CB83A9FA23E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9D83848157AF5624A9E29ED157A4C32E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_14D577AA99EB5FE89C805D02E6EFDB70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9D83848157AF5624A9E29ED157A4C32E" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_14D577AA99EB5FE89C805D02E6EFDB70" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6BCAFDBF10B5CB00EB3DF047DF664A79" xlink:type="locator" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_6BCAFDBF10B5CB00EB3DF047DF664A79" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_60873CF3C9406CFE40D8F047DF66E99D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:to="loc_srt_ProductOrServiceAxis_60873CF3C9406CFE40D8F047DF66E99D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_60873CF3C9406CFE40D8F047DF66E99D" xlink:to="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ProductsDerivedFromCabozantinibMember" xlink:label="loc_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5" xlink:to="loc_exel_ProductsDerivedFromCabozantinibMember_BF1C2D7A70117A68C887F047DF67CAE0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ResultingFromDiscoveryEffortsMember" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_C1F23CD9D8AD288A92C6F047DF660CE5" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_143A37D0031A0438F1A4F047DF67318C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_5E3C75442CFD2FD1B66AF047DF665C91" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_NumberofProductsinCommercialMarket" xlink:label="loc_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:to="loc_exel_NumberofProductsinCommercialMarket_B58CC3A816EC41DC6144F047DF68349D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_9D13C4E82521D609DD6AF047DF680E4C" xlink:to="loc_us-gaap_NumberOfOperatingSegments_FB7C8035EC27EF7F24FCF047DF68969A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E34A55486D755139778B61CA152EB9D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_7097C73C70C45D66BD66F5B03E4F4033" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E34A55486D755139778B61CA152EB9D" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_7097C73C70C45D66BD66F5B03E4F4033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_519AB26A6A5E5E9BB8698C2D21BF3D52" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E34A55486D755139778B61CA152EB9D" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_519AB26A6A5E5E9BB8698C2D21BF3D52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiscalPeriod" xlink:label="loc_us-gaap_FiscalPeriod_A30790E9AAAC54D6A7CDF7FF70DC09CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E34A55486D755139778B61CA152EB9D" xlink:to="loc_us-gaap_FiscalPeriod_A30790E9AAAC54D6A7CDF7FF70DC09CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_D7A2F14902C25B6EA9AFD4C4AF65D94F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E34A55486D755139778B61CA152EB9D" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_D7A2F14902C25B6EA9AFD4C4AF65D94F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_9A3C7306C9A25D50BE904A855A39E86D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E34A55486D755139778B61CA152EB9D" xlink:to="loc_us-gaap_UseOfEstimates_9A3C7306C9A25D50BE904A855A39E86D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4DDA9447149F5C35BE478670F3494751" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E34A55486D755139778B61CA152EB9D" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4DDA9447149F5C35BE478670F3494751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8FA144BC6B7455FB91534EA6B40C1747" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7E34A55486D755139778B61CA152EB9D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_8FA144BC6B7455FB91534EA6B40C1747" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8EEC77CD13525179ADBD6E4AEFF42985" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_830D225E806E59D4B7A1DF311B9DAE8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_8EEC77CD13525179ADBD6E4AEFF42985" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_830D225E806E59D4B7A1DF311B9DAE8E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B98F38B9B742578DBA804204166BAEAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_B98F38B9B742578DBA804204166BAEAC" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2179EDC3B3A45F8B8D5CB1CA50A53918" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_B7C8CA97568B5A2AA0485F5C989C460B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_B7C8CA97568B5A2AA0485F5C989C460B" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ComputerEquipmentAndSoftwareMember" xlink:label="loc_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_exel_ComputerEquipmentAndSoftwareMember_07BCA2E2F43C534A858B50DD23161935" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_FA6D83194E17502998A59CE891201747" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_FA6D83194E17502998A59CE891201747" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LaboratoryEquipmentMember" xlink:label="loc_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_exel_LaboratoryEquipmentMember_FD11A9FABE65513FB8BE2AD67FF99F50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_595960FA46955FFD9DA19F31C1BC41C1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_982E8481D38E5A2385F2C07D08CA062D" xlink:to="loc_us-gaap_ConstructionInProgressMember_595960FA46955FFD9DA19F31C1BC41C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B70A23073F0357B084EF94AEEEAEA2B3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_57544161E0BB58CC97E5140A97003D1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_57544161E0BB58CC97E5140A97003D1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8E93F2D3893952A7A035AC78B1D7F650" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_8E93F2D3893952A7A035AC78B1D7F650" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_C3B1A4AC0A3D5B128DD6549054A67D38" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_A95B0256D7A75AF28E28518CA0A3B653" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_C3B1A4AC0A3D5B128DD6549054A67D38" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4D0B24537DD8F456ACEA12B8E4815D1A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_C1D960ED24303E08E8C912B8E481578D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_4D0B24537DD8F456ACEA12B8E4815D1A" xlink:to="loc_us-gaap_Depreciation_C1D960ED24303E08E8C912B8E481578D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_265888DE35125C18B5574EABD8A17E84" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_10861936767453A3959A07B744B58898" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_265888DE35125C18B5574EABD8A17E84" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_10861936767453A3959A07B744B58898" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_EBA1A53267AA54C8AE44027952902FA6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_A2480D5639A95C75B82E648B633871DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_EBA1A53267AA54C8AE44027952902FA6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_A2480D5639A95C75B82E648B633871DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9EDDF86A562D0A949581B3E45212A70E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9EDDF86A562D0A949581B3E45212A70E" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_978FA7CD0CF11D671A68B3E45212DE35" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_6BCD9632072A606C021DB3E45213DDCC" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_E7B26FC132E4B59C8FE1B3E45213C510" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AllowanceForProductRebatesMember" xlink:label="loc_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_BF66121C8A901CA21437B3E45213A7AD" xlink:to="loc_exel_AllowanceForProductRebatesMember_B5BEF24851BD65F60245B3E45213BA84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_38FF6DD32B315BEB6E30B3E45212309E" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_FAECC361F702D8112462B3E452143212" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ECF4721C062092EB6BC2B3E452144FD1" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_CD7C05C6AA598169A38AB3E45215E938" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_7B41D738C3568DEF4350B3E4521428ED" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_B87A951BE8BB24C29E09B3E452157EEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_485F3F0DF88E661A0D9BB3E452152B24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_8B80419E2A4404BD0F0DB3E452153D13" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_0B0624F71C1FEC4B81DBB3E45214FBD7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_8B80419E2A4404BD0F0DB3E452153D13" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9A963A7D4BAD9574416517E2EDEC13BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_7420357A3A1803B87C8A17E2EDECF62E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9A963A7D4BAD9574416517E2EDEC13BC" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_7420357A3A1803B87C8A17E2EDECF62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7A0166B557659FA0398B17E2EDECCE10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9A963A7D4BAD9574416517E2EDEC13BC" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7A0166B557659FA0398B17E2EDECCE10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9F6362D694CD78FAEF8317E2EDEC613E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9A963A7D4BAD9574416517E2EDEC13BC" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_9F6362D694CD78FAEF8317E2EDEC613E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_4CCA7E9DC2A9DBB42C2617E2EDEC007D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9A963A7D4BAD9574416517E2EDEC13BC" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_4CCA7E9DC2A9DBB42C2617E2EDEC007D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_64D6A07E7C6257AFBF2C609AF91CA536" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_560F9DC2B79B5A11B04E9E30FC143BC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_64D6A07E7C6257AFBF2C609AF91CA536" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_560F9DC2B79B5A11B04E9E30FC143BC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_560F9DC2B79B5A11B04E9E30FC143BC6" xlink:to="loc_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_72BBEB55B7C257518D10A330CE1DD7A8" xlink:to="loc_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_FADFC7341B4359D2B43BB416484D4275" xlink:to="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CabometyxMember" xlink:label="loc_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:to="loc_exel_CabometyxMember_BA5A493A91AD523FAFA02FF0F54CCB8F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CometriqMember" xlink:label="loc_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_370FC5899F0D5D5392FB9021AEB85D7A" xlink:to="loc_exel_CometriqMember_EFE50CD1BE1950D28CFB7EDAC0BE315F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_249B7CF35D4C5274AC283F6A1685D64E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_560F9DC2B79B5A11B04E9E30FC143BC6" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_249B7CF35D4C5274AC283F6A1685D64E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7095DDFE493257BB90C00D27397D6C89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_249B7CF35D4C5274AC283F6A1685D64E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7095DDFE493257BB90C00D27397D6C89" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6B20DB6ED8742DDADBC4B3E452336FB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_6B20DB6ED8742DDADBC4B3E452336FB6" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2664187DF8E52F0D8B7EB3E452337322" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:to="loc_srt_ProductOrServiceAxis_2664187DF8E52F0D8B7EB3E452337322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2664187DF8E52F0D8B7EB3E452337322" xlink:to="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E" xlink:to="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ProductGrossMember" xlink:label="loc_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:to="loc_exel_ProductGrossMember_80DDD285E2BD09A5DA97B3E452349752" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_SalesDiscountsAndAllowancesMember" xlink:label="loc_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_C428EF5DBE74E2FDC76AB3E4523494C7" xlink:to="loc_exel_SalesDiscountsAndAllowancesMember_3CA16FBD297A6C682B1BB3E45234A7B8" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationMember" xlink:label="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_B46A640BD5715BDAAEA0B3E452348C6E" xlink:to="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicenseMember" xlink:label="loc_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:to="loc_us-gaap_LicenseMember_F60C673DDA19211FAF7DB3E452354945" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ResearchandDevelopmentMember" xlink:label="loc_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:to="loc_exel_ResearchandDevelopmentMember_A3D7509907FAA8F8088BB3E452355D2D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OtherCollaborationMember" xlink:label="loc_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_CollaborationMember_95878F4B06C57133FFA0B3E45235B517" xlink:to="loc_exel_OtherCollaborationMember_5C4582BF1FCFEA54E7DCB3E45235608D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_E0F83B51F528E8E6DF0CB3E452356380" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:to="loc_srt_MajorCustomersAxis_E0F83B51F528E8E6DF0CB3E452356380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_1A4F72B92C8B596AB1CCB3E45235314C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_E0F83B51F528E8E6DF0CB3E452356380" xlink:to="loc_srt_NameOfMajorCustomerDomain_1A4F72B92C8B596AB1CCB3E45235314C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_GlaxoSmithKlineMember" xlink:label="loc_exel_GlaxoSmithKlineMember_CC5A586814234D4D1DE6B3E45236B02E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_1A4F72B92C8B596AB1CCB3E45235314C" xlink:to="loc_exel_GlaxoSmithKlineMember_CC5A586814234D4D1DE6B3E45236B02E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_4D18C7DC3804FC8DA8C1B3E4523641CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:to="loc_us-gaap_TypeOfArrangementAxis_4D18C7DC3804FC8DA8C1B3E4523641CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DFB85815D5E9088272DB3E452369CCE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_4D18C7DC3804FC8DA8C1B3E4523641CA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DFB85815D5E9088272DB3E452369CCE" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborativeArrangementwithIpsenMember" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_22758885828F8E547F19B3E452365F4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0DFB85815D5E9088272DB3E452369CCE" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_22758885828F8E547F19B3E452365F4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_22C8AE1BDF0C9126B9BEB3E452376F64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_687250BE054F9CAF3118B3E452332E51" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_22C8AE1BDF0C9126B9BEB3E452376F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6DB574CFAE5D98F47EC5B3E452377804" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22C8AE1BDF0C9126B9BEB3E452376F64" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6DB574CFAE5D98F47EC5B3E452377804" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_B8F641AB694A93C1ABACB3E45237625E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_22C8AE1BDF0C9126B9BEB3E452376F64" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_B8F641AB694A93C1ABACB3E45237625E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B08643B244485F40937EF3BF46ECEA0B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTable" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_B08643B244485F40937EF3BF46ECEA0B" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_42CB2B3299855694AC9B5C8AB20C8436" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:to="loc_srt_StatementGeographicalAxis_42CB2B3299855694AC9B5C8AB20C8436" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_42CB2B3299855694AC9B5C8AB20C8436" xlink:to="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_07AA191EA9615F098E24593D1C3AB8DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:to="loc_country_US_07AA191EA9615F098E24593D1C3AB8DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EuropeMember" xlink:label="loc_srt_EuropeMember_4E9616F2DF1E5054AA66157C2ED97775" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:to="loc_srt_EuropeMember_4E9616F2DF1E5054AA66157C2ED97775" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_E6E81D1DE5B05ADBA6665FDF7EBD7119" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_3BE038445BC25A97A77472D0828988CB" xlink:to="loc_country_JP_E6E81D1DE5B05ADBA6665FDF7EBD7119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_523F939B94565EFDAAE66F1D33028735" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93E3C6C8BC8E55FC89C344C9B1C00F6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_2CF0B2FA6F505EC3AC48318D2072CB43" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_93E3C6C8BC8E55FC89C344C9B1C00F6E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3EA87F943CF467C39F49F047DF4CA263" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3EA87F943CF467C39F49F047DF4CA263" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_3CE3178F66B5CC40074CF047DF4CB3EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:to="loc_srt_MajorCustomersAxis_3CE3178F66B5CC40074CF047DF4CB3EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_3CE3178F66B5CC40074CF047DF4CB3EE" xlink:to="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_IpsenMember" xlink:label="loc_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_IpsenMember_B865C34C0C4B2E58FA8EF047DF4E8F0C" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_CaremarkL.L.C.Member" xlink:label="loc_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_CaremarkL.L.C.Member_F471FB8495CD3AD59E98F047DF4D4F70" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AffiliatesofMcKessonCorporationMember" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_279E0B92F7C5CF07EC15F047DF4D93F2" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ASDMember" xlink:label="loc_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_ASDMember_95B7C483909966636EC0F047DF4D5A41" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OtherCustomersMember" xlink:label="loc_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_B46B634433305283E121F047DF4DF66A" xlink:to="loc_exel_OtherCustomersMember_3BB7E67526CD23EF8BD1F047DF4EBC7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_9DC24ABBBD808DE1F1E7F047DF4EC7F6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_8F8FF7F507B56FB62BD6F047DF4F773E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_AB7B8FE13B27F84D6CC8F047DF4F1B71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_A0B33519872110CAF32EF047DF4F8EBD" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_B85B75E83E9CF2EB7315F047DF4F057F" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_79F5FA037B904CC9371BF047DF50AFB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_AAC0922F1147D61B62E3F047DF4C4033" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84CF510273C66A81F7EFF047DF507C9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_84CF510273C66A81F7EFF047DF507C9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_CE707E5164C08981AE3BF047DF50BB1D" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_BA3C9289F6757320581CF047DF50758B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E01220FA365B60BA27CD0037B9D5295F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_05C0227D1F6E79ACAB1F0037B9D6B5B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E01220FA365B60BA27CD0037B9D5295F" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_05C0227D1F6E79ACAB1F0037B9D6B5B9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_E01220FA365B60BA27CD0037B9D5295F" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_E0CA44DC9F558667F58D0037B9D68F6C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D75545D99886523192C9C8E70AC772FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9D0528BE81F354D0AE7378FF0F1C180C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_D75545D99886523192C9C8E70AC772FF" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_9D0528BE81F354D0AE7378FF0F1C180C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C9CD9FCE2A95BD5A233E42661117C37" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9C9CD9FCE2A95BD5A233E42661117C37" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_F0A0A7432746597F873B2BD57A7B885E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_939FA35144BD5AE1A079D97B825C984A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_939FA35144BD5AE1A079D97B825C984A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BC2796C31D7A56AAA48D85B1A6A51299" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_07C952AB70D8549184BA9A0A6AD7D1B3" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_BC2796C31D7A56AAA48D85B1A6A51299" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_F056921527E75969AB01154A509D7012" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_D0E5E059660158A28B1964AE3BE0BB44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_064203DFB1465517931905DD51D872FE" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_D0E5E059660158A28B1964AE3BE0BB44" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9D1C9C35C1E10D9AA9A203A4DA363E1B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9D1C9C35C1E10D9AA9A203A4DA363E1B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:to="loc_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_B30032D9DFB92A1A512703A4DA372133" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_99235F4654E98E53DC7803A4DA371061" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_69DD9B43A632E4025FDE03A4DA38E41C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_us-gaap_PerformanceSharesMember_BBEA21D7D3420EBB1B3F03A4DA384C0F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_PerformanceSharesAchievedBeforeDecember312020Member" xlink:label="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_exel_PerformanceSharesAchievedBeforeDecember312020Member_61168AD47B5468B1447503A9BF613F68" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_PerformanceSharesSecondProductApprovalMember" xlink:label="loc_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_97F23727FE3DC5EFBF9603A4DA3751E8" xlink:to="loc_exel_PerformanceSharesSecondProductApprovalMember_063799CB834297D9FCF103AA3964BC40" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_StatusAxis" xlink:label="loc_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:to="loc_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_StatusDomain" xlink:label="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusAxis_A55AF1C16E0F0EC458C803A4DA384DB9" xlink:to="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AchievedMember" xlink:label="loc_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:to="loc_exel_AchievedMember_AE130CD3991A17B3948703A4DA380789" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ProbableMember" xlink:label="loc_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:to="loc_exel_ProbableMember_8E71C6502898D2EA1E5D03A4DA381F8E" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_NotProbableMember" xlink:label="loc_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_StatusDomain_27EF53DC80535F20D8D603A4DA382383" xlink:to="loc_exel_NotProbableMember_A0765F93A91E03C6F65903A4DA3938BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_46187E8DDF4A5CF79C5F03A4DA3676AE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_F48317CDC0719E7F62D503A4DA394CD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_AEF782BC7B60A792B98103A4DA39A4F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_7681E6A525484DBC442403A4DA39D4B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_17E04E1A4E3505658A9303A4DA3A1D49" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_9FC98CB689E0D6AC364703A54F59BB01" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest_D919362A03E323B3658403A7F4EBF19C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_E25FF7A75CF3B128A8E003A4DA3A958E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_F6691F5874FFB559C1D703A4DA39A3B7" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_ED3EA681D356B31D25D703A4DA3A8F6C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1FD75B8D2B6A00532D11B3E4516BCAAD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_969AF404CB7FB05E5C8FB3E4516BCB4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1FD75B8D2B6A00532D11B3E4516BCAAD" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_969AF404CB7FB05E5C8FB3E4516BCB4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_47B4B5F59D4EDFD7108DB3E4516B109E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_969AF404CB7FB05E5C8FB3E4516BCB4C" xlink:to="loc_us-gaap_AwardTypeAxis_47B4B5F59D4EDFD7108DB3E4516B109E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9841BE6D3FB6498442DB3E4516C7EE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_47B4B5F59D4EDFD7108DB3E4516B109E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9841BE6D3FB6498442DB3E4516C7EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_67447978E2462F199903B3E4516C8EE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9841BE6D3FB6498442DB3E4516C7EE8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_67447978E2462F199903B3E4516C8EE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_969AF404CB7FB05E5C8FB3E4516BCB4C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_455D17C804750BE791C0B3E4516D4E1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_455D17C804750BE791C0B3E4516D4E1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5DF1F6F391EB23374E10B3E4516D8DB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_5DF1F6F391EB23374E10B3E4516D8DB8" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased_2FBDBBB9A8602B991F8CB3E4516D898E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_740DA94010C92654E157B3E4516DC852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ACBEA33A45245ABCDC36B3E4516DCE30" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_CE9069631135E0947E85B3E4516CDBDB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ACBEA33A45245ABCDC36B3E4516DCE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_B1BDFAFEA3E8525AD52EB3E4516E5067" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_C0E235A12E516C30B189B3E4516EF4F0" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue_849BDA9BFC66CBCD851FB3E4516EFD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_9B15DB665F1CE4781A92B3E4516E1195" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C2521345A7166ADEB6DDB3E4516E7616" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_105D961A2F2BAD8772E5B3E4516EE888" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_C2521345A7166ADEB6DDB3E4516E7616" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract_B124B51BEB9C87C2C379B3E4516F8C00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_8D37DC3B6BBBA04F172AB3E4516F862C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_586EB3C4BB8AF5D7A5A2B3E4516C2AA8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract_52A7F06BB0903B8EEDD0B3E4516FBFFF" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue_D1A212EE097C18B6D3A1B3E4516F238F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59009790AF8E54F0AD6522AF878178F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59009790AF8E54F0AD6522AF878178F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_136142F19A6E5BA4B5092C01B7A7104F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_136142F19A6E5BA4B5092C01B7A7104F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36D54B8635C35155AE628C17C10B66D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_36D54B8635C35155AE628C17C10B66D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6335DF02AE5E5F06A9E15E1A43202A15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6335DF02AE5E5F06A9E15E1A43202A15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41260A25DEAD52E9B5ED8BD90C183E64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_41260A25DEAD52E9B5ED8BD90C183E64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_FB8611C130375A999639119B355CFF37" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_FB8611C130375A999639119B355CFF37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71F982EFAFF55837AD19FDB150B5434C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_B253E6E54EEE550DA26B2120752D018A" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_71F982EFAFF55837AD19FDB150B5434C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23EFDA30030F5B9FBFA813661FF69133" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59009790AF8E54F0AD6522AF878178F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_23EFDA30030F5B9FBFA813661FF69133" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59009790AF8E54F0AD6522AF878178F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6D82C5A36745CA3A4FF56FFADD65F69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_E6D82C5A36745CA3A4FF56FFADD65F69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_366C7832C41F54C793C938201AAEE224" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_366C7832C41F54C793C938201AAEE224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_98849AF6899E569EBFC33C6FCC07394A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_98849AF6899E569EBFC33C6FCC07394A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E74D68D1D78E5422BCF4BA58C0B6D98F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_E74D68D1D78E5422BCF4BA58C0B6D98F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1220F50E2DFA5EF6A17B1538674B5638" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_1220F50E2DFA5EF6A17B1538674B5638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6AD3BF27C3235CB0BCF83278EBCD32A9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_E5506981ECC159F49DF72A73AC82CA2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_6AD3BF27C3235CB0BCF83278EBCD32A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_345782D85B585D1C8FE933586AA73102" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59009790AF8E54F0AD6522AF878178F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_345782D85B585D1C8FE933586AA73102" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59009790AF8E54F0AD6522AF878178F2" xlink:to="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_92E8B59FB74356069D7C8EB93885ED15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_92E8B59FB74356069D7C8EB93885ED15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F43B10AA851A59DD91C0C5E3954B60C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract_E2C88A96DCD8596B9436A38573825DA0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_F43B10AA851A59DD91C0C5E3954B60C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_FAB9B122A781516A8CDF22426714039D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_59009790AF8E54F0AD6522AF878178F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_FAB9B122A781516A8CDF22426714039D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E7CF9D071AA054489D6C669376BC1783" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_FAB9B122A781516A8CDF22426714039D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_E7CF9D071AA054489D6C669376BC1783" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6956E23C87B353F6B40270170E17C0B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_FAB9B122A781516A8CDF22426714039D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_6956E23C87B353F6B40270170E17C0B4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_687BA701CF1459A1867E17BD28A9E988" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_FDF05CD8690E5896BDCB57EE1C658CBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_687BA701CF1459A1867E17BD28A9E988" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_FDF05CD8690E5896BDCB57EE1C658CBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_E230C62F40535F77A65639D03DE1EFC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_687BA701CF1459A1867E17BD28A9E988" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock_E230C62F40535F77A65639D03DE1EFC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6CE420926E8A5E43AED026C321D79BF7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_687BA701CF1459A1867E17BD28A9E988" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_6CE420926E8A5E43AED026C321D79BF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_642D5D1D6336528DA2D0348D55E185C1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_687BA701CF1459A1867E17BD28A9E988" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_642D5D1D6336528DA2D0348D55E185C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_17171091DC4354008F7990B08F279D01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_687BA701CF1459A1867E17BD28A9E988" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_17171091DC4354008F7990B08F279D01" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E5FE741ED7705EDA8149A13AD6C61B24" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6C6D0665960507C93DE10E092249340" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_E5FE741ED7705EDA8149A13AD6C61B24" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6C6D0665960507C93DE10E092249340" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_72684AA298045B2CA28D4E0D6AC48ECC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6C6D0665960507C93DE10E092249340" xlink:to="loc_us-gaap_AwardTypeAxis_72684AA298045B2CA28D4E0D6AC48ECC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3CE879DFA7735A3AAB3BB7330DE7EC47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_72684AA298045B2CA28D4E0D6AC48ECC" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3CE879DFA7735A3AAB3BB7330DE7EC47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_99E37DB45F645D98B833853F14AF5883" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3CE879DFA7735A3AAB3BB7330DE7EC47" xlink:to="loc_us-gaap_EmployeeStockOptionMember_99E37DB45F645D98B833853F14AF5883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_61D4FA5477005B77B77F0759FD6054CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3CE879DFA7735A3AAB3BB7330DE7EC47" xlink:to="loc_us-gaap_EmployeeStockMember_61D4FA5477005B77B77F0759FD6054CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D6C6D0665960507C93DE10E092249340" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E1D29ECD7780533D9398EB87484D523C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_E1D29ECD7780533D9398EB87484D523C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E624A2FDC2845BA98A140BBCF67BED80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_E624A2FDC2845BA98A140BBCF67BED80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03E958890B895C8EAED3AEE121823CCA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_03E958890B895C8EAED3AEE121823CCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2165294CF2725B5BBEB46406B13895B3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DB2D435B00AC581F92C49B250BDF2E55" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2165294CF2725B5BBEB46406B13895B3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F9EC4C8B2325BAEA58128A16BCC413D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90AD70B222545824A2FA0E44491675E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1F9EC4C8B2325BAEA58128A16BCC413D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90AD70B222545824A2FA0E44491675E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_A0E25592FE865C71BB620C2C26C03823" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90AD70B222545824A2FA0E44491675E5" xlink:to="loc_us-gaap_AwardTypeAxis_A0E25592FE865C71BB620C2C26C03823" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66B74CD9AA465AE5B419EF2D00B81512" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_A0E25592FE865C71BB620C2C26C03823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66B74CD9AA465AE5B419EF2D00B81512" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1927665C74FC5836B4E644A933DE473D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66B74CD9AA465AE5B419EF2D00B81512" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1927665C74FC5836B4E644A933DE473D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockMember" xlink:label="loc_us-gaap_EmployeeStockMember_0055D20C1BB056B3AFED0A7BE85C9310" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_66B74CD9AA465AE5B419EF2D00B81512" xlink:to="loc_us-gaap_EmployeeStockMember_0055D20C1BB056B3AFED0A7BE85C9310" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A6931B82AE5756A996736000CA8D69F0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_90AD70B222545824A2FA0E44491675E5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A6931B82AE5756A996736000CA8D69F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5664F50C39CE5740A5AB286CC447A2A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A6931B82AE5756A996736000CA8D69F0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5664F50C39CE5740A5AB286CC447A2A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_18772A405E13950FFE850F83E4952710" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_F9103F06E7B3D5C160500F83F71D3CBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_18772A405E13950FFE850F83E4952710" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_F9103F06E7B3D5C160500F83F71D3CBD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_91BDE45DD2430310D5B20F9CE26D7B45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_91BDE45DD2430310D5B20F9CE26D7B45" xlink:to="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_7DE09A3003497CB506AF0F9CE26F002C" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_1892DA2E6F72C9E81F8B0F9CE26F2B1E" xlink:to="loc_us-gaap_SubsequentEventMember_5486FC899C301AF7CA930F9CE26F3691" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LeaseArrangementsAxis" xlink:label="loc_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:to="loc_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LeaseArrangementsDomain" xlink:label="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsAxis_73E8989728DDC0C927220FD5A244A38D" xlink:to="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_BuiltToSuitLeaseMember" xlink:label="loc_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_LeaseArrangementsDomain_B3CEF2A7997DCB71B9230FD5A246F4A1" xlink:to="loc_exel_BuiltToSuitLeaseMember_75B7CDA49781D18A2B0B0FD638A8535C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:to="loc_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3A2F9F645B7AB022985F0F9CE26EDB0E" xlink:to="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_AlamedaCaliforniaMember" xlink:label="loc_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_F97437AD679F0AC7A0FF0F9CE26E2504" xlink:to="loc_exel_AlamedaCaliforniaMember_07391CABA66682EC1C780F9CE26F1189" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_82A8432605220307A6420F9CE26E4A24" xlink:to="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="loc_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_us-gaap_AreaOfRealEstateProperty_A23D7A095B13A28537160F9CE270E573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_BB1DC71E62A3154AA4510F9CE2704AD4" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment_D8AACE7C210665FD1BB90F9CE270C18D" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage" xlink:label="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage_B1FC945D988EA6F5CD140F9CE2705A1A" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:label="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_LesseeOperatingLeaseNumberOfRenewalOptions_A70AB0F9F0C0B97726EB0F9CE270FF8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_F4556FACCB2A7433C5860FCB7778FD31" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod" xlink:label="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod_0CF7CF5B7DFCE5C36D9C0FD4B1D6B14F" xlink:type="arc" />
    <link:loc xlink:href="exel-20190927.xsd#exel_OperatingLeaseAdditionalAreaOfRealEstateProperty" xlink:label="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_472BA4E1FFA9733CA93D0F9CE2700A10" xlink:to="loc_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty_0E90C56871C6A7D60F5C0FDE6E16AA18" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exellogo19q3.jpg
<TEXT>
begin 644 exellogo19q3.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
MU0#; .  Y0#K /  ]@#[ 0$!!P$- 1,!&0$? 24!*P$R 3@!/@%% 4P!4@%9
M 6 !9P%N 74!? &# 8L!D@&: :$!J0&Q ;D!P0') =$!V0'A >D!\@'Z @,"
M# (4 AT")@(O C@"00)+ E0"70)G G$">@*$ HX"F *B JP"M@+! LL"U0+@
M NL"]0,  PL#%@,A RT#. -# T\#6@-F W(#?@.* Y8#H@.N [H#QP/3 ^ #
M[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C 2:!*@$M@3$!-,$X03P!/X%#04<
M!2L%.@5)!5@%9P5W!88%E@6F!;4%Q075!>4%]@8&!A8&)P8W!D@&609J!GL&
MC :=!J\&P ;1!N,&]0<'!QD'*P<]!T\'80=T!X8'F0>L![\'T@?E!_@("P@?
M"#((1@A:"&X(@@B6"*H(O@C2".<(^PD0"24).@E/"60)>0F/":0)N@G/">4)
M^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F NP"\@+X0OY
M#!(,*@Q##%P,=0R.#*<,P S9#/,-#0TF#4 -6@UT#8X-J0W##=X-^ X3#BX.
M20YD#G\.FPZV#M(.[@\)#R4/00]>#WH/E@^S#\\/[! )$"800Q!A$'X0FQ"Y
M$-<0]1$3$3$13Q%M$8P1JA')$>@2!Q(F$D429!*$$J,2PQ+C$P,3(Q-#$V,3
M@Q.D$\43Y10&%"<4211J%(L4K13.%/ 5$A4T%585>!6;%;T5X!8#%B86219L
M%H\6LA;6%OH7'1=!%V47B1>N%](7]Q@;&$ 891B*&*\8U1CZ&2 911EK&9$9
MMQG=&@0:*AI1&G<:GAK%&NP;%!L[&V,;BANR&]H< APJ'%(<>QRC',P<]1T>
M'4<=<!V9'<,=[!X6'D >:AZ4'KX>Z1\3'SX?:1^4'[\?ZB 5($$@;""8(,0@
M\"$<(4@A=2&A(<XA^R(G(E4B@B*O(MTC"B,X(V8CE"/"(_ D'R1-)'PDJR3:
M)0DE."5H)9<EQR7W)B<F5R:')K<FZ"<8)TDG>B>K)]PH#2@_*'$HHBC4*08I
M."EK*9TIT"H"*C4J:"J;*L\K BLV*VDKG2O1+ 4L.2QN+*(LURT,+4$M=BVK
M+>$N%BY,+H(NMR[N+R0O6B^1+\<O_C U,&PPI##;,1(Q2C&",;HQ\C(J,F,R
MFS+4,PTS1C-_,[@S\30K-&4TGC38-1,U336'-<(U_38W-G(VKC;I-R0W8#><
M-]<X%#A0.(PXR#D%.4(Y?SF\.?DZ-CIT.K(Z[SLM.VL[JCOH/"<\93RD/.,]
M(CUA/:$]X#X@/F ^H#[@/R$_83^B/^) (T!D0*9 YT$I06I!K$'N0C!"<D*U
M0O=#.D-]0\!$ T1'1(I$SD42155%FD7>1B)&9T:K1O!'-4=[1\!(!4A+2)%(
MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
M]&>.)F4?BP _&LJ]:%&G*K4VBFWZ+5F^%P]3$5H8>DKRDTEZMV7XGY&?\%+?
MCW)\>?VL?$$D4YDTGPW(=$T]0?E"PL1(X['?+YC9[KM]!7@%23SR74[R2,TD
MDC%G=CN9B>22>^:CK^",VS&KC\95QM;XJDG)_-[>BV7D?ZMY#D]#*<MH9;AE
M[E*,8KSLK7]6]7YL****\\]8**** "BBB@ HHHH **** /NS_@B)\>I-"^(W
MB#X=WD_^AZ] =4T]&/"7,0 D51ZO%AC[0#\?TPK\*_V/OB&WPK_:C\!ZZ)/*
MCL]:MTN&':"1Q%+_ .0W>OW4K^K/!?-Y8K)982H[NC*R_P ,M5^/-\C^#?I)
M</PP/$D,PI*RQ$$W_CA[K_\ )>5OSNPHHHK]@/YY"BBB@ HHHH **** "BBB
M@ K@OVD/VA=!_9A^$^H>*_$$O[BU'EVULKA9;^X(.R&/_:;!.?X5#,> :ZGQ
MEXRTOX>^%-0US6KR'3])TN!KFZN)3A8D49)]_8#DD@#).*_&7]NG]L?5/VP?
MBS)?_OK3PQI)>#1;!C_JHR>97'3S9, MCH JY.W)^ \0.-J608+]W9UYW4%V
M[R?DOQ>FUVOUCPE\,Z_%F9_O;QPM)IU)=^T(O^:75_96N]D^#^/GQTU[]H[X
MI:EXK\17'F7VH-A(D)\JTB'W(8P>B*#]222<DDGC:**_CC$8BKB*LJU:3E*3
M;;>[;W;/]&,'@Z.$H0PV&BHP@E&*6B26B2]$=9\#O@_JGQ\^+.A>$=&7-]K=
MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
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MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
M"C_AW]\$?^B5^!?_  41?X4>U0>S9_/U\WM1\WM7] O_  [^^"/_ $2OP+_X
M*(O\*/\ AW]\$?\ HE?@7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\"
M_P#@HB_PH_X=_?!'_HE?@7_P41?X4>U0>S9_/U\WM1\WM7] O_#O[X(_]$K\
M"_\ @HB_PH_X=_?!'_HE?@7_ ,%$7^%'M4'LV?S]?-[4?-[5_0+_ ,._O@C_
M -$K\"_^"B+_  H_X=_?!'_HE?@7_P %$7^%'M4'LV?S]?-[4?-[5_0+_P .
M_O@C_P!$K\"_^"B+_"C_ (=_?!'_ *)7X%_\%$7^%'M4'LV?S]?-[4?-[5_0
M+_P[^^"/_1*_ O\ X*(O\*UO"?[&WPE\"WRW6D_#7P-8W2G<L\>B6_FH?]ER
MA8?@11[5![-GXC_LT_L$?%+]JW4+?_A%_#-XNDS-A]9OU-KIT2YP6\UA\^/[
ML8=O:OUO_8'_ .":OA/]B+1VOUD'B'QM?0^7>:S-%M$*'!,-NG/EQY')R6?'
M) PJ_2:J$7 X Z#THK.4VRHQ2"BBBI*"BBB@ HHHH **** .%_:@_P"3:?B)
M_P!BSJ7_ *2RU_.I\WM7]%?[4'_)M/Q$_P"Q9U+_ -)9:_G4^;VK:D9U ^;V
MH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH ]-_8I_Y/(^
M$O\ V.6C_P#I=#7]#%?SS_L4_P#)Y'PE_P"QRT?_ -+H:_H8K"IN:T]@HHHK
M,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE_P""Q7_*./XC
M?]PW_P!.=I7TU7S+_P %BO\ E''\1O\ N&_^G.TJH[H#\-/F]J/F]J/F]J/F
M]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]JZ?X*_P#)8_"7_89L
M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
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M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
M/F]J/F]J/F]J/F]J #YO:CYO:CYO:ON?_@GU_P $;=7_ &A=)L?&7Q$FO/#?
M@^Z"SV-A" NH:O'U#G(/DPL.C$%V'("@JY3E8:5SXG\,>%-5\;:U#INBZ;J&
MK:C<'$5K96[W$TI_V40%C^ KZ(^&/_!(;X]_$V*&8>"VT"TFQB;6KR*S*9_O
M1$F8?]\5^S7P5_9W\#_LZ^'1I?@KPSI/AZUVA9#;0_OKC'0RRG,DC>[L37:5
MDZG8OV?<_)#PW_P;[?$R\B#:IXR\#Z>2,[;=KJY*].#F)!ZYP3^.:U?^(>CQ
ME_T43PS_ . 4_P#C7ZM45/M&5R(_)?6/^#?#XBP*?[/\<>"KIMN0+A;F#YO3
MY8WX]_TKA?%W_!#+X[>&T8V=KX5\0%<X%AJX0M]/M"1=??%?M%13]HPY$?@!
M\0O^"=WQO^&0D;5OAEXJ,<9(>2QM?[0C3'4EK<R*![YQ7C^H:;<:/?26MY;S
M6MU"=LD4R&.1#Z%3R*_I?KFOB-\&_"7Q?T[[+XJ\,Z#XCM]I54U*PBN=@_V=
MZDJ>^1@@TU4[D^S/YO\ YO:CYO:OV9^.'_!#GX.?$V.6?PVNL> ]0;)5K"X-
MS:%CW:&8L<>R.@KXG_:)_P"")_Q>^#*W%[X?AL_B!I$.6#Z5F.^51W:V?YB?
M]F)I#S5JHF2XM'Q]\WM1\WM5G6M$O/#>JW%AJ%I=:??6CF.>WN8FBEA<=596
M ((]",U6^;VJR0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU)_X(J_
M\$^!X:TJV^,?C"Q_XF%_&?\ A&+.=.;:%N#>D'^-QD1^B$MSO4KX;_P2T_X)
M?7W[27B2R\=>-K*:S^'NFS++;VTR%7\12*<A%!_Y=P?OO_%RJ_Q,G[%6]O'9
MP1PPQI%#$H1$1=JHHX  '0"LJDNB-(QZLDHHHK$T"BBB@#XK_P""Q?[!EQ^T
MQ\,H/&WA:R:Y\:>#X&#V\2YEU6QR6:)1WDC)9T Y;+J,EE%?&_\ P2O_ ."E
MDG[(WB%O!OB]YKCX?:Q<[_-P7DT&=L RJO5HFXWH.1C<O.Y7_9RO@G_@HS_P
M1TM?CKJFH>./AC]CTGQ;=%I]0TB5A#9ZN_4R1MTAF;OGY')R2AW,VD9+9DRC
MK='3?\%!_P#@GS<_\%'=5\&^+/"/C7P_:Z38Z;)%%,R-<Q7B2.'62-XS@CJ/
MP_+WS]BG]G>Y_92_9D\,> ;S4X=8N=!%SYEW#"8HY3-=37'"DDC;YNWD\[<\
M9P/QK^%G[2?QP_X)P^-KK0[>35_#;K+ONM!UFU,EE<$'!<1OQAL?ZR(J6 'S
M$8KZV^'G_!PVJV"1^+/AJ6NE4;KC2=4Q'(?:*1"5_P"_C=?;D<96LB5)7N?I
ME7YT_M3?\$+KGXM?'?7O%'@WQ5HOAS2-=G^W?V=<6DC?99WYEV%#C87RP&!M
MW;1P!3?%'_!PWX;M[*0Z+\-M<O+C'R"]U.*V3..I*)(>#V[CTKY9_:._X*S_
M !D_:G1M!L[I/"VCZ@Q@&F>'TD2>\#<"-Y<F5\YP50JK9Y4T1C)#E)'TE^W=
M_P %++[X"? :S^#WAWQA;^+_ (CP6 TOQ)XJL%,<5H%&QU0[FS=,O#NK?(VX
M_*_RIYW_ ,$5_P!@ZZ^*/Q&M?BMXEL9(_#'AF??HJ2I@:G?(>)%SUCA/.1P9
M H!.QQ1^P;_P17\2?%#5+'Q+\5K6Z\,^&(W65-%?,6I:F!SMD'6WC/0YQ(1D
M )D/7ZP>%?"NF^!_#=CH^CV-KINE:;"MO:VMO&(XK>-1A551P !1*22LA)-N
M[-"BBBLS0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
M!0__ (6'HEK\(O&5]NU[2X2OAV\G?YM0MT4DVS$]9(E!*^L:XZIEORF^;VJW
MX>\07WA+7K+5-,NI['4M-G2ZM;F!RDEO*C!D=2.0P8 @^HJ91NK%1E9G]+5%
M?-__  37_;QL?VU_@^K7LD%KXX\/HD.MVBX42DC"W4:_\\Y,'('W&RO3:3[M
M\1/B%H_PG\#:KXD\07T.FZ-HMNUU=W$A^6-%_F3P !R20!DD5SVL[&QY_P#M
MH_M;Z'^QI\$[[Q5JQCN;YLV^DZ=OVR:C=$':@[A1]YF[*#U) /X+_%_XM:]\
M=?B5K'BSQ-?/J&M:W<&XN)3]U>RH@_A15 55' 50.U>D?MX_MG:Q^VO\;KG7
M[SSK30=/W6NA::6^6RMMWWF'3S9,!G;G)PN=JJ!XI\WM6\(VU,92N'S>U'S>
MU'S>U'S>U62'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[5]J
M_P#!(7_@GB?VE?'B^//%UCN\!^&[C]S!,F5UN\7!$>#UA3@N>C'"<Y?:G*VH
M+4^A_P#@C)_P3O/PWT2V^+GC2PV^(-4A)\/64Z?-IULZX^TL#TDE4D+W6,GN
MY"_H30JA%P. .@]**YI2;=V;I6"BBBD,**** "BBB@ HHHH **** "OS?_X.
M(?\ D3/A;_U^:C_Z!;U^D%?F_P#\'$/_ ")GPM_Z_-1_] MZJ.Y,MC\NOF]J
M/F]J/F]J/F]JZ3$/F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VK],_P#@
MW3Z?&+_N"_\ N0K\S/F]J_3/_@W3Z?&+_N"_^Y"HJ?"5'<_3*BBBN<V"BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .
M%_:@_P"3:?B)_P!BSJ7_ *2RU_.I\WM7]%?[4'_)M/Q$_P"Q9U+_ -)9:_G4
M^;VK:D9U ^;VH^;VH^;VH^;VK4S#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;V
MH ]-_8I_Y/(^$O\ V.6C_P#I=#7]#%?SS_L4_P#)Y'PE_P"QRT?_ -+H:_H8
MK"IN:T]@HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYE
M_P""Q7_*./XC?]PW_P!.=I7TU7S+_P %BO\ E''\1O\ N&_^G.TJH[H#\-/F
M]J/F]J/F]J/F]JZ3G#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]JZ?X*
M_P#)8_"7_89L_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444
M %%%% !1110 4444 %?-_P#P4Q_9$'[4'P*DN=+MA)XN\*A[W2]H^>Z3 \VV
M_P"!A05_VT49 +5](45YN<95A\RP=3 XI7A-6?EV:\T]5YH]GA[/L7DN94<T
MP3M4I2379]T_*2NFNJ;/YY71HW*LI5E."".0:;7V!_P5P_9!_P"%*?%@>.-%
MM?+\,^,IV:=47"6-^06=/99 #(ON)!@ "OC^OX=S[)<1E./J8#$_%![]&NC7
MDUJ?Z>\*<383/\JHYM@W[M17MUC+:47YQ=UY[K1A1117CGT04444 %%%% !7
MZH?\$A?VO_\ A;GPQ;X?ZY=>9XB\(P#[$\C9>\L 0J_5HB50_P"R8^O-?E?7
M5_!+XOZQ\!/BGHOBS0Y?+U'1[@3*I.$G0\/$W^RZ%E/L:^OX(XHJ9%FD,6OX
M;]V:[Q>_S6Z]+;-GY[XF\#4N*LCJ8!V56/O4Y=IK9>DOA?D[[I'[XT5RGP3^
M+VD?'KX6Z+XMT.7S-/UJW$RJ2"T#]'B;'\2,&4^X-=77]KT*].M3C6I.\9)-
M-;-/5/YG^:.*PM7#5IX>O%QG!N,D]TT[-/S3"BBBMCG"BBB@ HHHH 9)(L,;
M.[*JJ,LQ. !ZFOR@_P""H'[>C?M%^,7\'>%[MO\ A!]"G/F31M\NLW"\>83W
MB0Y"#H>7Y^7;[#_P5G_;[_L>UO/A3X-O?]+G4Q^([Z%O]0A_Y<T/]YA_K".@
M.SDEPOYR5_.'BQQ][64LCR^7NK2I)=7_ ")]E]KN].CO_9'@#X4>PC#BC-X>
M_)7HQ:V3_P"7C7=_8[+WMVK%%%%?@1_6 4444 %%%% '9?L_?!;4_P!H?XQ:
M#X/TD;;K6;D1O+C*VT0^:65O9$#-[XQU-?N=\-_A]I?PI\!:1X;T6W6VTO1+
M5+2W0==JC&3ZLQR2>Y)/>OD/_@C=^RK_ ,*W^&=S\1M8MMFL>+H_)TT./FM[
M ,#N]O-<!O\ =1"/O&OMBOZQ\(^%?[-RWZ_77[VO9^:A]E?/XG\NQ_ _T@>/
M/[9SK^RL+*]#"MK3:53[3_[=^%>:DUHPHHHK];/Y_"BBB@ HHHH **** "BB
MB@ KYE_X+%?\HX_B-_W#?_3G:5]-5\R_\%BO^4<?Q&_[AO\ Z<[2JCN@/PT^
M;VH^;VH^;VH^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@
MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '"_M0?\FT_$3_L6=2_
M])9:_G4^;VK^BO\ :@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\
MWM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_R>1\)?^QRT?_TN
MAK^ABOYY_P!BG_D\CX2_]CEH_P#Z70U_0Q6%3<UI[!1116984444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7S+_P6*_Y1Q_$;_N&_P#ISM*^FJ^9
M?^"Q7_*./XC?]PW_ -.=I51W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'
MS>U !\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_P"PS9_^CTKF/F]JZ?X*_P#)
M8_"7_89L_P#T>E(#^CZBBBN4Z HHHH **** "BBB@ HHHH **** .-^/?P6T
MC]H;X2:UX1UI?]"UB QK*JY>UE'S1S)_M(P##L<8/!(K\.?B]\*]8^"/Q+UC
MPKKT'V?5-%N&MY@/NR#JLBGNCJ593W# U^_%?$O_  6%_9!_X61\/E^)6AVN
M[6_"\.S54C3YKRQSG><#EH22<_W"V?N@5^/^+?"/]HX'^TL,OWM%:]Y0W:]8
M_$O*ZW:/Z&^C_P"(7]C9K_8N,E;#XEJU]HU-D_2>D7Y\KT29^7M%%%?RF?WD
M%%%% !1110 4444 ?9G_  2%_; _X5'\3&^'VNW>SP[XNF'V%Y&^2ROSA5')
MP%E&$/\ M"/IEC7ZH5_/-#,UO*LD;-')&0RLIP5(Y!![8K]D_P#@G!^UTO[5
M?P*A_M&X5_%WAH)9:PI/S3\'RKG'I(%.>GSJ_ &*_I#P;XO]I3>18J7O1NZ;
M?5;N/RW7E?HD?QM]([P]]C57%.!C[L[1K)=);1G_ -O?#+SY7O)GT-1117[X
M?R@%%%% !7R__P %*/V[(?V6/ 7]AZ#<(_CO7H3]D PW]F0G(-RXZ9X(13U8
M$\A2#Z5^V!^U;HO[(WPDN?$&I;;K4KC-OI.G!MKW]QC@>R+P7;L.F25!_%GX
MH_$[6OC)X^U3Q-XBO9-0UC5IC-<3-P/0*HZ*BC"JHX 4 =*_(?%#CU930_L[
M R_VB:U:^Q%]?\3^SV6O:_\ 0?@?X4O/\6LXS.'^R4GHG_R\FNGG"/VN[]W7
MWK8M[>S:E>37%Q-+<7%P[22RR,6>1B<EF)Y)))))Y)-0T45_*3;;NS^]4DE9
M!1112 **** "O7?V(_V9KC]JK]H#2?#FR3^QX6^VZQ,F1Y-HA!<9'1G)"*>S
M.#T!KR*OV _X)9_LJ_\ #.O[/L.J:E;>7XH\9!-0O=X^>V@Q^X@]L*Q=@>0T
MC _=%?>>'?"SSO-HTJB_=4_>GZ+:/_;ST]+OH?EGB_QTN&,@G7HNU>K[E/NF
MUK+_ +<6O;FY4]SZ4TS3;?1=.M[.TACMK6TB6&"&-0J1(H 55 Z    >@JQ1
M17]GQBDK(_S;E)R=WN%%%%,04444 %%%% !1110 4444 %?,O_!8K_E''\1O
M^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\ TYVE5'= ?AI\WM1\WM1\WM1\WM72
M<X?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM73_!7_DL?A+_ +#-G_Z/
M2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH **** /YR?
MVAO"K>!?C]XXT1E\MM'\07]D5';R[B1/4^GJ?QKD/F]J^F/^"O7PR?X:?M[^
M,CY?EVOB P:U;'&-XFB7S#_W^64>^*^9_F]JZH['.P^;VH^;VH^;VH^;VI@'
MS>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 L4K02JZ,R.C!E93AE(Z$'UK]#O
MV&O^"X6H> [*S\,?%Z*\US3(ML,'B*W'F7UNO0?:(_\ ELHX^=?WF <B0FOS
MP^;VH^;VI2BGN-.Q_1Y\)?C;X1^._AE=8\'>(M)\1:<<!I;*<2&$D9"R+]Z-
ML?PN P]*ZFOYL_ /Q(\0?"KQ'#K'AG6M4T'5(?N75A<O;R@9!QN4@E3@9!X/
M<&OL+X$?\%V/BM\.%@M?%UEH_CS3X\*TDR?8;XJ.,"6(;#QW:)B3WZYQ=-]#
M1374_8JBOC/X-_\ !<KX,_$18X?$#:[X'O6 #?;[0W-KN/998-YQ[NB"OJ#X
M:_';P5\9K3SO"?BSP[XB3;N(T_4(KAT'^TJL64^Q -0XM;EW1UE%%%( HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
MV?\ PH_XB%_&7_1._#/_ (&S_P"%'(PYD?JU17Y2_P#$0OXR_P"B=^&?_ V?
M_"ON[]@#]J?4/VQOV=[;QIJ6DV>C74U]<6AMK:1I(P(V !RW.3FAQ:!23V/;
M****DH**** "BBB@ HHHH **** "BBB@ HHHH **** .-^/WP*\/_M)_";6/
M!OB:U^TZ7J\6PLO$EM(.4FC/\+HV"#[8.02#^"?[5O[,GB#]D?XTZIX-\0QE
MI;4^=97:KMBU&U8GRYT]FP01D[65E/*FOZ'J^??^"BO[#FG?ML_!:2QC6WM?
M&&AA[C0;]^ DA W0.?\ GE)M /\ =(5N=N#<)69,HW/P<^;VH^;VJ_XL\*:E
MX%\3ZAHVL65QINJZ7</:W=K.NV2"5"596'J"#5#YO:N@Q#YO:CYO:CYO:CYO
M:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^
M;VH^;VH^;VH /F]J/F]J/F]J/F]J %BB:>5416=W8*JJ,EB>@ ]:_:'_ (),
M_P#!/5?V4?AS_P )7XHLU'Q!\36X\U)%!;1K4X86P])&X:3W"K_"2?GK_@B[
M_P $[_\ A)-1L_C'XTL?^)?9R;_#%E.G_'Q,IQ]M8'^%""(\]6&_^%2?U(K&
MI+HC2,>H4445D:!1110 4444 %%%% !1110 4444 %%%% !7YO\ _!Q#_P B
M9\+?^OS4?_0+>OT@K\W_ /@XA_Y$SX6_]?FH_P#H%O51W)EL?EU\WM1\WM1\
MWM1\WM728A\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U?IG_ ,&Z?3XQ
M?]P7_P!R%?F9\WM7T+^P9_P4+UG]@W_A*O[(\.Z7KW_"5?9/-^USO'Y'V?S]
MNW;USY[9S_=%3)75BH[G[P45^4O_ !$+^,O^B=^&?_ V?_"C_B(7\9?]$[\,
M_P#@;/\ X5AR,TYD?JU17Y2_\1"_C+_HG?AG_P #9_\ "C_B(7\9?]$[\,_^
M!L_^%'(PYD?JU17Y2_\ $0OXR_Z)WX9_\#9_\*/^(A?QE_T3OPS_ .!L_P#A
M1R,.9'ZM45^4O_$0OXR_Z)WX9_\  V?_  H_XB%_&7_1._#/_@;/_A1R,.9'
MZM45^4O_ !$+^,O^B=^&?_ V?_"C_B(7\9?]$[\,_P#@;/\ X4<C#F1^K5%?
ME+_Q$+^,O^B=^&?_  -G_P */^(A?QE_T3OPS_X&S_X4<C#F1^K5%?E+_P 1
M"_C+_HG?AG_P-G_PH_XB%_&7_1._#/\ X&S_ .%'(PYD?JU17Y2_\1"_C+_H
MG?AG_P #9_\ "C_B(7\9?]$[\,_^!L_^%'(PYD?JU17PY_P3O_X*O^(?VT_C
MY-X/U3PGHVBVT6DSZC]HM;F21RT;Q*%PW&#YGZ5]QTFK;E)W"BBBD 4444 %
M%%% !1110!PO[4'_ ";3\1/^Q9U+_P!)9:_G4^;VK^BO]J#_ )-I^(G_ &+.
MI?\ I++7\ZGS>U;4C.H'S>U'S>U'S>U'S>U:F8?-[4?-[4?-[4?-[4 'S>U'
MS>U'S>U'S>U 'IO[%/\ R>1\)?\ L<M'_P#2Z&OZ&*_GG_8I_P"3R/A+_P!C
MEH__ *70U_0Q6%3<UI[!1116984444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7S+_P %BO\ E''\1O\ N&_^G.TKZ:KYE_X+%?\ *./XC?\ <-_]
M.=I51W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\
MWM0 ?-[5T_P5_P"2Q^$O^PS9_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^C
MZBBBN4Z HHHH **** "BBB@ HHHH **** "H;FUCOK:2&:..:&92DD;J&5U(
MP00>"".,&IJ*&KZ,$VG='XM_\%#/V3)OV4/CS=6=G"__  BNO;K[193DJD9/
MSVY/]Z)CCJ3M*$_>KP>OVZ_;B_9:M?VLO@/J&@[88]<L\WNC7+@#R;E0<*3V
M2091O0$-@E17XGZUHUWX<UF[T^_MYK.^L)GM[B"5=LD,B,59&'8A@01ZBOX[
M\3.$?[%S-SH+]Q5O*/9/K'Y=/)KS/]%/!7Q"7$V2*GBI7Q-"T9]Y+[,_^WDK
M/^\GLFBK1117YN?L@4444 %%%% !7J_[&/[3=]^RA\=]+\30^;-I;G[)JUJA
M_P"/JT<C> /[RD!U_P!I .A->445UX''5L'B(8K#RY9P::?FOZU[G!FF68;,
M<'4P&,CS4ZD7&2[IZ??V>Z>J/Z#O#?B*Q\8>'['5M,N8[S3]2@2ZMIXS\DT;
MJ&5A[$$&KU?GO_P1F_:]^TVLWPEUZZ_>0B2\\/22-]Y<EIK4?3+2+[&0=E%?
MH17]O\*\14<[RVGCZ.C>DE_+);K]5W33/\QN/.#\3PSG-7*L1JHN\)?S0?PR
M_1]I)KH%<W\6?BIHOP4^'>J>*/$5XMEI.DPF:9^K.>BH@_B=F(51W)%;NH7\
M.DZ?-=74T=O:VT;2S32,%2)%&69B>   22>U?D)_P4A_;IG_ &KOB'_9&ASS
MP^!- E(LHSE?[2FY#73K[\A >54D\%V \SCCC&AD& =9V=65U"/=]W_=77Y+
MJ>UX7^'>)XMS58=7C0IV=6?9?RKIS2V7;5V:5CS;]KC]J36OVL_B[=>(]4:2
MWL8\P:7I^_='I]N#PH[%CU9OXCZ  #RZBBOXRQV.KXRO/%8F3E.;NV^K?]?+
M8_T@RW+<-E^$IX'!P4*=-*,4MDE_6K>K>KU"BBBN4[@HHHH ***FL+&;5+Z&
MUMH9+BXN'6***-2SR.QP% '))) Q32;=D)R25V?1G_!,#]E/_AI/]H."\U*W
M,GA?P@4U'4=RY2XDS^XMS_OLI8CND;CC(K]BJ\<_88_9DA_94_9\TKP_(D9U
MN\'V_69EY\RZ<#<H/=4 "#U"YZDU['7]G>'7"JR3*8TZB_>U/>GZO:/_ &ZM
M/6[ZG^;WC#QT^)L_G5HROAZ5X4^S2>L_^WWK_AY4]@HHHK[T_*0HHHH ****
M "BBB@ HHHH **** "OF7_@L5_RCC^(W_<-_].=I7TU7S+_P6*_Y1Q_$;_N&
M_P#ISM*J.Z _#3YO:CYO:CYO:CYO:NDYP^;VH^;VH^;VH^;VH /F]J/F]J/F
M]J/F]J #YO:NG^"O_)8_"7_89L__ $>E<Q\WM73_  5_Y+'X2_[#-G_Z/2D!
M_1]1117*= 4444 %%%% !1110!^;?_!P5\"9+_0/!/Q(M(=W]GR/H&HN%RP1
M\S6Y/HH83C/K(H[\_E]\WM7]$_[47P)LOVF/@!XI\#WS)$FO63103,,BVN%(
M>&7'^Q*J-CN 1WK^>GQGX0U+X?>+M3T+6+62QU71[J2RN[>0?-#+&Q5E/T(-
M;4Y:6,IK6YG?-[4?-[4?-[4?-[5J0'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\
MWM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM4ME>S:;=QSV\TMO/"V
M])(V*NA]01R#47S>U'S>U 'N/PI_X*4?''X."./2?B)KMQ:Q\"WU1UU*(+_=
M G#E1_ND5])_"S_@X)\<:(T47C#P3X=\00KA6ETZ>73IS_M'=YJ$^P51].M?
MGW\WM1\WM4\J97,S]E_A5_P71^"WCIHX=<_X23P;<-PS7UC]IMP?9[<NV/=D
M7^M?27PK_:?^'?QO2/\ X1/QMX:UZ609%O:W\;7"_P"]$2)%_%17\ZWS>U+%
M*T$JNC,CHP964X92.A!]:CV:Z#]HS^F2BOP!^$'_  4/^-'P/:-=!^(7B!K6
M/ 6TU"8:A;!?[HCG#A1_NX/O7U7\&/\ @X+\3:28K?Q]X)TK6HAA6O-&G:SF
M X^8QR;T=NO *#GM4^S9?.C]4Z*^:?@=_P %;?@=\<6B@C\5+X7U*7'^A^(8
MQ8D'T\TDP$^PDS[5](6%_!JEG'<6LT-Q;S*'CEB<.DBGH01P1]*SLT434444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
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M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** */B3PQIOC'1+
MC3=8T^QU73;I=D]K>0+/!,OHR,"K#ZBOAO\ :X_X(9^"_B9;W.K?#&X7P3KI
M!?\ LZ9GFTN[;.<#.7@//5=R#  0=:^\J*:DUL%KG\XOQI^!_BK]GGQ_=^&?
M&&CW6BZQ9\F*5<K,A) DC<?+)&<'#*2#@]P<<I\WM7] O[:7[&OAG]M'X27'
MA_6H8K;5K=6ET?5ECS-IEQC@CNT;8 =,X8>C!6'X+_%#X:ZQ\'?B'K/A?7[4
MV>L:#=O9W474!U.,@]U(P0>A!!K>,KF,HV,+YO:CYO:CYO:CYO:K)#YO:CYO
M:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J_4W_ (-Y/&C7GPW^)7ATR'9INI6>
MHHA/&;B*2-B/_ 9<_A7Y9?-[5^B/_!O+J#Q_%;XD6H*^7-I-I*1W)29P/_0S
M^8J*GPE1W/U4HHHKG-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _GY_X*!_\GN?%7_L
M9K[_ -&M7D'S>U>O_P#!0/\ Y/<^*O\ V,U]_P"C6KR#YO:NJ.QSA\WM1\WM
M1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#^@7_@G[_P F0_"K
M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
MQ)^'>K?"3Q]JWAO7+9K35M%N6M;F/G&Y>C*>ZL,,I[J0>]8=?I?_ ,%D?V0?
M^$Q\*Q?%+0;7=JFAQ"WUR.-.;BT'W)SCJT1.">?D8<@1U^:%?Q+QEPS5R/,Y
MX*>L=X/O%[?-;/S3Z'^FGASQK0XHR2EF5.RG\-2*^S-;KT>DH^376X4445\J
M?=!1110 4444 %?=G_!&_P#; _X0_P 5R?"W7KK;IFMR&?0Y)&XM[L\O!ST6
M4#*C^^",$R5\)U8TO5+G0]3M[VSGFM;RSE6>":)BKPR*0RLI'(((!![$5[W#
M.?U\FS&GCZ'V7JOYHO=/U6W9V?0^5XUX3PO$F3ULIQ6TU[LNL9KX9+T>_=76
MS/Z%**\4_8-_:KM_VL_@-8ZS(\2>(M-Q8ZU N!LN% _> =DD&&'8'<O.TU[7
M7]PY;F%#'86&,PSO":33\G^JV:Z,_P P\XRG%97CJN78V/+4IR<9+S7;NGNG
MU5F%%%%=IYH4444 %%%% !7S+_P6*_Y1Q_$;_N&_^G.TKZ:KYE_X+%?\HX_B
M-_W#?_3G:54=T!^&GS>U'S>U'S>U'S>U=)SA\WM1\WM1\WM1\WM0 ?-[4?-[
M4?-[4?-[4 'S>U=/\%?^2Q^$O^PS9_\ H]*YCYO:NG^"O_)8_"7_ &&;/_T>
ME(#^CZBBBN4Z HHHH **** "L3XC_$/1_A+X$U;Q)X@OHM.T71;9[J[N).D:
M*.PZECP HY)( R2!6W7Y'?\ !:3]OG_A</CA_A7X5O=WA?PW<;M8N(7^74[Y
M"1Y>1UCA.1Z-)DX.Q#51C=BE*R/FC]MK]K?6/VS/CMJ'BO4?-M=-3_1='T]F
MRNGVBDE$XX+MDLY[LQ[!0/(OF]J/F]J/F]JZ%H8!\WM1\WM1\WM1\WM3 /F]
MJ/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#7\#_ ! UWX9^(8=6\.ZSJFA:I;_Z
MN[L+I[>9/8,A!P?3O7V/\ ?^"[/Q2^&R0V?C'3])\?:?'@&64?8;_'_76-2A
M_P"!1$GUKXA^;VH^;VI<J>XTVC]H_@W_ ,%N_@I\2HXH=:N]8\$WS\,FJ6;2
MVY;_ &98=XQ[N$Z=J^F/AS\<_!?Q>MUD\*^+/#GB)6&[&G:C%<,H]U5B5/L0
M"*_G$^;VI8)WMIHY(W:.2-@RLIPRD<@@^M9^S1?M&?TR45_/'X*_;*^+/P["
M+HOQ(\;6,,?W8!K$[0#H?]6S%.WI_6O2_#O_  5Z_:&\.A57X@37D2]4N]*L
MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
M\$^H?V0_AC_PD'B*UC;XA>)X%:\+ ,=)MSAEM%/][HTA'!8 <A 3\^?\$6/^
M"> N9;/XS>-+',<9W^%K&=/O,,@WS*?3I%[Y?LC5^G-85)=#2,>H4445F:!1
M110 4444 %%%% !1110!RGQM^#&@?M!_"[6/"'B:S6\T?6H##*O&^)NJ2H?X
M9$8!E/8@=>E?@I^UY^ROK_['WQLU+PAKBM)''_I&G7P7;'J5JQ(29?R(8?PL
MK#G&3_0M7@__  4%_8ETK]MKX)S:1)Y-IXHTG?<Z#J+C_CWF(&Z-CU\J0 *P
M[$*V"4 JHRL3*-S\$OF]J/F]JT_&_@K5?AQXOU+0=<L;C3=7TBX>UN[:9=KP
MR*<$'_$<$8(R"#69\WM708A\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO
M:CYO:CYO:CYO:@#] ?\ @C-_P41_X5;XAM_A-XTOMOAO6)B-!O9W^73+IS_Q
M[L3TBE;[O99#Z.2OZR5_,TK;3D<$<@CM7[$?\$@O^"B/_#1W@I/A_P"+[X-X
MZ\.V_P#HEQ,WS:W9H -V3]Z:,8#CJRX?GYR,:D>J-(RZ'V[11161H%%%% !1
M110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\ Z!;U
M4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U
M !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\W
MM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\W
MM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!W7[+W
M_)ROP[_[&;3?_2J*OZ*Z_G4_9>_Y.5^'?_8S:;_Z515_176%0TIA11169H%%
M%% !1110!PO[4'_)M/Q$_P"Q9U+_ -)9:_G4^;VK^BO]J#_DVGXB?]BSJ7_I
M++7\ZGS>U;4C.H'S>U'S>U'S>U'S>U:F8?-[4?-[4?-[4?-[4 'S>U'S>U'S
M>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !
M\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1
M\WM1\WM0 ?-[4?-[4?-[4?-[4 ?J+_P;O?\ (F?%+_K\T[_T"XK](*_.7_@W
MBL)(_AY\3KH[?+FU&QB7GG*13$_^AC]:_1JN:I\1M'8****DH*^9?^"Q7_*.
M/XC?]PW_ -.=I7TU7S+_ ,%BO^4<?Q&_[AO_ *<[2JCN@/PT^;VH^;VH^;VH
M^;VKI.</F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VKI_@K_R6/PE_P!A
MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
M&:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\ PX<^-W_/WX%_\&DO
M_P 9H_X<.?&[_G[\"_\ @TE_^,T<R#E9\6?-[4?-[5]I_P##ASXW?\_?@7_P
M:2__ !FC_APY\;O^?OP+_P"#27_XS1S(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!
M?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\ PX<^-W_/
MWX%_\&DO_P 9H_X<.?&[_G[\"_\ @TE_^,T<R#E9\6?-[4?-[5]I_P##ASXW
M?\_?@7_P:2__ !FC_APY\;O^?OP+_P"#27_XS1S(.5GQ9\WM1\WM7VG_ ,.'
M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
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M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
MXS1_PX<^-W_/WX%_\&DO_P 9KHYD8\K/BSYO:CYO:OM/_APY\;O^?OP+_P"#
M27_XS1_PX<^-W_/WX%_\&DO_ ,9HYD'*SXL^;VH^;VK[Z\(?\&^?Q(O;]1KW
MC;P3IEJ<9>Q^U7L@]?D>*(?^/5]5_LT?\$6?A-\"KRWU+7H[KXA:U#AE?5HU
M6QC8=UM5RI^DK2#Z4O:(.5GPU_P3>_X)9Z]^U7XAL?%'BRTN]%^&]NXF,C@Q
MS:Y@Y\J#N(ST:7IC(7)R5_9G0="LO"^B6>FZ;:P6.GZ?"EM;6\"!(X(T 545
M1P%    Z 59@@2V@6.-5CCC4*B*,*H'  'I3ZQE)LTC&P4445)04444 %%%%
M $-W=PV%I+<7$L<$$"&2261@J1J!DL2>  .237XI?MZ?M/R_M5_M"ZGK4$DA
MT#3_ /B7Z+$W&VV0G]X1_>D8LY[@,!_"*^[/^"P7[5?_  J7X.1^!=)N-FO>
M-8F6Y*-\]MIX.V0_]M3F,>JB3N!7Y55_-OC1Q5[6M'),._=A:4_.7V8_):OS
M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
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M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exhibit102image1601.jpg
<TEXT>
begin 644 exhibit102image1601.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,' WX# 2(  A$! Q$!_\0
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M>M&1ZT +136=$0N[*JJ,DDX %9J^)=!8976]-(/0BZ3_ !H U**S/^$CT/\
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M['M6RMM-!/\ VG) 19!S(+3O%_TUQZ]R.WUKI48V_K7R_K_(YG*5_P"M//\
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MT$1< 229_4T_1O @U'1;.\:X7=/$'.99<\_0XKM?$ZA_"NJJ>AM7_E4?A/\
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M_P C=XI_Z[Q?^@UU-);%3W"BBBF2%%%% !1110 4444 %%%% !1110 4444
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M1%E4?ZH^8I\O_=]#^==E&+;R+G^V/^/_  /,QZ9^7RN^,],<YZUQGQ-^T?\
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M/8885],Z'()O#^FRJ" ]K$P!]T%8SW.RC\)\'U]?_!+_ ))#H7_;Q_Z/DKY
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M?GCPK"0L.HR?7J2*Z:A":L%%%%,04444 %%%% !1110 4444 %%%% !1110
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MUOJ$D*PLY9"BG(^4XS6S7)_#;_D1K3_KK+_Z%765T+8X)JTF@HHHIDA1110
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M/#7_ "*ND?\ 7E#_ .@"L)[G;2^!'PI7U_\ !+_DD.A?]O'_ */DKY KZ_\
M@E_R2'0O^WC_ -'R5)H>@5Y1^T%9M<?#I)@X407L;$$=<Y7^M>KUYG\>.?AA
M<#_IZ@_]"H Y'PGH[Z#X<M["299F4L^]1@?,<XK:J.W&+6$#H(U_E4E="//;
MN[A1113$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 5=3_ .03>_\ 7!__ $$USGPU_P"1
M'M?^NLO_ *%71ZG_ ,@F]_ZX/_Z":YSX:_\ (CVO_767_P!"J>I:^!G6T445
M1 4444 %%%% ''?$/_CTT/\ ["D7\C79-]]OK7(?$ #[!I!]-3BQ^M=>WWV^
MM);LM_"A****9 4444 %%%% !1110 4444 %(WW&_P!T_P J6D;[C?[I_E0!
MR?PU_P"1)M_^NTO_ *%76UR7PU_Y$FW_ .NTO_H5=;2CL7/XF%%%%,@****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@"KJ?_ "";W_K@_P#Z":YSX:_\B/:_
M]=9?_0JZ/4_^03>_]<'_ /037.?#7_D1[7_KK+_Z%4]2U\#.MHHHJB HHHH
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MBO0-7NK;1[VUU.XE6"%R;>X=LX*X)4G'H1^IJ(O2YK4BN:R-FBL+_A-/#/\
MT&K;_P >_P */^$U\,_]!JV_\>_PJKHCEEV-VBL+_A-?#/\ T&K;_P >_P *
M/^$U\,_]!JV_\>_PHN@Y9=C=HK"_X37PS_T&K;_Q[_"C_A-?#/\ T&K;_P >
M_P *+H.678W:*PO^$T\-?]!JV_\ 'O\ "C_A-/#7_0:MO_'O\*+H.678W:*P
MO^$T\-?]!JV_\>_PH_X33PU_T&K;_P >_P *+H.678W:*P3XT\.XQ%J:3R'A
M8H49W8^@&.34=U>^(+JTFN;:WBTRWB0R#[2/,FD YQM'"@^^31=!ROJ=%16
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M %%%% !2-]QO]T_RI:1ON-_NG^5 ')_#7_D2XO\ KXE_F*ZVN2^&O_(EQ?\
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M2?XAD<>])-%.,NYT,WA_2/(D\K1]/\W8=F;9,;L<=O6N<TWP_?WEC'<M%X<
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MKY:Y_*I*Z3S@HHHH **** "BBB@ ILG^ID_W&_E3J;)_J9/]QOY4 <3\+/\
MD6[S_K]?_P!!6NXKAOA8?^*<O/:];_T%:[FICL74^)E'687N-#OX(H_,DDMW
M54_O$C@5P]EXFUOPQX;MX;SPO,(+2,(T[2X'7@]/>O1N]>4>+/$M[=PZQIDU
MZODHS*L ML'Y9 !\_ICOZ@T2TU*IJ^AZG;R^?:PS;2OF1J^T]LC.*BGTZRNI
M!)<6D,L@.0S+S^=%@R_V=:_,/]2G?_9%6-R_WE_.J,S/:#1X)X[5X;..60$Q
MQL%!;GG&>O-/_L;2^/\ B76O&,9B'&*Y3QG"Y\7^%+A K*+CRS@\YW*?Y5W#
MLJ*SNP55Y+$X %)%/1)B@=JHZ=JUIJNGM>VS/Y*LRDNNT@KUXJ^O)!%<-H\P
MT[1+403P^9?K(K6\I(!;+*'# ';V'/!XH;$E=&GX-U*UU6/6+JT<M%)J#NNX
M8."JXXKI:Y+X?:?)I>BWEE.J">&\:.0KR"0J]^]='>:E9Z>T(NIQ&96VID$_
MB?0>YXH6PYKWM#BM#NI[GXMZO]H"AH[9HT"_W05Q^.*[^O/-#_Y+%K?_ %P;
M_P!IUZ'2B.IN@I1U%)2CJ*HS.&\!\:WXG'_3X?YM7<5P_@3_ )#OBC_K\_JU
M=Q4QV+J?$%%%%40%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!5U/_D$WO\ UP?_ -!-<Y\-/^1'MO\
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M/^^139/BA:1(7DT/4D0=68 "CF0>SEV.[HKAA\3+<@$:!JA!Z?**/^%F0?\
M0 U3_OD4<R#V<NQW-%<-_P +,@_Z &J?]\BC_A9D'_0 U3_OD4<R#V<NQW-%
M<-_PLR#_ * &J?\ ?(IC_%&SC=5?1-25GX4-@%OI1S(/9R['>45PW_"RX/\
MH :I_P!\BC_A9D'_ $ -4_[Y%',@]G+L=S17#?\ "S(/^@!JG_?(H_X69!_T
M -4_[Y%',@]G+L=S17#?\+,@_P"@!JG_ 'R*/^%F0?\ 0 U3_OD4<R#V<NQW
M-%<-_P +,@_Z &J?]\BD;XG6R(7?0M355&22  *.9![.78[JBN%7XG6KH'30
MM392,@@ @TO_  LR#_H :I_WR*.9![.78[FBN&_X69!_T -4_P"^16IH/C*'
M7M2-DFF7EJ_EM('G  (&./UI\R!PDC;U/_D$WO\ UP?_ -!-<W\-/^1'MO\
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M0X7)J3.2SIG_ #X>&O\ OY_]A1G3/^?#PU_W\_\ L*ZSRX_^>:?]\BCRX_\
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M:@LO^0?:_P#7%/\ T$5/3)#-&:** #-<7XR7/BCPHWI<N/\ T&NTKD/&*_\
M$\\,-Z7I'Z"E+8N'Q'8$\FDS2GJ:2F0&:,T44 &:,T44 &:Q_%O_ ")^L?\
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M?)4FIZ!7F?QX_P"287''_+U!C_OJO3*\T^/'_),+C_KZ@_\ 0J ,:W_X]8>
M/W:\#Z5)4<'_ ![0_P"XO\JDKI/."BBB@ HHHH **** "G)]]?K3:<GWU^M
M''?#S_D&ZM_V$Y?Z5U]<A\//^0;JW_83E_I77TH[%S^)E#7/^1?U+_KVD_\
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M<?\ 'K-_US;^5<U\//\ D2K/_?D_]"-+J6OA9U-%%%,@**** "BBB@ HHHH
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M$@_Z#FL?^!!IK^ HF0@:]K"GL?M&<5UM%'*A\\CCT\ (,[_$6LO_ -ML4X^
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M='SWNB/T%?3=8SW.RC\!\ 5]?_!+_DD.A?\ ;Q_Z/DKY KZ_^"7_ "2'0O\
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M.$12S'T &35?3M1M=6L4O+*3S(')"M@C.#@U4GU[1S;2@:I9DE&&/.'I7/>
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MKV=S.ZS(JN0(788/3D"KJV-G',LR6D"2H"%=(P",]>E3C@Y'!/4BC46AB_\
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M  )L#\C7BOQ!'_%,KD?\O</\Z^B1P,"HJ;FU!>Z? %?7_P $O^20Z%_V\?\
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M:/PNJ:3/8P?:+^:)287E<_NXS&"!R-S'&."*]<N&E2VE:"-9)@A,:,VT,V.
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M>O4H R6\2%BQ5%&3WXKG_'QW>!]3YS\J=_\ ;6FXV1*G=HV[#_D&VG_7"/\
M]!%6*K:><Z79GUMXS_XZ*LU9DSB/%W_(\>$_^NQ_]"%=O7$>+O\ D>/"?_78
M_P#H0KMZE;LJ6R"BBBJ(,?Q6,^$M6'K;/_*HO!G_ ")FD_\ 7 ?S-3^*/^15
MU3_KV?\ E4'@S_D3-)_ZX#^9J?M%_8^9NT4451!'/"ES;RP2#,<J%&'L1BJ%
MEJ'D!+'4)!%=QC:K.<+.!T93W)[CJ#6G3)(8KA/+FB25#U5U##\C0.X[@\@@
MY[BEKD? BI&?$$: *JZG(%4=%'. !VKKJ2=T$E9V.*U6QM-1^*-C;WMM'<0_
MV:S;)!D9#-@UT2>'=$C^YI-D/^V(K$NN/BQI_OICC]6KKJ214F[(S_["TC_H
M%V?_ 'Y7_"C^PM(_Z!=G_P!^5_PK0HIV)NS/_L+2/^@79_\ ?E?\*7^P](_Z
M!=G_ -^5_P *OT46"[///'VG65HMHUM:00DE>8XPO\8KZCKYD^(Y(CLL#.67
M\/G%?3=93W.NC\)\ 5]?_!+_ ))#H7_;Q_Z/DKY KZ_^"7_)(="_[>/_ $?)
M4&IZ!6+XP_Y$S6O^O*7_ -!-;5<YXZO[.Q\&:K]KNH;?SK66.,RN%WL4.%&>
M_M0!T2_='TI:CMYHKBWCF@D26)U#(Z,"K ]P1U%24 %%%% !1110 R2..:-H
MY45XV&&5AD$>XKS;7_@[I\UPVH>%;R30+\\E(>;>0^Z=OPX]J],HH#<^?+O4
M_$'A*=;;QEI1BA)PFIV@+P/]<=#^1]JW+2\MK^V6XM)TFA<9#H<BO9)H8KB%
MH9XDEB<89'4,K#W!KS/7/@[9B=]0\(WSZ'>GDPC+6TGU3^'\./:M%-]3"=%/
M8XOQGJ\FF:)Y%IDW]\WV>W4=<G@G\/ZUI:%I,>AZ+;:='@^4OSL/XG/+'\ZY
M._@UK0?&UMJ'CFQ>VAMXO+M9X%+VY<_Q;AT/4]CQTKN+:Y@O(%GMIDFB;HZ-
MD5:=W<QG%Q5B6BBBJ,PHHHH **** .4^(QV^#)R>@FB/_CPKJ8CF&,^J+_*N
M4^)7_(D77_76/_T(5U,'_'M#_P!<U_D*74M_"B2BBBF0*/O"N1^'1!\.W ]+
MZ8']*ZX?>%<=\-_^0!>_]A"7^2TGN6OA9V%%%%,@*Y-B!\5XQZZ3Q_WV:ZRN
M0F_Y*Y:_]@MOYM29<.IU]%%%,@**** "BBB@ HHHH **** "LSQ(6'AC5-@!
M;[,^ 3@=*TZS?$/_ "+>I_\ 7K)_*D]AK<MV98V%L6 #>2F0#G'RBIZBM?\
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M_KV;^50>"_\ D3-)_P"N _F:G[1?V/F;M%%%40%*.HI*4=10!Q_@7_7>)/\
ML*R?UKKZY#P+_K_$@]-5D_K77TH[%S^(Y&Z_Y*QIW_8-?^;5UU<E<_\ )6+#
M_L&/_-JZVA!+H%%%%,@**** .&^(O^KL_JO_ *,%?3-?,/Q*ECC6Q#R!"64@
M$]0'&:^G(Y$EC62-U=' 964Y!!Z$&L9[G91^$^ J^O\ X)?\DAT+_MX_]'R5
MX!_PI+XA_P#0O?\ D[;_ /QROH_X6Z)J/ASX<:3I.K6_V>^@\[S(MZOMW3.P
MY4D'@@\&H-3L*\@_:*=AX#M$\HE3>H3)D84[6XQUKU^JFH:78:M;?9M2LK>\
M@#!O+N(A(N1T.".M 'C7P^^,^AQ:5H7A@:7JDEXD26VZ.-&5F [?-DC\*]3_
M .$F_P"H)K7_ ("?_7I8?!GA>WF2:#PYI,4J'*NEG&&4^H(%;@&!@=!0!A?\
M)-_U!-:_\!/_ *]'_"3?]036O_ 3_P"O6[10!A?\)-_U!-:_\!/_ *]'_"3?
M]036O_ 3_P"O6[10!A?\)-_U!-:_\!/_ *]'_"3?]036O_ 3_P"O6[10!A?\
M)-_U!-:_\!/_ *]'_"3?]036O_ 3_P"O6[10!SMQKT%W;O!<^'=6FA<8>.2Q
M#*P]""<&O,-?\$65H\FI>%(-:T&XZM!+;$VLGL03E?PS]*]QJ&YM;>\B\JZ@
MCFCSG9(@89^AH!JY\MV'Q61(A'J5INE08:2(X#'N<=JM6OQ8TR6\DCN;*>"W
M&?+E#;RWU7M^9KZ$_P"$+\+?]"WI/_@%'_A2'P7X6(P?#>D8_P"O*/\ PJ^=
MF7L8'AZ_$KPPR!C=3J3_  F!LBG?\+'\+_\ /[+_ -^&KW^UTG3K*W2WM+"U
M@A3[L<4*JJ_0 5-]DMO^?>+_ +X%'M&+V$3YZ_X61X7SC[;-_P!^&H_X6/X7
M_P"?V7_OPU?0OV2V_P"?>+_O@4?9+;_GWB_[X%'M&'L(GRQXV\::'K7A:>RL
M;F1YWD0A6B9> <GDU!'\7)$C1/['0[5"Y\\]A]*^I[S1],U"V:WO=.M+B!B"
M8YH593CIP16;_P (-X2_Z%C1O_ &/_"ESLI4HVL?-\?Q=W2HLFDJB%@&83$X
M'<XQ72?\+(\+YQ]MF_[\-7MJ>"/"B.KIX:T=64Y!%E'D'\JV/LEM_P ^\7_?
M IJ;$Z,6?/8^)'A?(_TV7_OPU<WX+\9:'H^DW4%[<R)))>22J!$6RI P>/I7
MU1]DMO\ GWB_[X%'V2V_Y]XO^^!1SL/8QM8^>C\2/"X'_'[-_P!^&K'U?XJV
M5K<QKI=O]MA*9=GW1E6STZ>E?3OV2V_Y]XO^^!5"_P##.@ZI(LFH:+IUTZ#:
MK3VR.0/09%'.P5&*/F(?%Z3OHZ?]_P _X55T[QW9W?CF+6=1C-G#'9M!A,R9
M/..WO7T[_P (-X2_Z%C1O_ &/_"K%EX5\/:;<>?8Z%IMM-@KYD-JB-@]L@4N
M=C]E'H>%CXD>%S_R^S?]^&H/Q(\+@?\ '[-_WX:OH7[);?\ /O%_WP*/LEM_
MS[Q?]\"G[1D^PB?/7_"R/"__ #^R_P#?AJ/^%D>%\X^VS?\ @.U?0OV2V_Y]
MXO\ O@4?9+;_ )]XO^^!1[1A[")\KW/Q;$=U,D&F)- KD1R&4J67L2,<4S_A
M;S_] =/^_P"?\*^E9O!GA>XF>:?PYI,DLC%G=[.,EB>I)Q3/^$&\)?\ 0L:-
M_P" ,?\ A2YV5[*'8\%TOXH:-<6ADU'?:3AB!&B-(".QSBKW_"R/"_\ S^R_
M]^&KWRQT/2=,@,%AIEG:Q%MQ2&!4!/K@#K5G[);?\^\7_? I\[)]A$\!L_'G
MAR_NTMH;YA(^<&2,JO SU-:W]LZ7_P!!"V_[^"O1?$.A37GB/PS=6EE&UO9W
M<DERPVC:IB90<'D\D=,UT3V\"HS+;1L0,A0HR?;FG[1B=!=&?/.K_$31-.CN
MXX)S<7L.0D80[';_ 'O2N*U+XH7>I:3<V+:?%$9XRGF1R'*Y]J^I-&T&%=!^
MSZK8VTDUTSRW,3QJZY=BQ4]CC./3BD_X0;PE_P!"QHW_ ( Q_P"%2YME1I11
M\S6OQ9N(+."&32DD>.-49_.(W$#&<8KL]-\>>']2EA@2[*3NFXJ\955.,D;C
M7LW_  @WA+_H6-&_\ 8_\*=K&C@IIT^GV,+265RC")55=T9!1@,X PIS_P !
MIJ;!T8L\N_MG2_\ H(6W_?P5D77C_P -V=U);RWS&2,X8QQ%E_ CK7T!]EM_
M^>$7_? KEO!/A^XTJWUQ=1L8XVN=9N[F#.QMT3ME#QG&1V/(]*?M&2J"ZL\B
M_P"%D>%_^?V7_OPU<GXV\9:3J8TJ3397G>UN1,RM&4X'3DU]8_9+;_GWB_[X
M%5+_ $#1M41$U#2;&Z5#E5GMT<*?;(I.;94:,4[GR^?B_(6).C)S_P!-S_A5
MBP^+,$]]%'>Z>+:W8G?*KERO'ICGFOHK_A!O"7_0L:-_X Q_X5-:^$/#5C<I
M<VGA_2X)T^[)%:1JR\8X(%+G8_90['AO_"R/"^?^/V;C_IW:C_A8_A?_ )_9
M?^_#5]"_9+;_ )]XO^^!1]DMO^?>+_O@4_:,GV$3YZ_X61X7Q_Q^S?\ ?AJ/
M^%D>%QC_ $V;G_IW:OH7[);?\^\7_? H^R6W_/O%_P!\"CVC#V$3Y:U+XL)!
MJ$L>GV,=S:C&R5V9">.>*J_\+>N?^@1#_P!_3_A7TY=^$O#E_<M<7F@:9<3M
MC=)+:(S''N14/_"#>$O^A8T;_P  8_\ "ESLKV4.Q\_Z-\4].NEF_M:/[&5Q
MY?EAI-WK]*U!\2/"Y'_'[-_WX:O>;#P]HNEJZZ?I%C:"0@N(+=$W8Z9P.:N?
M9+;_ )]XO^^!3YV2Z,3YZ/Q(\+C_ )?9OPMVIO\ PLKPO_S^3_\ @.U?0_V2
MV_Y]XO\ O@4?9+;_ )]XO^^!1[1A[")\\_\ "R?"^#B\FR!T^SMS7._\+?7_
M * A_P# G_[&OJ<V=J1@VT)'^X*Q_P#A!O"7_0L:/_X Q_X4<[&J,$?-5Y\6
M$NK&XMO['*^;&R;OM&<9&,_=K2\%^,M$L?#VG:7=7C"[!*$>4VT%F.,GIW'-
M?0?_  @WA+_H6-&_\ 8_\*75O#]O_P (Z]GI-A:PR0%);:)(U1=Z.'"^@!(Q
M^-+G=[C=*-K'E_\ ;6E_]!"V_P"_@K+OO'7AW3KHVT]\3(%#9CC+KS[BO>X[
M>!XU9K6-&(!*E5RI]..*YW1="FM?%WB2]N;*);6\>W-L_P IW!8\-P.1SZXJ
MO:,A4%W/'?\ A9'A?_G]E_[\-63K?Q2L+>VC.BJ+J<OAA.C*H7U^M?3?V2V_
MY]XO^^!5:]T/2=1B6.^TRSN8U;<JS0*X!]>12YV-48H^51\7=0QSI=J3[.U;
MFG_$/4-2@\VU\+W,ZCAGBDRN?^^:[3XZ^'=$TOX?K<:?I%A:3_;(U\R"W1&Q
MALC(%<E\+,?\(B^.OVE\_D*<6VQ5(1BKV'GQCKF/E\'7I/O)C_V6L.XU7Q%)
MXLAUR/PM=*\-LT B9B02<\YQ[]*]0R?6C)]:NS[F*FET/+]/UGQ59:E<W;>&
M9I!<G+1[2 @[A?3)Y[UC7%KX@N/"T>BGP_=CR[MKA9-IQ@_PXQ[]:]IR?6C)
M]:7+YC]IY'C^HZ_K5KJFG:MJF@O!:VC*HBP560A2%R2#R,G%0:-XYM;/QCJ>
MMW5I.(KU,"*(ABIRO<X]#7L<L4<Z[9HTD7.<.N147]GV7_/G;_\ ?H?X4<K[
MC]I&VJ.)_P"%M:+_ ,^&H?DG_P 556\^+EHK1&QTR9UR?,$[!?I@C/ZUZ!_9
M]E_SYV__ 'Z7_"D_L^R_Y\[?_OTO^%.TNY/-#L>77?Q.ANY4E;2)8ID4J)(+
MPHVT]5SMZ<"N(U6^CU"Z62*$PQ(FQ$+;BHR3UP,]:^B#IUB1@V5L0>WE+_A4
M::/I<98IIMFI?[V(5Y^O%2XM]2XU8QV1X_I_C6VL[4PR:;/*LC^9-&+K;'(W
M')0+[?C6Z?B\S.F-(5%WC>3-N.W/.!@<^G->C_V?9?\ /G;_ /?I?\*/[/LO
M^?.W_P"_2_X4^5]Q.<'NCBO^%M:+_P ^&H?DG_Q54=:^)NDZEH=]8Q65ZLEQ
M T:LX3 )'?FO0SIUB1@V5L1_UR7_  J%M#TAV#-I=D2#D$P+_A3M+N2I0['C
M.D>-#I6AQZ7_ &1:7$:R-(SREMQ)[@CH>@R/2KH^).H?9KBTDMEDM94**KR$
MM&,=F/)_&O8/L%E_SYV__?H?X4?V?9?\^=O_ -^A_A2Y7W+]I'L><#XO*JJ/
M[$/  _X^?_L:SM?^)0UO0[K31I7D^> /,\_=MP0>FWVKUC^S[+_GSM_^_2_X
M4Q]+T^5=LEA:NOHT*G^E%I=R5."=[#M-XTFR'I;Q_P#H(JS2       8 ':E
MJS(Y[Q!XRT[PY<Q6]U'/))*NX",# &>Y)%9'_"TM&_Y];K_OI/\ XJNMO=+T
M_42AOK*WN2@PIEC#;?IFJ?\ PBOA_&/[&LO^_0J7S&B<+:HPM$\<:%-<:C)+
M=+9122K(B3L,DE0&QC/<9_&MC_A,O#7_ $&K3\S_ (5,/"^@*21H]ES_ -,1
M2_\ ",:#_P! :Q_[\+1J)N#,7Q%XKT"Y\.:C!!JUM)+) RHBDY8XZ=*Q_#'Q
M!T/3O#MC8W9N$F@38Y$>1UZUV7_",:#_ - :Q_[\+2#POH  ']C6/'_3$46E
M>Y2E"UC)_P"%D^%_^?V;_P !VIX^(WA<_P#+_(/K U:G_",:#_T!K'_OPM'_
M  C&@_\ 0&L?^_"T>\+W/,SA\0?#!_YB6/K$W^%/'CWPQD'^U$_[X;_"KI\+
MZ ?^8-8_]^133X4\/G_F#6?_ 'Z%'O"]SS,/X>SQW3>(KB%M\4NHLZ-Z@Y(-
M=I56QTVQTN)HK&UBMT=MS+&N,GUJU32LA2=W<Y&Z_P"2L:=_V#7_ )M775R-
MS_R5BP_[!C_S:NNH0Y= HHHID!1110!Y7\7_ /C[T@_],I/YBOJ#PUC_ (17
M1\=/L4/_ * *^8/B_P#\?6D?]<Y/YBOI_P -?\BKH_\ UY0_^@"L)_$=M+X$
M:E%%%2:!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110!YO\=$5OA7?EE#%9H"N1T/F 5S6DV-MI^F6\%I D,>Q2548R<#D^
M]=/\<O\ DE>H?]=H/_1BU@6W_'I#_P!<U_E6E,YZ_0EHHHK4Y@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@#DKG_DK&G^^F/\ S:NMKD;O_DK&G?\ 8-?^;5UU)%RZ!1113("B
MBB@#S_XFV\4T=EOB#-PH;'*@N,U]-6EM'9V<%K$,1PQK&@]@,#^5?-GQ%_U=
MG]5_]&"OIFL9[G91^$****@U"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP/$TUZ+C0[*RU":Q^W7[02S0)&SA!;SR8'F*R_>C7MTS0!OT5S__  CVJ?\
M0YZY_P!^;+_Y'H_X1[5/^ASUS_OS9?\ R/0!T%%<_P#\(]JG_0YZY_WYLO\
MY'H_X1[5/^ASUS_OS9?_ "/0!T%%<_\ \(]JG_0YZY_WYLO_ )'H_P"$>U3_
M *'/7/\ OS9?_(] '045S_\ PCVJ?]#GKG_?FR_^1Z/^$>U3_H<]<_[\V7_R
M/0!T%%<__P (]JG_ $.>N?\ ?FR_^1Z/^$>U3_H<]<_[\V7_ ,CT =!17/\
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MS@^M6Z "BBB@#G_ G_)//#/_ &"K7_T4M=!7/^!/^2>>&?\ L%6O_HI:Z"@
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M<V2S=JN?\+'TO_H&ZM_X##_XJI32-'%M*QV-%<@OQ#T]_NZ5K+?2U!_K3_\
MA/[/_H#:W_X"?_7I\R%R2['645R?_"?V?_0&UO\ \!/_ *]'_"?V?_0&UO\
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M?]2-_P"2E'_%H/\ J1O_ "4KT"B@#S__ (M!_P!2-_Y*4?\ %H/^I&_\E*]
MHH \_P#^+0?]2-_Y*4?\6@_ZD;_R4KT"B@#@/^+0#_H1_P#R4K?_ .$[\'_]
M#7H?_@QA_P#BJZ"B@#G_ /A._!__ $->A_\ @QA_^*H_X3OP?_T->A_^#&'_
M .*KH** .?\ ^$[\'_\ 0UZ'_P"#&'_XJC_A._!__0UZ'_X,8?\ XJN@HH Y
M_P#X3OP?_P!#7H?_ (,8?_BJ/^$[\'_]#7H?_@QA_P#BJZ"B@#G_ /A._!__
M $->A_\ @QA_^*H_X3OP?_T->A_^#&'_ .*KH** .?\ ^$[\'_\ 0UZ'_P"#
M&'_XJC_A._!__0UZ'_X,8?\ XJN@HH Y_P#X3OP?_P!#7H?_ (,8?_BJ/^$[
M\'_]#7H?_@QA_P#BJZ"B@#G_  +Q\/?#0/\ T"K7_P!%+70444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Y)^T/_ ,D[@_Z_H_\ T%JX
M+X5_\BI+_P!?+?R%>C_'ZS:Y^&<DH<+]GNHI""/O9.W'_CV?PKC?!>@3>'=%
M:UFN(Y_-?SE**1@$#@YJX;F-=KEL='1116QR!1145Q<0VL#3SR".-.K'_/6@
M#E_B0K2>$PB#+-=Q #WR:ZWL/I7,:_:ZEXATZ*WM+#R8UN(YO,N90A(4Y^Z
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M%% 'G/QR_P"25:C_ -=H/_1BUSEI/ ;.#;-&0(UZ./2NC^.?_)*M1_ZZP?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 ><_'+_DE>H?\ 7:#_ -&+6!;?\>D/_7-?Y5O?',X^%6H<@?OH
M.O\ UT6L&U(-G!@@_NUZ'VK2F<^(Z$M%%%:G,%%%% '+>/\ _D7H/^OZ#^9K
MJ:Y+XC.8O"BR#JEW"P_ FNM[#Z4EN4_A04444R0HHHH **** "BBB@ HHHH
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M?& $/I.01\LG\Q7TYX:_Y%;2/^O*'_T 5A/XCMI? C4HHHJ30**** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MQC$<:A%'H ,"L)[G;2=XH?1114F@4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 97BC_D4M9_Z\9__ $6U7;#_ )!UK_UR
M3^0JEXH_Y%+6?^O&?_T6U7;#_D'6O_7)/Y"@"Q114<\ABMY) ,[%+8]<"@!Y
M 92K $$8(/>O+O'WPY\,VNEWWB6TGDT"[M8FF:>SX1R.@,?0DG XQVK0TO0/
M$=IHUIJWA[7-\UW$MU<6&HYDMY'<;FV,/FCR3VR/:N/\=>(=6\77NG^$KO1[
MG3/)F$^J@N)(R!R@5UZ@]><=N.*:W$VDKLQO VFW4=A-K.I.TFH:D0[L_4(/
MNC\>N/I75T@554*H"JHP .PI:W2L<#=W<****8@HHHH **** "BBB@ HHHH
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M1116IS!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MIJQ'T_\ K4[H.21V=%<;_P )Y=?]"IJWY?\ UJBN/B-]D17N?#>IPJS!0SX
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 97BC_D4M9_Z\9_\ T6U+-J=MHWA@ZE>/LM[6T$LA]@N:
M3Q1_R*6L_P#7C/\ ^BVKS#XH:L^K#0_!%HY'VB..ZU C^&)<;5/U(S^ ]:!-
MV5SG_"_VO5;C4?%.I+B\U:8N@)SLA'"K], #Z 5TE-CC2*-(XUVHBA5 [ 4Z
MNA*RL<,I<SN%%%%,D**** "BBB@#C?B-_P @G3/^PA'_ %KLJXWXC?\ ()TS
M_L(1_P!:[*I6[+?PH****H@*X[XD?\@"R_["$7\FKL:X[XD?\B_9?]A"+^34
MI;%P^)'9'[QI*4_>-)3("BBB@# \2JKWGAP,H8?VQ;\$9_C%>\_9+;_GWB_[
MX%>#>)5S?^&SN(QK-N<#O\XZU[_6,]SLH_ <7K<$*?$OPF%AC4&*\SA1S\BU
MT>KWMMI.FRW3Q*SCY8HU4;I9#PJ =R365K^A:I?^)=&U;3KFTB^P).K"X1FW
M>8 ,@#'3'K5ZST(I>IJ&I7;W]ZF?+9E"1PYZ[$' /N23[U!J+H>C1:=HMK:S
MPPO.J9E;8#EV.YOPR36C]CM?^?:'_O@5-10!#]CMO^?:'_O@4?8[7_GVA_[X
M%344 0_8[;_GVA_[X%'V.V_Y]H?^^!4U% $/V.U_Y]H?^^!1]CM?^?:'_O@5
M-10!#]CM?^?:'_O@4?8[;_GVA_[X%344 0_8[7_GVA_[X%'V.U_Y]H?^^!4U
M% $/V.U_Y]H?^^!1]CM?^?:'_O@5-10!#]CMO^?:'_O@4?8[7_GVA_[X%344
M <]J<$,?B?P^4AC4^9/R$ _Y9FNAK"U;_D9O#_\ OS_^BS6[0!\ 5]?_  2_
MY)#H7_;Q_P"CY*^0*^O_ ()?\DAT+_MX_P#1\E 'H%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !16IX:TV'6?%6D:7<-(L%[>PV\C1
MD!@KN%)&01G!]#7T7_PSCX/_ .@EKG_?^'_XU0!\P45]/_\ #./@_P#Z"6N?
M]_X?_C5(G[.G@V0935-;89QD7$)_]I4 ?,-%?3Q_9R\'*I9M3UP <DF>'C_R
M%0O[.?@UU#)JFMLIZ$7$)!_\A4 ?,-%?3_\ PSCX/_Z"6N?]_P"'_P"-4?\
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M.U[N ']8Z /F>BOIJ']GOP/<[O(UG6)=OWO+NH6Q^4=2_P##./@\#)U+7/\
MO_#_ /&J /F"BOIR+]G?P5.F^'5M9D3.-R7,)'Z14R;]GSP-;L%GUK5XF(R
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M!U!!R,C/&:9XVT33_$G[0<^E:M?M964L*EY_,5=NV'<.6XY(_6G?\(TOPO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+'B+3SXG/AX2'^T1:?;#'_L;MOYY[>]<Y%\3;-CJ_GZ!KMLFE1-)=/-;H I
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% '0>!/^2A^&?^PK:_\ HU:^OM6T>[O/&7AS
M5(@GV:P6Z$Y+8/[Q%"X'?D&BB@#D1\/+U["ZE976_D\0F_1?MC^5Y'V@/DH#
MMSL!/3.:T?"]AKVB^*M627P_(;*_U">?^T/[24HL;,67$.>#V..:** .]90R
ME6 *D8((X->1Z7\*+ZRU;3KF:=)$CU*0W)9MQDLX]K6Z$'C@QKP/6BB@#27P
M=XG7Q5_PE!NK0W)U,RFT\OYA;$>5L\W/_/,!L8^][U<U7PIJMQI_CU(8HW?6
M=ILU$@&[$*I@D_=Y!HHH C_L76M;\)Q:->:#-I:6][;./,U3[0\D:R!G(<'<
MI ''/TJO%\/[U;>WT^13)##KWVV2]^U.)[F#RW"EWSNWKN"<'D#-%% %SQ;X
M%O/$/B-+JWN9+:"+1Y;6*:.X9'$Q=64-@Y9" 0<GFEMM+\1:#<)?:3H=G*;S
M3K>UEL_M0C6SDB# 8)!WQ_-VYX]Z** *$GPVO'A6%+E8KFUTF&"SOD."ERK2
M%N/[A#X(/4&M;2_#6IV\/@3SHXU;1K=X[P!P=K&W\OY?7YJ** -_1M8N-3U#
M6+::R$"6%UY$<@D#><-H;./X>O2LWQMHFJ^(H=-TZQ>WAM?M0N+N6=!(N(_F
M1#&<;@7QGD?=HHH Y6'P]XN\/GPZT.G1:T=%GO(TV7"6^^"1%V'YB<8)88]%
M%.UKPEXM\3ZC<:ZQM-*NX(H186DFV=U:,B0XE! 3<_RG&<@444 5-=^'&OZQ
MK>M7D4R6]KK! O;<2\RHD*&, ]OWH*G_ &36G#I/B+1?%D.H0>'GU%#86MN9
M8]36!8V165]R$_/UR,CZ444 37.A>(;N;6=%_LV&+3M1U079U%[E3B+,9($8
M&=WR$#..N:@3P=XG3Q0OBC[5:?:3J9F:S\OYOLQ_=;/-SCB,!L8^][T44 =G
MX=UF?6[6\EGLQ:FWO9K90) XD5&P']L^AJCXEM-8AU73=<T6QBU":TCE@ELW
MF$)D23:<JYX!!0=>HS110!@:]X7\4>,/[.AU&33["WBCGEFC$?VA#(^41""1
MDJC$[O[QXKKO"UOJ=IX9L+36"K7]O%Y,KJVX2;3M#Y_V@ ?QHHH UZ*** "B
KBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O@"BB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>exhibit102image1701a.jpg
<TEXT>
begin 644 exhibit102image1701a.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<FL@17-C
M:&5N   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,T,@  DI(
M @    ,T,@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( WH"+@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5XE^U7_R2S3?
M^PU%_P"B)Z]MKQ+]JO\ Y)9IO_8:B_\ 1$] 'H?PO_Y)/X6_[!-M_P"BUKJJ
MY7X7_P#))_"W_8)MO_1:UU5 !1110 44R9VCA=XT,CJI*H#C<<=*\\\(>,/&
M.L>(DCU71XAI,I"&5-/N+62U?RW=E;S3API5$W* &+Y'0B@#T:BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>)?M5_\DLTW_L-1?\ HB>O;:\2_:K_ .26:;_V
M&HO_ $1/0!Z'\+_^23^%O^P3;?\ HM:ZJN5^%_\ R2?PM_V";;_T6M=50 44
M44 ([;(V8*6V@G:O4^PK&TSQ;H^JWWV"*Y:WU'!)L+R-H)\#J0C@%E_VEROO
M6G?>;_9US]G!,OE-L"]=V#C]:\W\)NUKKFCI8^%+F"XF<1:EJU_&\LSH+9V/
M[Z0EA^^"K@D\$_@ >GT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %>)?M5_\ )+--_P"PU%_Z(GKVVO$OVJ_^26:;_P!AJ+_T1/0!Z'\+_P#D
MD_A;_L$VW_HM:ZJN5^%__))_"W_8)MO_ $6M=50 4444 17437%G-"CF-I(V
M4./X21C-><^"/A;>^$?$4=^][HLMNJ@&"VTN2$HPB\O?'^^*([87>VTEN03S
MQZ710 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &;K6OV'A
M^&VDU)KC_2IO(@CMK26YDD?8SX"1*S?=1CG&,"LW_A/-(_Y\_$'_ (3FH?\
MQBCQ1_R,7@S_ +#4G_IOO*M:)XCCUJ[N88X/*$!(^:4%CABO*CITH J_\)YI
M'_/GX@_\)S4/_C%7=&\3Z;KUU<VMA]L2XM4CDFBO+">U=5<N$8"5%)!,;C(S
M]TUKUS=C_P E3UW_ + NF_\ H^^H Z2BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O$OVJ_P#DEFF_]AJ+_P!$3U[;7B7[5?\ R2S3?^PU
M%_Z(GH ]#^%__))_"W_8)MO_ $6M=57*_"__ ))/X6_[!-M_Z+6NJH ****
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M %%%% !1110 4444 %%%% !1110 5XE^U7_R2S3?^PU%_P"B)Z]MKQ+]JO\
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M?PM_V";;_P!%K754 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKK3+BVN-/N+E39V+V[(T3P* =TS@@B8]AT%=Y5PG&I'FCL"=PHHHJQA1110
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MHH **** "BBB@ HHHH **** "BBB@#F_B/\ \DL\5_\ 8%O/_1#UBUM?$?\
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M(H",S9,<R-]W Y!((Q53Q%HOQ2T'Q]IGA#4O'5[-?W\*W,$D>KW31(,N!DD
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MX4N+>2&7)21"C8/8C!KPOX,#'PCT;'?S\_\ ?^2O=Z\(^#'_ "2+1?\ MO\
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M]O-;&XD*S>9^]>2X9N>W)SCWK:J_W<O1E/8]AHHHKYDYC@O%/_)9_ G^Y?\
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M_1\E>[UX1\&/^21:+_VW_P#1\E>?F'\)>O\ F9U-CN:***\0Q"BBB@ HHHH
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MF# ^X]ZUIVL[C10;XP>%;.YFM-=DO=%O8'"O:WMHQD *A@W[O>,$-ZY]J/\
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MWC__ ))SXA_[!T__ * :Y/X>>(]-UN]\+VNFRR22Z=X<EAN-T+HJN&M%(!(
M;E&'&:ZSQ_\ \DY\0_\ 8.G_ /0#7A7@CXGV'AF^TN34(KBX@LM-EL]MO:JK
M O*DA.3*0_W6&<+VX]-*--SI.RU_X XJZ/I:BD5MR!AW&:6N$@**** "BBB@
M HHHH \I^.7_ "!'_P"P7/\ ^EMA7TDG^K7Z"OE']I$D#PV 2 1= ^_^IKZ/
M^'\\MU\-/#%Q<RO--+I%H\DDC%F=C"I))/))/>O>P2M13]3>'PG0T445VEA7
MB7[5?_)+--_[#47_ *(GKVVO$OVJ_P#DEFF_]AJ+_P!$3T >A_"__DD_A;_L
M$VW_ *+6I/'_ (@UGPYX8-UX9T1]:U.:9+>"W4':K-GYVQ_",<\CZCK4?PO_
M .23^%O^P3;?^BUI_P 0]<U_P]X-N=0\):/_ &QJ49 2VVLV!SEMJ\MCT')H
M \UT?X -XFO[KQ%\6+TWFL7Q#-:V!$4<'H"RCYB!@<<>[=:]'\ >%?#'@_2[
MW3/!TJR0"Z+7*BY\XQR[%^5CGY3M"G'OGO7S'K'CG7_&5WIMGXN\97FGRW6J
M16E]H<%LUFMK;LV&D,AX.!CA\XW9Z"OJ/P1X/\.^"]!-EX2BV6<\GGL_GF7S
M7("[MQ)[*.F!0!T=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% '/\ CZYGL_AMXENK.:2"XATFZDBEB<J\;"%B
M&4CD$$9!%>4?9)O^@UX@_P#!]>?_ !VO4_B/_P DL\5_]@6\_P#1#UYK6M-)
MWN<V(DU:S+_@1[J#XF6ELVIZI<P2Z7=R-%>:C/<+N62W"L!([ $!V&1ZFIK6
MR6]36+V[U[5GGCU6[2*TCU:\B%R!=2JJ*%D&W&/+'E@ %,G(X$7@O_DJUA_V
M"+W_ -&VM7=%:+=>+"MU_:;:MJ/]CEF&P'[9-YIXX W[RV[DIMQS6]&*<W_7
M]>?9:F<I/V:=_P"OZV[[$-SIXL?[+NX]>U:VN6UBUC>PEU:\F\A3<Q*R,&D.
M[<"$._*?O1M[9]7KS'6#;AK9-2%T=9&KV!ORC?NR/MD/E8SQY>_R]H'S ;L_
MQ9].J,0DFK?U_P #MW-:#;3O_7_![]C%\9:;<ZSX&US2K%0US?Z?/;0AFP-\
MD;*"3V&3S[5\\_L]:'?V&BZEJUS&BV>I^7]F<."S>6TBMQVY/?TKZ@KPCX,?
M\DBT7_MO_P"CY*\C'2:HV[LUJ;'<T445X1@%%%% !1110 51U'2;?4C'([20
M7,.?)N83MDBSUP>00>,@@@XY%7J*$VM@//?#'C+6+[XLZQX4OW@FM-/M3)',
M(MLKL#&,M@X_C/0#H*]"KP:'Q9I?@[]H+Q-J&MR21V\EN8%,<9<[CY+#@>RF
MNR/QV\% '%Q>'Z6QYKLJT)MIPCI9%N+Z'H]8]O&R>-M0DW9673[4!?0K)/D_
MCN'Y5QX^._@H_P#+>]'_ &['_&JG_"Z_!W]O"[%Q=>4;4QL?LS9#!P0,?0G_
M ":S5"KK[K%RL]3HKSG_ (7KX)_Y^;S_ ,!6I?\ A>O@G/\ Q]7?7K]E:I^K
MU?Y6+E9R7PP_Y.#\8?\ ;[_Z5)7N5>"?""^@U3XX>)K^S8M;W4-U-$Q&"5:Y
MC8'';@U[W6N+TJ+T0Y;G/>/_ /DG/B'_ +!T_P#Z :R/"'@KPQ>>"O#UW=>'
M]+EG;38'=WLXR9&:)<EN/F/?GO6OX_\ ^2<^(?\ L'3_ /H!J7P/_P D]\._
M]@NV_P#12UFI-4M._P"@=#<HHHK D**** "BBB@ HHHH \3_ &B+.XNX]'DA
MB)CLH;F>9RP "E[>/CG)^9U'X_6OH_P9IEWHO@?1-*U$1"YL+""VD,+EU8I&
MJD@D#T]*\&^.7_($?_L%S_\ I;85]))_JU^@KWL$[T4O4WAL.HHHKM+"O$OV
MJ_\ DEFF_P#8:B_]$3U[;7B7[5?_ "2S3?\ L-1?^B)Z /0_A?\ \DG\+?\
M8)MO_1:U:\:WGBBQ\/&X\#Z=::EJ:RKFVNWV*\?.[!W* W3&3BJOPO\ ^23^
M%O\ L$VW_HM:=\0[#Q9J7A&6W\!:C!I^JF13YLV #'SN4$JV">,''XB@#RO7
M/B;H6H1+9_&;X97^F\[5NI+;SH\^JR85A_P$FN_^$5AX*LO#%XWPXOY+O2[B
M],KK(['R9-B IA@&' 4_-D\]<8KP&ZL%\+:K'+\>]"\1:RSN=ER-86>(^F$!
M!''_ $T_ =*^AOA9JO@O5O";R_#NTCM-/2<I-$MN8F67:I.[/WCM*\Y/UXH
M[6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#F_B/_ ,DL\5_]@6\_]$/7FM>E?$?_ ))9XK_[ MY_Z(>O-:VI
M]3DQ/0T/!?\ R5:P_P"P1>_^C;6K^AS1/#J5J((5>\UF^ O 6_T(K>SJ"Q_A
M)8%EP0"SG..IH>"_^2K6'_8(O?\ T;:UIZ.]Z;+5XIUF_LQ]5O\ ^TW,0RB_
M:I0NSU!C";C@X'(YSC>E\;_K^O3J0_X2_K^OT&Z[+%"FGV;VT-Q):ZW9@WS;
MLW3->0J<'NZE@S D@&,8''R^FUYSJSWT=AID6FJ[Z/'JUD+.3R@2R?:H@P8G
MH@0R;6P"<#GIN]&J,1NOZ_KTZ&M#9_U_7KU"O"/@Q_R2+1?^V_\ Z/DKV[4M
M0M=(TJ[U+4)?)M+.%YYY-I;8B*68X ). #P!FO ?@9KEC?\ P\M]*MI2UWIA
M;[2A0@+YDLC)@]#D9Z5XN/3=)>IK4V/2:***\0Q"BBB@ HHHH **** /"K+P
MQI'BO]H7Q/8Z_:?:[:.V,RIYKIAP80#E2#T8_G7>?\*8\ _] '_R<G_^+KF?
M"'_)RWBK_KQ;_P!"@KU^NRO4G%I1DUHBY-HX;_A3'@'_ * /_DY/_P#%UG7/
MP?\ !,?B2PA71\6TMM/YD7VJ;YG#1;6SOR,#>,=]WL*]*K+U%@FN:.21\\LL
M8S[Q,W_LE91K5;_$_O)YF<U_PICP#_T ?_)R?_XNC_A3'@'_ * /_DY/_P#%
MUW-%3[>K_,_O#F9X+\(K*WTWXY^)[&RC\NVM8KN&%-Q.U%N8PHR>3P!UKWJO
M#?AA_P G!^,/^WW_ -*DKW*ML7K47HARW.>\?_\ ).?$/_8.G_\ 0#4O@?\
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MKUEZ^XBMK.5F"A;^W&3TRT@3_P!FQ]<5A'<E&I1114@>&_##_DX/QA_V^_\
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M[5?_ "2S3?\ L-1?^B)Z /0_A?\ \DG\+?\ 8)MO_1:U1^+WBO5?!_P^FO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGN5%%%> 8!1110 4444 %<9\2I[V.QT*'3KDV\EWJ\=NS>?+$I5HI?O&)T?
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M?^NK?S-5Z^>G\;.=[GE/QS .BL2 2-+G(]O],L:^DHP!$@ P HP!7S;\<O\
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MTU%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3UKT7]FBZ2X\#ZXMLQ-FFN3?9EY 2,I&0 #T'?'N: /9:*** "BBB@ HHHH
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MV?R?WTD>W=YF[[C#.=HZ^E<&+M[%W_K4N7PGT?17#?\ "F/ /_0!_P#)R?\
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M/%:UC/=V_BFWT&_UA;QY(W?2=3#*\J.HRT;D'YU9>2IY^4G)R-ONY7;V3O\
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MM-2G^T7D%K%'<3;R_F2*@#-N/)R03D\FKU15GSS;$W=A11168@HHHH ****
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M** "BBB@ HHHH **** (KNU@OK.:TO(4GM[B-HI8I%#*Z,,%2#P00<8KGO\
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M@FDWPPWDOF.A+NQP=[87:T: 9ZQEL#=75445$I.3NQ/4****D HHHH ****
M/*?CE_R!'_[!<_\ Z6V%?22?ZM?H*^9_CU=0VVD0I.Q4W5C/!#\I(9_M-G)M
MR.!\L;GG^[7TEI]Y!J.F6M[9R>;;W,*2Q/@C<C*"#@\]#7NX'^"OF;PV+%%%
M%=Q85XE^U7_R2S3?^PU%_P"B)Z]MKQ+]JO\ Y)9IO_8:B_\ 1$] 'H?PO_Y)
M/X6_[!-M_P"BUJI\5O"6J^-/!JZ;H$]I;WL=Y#<H]XS+&-ASSM5C^E6_A?\
M\DG\+?\ 8)MO_1:USOQ[U6\TWX;QPV=RUG%J.H065Y>*<&W@?=O?Z?*!_P "
MH \WNV\=3^/[+5+CXB_#P:Y91/9PQ_;2,!SRI7R^6S^->X>"+?QA;:/.OCZ]
MTV\OS.3"^FJP01;5P#E5YSN[=,5S*_ 3X;_V#]B&AJ5:/_C\^T2>;G'W]^[\
M<?=]L5!\ -4O+_P!=VEU=/>VVE:G-8V-XYSY\";2I![@;B ?3CM0!ZC1110
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MA'7FMVUN_3S83:.%>2_FPI'VC(PS;2<;<@X)&"<[XQZM9Z[X"\ ZPJ.EC?\
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MY6^O]?/SZD49THJ497LUT7FGY::?(P_^$X\)_P#0SZ-_X,(O_BJ/^$X\)_\
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M3ZJ="\(ZQJZP^>;"QGNA$6V[]D9;;GG&<8S7RGX(U_QKK/AN)=%AT,6U@%M
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M;S0Z9)%?1WD0-_,T&5L03@_)_=&6Q$>5P2>,U/\ Z9+J3VMF^SQ.N3<7+/\
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M ,11[+^\@L9'QV@BET=7EB1WATV=XF902C?:[%<CT.&89'8D=Z^E8P!$@ P
MHP!7R)\48?'4>F-_PE%SHLL7V&4D60DSY?VFUW#YE'.\PX]@WM7UVG^K7Z"O
M9P:Y:25[FT-AU%%%=A85XE^U7_R2S3?^PU%_Z(GKVVO$OVJ_^26:;_V&HO\
MT1/0!Z'\+_\ DD_A;_L$VW_HM:7X@7_C+3M @E^'FDV>JZFUTJRPWCA46':Q
M+#,B<[@@Z]SQZ)\+_P#DD_A;_L$VW_HM:ZDD*I+$  9)/:@#YXV?'C_A/O\
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MBJLXJ*=F^_1^IM";E!-[G+_\)/\ $S_HG]O_ .#:'_XJN:AF^(-AJ>MW/_"
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M6CR22,69V,*DDD\DD]Z][!P<*2YC>"LCH:***ZRPKQ+]JO\ Y)9IO_8:B_\
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M[\"#W"BN&E^*?A2&5XWOW+(<$I$S#\".#^%+!\3?#T[,T=Q*T7 0B!]S-SD
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M,]:L^ 6N;?QWXQTJ74;V]MK'[$(/M5U)-M+1,6(+DXR>?R]!7B\?Q3O$5O\
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M9E"9SC)* =C715Q57-RO/<AWOJ8WBO1EUS07M_*\V2*2.XB3=MWLCAMF>VX
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MC1O_  7Q?_$T?\(1X4_Z%C1O_!?%_P#$UN44!9&'_P (1X4_Z%C1O_!?%_\
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M^YQDU>KTS0*\2_:K_P"26:;_ -AJ+_T1/7MM>)?M5_\ )+--_P"PU%_Z(GH
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MKPN?+\L7*L/)V[LXW.W7</3[HZUUE95/BWOYDO<Y3XA^-_\ A O#T&J?V?\
M;_.NEM_*\[RL91VW9VM_<QC'>O,H/C[93^)+2_O?#\]I''&\4[V]V)6D0C(&
MPJ@.& P2> 6QU.>B_:'_ .2>V/\ V%(__14M=M!X)\*-;1D^&=&)* Y_L^+G
MC_=KJA[&%)2G&[=RU9+4\IU#]H*5]4D.E0I%8;U$8N; R2A?W>22MPH)YE('
M^R@S\Q*MM/CMK%W>"**&*1-Q+&'1W=PF7^;;]JZ\1<9_C;GY1O\ 7/\ A!_"
M?_0L:-_X+XO_ (FO/O"=C::;^TGXEM-.M8;2VCTM=D,$81%R+8G"C@<DG\:T
MC.A*+M#9#O'L9*?&?Q48VWZ4!((B54:+*09-J84G[1PNXN-V,@*IP2Q59(_C
M+XFD=E&F.?G4)MT*0EAYA#$_Z3P0@5@.<L2N0!O/M]%8>VI_R?U]Q/,NQX]K
M'QB+^#5%WX>UJWNY$A6\E-KY4&"RB4(^\D9&X*3SDBK'A[XZZ-J>L:?H\.AW
M5JMS-':Q%70JA8A5XXXY'3M7I6MZ8-7TF2UW*C[DEB9ER%D1@ZDCN-RC([C(
MK'7Q'I.E7-E!K-@^D7]W.MK$/LC/')*QP LR*5P>HR0<=0.0&I4I1LH:^H]+
M;'3UPWQG_P"21:U_VP_]'QUW-<-\9_\ DD6M?]L/_1\=8T/XL?5$QW1VMO\
M\>L7^X/Y5)4=O_QZQ?[@_E4E9""BBB@ HHHH \R^/7_).S_U\)_,5]$I_JU^
M@KYV^/7_ "3L_P#7PG\Q7T2G^K7Z"O<P/\(VI[#J***[S0*\2_:K_P"26:;_
M -AJ+_T1/7MM>)?M5_\ )+--_P"PU%_Z(GH ]#^%_P#R2?PM_P!@FV_]%K2_
M$#X@:5\.- @U?7+>\GMYKI;55LT5G#%68$AF48PA[^E)\+_^23^%O^P3;?\
MHM:\\_:K_P"26:;_ -AJ+_T1/0![;17F/_" ?$O_ **]+_X3\'_Q==CX2TC7
M-%TB2V\3>(V\1733ETNFLTMMB%5 3:I(."&.?]K':@#=KQ7QU-I=U\3M-LK^
MTU>:Z:\C2WFU>X6'38F(=MT2,C!V 0C(7.64;N:]JKS7QAXG^V:C-X7CU;2I
MY[J=;=;2UMY)[B,\N Y5MJ-M1C\V. 3VH ]*HHHH YOXC_\ )+/%?_8%O/\
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M,>>M>]0_ZB//!VC^5:58VHP^8W\*'UY3X?\ ^3GO%'_8+3_T&VKU:O*?#_\
MR<]XH_[!:?\ H-M4T=I^GZH(]3U:BBBN<D*X'XI,%N/!K,0 /$MH23VY-=]7
MG7Q:TX7=SX.F:XF0#Q!;VYB5OD;S#G<1W8;, ]@S>M;4/XB''<]%KAOC/_R2
M+6O^V'_H^.NYKAOC/_R2+6O^V'_H^.E0_BQ]4$=T4_\ A.O&EM+;V;_#MC-)
M;O-&JZS$2R1E QX7L9$XZ\\=#3K#Q[XTU.%I;/X<NZ*0"6UF).< _P 2CL1_
M*JG@OQ1JWB+QWIG]LZ?;V(_X1^:[MEAE+EHI9X57=V!_=9X[,,X/ ].K6HXP
M=G!7]7_F-V70X;_A*_'W_1-O_*[!_A1_PE?C[_HFW_E=@_PKN:*R]I'^1?C_
M )BNNQPW_"5^/O\ HFW_ )78/\*/^$K\??\ 1-O_ "NP?X5W-%'M(_R+\?\
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M,9'YUX_\&_ 6@77A;2O$UQ:M)J0>;YVD.PX9T^[TZ5[#7!?!/_DDVE_[\_\
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MH \E_:(_Y$?3O^PBO_HN2O=/AQ_R2SPI_P!@6S_]$)7A?[1'_(CZ=_V$5_\
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M!8PJ<!"[FVD5?;)^7)X&2>E9UXQG0G&6VG_I2V_5?<8R7OQOW_1_TG]YU_\
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MZU6UUS3+/4K='$BQ7ENLR*P! 8!@1G!(S[F@#P[_ (7%X$_X7[_PD?\ ;O\
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M\DY__B*[FBC4?O=_Z^\X;_A<W@+_ *#W_DG/_P#$4?\ "YO 7_0>_P#).?\
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MTBK&MLC( -)$@.\QDY+HH(W<#Y@ 1N'H]YK/B?P4Q7Q[HWFZ>O\ S'-)5I8
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MX9&4AE=3V96 8'L0#6#)HGB&?6= :^O+&\M=*OGN7N=K132*;:>%04 *ELS
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M,I(/USUSTZ CN_*P2V7]=#JJ*** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "O$OVJ_^26:;_P!AJ+_T1/7MM>)?M5_\DLTW_L-1?^B)Z /0_A?_
M ,DG\+?]@FV_]%K6-\>;:2[^"/B"&$QABL#9EE6-<"XC)^9B!T'KR>!R:V?A
M?_R2?PM_V";;_P!%K6%^T 0/@9XA!.,BWQSU_P!(CH \*U/PQK5W:Z?XIG^)
M^G:F]G"XM6C=Y;E NX8CC(R>5;!.*].^",S'X9R'_A)41WUVY;[2Q"B]&5SD
MR#<I8D-V;GD=:\LTE?$M_P"-])\9:;\+7N4MK2,0QP))]GEEB^19LXP" H 4
M=U!ZU[#\$;C6+OP5J5S]BM[.XFUV]:ZL7!B6!V*$KM() 4[EV\'\J /5M3BA
MGTJZBNBX@>%ED,:EF"D<X !R?;!K/\*PZ9!HWEZ'.+JR\PE)UEC=9"0"2"G'
ML<@'.2<YR;>N@GP]J&'*'[-)\P5&*_*></\ *?HW'K63X N[F^\(P7%[.+B2
M220B4,YW+N.,[@,''9?E].*%U![(Z6BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIKFG:=I$$4E^ETEW<LMLUGI[JI8A2P.PN,Y;))(YSZ41W8/9':4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *\2_:K_Y)9IO_ &&HO_1$]>VUXE^U7_R2S3?^PU%_Z(GH ]#^
M%_\ R2?PM_V";;_T6M='?72V.GW-VZEE@B:5@.I"C/\ 2N0\#SSVOP,T.XLU
MW3Q:%"\8QGYA""..]>;)X@U99)F:_N)!.CI*LDA97# @Y'3O^% %VY\;^(;F
M9I#J<L>[^&+"JH] !7K^@Z5/I&GK#<W\][)M7<92-JD#HO&<?4GI7@<<;RR+
M'$C.[D*JJ,EB>@ KZ/H I:TDLNAWJ6Z[Y6@<(H*C)QZMQ^?%>=S:AJ6C:;I<
M"O);PW#RDPS3)<23'Y ,R;V+D,6Y)8D#YJ[[Q)L_X1?4_-9D3[+)N91D@;3R
M!D?SKA-/UV\TW0-,71=0M))+R]<2B]+1M(AV_.AGE#G&5Z[F.00", D?B"7P
M_P!=CTZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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64,:-S\RH >>3^>!^5244 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>exhibit102image1701b.jpg
<TEXT>
begin 644 exhibit102image1701b.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<FL@17-C
M:&5N   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Q.0  DI(
M @    ,Q.0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( XL".@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MW_?]_P#&K%% %?[%%_>F_P"_[_XT?8HO[TW_ '_?_&K%% %?[%%_>F_[_O\
MXT?8HO[TW_?]_P#&K%% %?[%%_>F_P"_[_XT?8HO[TW_ '_?_&K%% %?[%%_
M>F_[_O\ XT?8HO[TW_?]_P#&K%% %?[%%_>F_P"_[_XT?8HO[TW_ '_?_&K%
M% %?[%%_>F_[_O\ XT?8HO[TW_?]_P#&K%% %?[%%_>F_P"_[_XT?8HO[TW_
M '_?_&K%% %?[%%_>F_[_O\ XT?8HO[TW_?]_P#&K%% %?[%%_>F_P"_[_XT
M?8HO[TW_ '_?_&K%% %?[%%_>F_[_O\ XT?8HO[TW_?]_P#&K%% %?[%%_>F
M_P"_[_XT?8HO[TW_ '_?_&K%% %?[%%_>F_[_O\ XT?8HO[TW_?]_P#&K%%
M%?[%%_>F_P"_[_XT?8HO[TW_ '_?_&K%% %?[%%_>F_[_O\ XT?8HO[TW_?]
M_P#&K%% %?[%%_>F_P"_[_XT?8HO[TW_ '_?_&K%% %?[%%_>F_[_O\ XT?8
MHO[TW_?]_P#&K%% %?[%%_>F_P"_[_XT?8HO[TW_ '_?_&K%% %?[%%_>F_[
M_O\ XT?8HO[TW_?]_P#&K%% %?[%%_>F_P"_[_XT?8HO[TW_ '_?_&K%% %?
M[%%_>F_[_O\ XT?8HO[TW_?]_P#&K%% %?[%%_>F_P"_[_XT?8HO[TW_ '_?
M_&K%% %?[%%_>F_[_O\ XT?8HO[TW_?]_P#&K%% %?[%%_>F_P"_[_XT?8HO
M[TW_ '_?_&K%% %?[%%_>F_[_O\ XT?8HO[TW_?]_P#&K%% %?[%%_>F_P"_
M[_XT?8HO[TW_ '_?_&K%% %?[%%_>F_[_O\ XT?8HO[TW_?]_P#&K%% %?[%
M%_>F_P"_[_XT?8HO[TW_ '_?_&K%% %?[%%_>F_[_O\ XT?8HO[TW_?]_P#&
MK%% %?[%%_>F_P"_[_XT?8HO[TW_ '_?_&K%9A\2Z$NN_P!B'6M/&K9Q]@-T
MGG_=W?ZO.[[O/3IS0!;^Q1?WIO\ O^_^-'V*+^]-_P!_W_QJQ10!7^Q1?WIO
M^_[_ .-'V*+^]-_W_?\ QJQ10!7^Q1?WIO\ O^_^-'V*+^]-_P!_W_QJQ10!
M7^Q1?WIO^_[_ .-'V*+^]-_W_?\ QJQ10 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %?-%S_P GS#_KHG_IO%?2]?-%S_R?,/\ KHG_ *;Q
M0!]+T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYHN?^3YA_P!=$_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %<WXH_Y&+P9_P!AJ3_TWWE=)7-^*/\ D8O!G_8:D_\
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M* "BBB@ KYHN?^3YA_UT3_TWBOI>OFBY_P"3YA_UT3_TWB@#Z7HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N:\5,J>(/!S.0JKK,I))X _L^\K
MI:YSQAI&IZH-'FT>&TGET^^>>2&[N6@61&MIX2 ZQN009@?N]C2=[:#6^IS'
M@*!'\>:Q?07-O<Q3><ZM$P)57D5E' R.Y^?DYRN1DU=\(32R^/=;$URC2*TF
MZ(088+Y@V;F PN!G R=V[)Y%0Z?IOBSPW9WDB:/I=Q \9>6*;Q#*P;"!<_\
M'D.=J =:/#>E^)M&3[1HF@:1!:742M]DD\13.B\#:1NLRPP.,!MOM5:*UNB)
MU:=^K-_PO_R,7C/_ +#4?_IOLZZ2N?\ "VFZK9SZW>:Y#9P7&J:@+I8;.Y:=
M(U%M!" 7:-"23"3]WN*Z"D,**** "BBB@ HHHH **** "BBB@ HHHH ****
M"OFBY_Y/F'_71/\ TWBOI>OFBY_Y/F'_ %T3_P!-XH ^EZ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P"@QUZ%6U7&U8R<4D-S:9YS_:/QA_Z&+6?_  2:3_\ )%']H_&'_H8M9_\
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MS.5R2,*<9'4D@'<4444 %%%% !1110 5Y?\ '/\ Y!O@O_L;K'^4E>H5Y?\
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MQHOC?JG_  D?Q'\1Z?9Z'9SE;3P['=B/D=Y,D'H>O5N<;1Q7TBH"J H 4#
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MSZOX@\.^"Y/$%I?:=!:AQ<I"%*\GKDG\J *FB_"[P+\0M"MO%W@"XU/PI=7
M;]YI\QC,3@X9"F<#!'\!4'K7MR*5C522Q QD]Z\!\!ZM\2_ WA^72H?A?-=I
M)>37(?\ M"./;O;.W&#TKWY"6C4LNUB,E<]/:@!:*** "BBB@ HHHH ****
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MP/\ @1KWI"6C5F7:2,D'M0 M%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 <WKVGZY_PE6EZSH-KI]W]ELKJTEAO;Q[;
M_6O;N&5EBDSCR"""!U%'V[QO_P!"]X?_ /!]/_\ (==)10!S_A;3=5LY];O-
M<ALX+C5-0%TL-G<M.D:BV@A +M&A))A)^[W%=!110 4444 %%%% !7AG[37B
MA]!L?",,-JLL@U7^TD=WP ;< !",<AO.ZY&-O?/'N=?-O[7/_,H_]OO_ +0I
M-75F!V?P_F,_PY\/L1C&G0I_WR@']*Z&N9^''_)-= _Z\8_Y5TU?,5/C?J<S
MW"N8UZ.X\+>'M5U71KQ88K:WEN19W$?F1;PI;"\AEW'L#CT KIZYGXC_ /)-
M=?\ ^O&3^5%/XDNX+<U/#FHRZOX6TK4KE46:\LH;B18P0H9T#$#))QD^M:58
M?@?_ ))[X=_[!=M_Z*6MRE-6DT)A1114@%%%% !1110 4444 %9M]_R'M+_[
M;?\ H(K2K,U+Y=:T<CJ9I%/T\IC_ # JH[@:=%%%2 4444 %%%% !1110 44
M44 %%%% !7B]QXI.D_M1:1;?9!,(M650WF;<_:[2WM\]#]W&[WZ<=:]HKYX\
M0?\ )V&G?]AK3/Y05WY>KU7Z%T]S[%HHHKW#<*^:+G_D^8?]=$_]-XKZ7KYH
MN?\ D^8?]=$_]-XH ^EZ\T\6^"_ L/C9_&GQ U*&3;''':VFH3@01;1V0_?)
M.3CD9)XSS7I=>3_$GX&6OCKQ%_PD5GK$ECJJQH@2XMTN+=MG3*$?GG(]J ()
M_CY:ZM=MIOPS\,ZGXIN4 !DCB,$$8.<$L1D#CN%'O7KR%C&I==K$<C.<&OGK
M1X?B/\*?%FL:UJGA:#Q-#JRP+<2:(X4QK$"@9857/0\C:!QU%?0J-OC5L%<C
M.#U% "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %>+_M)Z1:WV@>%KJ33?[1NTUV*UC@
M$YB\Z.56+Q;@<#>8D&[J,<8YKVBO+_CG_P @WP7_ -C=8_RDJ9.T6P//?"OB
MCQE8>%K#3[+X>O<QV$?V-IAJT2;WA)C<X*\?.C>OU/6M?_A,O'?_ $363_P<
MQ?\ Q-=#X0_Y EQ_V%-0_P#2V:MROGIU(\S]Q?C_ )G.VK['!?\ "9>._P#H
MFLG_ (.8O_B:P_&GBKQC=^"=7@U#P"]C;26KK+<G58Y/*7'+;0N3CTKUFN9^
M(_\ R377_P#KQD_E3IU(\Z]U;^?^8)J^Q:\#_P#)/?#O_8+MO_12UN5A^!_^
M2>^'?^P7;?\ HI:W*PG\;)>X4445(!1110 4444 %%%% !61K$JQ:UH 8$^=
M>21+CL?L\K<_@A_2M>L/Q!_R&_"__84?_P!([FJCO]_Y ;E%%%2 4444 %%%
M% !1110 4444 %%%% !7E$>A:=J'[3.BSW=OYDDFK3LS;V&3;Z=;30]#_#(2
M??H<CBO5Z\YT[_DY'0?^PIJ'_IIM:[<#_&+AN?0E%%%>\;A7S1<_\GS#_KHG
M_IO%?2]?-%S_ ,GS#_KHG_IO% 'TO7@GC_3-:\??'2[\,VGB.]T:VTG0_MT
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MXOYKHO;V&T%7/R@YQD@#%?1Z-OC5L$;@#@]10 ZBBB@ HHHH **** "BBB@
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MM#$A>G) QUR>E>Z !5 4  #  [4 +1110 4444 %%%% !1110 4444 %%%%
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M $TVM>C5YSIW_)R.@_\ 84U#_P!--K7;@?XQ<-SZ$HHHKWC<*^:+G_D^8?\
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M7@S_ +&6T_F:ZFSUKS+R.SU"U>RN)EW0Y8/', ,D*X[@=B >I (&:Y;XH_\
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M2]%%>0>,M7\?^(OBM<>$O FKVVB6^FZ<EY/<RPK(99&/RJ=P/!X' [$G/ H
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M:0GRN%"2QL3T D0]&&?1? VD^+/#E_X*OAI6ER6&J):-I['4'BB0K87AV/\
MNF97D-S)(< C?D#ALC.TB?7!X4U,1Z=I[1'PE>*[-?N&$7]EZ2&8#R3E@@C(
M7(!+.-P"AG]3V%+^5?<:\J['(+X[^,+-(JC5"8W6-P-&3Y6:5H54_NN"949
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MYHE8'!7!QD9X/0X]Q\#>+K_XHZ3+!=3PV45O*Z7WV1C')<#>P58R')$>!@R
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MZ\6I*ZZ+\D.1)7GOQA_Y!7AK_L8K7_T&2O0J\Z^,TJ0:'X=ED.$C\06S,<=
M%D)I4/XJ".YZ+16?INN6&JL4M97$H7?Y,\3Q2;<XW;7 )7_:''O6A6+36C$%
M?,/P-U2PTCQ[/<:K?6UC ;"1!+<S+&I8NG&6(&>#Q[5]/5\W_"[X4Z7XY\-W
M&IZE?7ENT5V]N([?: 0$1@<D'^\:[L,XJG/G>FGZEQM9W/=/^$X\)_\ 0SZ-
M_P"#"+_XJL;QCXQ\,W7@77K>V\1:3--+IMPD<<=]$S.QB8  !LDD]JYG_AG?
MPWDYU75=O8;X^/\ QRFR_L[>'C"_DZKJ8DVG87:,@'MD;.E3&.&33YG]P>[W
M._\  C[_ (=^'CC'_$LMQ^4:BMZJ&AZ3%H6@V6E6[O)%9PK"KO\ >8*,9-7Z
MY9M.3:(>X4445(!1110 5Y3\6O\ DH7PY_["A_\ 1MO7JU>3_%EU/Q%^'2!@
M674\E<\C,L&/Y5T8;^*OG^3*CN>L5RGQ/M;N\^&&O1V$_D2K:F1GWE<QH0\B
MY']Y%9<=#G!X-=474.$+#<02%SR0.I_4?G6)XX_Y)[XB_P"P7<_^BFK*F[33
M\Q+<XQ]6^)EOX.TSPIL\)_9BK:7:W %SYT36UY#8"7=G 82R1NIQT4G ("GA
M(-+^(=OX.EU&'7=/73YK)["2+RP7,#Z3#=,G^J[VUM"F<YWIUY+GO([?Q9Y'
MAS^TM2TM;PZA>AU6P=PDW_"068DRPF4./.*L,!?E4KU8.N/Y&N?\*IW?VCI_
MV;_GG]@??_R+&?O>=C_5?)]W[_S]/W=?4'24FT;XJ6MS&!XETL/J6H,I(C4Y
MFMM85 Q_<\#[7=F08ZJ2". E=[\'?"_Q*TJ+2-6OM?TN7PO?6D=U+8QIF9U^
MQK' ,^4,%52$'#_P'DDG.?>6WB/[9HV[5=+).K7X0C3)!M;_ (2*S#$_O^09
M2K <84%,DD..^\"6'B^;X9^&Q;:[H<=L^D6OEQRZ+,[JAA7 +"Z4,<=2 ,^@
MZ4 >?>!M8NM?_9O^(FJ7\:1SW,UVS(F[:!]CA QN)., =2:V?"?C?POJG@7P
M_I/B77[#3M,M-,MK:;3YYE$E](D2JPDYXB!'W.K?Q87Y6T9OA^GPY^ GC32H
MKR*Z2XM[FZ!B@:)4S;JFT!I')_U><[OXN@Q4>B^&-#N?"&D36>@:;J=P=-A>
M\$]I%>&R<JNXHS9RP.1L&<[0?][:G3Y[ZF52HX-%Y-8^%FF6D=MH/B33=(NH
MYY+BVFBN2S))(<OPQ^9&(Y3[IP,8(!'G/C[Q?I?C+QYH<,UY'_H&G:C]JN-/
MF!7>+61HGB;/!8C(5N01CD8)Q_"FGV&I^+O#,OC6)+;4':YWQ_9U*L%+<G@C
M"C!#9XY8=*U?B;HNGV'Q(\.Q^'K33V2X%W&&EL@RW"&/:X;:5,Q4$A23R2 3
MP2=G0Y'=/^O\_(Q5;F5FOZ_R\SS*Y%C>>&9%EBNENUT7S+6XGN5 D7^T,MN7
M;DL=S\[N,=\;J]"N? FIKX*E\96_C6[TN_;0K:5],LX9 9U@LU$;^8LHW JA
M;=@A<MQQBMW1=(\*^(-):VM_#=M-K'F_V7"84V0Q*%$TA*AL%@7^96Z,V. &
MQK^*M(GT+PYK.G7LE]-=P^&KM8W28NA0)@;<\+&$# K@<YQSMIN@K/FU]/ZV
M[B]K?;\?ZW[&QX'GFNO 6AW%U-)/--8PO)+*Y=G8H"22>2:S_B>N[X?7:D9!
MN;08+;<_Z5%W[5<\ ?\ ).?#W_8.@_\ 0!5'XIX'PYOL[,>?:Y\S.W_CYBZX
MYQ7Q\/\ >%Z_J;TW:JGYDGCSPY-X@^'3Z%X8*W5G<M;W%].QP+=@5+'<!R2!
MG;CY<=AQ7F=K<:7X5\:ZSIITV._TN\UVSA>6^B3? ^9QOB8D_+][$G'&< 'F
MO7]!6ZM?"%O>Z%-<O8QVZOJ\8FX=N#(82V2&"[B<$#& .>DFN^&]'\21V=S/
M#._A;3;M+N(HV/+D7.612#F'LP(]2.,U]ER<R4EO_6_GV,JDN2I*#VN_SZ>7
M<\+^%^C3:SJ/A:ZO+)CHMC?7D5YJ2N0BLT88;R3P>5QP,YY!YS[+X^U#4[O3
M]#6Z1DMQJ=N(&\C;]HCRW[T_W#P@V\?>SZ 7/"_A31_!^A-;JMT/",]PUS$M
MQ(6=G95 >0  [#MRH'0X)Z\5?'PUEM/T-KT7 M?[5A\@2,,B+Y_];_TT^YCV
MSWW9QK0Y</*_9_ET\^_D;X67-BHV_K_@=O,Z&BBBOBS **** "BBB@ HHHH
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M,T]2QX _Y)SX>_[!T'_H K'^,_\ R2+6O^V'_H^.MCP!_P DY\/?]@Z#_P!
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MY>"W[W(7CIBO==.2=C1335ST/]I+7+?6/A/8!(Y;6[AUJ$7-E< ++ Q@GX8
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MCPG_ -#/HW_@PB_^*H_X3CPG_P!#/HW_ (,(O_BJPO\ A3'@'_H _P#DY/\
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M;?1[V:Q\3:L;J.W=X1)>:(ZEPI*Y5"689QPH)/;FNG_X4QX!_P"@#_Y.3_\
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MY?D^PKT2O/?BE_R%?!'_ &,5M_Z%13]G.7+R_B"LV2_\+7A_Z$WQ=_X*Q_\
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MKT&MJ_\ $?\ 70<MPKSWXI?\A7P1_P!C%;?^A5Z%7GOQ2_Y"O@C_ +&*V_\
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M",@^M> Z?XT^'\>L6EAXQ^$$7A87D@CAN;_18A%D\#):-2!GN <=^.GOX
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M]+UY!\8_!WB_5?$.AZGX/U_6[.*>>*POK?3YW188BQ)N,*PZ9(.?]GD5W?\
MPL?P1_T.7A__ ,&D'_Q5'_"Q_!'_ $.7A_\ \&D'_P 50!P0^"/B;O\ %WQ5
M_P"!$G_QVO8$4K&JDEB!C)[USG_"Q_!'_0Y>'_\ P:0?_%4?\+'\$?\ 0Y>'
M_P#P:0?_ !5 !\0-:F\/^"KK4+8:@95FMHE&F)&]R?,GCCQ&LB.K-\_"E>>F
M5)W#EOAAJLDVK7-@MGX\MK?9/=G_ (232[:WMS)),'<J\<:L7+2,0N=N"W'
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M6Y572M.BTC1[+3;9G:&SMTMXVD(+%44*"< #.!Z5:KED[R;(ZA1114@%%%%
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M>TWX7:O=Z=H6F6ES'Y.R:"SC1US,@.& R."1^-*$:4Y*.NH*S9UW_"?^$/\
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MG&<XJS_P@_A/_H6-&_\ !?%_\367[I;W%H1?\+ \(;L?\)-I6<?\_:?XT?\
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M:?I6F-J&I7<=K:+C,TIVJ,G _.L>]\#: ;-SI6A:39WR8DMITLHU,<BG<IR
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M#YK\-? ?QSH&G26S:?X"U'S)3)YFJ0S32+P!M#"/[O&<>I/K6O\ \*C\;_\
M0N?"W_P!G_\ B*]]HK-TH-W:%9'@7_"H_''_ $+GPM_\ 9__ (BLKQ%\!O&_
MB'3TM/L/@#2]DHD\[3(9X9&P"-I;RSE><X]0*^DJ*%2@G=(+(^2?^&5/&_\
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M_%+5;-;<:UHMGAPY>'6M3<G&>,2EUQSGIG@<U]%T4>RA>]@LCY<_X9Z^*O\
MT-]A_P"#.Z_^-U>\.? 'QQX=MIH?LG@/5?-<-OU.*:9DXQA3Y8P/:OI6BJ<(
MM6L%CP+_ (5'XW_Z%SX6_P#@#/\ _$4?\*C\;_\ 0N?"W_P!G_\ B*]]HJ/8
MT^P<J/EKQ+^SIXZUS48[M(O"%A\@C,.E&6&,8).XJ8^O.,^PK%_X9?\ 'OVC
MR_.T?;MW>9]J?;]/N9S^%?7]%:))*R&?+7AW]G'QSH>I&]9?"-_\A3R-3,TT
M?..=HCZC'6NH;X2>-PI/_"-_"TX'06,W_P 17OM%1*G&3NQ63/G.R^!WCBSU
M;4+[^R_AU/\ ;C&?L\]O.T-OL!'[I?+^7.<GKDBDUWX'^.-8T>:R&D_#RQ,A
M4^?I]O-%,N&!^5BG&<8/MFOHVBCV<+WL%D?(G_#+7CO_ )_-$_\  F3_ .-U
MO^%_V?O'/AX76ZT\$:EY^SC5EFG\O;G[F(^,[N?7 ]*^G**N45)68SYTTOX*
M_$?2/M@LKGPS#'=W3W)BM]3U*VCC+8^54A**%& !D$XXSP,7O^%6?%'_ )_O
M#_\ X/M8_P#CE>^T5FZ4'NA61\[ZI\'/BEJ=@]K_ &OHEL'(R\6M:HYX(/20
MLO;N*P9/V<_BA,R-+XJTUS&=R%M1N3M/J/W7%?4U%5&$8[(+(^9_#OP#^)'A
MSS!:ZKH4BR*%"'5+^$( 2>/)"=R>N?YUM_\ "K/BC_S_ 'A__P 'VL?_ !RO
M?:*4J4).[061X%_PJSXH_P#/]X?_ /!]K'_QRJNI_!_XGZCI=S9R7^@A)XRC
M;=;U5S@]?ED<J?HP(KZ'HI>Q@N@61\I6W[._Q1L[=8+3Q!8P0IG;'%J,ZJN3
MDX 3'4UKZ)\$/BGI=Q--)K6E7+2*%_TC6+], $G@P[2>O<FOI:BK<(O=!8\"
M_P"%6?%'_G^\/_\ @^UC_P".57U#X/\ Q-U'3;BRFOO#XCN(S&Q_MO5GP",?
M==RI^A!'L:^A:*CV,%T"R/G,_!CXH1Z"FF6^JZ)"L4"PI)%K.IAL*,<*3Y8Z
M=-H7T %<M>?LV?$B^N%>^U33;IPF!)+?2O@ _=R4SWKZUHJXPC'9!8^9=%^!
M7Q1TV]-P^M:5<D1^6BW&K7R!>1R#$%;MC&<<]/2]K?P4^)6NZ3)I]U?^'UBD
M*DG^V-3EQ@@_=E+*>G=3_6OHRBE[.-[V"R/ O^%6?%'_ )_O#_\ X/M8_P#C
ME5-4^#_Q1U'3)K7^U-#A\P %XM;U1VQG.,2,RG.,<@]?QKZ(HJ51@N@61\K_
M /"@/BQ_T,UK_P"#2X_^(I]I^SO\05CU'[;/X9OYKZ(1-<:A---+%CHT;>7E
M6 XSZ5]2T5?+'L,^>['X,^-['3[>T_L/X9W'D1+'YUQ:3O))M &YFV<L<9)[
MFI_^%1^-_P#H7/A;_P" ,_\ \17OM%1[&'85D?/=_P#!KQQ>Z;<VHT+X:0>?
M"\?FV]I,DB9!&Y&V<,,Y![&L3_A2'Q@3Y;7Q/8V40^[!8WTMM"G^[''&J+D\
MG &223R37T_135."Z!9'S;I?P;^+UI<M)=^)K&]0IM$5WK=^%!R/F'E;3GC'
M)QSTK5_X59\4?^?[P_\ ^#[6/_CE>^T4G2@^@61X%_PJSXH_\_WA_P#\'VL?
M_'*PKCX!^/KK6=2OK@>$[B6]LC;,;JXN[C86&/,1I59A*H488G !XKZ:HIJE
M!;(+(^1/^&6O'?\ S^:)_P"!,G_QNM?PU^SKXYT'4I+IHO!^H[XC'Y6JF6>,
M9(.X*(^&XQGT)KZDHJVDU9C/ O\ A4?C?_H7/A;_ . ,_P#\11_PJ/QO_P!"
MY\+?_ &?_P"(KWVBL_8T^PN5'SUJ/P:\<WFEW5LN@_#6$S0M&)+:TF25,@C*
M,4P&'8]C7+^$OV>_&>A?$?0;J^DTWR+.^BO7>.=CNCBDC9L?)U^; !QD@]N:
M^K:*N,(QV"U@HHHJAA7S1<_\GS#_ *Z)_P"F\5]+U\T7/_)\P_ZZ)_Z;Q0!]
M+UYC\2/L;^+],34$=(#"!--$_P VPN>V#TY/3G->G5YM\4$TT:C8R7#RM=>2
MRM%'@?)SL))Z?,3ZY&>E %BR\":G81)-X>\2R+#(1($VLBN#WX)!X]JZ72M4
MMKKQ!J%G!?RS36_^N@EA53'\Q PP +#@@=>G7D5YGX>?S;NTM='UZ^LIY9%5
MH)$(C)P22"&P>1CE1UKT[29[B;5KP/JMM>P1NZ+&BA9(2&QM8>V",]^..Y ,
M7X@W:K<:)9K]G$\MV'0SW!B  X."&7)^;H<@_E4GA26]3Q-K%M<Z8ME;K*[0
MN(W7SP7SO.0 3DGD%NWW>,R>.=:O]*_LI-*<>;-= 2H4+9B ^8\$8QD'KT!.
M" :B\*REO%6K1_VFUXR/*7C;/[K,GRJ..@ Z'D9.,@YHC_G^@2V^[\V=C111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>exhibit102image1751a.jpg
<TEXT>
begin 644 exhibit102image1751a.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
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M5?#VB+>Z)I]_-JFK&>2,2-B];;G/H>U5SU[7Y_P,_P"S,3S<O,CWC_A+H/\
MGUD_[Z%'_"70?\^LG_?0KRG[)+_T$;W_ +Z3_P")H^R2_P#01O?^^T_^)J?:
MXC^=?<:?V37_ )U]QZM_PET'_/K)_P!]"E'BZV_BMI1]"#7B'BV2^L?"]]<P
M:MJ"RHJ[2)@,?.!U ![^M7IM':Z<2R:SK2L5&1'?,@Z>BX%/VF)M=S7W&?\
M9F)YG%27]7_R/8O^$MM/^?>?]/\ &C_A+;3_ )]Y_P!/\:\9_L ?]!O7O_!D
M]7UM[A451JNH8 P,RJ3^>WFAU<1TDON*658KK)'J_P#PEMI_S[S_ *?XT?\
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MY]/M"US0\.0#I=W R<G$</\ \;I?^$<@W;OM=QG&,^7#_P#&ZRY3K]BSI/\
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M/^%B>#?^AFTS_P "%H_X6)X-(R/$VE_^!"US?_".P_\ /Y<_]^X?_C= \.P
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M05S^N_\ (Q^&O^OF3_T"N@JY;+^NIC3^.?K^B%I***@V.>N/^2A6/_8/D_\
M0JZ&N>N/^2A6/_8/D_\ 0JZ&KET,:6\O7]$+2445!L7=-_X^&_W?ZBIM#U&W
M6WOH99! T5W+G=#O,O[S=CN,?X5!IO\ Q\-_N?U%0:/#<;]1EMI;L!;V4NT7
MF[8_7.#CO[5VY2_]JGZ?J?'9VO\ :GZ(EEUC3XM'BOKS4]2D,T8\W[,<;MV/
ME.<*,<Y^@]:V84DA2RNA=:BRF2'SY-QPZ.!\FT=QG%<!X@AE@^'\,=PDT<*/
M$Y$HD*/T/0DJ">!^.:W-[6NDV$C021 F$Q$A_P![T)'^L'([' SS7T.EOZ_K
M^O(\?7^OZ_KYFAJ<T4?C7PHMSAY5+YC8 #8J\!1[9]\^U>@;UV_VIM_T#=N^
MS=\_W\?WL_P_UKRY))(?'OAQGA^1&E8%T8&4YQG+$X/;CK^M>H[^?[6V?QX^
MQ_Q;NG3_ )Z_TX]ZSK=/Z_KU-:/7^OZ]#SOXT6-U=> X9;><1037T9C@WD*G
MRN>HXYZXZ \#K6MX-S_PAND[F+-Y R2,$\FLCXTZ>+SP'%<_:HX5GOT/ED_)
M'\KY^A]>.N.E:_@T%?!NDJ=Q(MP/FZ]3UKGG\/\ 7G_5SOPG\3Y?Y&Y1116!
MZ04444 %>??$4C^Q=9&1GSK#O_TTKT(=:\F\2V-HO@Z[N%MHA-OL3Y@4;LF4
MY.?>AD3V/6G^^WUIM.?[[?6FT%CD_P!8OU%<1\,QC1=6 Z#5[D?^/"NW3[Z_
M45Y?X(U?5K*SU>&R\-7.HQ?VK<'SX[J.,9W=,-S02W9H].HK%TK5]6O;WR;[
MPU<Z=#L+>?)<QR+D=%PO.3_2MJ@I.X5S'B?/_"1^$<8Q_:+YS_UQ>NH[UP&J
MZMJ5WXO\+07F@7%A$NH2>7-).CB3]VPX"\CKGFADR>AWU%%%!04444 %%%%
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M.UC&)H6.WSL=CZ #H>_TIL:+?0*JE+9;.(*-QXF4>OK&<?Y[O+"_#7VU;<0
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MN0!9O'$<L>X,4>W.#@@C/X@5N?8/'G?7]%/_ '#V_P :!)OL=517*_8/'?\
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MG(KWVH>YQU%[S"BBBD0%%%% !1110 4444 %>;^*O^/^]_WQ_2O2*\W\5?\
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MG\ZUY)25SE=:G3FU?KV?^1V]%<U_PF'_ %+^M?\ @/\ _7H_X3#_ *E_6O\
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MVKK*Y.Q_Y*MK'_8+M_\ T-JZR@F(4444%!1110 4444 %%%% !1110 4444
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M,**** "BBB@ HHHH *\P\;7MMI\M_<WDRPP(Z[G;.!G '3WKT^O)OB( 7F!
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M&<<X^E7Z"A<D4NYO[Q_.FT4 .W-_>/YT;F_O'\Z;10 [>W]X_G2%F/4DTE%
M"EB>I)^II*** "BBB@ HHHH **** "E!(.0<4E% "DDG).:2BB@ HHHH *X3
MQ=?6FF_$3PA=7US%;6Z1W>Z65@JKE0!DGWKNZX?Q5:V]Y\2?"$-U!%/"T5WF
M.5 RG"@\@\4,F>QM_P#":^%O^ACTO_P)7_&C_A-?"W_0QZ7_ .!*_P"-6?\
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M>?\ )/=#_P"O8?S-=+7,_#S_ ))[H?\ U[?U-=-0A1V04444#"BBB@ HHHH
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M">@'4GO^0HLVM/Z_KN%TM_Z_KL>.^!/BO);Z](FM:[-KDMXB06D45D49)2P
M X P<\_0=:]Q^:V<HA$^H3#+,>BCU/HH[#O^9K,2ST2Q=&AM]+DU&3&)1'&H
M3& #QT5>,#K7F/C'Q3K'EZ^MIJCV]K;[X6-N5S(5X.]BI;<_\.P@(.O)I)-?
MU_6@VU_7];GL(!@8VULWF7<GS33.,[?<_P!%KFUOM033)M1M;W:J.[2P-&I
M ;;M+XW&8XXYP"0,8QGC/#][X^.AV$EMKVE>3+9V\[;[,LZF4A%#L3EF&02?
M:F7-MXRM5O;MM1T9Y[2*ZD\P:<P+/#U.<X+$<[L<>M']?U^B#^OZ_5FI\-K:
MZ_X2OQQ#O=(VU63,C/E]@8@ ?7UKT90MTGV>W_=6$?RNZG&_'55/IZFOG'P#
MXKU1&OY(K^UM9=8OO])DELI&CC=CP"5.%4YQVQ79ZQXS\76>D7;RW%@(84,E
MN/[.ECCNU0C*H2?3G'<5H[/6_P#7^9"NM+?U_D>M?)>Q]HM-C'T$H'\D_G].
MO%^.YGGUOP=($V0?VH1&",,P\IOF]AZ"N<A\5>/=1MK5I9] B62<)Y<B-D#=
MM!9.N ><5!K\WCO5+R.6Y;2'_L*1;EI51U"NRL/N]6P.HZ@GIQ227?\ /_+<
MJ,FI)M?E_GL=_17E]QXK\:1:<;V*;0Y8HX@\@ ._<.67;U 5<')X((QR<5T$
M%KX[NK>.XC\0Z.D<JAU4V!) /(%0XV5ST(5U-V29V%5]0_Y!=Y_U[R?^@FN;
M_L[Q]_T,>C?^"\TR72O'DT$D3^(]&VR*4;&GGH1@U)I?R+/P\_Y)[H?_ %[?
MU-=-65X9T=_#_AJQTF2=9WM8]AD48#<D\#\:U:$..P4444#"BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "N;UN6Q;QEX:M+F%)9I!=-&'C
M# 80>O2NDKC/$/\ R4_P<?\ IE=_^@BADRV.S_ITHHHH*"BBB@#BO$0!\6:2
M?36;#'Y-7L]>,>(MW_"6:3@C']LV&?R:O9ZA[G)5^(****1F%%%% !1110 4
M444 %>36'_)<IO\ KI)_Z)->LUX9K-Q-;?&&)X)7B9M5MXV*'!*LR*P^A!(/
MUKNP6U3_  LX,=\5+_$CW.BBBN$[PHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HJG+JVGPZG#IDM[;I?SH7BMFD D=1G)"]2.#^57* "B
MBB@ HHHH P/&Z[O!6K#&?W!/ZBN(^$Z0IIFJ7%RY\J.X1E3'&[;P?<^@KN_&
M(W>#M7'_ $ZN?TKAOA28(M-U"XFW,4G01H.<L5/0=V[5Z%+_ '27J>=6_P!\
MC_A9Z$6VXO;T$$'$$ Y()Z<=W/Z?F:AO+9)K9SJ"L\UPICCAB;!3/93Z]RW]
M*F):%ENKI=]T_P L,"'.WV'OZM_2H;RY_LJWDO)P)[UUPJ*>%&1P/11D9/\
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M/Y4]DT=&&UE<M/\ =J*I7^[452=@4444""BBB@ HHHH **** "BBB@ HHHH
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M!M70+96D6/:RJA7&%Y<<XR?6N'O9@GQ$\) 0F4BP3*CL#*PSUKT#4<1V>/\
M1T:62!9Y8)6X.]@$7'?;CT[_ $KZK+U_LZ_KJ<E=^^4#X/\ #IC<MH%G'YD1
M$4@?/3 W-SD8&!C&.WI7-R:'I,%D\JZ=;RD1E2N2'7;:AP5!]&.X?3'-=;<P
M6EBK!]1$#8D*2_:VS\K$A.HR2/3GZUQLR6$TS!]7_>A69/\ 22<XM@ NXG!R
MWRGW.*[3%'0>%=&TB;PGI,MYH]D9!M 61"92S;A\W&<9VGGT_"M)_#^A>0$.
MG:5)'%U,4/S-*6.5 &>.1GZ>F:J^"YH5\+Z5YDHCD6)=\JJKLD>]L<X/)([
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MQOA;XO;KJ6C#*E,#S!\I[<+7LU%']IXG^87LX=D>#:YX-\1>%K&#4;R[TN2
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M% !1110 4444 %>>>.]671?'OA"\:UGNB%N$6&#&]V8*H SQU->AUYG\2/\
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M:38OINF0V<D_GM'NS)LV9RQ;I^-7:!)65@HHHH&%%%% !1110 4444 %%%%
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MM^3_ ,_+?X5T_CWP]HMK%X?>VTFQAWZQ!')Y=NJ[U.<J<#D>U=@WA;P[N/\
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M%E$;L&(VDCJ/I6O341(UVQHJ+Z*H _(4Z@$%%%% !7&>(?\ DI_@[_KE=_\
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MGUC_ -=KC_T:U=C7'?"W_DGUC_UVN/\ T:U=C0MB8_"@HHHH*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC/$/_)3O!W_7.[_]
M %=G7%^(F ^)W@W/>.['_CHH9,MCM****"@HHHH XKQ& ?%NCD@$C5[#!]/O
MU[/7C'B,$^+='(.,:O89&.OWZ]GJ);G)5^(****1F%%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% 'S1^T"I?XD:0JL48V<8# =/WC<UW+>%O$NX_\
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MO9Z^4_%NMV6K?&+0[O2;];B 2VB^9"QQN$G/\Z^K*A[G)4=Y!1112("BBB@
MK/;7--1RK7:9!P< FM"O)KRX:VC5E .3CFN+%XB=%Q4%>]Q6G*<806K/2/[>
MTO\ Y^U_[Y/^%']O:7_S]K_WR?\ "O*_[4E_YYI^M']J2_\ /-/UKF^MXG^5
M?U\SJ_L_&?RK[SU3^WM+_P"?M?\ OD_X4?V]I?\ S]K_ -\G_"O*_P"U)?\
MGFGZT?VI+_SS3]:/K>)_E7]?,/[/QG\J^\]4_M[2_P#G[7_OD_X4?V]I?_/V
MO_?)_P *\K_M27_GFGZU-:W\D\XC9% (/2D\9B4KN*_KYD5,%BZ<'.459>9Z
MW!<17,0EAD5T/0BI*PO"G_()?_KL?Y"MVO2H5'4IJ;ZG/!\T4PHHHK4H****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[/7S]=>*]*USQCH\5B;HN^KV3#S;9XQA<@\D>]?0-0]SFJ.\@HHHI&84444
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MN<=3XF%%%%(@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXS.UVLI4<D)A>H/7\*^CZA[G+/X@HHHI$!1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110!YKXG('Q?T<$\G1Y\?]_!6Q61XG_Y*_I'_ &!Y_P#T8*UZ
MN.QU4?A"BBBF:A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M "X)Z TE>=>(M'LM8\4^)GODDD-EHL<UOMF= CXD.< CT%=MI5Q_Q3FGW5S+
M@?8HI)9'/^P"2:!)W9H8/H:"".H-<A#X*T35Q)JFI64S7=Y(T[9N)$P&/RC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@"O-865S)YD]I!*^,;I(PQQ]2*B_LC3/^@=:?\ ?A?\*NT4 (    ,
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MQR%)[UCG!;'*KP?_ -?( /:Z*\JEG'A'XYJ'D:/2]8TDD(6.U'A7MGIA$_\
M'JY7X:^(M0T[QA=:OK,[_8?$EG<ZA"KN2$,4C'&/]P-^&* /?Z*\F^'6I2:/
M\,M;\;:K([27\\]_M=B?E!*HH],D''U%8GP@U+6-)\5'3]>N'D_X22R&JVQ=
MB</N;(YZ$KDX]A0![I17D%_?-\(_'-S>7+SOX2UO=)W?[+<@$X'LW;Z_[-:W
MPQTS4=4N+[QWKID6]U?_ (]+9F.VWMOX0!ZG _  ]S0!Z31110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN3;27<2SAT0QEL'<^2HQZG!Q]#38]7T^98C'=Q/YL331A6R712 S =P,C\Z
M+%PI>UE51EF0@#\*\^^$'ABYT;P(EIK>E+!>?:96*3(I;:2,>M=0OC3P\]M]
MH74D,?F^3D1ODO@DKC&<@ Y],59'B71C??8OM\8N-H;8P(X*[QR1C.WG'7%
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MMDR*6VG&#WKO8-3L;I;9H+N&1;I6: HX(D ZD>N*J-XFT9;R"T%_&T\X!C1
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M<,-SU]!7;V$;0Z=:Q.NUDB52OH0!Q5BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K/UFQE
MU&P6"%U1Q/#)EB<8217/Z+6A10!Q\W@V>761J(O&##5?MOE&5_+\OR=F-G3?
MGO\ K6EX1T[4-'T*WTV_2/-M&D:R+=/-OP,$_,HVCC@<XK>HH X[Q=X,N/$&
MH)>V=\+6:.V94)!XN%.8)/\ @.Z3_OJH_P#A#=1A\2Z?JMIJ%O'!IZQ6T%LT
M.2;<+M<%^Q.YCC&,HG-=K10!QUUX:U-5LY+=HI9+?5+F]V"Y>#*2&0J-RJ3_
M !C(Q@\T77A&\N]:DU1KA?WLN]K5IG,0_P!'$8<#&-ZN#@XY!/?&.QHH XZ?
MP;=2Z!HNFQ:G<6\MC$P:YCN'\P.8BH*MUVACT..*;%X6U&%5M(ET^*RGDM)I
MBC/NA:'9E$R/F4^6,$D$9/6NSHH XO2?!EUI>H1W*740C:WN5EMP#M$TKJ?,
M4]LA0&'J ?6MO2(-2TV+2]+>"%[2WT]4FN5DY$RA5"A<<@C<<]L#UK9HH YC
MQCX:OO%$%K:07\5G;Q%I79H?-8R8PF!D8QEFSG@A:J_V/XFC368HFT])-4V,
MUVLK@POY,<;$)MYP4+#D=178T4 >=IX UJTLK&VL]8MXWTZXEFLIUA,8C610
M"FP9&.9._<>E6O#_ (1U/PWJ5@\!AGMH+%+-\W3H0%ED;<5VD.=L@ZXY!]:[
MJB@#@8?"&NMI"V+7-E:O#;2V<4T19V*2R*SN00.0BX"^IZBMGPYIFK>'K>TT
MAS;W=BC3'[1&OE&),@QH$YXRS+P> JUTM% &1K5A>7%QI][8"![BRE9Q%.Q5
M'#(5/S '!YX.#W'>N?N_">N7FO:?K/V_3[>6P$8BMXK<[&R29@&)R@8,5X!S
MM4GTKMZ* "D)"@DD #DD]J6B@! 00"#D'H:6BB@ HHHH **** "D9E1=S,%'
MJ32T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>exhibit102image1751b.jpg
<TEXT>
begin 644 exhibit102image1751b.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0 ^8# 2(  A$! Q$!_\0
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M444 %%%% !1110!SOCR-9? NL1."4>W*L <9!P"*O>&E">&-+09PMK&!DDG
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M_H*V7_?]?\:Y*RU?3E^*&H737UL+=[$(LID&TL/+X!Z9H [^BLW_ (2'1O\
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M.<LL4>Q<XQT&!71T4 <__P (1X:_Z!%O^O\ C2_\(3X;QC^R(,>F6_QK?HH
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MB-7:UM1&%)-U&OS''4X_K6S61=VVHZBL *P6\:3I*0Q+M\ISCCBM>@ HHHH
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M_P"R:BU6]\:ZKILMDNB-9^:5!GM[K$B ,"=I!') (Z]ZZ2P_Y'#6O^O>U_\
M:M;= '#VVL>-H+2&%_#D<KQQJK2-<#+$#&3SWJ7^W?&?_0L0_P#@0/\ &NSH
MH XS^W?&?_0L0_\ @0/\:/[=\9_]"Q#_ .! _P :[.B@#C/[=\9_]"Q#_P"!
M _QH_MWQG_T+$/\ X$#_ !KLZ* .,_MWQG_T+$/_ ($#_&H+RZ\6ZQ%'I]SX
M>BAM9YXEN)!.#B+>I?C//R@C\:[JB@"KJ5LUYI5Y:H0&F@>-2>Q*D?UKP6/X
M8^.);2W6WLM&C\F%(F%_&DC,0H'RDJV!^5?0E% 'SU_PJ?Q\"3Y/A3K_ ,^<
M?_QNNC\#6?BW0(IYX]&L;MI<Q,UK*BQ95CRNWCUR,=17L58?A)@V@@J4(^T3
M<I;^2/\ 6-_#_7OU[T 9']N^,_\ H6(?_ @?XT?V[XS_ .A8A_\  @?XUV=%
M '&?V[XS_P"A8A_\"!_C1_;OC/\ Z%B'_P "!_C79T4 <9_;OC/_ *%B'_P(
M'^-']N^,_P#H6(?_  ('^-=G10!RFB'7M0\2&]UG2H[.&"T,4)64-EF<%OT5
M:H_%2PN;SPQ!-;J&6UNEEF_V8]K*3[XW#BNYK \;_P#(E:M_UP/\Q0!<\.?\
MBUIO_7LG\JTZS/#G_(M:;_U[)_*M.@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** ,#QO_R)6J_]</ZBKGAW_D6]-_Z]D_D*
MI^-_^1*U7_KA_45<\._\BWIO_7LG\A0!IT444 %%%% &?KO_ "+VI_\ 7I+_
M .@&O/\ PKQ\8+X>GAVT_F*] UW_ )%[4O\ KUE_] -><^#KJWN?C!?M!<PS
M*?#]J 8W##(*Y''^>: /5J*** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /FVYYNYC_MM_.O
M:K7_ (\X/^N:_P J\5N?^/J;_?;^=>IV^KWRVT0&D3$!  =QYX_W:]*MLCSJ
M.[-VBL;^V+[_ * T_P#WT?\ XFC^V+[_ * T_P#WT?\ XFL#<V:0D $DX ZF
ML?\ MB^_Z T__?1_^)J&ZU+4+BTFA729T,B%0V2<9'TH O1_:-1'G><]O;-S
M&L?#N/4GMGT%6+*Q@L(FC@# .V]BS%B3^/TKGDOO$2(J+:J%48 \@_XUK:%?
M7-]:2-=>7YB2;?D4@= >A[\T :E%%% !1110!S<WC"".9XTTZ^D"G&Y44 _F
M:33O$%M-J5Q(\,UI$Z*3YP'S..,C!/;^56CX4TW>[+YZ[SN($IZ_C3+#1[*/
M4K@1H9H8T"-YN'&_J<?08_.@"_\ VWIO_/VGY&C^V]-_Y^T_(U+_ &;8_P#/
MG;_]^Q1_9MC_ ,^=O_W[% &*-2L_^$C-QYP\DQ;=^TXSZ=*U?[;TW_G[3\C6
M<+.U_P"$F:+[-%Y?E9V;!C/KBM;^S;'_ )\[?_OV* (O[;TW_G[3\C63J/B"
MWAU*"5(9KN)(R5\D#Y7/'.2.W\S6W_9MC_SYV_\ W[%9=_HUE+J5N)$,,,B%
M%\K"#>.><>HS^5 $4'B^":=(VTZ]C#'&]D4@?7!KHZQ%\+::LB.?/8H=P!E/
M7\*VZ "BBB@ HHHH **** "BBB@ K%T;?_:VLAMN%N% Q[J&_P#9JVJRTT^[
MM+R\N;:XB?[3()&BE0C& !PP/H/2@#4HJO:W8N-Z-&8IHSAXV.<>A![@^M6*
M "O'O$G_ ",>H?\ 78U[#7CWB3_D8]0_Z[&MJ&[,:VQ[3X1_Y%'2_P#KW6MJ
ML7PC_P BCI?_ %[K6U7!/XF=T/A1#=0M<V<\"RM$TD;()$ZH2,9'N*X3P]9W
M%E\4=1CNKPW<S6.3*8PF>(1T'TKT&N+L2#\6M0(.?^)?_6*I*-32KF"X\8:]
MY$T<OEQ6T<FQ@VQAYN5..A'I705S>BV%I8>,/$/V2WCA\]+>>78,;Y&\S+'W
M.!724 %%%% !1110 4444 %%%% !1110 5S_ (5N8OL!LWG/VQ))9&@FNEEE
M5#(V"<?P^GITKH*Y;P;INEBU?5;:UL1>2O-"]Q:QLFY1*WR_-SUZ^] '4T44
M4 %%%% !1110 5@>-_\ D2M6_P"N!_F*WZP/&_\ R)6K?]<#_,4 7/#G_(M:
M;_U[)_*M.LSPY_R+6F_]>R?RK3H **** ,W4->TW2[J&VO+@QRRX*@1LPP6"
M@D@$*,D#)Q6E69J.@:?JMU%<W<<C21@ ;964, P8!@#AAN /-:= !1110 44
M44 %%%% !1110 4444 %4M3U>RT>&.6^E:-9'V(%C9RQP6X"@GHI/X5=JCJ>
MDVFKPQQW0D_=.71HI6C925*G!4@\AB/QH M03Q75O%<0N'BE0.C#^)2,@U)4
M5O;Q6EM%;0+LBB01HOHH& /RJ6@ HHHH **** .:^(19?AWX@=&*O'82R*P[
M%5)'ZBM308?L_A[38M[/LM8QN;JWRCDU-J>G6VL:7=:;>H7M;J)HI4#%2RD8
M(R.163_9&HZ-;*VCWT]S'"N/L-X^\.H_A60_,IQTR2/4=Z .AHJMI]_#J=A#
M>6Y/ERKD!A@J>X([$'(/TJS0 4444 9^N_\ (O:E_P!>LO\ Z :XOPG:6T.M
M64L5M#'([7(9TC"E@(X< D5VFN_\B]J7_7K+_P"@&N0\,.O]KV";AN#7)*YY
M'[N"@#OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK[T ;U%%% !1110 4444 %8'C?\ Y$K5O^N!_F*WZP/&_P#R)6K?]<#_ #%
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M_E7B=S_Q]3?[Y_G7MD'_ ![Q_P"Z/Y5Z5?9'G4=V24445@;A1110 5C>'O\
M57O_ %\G_P!!%;-9.@Q)"FH*@P/MLG?/I0!K4444 %%%% &-X;_X\)O^N[?R
M%;-<F/#NK122^5=P!'?<,,R_IBGVFDWK7SVUW>.-L8?=#(3C)Q@Y'L: .IHK
M&_X1_P#ZB-W_ -]"C_A'_P#J(W?_ 'T*  ?\C6W_ %PK9KE!I)_M\VWVR?'E
M[M_&[\_2M+_A'_\ J(W?_?0H V:*QO\ A'_^HC=_]]"L^ZTF^6^2VM+QSNC+
M[II",X.,# ]Q0!H>(_\ CTMO^OA?Y&N@A^X?K7&KX>U9YHS-=0%%8,<LS?EQ
MUKKXY JX.>M)C1G>*K'5-2\,WUEHTUM#?SH$1[I \6TL-X92K @KN&"#UKRG
M4O@OJVJ7EQ/;-I.A+-9E)H+">:6*YGW;^595\N,D+\HW;=@P#7M7G+Z&CSE]
M#4.-RU*Q\Z_\*!\5X8?;]%Y '^OE_P#C=:5O\$?$J>']1TV2^TD-<3P7,;K-
M(1NC$B[3^[& 1*QR,\J!CYLCWCSE]#1YR^AI<@^<X[PGX<UGPKX/OK*TL=#@
MU*2=I8(X+BX-MDJB[G:3<^>#P.#@#C)-<WH7A#XCZ!_:LMM>^'#=:BKM+/EP
MS3L^[SF_=<D LH0809SM)SN]5\Y?0T><OH:?*+F/(-)^&_BNPT]-,O-.\&:C
MIH(_<3I*'3( D9)1'N61\#+'."%V@  5W/P^\)OX/\-O8S>2+B>YDN94MW9H
M8RQ "QEANVA57[V3G/)KIO.7T-'G+Z&A1L#E<)ON#ZUSUL]W?ZCJ4$EX\<-O
M,J*L2A3@J&Z]>];TD@9<#/6L'1E(U76&+,=\X)SVXQ_("K1#-:""*VB$4*!4
M'./4^I]34E%%,05XYXA_Y&+4/^N[_P Z]CKQSQ!_R,6H?]=W_G6U#=F-;9'M
MOA7_ )%/2O\ KV3^5;%8_A7_ )%/2O\ KV3^5;%<$_B9W0^%%+6,?V)?[@A7
M[-)GS&*K]T]2.0/>N<FNF\*I%<V_EW%I> .=/C;,OF8&6A_O ]2I^N>372ZI
M_P @B]QN'[A_NQ[S]T]%_B/MWKCO#'B?PT]FNKWNN::M_=H#B6X16AB_ACVY
M^7CDC^\3[5)1V&FWYU&T^T&SNK3YL>7=1['^N,GBKE4M/U?3=55FT[4+6["_
M>\B97Q]<&KM !1110 4444 %%%% !1110 4444 %8OA;S/[$'F&8MY\W^M@$
M+?ZQOX1V]^_6MJL3PGC^PAM4*/M$W N//_Y:-_%_3MT[4 ;=%%% !1110 44
M44 %8'C?_D2M6_ZX'^8K?K \;_\ (E:M_P!<#_,4 7/#G_(M:;_U[)_*M.LS
MPY_R+6F_]>R?RK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#GO'<\UKX \07%M-)#/%83/')$Q5D8(2"".0:DT#1-/MK
M*SO5@,EVUNA-Q/(TLARHS\S$D9]JC\=HDO@;5XY%#(UN0P/<9'%7/#2+'X8T
MM$&%6UC"CT 44 :M%%% !1110!GZ[_R+VI?]>DO_ * :\_\ "H_XO%?\YSX>
MM/PY6O0-=_Y%[4O^O27_ - ->?\ A4C_ (7%?\]/#UIG\Q0!ZA1110 4444
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M "BBB@ HHHH **** "BBB@ K"\)$'0059"/M$_*6_DC_ %C?P_U[]:W:QO#
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MR!G\X':-IR:7PT -7L0IW 276#Z_NX* .]HHHH **** "BBB@ HHHH ****
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M^VVG_/U#_P!_!7C^LL&UW4&4@J;F0@@]?F-0BPO&+!;2<E3A@(SP>O/YTO\
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MA#_D4=+_ .N"T 9'_"N;'_H*ZK_X$4R7X;:?+"\3ZIJI5U*M_I'8C'I7:T4
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M]KZ;_P!!"T_[_+_C7*7MQ#<^(KAX)HY4^V:>-T;!AU?TH [>BBB@ K \;_\
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M_"@8!X_89X(_$5-8W\=_'(Z1RQF.0Q,LBX(8=: +5%%% !1110!1O5#7MBK
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M*Z_;6\1G\EH)3(I,2R*<HR$%6X/#'\0*V** *]A:+8:=;6:,SK;Q+$&;J0H
MR?RJQ110 4444 %%%% '-?$,@?#GQ&<XQITY!SCG8<?K5[PW8V%KH5B]C;6\
M2R6T9W0H!N^4<Y'6JWCE0W@G5E8 @P<@C(/(JYX< 7PUIBJ %%M&  , ?**
M-2BBB@ HHHH S]=_Y%[4O^O67_T UR/AC_D*:?\ []S_ .BX*Z[7?^1>U+_K
MUE_] ->;>";>6V^*EY9/J%Y=0Q:/#=(D[C:DDFP,0  .0!VH ]9HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_H1H UJKWW_(/N?^N3?R-6*KWW_(/N?^N3?R- &1??\ (+O?^O6'^9K7L?\
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MLS_A'-._NR_]_31_PCFG?W9?^_IK W-/S8_^>B?]]"CS8_\ GHG_ 'T*S/\
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MN#F[T]VLI_=HSM!_%=K?\"J"SSJOCJ]NSS;Z3"+.+T\Z3#R$>X7RQ^)HB/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,#QO\
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M $+3_P#@4E='10!SG]M:_P!O#3_^!24?VUK_ /T+3_\ @4E='10!SG]M:_\
M]"T__@4E UK7\<^&G_\  I*Z.B@#G/[:U_\ Z%I__ I*DBU?6G)\W0'B '!\
M]6S^5;]% '-WTFI:BL,3:9)&$E#D[@?Z^]=)110 R;_42?[I_E69X<_Y Z?[
M[_\ H1K#\>W]W9"P%K<RPB3S-^QL;L;<9_,UQ<6MZI!'Y<5_<(@.=JR$"M8T
MG)7,Y55%V/9J*\<_X2'6/^@E=?\ ?PT?\)#K'_02NO\ OX:?L'W)]LCU36_^
M0/<?0?S%3:?_ ,@ZV_ZY+_*O(Y-<U6:,QR:A<,AZJ9#@TJZ]JR($34;E548
M$AXH]@^X>V1[)17CG_"0ZQ_T$KK_ +^&I/\ A)M: _Y",_YT>P?</;(]?HKR
M#_A)M:_Z",WYBC_A)M:_Z",WYBCV$@]LCU^BO(/^$FUK_H(S?F*/^$FUK_H(
MS?F*/82#VR/7Z\=\1'/B+4,_\]V_G3_^$FUK_H(S?F*S)II+B9YIG+R.=S,>
MI-:4Z;B[LBI44EH>Y>!'9_!6FESDA7'X!V _2H_#FMSZCK.L0SR9@,WF:><#
M#P !&8>H\Q6_,'H16'X'M-0UKPG!;W%ZMOIT<DD9BM@1),-Q.&D)X'.#M /O
M77WNB6UU;VR0EK26T'^BS6^ T/&, ="I'!4\&O,G\3/1A\*.2\8Z8-;\6+93
M7%ZD,.C7$Z1VCX9GWJ.G<XZ5R*0RZ+\2-+L+6[NO)BNH>)FRQ#QQY5O;YV_&
MNDUR75-.\5@ZA)IMT)M(FMU9I3:[LNO4G//TK&BTS4=>\>0WUC)ID<D)6X"?
M:3,H6)85P2HR"3Z]JDH]*\53-'X<NXHW99[E?LT.PX8N_P HQ[\Y_"L,_#C3
MTMR#J>J':G)^T'GBMZTT>8WR:AJMT+N[CSY*(FR*#/7:N3D]MQ)./2M9EW*5
M/<8H \;\ ^%O#/C/2;B;4M+E>YMYBH=I2H*-TQM/MTKT&P\#:+I=J+;3Q=VL
M )81PW<BC)ZGKUI?!_A"U\'Z=-:V\\EPTTID>63KCLH&> *Z.@# N?!VEWMM
M);73WT\$J[9(Y+R1E8>A&:Y3Q!\-/"NC^'=0O['3FBN88&*/YSG'YFO2JS]<
MTUM7T.\T])1"UQ$4$A7=M)[X[T <EIDOAR[GT+3[XO\ VB+2-DY98I"/F6-B
M/E9A]X(>>]8OAZ\T]-(EL_%4MQ%>7&N76V8,R-$<A06=3\BG(7).#N KK].\
M%6L7A9]%U.<WQDD\U[@)Y3*XQM9,?=*X&#G/%,T#P2FE+JJZEJ#ZP-2P)?M,
M"+QSD''!SGF@#DO.L]'^(/B^/689/[)73K&&V@CC+$Q?-PBKR<-O/'(P3VJU
MJ$<%AXT\&3Z?.7T%X[NXEN&E\Q9&,1.]G)))*YY]*V]'\ #2?%::V=9N[I(;
M?[-!;3HI\N,;MHW]25#, 3S@U4U?X9V-SJMO?0ZO<6&G6L[736"@& ,P_>$9
M^ZK#.1TY)&,F@##\4+ILOA&PO_#1F:VFUFTCN]S,6BC67B,JW**'*G;QU%>M
M5YKXATB;Q-=)?>'+6\C6>XMS=RMLCM[M(Y%8-ACN) '# <CC)%>E4 >9_%3P
M_8Z?\,_$$]E;,))$3/[PD(OFAB%!X5<DG Q65XLEU"V^+^G7&G3PP30>'7E=
MYNFQ78L.AYZ=J](\76T-WX.UF&XB26-K*4E'&02$)'Z@&O(?&OB+2+3XNZ+<
MW=^AT]-+$-XT0,I $C,4(7/)*J#[$T =#:'QAX7MM*^V7MGMU*]\R?9&"Y>0
M[WW H.WR]>,#TKM/&43IHR:K A:XTF9;U .K*O$B_C&7'Y5YYXJ^*?A+6)-)
M-I?RL+6[$TNZW=<* >F1R?85T+_&KP)(C(^H3LK## V<F"/^^: +/A.1)?B'
MXMEC8-'(;=U8="#&I!JUXP_Y&;PI_P!?C?\ LE>>_#;Q=HVE:IKDDMY+-:O(
ML=K(L+;C$F0FX=0=N!SZ5T'B/Q5:^(-<T&+0F=[Z*9FC$T91<DH!DGM0!ZG1
M7&;_ (@_\\=)_P"_A_PHW_$'_GCI/_?P_P"% '0ZUJ$MA9HMJBR7ES((+=6^
M[O/<^P )/TJK#X5TQE+ZG"FJ73C]Y->H),G_ &5/"CV K@/&J>,9K6P6\9X)
MOM)-LVCR-YY;8V1PI^7;NS7*BU\;QNKI>^-G96!"^8YSSZ% /SH ^@XXTBC6
M.-%1$ 5548  Z "G52T<W3:+9&]W_:C GF^8 &W8YSCO5V@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .9^(FT_#?Q)N Q
M_9TV,^NPX_6M'PY/93>'[!;&6!XH[:-0(6!"_*...E:;HLB,CJ&5A@JPR"*R
M;WPW8S#SK*-+"^09BN;90C*?<#AE]0>#0!L45GZ+J#ZEIJRSQB.YC9H;B-3P
MLBG#8]LC(]B*T* "BBB@#/UW_D7M2_Z]9?\ T UR/AC_ )"FG_[]S_Z+@KK]
M=_Y%[4O^O67_ - ->?\ @O7+#4/%%OIUJ\KW-O'-/(#"Z@(Z0A6R0,@D&@#T
M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "H;L[;.=O2-C^E35!>_\>%Q_UR;^1IK<'L?.MK_Q
M^0?]=%_G7M]>'VI NX23@"1?YU[/_:%E_P _EO\ ]_5_QKT:_0\ZCU+-%5O[
M0LO^?RW_ ._J_P"-']H67_/Y;_\ ?U?\:P-RS15;^T++_G\M_P#OZO\ C4-W
MJMK#9S2QW4#.B$J!("2<<<4 /EO_ -\T-M"]Q*O#[2 J^Q8]_:H])MKFWBN3
M<K&KS7#RA4;=@''?UK+M/$^C6MK'"LDWRCYCY+<GN>G<ULZ?J-MJ=N9[5RR
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M_P#O\O\ C1_PD&C?]!2S_P"_R_XU1_X0?PS_ - >W_7_ !H_X0?PS_T![?\
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M?PKTS7?^1>U+_KTE_P#0#7 >%?\ DL-]_P!B[:?S% 'I]%%% !1110 4444
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MXJ:%M'^SE&>[GD5+)4.'\_JK ]MN-Q/H#4/A#=#I\]I>$'6(92=0?_GK*?\
MEH/]AAC;Z 8[5+H\4FIWC:]=(R[U*6,3CF*$_P 1'9GX)]!@>M/UJTG@FBUJ
MPC+W=LNV6)>MQ#U9/]X=5]^.YKSSO#Q7_P BY<?[\7_HQ:-"_P"/_7O^PA_[
M1BJ'Q!=07WA%[JVD$D,ODNC#N#(M3:%_Q_Z]_P!A#_VC%0 :[_Q_:#_V$?\
MVC+6-\2H?$TOAV&3PQ=-;SP3^;<E)5C9H0C9 +*1G.WM6YKUK>S_ -GSV,,<
M\EI=B9HY)/+W+L=>#@\_,*S]8OM=.AZ@'T2!5-M)DB^!P-I_V* /%7T/X@W=
M]#ON;MIS<C8S:G%Q)+ >?]5WCR#5:+0O'+Z;:1I-=?9HH+.6%/[3CPB"3;!C
M]U_"WY>]>CQW>L#4;=ETJ+>+NV*XNL\BT?'\/IS^E5O#MSJ%SX>@?4;);61;
M'3UC"R;O,071PY'\)/\ =[4 <'+X>\=)I]U:/+=?9C'>>='_ &G'AE\S]_\
M\LN['/O5N/0?B)#J$ICN;M;B6[(=AJD7S2K;]3^Z_P">7&:]'O?]3J/_ %QU
M/_T<M7_^8T?^PI+_ .D5 'C::5XULK$7)N[R""*TM%5UOXW*QDLT V^6,@-D
MXR,9ZU]&:']K.@:<=0)-Y]FC\\D@Y?:-W3CKFO,]4_Y%.7_KQTK^35ZM:_\
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M?6+^IK=K"\&?\B?IG_7+^IK=H ***S=9MM4NH;==*OX[*1+A'F9X?,WQ#[R
M=B?6@#2HHHH *\SOT5OC+;,R@E3'@D=/W35Z97FUW#/+\9(3#"TBQA'E(!_=
MKY9&X\8QD@=>] 'I-%%% 'GGQD /@R#(Z7J$?]\/78^'O^1<T[_KW3^5<O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MUZUZ#7&>-_\ D+^&/^P@G_H:4 +]O\??] ?3?^_W_P!E1]O\??\ 0'TW_O\
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MCJ$=BI'<' JOI.L^+8M(LX[;P]!- L2B.0S;2ZXX..V14WQ5=4\,6I9@H-X
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MF%%%%8&P5SF@Y_X2;Q#D_P#+6/\ ]!-='7.:%_R,WB'_ *ZQ?^@F@#HZ***
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MN$1ENH9?-B4L!@/P"G7&2,>]=%0 5C>*_P#D5=2_ZX&MFL;Q7_R*NI?]<#0
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MGL?3'YU2T&:X@TH6\=G*TQDD(+KM0 L2"3Z8]*VK2V-M$0S[Y78O(^,;F/\
M3L/I0!G2#Q& NQM-/S#.%?./Q-'_ !4'K:?]\G_&MFB@#&_XJ#UM/^^3_C1_
MQ4'K:?\ ?)_QK9HH YB;6M3L-3M+6Z6%O.EC0[%[,2,YSZBN@O)FM[&XF3&Z
M.-F7/3('%<QXB1V\1V+)&\GER0R,$7)"AFR<5NL)M294>%X;0$,PDX:3'08[
M#Z]: ,Q#XO9%;_B5#(S@[Z=_Q5__ %"O_'ZZ*B@#G?\ BK_^H5_X_1_Q5_\
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M2@G:,\X%:Z_$9[_4?L6A>'+[4V$9D9A-%$ H('\3>IKM]B_W1^5* !T 'TH
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M\TBZYY']E$DR75J8]OE]P!NQ[#FNA\*?\A'3?]ZY_P#1<% 'H%%%% !1110
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M:1O]<W5Q@TQO"^GOC+7/$0B'[YN@_K0!M45B_P#",V'F[LSXW;_]>V<_G_\
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M/*#_ *YK_*IJAM/^/*#_ *YK_*IJ "BBB@ HHHH QG_Y&U/^O8?S:MFL9_\
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MOB*\D>H>'7B=TD%W\K)%YC [X^B]_I6F6UH2;/[8NL^:(L_V4,9QG.<_=]Z
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M\A#3O]^Z_P#1<- 'H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %9VO?\ (NZG_P!>DO\ Z :T
M:CGACN;>2"9=T4JE'7U!&"*:=G<35U8^;XI7@F26-MLB,&4^A'(K7_X2S7?^
M@@__ 'PO^%>K'X>^&"Q/]G$9/03R?_%4+\/?#"L#_9Q..QGD_P#BJ[GBJ;W1
MQ+#5%LSRG_A+-=_Z"#_]\+_A1_PEFN_]!!_^^%_PKUO_ (03PS_T"D_[^/\
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M $#/_)B7_P"*I_6*7;\@^KU>YY7_ ,)EK_\ S_\ _D&/_P")H_X3+7_^?_\
M\@Q__$UZI_PK_P +_P#0,_\ )B7_ .*H_P"%?^%_^@9_Y,2__%4?6*7;\@^K
MU>YY7_PF6O\ _/\ _P#D&/\ ^)J.X\5:U=0-#->[HVZCRD&?R%>L?\*^\+_]
M S_R8E_^*IO_  KWPQ_T#V_[_P G_P 51]8I=OR#ZO5[GEB>+]=C146^PJC
M'DIT_P"^:7_A,M?_ .?_ /\ (,?_ ,37J?\ PKWPQ_T#F_[_ ,G_ ,52_P#"
MO_"__0,_\F)?_BJ/K%+M^0?5ZO<\O_X3;7?^?E/^_2_X4?\ ";:[_P _*?\
M?I?\*]/;X>^&&7 TXK[B>3^K5'_PKKPU_P ^<G_?]_\ &CZQ2[!["KW/-/\
MA-M=_P"?E/\ OTO^%'_";:[_ ,_*?]^E_P *]+_X5UX:_P"?.3_O^_\ C0?A
MSX:/_+I*/^V[?XT?6*/8/85>YY:?%6K&]%WYZ><%V9\M>GTQ[U/_ ,)MKO\
MS\I_WZ7_  KTK_A7'AO_ )]9?^_S?XTH^'/AL?\ +I*?^V[?XT?6*/8/85>Y
MYI_PFVN_\_*?]^E_PI1XVUP')N(S[&)?\*]*_P"%=>&O^?.3_O\ O_C1_P *
MZ\-?\^<G_?\ ?_&CZQ1[!["KW/./^$ZUK^_!_P!^A1_PG6M?WX/^_0KT?_A7
M7AK_ )\Y/^_[_P"-1GX:^'22?*N!["8T>WH]@]A5[GGG_"=:U_?@_P"_0J]X
M.UV]FU6+3V9/L[[V("\YV^OX5K^+_!.CZ+X<GOK-9Q,C(!NDR.6 -<MX)_Y&
MBW_W7_\ 036B<)P<HHS:G":4F>J4445SFX4444 %%%% !1110 4444 %>=?$
M/_D+6O\ UP_]F->BUYCXYNOM.MJH0KY*>7UZX).?UK2C\9G5^$J:%/=0PS?9
M[K5X06&18(6!^N&'-:WVW4O^@GXI_P"_+?\ QRND^% _XE.H'UG _P#':]!K
MFQ'\1G30_AH\:^VZE_T$_%/_ 'Y;_P".4?;=2_Z"?BG_ +\M_P#'*]EHK$U/
M$YS/=/')<7/B.:2([HGDMV)C.0<K^\X.5%3_ &W4O^@GXI_[\M_\<KV6B@#Q
M9-4O)7=(]9\2NZ??5$)*<D<CS..AIMLT]E$(;.Y\1VT(Z1PV[*HX Z>9[5TM
MA+-#>>-7@O/L<GVF-5GV[MF7<9Q@\\^E;?\ :%U->7:VD.M7$=O<B-F1H I*
M 949P=ISS^E '"_;=2_Z"?BG_ORW_P <H^VZE_T$_%/_ 'Y;_P".5W8GU0 #
M['KQPKC)DMN=W0]?X>WZYH,^J$$?8M>'"#B2V_AZ]_XN_P"F* /-=4N;R:&*
M*>\UF9&E VWZND8/8\2<D=0*]*TCPC>:?K4&HWFOW=^(8W1(I@< MC)Y8^E<
MWXUFOGTNU$]OJD4?V]6)N'A*<]%^7G [?K7IW:@ KRF[CM-#\3W;+]KN[FUU
M;[5%;1ECMBDC5Y"%^[]]^O&:]6KSAWN5^)NNK;1WLC-;*I^R-&&3Y(>?GXH
MU/\ A84?_0!U;_OR/\:/^%A1_P#0!U;_ +\C_&K9NM4+EOL&N >8K[?,M\8
MQMZ]#U/>F";50H'V37CA77/F6V3NZ'ZCM^N: *__  L*/_H ZM_WY'^-'_"P
MH_\ H ZM_P!^1_C5HW&J'/\ H.NC.S_EI;\;>O?^+O\ IBD%QJ@8'[%KIPSM
MCS+;G=T'7H.WZYH K?\ "PH_^@#JW_?D?XT?\+"C_P"@#JW_ 'Y'^-6#/JIC
M*_8]>!,:IN\RVSD'.[KU/0]J=]IU3S-_V#7,>89-OF6^,8QMZ]._K[T 5?\
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M_NO_ .@FO2_B+_R)=U_OQ_\ H8KRSPO?6VG:]#<W<GEPJK MM)Z@CH*[\/\
MPF<-?^*CURBL+_A,M _Y_P#_ ,@R?_$T?\)EH'_/_P#^09/_ (FIY)=BN:/<
MW:*PO^$RT#_G_P#_ "#)_P#$T?\ "9:!_P __P#Y!D_^)HY)=@YH]S=HK"_X
M3+0/^?\ _P#(,G_Q-'_"9:!_S_\ _D&3_P")HY)=@YH]S=HK"_X3+0/^?_\
M\@R?_$T?\)EH'_/_ /\ D&3_ .)HY)=@YH]S=HK"_P"$RT#_ )__ /R#)_\
M$T?\)EH'_/\ _P#D&3_XFCDEV#FCW-VO*/%W_(>G_P!XUW7_  F6@?\ /_\
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M<]*8-/T78,S:%NVOG&J2XW?P?Q=/7]*WO^$$\-?] M/^_C__ !5'_"">&O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWQ/_P ?&E_[\_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P!B[:?S% 'I]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%MWHEC8Z9;Z7]OAD>0M=PB;9"<YP^(CSDX^4GH:Z'_A,[S_H'P_^3/\ \8H
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M !1110 4444 %)M&[=@;O7%+10 4444 %%%% !1110 4444 %%%% !535?\
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M]>C5YS\;5#_#X*PRK7]L"/4;Z -O1/$&C1W&L%]5LUWW[,N9E&1L3D<UK_\
M"2Z'_P!!BQ_[_K_C6!HWA+09Y]6$NF0L([YD3)/RKL0XZ^YK5_X0KPY_T"8/
MU_QH M?\)+H?_08L?^_Z_P"-'_"2Z'_T&+'_ +_K_C57_A"O#G_0)@_7_&C_
M (0KPY_T"8/U_P : +7_  DNA_\ 08L?^_Z_XT?\)+H?_08L?^_Z_P"-5?\
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MZ6N=TF:WT;5+[1)+B..WB5+FT21P"L;E@4&>RLIQZ @5I/KND1RM$^J60D4
MLAG7(STR,T :%<9X(_Y#'B;_ *_F_P#1DE=%_;^C_P#04L_^_P"O^-<WX$=9
M=4\1R1L&C>\9D8=&!DDP1[4 =K1110!QGA#_ )&SQ7_U\)_Z%+79UQGA#_D;
M/%?_ %\)_P"A2UV= !1110 4444 4M8_Y E__P!>TG_H)KSOPE_R5Z]_[%RT
M_F*]$UC_ ) E_P#]>TG_ *":\[\) #XOWI Z^';3/YK0!ZC1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^/C2_P#?G_\ 1$E=%7 ?%W4+O1O"D&JV-PL%Q!=H@9XPZ[9 8VR#[,30!K>
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MWA:^TRU\HRV]XS-)!-AMK*'**-P/89SANF.>_H **** "BBB@ HHHH ****
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MF=XT1UV[VWL/O+QP#M&>@KU:B@#SR#X*^ FMXC<>&TCF* R)'J%PZJV.0&+
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M02/F]ZGL?".K6NGVUO+%:S211+&TG]J7"[R  3C9QGKB@#J/^$FT+_H,6/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7-1;9:0$$@<@;B!UY( '<T =[17B=W-\:]"TYM=N;C3;V*)?-GL$C4L$')X
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M$;JV4!HC^ '.,G!'('!K0^)/C7Q38>,_#^B>%+RU0:I &0S1JRLS,0#D@X&
M* /7:*\/UOQ!\7_!-A_;FM/I%]IL#J)XHE .&.!R ".2!D=R.*]CTC48M8T:
MQU.%66*[MTG16Z@,H(!_.@"[17 ?&#Q5JO@_P7'J6CRQQ737B0EGC#C:58G@
M_05QEUJGQIT_P\VORW6D2V45N+IT5$W&/&X\8';WH ]RHKFO WBL>+O!=EKT
ML*VK2JPE3=\JLC%6(/IQFO-? OQ@U'Q#\3Y])O7C_LB[:5-/ B"E=IRN3WRH
M/7N: /;Z*\S^(OB[Q%X&\1:3JVY)_"TSB&\B$(+Q-SSNZ\CD>ZD=ZD^)/Q#G
MT33-+LO##QW6M:RR&RVJ''EDCY\=\Y 'X^E 'I%%4M(COX='M(]5G2XU!8E^
MT2QIM5G[X'I7$_&+Q;JW@[PE;W^C2QQ7$EVL3,\8?Y2K'H?H* /0Z*\.U#6/
MC+H.A'Q#=W&CW5A#&L\L2(N2AQUX!Z'L<UZ/I?C>TU#X<KXODC\F$6CSR1DY
MVLN<K[\C _"@#JJ*\>^#GQ/U7QEJNI:9KLD1N%C%Q:[(PGR9PPXZXROZU%XV
M\8^-U^*T7A+PO=V</G6ZO&+B)2,[69LL03T% 'LU%>':MXO^*'P_>SU3Q4--
MO](DF$,J6P 89YX( (. <=1Q73:MXUU:W^-&@>';:>(:/?6?GRH8QN)VRG.[
MJ/NK0!Z717D>J_$37?%?C!/#?P],7EV[9OM5EC$D2#H<9X(_4GIQS6@_B[7-
M(^,]AX6U*ZCFTN^LE:!A$JL9 IRQ/NR/Q_M"@#TRBO%M?^*^J:=\98="AD3^
MPHKB&UN?W0)WN.3N[8)_\=-=%XI\8ZQ!\5_#?A/1I8ECN!Y]_NC#?N\DXS_"
M=J-_WT* /1Z*\L^,OQ"U/P;;Z99Z$Z#4KIVD?=&)-L2CT/J3U_V373:=K6H>
M+OAK#JV@W,5OJES:AHW9 ZK,/O*0>,9!'MF@#K:*\X^''Q&.N^']13Q&Z6NK
MZ,7^WAEV?(,_/CMC!!'J/>H_AKXK\2>.-7U76IV2#PRDC0V4!A&]SD<[NO Z
M^[>U 'I=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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9HH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>exhibit102image1801a.jpg
<TEXT>
begin 644 exhibit102image1801a.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0 YT# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#G_P!G'_DH
M>H?]@J3_ -&Q5]/U\P?LX_\ )0]0_P"P5)_Z-BKZ?H **Y_Q1K]QH2VI@BBD
M\XMG?GC&/3ZUSG_"P-0_Y]+;_P >_P :YZF*IPERRW,Y58Q=F>AT5YY_PL#4
M/^?2V_\ 'O\ &C_A8&H?\^EM_P"/?XU'UVCW)]O ]#HKSS_A8&H?\^EM_P"/
M?XTO_"P+_/-I;?\ CW^-'UVCW#V\#T*BN _X6#=?\^,/_?1H_P"%@W7_ #XP
M_P#?1I_7:/<?MX'?T5P'_"P;K_GQA_[Z-'_"P;K_ )\8?^^C1]=H]P]O [^B
MN _X6#=?\^,/_?1IR_$*?'S:?&3[2$?TH^N4>X>WAW.]HKA/^%A2_P#0.3_O
MZ?\ "C_A84O_ $#D_P"_I_PH^N4>X>VAW.[HKA/^%A2_] Y/^_I_PH_X6%+_
M - Y/^_I_P */KE'N'MH=SNZ*X0?$.3/S::I'M-C^E/_ .%B?]0O_P F/_L:
M?URCW_,/;0[G<45P_P#PL3_J%_\ DQ_]C1_PL3_J%_\ DQ_]C1]<H_S?F'MH
M=SN**X?_ (6)_P!0O_R8_P#L:/\ A8G_ %"__)C_ .QH^N4?YOS#VT.YW%%<
M4/B''CG37!]IO_K4?\+"B_Z!S_\ ?T?X4?6Z/\WYA[:'<[6D9E1&=V"JHR23
M@ 5Q?_"PHO\ H'/_ -_1_A6=JOBZ+5OL\$UFXL5??<0^9_K\?=4G'W<\D=\8
MZ9H^MT?Y@]M#N=!J/C*.VTN\U&PTR[U"TM8FE>=-L<;!1D[68C=TZJ"*W[*Y
M%[86UT$*">)9 I.2NX X_6N!UOQ?%JWAZ_TN.Q,/VJV>!7W@A-RD9QCM5K3O
M',%GI]M:O8R'R85CW*XYP ,XQ3^MT?Y@]M#N=W17'?\ "P;7_GQF_P"^A1_P
ML&U_Y\9O^^A1]:H_S#]M#N=C17'?\+!M?^?&;_OH4?\ "P;7_GQF_P"^A1]:
MH_S![:'<[&BN._X6#:_\^,W_ 'T*?_PL"P_Y]+G_ ,=_QH^M4?Y@]K#N==17
M)?\ "P-/_P"?2Y_\=_QH_P"%@:?_ ,^ES_X[_C3^M4?Y@]K#N=;17)?\+ T_
M_GTN?_'?\:/^%@:?_P ^ES_X[_C1]:H_S![6'<ZVBN37Q_IG\5M=CZ*I_P#9
MJ=_PGVE?\^]Y_P!\+_\ %4?6:7\P>UAW.JHKE?\ A/M*_P"?>\_[X7_XJC_A
M/M*_Y][S_OA?_BJ/K-+^8/:P[G545RO_  GVE?\ /O>?]\+_ /%4H\?:43CR
M+P>^Q?\ XJCZS2_F#VL.YU-%<Q_PG>D?W;G_ +]C_&C_ (3O2/[MS_W['^-/
MZQ2_F'[2'<Z>BN8_X3O2/[MS_P!^Q_C1_P )WI']VY_[]C_&CZQ2_F#VD.YT
M]%<Q_P )WI']VY_[]C_&GKXXT8C):=?8QT?6*7\R#VD.YTE%<Y_PF^C?WYO^
M_9H_X3?1O[\W_?LT?6*7\R#VD.YT=%<Y_P )OHW]^;_OV:/^$WT;^_-_W[-'
MUBE_,@]I#N='17.KXVT4G!EE'N8C3_\ A,]$_P"?E_\ OTW^%/V]+^9![2'<
MWZ*P/^$ST3_GY?\ []-_A1_PF>B?\_+_ /?IO\*/;TOYD'M(=S?HK _X3/1/
M^?E_^_3?X4?\)GHG_/R__?IO\*/;TOYD'M(=S?HK"'C#0B,_;L>WDO\ X4O_
M  F&@_\ /]_Y!?\ ^)H]M2_F7WCYX]S<HK#_ .$PT'_G^_\ (+__ !-'_"8:
M#_S_ '_D%_\ XFCVU/\ F7WASQ[FY16'_P )AH/_ #_?^07_ /B:5?%NA-TO
MQ^,;C^E/VU/^9?>'/'N;=%8W_"5:)_T$$_[Y;_"C_A*M$_Z""?\ ?+?X4>VI
M_P R^\.>/<V:*QO^$JT3_H()_P!\M_A1_P )5HG_ $$$_P"^6_PH]M3_ )E]
MX<\>YLT5C_\ "5:)_P!!!/\ OEO\*?\ \)+HW_01A_,T>UI_S+[PYX]S5HK*
M_P"$ET;_ *",/YFC_A)=&_Z",/YFG[6'=!SQ[FK165_PDNC?]!&'\S1_PDNC
M?]!&'\S1[6'=!SQ[FK168OB+1V&1J-O^+XJ:#6--N9EA@OH))&^ZBN"30JD'
MLQ\R[EVBBBK&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\P?LX_P#)0]0_[!4G
M_HV*OI^OF#]G'_DH>H?]@J3_ -&Q5]/T <1\0_N:=]9/_9:X&71]<N\36-J[
MPMT99 .G!ZGUKOOB']S3OK)_[+2^'/\ D!P?5O\ T(UYDTGB97[?Y'*U^]9R
MUCX4U/RF:\#AF(*K'.ORC'?(/-6AX4N .?M!/KYZ?_$UVE%:\D>Q=D<6?"EQ
MQC[0.?\ GNG_ ,31_P (I/Z7'_?]/_B:[2BCDCV"R.+'A2X!/_'QCT\Y./\
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M 4444 %%%% 'S!^SC_R4/4/^P5)_Z-BKZ?KY@_9Q_P"2AZA_V"I/_1L5?3]
M'$_$/_5Z?]9/_9:/#G_(#@^K?^A&CXA_ZO3_ *R?^RT>'/\ D!P?5O\ T(UY
MLO\ >9>G^1RO^*S5HHHK8T"BBB@ HHHH P_&'_(IW_\ N+_Z$*U;+_CPM_\
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MUR,A;.-N!G\:T:Y_Q'#?F\TN[L;,W36TC,R!PO48ZFF?VWK_ /T+3_\ @2M
M'1T5SG]MZ_\ ]"T__@2M']MZ_P#]"T__ ($K0!KZK>G3=*N;P(',*%MI.,U-
M9SFZLK>X*[3+&K[<],C-<CKNK:U-H=Y'/H#P1-&0TIN%.T>N*ZC2?^0-8_\
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MCXA_ZO3_ *R?^RT>'/\ D!P?5O\ T(UYLO\ >9>G^1RO^*S5HHHK8T"BBB@
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MXT :'VZT_P"?J#_OX*/MUI_S]0?]_!6>?"FA$8_LR']?\:/^$5T+_H&0?D:
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MB@ HHHH **** .=UC_D:]"^LO_H-=%7.ZQ_R-6A?63_T&NBH **** "BBB@
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M''PH'[Z/M_M"NDKG?&W_ "+C#_IM'_Z$* -\1I@?(OY4OEI_<7\J4?='TI:
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MZ_Y&<OCB>I4445ZAU!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M  F^@?\ /X?^_3?X5M?8;3_GU@_[]BC[#:?\^L'_ '[% &+_ ,)OH'_/X?\
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MA7BM:J%_K6G:9*L5Y=)"[+N4-GD4 9G_  A>E#HUW_W_ #2_\(9I?_/2\_\
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M%%% !1110 5C^*O^17U#_KD?YUL5C^*O^17U#_KD?YT 7M,_Y!5G_P!<$_\
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M"NF2W=Y>;]6U&)DF.(XI0%"D9& 1T_PITOAI;B-HKC5M3FA;AXWF&&'H?EH
MV8I4FA26,Y1U#*?4&GTR*)((8XHQA(U"J,]AQ3Z "F3?ZB3_ '3_ "I],F_U
M$G^Z?Y4 <M\/0!X?F Z?:6[_ .RM=97#^!]5T^QT)X;N]@@D\]CLD<*<8'-=
M-_PD&CGIJ=I_W]% &E7'^*?^1I\.?]=C_P"A+6]_PD&CCKJ=I_W]%<SKVH6E
M_P"*/#YL[J*<)/\ -Y;AMN67&<4 =Q1110 4444 %%%% !17)^-!<RRZ3;6T
M\D333E#L<KG@=Z+7PM'<VZRQZSJ>&ZAI>5/<'W% '645S!\'9_YC.I?A+2?\
M(<H&3K6I\?\ 3:@";1O^1JU[_>C_ /0:Z*N TJS.G^-;/R;FXD@N4D8-*Y)D
M 4@,?;TKOZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,
MCQ1_R+&H_P#7$U;TG_D#6.?^?>/_ -!%5/%'_(L:C_UQ-6]*_P"0/8_]>\?_
M *"* +E%%% '&WFCVFL^.;J&[#E$M$<;&V\YQ5W_ (071?[MQ_W^-.MO^2@7
MO_7BG_H0KHZ .:_X071?[MQ_W^-'_""Z-Z7/_?XUTM% '-?\(-HWI<_]_C1_
MP@VC>ES_ -_C72T4 <U_P@NC>ES_ -_C1_P@NB_W;G_O\:Z6B@#FO^$%T7^[
M<?\ ?XT?\(+HO]VX_P"_QKI:* .7F\$:-'!)(JW&Y5)'[X^E5_!G_(S6_P#N
MO_Z":ZJ[_P"/.?\ ZYM_*N5\&?\ (S6_^Z__ *":YZG\6'J9R^.)ZC1117J'
M4%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M**;8$@$YQFE.G^)B?^0Y;@?]>@KH** .>_L[Q-_T';?_ ,!!2BP\3=];MO\
MP%%=!10!@?8/$G_0:M__  %%2Z!=7TTFH6]_.D\EM/Y8=4"@C:#T_&MJN4L-
M9T[3=8UJ.]NXX7>Z#*&[C:* .KHK'_X2K0O^@G!^9H_X2K0O^@E!^9H V**Q
M_P#A*]"_Z"<'YFD_X2O0O^@G#^O^% #O%'_(L:C_ -<35O2?^0-8_P#7O'_Z
M"*P/$'B/1[O0+V""_BDEDB(51G)-;^D_\@:Q_P"O>/\ ]!% %RLS4QK1F3^S
M&LQ%M^?SPQ.?;%:=(6 ZD#ZF@# TK2]4CUZ?4]1DMF,D BQ"".A![UT%(&!Z
M$'Z&EH **** "BBB@ HHHH **** (;K_ (])O^N;?RKE_!7_ ",L7_7-_P"5
M=3=?\>DW_7-OY5RW@K_D98O^N;_RKGG_ !8>IG+XXGI]%%%>H=04444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH S='U:#5/&=A]F$@@ABD2,2#Y@"I./P[5Z%7E?A!1'XSB1?N+YJC\ :]4H
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MGZM*DMW$S.B[05D*\?@:TJ* .2TBQ@TWQQ>6ML&6$62L%+$\EAZUUM<W;?\
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MZY-_(US7@C_D8T_ZY/6$_P"- SE\<3TVBBBO3.H**** "BBB@ HHHH ****
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M%H 9JVNKI5_I]LUNTGVQRFX-C9R!^/6M>N!U;4IY]<TB;5M*DM(86=\;]Y?
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M+:/)J#Z]=1B+*R1&W3<K@X*_7- &7)9:]Y]E<1Z;=FYAD>2:9Y$W2%@%X],
M8JY(_B/[1$;?3K^.!<[D:Y5F.>N"?\BJMQ?Z_:6]PUSJ%W#)'$9(ED@0"3!
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M?^@"D_L"_P#^AAO_ ,E_PJ/PQ"]O=:S%),\[K= &1^K?*.M '14444 %%%%
M&1XH_P"18U#_ *XFK>E?\@>Q_P"O>/\ ]!%5/%'_ "+&H_\ 7$U;TK_D#V/_
M %[Q_P#H(H N5E:KK$VG31QQ:7>7@=<EH%R%]C6K10!RFBR75[XNNM0ETZZM
M(FM!&//0C)##O75T44 %%%% !1110 4444 %%%% %>__ .0=<_\ 7)OY&N<\
M##_BHA[0M_2NCO\ _D'7/_7)OY&N=\#?\C%_VQ;^E83_ (T#.7QQ/2Z***],
MZ@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7.*WHO"MK"\3I=768B&0-)N"D=.#QQ4NL:(VJ:GIER)0B6<A=E[MT(Q^5;-
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M]C_T 5NUA:#_ ,A37?\ K['_ * * -VBBB@ HHHH R/%'_(L:C_UQ-6])_Y
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M 4444 %%%% 'S!^SC_R4/4/^P5)_Z-BKZ?KY@_9Q_P"2AZA_V"I/_1L5?3]
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M7_T(5OUSWC;_ )%6Z^J?^A"@#?3_ %:_04ZFI]Q?I3J "BBB@ HHHH KW_\
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MM!K9I]-MFB(6XB17B8^N.A]CT-4?&7_(K7?_  #_ -"%;%G_ ,>5O_US7^5
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M)U:?\^%W^2_XUTLUO!< ">&.4#H'4'^=4[JTTVTMVE:PMB1PJB%<LW8#CJ:
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MR0>)K'9CYY-AR.QX->QT %%%% !1110 4444 %%%% !1110 4444 %86@_\
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M4 %%%% !1110 4444 %%%% !1110!\P?LX_\E#U#_L%2?^C8J^GZ^8/V<?\
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M1>/_ %WC_P#0JZ(=!7.^-O\ D7C_ -=X_P#T*NB'04 %%%% !1110!RVK_\
M(]:+_P!<W_K74UR^K?\ (]:+_P!<GKJ* .;\=?\ (KS?[Z_SJM(+C_A'UXN]
MOD+_  18Z#\:L>.^/"TW^^G\ZH.L/]A#Y+;/DKS]CDST'?I0!=U,7']ES[A=
M[=HSN2(#J.N.:/ 7_(?D_P"O=O\ T):KZ@L(TZ;:EL#M&"MG(IZCN>!5CP%_
MR'Y/^O=O_0EK"7\>!F_CB>D4445Z9U!1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M ?,'[./_ "4/4/\ L%2?^C8J^GZ^8/V<?^2AZA_V"I/_ $;%7T_0!R?C_P#Y
M MO_ -? _P#06KG=#T+3-3L&GO+1)I!(5#,3TP/\:Z+Q_P#\@6W_ .O@?^@M
M6=X4_P"02_\ UV/\A7FU/]Y^1S2_BCO^$2T'_H&Q?F?\:/\ A$M"_P"@=%^O
M^-;5%;%F*?".@D?\@Z+\S_C277A[3HK<S6>GPK<1$21E5P<J<\?E6W10!7:X
M2;3VGA?*M&64CZ5PO@F-8M;8H,%HB&]^$/\ ,FNSFTW)D-M</;F7.]0 RL3U
M.#W^E<WX>TATU/4!!=M&UI+Y ;8#N!5>>>A^6@#H=4BBOG@T^1%D5W$DJ'IL
M7GGZG J*3POHD@ ;38.#GY1C^5:%M:1VH8J6>1SEY'.6;ZG^E3T 8O\ PB.@
M_P#0-B_,_P"-8>H>'M*A\5:3:QV2+!,DID3)PV!Q7;5SFJ_\CIH?_7.;^5 %
MG_A$]"_Z!T7Z_P"-.3PKH<;%ETV')&.036Q10!DVMG::1JC);P)!#=( -HP"
MZYX^I!_2L'XBC.G6N>SL1]>/\:[">"*YA,4R!D/;^OL:Y/QGID@T"2X>\DE6
MWP41U&>6 Y;O0!K>%./#-H.R[P/8!S21:5I^JW-S?W-I%,)'"Q,ZYRJC&1[$
MYI=.T;RM.AMI+N22V W"( *#DY()')'-;( 50J@!0, #M0!C-X3T)F+'38LG
MT)']:/\ A$M"_P"@=%^9_P :VJ* .;\$J$T*15&%6YD 'XUTE<[X,_Y TW_7
MU+_.NBH **** "BBB@ IDW^HD_W3_*GTR;_42?[I_E0!X]X9N[FUURS-J5#R
M.(VW#A@3R/Y5ZQ'?,LRPW<)@D<X1MVY'/H#Z^QKR3PZ"-?TWG@W"8X_VA7L5
MQ!'<P/#*,HXP?;W'O0!D>+;F>T\/RRVTSPRAT =#@CFM"WT^WC9)BK22@</*
MY<CZ9Z5S7B6^CN/"#Q//$UTKJCH'&XLKX/'OBKJ^(=5"@?\ "-7G _YZ#_"@
M#I**YS_A(M5_Z%F\_P"_@_PH_P"$BU7_ *%J\_[^#_"@#HZ*YS_A(=4_Z%J\
M_P"_@_PH_P"$BU7_ *%J\_[^#_"@#HZ*YS_A(M5_Z%F\_P"_@_PH_P"$BU7_
M *%F\_[^#_"@"7QE_P BG??1?_0A6Q:?\><'_7-?Y5QGB36=0N_#]U#-H5S;
M1L%S*[@A?F'M79VG_'G!_P!<U_E0!1\Y-'D>.4D6KY>$_P!UNZ?CU'XBK%C!
M(H>YN!_I$W+#^X.R_A_/-5IH1K$SJ6*VT#?(R_Q2C^(?[I_7Z5;L;EYHVCF
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MA:<KJ&'V5^",^M &?XI\3:1J6BFWM;OS)3*C;=C#@')ZBMD>-?#^/^/_ /\
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M=04444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@4 %%%% !1110 4444 %%%% !1110 4444 %8>A?\A37/^OL?^@"MRL+0?\
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M/MEK_P _,/\ WV*Y$^$]=3_EQ;GTD0_R--_X1;7#_P N$G_?:_XT>UJ?R/\
MKY"YY?RG7_;+7_GYA_[^"L;QH0WA&\92""$((_WUK%?PMJ\4;2/I[!5!+'<O
M 'XT0>'M8O+2*:&TDD@E170[QAE(R#C-'M:G\C#GE_*=K;?\>L/^X/Y5+7%G
MP_X@C  M+@#T5P?Y&D_L/Q#_ ,^MW_WU_P#7H]M/^1ASR_E.UHKBO[#\0_\
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M ,A37?\ K['_ *"*W:P]"_Y"FN?]?8_] % &Y1110 4444 9'BC_ )%C4?\
MKB:@\):LNJZ,NV$Q_9ML!RV=V%'-3^*/^18U'_KB:D\/V=O9Z+:BWB6/S8DD
M?'\3%1DT :=<GKEZUAXQL)UM9KDBU<>7",MUKK*YV[_Y'S3_ /KTD_G0!C:Q
MJ=_>W^GW=KHU]&]H78;XNI8 #\.*DT[6M4COY+R_T>\>5X1%^ZBP."3_ %KM
MZ* .=_X2B;_H!:E_W[IDOB_[/$TL^CW\4:]6=0!_^NNEKG?&W_(MO_UVC_\
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M55^I[4EQX@2WN)(3IFJR%&V[X[1F5O<'N*V** ,V]UE;)XU-AJ$V]-V8+9G
M]CCH?:A]85-.2\^P:@0[;?*%LQD'N5Z@5I44 9MMK*W4%Q*+#4(_)7<5EMF5
MG]E'<TRSUQ+RZ2 :=J<);/SS6K(@X[DUJT4 8TGB%(YFB_LO5FVMMW+9L5/N
M#Z5+J&LK92F$V&H3$IG?!;,Z\^X[UJ4V0XB<GL#0!Y-X<_Y#D'T;_P!!-=U7
M"^'/^0Y!]&_]!-=U7E87X#DI?"<[XV&?#$V/^>B?^A"D7QIHP4#S)N!_SQ:K
M/BF-)=#D210READ&HI?#GAZWM#/+IT(4*">N2?0<]:Z34;_PFNCXSOG_ ._#
M4@\;:,>CW'_?AJU-)LULM,A@\I8\ ML'1<DG'X9J[@>@_*@#G_\ A-='_OW'
M_?AJ/^$TT?\ OW'_ 'X:N@VCT'Y4;1Z#\J .?_X331_[]Q_WX:C_ (331_[]
MQ_WX:N@VCT'Y4;1Z#\J .?\ ^$TT?^_<?]^&H_X331_[]Q_WX:N@VCT'Y4;1
MZ#\J .?_ .$TT?\ OW'_ 'X:C_A--'_OW'_?AJZ#:/0?E1M'H/RH YCPK<QW
MFIZW<PY,<LZLNX8.,>E=17.^'QC7M?\ ^OA?_0:Z*@ HHHH **** "BBB@ H
MHHH **** "BBB@ K#T+_ )"FN?\ 7V/_ $ 5N5A:#_R%-=_Z^_\ V44 ;M%%
M% !1110!D>*/^18U'_KB:MZ3QHUC_P!>\?\ Z"*J>*/^18U'_KB:MZ5_R!['
M_KWC_P#010!<K,U/7]/TF>.&[D99)%W*%4GBM.J=YI.GZA(KWEI%.RC"EUS@
M4 8=UXHTJX>W:&5A/'*I4LN!@G# GTQ_*MS^U]-_Z"-I_P!_E_QJM_PC.B?]
M NV_[XH_X1K11TTRV_[XH L_VOIO_00M/^_R_P"-8'C#4+*XT!HX+RWED,T9
M"I*&/WAV!K7_ .$;T;_H&V__ 'Q2#PUHH.1IEMD=]E &H/NCZ4M%% !1110
M4444 5-4_P"03=_]<6_E6-X '_$[N#_T['_T):V=4_Y!-W_UQ;^58_@#_D-7
M'_7N?_0EK!_QX&;_ (B/1****],Z@HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /
MF#]G'_DH>H?]@J3_ -&Q5]/U\P?LX_\ )0]0_P"P5)_Z-BKZ?H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#Y@_9Q_Y*'J'_ &"I/_1L5?3]?,'[
M./\ R4/4/^P5)_Z-BKZ?H **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "F3?ZB3_=/\J?3)O]1)_NG^5)[ >3
M^'/^0Y!]&_\ 037=5PWAO_D-Q?[K?R-=S7EX7X#DI?"<[XW_ .18F_ZZ1_\
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MI_=^J_RQ5JYN$M;=YI,X4=!U)[ >YJ.]MFN(08R%GC.^)CV;_ ]#]:IV<_\
M:\ZSE2L-LQ78>\PX;/\ N]![T 6+6W>*WEEFP;B;YI,=N.%'L!Q7*>!M1\FS
MOH'CE=$GW+Y<1;J.<X^E=L_^K;Z&O/?!4<LD6H&.&:3]Z,^7/Y>.M &[XLU,
M?\(W=)'%.IDVH3)"P&"0#R:V]*_Y ]C_ ->\?_H(KE?%D4T?AV=GM[A%#)\S
MW6\?>';-=5I/_(&L?^O>/_T$4 7**** "BBB@ HHHH **** "BBB@ HHHH I
MZM_R"+O_ *Y-_*LGX?\ _(6NO^N'_LPK6U;_ )!%W_UR;^59/P__ .0M=?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!\P?LX_\E#U#_L%2?\ HV*OI^OF#]G'_DH>H?\ 8*D_]&Q5]/T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !4%X<6-P1VC;^53U!>_\>%Q_P!<F_E2>PGL>5^'/^0Y!]&_]!-=U7#^
M&@3K<1'96)_*NXKR\+\!RTOA"N?U_P#Y#6@?]?+?^@UT%<QXKM(;[4-$M;A2
MT4EPRL <<;:Z34Z7>O\ >'YT;U_O#\ZY[_A!M!_Y]I/^_P W^-'_  @V@_\
M/M)_W^;_ !H Z'>O]X?G1O7^\/SKGO\ A!M!_P"?:3_O\W^-+_P@^A#_ )=Y
M/^_S?XT =!O7^\/SHWK_ 'A^=8'_  A.A_\ /O)_W];_ !H_X0K1/^?>3_OZ
MU &_O7^\/SHWK_>'YU@?\(5HG_/O)_W];_&C_A"=#_Y]Y/\ OZW^- &_O7^\
M/SHWK_>'YUS_ /P@^A'_ )=Y/^_S?XTG_"#:#_S[2?\ ?YO\: ,6TUF:Q\=7
MEC%$CQW=TH=FSD<=J[VN6\*V<-CJ>M6T"XBBG4("<D#'K74T %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ*@#E_\ A![/_H(ZC_W^_P#K4?\ "#V?_01U'_O]_P#6KJ** .7_ .$'L_\
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M"\X_Z:1_^A"NBKG_ !I_R+,W^^G_ *$* -]?NCZ4M(OW%^E+0 4444 %%%%
M%#6O^0-=?[E9OP_0G5KJ3/"P8Q]6'^%:6M?\@:Z_W*H?#[_C_O/^N0_G6'_,
M1$S_ .7B._HHHKTSJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^5/@'>3V/CJ^
MEM],N]0<Z9(IBM6B5@/-B^8^8Z#'&.N>1QUKZ+_X2'5/^A,US_O]9?\ R17S
M=\#-7CT3QG?W4D;29TQT5 <9)EB/7\#7O/\ PL3_ *A?_DQ_]C6-3$4Z;M)D
M2J1B[-FQ_P )#JG_ $)FN?\ ?ZR_^2*/^$AU3_H3-<_[_67_ ,D5C_\ "Q/^
MH7_Y,?\ V-'_  L3_J%_^3'_ -C4?7*/\WYD^VAW-C_A(=4_Z$S7/^_UE_\
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MV3Q;_P!!/3_^_)_PH Z2BN;^R>+?^@GI_P#WY/\ A1]D\6_]!/3_ /OR?\*
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MA_.L/^8B)G_R\1W]%%%>F=04444 %%%% !1110 4444 %%%% !1110 4444
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M4[KPM;6VHV*WRW<DUMI6H!OL^HN@4A"?N;NB!7(W>:0&'< ]6HKY0TGQ_/\
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MI;2%D,KG=@CGC'7\:[&BB@#(TW3;BTUK5+N79Y5TZ-'M.3P,<UKT44 %%%%
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?&WPO_ .1EN?\
MKS;_ -#2OI3P[_R K;_@7_H1KYW^#NEW.K>*[V&T4/*FGO)M+ 9'F1COQWKW
M"/P[XIAC$<4<Z(.BK=* /_'J\ZLIQK.2BWH<T[J=['645RW]A>+/2Y_\"U_^
M*H_L+Q9Z7/\ X%K_ /%4O:3_ )&+FE_*SJ:*Y;^PO%GI<_\ @6O_ ,51_87B
MSTN?_ M?_BJ/:3_D8<TOY6=317+?V%XL]+G_ ,"U_P#BJ/["\6>ES_X%K_\
M%4>TG_(PYI?RLZFN:\ _\AV?_KV;_P!"6H_["\6>ES_X%K_\56OX0T#4=+U*
M:XO8!$AA**-ZL220>Q/I2CSSJQ?*U8%S2FM#J[VQL]3LY+._M(+NUDQOAGC#
MHV"",J>#R ?PK'_X03P?_P!"IH?_ (+H?_B:Z"BO3.HS],T+1]$\W^R=*L;#
MSL>9]EMTBWXSC.T#.,GKZFK%[8V>I6<EI?VL%U:R8WPSQAT;!R,J>#R ?PJQ
M10!B1^#/"T,<T<7AK1T29-DJK8Q 2+N#88;>1E5.#W /:G_\(GX<_L[^SO\
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M]BZ5_P! RS_[\+_A1_8NE?\ 0,L_^_"_X4?5:W\X>RGW/._^$LO_ /GE;?\
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M***[CH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#@FF_^2JZ"B@#G_L?C#_H.Z'_X)IO_ )*H^Q^,/^@[H?\ X)IO_DJN@HH
MY_['XP_Z#NA_^":;_P"2J/L?C#_H.Z'_ .":;_Y*KH** ,/2-(U&UUB^U35-
M0M;N>ZMX+=5M;1H%18FE8'#2.2293W'05N444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'S!^SC_R4/4/^P5)_
MZ-BKZ?KY@_9Q_P"2AZA_V"I/_1L5?3] !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% 'S!^SC_R4/4/^P5)_P"C8J^G
MZ^8/V<?^2AZA_P!@J3_T;%7T_0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 445SGC+2?$.L:5%;^'-<32+@2
M9DF,6\LF#P/3G% &U;:C8WDD\=K>6\\ENVV98I58QGGA@#P>#U]*P7^(O@Z/
M4?L#^(]/%QNV;?-&,_[W3]:\3^'&GWI\,?$ZP74DBO541M>2R;0Q!EW$L>F[
M!Y/K7-VOB'P-'\,)=/F\*3-KOEM&+X#(\TYQ)OSD 9'RXH ^LI+F"*V:YDFC
M2!5WF5F 4+ZYZ8K$TKQSX7UN_-CINN65S=#_ )9))RWTSU_"O$?$HU%/A/\
M#[PT^HAXM5N-D\D+[\IO&Q,]PH<#'JH]*V_BO\.M \+^!X=:\/VAL-0TV:(K
M/$YW."0,L2>3G!S0![;=7=M8VSW-W<16\"?>EE<(J]N2>!S4B.DL:R1LKHP#
M*RG((/0@U\Z?%:V\4:GX'MO$MYXA671KL6[IIJ1;-K,F<DCK@YZU[MX4_P"1
M0T;_ *\8?_0!0!-K.NZ7X>L/MVKWL5I;;PGF2'C<>@KGO^%K^!/^AELO_'O\
M*YK]H3_DFR_]?T7\FKB-*\3?!B/2;&*^\/R/>+!&L[BV8[I-HW'[WKF@#V\^
M-_#(736.LVV-3.+(Y/[[YMO''KQ4>K^/?"V@:@UAJNMVUK=(H9HG)R >1T%>
M3?$VRL=/\:_#FUTRW6WLDD!AB48"J94/3\:H^,)?#L/[0\C^*A"=)%JOF><C
M,N[ROEX SUQ0![+I7Q \)ZW?I8Z=KUG/=/\ <B#8+>PSC)]JT=<\1Z/X;M%N
MM9U&"RA=MJF5N6/H!U/X5\[^/CX$U:?1;'X=6R-KDEVNU[.-T '8'=CG.#QT
MP>:Z3XNZ3J5KXTT'Q'J6C2Z[HEK:K%=01[M@<%MQ('0'*GG@[<&@#U30?'_A
M;Q-=?9=)UFWN+G!(AY5R!UP& S^%07OQ*\&:?>S6=WXAM(KB!S'+&2<JPX(/
M%>/7=]X&\:Z]H=UX:N8/"^NVURA,<]N8DEY&%RGR[@1CMG.*[KXK>"_#<7@?
MQ!K::-:+J?E^:;E4PV\LN3]: .GLOB7X-U"^@LK3Q!:2W,\@CBC4MEV)P ..
MYKJZ\I^$7@WPY/X&T'6Y=&M6U-<R"Y*_/N#G!^HP*]6H YW6/'GA;P_J#6&J
MZU;6MTJAC%)G(!Z'@57LOB5X-U&^@LK3Q!:2W,[B.*-2<NQ. !QW->.?$.\\
M/V'Q[^T>*+4W.E+9()(@A;)*';QD=\5UG@>]^%'B#Q-!!X>T#RM2@'VF*1[<
MJ$*D<YW'G.* /3-,\2Z-K-]>6.G:C#<W-DVVXCC/,9R1S^(-:M>(?!G_ )*5
MX\_Z[_\ M5Z[SXJ^(+KPU\.M4O[)BER56&-P<%"[!=P]P": +.L?$GPAH-\U
MCJ.NVT=RAP\:Y<H??:#BMO2-:TS7K%;W2KZ"\MF./,B;(!]#Z'V->:?#+X8^
M&G\#V.HZKID.H7^H1>?++<C?@-R /3COUS6#IUG'\-OCY;:-I4LB:-K4.]K4
MDL$)#8Q]&7@^C$4 >OZ]XKT'PQ$DFM:I;V?F?<61OF;Z*.34'A_QOX:\42-%
MH^KV]S,HW&($JX'KM.#7D/PX\/VOQ+\7^(O%7B:,7J0W'DV]M(Q*)UP,>@7
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MV*OI^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !4%Y;F[M);<3S0;QCS8&VNON#4]% 'E&F:[K>G^'O"5^
MD^I:S<ZC=RBXM_,CW2*(Y, ;MH &T-U[4R+7-=U>\T2&1]7A^UW>HK/;VLT4
M<D*I,JKO8\$("1P3GWKTN'1=-MX[..&RA1+)BULJKQ$2""5],@G\ZIWWA#P]
MJ:1I>:3;3+'))*FY>C.<N>/4\F@#6MXO(MHX?-DEV*%\R0Y9L=R>YKR76_&^
MO>'/$-]:2/+/;:9<2S7#NH^>&=1]F48'\+DK]%KUNW@BM;>.W@0)%$H1%'0
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M#/'I6C#8VMO=W-U# B7%R5,TBC!DVC"Y]<#B@"Q1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
9110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>exhibit102image1801b.jpg
<TEXT>
begin 644 exhibit102image1801b.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +0 [P# 2(  A$! Q$!_\0
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M^RJ"]\,?8[&XN?MF_P F-GV^5C.!G&<T?6,3_*OZ^8>TJ]CM/^$PT'_G^_\
M(+__ !-'_"8:#_S_ '_D%_\ XFN(TSPY_:.F6UY]K\OSHP^SR\XSVSFK7_"'
M_P#3]_Y!_P#LJ/K&)_E7]?,/:5>QUO\ PF&@_P#/]_Y!?_XFC_A,-!_Y_O\
MR"__ ,37)?\ "'_]/W_D'_[*C_A#_P#I^_\ (/\ ]E1]8Q/\J_KYA[2KV.M_
MX3#0?^?[_P @O_\ $T?\)AH/_/\ ?^07_P#B:X&UT3[3K-]I_P!HV_90A\S9
MG=N]L\5H_P#"'_\ 3]_Y!_\ LJ/K&)_E7]?,/:5>QUO_  F&@_\ /]_Y!?\
M^)H_X3#0?^?[_P @O_\ $UR7_"'_ /3]_P"0?_LJ/^$/_P"G[_R#_P#94?6,
M3_*OZ^8>TJ]CK?\ A,-!_P"?[_R"_P#\31_PF&@_\_W_ )!?_P")KDO^$/\
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M-QGS86E\S9TQVQG^M:/_  A__3]_Y!_^RH^L8G^5?U\P]I5['6_\)AH/_/\
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M2_X0_P#Z?O\ R#_]E1_PA_\ T_?^0?\ [*CZQB?Y5_7S#VE7L=;_ ,)AH/\
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M^07_ /B:/^$PT'_G^_\ (+__ !-<E_PA_P#T_?\ D'_[*C_A#_\ I^_\@_\
MV5'UC$_RK^OF'M*O8ZW_ (3#0?\ G^_\@O\ _$T?\)AH/_/]_P"07_\ B:Y+
M_A#_ /I^_P#(/_V5'_"'_P#3]_Y!_P#LJ/K&)_E7]?,/:5>QUO\ PF&@_P#/
M]_Y!?_XFC_A,-!_Y_O\ R"__ ,37)?\ "'_]/W_D'_[*JMQX4ODE MI()8\<
ML[%"#],'^='UC$_RK^OF'M*O8[?_ (3#0?\ G^_\@O\ _$T?\)AH/_/]_P"0
M7_\ B:Y+_A#_ /I^_P#(/_V5'_"'_P#3]_Y!_P#LJ/K&)_E7]?,/:5>QUO\
MPF&@_P#/]_Y!?_XFC_A,-!_Y_O\ R"__ ,37)?\ "'_]/W_D'_[*C_A#_P#I
M^_\ (/\ ]E1]8Q/\J_KYA[2KV.M_X3#0?^?[_P @O_\ $T?\)AH/_/\ ?^07
M_P#B:Y+_ (0__I^_\@__ &5'_"'_ /3]_P"0?_LJ/K&)_E7]?,/:5>QUO_"8
M:#_S_?\ D%__ (FC_A,-!_Y_O_(+_P#Q-<E_PA__ $_?^0?_ +*H;GPE=(@-
MK<12MW$@*?RS1]8Q/\J_KYA[2KV.S_X3#0?^?[_R"_\ \31_PF&@_P#/]_Y!
M?_XFO/;CP[JMM;R3R+9[47)Q.W_Q%:B^$"44F]P2.1Y73]:/K&)_E7]?,/:5
M>QUW_"8:#_S_ '_D%_\ XFC_ (3#0?\ G^_\@O\ _$UR7_"'_P#3]_Y!_P#L
MJ/\ A#_^G[_R#_\ 94?6,3_*OZ^8>TJ]CK?^$PT'_G^_\@O_ /$T?\)AH/\
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M^@EI_P#WY/\ A71T4 <Y]D\6_P#02T__ +\G_"C[)XM_Z"6G_P#?D_X5T=%
M'+W,?BRVM9IVU&P*Q(7($)R<#/I46G-XJU'3H+R/4+%4F7< T)R/TKH=5_Y
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M*/M]G_S]P?\ ?P5CQ^"]"$:A[$%@!D[VY/YT'P5H!.?L6/I(W^- &Q]OL_\
MG[@_[^"C[?9_\_<'_?P5C_\ "$Z#_P ^9_[^-_C1_P (3H/_ #YG_OXW^- &
MQ]OL_P#G[@_[^"JMP=.GD$HO8XI@,"6.8!L>A]1]:H_\(3H/_/F?^_C?XT?\
M(3H/_/F?^_C?XT 1C69+;Q%;V4FHV\UK)"SLYV@@CH,@XK:_M*P_Y_;;_OZO
M^-9/_"$Z#_SYG_OXW^-'_"$Z#_SYG_OXW^- &M_:5A_S^VW_ ']7_&C^TK#_
M )_;;_OZO^-9/_"$Z#_SYG_OXW^-'_"$Z#_SYG_OXW^- &M_:5A_S^VW_?U?
M\:/[2L/^?VV_[^K_ (UD_P#"$Z#_ ,^9_P"_C?XT?\(3H/\ SYG_ +^-_C0!
M'+<0W'CC3S#-'*!:R E&#8Y]JZ2N1@TBRT?QI8QV47EK);2,PW$Y/XUUU !1
M110 4444 %%%% !1110!3U7_ ) ][_UP?_T$U4\+_P#(LZ?_ -<A_.K>J_\
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MPET?_0)U/_P'-'_"71_] K4O^_!H Z.BN=_X2Z/_ *!6I?\ ?@T?\);%_P!
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MG'%+@C<I.<&M*@ HHHH **** "L'Q9_R"HO^NX_]!:MZL'Q9_P @J+_KN/\
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M!S7A;_D):]_U^'^M=+7,^%?^0EK_ /U^G^M=-0 4444 %%%% !1110 4444
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MNK#?PHFM+X$%%%%;F@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M2.Q?Q:S'JU]G_P B5W5<)_S-7_;[_P"SUW=>50WEZG)3ZA11172:A1110 44
M44 %%%% !1110 4444 <WXE94U707=@JB[)))P!Q71JP90RD%2,@CO7#_$D,
M;.PP1MWOG\A73:/<P)H=@&FB&+5"<N.!M% &G147VF#.//CX('WQU/2C[5;_
M //>+O\ QCMU_*@"6BH?M5OC/GQ8P#G>.AZ&E^TP9QYT>=VW&\=?3ZT 2T5#
M]JM\9^T18P3G>.@ZFE^U6_/[^+C&?G'?I^= $M1275O"VV6>)&QG#. :/M,!
M.//CSDC[XZCK7(>,?[*$EM=2):2S2*06D#OE1T^X?<T 7]/DCE\=ZD\;JZFU
MCY4Y'45TM<%X(,+:_>FW6)8_LZ\1JP&<C^]S7>T %%%% ',^%?\ D):__P!?
MI_K735Y3<VVN7&MZK_90N?+6Y</Y+[><G&>:]1M@XM81)GS BALGG..: ):*
M** "BBB@ HHHH **** "BBB@ HHHH Y^[_Y'G3_^O23^==!7">-8[Z37]/73
MQ,9_);_4G#8SS7<QY\I,YSM&<T .HHHH **** "BBB@ HHHH **** "BBB@
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M0EK_ /U^G^M=-7,^%O\ D):]_P!?A_K734 %%%% !1110 4444 %%%% !02
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MOEO_ $%:ZFN5\ G_ (D4WM<M_P"@K755U8;^%$VI? @HHHK<L**** "BBB@
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M_M.P_P"?ZV_[^K_C6#9>)])@21IIG^T2R,TA$9/?@9] ,"KO_"(:!_T#8_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 >3W'_(Y2_P#80/\ Z,KMZXBX_P"1
MRE_["!_]&5V]>50WEZG)3ZA11172:A1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !112$A02Q  ZDT <[9_\C[J7_7I'_2NCKF=/ECE\=ZD
MT;JZ_98^5.1VKIJ "BBB@#GO"XQ/K7O?O70UR6AZMI]A=ZQ'=WD,#F^<A9'
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M-#%;HZ;D4$$_05O4 %%%% '$^'%9O&FIG:<(9021ZN,?R-=%K-Q'IZ0:C)N
MAD"N5&24;@C'?G!_"M3 ]*JZC<M:6$LZJK,H& W3DXYH XOQ+KNFZY#8VD,D
MJ_Z4I=GC*[5(()Y^M=B-5TX +]OMN./]:O\ C7#>*YG7Q/IKW;P!(@C,T6<
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MU&V+F)U"^8,YP>*?X3(;PMIY!S^[Q^IH V:*** "BBB@ HHHH **** "N?\
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M/^OAOY+745UX?^%'T-J?P(****V+"BBB@ HHHH **** "BBB@ HHHH ****
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M****V+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV$#Z.W^-;]% '/?\(3H/_/F?^_C?XT?\(3H/_/F?^_C?XUT-% '/?\(3H/\
MSYG_ +^-_C1_PA.@_P#/F?\ OXW^-=#10!SW_"$Z#_SYG_OXW^-9\WP\T]YW
M>&YEB1CD(5#;?H:[&LT:S!+<3P6T4\\L#[) B<!O3)P* .6N? =I:B)OM32%
MY50(8P-V3SS],UM?\(3H/_/F?^_C?XUJ06\TMP+N[VAU!$42G(CSU.>[5=H
MY[_A"-!_Y\S_ -_&_P :S-:\/Z;I%M'-90&-W?:QW$\8SWKM*Y_Q;_QX0?\
M77^AK*M_#9%3X6;/@/\ Y $G_7PW\EKJ*Y?P'_R )/\ KX;^2UU%=>'_ (4?
M0VI_ @HHHK8L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /)[C_D<
MI?\ L('_ -&5V]<1<?\ (Y2_]A _^C*[>O*H;R]3DI]0HHHKI-0HHHH ****
M "BBB@ HHHH **** .+\8,%U%LD#.FS 9/4Y%=#H]U;KHE@#/$"+>/(+C^Z*
M74]!TW6)(WOK?S6C&%.]EP/P-4?^$)\/_P#/B?\ OZ_^- %Z[N-%A'G74EBN
MXXWOMY-<O]OT3[*!YUEN^SJ.BYSYG\\5M?\ "$^'_P#GQ/\ W]?_ !H_X0GP
M_P#\^)_[^O\ XT 93:AH7G-B>QQYTQ_AZ;./UIL5_H8";I[+@6N?N]C\W_UZ
MU_\ A"M _P"?$_\ ?U_\:7_A"] _Y\C_ -_7_P : ,=M0T/R6 GL<^5< <+U
M+_+^G2GRW?AZ:;9)/8F,W*$@%0"HCY_#-:O_  A>@?\ /D?^_K_XUES_  _M
M_M$CV\L8B8Y6.5&;9[ AA^M $&G75M<>*-#6VFCD$=HZL$.=IP>*[JN0L_",
MNDW'VRVN;2*1%/SF%S@8YZO73:=)-+IUO)<$&9XPS;1@9/M0!9HHHH **HZI
M<75O!$;-8C+)*J9ESM .?3WP/QJIGQ'_ '=,_-Z ,CQ;KFFWGA^ZM;:[22X+
M* @!SPPS_(UD0S7$-RMQ9ZII0B98V6.:<9#! N2/48-7;?X?>==RS:A< *Y+
M!("<Y)]2.E6_^%=Z3_SVNO\ OH?X4 4H_$6L2RRQC4](4QD EG #?0]ZQ==C
MNKQ);N>_TR1MOS)!."6.1R%'>NH_X5YI7_/Q=_\ ?8_PK-N_ :'4?L]G<E5$
M0DS,Q)/)!QCTX_.@#%\.Z\ND65S"UW/"S,&01Q*P)[YW#TK</C2V\SC5+[9Y
MN/\ CWCSLV_[O7/Z5$?AU<GK=P'_ +ZJU!\.8Q$OFZ@_F=]D?'ZF@"$>,XM@
MSJ=YNV-G]Q'C=GY>W3'6JVI>*H[O3;NW34;EVDB545XHP"3][) Z>E:;?#R'
M:=NI2[L<9C&,UFIX$NY;F:#[?#F+;D[&YR/K0!237+:TMXQ:F%Y7BC67SX58
M*ZJ%.#GI@9^HJ[=>(-(2SL4LY&>6TC,>)H RN"!DX)X.1FI/^%<7).3?6_\
MW[;_ !I1\.KH?\OMK_WZ/^- &--KL:-9WEN8C>I.TTB^7MB4[0H  Z\"KX^(
M6J]TLOP1O\:M_P#"O+K_ )_+7_OR?\:0_#JZ/_+[;?\ ?H_XT 9EYXVU&\CV
MO'9 C[KA&W+].:CM/&%]:6/V18K%XR,/O1B6[<\^G%:O_"N+G_G^M_\ OVW^
M-+_PKBX_Y_;?_OVW^- ''R3^;=M=2N'D9MQPQ_J*]MM91/:0S*"%D16 /;(K
MSN[^'\]K:R3&\@(4= C?XUZ):0&VLX("VXQQJF?7 Q0!-1110 4444 %%%%
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MS,9_*@#NB0H))P!R2:J?VMIWE^9]OM=F,Y\U>GYT:G-LM&A3F:<&*-?4GO\
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M_DHMO_V#S_Z$: .DHHHH *Y:^LUO?&T<9D>,I:B163&05<$=:ZFN>_YGX?\
M7@?_ $*@#8M[&*"0REGEF(P99&RV/0=@/I5FBB@ HHHH *XO1[Z6V\4:]$JJ
M\9EW;6D5,')&>:[2N"L 3XMUS"D_/VMO-[G\J -99 /$+WAC#3>4"%,\>U0>
M.#Z\5B:MK.KR^+8K.TOA:(X7"EPZ X[UK!#_ &JXV-_J%_YAW^T>U<Y>@_\
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M -]BL=_".A"-B+!<@'^-O\:K6'AG0)M.M9)+2,N\*,Q,AY) SWH Z'[9:_\
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M-?\ CPOO^O:/_P!&BNIM_P#CVB_W!_*@"2BBB@ HHHH **** "BBB@ HHHH
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M0?AT;]*X^;1;/3_$&@>78M;FXD;S897\SIC'J.]=W_9UE_SYV_\ WZ7_  H
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M\3S#_I@Q_5:]-H IZI8+JFF3V32&,2KC<!G'-4X[/6XXUC74;7:H"C-L>W_
MJT[FYAM+=Y[B18XD&69N@JI_:1N%Q8P/,S#B1E*QCW)/7Z"@!NGO?"^N(+NX
MAF6-$(,<6S!.>.I[ ?G6E5>TMOLT1#.9)7;?)(1]YO\ #VJQ0 4444 %%%%
M!1110!RGB/\ Y&WPY_UT?_V6NKKE?$7_ "-OAW_??_V6NJH P/&?'A:Z/NG_
M *$*V[?_ (]HO]P?RK#\;?\ (IW?U3_T,5N6_P#Q[1?[@_E0!)1110 4444
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MYWU2JF^61S>QFGHSS[_A++[_ )XVW_?+?XT?\)9??\\;;_OEO\:]!_L#2/\
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M8G_"4Z?_ '9_^^!_C3AXGTXC.Z4>Q2M/:P[E\\>YLT5CCQ-II/,D@^J&G?\
M"2:9_P ]F_[]FCVL.X<\>YK45E_\)%I7_/U_Y#;_  IPU_2V&1=C\48?TI^T
MAW0<T>YI45G#7=,)Q]K3\0?\*=_;6F_\_D?YT<\>X<R[E^BJ0U?3B,_;(?\
MOL4X:II[=+VW_&0"GS1[CNBW3)?]4_\ NFH/[2L?^?VV_P"_J_XT27MH8G N
MH?NG_EH*.9=PNCSKP#G_ (2>7_K@^/\ OH5Z?7F?@-'7Q+)N1E_<OU&/XEKT
MRF,Q?%G_ "*U_P#]<Q_,5J6?_'E;_P#7-?Y5E^+/^16O_P#KF/YBM2S_ ./*
M#_KFO\J8$U%%% !1110 4444 %%%% !1110!SM[_ ,CUI?\ U[2UT5<[>_\
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MF?\ ?3?XUTU% '+Z=I^MR^)8]3U2.U14MS"!"Q]<]_K74444 %%%% !1110
M5SOB[_CUMO\ ?/\ *NBKG?%W_'K;?[Y_E6-?^&R*GPLW/ G_ "+[?]=V_D*Z
M>N:\"_\ (O?]MF_I72UV8?\ A1]#:G\""BBBMBPHHHH **** "BBB@ HHHH
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M7^5=!J34444 %%%% !1110 4444 %%%% '.WW_(]:7_U[2UT5<[??\CUI?\
MU[2UT5 !1110 4444 %%%% !1110 4444 %%%% !7/\ C XTFW_Z^XOYUT%8
M'B[_ )!5O_U^0_\ H5 &_1110 4444 %<W+_ ,E$M_\ L'G_ -"-=)7-R_\
M)0[?_L'G_P!"- '24444 <I<_P#"86\4TQN=-\N,%L!3G _"MCP_?2ZEH5I>
M3X\V526VC R"1_2K&I_\@J[_ .N+_P C6=X._P"13L/]UO\ T(T ;E%%% !1
M110 4444 %%%% !7.^+O^/6V_P!\_P JZ*N=\7?\>MM_OG^58U_X;(J?"S9\
M L6T&8$Y"W+ >WRJ:ZJN4\ ?\@.X_P"OIO\ T!*ZNNS#_P */H;4_@04445L
M6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 51UG_D!:
MA_U[2?\ H)J]5'6O^0%J'_7M)_Z":F?PL4MF>;^%S_Q./K&W]*[6N)\+_P#(
M8'_7-J[:O-PW\,YJ7PF-XK5F\,7RJI9B@P ,GJ*I6_C#3X[:*-H+W<J '_1S
MZ5TU%=!H<[_PF>F_\\+[_P !VH_X3+3?^>%[_P" [5T5% '._P#"9Z;_ ,\+
M[_P':C_A,]-_YX7W_@.:Z*B@#G?^$ST[_GA??^ YH_X3+3O^?>^_\!S7144
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *HZU_R M0_P"O:3_T$U>JCK7_ " M0_Z]
MI/\ T$U,_A8I;,\V\+_\A@?]<VKMJXKPO_R&!_US:NUKS<-_#.:E\)5U![V.
MS9M/BBEN,C"RMA2,\\UAKK6MV^L6%GJ%E:QQW;LH:-RQ&!DUTU<WKW_(S>'O
M^NLG_H(KH-#I**** "BBB@ HHHH **** "BBB@#G;W_D>M,_Z]I*Z*N=O?\
MD>M,_P"O:2NBH **** "BBB@ HHHH **** "BBB@ HHHH *YSQE-%'I=NKR(
MK&ZB(!."0#R:Z.N0\5V<%]X@T.WN%+Q2.ZLN2,CCTH Z/^U]-_Z"%K_W^7_&
MD_M?3?\ H(6O_?Y?\:Y1-'\+R3&)-)O-V2%R[+OP<97+<U9_X1?0O^@%??\
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M <[>_P#(]:7_ ->TE=%7.WW_ "/>E_\ 7M+714 %%%% !1110 4444 %%%%
M!1110 4444 %<OX@_P"1I\/C_IJW\JZBN7U__D:O#_\ UT?^E &OI\$5QI,<
M<T:R(2W##/\ $:=]CN;;FSN"4'_+&<EE_!NH_6H+&_@M["*,L7F);$48W-]X
M]AT_&I\7]U]XBSB/9<-(?QZ#]: &2:U;VF%U &T<]-YRK?[I'7]#3_/O;O\
MX]XA;Q'_ ):S#+'Z*/ZG\*EAT^VAW$1AW;[SR?,S?4FHSIWDG=8S-;GKY?WH
MS_P'M^&* '1:="L@EF+7$PZ22G./H.@_ 5AG_DI"_P#7E_6MG[=+;\7UN44?
M\MHOG3\>X_'\ZYR;4+2#X@I<RW,2P-9[5D+?*23TS0!V5%%% %/5O^0/>_\
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MQSGJ:]#B!6&-6^\% -<[=11Q>.=+$<:(#;2YVJ!FNEH **** "BBB@ HHHH
M**** "BBB@ HHHH *YOQ+I&J7]]876F21));;CF0]"<>U=)10!Y])H'BB)9)
M46P=R<L$506_05GBW\3LZJ+2+<SL@&U.HZC]*]1K$@_X_+?_ *_)_P#T%J .
M3L=+\3WL0E$=M'&RAE+A?F!^F:M/H/B2.-G9[/"@DX _PKL-(_Y UE_UP3^0
MJQ=?\>DW_7-OY4 <%INDZ_J=A%>07-BD<HRH=.1SCG I)/ VL3W2327-@-I&
M1&"H(!ST"]:ZCPC_ ,BM8_[A_F:VZ "BBB@"GJQ']CWO/_+!_P#T$UG^#O\
MD4[#_=;_ -"-5V\#Z,Y8E;CYCD_OC6Y8V4.G645I;@B*(84$Y- %BBBB@ HH
MHH **** "BBB@ KG?%W_ !ZVW^^?Y5T5<YXN_P"/6V_WS_*L:_\ #9%3X6;/
M@#_D!W'_ %]-_P"@)75UR_@- N@2').^X8_3A1_2NHKLP_\ "CZ&U/X$%%%%
M;%A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VO_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-$;>0E'&16G_ ,(SHG_0+MO^_8JE??\ (]:7_P!>TM=%0!E?\(SHG_0+MO\
MOV*/^$9T3_H%VW_?L5JT4 97_",Z)_T"[;_OV*/^$9T3_H%VW_?L5JT4 97_
M  C.B?\ 0+MO^_8H_P"$9T3_ *!=M_W[%:M% &5_PC.B?] NV_[]BC_A&=$_
MZ!=M_P!^Q6K10!S.O:!I%OH-]-#IUNDB0L594Y!IOA_0-)N?#]C--I]N\CQ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ K,\1?\B[?_ /7$UIUF>(O^1=O_ /KB:BI\#]"9?"SSOPO_ ,AL
M?]<F_F*[:N(\+_\ (<'_ %Q?^8KMZ\_#_P ,YZ7PD-U=V]E 9[F9(H@0"[G
M&:JP:[I5S.D$-_!)*YPJ*_)JW/;P741BN(4EC/)1U!!_ US&JV%I9^)_#YM;
M6&$M+)N\M N?E'7%;FAUE%%% !1110 4444 %%%% !1110!SM]_R/6E_]>TM
M=%7):_?C3?%VFW+033A;>0;(5W,<^U3_ /"91?\ 0'U;_P !_P#Z] '345S7
M_"8Q?] C5/\ P'_^O2?\)E%_T!]5_P# ?_Z] '345R\GC>WB0O)I.J(@ZLT
M 'XYKI()1/;QS*"%D0. >HR,T 24444 %%%% &7XD_Y%O4/^N#4WPQ_R+.G?
M]<13O$G_ "+>H_\ 7!OY4WPQ_P BSIW_ %Q% &M1110 4444 %%%% !1110
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M\\+C_B<@_P#3)A_+_"NVKBO"_P#R%Q_US:NUKS\/_#1STOA"N;U[_D9O#O\
MUUD_]!%=)7-Z]_R,WAW_ *ZR?^@BMS0Z2BBB@ HHHH **** "BBB@ HHHH Y
MV]_Y'K3/^O:2NBKG;W_D>M,_Z]I*Z*@ HHHH Q?%O_(JZA_US'\Q6CIW_(+M
M/^N*?^@BL[Q;_P BKJ'_ %S'\Q6CIW_(,M/^N*?^@B@"S1110 4444 9?B3_
M )%K4?\ K@W\J;X8_P"19T[_ *XBG>)/^1:U'_K@W\J;X8_Y%G3_ /KB* -:
MBBB@ HHHH **** "BBB@ K#_ .9Y;_L'+_Z,:MRL)7#>.90,_+IZ@_\ ?9/]
M: -VBBD)P"?04 9D&L?;X?,T^UFE5B0LD@V)P<'D\]?05;L[4VZ.TC^9/*VZ
M1\8R?;V'05E^$)1+X<AP"-LDBG/^^3_6MV@ HHHH YJ3_DHL/_8//_H5=+7.
M/_R4&(_].)_]"-='0 4444 %%%% !7-^+O\ CWM?]]OY5TE<WXN_X][7_?;^
M58U_X;(J?"S>\"1A/#[,"3OG9C[< ?TKIZYOP/\ \BZ/^NS?TKI*[:'\*/H;
M4_@04445J6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9FI>(]"T:=8-4
MUK3K&9UWK'=721,RYQD!B.,@UIUS]G_R4/6?^P58?^C;N@ _X3OP?_T->A_^
M#&'_ .*H_P"$[\'_ /0UZ'_X,8?_ (JL;5O&]Y::G<6UK;P>7"YC)E#$D@X/
M0CO5+_A/M5_Y][/_ +X;_P"*KE>,I)V,77@G8Z;_ (3OP?\ ]#7H?_@QA_\
MBJ/^$[\'_P#0UZ'_ .#&'_XJN9_X3[5?^?>S_P"^&_\ BJ/^$^U7_GWL_P#O
MAO\ XJE]=I![>!TW_"=^#_\ H:]#_P#!C#_\51_PG?@__H:]#_\ !C#_ /%5
MS/\ PGVJ_P#/O9_]\-_\51_PGVJ_\^]G_P!\-_\ %4?7:0>W@=-_PG?@_P#Z
M&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %5S/_"?:K_S[V?\ WPW_ ,51
M_P )]JO_ #[V?_?#?_%4?7:0>W@=-_PG?@__ *&O0_\ P8P__%4?\)WX/_Z&
MO0__  8P_P#Q5<T/'^J9YM[/'^XW_P 57;Z/J']JZ3;WNS89 <KG.""0?Y5I
M2Q$*KM$J%2,G9&;_ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__
M !5=!16YH<__ ,)WX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5=
M!10!S_\ PG?@_P#Z&O0__!C#_P#%4?\ "=^#_P#H:]#_ /!C#_\ %5T%% '/
M_P#"=^#_ /H:]#_\&,/_ ,51_P )WX/_ .AKT/\ \&,/_P 57044 <__ ,)W
MX/\ ^AKT/_P8P_\ Q5'_  G?@_\ Z&O0_P#P8P__ !5=!10!S_\ PG?@_P#Z
M&O0__!C#_P#%59L?%?AS5+M;33]?TJ[N7!*PV]Y'([8&3A02>E:]<_XA_P"0
MYX3_ .PJ_P#Z175 '04444 %%%% !65XE_Y%R^_ZY5JUE>)?^1<OO^N515^!
M^A,OA9Y]X7_Y"X_ZYM7:UQ7A?_D+C_KFU=K7GX?^&CGI?"%<WKW_ ",WAW_K
MK)_Z"*M>*[NXLO#T\]M*T4JE<..HY%9[^%;ZZDMKF7Q!<M+#\T3&)?D)'/>M
MS0ZJBN=_L#5O^AENO^_*TO\ 8.K?]#)=?]^E_P : .AHKGO[!U;_ *&2Y_[]
M+_C1_8.K?]#)<_\ ?I?\: .AHKGO[ U;_H9+K_OTO^-)_8&K?]#+=?\ ?E:
M.BHKG?[ U;_H9;K_ +\K1_8&K?\ 0RW7_?I: .BHKG?[ U;_ *&6Z_[]+1_8
M&K?]#+=?]^EH AU>ZALO&>FSW#[(Q;N"<$\DX' ]S716]W!=!O)E#%>&7H5^
MH/(K@-;LKFQ\0:>MUJ$MZS!2K2*%V_O%XXKN+^UWQFYA&VZB&Y''?'\)]0:
M+M%1P2B>WCF7@.H8?B*7S8_[Z_G0!D>+?^16O_\ KF/_ $(5HZ=_R#+3_KBG
M_H(K,\62(?"VH .I/ECO[BM/3O\ D%VG_7%/_010!9HKFO$4VH-K.E6-E>M:
M"Y\S>ZJ#T&1Q2_V'KW_0RR?^ ZT =)17-_V'KW_0RR?^ ZT?V'KW_0RR?^ Z
MT :'B3_D6M1_ZX-_*F^&/^19T[_KB*S;CPYK5U;R03>(G>*1=K*8%Y%/M?#V
MJVEK';PZXZQQKM4"(<"@#I:*P/['UK_H//\ ]^A1_8^M?]!Y_P#OT* -^BL#
M^Q]:_P"@\_\ WZ%.\)7-U=:,S7<[3RI.Z;VZD T ;M%8OBR[N;+P]//:2F.8
M,@5AU&6 -4TT77F16_X223D _P"H6@#IJ*YO^P]>_P"AED_\!UH_L/7O^AED
M_P# =: .DKGX?^1\N?\ KQ3_ -"J/^P]>_Z&63_P'6JVC6UU:>,KJ.\O3=R_
M8U/F%0O&[I@4 =;37^XWTIU(W*D#TH Y_P %?\BZO_7:3_T(UT-<=HTFOZ18
M?8QH32A79@_GH,Y.>F:T/[7U_P#Z%YO_  (6@#H:*Y>Z\1:S90B6;P^X4L%&
M)PQ)/3@<U4_X334O^A=N?_'O_B: +[G_ (N%$/\ IP/_ *$:Z2N-T:ZOM6\7
M+J,^FS6L:6IBRX.,YSU(KLJ "BBB@ HHHH *YOQ=_P >]K_OM_*NDKF_%W_'
MO:_[[?RK&O\ PV14^%G0^!_^1='_ %V;^E=)7-^!_P#D71_UV;^E=)7;0_A1
M]#:G\""BBBM2PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG[/_DH>L_]
M@JP_]&W==!7/V?\ R4/6?^P58?\ HV[H X+40&\470(!!O7!![_.:U?LEM_S
M[Q?]\"LN_P#^1INO^OU__0S6U7AQ6K]3@6[(?LEM_P ^\7_? H^R6W_/O%_W
MP*FHJ[(=B'[);?\ /O%_WP*/LEM_S[Q?]\"IJ*+(+$/V2V_Y]XO^^!1]DMO^
M?>+_ +X%344606,76(HXO)\N-$SNSM7&>E>@>#_^16LO^!_^AM7!:Y_RP_X%
M_2N]\'_\BM9?\#_]#:M<'_'?I_D71^-FY17">-?$NO:-K$-OI>M^"K&!K<.T
M>NW3Q3%MS#*A2!LP!@^H:N:_X3OQA_T-?PJ_\&,W_P 57J'6>P453TF>:ZT:
MQN+B6UFGEMXWDDLV+0NQ4$F,GDH3T/IBO)?VC+"S_P"$-L-0^R0?;?[0CA^T
M^6/,\ORY3LW==N><=,T >S45\M_&1KB?XD>)Q GVV.WT^W$YN5'^A(6A(,)+
M=V902 /];(,=6KF+N^^U:7KVN6]U?3746M67V._O)-UXD?EW.W,@Y#82/.#C
M*CT% 'V717C/A&PL]-_:3\46EA:06MM'I2;(8(PB+D6Q.%' R23^-<+XUTE?
M[9\7ZRXM/$>DKJ6+Z6.X:"_TUE8HD:F0'"$OLX616$?\)4;0#Z@HKYCL?CMK
M>FM;:/I=MI4>D6Q2UM9[^"4RK N%1I?+?E@H!;:O7.!VJV?VBO$,$=]"^FZ/
M<S*RK;7,"S)%@,=S%&.Y@1TY0CN#TH ^D:Y_Q#_R'/"?_85?_P!(KJO)M8^,
M7B[3-4M-(MW\&:A>3(TINK2\)M@O9"[R($<;6)RW(9  #U]-O+UM2?P+?/$D
M3W-[YS1QS+*JEK"Y. Z\.!G[PX/44 =91110 4444 %97B7_ )%R^_ZY5JUD
M^)SCPU?8_P">?]145?@EZ$S^%GG_ (7_ .0N/^N;5VM<7X5 .L,3VA;'YK7:
M5Y^'_AHYZ7PE:_L+?4[1K6Z3?"Q!*Y(Z'/:K  50!T P*6BMS0**** "BBB@
M HHHH **** "BBB@#/O-&L[Z_M[R=&::#&SYN.N>1]:T*** ,/\ X1+1]A7R
M9^?^GF3^6<57'@;10,;;C_O\:Z2B@#C]0\ 64\:K93RV[ _,78N&'YUU=M#]
MGM88<[O+14SZX&*EHH R[[2FN]:TV_$P5;3?E"/O;ACK6I110 4444 %%%%
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M%4?^$/U[_GQ_\C)_\57B\E2,G[K.'EDF]#2HK-_X0_7O^?'_ ,C)_P#%4?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/_;/&'_0"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R+7044 <_]L\8?] +0_\
MP<S?_(M'VSQA_P! +0__  <S?_(M=!10!S_VSQA_T M#_P#!S-_\BT?;/&'_
M $ M#_\ !S-_\BUT%% '/_;/&'_0"T/_ ,',W_R+1]L\8?\ 0"T/_P ',W_R
M+7044 <_]L\8?] +0_\ P<S?_(M5WM?$>IZSHT^H6&E6EK87;W+M;ZA).[9@
MEB"A3 @ZR@YSVKJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&.N17K4<:11K'&BI&@"JJC  '8"N1U_X7^#_ !)>F\U'1XS<LVYY86:,N?\
M:VD9H \S?4HOB=\=])NM&1IM)T1%:2ZP0K;26SSZL0!ZXS6=I?@K3/&_QI\9
M6>IR7,<<$CRH;>3:<[P.>/>O>]%T#2?#EC]CT>PALX,Y*Q+C<?4GJ3]:CL/#
M.C:9K-YK%G81PZA>_P#'Q.I.9.<\\XZB@#PG4_"=I\+_ (P>$Y=-N9);2_E$
M;?:]KE,L$;G'HP(/45]&5CZWX5T/Q'+:RZOIT5W):,6@9\@H3C.,'V'Y5L4
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MOX5>#/$%^;Z^T:,7+-N=X7:+S#_M!2 : /-],O1\2?C[!K.E!VT?1H@/M!3
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTNU>&*%)&B+N^-TC,A!)(R,=/F-:.F^$$TX>'P+^:9=%CFBB\Q1ET<;5!/\
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M7<EU-<-(2L_F9WKY9.U000,@9^45T?A^WU2UT.VAUJ\2[U%0WG3H@4-EB1P
M.@P/PH RM2\0ZM_;5YIVAZ5#>M80I-=&:X\HL7R5CCX(+8!.3@=*=<>,(+?Q
M?IN@26LBM>0%WE8\0R$$I&V.-S!7[_P]\T:KX6N;O5I]0TS6[G2Y+N)8;P0Q
MJ_FJN=I4M]QP"1N'MQQ6;>?#/3[W4+C5)-0OO[4>YBN(;GSFQ%Y>-B[,[6P
M1EAD[C0!V]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
/ %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exhibit102image1851a.jpg
<TEXT>
begin 644 exhibit102image1851a.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
M   !    2@,#  $    !     %$0  $    ! 0   %$1  0    !   .PU$2
M  0    !   .PP       8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,
M"PL,&1(3#Q0=&A\>'1H<'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T
M,O_; $,!"0D)# L,& T-&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,O_  !$( W@$E@,!(@ "$0$#$0'_
MQ  ?   !!0$! 0$! 0           0(#! 4&!P@)"@O_Q "U$  " 0,# @0#
M!04$!    7T! @, !!$%$B$Q008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*"
M"0H6%Q@9&B4F)R@I*C0U-C<X.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS
M='5V=WAY>H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$
MQ<;'R,G*TM/4U=;7V-G:X>+CY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$!
M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M?_[!UQ_Z+:K^E_\ ((LO^N"?^@BJ'C#_ )$C7_\ L'7'_HMJ *G@7_D7)/\
MK_O/_2B2K/C'_D4M0_W!_P"A"JW@7_D7)/\ K_O/_2B2M;6M,&L:/=:>9WM_
M/3:)4 )0YSG!!':@#,\%?\@.;_K^N?\ T:U=%7":1H7CO1+)K.'6-#N4\V27
MS9[*178LQ8Y"N .O:M+1+_Q'_P )--I>LRZ9/&EH)]]E"Z%&+X4'<QZ@-^5
M'4T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^&_^*H_X3K5/^>%G_P!\-_\ %4?VGA_/[@_LO$=E]YZ%17GO_"=:I_SPL_\
MOAO_ (J@^.M4Q_J+0?\  &_^*H_M/#^?W!_9>(\OO/0J*\\_X3G5?^>5K_WP
MW_Q5'_"<ZK_SRM?^^&_^*H_M.AYC_LK$>7WGH=%>>?\ "<ZK_P \K7_OAO\
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MINAR07QU/4[LWVI%"BR;-D<*GJL:9.T' R223@9.  -FOH#YT**** "BBB@
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MC_GF?_BJAN/!^L71C,_B)Y#$V]-T1^4^H^:@#LZ*Y/\ X1OQ!_T,\W_?L_\
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MBBOH#YT**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** .6\=_P#('M_^O@?^@M7-^%O^
M0E+_ -<3_,5T?CL_\2BW'K./_037.^%O^0A,?^F1_F*\/$_[ZOD>_A?]Q?S.
MLHHHKM. **** "BBB@ HHHH **** "BBB@ HHHH **** "BIH@"AR >?2I-J
M_P!T?E5*)+D5:*M;5_NC\J-J_P!T?E1RAS%6BK6U?[H_*C:O]T?E1RAS%6BK
M6U?[H_*C:O\ ='Y4<H<Q5HJUM7^Z/RHVK_='Y4<H<Q5HJUM7^Z/RHVK_ '1^
M5'*',5:*M;5_NC\J-J_W1^5'*',5:*DE #C QQ4=2RD%%%% !7(^/L?8]/S_
M ,_/'UP:ZZN0\>JSVNFJJEF-T, #)/!H ZU/N+]*=2)]Q?I2T %%%% !1110
M!RW@(8T.X_Z^W_DM=37+^!/^0)<?]?3?^@K744 %%%96KZ@UC+:IYXA64OEO
M*,AX&>@H A\7 GPK?X_N#_T(5B^!)5EGO64' BA7D8Y"XIOB+6!+X?NHUO\
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M% !1110 4444 %%%% !1110 4444 <GX\_Y!UK_UU/\ *L#PK_Q_3?\ 7/\
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M1GT% 'H7FQ_\]%_.CS8_[Z_G7+_\(!I7_/>[_P"_G_UJ/^$ TK_GM=_]_/\
MZU '4>;'_?7\ZY;X?_\ (&O/^OQ__05I?^$ TK_GM=_]_/\ ZU,^'JA=$NE'
M07CC_P =6@#KJ*** "BBB@#&\3?\@H?]=!_6N8T^.YFU&WCM+A;:Y:0".9H_
M,"-V.W(S],UT_B;_ )!0_P"N@_K7/Z%_R'K'_KNO\Z\[%?QX?UU/2PG\"?\
M70ZK^PO&_P#T.UI_X)5_^.U>\'7.IW>CS2:I>I>RK=RQI<) (@Z*VW[H)[AN
M].UO69#*VC:05EU:9<''*VJG_EI)Z8[#J3CZUJ:9I\.E:9;V%OGRX$" MU;U
M)]R<D^YKZ ^=+=%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '(^/?^/&S_ .NA_E6'
MX5_X_)_^N?\ 6MSQ[_QXV?\ UT/\JP_"O_'Y/_US_K7A5_\ ?OZ['OX?_</Z
M[G54445W' %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !6+X@U2ZTT62VHBW7$_E$RJ2
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MR."IZA@>Q!P0>Q%5/#5_/?Z'$UV<W<+/;W!QC<Z,5+>V<!OQKZ ^=->BBB@
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M^OYUR/@*>&/1[L22HI-XYPS ?PK0!V%%0_:[;_GXB_[[%'VNV_Y^(O\ OL4
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MX/YUL>/O]18_[S_R%8_A7_CYN/\ <'\Z\*M_OW]=CWZ'_(O_ *[G4T445W'
M%%%% !1110 4444 %%%% !1110 4444 ,E4O"ZCJ5(%>>Z)X-U>QUNTNYTA\
MN*3<Q63)Q7HM% !1110 4444 %%%% !1110 4444 %%%% !1110!2U>VDO-'
MO+:+'F2PLBY.!DC%<CX5\*ZGI.MK=W:Q",1LI*ODY-=W10 4444 %9NLZ);:
MW!%%<M(JQOO4H<'.,5I44 <O_P (+IO_ #\7G_?VC_A!=-_Y^+S_ +^UU%%
M'+_\(+IO_/Q>?]_:/^$%TW_GXO/^_M=110!R_P#P@NF_\_%Y_P!_:/\ A!=-
M_P"?B\_[^UU%% '+IX%TV)=L=S>(N<X67 JYI_A>TTZ]CNH[F[=TSA9)21R/
M2MRB@ K)UCP_;:T\;7$LZ>6" (WP#]:UJ* .0O\ P/;_ -G3+:SW+S;/W:/,
M=I/;-.\%Z#?:+]K^VQHOF;=NUL],UUM% !1110 4444 %%%% !1110 4444
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M?_?0H%U;D9$\1^CBL'_A"-#_ .>,O_?YO\:0>!M# _U4W7_GLU &_P#:(/\
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M )[1_P#?0KC?#?A?3=1T&WNKI)3,^[<5E8#AB.@/M6I_PA&B?\\9O^_S?XT
M;WVF#_GO'Q_MBGI(D@)1U8 X.TYQ7/?\(/H?_/&;_O\ -_C5C1K"WT>_N[&
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR8'/YYI?!UZ-1\0ZU=^68_-V'83DKUH [6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *P/&'_('B_Z^HO\ T*M^N8\>DCPQ(0<$2I@_C0!T<D23
MV[0RJ&C=2K*>X-4$N+C31Y-VLDT"_<N$&XX]' [^_>K6GDMIMJS$DF)22>_%
M6: //GF2?QS!+$2T;W>0V",_NQZUZ#7$ZW*$^(&F;Y L:KN.XX Z\UTO]I/<
M_+IUNTX_Y[-\D0^AZM^ Q[T 3W6GVUTWF2)ME4<3(=KK^([>W2LL:E=6\WDV
MV=54=2@VLGU;[I_2KO\ 9CW)W:A<-/\ ],D^2,?AU/XDU?2-(D"1HJ*.@48
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MS1R?*0$8=#SGFKW@W_D4K#_=;_T-JN:]_P @#4/^N#_RJGX-_P"12L/]UO\
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M*UMG5M-P?^)A:?\ ?Y?\:YOP)>6T.@.LUS#&WVACAW .,"@#L:*J_P!I6/\
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MW:I\_P CU2BBBO?/G0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XGQ_]^P^DG_LM
M9WA3_777^ZO]:T/'Q_?6(_V7_I6?X4_UUT?]E?ZUX53_ ']_UT/H*?\ R+U_
M74Z>BBBNX\\P&\%: [%FL26)R3YTG_Q5-_X0CP]_SX'_ +_2?_%5T-% '/\
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MJ -6BLG_ (2;1-P']I09/3YJ=_PD>C_]!&#_ +ZH U**J6>J6.H,ZVEU',R
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M_P#O\_\ C6]%_JD_W13Z .?_ .$*T'_GT?\ [_/_ (T?\(5H7_/H_P#W^?\
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MX_S-;*(L<:HHPJ@ #T%.HH *YGQY_P BV?\ KLO]:Z:N7\?_ /(LM_UV3^M
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MV7_7%?Y54\5_\BOJ'_7*K>C_ /(%LO\ KBO\J +U%%% !1110 4444 %%%%
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MW_GPMO\ OT*FM[*UM&9K>WBB+#!*(!F@">BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKF?'CNGAEV1V4^:
MG*G'K0!TNX>HK.U#$%U:WJ$!@XBD]T;_  .*BC\-Z.8D)L8\E1ZT]?#FD(ZN
MMC&&4A@>>"* -2BBB@ HHHH **** "BBB@ HHHH S-?_ .0+/_P'_P!"%8'A
MC_D9++_>/_H)K?U__D"W'_ ?_0A6#X6&?$MG_O-_Z":\^O\ [U#Y?F>EA_\
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M%% !7+V__)1;S_KT7^E=17+VW_)1;S_KT7^E '44444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7+?$#_
M )%AO^NR?UKJ:Y?Q_P#\BPW_ %V3^M '2Q?ZE/\ =%/ID7^I3_=%/H ****
M"BBB@ HHHH **** "BBB@#-U_P#Y MQ_P'_T(5@^%?\ D9;/ZM_Z":WM?_Y
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MR_,]*A_NE3Y_D>H4445[Y\Z%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'GWCL_\
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M>YV.48E=BAAV)/UJU:6DBS/=W3*]RXVX7[L:_P!T?U- &3_P@WA__GS?_O\
M/_C1_P (-X?_ .?-_P#O\_\ C71T4 <X? WA_'_'F_\ W^?_ !K"\(^&=*U7
M1VN+R%I)!,R@B1EXP..#[UWS_<;Z5RWP^Y\./G_GX?\ DM %G_A!] _Y]'_[
M_/\ XTG_  @V@?\ /H__ '^?_&NCHH YS_A!O#__ #YO_P!_G_QJ&[\$Z#%9
MSR):.&2-F!\YNH'UKJ:KW_\ R#KK_KDW\C0!P/ASPE8ZQH<=V[.D^]@><JV/
M4=?R(K4_X1+3;8_Z5H[R*/\ EK:SNWYH3D?ANJYX#_Y%>/\ ZZ-734 <I;^%
M_"UX2L,99E^\AG<,OU4G(_&JT?P^MXM66Y%RK6JR;A;/%N^7TR376W-E;7@'
MVB!'*_=8CYE^AZC\*J_8;NWYL[UBHZ17(WC\&^\/QS0 S_A'-%_Z!=I_WZ%'
M_".:+_T"[3_OT*)=6>Q3=J-JT*YQYL9WH3_/]*CANY=:S]GF^SVO<@_OF_#^
M ?7GZ4 5KC3-#CF-O;:/:W%UWC6, )[LW\(_7T!JO/X(L;N!O-$<,[$<V\85
M4'H!W^IYKI+>VAM(A%!&$3.<#N?4GN?>I: /,]9\(P:;?Z9;17+M]LF,;,T:
M_+TZ8^M:O_"N8/\ G_?_ +\K5[Q2,ZYX=]KD_P UKJ: .(_X5S!_T$'_ ._*
MT?\ "N8/^@@__?E:[>B@#B/^%<P?]!!_^_2T?\*Y@_Z"#_\ ?I:[>B@#B/\
MA7,'_00?_ORM'_"N8/\ G_?_ +\K7;T4 <1_PKF#_G_?_ORM'_"N8/\ G_?_
M +\K7;T4 <1_PKF#_G_?_ORM9$OA%5\2)I$=TN'A,OFO"#CVP"*].KEY?^2B
MP?\ 7FU &7_PKEO^@E%_X#?_ &5'_"N6_P"@E%_X#?\ V5=VSJBEG8*HZDG
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M\S:C?AI(E<@2+CD9]*E_X0"R_P"@CJ'_ '\7_"NATDYT>R/_ $P3_P!!%7*
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M7OGSI@?\)EH_KJ'_ (++G_XW1_PF6C^NH?\ @LN?_C=;]% &!_PF6C^NH?\
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M?U__ $%:ZB@ HHHH :_W&^E<O\/QCPZX_P"GAC^BUU#_ '&^E<QX!_Y%YO\
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M)#(DD;7)PR,"#RO<5UE<I:^!;6VU""\^WW4DD4@D&_!R0:ZN@ HHHH ****
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M7'_8[U_&6H0QKY=O-Y4WF-&Q&5QT/0'@UV%% !1110 5SGCC_D6W_P"NT?\
MZ%71US?CD@>&VR?^6T?_ *%0!TE%(K*PRI!'J#2T %%%% &5KL,2Z1<R+&@<
M[<L%&?O"L7PE_P C/9_\#_\ 0&K<U_\ Y EQ_P !_P#0A6)X2'_%36GMO_\
M0&KSZW^]T_E^9Z5#_<ZGS_(].HHHKWSYT**** "BBB@#$U!8(O%&D7+RNDCI
M- JA,A\A6Y.>,;3^=;=<YXQU*WT33[/6+N-#;V=VKRR,K,8T(92R@=^0._7I
M6W8W:WUC#=I'+&DR!U65-K@'ID'D'V/- %BBBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#SKQO_P AY?\
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M=HKF&.:,\E)%!'Y&@#'TRWT74+?=8S/+Y9 ,@=MXXZ9/.*T_[/A\Y)=\VY
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M_P#05L?_  (3_&@#0HK/_M[1_P#H*V/_ ($)_C1_;NC_ /05L?\ P(3_ !H
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M09/X57'@W0 H']G*>.N]O\:N6FFNEU]LO9_M%U@A2%VI&#V4=OKUK1H P?\
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M6!K&M-=EM52+5U7E XO(%+0L.G)['].>U:;6&GW:"3[/ ZMR'4#G\10 Q/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH \U\9?\C%+_N)_*I?#'^ND_P"N*_\ H;5%XQ.?$<WLB?RJ
M;PS_ *Y_^N*_^AM7@T_][G\_S/H:O^YP^7Y'24445WGG!1110 4444 %%%%
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M* %48 '84M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% #&AB=MS1HQ]2H--^SP?\\8_^^11<7$=K;O-,V$4<\?H/
M>J2KJ=VN\R)9(>B;-[_B>@- %QH+95+-#$ .22HXJAI\45S>S:@D2K$5$4!V
MXW $DM^)/'L!ZU(-)\S;]MNIKI1_ ^%0_4#K^/%:(  P!@"@ HHHH :45CDJ
M"1T)%.HHH **** "BBB@ HHHH **** "N:\=?\BO-_OK_.NEKF_'0)\,2@=3
M(@_6@"'2A-_9-GA=7QY*XV,FWIVR>E)I@F^Q#"ZO]]_N,F/O'WKH-+@>VTFT
M@E $D<*JP!SR!5;2+B!+#:TT8(D?@N/[QH \_P!*\P^.9U5;LOYDO",HE_$D
MXKJKI;G[;9?N]7SO;&Z2+/W3T^:IQX=T,:I)J'VAC-(S,P%QM&3UZ8/ZTZYT
M[36U"P2-F?<[9 N7)^Z?]J@"IJJSBR^=-2"[AS</&5_\=.:7P?\ \C)!_NO_
M .@FK6MZ7;6VFM+$L@96'WIG8?D3BJO@_P#Y&2#_ '7_ /037GU?][A\OS/1
MI?[G4^?Y'I=%%%>^?/!1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MHHKWSYX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MOPM7']*3JI.U@5%M7NCWBBO$9-)U[[*"NE7X? Y$,A/Y54_LOQ+_ - W4_\
MP&?_  IRJ*/04:;EU/>:PM5U.RM=8MXM0G$4,4?G*"I(=R2 >!VP?SKRJUTC
MQ \A$VG:F%QQ_HS]?R%1W&C^(//8)IFHLHZ'[*Y_I1[16O8/9OFY;GINN>)M
M'G\/ZE#%>JTDEK*BKL;DE2 .E<_\)O\ F+_]L?\ V>N,.C>(6!!TG42#P?\
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M_)1(O^O+^IKIJ "BBB@ KBOA\,#5#ZRJ?U:NUKBOA\<C5!Z2J/U:@#M:***
M"BBB@#*\3?\ (LZC_P!<&J#P?_R*UE_NG^=3^)O^19U'_K@U0>#_ /D5K+_=
M/\Z -RBBB@ HHHH **** "BBB@ HHHH **** "BBB@#)\1_\@=_]]?YUE^#?
M^1BB_P!Q_P"5:?B3_D$-_OK6;X,&?$4?M&W\J\^I_OD/E^9Z-/\ W*?S_(])
MHHHKWSYX**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)8V4UU(K,D2%R%ZG%<W#J.FPW,>K:M?V[7;Y6&.*0,L"D=.._J30!5.BZ_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /'
M]3XU*\QVF?\ F:J?#G6M2U#6KBWO+V::)+4E4=L@$,H_E5O5/^0E>_\ 79_Y
MFL7X6?\ (Q7?_7H?_0UKYS"_Q7ZGTV+_ (2]#UJBBBO4/)"BBB@ HHHH ***
M* "BBB@ HHHH *P_&0!\(:GG_GC_ %%;E9?B-XX_#FH-*/D$+9XS2>PXNS1Y
M=X+=(8M0DFA=T:!XD982^'(&!QTZ5Z7X25H_#-G&XPZ!E93U!#'BO.O">DQ:
M\UUM4?Z.%/EJ=N\'/&><'BNYT;2-,M@\-C>7EK*YS) T@#@CV(J8*T4BJCO)
MMG34A('4@?6J']EM_P!!&^_[^+_\365JNDZ5>0(+[4+JX5'(1!*"2W0@ #K5
MD$WC%U/A>[PP/W>_^T*U['_D'VW_ %R7^5>?ZUX5AM-'GU!(Y+<1@;(G<,QR
M1RV!Q]*ZK2]5N?[(M+BXLB+=HE.^%MVT8[CK^5 &O>6J7MG-:R%@DJ%&*GD
M^E<[8V%F=6>RCLK:]M8AMEN&@13$^.%R  Q]<#C/)K:U)I+G0[EK%V:1X28F
MB/)..,5S>G?VY+I]O96TMC830YW18(8CW!!SZD@T :36EG)<3I::'8R) ^R1
MI"J$G /RC:<\$=2*Q/#5PEQ+XCD2W2W7RQB*/HN ]6'TO4TU%9M1OM-F9O\
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M7W^Y_44 7-$_Y =C_P!<$_E5^J&B_P#(#L?^N"?RJ_0 4444 %%%% !1110
M4444 8_B7_D$_P#;1?ZU0\%?\C!_VR;^E7_$O_()^L@_K5'P2,Z_](6_I7GS
M_P!\A\CT8?[E/YGHU%%%>^?/!1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWN9)"Y)P!U//0"K5 !1110 4R6*.>)HI8U>-NJL,@T^B@!$18T5$4*JC  &
M!2T44 %%%% !1110 4444 %%%% &-XF_Y!2_]=1_(U3\$?\ (>;_ *X-_,5<
M\3?\@H?]=1_(U3\$?\AYO^N#?S%<$O\ ?(_(]&/^Y3^9Z+1117O'SP4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 >2>)R5UC4V!P0[D&J?PUU6_OKR\@NKN6:**%2B.V0O/:KOBO_
M )"^I_5OY5C?"K_D)ZA_UQ7_ -"KY^A_'EZGT>(_W>/HOT/4Z***]$\P****
M +=%%%:F05YAXH\*7WB2PN(]0\,)-K1FD%AJUK<1Q^2GF'RC,=RM\JXRJA^.
M1AC@>GT4T[":N>3^(?"'B0:[J%S;VC:J+WPRVEF=9HT/G\99@[#@[<\9Y/;K
M3=+\,^(H-7^'TLNB3I%HUM)#>N9X#L+@H,8DRP&-QQV(ZG('K5%/F8N5'C*>
M ?$K?#?5] 6S6*\BU1KVU9KE<7(## !4Y7('!;;SCIU'H7A/2H[!;RY&BW>F
M37;(TXO+\W4LK@8R6WN, 8 .[)YR!@9Z2BAR;!12//\ 5[#6IOBMI&MP:#>2
MZ?8V\EO)*LUN-Q?.&4&0':,\Y /'0TW7[CQ9<^*HY8/!!U#3K!LV33:E!$IF
MY!G9<L3@'"C@@%B1DC;Z%11<+'&>)+:_U^+4= O_  E]IL9%"VFH+<0E!(RD
M&1D9@\>TGJH8]<9[]3IED--TJSL1*THMH$A$C=7VJ!D^YQ5JBE<=@HHHI#*K
M??;ZTE*WWV^M)61J%%%% !1110 4444 %%%% !1110!G:^[Q^'-4DC9D=;24
MJRG!!"'D5QOPOO;J\_M7[3<S3[?)V^;(6QG?G&:['Q""?#6J@ DFSFP!_N&N
M*^%,;Q_VOO1ESY.-PQ_?K*7\1&T?X<CT>BBBM3$*?%_K!3*?%_K!36XGL6**
M**T,RCK/]H_V->?V3L_M'RC]G\S&W?VSGM7")X->3QQI6L:;X?;0)[:1FU"Y
MAN(S!<IC&Q$1LMN/.YD3C)(S@5Z3133L)JYX?=>"/%4-H]C%HCW"Q^*#JPFC
MN80LD)4#Y0S@[N.AQU'OC4U+PAX@U*\^(>W2I(TUB*'["[SQ8D,7;AR5W=1D
M#WQ7KE%/F9/(CRK4?"FN3W7A'5'TJYECL;(V-]8VVH""=5V8#*ZNJGD<@/SP
M.YQZ#H5C%I'AZVM+73VM(H8SY=H)O-9!DD+N8\MSSR0#P"0,UJ44F[C2L>>^
M#M/US3O$GBJ\O- N8(M5G^T6QEG@*_*#\K['8@DD= 14LN@S^+]4TK4=6\-S
M:)?V9<SS^?#*9(RCKY2NC$D98-EE&,$#K7>T4[ARGENA>"-6B'A/2KZU\NW\
M.W$]P]YYJ%+DEB8Q& =PZ@G<%Q@]:]2HHI-W&E8*1ON-]*6D;[C?2D,JT445
MD:A1110!B^)_^06G_74?R-5O _\ R')/^O=OYK5GQ/\ \@M/^NH_D:Q- GU:
MWU!GT:RM[NY\L@QW$QB4+D9.0#SG''O7 _\ ?8_(]&/^XS^9U=_:IX2F_M?3
MU\K2R_\ Q,+-?]6BD\SH/X2IY8#@C)QD<]5G(R*XJZN_'5W:36TOAK1VCE0H
MP.HM@@C']RNDT&WN[/P]IMK?%3=PVT<<Q5MP+*H!.>_2O>/GC1HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M\H\=_P#(6U7_ *Y?^TQ65\)_];JW^[%_[/6SXUB,VNZC$#@R(J@^F8P*7P#X
M=DT:UN+I[A91=!0%"XV[2P_K7@TO]YFO-GT-;_=8/R1V5%%%=YYP4444 %%%
M% !7+^!/^0-<?]?+?R%=17+^!?\ D#7'_7RW\A0!U%%%% !1110 R;_42?[I
M_E7.>!/^1<'_ %V?^E='-_J)/]T_RKF_ ?/AL?\ 79_Z4 =/1110 4444 5M
M0_Y!MU_UQ?\ D:Q_!//A>W/^V_\ Z$:V;_\ Y!MU_P!<7_D:Q? __(JVW^\_
M_H1H Z*BBB@ HHHH H:U_P @2]_ZXM_*JWA7_D5]/_ZY?U-6=;_Y =]_UP;^
M55O"O_(KZ?\ ]<OZF@#8HHHH **** ,+QE_R)^I_]<OZBN3^$W_,7_[8_P#L
M]==XP&[PEJ*^L>/U%4/ _AQ-$TYKI;EI3?Q12%2F-G!..O/WOTK-Q;FF:QDE
M!HZJBBBM#(**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** ,3Q3_ ,@R/_KL/_06J#P)_P AN;_KV;_T):F\4_\ (.B'_38?R-1>!!_Q
M.9S_ -.Y_P#0EK@_YC8GHK_<9'H-%%%>\?/!1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 >5^.V9-7U)U)#+""".Q\L51^&.HWEZ
M-1BN;F26.(1^6K'(7);.*M?$-]FH:HW_ $Q _- *X'PYXEG\.FY,(/[_ &YP
M!_#GU!]:^?4N2O.7FSZ-QY\/"/DCW:BO,=/\>ZAJ%V(%9D)!.2J'I^%)J/CW
M4=/NS 6+D '("#K_ ,!K?ZW&]K/\/\S#ZG.U[K\?\CT^BO)O^%EZA_=;_P <
M_P#B:U?^$PU+^R?M_FG&S=LVK_/%#Q<5NG^'^8E@YO9K\?\ (]$HKR3_ (67
MJ7]P_FO_ ,35S3?'VI:A=BW^YD$[B%/3_@-#Q44KM/\ #_,%A)-V4E^/^1Z?
M7+> ^=&N/^OI_P"0KF=2\?ZGI]X;?:),*#N^4=?^ UD:?X[N-+@:&SM?+C9R
MY!D!Y/U6FL5%JZ3_  _S$\)).S:_'_(]FHKSO_A,=3_L?[?O'W-^S:O\\5C_
M /"S=4_YY+^:_P#Q-)8J,MD_P_S'+!SCNU^/^1ZY17E^F>/]4U"\%N0L>5)W
M?*>G_ :-3\?ZII]X;<!9,*#N^4=?^ T?6HWY;/\ #_,/J<[<UU^/^1Z;+_J9
M/]TUS7@'_D65_P"NSUQ;?$S5&!!ACP1CJ/\ "KVG>(+G2O#?FVBJD84R>6>>
M3[FAXJ*W3_KYA'"3ELU^/^1Z=17D?_"S=5_YXQ_I_A5W3/B!JFH7@@*H@*DY
M !Z?A3>)BE=I_A_F)863=DU^/^1Z?17E^J?$#5=/O3 JQN H.2 .OX52_P"%
MFZO_ ,\HOR'^%"Q,6KI/^OF#PLD[-K\?\CU6_P#^0;=?]<7_ )&L7P1_R*MM
M_O/_ .A&N;D\7:E+H#W3E#OB)*;1CGCK7/:?X^U#2[)+2U@A6)"2 >3R<T1Q
M4);)A+"3CNT>ST5Y?I?Q U;4+T0.D* J3D+Z4FJ_$#5]/OC BP,H4'+)ZT?6
MH7Y;,/JD^7FNCU&BO(?^%FZU_P \[?\ [YK:_P"$SU7^Q/MV8M_E[MNSBB6*
MA'=,(X2<MFCM=;_Y 5]_UP;^55O"O_(KZ?\ ]<A_.O,[CXC:Q=6\D$L=L8Y%
M*L A'!_&KGAWQKJ6Z'34C@2"-"%PI)X_&F\3%*[0EA9MV31ZQ17EVK?$'6+"
M^,$:6[*%!RR<\_C5'_A9VN=H[3_OV?\ &A8B+5T#PTT[,]?HKSS_ (335?["
M^W?N/,\O=MV<?SK#_P"%G:[_ ,\[3_OV?\:(XF$M@EA)QWL>A>,N/"&I?]<O
MZBN8^%EU<7":HDT\LBQB$(KN2%'S],].@K#E\;:KKEE>6%TEN(GMW)\M"#P,
MCO2>!M0NM-^W^2 OF>7G<OIN_P :SGB(J7-V-(8:3CR]6>PT5QW_  DNH?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI"'*3W:GU!C'_LE1W7PZT^:!Q%?7<<Q'RR,(WP?IMYKL:*/JM'^5?<'UNO\
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MVG_Q-13> K-@OD7MS&0>2X5LC\A76T4?4Z'\B#Z[B/YV<8?A_'VU.7_OT/\
M&C_A7\?_ $$Y?^_0KLZ*/J=#^5!]=Q'\[.67P'IH4!KF\)QR0RC_ -EI?^$$
MTS_GXO/^^U_^)KJ**/J=#^5!]=Q'\[.7_P"$$TS_ )^+S_OM?_B:/^$$TS_G
MXO/^^U_^)KJ**/J=#^5!]=Q'\[.8_P"$%TO_ )[WG_?:_P#Q-13> [,[?)O)
MT]=X#9_+%=911]2P_P#*@^O8C^=G'?\ " P_]!!_^_8_QK2T3PPFBWSW*W32
M[H_+VE,=P<]?:M^BG'"T8/FC'4F>+KSCRRE=!11170<X4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[.OO^?.X_P"_3?X4?VG5_D_,/[*H_P _Y'9_\(Y\//\ H#>%_P#P%M_\*/\
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M70__ !-=!10!S_\ P@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\
M$UT%% '/_P#"">#_ /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044
M <__ ,()X/\ ^A4T/_P70_\ Q-'_  @G@_\ Z%30_P#P70__ !-=!10!S_\
MP@G@_P#Z%30__!=#_P#$T?\ "">#_P#H5-#_ /!=#_\ $UT%% '/_P#"">#_
M /H5-#_\%T/_ ,31_P ()X/_ .A4T/\ \%T/_P 37044 <IH6E:=H_CG6K72
M["UL;=M-L9#%:PK$A8RW8+84 9P ,^PKJZY^S_Y*'K/_ &"K#_T;=UT% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^TDN[VYAMK>,9>69PB*/<G@5/7#?&'_DEFM?]<U_]"% &Q_PGO@[_H:M$_\
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M2W7 +$<\&OGWXJ_"SPQX*\+IJVE7UU!?"=%CBFF#>9Z[< $$=<^U+\2]2O\
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M^\_Y*'HW_8*O_P#T;:5E>/\ _F'?]M/_ &6M6\_Y*'HW_8*O_P#T;:5E>/\
M_F'?]M/_ &6N+,/]VE\OS1W9;_O4?G^3,_PG_P OG_ /_9JZ6N(TG5O[+\[]
MQYOF;?X]N,9]CZUI?\)9_P!.7_D7_P"M7FX;$TH4E&3U/3Q.&JSJN45H=+17
M-?\ "6?].7_D7_ZU'_"6?].7_D7_ .M6_P!;H]_S,/J5?^7\4=+17-?\)9_T
MY?\ D7_ZU'_"6?\ 3E_Y%_\ K4?6Z/?\P^I5_P"7\4=+17-?\)9_TY?^1?\
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MN]LSJ(O3<S"7<(MFW QCJ<U7^)?PT'Q!.ER)J7V&:P:3#>5O#!MON.A4?F:
M/.OVA+=;OQ=X6MG)"3(T;$=0#(HK:N_V=O#"6,LJZQJ,!2,MYDC)M7 ZM\O3
MUYK>^(7PHF\>/I,LFM_9YK& Q.YM]WFDXRWWACD=*Y#_ (9RN92$G\72&/N/
MLQ/Z%Z .>^&>I:KKOP]\7^#X_P!_%'8M-:G&-I)Y7\>M=K^SUXCM)_"]QX=D
MDCCOK.=Y%A)PSQMR6QWP<@^G'K7?^!O FE> ])>RTXR2RS$-<7$I^:5@/3H
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M1R>5LPI.0N,GID\U@S?#0R_%N/QS_:F @'^B>3Z1>7][/X]* ._ "@   #@
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M]>__ !ZC^S\-_+^+_P P_M+%?S?@O\C*_P"$ _ZB?_DO_P#94?\ " ?]1/\
M\E__ +*M7_A#=+_Y^M<_\'U[_P#'J/\ A#=+_P"?K7/_  ?7O_QZC^S\-_+^
M+_S#^TL5_-^"_P C*_X0#_J)_P#DO_\ 94?\(!_U$_\ R7_^RK5_X0W2_P#G
MZUS_ ,'U[_\ 'J/^$-TO_GZUS_P?7O\ \>H_L_#?R_B_\P_M+%?S?@O\BA:^
M!(8KA))[UID4Y*"+;G\<FNOKG_\ A#=+_P"?K7/_  ?7O_QZC_A#=+_Y^M<_
M\'U[_P#'JWI4*=%6IJQSUL14K-.H[V.@HKG_ /A#=+_Y^M<_\'U[_P#'J/\
MA#=+_P"?K7/_  ?7O_QZMC$Z"BN?_P"$-TO_ )^M<_\ !]>__'J/^$-TO_GZ
MUS_P?7O_ ,>H Z"BN?\ ^$-TO_GZUS_P?7O_ ,>H_P"$-TO_ )^M<_\ !]>_
M_'J .@HKG_\ A#=+_P"?K7/_  ?7O_QZC_A#=+_Y^M<_\'U[_P#'J .@HKG_
M /A#=+_Y^M<_\'U[_P#'J/\ A#=+_P"?K7/_  ?7O_QZ@#H**Y__ (0W2_\
MGZUS_P 'U[_\>H_X0W2_^?K7/_!]>_\ QZ@#H**Y_P#X0W2_^?K7/_!]>_\
MQZC_ (0W2_\ GZUS_P 'U[_\>H +/_DH>L_]@JP_]&W==!69I>@6&CSW$]J+
MIIKA4226ZO)KARJ%BHS(S$ %V.!_>-:= !1110 4444 %%%% !1110 4444
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M1QDEER@R0K!5'4^]=[X$\0#Q/X+TW5"09GBV3@#&)5^5^#R.0?PQ0!T=%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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C HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>exhibit102image1851b.jpg
<TEXT>
begin 644 exhibit102image1851b.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /?Z***
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M[9.SD<G//4UB>(6\2#P;&;2VW7OFW.Y?)0_+O;9P>.F* /0X91-!'* 0'4,
M>V13ZBM=_P!DA\P8?RUW#'?%2T %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#_GO'_WV*7SXCTE3_OH5XQYB?WU_.C>G]]?SH_M:7\GX_P# #^R(_P _X?\
M!/:/.B_YZI_WT*/.B_YZI_WT*\94%QE!NQUQS3MCC^%ORI_VM+^3\?\ @!_8
M\?Y_P_X)[)YT7_/5/^^A1YT7_/5/^^A7C6UO[I_*D4ACA3D^@I?VL_Y/Q_X
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MO]X?G1O7^\/SKQG:WH?RHP?0_E1_:S_D_'_@!_8Z_G_#_@GLV]?[P_.C>O\
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ME_YZ/_WT:/.E_P">K_\ ?1H_M=?R?C_P _L9_P _X?\ !/9J*\9\Z7_GJ_\
MWT:/.E_YZO\ ]]&C^UU_)^/_   _L9_S_A_P3V:BO&?.E_YZO_WT:/.E_P">
MK_\ ?1H_M=?R?C_P _L9_P _X?\ !/9J*\9\Z7_GH_\ WT:/.E_YZ/\ ]]&C
M^UU_)^/_   _L9_S_A_P3V:BO&?.E_YZ/_WT:]FKMPF+^L7TM8X<9@_JW+K>
MX4445V'$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !7F?C#_ )&2X_W4_P#017IE>;>,@!XBD([QH3^5
M>=FG\#YGIY3_ !_D:/AQ5.DJ2H/SMVK7"@= !]!63X;_ .00O^^U:]9T/X4?
M0O$?Q9>H5F:K<W\5Q9Q6(@S,6#&;.,@9 &/Q_*M.JU]:_:[?:K^7*C!XI,?=
M8=#_ $/L36QB<CJ'A&_U+4);V<P":3&[9(P'  Z8]A6UX8T.;0[.:.:99&E?
M=\N<#VJY'JT<6(]0Q:3#@F0XC;W5NGX=:NPW$-PNZ":.51QE&##]* )****
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M[V['^5 'J=%%% !1110 5RWBO_D*Z'_U\UU-<MXK_P"0KH?_ %\T =31110
M4444 %5=2_Y!EU_UR;^56JJZE_R#+K_KDW\J ,GP5_R*UK_P+^==!7/^"O\
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M1110 4444 %%%% !1110 5YKXR_Y&*7_ '$_E7I5>:^,O^1BE_W$_E7FYI_
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M&?\ (KVOX_SK?H **** "BBB@#E8?^2CS_\ 7H*ZJN6A_P"2BW'_ %ZK74T
M%%%% !1110!S/CK_ ) "_P#7=/YUT</^HC_W1_*N<\<?\@*/_KXC_G710?ZB
M/_='\J )**** "BBB@ KF/!G^JU/_K\?^==/7,>#/]3J7_7X_P#,T =/1110
M 4444 %%%% !1110 4444 >;5[37BU>TURY1]OY?J=F<_8^?Z!1117LGAA11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5YKXR_P"1BE_W$_E7I5>:^,O^1BE_W$_E7FYI_ 7J>GE/\=^G
M^1J>'/\ D#I_O-_.M:LGPY_R!T_WF_G6M4T/X4?0O$?Q9>H4445J8AVKE/!7
M75_>\;^9KJZY;P9_S%?^OMOYF@#J:*** "BBB@ HHHH **** "BBB@ HHHH
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M@^'1-/CN8[R24M*L>&4#&<\T =197, ;3<SQC$MUGYQ_>;%1V]Q"+: &>/\
MY!\@^^.N:HCX;VQ4'^T9NG]P4O\ PK:V_P"@C/\ ]\"@"_+<P?9Y_P!_'_R"
M@/OCK\W%+?7,!CU+$\9S:P@?..>6K/\ ^%;6W_01F_[X%'_"MK;_ *",W_?
MH ['[9:_\_,/)Q_K!4]<1_PK>V_Z"4__ 'P*E_X0$?\ 08N_\_C0!UEW_P >
M4_\ US;^5>-Z%-+'?H(I9(F) +1M@X+ $5V=SX%$-K++_:]TVQ"V#WP/K7%:
M."=6@C6/+,Z@;>_S ]Z /66BO=/'FPRR7<"_?ADY?'JK=S[&M"&:.XA2:)@\
M;@,K#N*?7+-XFT[0K^^T^Z\X;)]\82/("NH8_P#CQ:@#J:*Y8>/M&+E0+K@9
MSY7'\Z=_PGFC?]/7_?DT =/7'>.&9)M,=2597<@CL=M6QXZT8_\ /Q_W[_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>MJSOX;Q2%RDR\/"_#H?<?UZ5:H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .)NL_\
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MI]%% ##%&S%C&A8]25%)]G@W;O)CR>,[14E% #/)B_YY)_WR*/)B_P">2?\
M?(I]% #/)B_YY)_WR*< %&   .PI:* &LBN,.H8 YY&::;>%A@PQD>ZBI**
M&>3%_P \D_[Y%'DQ?\\D_P"^13Z* &>3%_SR3_OD4Y55!A5"CV%+10 4444
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M;?\ 7D?YB@#TNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M9--';PO-*X2-!EF/84^J&MJSZ'>JBEF,+ !1DGB@#A:]IKQ:O::Y<H^W\OU.
MS.?L?/\ 0****]D\,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4 %%%% !7+>/?^0'!_U\I_6NIKEO'O\ R X/^OI/ZT =0OW%^E+2+]Q?I2T
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MO7]&>IE'\=^GZHV_#_\ R!8/JW_H1K3K,\/_ /(%@^K?^A&M.E1_AQ]$.O\
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M &ZT_P"?F'_OL4?;K3_GYA_[[% %BBJ_VZT_Y^H?^^Q4L<L<R;XW5U]5.10
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M***]D\,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O,O%W_(RW7T3_T$5Z;7F7B[_D9;KZ)_Z"*\S-?X
M*]?T9ZF4?QWZ?J@T_P +Z5JEC'=74+/*V02'(Z$BK7_"#:%_S[/_ -_#6AX?
M_P"0+!]6_P#0C6G2H_PX^B'7_BR]6<AJW@[1K72;J>*W821QEE.\]:I:;X8T
MB?PU9WD\;B60Q[F4YSEP,8]\XKJ]>_Y -[_UR-9NBML\&Z>?-,7,0W 9ZR 8
M_'I^-:F15TWP?HT]F7DMV+"65<[NP=@/T JV?!.AGK;-_P!]FM/1_P#CP;_K
MO-_Z-:K] '/V.CV6@ZQ$;2,QQW49C.6S\PY _$9_*M35G:/1[UT8JZP.5(Z@
M[34MW:QWEN8I"PY!5E."I'0@^M9>H-J:Z7=6LMJ;HO"Z)+ 0"200-RDC'X$_
M2@#AO#$2P>([-H\J=Z#KV:+)_6O4I)$AB>21@J("S$]@*\ST."YBUU&6UFE:
MV>+S8T W+^ZQW('6N[,%UJ3+]K006H.?(#;FD]-Q' 'L,_6@#)M/"&EWMNMW
M=VS^?.3*^7(QN.<4Y_ .ALQ(CG7/99.*Z>B@#EO^%?Z'Z7'_ '\_^M7-^*?#
M6GZ3<:<EJ)0+AV5]SYZ;<8_.O3:XKQY_Q^:+_P!='_\ 9: (](\&:1=VNVY6
M=;J, 2@2<'(R&''0C^H[5H?\*_T/TN/^_O\ ]:M&0&TM[/4HP<1PJDX'\49
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M:S6T"2%YKBX$>,X4#!./7MUK4L_!F@7EN)5AG5@=KH93E&'4&M?7/^/G2/\
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M@ HHHH **** /-J]IKQ:O::Y<H^W\OU.S.?L?/\ 0****]D\,**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O,O%W_(RW7T3_ -!%>FUYEXN_Y&6Z^B?^@BO,S7^"O7]&>IE'\=^GZHVO
M#_\ R!8/JW_H1K3K,\/_ /(%@^K?^A&M.E1_AQ]$.O\ Q9>K,[7O^0#??]<6
MK-T1]G@[3V\WRN8ANVYZR 8_'I^-:/B#_D7[_P#ZXM_*L?0EU23PQ8I;I:A
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MI_\ "&:!_P ^"_\ ?;?XT?\ "&:!_P ^"_\ ?;?XT 9G_"Q])_Y];W_OA/\
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MG_([:#_P/^1KJZX[Q?9ZE)JNGW>GQR9A4CS47=L)]J .QHKSSS_%G_/[<?\
M@)_]:KFGP>*M1A>1-96/9(8RLD.#D8[8]Z .WHKE!I/BWOKD!_[9_P#UJ7^R
MO%?_ $&X/^^/_L: .JHKE/[)\6=M<@_[]_\ UJ:^E>+41F.NP<#/^K_^M0!A
MU[37BU>TURY1]OY?J=F<_8^?Z!1117LGAA1110 4444 %%%% !1110 4444
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M?^>J?]]"CSX?^>J?]]"N3_X5UIG_ #^7O_?:_P#Q-'_"NM,_Y_+W_OM?_B:
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MG+;",^8B( 6'M\@H ZCP[_R+MA_UQ6M.LWP__P B_8_]<16E0 4444 %%%%
M'(Z__P COH7X_P ZZ'4+IX52"WP;J8[8P>B^K'V%<UXEF2V\7Z--*<(BL2?Q
MKH]/@D+/>W0Q<3#A3_RS3LO]3[T 6+.U2SMEA0DXY9CU9CU)]S4&H6\FY+RU
M&;F$?=_YZ)W0_P!/>KU% %&>XCN]%GGB.4>!R,]1P>#[US'PV_Y!-Y_UW_\
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M4:?;-:VBI(P:5B7D8="S')_#L/84MM86UHS/%&?,88:1V+N?JQR:LT %%%%
M!4<_-O(/]@_RJ2F3?ZB3_=/\J /.:]IKQ:O::Y<H^W\OU.S.?L?/] HHHKV3
MPPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*/M_+]3LSG['S_0****]D\,**** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH Y7P[_ ,C3KW_71:VH_P#D8;C_ *](O_0WK%\._P#(T:]_UT%;4?\
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M44 %%%% '+>'?^1GUW_KJ*V8_P#D8;C_ *](O_0WK%\._P#(T:]_UT%;4?\
MR,-Q_P!>D7_H;T :%%%% !1110 56U#_ )!MU_UQ?^1JS2$!E*L 01@@]Z ,
M>XN8/^$9E431[OLC#&X9^Y5'P%_R*\?_ %U>M2_TVQ73KIELK8,(F((B7T/M
M67X"_P"17C_ZZOVH Z>BBB@ HHHH ***P_[0UN:YN4M;&T:.&8Q@O.03CD$C
M'H0: -6]_P"/"X_ZY-_(UQ?@+36FT>>9Y+F)7F^3RY2H; 'I[UM7=QXA^QS[
M]/L0OEMDBX/3'TI?!D#6WAY(&(+)*X)'UH T?[*3_G\OO_ AJ/[*3_G\OO\
MP(:K]% '"VMI):?$@AO-*O&61I&W%ACUKNJY/5EO%\9VDUG'#+(MN5"2.5'.
M>]:/VGQ'_P! ZQ_\"&_PH VZ*S--O;^>[N+>^MH(FB5&!BD+9W9]O:M.@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH *9+_J7_W33Z9-Q!)QGY3_ "H
MYSP-_P @*3_KN]=-7%>%KC4;'3)(8]+:X7SF;>LJ@<]N:VVU;554L=#DP!D_
MOTH VJ*@LKC[7907.PIYJ!]I.<9J>@ HHHH **** "BBB@ KD[G_ )*3:?\
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M4;3Q#/\ ;=2^U?Z*G\&.K-COVP?SK4T?_CUE_P"N\G_H5$?_ ",-Q_UZ1?\
MH;T :%%%% !1110 445'<3"WMI9V#,L:%R%ZG SQ0!%J/_(,NO\ KB_\C6#X
M"_Y%>/\ ZZO5.Z\=64]G-$MA?[I(V491<<CZUG>&O%-OHNCK9W%E>/('9LQH
M".?J10!Z)17)?\)_8_\ 0/O_ /OVO_Q5=5#()H4E (#J& ;J,T /HHHH *S+
MACIM^UV0?LDX F('^K8<!_H1@'TP/>M.JUY=QVD0+*TCR';'$@RSGT% !>,K
MZ;<,I#*86((/!&*S_#7_ ""W_P"N\G\ZK2Z/<K:W,WVDV*&-C]FM6)4<'KNR
M/R45/X64II#*79R)Y/F;J>: -NBBB@# N?\ D<;7_KB?ZUL7=Y#91;Y2<DX1
M%&6<^@'<US^I6\EQXNME2ZF@)@^]'MR.OJ#5N*VET>5KFX7[8F,-<_,98Q[@
MD_+_ +N/I0!?TZWEC22>X %Q</O=0<A>P7\!^N:NTU'61%=&#*PR&!R"*=0
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M/);R3/M$DD##:O4D CG_ .O3;/Q=ITD3"YFV2QCYRJ,5('\0XZ4 =#17)_\
M"7P->1S"X"6N_P OR3&=Q!_CSCUQQZ&MS^V;3^[<_P#@._\ A0!H45RM]XNM
MI&9+*[6-8AN9WC)WD?P 8_,UK0:_93V\<R"<JZA@5@<C\P* -2BN=U#Q591M
M]E@G,<[<,\D38B'J1CD^@J72_$5M<V8WO)++&Q1WC@8AB.AX'&1@X]Z -VBL
MU==L&O(;0R2)/-_JT>)EW?F*TJ "BBB@ K)M[BWEU6[N)IX@86^SQ*S@;0 "
MQ_$G'_ 16M67-X<T>XG>:;3X'DD8LS$<DGO0!->WEJ;"X N823$W_+0>AJIX
M9(.EN1S^_D_G4=WX9T1+*=UTV ,L;$';T.*@\##'A>$$YQ))_P"A&@#I****
M .>O)$C\86K2.J#R3RQQZUM?;;7_ )^8?^_@KF-6L[:]\=64-U"LL36S$JW0
MX-:__"+:'_T#+?\ [YH ?I;QQW5Y9PNC0QLLL>T@A0^<C\P?SK4JG8Z58::7
M-G:QP%\;M@ZU<H **** "BBB@ HHHH **** "BBB@ HHHH **** "F3?ZB3_
M '33Z9,,P2#U4_RH QO"W_(-D_ZZ'^0J_J=NTUKYD7%Q ?,B;T8=OH1P?K7F
M^DZ%K6HVTD]E)#Y7FLO[R1@<BK__  B?B7_GI:_]_FH ]!MYEN;6*=,[9$#C
M/H1FI:XVWL_&EK;QP13:>(XU"J/0?E4GE>./^>^G_E_]:@#KJ*Y+R_''_/?3
M_P O_K4>7XW_ .>]A_G\* .MHKDO+\;_ //:P_S^%'E^-_\ GO8?Y_"@#K:*
MY'R_''_/?3_R_P#K4OE>./\ GOI_Y?\ UJ .MKD+G_DJ%G_UZ'^3T[RO''_/
M?3_R_P#K5DZ9+J$GQ$A35'C:[BB9#Y0^7&PL/YT >AT444 %%%% !1110 5C
MZSX=MM:GAFFFFC:)2%\ML5L44 <3?^";E7C:POIG4??6:9@3]"*K?\(=J?\
M>/\ X&-_A7>2311#,DB)_O,!5"?4A/FWTTB>9N#(O*1^Y/3\!0!S6E>$4O+>
M1[F[NHY$E:/$<Y8''?-7O^$'M?\ H(7W_?VNCM+9+.UC@0DA!U/4GN:FH Y?
M_A"+7_H(7W_?RD/@>T/74+[_ +^UU-% 'FU>TUXM7M-<N4?;^7ZG9G/V/G^@
M4445[)X84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M* "F2_ZE_P#=-/IDO^I?_=- '-^!O^0)+_U\O_.NGKF/ O\ R I/^OAZZ>@
MHHHH **** "BBB@ HHHH *X2,?\ %UG;U!'_ )"%=W7"QG_BZK#T!_\ 10H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M24;,[;B$*!R.Z@<UZ910!PW_  D/B?\ YY:;_P!\M_C1_P )#XG_ .>6F_\
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MM+_Y][S_ +]?_7J0[[;Q!J5^F2(C$LR^L94Y/U'6ND4JZAEP589!'>@#E_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** .6\2?\C+H'_78_S%=37"_$!BMUI9'7<<<^ZUU U"\Q_P @\?\ @0E
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M3_(U?#O_ "!HO]YOYUJUD^'/^0.G^\W\ZUJFA_"CZ%8C^++U"BBBM3$****
M"BBB@ HHHH **** "N3\8'_B9>'_ 'O!_P"A+765R?C#_D)^'_\ K]'\UH W
M-0_X_M,_Z^&_]%O5]F5$+NP55&22>!6=JDB17.G22,$19V+,QP /+>F+')J[
MB2=62Q!RD3#!E]V]O0?G0 8?63DADTX'IT,_U]%_G]*U JA=H4!0,8QQBE'
MP** ,-HI= D:6W5I-,8YDA49,![LO^SZCMVK9BECGB66)U>-QE64Y!%/K&EM
MIM&E:ZL8VELV.Z>U7JOJR?U7O0!9L_\ D*:G_OQ_^@"N$T^W2^O9XII=1>5I
MI2H@EP JD9Z_6NVTNXAN[R_N+>19(G,95E/!^05ROA7_ )&+_@=S_P"A+0!?
MMO#&FWH=$U'4=Z\/%)*0R_4&M_1]'M]#LFMK9G9&<O\ .><X'^%+JD!\G[9"
M,7-N"ZD?Q <E3[$5<CD6:!9%Y5U##\: ,FPU]KFPAO)[&6&"5=PD4AP![XY'
MY5L1R)+&LD;!D89# \$5D>%?^16T_P#ZY?U-3VJ_8M4DM$X@F7SHU[*V?F ]
MN] &E1110 4444 %%%% !1110!P?Q$_X^=*^[]YOO=.HZUJ>1;_\^?AS\Q_\
M365\1"!=Z4,@?,QYZ=5K7\^''_'WH_\ WX_^O0!3MH8/MMZ#:Z"<2+@,1@?(
M/N_+T_KFN3M53_A-&4QV13[0XV-_J?Y=/PKI[&W%M?7$KZCICQDXC#1YR"!V
M]L8_/UKF+9U'C1G,MJ%-PWSLF8S^'I0!V%[#;BPN"+3P^#Y3<H1N'!Z?+UJ.
M6&W_ +)<_9= !\@\@C=]W_=ZU+>SPFPN0+K23^Z;A8<'H>G/6HYIX?['D_TK
M2<_9ST@Y^[]>M 'FJ$EH_;C_ #^=>X:7_P @BR_ZX)_Z"*\13[D7^\?Z5[=I
M?_((LO\ K@G_ *"* +=<%&?^+KL/\_ZFN]KS_P Q(OBN[R.J*,Y9C@?ZF@#J
M;%@FMZPS$!1Y1)/;Y34NGJ;N=]2D! <;(%/\,?K]3U_*L1[RVFU_4+0W4*0S
M&)Y9#( "@!^4'/4G]*Z$:IIJJ%%]:  8 $R_XT 0M_Q+M3W]+6\;#>B2]C]&
MZ?4#UKGO$T$4MQK,DD2,\>GQE&(R5^9NE=%<WNE7=M)!+?6I1Q@_OEX]^O6N
M1O[]+B'6EEGB>5+)(BRN")"&/(^H(H GT?P3I%]H]I=3?:/,EC#-MDP,_E5[
M_A7VB?\ 3S_W\'^%:WAS_D7;#'_/$5J4 <M_PK_1?^GG_OX/\*3_ (5_HO\
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M'_7ZU=/7,>#_ +VL?]?K4 =/1110!ROB?/\ PDGAK'_/P_\ [)755RWB<_\
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MQDW@K4[D()_$US($;<N^-C@^H^?K4G_"):S_ -#7>?\ ?+?_ !==?10!R/\
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M0Z<Q)O;[@Z"@#H;Z\W:?<C^U$;,3_+]C(SP>]13WO_$EE']JH/\ 1SQ]C/\
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MCE!,H(68#^, ]C5*=FU_5[C37?RK*T(\Z/.'G)Y'T3^=="B+&BHBA548  P
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M:W%O??:9(+6WFD=+"-I%#-E&*C)_WO:KUMI3VUC=&:"=-UO;N2Y89<O\WXT
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M%% !1110 4444 %%%% !1110 5YOXT_Y&%_^N:UZ17F_C3_D87_ZYK7G9I_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/\WX+_(\ZUCPFVDZ<UV;T2[6 VB+;U]\USL'_(1L/^ON+_T,5Z3XP_Y%N?\
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MR,<L82,,?4J01GWQ5$GCL7_)0K7_ +",7_H8KW&O-X?#^GVWQ$BAEG:1D"W
M9G"DR @C@?AQ7I%9PBTV:5))I!1116AF%<7\1K>QETZSDN603)*1'NDVG:1\
MW&>>B_2NTKS;XL_\PC_MM_[)45':-RZ:O)([S39K 6D%M8W$,D<42HBQRA\*
M!@=_2KM<CX+L+6[\'V?GP(QRV&QAASU!ZBMR&2:PNH[6XD:6"4XAF;[P;KL8
M]^.A]JI;$O<@\36.DWNEXU<Q+&C%HFDE\OY\' !R/?CVK%\%:/IEUX:ADELX
M96WN-S#)Z^M1_%+_ )%FV_Z_%_\ 0'JY\.O^1.M_^NDG_H1J$_?M8MQ_=WN6
M[70M+;5+]&L("J>7M&SIE:I>)=&TNWM+0I:V\"R7<<;R;1\JG()_K703Z5:7
M%PT\D;>8X 8JY&<=.AJ)]!T^1=LD3.OHTC'^M:&9Q5YH>D6$MH+&:&_>:?:T
M1D4\8)Z@\#C]:[*70-)$#G^S[<$*?X/:F_\ ",Z1@C[(!GT<_P"-23:-9""0
M[).%/_+5O3ZT >-WW_(WK_UVB_DM?2]>"2Z=82:D+EWQ<!E8#?W&,<?@*][K
M'*Y)J7R_4WS6+3C\_P! HHHKU3R HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH P_%_P#R+5S]4_\ 0A7#>'_^0U#]&_\
M037<^+O^1:NOJG_H0KS[2KJ.RU&.XE#%%SG:,GD$5X>/=L7!^GYGO9>F\'-+
MS_)'>T52&L:>5!^UQ\C/6D_MC3O^?N.NKVL.Z.7V53^5EZBJ']M:=_S])^M)
M_;>F_P#/TOY'_"E[6G_,OO#V-3^5_<:%>1:]_P E;C_Z_+7^4=>F?V[IG_/T
M/^^&_P *\O\ $4RQ_$./5L,UF;F!E<#[P4)G Z]C6=2I!I6:-J5*:;;B]CV&
MBN>U+QGH^EQ))*\T@=MH$<9S^N*SA\3- /\ #>#_ +9#_&M%5@]F8NE-;H[*
MBN>L/&NCZBCM \P"$ [H\55?XB^'XY&1I9PRD@_N31[6&UP]C4M>QU=%<HOQ
M%\.L0!/-DG 'DFK=WXRTBR17N))45C@'R\T.M!:7&J-1ZI'045RO_"P_#V.+
MB4_]LS5BW\::3=JS6YFD"G!PHX_6DZU-;L%0J/9'15XKXX)_X3V\&3]Z+_T6
ME>A-X_T-6*F60,#@@@?XUYGXEOX-5\83WEL_[F5X]K'MA5!_45G4JPDE9FM*
ME.+=T>SM>PV=G!ORTCH D:#+.<= *BCLIKR19]1QA3F.V4Y1/=O[S?H/UKS2
MW^(,]E(S+:Q3RD &9R<D>@]![58_X6E?_P#/E#^9K7VL.YC[&?8].NK.&\C"
M2J<J<HZG#(?4'L:IK=SZ>PBU [X2<)= 8'T<=C[]#[=*X=_B)JJ6OV@V$6S:
M#DA@.??\:IM\4;]U*MI]NRD8().#3=2*W%&G*6R,WQ0XA^(D\N"X6>)\+U/R
MJ>*[\>.+?_H%:E_WZ'^->807#:OXHBND@\O,T;&-,L% *CCVKWD=*FEU9=;H
MO(Y?_A-H/^@5J'_?"_XUF1ZQ'K'C?3I$MIX-D;*5F4 GZ8KNZY75/^1]TC_K
MD]:F)U5%%% ',^/#CPO(3_SU3^==!9_\>4'_ %S7^5<_X]_Y%:7_ *Z)_.N@
MM/\ CR@_ZYK_ "H FHHHH *PO&0SX0U,?],<_J*W:RO$UM+>>&M0MX(VDEDA
M(15ZDU,MF5'XD<=\*/\ CWU0?[<?\FKT:O)/ FGQ3?;A=SW5O@HJ&&0K\Q)
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M;6B/-O'?BRVUFVCTVUA8HDJS><Q(S\K#&TC_ &NN:Z_X>HT?A&!6&&$C\?\
M JU+_1-)FAFGETVT>41G#M"I(P..<5G^!/\ D5X?^NC?SIJ#4G)BE-.*BCI:
M***T,PJ.?_CWD_W3_*I*CG_X]Y/]T_RH \,OO^1O7_KM%_):^EZ^<+RPNG\3
M+<+ YA$L9WCI@!<U]'UEEC33]%^IMFB:<?5_H%%%%>H>2%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &1XFMY;KP_<Q01
MM)(=FU5&2?F']*\^&@ZL3_R#[C_O@UZQ17%B<#"O/GD['?A<?/#PY(J_4\H_
MX1_5_P#H'S_]\T[_ (1S6/\ H'S?D*]5HKG_ +)I?S,Z/[8J_P J/*_^$:UG
M_GPD_,?XT[_A&-:_Y\'_ .^E_P :]2HI_P!E4N[_  _R%_:];^5?C_F>7?\
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MT9@VY,9XIBIJ5A&N&2]A0 %=NR3 ].Q^G'UJY=WEO8V[3W4R11+U9S@5E_\
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MK!Y.,;/+X_E4/ABSN;#QE>VUW/Y\R6PR_/(^7'Z5W5<K9#_BXNHG_IV4?HM
M'54444 07G_'C<?]<F_E7*VFO:C;V4-PPMI+7[0;580")/E& 0<X).*ZJ\_X
M\;C_ *Y-_*N-T^WTZX=;&76_W1E\TVHC"?O#U&\]<9/3^E $VA.LGAW7)$.5
M:>9@?8U1T2XN[ZRMK,75Q;PP6C.! VTDCIN/7GJ,5?T8!?#VO   ">8 #MUJ
MA9O:WND:?;1::+JYAM2SS&<P[5&<C(Y;Z4 ='X2EDGT<RRN7D=PS,>I.Q>:W
MJP_"KQ2Z4SPQ>3$S@I'G.P;5XSWK<H *Y'XB GP_;A<;C=J!GI]UJZZN5\?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %>:>.21K<Q'!$*X_*O2Z\T\?<:M,1_S[C^1KSLS_@?-'I95_'^3,'X:
M:I?7E_=V]Q<R20I#N5&/ .X<UZ37EGPJ_P"0IJ!_Z8K_ .A5ZG44?@1I7^-A
M1116IB%%%07MQ]DL+BY SY4328]< F@"O-?2R7#6UA&LDB<22.<)'[>Y]A50
M:%++K-OJ=U?&26!2JHD85>?Q-1:?K>EVEC%#YTI8+EV^SR99CRQ/'<YJ[;:_
MIMW=+;17'[YAE4>-E)^F10!I4444 <SX]_Y%:7_KJG\ZJ0>"FDMXG_MN_&Y
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M$$CYO0@U>LO"FG7_ )HCU74/,B;9+$[C<A]"*27PGHD4S*^N2)-&,E?.0.H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC#3HA)?7BP*[;(\HC%FP3C"J?3'XUZ)7/>*2R2:1((W?R[Y7947)P%)/'TH
M\EUU+N6YAEFF%SNCSN3)"9=CM/'!SDX]Z]YC_P!6OT%>2>*-3-MJK":TGC,S
MBX7S %8KG R/^ FO6X_]6OT%9Q2YG8TFVXJZ'4445H9A7GOQ6_X\--_ZZO\
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M+,!@G/*#TK=_X0'3?^?N]_[Z3_XFMJV26\O!?3QM'&BE8(V^]SU8CL3Z5HT
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M5O\ CPTW_KJ_\A7H5>?_ !3C>2QTX(I8B1R<>F!45/A9=-VFC;\ ?\B3I_\
MVT_]&-72UYUX5\8:=I'ANTL+F*Y\Z+?NV(".78CJ?0UM#X@:0?\ EE=?]\I_
M\53A\*%/XF6M7GMX]8,<\#R[K9=I,A2-?G/WCT7MS5/4-,/VJS+3;(YGERD#
ML 1Y9;DY]JIW/C33WNVGA:9-T0C*O;HXX).?OCU-9L_B+3))Q-')-#(I<J4L
MQ@%AC.#)C/O5$F+>$M\2M/).29K(YSG^"/O7LM>/N\>I>++>[TF#SYXUB*K.
MPCW/&% .-W^R.,UV(U/QKWT2T_[['_QRLX1:;-*DDTCKZ*Y+^TO&?_0&M?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH **** "BBB@ HHHH **** "O-OB0S1WCR(=K+8E@1V(+UZ37FGQ,_X^)/\
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M=7(9"!@9KNO[.LO^?2#_ +]BC^S[+_GT@_[]B@"POW%^E+110!#=_P#'G/\
M]<V_E6'X(_Y%F'_>:MN\(%E.2< 1MDGZ5A>!F#>&8L$'#L#B@#I**** "BBB
M@#R273K"34A<N^+@,K ;^XQCC\!7O=?-%]_R-Z_]=HOY+7TO6.5II2U[?J;Y
MJTW'3O\ H%%%%>J>0%%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %>=?$*1(M46209C6T!;C/&YJ]%KS3XG?ZQS_P!.1_FU<&8J]#YH]#+':O\
M)B>!-0L;VRNTM$VO'("_R;<@CC^1KK*\X^$_^JU;ZQ?^SUZ/65%6II&U=WJ-
MA1116IB%%%% !7*:HBGQ]I)*@GRF.<?6MDRW.HRNEK)Y%JC%&F !9R."%SP
M.F:6/0[&.\CO&226ZC&%EED9B/UQ0!HT444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% $-X ;*<'H8VS^58'@0 >&(\ #,C
MDX^M=&Z+(C(X!5A@@]Q6;%H%G:1[;$S6ASD>5*V,_P"Z21^E &I15&TNIA<-
M9WFWSU&Y)%&!*OKCL1W%7J "BBB@#Q"\L+I_$RW"P.81+&=XZ8 7-?1]?/EQ
MK<D.M+8"%"ID1=Q)S\V/\:^@ZQRMRM*_E^IOFO+>-O/] HHHKU3R HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KSGXC0FXO5A! ,EIM!/;):O
M1J\V^)DCQ3F1&*NMGD$=CEJX<Q_@?-'H99_'^3,?P-':>'(KW[=J$"M.R;5)
MP<+GG]?TKKO^$CT;_H)6_P#WW7$?#RV@UN'4'U.&.Z:)D"&502H.[-=K_P (
MUHO_ $"[7_OV*QHW]FKFU>WM'8=_PD>C?]!*W_[[H_X2'1_^@C;_ /?5-_X1
MK1?^@7:_]^Q1_P (UHG_ $"[7_OV*U,1_P#PD&D_]!"#_OJH+WQ#IZV%P;>^
MA:<1,8U#=6P<#\ZD_P"$:T7_ *!=K_W[%07OAG2S87 M]-MEG,3>61&.&P<?
MK0!DVOC"&TM(;=-.<+$@4?OT[#ZU?TSQ?;:AJ*61MI(I)/N'>K@_7!XJC:^#
MK:ZM(;A+J,K*@<?Z)'W'TJ]IOA"VT_4H[[[0S21C"JD:(OX@#F@#HZ*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!LCB*
M)Y#G"J2<5QG_  L.W).+3:,\!Y<'^5=G(@DC9&Z,"#7++X#T],A+B;;G@,D;
M$?B5S0!1;QI:W=]9.T:1".7YI-Y;"D$'C'T_*N@_X2S0_P#G_7_OAO\ "LB3
MPG8VNH6**YF+RY:-XH\% #GHOKBM_P#L#1_^@7:?]^5_PH K'Q;H0ZZ@@_X
MW^%)_P )?H'_ $$H_P#OEO\ "K7_  C^C_\ 0+L_^_*_X5'-H&CB&0C2[,$*
M<?N5_P * /';[_D;U_Z[1?R6OI>O!)=.L)-2%R[XN RL!O[C&./P%>]UCE<D
MU+Y?J;YK%IQ^?Z!1117JGD!1110 4444 %%%% !1110 4444 %%%% !1110
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M* "N4U0#_A/M).!_JF_K75URNJ?\C[I'_7)Z .JHHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %>??$>6*":WFF&8UA.[C/>O0:\T^+!Q:+_P!<#_Z$
M*XLP5Z#7FOS.[+G:NGY/\A/ E[:WEE=FU7"K( WR[><5UE>?_"H?\2S4#_TV
M7_T&O0*PH*U-(Z,0[U&PHHHK4Q"BBB@ KEM3_P"1\TK_ *XM74URVI_\CYI7
M_7%J .IHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@""\(6QG). (V)/X5@^!&#>&(L$'$C ^U;]YC[%/GIY;?RK \"8_X1B+&/
M]8_3ZT =+1110 5'/_Q[R?[I_E4E1S_\>\G^Z?Y4 >&7W_(WK_UVB_DM?2]>
M"2Z=82:D+EWQ<!E8#?W&,<?@*][K'*Y)J7R_4WS6+3C\_P! HHHKU3R HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KS#XM2$P"+'"P*V?J_\
M]:O3Z\W^(T\-MJ$<TXS$MLNX8S_&PKCQ[M0?R_,[LNUQ"]'^1D_"K_D#WW_7
MP/\ T$5WU<)X5\0Z?!9SM'%*5:3'R(!R!]1ZBNDA\2:?*N7>2$^CIG^6:XZ-
M:"@N9I,[*]&;J/E3:]#7HK-_M_3/^?G_ ,AM_A2?\)!IG_/P?^^&_P *T]M3
M_F7WF7L*O\K^XTZ*S/\ A(-,_P"?@_\ ?#?X5!>:_9FQN!;3GSS$WE_(P^;'
M';UH]M2_F7WA["K_ "O[B<//JDC^5,T%DK%=Z??E(X.#V7/&>I]JDBT73X;I
M+E8-UPGW9)'9V'XDFL&V\3/;6L4"6"!(T" ><>@&/[M6;?Q8'N5CN+,QQGK*
MLFX+^&,T>VI?S+[P]A5_E?W'245F?\)!IG_/P?\ OAO\*;_PD6F_\]F_[X-'
MMZ7\R^\/85?Y7]QJT5E?\)%IO_/9O^^#1_PD6F_\]F_[X-'MZ7\R'["K_*_N
M-6BLK_A(M-_Y[-_WP:/^$BTW_GLW_?!H]O2_F0>PJ_RO[C5HK*_X2+3?^>S?
M]\&D_P"$CT[_ )Z/_P!\&CV]+^9!]7J_RLUJ*R/^$DTS_GJW_?!H_P"$ETS_
M )ZM_P!\FCV]+^9!]7J_RLUZ*R?^$DTT=9'_ .^#2?\ "2Z9_P ]6_[Y-'MZ
M7\R#ZO5_E9KT5DCQ)IIZ2N?^ &FGQ+IH./,?_OFCV]+^9!]7J_RLV**Q_P#A
M)M-_YZ/_ -\T'Q+IH&2[@>ZTO;TOYD'U>K_*S8HK&_X2C2_^>K?]\TH\3::W
M21S]%I^WI?S(/J]7^5FQ16,?$^F X,K#_@-)_P )3IG_ #T?_OG_ .O1[>E_
M,@^KU?Y6;5%8Q\3Z:HRS2 >I6F_\)7I7_/5OR'^-+V]+^8/J]7^5FW16*OBC
M3'^Z[M]%_P#KTA\5:6#@R.".Q _QH]O2_F#ZO5_E9MT5B?\ "5Z5_P ]6_(?
MXTK>*=-0;F,@7U*@#^='MZ7\P?5ZO\K-JBL'_A+])_YZM^G^-.3Q7IDF=C2-
MCKM /]:/K%+^8/J]7^4W**PCXMTI20TC@CJ#C_&D_P"$OTG_ )ZM^G^-'MZ7
M\P?5ZO\ *;U%8C>*=-1=S&15]2HQ_.HSXPTG_GHY_P"^?\:/K%+^8/JU7^4W
MZ*PD\6:;)G9YK8Z[0I_K36\8:2K%6=PPZ@[?\:/K%+^8?U:K_*;]%<__ ,)E
MI'_/5OS7_&I&\6::B[G\U5]2 !_.CZQ2_F#ZM5_E-RBN?_X3+2/^>K?FO^-.
M3Q=IDA(C\U\==NT_UH^L4NX?5JO\IO45SS>,])1BK.ZL.H)0$?\ CU)_PFVC
M_P#/1O\ OI/_ (JCZQ2[B^KU>QT5%8+^+=-C3>ZS*OJP4#^=1_\ ";:/_P ]
M&_[Z3_XJCZQ2[C^K5?Y3HJ*P(_&&F3$B+S7QUV[3C_QZF/XTTI&*LS!AU#,H
M(_6CZQ2[A]6J_P IT5%<Y_PFVD_WS_WVG^-2/XOT^)-\BR(G]YBH'\Z/K%+N
M'U:K_*;S*KJ58 JPP0>]9RZ%8PKBU1[5LY#02%<'Z=#^(K,/CC1\<2\_[Z?X
MU47QH\[L+>"UD4>D^2/K@4?6*7</JU7L=#:7$\=R;*\(:4+NCE P)%^G8CO5
M^N&F\7+)>VS3BTB,$N6Q/\V,$$8/X?E6H?'&D=I!_P!_$_QH^L4NX?5JO8Z6
MHY\_9Y,==A_E6%)XPL(8_,E1T0_Q,R@?SJE)X[T]E=5,&"" 3<K2^L4NX?5J
MO8\VOO\ D;U_Z[1?R6OI>OFN:%[OQ.)[;;-$LL;%D8$ #&3Q]*^E*K+=GZ+]
M19IO'U?Z!1117J'DA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7$^-_#%[K]RGD0F2$PA&VR*I!#$]S[BNVHK*M256')(UHUI49\\3QC1?A]X
MCTZ>X,EFIC?[F)T/?ZU1OOAKXKN+Z::.U0([$J#<*/ZU[K17*LNI)\UW^'^1
MV/,JKCRV7X_YG@7_  J_Q=_S[1_^!*_XUO:IX$\17>F+!#;() 5))F4=/QKU
M^BAY?2;3;?X?Y"6954FDEKZ_YG@?_"KO%W_/"+_P)7_&M71/A]XEL))FN+:,
MAP ,3J?ZU[/13EE]*2LV_P /\@CF-6+NDOQ_S/"[[X8^*+F^FFC@A".Y(!G7
M-5_^%5^*_P#GA!_X$"O?**:P%-*UW^'^0GF%5N]E^/\ F>0:IX#\0WFFK;Q6
MJ"0%22TR@<?C6'_PJKQ7_P \K?\ \"!7O=%*.7THJR;_ *^0Y9E5D[M+\?\
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M\!K&_P"%,ZO_ -!.Q_)_\*]IHI1P-**LKCEF%:3N['DVD?"_5],DE8W5I)O
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M[F2YLV60 $AVX_\ '>:];HHK:E0A2;<>IC6Q$ZR2ET"BBBMC **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH S/$&JRZ/I/VNWMDN9FN(+>.*24QJ6EF2(98*Q !
M<$\'I5+[9XP_Z 6A_P#@YF_^1:/&7_(#MO\ L*Z;_P"EL-:NIWRZ9ILUXZEA
M&N=H/4DX _,TI244Y/9#C%R:BMV97VSQA_T M#_\',W_ ,BT?;/&'_0"T/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY() #$@$D G\*;=:]H]C;6US=ZM8V]O=8^SRRW"(LN1D;23ALCGB@#/\0_\
M(<\)_P#85?\ ](KJN@KG_$/_ "'/"?\ V%7_ /2*ZKH* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **0LJ_>8#ZF@$$9!R* %HHS29'K0 M%%% !1137D2-"\
MCJBCDEC@"@!U%06U[:7BEK6YAG ."8Y V#^%3$A1DD >] "T4SS8_P"^OYTX
M.K'"L#]#0 M%13W$%K \UQ-'#$@RSR,%51[DU!8ZKIVJ(7T^_MKM5."T$JN!
M^1H N4457N;ZSLPINKJ"#<<#S9 N3^- %BBFHZR*&1@RGH0<@TI95^\P'U-
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MBBB@#G_&7_(#MO\ L*Z;_P"EL-3>+?\ D6+S_@'_ *&M0^,O^0';?]A73?\
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MACE5#<@9&& ]FHH Y":U6Q3P'9K]IVP7OE+]J*F7"V%R!O*\%N.<=ZZ^N?\
M$/\ R'/"?_85?_TBNJZ"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH X7XA>/=0\'-:Q
M:?X<NM5DN%9MZ9$:8/0D G-><_!3Q7KVM^,/$D^J7UU<'[*]P+625S'&_F X
M523M R0 .U?0%?-/PLU9-!\8>/-6DC,BV=I<3E >6VRYQ0!6\)^';CXQZQJE
M_P")?$DT#V\O[NSW9* YX52<*HQC@?6MOX>76J>#OC"?!-KK+ZMHSHRGYLI%
MB,N"!DA2#\I ..?I6/X#^'D_Q0N]4\4WVI'3$EN& 2Q0 [CR?H.?QJWX;M)_
MA!\9;?1)&BOK35O+A6?8!(%=L*?8[L9]0/I0!9^)NIMKOQE30I/$<VAZ=9VJ
MI/<B4JB-M,F< @9.Y5_"MKP7X#L;C7K:_P!,^)UQJWV.59)+>-B=P]#^\/'X
M50T[X<^%O'/Q'UZ\NO%']HG[1+-)8P1M%)&"Q #,W4+P./05B?$3PE:?"KQ3
MH&L>&;F>+S9.;=I=S_*1G'<J0<&@#H?BM\3_ !#;Q:KH6F:+>V,,4GEOJH9E
M.T,.4('&>!G/0UWOP=O;O4?A9H]U?74US<.9]\L\A=VQ,X&2>3P /PJ+XO2F
M;X.ZS*5*EX86VGMF5.*;\$?^21:)];C_ -'R4 >@U\S>.+F7QK\9Y/#>NZR=
M+T>VE\J(,<)P,@@'C<Q/4_\ UJ^F:\1O+/P7\9/%6HZ?);7NFZW8*4-P" 95
M5MI^7OCCKZT 87C7X4/X'TVW\5>"-3OY);:1=X5@[X)QN4J!D9P"N#P:U?BK
MK-WKWP-T;4[R![>YN9HS/$5*_,-P/'8$C(^M8?B3X?\ C#X7:7-KVA^*99-/
MM2 T>\H41F"CY3E3R1G%:'Q$\2S>+?@+H^L7**MS+=*LP48&]=RDCZXS^- %
M#PI\ [;Q)X5TW66\0RP->0B4Q"U#!<]L[N:]"\"?":S^&^KW>NMKCW2?8WB<
M/ (U1<JQ;.X]-E>?^$_@_KVN>%--U.V\8SVD-S")$@7S,1CTX;%=_H'PWU?P
MWX2\56=QKLNK7&IV+PP"0MB-O+<#&2>I<?E0!YOIEEK7QY\7WUS>ZA+9Z!9.
M"D*\^6#G8H7H7(!)8^_L*T?&'P>O_!$,?B+P1J.H//;,-\(YE _O J!N'JI'
M3UJY^S9J-L+77-,9T6Z+QS*A^\Z8()_ X_.O7?&/BJU\&^&KC6KN-I4B*JL2
MG!=B<  _YZ4 <-XM^)]]H7PHT[5O(-MKVI((HXI8\&-P/G?:>H';W9>U<?X6
M^"5WXQTJ'Q'XIUVZ^U:@@F1%^=]C %2S-[=AT&/I5/XR:X_C/P)X5\306,UK
M:O/<QLDA!*D[0O(]=C&O??#&HVNK>%M*O[,K]GGM8V0*00ORC*_4'(/N* /G
MZ9/$'P'\7V:K?O?>'KQOF1LA6'&[Y>=KCJ".M7OVCYUN)/#DL;$QR0R.GT.V
MM+]I&_MY++0]*1M]Z9FF\M>2%QM'YG^5<]\<[>6TT?P;;S,3+'8E6+=<@+0!
MZ3\%_'Y\5^'?[+U"4G6--4)(7/S31=%?GJ>Q]\'O7 ?#-V/[0NNY8\S7@//7
MYS5GXD:%>_#CQM8^/_#\>VSGE'VJ%!A5D/W@<?PN,_0Y]JROA!?Q:K\;]0U&
M%66*[%S.BMU 9MP!]^: ,\^#4\>?&_Q%I$M\]F!+/-YJQ[S\K 8QD>M:OBCX
M7Z]\*]._X2CPWXBFD6W91<[4\I@I8 $KDAUR1D'UZ=:T_ /_ "<EXB_W;G_T
M):]1^*NH6VG?#'7I+DKB6U:",$\L[_*N/Q.?P- %GX?>+!XT\&V>KLJ)<MF*
MYC3HLJ]<>QX./0UU%>5?L^6TT'PU:25&59[Z62/(^\N%7(_%2/PKU6@#YB\?
M>'E\5_M$S:&]RULMWY2F54WE<6X;ID>E=+_PS1:?]#1-_P" 0_\ BZYKQ[HM
MQXB_:*FTFTO6LI[GRE2X7.4Q;@]B#VQ^-=;:_ [Q%#>0RR>.;IHTD#,H,F2
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M_K+_ .2*/^$AU3_H3-<_[_67_P D4 =!17/_ /"0ZI_T)FN?]_K+_P"2*/\
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M\D.['W=RD9_6O//@[X&\0>!;;5K36)+5K>>1)(!!(6^8 AB<@8R-OY5Z?10
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M0^9\L84C;CKD>M>N444 >4_%SP#XD\>ZCI%OITMG%I=L"TK2R,&WL0"=H&"
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MRDC+1R.(E"CJ2"6?_@-;&H?#^UO;^]EAU;4[&SU!_,O;*UF"Q3L1AB>-RE@
M#M(S1=_#3PUJ5SJ=UJ=BE[=7S9\Z=06@4($58SC@ #(]S0!UX((R#D&BJNFV
M0T[2[6Q$LDRV\*Q"23&Y@H R<=^*M4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>exhibit102imagerent1601.jpg
<TEXT>
begin 644 exhibit102imagerent1601.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<FL@17-C
M:&5N   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,P.0  DI(
M @    ,P.0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( O<!BP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M&<9QG H TJ*** "BH#>VH)!N801U'F"IP0P!!R#R".] !1110 4444 %%%%
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MC\/W?K_7],4OB^_]"[1112&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY<HHHI %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTU."YU#5K&TFT+4HK=(7_M30K18(I"V_,3!68%EQG@]'' [[OPX_Y)9X4_[
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MD1*4!"Y]AQ5U+:"(2".&-!*Q>3:H&]CP2?4\4L,,=O"D,$:111J%1$4!5 X
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M()8;G8;*> 1RVHV*0CD.RN3G<&4XPP':FNO]=0>_]=C<HHHI %%%% !1110
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M([2WU![1+K[8K217J1/N&Q>&3;O7<6ZG.W'-=M?R0PZ;<R72&2!(F:1 ,[E
M.1COQ7E?@C2]3D^) >[@TJV73=/B5K=-!:U>+)D7:C>:RY  ^8%E*\#')KUF
M;>()/*57DVG:K' 8XX!-*?P%+XON_P _Z_I'E-M9W>G:'=:IJ?AU9= NK,1R
M-+X@DN;B"T/(5$:/:.",J'R<#DX%>L+C:,=,<5XY-X?\02:&VI6OP^\/V4Z
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MF5AM3GY@/[M;GA42PZ*EC+HC:*++$"6_G++&5 &"C@Y*\X^8 \=*<=$PEO\
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M1HX<9Y^ZR@@YQC&2,4X[-_UO_7]:BEV_K^OZ\CIZ***0!1110 4444 %%%%
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M "HFM+=FC+6\1,3;HR4'R'U'H:EHH *BEM;>>-TG@CD23&]70$-CIG/6I:*
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M/?"]WX;6_P#M^BZ9I\MRRLUQ:7\UW-<L,Y,KRH&)&>.3U/2M#X<?\DL\*?\
M8%L__1"5<MR$=)1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBN7\7>-E\)WFF0/HVJ:B+Z4HSV-I)-Y8"D_PJ<MD#Y>.,GM
M0!U%%8WAO7+C7[:YN9M(O-,@6;9;B]C,<LR;5.\QD I\Q88/IGO3O%&N-X=\
M/S:A%;"ZE#QQ11-)Y:L\CA%W-@[5RPR<' H>@+78UZYOX<?\DL\*?]@6S_\
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M=1>7)$V P!'NK @CUH6H;&G1110 4444 %%%% !1110 4444 %%%% !1110
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MS7#-Y,-E9R7,N%'S-M0$A1D9/N/6IELO1?D$=WZO\SG?AS)>63RZ=>VXC%]
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MB@ HHHH **** "BBD)"C+$ >] "T444 %%%% !12 @]"#VXI: "BBB@ HH)
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MCS"53&J@\'+ #G YZCK3;V?];_C_ $M!15FU_6W]?GJ8V@2VL$NFW7AWQ?\
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MGWFHI:QV6G3169CCL(T(PZ*68B0D E@1RJC@"O0@, #K[T:*-E_7]=1;N_\
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M;!!(%3ZUIFK3ZC;7^CW=F)+8$"WO;;>ISD$K(I#(2"!GYAQ]VA]/E^01TO\
M,Q?!]QI$GB"Y6Q?4+F^>U#7,NI7#O/ 5?'DE&^Y@G/'!R#R,&M;QK-9Q>%IA
M?V5Q?++)%%#;VLGERO,S@1['W+L;<00V1CK5/3-3V^*/+UCPV=/UFY@5'O+5
MEN(Y47) ,BX<*#G!=%&3@'-:_B#2[O5M.$-C=PVTBR"0?:+43QN5Y 9<@\$
MY5@<@<TGLOZZ@M&_ZZ'%:3<:?'XATA=5AUQ=9^TF%+'5[_S/LV8I#YR!24DX
M0KN!)&X\@\'T*^EAAT^XENUW0)$S2C&<J!SQWXKE+S4[JRU&PE\7>&X;B6&9
MA9ZAIS"?8Y0YQ&V)%)7=P@?@'FNJOH);JPEAM[@VTDBX64(K[?\ @+<'Z&B5
MW'0:LI(\H-SI<&AL^N:=XETZR\DW%CI]_JNZVO$4;A'N1VQP/]6YZ9X(!KU\
M?=%<1?)J>DZ";'Q'H>F:WHD"*&>RVPF-%/!,$IV@* #D2=N!7865VE]8Q7,4
M<T2R+D)/$8W7V*MR#5-JVA"WU/.+BYTZ36]1F-KXDTG1FNGBGU.TO]EJ9E;;
M(QC5R\0W @N%49R2>]=MX4DM)?"MBVG6_P!GM1&5BC\PO@ D?>/)SC.3US66
MMEXET7SQ#!IVO6<\C/+'M%I<'(P2>L<A.!U$=:7A2]L+O0HDTK39M,MK?]TM
MK)$$$>!T4J2C 9QE21G(SQ4K:Q4OBN<WXKGB/B[;9:5KT]S;VJ-?7FCW:Q>7
M$S-L#1EP92"KD!58CG'7%:G@:;29(=4CT-I;B*.Z4R7D]RT\ERS1(VYF;D$!
M@NWMMQQTJ>_T[Q!:ZU-JFC2Z=>"2,(;2\B,3[1R%6=,D#)8X9&Y;J*3PUJ%I
M)J6HVB:#+I%\93-> (C1R2;5^8R1D@L5*G#88CG%..UOZW!G24444@"BBB@
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M/FWLJD'VQV]ZZ2N+^&0@_L6];3]&CTK3WN0ULBV'V,RCRDWL8]JG[^\ D#(
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M1@='XHU>YT30VNK"VCN;EYHH(DFD,<8>1P@+L 2%!;)P#2>R_KK_ )@M)/\
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M3L-?L9M7/B6[AO)9KM7@FMXC%&R>2@X0NY7Y@W4\GGO7144+0 HHHH ****
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MKTVPBTO2[6PMMWDVL*0Q[CD[5  S^5-?"_Z[B>Z^?Z%FBBBD,**** "BBB@
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M:2-L'('&<''2NC\-:(FB6$X75+K57NYS<27=T8RTC%57_EFJKC"CH*<?A?\
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M7^2!ZNX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% $5T2MI,1%YQ"-^Z_O\?=_'I7FOA.)?^$DTRZM],U
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M\0ZUIND:Z=4M;:"V$RO>O<N+GY_,<EB=F[Y?E!ZCH.^[\./^26>%/^P+9_\
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M $0E2,Z2BBB@#B[VX\$^'9'UJ%--AOM1298YUC9O-Y_>$[ 2J[L;VQCUKHM
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M@/\ RR4H,+^ XJ_Y:%"A5=K9R,<'/6G    # '0"FM%;^NO]?\.#U=PHHHI
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
-10 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>exhibit102imagerent1701.jpg
<TEXT>
begin 644 exhibit102imagerent1701.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<FL@17-C
M:&5N   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,T-   DI(
M @    ,T-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                    ,C Q.3HQ,#HR.2 Q,CHT,#HT,P R,#$Y.C$P.C(Y
M(#$R.C0P.C0S    30!A '( :P @ $4 <P!C &@ 90!N    _^$+'FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X<&%C:V5T(&)E9VEN/2?ON[\G
M(&ED/2=7-4TP37!#96AI2'IR95-Z3E1C>FMC.60G/SX-"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B/CQR9&8Z4D1&('AM;&YS.G)D9CTB
M:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR9&8M<WEN=&%X+6YS(R(^
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](G5U:60Z9F%F-6)D9#4M8F$S
M9"TQ,61A+6%D,S$M9#,S9#<U,3@R9C%B(B!X;6QN<SID8STB:'1T<#HO+W!U
M<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B+SX\<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD,S-D-S4Q
M.#)F,6(B('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+R(^/'AM<#I#<F5A=&5$871E/C(P,3DM,3 M,CE4,3(Z-# Z-#,N-#0Q/"]X
M;7 Z0W)E871E1&%T93X\+W)D9CI$97-C<FEP=&EO;CX\<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB=75I9#IF868U8F1D-2UB83-D+3$Q9&$M860S,2UD
M,S-D-S4Q.#)F,6(B('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O9&,O96QE
M;65N=',O,2XQ+R(^/&1C.F-R96%T;W(^/')D9CI397$@>&UL;G,Z<F1F/2)H
M='1P.B\O=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX\
M<F1F.FQI/DUA<FL@17-C:&5N/"]R9&8Z;&D^/"]R9&8Z4V5Q/@T*"0D)/"]D
M8SIC<F5A=&]R/CPO<F1F.D1E<V-R:7!T:6]N/CPO<F1F.E)$1CX\+W@Z>&UP
M;65T83X-"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @/#]X<&%C:V5T(&5N9#TG
M=R<_/O_; $, !P4%!@4$!P8%!@@'!P@*$0L*"0D*%0\0#!$8%1H9&!48%QL>
M)R$;'24=%Q@B+B(E*"DK+"L:("\S+RHR)RHK*O_; $,!!P@("@D*% L+%"H<
M&!PJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ*BHJ
M*BHJ*BHJ*O_  !$( RD")P,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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MA3Y6K^0N9;'3T445(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%M;FUA$\_G2J@BC)(#L3PHX/)]*9'XAT>:UENH=4LY;>& 7,DT<ZLBQ'.'+
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MR+.R0(=SY*N&XZYR#^-/3^OD0^8S(_B1H<FLQZ6JW7VN2Y:W\OR@60JRKN8
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M,YYZ5Z-10O=5EZ":3=V<W_PGFD?\^?B#_P )S4/_ (Q1_P )YI'_ #Y^(/\
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M:.53,JS2S%Q'!'U9V**Q P,9Q@9R2 #2ZC*$WAB_FM]<MQ?VB0ZM*78"T)*
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M]P(55GD9AG'<D 8   KK:**0PKSZ#X4P1-Y;:DQM<0L(5A \J5!+F1#G@EI
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M+<0$NL0PV)/+"KND)(+98=>ORC-7PEX0U'0[^P;4(=-;[%:/;BZLPT;R;G)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR+@C<A5ASST;*D9!&*.J KV-CH!2_;3]2=ECG=[LQ:G(1%)@[MQ#_+C)X/3
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M?BC8ZC:QR:5HNJWLLS'R(42*,S1A=QD#/(J[<=B=WM0]%=AUM_6IW%%>>?\
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MLRQ@18@,.U0RD;2A/4'DYK(LO@_I4:.VH7<[LZ3Q,D1 3RW:0J/F!.Y1*PW
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M" =;ESC&.%]\BM;4;+BW/@'7[>$-'IC1:?&\-K<2PJBP+N>(B)V&!S$WW3T
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M9&J^$_#FO72W6N:!I>I7"((UEO+*.9U4$D*"P)QDDX]S5+_A7'@C_H3?#_\
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MG6XN2\<PB\P>7QL,B+C<PV@]!Q78_P#"N/!'_0F^'_\ P5P?_$T?\*X\$?\
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MU4E=V8SD==N#3[[PIXPGM)/LWB&6.Z:61PWVMPH'E@1C 7'W\DC&#[]*V_\
MA7'@C_H3?#__ (*X/_B:/^%<>"/^A-\/_P#@K@_^)I+0&KG/ZQX*UW4K/P\M
MU):ZC+I6I33R&ZF4EHBS>7\TD,F652H)P&R.'!YK//AOXB?;+*TDU7S$)DDF
MNOMK^6B[X=J%2GSD()4P<!N6)!.*[#_A7'@C_H3?#_\ X*X/_B:/^%<>"/\
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M* "BBB@ HHHH **** "N1N?B/I%K>RVLT,XEBO18D+)"P\P]!D28W''W/O\
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MBL3=Z?O\D$+E\9)V@G@$XQG'U!QD<UIU0TS0]/T=YFTVW$'GXW@,2.,X !.
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M196N5DEAC-MLD$9#%W"DEC@88YQQFM?4O#NG:M>+<WR3.ZP/;@+<.B['QN&
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M+Q[9D4(,R!8SDY!)<\@577[R5L=!;>#(K+3[VTL=3N[1;YVDG-O'#'EF"@L
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M@XR",^QJE_PL?P1_T.7A_P#\&D'_ ,57244 <W_PL?P1_P!#EX?_ /!I!_\
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M2Q.&212,AE(X((.014E%.[:L0DEL%%%%(84444 %%%% !1110 4444 %%%%
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M!C::3T_'\ 6ITM%4])EO)]+ADU)8UN6!+K&A11R<<$D],44 7**** "BBB@
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M4VN!<^8T<WE)*RD;!\H60#=P<@\"A7_!?D-_Y_GJ:6I>'++5+E[BX:=9&C"
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M&&[KDEH#KU8.@93E6&0?6EIL:>5$B LP50,L<DX]33J0E>VH5B^)&T=8K/\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 <WXJTR\O+O3[RQTVUNWL&:<.T@2?<,%40E3@,1\WS#.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M9MSR&XDW.,J=K'=RN54[3QQTY-'46MAFG>*[74/#UYJ\5A=1QVI?="6A:5L
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M2_!=W=WW@;1;K469[J:RB>5WZN2H^8^YZ_C1;2Y-];&W1112&%%%% !1110
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M]X=TY!";N9#GK5KP;8^%++6-8'A6">*X:0&]W6TT<>\Y; 9E"LPW<X)(& <
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M<6.F"_'.H2W5AY8EV%>3*Z!9-I9,X)P2N>U6;RU\!V<<CWL&@QK%Y1D+)%E
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MKTFN:3%(4EU2S1U8*5:X0$$]!UZTAEZBLJ]\3:58BQ,MP\PU!REL;2"2X$A
MR3^[5L*!U8X [FICKNDC;_Q,[,E_N 3J2_ . ,\\$'CU% %^N>\8^)I_#%A9
M2VFG_;YKR\6U2+=(,95FW?NXY'/W>@4_@*OVWB+1[J&&2/4K9?."%4DE"/\
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MXQ@]:2M8?7[O\C)N/B$]M%<7,NC2-:P/(NZ.<-(VUY$X3&,EHSWZ'.>U0O\
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M;80L@=_*C=F#B0D*"Y4?(02OWNU78_&FGW/A_4=5BM)YDL+@VTL*/"[,^5&
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MZA1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-YG_ "Q/[@''/+'8<'D9UY/%FK6T_P!CGTFU>\(B"[+MA&'9&9E=C'\A 0G
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M_K\0.AJAKG]G_P!AW7]LH)++RSYJE2V1[ <YSC&.<XQS5^JFJ6AO]*N;59A
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M@DXJ3:QX@%VK6%QJ4\7]J*HBGLMCM!N57SBWVD9W;070[?F+'&VJ>_\ 7?\
MS_ E;?UV_P BSIWA;5=.\.WMA_9VDW!N8T5HII6:)Y%50964Q_,6.YCGNJ\G
M)(NZ#X:GTS78+E[.VABM]/2T26.?=+-@+DRG8-Q&P <\#/K@96DZSXEG\+WO
M]H/=Q:@9E:%VLF&(OW>\#$. WS-P58 \;G"EJL^%-4\47.O"+Q#;SQPFV7:
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MUOK*:%[RXA\^-4N2P>,A5\Q4SC!"H-P'ISS0ALV:***0!1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M15=R@!)"1EUWGC& =V"< G KH:SM8U*QTV.V:_BDG:6=4@CB@:9R_7(4 G@
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MD 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@8XQ@ !FA>!=.\/ZG%?6=Q=2RQVJVH,[AV**JJ 7(WD?+D*3@%F('-=-10M
MW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
>**** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>exhibit102imagerent1751.jpg
<TEXT>
begin 644 exhibit102imagerent1751.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<FL@17-C
M:&5N   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,Q-0  DI(
M @    ,Q-0  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( 1("9 ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?3+BSLX+6T%L\PD PLTA<B3&/EX4#)->E44BD[.YP,?P^U9UGNY_$(CO[J2
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M(PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M O#MWH'B+Q2UW9WT:7U\+F"XFO3-'(C(O 4N2&#!@25&1M&2 ,.VK_KM_G^
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M>IK<KFO&G@NT\;6^F6NI-&UK97RW<L$D6]9U",NP\C'WLYYZ4G?H-6UOY_\
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M1&MOZ\OZ_P ST"BBBH*"J&MZWI_AW2)M4UBX^SV<.W?((V<@DA0 J@DDD@8
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M_A&%[<\5/_!_X']?\,';\?Z_K]3H9O&IC\/6>HG1+ZWN+Z\BM+:QO"D<CEV
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MM3ERZV![Z?UM_P $=1114B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110!Q/Q"U;3K";2[:?7O[)U.XF'V1GU VT0 9=[N-P
M60 <!6SDD #N*GBF\,VE^*]9&IR:='I]H]E9SQRK&3(JEW*L?5RB<<YC.*[2
M^U/2[&XMH=3O;.VFN7V6Z7$JHTK?W4!/S'V%1&XT?1U>TDD@M$5'NY!(=J*I
M?+.S'@99L\GUI=/O_K[BD[2OZ?U]Y@OJ$&M7FDQK>JUE961U&ZN8Y@1DJ4CR
MWU\QL^L8KDM-UW3=0BC9/%4W_"-W-]*5E&LN9H L(*)),'WIN8.X0L., CJM
M>FR2:7ITHN7,43W[+&)!SYI"DJ/H%#'TQDU /$?AS^R3J(UG2_[/\SRC=?:H
M_*WYQMWYQNSVZU3UO_77_AB%HE_7]=3A_#^O17OB?P_;3^(7AUL6"2:G9W%_
MM\P-#\J+;EL;\_O"P7( P3SBNC\!:G'?0ZS"FL'53;:E(JR/<+*P3"X^[P!G
M=@  =<5NKJVD2:I]A2_LFO\ RO.^SB9#+L_O[<YV^_2G:9J6F:I#)-H][:7D
M2.8W>UE6158=5)4GD>E.^M_ZW_I ]?Z\B[1114C"BBB@ K)\42&'PQ?.-3AT
MK$?_ !^32;$BY'5OX0>F[MG-:U0W9MQ9S?;3&MML/FF0@*%QSDGMBE+8:W/,
MX==L;7PUX;DM-6.FVT.JI;"-=4$\-S&&&YEF;#2QC. >!SR.!5GXEZV^^VBT
MK5A#Y27!FV:@;4(Z!""&4C?*N[(A;Y6!.[&!7:V&LZ'?:38W=E>VCV=UA+1]
MZA9#V5<]^.G7BI]2U32M)2)M7OK.R660)$;J98P[GH!N(R?8577Y_HOZ^8E=
M._E_G_7R.%\.ZM<7?BFT8ZC<R:A-?745[8R7#$0VJ*QA8PYVQG_5'< "=_4U
MZ/5(:KIG]L'35O[3^TC'YAM1,OG;/[VS.['OC%7:&[I"ZL****0PKS/5M7MK
MGQAK-GH'BF.VN[:RE6\@NM5VKYI*%=D;$^6$7=EU4#+CJ0<>F5GKJVCR7]U:
M+?V+7=JF^YA$R&2)?5USE1[FEU^\?0YGPAJ2G1]2AN]3>WMFN91I\\M_]I<0
MK&A=EFDSO"N7Y.0.G05SEKKT5YX<T-=1\0S)8&*^,M['J+1NUQ&X,2-(K D[
M2S;2<-@<$<5Z/:76BZE FL6-S97<"1-&EY#*KQJF06 8' 'RC/T]JJS>+O"E
MMIL%[<>(-&ALKAB(;A[V)8Y6'7:Q."1[4Y:_U\K_ *^HHZ._J<?HFOZU-XNT
M:77TU&SC;3I$DA="L#%8XV>9NV=Q8<_= '3<:3Q-XEM3XHE7POXA#:O#I\MP
MUFVH92<&!C#'' 6PS$XDW*N<#D_,!7H:ZC82SP0I>6SRW$1F@02J6EC&,NHS
MRO(Y''(J,:GI1UC^S1>V?]I"/S/LHE7S@G][9G=CWQ3>K^_]0CHEU.=\#W4<
M]]J,>FZE-J>F+#;O'/+=M<XF8,9%#L2>FP[<X&[@#I785!:W5I<F9+*>&4P2
M&*98G#>6_!*MCH>0<'GFIZ&[NXDK*P4444AA1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R7C@7]T+/3[
M70;S4;.Y<&]GM&@#QHK*P0"21/O$<D9P >,XQ0U?3I]=\.^*KP:6]]<7R/96
M,&U P2-616^<@#]XTC9ST(Q75:KK^G:(\"ZE+)$)VVJZV\CHO.,NRJ0@R0,L
M0/>HM5\4:5HDTRZG<>0EO;?:9I",JB9P,XY))#8 !SM-+I8I-J5UY&1:BYU#
M5K9KG3IUCT?3L_990F9+B0%=N<E<A%(ZX_>UA:;9:TU['KU[X7OX[M[N62[L
M6DMOXH!&ACQ*00H4*22I.XG&.!WEYK5G8I9M*S,+U]D.Q<D_(7)(] JDUG?\
M)OH/V-KG[1<86?R##]AG\\/MW8\G9YF-OS9VXV\YQS52UO?^M2(Z)6.:T73-
M6L]4T'3M3\/7;VVC6B[+V!X#%+<&#8Q;,@?:JDH!M.2<G  K:\%+?S3ZI?ZQ
MH=WI%Y=R(3%.T)0(J[45#'(V< <EL9+<#'33B\5Z-/J%O917;-)<Q^; _D2>
M5*-N_"R[=A;;\VT'..<58TG7;#6O/^P22EK=PDL<UO)"ZD\@[9%!P1T.,'L:
M;;;N_P"M0-"BBBI&%%%% !63XHACG\,7R3V=S>Q^7N,%HRB5L$'Y"Q W#&1D
M]JUJ@O;VWTZRDN[V4101#+N1G'X#DGM@=:3V&MS@9;36[K1M#N+S0[J\N[?4
MDN$D9+9+B*W# _O-KA Y[A.#@9Q4WCO2=7UZ:+[#IU[&D45S;EX&A+3APF$8
M.X A?!W$8<;1@KU/20>+M)EM--FN));.34G$5O;74#QS%^FTH1E><<GCD<\U
M/K/B32] \K^U;AXC*&8"."27:JXW.VQ3M09&7;"C(R:K_/\ 1"5T[]?^"SF?
M#FE>(M-\3.)DG2UENII[EBT)MV1E'EK'C]YN4X'S<84_[-=U5"UUS3;W5KC3
M+2[2:[M8UDFC0$[%8D#GIV/&<U?HZ(5K-A1112&%><>)_#VMZSK]U-9V=XT*
M6LT2Q736RPG+1MB$H=Y,FSGS<XSVKT>L>;Q7H]M?7-G=73V\MM$TSF:WD1"B
MXW%'*A7QD9"DD9&:.MPZ'*W5GJ5Y9Z_:)I5Q#/K4ANX;:1H_E2)(4*R$$J#(
M58 9/'7'.++Z/JM_I^LJNGR6:Z[J"!HY'3?;6_E1I(YVL0&(1@-I)RRGUQTE
MMXETJ[TBXU..X>.VM<B<SP20O"0 2&C=0RG!!P1R"/6JC>.=!6P%VUQ<A/,:
M)HOL$_G(R@%MT6S>H ())4  @]#3V^Y?=I_P N^ACKX>UJR^($&KK;VEQ:)%
M-$IB8K)%"%01Q ' Z@GTR3G'%,UC3]?U3Q5I][IEK=6AMU=\7PMS:Q.T#*)!
MY9\TR!F"D$E<!L#H:Z:W\2Z5<ZLFFPW#FXDC\R,F"01RK@'Y)"NQB 02 20*
MKWWC/1=,UA=,U":ZMYV)"R26$XA)"%S^^V>7PH)^]V-+8%Y&=X"T'4O#_P#;
M,&HP6\<<UXLL+PR%C-^YC5G.><EE.<\DY/I775G:1KNGZ[#+)ITDK>4P61)K
M>2%UR,@E)%5L$<@XP1TK1IMM[@%%%%( HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YGQ?8Z[J3V-MI5G
M8W>G>8)+V*YO7MVDVD%5!6-\KD9(XS@#.":J7FCZKJ?A[Q,T5O&-0UCS;:%+
MF4QK'"%,:9(5CC[SXQ_'6WKOB!- CCFN+"\GMBP$UQ J%+<$@;GW,"1D]%#'
MVJOK7BRVT2:^\ZUN+B*PL_M=PUNA=E!)VJ!TY".<D@#'/6ETL4FU)-;JQ5L;
M+59-6CN+RUCC?3=.$-LGG%HI)W^^=VT' "(,X_B:L?3?#WBJ&:+5KRQTLZPM
MQ+)<!=0D:.X$D83(/DC9MVH N&^4'G)R>LO=<2V_LY8K>2=[]CL1?O*@0NS'
MZ  8]6 K+'CJ!A)"NC:H=1CN# VG;8?.R$$F[/F>7MV$'[^><8SQ3EK>_P#6
MI$=E8S=(\.^(M-U72+>XM=.N]+TBS6&UF^VNDBR^7M>0Q^402>5'SC"DGDFM
M/PEH-_I%]JMU?!84OGC=8/MTMXRL 0S&60!L'@!.BA>,9Q4]KXPL[N_TV&.S
MO1;ZI&&L[UD012MY9DV8W;P=H)R5 X(SGBK6B^([/7KC4([%)@+"X\AY)$ 6
M4[0=R<\KSC/'0]N:IWOK_6H/4UJ***D84444 %9WB""2Y\/WD4-C#J#M&=MK
M-*8UE(YV[P"5/H0.#BM&J>JZG!HVESW]WN\F$9(09)R< #ZDCKQ2>PUN<@-"
M\3G0-)A:.VFFM]02\:*YU&20V\:D$1>:8RTIZ_,P!^O6KOBGP_J?B!&6*W@@
MF:.:T6Z2_D0I!(%R2@3#\C.W(^Z/FY.+R^*OL]GI3ZMI5]97.HS+!Y&U9!"Y
M./F=3MQZ8.3V'!J77_%%OX?DC26RO+QVBDN)%M50F*%,;Y&W,N0-PX7+'/ -
M5_G^B_3_ ((EH]-_^"_U*MAI.J6OCB:^:"V_LXZ?%9I(+AC*3&SMN*;,<[\?
M>[5TM8$'BOSO$T.C/HNI0_:$>6"]<P&&5$ RPVR%P/F4<H.2*WZ-;:B_K\ H
MHHI#"N"U_P &ZMK6O75[%Y%KF!XT:2_FG67YD9!Y3+MA&4&XIU[YKO:Q9/$T
M4&NR:7<Z??PN())X9O+5UN%3 ?8J,7R-R]5&<\9HZAT,*;1M=N+?6[9[2T2;
M7%>64^:9(;?;''$B9*?,6"L2=O'H<#.1-\/=7DTA+0I"T"W,TJ6S:G+YL>^-
M5!:Y\LO)R'RK#!# $D+@]K!XHL9O"+^(C'<16:1/*R2(!(H0D$8!QG(/>LL^
M/X3;P>3H6JS7<MR]L;-#;B1&50Q)8S",C##[KGKCJ#@\@OL_ZV([+3/$Z^)X
M+C4[33+JULK3R;2>.\>-E<H-[F'RL99AC[_RKT')S?OM#NM9U 3ZO!;2V\6G
MO#':"9MK32@B0EMO "@*&QG#-P*M_P#"0HGB*+2+C3[R!IU8P7,BIY4I4;F4
M88L"!W*@'L35>7Q=:QZ\VF_8KUPLWV<W:(AB\_R_,\K[V_=MYSMV]MV>*-_Z
M_KO^01TV_K^K?F,\*Z#=:3+?7=^Q\Z[,:K%]I:X\M(U(4;V523R>WY\FNBK+
MT378];^UI]CNK&XLYO)GM[H)N1BH8<HS*058'@]^<&M2FQ)6T"BBBD,****
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MVL3PIJU[K&EW$VIQV\=Q!>W%L5M]VS$<A0<GD\#KQ]!6W2*ZM!1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#+U;PSH6OS02ZYH]CJ,EOGR7NK=9#'G!.TL#CH/RI1X=TMM*FTVYLX[NT
MGE>:6*Y42!V=BQ)!Z\G\JYSXA:MIUA-I=M/KW]DZG<3#[(SZ@;:( ,N]W&X+
M( . K9R2 !W%3Q3>&;2_%>LC4Y-.CT^T>RLYXY5C)D52[E6/JY1..<QG%*^G
MW_U]]BDFY)>AU]IX>TNQ:X^S6D:1W$*P/$%&P1KNP@7H!\S''N:JP>"?"UK8
MO96WAW2X;5Y!*T*6<:HS@8#$ 8S@D9]*RWU"#6KS28UO5:RLK(ZC=7,<P(R5
M*1Y;Z^8V?6,5R6FZ[INH11LGBJ;_ (1NYOI2LHUES- %A!1))@^]-S!W"%AQ
M@$=5JGHW?^M2%JE_73_(]''A7P^NM+K"Z)IXU-  MX+9/-4!=HP^,_=X^E:-
MO;06<"PVL*0Q*20D:A0,G)X'N2:\PTGQ%%<:WHL4_B&6'6TTT3:G9RWIS)F
ME42V+8,F<2$JN1C!/(%:7PMU"ZNSJ"7E\]VWE6\H(OVNT!8-EMS$^6YQEHA\
MJ8&W.<T[;KM_F#T/0J***D84444 %5M2TZTU?3;C3]2MX[FUN$,<L4BAE8'V
M-6:R?%$AA\,7SC4X=*Q'_P ?DTFQ(N1U;^$'IN[9S2EMJ-7OH5W\#>%)[.RM
MI_#NES06*[;5)+1&$(X)VY'&2 >*MWGAK0]00I?:197"F4SD2VZL/,X^?D?>
MX'/L*\WD\0Z)%X7T6TMM;_L>Z-R8;%SKK-;,J,N^02LP$\>#A0P.2<8[C?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MW-=!0[7T!7MJ%%%%(84444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>exhibit102imagerent1801.jpg
<TEXT>
begin 644 exhibit102imagerent1801.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<FL@17-C
M:&5N   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,S-@  DI(
M @    ,S-@  ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( 1L"90,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
M     0(#! 4&!P@)"@O_Q "U$  " 0,# @0#!04$!    7T! @, !!$%$B$Q
M008346$'(G$4,H&1H0@C0K'!%5+1\"0S8G*""0H6%Q@9&B4F)R@I*C0U-C<X
M.3I#1$5&1TA)2E-455976%E:8V1E9F=H:6IS='5V=WAY>H.$A8:'B(F*DI.4
ME9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4U=;7V-G:X>+C
MY.7FY^CIZO'R\_3U]O?X^?K_Q  ? 0 # 0$! 0$! 0$!         0(#! 4&
M!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<  0(#$00%(3$&$D%1!V%Q$R(R
M@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9&B8G*"DJ-38W.#DZ0T1%1D=(
M24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"@X2%AH>(B8J2DY25EI>8F9JB
MHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR
M\_3U]O?X^?K_V@ , P$  A$#$0 _ /I&BBN>U'Q#>6/CC2-%^PQFSU&.8_:C
M-\X:-=V F.G/4G\* .AHKS-?BQ<#^U-^E0LUBCAH5G(>&7[0(8XY,KCYR=V5
MR  >O&;M_P#$'5=/T369GTBVDO=%OH[6Z5;DB(HXC8.IVY)Q(!MQU!YH6O\
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M:^LU>-;V5+:1WC8J2A5H3'CY1@A0WOR:["BDM &QH(XU1>B@ 4ZBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFDO[*8J\SLSJ4D#(R_.<94XP#U&:LQI\,8K6:W3QUI(26[L[L[=3M$ >V"!
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MRS%PY+<_-\P!&<X(&*UZ.@M;A7-ZAKFJVOB[^RX;:V>WDTRXNH,%FD>2-HP
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M0G)RJ+N4 DYQ5Q? 6A+8PVC+?2QPAT1I=2N'?RV #1EV<L8SM7Y"=O'2KO\
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M:V*H75A1112 **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ5O> [M+G0YXHO,D2UNGA%PVH27J3X .Y)I#N8<XQV*D=JZ7 YX'/7WH "J
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MVWMK';Q1-:.3'Y9<J2?,^;_6'. .@Z5G0^#M8@\,:'I,>KV.[29XY?-:Q?\
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M=V] 6J31V\$$=M;QP0($BB0(BCHJ@8 I]%%+<-@HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *1T$D;(V
M<,"#@X/YTM(V=AP=IQP?2D]@.;T_P+I>DI:0Z?-?+:V]PMQ]GN+V:X4LH;:!
MYC-M 9MWRXR0/2IM2\'V&H75]>":\AN[ZW^RRRK=2%?*Y^4(6VC[S8XX)S6+
M!K.JV^A:S,FHR:G&\Z6VDW<T4:M+*^$X$:J#&'88.,X5N2.:OV-_?:;XMO\
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ME#J,US<&RO3;Q3W<4<<LB^6C?.(P%R"Q' '0<9S37;R_4'^ITE%%%( HHHH
MQ_\ A%].&K7NI*UZMU?1"&9UO9@"H)( &["XW-C&,9-4T\ Z!'I\%DL-W]GA
MB,"I]NF^:(X)C8[\LG'W3D=?4U6_M+4%\3^([*_UA+6SMK&WN(9EA1?LH=I@
MQRV03B,<MD9[=JSC?>(_^$=TQQJ]R-4FNF%I;O;0A[V'S/E>==GR 1?,VS9C
M/K\M/K]P/2YT,WA*RO898]1GO;A)99'>,7<L<;*V/W916"E % P0>_\ >.5_
MX0W0S<2RO:,ZR^9F!YW:$&0$2$1D[5+ G) [GU-9GBW5=0BU-;/3=3.G+#IU
MS?M*D<;F1HB@"-O!POSDMC#=,$50TC6_$LWB.TCU!IX?[16<K;R01FWA14W1
MR(RXD)Y 8,V,G V\92U7]>GZ ]/O_K\SI+?PGI=K"R0_;%+EB\GV^;S'RFSE
M]^XX7@<\=1@U%/X*T:XTU[*9;MHY9UN97^W3"261<;69]VYL;5P"<#:,=*HZ
M%J.LZEX!O91=I-K DOH+>9D1 SQRR)'\O3C:O]<UAW>L:_;^#]0%K>ZY/K&E
M3,+C?%8%E/EAP7PH0PX()V#S.?6F]&[_ -?\,-)Z)>9Z/&@CC5%+$*  68L3
M]2>3]:=4-G.+JQ@N%=766-7#*" V1G(!J:AW3U)335T%%%%(84444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4CH
MLB,CJ&5A@@C((I:;*56%V=]BA22V<;1ZTGL",2Q\%>'-+FADTC1[/3O*F$^V
MSA6)7<*R@L% W8#MC/3-2WWA/0]0FNIY]-MQ<W<?E3W*1JLKH>JE\9P1Q]#7
M$Z-X@M;[0=:_X1G7CJ,5]=1V=@C:@;N:!I!M:1MS,R#[SA#T"9 &<#3M=7L=
M!\=:M9/K1>TLM&AE%H]PI$&PR;@J#H=JJ3WZ9/2G_7X7_P @M?;^M;+\3I]2
M\,:%K-W;W6K:-87MQ;8\B6XMTD:+!S\I(R.>>*;-X4\/W$=XEQHFGRI?$&Z5
M[9")\'=\W'S<\\]^:X?4KRVTJ+P_:ZAKK:5X@U&X6\*2ZB8(E#2AY0RE@LO!
M\I5()Z8 P2*L/B"SMO,N]:UZ\2!K2ZDUM%U"0?99%G18E4!AY).64!=NX<\G
MFBW3U_X(UJ]/+_@'H,?A/P]%96UG%H>G);6CE[>%;5 D3$Y)48P,GGBM>O,#
M;+K?@W08X-?OKG4+VX:"VN=.UJ;;''O+MO>)]LK1QKMW-NRPZ\UZ<!M4#DX'
M<TV2A:***0PHHHH R]0\-Z-JFL66J:CIMK<WMCG[--+$K-'GT)'MQZ5$G@[P
MU'?7-['H&FK=7887$PM$#S9.3N.,G) /-<[XXO[:Q\3:1+>7\4GE,'ATQ=0-
MO<.^XKYD2#_7G!*E#QC)INF>(=&_X6%JWV7Q*A@LX'2^M;G4M_[[>O*1,Q\M
M4'RDJ "7 Y(HCKMY_P!?UY!+3\/Z_KS.L/A[1C-=3'2K/S;Q2MR_D+F8'J&.
M.>G>K5G96NG6B6MA;Q6T"9VQ0H%49.3P/>N"O=1$WB3QEI<7BE8&.EPM$\UZ
M$6S<F8,1MQLQ\F2.>F36]X#NTN=#GBB\R1+6Z>$7#:A)>I/@ [DFD.YASC'8
MJ1VII?D#T?\ 78Z:BBBD 4444 9,_A3P_=3W4USHFGS2WB;+EWMD8S+G.&)'
MS#/K55O /A![>W@?PQI#0VK,T$9LH]L18@DJ,<9('3TKGI]?TVR\6^+8=7\2
M2BQM]/MYY%%YM:V^:;S @3!4X" X^;IDYQ6!_::#0])U5?$BZE!;F>2+3X?$
M,BSS!IE,<>^-C]H=%^0JQ();!/.:<5JD@EHG<]*;PMHLJ%;O3K>[)N&N=US$
MLA\QNI&1QP /H *L1:)I<-S<W$.G6J378*SR+"H:4'J&..17'>/M1MP]M=Q:
MQ&%T\3&738M7ELI;F0>60J^4<NP!QL/!,@]:R-0U77++5M4GTJZ>]OEMKV9X
MH[]IEB0(3"C6_*Q.K;5R!EB#][LN@[;6ZO\ 4] A\*>'[>V-O!HFGQP$N3&M
ML@4EQAN,=P2#ZTC>%/#SVD=J^AZ>UO$Y=(C:H55CU(&.I[^M<IHVL6TOA76;
M%-8AM9W218-2?5Y+J-G,&\NLDG*[,Y*K@+C(QT&%/>1GP_L&L%(M-NI2Q/BB
MZ U(B)3^ZN,[VP6P4Y :F]'KY"6J37F>O@   # '0"BH;.8W%C!,8WB,D:OY
M<GWDR,X/N*FH>CL).ZN%%%%(84444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 444V4J(7+@E0IR%!)(_"A[ 0RV5
MH\L,\L,>ZV8R1L1C8=I4G\B1^)ILMM9:I9D2)%<V\Z@Y&"LB]1R.HZ5YMH\U
MI-H^JV^AV-UH[:Y>QVL5C)836GD(RD/(-Z*&<HLCDKGD*"<\G5-W9>'/'>MW
MB6MXMO%H\0W&"8QL\;2'8KD;?NE  #CGCFC^OPN%K_UYV_S.Y5H+@L4,<IC8
MHQ!#;6'4>Q]J>8T.<HOS=>.M>::QI]I91^'-/U+3KE]5>9;R;5;?3YKC[,_F
MB20*Z*VQG8E>2!MSDX !I0V\%@);O4/#M[>-':70UN)=/D<W\IG3R0?E/G<!
MB"-P5/0<4?\ !_ %J]#UD(JXVJ!CI@=*6O%=4T=Y_#NAI96=S<1V]O<.D<NE
MW'RR-*&$,"L@:W=?NI*P "CH1R/:4)*+D$''()Z4VM+BN+1112&%%%% %>=;
M075M+<^4)@QC@9R,Y(R0ON0OZ5-Y:;B=BY/4XZUPWC?R(_%6D3+;-J%^!_HU
ME-I\LT;X;ETF4;8)!GEFXQQ[U'IEUI<7Q$U>_MM+O[!K>!X9MFE7 ^WMO4F4
MOLVOMQM3!)P6/2B.OX_@#T_#\3O?+3<3L7)ZG'6E "J H  Z 5P&G_V3<^/M
M;GBTW4-.$=K+!<,FG7$1OCN!:4RA '*XVIABW+8XQ6S\.\)X)M8/(N(# \J&
M.X@>)@/,8CAP"1@CFA;7$]'8Z>BBB@84444 -\J,DDHN3U..M C08PBC:<CC
MI7GT\MC8^+O%TUUI6I7UI+I]N9(A93RBY='FWHF1AOO(-H.,'TS7.3:$+OPK
M9C2[=WNFCN%L;.?2+F-;"9Y=RF$LB^5LSM#$+P,C R*:5VD#T/8(+.WMD*P0
MH@:1I3@=78Y+?4DU*%522% )ZD#K7#>-KRTO]-L7@CO;J:QUFV5OLUO-(%,<
MT;2DA 00%SR?]H#G-4-.L6/BKSYK&ZCO_MMZ^H7JVLB&6S*OY*B4#YL!HMJJ
M205/ (-"5U?^ME_F'2_]=?\ +\3T@(H& H '8"D\M-H&Q<+R!CI7GWAPV[?#
M>^T>>#4[5;B748@?[/G+QQM)*RM@KD_(P(]3QUK,'A>QU'P9/HW_  BVGR1-
M?BWTZ<:-Y 59$7S+@Q.#L*C?\QP&*+ZBBVMD'_!/5J*BM;:*RLX;6W79#!&L
M:+Z*!@#\A4M)^0E>VH4444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "@D 9/ %%-D.(F.SS/E/R#'S>W-#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>exhibit102imagerent1851.jpg
<TEXT>
begin 644 exhibit102imagerent1851.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $UA<FL@17-C
M:&5N   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,W,   DI(
M @    ,W,   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( 2D"S0,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M?_@9HL_Z];?Y_<*ZZ?UI<Z^BBBD,**** "BBB@ HHHH **** "BBB@ HHHH
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M)_B"MOXPM]&>SMY(+J5X(YX+S?(DBQM)B2/9A1A?[Y/(R!6=8_%<S:;]NO\
M09;:"71WU:V\NY65I40@,I&!M.6&.3D>G2G:_P#7K_D([J;2["YEFEN+&VED
MN(?(F>2%6,D7/R,2.5Y/!XY-53X9T$ZG!J1T73_MUL@2"Y^RIYD2@8 5L9
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M5KYNI2W4-Q:1Q1QV]N[*OD.JJ9&&%!!+=\XH"SL>RT5YU%\59&T>:^F\/RC
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MT,M_:WMK<7MZ-3N[>UM[&$,PAA"DNP+#@;AGN<C -*^E_P"NG^:&]';^NO\
MDSO**\[TCXI0KX5T:ZU:SNKJ^N[*"YN?L42!8O-?8F0[@_,XQA=Q'? YKT0'
M('&/:J<6F(***R/%FKS:!X.U?5[5(Y)K&SEN(TD!VLRJ2 <8..*ENRN.*<G9
M&O5:_P!.MM3A2&^C\V))%EV%B S*<C('49P<'CBO.= ^++R1O_:L<&KH?LT<
M-WH$1>.2>8,?(VL[8==HS\QQN&<5T<OQ$TR#4?LTMEJ"Q1W$5I<W9B3RK6>0
M*4B<[MV[YU!*AE!/)J^5WM_7];?AW)NK7-FR\.Z7I^K7&I6EKLN[C=YCF1F'
MS$%MJDX7) )P!DCFJ5OX&\/6NL/J4-@PN&:1PIGD:*-Y,[V2,ML1FR<E0"<G
MUK!A^)]A:0SB]\^^N5O+M!%:P)$8X8)-K,=\F"%R.0<MV7M6A<?$.Q:.[;1=
M/OM62UM1<27%LB^4A:/S$5BS!LE2#PI SSBHT4;]+?@59\UNM_Q.CTK2[/1-
M)MM,TN'R+.UC$4,6XML4=!DDD_B:MUD^&=:E\1>%['56LY+*2[@6412X.-R@
MY&#R.>.A]A7(:7XN\16FO^)%\5WVBKI/AU$>YDM+"9)) \6\$$S,!CIC!S[5
M4KJ34MR8V:3B>BT5Q@^)^D?96=['4A<K=16OV)8XY)BTH)C(V.5PVT_Q<=P.
M:6[^)FF66H/:3:7JY>*YBM)62V5A'-+&KHAPW).X#C(!ZX'-+^OZ^]#.RHKD
M[KQNDWPZUCQ)I5K)'/IT-SNM;U,-'-"#E'"L1U'8_0UFZ;\03IOABWUCQA>V
MLEM<RI']IL;&2"*U+)N D\R1B<G@,.,D"C_@?CL'_!_#<[ZBN,NOB=I5D3]I
MTW5D6*"WN;IC;KBTBFR$:3YN,$<@9(].M,/Q!@LM1O+2YBNM1F.J/8VD%C:
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M1JM/3_@?UZA>^O\ 7<C_ .$\TC_GS\0?^$YJ'_QBC_A/-(_Y\_$'_A.:A_\
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M'4,&!R:+_P"(FL:??7.DWU_HNGW>GO*DE]=P.L%ZZK&Z11KYH*.RR]V8C:<
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M$%YJ^I7DU_:K9/=2-&LD<"YPB[$ 'WFRV"3GKTQTL,,=O!'#"@2.-0J*!PH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMY6^0TK?><OJGA*]T[2-.ATJ+5Y=6:UEBN+RPDMECE>5@\@F\[)"ER6RBE@
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M@<@@]ZMR;O?^MW^I*BHV2Z?\-^@ZBBBH*"BBB@ HHHH **** "BBB@ HHHH
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MCJ</8:1KWB.UU234]+N=%U/47A^TM?+#+ ]NA.+9/*F+$8)W,=N=[=,X'1>
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MC$GF26@N%\U%_O%,Y ]Z5V&VG]=5^K/.(GTSQ)I^N:MJ<>NZ3-<O:$1V^BW
MEM8X)-T.%:$B1MV2VT, "!T&3V_@RZU&\T%I-4\Y@)W6VFN+;[/+-"#\KO'A
M=C'GC [' SBKUCXCT34[.XN]-U>QN[:U)6>:"Y1TB(&3N(.!QZU-I>KZ=K=B
M+W1K^VO[5F*B:VE61"1U&02*+@RY1112 *1ONGC/'04M% 'F/A_6$TE;Z'3;
M/4]6T'3;:7='/I,B7-O,KJ5MT)4>=G)Z D;02QS6AX6N4FT/4GABODU37+F:
M64-IUQ;QP2F'Y5S)&ORA44;\8+>YQ72VGBCP_-=ZG;6NIV/F::=U[MF0"+(R
M2QSQ[DU>TS5M/UJQ6]T>^MK^U<D+/;2K(A(ZC(.*'K%KNOZ_KR'?6_F><:1*
M =/NH].U*P@T;0C8WF=*E9DGWQ;0D93][L*.V4##G@\UTGPZ6X_L?49+B*;9
M-J,TT5S<6S6TETK8/F-$P!3G*XP,A<XYK:@\3Z#=)>O;:UI\RZ>2+MDND86^
M.N_!^7H>OI5K3=4L-8L4O=)O;>^M9,[)[:42(V.#AAQ5<U]?ZU=_Z_4CELDO
MZT5BU1114E!1110 4444 <.US86_Q@C$&GWB/)82PW%Q'IDWE/*S1,NZ8)L/
MRJ>=V!C&<\5RLP2YL?$]IHFG:G9VW]L6=VJ)H\T0:VC6!9"BO& Y!1CL ).W
MH0>?6OM]I]O-C]JA^UB/S3!Y@WA,XW;>N,\9JE;^*= N[2\NK36].FM[$D74
ML=TC+ 1UWD'"_C3B[)>7^=_S#J_/_*WY'-Z5J^I7&A7NFW,]W->7AN8])N+F
MU\B:>-8A^\D0*H3YR0#M7/R\<U0\'7^I:;I$Z-#JE]IUAI:-]GNM,\B2*X48
M,$0"*9!@=?FYQ\QS7>:?>:;J]O%J>EW%K>Q2(5CNK=UD#+GD!AVR.GM3)-=T
MF*QN;V75+-+6T<I<3M.H2%AC*LV< C(X/K2>E_3\KK]?O$NG]>?Z?<>;7VBZ
MIH,^BWDUQJ-M,UI=2W%QIMB+LB]E>-RA0H^%(#(&P.%QD9KJ[SQ1=:;X/6[U
M/1KNZU:WA@\VVM[.211.ZC[NU6)53G<5!P/4X%;PU[2#HHU<:G9G32H87GGK
MY)!.,[\XZ\5-?ZC9:78R7NI7<%I:Q#=)//($11ZECP*;VM_7]:_D-;W_ *?]
M?YGD=WI_DZ+I:Z5+J=MFTOA+?C1;AC-+,X:2 P% T:LQR&(!PH /)KU?0Q(/
M#VGB:S^PR"UC#6N[=Y)VCY,]\=,^U(->TAM%&KKJEF=-*[A>"=?)(SC._..O
M'6KX.1D4[[K^NO\ G_6MUN[_ -=/Z_I!1114C"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *YWQKK9T/15EAL+B\N9I/)A,-G)<B$L#F1UC5FV@9Z#GIWKH
MJ0D*,L0!ZFDU=6&M#@?#]K9W%YX=T;33<2:=H-B+IVN;=X7:1@T46Z-PI!P)
M6P0,?+[5FZ9KEOI$/C!=%T^[LY+B\C&FI+IDUM&[/##"NTNBC_69X'. 3TYK
MTF:2SL-US.T%OYKHC2N0N]B0J GN<D ?7%2R113E?-C20QL&7<H.UAT(]#57
MNW?KO]]P3:1YUXI6QTO3-+\'M8ZA]C:"(75_;Z9/<XBC8'8&C1OG9@>N, D]
M<9JV<4PO;#3I=,OOMFGZY>:C=RFRD\MK=Q.5(D*[7++(B[02W8CBO3(+NVNH
MR]M/',@=HRR.&&Y20R\=P001[5+N&[&1GTHNQ;:?UU7ZGD%R[^(],U?6+:SU
M6SNY[FQ,UI_9,\;P6<,V< 21A97P68JN[C"\XY[[P9=:E=Z7=-J<ES<1+=,M
MG<W=L+>:>$*N'>,*N#NW ?*N0 <<UT&] I)9< X)STI597&48,/4'-%]+?UT
M_P OS$U=W_K^O^ +1112&%(WW3QGCH*6B@#S'P_K":2M]#IMGJ>K:#IMM+NC
MGTF1+FWF5U*VZ$J/.SD] 2-H)8YK0\+7*3:'J3PQ7R:IKES-+*&TZXMXX)3#
M\JYDC7Y0J*-^,%O<XKMX9K8SSP6[1^9$P,R+U4L,@GW(YJ8$,,J01ZBAZQ:?
M56_K^N@[ZW\[GCYTY=8LM-V6VHZ3#HFDQV]RSZ5,VVY2:!T01[09E!B8DID8
M;[PSFNS^']KJ*P:QJ&J-DZE?_:(B+1[7<HBC3=Y+DLF2A.&.>YZUUI8 $D@
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M+'@&-5QU!44T]/E;]?Z_X(/5_.YY':R^%=2TKQ[I%MXDTF&VDOXI&GNKI;A
MOE0 O)EP64N"I)8<Y&:[#X;W-K+X?N8-.L]+AM+6[:**XT>(16EV-JDRQJ"<
M#)*GD\J>376".([@J)SPV /R-.4*% 0 *.@'2B_Y)?<.6K%HHHI""BBB@ HH
MHH X"74O#UG\:1"=5M%OI]+ECGADO09 ^^(JFPME?E!8* .,G'4USVC7?@2^
M;Q%?Z=?>&;;1YXHHOL,\\?E2%'.;BXC#<;F8*-PR0!GJ!7KVR/S,E5W]<XYI
MFV *WRQA>C<#'T-"V2_K>_ZAU;[V_)?Y'"> KW3H? ;V+75K;Q2W%Y';R0.#
M;R(&9RT'_3)5/ [!3R>M8/@ZW\*6?A_6-*N;3PQK>BV%E#<76I:79IY-PR;O
MDE7<X:4;0V=Q^]T'?U46=I)>17HC1IH8VBC<'.Q6() '09VC\JF58E0A @4$
MY  Q[T^_G^G]7#U_J_\ 5CQC6_#V@:'\,X[?4(/#NF:G>I/>Q6MZ%C:)Y,'9
M; =)%&Q05!.0/6N]UG5KF\\,QV>BP7<UW((8[R.%D^T6D4B;F)#,/GV@@<]3
MGM75L(W"LP5@#E2>>:4X7+' ]30]4T"Z?/\ $\0TM] _L/1[?Q=:QVFD0Z?>
M1V46IE/+,XGXV9)!D"\+_%PV*]9\)"]'@S1AJN_[=]AA^T>9][?L&[/OFM1A
M'L!<+M!R"<8'O3Z$]+?UU_S_  )MJOZ[?Y!1112*"BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH *Y+XC:AX;T_PTI\5P6%U'+*([6WU!D$4DQ!V[B_R@#DDG
MH!GKBNMI&17&'4,/<9I-75AIV9Y_HD,%['X4T*UU2+5K73+07US>6\HDCF*
MQQ ,"<C?O8<_\LJSO#OB70M('C@Z!J-I?2Q7JR6\,=X)WF=H(44YW$G,IVY]
M<BO28;"TMKR>[AA5)[@(LLG=@N=H^@R?S-)<Z;9W@B%S;HXBE69 1C#J<J>.
MN#S5WNW?KO\ -I_H):+[OP/,/%MKX4TBRT+PYJM[I=MKHCC==3OYHXGM4#[I
M)E=B,.S;L!>23SP#4%E+I#>(;.5I+;_A)%UF\.J/N'VA;'$V/,(^80[/*VY^
M7[N.:]>9(Y.656QQDC-+L7<6VC<1@G')%*_Z_P!>G?N'2W]=?\SQ 7'A:_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6!XR%B=!;^TI[Y%W 10V%U)!-<2$?+&IC(8DGMG'KP#6_6?K&@:1XA
MMDM]=TNSU*&-]Z1W<"RJK8QD!@<'!-)JZ&G9G+1VVHW,/A3PYK4_VB]AB6_U
M.3.[=Y.-H)[DRE#GOL-)I&IRZ!#XTGO[Z[U!=.O08S</N8YM86V*  !EFX
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? HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>exhibit102imagetma.jpg
<TEXT>
begin 644 exhibit102imagetma.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" *_!$X# 2(  A$! Q$!_\0
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MH_$&G?%#78]-FM;RTM[C[/?6MQ#'<6VJ$C[[!U89QQN R.Q%<]:>%?"GQ5U
M?V3?V_@SQ%)RND7LV=,NF](I]J^6W948/DG[XJL/3LKC<BM;?%B=K&WT[Q39
M_P#"6:5'B-)IIVCU*P7UBN<EL#KL;ANY%7]3^"]QJ5G+K'@353XRT2%"\]K]
MDD36-/&,GS(5W!U Y+QDH!U-<IXQ\':IX"U6>SUZPN-,NHWP%G "M[JP)5OP
M)K+@@A6?SEA0R,IP_4L/I77=F1/I^J?:5#J<KV(J[_:&:S[(LJ8"[5/85.8*
M([F;9,DV;H/5B[N//'%4=FU:?&^Q:LGF%FM/]',G\=4+R<7>G2V\OWC&W#G"
M]/6MB/$UJ?[P&:M> _#45]=W^MZA;)=Z)X<M_P"TYX9.([N<,$M[0GTEF>-&
M[B/S6_@-9RJ65RMSQCXF>"(O &B0>>MR+B:(S3J(SYEEC_EF1VS[UYOX+EL/
M%UXUUYAVJVV"+' 7W]#7T=X]GN/'NMWFI3K/-<ZP&>\^3AFQC)_"O%?&?PT3
MX<:G8W&FVJK;RC,R#H6SQ7']<YI<ATTZ=S0.EQZ>,AN0.#[U<\$>#KCQ)=32
MQ6.<Y>:=P1DCL#WS4-EX8U?QIYAM+.0+#]_8I*#\:]B_9]^'^I>,;-X;Z]O-
M'\.Z>I6XU!8C]G@FZK&SXP"?3KZ"NJ5[61LURG<?"36[_P 4? [5_"-E<R6M
M[;QG4HK1AM5X(5+.B9ZN<8"]22*\V@NH[BW1XA\LF68>X->FZ5XM\)_![Q-:
MZE8R7WC#Q!8NKQ^9</:V,3*P88 19'Y ZNH]5->:V\.WY!%'"C<A5Z+6-"C[
M.]NNIRU)7-;PCXUN?"\.NVJJ+BU\0:<;*5'.! P</'*/]I&!(_WC6?8SM';H
MC.9/+!"ENU2_9@G':C[, /EKI:L8QV'K%Y]*\8MU]JK3ZI'IJYD. *LV.HP:
MO:[E;<.M*.@-7,[Q;?1VFF+#-TD7?P/2O-O$/C"6[$4-K-_H\(P?7-=M\2;3
M[7%'.D[^9$A7RL<&O+[BR!CDX\J8G)Q72DF-:%JWUB=IW#3.(W&X\=ZJ:A?R
M27%ML+.WWB3Z9JK%))!!Y<A=CZD5/% \42S ?=^7\#5NCI<.:YZM\+C/?VL[
MN/EW#9[BNNFM]T>!7F'@?Q+?VL:Q09,0D50?]FO4BY$6\9.!V%<Y,B&&W^SK
M\U+-<^2H^9?FZ#/)IJ7!NHVZDYX'^-=-\&M)TOQ3XSFT#4X+5;S7+*2STBYF
M?:MM?9$D.2>%1O+,;-V$AH>A)RM_+]GMFE4!Y@.%/0UIZGH/D_#[1?$T&9K>
MZGN++4 W_+C<1F-D _V7CFC()ZL) /NFLC3;6XMVN(=0CEAN["0PW$<BE61\
MG@CL?7W%==\&KZWU'Q9-X'U258]"^($ TTS.<+I]^2QL[CT&V8JA)X"3R'^&
M@J,;''W3G5;-T;^)"H!Z9(Q7=_%*^_X6W\&M'\=S;?[>\*21>'-:"G+WH6-?
M(NV'^Z#$2.!Y40ZM7GB6EWIES)8ZA$\%[:RR0W,3##0NCE<$?A^6*Z;X1^*]
M-\'?$&*W\0LX\+>)!_8^I%%W%1(P9)<>J2)$W_ :45K<'*QB6NI>7>>9G=&1
MA6_O"MW3M*76G66(>9);J3&OJO4US]_X4OOAYK%_X<U==NH:1,UK*H.5# D'
M:>ZGJ#W!![U>\.>,#X#\2Z5>8C>UAE1;F.5MJO%N&\?E7F9EA958^Z=-&H=-
MI5GY,GVZ5Y-SC:J,,"+/84SQ?IOE>%CJ5KB0VLY@O%3EHU.P(P'H26!/;"^M
M=E\0?A?>:UH-MJ?A>2YUNQO 'M4C3?)*/=5YSFO0/V=/V ?%GB69M6\:7D?A
M;3-3LGMTT^ LUW<,Q!0RQE<)AE4\D'CI7AX' SIUKR.BI.\;'S#-:+!*".=W
M*XYI2Q!K<^)GPUO?@[\1=4\,ZED3:3.\43'_ );Q;FV/^*@'ZY]*PY#DU]8M
M3BY0+\TNX#FF$8-*N,\UIS6,VB!K-I)7;;\L@(;\:W[*-O$WP<GLK?YM8\(W
M<MU;K_SWT^78LJGV21FE_P"!-V%8%Y=S1_)']UJUOAQXU@\ ^+[75)+5;I50
MVU_"P^2YM&_UT9]F3<OXUC*"F]2HZ'*G08?%,!2S\PQDX8[>17:IITNK_#CR
MI!Y>I>#W18B?^7BRF^0?5UE0?+_=D8]JU?$OPZN_ACXMN-/0!;*1O-M+J([H
MKV%OF23=TW%&7('1B1VJ>PT2[D>::166SC1BSSC8K-CC:>]>?[6<*W(MC5[7
M.+2-7MY05X;L>]=/X1U+_A/O@_KGA=RRZMX/23Q'I!:4+'-;,Z1W5N5VY+99
M)5PPR0>.*YN>7>V>F.M019BU5;A',$BH4\Q>K ]5^AKT-;F7-<98W1U.(RN%
M&[J :N?;+AO"S:-'>S)IS7?]H"( ;5FV;"WXKQ4$4:K'L11$O]U>U+AHEV]J
M<HF<B-H$,A8#'.3BG$Y-%%*,;!3 G IA;(I9#DTFWBJ+EL2V[XJ61]U5@=AJ
MS#'N7=3CN03VY41<]>A^E8/C"\O]/\4Z9/8REDC7R&B[;&/-;UM#O?'>JGB.
MQ2RMH[D?ZQ)53CT)YK>)29:O8%CN&BC0(B\*!WJ2.T^SV^YP?+SCBEU.9EMC
M>K YM(76)Y=ORHS9(#'H"0K$#_9/I56XO/M0\K[:D,;J63##[W85MS%#M\3W
M12/YF'4-Q5K1+S2[?Q#:/KKW-GH?F*EY-9Q^;+$A/S,J]R%W$>X%:GC6QM/$
M/PDT3Q;I4,5H=*F_X1[Q!%&?N7*+OBG'KYR$ECTW)@5SIQ<Z6T<;M;Y(99%'
M.:) :GCWP==?#WQYJGAV_6%Y].D"^9$V^.;*A@RMT(((((Z@BG?#GX@6_P )
M?']GK-Y9G5+$[K+4K!U/EW=I*K++&<<X*D_D*W?%5R/''P1T?7_*VZEX-N1H
MFI&+YFNK9XV-I._NAB,!] L7=JY66#^T-,5#( \HX=3G-$0+_COP8WPK\>ZI
MH"7!FMH)%EL)>US:R#?')_P)&4GWR.U-\$^.KCX:^-=/\06Z"2+3IQ]JC/2:
MT.1.G_ HRZ_\"K;U./\ X6A\%X;LKY?B'P!+'I<S*,M=Z<WF&%_?8^8O9=OK
M7(_:TN;216&8W0A<=Q1*;0N5')_M!_![6?!?Q4OX$N%U;3;B87VC.S##6,O[
MV+I_TS=0?0JP[5OZ)'?:)9V&HVKO975C,EY'LZ1O&=RD'U! (^E=W8>%-2^+
M'PDT'SKG3-,U#PL\VGZ7MC*3:E:EQ+MED,A 6/S2%PG.YO2K!^ ^OZ7H\]WX
MIU/2?#.BLI*2R,;HW(Q_RPCA)<GT+;0#UQ7/]8CS<O47*8_QIBMK;QA!XKMK
M63^Q_B';C5+:&V4R&TNU!^W0$=@DVXKGJC!N]1V/PA\0S>%H=>NEM?"ND2#[
M1::EK,OV,S$9VF%6^:1L]"BE<]2*]-^&WQ7T*Y^$=QX8\$:1>?\ "0>&(;CQ
M%IVIZP\%S=W,L<02=8(A'M1F@#,J[I6+0H PS7BGBOQ+J?Q)U"35/$6N:CKV
MJW#>8US=2,Q&.P&<*/88%7*#EN4M#O\ ]L^ZTSXE:)I7Q/M+B>2'Q;"UMK[L
MN'CU2T58VD8=O.WJWO@XZ5\FZLUW:ZA8:C$466WE643AOWBN&RN!]0*^F_@]
MIEOX_P##GB?X>:A*$LO&D$<E@['BUU*&021GV5XUD0GZ>M> Z+X"OSK<>GZC
M9E+[2V_T^&0$ 2 Y&/48K.=948ZA*/,<YXIT?^R]06]EVK'?(9&6%@_DMT"O
M_=/L:]%^!7B=8=%-C<.F^<[HPISQ[^E=CJ<$?B1+:"XL[&YTX1%6@EDQY+_P
M[!W%8^B>!K/PM=3S16<,;(^UWC.>37+3S2$I<MR5"QNM;K;S/M^B_2D\AK6W
M&S[V\#\.]2+MD7=G++4D;,3DUZO304MR5W$$WR_=I4U"/3]0@O9,N+>12%].
M?O?45"_RI4+6OF'=O)7^[VK&=.,HOI?0%*QW/BEM*^*VN:?Y-R\/G;9;N8C#
M,01EL>H&<5L^ ?$&L1PS6^K^8?)4Q1.@W+M(]:\NLY3I\F^+Y/H:U&^(FKI8
M_9X;N6-<8P*^1S+(9U*7LJ235[W>YM"M:5SO/& NK31XO)DMY+0$"3=*%DQW
MP.?Y5Y9K$WVC5;A(%D%JKX02.'8#W8!0?R%137US<S?Z3,TC'OFF@3K( !^[
M]:[LGRF6&C[VXZU;G%=%A3 J-U:*+*$J[*=I]ZG)B)PQYIYECE"QJ?F3H>U?
M27NM3EB?3W[$&A^$T^'/]N+IME_PDUK<26E[>21C[1$RD%2C$;MI1D)P0,[O
M2NV^(OQ^T#X8O/=ZAJAO7F!0QP8D\S/&UL=,U\2S?%F3X:6MQMUV?3S<?,T=
ML0WF@>HKA?#7QN3Q+XV\I[=5L[E2?/).YG[9'K4)VT&[]#U'7=;AUSQIK.I6
ML7V6VU"?SHK=?NVXQ]T5D7NJK: [CAI#G\*E2)D3JVW879AU_P#UUS_BJ\MK
MFVM)$:Z0,/F=X]I49[U=F]6*[V9M2ZK8Q1%RW2J@UY6N8A:K]JFN'$44 &<L
M> ?SKD?$FE3^0\EI<))9[2PE=L?A]?:J?AF#4_AI%IWB#49;BU#,EQ8N%_>,
MN<@$=@>/P-+E2*/J@WWB/]CJVM+6QO#JESX^T9FU2V<C?I-SG?&4 Y/^BSJ.
M>]S*/X:\AM?#MS9V>VZMYK69@6;S4*F;_:YJ[X:^+NI?$+QZWBS5F\RZDEC&
M<Y\N-0%"CV"J!^%>G?M3>._#WC^+0+K2;JXDU.&WV3Q&+$8!//S>M)J*5^H-
M'DEK'L,<D+F&:,Y5UZBNWM/$.E?%RPM])UN:+P]JUHS"VU1%=_[3W!0HEP#M
M(*G'&/G.37%SJB9V].Q--O"MSINSRPQ]1U^M>?B:*JJTC2#L4/&?@"YT3Q5-
MINH>8D\0/[W'[N;WC;HP]Q6>VJ06$,$$$-Q'?6"^8)$C),C+R"?>NYTKXE1:
MGHT&A^+$\VQM\)I^K%2UQ8>D84?P$]3R:B\1_#R]^'!-W<WOVV+6HFFM+VW9
M9( N,8S]Y?HZJ?:O+A@%3E='1S7/J3X%>-O^%K_!_1M7=BU[:VJ07PQTE"@$
MGW;&X^[5T4$92X\Q?3%>+_LP:[IGPIM=&^RWVM:CHOBB%X?$5Q<VI2STK4D,
MK0HLGW<O%L)R<YVCO7O.GV(LH=WF"52I(?.:TJ19UTIZV/%/C;-IFD?'K06\
M0M'!IUWX>U",R.<*AVKL.?[V2W'LOK7Q5J_Q0T[PZ&TW36EU1[>3RX#(-HE3
M/)W<@'\#7U#_ ,%-7M=8T[P7;SJ65Q<A0G)ED(@# _0"/'^\:XKX%?L$V&H7
MD.N:K=306-S:#9;; ?)(0+G![D@MCU8TXSC3AS2,Y4YUJG)#<^8O&?G7NNQS
M&.2>YN!F.W5_/DB'IE0,_P#?(KUKX*_L0^*_B[IL5SJD?_"+:*^'^U3*'N6'
MHL0<,,^K8QZ&OJ+X8? 'P1\-K[[59Z3;WNHCE+^\7SG7Z))N5/\ @(%>A&=K
M^;SYY&>3U->9BLXFHVHGV.5\)1_B8MW_ +O_  3SGX-?LL^!_@2@O=.TV#6]
M79@?M]_ K2(?96!7/OC(KTF[U.2^=S*Q8R')SVJK-)F>GI&''!KYN=>=:7-5
M/N,/AJ%&G[.BE%=D0F:2)]@7Y31(A*_XU-.C>6<1RL>YC4M@>O%9BZZ=0N#:
M:8J:A=(<.'1Q#'[EB%#?\!)'O6M&A*;LEH35Q,*$.:H_=+<J&VM&>=X8+>,9
MDEF<(BCN<GC%)#9W^N+]ET#3FN97 \FXN@%LG)$N&#;@S@-$RDIQDJ-P)JIX
MQUCP[\*?#+:U\0]4B3248@QB)I%E+(Z+$EO\X.2V0[ D%1\PKU?]AC]JSX-?
MM+VNO:?8+J%EK]F-TYUF*.&2Z5W:5C%L=]YWQ%L=>!QS7M4,G7QRU_(^1S#B
MB"=J"^?_  #P_P"+_P 7OAS\!M;N;#Q;KZZQ( T<ENFF^<A5HIHY0MO\T(WB
M2(EIO-E4VJ;77)KKXM:/Q=^#%QXB\*WL,O\ ;UO(EM?7<GE 2LIVI(QX5R<8
M4U\>?'#X4:3XW_:C\>:CI>N)JVD7FHEX)U6145<?=.]5X/MFJ?@")](U[Q!\
M.3=AI-<TH:EX;FANF\JQU.UE,BPJ =F983*,D$[HXP/O5[=+ J,;QT\CY'$9
MQ*K-N:N[;]3]//A;_P &QO@_PY\)9M>^(?Q'U;_A85TIFLM2N(U@MM&NL'RP
M'.0^&PV[*@8^Z:O_  /^)J:S)JOA'Q5K>ACQ)X-U.ZT"XN9;Y%M]7-MMVW:O
MD!EEB9'#+P3YH'W#7SS\5OA;^T#_ ,%L_$WPZ@T3QA9ZEI%EX>MHM0L6NS:P
MZ,\?R3R30[U%U-Y@+$E6QE!N7<*L?M,_L3:G^QAXU\/?"_QY?OKWAWQ5IMK9
M6NMPH+&.6[19!;2.OSK$$D\V C)^2YSG)%=+IIQY6>/"6MV>Y_M7?M4:#^S_
M / :ZU:VEBU'6;B?^S],BL+A6>3?&YWH=K;E&T]!R<#(S7PK^T[8Q^$_BKH/
MQ"CT]+32OBA81ZE>Z=@A=,NRO^D63 \J >F>2IS52?7DT-5\9^)-!N[;6(1+
M;^#_  ;; ^7:1AF7S&#*Q#*Z9"E?FR/6NFD^'&J>.M!\1> _%&K77B+XG:V8
MO%,L$<"I:Z+)#$QD0\+MEEBDC0JBD?NASFKPU.--Z$5O>=SW7_@GO_P3N^'G
MQI^ NN:O9Z:;OSKK^S+^>*,O/'.R)E@HZX$@(]P:YCX&6&J?#ZR\9_#+5;:1
M]6^'M\EE;^<I5HHR,Y/H,G'UKT+_ ((B^-KOQKX!^)7@31M2FTK6]=MX;E+1
M-5?2S%B1D\Y)E^<L3\K(/X>:Y/\ ;3TN/]A#X@Z#'9ZY'XJ\8ZS9O!XHMC>&
MX38KJZ;YB6<R!BY&[)X%:8Z/MZ7(/"RY)\QUNCBQL_#6V^427DA$\@'($B]"
M#7&_%^;6O'MO;W!L;;25@&9-8#D!T'568_*&([5Y=K7[>MK:(L&A>#WN[QR+
M>(W5T)1(S<#"")=S9Z#//H:X[XQ^&OBMK'P^N?%GB73K_3]$M+F.V:TN3]F-
MN7.!BV0@ 9(Y=%/(KYF62MPM8].ICDSKO'/Q"T7X?VD5U#;R^))9,"/=-'"E
MO[9^9C] A^HKB-1_:EUW1O$=I?6EC;6MG;GRYK6-\I<*>I;N/2O.U1@BJ\YE
M6+Y N<KGUS71_"KX.:K\>/B+9^%M-WBXNP?.FCY2./\ B)/0$ ]*WP>3TL/^
M\?Q&'UIO8^QOC#X8\)_$GX2?;)-*MM:T/4+19]/@G'[N>-XPP1QZ$-A@?>OA
M*R_:[\9^ /VAM-OM<GFL?#WA2<VP\/V+;;*PM)(W63R8UVHQ$<C.N1R0.>:_
M5OP]^S]H/@#X)Z7X(#O?/H=@T NI5YE/)R>V>:_.G_@HS^S0GPQL;'Q- B0!
M[;_3G8A4\L 1(S$_Q ^4,?W=Q[5WX7W9.E+X)&SM)*HOBB?3_A/7Y=;T3S=D
M4=W&_EW,<<BR+&P)'RLI*LIZJ02"I4]ZV(_#&B^,M/FL?$&FVE]:QSB:-)_N
M[P" WUPS?@37SW_P3X^(%I?? A7F\^&ZTN?^Q)TDN%F$_E8>&7:$4Q@13I H
M)?*V0YR#7NUQ=O')Y;_>7OZU\;F&%GAL2Z?2^GH?I.!Q:Q&$YUVU]3A_[ L-
MFI3^;.FG6,PAA*)EFR."!W%3^$M5ET;5U@TQMNGW$#B\DE.SS9.@S4UQJ=J]
MS%IUK-Y$T/R0(WRQSCU8]JL6VF_V5:W,E_#;74$,RBXB5]R++_#MQU%?6MGY
MH>+_ +1GQ[OO!6FMHVCWIDU'/EN^1FR4]8U]C7AUE#K@N/[1=Y+G"EOWO C^
ME>A?M+'0H_C)I]]:6;6X;+:A!L(25\_>]^*G\8:U:76C7+:=;S7%I-&2L=K&
M9&B..,@=*ALS.#O-1T[QA;V;7%N;_5'86R6[ [69C@.?<5]+?"WX0:1^S[X#
M+1PK/X@U)<7OF<,DI& ![5\;6'B'4-*U/3I+6WF@U*WG3R25(DG?=P&';FON
M'2WO+CPWIVK^)D5=?U"WWS6\9W^0W3GT-3S#CN8NHP7;R6%BQ"S,N'0-\H;/
M'-='/HSV20P7T4/VBU&Y(E;(D(Y&:6%=.L+&&XD66>X"[V:1,?,.E:^A:2_B
MYUUB144ISC=VJU,U2&^%+P>&Y+K4(;6'^UM4D#&-FP(@>"*[30KB&:_C5]J7
M&PF5(^5W5AQ:?;WDDMZL,3QY^9V.#&W85-H=C<6-WYMLL3"5LRG=R*F4KBEN
M=EIUKLO0[2JJ-V)QD]J3Q+XQTWPY=+:ZE=K:22J60,0!CW)Z5PWQ[\=CP)\/
M;Z28)%*T9DLV!_?;@.&"^QKXF\6_M+7WBOX8SPZY<S:IKDS )/)U1.<\BG3P
MSJ.R,I2/</VL/CW+XR;_ (1_PW/FULO^/VY0]2.<(?XACO7R1XP@M-3U>*:1
MI1,!MB<+]_/K6]\%O%MVNFW4&?,8/Y:!C]V,_>KHM7^'J>*+NUM;5! BN-D@
MZA<\U-24\//E)C*YU/[.?AJXN+,Q7C^7J!8?9I$P?)3NN?2OIKXG_%#3/A/\
M)+#3M0>/3OMUHUM/=60,\DC-QYI4<G'M7D/P>\$PZ-+>6\5S-<R6WR%]N1(V
M.(U(ZD] .IK@/B-K5UJ/BV>/45N;2:Q?R8[&Y4QRVJG^$H>5_$4Z<I5)W9,M
M"'Q!\'M0\$^%8M8LYHO%'AUG"?VQIWS;&8\+<QEM\,A[*PS6')9IJF^/?T.&
M7/S >XK=\$^)-;^&OB8ZMH.HS:3=&-HF,:AUF1NJ,&!!4]QC!KH+K4_"OQ4G
MB^W6</@'Q'_JQ?62>9INI.>AFA3'DDGC,86,=2*]B.BL879D^&?BK>Z/81Z5
MKVDVGC?P[9H8;:RU&8QOIJ^L$H_>1@==BL$)ZJ:PIDM6U.[FLO.CLY'S;1R$
M,T2>A("C]!5C6/#%]X;UR[L+V33+BXLI-C2V5TMQ;R]\K(O##Z56=L$C 7=R
M0.],0*VSITI7GVU%_JA28\RKCL!/&_F&IA;Y6H[2+8*MEMD.:9/*0^8+2,Y[
MC9^==)HEA<^)OV<-1L[/S/\ B6^)%GU*&$;I9XA !#(%ZD(S3CT G8^E<O<2
MEUSC=_LG^=6?#/BC6O 6IKJ6DW)M9"ABEQR+A&^\C#T(X-8RC=6*C(N2-;WE
ME,UIJ4T*LX.V$!C(/0CM7*7OPHU/XN^(DTOPR_G7C@R2P7S"WAB Z[7.!GZD
M"N_O_C!:W*00VG@7PMHS;?WTUDMQOG;^]^\F=4^BJ!69/XL>)YIHT"/< JRK
MV!X(KS?JLE4YT=$*MCT.ZT?PK^SW\+['1VU*>X\4ZA;YNX[0)+;6YZ%9) >6
M]/+WK[BO%/[,#W4T#3//92'?Y;# )'0U/)%% IB5=D><XSG%1&[5#L4UZE.,
MFKLF=:Z&Q6?*KC8@_A'2K,C8.5I$;Y:*T.9L6*5Y&JS$P5N:B@&:E$ 8U.HC
M#URW74-5\I_]4W6I[2Q729A';\QU<FLH9+G!^]4QA6R;G[M/0KF&RZ'%?KEM
MN3ZUYQXRT:+3+V['EH7+_NR#7M&B?#U-7M/MEQ=2013,!$!WST_"HO%/PHAT
M!E,]O#>R;A\V<X'][ZBO.Q&94Z4N6^IK&GS'@>EZ7=70YMKB4@[<&,[,_6KF
MN^#[O1(5%U_HSSKYD<,?*[1USZ5[[86>E16OD?:;J&%./W,6XRMV)%87CSPJ
MEY:^<59I5.TR,N.#UKECG$W*U]"O9V.,^&O@74="CL+_ %1+NUT[4XFDLR\1
M6.X .#M)'S8/!QTKNTE.G75O-$^_[.PN)(OX9%7DH?8BM[P'I+^.?@?J_A&)
M%GUO0II?$&BR_P#+26#:6O+?Z;$,H'4L#7))>F6U65!MW#YE_3BO9I5%*'.C
M*43M/C3I%EH%YH'B?3HTAT/Q_9&]AACZ6%U"QBNK<^@65?DSRRNI[BN"UV+^
MU+?<LCP30J7CE3[ZL <5VGPS@D^)WA+Q+X#N-IN9K27Q!H#NWS1W-N@>2!?^
MNT46,=2T,0'WJX[3;^.>8,(\[LABW&,'%6M3/8[_ ..EZ_Q#DT+XD6\:I8^+
MHY(];6+GRM6@PLVX=O,RLH/<R28X6O/[ZV:[; /S1?O3@]2.WXUV/PCNI[ZW
M\0_#XB/[%XW*76GN[8%KJ4(=XBO_ %U7="?9_6N/:\71FNH;X/:7,4ABEAG'
MESJX)!4J<'=D8QUR*6Q6KV.Q^,^H+XWT#0_B3%EI_$$W]C>(U4?ZG48$)CE_
M[>(-DA/]\.!]VN5US0O,LC'<%>F%4GDL1@5Z+\&?@EXG\3>#=8M;C2KFU\)>
M)+<'_3&-G/!=(Q,-Y&KH=S(K3+P.DS<U['\)OV=/#GP[N8[Z^=?%VJ>6V!J$
M*S0P,>A$3;HRP[,5W#L16,ZJ6AM"@WN>:>*/AKXE_:)\%^%O$ECHW]G^);*"
M31]775%:UBU%8"ODWJL1\[/%*JMM!'^CK75?"_\ 9#\*:,89_%VHMXHN)!F3
M3D26WM8G[ 2A@[C\%'M7I&LM<ZC-&EPS^7$-@5A@-4"QS?:/(%K(\:<_NU+8
M^N.U9.M-JT3IC0Y3V'X4:5IGAS28(=#TG3M)BL8_*6*TB4!%/8D#+?5LFNKL
MH";Q9(W/F[@?E'.?IZ5XMI/QE\/_  2+2^)==L-/6]C,D5JLZ_:IATRD9(9@
M/45Y7\5/^"B-YK$5Q:>![(Z<JGRSJMT%>XE![K$R87]3Z&HIQDW>1G4*W_!3
M^^TF_P#COX?>R,<U_!I.W5&4_=<O)Y:_4$2'_@0]:^<XP63<:GUS5+S6]7GU
M#4;F2_NKMM\L\I^9V]:B>X0*BKZ?-GUKM4;'/=C"VXT!<FDF 2E@.ZJ$13N5
M;:*DBBS$=_.1@KZ@T31[9<U,G[P5-GT Z+PY\7-<\,>'H=*9=/UW2;?B"TU&
MU63[$,_<CD&V51]'QZ@U#XX^)VK?$&VCM[HQVUE;C]U90QHJ18Z990"Q]VR:
MQ!N52".M.C*QQ>_I6?U>/-S/<.;W;$"([*G5BPRQ/K2.F7VU-&YW4Y[<L^X=
MNM;2L1'<BV^53#)YC4]9EG=AG[APWL:69$092LVQ#&&TTDJX%.5\IFFAO,-2
MF D:;JD\L_Y%.CBVBB2<12JAZN,K5 1F/S#@?>]ZL".2V@P?O4V\B,-KN9<?
M,,MW"]R/>MSQ]X1/P_ET9C=&_LM=TV'4+6?@[A(@+(<=&1]RD=N,]:J(%#PQ
MH&H^,=;BTS2EA?4YU=XDF?8KA49R ?[Q"D =R0.]9FO:C]O\+!_+V212J78=
M<CTJ33M4N_#FMVFI6LC17NG7"7,4@_Y9[&# CZ$ _A7;_'2PLK[6+3Q)I5E!
M9>&O&MF][;01_P"KTV>%5CGMT]EF#@9YV[#WK2(&7\&?%=CJDE]X&UFX*:9X
M\4&UD<?ZO445_L['T&&E3/I*:^?'M]0L(EBNS-'=VK$21RC:RL#T(]1T-=UX
MRM#=?#_3-5M-JW^ER(Z.S;64ALC^5<E\7/$&H>,O$-IX@D_>7.J1^9>[3E5F
M. S9]7;<Y]V-6I);CNSO?V8O&UG<>)-6\,>(;PPZ-XP@-JX8_+#=C<;:?_>6
M1L?25CVK;N5^S1+"^,PO)$X7G8R.RG]0<>V*\&AL[EM11G@8L'#HQ!"[QTY^
MM?2GBG3HY?!/A[Q/';Q1V]Q:QV6LM&<B+4(XXU<MZ!P8W!/5FE ^[5.2Z#3-
M'X+>*K#P=XH>WU@M_P (QXFMGTG5B@W/$LF&6=5[R))'$RCU6N<U[P=J'P\\
M4ZUX=N8H6N-"NFMI-C[D7!/*'NIZ@]P0>]9RZ;<^)I/(TV.XFVRJRR0(72*0
M?=W$<#FO;OBCX%L'^$>A^-O%&I1:9>:/'#H6M1:*ZW;7<RB1;:68=1F".-"?
M5 .M$=@;. ^#&M+I7Q-TBWF6XNK#67&EWT=M&92D$Q"LY _N';(/>-:D\1?
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M!I$QC+ F<LI ZC<JLH;T!()KR[4/VWK/XM?LV^+-3\!V)MM;T<'3]6FO8?\
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M)<= S= :]/\ V?? /ANWAU_X>>,/$D%W=>,((HK?3=*9BD%\ )[9Y[AEVQ,
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M>ZY%>K&'*8R#QUH'ASPZEI=>%==N=5TZ]&Y[:_MWCO[%L\([ >4_U4CZ5CW
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MK++,JD-\[JY5>0.,-]:^S+C]GGP7IMYJ4,&@6Z:GJ"RS^:9'=E8DE556)"@
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M2Q$8!X5NQ^HK>BT+4]3U+3E\F"2*:>"Q98VW--&9,!V'9EWN0/>L+Q!JZZ?
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MRYD.=--69[M<7ML9=L>YNC1[1D&N)^,&G>7!%J@D19!A)%SSS7/1?%+4=/\
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MIL:YB;_IHQZAA7F8+'-3Y9[BF<?'>R1285BIZ,!WIS3@O@\9K.A+Q2?.=_\
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MGF_<\H32:O=2;O+7[M7?"NL"P=5D^Z2!^-;0@C)[:%_3/#40AN)9N%B!&?\
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MG)P:\?F/8W/HOX>6]U-XW^TQVODP0Q,CC!'FL>A-=5IM]+>:Q</<0K;F!&C
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M@98CHN2!GW'K73^*/B^WP(\02Z=JAF-]:SK EG&A:,1'[S>O%>=?#+XS>)?
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MYR#7I?[4VK?"_P#8%_9BGOD\02_#3Q1]E>RT^ZL+6._OV263?(;>W:,H-QW
MO'&BKO)W+UKGJ5W]@7(>"_#?]F7PA^R_JGA[1]?UO1O!_B#Q/J46D:8-4M9H
M];NGD:--QC$#-''F5<DLJ\'/2ONOX;?LU^"?@_ITEMJFER:O>WC+<MJFH ;K
M5@ 0(L* %^I;ZU_/S9?$:RO/B8?%6G7_ (D\4Z@VH03V]QJL9>\O;D ,1(%=
MMQ#[@,,3@=:^J/CC\>?VI/ ^DK\0/B/K7C/PYI/B*/SM*T2;8EN\.-NZ.VE1
M]J#'/F!F]&%<[7,O>W-.0^Q?C]J?@5?C-I>B:_X?C\4:#<^*O.FN)(V2!WDM
MV:)I^N1;SHH5PR##$D&O0?VE/A!X5_:C^#7]A-XGTS3=):]BNK*]LYHY!:D*
M5 R.,X9AC/>OS4\,?MQZS=>"=/FN_%>G:V;\L6L[>SCADMV3:2KL(D/\8QL9
M@>>>*X;Q!\9=3\8^+[K4$3[&\LOFQN9"#%CL,UG[-VL7RH^^_A5^S5H7[&^I
M>($M_&=QXKU/7C#L@%IY*A$,N)"-[D\R-SD#Y:\6_P""F/[1NL_#+1O#FEZ!
M'&NJ7UN+H7BM^\@9) V!VP=NT^S&OG)/VF/%VC^,+#7VUNYGN[!HX'C#;A+;
M*Q8H?^^F_P"^JZW]J3Q;=?MQ?&7PGI_@&S@6];0GDNE5OW.G>9NVB0_P.=I8
M*V#@@]ZN%$9]Q?LF?'W7?VS_  IJ\'A-/L&D7]GJ6G7NJ"!U73+HC,*"8':A
M6.:$XVEN.*]Z^$7P/TWP/)X.U;5YI4\5>&+&2R(M)VFM9D9MRH6D7S&"G>02
M1_K&XKS/_@G)\$O#O[)?PK;X?Z*;V^35&&H76H7LQ=K^[,48ED"D8BY15V@D
M$1@U]"K8+!%Y?W91QA>0*SFN65A.1^6G_!=W]E:V\$?%&V^(F@VKVVF>,O.N
MM:6)<0C4L*6)/K(TA?ZNV.E0_'3Q)%^TG^QIX8^*$3/<7FK:)#X"\9?+^]76
M;$":.Z8?[8C0ANA90*_1?]IO]GN']JO]G#Q/X!U!1&US&+W3Y"/NW,1#1X/N
M1M/LQK\K_P#@FUXU30O&_C'X*>-%^S+\3+&;3;6.;A-.\1(7^R2'/W267RV)
MZ5M3T=PCL-_X)8_M%?\ "IOVA_\ A'=3E,&A>*I?L5T2>(+QB!"1]7"H3V61
MCVK]/;FY.E^4O ;9MD [$U^/_P"U=\++[X:^*$\2Z9;R:1]FNQI.KVC1"$:5
MJ]HC?,AWL6\S;O)8)\PQMK]/OV5_C?:_M-?L_>'_ !9'&J7Y0V6MPIR(;R$*
MC9]F^\#WR:=:%_>&=C(9+FY*F%)-APNX]163\5_@7:?M"_!'Q=X'U6Z81ZW;
M/+;' /V*50#'L]<.JL/=172NA,FXH$ Z@53?5O[/U*&=>D<JM^1S7&M'<T6I
M^"GBOPQJ7@7Q/J.G:O:R6.M:'<G3];A>4.B749,9,?R@[6*%N2?O=:6T$<LW
MG*?GVE3^-?:7_!9[]F,^%OC;I_Q$L+?'ASXG!+&[=%XM]5C565S[RJ#G\?2O
MA[2%FM$9)HIH+F/B2*5"CQGT*GD5T1]XT*6LE-.NL'YQGI7HW[,LFHZCX[72
M8);33[?5#YCR7\IAMXQTWEL$Y'H 2>P-<<L"K+]K%M'>2J"1%(<+]<^U8VN:
MO=ZTX,S&2./]\D /RH5Y !%5*.E@/MBZA^&_PDO+I#+J7Q1\3PR!51PUEX>B
M'<MNV7,S#MA8U/0K6/\ $;XV>*?B1;V=GJ>IQQ:'8)ML]"L+2.SL+1<Y $<8
M <CL9-S>]>=_#KQG;>(_A_IUW=31VIA@S<IN^ZP^O>L?6/V@M)2[\C2[.ZO9
MBW^MF0)"O^\<[L_12/>N3V=@.R$PN9=^W9GKCO27I/:L?P7X[A\<+>(%@AO+
M1]K)"VY3QV-:!EE/.WBI:L..Y&MYY<N&ZU*FHM)<!0=H/<5@ZW<F"[\SG"\G
MCM3-,UL78\Q77YV'EA3\S#V%+FL6=9'90I<>8QW,>YJWK.L6<&FKO.)81QNX
M&._-=+X#_9V\6_$_P[)>Z=8?9[2%"TD]ZK1L@Z[@O5L>@Y->1>-KMM/\<1:7
MI-Z^L/I+1_:KN:U:%#< *2%CDR2H;<,-G( ]:RG48XQ.X\.:/K'BOPW>:OI&
MF32:59*?.O[B-DLE;&0GG8V;CV4G)]*X7X??%?3DNM87Q7IFJ7C3H[V$=M.L
M*VX ^\=T3Y(/..,^M=SXJ\=>(/'SV+^+-7EU=+==EM#,%CAL%_N0QJ B+[(%
M'M6'XIM].TZ[3<98[BX4A0$^\#UK)5DG9C<#5U70+30/ _AG5X[^ZU;2_$=H
MCP7<D>&BNDRMS X'W2CCY<\E"&[U2UFQFU*W$4'S,$*HY.""1UK1\&ZOINC?
M![Q5X.UK4K2SBF!\0:$UQ,L8BOHPJ-&2Q&WS820?^N*8ZUXUJW[0-QJVGK'I
M:&W!!!F;Y9%.>.*Z:=Y/R,]5H?;W[/'[8WAGX9_%?X>?%SQQ=64,MH9OA?XY
MM((1]LU&VFM9A;:CPF'8Q@1NS'Y?L\77=7Z3_!?_ ((S_L_Q?L8:QH/@KP_8
MV_\ PFNC2RR^,G476I/.RYBN%E8?+M;:X6/:I*#*FOYQ[#65O/$K2:K_ *<;
MF)H7>1OO,W1OJ*^FO"O_  4!^/\ XL_9>B^"OA;X@:CHFC: QLXUM3]GGO;0
MQQH('DR7,:K&1\I53YAR#752BY3Y*9G4VU..DE\1?L"_MA_;K[5-5TO6/"MT
MEI=W>D!'F=!MW[=Y52&QD\]37HW[5/[4'Q@_;@^,UAXPO-6NG\.Z:SIX>N+B
M5?M,5GOXW(I*AB "0">2:\5\9_">[^&OP:?^V=2>ZU S(L*9!%JA^\J^QKEM
M&^*FN^$M(BL8-1N[BTXBMXP,R1L>%1%ZG)KO=&%.5ZQC3NW[HGQ2BEE\>:S<
M7$OVBZFNI)&F<X>5Y&+R.1ZEV8_C6!8VL4+;6,CR@[<[:ZOP-\)O$_Q>\00)
M:Z7JE_?:G^\B5X&$DB_WQP?E'=L$"OK3X*?\$S1:""?Q[?I90Q,&>UTV8RW$
MC]0'G**N/78A_P!X5XN89OAJ#T?^9[F!R?%8EV@O\CY(\)?#76O'FL16.GV5
MYJ,^,);V<?G38[DH.0!W)X'<BOJ+X,?\$P[[4[2"Z\77 T6SN,2;,17MRP_N
M<?+$#_P-AV85]8^#_ 6@?#.Q>S\-Z19:3!(P>22),R3,.A=CEG/NQ)]ZUHKQ
MWN&9A\\ARQKXO'<1UJCY:&B[]3[K <*4J2O7=Y=NAC?"[X,>$?@=I@@\+Z+8
MZ>\8YN]OFW,I]Y'R_P#X]6Y+J,NH7#23#+MU8]::856X"GI2ZC((5X[\5\Y5
MQ#J.]9W9]1A\/2IQY8*WD12#R7^7FH)[E7EVFIX[5Y4+=,<%S]P'W-87B7Q%
MI]KJKZ=%J.CQ:G8*?ML4]TL;PL.<,#R#CL:NG2E+6*;1-2M"#M-I%VZC\M3)
M\HC'&2<8K#N_&1CDD33+";4IH3Y<DIVI9PN>@>9B$7Z$Y] :\D^+?[87A?P:
M^VT-[XAU)/D-CYQCL2WJ2@R^/][;Z@UX!\5?VE/B!\6P+.YU+^S-$7[FGV@5
M8(E_NJ%  'TKU,-D=>OKLCQ<9GV'HZ1U?D?1'QI^-L'@KP_J']L>-WT[Q$8'
M6SL]#03V\$A'R@ON.[G'.!]*_.?Q3XT\3?$?5W_X3;7M4U^\WG>MY.[+G/4#
M.%^B@"O4UTZU2;;'&!(3NW9).17%?&'019W46H=Y/]9]37U^ R>GAUKJSX?,
MLVK8F6ND>W?U,62Y_L:$):0)A%VJ0>U0Z'=2H[AN7F.6'MWJJVHF(9SP>E2Q
M7GE2"4_>SM_.O9C9:G@RLG9%C7/#%MY9E@.9!R *ELM#,/ATSRC_ $EQF,#L
M/?TH.H+#<?NN=G!J1M7D;<HQN<\YZ9J)2DQ>ASL%_P":62;B93@BKL5MYMOG
MUJAK.CS2ZM']FBDN+EF!=(E+9'?I6]-;OIDB+/!(7G8+#9P<W1)X"E#RK>@Q
M^%"D[692;12MK(H3\[[5^\H%6%AM[=5FGO;*TMV8*"[DR,3V"J"<GZ8]Z^J?
MV6?^"-_Q>_:FT^/5=1AMOAAX..)&OM9G(U"6/N5A1"[''JB#W'6OM7X"_LD?
M 3]B;Q3I_P#PB/AZ?XE^/(X]LGB'Q,!)%;/W,%FSR0IZC>I<$<$5+D^@Y3/D
M/]AS_@DSXQ_:LL9]7U'2=3\(>#FB9H-;UF#['+<''RM DA4S)_M1Y'N*^S_V
M<O\ @E?^S]^R_<6>KZ_IU_\ %CQ=;+Q/K(,5A#)VV0*"#S_>=J^@O$7B+6O'
MEE]O\4:G"R6B;O+N@EJD"#DE0H4;1ZXQ7S)\;O\ @J7\.?A3=S:5X9D;QYK4
M.46W4F.PC;U%QL*MC_8SGU%5&G.1CS7/IWQIXPO?%5E9#]QH6B:?'Y2V$<20
M64([8(  Q[5XC\9?V\_A;\#[:>T?69/$&N0*0NGZ3MN!O'9I,[$'KN;=Z*:^
M"_CQ^W%\4/CRDUMJ&N2:!H9/S:78*@B(]"0 S?5B37E>GZLEG9_Z.IB[<DY/
MYUVTL)?XC-SL?0GQH_X*7_$'XUZ1-IME./ FER@C;I;G[2Z_W7FX9L]PH13W
M4U\_Z;JLVF7+3[I;FX8_-</G=(?4CI5.5_M,V^4G.<G%2+XD@@*PLYE:5A'&
MD.&9G/08]?:N^,(0,^:Y;U+5#=[GD??*QP6/K6+JNIIHUMF21=W7;&=TF/I7
MT3\%/^";GQ%^-EE#J5_#9>#O#F-\UYJ63=$=?W<"-OSCNP&/2OL#P9_P22\$
M? KP)I_B22)]2\01W<.H6][K[+)-(L;!C"+9%8('QC,B;AGAA43KQ6Q/*?G%
M\&_V8_B-^T9.W_"/Z#-;:1NRVKZM_HMO&O?D\D^FU6KZ\_9?_P""4.FWVH)+
M="'Q_JUF[>>+[=;:/8IM1D)#IYDI.7()\O@#Y&S7V;X6\'Z7XBGLM8U>"?Q7
MJ$D>_P#LV_E-G9Z=CCF51ED&,E#PW3-4?BW^V?\ #[P%=G1O%WQ AL[0A8_[
M*T&"3['"J*$5(Q;AMJ!0!@MSCI7!4JRE\)))X4^'/@?P)!#IL]R/%6L6("Q:
M/:1HNC:<!_RS7:BL/;.WZ&M[QGXAB\'^ K_5O$&KV_@_P[O\R>UAGD02 1HD
M<*^6-[!5CP!T.XYJI\-OB/X.^*]C!)\/=9L-4TR!,RQ12#S[<9 ^:,X=.H^\
M!U%?!G_!2#]H/4OBQ\;I_"GRG0/"2?99(8GW-=3[0S,R^JON7\*RA%N5I%QV
M.L^//_!4^ZU/1WT'X4Z1+H=G%($_MR^\IYR,](8B"%4_[7S>AKY<^(WQ-\1?
M&#7UF\5ZU>ZZ]M\H:=N%.<CD5R7Q!URX\)Z;:O)LG>]3=%%&VYXNWS#J#6[^
MSG^S%\0/VD-4%OIMMJ8ADE"S7$2 6L:GJTDKD(K#J%W9.. :[XTX1V)EN;_A
MV[LM(\)7\L_AVZNUD;9_:"%VCB8C@$;2#]=P^E>P_L%^+_\ AI7PWXU^ NO>
M(+IKW6['[;X-BNM]S!#J%NLSF)07'EAXMRY!QR>#7I'QA_X)DZUJMU8MI/C#
M3O##VMM-:BU57GCF#!=@&P<%F+@DL,8'%?'/B'X?_$'_ ()]_'7PWX@U"S:S
MUGP]J"7=G=PL6BG50V]2_3YD+C'HS>E)Q3=T"9]]_P#!._XF77Q!^!DWA34\
M?VS\-[R7398I6_>26I96MW(ZX4,\0]H4]:]Z4QD;I0JYZ8[U\O?&'Q+H_P #
MOVM/ GQR\* Q?#+XY:9"+]59%CM)3(%EB*;MW[IR&'RG[W)KZ9OK3RKN2(%G
M6+ !QP>,\>M<-:/O7-XZE/Q"L<$!E11P<JPZJW8_A7Q__P %?/@ ?%?P>T7X
MJV8>\U#0Y!H^N2A?F\ILF*3CK^\=E/H&K[&N(DEMVC]:JVOA#3?&GA?6O!6M
M 2:%XHA-O<AAGRV)7:RCNRD!A[J*QYC;8_"73[J31[[S;=E^]\ISU3O75^*_
MB-:WGA^VBMM,2"*/#&>9E#EQT9%#$X_W@#[5C_&7X7:C\ OB;KO@W58C%JWA
M:Z%M-&W0Y&\$>H(((]B*7X7^%-'\5ZQ-J&IZA+)+ ?DLG \IAWR:ZM''4-SG
M-<\6W^O>(%NI+B\UC47@2W%S-*\C0Q1@A(U!)"J 3P .M=#X3^$UW\0M!NKJ
M\OY/-MF\M(3C/(]/2O5/A=X<\,>+/$-X-'@LXKRW;?+;J?D51RQ!ZXKG-8\>
M6?P_^(E_?VL$%S8[BCINXWG@;?4>]*T;:"V-GX(P7.F>%KJQOMH?2I5MX]IR
M-IKH[JW6*\RM>=?"[XX:99?%>>34[8OINH1.AM(Y1&J7##$9R5;.#VQ^->CI
M#+E5E #J/GQ6<D(;(^Z2D,>^G3*$/RU"MUMEQ4 # !]K4]'\E\+Z5'/#YDN:
M=#$?,^G-..XI;$OA[]FS4OVI/B=X:\':!<:;INKZO,\1O+R<0QJK*"<DD#*B
M-BHSR7QWK]-?A'_P;Q?!3]G[P%J$GQ UJ3QWXDBTJ>&.ZUFXETRTL;AHSL:-
M4E"/M8@@ONY'6OS%M[Z?1KY=4MT!N;*59+1@?FCE'*/@$=&P>HZ5]7>(/C!X
MU_;=T6WUSXJ>-M<NM$TJ QKHGA:'^S-)M'ZHNHWUQ&T>X8^ZC.Y7[IS6L96(
M/T4_9-E^'?@[]G*UO[*;P9X'TC1;V73;J-)H84DN8)-I\ML9F!.-I^8MVS7Y
MY_M2_&/X6?"K_@IKIWQ:\"^*+B_OK"Y1_$.FPZ9-(]U(&82?,-HB#Q.R$R+P
M #M-?)GQ@_:>\1^._$D_@?2;;1KC1M+5;*ULM#CGELI]I8[Q<S,9I"=P!.$'
MRCY374?#;_@F/\6/BMX)NM;;1Y[&QLK22\_LN_5H8K@(I;$6X9?/3Y>YJG>U
MT3(Z+]IW]O#P?^T_\6O$7B;Q3X#L+75XQ''HMIHEXSVXC&\M'>SO$N^0$@JT
M"A?WC<@BL#PQ^PKXB\9_!'Q-\6_&%A#;>&;2P?6=/\,V=\94>-!O!9G#OG8L
MA4'EB  :^E?V+_@%\.?VU?V&==TVQ\):1X0\8^$,C6I;2$/+&2H>VD,C#<H9
M2V[D %#Z5\Z_L\?\%"+'P/IUSX7\26VO>(-'^R#18H[(;Q<VW,:2%2RQ[D#$
M*2"<D5T4J5-QYI;DGKO_  1D_9^^&O[5=GXSEU'0=$@\3>'WM[^+3Y'_ -%:
MVDP/-#G^)"1GTSS7K'_!4CX9_![7/A7ILLOQ+T/PGXF\"7$5_;7=HWG%88R0
M8(N5#2EW5EP2,H,FORYU?Q+J_P .]>O]'T)M3\,6MTQVP01I/=A-P?RYG5<K
ME@IPI XKI_AE\*O&WQ?N)_+FM8C9V[SR7@EMDN88E&6!EF92BGNBOSD?*:F=
MUJMC3EN>E?M1_M,Z+\6_CMXI\:SPQZ0E_<P10V:NK-<;84B,\FTD!F9"YP2,
MN:SK*\74].1T;S(Y%R&]:]+LO^"3:?!C5_ NK_$SR;GPSXFNLRW-E*VY<1,^
MUR\>W:R'<NW.XIP:ROVE?V;KC]CGX_ZY\/)KF6[M=(:-])G<8:\LI4$L,KCL
M3&RY_P!H,.U<TK/82TE8X(VGE-Q1Y&\5>F \O@"JH<J>:E1-1/L48BS_ !4^
M E(^: NYZ?+TI5'9- ?<OA?18=-N9Y$"[I3YLN?:OD']L/\ :+U*;QW>Z98W
M<GV%',6Q#P2:^U#IZ_V#<P%2ES=P/"C@<AF& :_-+XT:>_@OXN7>D:HP:?3K
MH1RSJ=WFG.>37B4;O8]&3&>'/"^IRZ//<7D(^SEP223M_.M.^T&"+2(Y[>!O
ML^PJZ2+M <]"*ZS4/%1D\*2[$T]M-B7<8#*!\X'! J?PD+GXF>%+)+>.!QY1
MEE61MH)';ZT5E.+'!7,;X7? .+Q3J.FW4]X8?((O0T>&=G0Y"D>AKL_CM\8+
M[XDW)TV]@CM[>WXE3=@AQTP*T=.A7PCX-DO+2R:"XR$=D!WQ,?2LVZ\7>$_'
M6E1Z-XS2;2K^09M?$.GPE)%/9+B-01-D]9#\P'0&E1J2D[,SJZ'.?#CXA:K\
M,WE6T_LW5='NSF[TG4K5+JUN_<JW*OCHX.5[5T]E\/M!^,UT\G@:XC\.ZX06
ME\,ZG*[12GO]DN.1M_V)6+D]*Y;QE\'==^'NCC4_+CUCPV&"KK.G+)):J3]U
M9795\MSV5PI/I6-?W-KJ%M:'&Z1 '5U8JRD'C!'(->O&R1R[E[Q#X1U?P=JT
MNG:]IE]HU\#@0W-N\+ =\!P"150VB6UNJ*=Q4=?6II]2NM4N5GNI9KIP,*TS
MEW0>FXDD_B:9@>9][FB[ ;;2,@PU3/=!5J*XDQ4'WVII$\I-<,TL)(R!ZCM7
M(_$*XFM[.&!]B1GYB WS2D=R*[!,I;8Z#/ZUS/Q#TR+5I(!Y16^$1V2$84^V
M:H<=CB8/%CV*',$<R"0%XO,*^8.Z;AR,^O:O1_"NB>&_B8&_X1%F\/ZJ+.1K
MS2M;N$^S,P'2WNO,S)[!T#$\ 5YC#X-N-6S!"NV\W8E!XP:Z/3_AW?6WAZ]\
MN8-?6)^4;\8CQEA25[C//]:L&T*5H+VWGLYD)#1/&5(/N#R*JQ7[3Q!0<IG(
M%7X_%*W*FVOK=;BWD/$W\4 ] /2D;PY':J;C3[R*^LL_,'W)+;G^[@J ?^ D
MCWK>)<62QZQ,8!'*!,,?*6_Y8CT%1J5C4MFF.77KT;D8[5!=L1;D"M)#*]Y(
MUQ>\?=HF9%^4G ]31;N([0Y^_2Q16LL!:X+N?^>>.#4DI%=2Y?:F6C]5Y%$T
MOER;:G?5Q;6Q2VB$,?\ =%48]TTH9PV#T(%1+<TV+T<S30^2.<U%+#+:1F,
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MZ/>_M+?LA_%+X'3R3:=XDL]8D\0>'6+M$UKJ"PRH@)R.)2Y!4Y!!/!Q7S?\
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M!^SS^SC\)OV,=+V?"[P7H\.LM@3^(M1B^V:I*W0E&ERD0/=8XU%$I1Z&>Q\
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MCP7?>-K;X>HOA2V^)'[_ %JVT:1+Z]EC02 0O)&_D0I^]DRA9W.\X->+>'M
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MI;&3VKY__P"$BN]=O4NK:Y;3696C6Z5BS;"3P1SP>_!-=-.;2L3(^M/VFO\
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ML[Z7H&GW8U&XNY(K349$4C[5<.<*X! 8XSW K]Q;_P#9-^%UM:/M^'/@==P
MRNA6HP"P!P1'GH:_GW_:;^(.K:5,^F:9))9W#:<M]:72GYXI?,DY&>X\H?\
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M9[34%,T:HI818[5?\:>,/!6DWH\,>)O$>@VW]M#^SY=/^V)YTL4I$;J\9.X
MJY!XK2BY<UV$K=3XE\9^%-4^%GA/PWXYT%=5L=0T34C+'-) 8\>7)YY@SZ;2
M /41GT-?='P8^,UA^T5\,-/\9:3 D-OJJ 74*=+.Y3"21#V#AL9ZKM/>N'\
M>*?%7[8?P-U3P3XC\-:)X9GUZT&IZ!<,XE,M^I95!4."B.I\IG;&%N9#@XKY
M_P#V%OV@-,^#W[2>H?#A[R>P\+>*?*6%+J-@+'4LQB0(%5CS(#$21@+&,D5U
MUHJ2OU)A=/R/M^UTH3_-+]ZK7AW7IO"7BZUO(%W>4X1PW3RL@M_*APT/R_,3
M@;MW:HKV/-L<?-_#@^AKS^5K<Z;KH?EG_P %6_V98/V<?VF]3N-(C_XI/Q]G
M7]!DVX%ON)DNH/94E?:OJ,&OF3PMXM/@7Q"-;M\F.YMI+>1/]M^ ?PK]=_\
M@H9\ #^U%^QYK7V2+S?$_P .#_:6GJ!EGLAL6X0=_ND/CUA%?D!>0I9W%U#L
MW?O<HIZ'%;4V,H:!X3_MC76ENVQ),2S2 Y\Q^P-='8_#O7?$NHR6UAI[.]J?
M+F5%)C0$$Y)'08#'/^R?2NW_ &>_@S_PM-K[5+[4_#_A_1-*?RKF2]OC PD(
MROEJ(Y&<^@P,]-R]:]@\,^(O"/P@A=/"EIJ/BK5+F1;J;4_$^%L89HPX22"Q
MCEPQ422;6G8D;C\I'%:2D7J<)\-OV0O&/B&QM-4LM,%[IVGLJ2WUS-';Z;9<
MYXN9&2' Z_?SZ UN:]I,>C^*+JW>]T[5/*)7[18W"W%K+QUCD7AA[@U!\4_&
M7B3XN7*:IK>MWVO:CYJL/.41QJF>0B( D8_V451[4S6FM])TV.XD-O#Y[J-C
MR?,A/& #R:QYKDW9";(0@!<D-R":D0>6-M/O/,CN4X.T#Y<^E(4+2;J<=Q U
MMMBS4<4NPY%66?='BHXX HYJP*>H#[9&RL V_A@P^4#H6^HKOH_CAI]G;6]S
M:Z5=^)/$<<9%QK6OR"3R)/\ IW@C*+M_ZZ[SGVKA[YEV;1]:JR:J-)M7NIF;
M;&IR0.2.]6I+J3(N>)/$VK?$?5S?Z[J%SJ]U%E4DN&VK IZJB#"H/90![5EZ
MO?:?Y44<E['YV\+&F\=*\H\;_&6_\77,MKHQEL[4':)0-K2^Y%<_INBN+E9;
MFZ>XO I5%<\9/>LIQ<GH5!+J?5OPG\'6OC?QQ#I\,ME<&S0W4X$P* ISM8@\
M.>P/)KJ]>^*NK?#:XUVZT+P\J_V[<KY=R(-MS;R$;5,;8W@YY !%>&_!/X@Y
MMX]/N+B6QO+3"B1)F",W8E<[3]2*^F/@EXAN[_Q9;6?B6\2ZLY4\V&[6=5,,
MN,QR [2#C(8#C/'(KYVO4K1K\O0W7+T/%_BCX4UW1_#*:MXXU*ZGUS4&$D<D
M[M)/<+@G=<9RX/&.YQ7U'^PC_P $V/A;XL_;9UWX=>*]=\0:KJVEZ;#J\46G
MPK8V%^EQ )K>2.ZB8R3QX(5O,1#NRN*]4_;3_9"TWXG?!RS\9ZAXC\ Z"]V'
M?[;J]VFEB\W #:HPS/(NQMHRQR6YKYD\0_\ !1C3/V6OA#HWA[P?>Z/K7C:P
MTW^QEU^/38A=?8%E:1;8R.I9E7=@$A3@"O1P_.Y71A5/=/\ @L7^QYH&HP_"
MC5O"XT71?%G@F.\T#4M$:X2W>_M@[_9Y45B"Q$J^PQ,Q)KX_\1?#K6/"TD4.
MIQ6EO>LN9;6VN8[B2U/]V0QLR@_1C7G.O^+OBY^V1JKLU[(;2P@>0-<S>7#;
MP@9;>QX7CUK>L/V6OB/^R[\(]#\9+;Z7KGAGQY+(=/OM O?[0C=XPI=69"0I
M&X<9ZBO3E[3EU,XRMH:W@;XGZ_\ ">YE30)HET.\/^E:%<*LUC<@\'?'(&7=
MC@-MW#/!%;L_@/PO\60USX2NCX7\1O($&@:C)''IKL?X+6<N,9[(X+$G@UG?
M$GX0ZK\-]*&L>9:>)?"MQ(H@UK3(Y# <\ 2AP#"Q/17P3Z5S4TZ74)0A;F-C
ME1NXC]QBN7F.F6Y?\3^'-6\!>('TG6])U#1M4M6\NYANH2F&]CR"/<&J\=C'
M"DONV>.]7]2\0ZIXDT6TL]0U*:^M=*3R;190!Y"==H]JS8WP./NT]'N9M6'J
MV8L4Q5R*1Y1VI8S@T[6T!,-A!IQC&-Q^]3DSGBFR6KLV1U["DU<JZ%56@D4L
MR*7^YN.,U%J>DR2LHES(<AD8.5,#=BI'.171^$]5\.Z.?*\6:)>ZKI\W'VZS
MOY+>ZTT]BJ+E9%'4@C)Z;A69XXM[#0M5<^']=7Q3I+Q--#*+>2"Y&.@EB8?*
MW^ZSCWJ92C"',R;ZV&^(_B0?B'X:7P/XL>UU%@OF6^MW4?\ IUD%_P"68ER-
MP/\ MAC[UQWAOX9:7:>?'!&FHQ02!)KN7@GZ=C65<>!KCQ?HD^H7KW4<EZ?.
M6%TPR$=@.N*T/@UX1U'7;I=/DO=1L[$RKOCCCRH?/R_A7C8G&)+FYM#JPV'J
M5JD:-)7E)V2[OHCZ"_9G^&\5CJ+ZM#90V5O;*8+=%_Y>%;^-O0BF_M:ZQ.^B
M6UA#<W M;*1;JZ%NN]A(AR!BO3(8(?AO\.MLFW=IMN7>3/,[J,C/O7SII_Q$
MU3QY]OURY7^RTO&,JQ1\B1>Y;/0U\7@<-/,L9+$R^".B/Z1XNQ$.$^%*&283
M2O6]Z??=-_CHO)'T)\"?BB/&G@O1=?M#<++:,D\WF)MDWJ<A2/?%>XZ#XG3P
M;^T;'>EUA\._&K3(]6!SA(=:MOW%S".VZ10C8ZD)&?XJ^3/V9?&4CZDUJ9;<
M:9>(TOFF0;W8=,#N*^C='\.M\7_@AK_AF%57Q1X5G'C3PM+GF"YMMGFH#V$L
M*@'_ *X)ZUT976E@,R>'GI&>OS,^*Z7^M'!-+-:'O5\/I+T22?WJS]4>^Q3D
M9C*[".H-126<<TFT^N:Q?A-\2K;XQ?"_1?%"(\;ZS;)++$RX:UD "O&P[8<,
M.?2M^4!6SFOT;1:'\L/?0X7]HKX>2?$+X:S:7;0"XN)KA)$0_P 1'0"OBKXO
MZ5K/@K]E/QY;2Z!=^5I/BLVFH31)EK3-O:8\Q<APJ2F<;MN!W-?H;#+]KGV'
M&P\9I/"O@;0O#6K:C93Z'97/ACQC#)I6N6+_ .JNWN7!:9O<$EJVC5TY2XZZ
M'E'_  3+^-Q^(_[,UKHL$B3WO@AAILZ,W+1L RN/7)\P?\ K;^..G?\ "(?$
M_2?'@N[I8+41:-<VD4>Y!&S2E9L]<^9*J_0U\@_ /^V/^"9G[?H\$>)KC.B7
MEP=.O)%;<ES;R-(8+D=B<.".WSMZ5^@GBOP-#XS\.ZCH5[=?9;?5;4V!O(AN
M:T,NTK.GKL.V0>I05"7+*Y-2)XE_P42^&\WQ7^ B:]:(EQ-X2<"+GYIK:8+'
M(1Z@[HF^D8-?GE^S%\<#^R[^TSX=\31O+%8Z=J,<$^T<SV#Y$ZX[C:2?JHK]
M(?@CXI?Q[X$U[P9K#)_;OALS^'K]4#;0T;-!NCW ,R;4RC$#<NP]#7Y8?'SP
ME>^$-6OK&X1%U3PS++8S1*<@,&96(/<9!P?3%=,I\T;"IZ'[>7GC*&&15MH"
MRRLFV1@02K '/XYS^-2>/]+/B/3(EM$CCU#3'6ZMKLPK,]LZ?,I56!&0V"#C
M/%?*'[,O_!0?PEHO[%/A/Q9\2-2N$U33DETMTME$MUJ#02>4KE,C^ (,].#S
MQ7E7QU_X+*Z]\0K7[#\-]#C\/VETXMSJMX\;W95N-WEE2B_FQ'K7$Z1T2UC8
M_5[PUKH\5>&[#4/LXL9+^+S95&?W1'&.:Y7]JS]GNQ_:^_96\7?#N[47$NIP
MK/83N/FCN8W1XR/3)4H?:1J\5_8(_;9\.^.M1'PEN]8.KZI86(N[/6KTA)M4
M57VOO[;LO'@#L6]*^IX-1/AZYCF&8I+=U=HE]N<5G\)RQT=C\R_^"5L^L>(_
M@_?^&-;O+BRUCX?:_<:?<VA_UL,:(JB%E/(0N78'OMK]"?">K#Q#H<,2B&U,
M,?R)&V2R]R1ZU\8_M/K:_L.?\%.M,^)$J/%\/?V@+7R-9E"_)9:O&T2(7[*I
M$BG<?^>TO]VOI"SOE\%:U:ZG"2;6=0JEN,HW5F],4-75S7<]&M)C%%E%RG7>
MPP:^=?\ @KC\+7^+G[,NEZ[80&XU3PC=F2[F"_-]@DC,31_[BR-&_P"#'M7T
MA!-#>00RK<1SVLRYC\M@RL/K6/\ $3QMI_@_1-0TF?2H=7_MC2YXO[/N 1#<
MHRE60GT8$C\:=%M.\=PY;'Y _L%?''_A1_Q\U3P==3N/"?C"!W6/^!;H,OE%
M?]HX*_\  S7[*?\ !$.W-OJGQ4B=MS*-,W'U^>^K^?\ _:-E\1> ?B?#')HT
M>A7/AN[2Y@,9.2RN71^?=?T-?N]_P;Q>()O%WPU\6:Q<,6N=6TS1;N8GLSB\
M<C\-V/PKQ>(DEF&$?=O_ -)9RU)_OZ4?-_DS[X^)GQ7\._!OPA=:UXFU?3]%
MTVU4GS[VYCMT=@"1&K.0"YQP,Y-?./PC_P""Q?PE^+O[ OB7]I2S_P"$ETWX
M7^&7N4GFU*SC2]G>"01&.&&*1\L\K(B!BNXNO3.:]N_:0_9D\!_M6>#+/PW\
M1O"ND>+M LKV/5%L=2B$D'GQAE5RIR/E$C'\*_%_X4^(](\-?\&G?QPDU#PS
M#XHT^3Q-K&G06"3O9Q6TTFM116]X?)Q\MJ[17&S&T_9@&X)KU+J]K'K2Y;GZ
M8?L-_P#!8;X>?MV^,O$WA73_  G\3_AGXP\*Z9'KEQH7C[0TT>]N-/=@HNX@
M)9$,.]E4LS+@L.,<UC_L9_\ !:3PO^W'\1M$T?PK\$_VC](\/^)DF?3/&VO^
M#4M?"=T(XW?Y+Z.XD!W^6RIA3EL#C-?GG^RSXH_LG]KG]H2/5OC%'^U-J4W[
M-5Q(GQ1\$V5LTGA*TBFN$ETA+:&Z%M/*6*7"K*R3,8(P, FJW_!,;QOH_P"S
MO^TI^R3X-_9^_:.^(?QH\*_$W1]57QOX)UK78I[?PE:PV2R),+""21M)D,SM
M^X,TAWH?G[4?(?+%:'ZIZ/\ \%1OA3XG_;VMOV<M'U*;Q!\0&T:XUF\FTZ2W
MGTW2!"^Q[:X<2^:ESR#Y?EG ()(K4_X*$?\ !0SPE_P3:^#WA_Q=XL\.^./%
MB>*/$5KX6TO2?"FGQ7^IWM]<I*\2)%)+$IR(6'WLEBH )-?$?A?]EKX??LE?
M\'&_P>\+_#WPGHWA'09/@_JVI&ULHQYEW>R7[B6YFE.99Y64!2TK.<1\$5U7
M_!SS=SZ?^R'\%9(?$</@VZA^-'AUHO$4P1H?#TOEW82^=9"$9(&(E(<A3Y?)
M S1'EZDNW0],^"W_  7*\%_$SX^^%?A[XH^#/[2/P7U7QU++;Z'=?$;P8NAV
MFH3QIO,,;^>Y9R.@ Z\5]JOJ\=E'*\DD:PQ@LTF?EP/O$G&..Y[=Z_#3XB_$
M?4=#_;L_93\2^)_VS/A3^VNMC\2K?3H/"/AW2-)TRXT"2]A=?[76+3+B02&V
M*%]THX;8._%+6/VH_A[\"?V8?^"I'@7QKXP\.^%_''B3X@^*/['T.^U&.+4-
M8%Y;>3:M! 6\V16(!+*N%4YR!S5.RV+IK57ZGZR_';_@H3X?_9Y\9^+M/USP
MC\0O[+\#^"[OQUK&OV^D*^CPV5N)"85G,@S=2>4^R,J-P&<@<UZ-\!/CMIO[
M0_P3\'^.M&M;^STWQII%KK5C;7JI]H2"YACFB\SRFD0-LE3=M<@$D9X-?B9X
MB$=DVL^7N=+7_@GC;7L&]1NBE9<%U[DE6.?K5K5]+^%7QA_:=_9%\#_M.:\-
M"^!L/[-NCZWX;BU#Q+)H6BWVN@*I,TR2Q$3)"-R?/R4C&#NQ6=_(KW6D_P"M
ME^K9^F?P_P#^"M7A#XH:-J5[X;\"_%3Q FF_$Z?X47,-AHL-U+#JUOS/.PCG
M81V4:_,9I"AQSM-?4,>NV\Q9EN(VCC)7?D^6V#AOFQ@E2"#@\$$'%?SR_LIK
MH.H_LT?"N#P[K%UXE\)W7[=ZV^GZK?3M=3:KIYM(_+>25QN=I(Q&Q)Y)8UN^
M+_V!?AO^T5\#?^"F'Q5\4KK5QXT^'/Q/\67OA6XAU:\MH=&N+5/M4<P@BF6%
MWD?"EI(V9512"*HE*]N7=MK\;(_H$\_R6 \S=NSA<Y(QUP #TID5\L\K;3&R
MJQ52IY)!PP/N#P?2OQ&^*FJ^!_VI?VP?V3M(_:N\:36?PIN_V>]+\5Z3+J_B
M2;1[#7/%+F,SSS72S1G[0(PLBC<2S+&,'=@_2G_!LC<Z9J'[-'QPN=$UO5/$
MVDM\:/$2V.K:I,\]WJ=N$L?)GFD?#M*R;6;=SD^]"DKV)NMW_6A^D6M?\>C9
MXPH_]"6OY]OCM\(AXN_9>N_%UHCRZIX1U#;<K$NYYK"8Q1MD?],Y-A]EED/\
M-?T%ZR2;-]V.@_\ 0EK\COV)] L_$GA3Q/I%S LT6M6\UA,''RA)4*,?KM8X
MKYS%2:SW"/RG^2/,QEE7CZ,_.?\ 8H^*;_L]?M>V]C)KNH:%X3\9OLN'M1\V
M0'$2 >GF-C/4!SZ5^IK>"['PE<S?V?;Q^;.1(TYE:5YSC[S,Q))^I-?D/^U1
M\*-4^$/C#5--O_,AUSP;J*!".JKCS Z^J\J<^A%?K!\-O'^G_$WX-^%?%FD,
M9-)UFS$L38YQTY':OMZT>9*9K1U-BYCDGA5RP>4X#8'"G((/X8%<5\.;^PT*
MPU;P;=PF2TMG>U6VVY4V4[$+^1\Q#Z )ZUW6GIY<C-QY;C/'7/TKR#XU^+W^
M#7QH\(:U>"UM- U/S=+O[B:39(TTSVXMQ@]4$@R6[9'K4TI75BZD;Z'C7PSU
MJ/\ 9\\ ?$[X3>(TAN$^%'GZ_HQF.6O_  ]=^=+))@<[H&+X5<\J*^>/V@_@
MC<^!?&E[X$5/#U_JFGWEM<:7J"RDM!#>A95&\D;(IEN#.^],B16 ( KZ:_X*
M$:@?A1?:/\8T\%6OBV'P_IVH>%?$ME/.;<ZCI]];;(T<A6.Q)F+\ '+=17/_
M !$MM4_;6_X)_P#@WQ_8:=)_PEOP_$VBZMH<P8ZA/HQ.+62W,D@>6*V+JK'#
M;5F<D\"MZ7NU"%J9G_!&'QO96^H_$+0'G\J^VPZG'".C1LS1-CUP?+_[[KZQ
MU?6VN]UJ?N."4]Z_._X!^%-0_94\9:)\63(\OA>]NGT*Z:$[FCF>9(C%*H^Z
MF6#@GJT2^M?HQJ.B1R:I8SP%9+6Y"M;LAR&0XS7-C(\T^8Z(.QI>"X3HVAF0
M9#XXQV/8U\Q?\%L/@7J?Q2^!_A;XM:+;>9KW@51H]]/&Q6X:)@FR4$<Y"AAD
M= @YKZWNH8]-O1$O^K*Y%26.E6?C+2-6\-:JJ2Z5K]C-;2*_(25U*JWX9KGB
MVBGY'X3Z9^T#XMN[;5\:]J$D_B.Z?4;R^EG:>XOI69F=Y'<EF+,S'))ZUR6K
M79NDDEF:62=V\UG;)R17<_M%_"*;]FCXN>(/!EU9R1R^$-2G@6;:?])LY&C%
MO,?]ECNYZ;GQ7(3!;JW/]TC&#W%=D4I1MU+C9[GIW@3QPVH>%=.BDEC5C#E2
M[8R*TKV&X6'S_D:S;Y<!OGR>G%>:?#BYBU#[3I,EK%-)&"]H['YH@!T'XUH6
M?B_6/"$ZKK%H628865,L5'3GTKPI4U3J24NK.R$K*R/3M/\ #\.J7FF7$EVJ
M_9(##Y6X8&3U_"EUF.U\/Z@4662\3&2Q7.3^%<A%=QO&LT<L6'Y#%^/S]:Z7
MX=^$/$WQ2U5K'PYHU[J3P*9+B=4 CMT7EF=R0J@#DY-=,(Q6QE/S*=EJ4S/+
M<?/;0%OO$8Q5K3/#NK>.M1:TT73-4UR2Y^1F2W9XE!XRS#A1ZDD >M=Q;Z%X
M&\!NLNNZM>^-M3QE-(TJ]$.FD_\ 32Y"EFP?X45E/=A3]8^-WB#5]-:PTZ"S
M\':,5V_V;I5M&D4B^CL%#.?]IR3[U<J39*D>[?LJ_M6_\,4_!+4?#7B5#J^N
M6=XS6%A:3Q3Q(C)&!&9 ^S8C(QX8G]ZU>:_&3]NCXF?'"ZEWZO)X<T]\K]@T
MV01(5/9G4*S_ / B:\CL;'RIAM@BA3&/O58FM1!+A<$>U*-"-M2N8I6^FOIE
M['>0S/\ ;;>9;B-\_P 2G(_6OO\ \!^/[C]H#]G+2/$<TJ7NJ6C26-TV_+VT
MD9 <'T!R",]:^"KJU=DRG7I7T!_P31^*>F^ /B/J_A'5Y'BTSQL@B7</DBND
MW.K_ %95*'\/6L\312IW15.5I7/6/B/X1A^,_P '=0\+SS,C+&+FVG ^99(V
M5QCW.TK]&-?$NJ:#JGA99]_V/S]_^E+--ME1QT^6OO[Q;X3O/ /B2]L9D"O%
M,&@ _NCFOC/]MCX72P_%/^W(X?W>JPQNY'\4Z@J_YA%?ZLWI7SO([G?)<\>8
MT_V$_&(U?XE:U\.=<U'4/^$7^)-@^FW]O%;27"">9XHHYB(U9@(W*2%L!5$1
M)( -?:7[.OBW5M4\ 76E>*UBA\;> [^7PUX@"/N0S6Y$<<B-_$LD(BD![[S7
MYDZ=8W]G/;ZE:6GVV\T>X%PMOG F(5@4)P<!E9D)QP'-??7@+XO:-XF\8>!/
MB'%>(^D>-8!X'\76GF%VT_5+8#^SM0F.U1YES$JP,0-H,3 <@U[^!K^[[,\F
MK$^A;/4()4_<L\C>I%7+.(RRK))(P8C( J#1XX]!T.5Y+8,]O*L#Q@9(#?Q8
M]J[#_A%86T9;F$M(@7*,1U%>G\.AE%!X*CL9O&6EKJ0 LI)41I%^\KEP!^'?
M/M7RW^T9\7=4_8O^/FE>+/!/@_PAI6@ZI9Q2165OHZB!]6C>5W:X,;(TTJHU
ML4>1CTD^4A:^C;16,N?0UX[^WM\)]4^,?P*N-'TAI&N1?+J31(,F4"&6%E'J
M2LS<=SBE'65B:FA9_9A^)/B'XP^"KW4_&5M!9>*%FADOM@"&]$UI;74=T5 4
M+YHN6/R@#<L@'W37*_\ !0S]IW4O@/\ ".RTKP^[66M>)]RPW*-MDBMUVB5<
M]LAQCOP?2O,/^"?'QPM8O#S:?J5Q:6R^$P=#N99I@GFZ7),\FF2') W6\HFM
M .T=PI/+"MK_ (*,_!&_^.OQ)^'MKHNH::;NWBN-.U!9[D)%:!523S)#_"=K
M/VYVBG*E[Y,=KGSI^RE^SI%\?_%=UJ6N:A_8_@W1F,^KZO>7!\V3;\Q0&0G>
MQ&<#.37T9H7@OX8_M]ZKJ'PH^&UYJNE_#?288+[4;DJ\%WKX,VQH\YWHB&*)
MML;*#YK$CBOFOPG\-O%O[6VKR_#SP/('\ :3((KB[DWQ6NI7,?#22$@-Q('"
M\ E0#WKZU_9Q_8H;]BCQAX?\9:W\0$6_TT&S&DZ79""RECE5E.]F)D;!8-E\
M'Y170X\L>8RE9[GU+\+/@AX9^"%F+#PMI,&G) NUKO)>><^K%B23]3747$&Z
MYCD>5Y7<?-GUK?L=$36H8;WSH([:\02P.'&)4(^\#W%1:WXGT+PQ'Y?EI<W0
M.0V.,_6N65:Y$8-_".T?P]-*!P47^\W%-\5ZG:^$_#^H7",+R\2W>.*)/F.\
MCY3Q[URNM_$K4]75O+86\']U&K&M-6DLKR.6+YI7.7=S4*>AM&C+J?(/[05S
MJOQ3\(7UGXHE,IM4.ZWE/"2_>1C[]"/K7@O[)_CR]^'WQ\\)R:<NJW$%\EQH
M6LBYF>6Q@N/WKP.C8VQM)$&&S/WE0#[U>M?MZ_##Q-I'Q\FUJPG\0W'AK7[=
M9]2DB:*6QLI8@50'&UURFT?=<8C&6%> ?$3X17EOX.7XD>'?.5_#NIQVM^8U
M^?3[E%,MM,OL[B16/0&&,=ZZ+<T"X^Z['Z)Z;IRP:RMMO=H(G"C(Z@U\(?\
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M (F.I^'X/ME[:C[\MNN/,=0.2P##CZU\F7-TLDD'EY"P-OW!EY93]:_IF/\
MP16^&\K9;7?''7=@W]M@'_P%IC?\$7/AJ[KN\2>/,KP,7EL?_;6JJ9YG$EKA
M(_\ @:_R",\7'1TT_G_P#^9KQ'X@O?%OB5=3O)[FXD$:P+G&Y8PH41@9Y&U0
M/PK],O\ @WNB\?>"$\<>'=4\*Z[IWPX\2LFJZ;?75I)'#97J,JLL>[DB6+&2
M 1FVC&>37Z9C_@C!\-6F^7Q)X^W>OVRV_P#D6I)O^"+OPWRO_$_\<97C(O;4
M9_*UK/\ MC..7E6$C_X&O\B9_6I:^S7W_P# ,R.XBMY-D31W4H_UBC),1]&
M'!^M69M'\V#[3>:A'809QM9MH)[ 9'7VJQ+_ ,$7/AT\D>[Q%X[;:/DS?V_
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M^(Q6O#<2 ;7&".M-\67E]\._!5GJ/B;5M)NM=D,4%G:6EQYY%N $R64;5V@
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M[P?XQ74;'RL7"E]LC[0Z]Z]NE\>>&/BY977_  G]L?#7BRXE66+Q/IL+&&\
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MD^,6+PT:J[:^I^3<;<.SR/.:V7U%M*\?\+U7X%RW<1Q<??J?Q_/K+_!O7/\
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MQ\1>'_"?A^Q=$N=4UO4(M/LK8N0J^9-*RHN6*J,GDL!WK\H/V\OV5-;^$O\
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MO)H.E:3XKUQ[QUB:6XF62[PNQ>%X,3\EN,_=-?OS*VY?3%?BE\>?%]MX1_;
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M2TW5M#TRVURTOX#(EW'JT2I<C^^N(FZ?4U*X/RC_ )\K[W_F7'!8?^1?>_\
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M^+-QK_@#3]9\/^&+#6?'N@GRM.U-;9[BYM(B?*FV1HR_.OF'()P,-GI6O8?
M'QA\:O%_BFZ\77VH7/AGQ]I<*3"2Y=9+.0KO>%8/,>-5BGPR$9Z9K/\ U3RA
M;T%][_S(_L[#+["^]_YGYI>*/VF?B'H_B.PTRSTGPGJD=Q>+!+-#!/M*;6D9
MT)FSC8C$$CTXKV;4_CQX%\%^';O4-6\0Z8\B?ZJTLKQ)[H<=&C!W#GVKU/\
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MDNW(_>8^6,#!.X]A7R'-^W9>6_CVS\-^$?.L?!Z*WG:C?WC'R<'JJ$8C3')
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MQH.6P7'0>M*4I;,TT6Q]1?\ !)SXDZ5K?B3Q]\.?%>O-8Z'X@\.2"P2_$?\
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M)JT:'>S"0_>/  Q7G7[,WQ)TWPIXDU7PAXHLO^*3\11I'%=P2A;G3KI7RDB
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M[2W<1?9Y'^=0>Y7J"*J.84)[,?O=3UB!=C;11-CSMG>C2=0AU;1HKA%V,ZY
M(QFFK&7.]OO]J[8:ZK86A5F5+:]&#^\K2LR,_,QR>2OK6?+:>;<^:?OBK$)\
MYS\QC;!^8=J)JVPBE\0?B%;^!;%"\;2R3#]S&BYQ]?2O'_%7B_6/&T@^W7;6
MMD&W>3 V[\Q7HWQQTZX\2Z1ID]FL-E!IL?D3W0;$URQ/!*FN=T/X.W7B#0I9
M=+MKQ[N,;I)FB(A8#J"_3-73LUJ!SFE:5!I4OVRWEEMY&'F1SQD^8K#H1Z?6
MMGPKX&N_'-W/J]SJ=[<Z@7V2W3L9)I&/]XDDG\34O@SP5</>+!?L8(Y3R\?+
M0^P]J^C/"_PDOO GA"RO[+PU<+I,L\;R:E>6[PBY;/#1,1M<>X)K@S#%>PAS
M1-8(\&T_X+ZJNKS01VETQ.3*9(RJ?B>U4-:6'X,R"*YL]/F^W?O(_.DP% X.
MWU'_ ->OJOXC>*KKP+876JN9KJQU*58&@1-RIOXR^.F*\&^(_P"SY:?$S5EE
MU"6![6U&RT%W.#"$//[KY5^7/NW/>O(P^;5*MKFTH^Z;1MQ",GK2M!'- 6S\
MU,>Y%U3HX_+6O?V,!L&Y82#3D?;2%LU);P>:X%&Y$MRQ"WF0>]6-#UN;PCJJ
M7MM:6FHR^4RM!=Q++"X/4%2#^F#Z$5#H^B7WB'Q!%ING+&]W,P6-97V*Y/
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MKS!HHHC[1ABI_P"!9/O7J\-NTEND<@VVZ_,L0'R\=*P=9IW0.II8_*7X+_\
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MLS\4LT23M\]11.*'^>I+EN2&*%(-BFK?@_QM>?##Q;IFNZ>/])T^X1RN<"=
MV3$W^RV,'V)K,*!#2M$;F%@?NE2,T2CS0Y1QE9W/OGQ[K=MXOT#3/$>FR>=!
M=PQS+)W<,H(S[C.".Q!':O)?VR/A%:_&WX8VFOP1+<:SX?C\K9Z1_>8GVJS^
MP%\1[7Q+\+M5\&ZRJ>;I$DES8.3EVB=DW''H)&+?\#;TKKT>3P;KUQ;2()AY
M@M[NW;[MS&Q^8-]1D?C7S6+I<LK'K4_?C8_/VSU&TTDLU_"([:4&-&M_GY/
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M73+ 'RI.X9R6.XCU&WZ5] ?\$A/@#'(=0^)&IZ#%J;M']CTM9D)>"%)6\V9
M.3G:5]-N#5QX/I6UK5?_  -K]&5]12^W+[V?1-M_P5/^-TFNZA8R^++N&YTH
M1_:8VT'3B4,F[8,K"0?ND\$\$>M<Q\6?^"UWQ6^"N@1ZGK/C&^\J:<6ZK;Z!
MIOF;BK/D[XE&W"'G/7'K7H1\/:/XM\4>(+VULH[1;BYCW-MPTH5 BY^BJ!^%
M<3\9_P!F;P]\5O#L]C=Z3;ZI=6MQ%J$,4W N(XI$,D)_WDW\=20*7^J5&]G7
MJK_M]_Y L)'^>7WLX[X;_P#!?SXL_&7Q='HGA>^\<Z_J,A^Y9^&-'D5%[EVX
M"@=R37L.C_\ !2SXW^)-6OM/A\:%-3TU_+N;7^Q],D:!AU4E(F4D=\,:\E^&
M'@WPQ\.?#27'A*VT[P?I-I?P:EK,\44J75Y"XC$<:NB%L;DE5UWJ,L 1S7JG
MB3P3X>^'W[1?AWQMX+TBUL_!'Q 5KW6KK4W9$L99'PWE*J9!.68!L\GJ*)\(
M4%I[>K_X&_\ (/J:_GE][- _\%"OV@,Y_P"$KE.#_P! .P'_ +0K2_9BT[Q!
MXC^(FL>(-;9I+G7KF2\N9?+">=+(Q=WVJ H)9F/ [U[CIWPRT.^TJ"Z$=K+&
MR@DQD,''J#Z5HP>'[;P[$TZ1_8M.0_)+C&\>J]B*TPO"^'I5XU_:3E*-[<TF
MUJK/1KL][D+!Q4U/FDVN[N:5K9>1;>6F,@@*">M<%\7OVB_#?P7\2Z5I>J3+
M;7>I3112R7(VV]I$\BHTSOD ;=PZD<D<\TSQG\?K;3Y'AT:$WLB?+YTH*X/]
MX5^<?_!7WQ1KM_XT\-N=1O\ 4++5=,=+^!5RKD2K(H..<!HT;_@(KZ2R<CH<
M6]S["_M5OC5HW]K^)IO#?B9K6YCN="N].CADCT@JD8<12IN?YBB,0SMSBN$^
M+'PAT/XD3Z7+JFEQZG_9UTDL5G+*XAG<!@A9 =K,K$,,@G*"OD[_ ()<?'^7
MPMXYU#P-K5_+:Z=KLCW=EO;]TER%7Y&)/R[HXSC/4JH[U]MZSH5U?0S*\84"
M,AGE^41GU)[5I:4=CI@O=L>D?LS>"_!UOKE_JOB;[5I>LV?[I8I "S(1SM0J
MI7Z'/UKS?]J/QC?Z)^TEX<\2>$/AYI?BG2["QEL&\5R:X=/N[)9V ?3Y+9HS
MO5@BGS$SCS&YXKF/!'C?3M0\16NDP:G:ZEK&EPM&PCF#9'4GBMCQ?J##2I&N
M+)-1M;F=+:YM7SM*L<%N.P%$>;FNQ>QZW/)?V:/%TO@#]K;Q?X(O[.S\/Z;X
MXN9=1L;"&]-U%I=W$P9K=96P6,D4J*,C)^RKCO7T;>V/V6Z92-KC^'TKX.^*
M'P9UKX1Z^9_#OA[Q+'I?A'48;FQUJYL62WNKR-@\3I(,C:?F0DXX=N.*^W_
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M['8^#?@IX7\ [)]-TJ6:\48:\NY6DG8^_ 4?154>U=TC/J-NC7,N-H^52 %
MJ/XD>+]#^%'A+4]<\2:M;V.FZ= ]W<N=SN$12S81%9BV <#%?(,/_!;O]GMO
MB#_9,NK>+9X9IO)LI'TS%M? G&\'.X+G^\JGVK"*E+<A:RL?7Z2J\GEVT<DK
MLVT%5S'D^K5R_P <OB0_[/5K_:GC"*/3_"-KIMU>ZAKBWL"6VF21H&BAP[B2
M25SOQ&B?-@#>I-<5XP_;!FET\PZ)I5QHNDM(L:OM&92>A !) _W@#[5\,?\
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M%?1'P#_X)KZ?\=OV:?'^I_#F^U3_ (3CX?R26]];SPHLKE%<.L:J68AMC8R
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MM+LEC<Q3 !OG5V500 ,*,XITJ5V5S=3Y<T3PR][I;>6Q:67HA^_GT [U[/\
MLZ?\$O/B?\=[RUGNIT\'^&KB(NU]JMO*&8>B1C!8GU!Q[U]G?LL_\$S_  ?^
MSO?IJ/B::Y\8>)I'5XK:[*BUL7[%<*2V#R#N'TKL/VE_V\OAI^S;<RZ;K5_=
M>)O%O4:#HRQS*".\TA*I%CCAFW8Z(U=JI\IC.NVK(YWX _\ !.OX6?L[6MJS
MV]U\0==B 9;[5;?-O9N.@CBP47GG+;V'9A74?%S]K;P[\/O$5GH=UJYO_%$W
MR6N@Z GVN?9G!,IP(XL<<22*WH#7Q#\<_P!OGXD?'FY>SMKJ+P'X8F4C^S=!
MW+<W2_\ 3>Z!$I]"J>6A[H:\?TZ1= NX[JUD6&YM6#13!OGC<'(P/KS56NCF
MU>Y^I_@7XFZ'^U=\,?$VE0)-&-,N#HU_;3&"1XF=%)=3$[@KM?@[N2K>E>+_
M +#\-[_PC&K?""_OCI7B'X=>()[_ $6Z0;S!%+))',JC(W(,.IY'RRKR-PKY
M[_X)J?&2Y^&W[54>D1-<+I_BNTDMM1$8+%94626.8CU!5D^DQKZATKX)WWAK
M]MSPSXAL[JZ?3FDNFUF\5,_Z+):2J0<=OM"V;GT\K/8TI)<MF5RH\:_X* _M
M.^-O 'QH7PU<:U(8TB6]4P,\$$T.7&1"789S&WWBQX'-?47[,WQ'C\56UAX@
MABCT[0O&EO;W<=FQVQ:>52-9$0GKEU<^^:\&_P""I_P'TC5?C5X;U[5M9T?1
MK.UTB738P;>XNKS5$665DF1(U\O.V5<[I4P<<5X1H>K^+&T/2=.E\9:MH'@W
MP_-&^GF>+R;F]"MN4+$"XP3QG>5'=A13HKE&86O_ +..HP^,O']WJZC3M,\+
MZG<0RREP)KCR7D 2%.7?<$^\$*@GDBM+Q[J&L^,?^$"T,Z;>>"_AV)H+?4$,
MPNOM%PTNW[0_E)@%AY:]U^1<D5]F?L9?!7PA^WA\7]5U._U>[FU708H6O-#E
M(DES(ORR)/%*VT2;?,D2,E=\Q!KZ'_:K\5_ KX$?L]ZYX'\<ZMX?\(Z1J%D]
MO)8Z?(+C44N,?NI_LX!DW1L%8';C*C)%:\\8QL)JYY]\:=$U#]EG]F/7(O#%
M\=7A\+Z+=S:=:S[1OE\MY1E1GK(3GZU\@_LD?M6^+/$_PJ\4>,_&E@;WPQX4
MGMT&KPR1K;)<2--Y<+QJHPQ\H8VXZGBOIWX-_$1_VBO@=:W5K:?VE#JEA]BO
M;R=U4(S+L)QNW%F^]PI&3UK\M?C;X1O?@/\ %KQ5X'D@NK72;>Y$*VN]U2Y1
M92\%P4SM9MF[!(/^L;TKGEKHAJ,>IWW[3'[8GC3]J/Q!<2ZEJ+V&AE\6FGQ*
MJ(J?[1 #,?=B37E\%M%;1>5 ?WD0+,['J!UR:] ^"O['_P 0_P!HR[67PYHD
M[Z+"PCN;_48W@AB)[AL8Z?\ ZJ^B?AW_ ,$BWC\6$>(O%UL='M#&\XM8W9[E
MMJETW.$^7=N7A6R .16?+*UBO=6QX)^S_P#L@^-OVJ9U_P"$9T;R]+7B>_N'
M$4/^Z"3EL^H!'O7Z<^!_A>?A7\#?"_A:[L[+S=#L?L\DD3[@LN<K@]ZR=(\9
M^'/@YX=B\.>'C/;Z381%(XK6+=#&!W9NP^M=)X9TC6/$=K;7%Z1':S*)88HF
MW><.H8C^7UK5.$86ZDO4OZ;IC6^FV?F1KYYC)N'!YD;U-17B-8RQW-OM\Z*1
M94Y^;(.1Q]15WQ1K^B_#S0YK_P 4:_IGARSC^8F[N5ADD ]%;DGV )/85\E?
M'_\ X*W^&= 2ZTOX::%_;U]RBZMJ\1CA0="8XN'/L7*_[AKEY')W!)'N>L>$
M/^%7ZC+>3V=K>^%_$$$GFPW,*R16#32J[ JPP(XY(HY=W!!=N1BH?$?Q"^%-
MM^R5I^F_%/XY:/I7AW7+X7.BQP:5++J:103/$ZK;6\32R(71OWA:0 8);!K\
MYO'W[87Q.^(9>;6/%M[%:O9RZ;+96KK!:SPR@JZO%&%C<D$C<REAV->4P6J6
M\R>2FV9!\F&.T^_I5^R[E\M]C]<?$/\ P5^^$_P/^&\/AOX)O>>._$%JHCM]
M8UZPDMK338OXB(Y5B=Y!U7@KZ@U\8_&?_@HY\5_&OBN34[KX@^(=6C%TMQ<+
M<21K%+&IRR1PHBI"I'&U!BOF6Z\3W<:%)V,\G:.,[C]:]8^"_P"QY\0/C1I$
M>J'0I=.T$(9CJ-V1 )D')\L,09 ?501[TE0N[HNT8ZL_1?X-?$N+XH?##2?$
M27%MY.M6:W<=O$I4VJEG3826.YMT;9X7''%<[^TIIMAJOP;OIQHEO>ZB L,5
MS*#NMEW*S8^H4K]&-?,_[,?Q]TW]G&77]%\4330:)92-<6,[1/)L1G 95"J3
MEI),XQCKR*YC]HC_ (*2R?%*]:Q\/Q76B^';-&C9B^6U%NJR,FT;/IEOK2C3
MDIZC;35T;_[0/A^+Q)^S%H/B*RC_ +/?P3<FWFDA^]'(T@D@8?1F*_\  5]:
M\8^*'_!03XJ_&'2[719-=&E65C;K;W;V#>7/JCJH7S9I V_)P20I53DY4U](
M_L9:+I/Q)\%S^#]=U>YU32_BKI5RRH%#OIEW!-)$I51_$9%5ESU\M/6O@?QK
MX!U7X1_%35M&O;=8M1T;4'M+V.5@(RZN5(SZ''&>HQ73(B,CT?\ 94^.=W\"
MOVB] \1M*EQ;2W2VFI(\G#P2Y223_>0-O ]4%?J]9ZU;W\4-_ILJW>GW\?F6
M\P.=RD<Y_&OS3^'_ .R8GQ^\.W6I:7;6%O-91"2X;1[F2\@MB65 )V.5A.YU
MX7C&37UU^P_XAUGPYHUY\+_%=JFGZYHEK;WFD2Q,7M]5L90Y$T,G20 QN&*D
M@$8K.1MS'7_M'_#S6_%OAB#4[GXDW?A/PI:$VMQ:)$DD,\Q1G5&&Y2 0K#.>
MI'!KBO\ @G7\7$TSQIXB^%MS+&L.JR2ZOX:D1]R22%]UU'GH&88?'J:]E\9^
M&](U[P'>6>M:1I^M:;"?M<MI>2;(9W0$AF/L17S-^UAJOA?0=9\*_$CX*:+K
M>G)X*U""Z.VP=-,9D=O-_?\ *GS% C//1*2UC8QE\5S[16%3'E$&1]XGJ#5'
M4;1;H R<^6IQ]:L^&O&MC\3?!^C^)M)\LZ3XAM$O+=T/&TJ#@^C#H1V(([4M
MPB3MQR.]<\XV*YCE/$7P9T_]I'P!K_PPUR7&E>,[.54=A_R#KW;B"Y3_ &U<
M*![,:_$?QMX+U+X;>)=6\/:Q ;+5O#5\]E>PC_EE,CL,#\N/;%?N3JE[_P (
MSJ$.H;IO]$E650BYY4YKX,_X+=? &P_X65X?^-/AE97T/Q_;Q6OB*+R]HMM8
MA1V:1AV66-HOF/5D8#I1&S5I&U,^:_AS\0X_B UIH/V58-2BMVVS*,BXC'WM
MY['VKMK7P!;Q6L::;ILT_E1,9E2,E4(YP#7B'A[XC2^ =<W6VG1R7&<2^5EG
M*=R!WXK[5_X)Z_M1Z9\"=2\6Z]\5/!,DWA+5=*+>&8-0N18RW]TLJ,LJ(&,T
MD#(9%=E0CY0,\UXF*RN=6ITY#:1V_P#P3!_X)5Z#_P %#-!\6>)=6\4W%C9^
M$WDTN/2]+4QWB791&C\UI8RH7,B\(CYP?G7%?)/A:PMDU7[)J4;V]U8EH[N-
MTVE'!/&#WX_.OMO]E?\ ;!U+]F[P/XTB_9Y\'ZEJ,'Q O'U?Q3XV\7)]DTS2
M;ED7$>GNOECRXL-L60F5L<(W2OF0>)-!\$^*I[RRMQ\3/$U[<F^N=4U1I+;2
M]Q<NZ+;,%DG+$G]Y)Y.,_P"K85W83!4J"M")E=G.-#:R7LBVQ<1[OD++@H/3
M%336ZC@<>PH=9[^:2\N%CM[J\;S)XXD541O154  ?0"E8X;FO4YI6U%N,6+8
M:;/4CR4S[[4 ,B)\SVIT5JEY?(D]_%I,+.%:Z9'D$0[MM168X] *1V:)J8MF
M;V;GC(QFIU XC]I'Q%!;>/K#P_X4U/4O%42VGS7US:&UBNY=S;GB1B9 BC9]
M\*<D\5RG@/X!^)?B/)JEWYHN+;01G475\RVBX)RJ]Q@'GV-?0WP9M_"\7QUT
M"3Q>_P!DT=8SIAO3'N\IY3A2P) V>IR/K7I7A3P/X2_X)J_M!_$?Q5JGQ ^&
MGQ2T7Q-'<:=8^%-#OY[I[R"</LDN9K=_+MO*\QAY3R;F'0U4.7J0U8\ _9HM
MYO"7Q.\/6.F7UT-,\7[8K/4(I&C>[65I(D8E2.DJ!6&< 'FO2O&6NW_[*/QF
MGO\ 09-/N]2N+ V%\1-\D@,BRJ<C@D$'_OLUX5XV^/MI:ZQIZZ9!I^AKX9MY
M+?0]-TB.00::KS"9F\U_G9RV[DR.?G/S"L3X9? WXC?M3:C,?#*_;IX8S,\3
MW+2.B JI)9B6/+*.3WK>7+R^[V$>GZEJ*P?,3^[)VY]ZQ-8UU-*BDDS^\60*
MOXU=\2VI2Q9/X0-X^HZ5P7B"Z-]!;^<653\TA'9NU<RLG8Z#I+'Q;]JO"LGF
MM.7"I&%R&SV'O[5OQ7(2[DBE,MK<#K;S#9)']5ZC\:\VLKJ>X$@CD:!XYU>&
M<-MD1AT8=P1VKV&#XS0^,-/L+'XAVNJ^)%LXO*A\0V4D<6J62_[8(VW"]R9-
MTG& PINQ&IFQ0))<0,LLL<]O,LT<B$AHW4Y5ACH0:Y+QQXQM/B/\1-4@\8)<
M7<T\VY_$@E9]0A?& ""&+KZCKQP17IMU\*-3L-._M_PS=6_C/PID9N[$'[9:
MD]%N+?)>)_8;A[UYMXL:VTGQ7'.UL@^V?OI#)PRX_O#M6.VI2TU9:\.^%;/P
M7=B*UU6/6;*13+]J\IH/.(Z'RW^9?H:]"^#O@:?XC>-[.^-_<IIUL-[PJOR%
M@<BO'/$^J#4H9Y]/CPTDZQ(.BN3QP>XK[%_9R\"'P#\+;+[2H-W=QB:Y4_\
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M=$KTO_@G7_P0K^*7BP:3XX\9>-4^%L1 G:UL9%EU+ .=N<M&HXY!R:^K8O\
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M+?R[[QUN&N-1:#8V<+_JER0H),G 8G:<45*D8QLAGRG^SA\<?$_P1^(EQ?\
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MX##M%M9'._#< UX5\"_CGH.D?%RQMY##=^%M8@DTFX5S\UVDY\LAU[!@2O\
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MTY(ZD$UO31<MC[__ .":GQ3CT.;Q3\&;[4K*Y.AWDM[HEQ;3B6TDMR4+QPR
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M>V?M4^$(OV:_^"C,?BRSMH['P-\:[4ZQ*$XA@U-@?/0]@QD)DQU/F&I?VT_
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MB/\ #19M%O9=/US1WCUG0]1@ :6RNX?GCE3) W [@!D?>/-?07Q=^)EU)?\
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MNK:QGN:_67Q/:1Q7=MK$3$O:MY3#&?-B/.T^P<(_UC%? '_!5CX"IX$^)_\
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MA#2G[K13A3(X'L^#7R?X:\-_'+]N_P 7G5M0U3Q1\0#8F1%N]:EF6SLWD"Y
MY\I20J\8'W:WIQ;V*@DMSS:6X>Z,C!(]CJ2(RW4XXK[\_P""5W["GP+_ &E_
M@_=>--8FUKQ;K'AR^_LW5?#US,;2SL[G:C@E8P))(R'&"9 C%7!5MIKP76?^
M",_QUM=)AOE;PW)YZ^:D4.H'=;_[)RH&?]TD>]>Y_P#!*[]E?XY?L8_M'C5]
M?TVP?P7XIA^SZX4O59791+Y#%,[BRO(<84C$C9/%:2@^IJY+H?HOH.G6G@WP
MW9Z+H>EV&BZ/81^5!:6<2QPQ+Z*%  'T%:'DI>1J9,(5&!6I=Z1Y%X(XD7R?
MNI@]<U\T?M@?\%./AO\ L=ZE<Z'.]QXK\?I [VVAV,+?9U?;E5N)I BIDE>4
M+C!SSTKE>]C%W;/HZTTR5T_<PS2<]50E?SJ/Q+I<?A/PYJ.M:_J5EH.CZ?&9
MIKFXF$;I&!R5!ZGT !R2*_(']HS_ (*R_'SX]GRM#UFS^&NA(^ZWT[05\J^D
M(/R[KO=YTGNL7E1MT:-JZK4?CY!^T?\ L"7?A[XH_&*&W\7G4FB=-<;%PR)*
M)5B\F,^8&*M#@D8RO/2M(T;CM'J:'_!2W_@K_HOQ%TF'PC\$?&.K:78B%X-8
MO;;2Q:3ZESAMUP[B< C(*JBJ>XKXV^ ?[&?C?]H_6H5\-:+)]FG.3J^HMY-L
M%)Y8$MEC[(#GUK[L_8R_8=^%>A>$].\12Z,GC'5I%$J-?LZ^3[[%.UO7)!/O
M7TEXY\=Z!X/\,N=<UC0_#&DQH9$ANKE8,$=/+#8+_ADUT1I);A_A/EWX)?\
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M6N4^&?PEU7Q-=3 Q2V=JZ-,V1@;ATKT2:VT33K/1;#4(VA1H_,N+H+^\5U/
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M$_@OX/WD[?%KXD-:ZU ^V7PIX6LY-3U*W?&?+FF ^SP' R0Q;CG(%?6.D_\
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M8$+>8AN)(S=3=?-?.1251@=B?CB_A[PU!H'A/2[71-%M8_*BCMX5A6%?15
M'X"N0OKJ;45WW-S+.?\ ;[U1OM9F+$M@?2JWV^6[&%Z>IZ4I:E<I+-?I;IMC
M;R_I59M2$4>^6.:09QYFPXS]:;=QP"$A_P#6>W(J&;Q3<#13IV?W!(;\JF,;
M%1B/N=6C0X\Q]W]U1D5$-2$JX)"Q]]QP:HQ2^5&?D7<W\1JGXBTK7->TF&#P
MLFCS>(+JZCA@35=_V5AG+@E.0?+$A4GC<%!ZUIS 0:GK;Z/KL-Y;)N388F#<
M!L_Q?45K_:&>S^=M_O6)_:']L:2[M J.@,31,>8IL<*?3&1^8J/P-?:A<:08
M=6BACOK9WC>.%]ZD;CL8GU*;2?<FI4M0W.CTD&_+6W\$L;1\] 3P#7#_ !<^
M!6F_M&_"#Q1\.-<B,3SVOV.SO%D$<EO<J2]M<!F5AM$I"$X^[.W/%=AIUP;2
MYVMT]:?\1+1K5K?Q1B:\M["T:SOK&,MF>U)#R,H2.1FD 7*KM^8@#(J=I\Q+
M5C\J/V%O&VK?LW_MDVNB:U(NE:E;WDVE:B'.U+:Z2<HI&>NYXU7G^"0FOU-?
MQ-+\*?C#X1\<>&H[#2M.\5R&^\17]V#(L=U*Z[T#,P\LR #*JP'^R:^"?^"K
M'[+BZ1\:O#/Q!26:VL_%]]#;ZU<[-IMK^/)BG^DL6ULG@L"!7V[\!?#5EXY^
M"4^F^*[F76_ EK/ 9KB\0K!>W]N6B8[@,'YHP?ESRS<<5O-W5R.5&UX6>+X!
M_M/^)-+\S7?%I\<2?VE:ZK"B?8[6-Y20)%^9I' 1D#*54*1D'->_ZK/9^'6C
M;4[Z&V0KNVLX#D>NT\X'<UXW)^TLNA7IL=!TC2+>"S_<V\L*21+:QD@$;I#E
MO7)5?I7YD_M&_P#!1'XH?''4=3L+S5KK0M/BEV26=A=.HE_WBI!Q[9Q7.H<P
MO9W/T,_:7_X*K?#W]G:[?3(3/K&J8(C_ +,V2A_]YBP5?U/L:^"/VF/^"B7B
MC]JK7(]%NKR;P=H=U(%7[--YK,A/\;84?H*^8_/V7;W"2R0R,<L!R']S65XJ
MUF.ZL6W2QL1U"N"1]?2NJG02W%RV/OG]FO\ X)N_#"?[+JU_+<>-;N6198H+
MDLL!/^^ARW/\)R#W!KZ+^.7[6?PY_9,T&WM=?UK3-(DTZW,%MX;T>-'NU/8"
M%5 1?7)6ORF^%_C3XSWOA,V'AWQ!J^E>'40[/(.#(H_N'J?P->H?L]?\$KOC
M1^T+I6K>*KO2TT[1UADO'U.]OMVHWH52<B-F9B3C'S8-=/,H;"M<]4\;_P#!
M;O7]9TF\L/"W@;1[:/R7B@N[^^'VK)! E\M>%(ZXW-TZBMW]G/\ :2_:[_:S
MU2*;PQ\/=(O-$TF)IYI7CDM+:0K\P596E8,QZ  $'U%>D_"3_@GQ\,OV?+GX
M=Z[X7T^R^*^J>+!!J,]QKL3WCZ9"XCD15M85PC%3)N9PQ3RS\PP:]@^*OPQU
M?X(>.HO"7A3QAJH\2^--4&H*FGR?9 UHRRKAYP6WJKM&, *"$]JPG7N3R]"1
M_P#@HOHX^"?G>)'E\$^)=#+V?B&VU6-K)K.[C.&AMVD 6?(VL#&S ATY^85^
M;/@7PQ?_ +:/[7'B34]':XU&VU34?M*WUVNQOLH. LG9<(-BCN$JY_P55^!/
MBG]GO]J;Q%X-\1:O+KFE:E>C6-*O)XD629#''"6#@9!*VL2E0<8C7UKU_P#X
M(Q>/O#^C>%?B!9WEINU%M2M(SY:;Y)(3Y@7 ]CYF?3</6LH1YI7->6RN>R1_
ML:_"CX3ZJOB[Q%'IHM](>%8GU>_\JSA**H)B&%5F9E+8.]LDXKXM_P""BWQ
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M:%I8I7BDR#)M;YD;&1TJZ,TPU9]$_P#!7WXVI<-;?#2RU :AI>GS+)K,RO\
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M!7IT4'O7'4WNCNA>UD7?VR_^"1_BK_@FE\&OA]K7CBZ_MI_%DVR_CMURNE2
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MP#\L('"QJ?[JJ%4>RBCP_H4/COQAIVDS74EI:2R[KRY4<VMNJL\TJ]B5C5F
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M11R\9)SP#7YIPZ<NDRW5B+J&]ALI3%!/$'"3*23D!U5_S445'%[#Y@N7 ?\
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M;?(2F2W%>#?$WXN_#WX*^+IT\!:)K'Q0\:"9MWQ%\<W O(;24^=&#9:9NP,
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MK738I0DL#/MP<\<5ZO\ M/ZMJ5[\8-/34;B:#PU)"/*,?S?OBS?*P[8PF/\
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MD7O\MV3^(O%6VPEN]2OE@@M^999G"(._4D"O+O%G[1%M<0,?#J6NH*3CSII
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MCT=/%&@J+U+-= U5'6..W *OO'RR+G*?)*3BJG_#SWP=^QU\(6\"^ ?'>O\
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M&!@@]Z\^\&"'1UUSQ#.X6#PAI5QJ 5N%DO"C16J?]_Y(W'_7$^AJ_P#LY?\
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M9[KQG\3@^D6EK#$JN\L-H<7,ORME6=8TR"&('->6M^VW^R?_ ,$YK#[#\ O
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M+Q3\?],\/ZE=V9A,]Q"^U65<C\Z-#^/6@7D/^EQR17!Z83C\Z5K.X<K.IMM
M^SD/YC8';%3WDIFMPJN<(,!11HFMVOBFTS:3[O\ 9-/-ML#<'*]>.*O1[B&V
M]E'_ &:S-PU01,JVQ'>KL(66/8>]5[FS6"EH.[)[23%GBHX<%\'N-IIMN^(J
M0C+YHW0^8L'1TO+3[(698@<C!P0,YQFH)=-EMH_LL4\O]GNP$T&\XE0$'&<Y
M'(!X]*M3W)2QB,7^L) ;Z5+.X$N/X:CV:&I,U/B=XQNOB7\2]<\32CRI=;NW
MNY(S*TACW,2$W,2Q !P,GH!5OX&7T6C?%A=7OEA%KH5C=:O$2WS27$$$CP)C
MWF$5<M-<QV,N]S^Y^[G/\1Z4L5OON,MCIFER=!<Q?^#EM=:?\;_#'BRU@TG5
M-2\/R9GL]4N&@M]5A&0R-(%;:Q&,9&,J,U[W\?M7D^-GQB\-?$6Y\.0Z%H/@
MS3V6>VDUFWU&66YWAHF'DJH5"RXYKYRN=/BN+7RVA09]#6[X/\2'2OASXC\.
MI:QP/K,MLSWH8^8(H'>3RP.F&9AG_=%=4:]14_9]#&5/FFI,Q[MQK,BW<\C>
M9+\Q YS]:Z3X(:X/"/B_6O&5S8PZC8^ -'N-;2WE/R3SQX6",_69XS_P$^E8
M4BPS1M)&@A4\[5[5M_9O^$;_ &:?$7FRQI-XRU**S58VW2);6ZF5G([$R3PX
M]=K>E<4H,ZJ;]ZR/EOPMX<:]T.WGE56=HVPH.2HR<<?2O7/#M^/@S^R7XJ\2
M&%$.MS0^';=D.7W.3<R,1V4);*N?^FV.]=IX2T>PL/A(WAJT\,:"^MV]K++9
MZQ<3[)KJ(R;F\SLK*C,%'?8OK57XT?">ZOOV:OAUX+T_RY-4\3SW&HNTC;04
M>5;>#<>VXVCM]'SWK"C&2K:['UV>UL(\#3CAOB27-YOR\BO\&?V)?C+?? ;1
M/'/@_3[/_A'8XY,R&YVNVR1D9P.^&5ORKIO&6J^)M2_9+\1:QJ6I/>ZEJUS#
MX(@OI6 817,LEW= 'TBAMH@/7?7ZS?%/X:6/[)__  1WL['2WB2/1/#BZ5)<
MPX8PSR6_[Z;/]XRF23ZM7Y,_%6U;7?A3\"? EC)M?Q1+<ZQ+!_#<W5V'L[8M
M_M8BC..WFFO1J5()Z:GP[<GN<5XS^&_P:^'.@M;2O_I-M R)<6:>;-+(>1D
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M=1N.6YP*;JOPNUK3I"USITDH/)V1EJCZ]BJ>E2F_N+_XA5PYB7?+\TC\[/\
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MH7/RAAT/X5ERD\K/I VQAD52,;AD4EQ'Y1KDO@WXZN/B$MU#,V;C2V\O<?\
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M6-I%.?(C@AA"J/\ @+X_X"*^>O@7^SYIGQ.^($<&HZQ8^'[-01<7#SJCC_9
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M*#)8#WXZ5ZQ\0_BSX>\"^'K'5->FCTG4=1AB>[TN)U>>PE*+NC= 3MPV<<]
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M<:E>6VF6MS<^89C',=JP,/0U]AV'P4\.VFG?98[&)(<8Q]T_AW!^E8C?LJ^
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MF3!4K\T=RRD]0K.1TKPLTPS?OHUHR9>\2I=KX;T^S-O!KW[D^1=W3;9'3ON
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M9-6/)]<U67Q )=(5GE$THDED;@@#K6LQLM)TA;33XS+;(,732#;(#[#O6B?
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MQ_7(WMU-+7/GMK5X9, ,%!YW#%:.D3K9Y*GJ<FMWXBR)X@\37DUG;I;6JRA
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M('0A3^->"ZWXK;Q3(]Q);16\SG.$.:N.Q42B+P&=98_O2*5;(]:K7,94J!_
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M%=-X^_:7\7>-+&V5K6WTJQMXRD4$,F0R_C7S]/)ZVUM#1U2C\=_$*RZ^L"7
MN9HP?M'/$3>B^HKB(PL5J]XWS%E,>#[U7>0ZE?23/_K)3R/2KLVV+2!"RLWS
M@X K[#+Z*I4>26Y'-<U;7QE>:#X=T^STZXDM-BAG,?9@>*L>.O$U]XOU/2+B
M:[EO+B.T=)2XY!-85M)_IVW[-(@)Z[#Q6@94@DV(-A)W>;_%]/QKMYI<O+T%
MRHR]1A^SPVX4[=R'S/K7U!^S=K>F^'?V:/$1C2UN=<N9;6WM%=_FBS,KRRCW
M"1A/I,_I7S=?6RZEG*A<]A4NE7T_AJ16M[J6 Q\@+T;VK'E70.5'JWQZV7-N
M-UQ'-D9P6&8O85XR;3R--DG'W_,&W_=[UI:OXBE\4S&>X78Y[ U#JBNUI:JG
M0Q_-510RC-<^=G;]VGD-#"@DX\X;D]Q4,,#0C9ZU<O(S?I:(,"2WCV+G@58K
MH2)DAAV_Q^E5;C0TO_FD&3Z$4@A>UU("XVY_V3FMEH!+&9%,>U>N6YIQW%S'
M/OX?M]-4S>0N%&.*[3X/7*^%/$EO=B2.&.6W=R5;YE/N/6L6\@:\TW$(RVX5
MF>6=/O<K_K2P$OUJ92Y2;W.U\?\ BV6YN3J6[SYV^6)R>0IZY]*XMW^T>=+)
M,=\QRR@Y!K=U&S_M#P_)';?/+O#,/8=:YN:Q^R G*!<X +<U,:D6]2DCI? '
MC74/#<$EE:2%8)1O*[NK#I7:7GQ[N;3P.;<KG4,A7]J\PT)UANC+N7,/WN>0
M:??WHOC+<(V7D<%Q6EUT#E&ZCJ5]K8;?/*(F;>4'0FF-%Y4BRK]XK\PIZ7?&
MQ:%9HVYK2-VQ["VRRP,7,A$;'E17KWP*\9:GJM]'8,8AIT*X7?)A_;BO(&DP
M^1UJ]X9\47&AZW'<="AZYISIC/JJXMI6F;:/<?2H=PN+1F7[T;!6KS+3OVDU
MOV:UDS'*8& G'8XXKK_A-=A_#2?:;Y[JXN_WC%NN*YG"PKHZ($-%\O2F181>
M:E(0F3R/]7GY<4P(KG#<?6LAD,S&1\#[M/A7'':EEQ'\JU6N]1BTJ+?.2L8.
M"0,D"M%KN1RLK^(]9@\/6QGN'\N(K@-Z&O'O%OQ>FUK4_*7]U#;'RQ*IYDSW
M-1?'/Q[)XKU^.SMI)4TNWX/&/-]R*Y&[L8Y(?W&=F<]*OV:>ZN7'0],T#XJO
M900V[R?:UB( 60]175GXC2:E.?LMG;V^Y2"4;)Q7@\,%U#%YZE..Q;G\JW_A
MQXB \11M<73Q$C84;A>?>N&65X:4^=P5RG,]7TN)IU#[C)[D5T5IN$(9^BCB
METS2X8;6+9@K,NY"G((J6>(M'Y8_&MU!1?+'1$\US(N]0DNM0$,?W6K5@F:S
MCV'K3M.T1;<B1OO=JGO;7<=[5I\.P%-@UQ-\R[DSG!J:3$<04+M [41D@5.E
MNLXYK&2;)YB@9R9EXXCY%655&:2?=EI3N;WQQ3KBP6-/EJ.*':G-.*MHQ79<
M\/:[=^&O$$&IV5U)97EL&\F>/[T)*E3CZAF'XU1DVPX"#Y " /0>E2A=RXIL
MI0(5[UIRJ2L]@CN9C)&FK12Q1*W[LIY/\(SWKJ? 4!\+HUQY7VRYE<+LDZ1Q
MG[P%<FW^B7^\>M;5IX^N=/QL@A?_ &F;!K\\XAR/$5IMT(IHZ*<['9>([&S2
M8(&$%M<,'C5?O1'T I_A3XU^&_V=?B+;ZIX@T];^<PL;=T4N<]I&QT8$9 KC
M[OXS;U5+C0[21U(/GECNXKS'QKJ;Z]XAN[F:=PEPV^-!R(QZ5P\-\)UUB%/%
MI**U^9<J[Z'JOC[XW?#GXW>%9=)\02ZQI45IJDM_HVH6UF7GCBE0"2$@]%+J
M'^M3?#FU^$/A2_L;BT\0>)?$E^ULV_3;ZP,=I(?[I=2" ?8@^XKP6/4&MD_?
M72A.BAF (%2^"OBB=#\13K*8_L()"L&R:_2JF!IWYHF2K3/??B;\7-4^(%I%
MI;VUKH/A^T(-KH6G I9Q8Y!8Y+RL.S2L[>]<Q"^Z/[NTGK[U7\%^)K;QS!<S
M6Y8BV<(V\;<D^GK5^:()+MI4Z5M@=1O<;&Q'%(K_ +X+Z\5*L&*<UD&3?_&.
M:WY2#L/A,WG:;K-F?]6@8C\%KC"R1R\\=:[+X2)M@U!_^>S;3^(Q7)^(],^Q
M:S<1]HGPM2]!:C7F4=*KS?*K_)O$IPRGTIGW9:GW\UF,ZSX0?M ^+_V?+\3:
M%>O-IN"K:;(^V&3/<GK4'[2?CSPU^UU?Z-+X@\:>(?##:< UWI=MIQNK)9@<
M@@!D+8_WJYH0K<':>],/AV.,^:6 6-@K'^[FL7AU*7,Q\UB&[^%_AC2]>75M
M.\<7.I;3@F;0W@W?0&X./UKN/!&F>']<\1M9S>)+R*5K62["P*KG8@YSZ5X9
M\=O%LG@NZMHH6_<W<996!^<#IR.U<1\%O&MWX7^*#WL4IDN+S3YX!N;C:XP<
MUPXK(Z>)FI2>Q?M#UWQS^T'X?TK2K[3]%GFN]\P=;F1-KJ%_A ]#6/X2^,JZ
M[J%O;WJ11P7$99I=W*GL#7BFI0+97%U V%DW\,IR*Z#PMY&E-H\UQ;_:8(K^
M"6Y7&3/&&RRX]".*];#8..&H\D=B)/F/HRQU<:6;&>U:"3[+.ES& _!*'(%=
MK\4_VE?$_P 9M%NM*OK6TM;/4KA+J5HI=Q4IP% ]Z].U?P'\&OB?X%G\5V2W
M'A.&.T9K?3;.#*-)M^4/GE>:^;=$G\NRCF9%7<"<9^[S6L)JUC!P.T\/_&WQ
MCX(T632='U^]TK36(+6\(&V0CH36(WB35-1UT:G-J-RVHJXE6[(_>(1SQ587
M7VSYU/YT_P"?[QVY]C5.K);$^S3W-OQ_\6O$WQ,B2'7_ !%J&LQ1D$1W( "D
M=#6/)FXC0M\RQ#&X^E0@B>X_>>E<9\3?B2/#T4MK:M\^PX&:CWI[C5-+87QA
M\38-*M+Q8G'F6[_+S7B>N>(9?%VKR7<Y)9\L>>]9]]J]UJ@DDDSYDS[FID)^
MS2\]*UC3LBQP9C)S\KD8S_2NU^#O[1/BW]GXWA\&ZN-%N+H_OYH[2%K@-CHD
MS(957U5&"GN#7$W9\]^*(H%\Q6?YB@P%/:M^5.-AW9[!X<_:>_M[68[GQE?Z
MC=ZG>W<?VZ_$6Z00E@)&'8D+D@>U>DZ#XY\+-I\%TVL6VDO<1Y=&E5!N^K'K
MZ"OF;=(R<,2/I4*1?9I?.$*B3:5WACG!KYO,.&Z&+UE)Q?D7&=CZL\2?%+P)
MX-TZWOKG5AKM^(SY"QE9'@/]V0*?D/L:^7O&GBK_ (2CQMJ>J;!F_G\W9VB^
ME93*$;<)6'& N>!4*QQF3&>:VR?(*. ES0DY/NRI2N=CX(U(0:PLDTTB0J-_
MF#J2.@_&O:_A]XU@\7V=Q+'P\+A OI7SC%>O&OD@X7U':M;P9XQO/">M[H)I
M-F<O'_#,?4U[E;5F)]'7U\;>WDE+-N4$,JUQL_Q3L='LY%P8F"$A2,<]JXWQ
M=\7KRYNX9H)#;&5#YD2'Y<UPOB/6KC6)#)-M8=QNK!4T*R+^L^.[B^NIKE.'
MF;<V#WKUSX'_ !#/B31Q:7,*-]GC*[R>0:\#$RM:G:-OL*T_"/C6Z\*>88"5
M,IR2#1RV*NSZ6ANH8H )KI(^Y#,!52Z\2Z383!6O4+.<*-PYKY\U7Q-J7B>X
MW>>^3W)P*HSL]O*JSR;I(_F4AL\BDT(^I8WQ;Y&#NY&#U%4=:>2T\/W=TL?G
M>4""A[KCFN5^#/Q AU'PL3J$@5XW6(<]S5+]H+Q=J_A_2H[?2_,2"<AI)HAG
M\*6PTKGEOB'5X;G4&EMHMOVC)*MQY1]!68EVT$J+N. /WA/?V^E+<VEW=*]U
M-MP3W/2J=RSL@W;?;FM%%6NPV.MM?C1J5E8Q6%B_]G10_=,1[#M^-:FB?M$>
M(+;4(TN''V8N QW=!WKS0J8Y!OR%]:=<;IEVQ\CVH]FGL+<^K8]137K.&^M?
MFMW7);WI9K$G#L&^89&!7E7[//Q":UAGTV^FVV=N"%#'C..*RO%_QCU2T\37
M/D7TGE0/B&)#E&7ZU/*T[,#V.&+==#/"_P"UQ5'XJ>,8/!7AR)[<O]LD=<%!
MD$=^:\3G^,VM:W=;C</&IXV@\5'K/C.\UF&*.:ZF/DD80#*X^M7[,N*.^U_X
MZBTT#RY+>-;N9U:':<X7OGTKK?AAXWA\>Z<X;Y+NW<(5[O[U\^:S.MU.9B=O
MTJ[X,\>7/AS5EN;9MCPQ-&K9^]GUI.F7RGT?X]UN'P1X?-S.<?Z2D*[>3AC_
M "KSCXO?&0V^VUTV4,8G&=IZ5YAXJ^*&K^+ ([VZN"H.=J\BJ!6(6#3*2)Y'
M&0WIWJ>2P<NAZKX;_:;%E<16MY;HV\@--GYA6Q^TSXN^P>!-/GM;>::XO@K6
MY5"7>//) [BO)/"?PEU/XD:_):Z<ULK_ &=YU:64(ORCL?7T%>D^$?C\_AI-
M"NM7TBTU:\\#6#Z+]ENB561I#D2?44E'FERFOLK0YCBO".M^(M A@_M+2KU=
M'OYTB2XN(F2-68X4ECQFNL_:;^&EWH/CO1++4)XO.L-*M[E#$X99X;F,31G/
M]X(1N'8FI/&WCGXE?%WX<:C826,\GA:647JQ%#MM&097R^.0/6N=\9?$=O%G
M@+PI>WX2:_T:T737FW9EES(Y4L/9&2/Z1+6_L.70YXRYD8FGZR/!FL":*&UD
M!0Q?O[>.=2#_ +,BLH/N!D=B*[O]F[X&:-^T?\0!#XDUS_A'M)M+I(&D1@2L
M9//WJ\U\3LLB3+D%XVW)CVJ+P7K"V&H6ZW3,+74Y!'/C^ L<;A[BE!1<K,B=
M^A^@&M?LI_#O]A_X_>';_P #^/W\8> _$$AT[7E9HS)8"='C\Q44\["RMS_=
MKY4^+?P#G\-^.]8L[PYNK/4+FTDXW*3%/)%E3W!V9![@BOK70?V O"_@'_@G
MAXO^(WAO4-1UC7-+N(99HYHN&LV*I+*Q[!=XR>@&37Q5X_\ C/K'CG7&OKB^
M;S&1$.#U**$+'W8C<?<FN?$*$6T8KGN>LP3R:O%L<'?U -3P:5/$2C+A2<FN
M_P#&?P#\2_#&W%WK5AY,+<I<(<X]CG@$^E<FUZUX^UI CKU3/+?7WK\TJMQW
M3/0B)8F"R^53SZ4_4H)-7B,$BB2$\E6Z#W^M5Y+6-7\S!7V88-1OJEQNX7]W
M7%S^_P R+EN<1XX\%PVT@A>$26LAWI*WWLCIFLRR@FM-ZSJC1I$RHK'J,5Z+
MK5I_:^G R#]V&!SCOVKB_%FFWL$WFK;Q2K&I&"W./I7J4,5S:=3(YFUG_L^Q
M5H(S;RN=N4'&T]:?J\DDFGA8A A@8!7+X.?059M=]]9FX6(H+?Y3%CBJ.J16
MFIVT3W$?DC(("#(#=LUZM._44MBU#XGNX].V7\TI,CC_ $91F*1NQ)J]IS1:
MQ*UO<6MC:+'S(Z29+$=JR]2GEN[1+:*-=RD'<.X]JI77A6?4+E+AF:T6)Q&T
M<?/G$]\5U;1YD"9?UGQC=6&NQPVUI%%9V\9!,9SD>GXUG7WQ(NM3DB2WN)_(
M/'V5%S'%[9]*L_\ "(Z@VI75I]HV^9DQ<_(>.A-)I?ARYL-$N+&TB@@O78&Y
MF=MHC/HI[USJTW=E\Q9MI8C)F&.WED Q-;N^%)/<>M:36]PEF-T$+Q9 \F1L
M;17#0^%;[1O$-HTLADS*I5E.3MSSCVKUS4?#,_C35OLFDVTE[=HA>22-2551
M]X$C@?CCZU$[*5D$CE2#I=G<P3?-!<2B2*WC^:/CH2?:IM0=M4M+?_39[>Z@
M3RU '[LY[9JG?^']4\,ZONO%^S6;R".!#/%)OSQ_RS=P/Q(K4\2>#M9\-Z1)
M?75K')H[2*C-NSL<]!]*QE54'[Q)R_B&!3:HK++;:A:R+F6)<I-CG.>E-6 ^
M(]0\Z[;$;?*67EFSWQ4\^IC5=UN+XK]F^1;92#'^=1VL9TV?]^63CAUYYKN@
MIK20%O[+!I9$=C"JHGR^8>))#ZD5#/-J%]+L(\N-%.Z1>3-]:?!?J+R)9MX>
M3E9\=1Z?C6AJ<EQY&$,4,*R*KE'RP]L4344:%/3=2*VZE8R3'\FW'%4-2U*U
MD2=M0@(1) (HHUW!F[,?0BNGCGTW0+]DEDD99HFF1=OR#'J>QKDM-UN/Q8UX
MH5;7]\&C'_/11W.:F,)MW6P#[)XY;*8 W$,LK;GD1,G-2V6KOH\839\T@PDX
M_P!9]2.U+=ZM(+LPV4@\U.,'A&^IK/BU<VFH22W$2M*H(<*<Q.W;#=ZU<W'<
MS+<WA]M[3R7<S7#<@A>)#[T_P]X9UV_UR#>T+6SH7GB23<@4=<GUQ4OA&POO
M$6JK_:*WFGZ=+$S*T49+1O\ PJ!_=/<UW.G_  !UKP]X$F2WU-(;O69EOTF$
M@\L6Z??5FZ!B.@K"6.IKW;ZD\IY/\1WM+7QI;3:19I8PV@V"6(9+^Y]ZRM?T
M;_A,X+NZO6\P*VU6_BE/8D5U/Q!M9==U1#I\5K9Z?9@Q$PODW?\ M/Z&N>M-
M0&DZ[#$L#3A4.^-E^6N_#-2CSD21Y_<?#>V.GNOF.LV=VTC[H[@5F:MX!CAM
MK>.WS(;A-X8CYDQVKU_Q#H<$NHP7("^3>1F0JG)B]@*P;VWS:.+2UE$BN )F
M0@A>]=OUBR,^5'E0TZ]\+S!V.YE.<,<&NNTGXH3ZU'#'=Q(AC&Q3GM5;XB>$
M[_39(;J7S)XKI"\38RP^H[5E^ _"5YK5U)YT;AD1G 88.!790Q%XW#E1VR2)
M.N4;GU':KVG3SMA$)D?.1FL[POX7U#4X%^SIGODGC%=3:^%[N*S9XE:.XCX)
M88P:QJXA)W*CN+<7>HQVI:5&SZ 9-5/[.N+NS-TR.JK_ 'Q@UN0Z??:?HAN;
M^\E#X^4J,C-8R:YJ5W8F.3?=1'C)'-<[QK>B'S!I4T<X[[NG3BB_LF^TC.-O
MM2Z;?V-G.D-PLD2E"6&SOVI^GWD5Y%<+&RC8V5WG'R]_QKIHU6UJ',,2S1SQ
M27,GE$ _P\"H6UNWA7<I.>P(YI?M]LFV6[F=/,'R)CJ:WG.RN',0R*?/'!JO
MJ5RJ XW;_IQ5_1;1;^^E6::XC).(H]OWJZ"\33='T[[/-:;[W'.Y>]<GUO6Q
M)PMA!<3EIMOR0_?QVK8^'F@_\+*\5+I^FR W-PI95D.U"1[U/ \MK;S&*W*Q
MSG#KM^7FK.DQ_8VB_L.%;*\M?F,Z\,".>/6NBGBEU OZMX6O_ 'B5],U",1W
M-NC>8,\;AZ>M<^UIY]R]RW_+4[F-+XL\5:WJFJO?:K<76I7; CSF7.!]15?2
M]1E6!6<E@Q_U;=Q1.O&6PXZG96&G_9_"_FVL4HFF((E5#DKW%<YJ7AZUCO4F
MN(PS$Y6-/F(/N.U='8>.;VYB6RL5,;0QDQH!^ZP/[Q[&H1K^E:;X?FU6-!-J
M(D"7R..8Y#V3^\OO7%-S^R:\IEZ3X&;6M?=/*2#S5,K;#DDCM65K%LFFW<T*
MQ^0P;YD Z5;'Q$:VO7OH6^SS [8U7H0:RQ+=>(]4N+NXD8S2'.#TQ71A_:_:
M))K32Y+;3C=2; C.!'\W)!J"[G/]H;3D =<UT?@_P/'\0M4BL9K[^ST@B;#N
M0J[QTP3UH^)WP>U7X?6UG<27EGJ$4^%:59PS9)QT%>W"G+DYB9'-SW$43 9^
M8]*""R989]C2Z[I\%K=6^W/F1KB0'L:BCEEGN$3LY'Y5,9-[BCN#A@@Q^[1N
M@%=7H_Q1N_#MA#;V\2^:D9CW[N1FN7U.94O6MU_Y8-@4ZS0W-]M_Y;8W8]AU
MJ)HKE1W-I\>=6\,V,:J7N),<ANE=OX:^.*ZKX(O+Z]"KJ"G9%#GC!'7\*\0N
MKF:<R'MGY?I4<)E>#"D[P,X'I7.Z>EQGN'PL^+4=YJ"#5)<ACM!8]2>E=G\2
MEM8;+SX[R%CMV/;[QQGO^%?+NE17LY#/O5-PEB*]21TKH(M7N-3D>XN6?SB?
MFW]J(VM<"_XJ,45R?+/G =V'6L9)V8<,8_\ 8%3WUTK0\[MS=..*J0*;F-H_
MGC?:2LFWY6/]W/O4^UL+<K7%YY\I4%D;^\HZ5GW$;289)'E.\<L,'%:SZ?9?
MV;#,+RX@U,866W"?("?4UFZP9K.X7:OR 88KR*<9)LEJQ[[X?^*D.D_#FR@@
M"/=0H$ )[=Z[C0-1%_X?L[Q@%+Q%Y?:ODV+7)[&.&:([@G#+GFO6!\3;B;X1
M,MM^YFW*N2< H>HJN5\PXFCXF^,\]OXFE6U.^VC! YZGMBMSPI\<=-OM''V\
MLMUO5&3;P,]Z\$DU687&^,'8AX#<4MQJ<TH,NS82P;(K1T[E'UC'-:W-F9K=
MQ)$?ND<D?7TI+2)G/'0>M>%_";XYGPYH][;30^<TTH<$]3@5U$?[1R:C>6Z1
M6I5<@3L%.5K-PL3RGJ$D1?I4& &PU<7X]^,MKI5@);%Y6WD%<KV[UL>$O&-I
MXET:"X\V/>XPP9L-N^E1RW).AEM!Y&X=:KO:):JCW!13)]P$]:QYOC=X=\+Z
ME<:?JC2QRHC;65,_-CBO&OB#\8[WQ3?11VD\R1)*%CF(Q@9JN56L..Y[W-HZ
ML_./PJ >'PLI+8^8_N_4BJ_PX%S'X=5KVX\\R@;96-0^/[*\-SI@M;TQNDB%
MF4CE=W(^E9337PEFF^@*[;95_ ]Z\:^-&NQ:+J,L%F1'("0=OK7JGQ*^(=GH
M5O<O]H3STE41QJP(*]Z^;/&NNOXA\67ETRE$FER@]1711YG&T@*,]_/J\L7V
M@LQ53DFK5M!$[JH.$]:(-/EN;DXV#Y2/F;%-ATV?35!EV[<XRISS70U&UA:G
MK_[/_C*VT^TO+2Z*^9YH$)8XXKTU;BWU'41#%+ \V"V XS@5\W:'I[W^I+&C
M&.7864BKO@[Q9<>!?B1'<7,K2QH#&[$] :PY;!+8^BB<9/IUJ-9V,F1TZ4NE
MRQ>)[6.6TN[?R;A/,11(/,Q_NT)#Y"E58OMX)-0V2E<[+X/R)]LNK8_Q?O%'
MTKF?%,IN/$>HE_\ GM\GTK?^%-ON\2(P^_Y3+69XOLQ;>(KL-QAN/K64AM&)
M]ES+S4OEHH^O%.C;SH/E#,V>@':N9\5?%?0O#>MQV%S-*LGE-*YC7<8B.QJ8
MQ%RLW]3U"WT2SDGE*CRT)))P,^GUKPGQI\8=2ENW^RW,HCG?S!'Z$57^)GQG
MF^(MRD%D!;Z; V6R=K7)'1F'K7&W-ZS:F77+>8<G_9K916P2W-#5-7O?$^H"
MYU&XEF?&/F_A%/\ #2)9^*XW'W#$RCWS4$ADN4J:U00HI_Y:Q_=K6UEH'*QM
M_#Y-Y> =!)TJ]8>)FM-/2- 0T;ADDQ_J\>E9UTTDCR,R\RG<U,53]G*B1AG^
M&E*[CRLL^K?@#^W+!X8\.S>']3\&:#KJW]J\ GN9F#2NPPLYQT=<\"N-\6?$
M>'POI*6-Q$HFA!7S3UDSW%>!Z06L=1C8<&,Y'OBMSQYXNF\8I!]J4%K;"H<]
MJRC1L2V>M:-X^AN/"+_OBLG8KUK%\'^-KBZ\41QO>S/$3R'&*\ZTK6%TV/F:
M3R_[H&:EN=::X_?6;.C9 W$8(%.4;$GT1KGBO3])$JS2*&>%C%CN<<5\U^)?
M$%SJ>N222YW*Q4<]JL:GXEFO!_I-S/));_+'D<8K&O[A[F-Y<?O&.:J.@#);
MEA<>]3LZO#\_WZS[5I)(]S#]YG  ZYJU);-% ?-XE7@UM$N.Q/9*O>I9)H8I
MN35*SW8^;[U.N8%D.6JM+DRW-BSG5A\OW:K:K<$/A?N5/IH@72B ?WF*SII6
M="#6<M&(KN YXIB0;)=U2VL&Z3 JRUOAMM9.74!L.'D!-332+&^4/SBJ[MY$
MFWO4RF)5W9^:JC*X[L9/*;B,^8?FJ**&,0?-4DR;T\UA\O3-57W238_AJM@W
M'Q1*)./NU+-#'U'2HOEA^6A%+OC^&I;$/2Y9.!(WE^G:FW*^;AHOO;A4KPJH
MQ_#4&]8Y-B5+5P-G0=0>Q2XW,1!Y@W@'G=V('>NY_P"%CW>O^'ET]$@^S6ZY
M+S-M,^*X/1_#]]KLOEV@C,\,32?.VT;!R:RK[6=2U>U6VBM(F,8PC;N!]3ZT
MN4O4V+ZUD\36%Y-YJV$,4FWR@V"3[#O4NC>&]'=K827-VT_DG*21X!;MS47A
M70O[=6&&9FN+^%@S,?NQXZC/I7H8TZ+6;,LNF;M0T^50A528)(QRQWUX>,QD
MJ<^5,>YP=S\-[B:-YC*H786$3-A5]JPH=+N+"R5I42(NPVKGM[UZCXHT.7Q!
M827%B(]L]W'NBW?+&W0!?4>]:/C?X:6_A[0]VKC%W<2+M9.8T;L@;WJ*>:..
MXMCQRYMKNT=XQC9,VXX-,2T\B<9W!ONY/W?SKO\ _A4\NHW#13O=V<K?,O[O
M"HW9<GL:OZ[XKT;P_86GAG4]"M3=FW;S;R/+,)1]TKV(]Z]?"XVGB)<D?B#<
M\S:'R+CRU ?'!%7M(_=ZALE CC*'@>M4'MVL;T#=\R]2#_K3ZFI+F29KE&=6
M WA#QW-=TKH9;L[2VN9GBD/"FJ.N6D%E<QK"W[EU))]^U3MI;:?K5Q]HDQN;
MY O((J#Q+;*MH G16 %4F:+4CTC4=EV+4P1_,A8/WXJ9D668"1 RLI(8TS2[
M<?VE;-M#2N/*"^[<?E5GQ9=6^F:@VG[66YLF$4H093/7@]ZE[FA9\ ^)O['U
MY%A9V\ELLN.,BG?$'4%U7Q->71_Y?29WQV<#BL:WE_L6\EDM0)7F!!C/09[_
M (5"MRYB9Y&\SRF"L6/<USJ?+.YJYQ<.1GNGAS]H3Q!I_P *=,B?4K.ST:WL
MFM;P+.OV@;L_=3J>*\)2V@BU:<V<[S:7<$R6<DORR3+ZLO8YK<\/Q^&KN$R7
M]DEQ>1R#:#DKM[U'X]U32=4U:,:?;0VRP#:H4\&NB56^IQ*"CL8L=\ _S\'&
M#22PAS&,D1JP92O4$>E0ZD;6VC,SRAI/^>>?E-54>^U&P>2W3"MR#_##[ UR
M^T2E<SDVC[1\%?\ !0OXPZK^S')\)M#T'P[I?A_4+5K+4;_[ GVO6K)D9)(9
M7E\PE6W DQ^6/D'%?*7B#3O+\3:A#+&MN\,I!2'YER>3S^-:6F?M+Z[I^G:5
M;78")HEB]C"\9SYJMW/O6-HNK&1)+EY)Q)='>PV9_6JE[*:YGN9\Y^L/AC]J
M[7='9K/4X8]0M9N))7PQ8=U(Q@@U)JGP@^$7QY;SU4^$=7D.T262)%$SGH3'
MM S[@J/:N>-AI7B ?Z,\=J3TP1N_*N?U_P !R03_ ",\H'S"3OGM7RDO95O=
MGIZG:F1?%_\ 8!\>> ;>6\T>.+QIH\8+/<VCF:ZB'HT0 8GW0,OJ17S[J/VB
MQEDBDCGM?+;;)%<KY<D9]&4\@_6OI'PK\;/%?PVO$"7]UMC.1&QP/SZCZUZA
M%\?/ 'QSL5L?B%X<M;ZZ9=GVV5/-N$SW$S N/SQ[&N*IE-W:GL5N?$MM>[[8
M6YY!(<$<CBK<^CVFH6Q=N+DC ..*^G/&G_!-K2_%D,FH_#+QA]L_C32M0F5&
M'^RKA0A_$K]*\"^(GP=\;?"&^,'BCPY=:1&#M$VS,#_20$HW_ 6->/6P-6A4
MN'*CSBR\(#2M2G\VY#K,W^J8C:37.:_X172Q>2@FXBW[&A SL8]#]!77ZK;P
MZI<B'Y1M</O+8((KG/B9<:KX9\+ZC/8VXEDNVVM,#E@I&#7=@L4YSY)F<D>8
MQ^(+BSU"6W,V#;2B%)$.[KVKI99[PS B02&W^65P>8SZ#VKA/"]G;0XC8W&Y
M_P!Y*S)T<=*[&QUBWMK5\+)'*YP<K@RGU->]46G*B"1O$TKK<><LD2@_N\+]
M[WJ!=-DU*.(7.H7G^DCS@FSAP/6K\<T>I!(;B5DE3@*!P:DFLK@7FX2M*$0Q
M[1T3/:N64;%<Q=TBQDE*-&WG.JXA9NL:=P/:GS:E-;03Z=:&^:R<&XO(;!5D
M,DB]"V2 %]>?PJEI>GZDL<>)H[.UC'E2S[\.F?X0#US74ZWH6AMX2@T6VLP_
MVN19I;DK\\A'K6*:4[LHU?A1X?\ #OC'X:W\OBV&ZT^&:5;FP?2U6:;<H^48
M=E&S/7G/L:[70+6/7?A_<:?>3QW-E?1-Y<4A^[)C",?0BN.TXR^'/"MY):0Q
MR&PD$$*%N%C(YQ4UIJ4=KX<FOI%$6;9YU0G!R!G!':O Q\JDJEH]]!QW/![_
M $AO!'B*>P\J.>;3W*74@.=[=>/7BH]<\17;2H<2_8K@?*'7&SW%3^&_.\5V
MMYJ;.@;5)1.#N^:+'&T#TJ&*\6?69+74;JXF\C*1QNF(U'J#7V<;>RCS[V++
M6E:W=6?D)*PO[1/D4R'YAGN1ZBMBQQ82732_OX_-#X)Y/X5EVUK]G\RWMK47
M$CJ3&[ _-_M'W%48+XZ2\,<EQ=23QH?..SO7--)HGF-'7M0/B:2>1KAK&RBZ
MHGWG;MD5G:+K<5P@86F7CC,>X Y;/\57_%UY8G1+22.W,L]ZFXNJY*GISZ5F
M6?AJ_M;+[1;S/\J[9%7H<^GK791?+3L*[-.PM8+?2C%.QWR#K_?J]IYAT>VL
MX9;7[5:^8I"$$C=G@_2LWP[/->HMK+;PM(!\I9ONCU/H:U8[B]LKCR%57C\L
MIO!SU[BN.HKB/==-LCXI\/&*ZFCTR\CQ);-;D,CQCDH3[U1U#1I-6T H]](+
M1YE_T%.8RW8,>HKRNSOKW3M&AM8=2N'N(R&2)NA4=<FMOP?XWEU#Q5'8I*(/
MM+?Z0)&VJ\G0<FOGL1AI<_,BHFO\=? D>F^';2\M],TC19+;$4EKI\_FF\S_
M ,M6'7(KS5-.DMY0\:1-\ARS-AG'<D5UGQA\.:O9>)I7@2..>T.PS1OF/!_A
MW=.:XVWN&BD\RX5A>,<&/'[LI_%S7L8&K)1Y9&<BSIEQIFCVRSX,]Q)\L:./
MD7/O4MS<3ZC<1P/Y$8Q\X1@<>XIMZVEWEMMDCE@M4D"H G!/:JO]E007]QY>
M8[E#OB8?>*#J#774;:T)C$RO'SR7>C26D,<AEM952.;9S*/[QJ70-#E_LEKB
MY22&:)#'YD*[FE!Z[O2MB'Q]#>Z<WF6VV2*50 B[@P[DT[^VYKI;N>QDDA09
M5DQ@."/O55"M*/NLKE,;P-KS:K?C2[.&&&&)P'E9L,C=JZ+5$,>K7L4]Y(WV
M<E7"\^<V.#[UQT%W:P7:?8UN/,;F9Q'Q(WJ37;:;(MY91_Z+;^<%YF+?,M&(
MJARG/'29/$MLD U&X780_P!E8 *0/UK>T7P3+;WP>2>&VMY$+1JC@C\?2J>J
M:6]KJ,5U)A9T4[&B.XS+_M>E6[98[*W>^O&>07GS+:(-PB[?7-<4:K3(DC-G
MT1;S7_\ 3 LEM'GS'3YB#7&^.;""QU>3['N^S.V],C!'U]*]"&L_V18R0VNG
M"3[3^\5W!$H ]1VKC=7A98YKR:/]V\@\Q7X.3[5Z&'Q6MF2E<R]*T7^TX6G1
M1/<>8%6-NF#U-=!IGAEK>_G&JV"W,40+02OG,9'0"G^&-2MVOX_[/M0)%'S+
MCO70Z[K6J^2BO%"H+ A7; -:UL1)RLMA\I1T#Q)ITD$AO;7;= %HYBGS0D=A
M7/:IKMS?W32';<%SN,C']X!]*ZJ+3'\0ZFC".V9E4O)'$^X8'6N+\8%8/$_G
M6</E'8P"BE[OS#E-V\U&+5=(A&FW%U(RIBY5H\ /7*7&J7EA*0&F1XU,?"_*
M ?>NZ\">'+ZT\,^?@A+Q@\Y/W@U=/:^$M)U>R> 2JSA2\X? ;CKQZUF[K<.4
M\+N]0UFWL_EU&7RB.$R,$5D'Q)>P[=WS,G3FN_\ B!X'_L>%KFRV7.FS@M&K
MG#Q>VVN+M?"][_9KW,T/DH3\@;@D5U47'J+8WO#'CLV.CSJTS"2Z.YT[9J@E
MV9IRQ)YR!["N3NXVL[C><@UL:-JR7$.#EF S@<G%=^G+>(N<V8K2WDD3>3B/
MIQ6Y:-%<C,1(Q\I..1FL>YM[>TT:&\6X@+R$,(]XW8[Y':H8]>!G=UQ#">25
M/.:WHUDE[P>T.^\#Z+8ZMJJ6^JS;+.)2J2'MZ5D_%.2R@N?L=C=S26UE<)C<
M.#@YX]:F\*:%>>+/#TCB73OLH^8/-<!),?2MKX>? ./XI0WEQ::I(\NG'R_L
MLF '?J-O<CWK2MFT*4.65[!N<7J"+JMY+)_RT<[C4=G$T5VCL/EC7BM'7O#-
M]X)U]K.\6/[60?-56RL/L#45A;2:G<3(@9XXH78E!D9 JL+C*5:/- K5&58I
M]JU"[N#T,@Q6AII6UUUIN_DNOX8J#0(P-&20KN5_F=3][/TIUO=1ZC-<2*IC
M\L%,$8ZUU:/8I,BDNPUG^[YQ5OPZJE=[_?*E>G8]:I6L$=M9X[CM1:![6SEN
M?.DWBX5$C X*GK4V3]TB;ET/5_!_PHU#6O#QNH/L:Q6\+/%YLH4E1S^=<!JT
M\DS@_P 3'#X[5[GX:U.RF^'ZQ"WL+JXALWW6Z2YG7C[VP<\5XYX#U&WL]>5K
MJU%VLY/EQRC[S9P :Z,PC0IQCR=M2$Y=3*U R-"5VS>5%P65,UI:1X:U/6?#
M31VLGG6IF2=FF.UH-OH*Z;Q:UY;Q7,<5DMFQ<&6%!_J?85I^&_#5_J/AM8O*
M^RQSIY@D'6>,=<U\K6Q"6QO%'&ZGH9\4:BJ06:1RX_UT?*WG^VQZ U=TO2/^
M$'BDL];TQ[FRO7#-=PQF22T[84#M[UUK&*QT>W@TF.1!"0A!3&!71^#]7>UG
MGD=FN(8(VBGMY1A6R.WJ*Y?K<EL-H\(\>Z!I^@ZRO]EW'VNTF&Y&8C>P]QZU
M9@U=8O#IAG!EB<96-Q@(>Q%<SXOO(KGXJ7K6D/V2V2;Y(4^[&/05L:O*E]?6
MS1NVQ(SO4C W=J]K!5)3AS/\22/3;C9M2;=(\O(WC&16A<Z9%=V<JB8QR@Y$
M2<@KWJ#2KU-9U^-;E?+A@LY!T^4OCY>:S_#SRDK,2JN 8VWMCK7I1D..Y;TR
M**SG!W;.V16E;W?]B><\<A=9@=Q/K5;2-"-[J4L+[3Y:,_RG/ YJK+();4*&
M_=L<@T/4&K#+[5I[E(C-=2JL8VHG8BELO$MQIS 1LT>U@P8'D$4_0;2'5M6E
MCNLB..%S'QU8#BLU8R+3#_ZPU"B*,2UK^M2^);XS7,C3ESDLW6GK/]HMEBZ1
M(,@>XJK#%OL&Q]Y& :G6URL*.&Z9^3W%#B#1W_AWXM7FC^&(4D;S(K=U_=9^
M\*C\4_&2[UCS9;-?*\UP8U/'DIW KB-OE1BY5V/S!=O8YJ2_EE7<[JJ+U(!Y
MH44@6H_5]1;5KSS&E<OV8]:SYW>XGB25V(0@!B.:62Y 59#D>8,KNXR*BEN1
M*,_>^8#CFE.Z5UL2Y6=CIKC25NK02VS"94($A/44^[A#Z4(T^Z6##\*K3>';
MS1=)CEMYEV7A!>+=\P^H[5J2V4-C8QI=7$T$F,*%7,;_ $/<5Y\LPC%V90>&
M/-_X2*%ESG:0/=>]5O$%O&VIZDS8_P!< H_"FZ87TO4Q<17K2" %&5R!C/\
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M1L'@ >OO5;"M:&1OOCM7?'0H[3P.FIV&];>4!8T ^:53_$P[$5Y]?0M->>6
M?EZG^_[UX]'&^UE**Z,>X16<%[9ER?WW:LF>"6.?##OWK4%HUM+D5EZI<RRW
MX\P?(#7H4YDM6+2Z?*VES32SLL,4@7:O*Y/2HDDV@CO3KG4/^)(]HG^JEE65
MOJ*BDF5R63J:ZT[A'<6?:8BQ^]4<%S((L"K44,=S8O)_%&=K?6H+*)XY,MT
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M@[W/S?E5*YL,28A_6H69X/O\[>I7D5T2HPDK21H=,_B?2_%7R7=N%N&_C9<
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MDUZ)\9OA'I^C>,M-TNP8)++;-+<36_S8<=!FLGP\^HZ/%+I]GJ$VEW$(.67
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MNUPQ6%%P200*^>O"VCP:]<(UU,2EK)Y!9<$LS'(S^=<M>5XV8+4]NTB:SUF
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M$)]C4]SY:33)'SY;8%'-$!FG*(KG<?[I6H2FR-P1D \#U%/1BO6JNHZDMO\
M>/M1SP6C8;$8C\G?\Y4S<Y_YY?[(]JL6EZ&MOLK LBL)0^/XEZ4_2M._MFWD
M8;?W8);<<$5D_P!H^62H:;8#@[4ROYUC*M"_*GJ5S'<>)O$L6K^$[:/"R74J
M[YIC]Z(C^$>H-<:;K?)'O&V. Y&WGIVH6X$Z;4*GVS6?JVJKH6#<-M#\KMY;
M\JM+2Q$I'L7@WXHZ9;>'I8;V:Z'GH?)5(\B+CI[5RL%SYL\TN[>JJ=I-9>@[
MWT#S3Y:Q70W([-AG'OZ&E@E>UBVAD:/V;->7' QI3<H]0C(N:/<274>91]T;
MC]*RO%-R@0.A^6090^M3PZAMN\(W#*5VMPI%4-?$8M(P?*5(.%"MFMDK#<BA
M87Q^T)$S?+CY_8UJ2K%&_P"ZDB"_[;8KF)M5A2TG==WG%QCBLF;3&\2S;&NI
MHR?X5%=$9V)YCT.W=?L\D<<UONF8.<2#J*+JY:VLV\Q7.#@^6-PKC;#P:WAQ
M1O:0IW<CD5V.AZG>:AIR6L5N;:T+!?M>.9#VSVK.>(L',5;3589XC&I99 ,G
MS/E&/\:HS^+K+2?WKB9@.P3-5]<T"Y?Q/<6;;YO*D #J,HWU-1:E9O#=-;91
MI%.T@'C-%.M<.833/B1#=:K,]O:_)<(P9W!!!(JIHEHIU)&>1L?W#TI1I+*6
M5U=/+;#%%RH/UJ:UT^*"]&Z:0_AQ6DI!N=/LBB!$;<9P[]"?I70^!/#.JVEZ
M;O07154_.6?&5[K]#7+V]S')*L((X&[YN!@=:[3PUKL_A319)K./[3#=\>6?
MO)GC(%<\Y*VI4=#3E\9:]"]REXJC3A,&^RQME$Q_"O<@^M4[WXP:A>6]]%$'
ML(BWEP11_P#+-2.@]J2]\07FJRZ=$MM'#Y$9CRAR9,GJ:Z/P?X'@1+Z^UIEC
M15,=OL^9LD<$#ZUYTZ-!OFE%'0F</XS;7(O MG)>:A<SZ>@">43T)/%<SH^D
M:D\ZM /96SV]Z[;7-+U?Q8\6@VT<HCC0R(\Z[!*%[GWJCX+N7TPW6G7#[+M)
M IC)X;Z5T4^6E!NAI<F1A:EHVIV%H[NXD1IE25"W4GT]:V(OAQ<:9:^;<W=N
M]O*,HOF#="/I72'X?W&K3@W$B0QQQEUVMD\<]*Y75-(8N[1>9/N/S,1WITJU
MU>6YGL9^K6MRY2&V+WD,0VAF'.*R7\.:CXIE^QVMNWF6_P Y4 \ <UV'A70]
M1EE_<7"0[1N(=@JG';-=]X0\.1::#??;3;ZM=J0((\%=AX;-%7&..P]SQZ+X
M67'B&P#!_+O9&"JKG:.?>J:_#6^\-ZL]O<VT5U);OY<J,WR[CW![XKV?4O#]
MIIEUO><W++]U%Y'UX]*GU/35%E#,8HY/M"%VEE.)!^%<G]H2EN2X'GFB^&;K
M4_#VH[+./9I]PNYTYEP.<@=Q6SX'UV7Q=K,MO-JUQ&J6[Q6FY0 ,COZ<UMV,
M_P#9^6T@W7]I3Q-&J>7\DR'@DFC0OASINB01W.MR7=B0?G\F+<I?M@^GO4_6
M.9VCN*,;&#XF\+W/@OPM9V5Q;HUU,ZR27"?-YP!YR:ZOPO/HGB+R;-=%M)KI
MB J DDKW-1^+OB!IT.B7$%W(KVJ*8898OGF)(X^7TK+^!?QWTOX>_"3Q5H-_
MH$!\5W=XDFCZ_AC<VD('S1CL 36SA.4;3W-#L?BQI<.B^'DL=/T:RAC5U%PA
M;#Y]0.X]ZX!O!!U/Q%#':KY5NRGS"ARH;MS6U\$_BY#-XH1/%RC6I@VY[B=M
MK>7_ !(#T&1WP?I7=ZM\8?!GB'QAJW_"/:$VBZ%9[E:"2Y%PY?'R[2(X\C\*
M4?:1CR]"N8QIX?\ A7FE6L$<WVJ>;!;G_5>PIEUXNNKNX=;>%9!&<,3U]JYF
MQU&/Q3#?79N)[?\ >A(5"\'/2BTTW4?#KN)+MF:8[CM^8?G1&+3)OH?9EO<2
MV%Z&F7,(Y-=1:P^$/&%OY<>K3^'[X<%;I7>SG;W,<99/QR/5A7+_ -H,Z8E5
MOQ'%0311SI][9QC KKMW,S4\2>!;CPC?1QSMI[BX'F0RV=W%<03*.ZLC-^N#
M[5F7*D'Y>GO5$PM;D*@X7N3G-2)>3R2_/]VJVV-!9F:2/;VJ&UB-K,"A(/K5
M_"2'"TLUH8(M_(7^\1Q2<8R5I&A;T[QQ<Z)(&8><H['O6O'XLTGQ>W^DP^3(
M?]GBN7AB:<94JW?(-0W08\$Y]A7++"P^SIZ%W1V-Y\-8KJ+S+.99!_<S\IK!
M@TR\\(7DCVTEQ8W+]?)R5;\:IZ5KE]I6!#/(J_W#T-=-IGQ*5 ([ZW23U9>:
MYY>TANN:/XC-_P  ?M1>(O!]@VF:HL>N:;T:"[16C=?[K*00RGN&R#W%3WGP
M^^ GQIN?,U;PC_PBU]?MYCRZ%=2V4-L_^Q;QXMU7_96("L*XLM/\4G= PC!]
M>#6-K/@FXTJ-GA<R0^QY_*IC["?D2T:OC3_@EP]U.U_\/O$>D^)5,;21VUTW
MV:X9.XZE"?J4^E>'_$?X$^)_A=9PQ^)?#>IZ'&>(9'MR(77/:3)1O^ L:]6\
M->+]4\!L+C3]0N[*X)XQP<5Z=H/[;?B:TL5L]7M[?7[)5V.+G'[P>XQS]#6%
M?+835XL.4^,+>.&"39#<D[3M"2X4I[ 5I>28U.85>0?+FOK/59O@O\6;5_[5
M\'V_AVZF;<UUI<0BD1O4#:5 ]@H^HKBKW]D+1=7U5O\ A$/&AOX)3N\G446"
M0GMAMV /8J?K7A8K+JD5:)1\^:AX9L?&&@MIMU#\S<CY> ?6O(_''PSO/AOJ
MXBN8A?6$\;-#/G+1CT('0^U?47Q*_9O^(/PYU3S6TF.[T].LMB3.?TKSO6O+
MU[3[^QG2:WDY8I=)Y<GF <<'FL\#4K49<L]A2V/&="M'N]+7R_GME_ADX9/8
M"K,=^LMX%,7[N)" K# S7/V\E[;:S<PO,Z3VK%' ^X3VR:T(A-(RW%U+AH_O
M1KRDI]<U[LJT6O=(-/4XK76O#G^EZ?;2;>!&S<9]?PK#TNQ;1%/EYCC<<@="
M*FU?4[_4&4PVMM'!O!(+XX[U-JMXD0CD=AY+?+&B<C)Z&L/:-,!]CXF\R$V\
ML,=N(_E@G!^9T[AO2LG4O$^I3I<6MHD:K&X971L_*.M7+G05O5\BY8IY_P V
MY>35>TM7T1);>UMP8HOE:=^#(O<?C6M.HN:[#E*6D_$:QTA-HL4FNIOF:5P0
M@/\ O>M=0UQ!?6]K-Y=NES<IY_#?? ]?>H=-\.:1XGT46\MI-!!L,S+'$205
M]JQ-%\)SW#3W-MYKPI*/LR7 V97WJZU:/0KE.KN)H_&-GM+%IA]T2#;Y/^[Z
MUB/X?_L":3[7';W2S\EG?G=V.*O7KW"8,D,"76<?NFW*$[G/K23:58W1"R2R
M3[_G4RC#(*YXRN+E9'9VK'3A;BYGNT;Y_+E7$:X]_6D:5M+MC]C5))IY5W-,
M=H5>_-->TD$DLC7D\6GVR$A$&1(1R,TW0&_X2_0Q*L9DD?E+>4;4)['-5SV$
M/U32UL;MW1_)#GG9R'^M-BM(H(_,<[X^G')I+S0K[P]<17%^)I81&1+ B[E#
M]A]*RX/&#7$SQM;6]F%^<+OQP/K51O+1$R-#4U&GV#7,3LL*]5(P:Y]M5F\2
MVFVW,:<AMY;# #VKI(]6MM?TOSSMFBZ'TK*MET?0;B:[N(<#!58T&00:UBY0
M=F2&F21VH\G[8Z23'>)QU%=]H.MW%SI:VN^UG\H8-RTH\R7ZBN&?PC;>(M*B
MNXKB&U61=T,.X [>^1UJKJVEPPVUO_9L[Q7$";7"_=D;U8TJJYRN4]*GLK&2
MU8M]G2X4;O*1\\#K6*UY9WMGY,^Z!9^4;;P![GM7#3WL]G:136[*^MHA:4!N
M @^]SZXJSI7C.6^T[==0%[:Y( 2<;,D\9J*5'E=PY35?1KJ'6P;-T+VZD)+N
M^5D[C/O6V='F>.UN9<QQRQE_DY\D^@KE;)+D7#6R2S_90W"HN037<W44R6NF
MVZ27FT)F53'A<YJJ[*BAME97&LH8[]WFM64^4^.1]?2F'21HVBM&+-,!P,KR
MTH[DBMYK6)[<P+<RP[R&(1<C-7+1YK0)'#;I=3(,B24[?E[US4Y\KN7RHXG1
M?AW/XJUIS 9[>W0[]LB[$VCKR:ZI? 6AZ;&)H-2N(C/R_EH"N?K6Q?ZQ>^)U
M@M+6'R;;&+C'WB?0>HJ>_P!*T_2+ V[11P1YW%6..:FI6<G9%Q*TWPWT^[\/
M273ZD\ETJY@)QC9WR?6O%O$?P[\R[ED@TP7$4ZLTL[ Y_P#UUZ_9O;K;S0P$
M7$,[AF3_ )YMV K0U2!O#]M;PEHRUQ&9Q;Y& !_>]#7-&M.,K%N*>YQ?A+X6
MKXAT;0K>[U*X7PA'8N)[94!9)OX,KUS2W/@?3O ^C2-->WCA04L(Q%F<@]-R
M=1S5C5]0A\6W%K9:3J<NBWUS=QR2K#C[/(X/!9STI^H_%N]\$?$G7+*^\-6V
MN:KI;F+^T#N9&.W/RL.#7;3K2<K&$N5;'+^%-#U#43,[2R0Z@J-Q)P1^=,TF
M6SN1]BOXS+J*_P"MED7" _[W2M.7X@_\)5!_:EW;S:9?CY)%V%?F/IGK3?#.
MA_:X;]KZ1;BWGD$NUF^8X]J[%6C!V9GRF9::]?>%=:>:2>1-'0^5&5Y4YZ5N
MPP:9XYN1]D).P>5<"4; 6/\ =]15N66SF\.C3+NPS83RJ\812Q '<^AKH-,\
M Z8-O]FM+(B#:CS)LP>U.IC-/=W*2./\6_ &V\1^#[@_;/+BTF58!&2 K.>1
M@UY?XX^$U_X+@MYM0%LIG&8EBDW/M]QVKVKQC-;:7?1V<UZLGD+YMQ;(P,$T
MB\AMW<UY)XU\1-XKU^:]<..?W8Q]U?[H]C75@JDY:R):.8\,VEM+XDMEN8%D
MBBNHVE/4&,$;A^5;OQ6UW1K[QCK1T6TBL+)[E?LD<8_@QSD=JFTKPK'>P?:A
MNLD/[PQ*/DP/>L+6=!2?6UFBC_<W2F17?@G%>A.26IGRF/-IWGW# [MN<$@5
M4U#PH(Y<0SW339_U83K721:I]AL)X1;K(^X'S%Y/%&CZQ&=0B,DWE7D@W*R]
M5^OI67MI-W1$MCF+OPEJ%O.@>U*>9RC2 KFNC\,:;=>%K:5&2-C<N';:V2I]
M:L^*KV]U2Y3[5J)F$9Q%DC)%0:3J@MKN3SA)N4X!V\9H<Y?:'3.R\/S7K 1M
M/-<P2?O9/,&/F'2MVWTZTLK>6Z:*-[B[<;F;CR1T(%9X\5V5CX0BC_>MJ4V&
M"HF<CO5#1;^?4[TK-#<&WZ,"AKDJU'T.@A\7'2M.@GCMAE_XI"._MZUP6J"*
MTAC=G9_,&<D5ZAXC\&Q:U'&EN+:*-1Y:>:^PC/M6/KFB6FF6$.EW-K:M-"N&
MFW=_;UJ\/5?4GE.'TM\<KUQBM"-ECCP33Y] -K*4MSG^(D],#KS6)>W%[()'
MA@22+=\OF'%>C]870SY39&JQP1;?F/T&:Z3X<00'5?/,,DRL/F5E.".]<3IL
MFJP('&F1GOAR0#]*OVWQ$UVQ/RV\%K%T(C?G'TK?ZQ[MF&QW7C6UET*Z A6)
M;#4?WL<8;_5#IBN5N[]M-?9"P(/')K)U/XFW=S<"-+<7D?0&7(*?2HD\53!=
MO]GVC-_>D?%1&J',:5I<S1Q21+SYQW-CUI\K)%:F%P_FGMMYK-M-4N3<AD6.
M.4] C97\Z6_U[4M+U4//:Q2.O\8;.*)5[$EZUO4M+?R'68%CQE.]6YBUW;X9
MI,QC;C'%8MWXEU":[^T7")L8@QJ3\IJ2?Q5=W5R1L1/,^8K&<BG#&)!S6-O[
M+LAM% ZI\U07H"65PK#YT<% .I7O6'=^*IT(7]Z"HX*C/%4AXV,D@+^>H!PT
MI7Y@O>MOK"EH@YKG0:7->17MIJ=E<M#-9RG8I.,JT;QG]')_"J?B_5&M=6-R
MY:\F"-'M/O\ Q#Z5FZGX_M]-N-EE$;V%ONO,-K8^E;?@Y+!)VU:]D:XN'B9(
M+/&40$=?4$5A6JI1L3S&)#XCN'BMX[*ZGM;I(S$Q4<2$]V]#79>&/"6KQ:5;
MJTRW,Y7+L[XV'VKGO#/A1;:YEN+B1]DD@<C'6NS@E%](1;S/#&$)# <Y["IH
MZQN4F9XTV.&ZNTN!B[SN+KS\W;%=9X U>$V"F_D;[5"NT9'!]ZXU/.=FW.S2
M#DY[5W'AS1;36-*@-R-B,F9)%'S9_N_C658T+EWX#CU758]0M;N)Y94)W;QP
M/>IO"?C!M(\4)I5U<2Q@*=C8_=R?0U-I?A^RL8-D!,4$_P I(ZIGMCTK4N?"
MUG+9VR30QRMI\BI"2><9SFN6-6TK =UX8N"VJ0+EB2Z_>&#4W[5WA,>+4LHY
ME^:WMV\L^_44SP_8O%K,4Q)8>:HR:[_XP:.+EK.61 ^(LE3TQ7I1J6C<GE/C
M/PVD4NI2V^HSO;M8HRY49);LOXU06^V:EY[VBNJ-N$<G -=5\4K_ $VT^(;7
M=M9P-;PR8N #T;_&LW4M*O/%VKM=6]N\=E(P,/F+LRGO7'5Q">^P<IB3^.=6
MLO%#7]M<R*\JF-$_A@C/!5?:H984&I?:,A9.GRG[V:ZWQ9I^FZ+HOV:.$7%]
M+R"@SY/L*Y.+P[.+-U(9)MI*[^,40G3DK1'L5[*:+5]?DMT+"2&)W=@.,CG%
M9=GHNN:K=PWEFK)^\7/NN>0?:ND\'QV4=K.\ZM!>1*8Y#$N[[02/O-4R^-<V
M-O8Z495NH?EGRN(V7/.3ZXKDQ-2:7)$AZE[QEIR:9=6-_):Q7$]O'G[,#F)3
MZ@UC3:X/$:RRRAGDNV\[8!Q;X_A7VKT6TFTGQ/HT$<>U1:QF.9VXP?;UKDF2
MPT:6[ALU20 $)+)Q\N.:RPO-?ED5$Y>R\RY$[%%*[OW98X;%"GYOY5(L_P!J
MACVY78,*V.9/K5B[MA%!"X7YV7+C^X?2O6V*:*OE#'/7.:&82W:RR?P#%1R3
M$\U+;C[2GO[UI&=C,K:Y)<JD"0#="[@\=N>]5O$/C&R\+Z[%%</(-R[IO+7<
M0:FU#6)O#;EE57\U2%5SA<^OUKG-&T9-8\1^9>,\EP_+<4I5$]&9MRZ'3R_$
M#1KV%7M6O75N 6AP<U!)XA2SDS_9373%25\Y"O\ P*M*RL8_MZVD:6X6)@8R
M8DBX']X@ L?=LFN@UJ2_M%\E_L\@F7S 'C3]VHZJLF-P'L#BN"K42=NA7O6N
MS@-.\27VD2/<^0LHGSF-C@&L^YO[_4+DL99]-M) 6,,2Y0GZFN[G\ :EXF2U
M,,=M;I<#S$_>8B$0/S'=_>]!56/Q+'X?_M+19+2PU2VCN5\N6=3YC1CKAPP
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MS?"_Q7IWQ%ANPFFV=C'%)YA@#X  ZD>_H*V;;Q?<6<][#I2_;+"5_,"SC;(
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M=W$$<!(QNC@C80J1U&(\>U1VNKW-K-^\!4=#FM*+5HL;V:M)8>$E=&A@3?\
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MEP>:U_?.%M881N+R'A<>^:@^)W[-GCOX$>-]2TGQSX5UJQO+!B5.NVCVL]R
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MX0:=,9FF";D/6H-2GN[2-)D7RXE&$*GH*ZGQW=Q6-]]EL,1Q6_RLR]93[US
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M.(<E:3N#5B;3/''C:_TORX[SR]/9AOCB<,\GU7KBIO$O@^X\0VMM(EF+*XW
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M[XY\,)9?&?3X(Y]!GT'1[BRT?1[MH1:XB_M/39'-QG#%<-]Y@O0BN)\;'3/
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M,.JB.>,N0#UQ5.I*4=2'$] \)W<&DZ7YLLA*3D2?,/XATJAXJ>ZO/-OY;LW
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MYK6_^"6?Q2M8W:R/A;584/WH]1^^/8$!OS K#V-52NBN8^9](TPE3L1&&PL
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MNZ5K4FG),^FVA<!BA^4?0U=TV^;5$*%5)3F(L>(?I5_4X7U'2D-[)'?,C!9
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MQBM*>#JRV".Q\2^#/!$WQ(\8V&BV7D?VAJ5REO$[O@ L0H)QVY["OIWXQ_\
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MY,@E28WC/3&2>1BNQO/V:?@!.T6I7S>-M:NIHA'ON]0=FP%"J-VS=M"@#;D
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MNC\=?$Y_'VE"PU31;'5X 0T:W<*RQICH0K K^E?.WBW]K2ST:)O[)M6O$W
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*&RNBR>IG+8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6833880768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Potentially dilutive securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive shares (in shares)</a></td>
<td class="nump">6,153<span></span>
</td>
<td class="nump">5,687<span></span>
</td>
<td class="nump">5,740<span></span>
</td>
<td class="nump">2,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6644797984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">22,674,062<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,042,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(3,042,201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(160,241)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(35,045)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at end of period (in shares) | shares</a></td>
<td class="nump">20,478,861<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable at end of period (in shares) | shares</a></td>
<td class="nump">15,860,131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 8.71<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">20.81<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">4.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">16.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">23.41<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">9.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at end of period</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at end of period</a></td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at end of period | $</a></td>
<td class="nump">$ 186,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Exercisable at end of period | $</a></td>
<td class="nump">$ 181,542<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6626708816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 692<span></span>
</td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 1,768<span></span>
</td>
<td class="nump">$ 3,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">363<span></span>
</td>
<td class="nump">654<span></span>
</td>
<td class="nump">1,366<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease costs</a></td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">$ 1,977<span></span>
</td>
<td class="nump">$ 2,422<span></span>
</td>
<td class="nump">$ 4,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6841648320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Daiichi Sankyo (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79,935<span></span>
</td>
<td class="nump">62,451<span></span>
</td>
<td class="nump">162,441<span></span>
</td>
<td class="nump">182,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,130<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo | Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838663296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalties accruing to GSK</a></td>
<td class="nump">$ 7,964<span></span>
</td>
<td class="nump">$ 6,268<span></span>
</td>
<td class="nump">$ 23,079<span></span>
</td>
<td class="nump">$ 17,021<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GSK | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6835573408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>617</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>72,864</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(23,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(17,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,897</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6843799200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>704,084</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>525,438</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(48,148</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(30,410</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(139,060</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(82,384</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>191,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>162,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>565,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>443,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>51,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,988</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,445</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>62,451</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>162,441</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182,170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>225,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>727,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>625,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were offset by the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, License revenues and Research and development services revenues were recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 for all periods presented. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other collaboration revenues, which included the p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for all periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>187,410</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>158,262</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>552,315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>428,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,737</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>191,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>162,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>565,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>443,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>30,707</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,901</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>102,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>93,675</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>225,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>120,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105,638</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>83,516</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>88,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>70,503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>342,695</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>275,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>727,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>625,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>194,484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>572,957</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>453,342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>120,134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,374</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>225,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>727,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>625,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>92,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>139,381</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(130</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(321</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(92,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(11,466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(33,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(136,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,644</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,656</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6847142816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">7,537<span></span>
</td>
<td class="nump">7,360<span></span>
</td>
<td class="nump">22,577<span></span>
</td>
<td class="nump">18,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">97,295<span></span>
</td>
<td class="nump">44,741<span></span>
</td>
<td class="nump">242,516<span></span>
</td>
<td class="nump">124,986<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">51,265<span></span>
</td>
<td class="nump">48,120<span></span>
</td>
<td class="nump">170,218<span></span>
</td>
<td class="nump">153,989<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">156,097<span></span>
</td>
<td class="nump">100,221<span></span>
</td>
<td class="nump">435,311<span></span>
</td>
<td class="nump">297,971<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">115,606<span></span>
</td>
<td class="nump">125,176<span></span>
</td>
<td class="nump">292,154<span></span>
</td>
<td class="nump">327,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">7,191<span></span>
</td>
<td class="nump">3,507<span></span>
</td>
<td class="nump">20,253<span></span>
</td>
<td class="nump">8,099<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(140)<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="nump">368<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net:</a></td>
<td class="nump">7,051<span></span>
</td>
<td class="nump">3,778<span></span>
</td>
<td class="nump">20,941<span></span>
</td>
<td class="nump">8,467<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">122,657<span></span>
</td>
<td class="nump">128,954<span></span>
</td>
<td class="nump">313,095<span></span>
</td>
<td class="nump">335,720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(25,205)<span></span>
</td>
<td class="num">(2,324)<span></span>
</td>
<td class="num">(60,826)<span></span>
</td>
<td class="num">(5,739)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 126,630<span></span>
</td>
<td class="nump">$ 252,269<span></span>
</td>
<td class="nump">$ 329,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Shares used in computing net income per share, basic (in shares)</a></td>
<td class="nump">303,268<span></span>
</td>
<td class="nump">298,416<span></span>
</td>
<td class="nump">301,999<span></span>
</td>
<td class="nump">297,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in computing net income per share, diluted (in shares)</a></td>
<td class="nump">315,453<span></span>
</td>
<td class="nump">312,346<span></span>
</td>
<td class="nump">315,046<span></span>
</td>
<td class="nump">313,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 191,768<span></span>
</td>
<td class="nump">$ 162,946<span></span>
</td>
<td class="nump">$ 565,024<span></span>
</td>
<td class="nump">$ 443,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 79,935<span></span>
</td>
<td class="nump">$ 62,451<span></span>
</td>
<td class="nump">$ 162,441<span></span>
</td>
<td class="nump">$ 182,170<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6847059872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">191,768<span></span>
</td>
<td class="nump">162,946<span></span>
</td>
<td class="nump">565,024<span></span>
</td>
<td class="nump">443,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">187,410<span></span>
</td>
<td class="nump">158,262<span></span>
</td>
<td class="nump">552,315<span></span>
</td>
<td class="nump">428,317<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 4,358<span></span>
</td>
<td class="nump">$ 4,684<span></span>
</td>
<td class="nump">$ 12,709<span></span>
</td>
<td class="nump">$ 14,737<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6849662336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities under Topic 606 (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th" colspan="2"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Unbilled collaboration revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">15,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,399<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,897<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Amount of revenues recognized included in the beginning contract liability balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">$ 67,700<span></span>
</td>
<td class="nump">$ 48,200<span></span>
</td>
<td class="nump">$ 129,000<span></span>
</td>
<td class="nump">$ 151,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6850440080">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 252,269<span></span>
</td>
<td class="nump">$ 329,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,088<span></span>
</td>
<td class="nump">2,876<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">40,747<span></span>
</td>
<td class="nump">28,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash', window );">401(k) matching contributions made in common stock</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,079<span></span>
</td>
<td class="nump">3,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetAmortization', window );">Amortization and other changes in right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,367)<span></span>
</td>
<td class="nump">2,732<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred income taxes</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">56,339<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfOtherInvestments', window );">Gain on other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(730)<span></span>
</td>
<td class="num">(209)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Accretion of investments, net and other</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,970)<span></span>
</td>
<td class="num">(1,423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(7,017)<span></span>
</td>
<td class="num">(12,707)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">2,469<span></span>
</td>
<td class="num">(2,938)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory, net</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,528)<span></span>
</td>
<td class="num">(3,776)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Current portion of unbilled collaboration revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,640)<span></span>
</td>
<td class="num">(32,673)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">527<span></span>
</td>
<td class="num">(3,529)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other long-term assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(6,294)<span></span>
</td>
<td class="num">(542)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(2,708)<span></span>
</td>
<td class="num">(1,248)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and benefits</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(429)<span></span>
</td>
<td class="nump">6,210<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInAccruedClinicalLiabilities', window );">Accrued clinical trial liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">12,099<span></span>
</td>
<td class="num">(891)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInRebatesAndFeesPayable', window );">Rebates and fees due customers</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,828<span></span>
</td>
<td class="nump">4,124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInAccruedCollaborationLiability', window );">Accrued collaboration liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">554<span></span>
</td>
<td class="num">(577)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Current and long-term deferred revenue</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3,592<span></span>
</td>
<td class="num">(1,548)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6,087<span></span>
</td>
<td class="num">(974)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other current and long-term liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,940<span></span>
</td>
<td class="num">(3,321)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">368,935<span></span>
</td>
<td class="nump">311,129<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(5,575)<span></span>
</td>
<td class="num">(30,403)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0<span></span>
</td>
<td class="nump">308<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(887,698)<span></span>
</td>
<td class="num">(368,304)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">422,419<span></span>
</td>
<td class="nump">231,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">13,078<span></span>
</td>
<td class="nump">11,935<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments', window );">Proceeds from other equity investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">730<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(457,046)<span></span>
</td>
<td class="num">(155,051)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">14,811<span></span>
</td>
<td class="nump">10,390<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from employee stock purchase plan</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4,145<span></span>
</td>
<td class="nump">3,650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(3,369)<span></span>
</td>
<td class="num">(3,205)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments on financing lease obligation</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(34)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">15,553<span></span>
</td>
<td class="nump">10,835<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents and restricted cash</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(72,558)<span></span>
</td>
<td class="nump">166,913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">315,875<span></span>
</td>
<td class="nump">188,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">243,317<span></span>
</td>
<td class="nump">355,227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow disclosure:</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,944<span></span>
</td>
<td class="nump">17,180<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred to acquire Property and equipment</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">159<span></span>
</td>
<td class="nump">1,281<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions', window );">Unpaid liabilities incurred to acquire investments</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,961<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Amounts for the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include receipt of a tenant incentive payment and an amendment to our existing lease for office and research space. Amounts for the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include the transition adjustment for the adoption of Topic 842.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInAccruedClinicalLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in accrued clinical liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInAccruedClinicalLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInAccruedCollaborationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Accrued Collaboration Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInAccruedCollaborationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Lease Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInRebatesAndFeesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Rebates And Fees Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInRebatesAndFeesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-Use Asset, Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) included in earnings for investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense (reversal of expense) for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6831648608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">PROPERTY AND EQUIPMENT</a></td>
<td class="text">PROPERTY AND EQUIPMENT <div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Property and equipment consisted of the following (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, <br/>2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Leasehold improvements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Computer equipment and software</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,022</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Furniture and fixtures</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,053</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,709</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Laboratory equipment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,408</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Construction in progress</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>617</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>866</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>72,864</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,206</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less: accumulated depreciation and amortization</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(23,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(17,309</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Property and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49,467</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50,897</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Depreciation expense was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and for the comparable periods in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838652832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Revenues by disaggregated category were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Product revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Gross product revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>239,916</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>193,356</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>704,084</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>525,438</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Discounts and allowances</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(48,148</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(30,410</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(139,060</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(82,384</span></span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>191,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>162,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>565,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>443,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Collaboration revenues:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">License revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>68,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>51,323</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128,937</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development services revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(2)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,988</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10,560</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,814</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,464</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Other collaboration revenues</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(3)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>568</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(2,310</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,445</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total collaboration revenues</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>62,451</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>162,441</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182,170</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>225,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>727,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>625,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(2) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(3)</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were offset by the </span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, License revenues and Research and development services revenues were recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 for all periods presented. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other collaboration revenues, which included the p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for all periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues disaggregated by product were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">CABOMETYX</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>187,410</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>158,262</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>552,315</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>428,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">COMETRIQ</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,684</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,709</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,737</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net product revenues</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>191,768</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>162,946</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>565,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>443,054</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by significant customer were as follows (dollars in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>30,707</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>31,901</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,597</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>25,235</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>102,848</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>93,675</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>225,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Dollars</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Percent of Total</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>120,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Caremark L.L.C.</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>105,638</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>83,516</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of McKesson Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>88,496</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>71,249</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Affiliates of AmerisourceBergen Corporation</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>70,503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49,995</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Others, individually less than 10% of Total revenues for all periods presented</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>342,695</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>275,426</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>727,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>625,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Total revenues disaggregated by geographic region were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>194,484</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>166,270</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>572,957</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>453,342</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Europe</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,017</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,186</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>120,134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,038</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Japan</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,202</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,941</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>34,374</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,844</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:12px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,703</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>225,397</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>727,465</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>625,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Product Sales Discounts and Allowances</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Chargebacks and Discounts for Prompt Payment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,322</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,916</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,276</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Provision related to sales made in:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current period</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>92,769</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,190</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>35,422</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>139,381</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Prior periods</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(130</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(106</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(321</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Payments and customer credits issued</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(92,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(11,466</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(33,127</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(136,910</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Balance at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,644</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,656</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,126</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Unbilled collaboration revenue was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>zero</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of both </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. Deferred revenue was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$15.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$15.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. The amount of revenues recognized during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> that were included in the beginning deferred revenue balance as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and December 31, 2017 was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$67.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$129.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, in revenues under Topic 606 for performance obligations satisfied in previous periods as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$48.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$151.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the same periods in 2018. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen, Takeda and Daiichi Sankyo.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838570608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>706,807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>706,807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,191,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,218,337</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,220,888</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,247,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>796,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>844,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 11. Leases&#8221; for a description of the determination of the amount of operating lease liabilities. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities and Rebates and fees due to customers. Those financial assets and liabilities are carried at cost, which approximates their fair values.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>45
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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ML_S"2P6]5-:+AD9E"PY,I,EA9;$*CC*+1 XSS%D_44/,F2/Y6 9]HB^!CHI
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M911QT2:D4*$&<B[S$ -4-IF19EAIAI%&-FIJ@G$T(-V 64BI!)"N64CYDX%
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MG)^^N/-'8.^*W>6E="]=_VC\<S->VHTO77V:+B2CRZWH^E]02P,$%     @
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MC"]=E.KR++%]N3"4ICBV8&L7IKH\@ZG?6VYYN_JHSE/O#S7ZM#_G'@R,[1S
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MG49>H@ U!2P(@"XG,I[[=%87NX3Y1>AMB\."))>TY@XMSZEB=S"["+&+XX+
M2XWSWH^N.XPF0FCBO""))A76B4C*7"1EQE,26\I'?,:,(\ X00R2],I2RV=U
M08!@D2QV"".,$,)$_D@XZ53;4&UXZ9U_2!H[AF%&"&:..^9D80H]B4WE' AU
M*F88H)'(.7XZM$1"8QQ?X%)U8<BE?NS@!G.6$&=%_DJ6Z92LRUP^TIO&,-,
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M3S^%9'HNBX?#EW7YV'8?;?A<[V_7]E_::C?<'":'Z\N;_P%02P,$%     @
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MSQJ:^BT'B+(O.8RYRN"+@0(K V0Z'XPKI"$@M-X;GZ$98[QRT.@H<T'&0&0
MQ%("D37HK"NME;T",L,QD_PPQB&#]WZY-ZU8YZ#..H4RK>+"9^PXC%8'T"H_
M JT<8B;K+U](1B8S8 Z3U0&REI*L#N2J+-,?(,K%!I/5 ;)&258'$E7O/4LS
M0&;*'#$<IJH#5(V2JD[3<A'(>\DPH+-%$6UF(W29#Z> JC+S6SF-2[:^5'LS
MT*7)R#8#>H>YZ@!7H^2J0]\2F-77#:!C[XDR"8S#='6%!EG,]0JST(%4,XH
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MG'^%Z,!+26[\"C7^@<V.@LH%\\[;9ERST7'832^(S<\X_PM02P,$%     @
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M:+&%I9(:.B=-1RS4.;W;'XYIB(\!OR6,;G4FH9*S,<_!>*QRN@N"0$'I X/
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M8(NAH/;A^!'/=AJSR?"FGW\06[YQ\1=02P,$%     @ R8%>3X8-<U"V 0
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MC)NN[5SU?:Q?&-D./9J./XK\+U!+ P04    " #)@5Y/=IFD>< !   W!
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M5BE;!=JU1A,+548?-X?C+N CX&<+@UO8)'1R-N8M.%_*C":A()!0^* @\+C
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MDI T J3-KE:MU$K15FV?'1@N6AM3VX3MW]<VA%+J2'W!]G N,X:99!#R3=4
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M]1]L,134+AP/_FRF,9L,A_W\@]CRC8N_4$L#!!0    ( ,F!7D]>$0G%MP$
M -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;&U3VVZ<,!#]%<L?
M$(.7-)L5(&431:W42JM4;9Z],( 57ZAMEO3O:QM"2<*+[1F?<^;B<3YJ\V([
M (=>I5"VP)US_8$06W4@F;W2/2A_TV@CF?.F:8GM#; ZDJ0@-$F^$,FXPF4>
M?2=3YGIP@BLX&60'*9GY>P2AQP*G^,WQQ-O.!0<I\YZU\!/<K_YDO$46E9I+
M4)9KA0PT!;Y+#\<LX"/@-X?1KLXH5'+6^B48W^H")R$A$%"YH,#\=H%[$"((
M^33^S)IX"1F(Z_.;^F.LW==R9A;NM7CFM>L*O,>HAH8-PCWI\2O,]5QC-!?_
M'2X@/#QDXF-46MBXHFJP3LM9Q:<BV>NT<Q7W<;K)TIFV3: S@2Z$?8Q#ID Q
M\P?F6)D;/2(S];YGX8G3 _6]J8(SMB+>^>2M]UY*>G.;DTL0FC''"4-7F'1!
M$*^^A*!;(8[T$YUNTW>;&>XB?;>FI[?; MFF0!8%LG<"^P\E;F#VR8<@9-53
M"::-TV11I0<5)WGE70;VCL8W^0^?IOT',RU7%IVU\R\;^]]H[<"GDESY$>K\
M!UL, 8T+QQM_-M.838;3_?R#R/*-RW]02P,$%     @ R8%>3\&&-[ON 0
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M)XG(6/PWN(%P<)^)TRB4,.%+BJNQ2HXL+A7)7X>U:</:#R>[9 S# ]@8P*:
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M<?XEH@-?RNK*KU#M']CD*"A=,&^];88U&QR'[?B"V/2,LW]02P,$%     @
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M<SE?F#G08EC> K(^2,4'4$L#!!0    ( ,F!7D]")#$!! (   4&   9
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MHFDKFHGB==LR15W?-OL+4$L#!!0    ( ,F!7D\&( KS$@0  +L4   9
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M;L5<447G4\'/@6C/0T/-L0,3HK=K8XQV=^PWK:?4UM,<)?$T.AFB#K-H,7"
M 7%ZC5EY,#TBTA'T84!?& LX<H?7"RS'"!!G3A#_9%E_S'(5*/+JA2P!&NH%
MB)\ >PFP)<!7$>2.X"TFL9BZS2,%:8P<23PP2%#N;LT8EL(4)\219@Q+(($0
M^Y,CWN3(*#F4W#@'B9<@N5_>U$N0WB%OBR&#3$&.<88=>3VP)(&I\W>LQC"2
MPIPXN[ >PS!!"$-_<IDWN<PC[PV"W$N0WR\OB/WU(KY#X XT3#9-8N!(LO3
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MI"%$"D)7"AI"I""<&AMM" $@<_@-:0J1W6!L$W1M[-#U^&E6D6#5,C;:K,X
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M0&=4<[APPG-L<4WEK[,]488;I<*M-/"M?U:M?%Z4_CO-3@@4(;B7$"I".!!
M=),0*4+T08AO$F)%B._-D"A"<B\A581T($B\US=7KM82,CB;$'QQ2+_?.BBV
M-2A2OA^V(BB77[[C"T9Y]#P+TV3BG860PI0])AAA@)]>8Y86S(#PN(/!1F"S
M408&/;A.L# 1P,\T$U^JK.Y069N8.+/7$EI;&DI^.';A1W:!R"H028'H:DVT
M?I<])I&85F)\K1E?(M:W$%<V8ZO-V&)3ZV798^)1"A"'>:Y9O0NUC@V[(,YR
MK3$;TU6<VZM*K%4EEJITOXGA-TA]K;NKQ+"; /^3!J=6*ZEI)=.RE*F9)36\
M+$Q4E 4Z:FFB0)#[1F$66 RRSTK+M-*N7N;6NO-;2]B7;4)R_3_JC3Z!#2('
M>>!19XM/+1,='T6',W4>B$^H%B]!L0"6^!(4*UM\S<]F:SPH-C;]>59L,EO>
M7)WQWH?]_H+P$Y)#U5+G!3-^+LC/]QYCAGAG_ >^+8_\3C),:K1G8ICR,>E/
MYG["<*<N'=YP\YG]!U!+ P04    " #)@5Y/<9CY1$X"  #X!@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S."YX;6R-5=N.FS 0_17$!ZRQN64C@K2Y5*W4
M2M%6VSX[9!+0 J:V$[9_7]L0-@$KS0NVAW..SXQAG+2,OXL<0#H?55F+A9M+
MV<P1$ED.%15/K(%:O3DP7E&IEOR(1,.![@VI*A'QO A5M*C=-#&Q+4\3=I)E
M4<.6.^)4593_74+)VH6+W4O@M3CF4@=0FC3T"#]!OC5;KE9H4-D7%=2B8+7#
MX;!P7_!\$VN\ ?PJH!57<T=GLF/L72^^[1>NIPU!"9G4"E0-9UA!66HA9>-/
MK^D.6VKB]?RB_L7DKG+940$K5OXN]C)?N#/7V<.!GDKYRMJOT.<3NDZ?_'<X
M0ZG@VHG:(V.E,$\G.PG)JEY%6:GH1S<6M1G;7O]"LQ-(3R #0>U]C^#W!/^3
M$-PE!#TA>'2'L">$HQU0E[LIYII*FB:<M0[O/H>&ZJ\.ST-U7)D.FM,Q[U0]
MA8J>4W^&$W360CUFV6'(%09[\2UF;<$,"*0<##:(S<:23.CD=H/5%(&]V<C$
M?U4V]U5NC/K6>OE&P+^I%[$+!%:!P @$-PZ>1P7O,)'!U%T>,8X]?U02"XR$
M_O/X:*:PF,1!%(Y*,X5%)"0DL"<76I,+)\GY.+(+1%:!Z/'RQE:!^('RQM."
M1-Z5SZZZ4U08X]D(M9ZB,/&P/SJJC046A)X__O30U6]; 3^:'BJ<C)UJJ<MR
M%1W:] O1O_THOL3S%;;$UZJM=UWX4[Z[$WY0?BQJX>R85,W&M(0#8Q*4>^])
MG6NNKJ%A4<)!ZFFLYKQKQMU"LJ:_9]!PV:7_ %!+ P04    " #)@5Y/@ARM
M(D4"  #9!@  &0   'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6R-5=N.FS 0
M_17$!ZRYWT20-D%5*[72:JMNGQTR"6@-IK83MG]?VQ!*B%OE!>S#F3-G!ACG
M V7OO 80UD=+.KZQ:R'Z#"%>U=!B_D1[Z.23(V4M%G++3HCW#/!!![4$>8X3
MH18WG5WD&GMA14[/@C0=O#"+G]L6L]];('38V*Y]!5Z;4RT4@(J\QR?X#N)'
M_\+D#LTJAZ:%CC>TLQ@<-_:SFY6IXFO"6P,#7ZPM5<F>TG>U^7+8V(XR! 0J
MH12PO%U@!X0H(6GCUZ1ISRE5X')]5?^D:Y>U[#&''24_FX.H-W9B6P<XXC,1
MKW3X#%,]H6U-Q7^%"Q!)5TYDCHH2KJ]6=>:"MI.*M-+BC_'>=/H^3/K7,'.
M-P5XCP;X4X _![C!?P."*2"8 S0?C97HUI18X")G=+#8^')[K+XA-PMD\RL%
MZE[K9[([7**7PD_\'%V4T,39CAQOP?%N&;M[1IC<4DH#)9TI2'J<C7I&HYZ.
M]V^,>F8!WRC@:X'@1B!853IR(LWI-,<-_31=56MB)6EL-A,8S03W9MS(+! :
M!<+'VQ$9!2)#.\)5.T9.N"@TB%W',:>)C6GB![H>W_4S]OZ5)5EEN7F8&BVD
M=Q;"U1O=WE/29)4?+?ZH%MA)#RMN5?3<"65K@8[S<.=EI:?^R#7N9Z5OPH.L
M#$QXF)6A"8^R,C+A<5;&!OPYR<K$@&_3:6ZCOV6-0_\;9J>FX]:>"CE^])0X
M4BI =LQYDE]%+<^9>4/@*-0REFLV3MMQ(V@_'21H/LV*/U!+ P04    " #)
M@5Y/HV["H4D"  #S!@  &0   'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6R-
M5>V.FS 0?!7$ YS!?"8B2)?DJE9JI>BJ:W\[9!/0&4QM)[F^?6U#N 2L-'^P
MO<R,=\>PSLZ,OXL20#H?-6W$PBVE;.<(B:*$FH@GUD*CWNP9KXE42WY HN5
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M"*0R&-+ MC26>$+'MQNLI@C?2T=)_%?EY;[*3:*!U:_ " 0W?F&[0&@5"(U
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MVDG.]LH,4ST6==M23Q2OFI8L:/O"^3]02P,$%     @ R8%>3YZ$ESI# @
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M??/ N6*ZE7"B5_RDCU+MH& '96YG^EXTYXEFH'CMSDI!>V!;_ 502P,$%
M  @ R8%>3YPN-!LZ @  O08  !D   !X;"]W;W)K<VAE971S+W-H965T-#<N
M>&ULC57MCILP$'P5Q .<P7PF(DB7Y*I6:J7356U_.V03T!E,;2>YOGUM0S@"
M;GI_P%YF9F?7L&07QE]%"2"=MYHV8N664K9+A$110DW$ VNA44\.C-=$JBT_
M(M%R('M#JBG"GA>CFE2-FV<F]LSSC)TDK1IXYHXXU37A?]9 V67E^NXU\%(=
M2ZD#*,]:<H3O('^TSUSMT*"RKVIH1,4:A\-AY3[ZRZ=4XPW@9P47,5H[NI(=
M8Z]Z\V6_<CUM""@44BL0=3O#!BC50LK&[U[3'5)JXGA]5?]D:E>U[(B #:._
MJKTL5V[J.GLXD!.5+^SR&?IZ(M?IB_\*9Z *KIVH' 6CPER=XB0DJWL59:4F
M;]V]:LS]TNM?:78"[@EX(*C<]PA!3PC>">%=0M@3PH]FB'I"-,F NMI-,[=$
MDCSC[.+P[G5HB7[K_&6DCJO007,ZYIGJIU#1<Q[B,$-G+=1CUAT&CS"^E]QB
MMA;,@$#*P6 #VVRL\8R.;Q-LY@C?2R<F_JOR=%_EQFA@[5=@!,*;?D5V@= J
M$!J!8"00I-@N$%D%(HN#>')B'28VF,9@DD4\.=;-'!3C>-K2.0@'7K*8M'6.
M\A,/_^,-B*UEQ;.R C^Q"R16@>3CC4VM JG%P;0=-LQBD@2-OKT:^-$,0N$4
M[-1(;7 4'6;M(];?[B2^]I<;WQ+?JMG<C=)W^6ZP?R/\6#7"V3&I)H;YK@^,
M25#6O0=U2*7ZEPP;"@>IEXE:\VZB=AO)VOYG@88_5OX74$L#!!0    ( ,F!
M7D\="\'AE@(  - (   9    >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;(V6
M[6[;(!2&;\7R!=3&?-B-DDA-TFB3-JGJM.TW34ABU38>D*2[^P%V70=8FC\Q
M'#_G/;Q P-,S%Z_RP)B*WNJJD;/XH%0[21*Y.;":RCO>LD:_V7%14Z6[8I_(
M5C"ZM4EUE61I2I*:EDT\G]K8DYA/^5%59<.>1"2/=4W%WP6K^'D6@_@]\%SN
M#\H$DOFTI7OV@ZF?[9/0O610V98U:V3)FTBPW2Q^ )-U87@+_"K968[:D7'R
MPOFKZ7S=SN+4#(A5;*., M6/$UNRJC)">AA_>LUX*&D2Q^UW];7UKKV\4,F6
MO/I=;M5A%A=QM&4[>JS4,S]_8;T?'$>]^6_LQ"J-FY'H&AM>2?L;;8Y2\;I7
MT4.IZ5OW+!O[//?Z[VGAA*Q/R&Y-@'T"'!( NIJ ^@0T)%SG<<_C6PN0/H$X
M"4DW5W;R5U31^53P<R2Z[=-2LTO!A.CEW9B@74W[3L^_U-'3'&7Y-#D9H9Y9
M=$PV8K)+8ND3N+A$'GT$I ZS]AF4?3")-C*XR8)N,BL +P3NPP(P* "M !H)
M$.#,1H<0BS3=;* , F?2ECX& <IS?(FM_(+XWIFY@!*&)(/.Y/D8*" @*&P?
M!>TC;S0(IH[_CL&C.@ZQ_)18^74\U[X(3I%C^3ISX1<'_>* 7W>]L5<$I*EK
M.0 !%UKYU3S7M^BL?0@11,*^2= W"?AV_M,+$MCGT-_G/@8!+MQ]_AC ,,[<
MHV;M8Z#0N_@_BYH[YBY>%D'GQ:=KL/"1>_<02D;':\W$WMZ-,MKP8Z/,T3**
M=M?O$DQ6]K9TX@_Y9)T'XHNBOZZ3#_GNKO].Q;YL9/3"E;X4[-&]XUPQ/?+T
M3N^)@_Z\&#H5VRG3S'5;=)=LUU&\[;\?DN$C9OX/4$L#!!0    ( ,F!7D]/
M7JJ=[ 0  +P:   9    >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;)6947/J
M-A"%_PK#>ZXM:66;##!32#KM3#N3N7?:/CN@!.;:F-I.N/WWE8U#8?>(DI>
MG2/I2-K]O#+30U5_;S;.M:,?9;%K9N--V^[OHZA9;5R9-U^JO=OY_[Q4=9FW
M_K)^C9I][?)UWZ@L(AW'253FV]UX/NWO/=7S:?76%MN=>ZI'S5M9YO4_"U=4
MA]E8C3]N?-V^;MKN1C2?[O-7]\VU?^R?:G\5G7I9;TNW:[;5;E2[E]GX)W7_
M:/L&O>+/K3LT9]]'W52>J^I[=_'K>C:..T>N<*NVZR+W'^]NZ8JBZ\G[^'OH
M='P:LVMX_OVC]Y_[R?O)/.>-6U;%7]MUNYF-L_%H[5[RMZ+]6AU^<<.$['@T
MS/XW]^X*+^^<^#%65='T?T>KMZ:MRJ$7;Z7,?QP_M[O^\S#T_]$,-]!# WUJ
MH.AJ S,T,+<VH*$!W=K #@TL:Q =Y]XOYD/>YO-I71U&]3$>]GD7=NK>^NU:
M=3?[W>G_Y]>S\7??YV3,-'KO.AHTBZ-&GVGTI6(I%3:[E#Q(B8J9YE%J2/^G
MB?Q$3K/1<#:Z[\!<S(9P!P9V8/H.Z*(#RY;CJ$EZS>XX$ZTH-0E;%*G+=):1
MP7X(^B'@AXVS.&KLV3@FF? =DB*5:>S$0B<6.$F9$RL&N9LH9@1HLBRP)@ET
MD@ G+)(6B9RN5IGACI=2Y_=(46!E4N@G!7[8\B]2,8[V>::X'2DSRF8IB\"'
M5$26L59KUMNCE"F_U"J0$!F<7 8F-V&3R\!B$V6:)X34958;'5CL"?0SD7XH
M9GXF*"'8&BZE*)@0*L;HC($7Q=D9WY 32!1,"A4 N0)N>!@.(K95GDDQ=R2%
MF56)5@%/&,=* T^A:6$@*W,[TA5FJ$(0Y5!7$I Z2?AV+H&,TI1"AC!*%6(I
MI[J2H!2;=$UR:0235"&4<J@KR4AAY)KDT@A&J$(,Y4Q7 *)HBZ3LVA9A["G
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MA1Z+KD=W$\7;_OZ1#)>@Q3]02P,$%     @ R8%>3QD)N^SS @  F0L  !D
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MHM_;OEGL!THV0R,<C=WXZA]02P,$%     @ R8%>3Q1>ZY<+ @  CP4  !D
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M>:?\%"IZSL,LF@=G+=1CEAT&C3 0)+>8M0,S( *5P9 &<J6Q1!,ZNEU@-45
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M-\-1S/ @Q4$?,P7C6=?R?U!+ P04    " #)@5Y/I;:=-4T"   X!P  &0
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M!Y4\VNXU=^^Z/[_[@57M<#=)Q@O2]A]02P,$%     @ R8%>3^!/4<<U @
M"@<  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N>&ULC55K;YLP%/TKB!]0
MWB&-"%+)HYNT25&K;9\=<A-0#6:V$[I_/]NXE! OXPNV+^><>ZZ?24OH&RL
MN/5>X9HM[8+S9N$X+"^@0NR!-%"+/T="*\3%D)X<UE! !T6JL..[[LRI4%G;
M::)B.YHFY,QQ6<..6NQ<58C^R0"3=FE[]D?@I3P57 :<-&G0"5Z!_VAV5(R<
M7N505E"SDM06A>/2?O(6SY'$*\#/$EHVZ%NRDCTA;W+P];"T76D(,.1<*B#1
M7& %&$LA8>.WUK3[E)(X['^H;U7MHI8]8K B^%=YX,72GMO6 8[HC/D+:;^
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M/2IRT:A/*T)U<Q4Q,!\#*C*YSJ,!^719\VR2#]6E4AKAF'(IS"<%^3@"9#!
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MIQ:8/^&S4PNZ!0O!N9BZ%Z1+&1..E5)@G@78JYDK!"90A-ANA^_V,M["LS!
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M0!WR6-GQ7!D86\6F=:&NE6<LF[XV #*F5>98*C7F60.#RQTWS!H#J ,,KL8
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M971S+W-H965T-C@N>&ULC57;CILP$/T5Q <L5YLD(D@+2=5*K11MU?;9(4Y
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M\3BIQ=&X86['JK^2^HF1W7#=)N.=O_T/4$L#!!0    ( ,F!7D\IT_F?L@(
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MWF""&TQPBUD@F""^Q2PQ'G*+^8SQI+>8%<83=AA/U]L5':!%!Y8@O"8@*4Y
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M=',O<VAE970W,2YX;6R-5>V.FS 0?!7D!S@3"%\10;K+J6JE5HJN:OO;@4U
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M;IV>)>SH(G%WM:$V[+K(/V?K>6ML9Z>[FKC.RPH6ZK^RC76WI]'("UJM4@O
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MSX-[#%%#EI;E53I_7-.WI%4EZV?VAR / !IGHI<!'[2Q>+ Q=/#9-4W9'*4
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MJU'JH+4N2@QQ>I8,R"0^'D6+1/N643[L&\%N??W\G;.".@EK1V_;I>IJZ.B
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MY6?%I^#,I$_)LJQO'!EQ!.&B7B)BD8M<:O"F\W25PIE1@M-+I36A31I>5W-
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MO-Y#(E&@<E\:/^ >F(P=#2IJ2G"T'0)KZ0=5JD'HHE,0 <;(QUQ_2I:""'I
M"T@8^]!>QH&+Q%Z._9#M(R#HHFUD1&:3P(=_KJ5J1@D*<OIL\=- OM. 1!%L
MPH=S0:V$H>L'_%TXAME@#W5$K^;1QV481Q'_2P8?D%_\@&U Q.B:6[:H;=F&
MMTQA5)@R8\*^4K+'"\-!LQ*!@?&(!9*L=(MM2HA#;K43Q_V0:*HZG/-06P1/
M=?SDI='TSW+@ANZL<LN%ZI :AF)$DJ+P540,H$QWT+QATEGYR/(TG47IJ]3
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M9!GF, RKN%]?=Q*>03,B"<R@AZV'H@-;I)$66<!S6GWUT15H>X'IE>V<9CN
M@/)E;Y,O[8KD^K=]HPNPP(%S>_J7=AUR\S<R(6CPV8R[J: ;1NJ&T0>$)L,1
MD,/HNV]&5BT_D#^,13_#R<N[L5>BT16Z&#E?3E-=ZYRYQQ4IT@$N@'CH13ZO
MF%9NB?2Q?#8J]29D1A%N/5DUS4D0I 4Y!_2._CKTY/&0**1TGA3%,PP#;T/A
MY1%)LP*9$4?+;G-R#;1T'@&9)!08S .O$DIDQIC)Y5+>QKN&9NG/%?%TELC.
MG1&1' 1I:=3,H.?81=Y#3::*/E_HD%QDT!1V2N!0E<3\NT\7Y-V!Y:FVY-XM
MA(4J\+]KGB*L*"A.I5)DF\^<@PB*",V&JMM]9*_.;QUQ-*_/;YS9'T]OSO=Y
MAM8&@T#GPDVTI'A9)"1!PEI5)_%LSA[Q1:?_KU?'_U6,^5?;54H>]1^H4J,8
M]Y$SG;@1!^B@*,Y03R,0#=C!'TS=:>P#O7-:![W^<U.'$\([08.:)DA#(Y=!
M++PP^ TOIW4)0R^DA-Y@&KN1/X:_05&8PCQ@K!// _:,T9>?S2AIC!OPXQ&Z
M&:<P!PPFB"CB8.1Y+QJPVN=&/^V)]%(#YC9&HQ#^#=PP&M/?'OT+4X2A75E>
M<L7:'#G>, SHGXC_X?J?Z*&POR>'0F_Z_";_$Q-X[Q T+=OB2>^AN0 UVYG;
M4/"5PXI"CS%\G$USUQJ_P;[$R)J:F+B\E"J/N7<]$;1TRUB&B]PI<\W(D-T.
MY(ZYOQ,@I9S^\ME*/&/7!UH84<SSR)U$GA, N;8B*PP#WGOR8=C+7QF/:8&E
M+S/][>G%C?/3Z>7'<^?]^>GLXXV]7%;'8VP$JH47EF8^L.'" !&^P"@$%45_
MK\H>B?M'UY=;\0RE"5 6WZMJ+I$U1^9OBT*RCMV0HY;MND3UW/'%OS+E<M\,
MV*Z\UV:>:U>^JTJ@$3FN7Y'KJM+^1(;K09FN8AY8%M5WQUCU62>Y=F0=-E)5
M:QFKK;U%82IK[:&QI-!?X+EQ'(ODU8D["FR)_ =LER73M"N_5&V72"GM2BU5
MSXE\TJ_(*U6Y_9Q0>DA>J9C%)/8H)T[EE.[8*)$/6DL+W7NCU&).IF.X>/%3
MC'FV88SZ-"<\5:+(" *+J7;-6/07G^M.;0X$45M!T?XAB:EBXHHQN'I\+--7
MZ/0QLD-'922W8788YJ7<"P2"78.[2ZLG!'^F82&$ Y ^+F+X%7IA7JCE0BN:
M(C326WBN-00#Z7?^^S8GZTV1R:+5;'30<\@H#E, IHB<"TPHD8<W6\/ESGYT
M;2BH$7TA1J##7+)B,=@D I*88I*XZ+SJ 46 _ YS#\@D()@!C])M9*+1(G'@
M!A :FC"--Y-*R"=P8XNYTMN?,<+XWH@2$%N5U-ZFN<E2=310RQ($<@F:->=\
M?\@QMK62<ZW"?547IKTNEV%HLU3WQ*"FYLJWB(\1!LT<$E&(K"-KW<4DJWK=
M: J!=468>>W[4UDN6:2\T#>$'5<S-&$WG-Q4E<8C=<AY8Y!F,V8LOSD/ALVY
M4Q1 22P+AHJ29;Q+:63<N2J4@:#9)>89R*TFK\,7$4+#B5J:@[2CR7G'[=_V
MR&Z7((FU[4S\K0%]:ZUU18WK I7L;J O3U3 J[;U/Z:)JGSOR.!9F+./, $(
MM."S!6DR\IT_)L4=Y@5!Y]=P!I^29]B:9;*B DUGR3*#YM=9PCU>H&D?EO@:
MJ!&O1>'GX-'U59'2(&0X/PDKW2PIY0HL:Y&S2"=$V+;EB;G;9LL%&WWTM,:>
M;1XB%XW*TTB>*ZT[FV2>2F>6<I5#%_YXZF(R=XG+1P"$8JUE$HZ:>9]E5@;"
M$F:F]#Z!7H'^_5H@OO"1\7#$V(0/J[G4;MT@J["]:U5+"$ZR5D@JJV.>&_NE
M\(LST1,[8K4=7KXGO#PQUM?4P)]XR3TD1N%*94;3\8VL&JX)"S07M9:HP!GV
M]I0N/Z<#NO4<+IUV)Y"&A$=9KR-Z:C#W=, 9K!I2-/U2I<*$S33((;(@7@XH
M-UAC."L8.N-AU'Q 7W98'Q7K#F(%9G8^2X)#S#R1.<M?U):+:.,\P53N6X.]
MWZ"UXN05@N=+=U,I1X-2K C+I\E1E0@C)C!;=]\7A-,WR.\'6\)S17NIL.W5
M;PU=_$8L2ZGSW"O5&5H?\7# F.Y@ HI0:VXJ%>F'0AG! -:B>+A]C>I/F;A*
M.22F*PK\I K3CY=YO5ABLKWL%7U!="-3A;5:- 49H,FBJRY)"?(L2E+ITEZM
M0G0\0-JG6Y1*)"M5Q>+4H.U5X^1"'F<GA@M8[$?SD*+U.@1="$1ODX/@_8Y)
MZBB8SN5]M)N!]3!B>N-<#6>&#.2$UN@X@X&6Q*U$2C2FXX2'C>?@BX'>X%$(
MQQ2>#KEVMM&*,GM;I'VF=/0$JA!/>E^LLJ Q%;(J4(.):VHF0>=(["5!N6O[
M/&$4&TXU:JJ;'=N&NRM1F!,?Y+*+7!6]*NQSE^PL^81#):0!DYIL_8J$N#DJ
M7S#IY;-J)5G\;<L)8B@=MAD#R3]UKL"-B=5ZV*Y%Q33V'(J'N<"A7&SKD1D*
M8SHG%):6I%5I-&K)LE^-:?"A6T[NSY3M3KD^@A/"<%P!*<C6 E_MF02A.Q[[
M:+7VIE.AG_=(\6@["4=C++\6AQ-91?Q;SF/D.=%TW]&C06):MRI81SV-8(8R
M.:C],YF$HI&H*S<=CU2<6;Z6F(%-NFHLDM((6Q#_^^0SF6C_/1"8-H#_W\G"
MW*1@2G@^<A"PSJQ4Q,@<H3N*)\Y/\FXTW@@FD1..0V<\BK"NT7A<VR->[2-G
M.A99ZQ/*TW(C @^#G1J%#&I&A3Y):67?5<NTO]+F:SLE'90_;<V>;*(CH&>$
M=%?%S>%:U51C%/DY9-,U=.7.@H)M@)N^@[V+BCA,5U[&'N4:8=K>+Q0I*1#+
MVQ%Z"%8ZHA@8^(BAM &FWH9N/ KP8P@?IZ,I6ZG8OPRJ503GVJ0#):R'(7$?
M3J*]1LQYV$\!R487":N5(S<8Q0CLU+H=FXK%L8^)M90)>-+'E9E%8-]_M?R/
MFKG!/-M2@ =5V3S;L+2X<PRB6*L XJ# $\WSNF_ROM$F9L(+D359I<SUDK*X
M,L@TEII"FVQ/(%>F$@=2ME<5^IKMUULD 8-4%,I(F?-IQ&C4O"A8TT*UOR-_
MC]#\">D7M1\)KJH"$6@ 7>3]3&<S&@;>=\[.4]/JV39_5#!C&9#?R@+6X/OG
MGVW^LM8#?:G''U_/SO_\$7/LSW^R.<FN/MR>8VRZTWK2>8U6!ERFV19T)!9_
M/AA6C)$I^C5,-62A&%3YH-3O-@PWK^4CNOD3%GW/"XPC>6/$H%X+5'*)@$1/
MG+!>8MBML$*)J.]DE_2%C4$(^<"B.F7YJ_1)FSD01>EOR=Q0J)J6$$/>%R?#
M,CW<]B9Z5Q IO M6SZ")$R4,<'SJ T%7*1\S5K6TV((HC,TBS\.U0<O%0[P5
MY"=DI^5SG=ODNKOZ/@,#Y@9HL/ :\@<V6>@28+8YTQR 7).EB"8'31H/[H,.
M0256;88<\\6M<'PZ\.8;)=^;N^8<4P&6A;;!E.HYVSIQX1.$7I!V::4ZF5<P
M$R<)8>MGRZB?B&6Q&EI;9YT%RW@H6/0:9)Y),":"==%L^#>J.\ 6N?5Z2VX)
M40,<!A760MUNB9':M\0@G#+[ AQLD3R7ADU*!B.;:\?M_2QV3-3N;-5O@;E1
MPF7+"%$/+ZUO!0_3>B(D#O8^UJT=Q\N59AJZ"YDJI6&EF4 ..RB]+70C&"%I
M"-9(FB9MO:(V2X=:[=[#VF8_&Z;MC>47NK%C#PUN;!8TMF??&99&YHL$ K-T
M3^ F!M'5LE5E::-YLIP+J)%#5@:=1,BUG8L+8-IP5SHCG@F<B3\KY,<; HI#
M;O,VA[WUO<&?B<HH%#!;4_@L>U;HL*C>ZK<2EMQ!VYM1E;UF][H0_E!^2(:!
M"SG4=?X(]/Z$-7S/M:O;=2Z'UW#1R-].\"R;@$8RPUV(+CDMXJ=U_D1AO/X$
MM,&K'+N[S/.-<Y,G[$!&6<R%G_F_=4=$?("]B:(13TODI#!>6#A@TI>79WR'
M2 0/=8_(\>G39KW"SE74I$HBD4T9JR1X"X?%FD9,LY2E6OPAB@RGVP<0KHU
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M<N6 5&JT'O<K4(V>L*Z1K(%7EB8LJ1@=U_[#9AT=WJM!'M2"&26M<C[&]0'
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M+T]@+V *L!K1R*=5B1#%%!;1GTCD4W/O)CY!U\ GV">LY0Q[1X-$L(XQ?!?
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M1!=FZUKI2TVW"*2[\M!;?+>6EMYNT$A$;_VX1_)YSVS:.NDN;-L^" "[>'0
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M]J(]@<4Z:,TMS_?P<1/1KB8+D>3] BYN@UM[*>,];0O^G<]:H>+V>,\VWF_
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M$1$<[%N<DII=VH+#_XGX)U!+ P04    " #)@5Y/"<Q>VU4%  #:+@  #P
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M 60"0":]0$X]CCLT@$P!R+1'R%8D,P RZQ,R"2!S #+O$S(-((\!R.,^(;,
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M<U!+ 0(4 Q0    ( ,F!7D\GZ(<.@@   +$    0              "  >D
M  !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ R8%>3^3YC<#M    *P(
M !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%
M  @ R8%>3YE<G",0!@  G"<  !,              ( !M0(  'AL+W1H96UE
M+W1H96UE,2YX;6Q02P$"% ,4    " #)@5Y/H)K;[3 #   [#P  &
M        @ 'V"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%
M  @ R8%>3^Q>^Z&G!0  LQL  !@              ( !7 P  'AL+W=O<FMS
M:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( ,F!7D\T SH,J0(  (8)   8
M              "  3D2  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q02P$"
M% ,4    " #)@5Y/!!75DZP$   A%0  &               @ $8%0  >&PO
M=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ R8%>3UN.H7BP @
M: D  !@              ( !^AD  'AL+W=O<FMS:&5E=',O<VAE970U+GAM
M;%!+ 0(4 Q0    ( ,F!7D_0".[A(0(  %8&   8              "  > <
M  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    " #)@5Y/:A7I
M8* %  #*'   &               @ $W'P  >&PO=V]R:W-H965T<R]S:&5E
M=#<N>&UL4$L! A0#%     @ R8%>3S/Q<6&E!0  -1T  !@
M ( !#24  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    ( ,F!
M7D\WN*7?L0$  -(#   8              "  >@J  !X;"]W;W)K<VAE971S
M+W-H965T.2YX;6Q02P$"% ,4    " #)@5Y/$OLZFK<!  #2 P  &0
M        @ '/+   >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0
M   ( ,F!7D\N&65BLP$  -(#   9              "  ;TN  !X;"]W;W)K
M<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ R8%>3ZS'9F6V 0  T@,
M !D              ( !IS   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q0
M2P$"% ,4    " #)@5Y/>;3_\+8!  #2 P  &0              @ &4,@
M>&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( ,F!7D^9L=CI
MM@$  -(#   9              "  8$T  !X;"]W;W)K<VAE971S+W-H965T
M,30N>&UL4$L! A0#%     @ R8%>3UIFNM*V 0  T@,  !D
M ( !;C8  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4    " #)
M@5Y/*0I<U+<!  #2 P  &0              @ %;.   >&PO=V]R:W-H965T
M<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( ,F!7D_6B9[UM0$  -(#   9
M          "  4DZ  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#
M%     @ R8%>3X8-<U"V 0  T@,  !D              ( !-3P  'AL+W=O
M<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #)@5Y/](=?W\0!   W
M!   &0              @ $B/@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM
M;%!+ 0(4 Q0    ( ,F!7D^BP)^NM@$  -(#   9              "  1U
M  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ R8%>3VAF
M1',& @  - 8  !D              ( !"D(  'AL+W=O<FMS:&5E=',O<VAE
M970R,2YX;6Q02P$"% ,4    " #)@5Y/=IFD>< !   W!   &0
M    @ %'1   >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0    (
M ,F!7D^UBE$(LP$  -(#   9              "  3Y&  !X;"]W;W)K<VAE
M971S+W-H965T,C,N>&UL4$L! A0#%     @ R8%>3R]ZX(OH 0  9@4  !D
M             ( !*$@  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q02P$"
M% ,4    " #)@5Y/=9<@.K<!  #2 P  &0              @ %'2@  >&PO
M=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( ,F!7D]>$0G%MP$
M -(#   9              "  35,  !X;"]W;W)K<VAE971S+W-H965T,C8N
M>&UL4$L! A0#%     @ R8%>3\&&-[ON 0  9@4  !D              ( !
M(TX  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    " #)@5Y/
M<NF.-< !   W!   &0              @ %(4   >&PO=V]R:W-H965T<R]S
M:&5E=#(X+GAM;%!+ 0(4 Q0    ( ,F!7D^;OU!JLP$  -(#   9
M      "  3]2  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL4$L! A0#%
M  @ R8%>3S^@T??1 0  G 0  !D              ( !*50  'AL+W=O<FMS
M:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #)@5Y/0B0Q 00"   %!@
M&0              @ $Q5@  >&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+
M 0(4 Q0    ( ,F!7D_'F "IZ0,  + 1   9              "  6Q8  !X
M;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @ R8%>3Y^PXW&_
M @  PPD  !D              ( !C%P  'AL+W=O<FMS:&5E=',O<VAE970S
M,RYX;6Q02P$"% ,4    " #)@5Y/!B *\Q($  "[%   &0
M@ &"7P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( ,F!
M7D]"-]Q>P (  ,$)   9              "  <MC  !X;"]W;W)K<VAE971S
M+W-H965T,S4N>&UL4$L! A0#%     @ R8%>3Q>D&F\] P  0@X  !D
M         ( !PF8  'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"% ,4
M    " #)@5Y/)O2,W9P"   %"0  &0              @ $V:@  >&PO=V]R
M:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( ,F!7D]QF/E$3@(  /@&
M   9              "  0EM  !X;"]W;W)K<VAE971S+W-H965T,S@N>&UL
M4$L! A0#%     @ R8%>3X(<K2)% @  V08  !D              ( !CF\
M 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    " #)@5Y/HV["
MH4D"  #S!@  &0              @ $*<@  >&PO=V]R:W-H965T<R]S:&5E
M=#0P+GAM;%!+ 0(4 Q0    ( ,F!7D\(.#<),0(  /0&   9
M  "  8IT  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%     @
MR8%>3]<%Y,5N @  QP<  !D              ( !\G8  'AL+W=O<FMS:&5E
M=',O<VAE970T,BYX;6Q02P$"% ,4    " #)@5Y/PVMA'KT"   C"@  &0
M            @ &7>0  >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4
M Q0    ( ,F!7D^>A)<Z0P(  .X&   9              "  8M\  !X;"]W
M;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ R8%>3_R^%!T4 @
MP04  !D              ( !!7\  'AL+W=O<FMS:&5E=',O<VAE970T-2YX
M;6Q02P$"% ,4    " #)@5Y/ILRD.J("  "\"0  &0              @ %0
M@0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( ,F!7D^<
M+C0;.@(  +T&   9              "  2F$  !X;"]W;W)K<VAE971S+W-H
M965T-#<N>&UL4$L! A0#%     @ R8%>3QT+P>&6 @  T @  !D
M     ( !FH8  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( ,F!7D\256SRH@(  ! )   9              "
M 6&7  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @ R8%>
M3QD)N^SS @  F0L  !D              ( !.IH  'AL+W=O<FMS:&5E=',O
M<VAE970U-"YX;6Q02P$"% ,4    " #)@5Y/%%[KEPL"  "/!0  &0
M        @ %DG0  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0
M   ( ,F!7D\A7W= @0(  $X(   9              "  ::?  !X;"]W;W)K
M<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ R8%>3R=8"<?R P  ]Q(
M !D              ( !7J(  'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q0
M2P$"% ,4    " #)@5Y/I;:=-4T"   X!P  &0              @ &'I@
M>&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( ,F!7D]5ZBEV
MR0(  "0,   9              "  0NI  !X;"]W;W)K<VAE971S+W-H965T
M-3DN>&UL4$L! A0#%     @ R8%>3WB"R4,- P  Q0L  !D
M ( !"ZP  'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4    " #)
M@5Y/B'@.E*("   L"0  &0              @ %/KP  >&PO=V]R:W-H965T
M<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( ,F!7D_@3U''-0(   H'   9
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M970V-BYX;6Q02P$"% ,4    " #)@5Y/N^P2=D$"  !3!P  &0
M    @ $3P@  >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0    (
M ,F!7D\OTGP86@(  #@'   9              "  8O$  !X;"]W;W)K<VAE
M971S+W-H965T-C@N>&UL4$L! A0#%     @ R8%>3]<+1.!D @  _P<  !D
M             ( !',<  'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q02P$"
M% ,4    " #)@5Y/*=/YG[("  "0"@  &0              @ &WR0  >&PO
M=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( ,F!7D^%0291 0(
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M:V)O;VLN>&UL4$L! A0#%     @ R8%>3YR47O]1 @  JBH  !H
M     ( !+TD! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%
M  @ R8%>3VW:TR ( @  Q2D  !,              ( !N$L! %M#;VYT96YT
A7U1Y<&5S72YX;6Q02P4&     %  4 #B%0  \4T!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838554752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 13,139<span></span>
</td>
<td class="nump">$ 9,742<span></span>
</td>
<td class="nump">$ 40,747<span></span>
</td>
<td class="nump">$ 28,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">4,301<span></span>
</td>
<td class="nump">3,169<span></span>
</td>
<td class="nump">13,745<span></span>
</td>
<td class="nump">9,102<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="nump">$ 8,838<span></span>
</td>
<td class="nump">$ 6,573<span></span>
</td>
<td class="nump">$ 27,002<span></span>
</td>
<td class="nump">$ 19,228<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6830766240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 743,768<span></span>
</td>
<td class="nump">$ 674,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">474,569<span></span>
</td>
<td class="nump">153,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">$ 1,218,337<span></span>
</td>
<td class="nump">$ 828,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6831633888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Organization</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Exelixis, Inc. (Exelixis, we, our or us) is</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>four</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and have launched commercially. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>Two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat a specific form of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended September 27, 2019, June 28, 2019, September 28, 2018 and June 29, 2018, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended September 30, 2019, June 30, 2019, September 30, 2018 and June 30, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019 and the first day of the fiscal quarter ended September 27, 2019 are indicated as being as of July 1, 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating results for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> are not necessarily indicative of the results that may be expected for the year ending </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, included in our Annual Report on Form 10-K filed with the SEC on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">February&#160;22, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines for difficult-to-treat cancers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On July 1, 2019, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU No.&#160;2018-15,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense and requires us to expense the capitalized implementation costs over the term of the hosting arrangement, which includes reasonably certain renewals.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2018-15 was adopted using the prospective transition method in the accompanying Condensed Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we adopted ASU </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income (Topic 220) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the individual unit of account approach for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">releasing income tax effects from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accumulated other comprehensive income (loss)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we also adopted ASU 2017-08</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2017-08). ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">shortens the amortization period for certain callable debt securities held at a premium. Specifically, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">requires the premium to be amortized to the earliest call date. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The financial impact from the adoption of ASU 2017-08 was nominal.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the Financial Accounting Standards Board (FASB) issued ASU No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838767920">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 126,630<span></span>
</td>
<td class="nump">$ 252,269<span></span>
</td>
<td class="nump">$ 329,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains or losses on available-for-sale securities, net of tax impact of $___, $0, $___ and $0, respectively</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">461<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">3,369<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">461<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">3,369<span></span>
</td>
<td class="num">(166)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 97,913<span></span>
</td>
<td class="nump">$ 126,848<span></span>
</td>
<td class="nump">$ 255,638<span></span>
</td>
<td class="nump">$ 329,815<span></span>
</td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Reclassification adjustments to net income resulting from realized gains or losses on the sale of securities and the related tax impact were nominal or zero during the periods presented.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6851777952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">76,016<span></span>
</td>
<td class="nump">57,186<span></span>
</td>
<td class="nump">$ 120,133<span></span>
</td>
<td class="nump">145,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GSK | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">191,768<span></span>
</td>
<td class="nump">162,946<span></span>
</td>
<td class="nump">$ 565,024<span></span>
</td>
<td class="nump">443,054<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">239,916<span></span>
</td>
<td class="nump">193,356<span></span>
</td>
<td class="nump">704,084<span></span>
</td>
<td class="nump">525,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_SalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">48,148<span></span>
</td>
<td class="nump">30,410<span></span>
</td>
<td class="nump">139,060<span></span>
</td>
<td class="nump">82,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">79,935<span></span>
</td>
<td class="nump">62,451<span></span>
</td>
<td class="nump">162,441<span></span>
</td>
<td class="nump">182,170<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">68,035<span></span>
</td>
<td class="nump">51,323<span></span>
</td>
<td class="nump">128,937<span></span>
</td>
<td class="nump">152,261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResearchandDevelopmentMember', window );">Research and development services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">12,988<span></span>
</td>
<td class="nump">10,560<span></span>
</td>
<td class="nump">35,814<span></span>
</td>
<td class="nump">27,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_OtherCollaborationMember', window );">Other collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">$ (1,088)<span></span>
</td>
<td class="nump">$ 568<span></span>
</td>
<td class="num">$ (2,310)<span></span>
</td>
<td class="nump">$ 2,445<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_SalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_SalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResearchandDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResearchandDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_OtherCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_OtherCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6843994720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2018</a></td>
<td class="nump">$ 17,276<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">139,381<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(321)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(136,910)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September 30, 2019</a></td>
<td class="nump">19,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks and Discounts for Prompt Payment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2018</a></td>
<td class="nump">2,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">92,769<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(130)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(92,317)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September 30, 2019</a></td>
<td class="nump">2,644<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2018</a></td>
<td class="nump">3,038<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">11,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(106)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(11,466)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September 30, 2019</a></td>
<td class="nump">2,656<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December 31, 2018</a></td>
<td class="nump">11,916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">35,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(33,127)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at September 30, 2019</a></td>
<td class="nump">$ 14,126<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6849599216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Oct. 21, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover page.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 27,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-03<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">303,846,306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 13<br> -Subsection a-13<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6850478352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>169,606</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet (the Current Premises) as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We have made certain tenant improvements to the space leased on the Initial Premises, for which we received </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in reimbursements in January 2019. The Lease&#8217;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>8</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year of the initial term (the Early Termination Right); none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The April 2019 amendment to the Lease (the Third Lease Amendment) provides, among other things, for the (i) expansion of the Initial Premises by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>37,544</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>2,703</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for tenant improvements to the 1601 Expansion Space. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have surrendered the 1751 Space and we have taken possession of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for the Third Lease Amendment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,965</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs for operating leases, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>692</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,587</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>363</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,366</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>966</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,959</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,356</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,258</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space.</span></div></td></tr></table><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>4.20%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average remaining lease term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>8.3 years</span></span>.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeFinanceLeasesTextBlock', window );">LEASES</a></td>
<td class="text">LEASES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>169,606</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet (the Current Premises) as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We have made certain tenant improvements to the space leased on the Initial Premises, for which we received </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in reimbursements in January 2019. The Lease&#8217;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>8</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> year of the initial term (the Early Termination Right); none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The April 2019 amendment to the Lease (the Third Lease Amendment) provides, among other things, for the (i) expansion of the Initial Premises by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>37,544</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>2,703</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for tenant improvements to the 1601 Expansion Space. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we have surrendered the 1751 Space and we have taken possession of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for the Third Lease Amendment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,965</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs for operating leases, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>692</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,587</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>363</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,366</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>966</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash paid for amounts included in the measurement of lease liabilities for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$2.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,959</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,356</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,258</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space.</span></div></td></tr></table><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>4.20%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the weighted average remaining lease term is </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>8.3 years</span></span>.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeFinanceLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeFinanceLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6833560464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,838</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,139</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,747</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have several equity incentive plans under which we have granted stock options and restricted stock units (RSUs) to employees and directors. At </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>6,024,995</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares were available for grant under our equity incentive plans.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.57</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.82</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.0 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#8217; current expectations.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:46%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,674,062</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,042,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20.81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3,042,201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(160,241</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(35,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,478,861</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3.4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,860,131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.8 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>181,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>$38.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"><span>2.3 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for RSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:46%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,857,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,635,362</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(484,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12.33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(258,142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,749,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.2 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>175,448</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, there was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$166.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of unrecognized compensation expense related to our unvested RSUs, including those RSUs granted in September 2018 and September 2019 that will vest upon the achievement of specific performance targets (PSUs) described below. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>2.8 years</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2019, in connection with our long-term incentive compensation program, we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1,926,605</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(the target amount) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">that will vest upon the achievement of a performance target related to a product approval by the FDA (the 2019 PSUs); employees may earn </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>150%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the target amount</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, or an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>963,136</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares relative to the target amount, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">if the performance target is achieved before December 31, 2020 and may earn the full </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>200%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the target amount, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">or up to an additional </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1,926,605</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> shares relative to the target amount, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">if we receive a second product approval. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">During 2018 we awarded </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>693,131</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (the 2018 PSUs). The 2018 PSUs and 2019 PSUs were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Expense recognition for PSUs commences when it is determined that attainment of the performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is probable. During the quarter ended June </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we achieved one of the two </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product revenue related </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">targets</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>114,843</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the 2018 PSUs and determined that it was probable that we would achieve the second </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">product revenue related </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>172,272</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional 2018 PSUs. D</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">uring the quarter ended September 30, 2019, the second product revenue related performance target </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">of the 2018 PSUs </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">was achieved</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Those 2018 PSUs will vest over various dates through February 2021. We recognized </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$3.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in compensation expense related to those 2018 PSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively; the remaining unrecognized compensation expense for those 2018 PSUs was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The total unrecognized compensation expense for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">both the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019 PSUs and the remaining 2018 PSUs for which we have not yet determined that attainment of the performance </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">target</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> is probable was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$82.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6831836672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS</a></td>
<td class="text">COLLABORATION AGREEMENTS<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Daiichi Sankyo </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">and Bristol-Myers Squibb Company for other compounds and programs in our portfolio. See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for a description of each of our collaboration agreements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit-sharing payments. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See &#8220;Note 2. Revenues&#8221; for information on collaboration revenues recognized during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Commercial Collaborations</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Ipsen Collaboration </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>120,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$47.1 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Ipsen was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$7.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;">Takeda Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The collaboration agreement was subsequently amended in March 2018 and April 2019.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The second amendment to the collaboration agreement with Takeda, which was executed on April 29, 2019 and became effective on May 7, 2019 (the Amendment), among other things, reduced the amount of reimbursements we will receive from Takeda for costs associated with our required global pharmacovigilance activities and limits those reimbursements to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per year. It also increased the total potential development, regulatory and first-sale milestone payments to be paid to us by Takeda for second-line </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">RCC</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, first-line RCC and second-line HCC by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$12.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$102.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, including an increase from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$16.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the milestone we received for the April 2019 submission of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese Ministry of Health, Labour and Welfare</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (MHLW)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We continue to be eligible to receive additional development, regulatory and first-sale milestone payments for other potential future indications. The Amendment also increased the amount of Takeda&#8217;s total potential commercial milestones by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$89.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We continue to be eligible to receive royalties on net sales of cabozantinib in Japan.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,940</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,843</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$18.7 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the net contract liability for the collaboration agreement with Takeda was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$8.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> which was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Genentech Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and the subsequent clinical development. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in the European Union and multiple additional countries for use in the same indication. Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,507</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,004</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,614</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Daiichi Sankyo</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo was responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In&#160;January 2019, the Japanese MHLW approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2019, Daiichi Sankyo had its first commercial sale of MINNEBRO</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As a result of the launch,&#160;we&#160;received a&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;milestone payment from Daiichi Sankyo in June 2019. We are </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">eligible for low double-digit royalties on sales of MINNEBRO. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>0.5%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Ligand on net sales of MINNEBRO.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Daiichi Sankyo collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Such collaboration revenues were nominal or zero for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and 2018.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Iconic Therapeutics, Inc. (Iconic) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In May 2019, we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">entered into an exclusive option and license agreement with Iconic. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#8217;s lead oncology </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">antibody-drug conjugate</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> program, in exchange for an upfront payment to Iconic of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$7.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and a commitment for preclinical development funding. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we accrued </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$6.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the preclinical development funding commitment. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Both the upfront payment and the accrual for the preclinical development funding commitment were included in Research and development expenses in the accompanying Condensed Consolidated Statements of Income.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">If we exercise the option, we</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> would be required to make an option exercise fee payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$20.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> to Iconic, we would assume responsibilities for all subsequent clinical development and commercialization activities, and Iconic would become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$190.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential development, regulatory and first-sale milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$262.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in potential commercial milestone payments, as well as royalties on potential sales.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aurigene Discovery Technologies Limited (Aurigene) Collaboration</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In July 2019, we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">entered into</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> an exclusive collaboration, option and license agreement with Aurigene, and</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> India-based biotechnology company focused on oncology and inflammatory disorders, to in-license as many as </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>six</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> programs. Under the terms of the agreement, we made an upfront payment of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for exclusive options to license </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>three</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> preexisting programs. In addition, we and Aurigene selected </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>three</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> additional Aurigene-led drug discovery programs on mutually agreed upon targets, in exchange for additional option payments totaling </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$7.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. We are also responsible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$32.6 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in research funding for the discovery and preclinical development work on these programs. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we accrued </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.3 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the discovery and preclinical development funding commitment. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">For each option we decide to exercise, we would be required to pay an exercise fee of either </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$10.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> or </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$12.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, depending on the program, and would assume responsibilities for all subsequent clinical development, </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">commercialization and global manufacturing of that program. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Aurigene would then become eligible for up to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$148.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential development and regulatory milestone payments, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$280.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> per program in potential commercial milestone payments, as well as royalties on potential sales. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">GSK</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated in December 2014, we continue to be required to pay a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties accruing to GSK in connection with the sales of cabozantinib are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen. Such royalties accruing to GSK were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,021</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6833781744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 25, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option</div>
</th>
<th class="th"><div>May 31, 2017</div></th>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>ft&#178; </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember', window );">Alameda, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the Lease | renewal_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease option to extend period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod', window );">Option to terminate lease (after period)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty', window );">Operating lease, expansion (in square feet)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,335<span></span>
</td>
<td class="nump">37,544<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Built-To-Suit Lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod', window );">Option to terminate lease (after period)</a></td>
<td class="text">180 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event | Built-To-Suit Lease | Alameda, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet)</a></td>
<td class="nump">220,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">242 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment', window );">Estimated monthly base rent under Build-to-Suite Leases | $</a></td>
<td class="nump">$ 726<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage', window );">Monthly base rent, lease not yet commenced, annual percentage increase</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the Lease | renewal_option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease option to extend period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate After Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Additional Area Of Real Estate Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseAdditionalAreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LeaseArrangementsAxis=exel_BuiltToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>57
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel2019093010-q.htm": {
   "axisCustom": 2,
   "axisStandard": 19,
   "contextCount": 299,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20190927_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20190927_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "exel2019093010-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20190927_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-doc-2019-01-31.xml",
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20190927_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20190927.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd",
      "http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd",
      "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd",
      "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd",
      "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-parts-codification-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 510,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 36,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 41
   },
   "keyCustom": 57,
   "keyStandard": 325,
   "memberCustom": 36,
   "memberStandard": 35,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20190927",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Collaboration Agreements",
     "role": "http://www.exelixis.com/role/CollaborationAgreements",
     "shortName": "Collaboration Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:CashCashEquivalentsAndInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashAndInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:CashCashEquivalentsAndInvestmentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Property and Equipment",
     "role": "http://www.exelixis.com/role/PropertyAndEquipment",
     "shortName": "Property and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Income Taxes",
     "role": "http://www.exelixis.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Leases",
     "role": "http://www.exelixis.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeFinanceLeasesTextBlock",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Subsequent Events",
     "role": "http://www.exelixis.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Collaboration Agreements (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTables",
     "shortName": "Collaboration Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Property and Equipment (Tables)",
     "role": "http://www.exelixis.com/role/PropertyAndEquipmentTables",
     "shortName": "Property and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Leases (Tables)",
     "role": "http://www.exelixis.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "exel:NumberofProductsinCommercialMarket",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "exel:NumberofProductsinCommercialMarket",
      "reportCount": 1,
      "unique": true,
      "unitRef": "product",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CabometyxMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails",
     "shortName": "Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Revenues - Contract Assets and Liabilities under Topic 606 (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details",
     "shortName": "Revenues - Contract Assets and Liabilities under Topic 606 (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiabilityNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
     "shortName": "Collaboration Agreements - Ipsen Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Condensed Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborativeArrangementAnnualReimbursementLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
     "shortName": "Collaboration Agreements - Takeda Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborativeArrangementAnnualReimbursementLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403406 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
     "shortName": "Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember",
      "decimals": "-3",
      "lang": null,
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403407 - Disclosure - Collaboration Agreements - Daiichi Sankyo (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
     "shortName": "Collaboration Agreements - Daiichi Sankyo (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember",
      "decimals": "3",
      "lang": null,
      "name": "exel:CollaborationAgreementPercentOfRoyaltyOnNetSale",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403408 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
     "shortName": "Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403409 - Disclosure - Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
     "shortName": "Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementsUpfrontPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "D2019Q3Jul01-Jul31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementAdditionalOptionPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403410 - Disclosure - Collaboration Agreements - Aurigene Discovery Technologies Limited (Aurigene) Collaboration (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
     "shortName": "Collaboration Agreements - Aurigene Discovery Technologies Limited (Aurigene) Collaboration (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "D2019Q3Jul01-Jul31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "exel:CollaborationAgreementAdditionalOptionPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403411 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
     "shortName": "Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "I2018Q3Sept28",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unitRef": "investment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404405 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "investment",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Property and Equipment (Details)",
     "role": "http://www.exelixis.com/role/PropertyAndEquipmentDetails",
     "shortName": "Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Property and Equipment - Narrative (Details)",
     "role": "http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails",
     "shortName": "Property and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails",
     "shortName": "Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407405 - Disclosure - Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
     "shortName": "Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407406 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2018Q4",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407407 - Disclosure - Stock-Based Compensation - RSU Activity (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
     "shortName": "Stock-Based Compensation - RSU Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "lang": null,
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408401 - Disclosure - Income Taxes (Details)",
     "role": "http://www.exelixis.com/role/IncomeTaxesDetails",
     "shortName": "Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "exel:TenantLeaseImprovementsAllowance",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Leases - Narrative (Details)",
     "role": "http://www.exelixis.com/role/LeasesNarrativeDetails",
     "shortName": "Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Leases - Balance Sheet Classification of Lease Liabilities (Details)",
     "role": "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails",
     "shortName": "Leases - Balance Sheet Classification of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412404 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3QTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)",
     "role": "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Leases - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FI2019Q3_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AreaOfRealEstateProperty",
      "reportCount": 1,
      "unitRef": "sqft",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413401 - Disclosure - Subsequent Events (Details)",
     "role": "http://www.exelixis.com/role/SubsequentEventsDetails",
     "shortName": "Subsequent Events (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember",
      "decimals": null,
      "lang": "en-US",
      "name": "exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "FD2019Q3YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9999": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel2019093010-q.htm",
      "contextRef": "I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "",
     "isDefault": "false",
     "longName": "Uncategorized Items - exel2019093010-q.htm",
     "role": "http://xbrl.sec.gov/role/uncategorizedFacts",
     "shortName": "Uncategorized Items - exel2019093010-q.htm",
     "subGroupType": "",
     "uniqueAnchor": null
    }
   },
   "segmentCount": 71,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_ASDMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ASD [Member]",
        "label": "ASD [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "ASDMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AchievedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Achieved [Member]",
        "label": "Achieved [Member]",
        "terseLabel": "Achieved"
       }
      }
     },
     "localname": "AchievedMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AlamedaCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alameda, California [Member]",
        "label": "Alameda, California [Member]",
        "terseLabel": "Alameda, California"
       }
      }
     },
     "localname": "AlamedaCaliforniaMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_BuiltToSuitLeaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Built-To-Suit Lease [Member]",
        "label": "Built-To-Suit Lease [Member]",
        "terseLabel": "Built-To-Suit Lease"
       }
      }
     },
     "localname": "BuiltToSuitLeaseMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CaremarkL.L.C.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Caremark L.L.C. [Member]",
        "label": "Caremark L.L.C. [Member]",
        "terseLabel": "Caremark L.L.C."
       }
      }
     },
     "localname": "CaremarkL.L.C.Member",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashAndRestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash And Restricted Cash [Member]",
        "label": "Cash And Restricted Cash [Member]",
        "terseLabel": "Cash and restricted cash"
       }
      }
     },
     "localname": "CashAndRestrictedCashMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsAndInvestmentsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, and Investments [Text Block]",
        "label": "Cash, Cash Equivalents, and Investments [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsAndInvestmentsTextBlock",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "terseLabel": "Total cash and investments, Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "terseLabel": "Total cash and investments, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedLabel": "Total cash and investments, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Total cash and investments, Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Cash, restricted cash and certificates of deposit, Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Cash, cash equivalents, and restricted cash, Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedLabel": "Cash, cash equivalents, and restricted cash, Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks and Discounts for Prompt Payment"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementAdditionalOptionPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Additional Option Payments",
        "label": "Collaboration Agreement, Additional Option Payments",
        "terseLabel": "Additional option payments"
       }
      }
     },
     "localname": "CollaborationAgreementAdditionalOptionPayments",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementMilestonePaymentsEarned": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Milestone Payments Earned",
        "label": "Collaboration Agreement, Milestone Payments Earned",
        "terseLabel": "Milestone payments earned"
       }
      }
     },
     "localname": "CollaborationAgreementMilestonePaymentsEarned",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Drug Discovery Programs",
        "label": "Collaboration Agreement, Number Of Drug Discovery Programs",
        "terseLabel": "Collaboration agreement, number of drug discovery programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfDrugDiscoveryPrograms",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_CollaborationAgreementNumberOfPreexistingPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Preexisting Programs",
        "label": "Collaboration Agreement, Number Of Preexisting Programs",
        "terseLabel": "Collaboration agreement, number of preexisting programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfPreexistingPrograms",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_CollaborationAgreementNumberOfPrograms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Number Of Programs",
        "label": "Collaboration Agreement, Number Of Programs",
        "terseLabel": "Collaboration agreement, number of programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfPrograms",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "label": "Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option",
        "terseLabel": "Option exercise fee payment, if exercised"
       }
      }
     },
     "localname": "CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Research And Development Expense Accrued",
        "label": "Collaboration Agreement, Research And Development Expense Accrued",
        "terseLabel": "Preclinical development funding commitment accrued"
       }
      }
     },
     "localname": "CollaborationAgreementResearchAndDevelopmentExpenseAccrued",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementResearchAndDevelopmentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement, Research And Development Obligation",
        "label": "Collaboration Agreement, Research And Development Obligation",
        "terseLabel": "Research and development obligation"
       }
      }
     },
     "localname": "CollaborationAgreementResearchAndDevelopmentObligation",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]",
        "label": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementWithIconicTherapeuticsInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement With Iconic Therapeutics, Inc. [Member]",
        "label": "Collaboration Agreement With Iconic Therapeutics, Inc. [Member]",
        "terseLabel": "Collaboration Agreement with Iconic Therapeutics, Inc."
       }
      }
     },
     "localname": "CollaborationAgreementWithIconicTherapeuticsInc.Member",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementsUpfrontPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreements, Upfront Payments",
        "label": "Collaboration Agreements, Upfront Payments",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborationAgreementsUpfrontPayments",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborationAgreementwithDaiichiSankyoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "label": "Collaboration Agreement with Daiichi Sankyo [Member]",
        "terseLabel": "Collaboration Agreement with Daiichi Sankyo"
       }
      }
     },
     "localname": "CollaborationAgreementwithDaiichiSankyoMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "terseLabel": "Collaboration revenue",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "label": "Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "verboseLabel": "Maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementAnnualReimbursementLimit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Annual Reimbursement Limit",
        "label": "Collaborative Arrangement, Annual Reimbursement Limit",
        "verboseLabel": "Limit on reimbursement per year"
       }
      }
     },
     "localname": "CollaborativeArrangementAnnualReimbursementLimit",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits and losses on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount eligible for development and regulatory milestones under collaborations agreement.",
        "label": "Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones",
        "netLabel": "Maximum amount eligible for development, regulatory and first-sale milestones",
        "verboseLabel": "Maximum amount eligible for development and regulatory milestones"
       }
      }
     },
     "localname": "CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Computer Equipment And Software [Member].",
        "label": "Computer Equipment And Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_EarningsPerShareDenominatorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share, Denominator [Abstract]",
        "label": "Earnings Per Share, Denominator [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "EarningsPerShareDenominatorAbstract",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_EarningsPerShareNumeratorAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Earnings Per Share, Numerator [Abstract]",
        "label": "Earnings Per Share, Numerator [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareNumeratorAbstract",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_FinancingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financing Lease Liabilities [Abstract]",
        "label": "Financing Lease Liabilities [Abstract]",
        "terseLabel": "Financing lease liabilities:"
       }
      }
     },
     "localname": "FinancingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Glaxo Smith Kline [Member].",
        "label": "Glaxo Smith Kline [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IncreaseDecreaseInAccruedClinicalLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (decrease) in accrued clinical liabilities",
        "label": "Increase (Decrease) In Accrued Clinical Liabilities",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedClinicalLiabilities",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInAccruedCollaborationLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) in Accrued Collaboration Liability",
        "label": "Increase (Decrease) In Accrued Collaboration Liability",
        "terseLabel": "Accrued collaboration liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedCollaborationLiability",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones",
        "label": "Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible For Development And Regulatory Milestones",
        "verboseLabel": "Increase in maximum amount eligible for development and regulatory milestones"
       }
      }
     },
     "localname": "IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInLeaseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 19.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Lease Liability, Noncurrent",
        "label": "Increase (Decrease) In Lease Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseLiabilityNoncurrent",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase in Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "label": "Increase (Decrease) In Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement",
        "verboseLabel": "Increase in maximum amount eligible for commercial milestones under collaborations agreement"
       }
      }
     },
     "localname": "IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IncreaseDecreaseInRebatesAndFeesPayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Increase (Decrease) In Rebates And Fees Payable",
        "label": "Increase (Decrease) In Rebates And Fees Payable",
        "terseLabel": "Rebates and fees due customers"
       }
      }
     },
     "localname": "IncreaseDecreaseInRebatesAndFeesPayable",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratory Equipment [Member]",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LeaseArrangementsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Axis]",
        "terseLabel": "Lease Arrangements [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementsAxis",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LeaseArrangementsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Lease Arrangements [Axis]",
        "label": "Lease Arrangements [Domain]",
        "terseLabel": "Lease Arrangements [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementsDomain",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating And Financing Lease Liabilities [Table Text Block]",
        "label": "Lessee, Operating And Financing Lease Liabilities [Table Text Block]",
        "terseLabel": "Balance Sheet Classification of Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "label": "Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements",
        "terseLabel": "Tenant improvement reimbursements"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityTenantImprovementReimbursements",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment",
        "terseLabel": "Estimated monthly base rent under Build-to-Suite Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "label": "Lessee, Operating Lease, Not Yet Commenced, Monthly Base Payment, Annual Increase, Percentage",
        "terseLabel": "Monthly base rent, lease not yet commenced, annual percentage increase"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of options to extend the Lease"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Terminate After Period",
        "label": "Lessee, Operating Lease, Option To Terminate After Period",
        "terseLabel": "Option to terminate lease (after period)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToTerminateAfterPeriod",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "label": "Lessee, Operating Lease, Reduction Of Payments Due [Abstract]",
        "terseLabel": "Less:"
       }
      }
     },
     "localname": "LesseeOperatingLeaseReductionOfPaymentsDueAbstract",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions",
        "label": "Liabilities Expenditures Incurred But Not Yet Paid To Related Party Transactions",
        "terseLabel": "Unpaid liabilities incurred to acquire investments"
       }
      }
     },
     "localname": "LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NotProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Not Probable [Member]",
        "label": "Not Probable [Member]",
        "terseLabel": "Not Probable"
       }
      }
     },
     "localname": "NotProbableMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OperatingAndFinanceLeasesLiabilityLongTerm": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating And Finance Leases, Liability - Long Term",
        "label": "Operating And Finance Leases, Liability - Long Term",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeasesLiabilityLongTerm",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_OperatingAndFinanceLeasesLiabilityTotal": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating And Finance Leases, Liability - Total",
        "label": "Operating And Finance Leases, Liability - Total",
        "totalLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingAndFinanceLeasesLiabilityTotal",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_OperatingLeaseAdditionalAreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Additional Area Of Real Estate Property",
        "label": "Operating Lease, Additional Area Of Real Estate Property",
        "terseLabel": "Operating lease, expansion (in square feet)"
       }
      }
     },
     "localname": "OperatingLeaseAdditionalAreaOfRealEstateProperty",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "exel_OperatingLeaseLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Liabilities [Abstract]",
        "label": "Operating Lease Liabilities [Abstract]",
        "terseLabel": "Operating lease liabilities:"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesAbstract",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease Liabilities, Duration Of Maturity [Abstract]",
        "label": "Operating Lease Liabilities, Duration Of Maturity [Abstract]",
        "terseLabel": "Years ending December 31,"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesDurationOfMaturityAbstract",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Operating Lease, Surrendered Area Of Real Estate Property",
        "label": "Operating Lease, Surrendered Area Of Real Estate Property",
        "terseLabel": "Operating lease, surrendered (in square feet)"
       }
      }
     },
     "localname": "OperatingLeaseSurrenderedAreaOfRealEstateProperty",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Collaboration [Member]",
        "label": "Other Collaboration [Member]",
        "terseLabel": "Other collaboration revenues"
       }
      }
     },
     "localname": "OtherCollaborationMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_OtherCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Customers [Member]",
        "label": "Other Customers [Member]",
        "terseLabel": "Others, individually less than 10% of Total revenues for all periods presented"
       }
      }
     },
     "localname": "OtherCustomersMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in Other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_OwnershipInterestByMinorityShareholder": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Minority Ownership, Ownership Interest",
        "label": "Ownership Interest By Minority Shareholder",
        "terseLabel": "Beneficial ownership interest by BlackRock (more than)"
       }
      }
     },
     "localname": "OwnershipInterestByMinorityShareholder",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_PerformanceSharesAchievedBeforeDecember312020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Shares, Achieved Before December 31, 2020 [Member]",
        "label": "Performance Shares, Achieved Before December 31, 2020 [Member]",
        "terseLabel": "PSUs, achieved before December 31, 2020"
       }
      }
     },
     "localname": "PerformanceSharesAchievedBeforeDecember312020Member",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_PerformanceSharesSecondProductApprovalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Shares, Second Product Approval [Member]",
        "label": "Performance Shares, Second Product Approval [Member]",
        "terseLabel": "PSUs, second product approval"
       }
      }
     },
     "localname": "PerformanceSharesSecondProductApprovalMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProbableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Probable [Member]",
        "label": "Probable [Member]",
        "terseLabel": "Probable"
       }
      }
     },
     "localname": "ProbableMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromCabozantinibMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Products Derived from Cabozantinib [Member]",
        "label": "Products Derived From Cabozantinib [Member]",
        "terseLabel": "Products Derived from Cabozantinib"
       }
      }
     },
     "localname": "ProductsDerivedFromCabozantinibMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_RelatedPartyTransactionsAdvisoryFeesIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transactions, Advisory Fees Incurred",
        "label": "Related Party Transactions, Advisory Fees Incurred",
        "terseLabel": "Fees for advisory services paid to BlackRock"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAdvisoryFeesIncurred",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transactions, Cash And Investments Managed By Minority Owner",
        "label": "Related Party Transactions, Cash And Investments Managed By Minority Owner",
        "terseLabel": "Fair value of cash and investments managed by BlackRock"
       }
      }
     },
     "localname": "RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund",
        "label": "Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund",
        "terseLabel": "Fair value of cash and investments managed by BlackRock in the BlackRock Liquidity Money Market Fund"
       }
      }
     },
     "localname": "RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ResearchandDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development [Member]",
        "label": "Research and Development [Member]",
        "terseLabel": "Research and development services revenues"
       }
      }
     },
     "localname": "ResearchandDevelopmentMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from Discovery Efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RightOfUseAssetAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right-of-Use Asset, Amortization",
        "label": "Right-Of-Use Asset, Amortization",
        "terseLabel": "Amortization and other changes in right-of-use assets"
       }
      }
     },
     "localname": "RightOfUseAssetAmortization",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_RightOfUseAssetObtainedInExchangeForLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_SalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sales Discounts And Allowances [Member]",
        "label": "Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "SalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value",
        "periodEndLabel": "RSUs outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released",
        "negatedLabel": "Vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested And Released In Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and released (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest",
        "terseLabel": "Maximum potential to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermAbstract",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status [Axis]",
        "label": "Status [Axis]",
        "terseLabel": "Status [Axis]"
       }
      }
     },
     "localname": "StatusAxis",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_StatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Status [Axis]",
        "label": "Status [Domain]",
        "terseLabel": "Status [Domain]"
       }
      }
     },
     "localname": "StatusDomain",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_TenantLeaseImprovementsAllowance": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tenant Lease Improvements, Allowance",
        "label": "Tenant Lease Improvements, Allowance",
        "negatedTerseLabel": "Tenant improvement reimbursements",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantLeaseImprovementsAllowance",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20190927",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "invest_InvestmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment [Line Items]",
        "terseLabel": "Investment [Line Items]"
       }
      }
     },
     "localname": "InvestmentLineItems",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "invest_InvestmentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment [Table]",
        "terseLabel": "Investment [Table]"
       }
      }
     },
     "localname": "InvestmentTable",
     "nsuri": "http://xbrl.sec.gov/invest/2013-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r123",
      "r178",
      "r183",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r121",
      "r178",
      "r181",
      "r309",
      "r310"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r122",
      "r178",
      "r182",
      "r311",
      "r316",
      "r318"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "verboseLabel": "ASU No. 2014-09"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r264"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "ASU No. 2016-02"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r30",
      "r164"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r47",
      "r49",
      "r50"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income (loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r46",
      "r50",
      "r53",
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r189",
      "r191",
      "r223",
      "r224"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r191",
      "r217",
      "r222"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Compensation expense",
        "verboseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive shares (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "Area of Real Estate Property",
        "terseLabel": "Area of lease property (in square feet)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r120",
      "r287",
      "r300"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r3",
      "r4",
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "verboseLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r129"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Investments available-for-sale, Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r130"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Investments available-for-sale, Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r127",
      "r147"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Investments, available-for-sale, Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r131",
      "r133",
      "r297"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r131",
      "r132",
      "r296"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r124",
      "r128",
      "r147"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Investments available-for-sale, Fair Value",
        "totalLabel": "Total investments available-for-sale",
        "verboseLabel": "Total investments available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r193",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred to acquire Property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r1",
      "r27",
      "r82"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r77",
      "r82",
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r77",
      "r263"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net (decrease) increase in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r233",
      "r234",
      "r236"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r37",
      "r168",
      "r293",
      "r306"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r16",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 303,776,032 and 299,876,080 at September 30, 2019 and December 31, 2018, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r56",
      "r58",
      "r59"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r112",
      "r113",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r112",
      "r113",
      "r261",
      "r262",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r112",
      "r113",
      "r261",
      "r262",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r112",
      "r113",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r112",
      "r113",
      "r261",
      "r262"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r242",
      "r247",
      "r249"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r172",
      "r174",
      "r179"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, Net, Current",
        "terseLabel": "Unbilled collaboration revenue"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r172",
      "r173",
      "r179"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Net contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r172",
      "r173",
      "r179"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "netLabel": "Deferred revenue",
        "terseLabel": "Long-term portion of deferred revenue",
        "verboseLabel": "Net contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r180"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Amount of revenues recognized included in the beginning contract liability balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Adoption of Accounting Standards Update No's. (2014-09 and 2016-02)"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r111"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r138",
      "r152",
      "r155"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "In an Unrealized Loss Position 12 Months or Greater, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": {
     "auth_ref": [
      "r138",
      "r152"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss",
        "negatedLabel": "In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months": {
     "auth_ref": [
      "r138",
      "r152",
      "r155"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months",
        "terseLabel": "In an Unrealized Loss Position Less than 12 Months, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss": {
     "auth_ref": [
      "r138",
      "r152"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, Less than 12 Months, Accumulated Loss",
        "negatedLabel": "In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r139"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain (Loss)",
        "terseLabel": "Gain (loss) on sales of investments available-for-sale"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r135",
      "r148",
      "r155"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "totalLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r136",
      "r149"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTotalLabel": "Total, Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r134",
      "r151",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r137",
      "r150"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r229"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r80",
      "r162"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation expense"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r80",
      "r118"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DueToRelatedPartiesCurrent": {
     "auth_ref": [
      "r32",
      "r92",
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Due to Related Parties, Current",
        "terseLabel": "Payable to BlackRock"
       }
      }
     },
     "localname": "DueToRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r96",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r295",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Net income per share, basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r96",
      "r99",
      "r100",
      "r101",
      "r102",
      "r105",
      "r295",
      "r308"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Net income per share, diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r91",
      "r227",
      "r228"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r227",
      "r228",
      "r230"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. federal statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r218"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted-average cost recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options",
        "verboseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r253",
      "r254",
      "r255",
      "r259"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r253",
      "r254"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r254",
      "r282"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r253",
      "r254",
      "r256",
      "r257",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r258"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r254",
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r254",
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r258",
      "r260"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r266",
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "exel_OperatingAndFinanceLeasesLiabilityTotal",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "totalLabel": "Financing obligation for build-to-suit lease"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Current portion included in Other current liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FinanceLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r142",
      "r143",
      "r144",
      "r145",
      "r146",
      "r151",
      "r153",
      "r154",
      "r155"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r237",
      "r246",
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfOtherInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) included in earnings for investments classified as other.",
        "label": "Gain (Loss) on Sale of Other Investments",
        "negatedLabel": "Gain on other equity investments"
       }
      }
     },
     "localname": "GainLossOnSaleOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r160",
      "r161"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r89",
      "r119",
      "r231"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 21.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "negatedLabel": "Current portion of unbilled collaboration revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Current and long-term deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 22.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other long-term assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 20.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other current and long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in receivables classified as other.",
        "label": "Increase (Decrease) in Other Receivables",
        "negatedLabel": "Other receivables"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherReceivables",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in Inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r159"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r42"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r2",
      "r42",
      "r157"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r158"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Write-downs on inventory"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r275",
      "r277"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Components of Lease Expense"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeFinanceLeasesTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for finance leases of lessee. Includes, but is not limited to, description of lessee's finance lease and maturity analysis of finance lease liability.",
        "label": "Lessee, Finance Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeFinanceLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Five",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Four",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.",
        "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year",
        "terseLabel": "Remainder of 2019"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r276"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Present value adjustment"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease option to extend period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r268"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails",
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r278"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "LEASES"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r288",
      "r303"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r77"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r77",
      "r78",
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r54",
      "r57",
      "r60",
      "r81",
      "r104",
      "r294",
      "r307"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net income",
        "totalLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "verboseLabel": "Other income (expense), net:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r270",
      "r277"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]",
        "terseLabel": "Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "exel_OperatingAndFinanceLeasesLiabilityTotal",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liabilities",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails",
      "http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Current portion included in Other current liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Long-term portion of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r267",
      "r272"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r265"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r274",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average operating discount rate used to determine the operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r273",
      "r277"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term for operating lease"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r0",
      "r94",
      "r117",
      "r250"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r55",
      "r58",
      "r240",
      "r241",
      "r243"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "totalLabel": "Total other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r47",
      "r51",
      "r52",
      "r140"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "terseLabel": "Reclassification adjustments to net income resulting from realized gains or losses on sale of securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r44",
      "r47"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Net unrealized gains or losses on available-for-sale securities, net of tax impact of $___, $0, $___ and $0, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r45",
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "negatedTerseLabel": "Unrealized gains or losses on available-for-sale securities, tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Accretion of investments, net and other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.",
        "label": "Other Receivables, Net, Current",
        "terseLabel": "Other receivables"
       }
      }
     },
     "localname": "OtherReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r126"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale",
        "terseLabel": "Other-than-temporary impairment charges on available-for-sale securities"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r68",
      "r72",
      "r125"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense (reversal of expense) for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Expense (Reversal of Expense), Noncash",
        "terseLabel": "401(k) matching contributions made in common stock"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "PSUs"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r3",
      "r25",
      "r26"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r68",
      "r69",
      "r125"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfOtherInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale and maturity (principal being due) of other investments, prepayment and call (request of early payment) of other investments not otherwise defined in the taxonomy.",
        "label": "Proceeds from Sale and Maturity of Other Investments",
        "terseLabel": "Proceeds from other equity investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfOtherInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r68",
      "r69",
      "r125"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "terseLabel": "Proceeds from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r74",
      "r220"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from employee stock purchase plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r30",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r167"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "PROPERTY AND EQUIPMENT"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r29",
      "r163"
     ],
     "calculation": {
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r165",
      "r305"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r163"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r17",
      "r21",
      "r304",
      "r315"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfLongTermCapitalLeaseObligations": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).",
        "label": "Repayments of Long-term Capital Lease Obligations",
        "negatedTerseLabel": "Principal payments on financing lease obligation"
       }
      }
     },
     "localname": "RepaymentsOfLongTermCapitalLeaseObligations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r226",
      "r319"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r1",
      "r10",
      "r86"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "verboseLabel": "Restricted cash included in short-term restricted cash and investments"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r5",
      "r13",
      "r86",
      "r317"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "terseLabel": "Long-term restricted cash and investments",
        "verboseLabel": "Restricted cash included in long-term restricted cash and investments"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r19",
      "r171",
      "r302"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r177",
      "r178"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r176"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r63"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "terseLabel": "Royalties accruing to GSK"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Computation of Basic and Diluted Net Income Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r191",
      "r216",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r191",
      "r216",
      "r222"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r9",
      "r22",
      "r23",
      "r24"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "verboseLabel": "RSU Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r30",
      "r165"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/PropertyAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r10",
      "r86",
      "r286",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r193",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r195",
      "r206",
      "r208"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "verboseLabel": "Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "verboseLabel": "Valuation Assumptions Used to Estimate Grant-Date Fair Value"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "verboseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64",
      "r156"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r205"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "RSUs awarded (in shares)",
        "verboseLabel": "Awarded (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "RSUs outstanding at end of period (in shares)",
        "periodStartLabel": "RSUs outstanding at beginning of period (in shares)",
        "terseLabel": "Product revenue related performance targets, shares vested and released (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "RSUs outstanding at end of period (in dollars per share)",
        "periodStartLabel": "RSUs outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted Average Grant Date Fair Value Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "verboseLabel": "RSUs outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "verboseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "verboseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r212"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "verboseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Exercisable at end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable at end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r201"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock": {
     "auth_ref": [
      "r207"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value [Table Text Block]",
        "terseLabel": "Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Options outstanding at end of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r197",
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding at end of period (in shares)",
        "periodStartLabel": "Options outstanding at beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r196"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options outstanding at end of period (in dollars per share)",
        "periodStartLabel": "Options outstanding at beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price Per Share"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r190",
      "r194"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails",
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "verboseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value [Abstract]",
        "terseLabel": "Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r211",
      "r221"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "verboseLabel": "Expected life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r219"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "verboseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Exercisable at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "verboseLabel": "Options outstanding at end of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r14",
      "r289",
      "r290",
      "r292",
      "r299"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r38",
      "r170"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Potentially dilutive securities"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r170",
      "r171"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r15",
      "r16",
      "r170",
      "r171",
      "r199"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r15",
      "r16",
      "r171",
      "r192",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r238",
      "r239",
      "r245"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEventsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "SUBSEQUENT EVENTS"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosure:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r235"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r186",
      "r291",
      "r313"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashAndInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r115",
      "r116"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at September 30, 2019",
        "periodStartLabel": "Balance at December 31, 2018"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r271",
      "r277"
     ],
     "calculation": {
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r102"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r98",
      "r102"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Shares used in computing net income per share, diluted (in shares)",
        "totalLabel": "Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r97",
      "r102"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Shares used in computing net income per share, basic (in shares)",
        "verboseLabel": "Weighted-average shares of common stock outstanding used in computing basic net income per share (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=SL6284422-111562"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27290-111563"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27337-111563"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922890-210455"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130531-203044"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130532-203044"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944033&loc=SL49130533-203044"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL108322424-203045"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130556-203045"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=d3e5291-111683"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02(b))",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03(b))",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=6488278&loc=d3e604059-122996"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=116631420&loc=SL116631458-115580"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r321": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r322": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-13"
  },
  "r323": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r324": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r325": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6812-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24092-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6851897712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Jun. 28, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="nump">6,024,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,024,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 13,139<span></span>
</td>
<td class="nump">$ 9,742<span></span>
</td>
<td class="nump">$ 40,747<span></span>
</td>
<td class="nump">$ 28,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average cost recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average cost recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,635,362<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Product revenue related performance targets, shares vested and released (in shares)</a></td>
<td class="nump">9,749,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,749,823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,857,334<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,926,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">693,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Product revenue related performance targets, shares vested and released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">114,843<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Product revenue related performance targets, shares vested and released (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,272<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">PSUs | Not Probable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="nump">$ 82,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member', window );">PSUs, achieved before December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest', window );">Maximum potential to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">963,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesSecondProductApprovalMember', window );">PSUs, second product approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest', window );">Maximum potential to vest (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,926,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other than Options, Maximum Number Of Shares To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_AchievedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_AchievedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_ProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_ProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_StatusAxis=exel_NotProbableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_StatusAxis=exel_NotProbableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesAchievedBeforeDecember312020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=exel_PerformanceSharesSecondProductApprovalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=exel_PerformanceSharesSecondProductApprovalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6634998832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 1,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,922<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">11,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,170<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">7,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,836<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">20,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Write-downs on inventory</a></td>
<td class="nump">400<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">13,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,838<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in Other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 6,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,090<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>exel2019093010-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:exel="http://www.exelixis.com/20190927"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:utreg="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20190927.xsd" xlink:type="simple"/>
    <context id="FD2019Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="I2019Q4Oct21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-10-21</instant>
        </period>
    </context>
    <context id="FI2019Q3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="D2018Q3YTD1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="I2018Q2Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-28</instant>
        </period>
    </context>
    <context id="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-28</instant>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="I2018Q3Sept28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2018-09-28</instant>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-29</instant>
        </period>
    </context>
    <context id="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-28</instant>
        </period>
    </context>
    <context id="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-30</instant>
        </period>
    </context>
    <context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-30</instant>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-30</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2017Q4Dec29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2017-12-29</instant>
        </period>
    </context>
    <context id="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-30</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromCabozantinibMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_IpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_IpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_MajorCustomersAxis_exel_ASDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_ASDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CabometyxMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CometriqMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResearchandDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:SalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:OtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_ProductGrossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_IpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_ASDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:CaremarkL.L.C.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:OtherCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_IpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_ASDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:ASDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_StatementGeographicalAxis_srt_EuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_StatementGeographicalAxis_country_JP">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="D2019Q3June_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-29</startDate>
            <endDate>2019-04-29</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="D2019Q3Jul01-Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-29</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="D2019Q2April28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-28</startDate>
            <endDate>2019-04-28</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementWithIconicTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="D2019Q3Jul01-Jul31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborationAgreementwithDaiichiSankyoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">exel:CashAndRestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">exel:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:ProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-12-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesSecondProductApprovalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">exel:PerformanceSharesAchievedBeforeDecember312020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2019Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:AchievedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:StatusAxis">exel:NotProbableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2018Q3YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-09-29</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-29</endDate>
        </period>
    </context>
    <context id="D2018Q3QTD1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-06-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="D2018Q3YTD1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-30</startDate>
            <endDate>2018-09-28</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-28</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="I2019Q2Apr30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-04-30</instant>
        </period>
    </context>
    <context id="D2017Q2May01-May31_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-01</startDate>
            <endDate>2017-05-31</endDate>
        </period>
    </context>
    <context id="I2019Q1_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="FD2019Q3YTD_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-29</startDate>
            <endDate>2019-09-27</endDate>
        </period>
    </context>
    <context id="FI2019Q3_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-27</instant>
        </period>
    </context>
    <context id="I2019Q3Aug30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-08-30</instant>
        </period>
    </context>
    <context id="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-25</startDate>
            <endDate>2019-10-25</endDate>
        </period>
    </context>
    <context id="I2019Q4Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">exel:AlamedaCaliforniaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-25</instant>
        </period>
    </context>
    <context id="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="exel:LeaseArrangementsAxis">exel:BuiltToSuitLeaseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-25</startDate>
            <endDate>2019-10-25</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="program">
        <measure>exel:program</measure>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="renewal_option">
        <measure>exel:renewal_option</measure>
    </unit>
    <unit id="sqft">
        <measure>utreg:sqft</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q3YTD"
      id="Fact-90130B52240754BFBD4ACE2FBAD7E75C-wk-Fact-90130B52240754BFBD4ACE2FBAD7E75C">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q3YTD"
      id="Fact-3366777BF46E510C98916E6DBFF07E96-wk-Fact-3366777BF46E510C98916E6DBFF07E96">--01-03</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q3YTD"
      id="Fact-05083A5D1DD353D0AA93885FBC19CF82-wk-Fact-05083A5D1DD353D0AA93885FBC19CF82">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q3YTD"
      id="Fact-B75A1E0C17D05C4AACEB9F0B2F6CC94E-wk-Fact-B75A1E0C17D05C4AACEB9F0B2F6CC94E">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q3YTD"
      id="Fact-053840D9B6F751719E957327AFBEC5B4-wk-Fact-053840D9B6F751719E957327AFBEC5B4">0000939767</dei:EntityCentralIndexKey>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-1FDCD14F45CC5DDBB2A28AED832BD909-wk-Fact-1FDCD14F45CC5DDBB2A28AED832BD909"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-B710FC8934175587AF2B96D5BC1010C9-wk-Fact-B710FC8934175587AF2B96D5BC1010C9"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6-wk-Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-1922FCA641AF522EB2B857F94C40B32B-wk-Fact-1922FCA641AF522EB2B857F94C40B32B"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-3A3CB57BA0E558FB978C7EE61115D8C2-wk-Fact-3A3CB57BA0E558FB978C7EE61115D8C2"
      unitRef="shares">299876080</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-31CB9B5A4D885F20BD244C1134369DE0-wk-Fact-31CB9B5A4D885F20BD244C1134369DE0"
      unitRef="shares">303776032</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-96FAB434AD8F5D11AC63A2E44BFB4D84-wk-Fact-96FAB434AD8F5D11AC63A2E44BFB4D84"
      unitRef="shares">299876080</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-00D22AC9AE5755A3AEDC259B91811B94-wk-Fact-00D22AC9AE5755A3AEDC259B91811B94"
      unitRef="shares">303776032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="Fact-2B848B92F5E56EF406510331C239084F-wk-Fact-2B848B92F5E56EF406510331C239084F"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="D2018Q3QTD1"
      decimals="-5"
      id="Fact-89333FE7A1C25B4F812199DA398B6464-wk-Fact-89333FE7A1C25B4F812199DA398B6464"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="D2018Q3YTD1"
      decimals="-5"
      id="Fact-DDB856B579565390995F04925F386F17-wk-Fact-DDB856B579565390995F04925F386F17"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="Fact-6D709DEE66015CAEA33BF3270CDBFA98-wk-Fact-6D709DEE66015CAEA33BF3270CDBFA98"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="Fact-89E76D54C2C55D51A3BEFF93D9C10C7F-wk-Fact-89E76D54C2C55D51A3BEFF93D9C10C7F"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q3QTD"
      decimals="INF"
      id="Fact-4F55382AC8DA2ED35112D0C88F397AE3-wk-Fact-4F55382AC8DA2ED35112D0C88F397AE3"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q3YTD"
      decimals="INF"
      id="Fact-869F531062DD2F3E86E5D0C88EADE9E1-wk-Fact-869F531062DD2F3E86E5D0C88EADE9E1"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q3QTD"
      decimals="INF"
      id="Fact-AD89F39D7093AD7E455AD0C88E8956DE-wk-Fact-AD89F39D7093AD7E455AD0C88E8956DE"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="FI2019Q3_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      id="Fact-0B86817CA6062DE64B51CA96F70810DE-wk-Fact-0B86817CA6062DE64B51CA96F70810DE">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="I2019Q4Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="Fact-62A9290A95E8C913316D0FCB77CCEF6E-wk-Fact-62A9290A95E8C913316D0FCB77CCEF6E">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="Fact-3EDD54626C9C5D5BA8022B8844B1CC2C-wk-Fact-3EDD54626C9C5D5BA8022B8844B1CC2C"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="Fact-26C5E255184058CC8EDA74308334DDD5-wk-Fact-26C5E255184058CC8EDA74308334DDD5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="Fact-4D436781DBF75309969FF24DBE49959D-wk-Fact-4D436781DBF75309969FF24DBE49959D"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="Fact-031FC6C6A04E50B183ED2F8F2DF8E98E-wk-Fact-031FC6C6A04E50B183ED2F8F2DF8E98E"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="Fact-7C09168D16E6596E8CC06D0F4194272F-wk-Fact-7C09168D16E6596E8CC06D0F4194272F"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="Fact-C13A23C74E0D50B8899D4B80905C37A9-wk-Fact-C13A23C74E0D50B8899D4B80905C37A9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="Fact-8BFBAF39D5A55A316236CE66326C799D-wk-Fact-8BFBAF39D5A55A316236CE66326C799D"
      unitRef="usd">129000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="Fact-CD99ECE0ABB48F441D26D07CA252D54D-wk-Fact-CD99ECE0ABB48F441D26D07CA252D54D"
      unitRef="usd">936000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="D2018Q3QTD1"
      decimals="INF"
      id="Fact-F10A5A5724F95A6E88E9152B5142BF9D-wk-Fact-F10A5A5724F95A6E88E9152B5142BF9D"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="FD2019Q3QTD"
      decimals="INF"
      id="Fact-945E5B89E1005230B183EE73474C6481-wk-Fact-945E5B89E1005230B183EE73474C6481"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-907BC12DCE8D570AA65EDF690CD8E735-wk-Fact-907BC12DCE8D570AA65EDF690CD8E735"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-0ADDFDCFD15F55CA8AE32B7B19DDA8C1-wk-Fact-0ADDFDCFD15F55CA8AE32B7B19DDA8C1"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-CB6AD27B04B2595487B5177029EF3D5F-wk-Fact-CB6AD27B04B2595487B5177029EF3D5F"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-04B8693E63295C078A1B5748BC974E54-wk-Fact-04B8693E63295C078A1B5748BC974E54"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-07C6863E94BD55FABFECD845862794AE-wk-Fact-07C6863E94BD55FABFECD845862794AE"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q3"
      decimals="INF"
      id="Fact-F2662FA093745F70ACC49E2965E5C26B-wk-Fact-F2662FA093745F70ACC49E2965E5C26B"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-3"
      id="Fact-EB65A169AB0056192321F054FD5A5BDA-wk-Fact-EB65A169AB0056192321F054FD5A5BDA"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-3"
      id="Fact-CAD46E175A261649DB4EF054FAC96D9C-wk-Fact-CAD46E175A261649DB4EF054FAC96D9C"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <dei:DocumentType
      contextRef="FD2019Q3YTD"
      id="d143643716e440-wk-Fact-0947692385925B2DAD330D67576A8B6B">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="FD2019Q3YTD"
      id="d143643716e455-wk-Fact-648A81E047945122AFBDD0940B304D32">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q3YTD"
      id="d143643716e466-wk-Fact-4AA11BE69C615394BC8BEC576A9D1C88">2019-09-27</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q3YTD"
      id="d143643716e486-wk-Fact-A5FFAB5F4E655408BFD88CDED46FDE00">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q3YTD"
      id="d143643716e496-wk-Fact-4F10F9B88F845547B803E2D15061B0F4">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q3YTD"
      id="d143643716e518-wk-Fact-9E49C76B87615DE5AB10DCDD38DF8350">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q3YTD"
      id="d143643716e539-wk-Fact-7E66EEF6246359F19FEE3E38C626299C">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q3YTD"
      id="d143643716e544-wk-Fact-FB594FE10E6F5FB2BAC07CDEC387B865">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q3YTD"
      id="d143643716e559-wk-Fact-613513231A605E758D52D2C87371D223">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q3YTD"
      id="d143643716e565-wk-Fact-DB3EDB6DE6D3571BA680690FD90F3B0F">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q3YTD"
      id="d143643716e570-wk-Fact-D5E816E5648352B1AD99C65627F8D63A">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q3YTD"
      id="d143643716e575-wk-Fact-457A7E5EE0C958A58B6D609F030946F2">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q3YTD"
      id="d143643716e583-wk-Fact-64DEE6063C1E5631A737EB2BCA7EB2F4">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q3YTD"
      id="d143643716e588-wk-Fact-CDEDB53CCB5F51FC98BDFF92DBA8575A">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q3YTD"
      id="d143643716e629-wk-Fact-9E44922ABA7B55CBBBBCBBB2865A8D00">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q3YTD"
      id="d143643716e634-wk-Fact-9FEC905BCB8C5069A98350CB6B087349">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q3YTD"
      id="d143643716e639-wk-Fact-5D77922F9575547DBC612413AEECDAF3">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q3YTD"
      id="d143643716e644-wk-Fact-80711FE3D50C56AFA2A28ED97311F4F4">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q3YTD"
      id="d143643716e658-wk-Fact-848F3D5780D6538AA5062FD31B926B61">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q3YTD"
      id="d143643716e689-wk-Fact-5072A390211254CC89E7758685961739">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q3YTD"
      id="d143643716e740-wk-Fact-0F4FC365BC8356E08E79997FD59E82E1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q3YTD"
      id="d143643716e756-wk-Fact-B2F201B0B60F547594695F36EC4DD997">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q3YTD"
      id="d143643716e787-wk-Fact-C32EC84BEA8C5E65B63BB67382F191C8">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2019Q4Oct21"
      decimals="INF"
      id="d143643716e803-wk-Fact-9A3A41EE03765EE9BD8FE68B8ABB4E8C"
      unitRef="shares">303846306</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e578-wk-Fact-A2EF7BBAD72B5637A44FD42AF030F687"
      unitRef="usd">242317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e597-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7"
      unitRef="usd">314775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e612-wk-Fact-DE84CF33BB8D5292B41A416DCC90F33B"
      unitRef="usd">518350000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e631-wk-Fact-1B51FFE1147D5FE58E267C0E99DF0679"
      unitRef="usd">378559000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e651-wk-Fact-83BBDD0E14E05765B6C5DE136BF6A307"
      unitRef="usd">169788000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e670-wk-Fact-3E92163B9BE350AFB9540EBCDF6E7BE5"
      unitRef="usd">162771000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e690-wk-Fact-2E9292B583955A37BC811559AF1B0691"
      unitRef="usd">13801000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e709-wk-Fact-669EC1AB746A532489CA1474200178BF"
      unitRef="usd">16056000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e729-wk-Fact-D00F652C36A35B91801D7220E8E4CDBA"
      unitRef="usd">13366000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e748-wk-Fact-1CAD89A8AC4D5908802B975A1F373BBD"
      unitRef="usd">9838000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e768-wk-Fact-1E3B4536FB115AAFA275875AF72AB3A4"
      unitRef="usd">14490000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e787-wk-Fact-4755812CBC2651E2944688760840B953"
      unitRef="usd">15017000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e807-wk-Fact-568AE2AA79865175913CD8D815AFACC4"
      unitRef="usd">972112000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e826-wk-Fact-C2EB0F1D2C255F8E9B07698707668AA7"
      unitRef="usd">897016000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e846-wk-Fact-0C4D822199D15923A75EABD87BF6CEA1"
      unitRef="usd">486763000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e865-wk-Fact-70884DAF9D095D6F8EC7BDABD302EE15"
      unitRef="usd">157187000</us-gaap:LongTermInvestments>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e886-wk-Fact-B89A41F9770A5B909B2A62EEA3EE1ACC"
      unitRef="usd">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e905-wk-Fact-3F4129D37BE15987B315F13735F8FDBE"
      unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e925-wk-Fact-FFFCB7E5E0345888A600381F271F9035"
      unitRef="usd">49467000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e944-wk-Fact-C991BEDAA3F551B189FD2DED431834BC"
      unitRef="usd">50897000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e964-wk-Fact-11CD05BE41DC52F5A55F2028C864E6CD"
      unitRef="usd">17735000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e983-wk-Fact-85CE777F29DC5425AE5D2A1350EB3BAA"
      unitRef="usd">5867000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1003-wk-Fact-53B988AA586F51348268E4E070AD000E"
      unitRef="usd">186836000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1022-wk-Fact-E9FEA5177DA65B4C95480E3130D8839E"
      unitRef="usd">244111000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1042-wk-Fact-3CBF36F5437E5E64BFA89138571F020C"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1061-wk-Fact-4FA0D3DD22145129854A4C161726D0EC"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1081-wk-Fact-6CB28A01D6A9552C850A0AFD5FCD1B6A"
      unitRef="usd">7268000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1100-wk-Fact-3AF94EE58E535745846C93F98A4BA069"
      unitRef="usd">2424000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1125-wk-Fact-624AE281FEA75EEDB44208DD232226D5"
      unitRef="usd">1784865000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1144-wk-Fact-D20CC27ECE3A55B7A4EF8855DB4C6203"
      unitRef="usd">1422286000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1246-wk-Fact-BAF5EB4FC9485D2981589A0B8D8381F1"
      unitRef="usd">8352000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1265-wk-Fact-FC51C4202CA358D68E09A0F06F4AFD5E"
      unitRef="usd">10901000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1280-wk-Fact-6C8244381F905DE29971505CD97B7428"
      unitRef="usd">31713000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1299-wk-Fact-4E0A79CE4D22556C8CD82B6BFF283BEC"
      unitRef="usd">32142000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1320-wk-Fact-54F45C96743C5B8788A863C0311CA4E2"
      unitRef="usd">30330000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1339-wk-Fact-6C00EBF1ABD15088AAA6675B42373AEB"
      unitRef="usd">18231000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1359-wk-Fact-69FF45101EA655E5A48BA56AE8B9206D"
      unitRef="usd">16782000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1378-wk-Fact-DE1420696CD35A0DAC8D9C5F03CA227C"
      unitRef="usd">14954000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1398-wk-Fact-E59061B9E9405DEEA4FA05B5F49C32F7"
      unitRef="usd">7973000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1417-wk-Fact-9E5F11DE05B3550581DF7177D9B31246"
      unitRef="usd">7419000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1437-wk-Fact-E31153978311579A82147506D2EE97E4"
      unitRef="usd">45919000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1456-wk-Fact-7F0E267AC54F587AA0AFE7D5EBC39566"
      unitRef="usd">21825000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1476-wk-Fact-A869D86B20D3598D9A4EA8A309A82937"
      unitRef="usd">141069000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1495-wk-Fact-54D1CCCBA98756C59B50269447F29C65"
      unitRef="usd">105472000</us-gaap:LiabilitiesCurrent>
    <exel:OperatingAndFinanceLeasesLiabilityLongTerm
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1515-wk-Fact-4315B0293B5E519E9FEF2A0ED4B9280B"
      unitRef="usd">23705000</exel:OperatingAndFinanceLeasesLiabilityLongTerm>
    <exel:OperatingAndFinanceLeasesLiabilityLongTerm
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1534-wk-Fact-3B8C779DD1845402B360FDB026EE42CF"
      unitRef="usd">12178000</exel:OperatingAndFinanceLeasesLiabilityLongTerm>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1554-wk-Fact-33F7C8BE5DCD53C38384E77B5BDF1564"
      unitRef="usd">15399000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1573-wk-Fact-A224167B234059F188989D11E3324BC2"
      unitRef="usd">15897000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1593-wk-Fact-834F5FF4D4A1571494944FFC2649A5B4"
      unitRef="usd">975000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1612-wk-Fact-2B3D678BFB975C4D9FE3267DC25A4C4F"
      unitRef="usd">1286000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1632-wk-Fact-1A4DA437F0AE51969B9EB6139327951D"
      unitRef="usd">181148000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1651-wk-Fact-96ECA7A9CBA75A7ABDD94D5CA8925270"
      unitRef="usd">134833000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q3"
      id="d143645401e1671-wk-Fact-81AFE926392A55F799DF22FB90346128"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d143645401e1690-wk-Fact-6239E69403E55431B38A5B9E7597A2AE"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1752-wk-Fact-377CC9EDE0095E5FA6E0AE25E341FB29"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1771-wk-Fact-E48A728D16DA58FC9EC32263F9980934"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1791-wk-Fact-DCF649A807B7563191A726C436C2D529"
      unitRef="usd">304000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1810-wk-Fact-4B15B67A4563571C963E04A7E55BE47A"
      unitRef="usd">300000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1830-wk-Fact-99D5EE0577DD50D3A476BCE9F5225236"
      unitRef="usd">2228839000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1849-wk-Fact-F6C33F96BF935687A3F2657317EA8820"
      unitRef="usd">2168217000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1869-wk-Fact-8CAAA9D2E560596B96A1F1120873A265"
      unitRef="usd">2668000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1888-wk-Fact-3312CFD2A55C599E9B2030A1E7EF75BC"
      unitRef="usd">-701000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1909-wk-Fact-EB3BCB4D59F8580E9662F587003C8484"
      unitRef="usd">-628094000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1929-wk-Fact-73F0483E60EE53B29E4058F0AF045381"
      unitRef="usd">-880363000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1950-wk-Fact-291D88D306F657CDA774FA58C8EF7E56"
      unitRef="usd">1603717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e1969-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC"
      unitRef="usd">1287453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143645401e1994-wk-Fact-EDBBA10C3DB15245A79DF77EFA3B737F"
      unitRef="usd">1784865000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143645401e2013-wk-Fact-B0DA545136C555089C9EDE3307AB7DE0"
      unitRef="usd">1422286000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655124e707-wk-Fact-13C7A41F37725EB8B706C7A807584BBF"
      unitRef="usd">191768000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655124e726-wk-Fact-A3A260830AF7574094095B1E462A1635"
      unitRef="usd">162946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655124e745-wk-Fact-F0EFE7C281A95AD9B2D218FBA067F5D0"
      unitRef="usd">565024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655124e765-wk-Fact-2BCECF9B512F5FD6A12DE4E58A50DD70"
      unitRef="usd">443054000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d143655124e780-wk-Fact-43C7D839ACFA5CC29516954B25CA6CBF"
      unitRef="usd">79935000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d143655124e799-wk-Fact-E4ED43C9E7AC58B1A6BE7BF6E14F1B33"
      unitRef="usd">62451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d143655124e818-wk-Fact-95EF234B5DB954128FB68B0CD9D59DE3"
      unitRef="usd">162441000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d143655124e838-wk-Fact-FE403DC09F4A52B38F68D10219F89E45"
      unitRef="usd">182170000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e858-wk-Fact-0FD3BD1F4272593786021250887B7DCA"
      unitRef="usd">271703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e877-wk-Fact-E6B3BE7A5FD954AE933CF2B974B2DDA6"
      unitRef="usd">225397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e896-wk-Fact-7654B036962C5DE7B24FDFD8B0563694"
      unitRef="usd">727465000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e916-wk-Fact-2CB1AC25C2D25B03AD4E742BBB6610B2"
      unitRef="usd">625224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1018-wk-Fact-1040DACBC5725452A3C835D49E28C7C9"
      unitRef="usd">7537000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1037-wk-Fact-A6C99693899052FDA3B647CBE6E6CC75"
      unitRef="usd">7360000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1056-wk-Fact-27C0B897CDF551DA8F025B5960727005"
      unitRef="usd">22577000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1076-wk-Fact-EA40B67CC7F8502EBDA0F7E754048B4E"
      unitRef="usd">18996000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1096-wk-Fact-501D21B52F4156ACA18A28167EA19345"
      unitRef="usd">97295000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1115-wk-Fact-54D4F40502885CB2B29829CB3C9E20F3"
      unitRef="usd">44741000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1134-wk-Fact-0CC5349F94BF59F79C800F76C9B4997B"
      unitRef="usd">242516000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1154-wk-Fact-B47DDBAE42C35E7DBF42355EFEAA0A94"
      unitRef="usd">124986000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1174-wk-Fact-F16D75F287165F17AFA8B08BF64BD572"
      unitRef="usd">51265000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1193-wk-Fact-186335E0A0DA5725BAF0FAF7A9816159"
      unitRef="usd">48120000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1212-wk-Fact-1641454E46BF5E7FBAA5A5C7040FD34A"
      unitRef="usd">170218000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1232-wk-Fact-F71A419FE7245EF798793D32DEFAF9B0"
      unitRef="usd">153989000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1252-wk-Fact-7C248C1DBA7957F8BB746B76ABD22308"
      unitRef="usd">156097000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1271-wk-Fact-7D9A48DFF66957B895FBB046FB88B08B"
      unitRef="usd">100221000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1290-wk-Fact-2B6A170BD4EE59558CB444786FE6F299"
      unitRef="usd">435311000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1310-wk-Fact-ECA5FBBE64E058DE931990EC3350C8AF"
      unitRef="usd">297971000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1331-wk-Fact-B5FCD4A5AE635DDB878619B8322C4073"
      unitRef="usd">115606000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1350-wk-Fact-21E5C4CA204357FDAB0DDE12D68649AC"
      unitRef="usd">125176000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1369-wk-Fact-62A6CEE6EA2852AA9D1F3BEEC6B0FFFE"
      unitRef="usd">292154000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1389-wk-Fact-7D3EC453912D5473AC5486F8533DAC1A"
      unitRef="usd">327253000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1491-wk-Fact-CC812B7FA6CD58CAB275DE294D6E6443"
      unitRef="usd">7191000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1510-wk-Fact-977DE8F1A4B457EE8F4651EC066072FC"
      unitRef="usd">3507000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1529-wk-Fact-8D3C455B40825FFD9EF34AFA95720BE1"
      unitRef="usd">20253000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1549-wk-Fact-6EB78E55B2BB55B3B07C6D495ED7101B"
      unitRef="usd">8099000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1569-wk-Fact-99B049136B755D258ABEA56A97B528AA"
      unitRef="usd">-140000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1589-wk-Fact-6F969AA8BB7F5796AC737B0AF3155742"
      unitRef="usd">271000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1608-wk-Fact-FD6AB4A4D20E54D1ACCCCE70D92F8F62"
      unitRef="usd">688000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1628-wk-Fact-EC5DFF30A0C95BB5A356815B80814FA9"
      unitRef="usd">368000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1648-wk-Fact-F4596684920F5D09AE1591417E204F35"
      unitRef="usd">7051000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1667-wk-Fact-1F8CD777EDA75CF985EF902AD9D43634"
      unitRef="usd">3778000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1686-wk-Fact-71ED33DE8D025B79A4D19BE192C9C489"
      unitRef="usd">20941000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1706-wk-Fact-D5E2DF139D95506A96E80E6A2FE283F5"
      unitRef="usd">8467000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1726-wk-Fact-C7FEB46C50EF5D3488F91BC91A00C656"
      unitRef="usd">122657000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1745-wk-Fact-B28446BB5A775A578C14872234E8C7C3"
      unitRef="usd">128954000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1764-wk-Fact-07565F9CFD945B28B54122733E720D63"
      unitRef="usd">313095000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1784-wk-Fact-66E55983DD10518C96D2A3FA0EEAEB4D"
      unitRef="usd">335720000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1804-wk-Fact-D0F0357F5C845FC9A880552A5A9AFF5C"
      unitRef="usd">25205000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1824-wk-Fact-0B63F71E65D956AAAA459E920911C33E"
      unitRef="usd">2324000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1844-wk-Fact-03AEC7D5BAE05D13AC03CF5AD71E0ABE"
      unitRef="usd">60826000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1865-wk-Fact-C64E4939D7A055968A6A9FC2E64E3597"
      unitRef="usd">5739000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e1891-wk-Fact-33514420391A5101991C7BB7C90293A3"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e1910-wk-Fact-8C3C2FC35F795107AAE02B8C4A08884B"
      unitRef="usd">126630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e1929-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e1949-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3"
      unitRef="usd">329981000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d143655124e1969-wk-Fact-46B6F1340B325926B636C2196DE13C68"
      unitRef="usdPerShare">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q3QTD1"
      decimals="2"
      id="d143655124e1988-wk-Fact-8CA9C79F88205827970EA61D11A2992D"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d143655124e2007-wk-Fact-B75F2EEA889D5D88A99E107841855D59"
      unitRef="usdPerShare">0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q3YTD1"
      decimals="2"
      id="d143655124e2027-wk-Fact-19D1A4B42FA550EDB8287A92F1203E8E"
      unitRef="usdPerShare">1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d143655124e2047-wk-Fact-85C96FDDE2775831935EC174B4BAB3AC"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q3QTD1"
      decimals="2"
      id="d143655124e2066-wk-Fact-9472515601E8583EB376A8ADDF708C8C"
      unitRef="usdPerShare">0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d143655124e2085-wk-Fact-9C881D80109855308725A2DA072883D8"
      unitRef="usdPerShare">0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q3YTD1"
      decimals="2"
      id="d143655124e2105-wk-Fact-68993515AEDD56A8994B919BD2AB4430"
      unitRef="usdPerShare">1.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e2120-wk-Fact-B2460438003B573BB27D88592E43DFF0"
      unitRef="shares">303268000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e2139-wk-Fact-904A3CF19F5155C896687A434A608ABA"
      unitRef="shares">298416000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e2158-wk-Fact-F68635B2F0675E93843E7DCBDB37B465"
      unitRef="shares">301999000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e2178-wk-Fact-40A13BFAEDB552D8A32F7A6DB7E3A3FB"
      unitRef="shares">297700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655124e2199-wk-Fact-EEF4AE03E94B5C6E8E384202B0413F9A"
      unitRef="shares">315453000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655124e2218-wk-Fact-A9F1D9BC443D55E599B95686A10E4AEC"
      unitRef="shares">312346000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655124e2237-wk-Fact-B53428C464DB589AB5C824036B2F50A4"
      unitRef="shares">315046000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655124e2257-wk-Fact-6BD2776EB4935083A5A3E0C2DAA2ADAD"
      unitRef="shares">313200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143642947e625-wk-Fact-33514420391A5101991C7BB7C90293A3"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143642947e644-wk-Fact-8C3C2FC35F795107AAE02B8C4A08884B"
      unitRef="usd">126630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143642947e663-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143642947e683-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3"
      unitRef="usd">329981000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143642947e782-wk-Fact-D2CF652C6C6D541A8E57A47FBBD0AC49"
      unitRef="usd">461000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143642947e801-wk-Fact-F2E10EF5A2AA516EA18DC933946B00C4"
      unitRef="usd">218000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143642947e820-wk-Fact-22BD4054D3175141A024292FEF769ABE"
      unitRef="usd">3369000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143642947e840-wk-Fact-14E885DDB89252BF889F99D9D6F1341F"
      unitRef="usd">-166000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143642947e861-wk-Fact-42C46533EF0F5580AF0F69FA40565357"
      unitRef="usd">461000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143642947e880-wk-Fact-A0EF5891DC8151329B09346C90B42E7C"
      unitRef="usd">218000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143642947e899-wk-Fact-BDB33C7513E253C2BE77D94960FA67B6"
      unitRef="usd">3369000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143642947e919-wk-Fact-55B07392D26E5C4BAC3CB1A720BF2D7D"
      unitRef="usd">-166000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143642947e945-wk-Fact-229A18181488526EB628D9D23E03C30B"
      unitRef="usd">97913000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143642947e964-wk-Fact-F0D3EEB92CBE5732BD1182D396BAA157"
      unitRef="usd">126848000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143642947e983-wk-Fact-D2B8CF4E77B557A88052BA91F1A3E685"
      unitRef="usd">255638000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143642947e1003-wk-Fact-7D509D8DF6295AF2AB5343AA48390628"
      unitRef="usd">329815000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e818-wk-Fact-4619E8D81EDA54B7BEC12DDE76FCB237"
      unitRef="shares">302784854</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e837-wk-Fact-01180DF9A0285919B8025863814D970F"
      unitRef="usd">303000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e856-wk-Fact-649912CA37405B528593B8694925B0E4"
      unitRef="usd">2211668000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e876-wk-Fact-11A14997562C5F0AA1C4F7571A5B71CA"
      unitRef="usd">2207000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e895-wk-Fact-AED4EF1FF22D57E59BA14DCB146C83B7"
      unitRef="usd">-725546000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q2"
      decimals="-3"
      id="d143661439e915-wk-Fact-F1096C017F4F5B3E8319B344E8C92CE4"
      unitRef="usd">1488632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e1003-wk-Fact-5855043CE04C520DB2B19C0C582C8A3A"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143661439e1022-wk-Fact-33514420391A5101991C7BB7C90293A3"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e1096-wk-Fact-8B737285773A59A79849185C62CE926A"
      unitRef="usd">461000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143661439e1134-wk-Fact-42C46533EF0F5580AF0F69FA40565357"
      unitRef="usd">461000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e1155-wk-Fact-5269AD6ECE1955B1805BE730A0D38AF9"
      unitRef="shares">991178</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e1169-wk-Fact-2662AF1346F5595EA81EE5913B2FD410"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e1188-wk-Fact-956BA4354A4355AFA54644096B4894CE"
      unitRef="usd">4032000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143661439e1246-wk-Fact-6230E729206F5DC0BA7EEEAB22A9CEBC"
      unitRef="usd">4033000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3QTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e1300-wk-Fact-891410A9CB9651F2B4D8C1FFB83D926F"
      unitRef="usd">13139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143661439e1358-wk-Fact-617542DC16245F4CA4242DE5C3D79100"
      unitRef="usd">13139000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e1379-wk-Fact-7EC834A569625A1B81609C657AFF887E"
      unitRef="shares">303776032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e1398-wk-Fact-364A7A384A1E5756BA4390788275FFCE"
      unitRef="usd">304000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e1417-wk-Fact-796CD10F471E510CA705967C74048E7E"
      unitRef="usd">2228839000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e1437-wk-Fact-1ACA01126D17538F984029B56B84C7D3"
      unitRef="usd">2668000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e1456-wk-Fact-132D1A65F37557259B9A139D2EE245D7"
      unitRef="usd">-628094000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143661439e1476-wk-Fact-291D88D306F657CDA774FA58C8EF7E56"
      unitRef="usd">1603717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e1878-wk-Fact-5FADB7CC78C55B289AC3F82B5860C4B7"
      unitRef="shares">297892180</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e1897-wk-Fact-1290069A15DC55669A72898D0DB710B3"
      unitRef="usd">298000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e1916-wk-Fact-6570CACADE1E532385475A9E5006FC87"
      unitRef="usd">2142717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e1936-wk-Fact-6BB849B56179540B8B9B0E7F861A876D"
      unitRef="usd">-731000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q2Q2_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e1956-wk-Fact-FB45F43B11AF553893F216D03A878985"
      unitRef="usd">-1367082000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q2Q2"
      decimals="-3"
      id="d143661439e1976-wk-Fact-077DC83554FF5ED18CDE9430B51FCA08"
      unitRef="usd">775202000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e2064-wk-Fact-A07B8E7BCF5250099339ADE1C0893643"
      unitRef="usd">126630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143661439e2083-wk-Fact-8C3C2FC35F795107AAE02B8C4A08884B"
      unitRef="usd">126630000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e2157-wk-Fact-E76966D4F0D65E8492CC3DC02FB32121"
      unitRef="usd">218000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143661439e2195-wk-Fact-A0EF5891DC8151329B09346C90B42E7C"
      unitRef="usd">218000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e2216-wk-Fact-91435A8C81B151E3A9EAAB10802180D2"
      unitRef="shares">989704</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e2230-wk-Fact-6350E2F90ED3574198A9D84019D808A6"
      unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e2249-wk-Fact-C8635E38EAB2540FAF3232CCE0592844"
      unitRef="usd">4173000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143661439e2307-wk-Fact-AF67670B54FF517F8353D911F4F044DB"
      unitRef="usd">4174000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q3QTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e2361-wk-Fact-656BD245D14558019945D130F7655FEF"
      unitRef="usd">9742000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143661439e2419-wk-Fact-E255EF32B7595B29BB086179A59EF398"
      unitRef="usd">9742000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e2440-wk-Fact-44B1C45FFE7F5AF8B1E901BCA36F197B"
      unitRef="shares">298881884</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e2459-wk-Fact-35413FCEA78C59EFB742CEC6F16EEC2D"
      unitRef="usd">299000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e2478-wk-Fact-C105955B95FB5EF484C9CBB20DEABF16"
      unitRef="usd">2156632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e2498-wk-Fact-D6A2AD306E0352249DE89DBFDE5CB6CF"
      unitRef="usd">-513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e2518-wk-Fact-55D098EC8F4655E9828CA9E80730E462"
      unitRef="usd">-1240452000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28"
      decimals="-3"
      id="d143661439e2538-wk-Fact-CA55498B92C8585699BDCD209B6F0E65"
      unitRef="usd">915966000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e2957-wk-Fact-625BFFA518245725A183C6FE9C3EFE6F"
      unitRef="shares">299876080</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e2976-wk-Fact-3C0B3749D8055ED2BA0DE9DD87136772"
      unitRef="usd">300000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e2995-wk-Fact-25B89238DEC55D12B0248BCB672178DD"
      unitRef="usd">2168217000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e3015-wk-Fact-CCC753FF6F6853E6AF5C00D10B13ECEE"
      unitRef="usd">-701000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e3035-wk-Fact-A8D214661D475B3EA384D32B751DA4FE"
      unitRef="usd">-880363000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143661439e3055-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC"
      unitRef="usd">1287453000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e3143-wk-Fact-73F2E1010E9E5B65BC56E3AE0F7EECDB"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143661439e3162-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e3236-wk-Fact-B339D38806D15E84B4E13455D106521F"
      unitRef="usd">3369000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143661439e3274-wk-Fact-BDB33C7513E253C2BE77D94960FA67B6"
      unitRef="usd">3369000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e3295-wk-Fact-C0954B46F062518FA4AF10D6E8D6AC7B"
      unitRef="shares">3899952</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e3309-wk-Fact-AB512F97D4D75C5FA3F84216159110B0"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e3328-wk-Fact-1849FCB53FD35C9DB363B0C0B26A9868"
      unitRef="usd">19875000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143661439e3386-wk-Fact-781A819FB85454869F7F0D40145E664C"
      unitRef="usd">19879000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e3440-wk-Fact-7E61155DC064575C96F5E3CBD8E292AA"
      unitRef="usd">40747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143661439e3498-wk-Fact-8C90F5C2E32752AF80256DE9C422D45C"
      unitRef="usd">40747000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e3519-wk-Fact-7EC834A569625A1B81609C657AFF887E"
      unitRef="shares">303776032</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e3538-wk-Fact-364A7A384A1E5756BA4390788275FFCE"
      unitRef="usd">304000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e3557-wk-Fact-796CD10F471E510CA705967C74048E7E"
      unitRef="usd">2228839000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e3577-wk-Fact-1ACA01126D17538F984029B56B84C7D3"
      unitRef="usd">2668000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e3596-wk-Fact-132D1A65F37557259B9A139D2EE245D7"
      unitRef="usd">-628094000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143661439e3616-wk-Fact-291D88D306F657CDA774FA58C8EF7E56"
      unitRef="usd">1603717000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e4018-wk-Fact-7D9E00B98E4D5A68B824D5FF2D29BF2D"
      unitRef="shares">296209426</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e4037-wk-Fact-AD851AF0FB82520BAB83C473AF7F98C8"
      unitRef="usd">296000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e4056-wk-Fact-01C3DE3AAEFE5ABF8D547DE618D1E60A"
      unitRef="usd">2114184000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e4076-wk-Fact-C0E7B2AC014A5AEEA51163D5956C8922"
      unitRef="usd">-347000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e4096-wk-Fact-B3BF93EF26A65E91B9DB33297F326F3F"
      unitRef="usd">-1829172000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d143661439e4116-wk-Fact-ED274640F9F05D9687CA48894B15D11E"
      unitRef="usd">284961000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e4206-wk-Fact-759CBD1B3CDD5D4AAE5CBFD654C59CCF"
      unitRef="usd">258505000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member"
      decimals="-3"
      id="d143661439e4225-wk-Fact-604D4D268A705CCF94A8B9A68FAACA41"
      unitRef="usd">258505000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e4320-wk-Fact-2B2F0C25548C5C7B9D7CF3804B4C9F10"
      unitRef="usd">234000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Dec30_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-3"
      id="d143661439e4339-wk-Fact-A5D08D038E455D10A6DC6ABA1BE4F375"
      unitRef="usd">234000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e4432-wk-Fact-178E54675B945C1FA2CDC23FC869B647"
      unitRef="usd">329981000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143661439e4451-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3"
      unitRef="usd">329981000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e4525-wk-Fact-B6A273DD059158BF839EBF5994DC9CC1"
      unitRef="usd">-166000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143661439e4564-wk-Fact-55B07392D26E5C4BAC3CB1A720BF2D7D"
      unitRef="usd">-166000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e4586-wk-Fact-A0294D8CD23B51EBB25B3E729417E583"
      unitRef="shares">2672458</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e4600-wk-Fact-8117B4420F9E5556A35F6DE3764FF2F6"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e4619-wk-Fact-296B001AED85573AA8CD6952BE3B0C85"
      unitRef="usd">14118000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143661439e4677-wk-Fact-6829711E71975372B8CB130B68009480"
      unitRef="usd">14121000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q3YTD1_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e4731-wk-Fact-93E8EB80662A5508AAB75C178F78488D"
      unitRef="usd">28330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143661439e4789-wk-Fact-870BA21CAABF574FA5AB8F544790AC7D"
      unitRef="usd">28330000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d143661439e4810-wk-Fact-44B1C45FFE7F5AF8B1E901BCA36F197B"
      unitRef="shares">298881884</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-3"
      id="d143661439e4829-wk-Fact-35413FCEA78C59EFB742CEC6F16EEC2D"
      unitRef="usd">299000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-3"
      id="d143661439e4848-wk-Fact-C105955B95FB5EF484C9CBB20DEABF16"
      unitRef="usd">2156632000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-3"
      id="d143661439e4868-wk-Fact-D6A2AD306E0352249DE89DBFDE5CB6CF"
      unitRef="usd">-513000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-3"
      id="d143661439e4888-wk-Fact-55D098EC8F4655E9828CA9E80730E462"
      unitRef="usd">-1240452000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="I2018Q3Sept28"
      decimals="-3"
      id="d143661439e4908-wk-Fact-CA55498B92C8585699BDCD209B6F0E65"
      unitRef="usd">915966000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e536-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e555-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3"
      unitRef="usd">329981000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e611-wk-Fact-FADF3F9D623359CC8E397C4AEE68F0BB"
      unitRef="usd">6088000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e630-wk-Fact-687DC0EC7A055328985CC13FAEAC3F60"
      unitRef="usd">2876000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e650-wk-Fact-379233D815EA540D9711C40F0F0DEBDD"
      unitRef="usd">40747000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e669-wk-Fact-14830A2EDC8D59AAA0490B01504C27C9"
      unitRef="usd">28330000</us-gaap:ShareBasedCompensation>
    <us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e689-wk-Fact-64FEA128A25F5444ACD024AF5243408D"
      unitRef="usd">4079000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
    <us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e708-wk-Fact-3C49F038EE165E97B146594DD3A7BA9F"
      unitRef="usd">3232000</us-gaap:PensionAndOtherPostretirementBenefitsExpenseReversalOfExpenseNoncash>
    <exel:RightOfUseAssetAmortization
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e728-wk-Fact-9FA4A7DE7DBF535DB3030DA3BA26EF91"
      unitRef="usd">-6367000</exel:RightOfUseAssetAmortization>
    <exel:RightOfUseAssetAmortization
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e748-wk-Fact-5299E0C1830A5170B5131B1AD682F7B4"
      unitRef="usd">2732000</exel:RightOfUseAssetAmortization>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e768-wk-Fact-CD9DE337EEF75CBCB09DBBFED845442E"
      unitRef="usd">-56339000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e787-wk-Fact-7A4B1D314A285D8D84C7423CD3599D48"
      unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e807-wk-Fact-6951FB4A20855EA99C8AF906A0170940"
      unitRef="usd">730000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:GainLossOnSaleOfOtherInvestments
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e827-wk-Fact-3377730FF9845C118231F3EE8DD9B633"
      unitRef="usd">209000</us-gaap:GainLossOnSaleOfOtherInvestments>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e848-wk-Fact-1F45C8C47625558DA9020C7FF80A4A7A"
      unitRef="usd">3970000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e868-wk-Fact-7F3913B80239564AAB60364709A9C57F"
      unitRef="usd">1423000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e931-wk-Fact-7C53B864A84B5879AE8207014B7AC8A5"
      unitRef="usd">7017000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e951-wk-Fact-A764C342344B53AE9C67DAAAA4CE4D3A"
      unitRef="usd">12707000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e972-wk-Fact-FD57AA20FD515BDB9DAD2F462EFC3AA2"
      unitRef="usd">-2469000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e991-wk-Fact-88FE7D9BAF395E4B9E1D9D652DF1A6BB"
      unitRef="usd">2938000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1012-wk-Fact-78F9A0CC46D6567B82ACF82965A4A7F3"
      unitRef="usd">3528000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1032-wk-Fact-F3B9832BA9F75123A438E3DFA9CA1762"
      unitRef="usd">3776000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1053-wk-Fact-340E90A3B7575A6FA37415E046ED8CF5"
      unitRef="usd">2640000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1073-wk-Fact-04D6F38C6CEF5E5BA56FDC600F48AEEA"
      unitRef="usd">32673000</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1094-wk-Fact-A80BA1227D775499A2EA658BEF840459"
      unitRef="usd">-527000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1113-wk-Fact-EB06CC05C0DD58179535618B944040BB"
      unitRef="usd">3529000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1134-wk-Fact-A24622652B1956268043A377171FF81A"
      unitRef="usd">6294000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1154-wk-Fact-0964257EE6B55166A59B1075345CAC6B"
      unitRef="usd">542000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1175-wk-Fact-4189DB5D4EB35220AEFE8B058D0A54AA"
      unitRef="usd">-2708000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1195-wk-Fact-FA6EC6EB7F8A5B188FDB8B2BE982390F"
      unitRef="usd">-1248000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1216-wk-Fact-9A0B8D238D2F5A13812B918B91D2719A"
      unitRef="usd">-429000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1236-wk-Fact-AB80DB28465E5CC4AFCB552987EB9151"
      unitRef="usd">6210000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <exel:IncreaseDecreaseInAccruedClinicalLiabilities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1256-wk-Fact-AAAE082B4F855D2F9DE30F81EAB7ED75"
      unitRef="usd">12099000</exel:IncreaseDecreaseInAccruedClinicalLiabilities>
    <exel:IncreaseDecreaseInAccruedClinicalLiabilities
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1275-wk-Fact-9776E47C89425E1BB16947E3662AAEA7"
      unitRef="usd">-891000</exel:IncreaseDecreaseInAccruedClinicalLiabilities>
    <exel:IncreaseDecreaseInRebatesAndFeesPayable
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1296-wk-Fact-F947884CFE4D5D9583AA624A8B256AAE"
      unitRef="usd">1828000</exel:IncreaseDecreaseInRebatesAndFeesPayable>
    <exel:IncreaseDecreaseInRebatesAndFeesPayable
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1315-wk-Fact-1D1F49397861587F81F238FE304F4243"
      unitRef="usd">4124000</exel:IncreaseDecreaseInRebatesAndFeesPayable>
    <exel:IncreaseDecreaseInAccruedCollaborationLiability
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1336-wk-Fact-A0EE0207750954918D7DC725F9AEF3F5"
      unitRef="usd">554000</exel:IncreaseDecreaseInAccruedCollaborationLiability>
    <exel:IncreaseDecreaseInAccruedCollaborationLiability
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1355-wk-Fact-0D3934FCDF6759C6A95892E6D5E70E98"
      unitRef="usd">-577000</exel:IncreaseDecreaseInAccruedCollaborationLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1376-wk-Fact-9F79453FFFB85DE7AC5026AC0658A996"
      unitRef="usd">3592000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1395-wk-Fact-04B02366E9CC521280D54397E95569EC"
      unitRef="usd">-1548000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <exel:IncreaseDecreaseInLeaseLiabilityNoncurrent
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1416-wk-Fact-CCD2B9142326567087C49D3D1766A2E4"
      unitRef="usd">6087000</exel:IncreaseDecreaseInLeaseLiabilityNoncurrent>
    <exel:IncreaseDecreaseInLeaseLiabilityNoncurrent
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1435-wk-Fact-609F9524627C51DCBC53C5202148F305"
      unitRef="usd">-974000</exel:IncreaseDecreaseInLeaseLiabilityNoncurrent>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1456-wk-Fact-2CF7C89F1CC15B3B8D80F11E0C596558"
      unitRef="usd">15940000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1475-wk-Fact-458019B1323453C8B0297DD2DD9961F3"
      unitRef="usd">-3321000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1496-wk-Fact-2D4339A1FF885165ADDC15E950B8F27D"
      unitRef="usd">368935000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1515-wk-Fact-405EF42481985A92AF1F1042295D9518"
      unitRef="usd">311129000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1576-wk-Fact-E9FB5D606882500EA5CFCC573D8368DA"
      unitRef="usd">5575000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1596-wk-Fact-C1EFAE091B685E8097EDCFC55787CA74"
      unitRef="usd">30403000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1617-wk-Fact-6558493D57835C588730E811895421F6"
      unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1636-wk-Fact-CF9FF455C3D15DC2AFC9BE26D9776A77"
      unitRef="usd">308000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1656-wk-Fact-4B3358B1699E5AEBAA95EE8E442E645C"
      unitRef="usd">887698000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1676-wk-Fact-87C1FEC62BE45D959721880837F7DA26"
      unitRef="usd">368304000</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1697-wk-Fact-7D487A67969A5B2C8ABD232E8FD9FB32"
      unitRef="usd">422419000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1716-wk-Fact-6AF37F1DC7C75C5DB95024B7E7FF5FE9"
      unitRef="usd">231204000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1736-wk-Fact-CE3A8DB792A85EE6A69A2D06A86BA2A1"
      unitRef="usd">13078000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1755-wk-Fact-BA54CA04D42455BAA9FD8C00ADF5DFB7"
      unitRef="usd">11935000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1776-wk-Fact-73332485A6C15A30BE088E4DD16B6464"
      unitRef="usd">730000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1795-wk-Fact-2AE8F06EAA7A52648115C8268E4AF64A"
      unitRef="usd">209000</us-gaap:ProceedsFromSaleAndMaturityOfOtherInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1815-wk-Fact-F0CD44721B96595B838BB44319F3A92A"
      unitRef="usd">-457046000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1835-wk-Fact-4ABA710C285D56909232E99B0478594F"
      unitRef="usd">-155051000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1897-wk-Fact-1646697EC55A5FA8A877904A8250741A"
      unitRef="usd">14811000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1916-wk-Fact-25AB369FF65855C680BE21A08094E84A"
      unitRef="usd">10390000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1936-wk-Fact-7C4C4432E89054EEABF764C8BC9E3CF4"
      unitRef="usd">4145000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockPlans
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1955-wk-Fact-A83A01062C115771B1504CE3D4A8B6AE"
      unitRef="usd">3650000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e1975-wk-Fact-1350882C91CD5DBEA3C89E145A217080"
      unitRef="usd">3369000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e1995-wk-Fact-C387ACBE24B755D5A5D5F1DCC72BA077"
      unitRef="usd">3205000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e2016-wk-Fact-F26403CCAE055D999B4D6E426F025D5A"
      unitRef="usd">34000</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e2036-wk-Fact-027B13F1EDFF5C1DBF0488752BC73D0B"
      unitRef="usd">0</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e2056-wk-Fact-CF70CD229A6E511D88471E2AB1F2B0DC"
      unitRef="usd">15553000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e2075-wk-Fact-C60DC77D3BF954AAB7F8AAD6FAE4D597"
      unitRef="usd">10835000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e2095-wk-Fact-D8AE7123A1F051BDBEADA5336283FDA3"
      unitRef="usd">-72558000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e2115-wk-Fact-B802A525113659C987170ABFF8090950"
      unitRef="usd">166913000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143647870e2135-wk-Fact-811D8D4A22775A0FBC1C6BB6FF2394BA"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d143647870e2154-wk-Fact-01657473A2A055D8A1ABA999157FCC91"
      unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143647870e2179-wk-Fact-2F215124757457DC87AE35B7D9CCCBC3"
      unitRef="usd">243317000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2018Q3Sept28"
      decimals="-3"
      id="d143647870e2198-wk-Fact-CB6AEE8FC12F5B38A6B288EB0E1CCDB3"
      unitRef="usd">355227000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e2371-wk-Fact-DF694A70CE785E2FBC25B383B4F0BF21"
      unitRef="usd">12944000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e2390-wk-Fact-4780137C336F5EF1BD4398EF0E381194"
      unitRef="usd">17180000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e2410-wk-Fact-EF45BDBF588757A08420A1F54359C888"
      unitRef="usd">159000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e2429-wk-Fact-1343A9E7B4D8550E9AA846F6BAEA34C8"
      unitRef="usd">1281000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143647870e2449-wk-Fact-7B47872985DF34A362F303214B4522AB"
      unitRef="usd">8961000</exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions>
    <exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143647870e2468-wk-Fact-011F21154366628AAA9603214B6967D3"
      unitRef="usd">0</exel:LiabilitiesExpendituresIncurredButNotYetPaidToRelatedPartyTransactions>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1BE73F03E25352E1A73A1318780A90C9-0-wk-Fact-A14B3FCB6C165869946D51559933BBE5">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Exelixis, Inc. (Exelixis, we, our or us) is&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Since we were founded in 1994, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and have launched commercially. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;Two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are derived from cabozantinib, an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET. These are: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC) and previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#xae;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of a combination regimen to treat a specific form of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR), approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;st&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended September 27, 2019, June 28, 2019, September 28, 2018 and June 29, 2018, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended September 30, 2019, June 30, 2019, September 30, 2018 and June 30, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019 and the first day of the fiscal quarter ended September 27, 2019 are indicated as being as of July 1, 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Operating results for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; are not necessarily indicative of the results that may be expected for the year ending &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, included in our Annual Report on Form 10-K filed with the SEC on &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;February&#160;22, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines for difficult-to-treat cancers&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On July 1, 2019, we adopted&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU No.&#160;2018-15,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-15). ASU 2018-15&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense and requires us to expense the capitalized implementation costs over the term of the hosting arrangement, which includes reasonably certain renewals.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2018-15 was adopted using the prospective transition method in the accompanying Condensed Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2019, we adopted ASU &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018-02, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income (Topic 220) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the individual unit of account approach for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;releasing income tax effects from &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2019, we also adopted ASU 2017-08&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Receivables&#x2014;Nonrefundable Fees and Other Costs (Subtopic 310-20)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2017-08). ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;shortens the amortization period for certain callable debt securities held at a premium. Specifically, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;requires the premium to be amortized to the earliest call date. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The financial impact from the adoption of ASU 2017-08 was nominal.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2018, the Financial Accounting Standards Board (FASB) issued ASU No.&#160;2018-18,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d143648547e459-wk-Fact-D547572BD1F158FF84FC753E0FA1ED2F"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ProductsDerivedFromCabozantinibMember"
      decimals="INF"
      id="d143648547e463-wk-Fact-27D733CB59695F2FB2C75795035D4D33"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ResultingFromDiscoveryEffortsMember"
      decimals="INF"
      id="d143648547e467-wk-Fact-FC1F63C24DF45C49AD0ECCFD5F0891D4"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-909B3D41BF255495870E1DA0CAD7DF4D-0-wk-Fact-4AAB8E449F1B5D36B0B7E46340DB6A49">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-4A8F6278D4585F0992A067C48A7641A6-0-wk-Fact-4D6BFB10E55B56279D36BB62BC8D01D7">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="FD2019Q3YTD"
      id="TextSelection-F6A5206224E15CC5BE042868E411309C-0-wk-Fact-F7BAF78AFB165082BC6FCD91ACEBC700">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;st&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended September 27, 2019, June 28, 2019, September 28, 2018 and June 29, 2018, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended September 30, 2019, June 30, 2019, September 30, 2018 and June 30, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019 and the first day of the fiscal quarter ended September 27, 2019 are indicated as being as of July 1, 2019.&lt;/span&gt;&lt;/div&gt;</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-E3916892B95E5393A9D719A1AAFEFE59-0-wk-Fact-9117D5C8393A59C9A1FF4934F5B3BFF2">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We operate in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; business segment that focuses on the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;discovery, development and commercialization of new medicines for difficult-to-treat cancers&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. &lt;/span&gt;&lt;/div&gt;All of our long-lived assets are located in the U.S.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d143648547e561-wk-Fact-31186DDE8BB95C58940C6E4C3302005D"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q3YTD"
      id="TextSelection-646BBCFCBD3652DEBEE7E293B5AB01BE-0-wk-Fact-898AFF10392750D9B5262BBEEB034B7F">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-F7BE0A3612185221910CED788945DB3C-0-wk-Fact-8365F67F7DE85347827D02D731464B66">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On July 1, 2019, we adopted&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU No.&#160;2018-15,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-15). ASU 2018-15&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense and requires us to expense the capitalized implementation costs over the term of the hosting arrangement, which includes reasonably certain renewals.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2018-15 was adopted using the prospective transition method in the accompanying Condensed Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2019, we adopted ASU &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018-02, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Income Statement&#x2014;Reporting Comprehensive Income (Topic 220) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the individual unit of account approach for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;releasing income tax effects from &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Accumulated other comprehensive income (loss)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On January 1, 2019, we also adopted ASU 2017-08&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Receivables&#x2014;Nonrefundable Fees and Other Costs (Subtopic 310-20)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2017-08). ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;shortens the amortization period for certain callable debt securities held at a premium. Specifically, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;requires the premium to be amortized to the earliest call date. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2017-08 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The financial impact from the adoption of ASU 2017-08 was nominal.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In November 2018, the Financial Accounting Standards Board (FASB) issued ASU No.&#160;2018-18,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, the FASB issued ASU No.&#160;2017-04,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Intangibles&#x2014;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (ASU 2017-04)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#x2019;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In June 2016, the FASB issued ASU No.&#160;2016-13,&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt; Financial Instruments&#x2014;Credit Losses (Topic 326) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(ASU 2016-13)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-F05A88C7B2645309825CAF7C9E0776B6-0-wk-Fact-1A8CB2465E755F5AB9C79604AE5CD653">REVENUES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by disaggregated category were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;704,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;525,438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(48,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(30,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(139,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(82,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;191,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;162,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;565,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;443,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51,323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development services revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,560&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;62,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;162,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;727,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;625,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were offset by the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues, License revenues and Research and development services revenues were recorded in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 for all periods presented. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Other collaboration revenues, which included the p&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded in accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for all periods presented&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;187,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;158,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;552,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;428,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,737&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;191,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;162,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;565,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;443,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by significant customer were as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30,707&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;102,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;93,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;120,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;105,638&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;83,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;88,496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;70,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;342,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;275,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;727,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;625,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;194,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;572,957&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;453,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;120,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,844&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;727,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;625,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92,769&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;139,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(92,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11,466&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(33,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(136,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,656&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Unbilled collaboration revenue was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of both &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. Deferred revenue was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$15.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$15.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. The amount of revenues recognized during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; that were included in the beginning deferred revenue balance as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and December 31, 2017 was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we recognized &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$67.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$129.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, in revenues under Topic 606 for performance obligations satisfied in previous periods as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$48.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$151.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the same periods in 2018. Such revenues primarily related to milestone and royalty payments allocated to our license performance obligations of our collaborations with Ipsen, Takeda and Daiichi Sankyo.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-462A8F1555CA5612B255AAB6DF3DD392-0-wk-Fact-4CD78E78DAD556F496135EF75F05AE64">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Revenues by disaggregated category were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Product revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Gross product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;239,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;193,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;704,084&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;525,438&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Discounts and allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(48,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(30,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(139,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(82,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;191,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;162,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;565,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;443,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Collaboration revenues:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;License revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51,323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128,937&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development services revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10,560&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Other collaboration revenues&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(3)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(2,310&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,445&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;62,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;162,441&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;727,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;625,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;License revenues included the recognition of the portion of milestones allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant revenue reversal would not occur, as well as royalty revenues from Ipsen Pharma SAS (Ipsen), Genentech and Daiichi Sankyo. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(2) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Research and development services revenues included the recognition of deferred revenue for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, as well as development cost reimbursements earned on our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Other collaboration revenues included the profit on the U.S. commercialization of COTELLIC from Genentech and revenues on product supply services provided to Ipsen and Takeda Pharmaceutical Company Ltd. (Takeda), which were offset by the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt; royalty we are required to pay GlaxoSmithKline (GSK) on the net sales by Ipsen of any product incorporating cabozantinib.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues, License revenues and Research and development services revenues were recorded in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 for all periods presented. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Other collaboration revenues, which included the p&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded in accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for all periods presented&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues disaggregated by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;CABOMETYX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;187,410&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;158,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;552,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;428,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;COMETRIQ&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,737&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net product revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;191,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;162,946&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;565,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;443,054&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by significant customer were as follows (dollars in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;30,707&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;31,901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,597&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;25,235&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;102,848&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;93,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Dollars&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Percent of Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;120,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Caremark L.L.C.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;105,638&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;83,516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;88,496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;71,249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;70,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49,995&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Others, individually less than 10% of Total revenues for all periods presented&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;342,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;275,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;727,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;625,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Total revenues disaggregated by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;194,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;166,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;572,957&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;453,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Europe&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;120,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Japan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;34,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,844&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:12px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;225,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;727,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;625,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d143655126e710-wk-Fact-A05500D9E52C5EA0A5B40759B1EB4B39"
      unitRef="usd">239916000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d143655126e729-wk-Fact-71DB3522A75D5CC9B2CC69B7E837CCE3"
      unitRef="usd">193356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d143655126e748-wk-Fact-CD8E5D97B7785FB1ACE0BAF87932D61C"
      unitRef="usd">704084000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_ProductGrossMember"
      decimals="-3"
      id="d143655126e768-wk-Fact-9E6DDA6F634E55C5AFFD0458481823CB"
      unitRef="usd">525438000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d143655126e783-wk-Fact-E408B0284FED5977BD7C8C9BA423967E"
      unitRef="usd">48148000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d143655126e803-wk-Fact-952BD629E2AE5AB09A2DA3CF8C5C82F2"
      unitRef="usd">30410000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d143655126e823-wk-Fact-C59EB092C7995F87BFC7654F9D382FA1"
      unitRef="usd">139060000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_SalesDiscountsAndAllowancesMember"
      decimals="-3"
      id="d143655126e844-wk-Fact-7F4BDAC181335D88BF51584A99DAB484"
      unitRef="usd">82384000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655126e865-wk-Fact-13C7A41F37725EB8B706C7A807584BBF"
      unitRef="usd">191768000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655126e884-wk-Fact-A3A260830AF7574094095B1E462A1635"
      unitRef="usd">162946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655126e903-wk-Fact-F0EFE7C281A95AD9B2D218FBA067F5D0"
      unitRef="usd">565024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655126e923-wk-Fact-2BCECF9B512F5FD6A12DE4E58A50DD70"
      unitRef="usd">443054000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d143655126e1027-wk-Fact-F8548ACE1FDF525DB4873DD5A1EE7F2D"
      unitRef="usd">68035000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d143655126e1046-wk-Fact-EEB94F9C761052A6AFE208ED24F18CC6"
      unitRef="usd">51323000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d143655126e1065-wk-Fact-2952866758B95F14A852A785A6D7F24F"
      unitRef="usd">128937000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_LicenseMember"
      decimals="-3"
      id="d143655126e1085-wk-Fact-B2A0CA8381D65BE9827BD7CC4BA18A51"
      unitRef="usd">152261000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember"
      decimals="-3"
      id="d143655126e1107-wk-Fact-4F5E62DD18E2505783226D86D484E151"
      unitRef="usd">12988000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember"
      decimals="-3"
      id="d143655126e1126-wk-Fact-57EB6D8A5D74565999FBF4E1DC86F010"
      unitRef="usd">10560000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember"
      decimals="-3"
      id="d143655126e1145-wk-Fact-7B6A7B64A8FD5460AB2294EF6A484111"
      unitRef="usd">35814000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_ResearchandDevelopmentMember"
      decimals="-3"
      id="d143655126e1165-wk-Fact-653096BDB80B5D648A13DA2A59B769B1"
      unitRef="usd">27464000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember"
      decimals="-3"
      id="d143655126e1187-wk-Fact-02EE4B446411586CA6647A8B7DB1FECF"
      unitRef="usd">-1088000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_OtherCollaborationMember"
      decimals="-3"
      id="d143655126e1207-wk-Fact-EA7955AB20CB5750B6F677B598441905"
      unitRef="usd">568000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_OtherCollaborationMember"
      decimals="-3"
      id="d143655126e1226-wk-Fact-E508656BD0085748AF8C587334B10DB7"
      unitRef="usd">-2310000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_OtherCollaborationMember"
      decimals="-3"
      id="d143655126e1247-wk-Fact-4BD41FD23C7153E7B36D613A07FA9178"
      unitRef="usd">2445000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d143655126e1267-wk-Fact-43C7D839ACFA5CC29516954B25CA6CBF"
      unitRef="usd">79935000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d143655126e1286-wk-Fact-E4ED43C9E7AC58B1A6BE7BF6E14F1B33"
      unitRef="usd">62451000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d143655126e1305-wk-Fact-95EF234B5DB954128FB68B0CD9D59DE3"
      unitRef="usd">162441000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CollaborationMember"
      decimals="-3"
      id="d143655126e1325-wk-Fact-FE403DC09F4A52B38F68D10219F89E45"
      unitRef="usd">182170000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655126e1351-wk-Fact-0FD3BD1F4272593786021250887B7DCA"
      unitRef="usd">271703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655126e1370-wk-Fact-E6B3BE7A5FD954AE933CF2B974B2DDA6"
      unitRef="usd">225397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655126e1389-wk-Fact-7654B036962C5DE7B24FDFD8B0563694"
      unitRef="usd">727465000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655126e1409-wk-Fact-2CB1AC25C2D25B03AD4E742BBB6610B2"
      unitRef="usd">625224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="2"
      id="d143655126e1439-wk-Fact-5AE28279074556DFB8A3C8C48DA57017"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d143655126e1675-wk-Fact-7B83B21719855D99816A17AEA5F0EA78"
      unitRef="usd">187410000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d143655126e1694-wk-Fact-808D21C66880500D8E9DE5E5443D48AC"
      unitRef="usd">158262000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d143655126e1713-wk-Fact-B23FAFFE8E725087A0B851D4A023A7E4"
      unitRef="usd">552315000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CabometyxMember"
      decimals="-3"
      id="d143655126e1733-wk-Fact-14A4C33445E25E1A986B51C11B9EFBB6"
      unitRef="usd">428317000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d143655126e1748-wk-Fact-390E7726E03D5B56833995CB61817D40"
      unitRef="usd">4358000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d143655126e1767-wk-Fact-63ADB9EFE55E503DBE613FB0FF6456EC"
      unitRef="usd">4684000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d143655126e1786-wk-Fact-2A973B372ED953D997D4D566D1390BB7"
      unitRef="usd">12709000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_exel_CometriqMember"
      decimals="-3"
      id="d143655126e1806-wk-Fact-0785016859F85242870A1D64A4C4BBA7"
      unitRef="usd">14737000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655126e1831-wk-Fact-13C7A41F37725EB8B706C7A807584BBF"
      unitRef="usd">191768000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655126e1850-wk-Fact-A3A260830AF7574094095B1E462A1635"
      unitRef="usd">162946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655126e1869-wk-Fact-F0EFE7C281A95AD9B2D218FBA067F5D0"
      unitRef="usd">565024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_ProductOrServiceAxis_us-gaap_ProductMember"
      decimals="-3"
      id="d143655126e1889-wk-Fact-2BCECF9B512F5FD6A12DE4E58A50DD70"
      unitRef="usd">443054000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_IpsenMember"
      decimals="-3"
      id="d143655126e2152-wk-Fact-9B7D081826035C019236728F0BE4BA88"
      unitRef="usd">76016000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2166-wk-Fact-FFC3A404A5ED5C568336E13BB256CDBA"
      unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_IpsenMember"
      decimals="-3"
      id="d143655126e2186-wk-Fact-7ABC7DC3501B5BAFB407A66B1D79D272"
      unitRef="usd">57186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2201-wk-Fact-D7CB49840D4956CFB3583CF2C6A9CA64"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member"
      decimals="-3"
      id="d143655126e2217-wk-Fact-99028D1B39425DC8A1F03355A62CCBEC"
      unitRef="usd">35703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2236-wk-Fact-94A64B1CA0B85F4B908858DB9B1ED0AD"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member"
      decimals="-3"
      id="d143655126e2251-wk-Fact-F9C5FE3A68565A32940CF5C277DE3BB7"
      unitRef="usd">30707000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2271-wk-Fact-D382940789CD55BB87F82D42AD854C34"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember"
      decimals="-3"
      id="d143655126e2287-wk-Fact-4B2F682AE9315C50BA5618C5422683AB"
      unitRef="usd">31901000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2306-wk-Fact-9364A2797B3A5DFC9CD03B6A91C584E0"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember"
      decimals="-3"
      id="d143655126e2321-wk-Fact-51E94386F12750C6863E0A80A30DAC5A"
      unitRef="usd">26597000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2341-wk-Fact-22E1F711BFEE5CD7B9144E200D8F19BB"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_ASDMember"
      decimals="-3"
      id="d143655126e2357-wk-Fact-D62CB7DB0D125DC0BBAE8053CC584888"
      unitRef="usd">25235000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2376-wk-Fact-1B5DD8743F315769BF22B3C95CAD5F1B"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_ASDMember"
      decimals="-3"
      id="d143655126e2391-wk-Fact-CC0B308C26235629B3577FAA9E625700"
      unitRef="usd">17232000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2411-wk-Fact-C8166CFD30155F83BC68E2A6701B4A2C"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember"
      decimals="-3"
      id="d143655126e2427-wk-Fact-75A975CED3EB59119894C9176CAC424B"
      unitRef="usd">102848000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3QTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2446-wk-Fact-791B996DC4C95B9C91CF51EB02BC595B"
      unitRef="number">0.38</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember"
      decimals="-3"
      id="d143655126e2461-wk-Fact-1C0250E0BBA75623B0ADCBBC553AE7EA"
      unitRef="usd">93675000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3QTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2480-wk-Fact-2C73EA1E8AD75290B38814564DE8D277"
      unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655126e2501-wk-Fact-0FD3BD1F4272593786021250887B7DCA"
      unitRef="usd">271703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3QTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="d143655126e2515-wk-Fact-99B589D163B759C896DABC294B2E4AFD"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655126e2535-wk-Fact-E6B3BE7A5FD954AE933CF2B974B2DDA6"
      unitRef="usd">225397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3QTD1_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="d143655126e2550-wk-Fact-2E7B13068C7D5AE1987436FC0388AE05"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_IpsenMember"
      decimals="-3"
      id="d143655126e2808-wk-Fact-C3021ACC073751E08B7720AA2C9EA882"
      unitRef="usd">120133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2822-wk-Fact-D1BBF961050758E1AE78495573E2F240"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_IpsenMember"
      decimals="-3"
      id="d143655126e2842-wk-Fact-493F645032D3586A98C31438842E5688"
      unitRef="usd">145038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_IpsenMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2857-wk-Fact-BBA8FC109E8256F1A56E9D1E10FCA2D0"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member"
      decimals="-3"
      id="d143655126e2873-wk-Fact-1E70263BBA195B0CAF4055F6FCCEACFC"
      unitRef="usd">105638000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2892-wk-Fact-41FCFD6864D7507E91673B4F517D3CA0"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member"
      decimals="-3"
      id="d143655126e2907-wk-Fact-78C492C22B765C0D81E4FAE01386B10A"
      unitRef="usd">83516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_CaremarkL.L.C.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2927-wk-Fact-7A1B335AEE2F5EBAA228E57ECA54A12E"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember"
      decimals="-3"
      id="d143655126e2943-wk-Fact-4EF63E3BA3025DA78468FBC1C80376F4"
      unitRef="usd">88496000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2962-wk-Fact-0C27373C856F5993A4B30A7AB05A8D50"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember"
      decimals="-3"
      id="d143655126e2977-wk-Fact-369E78893BBF53BC818ED353EB78B837"
      unitRef="usd">71249000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_AffiliatesofMcKessonCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e2997-wk-Fact-BEFB9C0DCDD05BA0B79D461DB3ACDD2D"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_ASDMember"
      decimals="-3"
      id="d143655126e3013-wk-Fact-870B81D620D7504D8874C98751431145"
      unitRef="usd">70503000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e3032-wk-Fact-13072B89EC9E5E8C9A69BD1A790D469E"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_ASDMember"
      decimals="-3"
      id="d143655126e3047-wk-Fact-23025FE225515010AFF69C52446DB8D8"
      unitRef="usd">49995000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_ASDMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e3067-wk-Fact-94F71A0157B859EA894220D2AD383784"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember"
      decimals="-3"
      id="d143655126e3083-wk-Fact-EE6DF48638A25AD1A45D01E93FC8C7AE"
      unitRef="usd">342695000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e3101-wk-Fact-6C2BF7CCB1C858FF84690DD29FCDCB8D"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember"
      decimals="-3"
      id="d143655126e3115-wk-Fact-1DE4EF391E0251139CE42B68B4CF878A"
      unitRef="usd">275426000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3YTD1_srt_MajorCustomersAxis_exel_OtherCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d143655126e3134-wk-Fact-16E7995F3E73549696E9B5AEE8096F16"
      unitRef="number">0.45</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655126e3155-wk-Fact-7654B036962C5DE7B24FDFD8B0563694"
      unitRef="usd">727465000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q3YTD_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="d143655126e3169-wk-Fact-291A4FE8928E58FD9368AA48584057E6"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655126e3189-wk-Fact-2CB1AC25C2D25B03AD4E742BBB6610B2"
      unitRef="usd">625224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="D2018Q3YTD1_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="INF"
      id="d143655126e3204-wk-Fact-8FDDC0831FD85A2888C1C9FF62731342"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d143655126e3417-wk-Fact-C92B044177655B4A98DAF1C6F10BA320"
      unitRef="usd">194484000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d143655126e3436-wk-Fact-C2FEE3005C9E54CB8D16FA8EE5EFE51F"
      unitRef="usd">166270000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d143655126e3455-wk-Fact-A49F0584D1655F47AF176354EF630932"
      unitRef="usd">572957000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_StatementGeographicalAxis_country_US"
      decimals="-3"
      id="d143655126e3475-wk-Fact-5E04756B8D9C5771A359B45445A28CAD"
      unitRef="usd">453342000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d143655126e3490-wk-Fact-1FF85895C6095AB8A2E234D2B5D9DD25"
      unitRef="usd">76017000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d143655126e3509-wk-Fact-3F084D8012745835B21A5F5FA0B38366"
      unitRef="usd">57186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d143655126e3528-wk-Fact-C051CB103B8B579CB3A2D13C4484B78F"
      unitRef="usd">120134000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_StatementGeographicalAxis_srt_EuropeMember"
      decimals="-3"
      id="d143655126e3548-wk-Fact-27AA792A73175E82AED66272E228541B"
      unitRef="usd">145038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d143655126e3568-wk-Fact-742D1A387BB85C62AC146934A87D55C8"
      unitRef="usd">1202000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d143655126e3587-wk-Fact-A3BBB8E6D3345D0489849AA9070B52E3"
      unitRef="usd">1941000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d143655126e3606-wk-Fact-0F4E7B80F74D5F0D89E2FF9703427F1D"
      unitRef="usd">34374000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_srt_StatementGeographicalAxis_country_JP"
      decimals="-3"
      id="d143655126e3626-wk-Fact-8AA2B5DD5CAA594497F8C21F2C99919D"
      unitRef="usd">26844000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143655126e3651-wk-Fact-0FD3BD1F4272593786021250887B7DCA"
      unitRef="usd">271703000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143655126e3670-wk-Fact-E6B3BE7A5FD954AE933CF2B974B2DDA6"
      unitRef="usd">225397000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655126e3689-wk-Fact-7654B036962C5DE7B24FDFD8B0563694"
      unitRef="usd">727465000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143655126e3709-wk-Fact-2CB1AC25C2D25B03AD4E742BBB6610B2"
      unitRef="usd">625224000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-8415C991A2475EFFBA35B375D59BA03C-0-wk-Fact-3E9CAFA6B7C25A599A9CF3CE07146059">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Chargebacks and Discounts for Prompt Payment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,916&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;92,769&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;35,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;139,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Prior periods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(92,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(11,466&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(33,127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(136,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Balance at September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,656&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d143655126e3861-wk-Fact-25BFD09C54F9559387E2824FEBCE19EE"
      unitRef="usd">2322000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d143655126e3880-wk-Fact-D5094717E0B25C74AB93ACD83C090EEE"
      unitRef="usd">3038000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d143655126e3899-wk-Fact-90617D66BA345C7EA9440879264380DA"
      unitRef="usd">11916000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143655126e3919-wk-Fact-211D85F132F050978B0CB8128A3473A1"
      unitRef="usd">17276000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d143655126e4016-wk-Fact-35C3D83D62EA59C7BBBE645A87F573FE"
      unitRef="usd">92769000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d143655126e4035-wk-Fact-02958B032F595E79B01F28396D4A8C62"
      unitRef="usd">11190000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d143655126e4054-wk-Fact-7DBCDEB3B8FE5A91B4FD84CC863D3AED"
      unitRef="usd">35422000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655126e4074-wk-Fact-30F9A7E5D79553C29A2D977752DAACC3"
      unitRef="usd">139381000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d143655126e4094-wk-Fact-964128BA8E4F55C19C2B3A97C2A26A12"
      unitRef="usd">-130000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d143655126e4114-wk-Fact-48511F0384C255E2B26118D6CA51A780"
      unitRef="usd">-106000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d143655126e4134-wk-Fact-511474CFE8F758929081E08B18E45E36"
      unitRef="usd">-85000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655126e4155-wk-Fact-129FAD03E82E510294A289B33AC67EFB"
      unitRef="usd">-321000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d143655126e4176-wk-Fact-9E386B4730725BA38EC14162DB36D4C2"
      unitRef="usd">92317000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d143655126e4196-wk-Fact-0674BF3DE80051A380E3CA416C65EC3D"
      unitRef="usd">11466000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q3YTD_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d143655126e4216-wk-Fact-F1B04CCC7E83568E888F387DBB2E6DCB"
      unitRef="usd">33127000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143655126e4237-wk-Fact-FE3CCB57BD2959C59065FB0934877BD9"
      unitRef="usd">136910000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_ChargebacksAndDiscountsForPromptPaymentMember"
      decimals="-3"
      id="d143655126e4263-wk-Fact-374815A8F1BC5C89994C738D8F4833CA"
      unitRef="usd">2644000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"
      decimals="-3"
      id="d143655126e4282-wk-Fact-30FA4A3D136D5EBA9475C567845C4455"
      unitRef="usd">2656000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3_us-gaap_ValuationAllowancesAndReservesTypeAxis_exel_AllowanceForProductRebatesMember"
      decimals="-3"
      id="d143655126e4301-wk-Fact-DC3685B8063559919114CBFD5510CCEA"
      unitRef="usd">14126000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143655126e4321-wk-Fact-A23F1320DA6A51A3AF5A36930B462814"
      unitRef="usd">19426000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-7455B4ACE00F51B2B5996B22F3F191A7-0-wk-Fact-45EE4EE2A42D521C92D400583329C8A7">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Unbilled collaboration revenue was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of both &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. &lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues, License revenues and Research and development services revenues were recorded in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 606 for all periods presented. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Other collaboration revenues, which included the p&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;recorded in accordance with &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Topic 808 &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for all periods presented&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d143655126e4345-wk-Fact-91CFF63C0F1CFEF4EEFF03297D9FB3C9"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d143655126e4361-wk-Fact-834316E65C1611A2263A0F987DCEFBCD"
      unitRef="usd">15400000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-5"
      id="d143655126e4365-wk-Fact-2AFBD85DCDBD4976AA1A0F984B8AC9BB"
      unitRef="usd">15900000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d143655126e4395-wk-Fact-C2CDC2D901AF7F6FC1BCFA3F958B63CE"
      unitRef="usd">2700000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="D2018Q3YTD1"
      decimals="-5"
      id="d143655126e4399-wk-Fact-51CDBD3DC2D1AA23FF31FA3F95C06564"
      unitRef="usd">6100000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d143655126e4427-wk-Fact-8771FEF48A3A529A9452D26F3536E628"
      unitRef="usd">67700000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d143655126e4431-wk-Fact-CC5314AD523B58289355CBE3EF1AC2BB"
      unitRef="usd">129000000.0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="D2018Q3QTD1"
      decimals="-5"
      id="d143655126e4435-wk-Fact-21808AF773FA5350AB1EE96D4B6CBE41"
      unitRef="usd">48200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="D2018Q3YTD1"
      decimals="-5"
      id="d143655126e4440-wk-Fact-0DD0A3FF21E857A2A3FC8BCBDF12E158"
      unitRef="usd">151800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-BC85AA04AC115D8C9F2CBCDA58AAB9D6-0-wk-Fact-04AC739539F259BFBDCB2EC6DBCB21BD">COLLABORATION AGREEMENTS&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of cabozantinib, as well as with smaller, discovery-focused biotechnology companies to expand our product pipeline. Additionally, in line with our business strategy prior to the commercialization of our first product, COMETRIQ, we entered into other collaborations with leading pharmaceutical companies including Genentech, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Daiichi Sankyo &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;and Bristol-Myers Squibb Company for other compounds and programs in our portfolio. See &#x201c;Note 3. Collaboration Agreements&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for a description of each of our collaboration agreements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under these collaborations, we are generally entitled to receive milestone and royalty payments, and for certain collaborations, payments for product supply services, development cost reimbursements, and/or profit-sharing payments. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &#x201c;Note 2. Revenues&#x201d; for information on collaboration revenues recognized during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Commercial Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In February 2016, we entered into a collaboration and license agreement with Ipsen for the commercialization and further development of cabozantinib. Pursuant to the terms of the collaboration agreement, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S., Canada and Japan. The collaboration agreement was subsequently amended on three occasions, including in December 2016 to include &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;commercialization rights in Canada. We have also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;120,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$47.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the net contract liability for the collaboration agreement with Ipsen was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$7.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;font-weight:bold;text-decoration:none;"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda. Pursuant to this collaboration agreement, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The collaboration agreement was subsequently amended in March 2018 and April 2019.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The second amendment to the collaboration agreement with Takeda, which was executed on April 29, 2019 and became effective on May 7, 2019 (the Amendment), among other things, reduced the amount of reimbursements we will receive from Takeda for costs associated with our required global pharmacovigilance activities and limits those reimbursements to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per year. It also increased the total potential development, regulatory and first-sale milestone payments to be paid to us by Takeda for second-line &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;RCC&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, first-line RCC and second-line HCC by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$12.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$102.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, including an increase from &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$16.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the milestone we received for the April 2019 submission of a regulatory application for cabozantinib as a treatment for patients with advanced RCC to the Japanese Ministry of Health, Labour and Welfare&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; (MHLW)&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We continue to be eligible to receive additional development, regulatory and first-sale milestone payments for other potential future indications. The Amendment also increased the amount of Takeda&#x2019;s total potential commercial milestones by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$89.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We continue to be eligible to receive royalties on net sales of cabozantinib in Japan.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$18.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the transaction price allocated to our research and development services performance obligation had not been satisfied. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the net contract liability for the collaboration agreement with Takeda was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; which was included in the Long-term portion of deferred revenue in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech pursuant to a worldwide collaboration agreement. Under the terms of the collaboration agreement, we developed cobimetinib through the determination of the maximum tolerated dose in a phase 1 clinical trial, and Genentech had the option to co-develop cobimetinib, an option that Genentech exercised, and in March 2009, we granted to Genentech an exclusive worldwide revenue-bearing license to cobimetinib, at which point Genentech became responsible for completing the phase 1 clinical trial and the subsequent clinical development. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In&#160;November&#160;2015, the U.S. Food and Drug Administration (FDA) approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s Zelboraf (vemurafenib) as a treatment for patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with Zelboraf has also been approved in the European Union and multiple additional countries for use in the same indication. Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,004&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Daiichi Sankyo&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In March 2006, we entered into a collaboration agreement with Daiichi Sankyo pursuant to which we granted to Daiichi Sankyo an exclusive, worldwide license to certain intellectual property primarily relating to compounds that modulate MR, including esaxerenone, an oral, non-steroidal, selective MR antagonist. Daiichi Sankyo was responsible for all further preclinical and clinical development, regulatory, manufacturing and commercialization activities for the compounds. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In&#160;January 2019, the Japanese MHLW approved esaxerenone, under the brand name MINNEBRO, as a treatment for patients with hypertension and in May &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019, Daiichi Sankyo had its first commercial sale of MINNEBRO&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As a result of the launch,&#160;we&#160;received a&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;milestone payment from Daiichi Sankyo in June 2019. We are &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;eligible for low double-digit royalties on sales of MINNEBRO. In addition, pursuant to a license agreement we entered into with Ligand Pharmaceuticals, Inc. (Ligand), we are required to pay a royalty of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;0.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to Ligand on net sales of MINNEBRO.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Daiichi Sankyo collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Such collaboration revenues were nominal or zero for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Iconic Therapeutics, Inc. (Iconic) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2019, we &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;entered into an exclusive option and license agreement with Iconic. Under the terms of the agreement, we gained an exclusive option to license ICON-2, Iconic&#x2019;s lead oncology &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;antibody-drug conjugate&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; program, in exchange for an upfront payment to Iconic of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$7.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and a commitment for preclinical development funding. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we accrued &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the preclinical development funding commitment. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Both the upfront payment and the accrual for the preclinical development funding commitment were included in Research and development expenses in the accompanying Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;If we exercise the option, we&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; would be required to make an option exercise fee payment of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$20.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; to Iconic, we would assume responsibilities for all subsequent clinical development and commercialization activities, and Iconic would become eligible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$190.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in potential development, regulatory and first-sale milestone payments, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$262.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in potential commercial milestone payments, as well as royalties on potential sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aurigene Discovery Technologies Limited (Aurigene) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In July 2019, we &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;entered into&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; an exclusive collaboration, option and license agreement with Aurigene, and&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; India-based biotechnology company focused on oncology and inflammatory disorders, to in-license as many as &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; programs. Under the terms of the agreement, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for exclusive options to license &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; preexisting programs. In addition, we and Aurigene selected &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; additional Aurigene-led drug discovery programs on mutually agreed upon targets, in exchange for additional option payments totaling &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$7.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We are also responsible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$32.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in research funding for the discovery and preclinical development work on these programs. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we accrued &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the discovery and preclinical development funding commitment. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;For each option we decide to exercise, we would be required to pay an exercise fee of either &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$10.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$12.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, depending on the program, and would assume responsibilities for all subsequent clinical development, &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;commercialization and global manufacturing of that program. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Aurigene would then become eligible for up to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$148.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per program in potential development and regulatory milestone payments, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$280.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; per program in potential commercial milestone payments, as well as royalties on potential sales. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Under the terms of the agreement, Aurigene retains limited development and commercial rights for India and Russia.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;GSK&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK. Under the terms of the collaboration agreement, GSK had the right to choose cabozantinib for further development and commercialization, but notified us in October 2008 that it had waived its right to select the compound for such activities. Although the collaboration agreement was terminated in December 2014, we continue to be required to pay a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; royalty to GSK on the net sales of any product incorporating cabozantinib by us and our collaboration partners. Royalties accruing to GSK in connection with the sales of cabozantinib are included in Cost of goods sold for sales by us and as a reduction of Collaboration revenues for sales by Ipsen. Such royalties accruing to GSK were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d143663103e667-wk-Fact-EBC42824D29658AA92FBAF6D3814B71F"
      unitRef="usd">76016000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d143663103e686-wk-Fact-0F024F41042F52C9B1212CF5D589FD52"
      unitRef="usd">57186000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d143663103e705-wk-Fact-F4DA74CE4A5658CE9C7EA9BAD2B77C6D"
      unitRef="usd">120133000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-3"
      id="d143663103e725-wk-Fact-14718243279852439359F4D23AD983FE"
      unitRef="usd">145038000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d143663103e742-wk-Fact-0F9A815B5D045806B8820CED56EE33DC"
      unitRef="usd">47100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="-5"
      id="d143663103e751-wk-Fact-64F1910F27415835A4AE5118A203F7BB"
      unitRef="usd">7200000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <exel:CollaborativeArrangementAnnualReimbursementLimit
      contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d143663103e770-wk-Fact-71A6D930FB0C5B9090B1F186ACC1C789"
      unitRef="usd">1000000.0</exel:CollaborativeArrangementAnnualReimbursementLimit>
    <exel:IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d143663103e778-wk-Fact-4B7FB4BA35C353A7AC61709E1724F381"
      unitRef="usd">12000000.0</exel:IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d143663103e782-wk-Fact-FBD88E9C370152AB8C6128813764712A"
      unitRef="usd">102000000.0</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborationAgreementMilestonePaymentsEarned
      contextRef="D2019Q2April28_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d143663103e786-wk-Fact-B3AE80B6206D5A06943006337558E689"
      unitRef="usd">10000000.0</exel:CollaborationAgreementMilestonePaymentsEarned>
    <exel:CollaborationAgreementMilestonePaymentsEarned
      contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d143663103e791-wk-Fact-346788C394195CA08319C6DC63BDEE74"
      unitRef="usd">16000000.0</exel:CollaborationAgreementMilestonePaymentsEarned>
    <exel:IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="D2019Q2Apr29-Apr29_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d143663103e799-wk-Fact-E22C4499D73A5F74B953E8FE6CA4850A"
      unitRef="usd">6000000.0</exel:IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="I2019Q2TakedaAmend_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d143663103e803-wk-Fact-EB17F8D082155896A03405DF8EDDA676"
      unitRef="usd">89000000.0</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-D2F2CC9C7DFD515F84009ADF831F770C-0-wk-Fact-EA641A6B751F57C985C807742D965B1F">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Takeda collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,940&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,245&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Ipsen collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;76,016&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;57,186&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;120,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;145,038&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,935&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,507&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,004&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Daiichi Sankyo collaboration revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,130&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Such royalties accruing to GSK were as follows (in thousands):&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Royalties accruing to GSK&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,079&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d143663103e1013-wk-Fact-245F5EE0656B52F5B574102C36CDBF7B"
      unitRef="usd">1187000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d143663103e1032-wk-Fact-BEA97BEA980E5F9995EC3490B787D152"
      unitRef="usd">1940000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d143663103e1051-wk-Fact-0B71BBC1020E53A1A31621A7A7C32F4B"
      unitRef="usd">14245000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-3"
      id="d143663103e1071-wk-Fact-AD3148F1BFB95E619857A9B5B011D16B"
      unitRef="usd">6843000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d143663103e1088-wk-Fact-AE6470107FD85C3C9F63624C8D717461"
      unitRef="usd">18700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:ContractWithCustomerLiability
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithTakedaMember"
      decimals="-5"
      id="d143663103e1102-wk-Fact-262DDB35A41C55259BE3B60EBCB36067"
      unitRef="usd">8200000</us-gaap:ContractWithCustomerLiability>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d143663103e1324-wk-Fact-C7B8D124F9B85EE3BC114EC4BD082EE6"
      unitRef="usd">1102000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d143663103e1343-wk-Fact-4E9CD515F479554CA31F80CF37A111C7"
      unitRef="usd">1935000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d143663103e1362-wk-Fact-9CC7BB8C2F5354AF900F11278E577348"
      unitRef="usd">3507000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d143663103e1382-wk-Fact-8B027B196F8F552E98F3CBA5200B9FC1"
      unitRef="usd">6004000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d143663103e1402-wk-Fact-B17D01D8A5A55FB69FDCD715A6D67E32"
      unitRef="usd">1614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d143663103e1421-wk-Fact-758D86C9D4155012944A95B0172A217B"
      unitRef="usd">1390000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d143663103e1440-wk-Fact-D0C735EBB208534DB2CE99C3C1FD784D"
      unitRef="usd">4426000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithGenentechMember"
      decimals="-3"
      id="d143663103e1460-wk-Fact-EF223054A1115468A7DFE1E2B0178C01"
      unitRef="usd">4285000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2019Q3June_srt_ProductOrServiceAxis_exel_CollaborationMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-5"
      id="d143663103e1487-wk-Fact-72BC68C00AE75A78A80C4E4249BB52F9"
      unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="3"
      id="d143663103e1493-wk-Fact-1DC405181E477D3870A0B447FFB9871F"
      unitRef="number">0.005</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-3"
      id="d143663103e1612-wk-Fact-72E9B2B9D18B5744BACB7F29F0D964CF"
      unitRef="usd">20130000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementwithDaiichiSankyoMember"
      decimals="-3"
      id="d143663103e1631-wk-Fact-2FAEBCB33C065D66A0CDD57DB4884481"
      unitRef="usd">20000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborationAgreementsUpfrontPayments
      contextRef="D2019Q2May01-May31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d143663103e1662-wk-Fact-A3E07891857A58C58BE8BB1FE4DB579B"
      unitRef="usd">7500000</exel:CollaborationAgreementsUpfrontPayments>
    <exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d143663103e1670-wk-Fact-22144DC4186F5BBD96B1B1BAD87E6880"
      unitRef="usd">6600000</exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d143663103e1681-wk-Fact-9F8E204184835D219A340378FDBEB104"
      unitRef="usd">20000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d143663103e1685-wk-Fact-BAFE238F798A51348AA11224B1EDFF36"
      unitRef="usd">190600000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithIconicTherapeuticsInc.Member"
      decimals="-5"
      id="d143663103e1689-wk-Fact-013EE803F11E5FCD92AB59CD7DE13140"
      unitRef="usd">262500000</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborationAgreementNumberOfPrograms
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="INF"
      id="d143663103e1705-wk-Fact-56CFDD5FCDBB53FE81B75348020E2BBE"
      unitRef="program">6</exel:CollaborationAgreementNumberOfPrograms>
    <exel:CollaborationAgreementsUpfrontPayments
      contextRef="D2019Q3Jul01-Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d143663103e1709-wk-Fact-E541BDBD60585330A243C8D93A0D26A6"
      unitRef="usd">10000000.0</exel:CollaborationAgreementsUpfrontPayments>
    <exel:CollaborationAgreementNumberOfPreexistingPrograms
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="INF"
      id="d143663103e1713-wk-Fact-D44D73DBD29F5B9AF947B476BA31BD88"
      unitRef="program">3</exel:CollaborationAgreementNumberOfPreexistingPrograms>
    <exel:CollaborationAgreementNumberOfDrugDiscoveryPrograms
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="INF"
      id="d143663103e1717-wk-Fact-5C2E773D137C996F25ABB47AB0AB9BAE"
      unitRef="program">3</exel:CollaborationAgreementNumberOfDrugDiscoveryPrograms>
    <exel:CollaborationAgreementAdditionalOptionPayments
      contextRef="D2019Q3Jul01-Jul31"
      decimals="-5"
      id="d143663103e1722-wk-Fact-D0D37010AB0434A0CD31F05803A758C1"
      unitRef="usd">7500000</exel:CollaborationAgreementAdditionalOptionPayments>
    <exel:CollaborationAgreementResearchAndDevelopmentObligation
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d143663103e1726-wk-Fact-A76A63EB248E5113AA20F91C04D86586"
      unitRef="usd">32600000</exel:CollaborationAgreementResearchAndDevelopmentObligation>
    <exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued
      contextRef="FI2019Q3_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d143663103e1736-wk-Fact-09C29C41B8F9ABCA4637F06720FA2076"
      unitRef="usd">1300000</exel:CollaborationAgreementResearchAndDevelopmentExpenseAccrued>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MinimumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d143663103e1743-wk-Fact-3EA62E15CBE056B38053E85CC0083F37"
      unitRef="usd">10000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption
      contextRef="I2019Q3Jul31_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d143663103e1747-wk-Fact-131604BD33DE5B2A9F833A0535B1C99F"
      unitRef="usd">12000000.0</exel:CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption>
    <exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d143663103e1756-wk-Fact-9EA58BD0E85E58D785CF57E115ED5C50"
      unitRef="usd">148800000</exel:CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones>
    <exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement
      contextRef="I2019Q3Jul31_us-gaap_TypeOfArrangementAxis_exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember"
      decimals="-5"
      id="d143663103e1760-wk-Fact-1151E56DB7ED52B88D5EE3051FF8E4EF"
      unitRef="usd">280000000.0</exel:CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="FD2019Q3YTD_srt_MajorCustomersAxis_exel_GlaxoSmithKlineMember_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementwithIpsenMember"
      decimals="2"
      id="d143663103e1773-wk-Fact-5AE28279074556DFB8A3C8C48DA57017"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="FD2019Q3QTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-3"
      id="d143663103e1980-wk-Fact-9BCFC6093928514DA0E11771E52C44BA"
      unitRef="usd">7964000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="D2018Q3QTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-3"
      id="d143663103e1999-wk-Fact-9428C6B8D4185E73875FAA3AF619813B"
      unitRef="usd">6268000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="FD2019Q3YTD_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-3"
      id="d143663103e2018-wk-Fact-C1FCF709D1D1553FA971C1788C0027F3"
      unitRef="usd">23079000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="D2018Q3YTD1_us-gaap_TypeOfArrangementAxis_exel_CollaborativeArrangementswithGlaxoSmithKlineMember"
      decimals="-3"
      id="d143663103e2038-wk-Fact-12DA99DA6E7852618D1FE63B87EC2885"
      unitRef="usd">17021000</us-gaap:RoyaltyExpense>
    <exel:CashCashEquivalentsAndInvestmentsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-C4B8357B2A3551509C17F4016BA28FDC-0-wk-Fact-6928CB05B8C1538F973C722A60FBE312">CASH AND INVESTMENTS &lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;242,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;353,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;243,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;355,227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;188,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cash and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments by security type were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;703,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,549&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,214,736&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,218,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,244,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,248,430&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;852,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Gains and losses on the sales of investments available-for-sale were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;nominal&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;73,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;77,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;119,808&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;124,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;275,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320,167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;There were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;199&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; investments in an unrealized loss position as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. During the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; we did &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;no&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;743,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;674,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;474,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,218,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Related Party Transactions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;BlackRock,&#160;Inc. (BlackRock), a global provider of investment, advisory and risk management solutions, reported that as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the most recent date for which they reported ownership data, their beneficial ownership was more than &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of our outstanding common stock. BlackRock manages a portion of our cash and investments portfolio. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, the fair value of cash and investments managed by BlackRock was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$470.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$298.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, which included &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$3.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; invested in the BlackRock Liquidity Money Market Fund. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we also had a &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$9.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; payable to BlackRock for unsettled trades that was included in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Other current liabilities in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; We incurred &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in fees for BlackRock advisory services performed during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</exel:CashCashEquivalentsAndInvestmentsTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-63C82923299E58B4A0D0288A3CA4CAF0-0-wk-Fact-54038BC2FA5453888AA5965A8294FA9C">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;242,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;353,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;243,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;355,227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;188,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-C35F7BAB66415625A631FA4193CB766C-0-wk-Fact-F6EEBCDC5F5A5AE9AAE738E4FD84FE3C">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;242,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;314,775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;353,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;183,164&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in short-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Restricted cash included in long-term restricted cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,646&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;243,317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,875&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;355,227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;188,314&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e558-wk-Fact-A2EF7BBAD72B5637A44FD42AF030F687"
      unitRef="usd">242317000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e577-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7"
      unitRef="usd">314775000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I2018Q3Sept28"
      decimals="-3"
      id="d143671945e596-wk-Fact-9A4B2A109056533283BC18C08A46E7C3"
      unitRef="usd">353623000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d143671945e616-wk-Fact-ACAFF014B6F357E6BAEC1C510EC5B7DA"
      unitRef="usd">183164000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e631-wk-Fact-02571D7B7E7F5AF49B05E69736731F3B"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e650-wk-Fact-D04C68F48EE857BBAB9EB561BCBE190C"
      unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="I2018Q3Sept28"
      decimals="-3"
      id="d143671945e669-wk-Fact-59DF140D0E5C5F86B2234C21D421CCCB"
      unitRef="usd">504000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d143671945e689-wk-Fact-00137C9ABCFC5CAAB0F59D00A6FEE760"
      unitRef="usd">504000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e709-wk-Fact-B89A41F9770A5B909B2A62EEA3EE1ACC"
      unitRef="usd">1000000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e728-wk-Fact-3F4129D37BE15987B315F13735F8FDBE"
      unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="I2018Q3Sept28"
      decimals="-3"
      id="d143671945e747-wk-Fact-0AC9E33ADF7F545AAF228A016AC20E7F"
      unitRef="usd">1100000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d143671945e767-wk-Fact-EDB4EAD74619585CB3B95E0AEE698322"
      unitRef="usd">4646000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e792-wk-Fact-2F215124757457DC87AE35B7D9CCCBC3"
      unitRef="usd">243317000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e811-wk-Fact-811D8D4A22775A0FBC1C6BB6FF2394BA"
      unitRef="usd">315875000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2018Q3Sept28"
      decimals="-3"
      id="d143671945e830-wk-Fact-CB6AEE8FC12F5B38A6B288EB0E1CCDB3"
      unitRef="usd">355227000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="I2017Q4Dec29"
      decimals="-3"
      id="d143671945e850-wk-Fact-01657473A2A055D8A1ABA999157FCC91"
      unitRef="usd">188314000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-4ED0E32BB7495E65861A93FF307AFB54-0-wk-Fact-BB7407C47FD15358BCC5BFF8EDFD0437">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash and investments by security type were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;703,325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,549&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,214,736&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,218,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;901&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,244,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,248,430&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Investments available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Cash and restricted cash&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total cash and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;852,322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;851,621&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143671945e1175-wk-Fact-337A61FADBA85DD2BA0BCE8820A0815F"
      unitRef="usd">26641000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143671945e1194-wk-Fact-B57C6114AD4450969AA6A25471F45D37"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143671945e1213-wk-Fact-3AD4B2EADBE95BB187E3E28021147F04"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143671945e1233-wk-Fact-44580F5B60555029B82B538AE6E68C36"
      unitRef="usd">26641000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e1248-wk-Fact-9AF943076B2E5270BD071DF85247BFE5"
      unitRef="usd">332239000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e1267-wk-Fact-A272ABCA01EB5054AC9A39B1ADC4F43B"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e1286-wk-Fact-7DA2A061CFA05911992ACA5D92FF83B2"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e1306-wk-Fact-967198C6C8CD53C28A2621913C442033"
      unitRef="usd">332239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e1326-wk-Fact-D5F348F2D5995AB580E0BA86CFB2FDD0"
      unitRef="usd">703325000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e1345-wk-Fact-BF5F6FB2E3975842BCD29FB733E0CF07"
      unitRef="usd">3549000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e1364-wk-Fact-4C938D4A10A35D3E9FAE4E5CAE8EC87A"
      unitRef="usd">67000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e1385-wk-Fact-72B1FD27DEB5568D9CC7819DE5F31132"
      unitRef="usd">706807000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e1405-wk-Fact-11F5239A25595248916D0CEC518C107E"
      unitRef="usd">152531000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e1424-wk-Fact-EC8CFF49953B55AD9130C13390EF3E20"
      unitRef="usd">143000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e1443-wk-Fact-FD5B9BB95419505783D3B77039507365"
      unitRef="usd">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e1464-wk-Fact-57C7F017A9465FD185D052B1CC801043"
      unitRef="usd">152650000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e1484-wk-Fact-77FE5F447BD95D8EB47808E698D94B0C"
      unitRef="usd">1214736000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e1503-wk-Fact-0E994E623A3C50FF9A1B2D4393EE0AEA"
      unitRef="usd">3692000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e1522-wk-Fact-61FA6FE58E935F84B7EBC1C54114513F"
      unitRef="usd">91000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e1543-wk-Fact-E91A118BF7525CB2975AC30E5897A32B"
      unitRef="usd">1218337000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d143671945e1563-wk-Fact-C63413E8BCF150D69AED84E98FF6FFF6"
      unitRef="usd">901000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d143671945e1582-wk-Fact-6331428E98FC5E53B9C781F486E06AD2"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d143671945e1601-wk-Fact-93831773EB6454C8A74A4103558D224F"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d143671945e1621-wk-Fact-8B07DC6CBFA556B29F11CCD545042B25"
      unitRef="usd">901000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143671945e1641-wk-Fact-B9E9652CADE85206AFBE25497CCBAAF3"
      unitRef="usd">29189000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143671945e1660-wk-Fact-847CDF1CC49C558D9A2335CD19783178"
      unitRef="usd">3000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143671945e1679-wk-Fact-9FD3DB6D12735EA6840BCF9BB7EBE19C"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143671945e1699-wk-Fact-BA972B93B77956109CACAFF79563D500"
      unitRef="usd">29192000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e1724-wk-Fact-A88C2584601D5095A87EB6167D48C3AE"
      unitRef="usd">1244826000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e1743-wk-Fact-E346D3A5D53E50B1A9336544350FA0D8"
      unitRef="usd">3695000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e1762-wk-Fact-C9747740D6635CA7A90217CD91755BC5"
      unitRef="usd">91000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e1783-wk-Fact-BACEC49ED2CB5A4FAE3CE403AB8BF865"
      unitRef="usd">1248430000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143671945e2089-wk-Fact-83FD683CE5A95741AE6F735F27ED50E8"
      unitRef="usd">47744000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143671945e2108-wk-Fact-56F22C4802B25E3499EFCF77A3EE7F04"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143671945e2127-wk-Fact-36C927A1BBEC52DEB7445661ECDD8627"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143671945e2147-wk-Fact-18005F6D372156A985DDD4232885BE31"
      unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e2162-wk-Fact-716904550C0E51FFAABB9FFD662EAFC1"
      unitRef="usd">381134000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e2181-wk-Fact-66ACBB81F5DB5CAFA94DFEEF66A9150A"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e2200-wk-Fact-1801E8AB406A5CEE883E2266084AAD18"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e2221-wk-Fact-FB53A528BD1051AF8441F4229C83D9DF"
      unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e2241-wk-Fact-2BF966242943571DB60C36593A2511F2"
      unitRef="usd">344741000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e2260-wk-Fact-2F3B72FD629452FBA1EA6453878E2A15"
      unitRef="usd">180000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e2279-wk-Fact-DA19868D011753F1B4AFC96E61F2BF0B"
      unitRef="usd">857000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e2300-wk-Fact-476C2DD2FD4B5AC794C15B90F408463A"
      unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e2320-wk-Fact-E4C1AD9AAF345FE5AC2A1AACC4564F59"
      unitRef="usd">55224000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e2339-wk-Fact-B334E6C73BC75C73A9B616A41C2E7410"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e2358-wk-Fact-5EB25CB135BA5119B567076D530119F4"
      unitRef="usd">25000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e2379-wk-Fact-0FE0E6CB84E25BD3A23E44D6F827809A"
      unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e2399-wk-Fact-788246C0DC815E939BB0CEE689E3A4B5"
      unitRef="usd">828843000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e2418-wk-Fact-2E752FFE534E5696994306A28DA515DE"
      unitRef="usd">182000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e2437-wk-Fact-2FD6E16E5D9957A78FC462637DB276CF"
      unitRef="usd">883000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e2458-wk-Fact-49FC0313E7EF513E8D58AB82AFF52A84"
      unitRef="usd">828142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d143671945e2478-wk-Fact-DBBD08CB6AF45D6EB156FB3ED487E8DF"
      unitRef="usd">6883000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d143671945e2497-wk-Fact-798BB587C1A6503B83124495F8E07655"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d143671945e2516-wk-Fact-616ABFAC518D57C8BFEFC2A221F486C0"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_exel_CashAndRestrictedCashMember"
      decimals="-3"
      id="d143671945e2536-wk-Fact-01729804E0C354F29F1903B6A5D50CB8"
      unitRef="usd">6883000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143671945e2556-wk-Fact-ACA1FB55281355998E6CB5712632B238"
      unitRef="usd">16596000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143671945e2575-wk-Fact-E69866A06E1654CE8B697DB59E7817E8"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143671945e2594-wk-Fact-01EB61A5F8AB597EAE1177AFE172A6EC"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143671945e2614-wk-Fact-A9528E77A54B5BADA8568A9BBE7327C8"
      unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e2639-wk-Fact-5777066680C35A50827677DE686C9CA5"
      unitRef="usd">852322000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e2658-wk-Fact-A7F844565EA750F581DFBB22392831EB"
      unitRef="usd">182000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e2677-wk-Fact-BA7BE1D9B9E2598D91F2ECE2D1CA7708"
      unitRef="usd">883000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e2698-wk-Fact-2EA494E595F5583091C1D748AD1961EF"
      unitRef="usd">851621000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-F5EB6F008AF45E3EB1FE7354BA2E2350-0-wk-Fact-21422133549159CE81A2B2EC6EA83EE1">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;73,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;77,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;46,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;119,808&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;124,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="24"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position Less than 12 Months&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;In an Unrealized Loss Position 12 Months or Greater&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;236,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;39,627&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;275,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(857&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;37,287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;271,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;320,167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(883&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3148-wk-Fact-CFAAE8E4AC7654DD9704D25AD31FB2CA"
      unitRef="usd">73064000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3167-wk-Fact-8120CBF24D5D5496AB97BC4511A91B47"
      unitRef="usd">66000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3187-wk-Fact-AE49D6BBB9A25542B2D1E7F004CF8F8F"
      unitRef="usd">4398000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3207-wk-Fact-43DDBB014D215152B0A44A5CA8ABFBA9"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3227-wk-Fact-504B5EFCED5E5562A3B6909CE7B1ED24"
      unitRef="usd">77462000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3247-wk-Fact-BEBB0389CE46552A985F9F530ABC363E"
      unitRef="usd">67000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e3263-wk-Fact-EA39A5DEFA9C58BC9AE3D6868BECC033"
      unitRef="usd">46744000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e3282-wk-Fact-F9D198314EE65B038AA1F360F9F18232"
      unitRef="usd">24000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e3302-wk-Fact-049D1EC2CD2855DCBB27EB50B8F7ACDB"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e3322-wk-Fact-16A9BB4B63EF5F7EB6F45D9393027530"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e3341-wk-Fact-CC8A62AD9F9755F89A015CC6C866540D"
      unitRef="usd">46744000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q3_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e3360-wk-Fact-E245764C81B3592E973759AE060AC8CE"
      unitRef="usd">24000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e3387-wk-Fact-A31AB5A465B455008D698E03DB5D20E5"
      unitRef="usd">119808000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e3406-wk-Fact-7EA86A7C6C0053228910240280CD8C35"
      unitRef="usd">90000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e3426-wk-Fact-B3D9151747FC5A5BB4C127293EDA5298"
      unitRef="usd">4398000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e3446-wk-Fact-2D915A5E86855F3BB494C9AF0627F201"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e3466-wk-Fact-3829F0E9F0E75322ABFC8F13025C79F0"
      unitRef="usd">124206000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e3486-wk-Fact-A00EC9C8D39554EFBA52CA998AF4C936"
      unitRef="usd">91000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3907-wk-Fact-AF3FC49B17C657C9A9AD9BE9B8578089"
      unitRef="usd">236162000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3926-wk-Fact-07482191F7245442A44858F9784E6D49"
      unitRef="usd">606000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3946-wk-Fact-5C68B722921D5037992C07476F133306"
      unitRef="usd">39627000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3966-wk-Fact-FDAA055594D4500CB11E10E4BAEC5CD9"
      unitRef="usd">251000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e3986-wk-Fact-4A0F6E0262465DB5AF54FEC602E6327C"
      unitRef="usd">275789000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143671945e4006-wk-Fact-423E2EFEEE585CE69D5B28BDCEC928D3"
      unitRef="usd">857000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e4022-wk-Fact-22E351281A7B5989A036AD7513FEEB78"
      unitRef="usd">28105000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e4041-wk-Fact-D85D6E65A1E65D0485F7686D327FBA92"
      unitRef="usd">16000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e4061-wk-Fact-D9FB17BCEF0556389E5EB822144D10F9"
      unitRef="usd">9182000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e4081-wk-Fact-989941EF5D4D5288ACA7DD17BADB4975"
      unitRef="usd">9000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e4101-wk-Fact-0F40D14108C95881B18733EFAB26A002"
      unitRef="usd">37287000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143671945e4120-wk-Fact-D9A32A9CC2075EE5A9AEACA925881DBF"
      unitRef="usd">25000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e4142-wk-Fact-DC15A9B211C45B71A428A03713FC9847"
      unitRef="usd">7091000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e4161-wk-Fact-E6B5EB9E5449534987D467B3FDC53E7E"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e4181-wk-Fact-2453EA623EB1592E9B0B46E46C08305F"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e4201-wk-Fact-2428B557AABC5B2C8831318D2422FDCF"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e4220-wk-Fact-B8D31D23BFE35DC0B406F495C7D35289"
      unitRef="usd">7091000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143671945e4239-wk-Fact-EB4E55C4AD8F5E80AC0BE55F0217AC6B"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e4266-wk-Fact-D0B8639509985886B8B5B308813BAE53"
      unitRef="usd">271358000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e4285-wk-Fact-1A6527AD5F78575C9E07BC0F5FB8AA79"
      unitRef="usd">623000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e4305-wk-Fact-D593E064BEA75D64B44600EB4C395546"
      unitRef="usd">48809000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e4325-wk-Fact-F045672B07E559F9B9661B75EFDBE4FC"
      unitRef="usd">260000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e4345-wk-Fact-920BAFF7821957BB84F7E09E73E319BA"
      unitRef="usd">320167000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e4365-wk-Fact-18CDC15B051A5AC8A196DED3CB775E8A"
      unitRef="usd">883000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="FI2019Q3"
      decimals="INF"
      id="d143671945e4380-wk-Fact-D76360FDF39E5DF495927D6693530966"
      unitRef="investment">43</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="FI2018Q4"
      decimals="INF"
      id="d143671945e4384-wk-Fact-2B3B3A947F785757BCCDAD67C03ACD04"
      unitRef="investment">199</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d143671945e4409-wk-Fact-3C36AE4E3A495EE18974951EA7C432D8"
      unitRef="usd">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-15E4062619C95B35B2CE6529208723ED-0-wk-Fact-2F459344FE7756C39BF466BD2DCA2E02">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing in one year or less&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;743,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;674,455&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;474,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;153,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,218,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e4523-wk-Fact-21780DCB01985417BEDBE2743BE6C52F"
      unitRef="usd">743768000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e4542-wk-Fact-77D67A9592F856CBA07C91D661774764"
      unitRef="usd">674455000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e4557-wk-Fact-2EA321E64A35505793021CFB866EDE42"
      unitRef="usd">474569000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e4576-wk-Fact-2172B57EADFF50EBA3CDB98722D0BDFC"
      unitRef="usd">153687000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143671945e4601-wk-Fact-E91A118BF7525CB2975AC30E5897A32B"
      unitRef="usd">1218337000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143671945e4620-wk-Fact-49FC0313E7EF513E8D58AB82AFF52A84"
      unitRef="usd">828142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:OwnershipInterestByMinorityShareholder
      contextRef="FI2018Q4"
      decimals="2"
      id="d143671945e4640-wk-Fact-5E75EC7332A85270B217018FB60833C8"
      unitRef="number">0.10</exel:OwnershipInterestByMinorityShareholder>
    <exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner
      contextRef="FI2019Q3"
      decimals="-5"
      id="d143671945e4654-wk-Fact-B475DFF648E053CD91BA04CF5D42CF18"
      unitRef="usd">470800000</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner>
    <exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner
      contextRef="FI2018Q4"
      decimals="-5"
      id="d143671945e4659-wk-Fact-BAF5556FC5AE5113BBB19BAE06D04436"
      unitRef="usd">298500000</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner>
    <exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund
      contextRef="FI2019Q3"
      decimals="-5"
      id="d143671945e4663-wk-Fact-C4F6D4D1D4405108AD478E2D28F724DC"
      unitRef="usd">1900000</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund>
    <exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund
      contextRef="FI2018Q4"
      decimals="-5"
      id="d143671945e4667-wk-Fact-2DDA9FD7738D59998881FB7AD31EFEE6"
      unitRef="usd">3000000.0</exel:RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund>
    <us-gaap:DueToRelatedPartiesCurrent
      contextRef="FI2019Q3"
      decimals="-5"
      id="d143671945e4675-wk-Fact-6C562E809D33CD53CCD8003E9DF8DA66"
      unitRef="usd">9000000.0</us-gaap:DueToRelatedPartiesCurrent>
    <exel:RelatedPartyTransactionsAdvisoryFeesIncurred
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d143671945e4684-wk-Fact-9C21F5556764526EAF68FAECF645EDCA"
      unitRef="usd">200000</exel:RelatedPartyTransactionsAdvisoryFeesIncurred>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-6995F3DB6AE75E758EE6188561F3684E-0-wk-Fact-71C27A01E46152AFBF2B8872D07D039B">INVENTORY&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion included in Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,886&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Write-downs related to excess and expiring inventory are charged to Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.8 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory not expected to be used in production or sold in the next 12 months is classified as Other long-term assets in the accompanying Condensed Consolidated Balance Sheets. As of both &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the long-term portion of inventory consisted of portions of our raw materials and finished goods, and as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, also a portion of our work in process.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-112526C7CCBE562A8F19F1AA5DC284C9-0-wk-Fact-704AA602CEFD50D5B50427C75E1F15A0">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Raw materials&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,906&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7,311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,836&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion included in Other long-term assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,886&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,090&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;11,928&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143657110e514-wk-Fact-ECE0497F7C3B51FA8C555B05ABC338F4"
      unitRef="usd">1906000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143657110e533-wk-Fact-511D99820A4B5F9F80B3885182B49CDC"
      unitRef="usd">1922000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143657110e548-wk-Fact-A27757F1D40F5181AC8FF3FC9BF4B7C2"
      unitRef="usd">11035000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143657110e567-wk-Fact-E9CB03A31A9C5297835A04F7E94EADE3"
      unitRef="usd">6170000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143657110e587-wk-Fact-FFCCB9C06B7C5BF5AAE4C03AE71536D9"
      unitRef="usd">7311000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143657110e606-wk-Fact-085E320AED60516BBDE74DF418458A5B"
      unitRef="usd">3836000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143657110e631-wk-Fact-C05DECB69BF15ECBBCB11B1B2155E936"
      unitRef="usd">20252000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143657110e650-wk-Fact-6C65BEC07798519AA7754C3436057C22"
      unitRef="usd">11928000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember"
      decimals="-3"
      id="d143657110e752-wk-Fact-944E4D5054F75A1384514F3D3FABA1EE"
      unitRef="usd">13366000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_InventoriesMember"
      decimals="-3"
      id="d143657110e771-wk-Fact-70F8572A0D315F7386646E0B51872C20"
      unitRef="usd">9838000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q3_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember"
      decimals="-3"
      id="d143657110e786-wk-Fact-160D7639DFC0553D9C0797B8D703595D"
      unitRef="usd">6886000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_exel_OtherLongtermAssetsMember"
      decimals="-3"
      id="d143657110e805-wk-Fact-4AAB4C196BF158B7B3690C9E8D821B96"
      unitRef="usd">2090000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143657110e830-wk-Fact-C05DECB69BF15ECBBCB11B1B2155E936"
      unitRef="usd">20252000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143657110e849-wk-Fact-6C65BEC07798519AA7754C3436057C22"
      unitRef="usd">11928000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d143657110e863-wk-Fact-ECE9900BAD12568B89D9DC1AA8AC9CF2"
      unitRef="usd">400000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="D2018Q3YTD1"
      decimals="-5"
      id="d143657110e867-wk-Fact-6D22965D90685A3086091F6BFD17D839"
      unitRef="usd">800000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-D807BB3E6F5B5D068CD5B838B42DE491-0-wk-Fact-572FE19D83F05A0EB91EEB144DB2BECE">PROPERTY AND EQUIPMENT &lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,769&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72,864&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Depreciation expense was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$6.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and for the comparable periods in &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-6F7214D306D85950B9AEDAAF5ED079B8-0-wk-Fact-4965F52DD1FA55418F7734C8FE2647BA">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Property and equipment consisted of the following (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Leasehold improvements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,769&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,941&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Computer equipment and software&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,017&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,022&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,053&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Laboratory equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;617&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;866&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;72,864&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;68,206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(23,397&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(17,309&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Property and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49,467&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50,897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d143660005e501-wk-Fact-4DCB05F2FA2557FCAFF7BD7ECED43A2E"
      unitRef="usd">33769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember"
      decimals="-3"
      id="d143660005e520-wk-Fact-402BF78B61605C9AA70D86C7924DCAD1"
      unitRef="usd">33941000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember"
      decimals="-3"
      id="d143660005e535-wk-Fact-706B01DE05B155368D16A61AF221F143"
      unitRef="usd">17017000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_ComputerEquipmentAndSoftwareMember"
      decimals="-3"
      id="d143660005e554-wk-Fact-79B6C4AC254D5BE19857115BC5DEF965"
      unitRef="usd">15022000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d143660005e574-wk-Fact-65577948D0415DC6BF420D73CF8E5B5F"
      unitRef="usd">13053000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-3"
      id="d143660005e593-wk-Fact-E20D57F00E7251F69E228B23F1636FED"
      unitRef="usd">12709000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember"
      decimals="-3"
      id="d143660005e613-wk-Fact-F3CBEA8C8FBF52019B8AEA63E45EC373"
      unitRef="usd">8408000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_exel_LaboratoryEquipmentMember"
      decimals="-3"
      id="d143660005e632-wk-Fact-B8C396A8E49658CDB462786A6EBE691D"
      unitRef="usd">5668000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d143660005e652-wk-Fact-57901F8602EA520E9D294C213D9705E5"
      unitRef="usd">617000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-3"
      id="d143660005e671-wk-Fact-CA2AFB0FA14A54DCBF8EF340ACDFF9FE"
      unitRef="usd">866000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143660005e691-wk-Fact-0A9414B32014507B82A0C9C6FAC9C443"
      unitRef="usd">72864000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143660005e710-wk-Fact-AF5E9D08B25353B4AA4EDC8EC67048D9"
      unitRef="usd">68206000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143660005e730-wk-Fact-3C718879C78B59549736A659DB48ABA8"
      unitRef="usd">23397000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143660005e750-wk-Fact-9682A3F265A55C0887F6AE30FDF54EA9"
      unitRef="usd">17309000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143660005e776-wk-Fact-FFFCB7E5E0345888A600381F271F9035"
      unitRef="usd">49467000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143660005e795-wk-Fact-C991BEDAA3F551B189FD2DED431834BC"
      unitRef="usd">50897000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="FD2019Q3QTD"
      decimals="-5"
      id="d143660005e810-wk-Fact-ACCA02623D5E0973B412F05905880943"
      unitRef="usd">2100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d143660005e814-wk-Fact-555A49264CDD56E38A2B6434E71CF7E3"
      unitRef="usd">6100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D2018Q3QTD1"
      decimals="-5"
      id="d143660005e826-wk-Fact-1DC4C34AFAA2F866EFE8B4A53C3FD65C"
      unitRef="usd">1700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="D2018Q3YTD1"
      decimals="-5"
      id="d143660005e831-wk-Fact-1B1B0564332C54BB94D407397D4D1E9D"
      unitRef="usd">2900000</us-gaap:Depreciation>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-901C6A70EBAD51CBBD5167883D0CC259-0-wk-Fact-57207428418E58DF872D369099D97D0D">STOCK-BASED COMPENSATION&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,747&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We have several equity incentive plans under which we have granted stock options and restricted stock units (RSUs) to employees and directors. At &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;6,024,995&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares were available for grant under our equity incentive plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We used a Monte Carlo simulation pricing model to value stock options that include market vesting conditions and a Black-Scholes Merton option pricing model to value other stock options and ESPP purchases. The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.0 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We considered our implied volatility and our historical volatility in developing our estimates of expected volatility. The assumptions for the expected life of stock options were based on historical exercise patterns and post-vesting termination behavior. The risk-free interest rate is based on U.S. Treasury rates with the same or similar term as the underlying award. Our dividend rate is based on historical experience and our investors&#x2019; current expectations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The fair value of RSUs was based on the closing price of the underlying common stock on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for stock options during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Exercise Price Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,674,062&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,042,286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3,042,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(160,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(35,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,478,861&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,860,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$38.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to our unvested stock options. The compensation expense for the unvested stock options will be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;2.3 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for RSUs during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair&#160;Value Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,857,334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,635,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(484,731&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(258,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,749,823&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;175,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, there was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$166.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of unrecognized compensation expense related to our unvested RSUs, including those RSUs granted in September 2018 and September 2019 that will vest upon the achievement of specific performance targets (PSUs) described below. The compensation expense for the unvested RSUs will be recognized over a weighted-average period of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;2.8 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During 2019, in connection with our long-term incentive compensation program, we awarded &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1,926,605&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; RSUs &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;(the target amount) &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;that will vest upon the achievement of a performance target related to a product approval by the FDA (the 2019 PSUs); employees may earn &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;150%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the target amount&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, or an additional &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;963,136&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares relative to the target amount, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;if the performance target is achieved before December 31, 2020 and may earn the full &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;200%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the target amount, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;or up to an additional &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1,926,605&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; shares relative to the target amount, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;if we receive a second product approval. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;During 2018 we awarded &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;693,131&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; RSUs that will vest upon the achievement of certain product revenue, late-stage clinical development and pipeline expansion performance targets (the 2018 PSUs). The 2018 PSUs and 2019 PSUs were designed to drive the performance of our management team and employees toward the achievement of key corporate objectives and will be forfeited if the performance targets are not met by December 31, 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Expense recognition for PSUs commences when it is determined that attainment of the performance &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;target&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; is probable. During the quarter ended June &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we achieved one of the two &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;product revenue related &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;targets&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;114,843&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; of the 2018 PSUs and determined that it was probable that we would achieve the second &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;product revenue related &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;performance &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;target&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;172,272&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; additional 2018 PSUs. D&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;uring the quarter ended September 30, 2019, the second product revenue related performance target &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;of the 2018 PSUs &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;was achieved&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. Those 2018 PSUs will vest over various dates through February 2021. We recognized &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$0.9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$3.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in compensation expense related to those 2018 PSUs during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively; the remaining unrecognized compensation expense for those 2018 PSUs was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. The total unrecognized compensation expense for &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;both the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;2019 PSUs and the remaining 2018 PSUs for which we have not yet determined that attainment of the performance &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;target&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; is probable was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$82.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-CA0545C00FED5C2D81FCA2BDE7354588-0-wk-Fact-36FD582755F5514F90A881B5D0DAF4F8">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,573&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;27,002&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19,228&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;40,747&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;28,330&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d143674968e639-wk-Fact-C62701B908255334B4CB57D8FA8608C6"
      unitRef="usd">4301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q3QTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d143674968e658-wk-Fact-EB1314AE60955CD088C8FD1DFB294E1F"
      unitRef="usd">3169000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d143674968e677-wk-Fact-16807CD9F7F0519B8A7532B741C6C87E"
      unitRef="usd">13745000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q3YTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="d143674968e697-wk-Fact-647291F1FC1D5DDE9BC6A7F87801D0F6"
      unitRef="usd">9102000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d143674968e712-wk-Fact-99484990538359E1801AFC3B1F708836"
      unitRef="usd">8838000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q3QTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d143674968e731-wk-Fact-F7882D71944052A785D043299B32A643"
      unitRef="usd">6573000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d143674968e750-wk-Fact-A8B2D3FD779F59EEA9948C66EF69175D"
      unitRef="usd">27002000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q3YTD1_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="d143674968e770-wk-Fact-6DB2B76C7B5A56C488C38D689E74C5E0"
      unitRef="usd">19228000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143674968e795-wk-Fact-F717B99DCA7F58808ABA00BCB3FF9AB7"
      unitRef="usd">13139000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143674968e814-wk-Fact-E0789D6740D25554B7EC3B0B3604A2D8"
      unitRef="usd">9742000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143674968e833-wk-Fact-498D1EB89533578CB672D3FB7970E3D6"
      unitRef="usd">40747000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143674968e853-wk-Fact-7767985AB1CB511B94D3B4DD1F0F68B6"
      unitRef="usd">28330000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q3"
      decimals="INF"
      id="d143674968e878-wk-Fact-F0B0A82238505028984DD8A6C52C43D1"
      unitRef="shares">6024995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-5FD1B6EE3B6A5E5281B9B9541BD5F448-0-wk-Fact-D2C2DE752A985CFF8D3EAA20EF072417">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6.96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1093-wk-Fact-BB0741BC6FC7582AB6625933CADCBC0A"
      unitRef="usdPerShare">7.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1112-wk-Fact-B1457153AD1E5B85854E32DFB0D1D3D1"
      unitRef="usdPerShare">8.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1131-wk-Fact-9F3A3CADB8375024989209566088AE4A"
      unitRef="usdPerShare">8.57</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1151-wk-Fact-4BF439A8DE385045B64845C474DC6235"
      unitRef="usdPerShare">9.13</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1171-wk-Fact-223AAD6C12585F268E2A3B16155E3A6E"
      unitRef="usdPerShare">5.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1190-wk-Fact-798DA50E194F501884F1E8B79ECE31E7"
      unitRef="usdPerShare">6.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1209-wk-Fact-815DC44774395812A319465BBF389B5D"
      unitRef="usdPerShare">4.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1229-wk-Fact-4232E61BBED4501E801D9F0ED694639A"
      unitRef="usdPerShare">6.96</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-7A05F98B42575D129F061BCE6A4DD637-0-wk-Fact-01641E1E41A050DABDAF1F2A698C0AD6">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Stock options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.0 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;ESPP:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.09&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expected life&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6 months&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d143674968e1467-wk-Fact-5A070C540F10598D9285FA315431F529"
      unitRef="number">0.0157</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d143674968e1482-wk-Fact-7CE8795E7F12571CAD9B27384DE9D549"
      unitRef="number">0.0291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d143674968e1497-wk-Fact-1D234BD904AE5CA1948D4DE3DBF033D6"
      unitRef="number">0.0182</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d143674968e1512-wk-Fact-6348CD79F9B25E4D869D8CCB54EEF21F"
      unitRef="number">0.0283</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1529-wk-Fact-353F876E0D8B58FBA957E65452BF8F72"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1544-wk-Fact-39EF00A402C45480BBC7A5B316FE6AEE"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1559-wk-Fact-E02E64A472575D4D886391531806933C"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1574-wk-Fact-BD386A0E39A353179899351C95A640B8"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1591-wk-Fact-272CE0DFE0FA59918CA712E4A84F6D9C"
      unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1606-wk-Fact-04F0B1D7E92E5970B4965896A59EA3AC"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1621-wk-Fact-4289D643EFE455C3A5EAB5C4821A4A27"
      unitRef="number">0.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="2"
      id="d143674968e1636-wk-Fact-6D88B87E32E5549A81F3B76F937AC7B1"
      unitRef="number">0.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d143674968e1653-wk-Fact-22FC4A45F0935B43AB55DF874365EEE8">P4Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d143674968e1667-wk-Fact-FB9186E5457955D69015CC412AFAF3F8">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d143674968e1681-wk-Fact-607841F135F5501CA043E8279C47578D">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d143674968e1695-wk-Fact-892763382AD35727A5EBE579ED9B6942">P4Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d143674968e1773-wk-Fact-533C42963F6C570B99FDC79203D179BB"
      unitRef="number">0.0209</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d143674968e1788-wk-Fact-01F286598A6A5880BB60EB7A7A0340BF"
      unitRef="number">0.0211</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d143674968e1803-wk-Fact-79FCD18DC0BD542E9014A388D2111253"
      unitRef="number">0.0234</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="4"
      id="d143674968e1818-wk-Fact-00F2E7EE8C8B5887AD5363D49B04016D"
      unitRef="number">0.0174</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1835-wk-Fact-0BAE95D5170B52E3AA31AB764A2AF462"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1850-wk-Fact-B64A85C597EF578BBC1DDDF1D96B5E64"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1865-wk-Fact-AE7CB2CF49B854A890E85C5ED5832194"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1880-wk-Fact-BB01805194585D42BC1BC49F628C8EE2"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1897-wk-Fact-B2DD9A2CC05D589B9638FF6687D06861"
      unitRef="number">0.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1912-wk-Fact-E250BB8FC4C65023BA790476DD0889BD"
      unitRef="number">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1927-wk-Fact-F9AB99C99817516287CE7B92B195BCF3"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      decimals="2"
      id="d143674968e1942-wk-Fact-AE72B75F26EA586C9ED81092F5B83CF6"
      unitRef="number">0.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d143674968e1960-wk-Fact-41F28C3F86E6560A9165BE80CB2A69EA">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q3QTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d143674968e1974-wk-Fact-A447D81345CA510BA0289F6EB27A1BE0">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d143674968e1988-wk-Fact-0BC4603A5EEA5EB68B7D92CB9AAF188B">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="D2018Q3YTD1_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockMember"
      id="d143674968e2002-wk-Fact-F8AFC08B7BA85B63877C8D03E4B68B9C">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-34DEFEA1649651CBA4B65C0C00888C51-0-wk-Fact-DB04720DEC9C5A6F96781CDA3E47EF69">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for stock options during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Exercise Price Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;22,674,062&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;8.71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,042,286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20.81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(3,042,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4.94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(160,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16.76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(35,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Options outstanding at September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;20,478,861&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3.4 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;186,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Exercisable at September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,860,131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;7.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.8 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;181,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4"
      decimals="INF"
      id="d143674968e2170-wk-Fact-6B64D35BF76A538BAAC77DB319B276D7"
      unitRef="shares">22674062</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d143674968e2189-wk-Fact-BB985348AE2C54E0938FB50EE6042FB4"
      unitRef="usdPerShare">8.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d143674968e2235-wk-Fact-239843759B2A54FD856FD78177234CF2"
      unitRef="shares">1042286</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d143674968e2254-wk-Fact-B5F29355D2FF599B8230B9A1896740CF"
      unitRef="usdPerShare">20.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d143674968e2300-wk-Fact-34FACB7DF8595CD8AB9B38051F3BCE58"
      unitRef="shares">3042201</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d143674968e2320-wk-Fact-A44B26FA1A6C54699D16E3959E99B8D0"
      unitRef="usdPerShare">4.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d143674968e2366-wk-Fact-435B1FA3A7455176AA72D836D9C3B6C1"
      unitRef="shares">160241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d143674968e2386-wk-Fact-F7DB2F5786545435A61BA49836591F0C"
      unitRef="usdPerShare">16.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d143674968e2432-wk-Fact-69D74B8552B05C37B3361208A2B3C22C"
      unitRef="shares">35045</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d143674968e2452-wk-Fact-7CDD322371595D578425599B76100E36"
      unitRef="usdPerShare">23.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q3"
      decimals="INF"
      id="d143674968e2498-wk-Fact-A3B9FD49714559CF9362EF3510579F48"
      unitRef="shares">20478861</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q3"
      decimals="2"
      id="d143674968e2517-wk-Fact-3991AB6E3F065BE38D0F1049FDFE1415"
      unitRef="usdPerShare">9.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q3YTD"
      id="d143674968e2531-wk-Fact-F11FE3C0BD45524ABF9EBECBD4EEF916">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143674968e2547-wk-Fact-CC60CACB9F9C5A4E8B2BE3BA1A9D8527"
      unitRef="usd">186407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="FI2019Q3"
      decimals="INF"
      id="d143674968e2562-wk-Fact-FE67A4B1751B5AAC90B00EFFD1A3EFA9"
      unitRef="shares">15860131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="FI2019Q3"
      decimals="2"
      id="d143674968e2581-wk-Fact-20E7C3561B6F5017B2207E8C61C2BF32"
      unitRef="usdPerShare">7.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q3YTD"
      id="d143674968e2595-wk-Fact-31D4C8490CB7576BA034131C4E7DB789">P2Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143674968e2611-wk-Fact-12D23F71CDF151C79D0C9870600D487D"
      unitRef="usd">181542000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-5"
      id="d143674968e2636-wk-Fact-BE9636119A235B8D8A561156B1CE1B7B"
      unitRef="usd">38000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d143674968e2640-wk-Fact-EFF9E6B88A9D5045BEA5D8E95DCE1114">P2Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-8BCD520A6EC459FBBDC80A21558D6705-0-wk-Fact-2FA2C8BF21FD58EAABF75A0D2742B6AF">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Activity for RSUs during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was as follows (dollars in thousands&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;"&gt;, &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Grant&#160;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fair&#160;Value Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Weighted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Term&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Intrinsic&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,857,334&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Awarded&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,635,362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Vested and released&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(484,731&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(258,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;18.47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;RSUs outstanding at September 30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;9,749,823&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;19.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2.2 years&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;175,448&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d143674968e2793-wk-Fact-A71E1C1511C25EBEB0A0865EC47924EF"
      unitRef="shares">4857334</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d143674968e2812-wk-Fact-609F3C1A506F5887AA552DB30ED33F19"
      unitRef="usdPerShare">18.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d143674968e2858-wk-Fact-15FEE31749CC57518B64075964FA72D3"
      unitRef="shares">5635362</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d143674968e2877-wk-Fact-56F6AB6BA39257BDBFF55D282180E468"
      unitRef="usdPerShare">19.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d143674968e2923-wk-Fact-E1BEE2B3B23A591FA5D58D942153A5DB"
      unitRef="shares">484731</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d143674968e2943-wk-Fact-679BADBD1A005665947765552FC5F2CA"
      unitRef="usdPerShare">12.33</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d143674968e2989-wk-Fact-4342E17DBBAA5E63ADC8EF298947100E"
      unitRef="shares">258142</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d143674968e3009-wk-Fact-B773D76588F7531095C23D3A7C21B102"
      unitRef="usdPerShare">18.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="d143674968e3055-wk-Fact-D03D21B3748759C78DD612D1EC0E3D25"
      unitRef="shares">9749823</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d143674968e3074-wk-Fact-62EFD57E2BA75AC789F5B6403C222A9E"
      unitRef="usdPerShare">19.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d143674968e3088-wk-Fact-422446928FB1556DB02EB522B35E50AC">P2Y2M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue
      contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d143674968e3104-wk-Fact-D5DB4F92AFAC53ABACFD132F0CF48BD2"
      unitRef="usd">175448000</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q3_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d143674968e3127-wk-Fact-C7567192148E5985A2CEBF396C91C579"
      unitRef="usd">166000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d143674968e3131-wk-Fact-E88B5B4A9E2958E988D9AFF45A12F7A3">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d143674968e3138-wk-Fact-B2DFCA7301D040D8B2A9B4AFAFCB5C7D"
      unitRef="shares">1926605</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member"
      decimals="INF"
      id="d143674968e3146-wk-Fact-7D2499B902C18379CF0D03A54F6BAA00"
      unitRef="number">1.50</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesAchievedBeforeDecember312020Member"
      decimals="INF"
      id="d143674968e3152-wk-Fact-E1D756560B8DCC4AFF0E03A7F4FAAC1D"
      unitRef="shares">963136</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember"
      decimals="INF"
      id="d143674968e3159-wk-Fact-4F89A92DC28A14952C1003A5B2E95EF6"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_exel_PerformanceSharesSecondProductApprovalMember"
      decimals="INF"
      id="d143674968e3165-wk-Fact-5FEE1391A41D2302C7D903A7F4FEDA5B"
      unitRef="shares">1926605</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherthanOptionsMaximumNumberOfSharesToVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="D2018Q4Q4YTD-DEC3017-DEC2818_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d143674968e3173-wk-Fact-2D5D3F2F6FBA56EDA026C82EE25919A3"
      unitRef="shares">693131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q2_exel_StatusAxis_exel_AchievedMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d143674968e3196-wk-Fact-9CA243739686566CBEFF8E14D139A89B"
      unitRef="shares">114843</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q2_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d143674968e3209-wk-Fact-2230C8136FE95CFABACD4134E165762B"
      unitRef="shares">172272</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3QTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d143674968e3221-wk-Fact-AEA461C020C9A58C7E18B4AF77F8BAC5"
      unitRef="usd">900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q3YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d143674968e3226-wk-Fact-7F0A28D63D5A53ADAD0CDFC84FB1B94E"
      unitRef="usd">3500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q3_exel_StatusAxis_exel_ProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d143674968e3238-wk-Fact-64A6E3348EDA5F9EBFD37B1BFFF884D4"
      unitRef="usd">1700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q3_exel_StatusAxis_exel_NotProbableMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d143674968e3255-wk-Fact-E93D9E84221659DFAC6425787B148091"
      unitRef="usd">82400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-D8E336F84EB15A119F445D0EB22BEEF8-0-wk-Fact-F265E97DFDB75C8E87D3556C1594AD9C">INCOME TAXES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Our effective income tax rate was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;20.5%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;19.4%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively, as compared to &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1.8%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;1.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, respectively. &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Provision for income taxes &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;relating to our pre-tax income &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was largely offset by a valuation allowance against our net operating loss carryforwards and other deferred tax assets. At December 31, 2018, we released substantially all of our valuation allowance against our deferred tax assets, after we determined that it was more likely than not that these deferred tax assets would be realized.&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The effective tax rate for the&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; differed from the U.S. federal statutory rate of&#160;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;21%&lt;/span&gt;&lt;/span&gt;&#160;primarily due to excess tax benefits related to the exercise of certain stock options during those periods.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q3QTD"
      decimals="3"
      id="d143667629e431-wk-Fact-738EF8E4B1A457F184297C63551BA2F3"
      unitRef="number">0.205</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q3YTD"
      decimals="3"
      id="d143667629e435-wk-Fact-BAAD485ABBBE57ADBF1B4EF3E417CCAB"
      unitRef="number">0.194</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="D2018Q3QTD1"
      decimals="3"
      id="d143667629e449-wk-Fact-1B42BDC211F45D36B71B654C154FDC35"
      unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="D2018Q3YTD1"
      decimals="3"
      id="d143667629e454-wk-Fact-567CA0013E885E109CD4781A8921B4EF"
      unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q3YTD"
      decimals="INF"
      id="d143667629e494-wk-Fact-76B5A5EAC767B4AB8BD9D0CA74D2FA93"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1CA8933A9964558C902EB15BD7C2EABF-0-wk-Fact-D50DEFEC6318520A86E3EA270A96859A">NET INCOME PER SHARE&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;97,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126,630&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;252,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;329,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;303,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;298,416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;301,999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;297,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,047&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;312,346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;313,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Dilutive securities include outstanding stock options, unvested RSUs and ESPP contributions. Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-D6688AE1DC515E9A8952676AEBF23204-0-wk-Fact-DA30B75D3BF95359AA3381FEEB36F69E">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Numerator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;97,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;126,630&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;252,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;329,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Denominator:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding used in computing basic net income per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;303,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;298,416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;301,999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;297,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;13,047&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;15,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;312,346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;315,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;313,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:20px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Net income per share, diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;0.80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1.05&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143664420e720-wk-Fact-33514420391A5101991C7BB7C90293A3"
      unitRef="usd">97452000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143664420e739-wk-Fact-8C3C2FC35F795107AAE02B8C4A08884B"
      unitRef="usd">126630000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143664420e758-wk-Fact-CCF41ECC0D505BBDB32B1D66AC205ED7"
      unitRef="usd">252269000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143664420e778-wk-Fact-7923EE2A64765CCAAA00EC2CE31460C3"
      unitRef="usd">329981000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143664420e875-wk-Fact-B2460438003B573BB27D88592E43DFF0"
      unitRef="shares">303268000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143664420e894-wk-Fact-904A3CF19F5155C896687A434A608ABA"
      unitRef="shares">298416000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143664420e913-wk-Fact-F68635B2F0675E93843E7DCBDB37B465"
      unitRef="shares">301999000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143664420e933-wk-Fact-40A13BFAEDB552D8A32F7A6DB7E3A3FB"
      unitRef="shares">297700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143664420e953-wk-Fact-3769215076BB57A0A3B9877CEA07DBCE"
      unitRef="shares">12185000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143664420e972-wk-Fact-E5BB75B624015322B41F960DA950A2EC"
      unitRef="shares">13930000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143664420e991-wk-Fact-A787E60DD6A05F97B400FF1B9AADE45C"
      unitRef="shares">13047000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143664420e1011-wk-Fact-5ED4FD084F285F4791DA8BA229BEE364"
      unitRef="shares">15500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143664420e1031-wk-Fact-EEF4AE03E94B5C6E8E384202B0413F9A"
      unitRef="shares">315453000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143664420e1050-wk-Fact-A9F1D9BC443D55E599B95686A10E4AEC"
      unitRef="shares">312346000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143664420e1069-wk-Fact-B53428C464DB589AB5C824036B2F50A4"
      unitRef="shares">315046000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143664420e1089-wk-Fact-6BD2776EB4935083A5A3E0C2DAA2ADAD"
      unitRef="shares">313200000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d143664420e1196-wk-Fact-46B6F1340B325926B636C2196DE13C68"
      unitRef="usdPerShare">0.32</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q3QTD1"
      decimals="2"
      id="d143664420e1215-wk-Fact-8CA9C79F88205827970EA61D11A2992D"
      unitRef="usdPerShare">0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d143664420e1234-wk-Fact-B75F2EEA889D5D88A99E107841855D59"
      unitRef="usdPerShare">0.84</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="D2018Q3YTD1"
      decimals="2"
      id="d143664420e1254-wk-Fact-19D1A4B42FA550EDB8287A92F1203E8E"
      unitRef="usdPerShare">1.11</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3QTD"
      decimals="2"
      id="d143664420e1274-wk-Fact-85C96FDDE2775831935EC174B4BAB3AC"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q3QTD1"
      decimals="2"
      id="d143664420e1293-wk-Fact-9472515601E8583EB376A8ADDF708C8C"
      unitRef="usdPerShare">0.41</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q3YTD"
      decimals="2"
      id="d143664420e1312-wk-Fact-9C881D80109855308725A2DA072883D8"
      unitRef="usdPerShare">0.80</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="D2018Q3YTD1"
      decimals="2"
      id="d143664420e1332-wk-Fact-68993515AEDD56A8994B919BD2AB4430"
      unitRef="usdPerShare">1.05</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1B397273EFB9527BA2A322652F56D347-0-wk-Fact-D5D15E63D5765B40AA554E76AD56970A">Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&#160;&lt;/span&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Potentially dilutive securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;6,153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;5,740&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,938&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q3QTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d143664420e1515-wk-Fact-2170CAEE363251A2B5F741D45DEE80CF"
      unitRef="shares">6153000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D2018Q3QTD1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d143664420e1529-wk-Fact-4EA3D9CFA8B053078A00BB3C260EB3F1"
      unitRef="shares">5687000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d143664420e1543-wk-Fact-397100959AF6595A89FA5A5A6CC6129D"
      unitRef="shares">5740000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="D2018Q3YTD1_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockCompensationPlanMember"
      decimals="-3"
      id="d143664420e1557-wk-Fact-5FE36E95409E522E8CBCD5D66B6BC2B5"
      unitRef="shares">2938000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-97735B41758A58058A1E5255193A307F-0-wk-Fact-B8D4B1E1C44D549BA8BBE42F5197E471">FAIR VALUE MEASUREMENTS&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,191,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,218,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,220,888&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,247,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;796,994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;844,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;We did not have any financial liabilities measured and recorded at fair value on a recurring basis as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We did not have any financial assets or liabilities classified as Level 3 in the fair value hierarchy as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. There were no transfers of financial assets or liabilities between Levels 1, 2 and 3 during the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;three and nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; or &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See &#x201c;Note 11. Leases&#x201d; for a description of the determination of the amount of operating lease liabilities. Our remaining financial assets and liabilities include cash and restricted cash, Trade receivables, net, Other receivables, Accounts payable, Accrued compensation and benefits, Accrued clinical trial liabilities, Accrued collaboration liabilities and Rebates and fees due to customers. Those financial assets and liabilities are carried at cost, which approximates their fair values.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-4CA41CEF47535BE6A71C7DB25F503E38-0-wk-Fact-A49D75EC355950A299B77D16687D5726">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;332,239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;706,807&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;152,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,191,696&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,218,337&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;29,192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,220,888&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,247,529&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Commercial paper&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;381,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Corporate bonds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;344,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;U.S. Treasury and government sponsored enterprises&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;55,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total investments available-for-sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;780,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;828,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Certificates of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;16,596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;47,744&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;796,994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;844,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143665822e589-wk-Fact-5E944502D05E5B639F826A5D3C6A2185"
      unitRef="usd">26641000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143665822e608-wk-Fact-F6D6D631DDBE579D86980F9A455EFFCA"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143665822e627-wk-Fact-907E98BB300A5F628BADAE4A09ED77F5"
      unitRef="usd">26641000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143665822e643-wk-Fact-805B49093CBC503692ED72AA471F0470"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143665822e662-wk-Fact-4CA5942CAE115017B1AC56F3D70C28B6"
      unitRef="usd">332239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143665822e681-wk-Fact-2FA5F044FC445065938D03DC98FAA3A8"
      unitRef="usd">332239000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143665822e702-wk-Fact-5C338E39D6125169AF1201A0653A3711"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143665822e721-wk-Fact-9FF81BB40BDE5170ACFB9476F028BCFD"
      unitRef="usd">706807000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143665822e740-wk-Fact-1B6EC08818665CBBB98E7121C0EF7CD0"
      unitRef="usd">706807000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143665822e761-wk-Fact-8649669847B855BB95A673E148603501"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143665822e780-wk-Fact-CE98B93F9850555BAC72FDA0F1C76411"
      unitRef="usd">152650000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143665822e799-wk-Fact-B8A692BA52E05758B864609DD26C0EAB"
      unitRef="usd">152650000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e820-wk-Fact-C45F0725EB575FADA2334C69C91A71EE"
      unitRef="usd">26641000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e839-wk-Fact-EC0AFEE2201259E984C1498D3BE5D0E3"
      unitRef="usd">1191696000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e858-wk-Fact-7EFE5CC2CACB588E9A2D0D7BDE55B5A1"
      unitRef="usd">1218337000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143665822e879-wk-Fact-DAD9B67489675230BBABE24F17692345"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143665822e898-wk-Fact-A0AA4DD1EF765388B31D4F35976911E4"
      unitRef="usd">29192000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143665822e917-wk-Fact-87A82FC157A057C4AF4743C1CE21B732"
      unitRef="usd">29192000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e943-wk-Fact-7A2FEF06CCDE5483A292A2AD9CA1720C"
      unitRef="usd">26641000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e962-wk-Fact-E5C97B29F7ED519CBE92543DEA87514D"
      unitRef="usd">1220888000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2019Q3_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e981-wk-Fact-7A1FBEA4679B582CAB8255CE3728890D"
      unitRef="usd">1247529000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143665822e1145-wk-Fact-3954DC7118BE522B9DD6DDDAFB1BD18A"
      unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143665822e1164-wk-Fact-CCE6079BB812545CB252CD97DD38623A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-3"
      id="d143665822e1183-wk-Fact-124E5DA8D46358E08279D27F09170B16"
      unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143665822e1199-wk-Fact-18F9FC603BBD5EEA90F5EB3C6B5B3EDF"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143665822e1218-wk-Fact-146023E096EA5E399651720A1C17F687"
      unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CommercialPaperMember"
      decimals="-3"
      id="d143665822e1237-wk-Fact-00E39D1BB25D56CB92ED15FD33074A9B"
      unitRef="usd">381133000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143665822e1258-wk-Fact-D83521A0D25050219C5DC15762AB040F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143665822e1277-wk-Fact-4959B09F66815E41AAD52F545830698E"
      unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateBondSecuritiesMember"
      decimals="-3"
      id="d143665822e1296-wk-Fact-3F9D16759B3253D8B9B1630170963386"
      unitRef="usd">344064000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143665822e1317-wk-Fact-50AD1B97330F51E2BAAEB299C34D8B17"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143665822e1336-wk-Fact-ABC67A5FD2D451A1BA692B1D5E4FD46A"
      unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USTreasuryAndGovernmentMember"
      decimals="-3"
      id="d143665822e1355-wk-Fact-7593CBBD03B35C078B56EBEA4C652EBF"
      unitRef="usd">55201000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e1376-wk-Fact-4F77915F61055B5A86056ABF2DD97F36"
      unitRef="usd">47744000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e1395-wk-Fact-664218DA3284530CBB9B8E2785B309E4"
      unitRef="usd">780398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e1414-wk-Fact-5CCB09C813745A228066D4B223793599"
      unitRef="usd">828142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143665822e1435-wk-Fact-1E2CBC7FE3E45346A4EB9E3C3E92C6CF"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143665822e1454-wk-Fact-E19A6075A4D55C73B66C640970AD65AA"
      unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CertificatesOfDepositMember"
      decimals="-3"
      id="d143665822e1473-wk-Fact-E0E3AF894E915D8AA7EED84DFAC6F03D"
      unitRef="usd">16596000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e1499-wk-Fact-3F3672B587045025B42FDDFE25FD379A"
      unitRef="usd">47744000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e1518-wk-Fact-2249445266015242A615BEF15BFD34DA"
      unitRef="usd">796994000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-3"
      id="d143665822e1537-wk-Fact-992D38885D8D5148A2F463F4E52781BB"
      unitRef="usd">844738000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LesseeFinanceLeasesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1B66225082BA5B44A5C8DEBEA52D7F31-0-wk-Fact-D55B96AF23D15896A7FC2C6955D94ED1">LEASES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;169,606&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet (the Current Premises) as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We have made certain tenant improvements to the space leased on the Initial Premises, for which we received &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in reimbursements in January 2019. The Lease&#x2019;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;th&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year of the initial term (the Early Termination Right); none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The April 2019 amendment to the Lease (the Third Lease Amendment) provides, among other things, for the (i) expansion of the Initial Premises by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;37,544&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;2,703&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for tenant improvements to the 1601 Expansion Space. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we have surrendered the 1751 Space and we have taken possession of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for the Third Lease Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,661&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financing lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of lease costs for operating leases, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,587&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Remainder of 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Years ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,731&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,959&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Present value adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tenant improvement reimbursements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;4.20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the weighted average remaining lease term is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;8.3 years&lt;/span&gt;&lt;/span&gt;.</us-gaap:LesseeFinanceLeasesTextBlock>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-163174E70F8955A499118BE05BA795B4-0-wk-Fact-29B6146B1FF9527386750E5DB0C360D1">LEASES&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In May 2017, we entered into a Lease Agreement (the Lease) for our corporate headquarters located at 1851, 1801 and 1751 Harbor Bay Parkway, Alameda, California (the Initial Premises). The Lease was subsequently amended in October 2017, June 2018 and April 2019, resulting in the addition of the building located at 1601 Harbor Bay Parkway and increasing the leased space to an aggregate of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;169,606&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet (the Current Premises) as of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. We have made certain tenant improvements to the space leased on the Initial Premises, for which we received &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$8.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; in reimbursements in January 2019. The Lease&#x2019;s initial term is through January 31, 2028. Rent payments began February 1, 2018, following the conclusion of a partial twelve-month rent abatement period. We have &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; five-year options to extend the Lease and a one-time option to terminate the Lease without cause on the last day of the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;th&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; year of the initial term (the Early Termination Right); none of these optional periods have been considered in the determination of the right-of-use asset or the lease liability for the Lease as we did not consider it reasonably certain that we would exercise any such options. The Lease further provides that we are obligated to pay the landlord certain variable costs, including taxes and operating expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The April 2019 amendment to the Lease (the Third Lease Amendment) provides, among other things, for the (i) expansion of the Initial Premises by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;37,544&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office facilities located at 1601 Harbor Bay Parkway, Alameda, California (the 1601 Expansion Space) and (ii) surrender of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;2,703&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office facilities located at 1751 Harbor Bay Parkway, Alameda, California (the 1751 Space). The term for the 1601 Expansion Space will run coterminous with the term of the Lease for the existing space. We have been provided an allowance of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$1.7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; for tenant improvements to the 1601 Expansion Space. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we have surrendered the 1751 Space and we have taken possession of the 1601 Expansion Space, and accordingly we have adjusted our right-of-use asset and lease liability, and have begun to recognize lease costs for the Third Lease Amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,661&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financing lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of lease costs for operating leases, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,587&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Cash paid for amounts included in the measurement of lease liabilities for the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;nine months ended&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$2.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; and was included in Net cash provided by operating activities in our Condensed Consolidated Statements of Cash Flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Remainder of 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Years ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,731&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,959&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Present value adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tenant improvement reimbursements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:0px;padding-bottom:0px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:48px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, we use our incremental borrowing rate. The weighted average discount rate used to determine the operating lease liability was &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;4.20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the weighted average remaining lease term is &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;8.3 years&lt;/span&gt;&lt;/span&gt;.</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="FI2019Q3_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d143670801e424-wk-Fact-1E9A5513AD445625AB3CB4DF9B760982"
      unitRef="sqft">169606</us-gaap:AreaOfRealEstateProperty>
    <exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements
      contextRef="I2019Q1_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="-5"
      id="d143670801e432-wk-Fact-FF3D326C8CFA5927876ACA1327AB6CD9"
      unitRef="usd">8200000</exel:LesseeOperatingLeaseLiabilityTenantImprovementReimbursements>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="FD2019Q3YTD_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="INF"
      id="d143670801e436-wk-Fact-FCE670852B3B372607AFCA97D9302A56"
      unitRef="renewal_option">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod
      contextRef="D2017Q2May01-May31_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      id="d143670801e440-wk-Fact-991E7FB9B6D779CBDC260FE320954FBC">P8Y</exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod>
    <exel:OperatingLeaseAdditionalAreaOfRealEstateProperty
      contextRef="I2019Q2Apr30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d143670801e453-wk-Fact-F61F288917055701A54B690E6DAA603F"
      unitRef="sqft">37544</exel:OperatingLeaseAdditionalAreaOfRealEstateProperty>
    <exel:OperatingLeaseSurrenderedAreaOfRealEstateProperty
      contextRef="I2019Q2Apr30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d143670801e457-wk-Fact-0D32F2D499295CC3B715C2D1ED7595A7"
      unitRef="sqft">2703</exel:OperatingLeaseSurrenderedAreaOfRealEstateProperty>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="I2019Q2Apr30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="-5"
      id="d143670801e461-wk-Fact-9DC20545C22451A79E3C14ED9B644690"
      unitRef="usd">1700000</exel:TenantLeaseImprovementsAllowance>
    <exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-1EAEF0C8ED9B567A81849DC40062A287-0-wk-Fact-E2EB34205879518193DF84F373BE176F">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The balance sheet classification of our lease liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;September&#160;30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,695&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;23,661&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;12,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,837&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Financing lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Current portion included in Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Long-term portion of lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total financing lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,450&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;14,965&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</exel:LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e586-wk-Fact-58878CD749C55E9FAF6BB8DE5360E150"
      unitRef="usd">2695000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143670801e605-wk-Fact-51A717694F0A5265AFF1A577BAB8A4F8"
      unitRef="usd">2738000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e620-wk-Fact-1690CE2B290A5E6AAC589FBB36970521"
      unitRef="usd">23661000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143670801e639-wk-Fact-07568CEE8CD8552C827CB11F03AA763F"
      unitRef="usd">12099000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e659-wk-Fact-49E54CFCE6F05ACF9DE33946C151018E"
      unitRef="usd">26356000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143670801e678-wk-Fact-193212A5733E5CDC9DBB4B2A24528628"
      unitRef="usd">14837000</us-gaap:OperatingLeaseLiability>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e739-wk-Fact-8F62FEE0596356A1A0540C3CC361BA4A"
      unitRef="usd">50000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143670801e758-wk-Fact-FAFA0B271B7A53DA99C1B99DF42170C2"
      unitRef="usd">49000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e778-wk-Fact-A36D0507F78A57A4A5897D79CD703429"
      unitRef="usd">44000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143670801e797-wk-Fact-3C9E2889C598597887C86F97D814B38D"
      unitRef="usd">79000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiability
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e817-wk-Fact-F08B55C6593D5E90A2C49C2A13550B1A"
      unitRef="usd">94000</us-gaap:FinanceLeaseLiability>
    <us-gaap:FinanceLeaseLiability
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143670801e836-wk-Fact-4DEC2E9632165F739FA846F5CA79F8C2"
      unitRef="usd">128000</us-gaap:FinanceLeaseLiability>
    <exel:OperatingAndFinanceLeasesLiabilityTotal
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e861-wk-Fact-7119BC44EE5150479574F177510CFED0"
      unitRef="usd">26450000</exel:OperatingAndFinanceLeasesLiabilityTotal>
    <exel:OperatingAndFinanceLeasesLiabilityTotal
      contextRef="FI2018Q4"
      decimals="-3"
      id="d143670801e880-wk-Fact-070A9FB005CD50DB9D803A0938D5824F"
      unitRef="usd">14965000</exel:OperatingAndFinanceLeasesLiabilityTotal>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-4260E94805715DE0B9F4D3A21001EE00-0-wk-Fact-F80F2B9C3A8D5BC3A7F18F89D15D611F">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The components of lease costs for operating leases, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:2%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Three Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Nine Months Ended September 30,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,768&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,587&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;1,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;2,422&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;4,953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143670801e1097-wk-Fact-328FC93EC67E5E2DBA8A3F676A2AFC46"
      unitRef="usd">692000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143670801e1116-wk-Fact-B10AADDEBAE85A13A874AEC301304592"
      unitRef="usd">1614000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143670801e1135-wk-Fact-0C249F6F98B7562983513ADD589F96B8"
      unitRef="usd">1768000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143670801e1155-wk-Fact-0C58184363F252A289F684C21B253115"
      unitRef="usd">3587000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143670801e1170-wk-Fact-8749271C523452F787865EAE2F2D8658"
      unitRef="usd">274000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143670801e1189-wk-Fact-137720D0471A54E0B93E0CBDACFCA8B4"
      unitRef="usd">363000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143670801e1208-wk-Fact-144B8463FFBE56EBBDB673665C3E2CAF"
      unitRef="usd">654000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143670801e1228-wk-Fact-F774A225473354EEA7B338407088C27E"
      unitRef="usd">1366000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q3QTD"
      decimals="-3"
      id="d143670801e1253-wk-Fact-BF77F3F4305558AA8B5DAEA04BEB3EA3"
      unitRef="usd">966000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="D2018Q3QTD1"
      decimals="-3"
      id="d143670801e1272-wk-Fact-8EE1724AC89555248604A02807F20EDB"
      unitRef="usd">1977000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="FD2019Q3YTD"
      decimals="-3"
      id="d143670801e1291-wk-Fact-D693863BAC5A5E0DB413D47DAF4D9FB8"
      unitRef="usd">2422000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="D2018Q3YTD1"
      decimals="-3"
      id="d143670801e1311-wk-Fact-49E93B6919665C9D9DA8846DDFFD3A50"
      unitRef="usd">4953000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q3YTD"
      decimals="-5"
      id="d143670801e1332-wk-Fact-E7C4122A516658E79E628348C5C8D785"
      unitRef="usd">2100000</us-gaap:OperatingLeasePayments>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-29F67A61DE815D16BBFBADFC5D20D8A1-0-wk-Fact-7E52B614E63555CCA41AEA92E5A53CA8">&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;"&gt;September&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, the maturities of our operating lease liabilities were as follows (in thousands):&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Remainder of 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;745&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Years ending December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,731&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;3,959&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;17,444&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Total lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;33,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Less:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Present value adjustment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(5,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Tenant improvement reimbursements&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;&#160;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;(1,742&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;Operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;span&gt;26,356&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;padding-left:24px;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;(1) &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"&gt;Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1371-wk-Fact-A51E7FB0C028530498F8851E54EFB6F4"
      unitRef="usd">745000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1407-wk-Fact-8BE4A1D8031454A2B9C3D5097D2FE1D6"
      unitRef="usd">3625000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1427-wk-Fact-B5640C40C0775411927288034EDEC2D4"
      unitRef="usd">3731000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1447-wk-Fact-EB3E61D712CB5DF391EFAED36CF9D458"
      unitRef="usd">3852000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1467-wk-Fact-63A6FEF6685C5F7BAB719EE740D990E6"
      unitRef="usd">3959000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1487-wk-Fact-25419927EF765F09B6C366224B46A0C1"
      unitRef="usd">17444000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1507-wk-Fact-571DB291A3C85BBEB86F4CCB5CB7747A"
      unitRef="usd">33356000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1548-wk-Fact-2D93B9F978DE5A529D82CA25536CB83B"
      unitRef="usd">5258000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <exel:TenantLeaseImprovementsAllowance
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1571-wk-Fact-CF3FC5A4D6A35F1DB0F06AF54BDAF52D"
      unitRef="usd">1742000</exel:TenantLeaseImprovementsAllowance>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q3"
      decimals="-3"
      id="d143670801e1598-wk-Fact-49E54CFCE6F05ACF9DE33946C151018E"
      unitRef="usd">26356000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q3"
      decimals="4"
      id="d143670801e1622-wk-Fact-0F2A1E3A20BE5D09B0575E4235D32049"
      unitRef="number">0.0420</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q3"
      id="d143670801e1630-wk-Fact-BDC0E8A196AE53C0874F75B8EEEC3946">P8Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="FD2019Q3YTD"
      id="TextSelection-79571114B1D9385A2EB00F81A189ABB6-0-wk-Fact-891A664A1F067727FC240F83F72DADB8">&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;NOTE 12. SUBSEQUENT EVENTS&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Build to Suit Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On &lt;/span&gt;&lt;span style="color:#000000;font-family:Calibri,sans-serif;font-size:10pt;"&gt;October 25, 2019&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) with Ernst Development Partners, Inc. (Ernst), for approximately &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;220,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises. The term of the Build-to-Suit Lease is for a period of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;242&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; months (the Term), which will begin on the completion of the building and tenant improvements by Ernst. The Term is currently anticipated to begin on &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;October 25, 2021&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;. The monthly base rent under the Build-to-Suit Lease will equal to a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by Ernst and any development costs we pay) and is currently estimated to be about &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;$726,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;, subject to an annual increase of &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; during the Term. The monthly base rent will begin sixty days following commencement of the Term. We will also be responsible for paying operating expenses related to the New Premises. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;The Build-to-Suit Lease includes &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;th&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See Part II, Item 5 of this Quarterly Report on Form 10-Q for more information about the Build to Suit Lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;"&gt;Fourth Amendment to the Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;In the fourth quarter of 2019, Hillwood Enterprises, L.P. (Hillwood) is expected to purchase the project known as 1750 North Loop Road and 1601, 1701, 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California from Ascentris 105, LLC (the Purchase), which project includes the Current Premises. Effective upon the Purchase, Hillwood will become the landlord pursuant to the Lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;On August 30, 2019, we entered into an amendment to the Lease with Hillwood (the Fourth Lease Amendment), pursuant to which each of our rights and obligations are contingent upon the Purchase. Effective upon the Purchase, the Fourth Lease Amendment will provide for, among other things, the (i) expansion of the Current Premises by &lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;&lt;span&gt;59,335&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt; square feet of laboratory facilities located at 1701 Harbor Bay Parkway, Alameda, California, (ii) extension of the Lease term through October 31, 2031 and (iii) elimination of the Early Termination Right. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;As of September 30, 2019, we have not yet recorded a right-of-use asset or lease liability for the Fourth Lease Amendment, and the remainder of the disclosures in this note do not reflect the impact of this amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"&gt;&lt;span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"&gt;See Part II, Item 5 of this Quarterly Report on Form 10-Q for more information about the Fourth Lease Amendment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="I2019Q4Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="d143675358e428-wk-Fact-6834FC4F972510C083EE012249CF8C03"
      unitRef="sqft">220000</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="I2019Q4Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d143675358e432-wk-Fact-71AB05984899C41494810137DB2FA292">P242M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment
      contextRef="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="-3"
      id="d143675358e440-wk-Fact-BC101FFF2C8C22E9261A016537B255D9"
      unitRef="usd">726000</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePayment>
    <exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage
      contextRef="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="2"
      id="d143675358e445-wk-Fact-29B7486EF6CCF3082F7B03BF51293920"
      unitRef="number">0.03</exel:LesseeOperatingLeaseNotYetCommencedMonthlyBasePaymentAnnualIncreasePercentage>
    <exel:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d143675358e452-wk-Fact-F7F5A65F69878B2F87250124CCE236FF"
      unitRef="renewal_option">2</exel:LesseeOperatingLeaseNumberOfRenewalOptions>
    <exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod
      contextRef="D2019Q4Oct25-Oct25_exel_LeaseArrangementsAxis_exel_BuiltToSuitLeaseMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      id="d143675358e456-wk-Fact-E203FBD076C46F4328020FD4B1E1CAD3">P180M</exel:LesseeOperatingLeaseOptionToTerminateAfterPeriod>
    <exel:OperatingLeaseAdditionalAreaOfRealEstateProperty
      contextRef="I2019Q3Aug30_srt_StatementGeographicalAxis_exel_AlamedaCaliforniaMember"
      decimals="0"
      id="d143675358e474-wk-Fact-D128E4A7BC7FF63E1CC5F05F04E8A666"
      unitRef="sqft">59335</exel:OperatingLeaseAdditionalAreaOfRealEstateProperty>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact-07C6863E94BD55FABFECD845862794AE-wk-Fact-07C6863E94BD55FABFECD845862794AE"
          xlink:label="Fact-07C6863E94BD55FABFECD845862794AE-wk-Fact-07C6863E94BD55FABFECD845862794AE"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl" xlink:label="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-07C6863E94BD55FABFECD845862794AE-wk-Fact-07C6863E94BD55FABFECD845862794AE"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143642947e840-wk-Fact-14E885DDB89252BF889F99D9D6F1341F"
          xlink:label="d143642947e840-wk-Fact-14E885DDB89252BF889F99D9D6F1341F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl" xlink:label="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Reclassification adjustments to net income resulting from realized gains or losses on the sale of securities and the related tax impact were nominal or zero during the periods presented.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143642947e840-wk-Fact-14E885DDB89252BF889F99D9D6F1341F"
          xlink:to="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e631-wk-Fact-1B51FFE1147D5FE58E267C0E99DF0679"
          xlink:label="d143645401e631-wk-Fact-1B51FFE1147D5FE58E267C0E99DF0679"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e631-wk-Fact-1B51FFE1147D5FE58E267C0E99DF0679"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e748-wk-Fact-1CAD89A8AC4D5908802B975A1F373BBD"
          xlink:label="d143645401e748-wk-Fact-1CAD89A8AC4D5908802B975A1F373BBD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e748-wk-Fact-1CAD89A8AC4D5908802B975A1F373BBD"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-1FDCD14F45CC5DDBB2A28AED832BD909-wk-Fact-1FDCD14F45CC5DDBB2A28AED832BD909"
          xlink:label="Fact-1FDCD14F45CC5DDBB2A28AED832BD909-wk-Fact-1FDCD14F45CC5DDBB2A28AED832BD909"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-1FDCD14F45CC5DDBB2A28AED832BD909-wk-Fact-1FDCD14F45CC5DDBB2A28AED832BD909"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143642947e820-wk-Fact-22BD4054D3175141A024292FEF769ABE"
          xlink:label="d143642947e820-wk-Fact-22BD4054D3175141A024292FEF769ABE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143642947e820-wk-Fact-22BD4054D3175141A024292FEF769ABE"
          xlink:to="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1612-wk-Fact-2B3D678BFB975C4D9FE3267DC25A4C4F"
          xlink:label="d143645401e1612-wk-Fact-2B3D678BFB975C4D9FE3267DC25A4C4F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1612-wk-Fact-2B3D678BFB975C4D9FE3267DC25A4C4F"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1888-wk-Fact-3312CFD2A55C599E9B2030A1E7EF75BC"
          xlink:label="d143645401e1888-wk-Fact-3312CFD2A55C599E9B2030A1E7EF75BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1888-wk-Fact-3312CFD2A55C599E9B2030A1E7EF75BC"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143671945e577-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7"
          xlink:label="d143671945e577-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d143645401e597-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7"
          xlink:label="d143645401e597-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143671945e577-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e597-wk-Fact-35022F2D191B5B7CA8A9A78EDBB1AAE7"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-3A3CB57BA0E558FB978C7EE61115D8C2-wk-Fact-3A3CB57BA0E558FB978C7EE61115D8C2"
          xlink:label="Fact-3A3CB57BA0E558FB978C7EE61115D8C2-wk-Fact-3A3CB57BA0E558FB978C7EE61115D8C2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-3A3CB57BA0E558FB978C7EE61115D8C2-wk-Fact-3A3CB57BA0E558FB978C7EE61115D8C2"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1100-wk-Fact-3AF94EE58E535745846C93F98A4BA069"
          xlink:label="d143645401e1100-wk-Fact-3AF94EE58E535745846C93F98A4BA069"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1100-wk-Fact-3AF94EE58E535745846C93F98A4BA069"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1534-wk-Fact-3B8C779DD1845402B360FDB026EE42CF"
          xlink:label="d143645401e1534-wk-Fact-3B8C779DD1845402B360FDB026EE42CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1534-wk-Fact-3B8C779DD1845402B360FDB026EE42CF"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e670-wk-Fact-3E92163B9BE350AFB9540EBCDF6E7BE5"
          xlink:label="d143645401e670-wk-Fact-3E92163B9BE350AFB9540EBCDF6E7BE5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e670-wk-Fact-3E92163B9BE350AFB9540EBCDF6E7BE5"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143671945e728-wk-Fact-3F4129D37BE15987B315F13735F8FDBE"
          xlink:label="d143671945e728-wk-Fact-3F4129D37BE15987B315F13735F8FDBE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d143645401e905-wk-Fact-3F4129D37BE15987B315F13735F8FDBE"
          xlink:label="d143645401e905-wk-Fact-3F4129D37BE15987B315F13735F8FDBE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143671945e728-wk-Fact-3F4129D37BE15987B315F13735F8FDBE"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e905-wk-Fact-3F4129D37BE15987B315F13735F8FDBE"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e787-wk-Fact-4755812CBC2651E2944688760840B953"
          xlink:label="d143645401e787-wk-Fact-4755812CBC2651E2944688760840B953"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e787-wk-Fact-4755812CBC2651E2944688760840B953"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143647870e2390-wk-Fact-4780137C336F5EF1BD4398EF0E381194"
          xlink:label="d143647870e2390-wk-Fact-4780137C336F5EF1BD4398EF0E381194"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-DBCE478F5687586C8FE8858A03A0EF92-0-wk-Footnote-DBCE478F5687586C8FE8858A03A0EF92_lbl" xlink:label="TextSelection-DBCE478F5687586C8FE8858A03A0EF92-0-wk-Footnote-DBCE478F5687586C8FE8858A03A0EF92_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:9pt;"><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Amounts for the </xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">nine months ended</xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">September&#160;30, 2019</xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include receipt of a tenant incentive payment and an amendment to our existing lease for office and research space. Amounts for the </xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">nine months ended</xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> </xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">September&#160;30, 2018</xhtml:span><xhtml:span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;"> include the transition adjustment for the adoption of Topic 842.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143647870e2390-wk-Fact-4780137C336F5EF1BD4398EF0E381194"
          xlink:to="TextSelection-DBCE478F5687586C8FE8858A03A0EF92-0-wk-Footnote-DBCE478F5687586C8FE8858A03A0EF92_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1810-wk-Fact-4B15B67A4563571C963E04A7E55BE47A"
          xlink:label="d143645401e1810-wk-Fact-4B15B67A4563571C963E04A7E55BE47A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1810-wk-Fact-4B15B67A4563571C963E04A7E55BE47A"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1299-wk-Fact-4E0A79CE4D22556C8CD82B6BFF283BEC"
          xlink:label="d143645401e1299-wk-Fact-4E0A79CE4D22556C8CD82B6BFF283BEC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1299-wk-Fact-4E0A79CE4D22556C8CD82B6BFF283BEC"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1061-wk-Fact-4FA0D3DD22145129854A4C161726D0EC"
          xlink:label="d143645401e1061-wk-Fact-4FA0D3DD22145129854A4C161726D0EC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1061-wk-Fact-4FA0D3DD22145129854A4C161726D0EC"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1495-wk-Fact-54D1CCCBA98756C59B50269447F29C65"
          xlink:label="d143645401e1495-wk-Fact-54D1CCCBA98756C59B50269447F29C65"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1495-wk-Fact-54D1CCCBA98756C59B50269447F29C65"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1690-wk-Fact-6239E69403E55431B38A5B9E7597A2AE"
          xlink:label="d143645401e1690-wk-Fact-6239E69403E55431B38A5B9E7597A2AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1690-wk-Fact-6239E69403E55431B38A5B9E7597A2AE"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e709-wk-Fact-669EC1AB746A532489CA1474200178BF"
          xlink:label="d143645401e709-wk-Fact-669EC1AB746A532489CA1474200178BF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e709-wk-Fact-669EC1AB746A532489CA1474200178BF"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1339-wk-Fact-6C00EBF1ABD15088AAA6675B42373AEB"
          xlink:label="d143645401e1339-wk-Fact-6C00EBF1ABD15088AAA6675B42373AEB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1339-wk-Fact-6C00EBF1ABD15088AAA6675B42373AEB"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e865-wk-Fact-70884DAF9D095D6F8EC7BDABD302EE15"
          xlink:label="d143645401e865-wk-Fact-70884DAF9D095D6F8EC7BDABD302EE15"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e865-wk-Fact-70884DAF9D095D6F8EC7BDABD302EE15"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1929-wk-Fact-73F0483E60EE53B29E4058F0AF045381"
          xlink:label="d143645401e1929-wk-Fact-73F0483E60EE53B29E4058F0AF045381"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1929-wk-Fact-73F0483E60EE53B29E4058F0AF045381"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1456-wk-Fact-7F0E267AC54F587AA0AFE7D5EBC39566"
          xlink:label="d143645401e1456-wk-Fact-7F0E267AC54F587AA0AFE7D5EBC39566"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1456-wk-Fact-7F0E267AC54F587AA0AFE7D5EBC39566"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e983-wk-Fact-85CE777F29DC5425AE5D2A1350EB3BAA"
          xlink:label="d143645401e983-wk-Fact-85CE777F29DC5425AE5D2A1350EB3BAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e983-wk-Fact-85CE777F29DC5425AE5D2A1350EB3BAA"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-907BC12DCE8D570AA65EDF690CD8E735-wk-Fact-907BC12DCE8D570AA65EDF690CD8E735"
          xlink:label="Fact-907BC12DCE8D570AA65EDF690CD8E735-wk-Fact-907BC12DCE8D570AA65EDF690CD8E735"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-907BC12DCE8D570AA65EDF690CD8E735-wk-Fact-907BC12DCE8D570AA65EDF690CD8E735"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1651-wk-Fact-96ECA7A9CBA75A7ABDD94D5CA8925270"
          xlink:label="d143645401e1651-wk-Fact-96ECA7A9CBA75A7ABDD94D5CA8925270"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1651-wk-Fact-96ECA7A9CBA75A7ABDD94D5CA8925270"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-96FAB434AD8F5D11AC63A2E44BFB4D84-wk-Fact-96FAB434AD8F5D11AC63A2E44BFB4D84"
          xlink:label="Fact-96FAB434AD8F5D11AC63A2E44BFB4D84-wk-Fact-96FAB434AD8F5D11AC63A2E44BFB4D84"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-96FAB434AD8F5D11AC63A2E44BFB4D84-wk-Fact-96FAB434AD8F5D11AC63A2E44BFB4D84"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1417-wk-Fact-9E5F11DE05B3550581DF7177D9B31246"
          xlink:label="d143645401e1417-wk-Fact-9E5F11DE05B3550581DF7177D9B31246"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1417-wk-Fact-9E5F11DE05B3550581DF7177D9B31246"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1573-wk-Fact-A224167B234059F188989D11E3324BC2"
          xlink:label="d143645401e1573-wk-Fact-A224167B234059F188989D11E3324BC2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1573-wk-Fact-A224167B234059F188989D11E3324BC2"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e2013-wk-Fact-B0DA545136C555089C9EDE3307AB7DE0"
          xlink:label="d143645401e2013-wk-Fact-B0DA545136C555089C9EDE3307AB7DE0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e2013-wk-Fact-B0DA545136C555089C9EDE3307AB7DE0"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e826-wk-Fact-C2EB0F1D2C255F8E9B07698707668AA7"
          xlink:label="d143645401e826-wk-Fact-C2EB0F1D2C255F8E9B07698707668AA7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e826-wk-Fact-C2EB0F1D2C255F8E9B07698707668AA7"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6-wk-Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6"
          xlink:label="Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6-wk-Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6-wk-Fact-C5A6D3FB5C565B4996E1ACD2D396A7D6"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143660005e795-wk-Fact-C991BEDAA3F551B189FD2DED431834BC"
          xlink:label="d143660005e795-wk-Fact-C991BEDAA3F551B189FD2DED431834BC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d143645401e944-wk-Fact-C991BEDAA3F551B189FD2DED431834BC"
          xlink:label="d143645401e944-wk-Fact-C991BEDAA3F551B189FD2DED431834BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143660005e795-wk-Fact-C991BEDAA3F551B189FD2DED431834BC"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e944-wk-Fact-C991BEDAA3F551B189FD2DED431834BC"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-CB6AD27B04B2595487B5177029EF3D5F-wk-Fact-CB6AD27B04B2595487B5177029EF3D5F"
          xlink:label="Fact-CB6AD27B04B2595487B5177029EF3D5F-wk-Fact-CB6AD27B04B2595487B5177029EF3D5F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-CB6AD27B04B2595487B5177029EF3D5F-wk-Fact-CB6AD27B04B2595487B5177029EF3D5F"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143671945e650-wk-Fact-D04C68F48EE857BBAB9EB561BCBE190C"
          xlink:label="d143671945e650-wk-Fact-D04C68F48EE857BBAB9EB561BCBE190C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143671945e650-wk-Fact-D04C68F48EE857BBAB9EB561BCBE190C"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1144-wk-Fact-D20CC27ECE3A55B7A4EF8855DB4C6203"
          xlink:label="d143645401e1144-wk-Fact-D20CC27ECE3A55B7A4EF8855DB4C6203"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1144-wk-Fact-D20CC27ECE3A55B7A4EF8855DB4C6203"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143642947e782-wk-Fact-D2CF652C6C6D541A8E57A47FBBD0AC49"
          xlink:label="d143642947e782-wk-Fact-D2CF652C6C6D541A8E57A47FBBD0AC49"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143642947e782-wk-Fact-D2CF652C6C6D541A8E57A47FBBD0AC49"
          xlink:to="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1378-wk-Fact-DE1420696CD35A0DAC8D9C5F03CA227C"
          xlink:label="d143645401e1378-wk-Fact-DE1420696CD35A0DAC8D9C5F03CA227C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1378-wk-Fact-DE1420696CD35A0DAC8D9C5F03CA227C"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143647870e2371-wk-Fact-DF694A70CE785E2FBC25B383B4F0BF21"
          xlink:label="d143647870e2371-wk-Fact-DF694A70CE785E2FBC25B383B4F0BF21"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143647870e2371-wk-Fact-DF694A70CE785E2FBC25B383B4F0BF21"
          xlink:to="TextSelection-DBCE478F5687586C8FE8858A03A0EF92-0-wk-Footnote-DBCE478F5687586C8FE8858A03A0EF92_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1771-wk-Fact-E48A728D16DA58FC9EC32263F9980934"
          xlink:label="d143645401e1771-wk-Fact-E48A728D16DA58FC9EC32263F9980934"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1771-wk-Fact-E48A728D16DA58FC9EC32263F9980934"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1022-wk-Fact-E9FEA5177DA65B4C95480E3130D8839E"
          xlink:label="d143645401e1022-wk-Fact-E9FEA5177DA65B4C95480E3130D8839E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1022-wk-Fact-E9FEA5177DA65B4C95480E3130D8839E"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143661439e3055-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC"
          xlink:label="d143661439e3055-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d143645401e1969-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC"
          xlink:label="d143645401e1969-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143661439e3055-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1969-wk-Fact-EBEFC65F01E65D3E91217224B15EAFAC"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143642947e801-wk-Fact-F2E10EF5A2AA516EA18DC933946B00C4"
          xlink:label="d143642947e801-wk-Fact-F2E10EF5A2AA516EA18DC933946B00C4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143642947e801-wk-Fact-F2E10EF5A2AA516EA18DC933946B00C4"
          xlink:to="TextSelection-146C5D73C11F51F7AE8F5B642B5FA6A2-0-wk-Footnote-146C5D73C11F51F7AE8F5B642B5FA6A2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1849-wk-Fact-F6C33F96BF935687A3F2657317EA8820"
          xlink:label="d143645401e1849-wk-Fact-F6C33F96BF935687A3F2657317EA8820"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1849-wk-Fact-F6C33F96BF935687A3F2657317EA8820"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d143645401e1265-wk-Fact-FC51C4202CA358D68E09A0F06F4AFD5E"
          xlink:label="d143645401e1265-wk-Fact-FC51C4202CA358D68E09A0F06F4AFD5E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d143645401e1265-wk-Fact-FC51C4202CA358D68E09A0F06F4AFD5E"
          xlink:to="TextSelection-A725F07B615359A09F872EBFDD6C0B4E-0-wk-Footnote-A725F07B615359A09F872EBFDD6C0B4E_lbl"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6626947360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Maturities of Operating Lease Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">Remainder of 2019</a></td>
<td class="nump">$ 745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract', window );"><strong>Years ending December 31,</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2020</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2021</a></td>
<td class="nump">3,731<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2022</a></td>
<td class="nump">3,852<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2023</a></td>
<td class="nump">3,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">17,444<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">33,356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Present value adjustment</a></td>
<td class="num">(5,258)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvement reimbursements</a></td>
<td class="num">(1,742)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">$ 26,356<span></span>
</td>
<td class="nump">$ 14,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Reduction Of Payments Due [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseReductionOfPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities, Duration Of Maturity [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesDurationOfMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease having an initial or remaining lease term in excess of one year due in remainder of fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6849794976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">$ 1,218,337<span></span>
</td>
<td class="nump">$ 828,142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">1,218,337<span></span>
</td>
<td class="nump">828,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,247,529<span></span>
</td>
<td class="nump">844,738<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">26,641<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">26,641<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">1,191,696<span></span>
</td>
<td class="nump">780,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,220,888<span></span>
</td>
<td class="nump">796,994<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">26,641<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">26,641<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">26,641<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">332,239<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">332,239<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">332,239<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">706,807<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">706,807<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">706,807<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">152,650<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">152,650<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total investments available-for-sale</a></td>
<td class="nump">152,650<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">29,192<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">29,192<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Certificates of deposit</a></td>
<td class="nump">$ 29,192<span></span>
</td>
<td class="nump">$ 16,596<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6625374464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - RSU Activity (Details) - RSUs<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at beginning of period (in shares) | shares</a></td>
<td class="nump">4,857,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Awarded (in shares) | shares</a></td>
<td class="nump">5,635,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased', window );">Vested and released (in shares) | shares</a></td>
<td class="num">(484,731)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(258,142)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at end of period (in shares) | shares</a></td>
<td class="nump">9,749,823<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding at beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 18.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Awarded (in dollars per share) | $ / shares</a></td>
<td class="nump">19.54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and released (in dollars per share) | $ / shares</a></td>
<td class="nump">12.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">18.47<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">RSUs outstanding at end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 19.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">RSUs outstanding at end of period</a></td>
<td class="text">2 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue', window );">RSUs outstanding at end of period | $</a></td>
<td class="nump">$ 175,448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Vested and Released in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndReleasedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Weighted Average Contractual Term [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsWeightedAverageContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838693984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits and losses on U.S. commercialization</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="nump">1,935<span></span>
</td>
<td class="nump">3,507<span></span>
</td>
<td class="nump">6,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">$ 1,390<span></span>
</td>
<td class="nump">$ 4,426<span></span>
</td>
<td class="nump">$ 4,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6847351360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Aurigene Discovery Technologies Limited (Aurigene) Collaboration (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 31, 2019 </div>
<div>USD ($) </div>
<div>program</div>
</th>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementAdditionalOptionPayments', window );">Additional option payments</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember', window );">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementNumberOfPrograms', window );">Collaboration agreement, number of programs | program</a></td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementNumberOfPreexistingPrograms', window );">Collaboration agreement, number of preexisting programs | program</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms', window );">Collaboration agreement, number of drug discovery programs | program</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementResearchAndDevelopmentObligation', window );">Research and development obligation</a></td>
<td class="nump">$ 32.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued', window );">Preclinical development funding commitment accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">148.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">280.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember', window );">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Option exercise fee payment, if exercised</a></td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember', window );">Collaboration Agreement With Aurigene Discovery Technologies Limited Collaboration Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Option exercise fee payment, if exercised</a></td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementAdditionalOptionPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Additional Option Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementAdditionalOptionPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Drug Discovery Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementNumberOfDrugDiscoveryPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementNumberOfPreexistingPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Preexisting Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementNumberOfPreexistingPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementNumberOfPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Number Of Programs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementNumberOfPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Research And Development Expense Accrued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementResearchAndDevelopmentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Research And Development Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementResearchAndDevelopmentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithAurigeneDiscoveryTechnologiesLimitedCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6715281280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We allocated the stock-based compensation expense for our equity incentive plans and our 2000 Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Research and development</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,301</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,169</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Selling, general and administrative</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8,838</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,573</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>27,002</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19,228</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total stock-based compensation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,139</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>40,747</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,330</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock', window );">Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases</a></td>
<td class="text">The weighted average grant-date fair value per share of stock options and ESPP purchases were as follows:<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.57</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.13</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5.39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.19</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6.96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Valuation Assumptions Used to Estimate Grant-Date Fair Value</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The grant-date fair value of stock option grants and ESPP purchases was estimated using the following assumptions:</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Stock options:</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.57</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.82</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.0 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.4 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">ESPP:</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Risk-free interest rate</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.09</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.11</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.34</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.74</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dividend yield</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Volatility</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>43</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>51</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expected life</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6 months</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for stock options during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:46%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Exercise Price Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>22,674,062</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>8.71</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,042,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20.81</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercised</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(3,042,201</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4.94</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(160,241</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16.76</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Expired</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(35,045</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23.41</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Options outstanding at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,478,861</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9.80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3.4 years</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>186,407</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Exercisable at September 30, 2019</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,860,131</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7.02</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.8 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>181,542</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">RSU Activity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Activity for RSUs during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was as follows (dollars in thousands</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-weight:bold;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:46%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Shares</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Grant&#160;Date</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair&#160;Value Per Share</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Weighted</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Average</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Remaining</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contractual</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Term</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Aggregate</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Intrinsic</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Value</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at December 31, 2018</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,857,334</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.42</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Awarded</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,635,362</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Vested and released</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(484,731</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12.33</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Forfeited</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(258,142</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>18.47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">RSUs outstanding at September 30, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,749,823</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>19.37</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2.2 years</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>175,448</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the weighted-average grant-date fair value of equity options or other equity instruments granted during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6850478352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Takeda collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,187</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,940</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,245</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,843</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div>Collaboration revenues under the collaboration agreement with Ipsen were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Ipsen collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>76,016</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>57,186</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>120,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>145,038</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div>Profits on U.S. commercialization and Royalty revenues on ex-U.S. sales were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Profits on U.S. commercialization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,935</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,507</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,004</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalty revenues on ex-U.S. sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,614</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,426</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,285</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Collaboration revenues under the collaboration agreement with Daiichi Sankyo were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Daiichi Sankyo collaboration revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,130</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,000</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div>Such royalties accruing to GSK were as follows (in thousands):<div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Royalties accruing to GSK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,964</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,268</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,079</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,021</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0000939767-19-000190-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-19-000190-xbrl.zip
M4$L#!!0    ( ,F!7D_CY^F[=!8  )8! 0 1    97AE;"TR,#$Y,#DR-RYX
M<V3M/=ERX[:R[_D*7KW<255D2_8LF:EX3LG+3*GBK2S-F7.?3D$D)*%, @H
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MZX13.*PK,CHFCV*4(.EQUAW\1AA^F(,.OL3&[+F8-#[_\O]02P,$%     @
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MR ].AV!$7=,O<P[HG;%P/]4TV;9]<6TQ)&\?E%]J3'0E%0>04!<Z+_R&M*2
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MF77 ^,!:[@D"E0]JS%EH*438$-9A=TE^+_W=%SBC+0&_OM<77SR-3Z%<-M.
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M8!P_:$_]/AABHYV\VKZG^\'YU=<7K6\/ZX;]&4MGF83,,*"\8\![&9: %"'
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MX=>;:6WJ,Q1HA+XY2JXQ +M[%W37>ZUCU7=J>^_9MU'#B-HSO>S+5O*,D+3
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M&&<DH"@H\0;!2FVG4IQE89_:,FYY5- ,NQ^<&I6><1Y4.J_ :@,<4QYS8JS
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MYOU],:&.$8TU(4Q:S+@W2M *,VI]\^#=\RAJWM&>?2)Q=+13OY#Z_"ZH-Y1
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MOCF!B!-! 5:6*AKF@M0^;/%>8&JX)':$UYIT2)UAP1M41WI5ELOLPBZ+]<T
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M=O<F+?[*%GXYOS@<:[R]0<(UDD!A[QQ$PFG.(>/5Z+S"([J.Y;3"S7M <\B
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MH)+"P')'POH(/.#-?1>]70,V&",ZQ.V4)M&&T'$41]I##UHFC$)( OT!X4
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M<==@]8H,#QYT<VHV'0?:< 4*TC*[SF<7#],C#\;/[&F51$O%*,DI$SJ,4RE
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MV2*YE=YX&,:EL&1$&]*\E$OGI0C.@$?= =V80/$@:[FK8-Z3)Q)%J?+00.:
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M<32FPQDDD6DI"-2.6>PU(^$?!%7(&N[.*_^Q-DN&R"9K!NP/ZG:'\*BB"%\
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M/XY$]]-2,8FA%D@YRBE34C*.&0# *&&9K)?Q]N-(-$LD4)8#C1"BA(J5CJ6
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MKMTH<! 07\XL-'< NMPD]P6F7I\MAZ/,07('H,Y/<;THM-/9EVT^)K,]&9J
MRO:UH [77^PT=K/>SBYT?VED_.>J_KR>WWU97,V733J=L505*D>Z2<9!FA84
M=SLQLN3 :F>D7PN1=?80C]-TN"=OIY5V.,K<M-:%+9L%26WGP6*D_MO3A<B3
M1+R@(F&(&U=' ME0A^Q*#EI2?7[:4IL;JH*@C+ R)X4"3! &U+ZM% .K<K%^
M+0RJ)4[3OI[,6:C)(*3U49,0^ZAV>G*,BF-ZTINZ">A)?QOJD)W)8?['EO/;
MZGHNYLO%3;U>+>9M&@1(5D#!.,OSG*920$%HMX<"(2VL)X"^#416DQ;66?(
MS&$ZX\V:Q11P",+<E.0%KGSF@-ZD.4P"AR#/;Q;H1:+=+/"(T<>F@7TYFL \
ML+<)=< ^TZLZY=UB5;W5Z>-FADC*&9)0*5:0+#.;UN6N.0( @Z!'@8I](T-7
MR?UFH"4-MGY%<@X\GM;@02ETTV$_]H8H7=FS8U^]XD[H) M8/,PX7</BRXOU
M#63K:GY^\[&:+^7&3%P_K.N[:KW]/F-I5NJ,LL <ZGDKQ1F!>=><Q,3M.F/?
M1F)G?1J7.=R[;!9A[UI4R4^+5;+YQ[TYXWM35=L_.UXRYLVHG1(-0J9C1MCR
M:$ E.U1)!VO@V\..D'-"B'KS.0TAZF_&T]O PO!B*T3OJLVFJLYU$SJ17GUN
MUN OJ_7M^8VH5[O3EIS#4A H\Y1E$"/&$(9=PXB53D<@ S0769SVV%IYTA]Q
MZZ9$(2BUTZ2!V713IQVXL^2!T ;?66(0[BX!V6$<5JI>Y^R$: 4D?!KR%=*@
M.EKG="ID>][J^WK[]VIK[IRI-"G7O^CFORR_<_V=#_/O9@UA5E+&A"0BA2#/
ML2HAYT4'1$"G$N(8S4>6/!UH%K?--=*W.VQ)\]S:VDQN[E>Z!R9FE_;ZS7:W
M>5[M!K+E?>$QO6*QCC>^0P*IIKDE2:-.]K#/DA:XN9I-)WX[Z.,[Q:D^;VSG
M^-9)1W*2;5V?!VW'J_YB^F "JY21#:P'Z\^QHR!;K>[GR[>KJ[7Y\0^5[OMZ
M8'RN9APJ42!<%I1*EBLL2H@Z@)A!%C<Z>L.*'#5_>1HKS]H9PTJ+P'<M E</
M(C!O;$CN]N"316M/;+WV=VJLX#J(/X<-NF?)SJBDL^HL>;!KNAZ.':D'\?0X
M$=S/XQ'#^S&N@X;]W@[]4=.!_H;W3A,"<>^?/MR;[5BS,KFJ_I@OS^_,>-O,
M& ',W!:@@ "\("3-)>]:5XK:'U$(V&;DP+]#95:PZAV@9%LGNY=JF[MK70\R
MA&3;-VC')SI41-Z1?VYV/1JL20MV),+[QM#XQ(<.D,X.Z!'U7F3'*:3UXW>J
M\:JG5:\&HQ"L]=F!:ALVR\4SA3#.%1."IXR@+!.8YD )3@BAJLR<KHSIVU;D
MR+([E;2+*@=!Y:YYV+[_)I03J_X[4+$(#11!.MFZ/+6Q-]C6TP%9COM./C1/
M=]/)RQJ+'2=_EKPSY9U<7M:FS<5JOJV:9PX_-(-X!H0B0F%.2B4D%EE>%@*H
M$G%8YAPBU2M?[M5R]'WU3M6V';IVO>RGW1.E.Y6SK/J)1+YG^CP8[X$DL/7%
M99WL$2<-Y.2#0ZB)Y(.>&?5@O@B<5WO[Q#^]/D652Y(=A/*)IMIA;'LMX0[(
MH%78>MPZN[Y>F/;GRZ/%9T 60."<$BAR1DH=-K'!(',)<\8@M0Y;P5L>MASL
M3.?D=_/5Q@Q5OWK52/Q;1*Y1J7>+7,_4\0%MTE2]GCM6O0[A H? -:HK_ )7
M<)?8Q2U7IH[%K6B,3R!NQ;.M'J+/NBT7=1__0??.+5M=RW_<+^Z:#9+]<Z\E
MX"G"&2E+JJ=\.1.2P913B2C$Y:L[V^$:BJ>/';:SI$'7/,NYQS?:TT>O,G9B
MA2,<V]-8XPAH3QVK7[H-O+*Z6U=7BUUT$[ L<B!W#S!)0"45Q;X)8E<PZ_7!
MD=.]0RPFU:M6MEMY?C3925$TAMQ4YQ#&L,IRV/()$?'B:1IZX0>]#M!/W%3@
M[<H<CZS7W\O%YFI9;^X/WED7M,A5FJ8L%P #F2&9E3*#D@%6 CUKM>SMIYK(
MJ/XHFJ<4Z=1"9(J+- ,4,UR2@A <,>3N424/L$:+M"<H.C$\0A [C=$2Q)(Z
M?+?S'$OB?FT*2'?/D7%18*9(QDJ..,D9D(1WHXADW.FAGI=;R " F4A+PH7.
MSR5F7#']E2)/$5<8Q+[T90_J+&EAO?J67DCZ'$4H&G.>\F-/6ESE.>3%1G.\
M>)R8VOC9<$QG>C!BJS!\KCO1577QI:JV[PR+.C%H[L0#*900E#H^HYQQBJ@4
MJ!LE/"-.(G.T$<ZSG*E,H+2 F+.<9UI$":$"(@QR'EMG6EQ) RSID'F]0^C/
MHYW:#$*AF^#XL1=%<XZQ<T)V>A,Z#>7I;T8=N*/UUY_V%CV"TS3+4J@8)$RR
M5 \;VHT<J@=47P5JF\%EFBK)90H*AA'&%*29;EK(4A60B'PD#?)ZD; /F_XZ
M%('(,$HTRJ.$QQER5"-'6J>K1ZZ&6"B2%S>NLZY%M6FOF$,@8P5 C/,"9E)2
M)(JL'3R2E*E3A>GS3]>?I& )4ED4'*N4%#+'2/$BITK_#\>N*>UF"W?UNADV
MB]75\OZZNM9_2/:IJ-_$RX%!MTE7'/+\)EP:RT@/$SYCPV*:Y<[<-(2E!_XC
MTRM?)NSJ9[9?JO6[>O79U#*RS:;:[D>"9!0J#K(,$XXQ9BG)NY' 66DUL7JE
M"5(@F H%TPPS\V0]%YDL<U3(#$"2T=CGG@VF-P;4BY+2P$Z6^Y^9-\A=ZC+\
MJ3TM,@.RZJ8T.\H>:-W!\KG;MP=W+L4K@W#H6:7BR:5E,<HQRX]6G?2F:@KE
M)?V-J(-V'\]5]G?[.STIT'/:C!&>*0XADP4CL!L- !78:XG]X>.58EA1F6(E
M]' 3@JF\1)"J#.GY=('Y4.OK/>[U]2'-<6$]#E^^FWKC7>+[G!";Y71W]J:5
MZ/D8<&PAW9<+9P7Y./_CE[D>D8OY<C.34O"\5-*<*4H5I:6BH!L/%-ME>J=;
M4"IEI7GBE98<0\+-^4N8<<9+J6.Y()%U1&-);CLPGO+AQIBC@D0CRWMKSE"V
MAW26_+RN-];GH@.KR2$Y-H+B1>;$-,7/AF.RTH,19V7Y6[W^_>WJP[J^JC:;
M69F74D]9,45,R5*F-(==J%6<D]Q+6AXW 24BN& 8*XDP%&F1*IEF6CH)(:DL
M8]?9&3!FNGBW@^.I+HZL.<I+/,*\]:6CK04UKL(\XL=&8OP(G9C&>!IQ3&3Z
M<.*L,FJQ6FR^5-<_U_6U#L=%4::09BAG.<>29"(O=N.%(T"EU>-2KS0!@% 4
MZ\\3E&*I$S ]O=,M<$8!01F+/1/JP"2?#1I/D7$DS5%DXO'E+3)[UAI,XVK,
M(WIL-,:/SXEIC*<1QS2F#R?.&M/TEAG$HI18(*#G7[3@0C& NF&2(:HG1_5V
MOG34EMU'ZRD>II)CDA/])T(X!"4A>4:8'IDY=GM,=X_">J!<FE_QE!)+;APE
M)#PMWM(QIE0T;=M(A!M?$Y,&1_#'),&' _=)S7JQK<KZC]4,%R)5.6!9"7.&
M 26\V'=Y4J9^"ZX/'Y^F2 \AHB4-"@RP9)@I2DI!229S F-?"-@ >7.MD6R2
M9CNLUZZZ"VVN,YHHC/DNN3[0-M8$IJ/#:O+BS-W$E,/#@*.3%D\NK(\:[D]@
MF,=";LTIO&8;\&.U-,]4B'JSW5Q\F:\K<_?V=7M!ZF9_6J,HH2A$AD53FULP
M5K 49 R5+,LS";GMJ;NX*.(-L0;4FP95=U]QPM9K_2/5J.>#^Q%Z8I .Y*EI
M#.BAC'UZMG!(CJV?<;W2TYK[I8;4-&VN2[X^!'?0ZS?\^\//='<J_S%?7^_.
M7Z <4B)I62K$L%"D$%AU^$C.G'9SAD,5.;'I##%W'1^*RJ$QA\JR23Y]3UY4
M'V.2WRFO 5UL%Q:FZ5W'"#&L8^,\?AO*#R<"R_"^GD:,&<'NI^_QCL2\]0.^
M30/Z5W:G9S)-<EH6I>)%RB##,"5M&R2%F=NKO4Z?'#D"[,:W0>-U;LZ1)3L!
MCD>0FXC:<Q/GS=U#&DYHF!]=T] A3^Q/G]3MP8!U)NJM4@_H5M?F3I_W\]NJ
M/0!3$)5J4$3)K!18*JZ*O(.*H;2Z=7%4@ .JD]>)NG&\9IEG3MUA_FHYRLF]
M&'R>2AW'=-\TU'M<"IXFE./[PS:6R-N[9?V]JBZV]=7ONZN!VPKYHD@SK%".
MD2RHQ+I10KOV(,B=3BKZMQ)[U<$ <GO6)P!S=J(\#&E!EWOW5XN/<XKQ*&,G
MM+,_R],0P !VU*'[GYL4?:PVV_7B:EM=-RW^NEIL-Q\O?FW;S(NR+#C*6)ZE
M$H$4JU*V;5*)H-7C;V%:BBQ)&HBC$O4DSDZ-AN/,39$><"4[,6^0)3\9&O\\
MD@Z=Y.J$%H7A>!IZ%,B6.D8O=+P%NEK?U.O;W<T1.OQU1P@YERR%)2DSE +)
M.>19M]A'D0!6S^OT;2.R%GUPUB)OLNQ4: B>W/3G -%NUV*L*QR.4'-";OJ2
M.0VAZ6W%TSNO@[!B=;7#LZ;8U9=%];6ZYI7^>E565TW3&4Q!"CJ-@S"GK$2$
M8Y13#A$BV-R(PE4.,Y7;OXX2H_$!Y.@LF;<XDT\-T*1#FF3P+#%@'6XQB.*!
MTU(V"?+[:MQ9T@%.^!$O^%PJ$<4=#M=-C.T6OXLH(KG'[IX*#\I>"$G1V9_
MW191S:L'ZL5]HMM%I6FZ_K"NK^^OMNSN;EU_G2_;]D&>D:(0G.KH6I"R4$)!
MW3[+BAQQ@8!_6.O3ZB#Q;-, -,=3#<)DWD+L(YN]F/8)7T.1W#]N[9 F+=2D
MPQHD6O6BO4^8&HK^</')VPV>4>D$0];A* 3+4XQ#0>PZ&8#",6<5>2YT![W?
M-!48#&.FH("Y! I(@3 5=#]K*[G5P6/7SXR^9V60.-5(.;-B$0,B$>*X'S4
M%P["'(D3/]FUX\9.3Q\,.Z:6'J9/0 M]4-?]'.ZL8^W^?TJD,EMM%. ,JQ24
MM.SV_VF:4:NZ3_=/'4C+G"JJ/+BQUK,(M/@I6FQ&G%4M C-^NM91D^@<(PDO
M<D>KK?RYF(S0N>)^+G5>EEN)7;=(T::%3,(,B#(K"L@@X5F!:%<Z2P&A]HF;
MX^?&+B-MT3B,:U=B++0N(B=N:K=?IO28?KORXJ!X$?GQTSQ[GNRD[K&!Q\3.
MDX8)R)TO\KI_)W!9(5W7G\RYH;8%*LWSU1BDM*!E*AF4N.Q:@(K:W^?N^+FQ
M5SE;-"XK:X[$V"Q9QN/$<5&R!>*UXNC(B\N:8CQ^/%<-K7FR7!)\9.#113\_
M&B8@>;[(Z_Z=P$'RWM?;)XTP0'*LBHP54(),Y"K'1=M(D5%N54;E^=&1A4\#
M2CS$SX,B"_V+RXZ;!!X2XR.#'@PY*&%<IOS$T(TQ.T%\9N<Q3?0G9 *RV -\
M':13!#[;>>SDT+N'B^GSO( *4X*4XA@7 I9=HEJPC).@)SG[PXF]PFAQY<0K
M-TZ\\WW98@AGGI;^B?K1<4ET&!>.<Q+T5>)?4.41O#J-6M\A#78]TQF:Z^@1
MX_V]B6/MI2<;]G6^6)KPINKUS_IWMS.%: :)* 4@L)!$Y6F).[A(E,/$D;X@
M8Z?X#3QSM=%F5_L_[Q VNQ.?#<;DI\6J_?:?!XH?O5T;.:H,Z=6!8\U9\M G
MVO,@[%&?:"S\08+0*WZ*$9I"=8T?/& %HR%4& OK%^?K":KUUT5;3?8,_?MZ
M];7:;*O=[0F;YM;TP^^;^R+U_.WOU?9C=55_7BW^H[J>,:D(3;D@/ >,%"DO
M*-P'8Z2L"H['1QDYO/VZ6N^Q)%>'<EA],W^V7-8:GR?7*Q<F[4C_B/;BE0U[
M>[H 9@Q(S(K3]VJ;/-APEK#;^G[HV!7-)2>"U_C=8!K1:P(\'+N38F3/C!Z_
M/E3K17VMHV_[)?-S<$9R"F7.<(J1J3D4"*6H,Z)$W._.GFE CQSI_E8M/G_1
M=KR9?ZW6\\^5CG9:!-</").[!O9$ IZG^T>.@O$]/UIHW)G63/ .C/LG"94O
M^FV,^-FO _V3!]6>Y P5:4/X,/K:J/S'_6+[_>UJLUTWN[6;YB7YRR_S57M7
M7#/IW;Q=[:R902(!DI AF6& <TQ9D;7P&2R1T_N&DP$=.>2:&YJ2N0&N]77X
M-=+@+HZ\9CJF=P=?0]T9FQQ8FS3F)EMM;W=?X]EN+773O%)[.CN;UK*JHRMC
M++/&ZDW3B+'3HR74,FQ<O]F=2C/ /KV._9,S]E_FWQ:W][<?ZJW^[F*^O*S_
M76<7LT*)@@J>TT*",F<BRY'9-\5(X8)S8#6KG2;RR!&V197<=;"2;9V8A.W,
MS&:O3!7:9Y?*Q,GQ9W6N;VJ@1PZ\W"_P7CX*O%W/VMN>7-:)L?Z'[DTN9R*G
M!CY^#>J4>Y?E <^!G7:LH':RG6<"];K3Y:;^$8:_:QX7+@?=/K/A<<E :TA9
MP"++4P8RF:49SW1*:A9ZB$*2*UA8W>,]8?AC973N"R@3)M$ZK9L<\MBY';>,
MOKS'HDK7Q]HZMO-]'9MGBC<Y)SGG>9.S8*AD;]+=S2'G&]J!)Q._R?:FJ61_
MTR7H60HX7:@3V2?;[Q#NK)G)%"M%&,%"91RFE%$)NO7( MO=<3 ]U)&SONZ6
MS'7UM5K=5_K?S3OH9A%O?['F=K[^7&W-=;([]6SK%N:K:_/C52/0$]QD<^X?
M8^^RQ>P:4]UFV]O<'6[X9]EG>^+,43;:?#O4/_M.FS<O@VVU]?.<]>O?R\;'
MU?7+ALA=(?Y,EIED.85EAG.>P3+%^\.%C*K<Z7VT0$U&CHJ/-,_K/$(H:NUB
MT@BL!BZ'E*^0'.?M<2O:3DAW8-ZGH;NAC7KZC'D,SJQG(UO=LNEQYS=JL=+9
M[6*^_%!OFDI!]DG+\?QJ.T. EXJDHD1$$,5QCB26:9;F.4PY J5MHFC3%I&0
M0$)S2/(2 P49T^86)51I6N9<HHA#LH-GCI/N 28=PN2W#N/0UQI8T'8JFPK)
M^C0&9%B3GN8PX?FR'8SO%O-/BZ5NJ=JPU>[5Q2_U4I.YV>5'^^8+"%(I"\B9
M'OBZ:2!(T0U(!4'NDH!8-\I3QGC&%"*<X33+J)0HDQE)><YR@IU&ID<*\NXM
MXV_?O;U\*R\2]KY,+B[/Q;_]M_-WI?QX\7_^9YI"\G\G\K__^O;R[VZ)23C2
M[51P%+[=E/  8K.HT4Y=QQ) 6\9.B&!PTJ<AA.'-JB-W5M?LY&B#)2404I!2
MR3%1E-!2E-UHI"6V>IO1HAF@/Q.)LD @4YAS0HG 0BL\1!"I0L0^%'Z(K!.Y
MJD'X+XZKBCV8M,WN!B'1-:=[ /5_=3K&MMOUXM/]MKDF9%OK^=?:9'WCY7<>
M@A: [6E(6 A#GF5P@;BQ?K5:]X9JO6X?RGZ\EZ0[U[_/E_>5EL]F3:M<;*Z6
M]>;>7.SQ@*K,".<P%TC!@@L 6=Z-0)%+I_LQ^F(I<:X4EIA) '')*%.40<$
M!%R8F[.B;[^T\).-P>_X('9L/]@IX91<X":7#^PWT)_?KW1FQ#)I+&@RP]T.
MQH$1HZEH3])/2.U0[IR&'@]F[=.GP =EV4_9-8[S=;,^<-W@^5"M&X SD..,
M:8F@BI8JQR*%F6B%(\,<TMG7:OVI]I/PHXV*+*49A3E"0N*,,D:1)%!F.2<I
M$\KI,>1#?/9JH:7@:R,%9K/[NEXNY^N-V2C?;7P[[GN'HMI'HP?AN*<4&[;;
M1YCT%W<2K''NA'E,K3U&GK6D]F9_BLK9WZB3 AF(,S\=W*DRN]]^J=?-A3[F
M*CK.*,ED27D.<XE5V@U* #COHW_/&H-0P8P@G:*! @O)M%4,9A)J2U,J2J?T
MR$OWVIK)^1Z2?[%/7UY]Q"XJH3U%KJ7V =R8PO:4*&M!\V9XBD+F;\Q) >O)
M41_A>KO9W.L&099!1*DJJ10080%S3KO!A13NE;0];JB4N)#Z<S,!L*)ID6)4
M9/H_!>8TQ4Y/6O01K$4#)ZQ8V7+I+U012 PC4CM@XPO4#H>C.#FR.EUA<C7$
M0I2\N+$5)%'?WM8KSTEN"@4B4"F24XZ43O-$"=IAAC*<.>W[]@*"L(*I3C51
MGA<80\@AERH3JB!$9"B-O1>\P^ZS1!B7?CN5FPSS;CK8DO[#K0SVH?N$J@[B
MQ6GH[C"FUB.,$F_M/CK_)JE212'*5!)%=1*D,LPZC6!*(+>LTJ9%EBE>I&4)
M2I%AJ@J*$66"%D0)JA1U>L!A NN 04AV%N)!V.VCMQ-:_K.@S4XW>Y,^.7GL
M;]%Q%0S$EH?8/9NKRR(K85&0LJ09TV,.9*!;A$= I?XB]ZPEAO)"Y+F@5*??
M&:,, )"G)0=,%$H!IW1G[,6^7HPZ*UI4*OLHV<AK?"<HLE,M;V(GIU;^EAQ7
MJ9[L>*M3.VDO* 4%AC+GJ2BDS% FNJ,**.=0]E2FMI54 (7T/! +PC$J<P93
M0#(J2LBSE*+X6Z^!5O2\6?14HPCT]5>BLU%6\HYPXR)!CFQ.5'Y<K7A->KQ8
M\9:=\_OM9CM?72]6GV>,E( JJE)I@C;1$Q0%NU&COU7VU)[#IC@L(4Z9GOD(
M@;',F1 0HE20G #.!YCSM0)4/V *J$).I'I*42PV0^C1 ;:11>D B8LR^9 [
M47GR,N4UC?+GQU:HU'RQ6R5[L<XU0RF43,=U/98R2'EN5E$$8?H;6&2VAZQ[
MM1%O3!E8[0+)%):?3[%T8DP%(7<:8RJ,*76$SN<YIMAF4VW-@:B#XU&_5'.#
MX?I\];&ZNE^O]=#6/_"^-J\Z[O[*YYO%YM(<.IFE!688*\$H8(I+!'-:MOAP
M(0JGM\.&0Q5Y4^]AW)XE>[3-7M(AWN2W!NSQ03RVZQRU<U)>\Q7:7@Z+J[I]
M^;61Z,%\.#$]'\[N8^(_,//6D:*[..#A1B/V;;&9@3+/0,X*Q"BAB"N(3*'4
MKC6$A'+2?<\V8JOX_N*,!UPZ]]+(7"7;ET-+ 1Z /D<Y]6 NCG:^3,TI)>Q)
MYD1TK:\53U4J""NVFG.YGJ\V-WK FH/ZS4."6ND.[C YN%SM4G_PYN5OE?7M
M?+&:97G.D%0R*XHB5["4A5(=1 X)<A&J08&-H&YZ:KD#YRAPPSK,3A4GZZO^
M4FKAIBAJ&I+2$Q(\BN>FH=OCF%Y/8.2X18A?ZE7U_9?Y^O=JJ^Y7USI1;J[2
M)#PM ,N4E-#< 4((S$G7F&)N1<6>3416[095<MO 2FX,+C>E]B7.3G,'X,Q-
M/7=T[1 E#:3DMQVH@:7S969.B&!/*J<A9WV-J(-V+_?]T6K=7)DWOZO6;5O"
MS*3SG B2XA266&!1M&WE .9.+S;[M1!98!Y )7<&E?O^IP=I]AN?<?ERW_%L
MJ6H C20M+]+RRA:G/XW3$):>-KRPJ=F7$7M96=_5Z_FVXK7)KJ[NU^U*7]-F
MGLN2(<H+SB M<ZXUK<N6\BR#CJ>B^K04769:<,FGVCF)Z<FAK=H,19^KZG3,
M&6#) [+1Y.<$3R=E* 2_4Y&C(+8\DZ5P#-G*TZ\7E^MFT^&[GOS]7'^MUBLS
MF^O:5$7*5,YI1AD5'*6E@EV;L'!;2^O74F1Y^O4O%W]).GS-/N#G/<)D<U>O
M-K4Y1:W_5JWOUHM-Y:A@/6FV4[#A&'93L%\O'E/[ &TD"3M)U D)"T/P-"0L
MD"UUC"[HF&%5Z^WB9F'>(=B<WY35G;GQO&T1Y5*ADD)2",D%)$3_;9_32>#T
MW$F?=F)G5P?0S+GFZQTXQRRK#X^6.=9 %#IF6$_8:W&-E5\=Y^A4=A6 V6D(
M4Q!+GF96P=AQ+KCCW_=__&^+:JU__\OW=]573:;93Y40("E@JG@F4THR)H7H
M&D^%S+RJZ?HU.5BI7+('MRN\8O_N5VP1B&G+VHOA27;</^S!;]QRMI.,V=2J
MA:%\&BH7VJAC568A.7/6OK:<K=D>? ZCW3"D. 4*4HT %AEA::X$[C 053JM
ML(=M>50E]*K+",R\HR0.3GI(91REP,*).AN)#.J"B2EE6-N."68$!IUU\^WJ
M[GZ[:60:=EDJ9WE*&"DRP+%Y/904W>H?285P6HGKTTYD36RP)-!3]7QX<]2X
MR)3Y*MI9L@-VEK0,CC1Y/<&3C7SU8'=B8M7'DF/2U)N=/D*4MBT"D"*H)8]D
MA+,R@SP5W1H> 9"[G0/HT<X@0I3V%R)KWOR%* 9EH80HG9 0I5Y"Y,KN=(7(
MV1(+(?)CQV,5[2 O4^OJ'_?5ZNK[;@Y+, #<9&1E3H$L<$:[.2RA!?5=0O-N
M+W9!Z .N9 ^L[\*9/[G.JV:#\.JF7EZ4QEXK.\:3W4)9;Y8GIF(A+#J^1!:(
MK3[K8_MVVQDF4*@D:8X5  @4DN5"@+V>TISW715S;6\<50NV".9,K__25TQF
M@^C:9%:ZGC#EN+[ER_/$E"V$119K6?W8ZK7ROS_*WJ:*,E4 D5) + !2)48Y
M[&XXT4J;D=X+_JX-1M:V/9P :_G.7/98PH])H__T\N&VCI$GEB>H<EVI]V5Z
MNE+F;Y+-NGP_OH:\,^G=8E6]W5:WFYG"99DB6A"J_TF0*"ED'<8TI7X+^(,@
M&VP;]"S9V=-LRAU8E'0F)?7JU&T]C5W);\:RI#%MA)N6'!SN*,V3\[6_A@_F
MYLG>S[3WB$VH&-3S$XLIP]H>X:XF7P_81BGV=;Y8FON@5+V^F"^KAW,C9?5I
M^_"W64[3(I=9F>9$Y07)S)I&U[P.D\KMBM]@S;HHCM=UOY?U=JYI6WVM-MO=
M91KS#ON;FWK]9J/1#RL@MMR=T(;@]$]CV(<WJX[<;>T&:_5-#RDQWWPQ_Y?_
MN%]\U6TWB>QFNUY<;:MK\PTM'X^_</"3+]P9.BLQ +#D&0,IA  PQD&W.DF!
MY<['.,@BIY2]CD.,Y*O3V>#TW>26#1IP9XGY9W* T<SN._B[;VJ+GGWMT2^\
M>&/RI!U]75\U%^;,MXMZ]0,[_)$=4W?\DSANV&VB,RA2TL3F*'R_$,#']>NX
M47YDV^LIC"S'Y+Z9=QQICW,H"@$*P4'.\Y+QKCVDH..#'?[M#)2^W^QOQ9OO
MU@ZNYGJ*I85AODUNC!)\-;C=EGMZD&NW=#,,JVZ!=X>IIWP&F@8=H^?4O*<W
MI1.9Z/2WX^G,)A SKTG3=;68"7.P>_]B@8(JDP7&@!68*<J+E.I_$R@I!>;%
MHE=&B_L'1DQ+#8[D;OZY^HO+6-AT@V%37?WE<_WUK]JFW3C0?WC:_9_9^T)W
M]^=DW.[= W?=MS?8=]^RS5S-998S7 HJ09IG.<^0RDF&5=I]?(XPL)E$.W]H
MY/EOAR4Q8.R"HCLOKX_J:)2X#6H[-D(,ZT.#CXQJ+T[&']1^L.N>?<%]2/_W
M^_E:#YCE]X_57;W6XE$B6::P*%+&88F0XKEH6T)%3E+7T>WZ^4,-]#VN9 ?,
M?= [,V<__F.2YBD%UGR%E(4G/+RB$+ZL34<LO"UX03?ZL6$C(4PW<]V4RBWG
MGV<B+3CA).<8TE(H1I#(.HF2!%@5J;E_:F2YV(-)#!I[C7"DYG5EB,>*XVS8
MCI 0(O#(Y"-#WX^6\0>\)^ZZ;X=PSP\^5.M%?2U7U^5\6\VDP!*ILD0\8XQE
MD E&VG8@@,QJ \W_TX?*#7:H$@TK,;C<4P-'TNP3@WA\>:8%ME2%S H>D?!*
M3N!'V/@"T1/_"_E 'R9<!$,M-E?SY=^K^5KIKVQF F(N(&"IH( 5#(D\[:0)
M"JRL+A3L\_E#B<8.5V* )0TR=]EPILY>.&*RYBD=]H2%%(\G1+PB'[ZT34=
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M2"73$PR9=6$,<6;U^F*LMH<+*_4J89_7U<$(?((X@/#U<4*/2#,0_X&"SN:
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M57+Q]N?W;]5;P=Y?)DR(\U_?7[Y]_W/RX?S=6_%67KB%D>GU"KNX\T-W"+=
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MKJJW*SV>=7KQ<;ZM9AI;#@O!L4*2%)()0K-VA&$*4.$6O./CE;!,"RE*0BC
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M:1^/W@/UX#7Y&%Z3B^*@?=&J7]3Z=QWE6KV+G>+M!M6+8G$3WN/INR7E,N$
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M<EIHAY4<1T+<KZ3X*A OU0W3(3B#XF!"9:HL;UE<5/S\N#_:];A+ 2WFTF&
MH =A*"HH;2>2%!ZQF$#XE:$(Q!3Y,%D]Q90YK+@V"C)*P^@&T-SG-_<[1*IU
M4U!:KJ[N[J_+Z_H0RJYSS57[B2-'$!<8C\6Z7RP\(<RC_,#%GJ5^7'0[!J8-
M>$\C=2+&303Q/,+:5,I465[#)&SV-B#1C>NDTHQ1@J (_T' K.DFF>.^U_GT
M_J,AP)4#EA& )!7"*$6,5T088T#XALS,:?55=[^$W_NZ9[7JYFDTFX3$8B >
MQ6.9T$U'90<!9\%F!W'B"6T UK/FM"'Z]*.UP4B-9+9+[HAABA)-;(@)K;.4
MLVZR24&B+HM\:0SHA,":D4#.AA)E!/+"UZLFR&/#9%PGI8'WC175R^EX$@)[
M'<E1M)44Q%1D-0N"BJ>EWEC.FHSZ:]&/@B)1Z54/],O58G5U*BNE0&L0_H>L
M%19X:3%U[:P)<\GWKP>^/A0CGAEBL%$:41C2(\8]E9A:@C3R(/>QN[V X^J!
M"2#M40^<%LTX/CH F:@>F #2B'K@M- .JP>.A+A?/?!5(%ZJ!Z9#< ;UP(3*
M5%G>LK@X<S=N^7S2'KP*LEP29)C34 I.%=A/(TIZD7W/@010S"--(*164$&]
M0<)SXB#GSF6_4B%_+7 <SOU"T<D@'L+_Y5RJ@*=0.A&;)@%W'@%J&E6J#"]?
M NXZRLPEQX$QB3%:4>VY\=;);EH%TNQU/TS?L3Q7TE"DH(>:&L0UDEX8(24%
M5H;I_!-6_D;#.X*U,B&;BKC.5?-[!:M8^AJ \HP9;(@V?4AL,$JC>.Q24 TY
MXI89I;RS#(549A\42!%5Z7M^! B)1%(X"8&GS"O%B;8(AA!3,R6%SESG.R0M
MU>>[Y>UN7W]]A]7G^^7=]2_;ZI?-_7*[8[$$S/4ZH"/X*BF6:5AJ!LP4RT>]
M49PQ"_77H0_W1"(2M^E/K:Z/!]WL1VTJ\)= 00M"NFD-@(0[@Q$0[7S1P@#6
MAX"B!G2 $8J9#\_VE$BE')4.">FD\>'[TZP[# R:TB+;H^)W#E"'KD/4AV$?
MT-3FB*>*7XI&TG/@/&1;X(1XC]T<. [WR%V"IW%Y=:]@(EAG4"%,KM*S^P:3
MXM4W4K7+S>+V=EWN@K5W-Q_*[^7JOORT^'QWM%$=4 -0"+2@9XY+992&/H#(
MM;1,4RUC\NXT(V;.OA\*6:?>K9AQ86LB=/N%L=,#&^<]7L2T^%LC8W&V<S.]
MD#L1^J9%?AZA<&*=JISO:D2H_*&L]0^TV@[<=&/HKB -#'PXUMB>:6R/-&X>
MB>: 4818(SVE@M4+-\)VH@G/^M]4/95 F0E376V7WW?+D_7I?;>ZKL.55N2B
MD[DI!GQ<WJZ6-\NKQ6I;F,6VO*W6]:\%/CC<_EL_XZ!Y1" YF7U[!/1S-&T<
M93_4H'AWTW:ZZ91HXM&CQ@U/[!W![&>T9432,$>;#DLJIK1MO\0C$;8O)293
MFVX&B<OD*E=GG"ICMN.::K.]))Q2)XQ6@ +!C>=&TMU1=B6U%KV:!)YXO"=&
M 4(AD5;6;9VTYL8J@YFI!Z)1K3L2G(:]"C*-V7?;#[)^J4MFM(96N=H"O#F%
MU 0;;>OQ>^^QC0)O'JG&& 5.[JP=@$7_'D'K94U3AW$PU-0J!Z&ES$).( 6V
MG0H*.D)CV./ITY$D&BH<^,^'S(<1X;A1ECIK&8(4YJZ'= (-YHX!>/6CCKQ0
MQ3'''J6S$<<3-$[PQG#DYD$;(^1_TM1H'!)]2>/P?&:EM98P *"22!MEK-R_
M_!BXF*T AZ<"IP#D*I <]4%JH( 2##B-#668X#B2&+?<5C-$Y.ZD"'3Z44,>
M8.(HX6Q,T(<!X@&:Q\P?('<U]M6(J#$>M0"J5NIV738-@/ZZW'YY$Q1<7GWZ
M$H*4;^7]=GFU>;.Z^G-[^3<CSDBH%$-4>0:Y<)!XA1U1'B'G^_<HSS1^YA#C
M@=3%7NSB'T'N8B=X<2SY15'+'E%.RF66'I7 &5@DCK9>,L9?3QJC^-M.\)@B
M7RZK1-3T9F"=826\7%;J5ZX;!MM+U;G,1IA!,2ZWAM5TK_1H9[CY_5M 9[7M
M&F]?PI"3"\8IP?6%(0 2S$T[,M9,]K\5,M%XF9U=*T[Q;2?/:+Z,QW.PU\H*
M91(O%7BNP[<3\@P CW9 68%.ZG!B !_C6QXC$N=+!N,Y6]\Q7*/7?<5(M$;X
MAGHU*/SZ%[6ZMN7W\J[Z5G_7_?&M7&U*=76UOB^O+[%"T%DMM0\YFQ<*$LLZ
M:0R%O:JMN67([$/>K\NK\,GEU>*NN#X(6=S<[S9?7%5?ORZWS;<6.XE'LV :
MTPQV/9-;)8D[NB@ZN9LE]2/)BU;T0LW*/J,]U^1V2NK-$MAKC)/K UZ<XTMJ
MCMDZP[1:ONX@,Z ZPFF^^U;_T_U1KJ^6F]*79>NW?_^V_V[P";M/7=;K:\);
M0#$4AF+!#!6=5,2#7I<C3"5+]ET1S>0O6V&+F[+LDK*+8GFS_\%X;DYKH<$^
M]&S&2>1+6X-U"A1!@R[IJ+.0PX_J$&CWX9F9;K1[/9L)$[O9E*8<XW%C\(SS
MO%DL-5L/G$?;USUQ1I1C/?*#*S]^6_RQ_'K_57VM-SRZN^7M\O-=Z:OU4;C0
MW)UT>W]7F_+';\N[<K.M5N7FTD& E>70"HZ8%R'AIEVR38S"]G)5;N/\\U22
M]>*3_86-VSAOW<I=+!K!B[*5O#E6<)0"7Q3KO>C-48*;Y7JS_66S"!_]NE=E
MF%N8S,)Q'GY6YDU[M])%T9E]IU#1:=1<O7N<GNVNZ-U;_K>?Q=3#(H(YFGQ8
MA-!S6C=3^6AF'Z9R<;^ZKGNZ';N'3;'H',3+NP2BPX9$H/<((Z8V[[S"BLFU
M?R',.(\5!H0=W;O^DHRF^OJU#H46=P>I?J]GS8.8:K-_SJ4(T1 6"EAMA43
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M6\1UD F /<U<9\!T&'-UPA7/Y7/3(AIQL^:TR Z[4G,<POUNTGP5AV<H/S&
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M/;!,=2DTU )IB9VHU_.\QI [:YA44%D0V2MX+TCOF;=KX%,]*5*-K%&]#MK
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MN'>0V8 TGHW3^B=QZA0G#/9.2#<[$.[G:>2$X<V.V_=WY7V@;+,]_>:Q84T
ME2JWQ *A.=\]B^"UR.)!)YIWB*!P&C$L<ZN51^;3,\Z90-Q4UP(1-L24\D^'
M^GI[#+O-L>HQG31(PDC@GU&RQ3@G/Z.0GRY+!#KW5:2(4)OCYH=.C/\H.11_
M>AVH-\4]V;N[/+XP[W!L11K"A>$.8^>LA<[_:E>*8F=\(+>1_] Q#<=(YA 0
MXR@A3'$F@<^.U%!:OR>06."U_/C?F?S%9&]^^=5^_!1PXBTZN>=E>TQ>PX1Y
MMYGVR2&=BWH3X!'4=L?BTE)^55[>5__.]MCW%*E_A' <%SQ)@!4;=5KSBL3J
MI!;(SS-I*Q7#XR:F9%:5:>.RPX,M56Y;%5^*Y=JGO^WE</]8KHKY[>)?Q=5_
ME[?5K3)_GR^6U8UQ[Y9'RYZKQ=K_(^-_6U_&L"BO/LW_G DJ$>3:,&.1Y=+7
MMQ0:P/SW2QWG*N]PJ>H8,%M]Z+TO9#U8D-UX[&L?T-FM-\#7PK[HG7^;+VZK
M?4\_79>KG]8^0HZ6"2ZJBUNSQ=W7^6675V:&]GJ[QF:RGN[QGLTC<QZ_+GKQ
M:+U5/G+W1^_NB^PH0':69Y7IS7WE.Y.SK<W9UNB+ZI[:$1[*B>NW,QW2F%$R
MC7YI5 :>>\=G5&_T37<5J _%Y>U\O5Y<+R[K>DU>_<_]-@M7_9]\I]^X<E5]
MD^^NCU;+B\V[ZPIOGCNC 9; 8J.9Q( +M<7+0)Z#H(M&QD.9N%]["CZ;[]&O
MLTUY?"&B_UON;^M;$NN9H'-)LDZ+Y77G!?01@Z)?3IQ6/$3/C-]%R\&V;5!4
MUM7WV'_<1<"CO4L^EOP?3281]G96AW0X7(!,.RD.R$/+U#BT9P)O^6S>^7AZ
MK==1.TI(KJR6#&M'M *BNG:OGIT15# 6M-C4>E"98PX,H4A(030CU5M&%'-%
M$>(,FM3;MC[87^TO_["!EVK%H[1=MAB%S3#QWT$\/+947QOXAT>9-3!'O'>K
M+8%G!#FZ#Z:AK_'->OZ&S]B\M5MJ*6_]K\OMBT;R9E74NPBKH#3SQ>+RR^+C
M?/G[0[G;=L:$<AHA90A&3E/!J<P5LIA BRUH]Y1Q@F%3+[@<@\WV:+>?[@YO
MM@4<LB@0E_DV2S&CD1ZX&M.>[Q]O=TU.?,B"S&@.Z+@F$],1+==D0B@ZN2R3
MA.<IK,RD,:Q,'J-A];@I/F^.YLJ:^>%=8_!A-RO2S*O-&)<< $5S1C1R!"A
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M43#GQE""!2!84N9-#JI_]YAZU[_+8F =.$=2EU(MA-MI?*]Q3&E;IH7ST_H
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MI$+#G&JFE5-<  2 XQAKI(&/A.[;N'H.G%BN?YYO[E<UN&KK_Y-M1-G;.(<
M^G+?KHL?C?; )K_%Q0\[Q!>9ASS:@P@A?+;>JQ7)+=.834ACVMD]6E'Y"[OR
M[<3-$PV,[78QS_B[:[=87\YO_Y^ON&>( $D8SJ523#NF!7&N 804#SJTD!!&
M\MF,':A*9*O/K<N5<&GX;SE#.@WJDRGM^B)[Y*,M_JPR8(Q[YKH0?6[&-KWW
MIB'(0QCZ[,5U W#;X4Z>HV1A[K<5][OK7<7WL,\9G&ECL*'*@-Q8(P S= >C
MGL?N>"M/G,$3"W/EAW5U?7VE#J:XK/N1#,&+SK>_1.*\S2S&R'0'3G"<;BVJ
M,G?7J[^[SAK,;>K>@9S1^3*>X9T2Y3J>.,[I<B-/*\).SK@DY'X*DS$IS3M]
M+T\*'J,V'K[_J63\TQ_EC'/,H62"YI@A"''NFZ &1=4:1>\V L9.G,ERD(,$
M744(N1%;B42\INP?JJF:"G/F04^P9S@PVK=1Z.";%]0==+&N2TO0F<4DVNG#
ML9BYZ@43:+V"$VF%DQH1N<-AI0-!+QG''SV]?L*$^MF.X 0*&IW;832T@CUA
M%:W@Q=+1( ^]0"4-LZ^/EG9@,H6:.O\QS#"3!&E :*Z@4!P!Z__;P##,I1+3
M5H.GU](\G9:VHS>^E$9G=A EK5!/5T@K=)%T-,@]+T]&P\SKH:(=>$PBHHMO
MQ4P(()SAE#-HB#)6.:$;&%PRE4Q$VPR>7D110A%M16\"$8W-[# BZE%/6$0]
MNE@B&N*>%RBB0>;U$=%P'F.+J+SVHK/'PK'7;P6AXH1+BJ1G&C988'52*H&2
MAB%(+*>?OA2K8EXA2B.J@73'5=9T3*>6U]HC4Q?91_1&4-IN[GI9<MO1QHZ:
MVX?1V,([DTAS#"@0"CK&@918X&9XQ F>;:I3WG&U]H>#!LGK'E][>:T/KF]O
M??SZHQNP$],;5UNC,IM83J<IGQ$4L[437I9(MC>KHRX&\M;YW=0/177[4[TU
MX+EMR=QP1A! 1DA-G: 2&+)#X2"WMM=KJ3W'3EQW5HC_L^?[FGW9/2^(4R V
MDB[N$5=[E1K,;0]1#..+GB^<#NB3R.^:]O)-]_=,SQ-V:BM90NHGL),LI74_
M>K$T*HM12O=_+)LG)(HK^^>E_U%9/Y0SHTI:+B0GP&"ML .&V@:+TP+/EL7-
MW/]+$2KYSAA:?=!B^T$?PVW]/;_W_ZRZUN#;_+9JUZ_^YWZ]N3OW8,.0#HA0
MZ:=E/EG9?PP[V^+.ML GU .<XK9K0]#;5R^@.^AO8TBK$(G1."]M&F*YLTYY
MU7>Y8CD6TC1C^C_FC=Y^BO7@YH\&[""NGSK,3'__[N8JYBOOR9XS;$O?!"J>
M>+8$/6<8QE"_BPT>9@A@@8S3#!H*<JL01\UZDP,8]G@@K/T8B;OI0TK<3C6V
M>:5PP,/QSST7'8O1:>2NWE:T.MT>RDJ[LY&KF_ER\:^ZG97+JX_W=W?SU<.[
MZX^+F^7B>G'I/^7WY>WBTL?2I_GGVV)6/2K%",:Y=B9W!BI*JPV$S#A*B1:P
M_<'(V".G_LJ.\-;7->\05YW[$>:L 9W]5L,..J<7W1DM)KE&]4-8#_ B71!R
M3G),5W0\)!G;)2T/2 8R=:J<2\;X!,J[=+:50\1L^+-!:U.L%M^**^=YT///
MY;_\V(OEXO/N0BWEH,X-DPQ R"3EFG.V&YAI:5M5@A&'2YRN&I#9#F5614=V
MC#/\"9V^!+?(1L-S&Y:"OJ/5/:6UQQ-%??D-?[5H0)Y[/61T)HPC/VYTGI%3
M>20NG1-('I$->N95I*A<M;U _/ZV:JNJ(>N'.[X5JP=[?5VN-LV3'1 CB9CQ
M=$$),.(.2MP,BR#7(?>(]QXL<8K80]Q^5'N0V0YEV 78_:EMD1Z&9C4L.1P(
M=<\2VO%J\?[,AMTP/BC#G2\:[\ETZPO'?\3&J900D\@))(2HYI2) B[-Q-?;
MQ;)XLRGNUC-A(-+8\ISDU12<,&;?NW!@<?OLD&3TR4V 5="S&GNB*9@ S\2=
M"4OCE-2S85/R1YIIL31^&6IJK(U_HL^/[2F+,$<63O\$,EM:^SK.E75ELE7N
M^^6^RJKE==.)+9:ZO+LK5I>+^>W/\]7OQ6:F"-<:20ZIU1@:32%N,BY'6+1_
MDB/"6(GSVA9A=<'MUV:R8?-EOLG\!U^LBJMLL?2_+[++/>SLKL;]]79^>?IP
M01K66V2Q@0D/RUD'KO<3.Y[> \!LBW!@5@-RT<#L=LL\?5ENEV-^3,6IC!*1
MQ GDCYC6E&E"+6PKS7;@=]?[;0@?BYMZ#\_,*:8Y0,3JG%G'7(Z=;L835,B0
MS33=1QDL'WR^]Z17FTC7.VAA^WM[\'A>YX>EL*O"'[8E??P1?4EV(YUDY\Q^
MI/Z,3F-'4@0[RMBQ%B9"'R^_%%?WM\6[ZZ/'D;X5<K7RT;;;4KB\^L73<>(?
M?_*_6L_K4Q7;E>=/Q9\;Y4GZ?<8(L% S 0QQBGB(6%F;HYP28IG-6^UA&@(G
M5<YI!B"&@A)@<FD1)CFER@C,*$V]A-R85GW,CXS+/NS>KJMVW'_WM)B\615%
M^&F(41W>3F]?BJ_#%/NQ:X_0UJ]X'O]^^Y"<;XZ63^)ANZDGJZS):G,&?I4I
MH6/.)(LIA,,TTLTDF"BG][$&S,F< BF7R_OY[8?CLP]O%W>+S0P))PCUY3^Q
MDC!E'4<4>C&SQG )I)P=/T1_OJF-/G:(6!W#;*U9-8RL?D7U"%SF:Y/LX=SS
M1$/PWF*.9E3"(V6'BVR+-GL$-ZOQCLI_P&S.J'[H-K<3UQ_M9GI":3HU[Y.,
M[@G, J6SK1PB8 ,RU9OEY:HZEV**[?^_69Y"]?/\S\7=_=WV]*2]7=PL?!9U
MY>KHM7&?@C\4-_>WE>,>?E[<%NM-N2S6,\%Y=44UT=P@P#AR3JD&MV T#\AN
MD\";/",V5E8SO7=;.[)Y;4A6["S)KLM5=G6PI:[O5WMKLKN].0'Z/0EVV^3<
M20!-EZ?W_O];8^"_9V^>]FF/TL7.S-T)^:PQ-/.69D>FUDO7!V.SGU]NE 14
M!I, G+Z:B!<UUT^B9AX<->UJD2$<<ZI^F5103*#FF18?Y50_WVZS .5R/Y&Z
M'[.Y',C.5\OB:F8X,3E0QE=TRDGF",&\ 4 M:_6R6X)A$T]+[V'M[]3,BAI8
MMZXS!L]A+?_ %'?N]X_G\B\."GZXI\R.3'NW3G]@^GNW^7W=$-SC_YB@%@U^
M1)8GD.D2&7:BM8_.7<>^_E1N/-J'LL^&]4K@(QO6>R-FQ%*LD,*8"H,H<UIR
MTJ EQNE>W?Q@*"?3PQ]O1=R;EMW7:[&7CXS+YF&+L6-3W*V1GV0$1&G?S_7H
MQ_OY#E'PS(K\.G1)?FR:^S7JDXR&GNWY8L!0Z-J'Q^*]??<]N*<G4(E,@87S
MG?9(7FF[L4R7R_I6W7\N-E_TO8?A01VNV.)8.FPD800QSHF6".#=F() %_0D
M4+^14N]R+3:^5M@"W-\8]Q"V9:LGE>=S_? LAC;*._+^\,"R!MG1?;3#;H$Z
M2].934QQZ)W&-J1(MI0I C!P]^N7^:I07DZOO&I^+9;K;5=XF+94#X<?V;6&
M\H_YZLK^[[U']6:YWJSJ>F-=[]G[]&6^?/>UEM=?RN4W+[[%U0>ONEZ5JW]I
MIJT 5% $(2(6",PL)PI93"#51IF@)R4G!CWU'MG*E,!S 1-CJ.WFUVFA3B?L
MM14_?:[,R(Y-?;05]O-#=OQS.WNSVN"+;&MR=F3S\=[9G=D7V=YP_\O]L8EM
M1&6_561D.S:&WDX[J*O/[;"=9LQ-(]M-E9RG^W G"G-J^7BK #-,B('5@1K,
M"%"6":C!#K_!%LK9UV*U**\^;N:KS602<DOL(9K]U,S6\OWAXS_667F_66_F
MRZOJ]-G<JW5QLU@NJ]]4I[SKOSG[VV*9K6NM_?=7IZY;?XPKK($Q\9?1U%!>
MAI?33IX;7TG_[O^*S?K-\GW]?<^(<=!1AP2T*D>(><A[^-PHWF[-:7*PDR]"
MU:B+5ZF/CZD>11X[>ONUJV-76@83QUY^:[7\G@[[K[6JU[O8Z@="KF:Y\Y6P
M4D)R"G(E!'1<[^$+;ML]XC8YV*VTL<^[;UM(NWWS6U"M='+BWFZQZ#XEO(FG
M?C)U?NI'[:9^=C_7=NKGTZ.IGUTD;??6;^U^J=$3L%@_)=SI5^\'CZ9YFVAJ
MM[P_H*=.K?=/,5@FL %@DK24$__(I]*CNG)U72R\$?M*DF%@I,   BUR2GPA
M25AC@>8D#WM/=TK(DU=C>TCA-=@4^1I]'2Z1BR>^"'>((A]$6[M?RWS'=PX=
M9<JC>UB]]EF/'LP,-O'1UWOCY]RG\]I2*RL1DICDF$BEC49TC]\BL%MAL\O1
M<VXH\O#UM<;(7JMKA6\[_F]=;:*Q\-HUM#,OHZVKA7EN0OKYSV)Q\Z5JP+X5
MJ_E-44^)&U^VN_EB]>O\]KXXWH<! 3&"0IF[7$G#&<MMLP_#6L[YQ+841K4M
M\9[#!FNV YO5:+,*;E;AS6K 52V[+8^GTA(E"J2QVZ;Q8VBJK=71_L:6,?N;
M_+RN-UN_OAV/(=$Q;H61)([_,G5(&O:&KU821L%+JFEF"BKCI/,EF_7-+9&&
MY+8QC0#*)KDAL[]9D]NK>56=$ERMZSM>Z_YR,E.],8/IY10S42/HU50P?[VR
M9>*U2NLP_;\")9RR"58E@?X>OQ1YO+/PQ_9I8'-$)/05%J0: 06Y:.QSV(%I
M[FON;]>@&Y^G6VQ$#Y>Q*XXQXV2J9<>6D\."]%^M^@B,B0GLY(\7MZ^]#DG&
MVTAG 6)[?FJ'!=K;R;%01@KE-*5::<,)='L[#6A_'>V+M"[QHL^IHP==*Y67
M2_3$CBN,$T$OZ%Q#=8]AI#+FM43P-(],C!/)+_!L1;K"?/S3&'V*[LEB;1VP
M?ZWS'0GX&^D@2*I(&']Z<+?_]MYKX8^-$PH2HR@E#FJ+&8=2Y(UQ$ HRE;G!
MJ$8EGQA\?,YDNE.#<4-E['G!T6)DJI."1X3\U>8#0V)AS#,N<8/UM<\$IB%M
MZ),Q*7P^?MD1L."J<Y)#A(EDD%)IK*+&-*8Q"ND$S]/T-VHR1VT"RI$7)OJO
M9PM*VV!Z[8*?@K(I;D$)\_?("SY/S&EN.[^?WWXJ5G?-?OR9@CE6!"JKA.9,
MYQJQ9A'+<0W !!9W(EDR].F=#\7=?%%O>#U"G%60)S$/'BL^1EVU&2$TNK21
M+>>S?^HSG_U=_#V-NC:'<%YB $YBT66$0.RQP/)R G+L=91V?AU^S21RO+WJ
M]9'87 VS%I+$P^-/0+P[-+Y/+-S72T],7<^X0<QHI*A22@+L(,OEWD::MWQF
M]&7:EGP5Y(?3$5-9!DD2.6.OAHP=,E-=%#GBY9E*XG1K=?K)IA<V2]8A,$:9
M+DL9P*]]WBPI=X--H*6/@*"JY?./;?P<;*.\N5G55UF^\88LENO%93TCN*_"
M2"Z9 ]X:( !2W%ICFGOCG7+.!=^*,TDK$L^@[>%E>WPA^T:GSU](M3%) UY#
M97$RRL:]I&8,?_^H8)AT#$ZH.)@V3\\5 M-&/(7ELQ/&S R4.<RM!8)IR!4U
M2,+&B!QQUW97Q$3A3V'_PR16)SK[?]3UL"'</O 1I7;+#:?3^LN.IDDL;@T1
M57V."VW+P<OCZ)H_+AO71S_W=1==\SJZBFUT+8ZBJSQ4C>4NNN;[Z%KLH^M;
MQ<%_3';EZH33AE^JZAL]KWIMJC<YPRQ&Q?'AH:0[_FK>^E_]U[\U?^+_I_I,
M_^O?_C]02P,$%     @ R8%>3T X+ D;C   U2,' !4   !E>&5L+3(P,3DP
M.3(W7W!R92YX;6SLO6EWXSBR)OQ]?D5-S^?JPK[<,SUSL-;DF:QROIFNVW/G
M"X]2IFU.R:*O)&>E^]>_@"0ZO6@A!9*B9?>2BQ, @2<> !&!0."__\_O-Y.?
MON6S>5%.__$W^'?PMY_RZ;B\**97__C;'U]^5E_,AP]_^Y__X[_\]__Z\\__
M1W_^^),MQW<W^73QDYGEHT5^\=-?Q>+ZIW]>Y/,_?[J<E3<__;.<_5E\&_W\
M\ZK23\L_3(KIG_\6?_DZFN<_?9\7_S8?7^<WHX_E>+18?OMZL;C]MU]^^>NO
MO_[^_>ML\O=R=O4+ @#_\E!K:XGXMY^K8C_''_T,T<\8_OW[_.)O/X413N?+
M;]?X2%7\^XOR?^%E:2BE_&7YKP]%Y\6F@J%9^,O_^>WCE^4X?RZF\\5H.L[_
M]C_^RT\_K>"8E9/\<W[Y4_S]C\\?GC22?\\GQ?=B_O=Q>?-++/"+&<VOU?3B
MP_1;/E]$ <Q#!Y;M7,_RRW_\+=8(8X<22,3CR/_;]AJ+^]O\'W^;%S>WDS#B
M7]KKDA\5LW\?3>[R\.-?9^5\_L<TL&12_"N_^!C^EL_/+A^55M]&Q63T=9+[
M<O9E-,D_3)\6_U3.BT@.FR]"P0/&VTMWN@?S[#+^H_O/NS"M)LN>/BFG[TTY
M7<Q&X\7=:/+;:'$W*Q;WZ9BU\-7.H'G2CR_Y>/GQ\_"U@X==M\7.AO3[:#8+
M2^&WPX>PK87.NOPY'Y?3<3$IEDOXBB\O.?,Y%)\5X[!5Q'\[>'0M?*PS(,[C
MJG' F)[6:ZM[Y22L8N5LB9.ZFN5YO=UB=[5N.Z?"=+O*I[DMYN,RJ"/WY_GX
M>EI.RJLBGW\L;HH@T*K,DR;JTJG;SW8+SI,??\Z_Y=.[/.QD%_EL<X5_!H7,
MCHIB?%U\&4W_O"_30&K[\\,#Z\/M/$]D4EN?'1XXYZ,_\XM1_^AL_&ZW\+0X
M:8XW 3Z$;;(8GU_GL]%M?K<HQD&U&:]^V.+*>>!7.AYZG%!M#G)?>]T.YW-Y
M/YHL[FO.EU_#'C5=A/TK;<SM?'10P,S_[!62%Y_K%HR:NF>=REUW-"[H+4[/
M_0VV-J @\ND\V!3E=%Y.BHOH]]*C2?3G?+G.\SK*==T6>NORI]$L@'B=A[5[
M-$GO_\;FNAS,ET7X=<F#E2WH)^5?A\EA9TN]#:&\N9WEUZ%,,.##7EK>Y.F#
MV=[F$8>53KQ#/M#7@%L2W7&D]651CO^\+B=A@YM'O\KB/GD@VYML;5#!</\T
MNJJ!^;."+77@P6'Z6SZ:W\WJ>5MV5NJR8S6WW#IUN^QF/:VF1M66.KF:C^>C
M[_L[M:%H^YVH*<;M-5KK4E"*%^5L[T+QHF#;':B-R.;R;7>G'H&W%&^I,Q_#
MK-C?AZ>E6OWT8PW13$;S>7%9C-?^^V6)C\7H:S$I%D5M1B<WW.H H_913E<[
MW?(G[OMMW X;#:9F(ZUV?'U@5\0CT+/;/%I/TZLDD1S28JM#:GJ MKM6JUVK
MMQAL*MM2-W[/%VO=.)]]N0[Z\;Z^;*W058?B)+A;K*>P'LV+L9I>V&)R%_3)
M%X5K2KC5CW0U\$_E(DS]8C19_FUET=R4TZ7>_'L9"T_N+O*+#],GG7_>Z65\
M0B(ZG?>D*PCK3:\]U5KJW-GL:C0M_K5R54TOOMS=W(QF]\$.*JZFRTUJNE#C
M<7DWC<OCIV QC8O]74]J])@#JTG%-MH^YC [E6-'\OPT*\,NO;@/_8AV^6VT
MG?;U?U>=#KM5DT4UJG;8R:;J1Y,V.NQVO;5S?\V6NE@=LNSKT/-R+7]>C8,4
MEAIK'/$TAL-^SN?Y[%N^MCSF,4;PQZPUHT5^5<Z6RN\RF.1N%8ZD)I/RKV7Y
MFJSHK0,M U;% JKY/%]^^)'2OSPP.R]OBS$#K"$.A[;;\O""[A"FP,7=>%']
M)( \NKJ:Y5?+DY#[];\V'-V!S;8\N.IW??_DZVM*U76L'-9:1T-Y!N.O>7DU
M&]U>%^//^57]<\>T5OL9VN,UX&Z^".KMK)W1[6^XY0'6VXDVEVZI*TM3)]B%
M\3CC)OI@EIK:OB[MKM5IU^+R/H[R<J'Y\C[/-Q=KYI7JX%.=@M!4\VK62J==
M_SR_6^_T=9?9INUTVOWE3\]NE_1H8QC[V^MT./56H#IU.^UF//%:3<GY_.YF
MB=;\CU#FO'3S17$3YNBOL[!JV_"'AP.R)+&T\,%. ?EG7EQ=QU#M;_EL=+6A
M,^MCZ!6SEAKU_/;VT]UL?!T]KDG8M/OMMF"Z^SK/__,N&&GN6YW3Z&WE.^I.
M7<!W5SNH<X]O_<E5[Z8KC>?CZ&O^+!QE4[W);/:D6KQN*.-U0\B6G=[46LL]
M#59#NYU]WF#+_?V4SXHR&K'M]GISLYWT_<MB-&L9\VT-M]S_\WPVS]OM^<LF
MV^YSN1A-6N[SBR;;Z_,!Q%B\[&9-%MS.\GE8"Y=;S\?P@W7YV.[!]X=7'\N_
M+_+I17ZQO*!<?2ZH_)O&M1S3Y6C^=3FPN_G/5Z/1[2]Q\?XEGRSFU4^6R_G/
M *ZO8O^W]8^S1WVP^=?%VJFXJ*Y=1J?7U_G2[5-U<1+!^<??0G>RYHUD1E#D
M#,)60TP%HTHXX %U&CJNE4=/@5B:.>5L#?LV)%YN5_$GV>9;B8^O_ 6<=6CL
MSPU#:]A"9@7!"D% K6>4<BVX H1(9AE3Q")69UR/":5FXY_*V44^^\??X-]^
M"O]RF<]FZ[ULQ]WY);T6+U:%T6S\@I9/*ZY+_'*[#-C\>7Q=3"ZJVC&50/<"
M+_L /@RSFL._;)S$W4SO'B^_G_#: 0WU1@*#-18&",DH,5IRY0440AA^R-K1
M#A*QYX\Z_$Q^2WMT!P0U:F=08> Q$4P+; /CH0[39SUV;*!XL^M+;5*478/^
M8VWIEFR^F(ZFXV(T^3 -&"P3P*BP_NP@V)8:8>WD"&LK'352 <XD):0:'W2V
MUF;\>DC5JL3++A#NBT'GL]%T'F03-]4O^>Q;,2ZF5V>7&P8QCVDWYIO_R98W
MHV*Z@W9M?B;CQ&MC!5 *:4L]T$*#"DD-,#TMKB;SJ1R,*/HBM2EGM_'J8:[+
M.,9JGO^6WWS-9SM8NK->!H2 6@JNK?/2 ^ L1]58E0#^M&AW')J4W0FD+_+]
M\>5\MKSW$L-R?HVWFZ81BKWDVUDO ]8HQ%#8BK!42(4I#F U5LZE32 ?>B??
M1O*U*9#^5KZ;FWP6<?@TNLUG-5:\#>4SZVS860PW!CJE.=$"A:U%.B:]"ZHU
M22 ;?B?;EI4N71!]D2SF3KRXF^1GE\\UYQ]+],=BFG]8Y#>[;)%&[6148QW6
M>@,E-E(JHQE^6.V- >:T5L N+90N<>^+@]M['F,3B^E=>3??["I3X_'=S=UD
M>1P8?ES#+]7ZMS+$M-*:8@R !2"H\0+0A\T#GIH+IR.^E<.24E_,W[TR[!OK
MQWP^/[\>32'Z+92\WK4\M_NA3#LAM3'<&J*Q5T)3\2!7K)$^+<X?D8V-O)L=
MB_%U3HIG(NAMCCS[;L:!L#Z K+@'A&J#T0^LA6&J%Y5G1SS.^Z3I0ZZO8PY5
M8SV;?2RG5SN-SG8_E#%GF""*2$"  P)#1/V#C)5RIV6MGLH<213CZYP4?6TL
M>[Z; <T\@0Z$7X"#DCI&6(4UP  F3!GROK'T-VG2Y#J,.;1YI =/C<W-94I!
MSI$CBAH%PA9K"'Q !BN'$QA/&V\2+\(>WRK?6Q'6D&G<UH)?J_7,,!1V34))
M7 <DP3*L !5NWJH4>X$=N*R_#/%]YWI[(CQV#&-KC]&<<*@BLHP)!01EPE'&
MJ4)"(^LI1Q):J&J%#?3M0X]C^I$Y+.;/+J9GT_P_\M'L0?8'.<SK-)P!%.:=
MUH90I"AA1 $"%><!+8>@<&\W@+HVE6J[QCN0Q_%/@)X.2ET&&88QG5_/RKNK
M:U]\6PYOWB:1]WXCDP  HZVEPF#J$-6 ,B\PPV%UIP:#TSJ]'!"GVQ;-,.C]
MXV\'L_?'WS*! $*:(D\]I$'QD)883JV7T'CC4<IQ9',/6N<*X]')>3#R1U+W
MFCW"=\*JG&<H;']A,U2:.@N1TI:'G1 QC 5V_* ;:X^1F.?COU^5WWXIEEV*
M..#UGR,"^!$"JY\^ZONVBR6;"V:4>LZ], 082* )[ 9H/1*EP][^9E6LVB(N
M6\3W]5T7@<I2!;5T@%IG+0L[I5^/3V/L4\Y<!L2?5.'6O!G2#,SWFR';HR\Q
MIM"Q&'@IF4-826 KR6@)T!NY&5*;3UW>#&DFBKY(_5LYS>]_&\W^S!?^;GJQ
M_TK(Y@J9-]A Z275$F$(K4(/HS,*X1-S41R'&&4'DGA=<?C*!J,@QEE9S2E!
MT#@.UV-SR(%^XG_>%LO:$,3KON9FI196 B(M-X9S9SQ\&*NW2;<K!QA.,Q#2
MM2>0UWW-#4JLJ R#0T1[Y0V$3E5CU6%M[R4PY6V1KTV!["??C@0]X?.?@YTU
M*\;+Q,3SZZU<VE<EHT I#372&&IM89@DA%2]IA2E7&!K'NUQVC1J61:][9WY
M;+%ZG6J9FSV_C>?Q^W?.[;4RS1WRT.%X"]0QQPP4;#U.KUC2_8;ZP1=O@W/M
MBZ,9[1+\M!]WW(O<7CC#\;8Q$328.5@2)+D@M!H-8B[%WS8@2Z E?UMK.![K
MK.]9(-%-&6C^KYC@=KZ(SV,U.?/;UU1F@? 8"($% 3%/&B'65(@PK_MUF75V
M]M<&)?:<\;6,]$"X]R,\[5FRNE_#PJWSRS(^V/7]<$+6:S\C7 ;S!QI$65 @
M$&(:52Y-3X1/\;<->?WKG*6=P#]TZL9 RRZI^Z3]S"CCPN[E/6<8> 49XKC"
M#E"3HA?6]Z?T<-=B0.1-$< IQO<XA!RPA @C)0&:!PP>\(?4]'/=YQ16SY80
M[LW(?9D[]ZF)_L)F?U1REQF<TFYF#1 *::FH PIP$@R_]69"@,4R)=IL0%=Q
M.F!CG[ G>?(.[N0&)627^Z_-[V2*<8< ,P ;3YF6@*Q/S1ED#- 4G^& _#<M
MTG((8A@$3;?<[.KD.YE6RCLK@54"4"LIQ=@%?#!@2!CB4DY(^(FJDT,0Q'&(
M^N/=IV(^GI3SN]FF&-%.OI,A2+5EU%!KI=8(,^E$M=\X6B]%^Q:BBJ;KZ;=\
M]K5\"RMJNB".0]3X)FZZ$_0H_<@$4\+Z\(M1/CKRC*&ZPE=IDW*U1YZD/OL:
MQ#34:7"P/W8XG<L\ E0!A"1&SO-@,6L)*TD8 5)R,4#PKFH/27BO;AKM\PT/
MIW.9@#9 AH7"D FE.0 NGB<QBH$B2J48K+#^T=U;,P6.)+Z!3J3CS) ,$$R$
MXSRL05"Z8'UY_[ (*4F2<HF>YGG@\*1RI,NLNQ\4/^'+JYQJS2#R&C(@9=C"
MK2.!BC;(2$/+:VT7W2"Q.V_.YT=J2%(.I><-93R^$@(T0YP:["G0@.HU(H8#
MEW*]8H"7>+J@2J,$2(GX#SG-U^]W,>;P[++Z>]N)OEZTGP%E 63,6TD<0( [
M87F%'>+^Q-Z#.3IWNQ%+7Y0^6USGLYB0^#R_B1=-9O<?;FY'Q6RI4H3Q[![[
M#BZG-9QQ#(T'CFM"J8]I7ZU@%5I$).6W'N!5HQY(W*L\#C9)SOZ:!K"OB]L/
MTX!ZP$3?_U9,RYA5Y,MU@/*ZG%QLO_=1KW8&C!"8<2N,58(:KRT7U5@@P/(T
M8EYZX%9WH!],H,_YTKS^-)HM[I<7$<*XXO+[4MO_;30=7>47/WJ[',@V:J6V
MFU$!@<'2($:=D-XXR>3#^#E*V94'>.^H:]+U+(ZCT7%5( \%G]UQ[XJG6S^8
M$1)6?RV5LQ0Q3B"002-?(69QP.PT@F!>"X';DE-OIM-=?EX^&G3,P7LWBY+8
M90]MK90YQR6!81^QPBF+G((NSE\GK3,FC+:76)=38&/K6+>^5JJ+;\6\G-W[
M/)]_F(YCIQHO?YO:R(2#A&A@K8(JZ+30,53IM!89FA(OU3@,Y55SJ&OHC^0/
M_IR/R^FXF!3+UE8)K5]ZOI]ZQ=^:ZSC,8::=]8$P.&9$E4! ;K!VGDDOZSE*
MNXMP#SU_+K#]H]]=,2/<8\* D8H*"@073G*%D%;$0))VWQ8.8.[7%NB&"/36
M4.OS%L2&3B_,:#:[+Z97^Y) UZJ?41K@1 HS(QGE*KZ2AR127 6<;<W<H&T=
M)G09[M@V%>HQ+ GLOHCV=)/8K_EN+)\Q1[5W-*"';!BG48IIC<)DE<@+Q5),
ML,:>_5=,I#; /0YQ?B]7"E0#[ORH$O 2W %#H> QC[F3WB)%H28P#)(EN: :
M^]1/ACX'X_NV;_H)#(1R6!$D$*7<B:!=0&6)EQARYE/.=YK[X#O/*]_ACMB7
M"(YD@RW3O+P=<\H8:HR2074)>Y!#7 *%-$/(6"><I[6,BVZ0^/%2^PN*/2/6
M>9"/#IWX<P<D![2682(QHPHJC2 ECBXM$VP("FMN1.C-QN34)DW9MQ#ZVN-^
MC&1+_^,JTHR7=1K*%* NQC(:$Z_R8RNQ)X:'I5R$U128$\D]<Q1*=H!_;_E/
MG]R/B,$59]/G6UH=,C9J)Z,00$((=DP&R.,C@6%+#U8,=!Y&??3-1LP<RL4N
MX1]RQ.+#1=':1&WQ*T$KI9H"3 EEF"JMA-=$0L$\408ID.+C>-W!.8?2^'C"
MZ8ODCT TD]%\7EP6\;Q\TP.CHT5]5J<TFSFIN0,,$1EDPSU7D" KK36"*2?H
MVPWW.93&/4JC'U.WG 3.Q=3N4;I7LSR_>>QPZ=W2/9M=C:;%OY;=":#.RTEQ
ML>K;].+3HU$^RM;[)?QDU>L:1G K[6>8(AAS#'(#PQJDO: <>6"!<<9*<<R;
M*H_D^2U7L]EH>K7L^X]L"W76G :M9&'%=0A*0Q675%DN"./<.**]%H:=VENX
M/?/GQ3,,7<GEF(N-"NOE53Y=9@2)V?WOS_/Q];2<E%=AQ?Y8W!2+_*(J\Z2)
M8T<YO([%RB%EB5(>!HK%W-0<2>D!X=:9L-V16LD,.O>7;"%VC&R)1QM;_OEQ
M@,^V]R6[^UB&N$&<(@V]\B+\!K0G%;)>Z*1+OJ>Z]-5FXW:7S''$UY<9$1\C
M.+M\U/$]#V!N+)]1KBUR'E&-!/%8^Z#G/L ,0$H*RP%2\YCD>/Y$80OBZ"W#
M[PM\1ILAV?OL2,.6,JR54_%B+9.>,F,9T7R-!Q:2GYC2F,B)YRE_.\7Z\#0>
M&Y6[?Q:+ZSKZW>;:>]Y7ZNR+F<3"8V>XHTA:ZKB3OMJEL 1IZ3N&Q\_.&%4.
M45H'KJ[SV>+1RAK^]GQ5#3_*/D?4MFS83_X]TP$XPS62P2ZC1A(L^0.&2"?E
MF![@F=T -N@4^#NGS-:%[EF)+)CS2N PZZ#%P'.HL!!5OS5S)Q)]<*"LGDOZ
M(,RZE/5OQ;2XN;O9*>TG93*EE*10$6 XCB^%*1$(O^H[L:'[)R;OIA(KV\&M
M4YF/ON^7^>,R&3?<A/YZ$2QEA)RFX$??B38I#UX-:&MH1>8)N/46^)J^X7W<
M\21?%Y_)I/2*,@X,-D1*AK3UK$(RS*H3>V%Y ,K) *38LN'WD'EH5E[-1ANI
MVZ!VIHFRD@-('39 2.RL?AB+!.)$]L'CTF"_M98HEI8I-O_C-D W77P:W3\Y
MM*Y'L>>U,R$1E9IRZ#6C@GE+M%J/A4IK3V3;'3K%$L72V2J6Y\$46133J]0%
M[45#F5"8 "\I5]:H !QV7%<CY$BDN (&N-L.E7CM2:@C#MK9W=6#BRR-A1N;
MRARTF@?E&0(;PZ"L8N3'3*/,GU;,X]!YV(:,6F:BNKA8QF6.)F>W\??#-MYM
MK632.D"LM5P)"8CQA$CL 9,0$HA(DHXWP&#%H?*O)?&T3+W/0:RAR7@7P^;?
M\DEY&W]Z]G527"T+-J/@OM8R%V_06A%S3A"HM*=2N6J:$>Y37LP98):QH5*Q
M93'U0DGW_3:?SG,U'L_NMB>(.KS%C KA*.+$&4V$8-;Q,!<!XU)#*R%-T18'
MF'+L=5$S250MTW.U>KOO^6Q<S'.?Y^N%_(_;AY\&%7=5JAE-F[2<$>VM#[,3
M<&R,)-0+6IW-4J'-B64W&RI=.Q19&[1] L;:J:]NRKLPH\):7ZSN"3V:9\N$
M E?Q"9MR=O];,<GGBW*ZXZV7UK^4P:"(2V(T%#*@@XR4#CY@)'5*\N;&3^KU
MDL1D2,0^CA!;(OI#[,J6?IORYB9.R-'D1T__F 9F/)G9\X=VZI&^[:]FF$$>
ME@FIM+;42$8LK[!C!I 49T'S)_+>X@PXLD2/>6'DR8\_AWD^O=LTMB=!9G94
M%$'"7T;3/^_+]XLC=4+U!0,NJ*[( 800A5XKZ->$\%34F^+O%T<V'0]+@JG%
M-FPW%'FG%8*DTK \1BC%O3# T\R>V=C]Q9%FXGM=%T<XTLP3$L .(Q/2*0?
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M.)1JP4G43$S'=!*]7R9K?GT'(^T<XLXC29 V7 <E #M"H<->UDM<_>[WV1C
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M:4,5I1@Z+3R&PODP4,CMJ>71.R8Y:GDDFXGC]#V2E!M$F/28*4R)@0H[:G1
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MM!@:IFB*/V?8:5HZ54;:0WRPQO)JGESGBY@&]0U:SBHN"!13*#3"'FO//+:
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M)"-P0)[#=D5?=@?P\6:QC<_&3$YK,@-,$'3*!1L<.@R%9CX^3\%5^(?HR1G
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MO77B&+6&1AH@C09,,ZMT-4;B8<K%W<8V_1M:9%N2Q_'N?"Q5I=.Z\N&UI)X
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M=NC5?/;'?+$-0OI]F=C\H?PTO^*(_T"11%IQJH5C1CL%(N>Y 1:>>.<MIF;
M8G O3CLS[G6QV6F#1]9?8704C.0,5$TUEHBF,]QN8VVW:P^<_*A11%41\7T"
M>,L4[[&PP'<SWTN&+Z_+Y54MM+WPAB@TRO7T  0'%32B2IK]^JWOZ8+T44OJ
MUJ,V!-Z:TWP4F-N1[EUQ5=XNY_\ICETRG/>BJ *GG#BN6+*A9= ^2+JG!L>T
MB<P;X17KH!AL2OPAH9CLVIMR=9<5NC=_+.:W6UZ_3[^N;^;%=39^B\_S\GY]
MLE=/\Y='9JT67CE+M$J**B.6\#W5$!)-G,(C+/<S!&0[94BO&G[2-1X#'AY^
MXN;KV>WMZL$E8+[L_O7'4?!Y;LV$A!>6DZ1Y!1.(Y4CIH'(93#I@^M$3SLQS
M@X+=BDY5>#XV+ )'(0/3"&5 8VP0\\I3%"QF:5-46NWT5/K*&'B>+MP>J;N,
M(=KMZ3>K7=/T ]'^AQZ-@ACCDX)HA$WD 2P=1II2E+1#YX2>R#U/NTPM6Z5I
M#^C([I[=! ]'YQ]]/@;M@A648<,H*$?2;^GTPYQ)YA@1$\K_:,;2[['1F)@]
MEI_)\SU95/";YR(5:8. 5"H@!PZH(L$H1+#V1D(B39_ Z+)96TL<_3Z#O38M
MZV=@S/Y(1^3FR]\G<BR^?2P:#9HIJA76#@@-.FA$0D !DE)L9),+V!&)@(:<
M*5LC8'WVYH^NYO\^6=+ZR5/1!P_(.FP\5H <D388X9VVR'B*82*WZVTRMPG]
M^A+I!_2=5Q5J?)X:&@E3Z30,%!RS0 33ED@:N,8\$8VS)MZT$2*F5<VQ(QKW
MA:H3II?_^VIQGTL:Y!N0]+_K#[._ZQOS+[TM]Y0'YX)/TC2I8R;M5HO2IA-4
M"<>M5+T<13W=);0'DO,*:;1 ^%[=7_O?S9=OW%Z[TAE??B"OER'(&>Z=%(PX
MIYVQ["$(@5(>S,2\7EP*DKL4(V!!69T;ZLG]:HEOU)UWA%IIZQ@XQ^MU'JG'
M[/4BG#,LA0O2 TE:GTRZVGXE@I(F^6\C!$T[3#WE]3J/II?A]3*,:\Z0<2 P
M&*>UU[MH6LJDY1.)DFG.TDI>K_.(.6ZOE\W!U &<\8)Y$IP57._7HIB=4*IB
M"_P\ZO,ZCY*UG2*[CVZ+VA]WC'S_9)3(N632@R?&(:7!:24>YRA@8L=%3?Z4
M;=*P-I^W"0HOE\@[SO:3 R.UR:0*QA$E-+=<$H/-?@5:F"9792-T>+2 @K9)
MVL CNE@\-'Q*9#_E%OWNT:A "AF80=PF44=I"(^"#@S@)L+^;,8/=\5QKKAO
MB9Q]Z0&OTE*7Z\/%@5Y\+@:.+!?4Y9Y.!..@@W#[M:2-T>NU:)?0:,[,Y^U
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M9_R@&UX='(QEHP?ZZ_N\?7<<6>O/L_DB4SB4JU_2V&,1)%U],H;<YDQ89Y'
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M8LEOXP5;+7:,YA ?^.);\T0;(W.7=0%<*\4%Y0@AJZ7C*DP-Q(,KGKVS;/1
MKY>E.IZ4Z B<LP#(4F431QC2H V1/)G!3&BBIV:[]0C@81.ASV1L/W[5^S_6
MQ;_OTV#_.0NIP7RASR=2I=;>@2$12R&(9@@\I@I02 93^E52SQ0044V1ZF>5
ME=(+#XV)06%$ ^)>&.K XAPRE=<9!';4FE[MDQX$16-V/]_^+1%VD(TZ]-U%
MF_M589,L-W".,(J29NW $!22D"3<"<,J^<E[6>7)JX,7'H_I7)*,DH0A0A!%
M0G.V7YU/:EZ32FJ7M$LK,_GX+JU#T]Y4UF=3/>VT/S B"N>1VO:(9TI8 XCK
ML%M?0(A,+6^M$8M/X*4>20>$S&G'^J$QZ214Q&GB>1#$*B]QD&:_1F)PDR;V
M%P";LSE]&CFUZ#H0=D[Z'%]\/@*3/%BIE*4(ZR"L5G2_-LI5D_H3EX&9<WE\
M'#6UJ'H:,0?:][PJDFGZU,ETX+PY_' 4U$LEE2#2.8ML>GWNI><@B5BFJ6QB
M1(S18=?&4=,:-=OC^\%#X]CCT5#K ]%"*>&L$=@H0G>SY8'IB>S]-MAUE/.U
MJ%F;]^9^OMA\*-_?SS?;F1R4^T>>C@*,L$ZG U)BAZ4F!B5IYSB56@*%B2B8
M[;"K;)N<-16$]6KS1#E(?WNN&*0?Q?>)']ME_E*4MZO9IX_SJ]GBP*EP]/E(
M-0DJYQ8;H0TB1$G8JU'>&=1$F1QC5_HV#H8V"=HI2(K;YS,\>( <?3X&)1@5
MVG&A M)6:!0>UT0 3<2YT1)?R_8I6OL4T8O977$]L[/%_*9<+>>SX\?(@<<C
M$E1AJXWFG$OB+;9"[O5<G%3J"?&_.<?*U@DZD*GYJDHLP8$AD0EB-/,X!*T$
MI=DR<@\K% CI1F$N(VQ3VZ5OJRY->PM=7A6S7)Y]MO#K+#W?KLI/Q6KSY5@4
M\X$A41/JTLY28'"2MTFI$ICO5^A!3.U2O#&CG\<GMT/7OI#SJEBOB^)-FF)B
MUO)VJVKGW*2<6; \=<]T>G T!CLKL.=$4PQ,:P9XOVJF7:_=;2X03:U3N($C
MY/N9O"XW_RHVMKQ+Y_55<?U;FM+'Q9<<Q+&+X3CL)JGQLNBDUM8+2W"N6Q(<
M-D;M5VIQ(P?:^.VD^ECJC>+]8DLOE_>SQ:_+JU5^_&VQNLI\O7WIUKC]CT2#
M@U7;:F#2:Q[ .LSVE &-F^2NCU^W&@*++7&B78S>9TLBG_;+XJ_98A>L=A8
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M96PR,#$Y,#DS,#$P+7$N:'1M[+UI=]M&MB[\^=Y?P:L^YZST79)=\^ DOJL
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M[E\W&/6R:<'8%H^IT4HLL1#-UJ%6V8P::BU[)[E.#$A,!'+6C[(:!WFN2[W
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M!61G[MRCER,O?CJ8#MW@S3/\L5^Z-6VQ-L.)"#60W \X)E0([@6^3SB"0"+
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M6QT92AE *A%6G&KE!8)[(?.UFIOOM%1]J36N1+!3;NOX[?_TC M3#PY$C$Y
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M#*&OB$9C9,;W<7<,2W]$WP]3PF[=:()3C-U)Z@=F @\%3[ARH)X/@/9"J+S
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MWLK .(!7DDBKE9=(4.09?[BDMD5$O(NY/82A#H.=&K*9>S/W[M..9^[=+((
M="6"H &B36P4L1(D<*6,LXX@97A GN]P7-J">ILX:\;049QGG[\ZDOZYVHG;
MYZN?*Y<3MZ5\>UE6Y(4)^M,=@<=)O%<N.'4(*<=W60+=O*4_C/0V?]RD5"^.
M]V_7TL:7^\-9V2NB: _C%Q?7W<_W&NGN\_V=799%]SQ5AW2'W^)5%,/1M)P4
MW7%JS%+TXP5^'G<'\:;'T]30)3I^D[*(BQ(O+I65Q-\JZ4M>81'ZP^[PO!_?
M?FO(3'ZJ+=6-_-Q?NOK"O-GOI85[&*E^7HYO/CS)T=M/X[+[S[?=BWBQOW0'
M7[K?)O$2?KX<+U9JT]LGZ.[M5U!__%[E_%:[3[[/Z@^+RW'BRW^;0 A6"2U5
M$ QXT$I)@5S WD1[&SOVW-6<7]Y9(I(D<PF"291NE[-;HY?'9*JV:'41:5("
MJH=?YE_W*6JM^&G^;_[7=W][=]HIWKVW=3"TYT+MR7OGWY]Z5\3?3D]^?>?T
M67QP>A;_^<V_/SLM3D)\=&+_[U].?G7^XVF5+"G^7/B__O[N[._%VTK)5E39
MXKO\H3^,'#::Q3_J33I%^?4\F@%%E5Y21!+K_MCF:Y\-N]'TB4S[A*N\9T"B
M>T8V>I VZS>R\A5K.77U&H;);AK<I6HT=UHJ0Z$X+P>#Q:M5(D]Z'._M_.;Q
M XMWUK^*&NI]^:7X.+KJUER<J^[X<W\XO[SN;#JZ>6+N,57/?.GWII?QW7%]
M%J94Y.Y!]WI2_G+S2XU-W]RFVRVS2^F;Q[/QYM_!XE>\J9E]\]?DXR_AIE\2
M!_I=Q[V&KYH$^FHYW6N3NN^X3W4'J='<[AICJA<POZI9D?/7TL?<4&E-,507
M$[W1T;A*ODX^:!FOX'UDX>*W^.;+2>$C.??JR;2J;7G%KR52/$O4!A(USS0K
MJIC,<48[;P6&OBG&HR\;UIAL07B>D*#?6G%:9N-4SEM*R8E69/7[(C$G"UD6
MLI<*V3)IH9*L*G-A+F.KZ0O5,_,<AN*'U/[Z2(]SLNQM4?9<>=$_[T^S9&7)
M>J%DG8VF"ZVY>D"V",A5S\\/R[)]G^7L)7(VK_;+A)6%YSGJ[VHT&QZIMLOW
ME^^OM?=WC*TP5WH*N/*\BH+.UX?BY_<5:')Y]BVK2ZV,3>0$3 @:L"0,! &-
M);4\>&6I#Y[7*ALV[R<0YLE:K#6M!%1'"MY!LLGAZ(_*43O3O%K%&ONN%UYW
M[[>6YKI.! Z)",5R6!>UR%#!TK0? .^(T<AYY9P4F'(A=E)9L 7*?&YF+$69
M)C--9IK,-!EI<F5.:307I2)4.F\!'"8&$2:--5P0+*3;2<N59]+D\M!R:RT$
MN.S$9<C$F8DS$^<1$.>ZTE6*\)(YK;4": @\< G4<QW (N0P,IAZZWV;F?,U
MV@<(U.10RK5B=SREJYF$,PD?%0G3)0EKZ0AF\17'!!CJ-97,57V5L=,LM)F$
MM]\Z0$K4H;S1IBV9=3/K9M8]0-9=2[JP)%UO?+ < L*>@Z->X>@D$\(,!J^#
MMKLDW29FI7>(%!T&.R'*=OKY!]S!_GTY+?J52[,CKMLI>/.,W3;JS\.9L9OE
M*\M7EJ\L7UF^LGQE^7JN\Q1_WCI/@@;B,<+(*P^&@[' /=4>!>&]K<^@C_;K
M/"*?2N'N^4!I4)?Z*_W[F=MI[.E[9Z9 .H0W.;$BXS#CL#$<<K)R?!<8]M8B
M!PB,<882@QWGVA($WHGGX3!#Z-BSVZL#U>)\]43U^?&'_9V)F<>W'L91P!&,
M;\VBFD4UBVH6U2RJN[?("5U6;!A*E:-2(NXP>,D,\YBRE)6,.!!<*UU[+'4M
M&>C16C^Y..M^??!\\4-W'#WBIGSIQI/IOE?%T:&->@:9%3(K9 66136+ZK,5
MF&!+!>:B"K,",/4$J"7&"^$44QP%S86IS>3<E@++BN:X4U[>32:SJL/"Z"(%
MHE*CT$E*P8IBT2O'15E9,RDH%84HA:>ZP][B#=>S\?EE=U(6UX/X^8>8,+,A
MJE<JY"Q2$&U1'A!/H\N"9CI@Y+B7CFLK:@<V5;9;VH*RYV;CE.,6KV34FW=7
MJ'Z:N,*]A/L(^JI-3U.FZ+9Z+=".5*JC&IU!UEJU?4S:^4#@2I%:5@08P"0H
MX9@38"%H&B0CF&-0&".#-H3K?W4'L_+UT/I<O<TR0C-"VXA0LAP\AR53P1J@
MP5&P*AK-G!IDD2%<*\EE>Q"J>]NM,,>IA1%DR&;([DD0)LM7EJ\L7UF^]L+D
MD,NC)2&QEE@%(X$!DUP%$9!C"#/PG+.'*]::,3F:,A-R0MB>)H15LO3V4Q*8
M*BWL1F)>^T1A3U1"^R+'K9+=MBJ1+*I95+.HML(08@PM#2'/,09P%G$& JSB
M 3RUQDE/%-'ZOB&D>_\SFTRKZ>%GHT?"(95!].F^0?0Q'3--^M/RM!S_T3\O
MYQ;4Q_)\]'E8?4IE3.U+I(:ACF [:028N2)S159K652SJ&91S:+:=E'=T )3
MR],O:14*8(FG1 #102("W'EE&2&.02T4]6H66+::CCR-;&5.ST;CRM=NWIWA
M;/3Z:]$;S3X-RA=-9]NW/FJ U8HS9B5E&KCB:5"/D9%*E>4@= A2BEKSRB?.
MZHDP;DO^&*(=D6;UT"8SR-;*4SM[K1W!4=.^T$!;^DANNB*'Q(-T:1)1SK1(
MG7LU]B" &QW?@H24T4(*P>ZNB6^SC/G\43U-9O%EELPLF5ER7UER9;*C4-PZ
MC (3D24QLEH@4%Q8P1"3OFXMMH@EMQV=)QU"9$?21BN6,F]FWLR\N:>\*9:\
MB;75"&/"'1;1Z@Q*,D24B6:F9%8XVF;>W&%K =+A7&;^S/R9^?/P^7/MC)UH
M62X)E!*'-8= !:21XLHHC:ERQ'O"H-XIL44$NOT9.SP:GDCMU&&OT\D^0? Y
MLW8RZ6;2W7_27<>Y'"\YERCLI'04\<!!6*>%8$&#M-('X:'62F2;G-O(B!V>
MCH":':6[GP9F=6#\<[4-M\]7/U<N)^Y)^?:RK)@+$_2G^]*-[C% >KQR"ZFO
M1SF^2QJW;^D/(]O-'S<LY/4;;OR6ZE^Z\A5K[W?U&H9)6 =WOA*CN9*H]J8X
M+P>#Q:O5\69Z'._M_.;Q ZMTUK\J)\7[\DOQ<735K:F4J^[X<W\XO[SN;#JZ
M>6*NH:IGOO1[T\OX[K@^"^D]CPCM7D_*7VY^^?-]67USFW^PS+>A;QY/3YA_
M!XM?\::&M/EK\O&7<-,OB0/]KN->PU?-BGFU++>U:6YW-%9=)S6:[59C3/4"
MBD]_NTBX6ESK_+7T,3=46CWS9<ZNGZ(E,B>J: *,QE4Z6E+[9;R"]Y&%B]_B
MFR\GA8_DW*MG%\FV)5J]EDCQ+%$;2-3\$+ZH;.#C]"YO!2::X>/1EPVS;K<@
M/$_(6&RM."U/*RN3-AU91BNR^GUQ<)F%+ O92X5L>;13259UOC.7L=5#GNJ9
MU \TBUP6N89%SI47_?/^-$M6EJP72M;9:+I0EJMQR*J,2_RY>GX>D\QF?9:S
ME\C9O.HA$U86GN>HOZO1;'BDVB[?7[Z_UM[?,38%6ZFM=.5Y%?R<KP_%5014
MO'8I^9X=GC.$E_5$PBF/D%'2,P>:2R-)_"4$XH@R\>?SZRK3B;CX*XM;1E1+
M:BN)XAV"5(<1OHM"ZW8>JK>*.?9=-[SNWF\MHVB="!P2&=)E^KMV$K .*$06
M!(*,-I):)J@.(BAI'^ZVWG FT99H\]FI[BI39:;*3)69*B-5PC+I$F%+G:=:
M^^!!FR =,.$\Q])ASU&M.6++J')Y;KFM*DN,60?+1I/=,WEF\LSDV5+R7%<F
MQ)#@*W/RO#!$6X29!NV]!HPY=:" 6ZE2<ER[V;/I6LM-JH?H;KJCU9EDG^I'
MGE,QE(DX$_%1$?%*O::A)BCJ ^&:@U?8I!%KE"@1*.&!AI83\?9K-G%'$M7!
MHM%F=)E[,_=F[CU [EU'O7BE;-,[(AAG**B P"DNA=5,2L4,!H?Q3GHTK5)O
M$UZ_9!W%\?'Z_ ?<X5?W1M>53(\NBNC_I/R8>#'%:3K[[(Y[D^+WZUY4V<4/
M^O3W'XOWHY_2T31[BU2GN%FHYW_]2B9/"E/US^,%?2S_*(>SLK@8CZX*FR0]
M2MND^-*?7A9V-HFK%H%2_' VNNZ?%QSQ7343V"GMY/&);=3\AS,^,<M7EJ\L
M7UF^LGQE^<KR]5RWCZ"5\<*@K''84.L<.*:U!VN"X\!L?,76(FYV?M+0_Z/T
M%Q?E^?3DXGWY96F ?QCWA^?]ZT'Y;CB?V7)R<6.IUUT]^5<<73V*5HZ!;P?&
MA-'XW@>/AO'7\RH(5SO^6+SIUOJ?&__)XD=J'H3;:23O>SXIR X@.(2)R)D9
M#H\9"-PR T?,,4>X3-VZ(Q,HIJ51FLN@M=4,'PHS9% ?>T7#G5C2Z>\I6C0G
MA2@F_"TBVPH9_5IV)^5M3$@R\NI'%GMB#+=OEEJKT-)6)9E%-8MJ%M4LJEE4
MLZAF4<VBND>BNIG[3 E:ML$V)"!+ )BT8(513MA )6*&614PVG/WF2/2LL :
MW4EQ1R:83#"O2#!T.8)9@T/2(2H] W 8:>XLUT9CXUF:=W(H!).YX9CSO-Z7
MTZ)?E;#D?*E6!(CSJ4^6KRQ?6;ZR?&7YRO*5Y6NOY6LSKXM1LIPH*:0'Q@48
MQ<#BH(EUEM!@)5>&L]I$R6B_SBNP4R?TNXZ4JQPI^O<SA]L21*%$=91LLF(F
MXS#CL#$< E[F+2I"O2<Z0HZ#M5IKA+PEUE/,.+*UT=B;X3!#Z-AS@:H&&E$\
M5CIH%(/G#;'8WV!D/IC+<?,LJEE4LZAF4<VB>H2BNF'K'E@I%S!<$T&=0Z P
M2!,D5=X$4(HYJZRME0L\UJDLV>?16#^Y..M^?;"1Q(?N.#K$3;G2K]([#?.=
M=/&MX^8E<I9;]&1FR4HPB^K1B.JF2I"S6R4(8)"@BCC"/5AFM*768"T(2L,[
M1&U\Q[:48%96NU%6!YQX\VXRF55S?D87*1R6IE1/4LNO*%F]<ER4E5&54G.B
M'*8@67?86[SA>C8^O^Q.RN)Z$#__$--V-@M7@UR6V6M$HB$LK2/4 /;&$##4
MB_@D%AYD+5Q==5=+6U#VW&R<LNBJG+SYC)_JIXDKW$O4$7FC6\_2>[Y%O+5I
M/QTN2">NRB&$QO/ITL'!E:-E\K[$6!C&" K* P#7% )WG@K.0B"!;PC7_^H.
M9N7KH?791U@9H1FA;40H7F:_$\4-0EA[)P$$U3KJ5JZ &$\-LK*6_?YZ"-6]
M[<XV28--<%:J&;+[$LC)\I7E*\M7EJ^],#G$<APEET0)C+W 2@ 5Q$AK,$6&
M2X04D[6*W@9-CH;,!)+3TO8T+:V2I;>?DL!4R6DW$O/:IQ)[HA+RV=%>*I$L
MJEE4LZBVPA 2=)E[KZB7WDC$.=$ 2&IM!%@L9!"225D[Y5QI#G V>B0<4AE$
MG^X;1!_3,=.D/RU/R_$?_?-R;D%]+,]'GX?5IU3&U+Y$:HCL4(H.NA-!YHJ#
MYHJLUK*H9E'-HII%]14L,+D\_9("&4VPC997 ,&"!FUD ,:$0MK6\\Q>S0++
M5E.C$:W]"UR9[J#*(NM.B]/R>EJ9T@5%G32.3SYG\^:#%A?W1Z^_%KW1[-.@
MO!VV^)PEVK>YG1(O4U48,]@R",&+ #I(@[U"V%A-><!*F%H;N&7"R#R;[&0V
MG:3N:W%-'FKT1M.V$=F6)#(E.U+B^/]&.[JM$ZIVCO<\@O.F?>&"M@POWG1%
M#HD,R=(NHL P#=9K(2TH'XQ@Q'H;F9![;TG-+MK6$.-MT.:S[2>E,E5FJLQ4
MF:E2,GE+E18C4 !&03#@0WS-*FL,0<Y'IQ(_G.+<(JK<>K"^@X%W."69/#-Y
M9O(\?/)<6^@I^9(]'==$.XJX1Q0(8<IYJ9P)+HU/Y?6QJ:UCS]=H>P"XR<J2
MC67P216EK8'E<WHC9"+.1'P,1"SE2L6]0TIZ*P/C %Y)(JU67B)!D6><M)V(
M7];*=:/Z_0YAJ,-@IX9LYM[,O?NTXYE[-XL@*+020=  3$FCB)4@@2MEG'4$
M*<,#\OSA$LQM4F\#7K_"T%'--CS93Y^_.I+^N=J)V^>KG]6/^1_=/'[@\E)7
MD')\[_+C-I9O+\N*[#!!?[H#$)S@4/^$.ZR";M[2'T8ZG#]N$@6+=(#;M>?W
M%J;Z>3F^^?#K[N?R[:=QV?WGV^Y%O-A?NH,OW6^3> D_7XX7*]6M(#2Q06+"
M!5@E+1!IM,% A*%1UKP"*=/?=.\L\:;K1M#==:L$X_%%DO,UZCYY@:H_+"['
M"5W_-H$0K!):JB 8\*"5D@*Y@+TA@+%CS]V&^>6=);%+C6=L@GHTF6[WH;NQ
M,-86K2Y;38I.]?#+_.L^18Z+G^;_YG]]][=WIYWBW7O[TUU1:M6%VI/WSK\_
M]:Z(OYV>_/K.Z;/XX/0L_O.;?W]V6IR$PNK3OQ3AUY/_/FWQG?S0'Q;3R]$L
M_E%O\F.;+W0V[$;--RU[3[C*#>BR?MDK'[B62U>_<9B4Y.#N=Z*YA5IIA>*\
M' P6KU99&^EQO)/SF\</+-59_ZJ<%._++\7'T56W9L]>=<>?^\/YY75GT]'-
M$W/SN'KF2[\WO8SOCJNQT)N1LP?=ZTGYR\TO-3)\<YM;=9M+6/'M(YE7\Z\0
M]$]_?E-3\8NO_\Y+WWNM\9<V^[/UV657T;T8E'=U+=YZ>IEZ :Y435O/7TL?
M<R.Z-=A5EQ)-O=&X2FU,!EZY:?:I6)=]>L?,JQMRC2:AUL#>EJ5\'PFD^"V^
M^7)2^,@KO;M)?\]*?7Q(.+-LKLHF?079?,+2ME9:H^^HCC/2DT7GY:+S4/;R
MQFQV0*T)=CZA]\7Y^^HG>(D8+?[Z62'#==O>1$E*,[>W)A[(1'3X2Z#+%J?6
M!H:]M<@! F.<H<1@Q[FV!(%W3YF,%U(%B:HJ2)K(Y '2(;S1),C659 <<X58
M)I@#)AB 8QSYUSZ">::?AO;!@EFICBRFHV(<K;WA>7]0%L-;TR8]GQZ==R>7
MQ?5X]$<_.;>?OA6CZS)9AL//1=KT/_K3?CGYY85&=^;DUM_?T>QEPQX-Y?M
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M!]-F'6W>(3A/C]EC9WFN4@?]8;K38CKNQY\K#0N.WJA>"V)8 ;'6'DEB6)
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M,X_4XSSTO<SG;$7YM1R?]R?56=MD.CK_9S&Z3MHBG[:MM1A6,EDP9YPKX2V
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MG4X&\_ZL& *@+];HEVSZ>_Z@VMI7Y=U-1_>'C^G2TXU6/-TP[;X_&_L^F0Y
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MFZF5BNBK!\L//KJHRNP)#A#OX]["GKSUFU+MA8_/K#]MX65+K3Q;VL#E<@"
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MPBP#%L68*^&,$$P:965L<9JX/:6$!F *I+<2+/LX4"I@F>&[N^V7'FK7G_%
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M+ZB'N-'$._3ND..]DH.V,.(&3^Z*@Q126WCVK3S9_JO6)<N:(+GM&Q"W'^=
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M+!Q(:T\'ID@2JW3B=,(3Y;01VL;82(U F=#/.)1Y-*N]'D6AS6J6+U(?> 5
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M&X+6%6C@7=<58'@D70'XT=3./]Z7=36XNT+*#]8)W 7 2>Z#5DIXK[4"+Q=
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M/GV_[BZ*_HC]VJRLN(/]"H*GDSF/DSGMO:?G;<0K+PR^Y:/KD^BKM_B"7M@
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M%S)8^!QK_>Q[7A>,6?Q:VY?>(KT<%D7E7\I65+ZKJU%E1)>F2]/F#3V#9P!
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M/^5C?[0,J_^:*BTU>MHC$4HM3>:^MD2_))CUYM4>X3>+(?DDELGI\#(O<UA
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MK]&)J;.FQ=&&I[.N-W2]P0JHB2#:6(VP-X" ::LT509K9UE@Z[V4NA"G: T
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M5PX%5S"2=0\@'@BQ3*+$SN0I4\H'&X30U'L1$'NMC@3[ 9M=UF5GH,E <^I
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MYVR#8\[>L./)5<JB+8LOXP=3-TZL+RPAC0X2Q 05?7M&%*,@L#,<6<I!44T
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M\>MEW.>NTGXQN2[?'!NR?HX(\S6N2_%[6I@Y2W9RM>+&OUS"!N9N@-G!*/[
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MX9IQ,^-FYPW71N5E<%HC %#,,4#(&HP]1IX9[2U8M_?>MUW"40*Y^VTV7#,
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M.F\DBO\T'W2M]14@/-OIAI6V\PV'"^C=>AY%$:<Q:L[H,(LIG[",=96-T0$
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MB3)"QAH:@M)&M!QX:.=0!=/=\9T^1S2Z&5K,IRX9+C-<M@>73:XLCX14+GZ
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M>BJ65L9_\M\9Z 5%$&5Z03R$(W;R1W])15+>'/3V\_BB&$V^7<SNJ[R11)V
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M,'X-E==\([C1,!1)G 5\Y\7V5@XVS'H;ALIKBQE1L/RP(-\ZT;=\"+<,JOJ
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M@QM&75_%INMW:$JUG>4M#E:*7XUI_N[%C8^1U#Y[8/[_SJZR2H<#P56I9+"
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M8Q6/J1B7G[Y^>']YUFFU5("+ NC'N4_*SHIU;THL/#\2[.OT(P]E R0YIF
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M.X'.SBR8#.]'8%;L1C5EW2#/:_H]/G!]]Y["E6L[;X 0;N_6BQ,9_@%/3>%
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M6?@I($:6^H$):CA_[LSBB#F*E5Y4+ ."IO%,Q%.)+J6D$GX)/9?5*Y )?N.
M/@'T<PUB*C9:FZ4Q,V"[) +\S.W9_RM3V),P<2XF$^''24Z I&1@EQX2X>G
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M?1'%^B4\429I%&*W[R"(QM327'5 3[&C^80;:/MA"EPFQVDF FR4O0!Z+)V
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M_6ZQU&+I06-IC4S4"LZ@!:#^TCEO##? %OP;:%<X0%3W#I1E8U7O'P!/'-V
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M?BXQZ&:=7R/]OLE\^8E:NR*K89N14H&1X%QN9)G;F0\P![P59!ZPEK:?D/X
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MG"1HM-I==SBPH*'\('])!2PA?Y_^:TQG[0)H96]7K\OP]>H22B+6'>AO^"&
M0_KZK-V%=XI)#Y^PQ?A;1?F<N/]OP__*Q" *.&,9!&JF?WW1?$&OX5MC_5K-
M976Q&^AA3O>;/Y>)\U'>.E^BN0C?..N[4_9$W?I>.F,JO<CY\L&.*YC5B[OW
MKTRL,OIU^:%[(SUG>CQ8S/#"\9[9;Y>.?;/-Y]B?BQA^ZOCA.,@\V,7%6N]
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M-%BU?8_:?D@'[&/2?R[EO_\R/&\TM;6 TX<_ ;+!VM=@D3""(/).XFCNO%^
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M/"B%;S.MJY"E"SVZDRP3@#Y7Q:^FR#K1+>QG$!#[<!E1NGLAGQ.R.2AJG>,
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MWQM5+1) )0^183!0',V(X$62WN<W\Y/\'?# WQ13X8<)'^@*_,$HGRCQM9=
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MDAP: 4OQ9["#)>-W=L'Q.6BT3W)4HP051=XA3_0YJ(^$^:#SM'\IZGGX!1$
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M9A(U3A!H\I^T0M&D.D1%B6.$K9*,ISLD0:*V&-^=K;)D$8R3]RQ9?3' LQ3
M3"6XW]R08R[D:>KHFU3TD1&JC$629RH!*UX_;K!:#[NJ$MU+>5,RFL+-<W74
MQI4RV3KC")8_(4>YLQ@N2'U[7K1P[+N'#?7]CR$T=I2WD[C'M$I7C;K)'=T/
MG1&0I9=L):1:AL0<2TL,2HP>\BI82G8HN$DH#&!;'BR.SJ_)..2)[]%WF&^Y
M*I0V3?3D.K($C_I?I7NV;?L]*1F"AJZDB9U&2$+E^8T9UK(G,?$ 4MKC>[Z@
M)*U?M8@(H65F:T#V]&*A#%FY8.D@H3V(S^5["DD#SIYO^G6YZZ$^A"H:$2],
MI&2T3 RT&3YG72R[M'^5 R@3L\W<(W#O4_#Q#.61UM0<[24Y,7EUA=PI\?<H
M/.=MU&/2Q1BF%XP,T1N^&-!_]B9,LSBK-QNH.H<FI^5,PK<@14B()7$^^>$>
MVGM%.)YPL(M6I.<H'M3Y#JHYE^6[0OU0R1EI%0,%>;*+B-98CO%'P+V-X)#>
MJD5P0NMC42@%@JYI4&WA)(9;#V?-+VQ7U[O6OG]3+*F.G;LAF8.[!FWWOJ^,
M$B#Q=V\*[-=/P>]<UO4K/.GE30G:%4'=X*^ZT"AN6Y3HX8^=W7O:VT9.?1\4
MP"H<(@?/;Q2.1(4 ,RY89#OR$;0^,"/D#/YJPHGE2 WITS2Q\\4/0O<PL)3V
M=04;N:!Z*1K*1UQI\.U<:3!7&KRIU P4M],=BZL^>.\^*Q)S! Z\CXB]?+[9
MJO8:Q$W(WH_%7,',D>)"3@*.K@XV922+'!7D0#GE2V*W=SWV^$JT_JP^@;.&
M9(>(]A$<KK=009E+F)N?OJ$">FYOJR,RYYVK$Q/P;W])IGQ@MMY<T4:+3G'G
MRGO=Z1*TY.K!X',33_,0TQ;6KKB2.'$,G !J"'87!G[HN4Z%_/!\GU\5B>%F
MGN/N^(%+QE/SW,#D#YJB8Y@I DV"0$7)BV)539DV=+(XO\[3PW?BM+/%L@&$
M$_Y&_[JJZS5YQV]AVKR='?-AU88S$BL2G=W82,1@UL5*>D+"YZHB#.$YW/_G
MY(-Q$3(E>B[S ]F:X=<^W7BQ0M6,QCM_LIU_SGO]<*W$M\XRFM?+[AHGI)%:
MZ$2S/&C;VK-#A=,8;,0@8U71@3IB#ZWW_HEV_NNS+S\[_YRZI'9!SC\ D0\)
M_P<8]E???GK^^ ,.6R)K'XK7N**\3+#^NRW%.=?%^OV_XD,-_45QZ%"+PR_X
M_%,F-_Y HD-F%W4\\"H%/VK%=4"?/\9KO\DT0 >DJ9-L9'=J%J0%",HYG+IF
M)ZT@%84ZE\&KE6#R*/JNC'/H97S=2=!U5P<=PN38"K:&5^%^#B9,JXU"',72
M K8*O9V##W)4FC-W*+FB]!,E=O_ D6 *]\(>&M.QTHBMZ,IU&GVWR%?;,GS1
MH+>L#MX77::H=[&-DON+JK#6]^@CA;G]Y!"L-?;6\U?%.O^.2ZEL\K$G,Z47
M/3&58.L@+RW!3S1/O?U0-'_HOZ5=NM^9"-HZ>PS# 4KM'>%_UUDQJCU%W)!J
MOS1EBY0N6HXD6@"R:V;TD7(V052K.4!ZBC-6 J4&3WAKMF!<)CU9%NTPKR9R
M'$@L:YF<I>Y'_+\QLN+GXE+9FBNR-5&O)DV/3]>PZ @9$%!&)CGSX"R%?U1M
M+L5DL.UA!;",(&9:K3A+PL]WRX2NZ YXED("+Z]40$NTOB65*DA'A1,?7*#-
MI@4O8J&E=A%OL2K8I+1><?\(E4BD&-W7PW"0A%.Q7'6.,I38YJ4$14[\PH?I
M-0G-V0/)Q$F/^76^ZZ=[S$F[2I/Y [;&[A='WO@#LA(WH!2F^^NP]'I/$.O
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MX[7G./F$!.^N:[9,AN>!]>_X.+ E;'1]"TXQL#5DI$]\8AV9TPR8.Y^/=P.
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M"^<;RBHEC19IYZQF!K!XYXL?KPG_S(KBW1647'=37\Y2/ &^B*VW97C]>I"
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MCA;*P=?6ER?D+"D)B>O"\RC>/*$PNWK0;3*2>;H^B#_1+[2D]JVJ2<);RF%
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M%)?#IN&>,S6B >H?AQ7C0VX2%'C)ZW3<6N1"9"@+DHP']7T4J"J#*0@MTU.
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M*8\):,%LQAVL"'.YT%BP1@5[.N6*!?&K\\!SF7$>&"Y^DFKJ:J@#B5@ Z9N
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MPH7^=QN@SY!@Y%B<!5OR'\Y:K;=I^T2=/DH'R9K$8^;PS-/U/=SGF/RSK;U
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M"!?'*5@,NSQ2F)!]&K3A&L,UNS3EQHL^A09+;+-P]Z*).')ETNS>Q\E\"%I
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M5$Z= ^8"70?"XS:T!1S<"#TD8@'C!3@W>!9Z(IU&0^,_C*P_H*-^)>-S(VN
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MZN,M/C#0T77>H*G8 V:$0W=:<'$"C2/&H2Y**RX""]@8]6=:7:!NW/,T:<*
MMKEW3Q%I9;MA2S9L<6UIX0V9&O]@*PS%/0L\@WJ\KT0&D;97L'8G<# "FOK<
M'/D218M+)V'F<ANIN#J]D^Y3KZE.!)@R%<R?VR/!]65XT)<$D1O'JS#@J<\
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M6\&LH&'NSZSX\ .8]<4QW\F*F(]KWKL&8H '[\%\_ST+%3&WB//V<S@K+K2
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MX'CC!#89NUZZ 5Q/Q.(%42+%)C[@>G_/?)&V47]2KS.5%/X=X)YH(:_61=*
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M6FE9A?,+RV>WW_+9SR&MUJA75P>Z\3> ^(A= X!P&FOT_RKGYF,>=\$54,5
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M3^")0^.B&D4<;6*ZGDFN$D14[&1W6ZC<PBWR\IRXO3M!WF:;^7NZ#FD4B,O
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M-]P%A)!]7*2$W3=*>'64,%A,"0,;)>RVWV3""Z2$%9CECZVR]NL+157V<9Y
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MJ\/H:GSP-XS^K N\.HPN=**?*4;_\6YG$ WG[__Y;F><3H+W_Q]02P,$%
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M0QYSNR,A_ @.(:8AO_\W.3'O\0FV/^,>/ZF+DNG8G\!2_%);B'%R%64I@0!
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MDE0(M>F>W'!O'&%Q&7]Z?W8>'(__/G[WX2/=\N/PT_G[\:>S;G#Z?K35#<(
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M"Z>:2HCA+$_#O SCXB;8X%^1H8;CDTO<(X-?75]&<&BT.LMIQ'#4(FSL1;O
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M!;I LZ^1*QU*B2564HA"H@*F(+P "SIG&WU.=2[A(BV%:,8BR4FB7H,,AU&
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MA$\D_7W/M>V8V= 06E\X?4X.%&/]::([;8CTE0PFV0>"\6^W!)N,O:\P[ R
MF-^5O1!MQ-FQ6)FC[;)9\_+QT7#6!_[B8(5\^:'A-#8W%TX0UFN#NR;',77
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MTU@TKI5A98E)A XZ\#$%O6%RQE\0Z08O8H6I^*'UA(!DF*?A,L(MK?"G<,[
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MF*_UVO%2K\&%FE'^5S?;L%T\/$;G>O2*1G0M/=FEH50<>=6'8 V)(G!($&&
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M*I"W%%H:SV,3M>\B8ZP16>(DCV:1P*<SQ'X*.MH-_'1);#EL Y8%V&*:/0H
M-/\[=7@XVIFV\,?-HC*0@JD<[.\L>\,*['-N4L46A6Y9(5+W+DYALG@D-AAF
MPT44OGEJN<F#E]SD2VYR/9OI,IR).UT]3OYIXL/B8%>TZ50F1HXX^L!68B3,
M-[!4(.-1JQ AP#,1N^UR=Q%FGQ7#45:%72STPM!1P4MIT5FI\(SP5>!=M00F
ME5JEQW@&$VL84NI_ZF 8.G!1+LG.&@)%T^'HN073P7$9K+6N+,UB>Z0N41>P
M6K9H%&ZV)%N%OA7G1+AFC2XSF#N&FJ5,F84)D-8K!2E;-ZT4TAX[_"G8"0H=
M$H-\PQB:<%/4[$.BGA5$F"4 3Y[;EEFU8RZ($J:<17P<'98D.8US3N&Z5$EN
MT$CCNE=MDCF5'C-A3*;LORS.7U;.70.W6JUI[5K6JP5-3G#)+,4NIS&WFKP5
MPR7]PG2P3@?SG&]TIIUVD8W1+#.UB,J%.U>Z6DSNA38CPQ-86B&&\L\OQ6T1
M=099"N(6O,=$U2KVVI#USR(6\Z5=(;4F"6R^G8/XV?0R0C!SY7.W.L$&_GTY
M?%M^01,&^*%9HRH-R<YMR^RD1/A5-%F\=@&=<N-$78NXE#(>V\G;?,+U'1KA
M8 Y0!F[Q-=@^SV1KM.\-4UBJA12%ZAJJ^>FB* ]T6H8H_Z_##/O"-?!M5.*F
M&CY/O\;=<V\QVMS!]'AQON8(K72U;[J1Y39H;"G?WKJ=Y^(/GIO(1>XQMHUG
M3^=A#C8F'3_<2/O0=)[>&FAQ]0<2*KQ3!>S9Y[(O[[@Q#3-7/BWCI=2L+5&\
M:TTK%A7Q3Y+&Q1KS *D$*@+B>4Q<>V"5D/G@V%$J+DYSLDH2_5<WGHJ'4E\I
MD5:Y[EG,T6VY">D'3_5241H[AH$YAV)D<W$#. /P2DI"B,C#1?U1,%&=(&]9
MHQWWD87/\YC0]L-JL[IX[-CS,6E?W&=>9U7XMYEQB3]>YVZ!977Z6EAFV%9@
MK!R!8,6$R!WT7\A(A'R9,N"F=2 D9W D;B5MI'O/,4+&@\Y00UV\;XX,NZ9J
MR(+)O$&M1B>:%VX=WC/90:OEO:7Z,"098I9HJ@]8CI1S>=RC!2L=N:0352VG
MZYD '$\Q3"#Y^OSCF6WZXWA44EO-C$7UYX=<XI<QHS1BG>8Q*7F\%>C[A""N
M#M<%L?Q*8L9]SE64;X:;5UCQX_UT@?4 &<;2B-V!GW+[_5R2'FF^:)%<O$$;
MN-&HWQ*7M552G 8B9N8 :8;M-%1@P5S4G6!Y(''TV')!Y*308%_.$SR+1,N7
ME2&_IAREFS0VO&EZ$03TZH)8=%T:>5-<MHR"KYAN/8OY6Q'9\UB<Z?@6-29G
MQZV;H\A79F]VA :%\IM8NSV/IBK316UJ6F+PC=#K='NS72\R0@MCU682<:CN
MEEW[G6>&#E\R0S]N9NC>SV_[\=5X?0W6ETBDL"=KNTCK02E)UJ;>LY!M*V)O
MC'IU!!G-$@)D8Y5]Y@R&2F9^8D ST O)N/2A!C]#*HYR,1!LA?<SF\[V^108
M,3IPME6/TD4/+>#]0,6YNL:211]-_UQF:Y5A(M$WBKF2:I2X*26?I**QHOHT
M\9I8>+[KLC'LD.W-YB<Y7])ZQAC6"IQBQ02X'O[3@7V:D**$Z_Q<FB[5HN0T
M5L)*< )!PL)EPET^W1=R&?'TC^9(NLY!9GV#JS#F:J?6V6B<!,,5;[J?U)JG
MP"1$B4,(:/NB<.AQAIN$JWUH*X9+G/<,4WY&2O+ I0[-%OHMGU&Z;E7P2MS\
M:CBUXB0W1%XOPHRDZJ_AO^%O:9D'OQGX@LLYZ>#?]S:FG4ZM86Z'N2WB*)R8
M;E "/G),^&JN]I84(3%7H(\@_/A-HW0K*/ :RNQRC9#P)TWC,%K0;K/ORP<S
MR@MEH&V<P&A[2N$[D<]B0[7O)\HDZM)-FATIJG([-M4(0ZLHN$KUL%\P>DW.
M\)1$8_\OY(QHOC<66.B28QLW*K:]JCR[NOU<IW$BB2AD=(,-MUE<9MCC-N\:
M@3X-8[0=LN!&A02(K_&3/(_U76$.>.# 6OSPC(J-2@2X?N(.'!\<V=$B& XV
MPD[GV4S=G2O5W&U9%<#3,"\EFHLD-BD,>9%4&,";.Y7!%)M,7[WXB,I)VOFF
M_7@J4>.86WODLUEQ^:\2BVKM(.[(1/U=]LJQ-<R6W[")Y=HM@3*E==PK@%N/
MN5@B9^KNO[G.\[!45L;\W%I'RX*+^Y'2&75:3X/A:>@I_#SF:T6,CR?+)3"F
MPXV)W3QJP.00E]2SF)05@1.#@S&&)8D]EFQ4(XYFGDMBVWC8Z.R3#8CU1;3Q
ME"8 ET;T=,5,ZFD)*%5A)-3]VZS1XW9YM27"1I@; :WQ%42@9S\V/[%NNJ'<
MU;U;P3!:2!P#1!)#3[ D52P=0SC>5K4:F)8F^)H-\0">26GN4+DU[M8JV0YU
MJ*0;SI ,\,]-5F?K?KMSWP,BO)6>H#9/5<*";O5[2SZ =<646FH@6"(\$'G,
M5/CI6R05T4IBM:$^1&()IG5,A+EZM,^Q+ERR_!4/DO;LM$30HM#TNI$+ 64V
MCT@ZN<W"17A1$^VM>5U)9 NB(,K<QIMH\U_!YO<:+5P@\Q3R>3VY#N^SQR+Q
M.%8.F*^Y.G1-+![GEY(OS1W%Y>?RYN%4UW-Z=:]>I7[ER*R)KHM^^8:*VJ<K
M)VQ#;5UL=1_ZJ?_Y'SO]>]X)6I-<(4D5_?'%L" T:9/.?<S!VM[TU<]6EDZ,
M9D(2)6(MKF :B5G4$D:#XQ&10*&RMYP(BRK-(YVM*APO4K7.T&VS=04I4:WJ
M-Y767FC=OX_0=R$*%$G&^,0@'9:Y$1(Q6\^#KN)5;#S'4EJ$?6O8<;)H<?D5
MMSA!.G90WW1-%PFED!.*"#-09\P\@1&UV%&Z[4@H0]($BL0CYIACQ-8D!;.1
MRZ!B[_IU/E13VXSO/ 7=VW[)0?\H.>A[-B/48YD1'QE]]S888K%*\ DG9FV&
M0Y6TU*4II:X["_C5I0[3D\PQ1'*29J(/%U2_@9*,?@"RY B%[B<&E:G-XEK%
M<[C11N]UK[^.P?^4ETO]6RKU  ].-D21+M_6-I&]P;)X]7-Q^=-KN,'/ZQA)
MIS'2JP-E3 3EV=[(\*Y:](C.NQ5(+J@[37IA=5=)\;KID@'T#]S'-MQ>:/T2
MF!WDI3G4I+.V8>?4[4XH04X_K.^[W-W&6@/_%P:U6EPV]4#$7"=Z'0V%%\VU
M%EZ-A'ECV*.8:BJ"G6U^*=/LL_9(\(2#$\.S*[>[:5Q'"G/HR;#1SR;6.R=:
MC:J8TJO5M=>GPR%U;%BFR8V3SB:^,39T0DT:'!B^8%UG>ITASQ-B+@O)?>NS
MG;)7*L ,E<Q,[MA=I J!,5EG! U9L4D;]V=3E+;U=&S5;V\YO7@DZ)A&2:G\
M'HT<M5$SVQR!%IL&@(9+_"=6\K;WR_6.P02!.0P4/+MB'B@.\U@N38W.1L0,
MT3/KJ$^=6,4FY6&4E=V2HU&GD[>:E54EE&O=NCN5(^;BHJ2RX&+,NS1%FL2U
MR=PUQB3&,TR;!N18LY2+U"X8]^,<37G;R(".;<--F;C4K)*;G]0]WM),\3$@
MR8XT !N]@P[/DY9B;;<7^G *G#2F>&XEB:5J/9J2(2=<SLQ@:WTD.S*:V@H;
M:5/HKD2</8\E@<M"K?YZ8M!WO3F6.<H-0A>="]ANPJ!\E9*CY$:Y.3CE;>C;
M!BKBHOK.SMXWXZ$9RALOMZSG&);=V*FL6E,L3K?CH,B\_X+.^ZV?57:]AN,?
MM^O<6-JZ2)]#=W%:=+V5[Z$OV)C3KDVJ-:S^!IRF^Z1GK^Z#=1*T(Z4K.M"D
M9) K!%.F<&H]UGLR2KFMDI-5%"Y]5[RX6 =S=L)D9FC)N9N!9&C9SS<,0&8-
MF(N]92A:"%[3G3UF[RCWM+R;:C7BOV4)G99?Q#CMO%%E^TQ!]D6%K@0BS(C;
M#:W)J@G=U&&7V^+"U%%(0B-9G#XU&0DHBLE0V.4RI(P+Z114JQ+@P.RW6^GB
M!C["#(\#P?#&5[*MC]4\1')VRY_.;:L2@>YIS*\]%UZ3!6LO5<3-7V^7<W=:
M]=4+:_76VA:V[KDQ^T8TC12V#FKM-U&;BNK[Y\Z+8V#91;>Y?8T=[F8'-73F
MXLSJ'9;( &(&$SB0X!6JI&D^J#)BI22C A^T]AEJQ$,G/G6>DKS,KB)1X+3_
M0MW1J!*4MR%">5]9N_K>II3@[>Z;3R]MQ\4N4,258FC"@)F:55TEV\%1UWA5
MVWKBP&U6,RD7$R;>H15UGZ>KT?T'3. /R5JA'KZ$I<.CF4=?BIO-.<[8QL[>
M;J?N97Y6:BEL'#@'[#IQYP^'3L%DIF"R6N:G0<G1M+G\\L9&N*'AVIXH]&/V
M5T)]]NV@9.[HK(17811+5ZBZ=>&0$1+L-M=15$FP&LK R[24VAU: A=T,[LB
M#T<\KCE9)$RN0]%>V,Z7:9%.TR6Q)&V$-6<P3V/!5X:VX57'[[7X6M" Q*F(
M&DC,B32QBT?Z]@9M1?]D.R84[+>:06:?LX&;YEZ-  I=?:0%7GN711\"D*1U
MK4'1%(*E,@^TH4 5^B0?U^6A!2KYL28SF!J<S12> O(6,1I%ONFR!-$YU<%T
MFF@6 NXGNL4,]5);*'V<PR );0][7,L+_2_IE$C0L)9G45E:9(3.):'>6)?0
MJV41X7/1XQ(&'$T;A)U:S+G5)PN;H\H)HG_ ZY;8*IT.BJ#.^4 BQ%Y$W'4J
MG<"9=8T&1:IIKD2/PF95R#'&@ M<20PXS)E(62LZ,-VZ9C]7#]^L(>[A*2@Y
MU<XO_9,M%$#-4 !\VR8]=O?-<3?9 Z<:>]_Q2#*%R@.7:QEFC;G[6Q?="$(3
MIZ!:'8YFQ#>U2=)331)5_]8V*-:]0%!%!!M[OHRIC,W9V9%!6E)>*3=8B4F:
M?C:&M=Y2>D!L;;%-1_-!N<&\ <>CP\\E<6PT^)M8TX 1&3)HN)+"V&&DZ0Q.
M>O<OG2X+"3^&I^TJ,460M0IK.],IUF]H8#Q=@$.U\727'E=F%$\#3, %-Q6'
ML5^DH.OF(:$A$<4!RD#:741Y3OCL,,J5B;+K)YS.&Q]B4Y4T40VJ]_:]:L)>
M?G0@4XYCPKL3PR:5]]-+[5C?>.S9WW!]C 3\;524V-I8.ZU#Z]Q_8B*%!I&,
M2ZE#:M_B<'RKPR"?ZZCRM_@/[Z+/"J-E?O#&,:!O7[[VQ;G QIN:E=RN3\U!
M<)HV5U',9+]76O^T> OU1/466<WF*$]L14.5GJ*@D9)M"/)HSAR285RE#NC6
M?OCDTLZ]E[3SCY)V7N_><7J#I=1TAD*#GIN#0!O,] D#"9HP1NFZ#*1=\1ET
MOQ+3!;>"671#_EKIL\M!^I>80.U%<*SC\%IX'Q&E(S ?+\]C,WXU24Z!#J)'
MF1J<8TNPGF(GH I9Z[G0WFF8D!,M"%^5,)O"C>2F36"5W\!-V+BV3U=#D;AC
M!L8(04/(3YD&A:+^V20J=*MF8O!!PC^T0>6+M#'G1:I@.,22'Q4N8I*)G\I8
MX^](!]D[FR11S>Q"G:T]\\%N+78LXR3<$W9<M@ A.[P&W._//Z&#L8 =FN\=
MCT>C_G"T<WQ\?'BT,S@YZ._V=DZ.!]O]XZ.]HUW8T:_#IP,9WGTLG,8'VDMK
M:T(*NW[<1#(5QK"?9M6>-39$5>UL29$%N@^:$'Z[Q08K@5S-6ONT-IO !F90
M8,S4 A^G@V"Z>ZCM =F5'NS$=GE%M:S@O^")[TI7Q*X30^F:2FX3%R29HTH2
M'.;U;-D"E5>:KN85]AMQO<F<A6?/],CP;V2.9 LV&1G&R&Q=&,L3)TN:_=Z\
M"8*-L$/AH*[7V3[-W 1#E:'(UM)FMN:[XCTY+:/F99903 TIS+Y8KE*7D"&,
M;:4\-FTIK+O@0L>I /<RC2M(2XJ25?HBR(_JH2KQNMX&2 Y)D3#VTOF%M2!W
MVL7!@J8TO;20M<[V30AW>K,0[UBM</5![&T5S?IF,,AIQZQBDP-/3@8%&^KU
MKM)-U13-2D=:V&YO<90;LXX.QB)U%G;I#:<ZM$P5@9+PP6=Y#7<HP,.JIO$%
MG##T*G&]<] ;[(QW][8'N[N'V_WM<>_@@,7U[OCPZ.3HB8GKO:W'D=:_YVHM
M4OJI54.$CZ4>?R<X($8-:=>OJ5'W3O\M_7$F42 YX"Q+,N=Q$F\B*];IP6W/
MO2>.C.=)DH?DKD/(H4,/"8AY[9=309>%)6F2US 'U<&!B5/DSE^$)CN OTQ2
M+="9!,^0HS<$#9.<Q"K+% ^GCC]B^9YPABJ5+E;A!/Z*C7C1D\B4](!W?ON9
MB LQ:D!L$(6A(2:#8SZG*;TT) TR.V!^P]QT=<6S+2S%BJ@NSYDV G1]'4\0
MQGN]H"86%#EKMY+46,MJCWBXZXA7?&^*C_LLF!R2T.DJ6XK%%H?8$,A]<H6,
M%,;3:7P[3O,4]DU*PUQH)Z@"K.VVZ].N+BA#?O)E88IV$3]8>3"R//""2$S;
M)/HR=5%J@ _O1'>35A2MIO68A+'K@HFFK4*"T<L2W<VS99Y0T=!B*\F/#4TJ
MUY9Q[9A =JBPC!RFY$;#AIM;@U^'.3<+ ]U71CD7.R:I3I(:T$;%&;[0=23F
M8;HVSN' T=I:3I^?KC7]H?!ARSAD)A.JN0QEX-P:A;7^521[3?<!0TN=X(C5
MR;<-4JV?7[= 4BX"9&*I+(MF5).'Y;+78?RY;BN5!7Y7>QBNG5?=ZB1;<!=7
M=B0^DF (X##B;$EO++: 63BYW0^]B+Z[NXBDEJQ1.K3.0UU"!Y%43E[&BJBN
MP!!D'/-@$DUOIG'M7#'E:NIL3B:5:JMU;,#HU:?!J8/$;V7K8C F]:I/A;NQ
M]$6C"2DT-<7 KBN1]"GRU]PI%;8;0R\S!X[==K%4U<EIQVDF9*FV#X8&+M!#
MN),+2NRIB@VQ<%= "B!@N-;5L%3H35Y?KB:+VSU-[4)%(WVZ6BM.A1!(#W]F
M!F^D>5/W3:-22@HL\6]SO]VP75=WPIBU6!F1:3Q#+/=-.&Z&)"*:Y-0S'%*G
M*1PQXU(W@2E%\$D@5YEU$1R1.(X8-CI)4.%\XM0>[;7>V^#WY0P')7GWH>XO
M.*/#<H:%6)0,'G2#_G;OT,L(CN#EPHLT.*=F*"-NT"G;ZD.&?[Y/MX)=?$Y_
MK[<)?]G\=;AY_!&]TG"*30L1?(K!K7Q=59YNPG]U:_O+: )G=;S96YL)N*$K
MZ%K6DVT_9TT%#[A(9V2N=7@#@Q)B;#2'UT)M_S@:P<<:T#.QJP>J![G7G?:4
M]>3KFTHD" 8JQ.CCF)X#U[#-*I4G#-%@39P8!!F&*IXY(V'!,E-Q>".6+=_,
MR1E3.>=%!&_A8"4PK38/&;R>BHDU:S39!%G)QU7,*A/,I##F;L=FX:NI)?UK
M?![U><,P!:T/"& R1]P7),:;.29Z228UJ+2*5NR:-G+T:Q&?11WFIE];0]N]
MAHZD3)W?$D*\\6?W#ZUA$<"APO7Y50RO 85;K2K UX&551<I,0DZ[SNYT3O2
MV 44H*]V.M,!$K(-IEDT4=29[]'$T%K*T4@,>7U9:&\FG*^1D]VB15W2&<*L
MV"B:WKYX4TZ#H)P72\*Q=>3XF@W-[;VJ+;+NF+374!J2<'Q?Z?8G*,Y875&P
M60]#^Q2N.5)<FN>ZB6X4O-2Q&L59!;NC@\Q4]M ,US5'FW]BS"U)ENE2(<%L
MR"1E%L=A<09F;'D-?6 .[Y;KFK9R/NI2F9:*EDI:R%3Z$Q'7>@MV7'(2C(*3
MF>A:)BW<4*"<,#'5-9ZDF#UV!WF!$_Z'%@:&YTL<J&FX1,(!\&$+W?O8ZVG0
M1(P2,4)'_/=FBI2AO5^W^MWM]"GMUBD)=O$0_R1=2ITM1:=EII^3]!IT)R8E
MGAR8H?\"9G@!,WQ3K!E]9#0!!+['?%>LS2CAW=5%G0AS0(%B0WQTS<<RFUZB
M0AEJ0Z*+,B]W@[TA(VXQ,'.LIB "#++?1)NOT$6ZTES.V@-Z-->'3\!X<V=]
M_@_.V*L'?INFZ5W'&[WJ<#1Q9@I$C-6RD7K(.] GJ#W2# 3@IB&_M,W93,-9
MLZ%DNQ%,1!?QR-[K4*G3*]E#2?&*AO!1*:L%1BEXA&!TG";3K6#C/N;[U<_X
MP+^NQ8A_)11#$9TZ73VMW*1Q./MG.)5<I6LG6*@P]G4FA<CC"H3:1J-53*A_
M2E,39&F8<YL@L;Z<FKKFSJ^+,"GGB*_-='<A,.0X<QY1O87I022/@,$C;RB!
MIJ?2&S:^J7HBUR&6Q79UN%[%<Z:L*)Q=(Y'_G&*Y'!(31XX 4\QNK:&K[D;H
MWGHOEZ/'I8;##\T.J_+]<F:Z?J@Z\C;B(->&N"RSO SM*IH(5]L-L8KD]/S7
MX-/X[.-X=!Z<?PC.?QT')Q\^C7_Y</K^E^"/X>G?QY]@3L?OA^_/ [SJ].1T
M-'SW[G_XN[/:#>"[X.SWT:_!;\/S\_&G,[KCQT\?_GYZ=OKA_5GPX22 WY_"
M,]Z?#H/1Z=]/WP6C#\?CX QN %<$O=U!OQL,WQ_#__X'OOKMX_#3\.C=.'@W
M_",X?4_W.SL?GH_]6W5A$+\,/QWCL/$2_?C1!WB#\7%P]#_!,/AE_'[\:?@.
M+GTW'IZ-N\$?OY["4&EXQ_ RPS-X^7?O/OQQ]N8[+R;6P<+J*P7''^ ]WG\X
M#\;_@%4[QB49O1N>_H8+,3RGJ1G!?)R>?_@4P/_SSW#28)K/_\?^_/^]__ '
M7G#VNUG:\3].S\YQ"7X]/<.O?AU_"DZ&?X>_R8W/3W^C51G_8SSZ_5ROA!X9
M+BF. >3F"=W^/2[*KZ>_Z7O]\>'W=\?!K\._T^J-/YW2/AN>G,#S806=IYZ-
MS\_?C7\;PYZD_8>/.1X?R3LY#SWFU]K2,57ZO^]\:5M\\U"B!Q197-ZL.M<,
M3&%!^%<W$*=!6H4!:GMMIQOO)0+I Y:H1.0:FUJ-80QR;1;"M66"(A[?#@1M
M$H7WS#!Z#WB(R6/A(2P6])/UNN^#UHEJ3.8EU9%-J"V< ()M(( V0=-XK+5,
MNL4V!'ZTM,').J:HRXE*CBV9<)?0<7CTXSI'H-.9<A5K>]T5CS^%&>(,L&[J
MB/_%O'X97VAH'D:\J)6"DUNCY(60BW )Q/T&C.]MX^FH\5L_2R*0NJ^9QS\9
MZA=:\UIN=QER1:)C0LF3[I04R&X)^E>SND]/&$X?2Q@VM8;1:=+*(AI/?DVR
M\E[7J#<8K)_"O;T%@"?W+ZC$D7!%JZIDK[%\0GXX@=59H'"X9HH#@3H36"!+
ML5^$""_\A'O'+[BKC$%'-^)MW5Y#^-.FY4Z3ZNGU$ 8;!*>9PTP4M9-.KM6"
M6)KJ.=N.="'2;B1U4T)H+P6X_UD2$Y/Y/0P4"\9)D+>,E#'0Q*;"_A<!J6F\
M5-^66.@XXN5G@OG5CJ2I6USYNBYE4\.(>9C<?'352"D ,.45))J]3/=E,@GA
MRL1WOW[FD;DF^JRXL+AI 3A(YT!7JL^C#0:S1!Q(E-$A%]H/]9%_;I/H!+ZR
M>/*L2078EBP^FNY^4;OW<^CO>.J]_$X<2^\/8DE0,/FLRI+T6GI1*[:!L&Y#
M8[1PNN9JAI3 72:#Z1*>*W;2&][1YZK^IG-?(G*)Z86EH(-!79QSB?)EFH?<
M'%MO7ESW+]&T&\S!QU@PY1">WW 6I2%[* LC,L DH& 0V5:5$%9[#F=C"OZ0
MHGMAW.@^3:V&,[GF]/PPE^P@A>*ZC9+5Y(:Q\J<;3,I")P\I$$=BL4O!^3"?
M8)L>6U9C/L!\EX!H]?R;BVP]GQ8'!>H4'=G""I0H9P/8-A1@)NH8(V9"96""
M6().8T0R0Z6Y.S7G*M$7QJR;P'=-"1&&Y32*MZL5TK^U'V/@!U4,N"X0JC3(
M:6Q6AQ4<LE_,CK6OW]71AMHE>LK:KR"L:_7K*"%X6>OW=%3:G\]?+V&WEX4<
M!/S60[XB)%U\  $L2.DI+5Z75HX639;*6>W<K_^9*2Q;S&BT$F".=,P2F9,N
MDJC@'H8W7<*UIKE$B.$>)EH\#;-IE*0@,Z(I?4 O(9=)Z)=HG<S':.;+/X+1
M98A)61@%2&7"W4\IH?X1C9<9;J&-\]&[CQWGYQ0>I_VF0)C$2N *LRR*8]*O
M<1DAB_I22YIK7$L) ?,<TMK4>S R$G@9IUKX>;B.3 >R==H\PXXD:00R-PFY
M0]Q%R TX+A0]9T'-^_*TS*;4S)0ZT? :+U+$>('\F#$6K>%4.IX4P_<)@CX5
MHXALQ2QBFGQ[3\(\T5UI(-C H#)7\A)8[17?3"_A987=;1(M00C<X%&$>0]I
MHX5PI\L;E$$@S^&UZ06;1+O;&8W>A5ZZRW!F^#HIIS%Q0'$1F@S"_+R#=7DS
M1#W+N0EH9"FL)?P)6VR"RP%WF$EYG&;9,F_CEQ7:J;RF#@3&G/4LGXFR:@S_
M?:G"F($8M!.2JRA+$\VK5D5RD%W$MA &Z_#A:6* -$XX@H ':>RXG=0.CW[=
M9EKSX%A!B#;&OW)#-D<7H[">=P75[H*;FVU4!PYNG_KDT T[+^B&%W3#M^P=
M>[YL21'%B/*(&S(WP/UN!ZA:0FM;(4+ET77@L36$T5N7]HK$5">\00[4JJVL
M2$1=I@S9A ?J=6.6+:P1EA#"YAG:,,$@^7YWV\%4OZ_6H^NB*-.XQ1G9-%U&
MML0[#^?(K@M.3 @_5JJP!J)?W]5U9T68M+!R.O?ZIRWC,'&[7S&MCD^#42W0
MNJ5)=-G:!-GKL2O&N;7,J_>!?4*(ZA6A%$,6^17$E^Z\<ZOG+K':+1(T^G *
MJ<*PMG*FU(L:GR8%FF&7X15I[B!7TY*"0@:<$:V.\NB\NB!*H\Q6=O$R<G%7
MQ86[%]]-C.A3G@.$]XD!O9Z>$6"I+@@4*0&<F0D0X0KX[;XIS"1MO[N"593P
M-19N3B.SI@;900P#[L:B3%"*AHN2EK%8>N9^0N!M8O9%$TN> NL*9B%I^]*@
MD=O=>M/M&Q<NRG4[LJ9-ZE)XB5&)G 8.!&R5U7,KKJ2XM*W+.7(D)Q>K;HV\
MCI(K9)^]T&"4%%8:3=@+VU41+<VD7+*9I- VUED,@WOFRARS"%18!*(4_0U'
M@LCS1;2XDN2=(=1Q2.'\"VRP5BS2*1>4<9^HYI<S_2\\V:P1(HV2@#!0UPKU
MA%><9TB%=+N).=5:+F$M8MZDZ"YZJ!1&!246RB/Z S.1]7:)]EV:>#.^@PU7
M2VI5Q+*IB7"1X=:^1V5QT]HL\IN.>TC^FBDZ3=0%/%>'=Q&@A>V9%X2*)^\(
M7L419EC:H<'SEZ;2R-ML7QO$:YKT1"0\AVU=W6N78W6L<LG@3K% VN-;ZLL4
M5:S<DZ:E';+/'*:DW/1AMC6$U,K5Z,25I>@.X?4>QMG_!/?T'Y7J![]"ZG;;
MJB'YK(T)2WN9XLS7"9B[5?UOF@Q8LD*'F6IL?5E8^?_&I\,+)6&4&8\5W7U\
MPT=""?RRIN2@1P?:];(1UOJ+];85$QKEOAME[#)WMDMY* 4ZEA!"XJL6"+AJ
MCEE7%(;GPN\QT,AU5@$)VGU;]2S\!H@> 9T[7DWJ:]^(F?&%G&X&PY3B".:X
MS8Q]C7^KE>MWD= 7Q%G&19.:J:XK"EKC*V&H3 YUI>PW7>_CI4#&,^*8PJU1
M_ZG^O,6C,?7D8H"K+RI#UBJN6)>L/UU#NQP_;9$-[[1NJJ2?J)++S+14)^=^
M;5U%7+ES38%+ _,R;!_493JG2!Z6<-XXQ)LIB#?UF;*'"<\!EB4KHN.CG>%P
M?5EN@+_FFOE6*Z%*WI&V!0^?ME+(7>$2F+,K6YD:VDL\_2+6I'WCRCORSB25
M[L4G0^G(8P=**ZF)7I\T F/V2'1(JP 8-8VS7@C&VI=(7X8!*J:LNN=%NQV1
MX16 >9V-4+K:BEB3*'O4TI1?UU:84J$;, 5Q"V(:I.1\P00NTOPMU.7TY9(3
MTA^I_N?4C9^#/"(L@B46K)7TA08K6ZENM\K.ZL9GL0/;MV %5[P:%J1-<H\+
M_046=/^P(*L57X!!]PD,NDM)\ /BAAY#4K2+BE,)&U]Q> +!MCJ$<>UX'0+'
MH(8JK0>7P!Y)UZ4ANC6CR%6BPPZ3GYAB[+:@<PNC$_8@H>8/(%]HC-+&/#5$
MI\2[4PU\"765!$6FAA30E5*L31RT,..7L<D$;G/9X\9ZEIV'YV1IBN%-Q,;=
MC,U\6HZ57RVS1Z7ITKEV#84-KQAR^YGR<X\2C^4.AIPXP$;. N(6++F2E0$/
M")8ZU0!OF.OUPM$+3YO=FN-HP8U]>\2>8@,ZC%</I[LO[L6UGUPN??"22_]1
M<NEUQ;7>W?04<SKWGYVQ^;SO)SGCBJ]:EJ2FNN^:)[F7',FM>:3N5R62OI(>
MQL$3:'Z8NQ'>>EF&68>1?]^>:G@.1NQ5>\2E@9).HI@F!M-UF%@M[H6LV^\K
M'A.L)133%5L>K>JD.8=FT-85OD.W(S(G\M*("@$NLA3&2V#8RH^V[M5*O'5M
MUV@Z8G<'KDK4\].M/0[/UM]@TRPO@W&6((1):RYJ!E 60K"**N!&6(FM>GIZ
M 6KU2 'JDSA%\I<T7$O_T#KB"8D[:*6E-5WH.EH@RV?*[\/AM.IPE'(X_:QA
M3.8"M X*S!1IT#BY@IQ-LA?EQ,6**A!- G H8WA5QW-@]4R34*.T)!(4M"FN
MJ2<<6C#X%Y9QJB&^Z;23.-X='>P>[QWO'QSW]P?#G?'1:,3M) YZXY/CG2?6
M3F+_D;;G&7>JX;WQ>R&&RO>9'WFN'29JJD$ORKHDAA,0F[@-IJLLZ%370"R7
MF529B)XD&F(..>?JFJ),RY J5T*7#74MYL;*W8HYF1)&OCX*9IB#1S*1CM:7
MK4+*80H62LBYMJ.P\415=Q )I]]Q A0\;(PHOV0JK*EI-<JM*$Q?JPV749\0
M(1%A*2[3]'.YS)LQ@%6Z)]/8F:BBP0F3KM@AM1V?<TE)4&J91%_F6EQ5MNZ3
M$S:/1M_RWL'6O!/7].8^4$<41$9*U%FD\7U,P%TN)&(KFZG"/FQ<2<YO:0B]
MNWNT4[F/V;Q(Z/#T[> &TQ*A=[%T14,W/RN75#I4\?*M-^4T,M"7P'[7#^KM
M27S%\6CW-R:=&C&QJ4_5\M6MFD^Y<A19]35C9,1H$ -:MEU"V/.9\%2%DU!Z
M'</A/@ISZ01FW'+=%%BW4+ 8Q7J7CDH@EP)$/%^ZP,_,&)5_P$3EJ;KBWA!\
M&LW:B64(OID K9P?8J0&0T;:'M7K4R5L!Q$"<L"T(D,6O3*;Z.R6EY(@\6"Z
MLS7EQDS>S;#B4+:4)L$L56UUO"7@]&H$;^QA,@4U51O72@25M;!]4A9-O?R)
MJNINH2K' N=H+G)VQ03C!>,\%UB;L>4"PRZ-KVF([ DX.RT)4]5$:F]FBU ?
MR.)72;H[2%6]$JW#>\OEJK=L$G91J1&2QK_=U%O<R&*729F'6F\1CI@*-0,'
M-6S6R+R?)?2FE!GR-W9A -2. Y9$[S'*PDI*J>WY[8]%_T@_\:VFLKS][6'3
M2 I/>*3KW.$>4EJNHFRC:?;=U'Z+\. Z/,R19,,ANG(XM]Q3.L_C:;8B"9_3
M0"BN!9/M+U#%5:R<;-X0U'3H&U?=-/:]\_)W'8MYPJ7!ZB)*"-!MZJ1S<*TO
M@XV]XM('/CN-;CEGFU3[G\FQJF7MY'0UG"B6M1S8-OI DV?($0<M$,5\#2.J
M-7FGAATT"8@H?QT2])=+\9B=@7+8FL#]_@)C*PWE^EC7'R2C9GAUGZ<KC@ZI
M-UO7KK48>U5.4H"1G1JO:IK'N5J#,J_-BMSLM,IF:(/(<N%:X72T1H,;!Z][
M#?D'>^Z8T<;LJJ;L<[\5H6%C-490C[$*IJ=31'%\K$91,U4WCFI'O#8NBY3
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M*I6^H,@ B1CX$OQC76GV"$EHRMM",7\+XD)VUR13(M!2],TSK[[@OOU?@<T
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MXD@:B1 IAO@[<%?=ALFCTA&7@L%X$G&&I]8A[-7L#Z>(->P^;W@(VTV-DAP
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M620)NRPDQ\@]S4"'0,D^GB8?M1BV@=4C'W HD5(+9*64QVRHF@#] \D!Q/E
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M.-C[AAWXAAWXFK6#G:ZP"V+.)T.,#N8:W;R@X9P;GKFQ!RDDY\2V29MIE%G
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M;1ZB4G>[HH&%H6SJ=1/J0_9-2^LUW%&:46<!UYNQU(D=$]FH>.?1\E5CR3X
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M7KS-10<@%H]7%80_OXM$_NX1<O$1=E2 5^[/&2#8C(X]?&NX'^)$@PG)DC>
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MYZC@[N);(;950MZA;YHJVD&@UD81^.J)&]7'OG'?GS<?(0A )WFKFFV/"N>
M7!'CW\TCLZU"Q6_8PC.C\$4B(0#L +QE612BRRL=6X2,0I(&@EZZU]+.L1/X
M/HB^&/&9!*.PENCCQPJPX&"M83O4\L8M)>U91%"01VXFV&G97R+MU@AMW-X
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MAD=,'@:2X#F[/\P%"=FNEZU'QH*(4KTLI]J)(-T&V&ANJ>MCD@5/,^Q)\_W
MA\C%IOAL4LDC-PD,Z0V7U(KFMIP69CSJ^WA"0]\4Q31:(3-#0-$W!PZN9=Z
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MS5G.G:.78*1- :%@@ZTA,C^=N7F$>!$HT\" B%*1*_JXM>"1$/@[A*95X5$
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M^:O3P]?GX[/3 WI[QP='9T<=FK@_^]M[^5Q&N5W5SKM?#,X\[ ]WUV4)2!D
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MUU68F!70.82IB\JK3QE\!/.(38"2 (%V,L9?*FQV1, &I+++16:*^T@E= 4
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M 3EI))'<,<</GIQ3&X0P%P4A"V,ABB+-:GHR7(]&.A2]$(\$8'.>L,I]:2S
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M2?EI'4P8@4*^!& 8[#:/.K@<AQC>8(D[";D&I-/_,T1.,2ZJ+_('\),1D25
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MR9;\= .R+A<:]"7-5*Z>54]U"FBMZMG?$E(5$^'O,SI*R!(+]SJ47'+('%E
M<+22EX/S6F-JGHZIV:TQ->N/J5GN2ELZ8)'R!JEIL(@XI0#9V&J$B'F0JY6.
M/MGO5+WQIQ0OV]R>O6&862EU!H%#;CB&^USCR4,N>8D2IMB1NLT4DO1HSVAK
MQ:@'JNVV#!'03'S/0^E\B>N5:B 3\PA9'_R#=Y&XV+!5,NW9_%<CQ#H=;0#A
MHZR$4M%"%#NDH'2YC*:L^QP'"FJ2Q>,R#3)R-Z]IM]-X=+!NH==9YI24VY1E
M#I:^L;TU6^9T'8TA2;"W]Q'E4'QKT1Q*8R(WI;IF*@]'/G8#&YSPH[X9M6M;
M>HV6#N2",MR+ZL0S6H,N4OUSW&GF22Q)^AB^DD[M-<$T*!*>#NPY($#%J2?F
ME1.@!50!DT'ES<8[#5 @^L3@#'9<1V,[%@))V)L4JPMGN]:-7A,IH.-<$W=C
M@S=M7@"-ET;#Z'+>29Q,(Y<).[R&?1H0,_ P!3Q/;A5R3]5O-#VH+D,#)SW.
MJPYJ$^?R7)G?YPU.@B$X)Y3QG8Q#2RQ3IR![SG#39/A0/$RWT0,B'>*$._U$
MR<224BC<-6K9!A-DYF3->VVFL10^8K@B*=RZ'L$EF^08NY BY$<EVJP.C0L'
M/1:Y1C;.= D:Q,EPG5/%HW4;5#'2.*P'UU5787/)1I%>?JR%GV4@A;E3XKJH
MO80K."?<\[)-*.<W8E0L[VRLU,2:?]Y7977-?G-MB&V8(:8/P!Q5L'%66J_2
M2C-JF@4#\;J@H 6P3NU(6AJHCO:(1A SM3U#P&T,;U7"19/ISCX\*+<B\TK@
M;D.03Z5KRITX@I4VB.6#LMR$YF(9&R%B 5(D3]\EPTC'>I&?L> NS%S_TE5:
MT4;I4)K5E!OW*<&V#")G<OH6,*T_=*<B/2G^D7X#$@_/BR/9Z1RT'?3"634-
MCEG ([7S-R+^A323UB7.@QU;Q_\5S#(FC]STLF>_S-T$@@3XAJ\OD#8_>>G)
M$'%(L^;T>2M08V/)FKQ1UR3@$LDU9#IA.'FN67?*?GNW5;A2G4QD9=N?\I57
M!IB)7<2E%[05()V&O,SEJS!95>S=.=$F ]!ICX%-9%I!AZ<M),=GL"C7'!%Y
MPCFP+9:%IO#M)\0ZN%81EMCSVB]J^XZ.]=M*:JJ0KR4U']S1U5\ )#O+;;M'
M)I[XA/IBTY.G4L\>$<XC75XOHWJ(I *P@HPY:!<2A4E5@VQ2/I@2SZ+K!^(&
M4@?\V1:2!KKT+H:H"_2=8G *CDXA5T([S:2LS%$S%XX1SH'RLRGL0!J%#=;)
M-$NLW_#4BC4X\\ZJ0;99.(*6XQ25?5<A"9^0NX FM328LW$,<@HE6%;LGN/A
ML)%G%9J+^:Y_RT#S1+F^U0CT4'SQ^N?6!N2E'=!K5^=LGYZSW:MSMJ\M9SN:
MYOJ@0:5BHT!8:@HBK\,A_-\F]27)\[07AR4[B^ZBQ@P3C3[WV&C-Q]%F&36A
MZPBM::S#&,D%: 562>B/>2!LVZT@BE$=0B/;TGVB;>-DBJW.^\%=&CO4A*_X
MCL"&G="MUZGK7FBJ.K0&MSMTU^"VKRPVGJ@Q^B>'$$&-KZ<XG$_T4V4LS.U[
M[\;"RITI*]W#7[B>_5"';LE/+$S1V27-;N5:EK,S339*DP(,I>!0**(IUA;U
MR2VP0>OS$KJ2##^"OU.I,HQLQK$TK3V+U<91ED'X&AE"F7K1N-!:;'S-![1E
M )W(\WRJ^Y-F<?Z%IE&QXDSRGQ/I('XSSBO2?LY4N'LAT0Y2^@2.%;:]RBPS
M5/I6:R._]"1:%"B7+WG-,Q.HE>TGJG*D+<,M0"XC^OU0>?T[^WOJ,WB X(BU
M458PPTC *99#KIM$%2TG-#4 #M<?=0O0XYQ2522\Y7A!T0MBJO@JSFVMH.V>
MO'Q8I+N#CEO)O=<LIY0X-19?<Z$W,V/DJVYGLXHP<;\R3#Q7N=F<\]6:#52S
MFWTA#E'F0JGHS.E\1T0?#@Y&)3T1%9T:^W/:OZ&VIM@A/IT.^XRK-DF,4@(=
M;Q/Z+I%PT 6B:5CPUVEBLR;IU#-<@6(/,-\_\2X-B?8I[-]%68[%%_CHO#Q\
MT[,DM]JO,=6#&IL9W'#"?P2S!9D_5CP<'5;PC.NNZ6HNW=ZE@GV1F?6Y"9TZ
M3Q';-KTT,^A\F4E+O1+A TS13R_J\UMBOE'@5SHK@ 9$G-REPSN=$DWE7&>:
M3D6-4/>7L9EB<)?5K0#+Z)\"-2S YS EC[P!U/TDC+.>&B-2K"CA2=,13LVR
ME_ B=+EYZ,G$RW4'W#<Y)KT;=[+IP_@+,EUC((-.V<Q(K%J.$?%50#:/2Z:0
MQM>*V?N -:%&P@?%7C(0"/84*SB6DEVYD&"SP0FI9BKDT&Q0\02C(:@XXTG(
MO0D=+GD2NSE6J8>K7I.D@1V5H!XI59EXVCAK#V(4*8-^J(8[=/H^;IY:CU:D
MUH7"A7>L,PS5YH?& +M1*YLE'+N$7,,$F9S2G!J+6+Q7QD@U6_,)L5-'5D7H
M^1!:27Y&WCIN9G:! MO"/X&M8G^]H_[;)^VO?G >9KUHJ'X]QM[3:G]/H RH
MTX==P._#GXJ6)E<SD06!IAJ>0J&-<@^?VD+U(9B@@T$>3USF*:4BVU&[A2B.
M:0)+<:V,3"7_N3 7%1S8PB7)JV*M&RVE%</%)-,BJ QC V-H/XZ<F+Y#"S30
M5%_6=AF+T@(6<'.MU##U!!:#CWIH ?5C1TF%41Q50D28-^\B.HW&Q:TIHAT:
M7YM%*!E1$+DO+6D_46KXG#CKOP'M_,!7GF9-JF@-QQ>AL26QK:NT-,<=!G:Y
M!/ZD[@ET>9@K72?7U'Y"XDC\&A,*1D:ZAV91P^EF7141@GA@/6-^SZ1JL YM
M68M>B)>*V42)SZ;H-(O%KTVCF=MI;$$KG=\NN=(%G$D1<L7R!@N1@?*=Z3@H
M;<C+9>24W%)J&2=NF'H?77T1V8#0UP$V:B!&%S-7K9JS?147PJ#R0F"'.[1Q
MFM%7:+,$X1L[TE.\'JC=,,-Q<ZM"&EK^N51H^JI&O7$#J1&]8Z#+@+/@&WQ4
M&]+B_BP=]G-,S=JM1@A^2: H6_6)C>MIJ&7T%F9N<NP)8:$HYS=J%/L6P&=@
M?TXP+;U:>D\SP@L:X7(A+7C[V-#JQ%IV7'6++Y(*5$HC$I/"\Q>=@1-@''SO
M)DO5-A4JD MK7L;-&3!RJ#20.MY9Q DF"=" RB!ZL"IA=^Z7N9!%0C(+:KD\
MN\VS*6]F(<JL/G(<-IQU#N  \A&8N>A6H*:BW[FQ('_VMQZU+P83CMWYP':>
MK_M,G4)\>@IQOTXAOK84HNYIY3]J>Q\*",6*[QTTPB9]=4[*PO/S7/W^+; _
MPU4-C[IN?M#I"A/1SZW/[&9<O@'MMG>:,YTTO,]8B6$@R*Y=L2.27KBVS:UA
MA2/M&VEVET^(=&FKQS5UY-*U0X&8#*3^?&1XEU4MQ+9:LY^HUD7N7WC@X^Y@
MR9U"B(P:%/ON?"OR)!8&5<ERP@Y W3(XC,$-3$$8L]O@"ZCK:M.@ROVL&HMW
MZ.3D0KRRNPY+/Z!K9- X:&H/S8$Q$8"]U\NF49GKEW&+W/.VE'LNN9"/K"VF
M.6R>V7([RVRQ]8,#$F59_92";VCB2DWC0J*+*US&"_W4^%?:LD7JXR)6V-(Z
M(KW0E8P1S1I<RO!O%X1/%":S%2C:IPC0-$W"Q3LY+H5>,%.)@=%BU,_26S:+
MFP3XL7YC'$\H%"_G5R#>CUDX6:CV2KVEXGN7R5<UBD+-6D^-[DO3Q$ 5!LXZ
MT,41/^ICS*@SO0&4SNY6*]C9VGZO<_:_JIVYA[Z4W41))60N$#[;/F];(K3,
M8$4/(F79JFF".A=7QX<G774#!V#V')Z=7EY=_'9X=7QV&IQ]"JY^[0;'G\\O
MSO[9_=P]O;K<>%JDW?;VFM B?0X3I2!0\CY%R^J4?(S!4V"2Y_(A;W^V$;Q:
M G]5#87GI80(?7"53@I9!$9\N:KFF=>V^_4VOH[51?YF>4W@V&1!K2&6CG E
MAK2DM)N#*'(,'3%R]]K;C4%3X&H%8-<+6R EBIO?:E-Y)6NB*XI>E?Q[*0!_
MNSC'LH;0*LT%XG@>)E_2>\(+1-DS]*PJ0\266\S  4Y^BZG:UL;9//U7*LG#
M^QJRXJE^7+[PT\C!*$_:5132Q;983(5I4;12T=IIH(N,_W-RJUS(F]L*U%U3
MD@I:NB@J?S,-,R4# '\<A5_CT70$-+"4KQE.1V-HT6Q-LN'GT_7-9M5B8YV4
MY7* !EV+S-,^C^SX,\1%?=R/O+C!4A6@CEEH#Q9.G_NCZ[A/P $[!L]2T)&%
M=%\N5K!S0_D#NI@P!+QE*QBJ=^>]<(S7?Y:F _P?_>SA'KMWJ[WN*8F"BTU)
MQ;"E\3,MJT\6YR\S[)E%"5EJIX4Y(RVS.KB#^="[J+PR3(8QN[;'!WW*/($-
MBG[8,ECZ6:X3O;ILTNB#HL,NCGKY&,Y#%*?7>"1#0+V$4 F@4\6 <XB@YYJ:
MJ=IR4ALV>ZR[Q;/:[FJB8R_9LE4W915AF@:), U< !R%R3YK/]BTE[-@]I+8
M1J1$.F!B#7B,$F5;NQA4J965EGGZ+B&U7%3J:=J3QSE((J:9+@DZ45B[HFF6
M"TDN1PL1@@[8%&%;B-AKOB?@'&(T8MC?CP+R+L\%7U7"E,L.E^O)*TL)?:VO
M> L%V5O5=X.3;)H]0JWE,,1*" T+<?*\EEZ!@&%('?ON >1O [ 0R^4T;D.:
M FL;;^-*H(8!I$2 >52O0*]:DPQ-$\8'.A!1_0=G'-+D#FHGBX^B[WL*BXL1
M&VA]2'A)JUL4VJF//3YV* <=)TYM]CS(?HSB@BR82(LVI5!(;7B_Y\M"H%1F
M>D:HRG73"(@M:8^=$\L@'5?J8B!)<[?>FH&+:/6MY-[FJ\Q)%2SY E^DK+M\
M-90Z.>;V3C@[X/1U=&**IOJ(W <GK5']0 Z"NY'\63L)Q5""**;8LC3$TXJ=
MP$-PLB*-_3%U9Q4E1DKI(KZ+&D=HLN:B3=*28B&:I85$GS-1G"3!0W&:SN*Q
M]5OHNV<5.,0)5(Y0O$/=CO^>2O"6&EM0C11H!<T"9-EQ/H)PJGU] R8O9SVJ
M%49E;P/9$8<90G,QZ8=8M5%V5JN2K_2-H>.JJ*"JRH^(;5.]#7"G (E"&?-<
M7HWJ"PU,+%#9%AV&=^G*-"TN61:5K#BC7?Q677@0!46G5TNT-@&(,*WG&.%$
MD@2#2N&H&*QD>8WUJ"U:MX1-Y()1*>56V((7 LS6G>W4*M6PB:?#)M[6L(G7
M!IM K?#!BKB6"YHM%!E53L 1U4>7U<%"]-$5U<)NAI>>[]43HH:U+BIUH@F'
M37%K;6B%8>RRX!C>VM_JT%58'?P1%Z#DG5:;G3XSVHD6K3XB],OG<^V'+S6$
M6!&QTWAS3Z ,?Z*+KK4_514_LT;^?)&SY9/&( *Y!&@7HC5,(#W:/<9?D2U;
M&0N!6EY@+V1:5R6O@K.OLCM,"S=UP/LWT42WEL=+F5J)SS4^3";_.N+"N7++
M:SJAP,''3RW_RCK.)=2+4R3O)=Q:".1O3!*#5U*KH!3,%%JKWZA'1CZL ABK
M_6F/:Q&\[;DC#76W\UQN,HSJ1BF\D$_L:G6S9^Y8N("FH&G)8.1"85WB)J[8
MK.)MN_S25YQD-LS&K7%Q,]V'>US2:L@<"UW'S2:&NB 1GEV>F1!W6M77;/5Y
M\HG,<X ! 2Q;)<]-/0?4JJ:3RTO+:H07*#(,N^V\7<?5K@1W%:GB_'O7D$H"
M9U@8.(2Q-2F(JO[8FTS#H7Q57. YM9A4\PJ?=S5'U1&["P!_ Y;>&)6U/&?S
M^SSMMG?7)TEI; V^%X</R\Y0%D/M1;T$=I?2 #?JW\,'DW8SKE4A=Z.^@=$#
MEW6SPFQ21QCM-BCHQOI=*HUA3"1[X _>2':I9LI"(ZZ8\?9YQ'!O3<3P]S #
M\S5F$II?R)J-E\,P"[@&?\Q?7_$5%B':RTK,I@-0;1G1YD&TFU SL1(X]303
M 3[/HE&,FC!W+@U'WD-3X.\FF#/G5?JVNZ>U>8 OL)G_X&.B'81WQ';@DV1^
M"-D43.CB H,\$4M?+IA#9V81C!7A>8(](0B,Z%@*)-%P]>G*(YX%:&*H#ICZ
M47X;CW'XDD/CK@ 660RX?T.J>0*._$2Y>-O-X"$*,[.M_9GWR+-TR67)7HI*
MM>+B&XI8W!/$XN759= Y/0HZ)R=GOW=.#[L;KTSWU@:DZ/HKY-XL\6KWS'T3
MZWVKNS5^^Q(MM#NK,;*PWER] -#EI;IS3V3'KLYG,N$WSK74HXP(YV6@<AVI
M!="Q,0#*EDY,%'JCLQ.[!C&E*M=_N16_P*<R2J?J49#3PF+JOQSLM[>V8 4#
M**I%1$2N_HB4/JDV$C1!$44&J(R"3&!#Y$99+EW![>']YUNX(DOFR15V3B^/
M?_IX]KD3_']O]]N[;W:VMM\%OV2INEH[ZE7!=M  = ",[',TN4W[S14EDW=W
MEK#QZF2O6I!PK2[9AENF]#17C]!<JO8Q4L]Q(VU:FBO()2W(W01W(3XV4N:8
M$GF@T3'V)<;<$* WB+].,(.-"3P,R*HSE6,Z&:C0(B F:5B-6D*'OB0N\#Y6
M]IIN4B"F^Q7!2'*#<J$:TY,4HC..QK1@Y32^)()H_8WZL'!0JZ$X2K%_8E,[
M!-H2XIP:J/E,KR=$*U$8GPD*A@^D8M(A1*:+KJVS(0RXZAO;?=B;#C7/7V6T
M5/ XRD$&OAT<&6LL3_,$.^YI""R1$E-8-,I]STI1/S4O'$&1?W!>-C]HQ-)+
MBQ2S6F/C.#B/:HJ+DJLER ?8:6$ [#$S0I VR8L9$\P";_U6@1S#7GT']#$*
MOU"IFLQ32B,M%@W38@;E,2Z$4286,=.]2TJ)/IMR@#)[D/>T!40(EKH@)B\4
M<4YX6HB![[!8R_=&8E=ZS$M;S$4R"DFT: ]SKEXEC>)1)1BHL>*O8=#/PGL#
M@PE"*"&;%?NAR<29'\=HFTW6%QPHG&%U&\9 0A5"OB*W6KY9[#Z?B&$':.E:
ML$0SEQG(KX+N'1^&HV@0 E=_G$MK*%RGB8:JV:A/ZQ"AK+G9$6>C^M.H@N]%
M:F?!F) &2$P:0]H75J"/P1P +%+=MD4R55&M'0WSZ!X.C@@2TT<Y3)GY)!V[
MZM:B*B52S((!>X^($5\DAIIBH6KPKJ:2DSYU/+!(N=)Q[KX?U@EG7WH(EZW2
M(086/0RY5W5U*16U>HA4"?G/#:F*MP>P+D(BY3\B,\4*E"S"=GD)0H+L.7AB
MF34T96%HRD$-35E_:,KWZ_F[XG "V31E>CK;Z%I2J*&">=R;QV\5[%/NE^7G
M4$,FU+XV_:H"!O@$I0$1\V]Z&Q9+ L0$\I@%4"0_5A><I87EI_U T[4;(+$R
MH3G+#=D L%I</L-R@4X0BJ\.M,@M.X^J@R@A=MO%]<-RWTBW$]/JW8FA,,V>
MCH5_*' [%O-LLO-1X5*WXT+5V%>"]!8]N&L#*-9F&S&!<-VQ4&&625DTJ_@<
MIZ9P^864@Q';NM*\CQ-T/_/<XQD87[#@+;WT4N>5]JQ:L:8Q806AQP +RN[S
M9?');V#DN;KQZ&JOBG-C^Z_^KCAV?4%V1TP;,CB 5B#3C7?:^$3D^F9D274Q
M3 :\AU$X,3UZ;3V -,,6PR]H\IY5;#%C.9HNA? @5F83T@A7%*.4ZB(U?6Q(
M%./#!R1@!UP=YBFU\M8Q%>.3S<*/H=N!]/7P5'\1B,/R6E"PE"BP:3NA%\="
M[\:6Q?9FSD0"5NZRV6%!OL[;Y@;6UCB0J5E;)\E^(-T$?PMIK2-!]L4CW=S&
M=(;1K7"LP+HG.J!6X-)EQ4(^^[AG4(%V^8WG:L*V4@+AR\G#(V_;1MN%3:GS
MLM\E"%_S--\O/2&TH@"Z913FEO5+G,G>,V]\(<_!-3O]*;)]Z[9-,RYN9H^V
MQ)B!<6K::I="EEMX2C(=0>B+$ YDHL2S 98B5$J/ITA(5?CMK+%M8#OKZCXE
MJ[U5KHZ#CCJ02A(^0$C]B B[#473DNZ3;V;E+QT&Q[X>1GB"Y!B("X'YF!]6
M!=TVKS_!UR]CJ7YH2A"2,<U2,L'[,N?$_.3H@1]S]/G4#5<F"^+"@QP:&&'9
M(PD!73VEQ?;,=O7)+B.:*V!UKB:CLPLS$@HTX[HMO#(4605A'$G+$0ZA/K7L
MOL5"8?BC2!H<7,"RA *_JI>>J@FPZX5^>_%JY.@HC@GN9^3/;%#.1I;O&0 "
M*])>%FRKX*D#'A9#LEF/^@]9FV=AO*74 9,8@XE7S6*A8YHFA-V'FQ,)/= F
MC>'247<0ZDV?P-EM?5NN<"UTDGMA@L2O,!AL"D"R"U:D9ZC%UA16C[P0K7)C
M,9:;;I?R9M9I8\$KKPWBUY>N_R" ;UU^GG**>. 0/7B/>J$J0G^?B"RQB#K4
M29)!<*C^%D^\A+Q@]D5-S3=T"@!)RR/B/D>S*NAI,:UCK.N+"ALAJRD]M\UI
M1S-^D9CDXU9[]7>%.U*6H24??_":2+F5%ZX8557FI%WUX;=MYR^<R3;1>SA=
M*M<V]SRC01D-7!R,?H_'(9B)[9BYI_#F._!#("\:-LM1 \@%8F=[MPN\TZ;6
MDP@#*A=?<UK)6R:I?3 >QRTA;$4-6,_1.$QB.MNZSM)MUQ@GSH4,_%Z0<1RC
MHRT=,/F9Q4:*YI#Y+M4'.6;010A]FEF'C;@C<K,KHB07VNE"?KJ8YR_NDA14
MB9!7T$W6.^?NW*RS(OM76=*XR)96/9TU4^E!GLB_CKU8#G^96,1HM])=K-YU
M-#LRHM^*+9^@/:KZ3YY/:5[>L$IIY+H"P%IXU^@@DW/V2$"H3;K*CM3,+ S:
MN-!!=2^\U88.BE;-AUDJ[,-\.5Y2J*%3LA(-(;R2[&$<32L<)Q&_JN+9?K-H
M$EK0G%G6(;?O)FM0Z:8LB^Y2+OV9)CK[QOPD2ITE^2#*4',U)$>)>4PLMH,6
M>\KAR!Z:5(H$XR@:F*M-(!V77KA<#]WXSQ5@:9\7@SG6*-*8=0?,A1MN-2RO
M 3-/!\R\JP$SZP^86>Y*DV^J34?C(3K7]]/]0ZL/J>U$%YSTX#;4X3)A]H.^
M(*FVV)8T',E1FU?KWBM,3O7 \&ONV8P1"OE'*3^E&<C8. )W;?8P9PV1(>R+
M6G+208B)$]1&"H'! &&5WP<[0:/YN#3XA.AWQIPBS=>WV*EZ QAQFU,S7"P8
M]MNNC]U&,MV7;FS*UT!G4>'DJLW/N-+\O"(+OF2<Z*6GN#)=Z<>7Y^_?X3$3
M&KK2.5+Z1VT0??WW:#C,@T]A=I-2;0>!A4PX-K@.DR]!8S79'YC587 ,HUE>
MVD=;.E2^@,A?3?'ALWB(VFB@K$&F)X8I(Z<)U75H%_Y2&9V?E%79B_->&GP,
M'[ TC(])%MY3&R_U8FPU2U%J /=1Y4V%O>55<S-W/ '=Z37=<MNLU4"[T70X
MB<?@OJLQJGD1UR94=#RX1G)5<%97&J$'B!J;TS*4E<^I&?R,I?='VV=/,QSF
M)OB+-YOCC#.IV%2=XA##_)@X2*+[J&\HPT/3Z!LVMJ("?CR<*FT??X7"J;=;
M33M^4E4SO_HLS-)T^DK&IX[ME9(NI9'',5U/RW5=ILE0.KG:2D*20'FQ9?C*
M';7#]=X/7IY37(VETJ#-4)P-)K3.8U Q81)!'[]>.GXP\;8F*!5L;8=%LU9K
M.SB/-_$=\[+2-N9VJ8W8(#F=8CC6+ML%V&8/;RC\N;?/QW8,6#-=+X0YZJOC
M-V5QU8:'1_^(LN&>YE@YQDR(E*KS_(95#^40JQ:,VP;D9(X;J:9M(\[DQ$U8
MS8#:N5.E!U;,,H)/L":Q/'0=7M'=Y@;3+(ES#Y^0?6%"[\KQ,.Q%=CGBK/<X
MX<)BE,&"3A=C#.(TX5Y6#<GJMHQ!"[R!(6D,]6Y8.08%C+;#5;&/UP^B8RRG
MP-FLD(#Z(PWIM#*WL(3@30%/_X.=M/;?@85%7-ZB6:S4I@[1F86T7R'CWK]$
M<_:S:D[%SH+N%D'+;[L.U9/#-3Y6U&S<Q<V69'-M]P^;5H)F0=N);FO?:T$"
M\JJCCI80P (F0S?9O*#85VH/,H#B*"_'T.RBV EO$LZA>M&R:**.).UYJ XF
M.JF0".%M2I6\(RFK;SRP $F5]>DRW_F^ 6+-_6R'L:: Q4RIGR"QN'LZ%>\X
M[^6CRK2,GL"(9U))&D 63GTR0:V@-*7 .ADY[3[#]C_GP24+?Z]R.EN^+[L5
MT38KN&\65*Q*9]@4E'AVP5"B:S0'$<9=0Y==F;+N26NK GL[*+<LU:J%=)TN
M+5AH!UHSMJ % Y+':>]IFB U*.?MEKD306-)-A7^\N=XHK[=4S80X.6784NU
MI#K63N;F2R6P^HYQBV\(7-Q&PS*VW.LD<\Q1W:^36W5/@6NKN0]%"5I\J(:U
MH6A0+@CJ>$R<<ZXGB[%8T.!TQVBL$]92.#W Y]UE4CF0"\X1:_/4F/V 1TGR
M&A]V#@\I*'MLH8LUW\+^"CJ'@\L 9_>-; 0MLL7KAAI_*43WM7;A\G@0;BG)
MYDKYLOF/!MQTG":52A1+!L?0D4?';ZVKT:MVP3:"A0/VB(0X"O$"4J-X,/MM
M];=P["2_Q"P$]I$]-QV1$VWZ8Z4]4_OETHYD'1<;3;A%U[H:HH>V@=X*H',@
M)RH<_H3F"'<[:9D@#G8BRUR_(U,&+B [C1Z &I1TOI,76NVGRH4C:G@P.G;^
MR)QG[ZTRDC<W*N:BF"L1J-56;/7&%.[RV?WG:(46-;6DJT#9.YBWK&2B &<)
MMXBR)*X UW3<'&>')]29+9!J&RT+\+GZ]J-CD7)"D,73[=.#QK6 &R;2$FX@
M[<;05%_X0()Z+A"!U.GRIZ?+W]?I\O5/EY?-S^6NO>4[XUW53^^%66:44X3(
MD"2QPR%*QZNOVK,5[LR[T-992O. &4%KC9T!L,F2E&45KQ:(:52[^UBJ.?\N
M=GWW1-W$%H>6%7;H.][OMUDP172RMMR%B$O9+SSX.:L'1,_896TH41+?MWR+
M)&9':UY$(1T,((=O19O @0XA_QQ<"*M>^1G*L:5' #_Z,(Q'A-$N5*W(5X=Q
MR'T;K*"WKQ\#Q4SRM+A.B;,4_9?B%5:[A?X3IPW6&*HO *)<I!./T=U!43/9
MR##/U4P).R+)S QR!13Z=P*&)(\83-_2Z8*8N.%*E>BMQ9E0B-+?":^"&0.F
M2K6]MHP<:@MEBV<-KQJ)L"D[NL*#A.4*)X6:;O8FI<E,-!@0(ZU8G$@AOLAO
M7P02XZY2=#N)*.99EXK31%OYXO$U+1D:MH0'"&EUO2=!@Z200YY 4E:,H1#"
M%SWD1AXA?S'@S%LHU'(F;X%@'6_EP4+S YE5K[Q)TSZ%9 )UZ,B9]CT1%;!O
M&)SH1VG#E]VI_>ES#QP]%EO84F]@!.N\%AFX^KEX]=+-I6(3=/+(0Q!8O>5.
MBQFB.O0ZY9X70C-JG;5"-)Z=WT!G!(W)UNPG/\;=QUX"YEG<A ")_\H7F,7)
MZHD+S;A%015B>,:SDNAPY5%OFL74VF&1D()<X1SQJ(S YU*(E7&D@(.&SE>,
MO-#L7H#^JE9?OH+IL/<E2>^'4?^&HE!4ODHI<(!7L*$'ME"<]929/;%P?S/.
M&1&68CS']>$?S";+Y]>1:3#L-(3%2SW"*P=[4#'*0TL, U89K"!A#QC5* H3
MQA; HJE]3^(P.%2N.0!YE/9STB/;[_>WV@<MJP-P@6Q$IU90EWE_2Q$[^3U8
M,0D;Y&JCH(GBDR=0]4Z^%+CC:L !D4:'AY!%O7C"6UEYEC(,0085PRV.DZT5
M&@[]1:H]3L#B=\^_A#FYK1D$0H;1'1+/2?0&$;0?><"HBJ@TC&G@2(]!_D1W
MQ;$/+S>GA@5XP(M227*09AI@/9@"57:+RHIQ5&H$X80S^R"-68R4[KI2RCNM
M%Z$49MCC50Y=M5^,?O>L:.2BX6&&@)<2015OEUA_/*-^Q;H=YOBY\Q.+PB)N
M^,I+^232E!0HQGC#/3@>_:F8;"9DZJB^&6LR)\[<8O-K4BHV7LJ4[:3^@&PZ
M7\!VY0C(WQ*<GF^!SGD1EPLYM*CCXTKI,NF[QM<F.91";E;QBW3@ATI5)*86
M#[4+1^4\/(I8IJ,Q<EZ17B7++C=]XV:6>0D$"ZZXA^;Z9RY?A+Z>&4!9,'4#
MJDATJS=EQ4ST-GE9L5.]W>;6DR9?'"Y3BLA@2TUU S1!XXS&T/606]*%NGJA
MXIA4$*\M::PU!X/LT_?=F#I?]O1\V?96G3"K$V8>K%P\P_X@0B<ZOVYWF*OE
M:-;F"[F;9U[.FFR0:U4*]E\F!0V/057?4P^-O@>WXIIJ8)R+'4FE__QEX96O
MSCM&7XFSYNGVA.#T'C%?;R,8B_#!CH*B/2CA58P=ECA/I-994ZX([XD#,/'R
MHVGV5Y^M#4N/YC[>DWH@"*-="+A=L=<RXXVC2QE\)[J4%=.>7%;$_4K^T,"B
M%OZQ"/SFKF-4H5Y!_(1!*>H#!=YL\)?]G?WJ]HA\I$U[Q%7[W\?<C0H&&YQ
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MEN8[EH0_9$9Z\5B?28VUDM5@'S3'5I[@&&M9G$-*N_:WCES/6:2%&P '?<T
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M2P[#>\OL:F%)'F1=#<-Y"P$]:%6ANS>4!^,=BRR;-NV>3Q Y95((J6K@B\G
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M/*K &VTT)>7YZ7]7 C=:^BA2%-L\$ HTC4HNQSC*J]DJ:N663B:CRQ9GWB\
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MK*8T3L).ZQQ0'K?JX("B54<=6'2 A6OKKYKK*XO&PY#I#[!"IP*\]2).VHP
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M[08??SL^P7>K7S<ZS:![TCV\NC@^[)P$YV>_=R_@QXV/S>"R>ZA>:(U#?;]
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MNS1O[QRWECS'ZL@?_/?_^*^?KM/^P]__S__ZZ78R&O[]_P=02P,$%     @
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MX',%[0@L2X <) D@E&81]R.B,[RLZ&=,L6(35"#F6D"C@:W+C)L(%-0I\ZV
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M3:=L?R[Q.JC3;&R6]2=^8K"9D*5_ZH<0;]HU_/''^=NV_57*^?\!4$L#!!0
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M48*@H@03C **2&)GA>HC.B0QN]8]C ?DO0;E!16$ST4H@"KPMI,=_QR2(5R
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M7SP7UL)ANF @-B&.(;Y(,!LAG0X>4"H60?X3$E74AM=M]HB&:W32W:YI]1*
MQ]UBI"J*X0B2*H6]65F4((TOL2C(0N0,1-D+".SC'#H<$-M<) AR\KR?MNB5
M9"D&8@$/*AP%1ADOW$B'%3L(YK)A@<H<C#0(1YTOPFK5HL%U+%=P4)#/ HIA
MK$7!EH(91%"J!7RO#R8S.$KP5!I4]7;8WK1A<%.IP1#5RJA,J8'EQ2*6$Y*.
M:#IFCYD]#M%?:7!XR4I[O98D+\52?CN$6M*D,P<\DLT-"6G5!><3K)(-^>LB
MJBA)+6/K9(*T5XO 3G^039EK<%#'VQ$*+0M)NQ[/Q1A6XX%-9#RID%&-)U$U
M4*\ ._4[ZF'8G)'\,=P!^]UQ77;@,,ME),&CM^NT)>U0249*.D -T3!;8U)$
M*X'HU?D&+T7!Q21&UQLA5$W5U!R@U)_24SBL>S BY?0Y5:T&ZQDF*?"BPX7;
MVC#"Z\!_T9Y&ON8)@_WF!3X+V^I(#6BR;&G6V"R-N6%:@=(U3@:9J@PWD+J6
MRX0<Z;S,5!JTZL>+V4*#(>T)@]1C(> /<5!@EHHVA^QB2^X<F\X17A?BK\>R
MKHBL"*!^K$8(,6@%&7[% J4C6"(%JZR]B+@<I9@#(0OY7+BB)F6F8)7]<"UD
MUJUBA%190;*2C4BD3<!^?QMOIPTDW*I',ZQDN"P>4-=CT9;90[03%,46$=Y1
MI?S^9*-EQ?-0!O8'S3@):8Q%4"T$*+S]>EY1?5&S7JN'BKA8;M))NA&&L9"M
MA,FX&?"M7C5L!;?3PPMJ4^9] ;?9FBB$8J%:2^68I 8RGA]9U0J(;M9LAPF_
M!T-*<,6.PB#V!T0O CP7E.[X-]I7@_U>)99BT\ZZ+EL51\I:\N-$'"292;;&
M$.XFK$ET#.001J150'SM"":+R4P \EH*K#\<,6-DII9TQFK1WA[9)8,$$">8
M1K@*8F@2K36@:,Z:2RG1#+@/1T(6!UL(.2JXB"1(;S230;%JV.K,2*Y& 62/
M 1 LVG:\&:&#%A !@4=@;?%LNXF6$-8:RZ8XCVJ--AN^IB?B$$F/WPVHL8#>
M*N#E"&=)(!8'U]#5J*\%:DW:ZVY1!$W3 ;<.-"0F%X,0G[7;VSK6DH'AIY!<
M(-Z*1D)(-&T#KC<.Q>TN"&ZW00[G3VEMM\^G^G"RP3E4)E\.^3DH;L/P/(+G
M\=X>(0MG'(PY$LVYHWPP;[8UXWFG*ZQ!9KO/'J\*6 :KXV%O.$P5?(I/":4K
M&IC;BH<QV$/!@;0WT\:L> $5BT4SX%M4$RL(EE.*+LR%.PH.S>M)5C1(0#.I
MFIEI2[PK##2B)2 :&XZ&N$26:T)JH:&Z\6H-1)E L=9D\YX*%VB"C"M3+Q-Z
M :&*M@)6J$3$8"3&E[+!8).*^8KV>"U0L[LK55K*Q!IEOB87TU@18@+M=MZI
MX7R-;Z):%56R!4H/M1R]/8S?&2_ %:PN 4\B-UIV7#*@N"-<IR)ZM&ZOV/ET
M2;7B'H(A_14]65?CC32I^FG< C&10*-8(=T)P 2^*2NAWAZ[BZE6"@9-45DQ
MF\<K&51OP8D(Q DU-L; 97LRQ[+AA@&G/$H^%!$ENAHJ:]F=VB,6G1@3 /5"
MV)R7]3KP2(129$LM/A.%PB$]CJ1;.<QKCK>T;,BIV50,JWBQ.N;WQIA".527
M"]5R*Z1EW;_Z17QOSS_[HC[F;FLZW];J"J1JMB*H,9B<3=?,,9@-%@H\K,BP
M)V$7PIEBM>TE_87>'@=7D^R!:B/6;&&Y4DW.VS1?R]XHM%)0K.'WU+"<N<H@
M9 V.1.TH9E,MP.8:S73- 8N^J"V1R2 P*63CJ Z\;V]/,AO &)^Y@/,I!E/K
MU?_Z]X9?_%I141 M%^$TKD$6TF1,S6 Q(I5,068/;4O:S2U:#C0J;<!".2-!
MBL.3IH.^77^9 3+]G_N9YW_T-R.[!U24_W/(@._]'T0&<O+_063_MA1@D)S,
MF?/CN8.=YPN^/R'Q+XZ?_-HQB]D#)X5F4:5JC2UQ N6>"Q[,E&5^5@XSLR##
M0OLQ!V_KMZ)FOC]G%_%^7$!PLR!BO)7C!G#^=/JN6-UEKMXY]_0=5OX_Q+K+
M]%VQAG59DDNLNLOK>AV@QMRH&7>@5H?%Z7$[$<2!6 D<<YC=%@0SXR[\>[2_
M,G]7]%&AQ,N=\UTNE:U6YVIZN2QV#AM]/_UG[W]"KZ#+#8'WZ.7BOSJF,GO@
MS-4L^4?&#="0XSD+FK/8^ZTLSO8CF!7I!PF V(^CHHC81<YN[9PR^L7<G^#D
M?\EU!R+:;0XQU\_:S'B_%7"EG\W9[?T.%!-XQ.;@1 ?_/5K^9VSY'FWYOV;[
M/YS_$_SZ/^3[K[[_4:=_ROB?",0G5VMEO;7KB:*84/G/3Q0-G'&;Q7*=Y>=6
M6;!49U>[//L9I/Q+<Q*M.0?.(O9^5+2;^ZV8S=Z?PSAS/]!YU(K81%00?T#Z
M"\G^@-C("Z7OSFIA_2@>1]%9%FR6&?W^K-8N4#^;62V+-8/5!4("O/]WCVO]
MVM2?X>7R;$D2^+GP]]#?/_AUI_2_R_1_S]O\!TS_U0-R_Y]G^L[;'S3_>ZOY
MB77,WN6<Y:Q8C07YJA;1RZ*L"G,C.MC<;/B?0.Q$ :QU%GC"USE!_X[:B-O3
MI\HYG=5;?0@VL\.NGT -'*R%?W:R=N#(+OS=F=W.<6'XA_/"X*[O?Z'M7F3W
M(KL7V;W([D5V+[)[D=V+[%YD]R*[%_D?:#_^P2!0SL^9;DR?-W?'.Z/2E,LU
M/Q(->Z@ :>KJ,IE&^0)RJ3QH3Y.I6*KI4:^S+YW)]@U[SC3(-,(TU(283"Q7
MU8(Q3[SS=XLHTM57!4"FG[2O7C9U=3Y7]?LB?7VF_ZR-X32]9C)U1<#8PH/2
M!(Q/!6/5J&F=YQO >%Q.Z8P'#>Z,=;!!,)[0&4L[QX<-P.P<']$9\\42#\:=
M/6M\D>^,'P7CWS;J AAW!\#X](8L&&"\&HP/4NM%&8PW=^86!;9J,@T>U7E>
M$[@\&)O!>)0>C[K >+;)-'R4M,LXM\NX)C1K':)<9:VE=_ZJ2=\,[I ^Q.'
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M3[<[:^E-GDRY+F?L_*7GYS"S\!U;F+ E*A8[!HU$QMR)_<XW2-\<H2;5<QO
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M=U[5%VB>!7ZFLA0IIE1/Y$BE"+T0*:'GXZE8'_%R?<O,U?((='DI>7*?#4O
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MBDL3L W24A\\,Q]\[-J3PM @K?2M<W\(\B;3%_]9_#>LE[HH62HOG+S'Q"C
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M)  "R'"*;,C#PLM_.?!4%=_&;GI=++BXI>&4LN.X@T@%,<,/=XM$E+3NN__
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M^DN"<S M72'B3OJRYE*"K_$21&(@>DL8R><K5*U"DC/AQ%DM?>[*C=5QY&6
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M->)&I3]5\2I*KJ^W:V1X1+.[0S:$ZX0&[[T[WB"0CF@)XB*R3AOI!%A%^^5
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M_&8VXA.$3RY\[_RCM!MBRNU*D>4W1FRFSVOUNER8;6LH\5E$'KI#*'$IR0A
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MO?.YX*F2?JI2COU1D;R[(V^K"A.3XR&P..US*GMGM9CEWF3E^V<5;5U-P?R
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M4Y(AXC#<!"#-^E1OLLZTCBONQN*#S\H3D^H1<B &2'M21)_\%KUC@'H^T]O
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MP^JR#F>DL[2T+-KFO8_Y]8(O1P;MD$_L(F^'Z [2(M-HKQ!*7\V'+@(:&[1
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MI$T\!R9JF?L!_>V)D-2##XGB>)6)@D*<YR1OT80_M&=PD>O8\."H:@_]O8C
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M:@ /A1"*\(AE=_PA+=\FKL01!U'1O',"HAL#:)PJK[.\193AI\M:]\U=+42
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M;4DU<IW[-LN;6?OSW3[[O]$0M?=GDB(Q,,_O KXI?A+,-*Z5L6@D73=J9-(
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M2A$-#V:[-9&>R!NCGL7^L>'&&H_^G+M;CZ=EYYZ5#O@S\?0_DW#Z7W%1@,(
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M#OYV/+_!\]%WW.T-U[SVWL_N4&B_4" S/5H>/"$E)$(?6R'J<!3[X^$'WH)
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M,#$Y,#DR-U]D968N>&UL4$L! A0#%     @ R8%>3ZWS9LN_Z   O8<+ !4
M             ( !PY(  &5X96PM,C Q.3 Y,C=?;&%B+GAM;%!+ 0(4 Q0
M   ( ,F!7D] ."P)&XP  -4C!P 5              "  ;5[ 0!E>&5L+3(P
M,3DP.3(W7W!R92YX;6Q02P$"% ,4    " #)@5Y/#U'?/?>Y @!#/", %
M            @ $#" ( 97AE;#(P,3DP.3,P,3 M<2YH=&U02P$"% ,4
M" #)@5Y/8IGSW)02   ?B0  &@              @ $LP@0 97AE;#(P,3DP
M.3,P97AH:6)I=#$P,2YH=&U02P$"% ,4    " #)@5Y/:.S]$ LO    3 $
M&@              @ 'XU 0 97AE;#(P,3DP.3,P97AH:6)I=#$P,BYH=&U0
M2P$"% ,4    " #)@5Y/2'RVMVAJ 0 S.PD &@              @ $[! 4
M97AE;#(P,3DP.3,P97AH:6)I=#$P,RYH=&U02P$"% ,4    " #)@5Y/Z]TQ
MU4L(  "V(@  &@              @ ';;@8 97AE;#(P,3DP.3,P97AH:6)I
M=#,Q,2YH=&U02P$"% ,4    " #)@5Y/<XVZ258(  #P(@  &@
M    @ %>=P8 97AE;#(P,3DP.3,P97AH:6)I=#,Q,BYH=&U02P$"% ,4
M" #)@5Y/R&*+C? %    (P  &@              @ 'L?P8 97AE;#(P,3DP
M.3,P97AH:6)I=#,R,2YH=&U02P$"% ,4    " #)@5Y/8=$JD5D1 0#"Q@$
M$               @ $4A@8 97AE;&QO9V\Q.7$S+FIP9U!+!08     #0 -
+ 'L#  ";EP<    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6833560464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>97,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>126,630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>252,269</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>329,981</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>303,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>298,416</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>301,999</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>297,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>312,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>313,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.31</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Dilutive securities include outstanding stock options, unvested RSUs and ESPP contributions. Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Potentially dilutive securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6830829072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,252</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,090</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,252</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Write-downs related to excess and expiring inventory are charged to Cost of goods sold or the cost of supplied product included in Collaboration revenues. Such write-downs were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.4 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory not expected to be used in production or sold in the next 12 months is classified as Other long-term assets in the accompanying Condensed Consolidated Balance Sheets. As of both </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the long-term portion of inventory consisted of portions of our raw materials and finished goods, and as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, also a portion of our work in process.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6666490400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 76,016<span></span>
</td>
<td class="nump">$ 57,186<span></span>
</td>
<td class="nump">$ 120,133<span></span>
</td>
<td class="nump">$ 145,038<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6850164240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 29, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">296,209,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 29, 2017</a></td>
<td class="nump">$ 284,961<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 296<span></span>
</td>
<td class="nump">$ 2,114,184<span></span>
</td>
<td class="num">$ (347)<span></span>
</td>
<td class="num">$ (1,829,172)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">329,981<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">329,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(166)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">2,672,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">14,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">14,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">28,330<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 28, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">298,881,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 28, 2018</a></td>
<td class="nump">915,966<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">2,156,632<span></span>
</td>
<td class="num">(513)<span></span>
</td>
<td class="num">(1,240,452)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 29, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">297,892,180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 29, 2018</a></td>
<td class="nump">775,202<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">2,142,717<span></span>
</td>
<td class="num">(731)<span></span>
</td>
<td class="num">(1,367,082)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">126,630<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,630<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">218<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">989,704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">4,174<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,742<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 28, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">298,881,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 28, 2018</a></td>
<td class="nump">$ 915,966<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 299<span></span>
</td>
<td class="nump">2,156,632<span></span>
</td>
<td class="num">(513)<span></span>
</td>
<td class="num">(1,240,452)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Dec. 28, 2018</a></td>
<td class="nump">299,876,080<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">299,876,080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 28, 2018</a></td>
<td class="nump">$ 1,287,453<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">2,168,217<span></span>
</td>
<td class="num">(701)<span></span>
</td>
<td class="num">(880,363)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">252,269<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">252,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">3,369<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">3,899,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">19,879<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">19,875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 40,747<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 27, 2019</a></td>
<td class="nump">303,776,032<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">303,776,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 27, 2019</a></td>
<td class="nump">$ 1,603,717<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">2,228,839<span></span>
</td>
<td class="nump">2,668<span></span>
</td>
<td class="num">(628,094)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Jun. 28, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">302,784,854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Jun. 28, 2019</a></td>
<td class="nump">1,488,632<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">2,211,668<span></span>
</td>
<td class="nump">2,207<span></span>
</td>
<td class="num">(725,546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">97,452<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">461<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">991,178<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">4,033<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 13,139<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,139<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance (in shares) at Sep. 27, 2019</a></td>
<td class="nump">303,776,032<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">303,776,032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Sep. 27, 2019</a></td>
<td class="nump">$ 1,603,717<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 304<span></span>
</td>
<td class="nump">$ 2,228,839<span></span>
</td>
<td class="nump">$ 2,668<span></span>
</td>
<td class="num">$ (628,094)<span></span>
</td>
</tr>
<tr><td colspan="7"></td></tr>
<tr><td colspan="7"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118258462&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116855982&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6832547280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock', window );">Balance Sheet Classification of Lease Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The balance sheet classification of our lease liabilities were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,695</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>23,661</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,099</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total operating lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,837</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Financing lease liabilities:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Other current liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion of lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>44</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>79</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financing lease liabilities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,450</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>14,965</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Components of Lease Expense</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The components of lease costs for operating leases, which were included in Selling, general and administrative expenses in our Condensed Consolidated Statements of Income, were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>692</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,614</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,587</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Variable lease cost</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>363</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,366</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease costs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>966</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,422</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,953</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the maturities of our operating lease liabilities were as follows (in thousands):&#160;</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:87%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Remainder of 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>745</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Years ending December&#160;31,</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2020</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,625</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2021</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,731</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2022</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,852</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">2023</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,959</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Thereafter</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>17,444</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total lease payments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>33,356</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Less:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Present value adjustment</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(5,258</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Tenant improvement reimbursements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#160;(1)</sup></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1,742</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,356</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:left;padding-left:48px;text-indent:-24px;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">____________________</span></div><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">(1) </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;">Represents anticipated tenant improvement reimbursements applicable to the portion of the 1601 Expansion Space.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating And Financing Lease Liabilities [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingAndFinancingLeaseLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6847218736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 76,016<span></span>
</td>
<td class="nump">$ 57,186<span></span>
</td>
<td class="nump">$ 120,133<span></span>
</td>
<td class="nump">$ 145,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member', window );">Caremark L.L.C.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 35,703<span></span>
</td>
<td class="nump">$ 30,707<span></span>
</td>
<td class="nump">$ 105,638<span></span>
</td>
<td class="nump">$ 83,516<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member', window );">Caremark L.L.C. | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 31,901<span></span>
</td>
<td class="nump">$ 26,597<span></span>
</td>
<td class="nump">$ 88,496<span></span>
</td>
<td class="nump">$ 71,249<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_ASDMember', window );">Affiliates of AmerisourceBergen Corporation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 25,235<span></span>
</td>
<td class="nump">$ 17,232<span></span>
</td>
<td class="nump">$ 70,503<span></span>
</td>
<td class="nump">$ 49,995<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_ASDMember', window );">Affiliates of AmerisourceBergen Corporation | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_OtherCustomersMember', window );">Others, individually less than 10% of Total revenues for all periods presented</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 102,848<span></span>
</td>
<td class="nump">$ 93,675<span></span>
</td>
<td class="nump">$ 342,695<span></span>
</td>
<td class="nump">$ 275,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_OtherCustomersMember', window );">Others, individually less than 10% of Total revenues for all periods presented | Revenue | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_CaremarkL.L.C.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_ASDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_ASDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_OtherCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_OtherCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6839006960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td colspan="2" class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td colspan="2" class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td colspan="2" class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td colspan="2" class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">303,776,032<span></span>
</td>
<td colspan="2" class="nump">299,876,080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">303,776,032<span></span>
</td>
<td colspan="2" class="nump">299,876,080<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6634782752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 6.1<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6668776704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Sep. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Sep. 28, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 28, 2018 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Gain (loss) on sales of investments available-for-sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary impairment charges on available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OwnershipInterestByMinorityShareholder', window );">Beneficial ownership interest by BlackRock (more than)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner', window );">Fair value of cash and investments managed by BlackRock</a></td>
<td class="nump">470,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">470,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 298,500,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund', window );">Fair value of cash and investments managed by BlackRock in the BlackRock Liquidity Money Market Fund</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DueToRelatedPartiesCurrent', window );">Payable to BlackRock</a></td>
<td class="nump">$ 9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RelatedPartyTransactionsAdvisoryFeesIncurred', window );">Fees for advisory services paid to BlackRock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OwnershipInterestByMinorityShareholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minority Ownership, Ownership Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OwnershipInterestByMinorityShareholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RelatedPartyTransactionsAdvisoryFeesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Advisory Fees Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RelatedPartyTransactionsAdvisoryFeesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Cash And Investments Managed By Minority Owner</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Related Party Transactions, Cash And Investments Managed By Minority Owner, Invested In Money Market Fund</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RelatedPartyTransactionsCashAndInvestmentsManagedByMinorityOwnerInvestedInMoneyMarketFund</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DueToRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DueToRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6837959168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.57%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">1.82%<span></span>
</td>
<td class="nump">2.83%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
<td class="nump">48.00%<span></span>
</td>
<td class="nump">55.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
<td class="text">4 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.11%<span></span>
</td>
<td class="nump">2.34%<span></span>
</td>
<td class="nump">1.74%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">43.00%<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6644856752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 242,317<span></span>
</td>
<td class="nump">$ 314,775<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 353,623<span></span>
</td>
<td class="nump">$ 183,164<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash included in short-term restricted cash and investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">504<span></span>
</td>
<td class="nump">504<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash included in long-term restricted cash and investments</a></td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">1,100<span></span>
</td>
<td class="nump">4,646<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 243,317<span></span>
</td>
<td class="nump">$ 315,875<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 355,227<span></span>
</td>
<td class="nump">$ 188,314<span></span>
</td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838596960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,187<span></span>
</td>
<td class="nump">$ 1,940<span></span>
</td>
<td class="nump">$ 14,245<span></span>
</td>
<td class="nump">$ 6,843<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6624590176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember', window );">Collaboration Agreement with Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 20,130<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementwithDaiichiSankyoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838609680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Balance Sheet Classification of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseLiabilitiesAbstract', window );"><strong>Operating lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion included in Other current liabilities</a></td>
<td class="nump">$ 2,695<span></span>
</td>
<td class="nump">$ 2,738<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">23,661<span></span>
</td>
<td class="nump">12,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">26,356<span></span>
</td>
<td class="nump">14,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_FinancingLeaseLiabilitiesAbstract', window );"><strong>Financing lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Current portion included in Other current liabilities</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">49<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">44<span></span>
</td>
<td class="nump">79<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiability', window );">Financing obligation for build-to-suit lease</a></td>
<td class="nump">94<span></span>
</td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiabilityTotal', window );">Total lease liabilities</a></td>
<td class="nump">$ 26,450<span></span>
</td>
<td class="nump">$ 14,965<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_FinancingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financing Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_FinancingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingAndFinanceLeasesLiabilityTotal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Leases, Liability - Total</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingAndFinanceLeasesLiabilityTotal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Liabilities [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6826955920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareNumeratorAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 97,452<span></span>
</td>
<td class="nump">$ 126,630<span></span>
</td>
<td class="nump">$ 252,269<span></span>
</td>
<td class="nump">$ 329,981<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_EarningsPerShareDenominatorAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares of common stock outstanding used in computing basic net income per share (in shares)</a></td>
<td class="nump">303,268<span></span>
</td>
<td class="nump">298,416<span></span>
</td>
<td class="nump">301,999<span></span>
</td>
<td class="nump">297,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">12,185<span></span>
</td>
<td class="nump">13,930<span></span>
</td>
<td class="nump">13,047<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share (in shares)</a></td>
<td class="nump">315,453<span></span>
</td>
<td class="nump">312,346<span></span>
</td>
<td class="nump">315,046<span></span>
</td>
<td class="nump">313,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share, basic (in dollars per share)</a></td>
<td class="nump">$ 0.32<span></span>
</td>
<td class="nump">$ 0.42<span></span>
</td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share, diluted (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.41<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareDenominatorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Denominator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareDenominatorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_EarningsPerShareNumeratorAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Numerator [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_EarningsPerShareNumeratorAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838650528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventory</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Inventory consisted of the following (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Raw materials</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,906</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Work in process</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,035</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Finished goods</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,311</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,836</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,252</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;font-style:italic;">Balance Sheet classification:</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Current portion included in Inventory</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,366</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,838</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Long-term portion included in Other long-term assets</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,886</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,090</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>20,252</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>11,928</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838799600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Consolidation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Basis of Presentation</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">st</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. Fiscal year 2019, which is a 53-week fiscal year, will end on January 3, 2020 and fiscal year 2018, which was a 52-week fiscal year, ended on December 28, 2018. For convenience, references in this report as of and for the fiscal periods ended September 27, 2019, June 28, 2019, September 28, 2018 and June 29, 2018, and as of and for the fiscal years ending January 3, 2020, and ended December 28, 2018 and December 29, 2017, are indicated as being as of and for the periods ended September 30, 2019, June 30, 2019, September 30, 2018 and June 30, 2018 and the years ending December&#160;31, 2019, and ended December&#160;31, 2018 and December 31, 2017, respectively. Similarly, references in this report to the first day of the fiscal year ended January 3, 2020 are indicated as being as of January 1, 2019 and the first day of the fiscal quarter ended September 27, 2019 are indicated as being as of July 1, 2019.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Segment Information</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We operate in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>one</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> business segment that focuses on the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">discovery, development and commercialization of new medicines for difficult-to-treat cancers</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our Chief Executive Officer, as the chief operating decision-maker, manages and allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. </span></div>All of our long-lived assets are located in the U.S.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Use of Estimates</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns, sales allowances, and milestone payments included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; the recoverability of inventory; the amounts of operating lease right-of-use assets and lease liabilities; the amounts of deferred tax assets and liabilities including the related valuation allowance; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recently Adopted Accounting Pronouncements</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On July 1, 2019, we adopted</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU No.&#160;2018-15,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-15). ASU 2018-15</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> requires a customer in a hosting arrangement that is a service contract to follow the guidance in Accounting Standards Codification (ASC) Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense and requires us to expense the capitalized implementation costs over the term of the hosting arrangement, which includes reasonably certain renewals.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2018-15 was adopted using the prospective transition method in the accompanying Condensed Consolidated Financial Statements. The adoption of ASU 2018-15 did not have a material impact on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we adopted ASU </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">2018-02, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Income Statement&#8212;Reporting Comprehensive Income (Topic 220) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2018-02). There was no financial impact from the adoption of ASU 2018-02 and we </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">did not make an election to reclassify the income tax effects of the Tax Cuts and Jobs Act of 2017 from Accumulated other comprehensive income (loss) to Accumulated deficit. In connection with the adoption of ASU 2018-02, we have adopted </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the individual unit of account approach for </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">releasing income tax effects from </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Accumulated other comprehensive income (loss)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On January 1, 2019, we also adopted ASU 2017-08</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Receivables&#8212;Nonrefundable Fees and Other Costs (Subtopic 310-20)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2017-08). ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">shortens the amortization period for certain callable debt securities held at a premium. Specifically, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">requires the premium to be amortized to the earliest call date. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2017-08 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">does not require an accounting change for securities held at a discount; the discount continues to be amortized to maturity. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The financial impact from the adoption of ASU 2017-08 was nominal.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In November 2018, the Financial Accounting Standards Board (FASB) issued ASU No.&#160;2018-18,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2018-18). ASU 2018-18 clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue under Topic 606 when the counterparty is a customer for a distinct good or service (i.e. a unit of account). For units of account that are in the scope of Topic 606, all of the guidance in Topic 606 should be applied, including the guidance on recognition, measurement, presentation and disclosure. ASU 2018-18 also adds a reference in ASC Topic 808, </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">Collaborative Arrangements</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (Topic 808) to the unit of account guidance in Topic 606 and requires that it be applied only to assess whether transactions in a collaborative arrangement are in the scope of Topic 606. ASU 2018-18 will preclude entities from presenting amounts related to transactions with a counterparty in a collaborative arrangement that is not a customer as revenue from contracts with customers. ASU 2018-18 is effective for us for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We are in the process of assessing the impact of ASU 2018-18 on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In January 2017, the FASB issued ASU No.&#160;2017-04,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Intangibles&#8212;Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> (ASU 2017-04)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> ASU 2017-04 eliminated Step 2 from the goodwill impairment test. Instead, under the amendments in ASU 2017-04, an entity should perform its annual, or interim, goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity should recognize an impairment charge for the amount by which the carrying amount exceeds the reporting unit&#8217;s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. Additionally, an entity should consider income tax effects from any tax deductible goodwill on the carrying amount of the reporting unit when measuring the goodwill impairment loss, if applicable. ASU 2017-04 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2017-04 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In June 2016, the FASB issued ASU No.&#160;2016-13,</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;"> Financial Instruments&#8212;Credit Losses (Topic 326) </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">(ASU 2016-13)</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:italic;">. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">ASU 2016-13 implements an impairment model, known as the current expected credit loss model that is based on expected losses rather than incurred losses. Under the new guidance, an entity will recognize as an allowance its estimate of expected credit losses. 2016-13 is effective for all interim and annual reporting periods beginning after December 15, 2019. Early adoption is permitted. We do not expect the adoption of ASU 2016-13 to have a material impact on our Condensed Consolidated Financial Statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Chargebacks and discounts for prompt payment are recorded as a reduction of trade receivables and the remaining reserve balances are classified as Other current liabilities in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Contract Assets and Liabilities </span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">We receive payments from our licensees based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as unbilled collaboration revenue when recognized. Unbilled collaboration revenue was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>zero</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> as of both </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span>. Upfront and milestone payments may require deferral of revenue recognition to a future period until we perform our obligations under these arrangements and are recorded as deferred revenue upon receipt or when due. <div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues are attributed to geographic region based on the ship-to location. Collaboration revenues are attributed to geographic region based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues, License revenues and Research and development services revenues were recorded in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 606 for all periods presented. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Net product revenues and License revenues related to goods and intellectual property licenses transferred at a point in time and Research and development services revenues related to services performed over time. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other collaboration revenues, which included the p</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">rofit on the U.S. commercialization of COTELLIC and net losses on product supply services, were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">recorded in accordance with </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Topic 808 </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for all periods presented</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=d3e5291-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6831519296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,239</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>706,807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>706,807</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,191,696</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,218,337</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,220,888</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,247,529</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Level&#160;2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>780,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total financial assets carried at fair value</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>796,994</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>844,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6832461840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Takeda Collaboration (Details) - Collaborative Arrangement with Takeda - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Apr. 29, 2019</div></th>
<th class="th"><div>Apr. 28, 2019</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAnnualReimbursementLimit', window );">Limit on reimbursement per year</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Increase in maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development and regulatory milestones</a></td>
<td class="nump">102.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementMilestonePaymentsEarned', window );">Milestone payments earned</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Increase in maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="nump">$ 89.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Net contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementMilestonePaymentsEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Milestone Payments Earned</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementMilestonePaymentsEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAnnualReimbursementLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Annual Reimbursement Limit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAnnualReimbursementLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Collaborative Arrangement, Maximum Amount Eligible for Development and Regulatory Milestones</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInCollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_IncreaseDecreaseInMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6650343632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details) - Collaboration Agreement with Iconic Therapeutics, Inc. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementsUpfrontPayments', window );">Upfront payment</a></td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued', window );">Preclinical development funding commitment accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption', window );">Option exercise fee payment, if exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones', window );">Maximum amount eligible for development, regulatory and first-sale milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">190.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement', window );">Maximum amount eligible for commercial milestones under collaborations agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 262.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Option Exercise Fee Payment, Upon Exercising Option</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementOptionExerciseFeePaymentUponExercisingOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Research And Development Expense Accrued</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementResearchAndDevelopmentExpenseAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementsUpfrontPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreements, Upfront Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementsUpfrontPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Agreement, Maximum Amount Eligible For Commercial Milestones Under Collaborations Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeAgreementMaximumAmountEligibleForCommercialMilestonesUnderCollaborationsAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount eligible for development and regulatory milestones under collaborations agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementMaximumAmountEligibleForDevelopmentAndRegulatoryMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborationAgreementWithIconicTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6850751200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Dec. 29, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, Amortized Cost</a></td>
<td class="nump">$ 1,214,736<span></span>
</td>
<td class="nump">$ 828,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">3,692<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, Fair Value</a></td>
<td class="nump">1,218,337<span></span>
</td>
<td class="nump">828,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">243,317<span></span>
</td>
<td class="nump">315,875<span></span>
</td>
<td class="nump">$ 355,227<span></span>
</td>
<td class="nump">$ 188,314<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Total cash and investments, Amortized Cost</a></td>
<td class="nump">1,244,826<span></span>
</td>
<td class="nump">852,322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Total cash and investments, Gross Unrealized Gains</a></td>
<td class="nump">3,695<span></span>
</td>
<td class="nump">182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Total cash and investments, Gross Unrealized Losses</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(883)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Total cash and investments, Fair Value</a></td>
<td class="nump">1,248,430<span></span>
</td>
<td class="nump">851,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, Amortized Cost</a></td>
<td class="nump">26,641<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, Fair Value</a></td>
<td class="nump">26,641<span></span>
</td>
<td class="nump">47,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, Amortized Cost</a></td>
<td class="nump">332,239<span></span>
</td>
<td class="nump">381,134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, Fair Value</a></td>
<td class="nump">332,239<span></span>
</td>
<td class="nump">381,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, Amortized Cost</a></td>
<td class="nump">703,325<span></span>
</td>
<td class="nump">344,741<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">3,549<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, Fair Value</a></td>
<td class="nump">706,807<span></span>
</td>
<td class="nump">344,064<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Investments, available-for-sale, Amortized Cost</a></td>
<td class="nump">152,531<span></span>
</td>
<td class="nump">55,224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Investments available-for-sale, Fair Value</a></td>
<td class="nump">152,650<span></span>
</td>
<td class="nump">55,201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=exel_CashAndRestrictedCashMember', window );">Cash and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Cash, cash equivalents, and restricted cash, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Cash, cash equivalents, and restricted cash, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Cash, restricted cash and certificates of deposit, Fair Value</a></td>
<td class="nump">901<span></span>
</td>
<td class="nump">6,883<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_invest_InvestmentLineItems', window );"><strong>Investment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Investments available-for-sale, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Investments available-for-sale, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">29,189<span></span>
</td>
<td class="nump">16,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Cash, cash equivalents, and restricted cash, Gross Unrealized Gains</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Cash, cash equivalents, and restricted cash, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Cash, restricted cash and certificates of deposit, Fair Value</a></td>
<td class="nump">$ 29,192<span></span>
</td>
<td class="nump">$ 16,596<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_invest_InvestmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">invest_InvestmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>invest_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=exel_CashAndRestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=exel_CashAndRestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6833463456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 31, 2017</div></th>
<th class="th">
<div>Sep. 27, 2019 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>renewal_option</div>
</th>
<th class="th">
<div>Aug. 30, 2019 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Apr. 30, 2019 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,742<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for amounts included in the measurement of lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average operating discount rate used to determine the operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term for operating lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember', window );">Alameda, California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of lease property (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements', window );">Tenant improvement reimbursements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of options to extend the Lease | renewal_option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod', window );">Option to terminate lease (after period)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease option to extend period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty', window );">Operating lease, expansion (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">59,335<span></span>
</td>
<td class="nump">37,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty', window );">Operating lease, surrendered (in square feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_TenantLeaseImprovementsAllowance', window );">Tenant improvement allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseLiabilityTenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Terminate After Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_LesseeOperatingLeaseOptionToTerminateAfterPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseAdditionalAreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Additional Area Of Real Estate Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseAdditionalAreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Surrendered Area Of Real Estate Property</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingLeaseSurrenderedAreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_TenantLeaseImprovementsAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tenant Lease Improvements, Allowance</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_TenantLeaseImprovementsAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=exel_AlamedaCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6847346688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 29, 2018</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">20.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">19.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>299</ContextCount>
  <ElementCount>382</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>71</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001501 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003001 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1005000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Collaboration Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreements</Role>
      <ShortName>Collaboration Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Collaboration Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTables</Role>
      <ShortName>Collaboration Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashAndInvestments</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipment</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Leases</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2401402 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesByDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedByProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedBySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedByGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesAndEndingReserveBalancesForSignificantCategoriesOfDiscountsAndAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Revenues - Contract Assets and Liabilities under Topic 606 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsAndLiabilitiesUnderTopic606Details</Role>
      <ShortName>Revenues - Contract Assets and Liabilities under Topic 606 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithIpsenDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Collaboration Agreements - Ipsen Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIpsenCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Ipsen Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithTakedaDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Collaboration Agreements - Takeda Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsTakedaCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Takeda Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGenentechDetails</Role>
      <ShortName>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2403407 - Disclosure - Collaboration Agreements - Daiichi Sankyo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsDaiichiSankyoDetails</Role>
      <ShortName>Collaboration Agreements - Daiichi Sankyo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2403408 - Disclosure - Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsCollaborationRevenuesUnderCollaborationAgreementWithDaiichiSankyoDetails</Role>
      <ShortName>Collaboration Agreements - Collaboration Revenues under the Collaboration Agreement with Daiichi Sankyo (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2403409 - Disclosure - Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsIconicTherapeuticsIncIconicCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Iconic Therapeutics, Inc. (Iconic) Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2403410 - Disclosure - Collaboration Agreements - Aurigene Discovery Technologies Limited (Aurigene) Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsAurigeneDiscoveryTechnologiesLimitedAurigeneCollaborationDetails</Role>
      <ShortName>Collaboration Agreements - Aurigene Discovery Technologies Limited (Aurigene) Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2403411 - Disclosure - Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsRoyaltyRevenuesUnderCollaborationAgreementWithGskDetails</Role>
      <ShortName>Collaboration Agreements - Royalty Revenues under the Collaboration Agreement with GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsReconciliationOfCashCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsInvestmentsBySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsFairValueAndGrossUnrealizedLossesOfInvestmentsAvailableForSaleInUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2404406 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashAndInvestmentsFairValueOfCashEquivalentsAndInvestmentsByContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationWeightedAverageGrantDateFairValueOfStockOptionsAndEsppPurchasesDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationValuationAssumptionsUsedToEstimateGrantDateFairValueDetails</Role>
      <ShortName>Stock-Based Compensation - Valuation Assumptions Used to Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2407406 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2407407 - Disclosure - Stock-Based Compensation - RSU Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationRsuActivityDetails</Role>
      <ShortName>Stock-Based Compensation - RSU Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2408401 - Disclosure - Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/IncomeTaxesDetails</Role>
      <ShortName>Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/IncomeTaxes</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationOfBasicAndDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentialSharesOfCommonStockNotIncludedInComputationOfDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Leases - Balance Sheet Classification of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesBalanceSheetClassificationOfLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Balance Sheet Classification of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2412404 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesComponentsOfLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/LeasesMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2413401 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/SubsequentEvents</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="exel2019093010-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9999.htm</HtmlFileName>
      <LongName>Uncategorized Items - exel2019093010-q.htm</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/role/uncategorizedFacts</Role>
      <ShortName>Uncategorized Items - exel2019093010-q.htm</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel2019093010-q.htm">exel2019093010-q.htm</File>
    <File>exel-20190927.xsd</File>
    <File>exel-20190927_cal.xml</File>
    <File>exel-20190927_def.xml</File>
    <File>exel-20190927_lab.xml</File>
    <File>exel-20190927_pre.xml</File>
    <File>exel20190930exhibit101.htm</File>
    <File>exel20190930exhibit102.htm</File>
    <File>exel20190930exhibit103.htm</File>
    <File>exel20190930exhibit311.htm</File>
    <File>exel20190930exhibit312.htm</File>
    <File>exel20190930exhibit321.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exellogo19q3.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/invest/2013-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838673984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Computation of Basic and Diluted Net Income Per Share</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The basic and diluted net income per share were computed as follows (in thousands, except per share amounts):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Numerator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>97,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>126,630</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>252,269</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>329,981</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Denominator:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding used in computing basic net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>303,268</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>298,416</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>301,999</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>297,700</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Dilutive securities</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>12,185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,930</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>13,047</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>15,500</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Weighted-average shares of common stock outstanding and dilutive securities used in computing diluted net income per share</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,453</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>312,346</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,046</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>313,200</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, basic</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.32</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.42</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.84</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Net income per share, diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.31</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>0.80</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1.05</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</a></td>
<td class="text">Potential shares of common stock not included in the computation of diluted net income per share because to do so would be anti-dilutive, were as follows (in thousands):<span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;</span><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:44%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:2%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Three Months Ended September 30,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Nine Months Ended September 30,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Potentially dilutive securities</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,153</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,687</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>5,740</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2,938</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6668889584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>242,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>353,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>183,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>243,317</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>355,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>188,314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>242,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>353,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>183,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>243,317</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>355,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>188,314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Investments by Security Type</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments by security type were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>703,325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>706,807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,214,736</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,218,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,189</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,244,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,695</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,248,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,843</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>852,322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>851,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>73,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77,462</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>119,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(90</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>124,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>236,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>275,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,287</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(623</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>320,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>743,768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>674,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>474,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,218,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6843630992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">SUBSEQUENT EVENTS</a></td>
<td class="text"><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">NOTE 12. SUBSEQUENT EVENTS</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Build to Suit Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On </span><span style="color:#000000;font-family:Calibri,sans-serif;font-size:10pt;">October 25, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we entered into a build-to-suit Lease Agreement (the Build-to-Suit Lease) with Ernst Development Partners, Inc. (Ernst), for approximately </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>220,000</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of office space located in Alameda, California (the New Premises), adjacent to the Current Premises. The term of the Build-to-Suit Lease is for a period of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>242</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> months (the Term), which will begin on the completion of the building and tenant improvements by Ernst. The Term is currently anticipated to begin on </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">October 25, 2021</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">. The monthly base rent under the Build-to-Suit Lease will equal to a percentage of the total development costs incurred in connection with the development of the New Premises (excluding the cost of the tenant improvements in excess of the allowance provided by Ernst and any development costs we pay) and is currently estimated to be about </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$726,000</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, subject to an annual increase of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>3%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the Term. The monthly base rent will begin sixty days following commencement of the Term. We will also be responsible for paying operating expenses related to the New Premises. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Build-to-Suit Lease includes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>two</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> five-year options to extend the term of the Build-to-Suit Lease, exercisable under certain conditions and at a market rate determined in accordance with the Build-to-Suit Lease. We have a one-time option to terminate the Build-to-Suit Lease without cause after the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>180</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><sup style="vertical-align:top;line-height:120%;font-size:pt">th</sup></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> month of the Term, exercisable under certain conditions as described in the Build-to-Suit Lease and subject to a termination payment calculated in accordance with the Build-to-Suit Lease. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See Part II, Item 5 of this Quarterly Report on Form 10-Q for more information about the Build to Suit Lease.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fourth Amendment to the Lease</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">In the fourth quarter of 2019, Hillwood Enterprises, L.P. (Hillwood) is expected to purchase the project known as 1750 North Loop Road and 1601, 1701, 1751, 1801 and 1851 Harbor Bay Parkway, Alameda, California from Ascentris 105, LLC (the Purchase), which project includes the Current Premises. Effective upon the Purchase, Hillwood will become the landlord pursuant to the Lease.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">On August 30, 2019, we entered into an amendment to the Lease with Hillwood (the Fourth Lease Amendment), pursuant to which each of our rights and obligations are contingent upon the Purchase. Effective upon the Purchase, the Fourth Lease Amendment will provide for, among other things, the (i) expansion of the Current Premises by </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>59,335</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> square feet of laboratory facilities located at 1701 Harbor Bay Parkway, Alameda, California, (ii) extension of the Lease term through October 31, 2031 and (iii) elimination of the Early Termination Right. </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">As of September 30, 2019, we have not yet recorded a right-of-use asset or lease liability for the Fourth Lease Amendment, and the remainder of the disclosures in this note do not reflect the impact of this amendment.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">See Part II, Item 5 of this Quarterly Report on Form 10-Q for more information about the Fourth Lease Amendment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6833703600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td>
<td class="text">INCOME TAXES<div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Our effective income tax rate was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>20.5%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>19.4%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, as compared to </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1.8%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>1.7%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The Provision for income taxes </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">relating to our pre-tax income </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">for the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> was largely offset by a valuation allowance against our net operating loss carryforwards and other deferred tax assets. At December 31, 2018, we released substantially all of our valuation allowance against our deferred tax assets, after we determined that it was more likely than not that these deferred tax assets would be realized.</span></div><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The effective tax rate for the&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> differed from the U.S. federal statutory rate of&#160;</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>21%</span></span>&#160;primarily due to excess tax benefits related to the exercise of certain stock options during those periods.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838625008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 27, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsAndInvestmentsTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS <div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash, Cash Equivalents and Restricted Cash</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">A reconciliation of Cash, cash equivalents, and restricted cash reported within our Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December 31, 2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>242,317</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>314,775</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>353,623</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>183,164</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in short-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>504</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Restricted cash included in long-term restricted cash and investments</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,646</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash, cash equivalents, and restricted cash as reported within the accompanying Condensed Consolidated Statements of Cash Flows</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>243,317</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>315,875</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>355,227</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>188,314</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Restricted cash includes certificates of deposit used to collateralize letters of credit and, in prior periods, a purchasing card program.</span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cash and Investments</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Cash and investments by security type were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>26,641</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>332,239</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>703,325</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,549</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>706,807</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>143</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>152,650</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,214,736</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,692</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,218,337</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>901</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,189</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>29,192</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,244,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>3,695</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,248,430</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"/></tr><tr><td style="width:45%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Amortized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gains</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Unrealized</span></div><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Investments available-for-sale:</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>47,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,134</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>381,133</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,741</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>344,064</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,224</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>55,201</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,843</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Cash and restricted cash</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>6,883</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Certificates of deposit</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>16,596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total cash and investments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>852,322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>851,621</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Gains and losses on the sales of investments available-for-sale were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nominal</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value and gross unrealized losses on investments available-for-sale in an unrealized loss position were as follows (in thousands): </span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>73,064</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(66</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,398</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>77,462</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>46,744</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(24</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>119,808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(90</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>4,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>124,206</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(91</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="24"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position Less than 12 Months</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">In an Unrealized Loss Position 12 Months or Greater</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Gross<br/>Unrealized<br/>Losses</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Corporate bonds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>236,162</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(606</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>39,627</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(251</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>275,789</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(857</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">U.S. Treasury and government sponsored enterprises</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>28,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(16</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>9,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>37,287</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(25</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Commercial paper</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>7,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>271,358</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(623</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>48,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>320,167</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>(883</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">)</span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">There were </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>43</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>199</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> investments in an unrealized loss position as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively. During the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">three and nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> we did </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>no</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">t record any other-than-temporary impairment charges on our available-for-sale securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk, but were primarily associated with changes in interest rates. Based on the scheduled maturities of our investments and our determination that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis, we concluded that the unrealized losses in our investment securities were not other-than-temporary.</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">The fair value of investments available-for-sale by contractual maturity were as follows (in thousands):</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:0px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">September&#160;30, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing in one year or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>743,768</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>674,455</span></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Maturing after one year through five years</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>474,569</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>153,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">Total investments available-for-sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>1,218,337</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;"><span>828,142</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Calibri,sans-serif;font-size:10pt;"><br/></span></div><div style="line-height:120%;padding-top:12px;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;font-style:normal;font-weight:bold;text-decoration:none;">Related Party Transactions</span></div><div style="line-height:120%;padding-bottom:0px;padding-top:12px;text-align:left;padding-left:0px;text-indent:48px;font-size:10pt;"><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">&#160;BlackRock,&#160;Inc. (BlackRock), a global provider of investment, advisory and risk management solutions, reported that as of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, the most recent date for which they reported ownership data, their beneficial ownership was more than </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>10%</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> of our outstanding common stock. BlackRock manages a portion of our cash and investments portfolio. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">December&#160;31, 2018</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, respectively, the fair value of cash and investments managed by BlackRock was </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$470.8 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$298.5 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, which included </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$1.9 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> and </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$3.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> invested in the BlackRock Liquidity Money Market Fund. As of </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">, we also had a </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$9.0 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> payable to BlackRock for unsettled trades that was included in </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">Other current liabilities in the accompanying Condensed Consolidated Balance Sheets.</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> We incurred </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"><span>$0.2 million</span></span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> in fees for BlackRock advisory services performed during the </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">nine months ended</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;"> </span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;text-decoration:none;">September&#160;30, 2019</span><span style="font-family:Calibri,sans-serif;font-size:10pt;color:#000000;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsAndInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, and Investments [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsAndInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R9999.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6631769664">
<tr>
<th class="tl" colspan="1">Label</th>
<th class="tl"><strong>Element</strong></th>
<th class="th" colspan="1">Value</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 258,505,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Accounting Standards Update 2014-09 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">258,505,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">234,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member] | Retained Earnings [Member]</a></td>
<td class="th" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative Effect of New Accounting Principle in Period of Adoption</a></td>
<td class="th" style="border-bottom: 0px;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
<td class="nump">$ 234,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6838720704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized gains or losses on available-for-sale securities, tax impact</a></td>
<td class="num">$ (129)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (936)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassification adjustments to net income resulting from realized gains or losses on sale of securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6843494336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 27, 2019 </div>
<div>segment </div>
<div>product</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember', window );">Products Derived from Cabozantinib</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from Discovery Efforts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromCabozantinibMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6847314448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 271,703<span></span>
</td>
<td class="nump">$ 225,397<span></span>
</td>
<td class="nump">$ 727,465<span></span>
</td>
<td class="nump">$ 625,224<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">194,484<span></span>
</td>
<td class="nump">166,270<span></span>
</td>
<td class="nump">572,957<span></span>
</td>
<td class="nump">453,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">76,017<span></span>
</td>
<td class="nump">57,186<span></span>
</td>
<td class="nump">120,134<span></span>
</td>
<td class="nump">145,038<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 1,202<span></span>
</td>
<td class="nump">$ 1,941<span></span>
</td>
<td class="nump">$ 34,374<span></span>
</td>
<td class="nump">$ 26,844<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6850314512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 242,317<span></span>
</td>
<td colspan="2" class="nump">$ 314,775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">518,350<span></span>
</td>
<td colspan="2" class="nump">378,559<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">169,788<span></span>
</td>
<td colspan="2" class="nump">162,771<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">13,801<span></span>
</td>
<td colspan="2" class="nump">16,056<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, net</a></td>
<td class="nump">13,366<span></span>
</td>
<td colspan="2" class="nump">9,838<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">14,490<span></span>
</td>
<td colspan="2" class="nump">15,017<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">972,112<span></span>
</td>
<td colspan="2" class="nump">897,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">486,763<span></span>
</td>
<td colspan="2" class="nump">157,187<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Long-term restricted cash and investments</a></td>
<td class="nump">1,000<span></span>
</td>
<td colspan="2" class="nump">1,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">49,467<span></span>
</td>
<td colspan="2" class="nump">50,897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">17,735<span></span>
</td>
<td colspan="2" class="nump">5,867<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">186,836<span></span>
</td>
<td colspan="2" class="nump">244,111<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td colspan="2" class="nump">63,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">7,268<span></span>
</td>
<td colspan="2" class="nump">2,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,784,865<span></span>
</td>
<td colspan="2" class="nump">1,422,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">8,352<span></span>
</td>
<td colspan="2" class="nump">10,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">31,713<span></span>
</td>
<td colspan="2" class="nump">32,142<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">30,330<span></span>
</td>
<td colspan="2" class="nump">18,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">16,782<span></span>
</td>
<td colspan="2" class="nump">14,954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">7,973<span></span>
</td>
<td colspan="2" class="nump">7,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">45,919<span></span>
</td>
<td colspan="2" class="nump">21,825<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">141,069<span></span>
</td>
<td colspan="2" class="nump">105,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OperatingAndFinanceLeasesLiabilityLongTerm', window );">Long-term portion of lease liabilities</a></td>
<td class="nump">23,705<span></span>
</td>
<td colspan="2" class="nump">12,178<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenue</a></td>
<td class="nump">15,399<span></span>
</td>
<td colspan="2" class="nump">15,897<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">975<span></span>
</td>
<td colspan="2" class="nump">1,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">181,148<span></span>
</td>
<td colspan="2" class="nump">134,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments</a></td>
<td class="text"> <span></span>
</td>
<td colspan="2" class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td colspan="2" class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000,000 shares authorized; issued and outstanding: 303,776,032 and 299,876,080 at September 30, 2019 and December 31, 2018, respectively</a></td>
<td class="nump">304<span></span>
</td>
<td colspan="2" class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,228,839<span></span>
</td>
<td colspan="2" class="nump">2,168,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="nump">2,668<span></span>
</td>
<td colspan="2" class="num">(701)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(628,094)<span></span>
</td>
<td colspan="2" class="num">(880,363)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">1,603,717<span></span>
</td>
<td colspan="2" class="nump">1,287,453<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 1,784,865<span></span>
</td>
<td colspan="2" class="nump">$ 1,422,286<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OperatingAndFinanceLeasesLiabilityLongTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating And Finance Leases, Liability - Long Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OperatingAndFinanceLeasesLiabilityLongTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e604059-122996<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116631420&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6666269984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements - Ipsen Collaboration (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Net contract liability</a></td>
<td class="nump">$ 15,399<span></span>
</td>
<td colspan="2" class="nump">$ 15,897<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">47,100<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Net contract liability</a></td>
<td class="nump">$ 7,200<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118944033&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6625461040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted Average Grant-Date Fair Value of Stock Options and ESPP Purchases (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Sep. 28, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 7.71<span></span>
</td>
<td class="nump">$ 8.67<span></span>
</td>
<td class="nump">$ 8.57<span></span>
</td>
<td class="nump">$ 9.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="nump">$ 5.39<span></span>
</td>
<td class="nump">$ 6.19<span></span>
</td>
<td class="nump">$ 4.93<span></span>
</td>
<td class="nump">$ 6.96<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6644948544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th" colspan="2"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 72,864<span></span>
</td>
<td class="nump">$ 68,206<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(23,397)<span></span>
</td>
<td class="num">(17,309)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">49,467<span></span>
</td>
<td class="nump">50,897<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">33,769<span></span>
</td>
<td class="nump">33,941<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">17,017<span></span>
</td>
<td class="nump">15,022<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">13,053<span></span>
</td>
<td class="nump">12,709<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">8,408<span></span>
</td>
<td class="nump">5,668<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 617<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Calibri,sans-serif;font-size:9pt;">The Condensed Consolidated Balance Sheet as of December 31, 2018 has been derived from the audited financial statements as of that date.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=exel_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3</span><table class="report" border="0" cellspacing="2" id="idp6844076096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 27, 2019</div></th>
<th class="th"><div>Dec. 28, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="nump">$ 119,808<span></span>
</td>
<td class="nump">$ 271,358<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(90)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="nump">4,398<span></span>
</td>
<td class="nump">48,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(260)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">124,206<span></span>
</td>
<td class="nump">320,167<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="num">(91)<span></span>
</td>
<td class="num">(883)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="nump">73,064<span></span>
</td>
<td class="nump">236,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(66)<span></span>
</td>
<td class="num">(606)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="nump">4,398<span></span>
</td>
<td class="nump">39,627<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(251)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">77,462<span></span>
</td>
<td class="nump">275,789<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="num">(67)<span></span>
</td>
<td class="num">(857)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="nump">46,744<span></span>
</td>
<td class="nump">28,105<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="nump">46,744<span></span>
</td>
<td class="nump">37,287<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="num">$ (24)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months', window );">In an Unrealized Loss Position Less than 12 Months, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss', window );">In an Unrealized Loss Position Less than 12 Months, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">In an Unrealized Loss Position 12 Months or Greater, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss', window );">In an Unrealized Loss Position 12 Months or Greater, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Total, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,091<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Total, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for less than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27337-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118942371&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118955579&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
